{
    "5bc844fc-e852-4270-bfaf-36ea9eface3d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in conrast all the secondary trial subjects receive these.",
        "Label": "Contradiction",
        "entail": "The statement \"All the primary trial participants do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, in contrast all the secondary trial subjects receive these\" is entailed by the information presented in the CTRs. \n\nIn the primary trial, the intervention section specifies that patients undergo FLT PET scan with [F18] fluorothymidine and Ki67 staining of tumor tissue, but it does not mention any administration of oral capecitabine, oral lapatinib ditosylate, or cixutumumab IV. \n\nIn the secondary trial, the intervention sections for both arms A and B specify that participants receive either oral capecitabine and oral lapatinib ditosylate alone in arm A or in combination with cixutumumumab IV in arm B. \n\nSince the primary trial does not report the administration of oral capecitabine, oral lapatinib ditosylate, or cixutumumab IV, and the secondary trial explicitly states that all participants in both arms receive at least one of these interventions, it follows that all primary trial participants do not receive these interventions, while all secondary trial subjects do receive them. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial includes an intervention arm that involves the use of oral capecitabine and lapatinib ditosylate (INTERVENTION 1 in the primary trial), but it does not include the use of cixutumumab IV. Conversely, in the secondary trial, both arms include the use of oral capecitabine and lapatinib ditosylate, but only arm B includes the use of cixutumumab IV. Therefore, not all primary trial participants do not receive any of these medications, and not all secondary trial subjects receive all three medications.</s>"
    },
    "86b7cb3d-6186-4a04-9aa6-b174ab764eed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails patients who meet certain blood count criteria (platelet count > 100,000/mm\u00b3, ANC < 1,700/mm\u00b3, and hemoglobin between 4 to 5 g/dL) and are eligible for the primary trial as per the CTR. The CTR specifies a platelet count requirement of > 100,000/mm\u00b3, while the lower limit for ANC and hemoglobin are < 1,500/mm\u00b3 and > 9.0 g/dL, respectively. However, the statement allows for a lower ANC value and a broader hemoglobin range, which falls within the permissible variations and does not contradict the CTR information. Thus, the statement is entailed by the CTR.</s>",
        "contradict": "The statement \"Patients with Platelet count over 100,000/mm\u00b3, ANC < 1,700/mm\u00b3 and Hemoglobin between 4 to 5 grams per deciliter are eligible for the primary trial\" can be contradicted by the information present in the CTRs as follows:\n\n1. Platelet count: The CTR specifies a minimum platelet count of 100,000/mm\u00b3 for trial eligibility.\n2. ANC: The CTR states that ANC must be 1,500/mm\u00b3 for trial eligibility.\n3. Hemoglobin: The CTR does not specify a minimum hemoglobin level for eligibility but only gives an example of 9.0 g/dL. However, it does state that patients must be asymptomatic for 2 months without evidence of progression prior to study entry, which may indicate that severe anemia (hemoglobin much lower than 9.0 g/dL) is not allowed. Thus, the eligibility criteria for hemoglobin is not exactly within the range stated in the expert's claim.\n\nTherefore, the expert's statement contradicts the platelet count and ANC eligibility criteria in the CTR, and the hemoglobin eligibility criteria may be contradictory depending on the specific patients meeting the study criteria.</s>"
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Heart-related adverse events were recorded in both the primary trial and the secondary trial\" is entailed by the CTR information as follows: In the primary trial, \"Atrial fibrillation\" and \"Cardiac failure congestive\" are mentioned as adverse events, while in the secondary trial, \"Atrial fibrillation\" is mentioned as an adverse event. Therefore, the statement is entailed as it correctly references the presence of heart-related adverse events in both trials.</s>",
        "contradict": "The expert's statement \"Heart-related adverse events were recorded in both the primary trial and the secondary trial\" is not necessarily in contradiction with the CTRs provided, as both trials report instances of atrial fibrilation and atrial flutter in their adverse events sections. However, the frequency and percentage of heart-related adverse events differ significantly between the two trials, and the expert's statement doesn't provide enough detail or specify which types of heart-related adverse events are being compared across the trials. This ambiguity can lead to potential misinterpretation or incorrect assumptions about the entailment relationship between the statement and the CTRs. To establish entailment, a clearer and more precise statement would be required, specifying which types of heart-related adverse events are being compared and their corresponding frequencies or percentages across the trials.</s>"
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events weren't recorded in both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "Given the information in the CTRs, the statement \"Heart-related adverse events weren't recorded in both the primary trial and the secondary trial\" can be entailed because:\n\n1. In the primary trial, none of the listed adverse events were heart-related (atrial fibrilation and atrial flutter are types of arrhythmia, but they are not specifically labeled as \"heart-related\" in the provided text).\n2. In the secondary trial, the listed adverse events include cardiac failure congestive (0.13%) and left ventricular dysfunction (0.26%), but these events do not constitute a significant proportion of the total adverse events (0.37% and 0.26% respectively), and the total percentage of heart-related adverse events is still relatively low (0.49%).\n\nThus, the statement is in agreement with the data provided in the CTRs and does not contradict any of the information presented.</s>",
        "contradict": "The statement \"Heart-related adverse events weren't recorded in both the primary trial and the secondary trial\" is contradicted by the information in the CTRs due to the presence of atrial fibration and atrial flutter in the secondary trial, which are considered heart-related adverse events.</s>"
    },
    "dbed5471-c2fc-45b5-b26f-430c9fa37a37_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Both trials recorded Heart-related adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Both trials recorded Heart-related adverse events\" is entailed by the information in the CTRs due to the occurrence of adverse events such as supraventricular tachycardia, atrial fibrillation, and atrial flutter in Trial 1, and Febrile neutropenia and cardiac failure congestive in Trial 2, which fall under the heart-related category. The statement does not contradict any information in the CTRs and is a valid generalization based on the data provided.</s>",
        "contradict": "The statement \"Both trials recorded Heart-related adverse events\" does not convey specific heart-related adverse events mentioned in the CTRs. While both trials do report adverse events, the given statement does not entail the presence of identical or similar heart-related adverse events across the trials as described in their respective sections. The CTRs detail varying types and frequencies of heart-related adverse events, including but not limited to atrial fibrillation, atrial flutter, cardiac failure congestive, confusional state, febrile neutropenia, hypersensitivity, supraventricular tachycardia, and ventricular dysfunction. The statement does not provide enough detail to establish semantic entailment with the information present in the CTRs.</s>"
    },
    "20c35c89-8d23-4be3-b603-ac0ee0f3b4de": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. \"Patients with histologic confirmation of invasive breast carcinoma\": The primary and secondary trial both include this eligibility criterion.\n2. \"Bilateral breast cancer is eligible\": The secondary trial explicitly states that patients with bilateral breast cancer are eligible. This criterion can be inferred from the primary trial's inclusion of patients with \"second primary breast cancers.\"\n3. T, N, and M stages: The primary trial includes specific T, N, and M eligibility criteria (T1N1-3M0 or T2-4N0-3M0), but it also allows for some flexibility with the N and M stages. The secondary trial specifically states that patients should have T1N1M1 stages. Since T1 is included in the primary trial's eligibility, the statement is consistent with this information in the CTR. Additionally, the primary trial allows for a maximum N and M stage of 3, which is also included in the eligibility criteria for the secondary trial.\n\nThus, the statement is entailed by the information contained in the CTRs. However, it's important to note that this statement does not entail the entirety of the inclusion criteria for the primary trial; it only applies to a subset of the eligibility criteria.</s>",
        "contradict": "The statement \"Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T1 N1 M1) are eligible for the primary trial\" is contradicted by the inclusion criteria in the CTR as stated:\n\n1. Patients should have clinically measurable disease to be treated in the neoadjuvant setting.\n\nBilateral breast carcinoma with T1 N1 M1 staging does not necessarily meet the requirement for having clinically measurable disease. The M1 designation indicates the presence of distant metastases, which typically makes the disease inoperable and unsuitable for neoadjuvant treatment.\n\nThus, while histologic confirmation of invasive bilateral breast carcinoma with T1 N1 M1 staging is mentioned in the expert statement as an eligibility criterion, this statement contradicts the CTR's inclusion criteria by potentially including patients with advanced disease that is not clinically measurable and not suitable for neoadjuvant treatment.</s>"
    },
    "f17cb242-419d-4f5d-bfa4-41494ed5ac0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "entail": "The statement does not follow from the provided CTRs, as laser therapy is not mentioned in the secondary trial alongside neoadjuvant chemotherapy. Therefore, there is no semantic entailment relationship between the CTRs and the statement. \n\nExplanation: \n\nThe provided statement asserts that \"Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy.\" However, based on the information in the CTRs, this statement is not semantically entailed. In the primary trial, laser therapy is listed as one of the interventions (INTERVENTION 1), but there is no mention that it is used in conjunction with neoadjuvant chemotherapy. In the secondary trial (INTERVENTION 1 for HR+, HER2+ Breast Cancer and INTERVENTION 2 for HR+, HER2- Breast Cancer), abemaciclib is the specified intervention, and no mention is made of laser therapy or neoadjuvant chemotherapy being used in the same cohort. Consequently, the statement is not a logical consequence of the provided CTRs.</s>",
        "contradict": "The statement \"Laser Therapy is in each cohort of the primary trial and the secondary trial, along with neoadjuvant chemotherapy\" is contradicted by the information present in the CTRs as follows: The primary trial consists of two interventions, one being laser therapy alone (without mention of neoadjuvant chemotherapy) and the second being manual lymphatic drainage alone. The secondary trial has two different interventions for the same drug, abemaciclib. The first intervention is for hormone receptor positive, HER2 positive (HR+, HER2+) patients receiving concurrent trastuzumab, and the second intervention is for hormone receptor positive, HER2 negative (HR+, HER2-) patients. Neither of these interventions mentions the inclusion of laser therapy or neoadjuvant chemotherapy.</s>"
    },
    "fc5c4554-7ce9-4c16-b374-a3cd9d15b021": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT01027416",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial\" can be entailed by the information in the CTRs as follows:\n\nIn Primary Trial, the inclusion criteria state that patients must have participated in a preceding phase II clinical study and been considered to need to continue the therapy by the investigator or subinvestigator.\n\nIn Secondary Trial, there is no explicit statement about participation in a previous clinical study. However, since the trial specifically selects patients who have undergone a core biopsy and are planning for surgical excision, it can be inferred that these patients have likely gone through some form of clinical evaluation and treatment process before being considered for this trial.\n\nBoth primary and secondary trial inclusion criteria necessitate that patients have been part of a previous clinical study, either explicitly stated or implicitly inferred. The statement, therefore, harmonizes with the clinical trial data and is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients must have already participated in a specific clinical study to participate in the primary trial or the secondary trial\" is contradicted by the information presented in the CTRs in several ways:\n\n1. In the primary trial, the inclusion criteria state that patients \"had participated in the preceding phase II clinical study\". However, this does not mean that all patients had previously participated in the same specific clinical study. It only specifies that they had participated in a preceding phase II study.\n2. In the secondary trial, there is no mention of any requirement for previous participation in a specific clinical study. Therefore, this statement cannot be entailed from the information presented in the CTR for the secondary trial.\n3. Additionally, the secondary trial has its own unique set of inclusion and exclusion criteria, different from the primary trial. This further supports the notion that patients do not necessarily need to have participated in a specific clinical study before joining the secondary trial.</s>"
    },
    "96b77cdd-aa9f-4770-8447-8a04d9ca5da7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Clinical stage II (T2 N1) invasive mammary carcinoma are not eligible for the primary trial\" is entailed by the CTRs since T2 N1 is listed under the Exclusion Criteria for the primary trial. Therefore, the statement's assertion aligns with the clinical trial data, is substantiated within the CTR, and does not contradict any provided descriptions.</s>",
        "contradict": "The information in the statement contradicts the inclusion criteria of the primary trial which states that patients with Clinical stage II (T2 N1) invasive mammary carcinoma are eligible for the trial, provided they do not undergo preoperative neoadjuvant therapy.</s>"
    },
    "c73faed2-371b-4238-bf7d-293fae380203": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention.",
        "Label": "Contradiction",
        "entail": "1. In the primary CTR, Intervention 1 specifies \"Adjuvant Radiotherapy.\" This section does not mention any additional interventions or medications.\n2. In the secondary CTR, Intervention 1 is described as \"Hypnotherapy,\" which is different from the primary trial. Intervention 2, however, includes \"Gabapentin.\"\n3. There is no contradiction between the primary CTR's Intervention 1 and the secondary CTR's Intervention 1. Both trials involve distinct interventions.\n4. The statement made by the clinical trial expert does entail both trials having hypnotherapy-based interventions. It correctly identifies a similarity between the two trials in terms of one intervention (hypnotherapy).\n5. The statement also mentions the use of pain medication in the secondary trial, which is described in Intervention 2 (gabapentin).\n6. The statement is consistent with the information in the CTRs as it correctly identifies a similarity and a difference between the trials.\n7. The statement does not contradict any information provided in the CTRs.\n8. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is potentially contradictory to the information presented in the CTRs as neither the Primary nor the Secondary trial mentions any use of pain medication in their respective interventions. While the Secondary trial includes an intervention group receiving Gabapentin, it does not imply that this medication was used for pain relief specifically. Therefore, the expert's statement that \"the primary trial and the secondary trial have Hypnotherapy based interventions, the secondary trial also used pain medication in its intervention\" could be contradictory if taken to imply that pain medication was used in addition to Hypnotherapy in the Secondary trial, which is not explicitly stated in the provided CTR information.</s>"
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial\" is entailed by the CTR as follows:\n\n1. Gender: Adele is female, as required by the CTR's inclusion criteria: \"Must be female\"\n2. Histologically Confirmed Breast Cancer: Adele's diagnosis of breast cancer is stated in the expert's description, which aligns with the CTR's criterion.\n3. Stage II: The given stage of Adele's breast cancer matches the CTR's requirement.\n4. ER+: ER status is stated in the expert's description, and it's compatible with ER positivity as per the CTR.\n5. ECOG 0: Adele's ECOG performance status is within the allowed range according to the CTR's criteria.\n6. Age: Adele's age is within the acceptable range as specified in the CTR's inclusion criteria: \"Postmenopausal.\"\n7. No Prior Treatment: According to the CTR, no prior treatment for current breast cancer is required.\n\nTherefore, all conditions stated by the clinical trial expert match the inclusion criteria presented in the CTR, making the statement entailed by the provided information.</s>",
        "contradict": "The statement \"Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she is eligible for the primary trial\" can be contradicted by the information present in the CTRs because the CTR specifies that patients must be postmenopausal, but no age limit is explicitly stated in the expert's statement regarding Adele. The CTR also excludes patients with significant renal dysfunction (serum creatinine > 1.5 x upper limit of normal), which is not mentioned in the expert's statement regarding Adele. Additionally, the expert's statement does not mention if Adele has received prior treatment for her breast cancer or if she has any history of aspirin or NSAID-induced allergies, both of which are specified as exclusion criteria in the CTR. Finally, it is unclear if Adele has any history of myocardial infarction or other thrombotic events, which are also listed as exclusion criteria in the CTR.</s>"
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she isn't eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The woman, Adele, is described as having Stage II histologically confirmed ER+ breast cancer with an ECOG performance status of 0. However, she is not eligible for the primary trial due to her age exceeding the postmenopausal requirement. The CTR for the primary trial states that patients must be female with histologically confirmed breast cancer, Stage II-IV disease, ER and/or PR positive, ECOG Performance Status 0-1, and postmenopausal. Therefore, although Adele meets the criteria of breast cancer diagnosis, stage, hormone receptor status, and ECOG performance status, she does not fulfill the age requirement. Consequently, her exclusion from the primary trial is entailed by the stated information in the CTR.</s>",
        "contradict": "The statement that \"Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she isn't eligible for the primary trial\" contradicts the CTR in multiple ways:\n\n1. Age: Adele is 85 years old, which is above the upper age limit for eligibility in the primary trial as stated in the inclusion criteria: \"Postmenopausal.\"\n2. ECOG Performance Status: Adele has an ECOG Performance Status of 0, which meets the inclusion criteria for the primary trial. However, the statement asserts that she isn't eligible, which is a contradiction.\n\nTherefore, the statement is in contradiction with the information provided in the Primary CTR regarding the inclusion criteria for the trial.</s>"
    },
    "8765009d-ffc4-4395-ab7a-11ecdfd43a40_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Since Adele is an 85 year old woman with Stage II histologically confirmed ER+ breast cancer with an ECOG of 0, she can participate in the primary trial)",
        "Label": "Entailment",
        "entail": "Adele's eligibility for the primary trial is determined by the following inclusion criteria from the CTR: female gender, histologically confirmed breast cancer, Stage II disease, ER and/or PR positive, ECOG Performance Status 0, presence of tumor following core needle biopsy as determined by physical exam or radiographic evaluation, postmenopausal, and no prior treatment for current breast cancer (except for adequately treated basal cell, squamous cell skin cancer, and other in situ cancers). \n\nAdele's characteristics meet all the mentioned criteria, as she is a female with histologically confirmed ER+ breast cancer, has Stage II disease, an ECOG of 0, has a presence of tumor following biopsy, is postmenopausal, and has not received prior treatment for current breast cancer. Therefore, her eligibility is entailed by the information present in the CTRs.</s>",
        "contradict": "Adele's age (85 years) is not mentioned among the inclusion criteria for the primary trial. The primary trial only requires participants to be female with histologically confirmed breast cancer, Stage II-IV disease, ER and/or PR positive, ECOG Performance Status 0-1, postmenopausal with no prior treatment for current breast cancer, and meet certain exclusion criteria. Age is not explicitly stated. Therefore, the statement that \"she can participate in the primary trial\" may be incorrect for Adele, even though she meets most other inclusion criteria.</s>"
    },
    "0ad7293d-df35-42e8-881d-f2afc3f7d3fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs. \n\nExplanation: \n\nThe primary trial's Intervention 1 involves the use of Accelerated Intensity Modulated Radiation Therapy (AIMRT) with a total dose of 40.5 Gy, while the secondary trial's Intervention 1 is a breast tissue expander (AeroForm) that does not involve radiotherapy. Therefore, the statement that \"Only patients in the primary trial receive 40.5 Gy of brachytherapy, patients in the secondary trial receive no radiotherapy whatsoever\" is incorrect because it contradicts the facts presented in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the primary trial describes the use of Accelerated Intensity Modulated Radiation Therapy (AIMRT) involving a total dose of 40.5 Gy to the entire breast, not brachytherapy as stated in the expert's claim. In contrast, the secondary trial describes the use of an AeroForm Tissue Expander and no radiotherapy at all.</s>"
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Certain drinks are banned for patients undertaking the primary trial.",
        "Label": "Entailment",
        "entail": "Grapefruit juice is not explicitly mentioned in the primary trial's inclusion criteria or exclusion criteria as a banned drink for patients. However, the inclusion criteria state that patients must agree not to consume grapefruit juice while on the study, suggesting that grapefruit juice is indeed banned. The secondary trial's statement, \"Certain drinks are banned for patients undertaking the primary trial,\" can be entailed as it includes grapefruit juice among the banned beverages, which is consistent with the information provided in the primary CTR.</s>",
        "contradict": "The expert's statement \"Certain drinks are banned for patients undertaking the primary trial\" is not directly contradicted by the information in the CTRs. However, it is less informative since the CTRs explicitly state that patients must not consume grapefruit juice while on the study. The expert's statement could potentially entail the ban on grapefruit juice but also encompasses other drinks not mentioned in the CTRs. Therefore, the expert's statement is not a contradiction but a more generalized version of the information in the CTRs.</s>"
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "No drinks are banned for patients undertaking the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"No drinks are banned for patients undertaking the primary trial\" is not entailed by the information present in the CTRs. The statement contradicts the information in the CTRs which specifies that patients must agree not to consume grapefruit juice while on the study.</s>",
        "contradict": "The statement \"No drinks are banned for patients undertaking the primary trial\" is contradictory to the inclusion criteria of the primary trial, specifically the statement \"Patients must agree not to consume grapefruit juice while on the study.\" Therefore, the statement cannot hold for the primary trial as described in the CTR.</s>"
    },
    "2bc1e094-41a1-46d9-9b0c-b5a47f23323d_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Patients undertaking the primary trial are baned from consuming certain drinks.",
        "Label": "Entailment",
        "entail": "The CTR of the primary trial specifies that patients are required to agree not to consume grapefruit juice while on the study. This requirement is not explicit in the statement, but grapefruit juice is indeed a type of drink mentioned in the CTR. Hence, the statement \"Patients undertaking the primary trial are baned from consuming certain drinks\" is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Patients undertaking the primary trial are baned from consuming certain drinks\" is not an accurate representation of the information present in the provided CTRs. While it is true that patients in the primary trial are not allowed to consume grapefruit juice, the statement does not specify this and instead vaguely mentions \"certain drinks.\" The CTRs explicitly state this restriction, making the expert's statement contradictory if taken out of context.</s>"
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Most of the cases of CHF in the primary trial, were in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"Most of the cases of CHF in the primary trial, were in cohort 1\" can be entailed by the information present in the CTRs if there is at least one instance of congestive cardiac failure (CHF) reported in cohort 1 of the primary trial, while the total number of CHF cases in cohort 1 constitutes a majority (i.e., more than 50%) of all the CHF cases reported across both cohorts in the primary and secondary trials.\n\nIn the given CTR for the primary trial, one case of congestive cardiac failure (1/32) is reported, and the total number of participants in cohort 1 is unknown. To determine whether most of the cases of CHF in the primary trial were in cohort 1, it is necessary to compare the number of CHF cases in each cohort or have additional information about the total number of participants in each cohort.\n\nAssuming there is no conflicting information available, the given statement can be entailed if the following is true:\n\n1. Cohort 1 of the primary trial has a larger number of participants compared to cohort 2.\n2. The reported case of CHF in the primary trial belongs to cohort 1.\n\nTherefore, with the information provided, the statement cannot be definitively determined to be entailed or false without further context regarding the number of participants in each cohort. The given information from the CTRs allows for the possibility that most (but not necessarily all) of the cases of CHF were in cohort 1 if cohort 1 had a significantly larger number of participants. However, the current data does not provide sufficient evidence to confirm this claim.</s>",
        "contradict": "The statement \"Most of the cases of CHF in the primary trial, were in cohort 1\" cannot be definitively contradicted by the provided CTR information. However, it can potentially be misleading without additional context. The CTRs only report the occurrence of one case of congestive cardiac failure in cohort 1 of trial 1 and none in cohort 2 of trial 1 or trial 2. Therefore, the CTR data alone does not allow for a definitive conclusion about \"most\" cases in trial 1 being in cohort 1. Additional context or information about the total number of participants with CHF across all trials and cohorts would be necessary to properly evaluate the statement.</s>"
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Most of the cases of CHF in the primary trial, weren't in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Most of the cases of CHF (Cardiac Failure Congestive) in the primary trial, weren't in cohort 1\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial's Adverse Events 1 section for the entire cohort, there is only one instance of Cardiac Failure Congestive (1/32, or roughly 3.13%).\n2. In the primary trial's Eligibility Criteria or other sections, no information suggests that cohort 1 specifically had an unusually high or low incidence of Cardiac Failure Congestive.\n3. Given that there's only one reported case of Cardiac Failure Congestive across all cohorts in the primary trial, and that most cases weren't in cohort 1, it is reasonable to infer that no or fewer than one case of Cardiac Failure Congestive was present in cohort 1.\n\nThis inference is consistent with the provided data, as no contradiction exists, and the statement finds substantial justification within the CTR.</s>",
        "contradict": "The statement \"Most of the cases of CHF in the primary trial, weren't in cohort 1\" cannot be directly contradicted by the information present in the CTRs as there is no mention of CHF (Congestive Heart Failure) in either the primary or secondary CTRs.</s>"
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "Cohort 1. had most cases of of CHF in the primary trial",
        "Label": "Entailment",
        "entail": "The statement that \"Cohort 1 had the most cases of CHF (Cardiac Failure Congestive) in the primary trial\" is entailed by the data presented in the CTRs if we consider the number of cases of Cardiac Failure Congestive (3.13%) in Cohort 1 of Trial 1 (1/32) and the number of cases of Cardiac Failure Congestive in Cohort 1 of Trial 2 is not mentioned. Since the statement only refers to the primary trial and specifically mentions Cohort 1, it is entailed by the information that 1 out of 32 participants in Cohort 1 of the primary trial experienced Cardiac Failure Congestive.</s>",
        "contradict": "The statement cannot be definitively confirmed or contradicted based on the provided CTR data. The CTRs only report the occurrence of one case of congestive cardiac failure (CHF) in each trial, within the \"Adverse Events\" sections for the primary and secondary trials respectively. Therefore, neither cohort had a \"most\" number of cases of CHF, as stated in the expert's comment. Instead, both trials each had one reported case.</s>"
    },
    "c3257f7b-f5b4-4a9c-8a8f-b037f27caa8f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial must have a life expectancy over 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"Candidates for the primary trial must have a life expectancy over 6 months\" is entailed by the CTR information since it does not explicitly state or indicate a requirement for shorter life expectancies, and the absence of such a requirement is implied through the use of the qualifier \"not specified\" for the life expectancy criteria in the CTR. Therefore, the expert's statement, which sets a minimum life expectancy requirement, can be considered a logical implication of the given CTR information.</s>",
        "contradict": "The statement \"Candidates for the primary trial must have a life expectancy over 6 months\" contradicts the information in the CTR as it is not mentioned anywhere in the Primary or Secondary trial's Eligibility Criteria that the patients' life expectancy must be over 6 months.</s>"
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "Patients eligible for the primary trial must live in the USA.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criterion states \"Residence in Pilsen, Little Village, East Side or South Chicago,\" which implies that these locations are within the USA. Therefore, the expert's statement that \"Patients eligible for the primary trial must live in the USA\" is entailed by the information provided in the primary trial's inclusion criteria in the CTR.</s>",
        "contradict": "The statement \"Patients eligible for the primary trial must live in the USA\" is contradicted by the inclusion criteria of the primary trial mentioned in the CTR, which specifically includes women residing in certain neighborhoods in Chicago, Illinois, USA, without specifying that they must be U.S. citizens or permanent residents.</s>"
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "Patients eligible for the primary trial mustn't live in the USA.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients eligible for the primary trial mustn't live in the USA\" is not entailed by the information present in the CTRs. The CTRs provide details of the inclusion and exclusion criteria for the primary and secondary trials, but they do not indicate where the patients must live to be eligible or excluded. Therefore, no entailment exists between the CTRs and the statement made by the clinical trial expert.</s>",
        "contradict": "The information in the statement contradicts the inclusion criteria of the primary trial specified in the CTR, which requires participants to be residents of specific areas in the USA.</s>"
    },
    "17a821f8-5e68-4bf7-ac01-3f96ddfc5187_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Statement": "To be eliegible for the primary trial, a patient must live in the USA",
        "Label": "Entailment",
        "entail": "The statement \"To be eligible for the primary trial, a patient must live in the USA\" can be entailed by the information in the CTRs since there are no explicit mention of any location outside the USA as a requirement for patient eligibility in both the primary and secondary CTRs provided. In other words, the CTRs are silent on patients living outside the USA, implying an implicit requirement of residence within the USA for eligibility.</s>",
        "contradict": "The information in the statement that a patient must live in the USA to be eligible for the primary trial is contradictory to the CTR as it does not appear anywhere in either the inclusion or exclusion criteria that participation is limited to USA residents.</s>"
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial do not receive the same dosage of AIMRT.",
        "Label": "Entailment",
        "entail": "The statement asserts that patients in group 1 of the secondary trial receive a different dosage of AIMRT compared to the primary trial. This can be entailed by the CTR information as follows:\n\n1. In the primary trial, the subjects are randomly assigned to receive placebo or a local anesthetic solution. There is no mention of AIMRT in the primary trial.\n2. In the secondary trial, patients do receive AIMRT; however, the dosage information provided specifies a total of 40.5 Gy in 15 fractions for all patients, without any indication of separate dosages for different groups.\n\nGiven that the statement only concerns group 1 of the secondary trial, the entailment is based on the premise that there is no mention of AIMRT in the primary trial, and the secondary trial's dosage information does not distinguish between groups.</s>",
        "contradict": "Patients in the primary trial receive a treatment other than AIMRT in the INTERVENTION section, and no dosage information for AIMRT is provided. Therefore, it's impossible to compare dosages between the two trials based on the given information.</s>"
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of AIMRT.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in group 1 of the secondary trial and the primary trial receive the same dosage of AIMRT\" is entailed by the information in the CTRs as both trials state that patients in the primary trial receive a total of 40.5 Gy to the entire breast, and patients in the secondary trial receive a total of 40.5 Gy to the entire breast. This dosage is delivered in uniform daily doses of 2.7 Gy/fraction x 15 fractions for three weeks in both trials, with an additional concurrent boost of 0.50 Gy to the original tumor bed in the secondary trial. Therefore, the dosage received by patients in group 1 of the secondary trial is equivalent to the dosage administered to patients in the primary trial.</s>",
        "contradict": "The statement \"Patients in group 1 of the secondary trial and the primary trial receive the same dosage of AIMRT\" can be contradicted by the information present in the CTRs since the CTRs do not provide identical descriptions of the intervention dosages for the primary and secondary trials. In the primary trial, no radiation therapy is mentioned in the intervention sections. In contrast, the secondary trial specifies \"All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions\" for AIMRT, which does not correspond to the dosage described in the statement.</s>"
    },
    "d76d6c7f-ba39-483c-a89e-152af5ae2878_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Different dosages of AIMRT were given to group 1 of the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "In the primary CTR, Intervention 1 is a placebo with no specified dose, while Intervention 2 involves administering a local anesthetic solution containing 0.25 % bupivacaine, epinephrine, and dexamethasone with unmentioned dosages. In contrast, the secondary CTR mentions Intervention 1 as Accelerated Intensity Modulated Radiation Therapy (AIMRT) with a total dose of 40.5 Gy and a concurrent boost of 0.50 Gy, but it does not provide information on any specific group's dosage. \n\nDespite the lack of explicit dose information for Group 1 in the secondary trial's CTR, the statement can still be entailed by the CTRs because there is no inconsistency between them. The statement asserts that different dosages were given in the secondary and primary trials without specifying which groups received these dosages or what the dosages actually are. The CTRs do not contradict this claim, as they only describe different interventions with no mention of identical dosages for both trials. Therefore, the statement is semantically entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Different dosages of AIMRT were given to group 1 of the secondary trial and the primary trial\" is contradicted by the information in the CTRs because the primary trial does not involve radiation therapy. The primary trial focuses on the interventions given during surgery using saline or a local anesthetic solution. The secondary trial's intervention involves radiation therapy, but the information provided does not specify different dosages for group 1 compared to the primary trial.</s>"
    },
    "65f3e755-3e23-4e84-a218-87922759094d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial administers letrozole for 28 days, whereas the secondary trial administers is intervention over 4 cycles of 21 days.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because, in the primary trial, letrozole is given for a 28-day treatment period in both Part A and Part B interventions. Though not explicitly stated, it can be inferred that each treatment period also lasts 28 days based on the given information about monitoring blood levels of estrogens and vitamin D at the start and end of each period. In contrast, the secondary trial administers Neratinib for each cycle over 21 days, implying a 21-day treatment period for each intervention, not necessarily for the entire trial. While the length of treatment differs between the trials, it doesn't contradict the provided information in the CTRs. The statement focuses on the duration of intervention and is consistent with the given data.</s>",
        "contradict": "The statement \"the primary trial administers letrozole for 28 days, whereas the secondary trial administers intervention over 4 cycles of 21 days\" is contradictory to the information in the CTRs as follows:\n\n1. In the primary trial, letrozole is given for two separate parts, Part A and Part B. In Part A, letrozole is administered for 28 days. In Part B, only overweight/obese participants from Part A receive a double dose of letrozole for another 28 days. Therefore, each participant receives letrozole for a total of 28+28 = 56 days.\n\n2. In contrast, the secondary trial administers Neratinib for four cycles, with each cycle lasting 21 days. Since the trial is not about letrozole, but rather comparing it with Neratinib, the statement is not directly related to the primary CTR, but it is important to note that the duration of Neratinib administration in this trial is not mentioned in the provided context.\n\nThe statement implies that the primary trial administers letrozole for 28 days, while the secondary trial administers its intervention for 84 days (4 cycles x 21 days). However, the primary trial actually administers letrozole for 56 days, making the statement contradictory to the provided information in the CTRs.\n\nIt is also crucial to remember that the provided statement only discusses the duration of administration and does not account for other essential differences between the two trials, such as patient populations, dosing schedules, or outcomes measures.</s>"
    },
    "d3590771-806b-4754-a455-38113bfedfca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 day. Renal function is not relevant for inclusion.",
        "Label": "Contradiction",
        "entail": "The statement that trial candidates must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 days is entailed by the information present in the CTRs as follows:\n\n1. Adequate colon function is already stated in the Primary Trial's Eligibility Criteria, specifically in the requirement that patients have adequate gastrointestinal function.\n2. Adequate liver function is also mentioned in the Primary Trial's Eligibility Criteria. Patients are required to have adequate hepatic function as shown by serum bilirubin levels within the normal limits and both AST and ALT levels <1.5 times the ULN (unless they have liver metastases).\n3. The exclusion of patients currently receiving amiodarone is mentioned in the Primary Trial's Exclusion Criteria, and patients who have received amiodarone in the last 28 days are also considered ineligible.\n\nTherefore, the statement that trial candidates must have adequate colon and liver function, and must not be currently receiving amiodarone or have received amiodarone in the last 28 days is a logical consequence of the information presented in the Primary Trial's Eligibility Criteria and Exclusion Criteria.\n\nThe statement that renal function is not relevant for inclusion is not entailed by the information present in the CTRs, as the Primary Trial's Eligibility Criteria include a requirement for adequate renal function.</s>",
        "contradict": "The statement contradicts the CTR inclusion criteria regarding amiodarone use, as the primary trial candidates are specified to have not received amiodarone within 28 days, whereas the CTR includes patients who may continue receiving amiodarone under certain conditions (see section 5.3.2.) if the biphosphonate treatment was initiated more than three weeks before first ASCI administration. Therefore, the statement's assertion does not harmonize with clinical trial data from the provided CTR.</s>"
    },
    "941b960f-8d57-4830-9d4c-8e96765ba76c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "both the primary trial and the secondary trial administer Bevacizumab to every single HER2+ patient.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Arm 1 (Yoga Intervention) and Arm 2 (Educational Wellness Group) do not involve the administration of Bevacizumab to all HER2+ patients. However, in the secondary trial, both arms (Arm A: ET and Arm B: ET-B) include the use of Bevacizumab for HER2+ patients, either as a combination therapy with letrozole or fulvestrant or as a single agent. Thus, the statement can be entailed by the information present in the CTRs, as it applies to the secondary trial specifically. In the context of the primary trial, the statement is not accurate.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as not all patients in the primary trial received Bevacizumab. Arm 1 of the primary trial utilized a Yoga Intervention and Arm 2 employed an Educational Wellness Group, neither of which included Bevacizumab in their treatment regimens. Contrarily, in the secondary trial, only Arm B (ET-B) administered Bevacizumab to patients in conjunction with endocrine treatment.</s>"
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the following facts from the CTRs:\n\n1. In the primary trial, Intervention 1 uses AeroForm Tissue Expansion, which involves inflating the expander with carbon dioxide by remote control.\n2. In the primary trial, Intervention 2 uses Saline Tissue Expansion, which involves inflating the expander with saline through needle injections.\n3. In the secondary trial, Intervention 1 uses FFDM (Film-Screen Digitial Mammography) and DBT (Digital Breast Tomosynthesis) scans, which are imaging techniques and do not involve any form of tissue expansion or gas usage.\n4. In the secondary trial, Intervention 2 uses FFDM exam only, which is also an imaging technique without any tissue expansion or gas usage.\n\nThus, the statement that \"CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and not used in either of the study groups in the secondary trial\" is entailed by the provided CTRs.</s>",
        "contradict": "The statement does not directly contradict the CTR information; however, the statement is incomplete and ambiguous. It only mentions the use of CO2 in the primary trial but does not specify which intervention group uses CO2. The CTR, however, clearly states that CO2 is used only in the AeroForm Tissue Expansion intervention group. The statement in the secondary trial does not mention any use of CO2 at all. Therefore, the statement as it is written is not an accurate representation of the CTR information as it omits the important detail of which intervention group in the primary trial uses CO2. To avoid contradiction or misunderstanding, the expert statement should be more explicit, specifying which study group in the primary trial uses CO2 for tissue expansion, and that it is not used at all in the secondary trial.</s>"
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and used in either of the study groups in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement asserts that CO2 is used in one of the study groups of the primary trial and in either of the study groups of the secondary trial. This can be entailed by the information in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 utilizes AeroForm Tissue Expansion, and it's specified that this tissue expander inflates by releasing carbon dioxide from an internal reservoir using remote control. Therefore, CO2 is used in Intervention 1 of the primary trial.\n2. In the secondary trial, Intervention 1 involves Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT), which are imaging procedures performed on a Siemens MAMMOMAT Inspiration machine. Although the intervention description in the CTR does not explicitly mention CO2 usage, it doesn't contradict the statement that CO2 is used in either study group, as there could be other procedures or equipment within the trial unrelated to the interventions that may involve CO2 use.\n3. Furthermore, Intervention 2 in the secondary trial involves FFDM only. While this intervention does not directly involve CO2, the statement allows for CO2 use in either study group. So even though CO2 is not mentioned explicitly in Intervention 2, the statement is still entailed by the CTR information.\n\nThus, the statement is entailed by the CTRs since CO2 usage in one of the primary trial's study groups and either of the secondary trial's study groups is consistent with the provided CTR descriptions.</s>",
        "contradict": "The statement \"CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and used in either of the study groups in the secondary trial\" is not directly contradictory to the information presented in the CTRs. However, it is less specific and can potentially encompass different interpretations compared to the provided trial details.\n\nThe primary trial consists of two study groups - AeroForm Tissue Expansion using carbon dioxide and Saline Tissue Expansion. The statement correctly mentions that carbon dioxide is part of the intervention in one of these study groups (AeroForm). However, it is incorrect in stating that carbon dioxide is used in either of the study groups in the secondary trial, as the secondary trial only compares Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT). No information regarding the use of carbon dioxide in the secondary trial is provided in the given CTR sections.\n\nTherefore, while the statement is not a direct contradiction of the facts presented in the CTRs, it is not an exact reflection of the trials' interventions either. It is important to ensure clarity and precision when comparing trials or drawing conclusions from their findings.</s>"
    },
    "f79a9011-0a68-4255-a40f-5d73af412bf0_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 was not used in either of the study groups in the secondary trial, and only used in a single one of the study groups in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"CO2 was not used in either of the study groups in the secondary trial, and only used in a single one of the study groups in the primary trial\" is entailed by the CTRs because:\n\n1. In the primary trial, Intervention 1 specifies the use of \"AeroForm Tissue Expansion,\" which is a breast tissue expander that is inflated using carbon dioxide. The statement confirms that CO2 was used in one of the primary study groups.\n2. In the primary trial, Intervention 2 does not mention the use of CO2 in the saline tissue expansion procedure.\n3. In the secondary trial, neither Intervention 1 nor Intervention 2 mentions the use of CO2.\n\nTherefore, the statement that \"CO2 was not used in either of the study groups in the secondary trial, and only used in a single one of the study groups in the primary trial\" is consistent with the information in the CTRs and does not contradict any descriptions.</s>",
        "contradict": "The statement is contradicted by the information in the primary trial's Intervention 1 section, as it specifies the use of CO2 in one of the study groups (AeroForm Tissue Expansion) through a remote control system. Therefore, the statement is not entailed by the information provided in the CTRs.</s>"
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were no completed suicides in either the primary trial or the secondary trial, however there was one attempt in cohort 1 of the secondary trial\" is entailed by the information present in the CTRs as follows: In the primary CTR, there is no record of any completed suicide among the 116 participants under the \"Adverse Events\" section. Similarly, in the secondary CTR, there is no mention of any completed suicide among the 54 participants in either the \"Adversely Events 1\" or \"Adverse Events 2\" sections. The statement does introduce new information with the mention of a suicide attempt in cohort 1 of the secondary trial, but this is compatible with the information in the CTR as the CTRs report adverse events without specifying their outcome as completed or incomplete. Therefore, the statement does not contradict the information in the CTRs and can be considered entailed.</s>",
        "contradict": "The information in the statement is contradicted by the information in the CTRs because the CTR for the secondary trial reports one suicide attempt, while the statement asserts that there were no completed suicides in either trial.</s>"
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were completed suicides in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were completed suicides in either the primary trial or the secondary trial\" can be entailed by the CTRs if we find at least one instance of a completed suicide reported in either Adverse Events section. However, based on the provided CTR data, there is a reported suicide attempt in the Secondary Trial's Adverse Events 1 section, which does not entail a completed suicide. Therefore, the statement is not directly entailed by the provided CTR information, but it is possible that the CTRs do entail such an occurrence if more comprehensive trial data is available.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs as neither of them reports any completed suicides among the participants.</s>"
    },
    "1b4f8828-cc7f-4831-a1c0-cc14e6ad23af_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There was one attempted suicide in the cohort 1 of the secondary trial, but no complete ones in any of the trials.",
        "Label": "Entailment",
        "entail": "The statement \"There was one attempted suicide in the cohort 1 of the secondary trial, but no complete ones in any of the trials\" can be entailed by the CTRs since neither Adverse Events 1 nor Adverse Events 2 report any instance of \"myocardial infarction\" or \"pericardial effusion,\" which are conditions commonly associated with fatal outcomes in clinical trials. The statement also aligns with the occurrence of one reported suicide attempt in the secondary trial's Adverse Events 1 section.</s>",
        "contradict": "The expert's statement does not entail the information in the CTRs because it goes beyond the data provided. The CTRs mention instances of suicide attempts in the secondary trial, but they do not mention any complete suicides occurring in any trial. The expert's statement asserts that there were no complete suicides at all, which contradicts the possibility implied by the CTR data.</s>"
    },
    "57f3a264-9119-4931-9f9c-9cb20e945973": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course.",
        "Label": "Contradiction",
        "entail": "In the primary trial, participants received lapatinib, an oral medication known as a tyrosine kinase inhibitor, and paclitaxel, an intravenously administered chemotherapeutic agent. The secondary trial, however, does not involve any medication or intervention in the form of chemotherapy; rather, it focuses on the use of different types of acellular dermal matrices (AlloDerm RTU and SurgiMend PRS) for tissue reconstruction during surgery, which can be categorized as physical therapies. Therefore, the statement that \"the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course\" is entailed by the information present in the CTRs as the primary trial indeed involves chemotherapy treatment, while the secondary trial does not.</s>",
        "contradict": "The statement \"the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing a physcotherapy course\" is contradictory to the information provided in the CTRs. The primary trial involves the use of lapatinib, an oral tyrosine kinase inhibitor, and paclitaxel, a chemotherapy drug administered intravenously. The secondary trial, however, is not related to a chemotherapy or physiotherapy treatment. Instead, it focuses on the use of AlloDerm RTU and SurgiMend PRS, which are both acellular dermal matrices used in surgical procedures. The misconception arises from the use of inappropriate terminology in the statement, as lapatinib and paclitaxel are not classified as physiotherapies but rather chemotherapies.</s>"
    },
    "589e2f5b-9286-465b-8162-bb1549cd5ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). ",
        "Label": "Entailment",
        "entail": "Based on the CTR information, each patient in both arms (Fulvestrant 250 mg and Fulvestrant 250 mg + Loading Dose) underwent assessment for objective response as per RECIST criteria up to data cut-off. The objective response is defined as having a best overall response of either complete response (CR) or partial response (PR). The statement that \"at least 4 patients in both cohorts achieved either complete response (CR) or partial response (PR)\" is entailed by the CTR data since there are 45 participants in the Fulvestrant 250 mg arm and 11.1% of them achieved ORR, which translates to 5 patients. Similarly, there are 51 participants in the Fulvestrant 250 mg + Loading Dose arm and 17.6% of them achieved ORR, which translates to 9 patients. Therefore, at least 14 patients (5+9) in both cohorts achieved OR, and it is reasonable to assume that some of them had a CR or PR as per the definition of OR.</s>",
        "contradict": "The statement \"At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR)\" cannot be directly contradicted by the given CTRs. However, it is important to note that the CTRs do not provide explicit information about the number of patients in each cohort who experienced CR or PR. The CTRs only mention the percentage of participants who had an objective response in each arm (i.e., 11.1% for Fulvestrant 250mg and 17.6% for Fulvestrant 250mg+Loading Dose). While it's possible for there to be more than 4 patients with ORR in each arm (given the larger number of participants in the second cohort), the CTRs do not provide enough information to definitively confirm or deny the expert's statement. Therefore, the statement is not contradicted by the available information, but it also does not follow directly from it.</s>"
    },
    "8275f846-59b6-404d-a6d8-e01335279f1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "Less than 1/4 patients in the primary trial experienced adverse events.",
        "Label": "Contradiction",
        "entail": "33.33% of patients in the primary trial experienced adverse events, which is less than 25% or 1/4 when expressed as a fraction. The given percentage in the CTR (33.33%) is less than 25%.</s>",
        "contradict": "The statement \"Less than 1/4 patients in the primary trial experienced adverse events\" contradicts the information in the CTR because the CTR reports that 33.33% (or 8 out of 24) of patients experienced adverse events. Therefore, more than 1/4 of the patients in the trial experienced adverse events, which is not consistent with the statement.</s>"
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "Both Cohorts of the primary trial receive their treatment via Subcutaneous administration.",
        "Label": "Entailment",
        "entail": "The statement \"Both Cohorts of the primary trial receive their treatment via Subcutaneous administration\" is entailed by the CTRs because both Intervention 1 and Intervention 2 specify that the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine will be administered to research participants via subcutaneous injection.</s>",
        "contradict": "Although both cohorts do receive their treatment via subcutaneous administration as stated, the discrepancy lies in the dosage of the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine given to each cohort. In the primary trial, the initial cohort receives 300 micrograms per dose, whereas the escalation cohort receives 500 micrograms per dose. Therefore, the statement's claim that \"both Cohorts of the primary trial receive the same treatment\" is not entailed by the CTR information and is an oversimplification that could lead to incorrect conclusions.</s>"
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "No Cohorts of the primary trial receive their treatment via Subcutaneous administration.",
        "Label": "Contradiction",
        "entail": "The statement \"No Cohorts of the primary trial receive their treatment via Subcutaneous administration\" is not entailed by the information present in the CTRs. Contrarily, the CTRs explicitly specify that all research participants in both cohorts receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection. Therefore, the statement runs contradictory to the provided CTR data.</s>",
        "contradict": "The statement is contradictory to the CTR information as it incorrectly asserts that there are no cohorts in the primary trial receiving subcutaneous administration of the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine. However, both the initial and escalation cohorts in the primary trial receive the vaccine via subcutaneous injection, as specified in the CTR.</s>"
    },
    "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Statement": "Treatment was received via subcutaneous administration in both cohorts of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"Treatment was received via subcutaneous administration in both cohorts of the primary trial\" is entailed by the CTRs' information since:\n\n1. In the primary trial, Intervention 1 and Intervention 2 specify \"Subcutaneous administration\" for both cohorts receiving the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine in each cohort.\n2. The expert's statement does not contradict or provide additional requirements beyond the existing information in the CTRs, thus maintaining consistency.\n\nTherefore, the expert's statement is a logical consequence of the information contained within the CTRs, making the entailment relationship valid.</s>",
        "contradict": "Despite the statement that \"treatment was received via subcutaneous administration in both cohorts of the primary trial,\" the CTRs provide different dosages for each cohort (300 micrograms in Initial Cohort vs 500 micrograms in Escalation Cohort). This discrepancy in dosages, though both administered via the same route (subcutaneous), could potentially result in varying treatment effects or adverse events. Consequently, the statement does not entail the information provided in the CTRs and can be contradicted if additional context, such as the comparison of outcomes between the cohorts, is considered.</s>"
    },
    "18d9991c-ca96-4bab-93af-77654857a07f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial does not accept patients with grade 1 alopecia.",
        "Label": "Entailment",
        "entail": "The CTR states that \"existing anti-cancer therapy-related toxicities of Grade \u2265 2, except that alopecia and Grade 2 neuropathy are acceptable.\" Therefore, patients with Grade 1 alopecia are not explicitly excluded in the CTR, but they do not meet the inclusion criterion since their toxicity level is below Grade 2. Thus, the statement from the expert that the primary trial does not accept patients with Grade 1 alopecia is entailed by the information present in the CTR.</s>",
        "contradict": "The primary trial's inclusion criteria state that \"alopecia and Grade 2 neuropathy are acceptable\" (emphasis added). Therefore, the statement that the primary trial \"does not accept patients with grade 1 alopecia\" contradicts the provided information in the CTRs.</s>"
    },
    "18d9991c-ca96-4bab-93af-77654857a07f_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "The primary trial accepts patients with grade 1 alopecia.",
        "Label": "Contradiction",
        "entail": "The primary trial inclusion criteria state that \"grade 2 neuropathy is acceptable.\" While grade 1 alopecia is not explicitly stated as an acceptable inclusion criteria, it is listed as an acceptable toxicity, which is less severe than grade 2. Therefore, it can be inferred that patients with grade 1 alopecia would be considered eligible based on the less stringent criterion. This inference aligns with the information in the CTRs, which do not exclude participants with grade 1 alopecia.</s>",
        "contradict": "The statement \"The primary trial accepts patients with grade 1 alopecia\" can be contradicted by the information present in the CTRs because while the primary trial may accept patients with grade 1 alopecia, other exclusion criteria listed in the CTRs, such as \"existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable,\" do not explicitly state that grade 1 alopecia is an acceptable condition, but instead only mention grade 1 and 2 alopecia as exceptions for acceptable toxicities. This subtle difference in phrasing implies that only grade 2 alopecia and higher are explicitly acceptable, not grade 1. Therefore, the statement can be contradicted by the more precise and comprehensive information provided in the CTRs.</s>"
    },
    "18d9991c-ca96-4bab-93af-77654857a07f_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "Patients with grade 1 alopecia are not accepted in the primary trial.",
        "Label": "Entailment",
        "entail": "according to the CTR, patients with alopecia of any grade are considered eligible for the primary trial, but they must meet all other inclusion criteria. The statement \"Patients with grade 1 alopecia are not accepted in the primary trial\" is in contradiction to the CTR as it incorrectly states that patients with grade 1 alopecia are excluded. Therefore, it cannot be entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"Patients with grade 1 alopecia are not accepted in the primary trial.\" contradicts the information in the CTR, as grade 1 alopecia is listed as an acceptable toxicity in the primary trial's exclusion criteria. The statement incorrectly assumes that grade 1 alopecia is a reason for exclusion, while the CTR explicitly states that it is acceptable for trial participants.</s>"
    },
    "6fb9056d-277c-4dc2-9b45-d7661bb41831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography.",
        "Label": "Contradiction",
        "entail": "The statement \"Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography\" can be entailed by the information in the CTRs as follows:\n\n1. In the primary trial, participants in cohort 1 undergo Mammography as stated in the INTERVENTION for Intervention 1.\n2. In the secondary trial, participants in cohort 1 receive 6 mg of Estradiol daily (2 mg tid) as specified in the INTERVENTION for Intervention 1. The statement mentions this dose as a supplementation for Mammography, aligning with the information in the CTR that Mammography is performed without any explicit mention of additional treatments. Therefore, it can be inferred that this Estradiol supplementation is administered alongside Mammography. \n\nHence, the statement that participants in the first cohort of the primary trial undergo Mammography, while those in the first cohort of the secondary trial receive 6 mg Estradiol as a supplementation for Mammography, is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol as supplementation for the Mammography\" can be contradicted by the information present in the CTRs, as the primary trial's cohort 1 did not receive any form of hormonal supplementation with estradiol during their mammography. Instead, only mammography was performed. Therefore, the statement's assertion that participants in the secondary trial's cohort 1 receive estradiol as a supplement during mammography contradicts the information in the primary CTR.</s>"
    },
    "52b23601-2276-4634-96c7-8b6e55596085": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Entailment",
        "entail": "The statement \"A single patient in the primary trial experienced a clinically significant inflammation of the back of the throat\" can be entailed by the information present in the CTRs if the inflammation of the back of the throat falls under the category of acute pharyngitis. This condition is listed as one of the adverse events in the primary trial, with an occurrence rate of 1.59% (or one patient out of 63) in the total cohort. The statement does not contradict the CTRs, and the patient's experience aligns with the provided data.</s>",
        "contradict": "The statement does not provide enough specific information to be directly contradicted or entailed by the data in the CTRs. The statement mentions \"inflammation of the back of the throat,\" which is not explicitly mentioned or ruled out in the CTR data. Therefore, it is neither contradictory nor entailed by the information provided. However, if additional information is available, such as the patient's identification and the presence or absence of \"acute pharyngitis\" in the CTR, the statement could potentially be evaluated for entailment or contradiction accordingly.</s>"
    },
    "52b23601-2276-4634-96c7-8b6e55596085_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "No patient in the primary trial experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Contradiction",
        "entail": "The statement \"No patient in the primary trial experienced a clinically significant inflammation of the back of the throat\" is not directly entailed by the information present in the CTR. The CTR mentions only one occurrence of pharyngitis (inflammation of the back of the throat), which is not considered clinically significant according to the CTR's reporting (it is categorized under \"Acute Pharyngitis\" with a frequency of 1/63). The statement's claim of \"clinically significant\" is not explicitly stated or entailed in the CTR.</s>",
        "contradict": "The expert's statement \"No patient in the primary trial experienced a clinically significant inflammation of the back of the throat\" is contradicted by the CTR information as one patient in the primary trial did experience Acute Pharyngitis, which is a condition involving inflammation of the back of the throat.</s>"
    },
    "52b23601-2276-4634-96c7-8b6e55596085_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "A clinically significant inflammation of the back of the throat was experienced by a single patient in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A clinically significant inflammation of the back of the throat was experienced by a single patient in the primary trial\" can be entailed by the information present in the CTR under Adverse Events 1, with the occurrence of Acute Pharyngitis (1/63, 1.59%). This statement is harmonious with the clinical trial data, finds substantiation in the CTR, and does not contradict the provided descriptions. The term \"clinically significant\" is implicitly included in the definition of \"Adverse Events\" in a clinical trial context, as the events reported are assumed to have clinical relevance.</s>",
        "contradict": "The expert's statement \"A clinically significant inflammation of the back of the throat was experienced by a single patient in the primary trial\" cannot be definitively contradicted by the information present in the CTR, as the CTR does not provide information about any inflammation of the back of the throat specifically. However, it is worth noting that the term \"pharyngitis,\" which is inflammation of the pharynx (back of the throat), is mentioned only once in the primary trial data, and the description is ambiguous, only mentioning \"Acute Pharyngitis\" without specifying the severity or clinical significance of the condition. Thus, the expert's statement could be consistent with the CTR, depending on whether the expert's definition of \"clinically significant\" inflammation matches the definition of \"acute\" or not. However, the statement should be regarded as less specific than the data reported in the trial. Therefore, it does not entail the information in the CTR but may be consistent.</s>"
    },
    "95e05332-4926-4381-90a4-87941269e7bf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved partial response (PR).",
        "Label": "Contradiction",
        "entail": "The statement \"More than 5% of the primary trial participants achieved partial response (PR)\" can be entailed by the information in the CTR through the following reasoning:\n\n1. According to the Primary Trial's Outcome Measurement section, the response measurement includes partial response (PR).\n2. The Results 1 section of the Primary Trial specifies that the overall number of participants analyzed is 41.\n3. To determine if more than 5% of participants had a partial response, we need to find the number of participants with PR.\n4. The information in the Results 1 section does not provide the exact number of participants with PR. However, it does mention the overall number of participants, implying that the number of participants with PR can be determined from the provided data.\n5. Since we do not have that information directly stated in the CTR, it's an assumption that the data could be available in the full report but was not included in the excerpt provided.\n6. If the assumption is correct, we can calculate the percentage of participants with PR by dividing the number of participants with PR by the overall number of participants (41) and then multiplying by 100 to find the percentage.\n7. If more than 5% of participants had a PR, the statement made by the clinical trial expert is entailed by the information present in the CTR.\n\nHowever, if the full CTR report does not provide the number of participants with PR, then the statement would not be entailed by the information in the CTR.</s>",
        "contradict": "The information in the statement \"More than 5% of the primary trial participants achieved partial response (PR)\" cannot be definitively determined as either entailing or being contradicted by the information in the CTRs, as there is no direct data provided in the CTRs regarding the number of participants achieving PR. The CTR reports only the overall number of participants analyzed and the number of participants with objective response, which includes both CR and PR, but not their specific proportions. Hence, the statement's claim goes beyond the information provided in the CTRs.</s>"
    },
    "20d51467-b059-4f39-b636-d32f2dc692da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions orally.",
        "Label": "Contradiction",
        "entail": "In the primary trial, paclitaxel is administered intravenously, but the administration of suramin, which is part of intervention 1, is done orally during the week before paclitaxel infusion, making it a partial oral administration. In the secondary trial, both ipatasertib and placebo are administered orally as daily medications alongside intravenous paclitaxel. Therefore, the statement that both primary and secondary trials at least partly administer their interventions orally is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Both the primary trial and the secondary trial at least partly administer their interventions orally\" is not a contradiction to the information in the CTRs. However, the statement does not accurately reflect the full scope of intervention administration methods used in both trials. In the primary trial, Suramin is infused intravenously, while Paclitaxel is administered intravenously as well but with a different schedule compared to the secondary trial. In contrast, in the secondary trial, Ipatasertib is administered orally, and Paclitaxel is administered intravenously, as stated in the CTRs. Therefore, while the statement is not contradictory, it is not entirely accurate either. The statement focuses only on the oral administration portion of the interventions but fails to acknowledge the differences in routes of administration for Suramin and Paclitaxel between trials.</s>"
    },
    "15c83d26-f9ba-44cc-a920-6941781cdd8b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia affected the majority of patients in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Neutropenia affected the majority of patients in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nIn the Primary Trial, Adverse Events Section 1, Neutropenia occurred in 4 out of 69 patients (5.80%). This percentage represents the proportion of participants with neutropenia in cohort 1. Since a majority can be defined as more than 50% of the population, having 4 out of 69 patients (approximately 5.8%) affected by neutropenia is close to, but not quite, a majority. However, if we consider \"affected the majority\" as a term with a degree of flexibility, allowing it to refer to a significant proportion of the population, then the statement can be considered entailed by the information in the CTR.\n\nAdditionally, the statement does not contradict any information in the CTR, nor does it assert anything beyond what can be inferred from the provided data.</s>",
        "contradict": "The statement \"Neutropenia affected the majority of patients in cohort 1 of the primary trial\" cannot be directly contradicted by the provided CTR data. However, the statement can be contradicted if we consider the percentage of patients with neutropenia in relation to the total patient count in cohort 1. The CTR data shows that only 5.80% of patients in cohort 1 experienced neutropenia. This percentage is not considered the \"majority.\" The discrepancy between the statement and the CTR data lies in the use of the term \"majority\" which can be misinterpreted to mean a larger number than 50%, while the actual percentage given in the CTR is below that threshold.</s>"
    },
    "e100212f-5bef-4f84-a3c1-d18a6b3e8355": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial has a shorter time frame than the secondary trial, both of these studies employ the same units of measure in their evaluation\" is entailed by the information present in the CTRs because:\n\n1. The time frame for the outcome measurement in the primary trial (the first of 4, 21 Day Chemotherapy Cycles) is shorter than the time frame for the outcome measurement in the secondary trial (6 months).\n2. Both trials use the same unit of measure for reporting duration, which is days.</s>",
        "contradict": "Although both trials utilize the same units of measure (days for the primary trial and months for the secondary trial), the comparison made in the statement is incorrect because the time frames being compared are not directly applicable. The primary trial evaluates the duration of moderate neutropenia post-first chemotherapy administration for a specific time frame within each 21-day chemotherapy cycle, while the secondary trial assesses the number of patients experiencing Congestive Heart Failure (CHF) during a 6-month time frame while on active treatment. Therefore, their time frames are not directly comparable, and the statement does not hold entailment to the information in the CTRs.</s>"
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Entailment",
        "entail": "The statement entails that the primary trial is investigating the use of a novel radiotracer, specifically 89Zr-trastuzumab, for visualizing HER2+ lesions. The CTR of the primary trial states that \"89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions\" (INTERVENTION 1 section). Therefore, the trial's purpose, as described by the expert, is an accurate reflection of the information provided in the CTR.</s>",
        "contradict": "The statement from the clinical trials expert does not contradict the information in the CTR, but it is not a complete representation of it. The statement focuses specifically on the testing of 89Zr-trastuzumab for visualization of HER2+ lesions in the primary trial. However, the CTR also mentions that 89Zr-pertuzumab may allow for specific visualization of HER2+ lesions, and that both radiotracers are used for PET/CT imaging to evaluate all identifiable malignant lesions in the trial. Thus, the statement does not contradict the CTR, but it may not fully capture the extent of the interventions being tested in the trial.</s>"
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "The primary trial isn't testing a novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information in the CTRs as it contradicts the description of the primary trial's intervention section. The CTR explicitly states that \"89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions\" and \"PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions,\" whereas the statement asserts that the primary trial \"isn't testing a novel radiotracer called 89Zr-trastuzumab for visualization of HER2+ lesions.\"</s>",
        "contradict": "The statement contradicts the CTR information in the primary trial by asserting that 89Zr-trastuzumab isn't being tested for visualization of HER2+ lesions in that trial, while the CTR clearly states that 89Zr-trastuzumab is a novel radiotracer used to allow excellent visualization of HER2+ lesions in the context of HER2- targeted PET/CT.</s>"
    },
    "56d2a387-49dd-49b9-93bb-bcb092bf2714_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "A novel radiotracer called 89Zr-trastuzumab to evaluate its use for visualization of HER2+ lesions is being tested by the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement entails the information in the CTR as it accurately reflects that a novel radiotracer, specifically 89Zr-trastuzumab, is being used in the primary trial for visualization of HER2+ lesions, which aligns with the description in the CTR.</s>",
        "contradict": "While the statement acknowledges the testing of a novel radiotracer (89Zr-trastuzumab) for visualization of HER2+ lesions, it does not explicitly mention the primary trial or the fact that it is being used in conjunction with another novel radiotracer (89Zr-pertuzumab) and PET/CT imaging as stated in the CTRs. Therefore, the statement's scope is narrower than the information in the CTRs, leaving room for potential contradictions or misalignments.</s>"
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their prior treatments.",
        "Label": "Entailment",
        "entail": "The statement \"Participants of the primary trial are assigned an intervention depending on their prior treatments\" is entailed by the CTR information because: \n\n1. According to the CTR, participants in the Primary Trial receive different interventions based on their prior use of Trastuzumab.\n2. In CTR Intervention 1, participants have undergone prior Trastuzumab treatment, and they receive Neratinib 240 mg daily.\n3. In CTR Intervention 2, participants do not have prior Trastuzumab treatment, and they also receive Neratinib 240 mg daily. \n4. Thus, the statement \"Participants of the primary trial are assigned an intervention depending on their prior treatments\" is a consequence of the given trial information.</s>",
        "contradict": "The statement \"Participants of the primary trial are assigned an intervention depending on their prior treatments\" is not directly contradicted by the information in the CTRs. However, the statement does not fully capture the specifics outlined in the CTRs. The CTRs detail that the assignment of interventions in the primary trial is based on prior trastuzumab treatment, but the statement does not mention trastuzumab explicitly. This subtle difference may lead to potential confusion and misinterpretation of the information. However, the statement does not contradict any data in the CTRs.</s>"
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial aren't assigned an intervention depending on their prior treatments.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants of the primary trial aren't assigned an intervention depending on their prior treatments\" is entailed by the information in the CTRs because both intervention descriptions list the same dose and dosage form of Neratinib (240mg daily with 80mg capsules and 40mg coated tablets) for both groups - those with prior Trastuzumab treatment (INTERVENTION 1) and those without prior Trastuzumab treatment (INTERVENTION 2). Therefore, the intervention assignment doesn't depend on the participants' prior treatments, as claimed in the statement.</s>",
        "contradict": "The information in the CTRs contradicts the statement as the assignment of Intervention 1 (Neratinib with prior Trastuzumab treatment) and Intervention 2 (Neratinib without prior Trastuzumab treatment) is explicitly stated to depend on participants' prior Trastuzumab treatment status.</s>"
    },
    "2485a3e1-7520-47d2-b941-32ebf91e5b65_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": " Depending on their prior treatments participants of the primary trial are assigned an intervention.",
        "Label": "Entailment",
        "entail": "The statement \"Depending on their prior treatments, participants of the primary trial are assigned an intervention\" can be entailed by the information in the CTRs since the reports clearly specify that the trial involves two intervention groups: one for participants with prior trastuzumab treatment and another for those with no prior trastuzumab treatment. The CTRs state that the intervention for the first group includes Neratinib 240mg daily, and for the second group also Neratinib 240mg daily. This means that participants are indeed assigned a specific intervention based on their prior treatment history, as stated in the expert's comment.</s>",
        "contradict": "The statement \"Depending on their prior treatments participants of the primary trial are assigned an intervention\" is not a direct contradiction of the information in the CTRs, but it is an oversimplification that could potentially be misleading without proper context. The CTRs clearly state that participants in the primary trial are assigned different interventions based on their prior trastuzumab treatment status, but they do not explicitly state that this is the only factor influencing the intervention assignment. There could be other factors at play that are not mentioned in the CTR excerpt provided. Therefore, while the statement is not an outright contradiction, it may not fully capture the complexity of the trial design as described in the CTRs.</s>"
    },
    "b97d9465-db14-43af-9451-4b824e67abb8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs because each trial has distinct inclusion criteria, meaning patients may meet the requirements for one trial but not the other, depending on factors such as the presence or absence of certain conditions, treatments, and laboratory values. The CTRs detail these differences in their respective inclusion criteria sections, thereby supporting the statement.</s>",
        "contradict": "The statement is not contradictory to the CTR information, but it does not directly entail it either. While the CTRs do indeed specify different inclusion criteria for their respective cohorts, the statement correctly identifies this fact without asserting any specific contradictory or entailing relationship between the CTRs or their patient populations.</s>"
    },
    "798c0983-5265-47ea-bfcd-735738793482": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently been receiving Tamoxifen to treat breast cancer, they are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The patient being excluded from the primary trial due to prior Tamoxifen treatment aligns with the CTR's exclusion criterion. The primary trial states that prior endocrine therapy is not allowed. Tamoxifen is a type of endocrine therapy, and the statement's assertion falls in harmony with this exclusion criterion.</s>",
        "contradict": "The patient described in the expert statement is excluded from the primary trial based on prior endocrine therapy with Tamoxifen for breast cancer. However, the CTR specifies that prior endocrine therapy for breast cancer, including Tamoxifen, is not allowed within the 5 years preceding the trial start, but allows for its use more than 5 years before for the prevention of breast cancer in patients with no history of breast cancer. The expert statement contradicts the CTR as it does not acknowledge the 5-year window for prior endocrine therapy with Tamoxifen.</s>"
    },
    "798c0983-5265-47ea-bfcd-735738793482_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently been receiving Tamoxifen to treat breast cancer, they aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail any information from the CTRs as it mentions \"a patient has recently been receiving Tamoxifen to treat breast cancer,\" which is not specified in the provided inclusion or exclusion criteria for the primary trial. However, the statement does not contradict the CTR information and does not exclude a patient who has received Tamoxifen from participating in the trial based on the given eligibility criteria.</s>",
        "contradict": "The statement \"A patient has recently been receiving Tamoxifen to treat breast cancer, they aren't excluded from the primary trial\" can be contradicted by the information in the CTRs for the following reasons:\n\n1. The primary trial specifies that prior endocrine therapy is not allowed for patients. Since the patient mentioned in the statement has been receiving Tamoxifen, which is an endocrine therapy, they would not meet the eligibility criteria as stated in the CTR.\n\n2. The patient's current status of receiving Tamoxifen also implies they have a history of breast cancer. However, the primary trial excludes patients with prior history of breast cancer. Therefore, this statement contradicts the eligibility criteria stated in the CTR.\n\n3. Additionally, the statement does not mention whether the patient has undergone surgery for their breast cancer or is currently planning to undergo surgery, which is a requirement for the primary trial. Therefore, even if the patient was previously diagnosed with breast cancer and completed Tamoxifen treatment, they would not meet the eligibility criteria due to the exclusion of systemic drug treatment to induce ovarian suppression for pre-menopausal women, which the statement does not address.</s>"
    },
    "798c0983-5265-47ea-bfcd-735738793482_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "An exclusion criteria of the primary trial is recently receiving Tamoxifen to treat breast cancer.",
        "Label": "Entailment",
        "entail": "The statement \"An exclusion criteria of the primary trial is recently receiving Tamoxifen to treat breast cancer\" is entailed by the information present in the CTRs. The CTR states that \"Prior endocrine therapy for any histologically confirmed cancer is not allowed.\" Tamoxifen is an endocrine therapy for breast cancer. Therefore, patients receiving Tamoxifen are excluded from the study, as stated in the CTR.</s>",
        "contradict": "The statement \"An exclusion criteria of the primary trial is recently receiving Tamoxifen to treat breast cancer\" contradicts the information present in the CTRs because the CTRs state that \"Prior endocrine therapy for any histologically confirmed cancer is not allowed, except for prior endocrine therapy that was administered 5 years ago for the prevention of breast cancer in patients with no history of breast cancer.\" Tamoxifen is an endocrine therapy used in the prevention and treatment of breast cancer. Therefore, patients who have received Tamoxifen within the past 5 years would not meet the eligibility criteria for the primary trial, but the statement incorrectly identifies this as an exclusion criterion.</s>"
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention.",
        "Label": "Entailment",
        "entail": "The statement \"Neither the primary trial nor NCT0306117 use chemotherapy or radiotherapy in their intervention\" can be entailed by the information present in the CTRs because:\n\n1. The primary trial's two intervention groups, INTERVENTION 1 and INTERVENTION 2, do not include chemotherapy or radiotherapy within the text message management and web-based CPM-DA interventions described.\n2. The secondary trial's two intervention groups, Arm I and Arm II, also do not involve chemotherapy or radiotherapy. In Arm I, participants receive a web-based CPM-DA and undergo ancillary studies, while Arm II participants undergo usual care and receive information from a medical oncologist about CPM but do not receive chemotherapy or radiotherapy directly as part of this trial.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly, as chemotherapy and radiotherapy are not mentioned in the provided intervention details. However, it can be contradicted by unmentioned sections of the CTRs or by other trials not specified in the description. The statement only assesses the presence or absence of chemotherapy or radiotherapy in the stated interventions, while the CTRs may include additional information about interventions in different trials or arms.</s>"
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Both the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention.",
        "Label": "Contradiction",
        "entail": "The statement \"Both the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention\" does not explicitly entail information directly from the provided CTRs as the interventions described in the CTRs do not involve chemotherapy or radiotherapy, but rather text message management prompts for one arm and web-based CPM-DA and usual care for another arm in the secondary trial. However, it's essential to note that the primary trial's intervention does not have enough information to rule out the presence of chemotherapy or radiotherapy. Therefore, the statement may still potentially be true given the context of the clinical trials. However, the statement does not strictly follow from the given CTR information. The CTRs do not entail the statement but do not contradict it either.\n\nFor the primary trial, the intervention text does not mention the use of chemotherapy or radiotherapy; it only describes the text message management prompts. For the secondary trial, both arms involve interventions different from chemotherapy or radiotherapy.\n\nThus, while the statement is plausible, it does not follow strictly from the given information. In a larger context, if there were additional trials or information indicating that chemotherapy or radiotherapy was used in one or both trials, the statement would be entailed. However, with the current information, it does not follow strictly from the provided CTRs.</s>",
        "contradict": "The statement \"Both the primary trial or NCT0306117 use chemotherapy or radiotherapy in their intervention\" cannot be directly contradicted by the information in the provided CTRs. However, it does not entail semantic equality as neither trial explicitly states the use of chemotherapy or radiotherapy in their interventions. The primary trial mentions text message management prompts for managing hot flashes and vaginal dryness, and the secondary trial mentions a web-based CPM-DA (Cognitive Behavioral Therapy for Insomnia and Dysoxenia) and usual care. Neither description includes chemotherapy or radiotherapy, thus the statement falls short of entailing the information within the CTRs.</s>"
    },
    "127e9179-6781-4b9a-abe9-080d2ffad591_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither NCT02176083 or the secondary trial use chemotherapy or radiotherapy in their intervention.",
        "Label": "Entailment",
        "entail": "The statement \"Neither NCT02176083 or the secondary trial use chemotherapy or radiotherapy in their intervention\" is entailed by the information in the CTRs as neither the primary nor the secondary trial mentions the use of chemotherapy or radiotherapy in their intervention sections. In the primary trial, participants in both intervention arms receive text message management prompts and access to a web-based Comprehensive Pain Management and Decision Aid (CPM-DA) system, but there is no mention of chemotherapy or radiotherapy. Similarly, in the secondary trial, patients in Arm I undergo usual care and are administered surveys for ancillary studies, while patients in Arm II receive information from a medical oncologist about CPM but no details of chemotherapy or radiotherapy are provided. Therefore, the statement is consistent with the information in the CTRs and is entailed by it.</s>",
        "contradict": "The statement \"Neither NCT02176083 or the secondary trial use chemotherapy or radiotherapy in their intervention\" does not contradict the information in the CTRs. However, it does not entail it as well since the statement only mentions the absence of chemotherapy and radiotherapy, while the CTRs explicitly describe the interventions as text message management for hot flashes and vaginal dryness in the primary trial, and web-based CPM-DA and usual care in the secondary trial, without any mention of chemotherapy or radiotherapy. Therefore, the statement is neither contradictory nor entailing based on the provided information. However, the statement is consistent with the data in the CTRs.</s>"
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial.",
        "Label": "Entailment",
        "entail": "Agatha's eligibility for the primary trial is confirmed as she satisfies the inclusion criteria: female, 18-70 years old, adenocarcinoma of the breast, no evidence of metastatic disease. Her age (50 years old) falls within the specified range, her breast cancer type and absence of metastasis align with the criteria.\n\nAgatha is not eligible for the secondary trial due to not meeting some of its inclusion criteria: she is not of the specified age range (not between 52-75 years old), ethnicity (not Latina/Hispanic/Chicana), and residency (does not reside in the specified locations). Furthermore, she has a history of breast cancer, which is an inclusion criterion for the primary trial but a exclusion criterion for the secondary trial. Therefore, Agatha's eligibility status as described in the expert statement is consistent with the information provided in the CTRs.</s>",
        "contradict": "Agatha's eligibility for the primary trial is based on having adenocarcinoma of the breast and no evidence of metastatic disease, which is in line with the primary trial's inclusion criteria. However, her age (50 years old) falls outside the primary trial's age range (18-70 years). Therefore, she may not be eligible for the primary trial despite meeting some inclusion criteria.\n\nHowever, the reason Agatha is not eligible for the secondary trial is not directly contradictory to the primary trial's information. Her ineligibility for the secondary trial is based on her age not falling within the age range specified (52-75) and her ethnicity not being Latina/Hispanic/Chicana. These criteria are distinct from those in the primary trial.\n\nThe information in the statement does not contradict the primary trial's inclusion criteria, but Agatha's age and ethnicity render her ineligible for the secondary trial.</s>"
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 50th birthday last week, she hases a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the secondary trial but not the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the secondary trial but not the primary trial\" is entailed by the information present in the CTRs as follows:\n\nAgatha's age (50 years old) falls within the secondary trial's age range (52-75 years old). She has a histologically confirmed adenocarcinoma of the breast which fulfills the inclusion criteria for both trials. However, her eligibility for the secondary trial is further conditioned on her being a Latina/Hispanic/Chicana female, residing in Pilsen, Little Village, East Side or South Chicago, having no history of health volunteerism, and lacking a mammogram within the last two years \u2013 none of which are mentioned in the statement. Therefore she is only eligible for the secondary trial but not the primary trial as stated, due to the different eligibility criteria in each trial.\n\nThe statement does not contradict any information in the CTRs, as it does not claim Agatha has a severe hypersensitivity reaction to Taxotere, previous treatment with certain medications, or a mammogram in the last two years.\n\nAdditionally, Agatha's eligibility for the secondary trial despite having a prior invasive breast cancer (if diagnosed more than 5 years before entering the study) is also in line with the secondary trial's inclusion criteria which do not exclude such patients. Therefore, the statement is semantically entailed by the information present in the CTRs.</s>",
        "contradict": "Agatha's eligibility for the secondary trial is determined by her age (50-75 years old), ethnicity (Latina/Hispanic/Chicana), residence, health volunteerism history, and lack of breast cancer diagnosis and recent mammogram. However, the primary trial's eligibility criteria specify that patients must be female, 18-70 years old, have adenocarcinoma of the breast, no evidence of metastatic disease, and no severe hypersensitivity reaction to Taxotere, previous treatment with certain agents, or fluoropyrimidine within the last 5 years. \n\nAgatha's age and breast cancer diagnosis meet the inclusion criteria for the primary trial, but her age is below the specified range for the secondary trial, and she doesn't meet other inclusion criteria for the secondary trial. Therefore, the statement that \" Agatha is eligible for the secondary trial but not the primary trial\" is contradictory to the information in the provided CTRs.</s>"
    },
    "a54e1dfa-3975-4dc6-8530-c0adc79b1b0d_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Since Agatha had her 50th birthday last week, and she has a histologically confirmed adenocarcinoma of the breast with no evidence of metastatic disease, she is not eligible for the secondary trial but is eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Agatha's eligibility for the primary trial is determined by the following criteria from the CTR: female patients, 18-70 years of age, adenocarcinoma of the breast, no evidence of metastatic disease. Agatha meets these requirements: she is female, her age is between 18 and 70, she has breast adenocarcinoma, and there is no evidence of metastatic disease for her.\n\nHowever, her eligibility for the secondary trial is determined by different criteria. These include age, ethnicity, residency, health volunteerism history, breast cancer history, and mammogram history. Agatha does not meet the age requirement (she had her 50th birthday, but the age range for the secondary trial is 52-75), which makes her ineligible for that trial.\n\nTherefore, the statement that \"Agatha is not eligible for the secondary trial but is eligible for the primary trial\" is entailed by the CTR information, as Agatha meets the inclusion criteria for the primary trial and does not meet the inclusion criteria for the secondary trial. This statement does not contradict the CTR descriptions, and its assertion harmonizes with the clinical trial data.</s>",
        "contradict": "Agatha's eligibility for the primary trial is established based on having a histologically confirmed adenocarcinoma of the breast with no evidence of metastatic disease. However, her eligibility for the secondary trial is contingent on additional criteria, namely being between 52-75 years old, identifying as Latina/Hispanic/Chicana, residing in specific Chicago neighborhoods, having no history of breast cancer, and not having had a mammogram in the last two years. \n\nThe statement does not provide evidence that Agatha meets these additional criteria for the secondary trial and, therefore, contradicts the information presented in the CTR for that trial. Consequently, based on the information available, Agatha's eligibility for the secondary trial cannot be determined solely from the statement, making the statement contradictory to the CTR.</s>"
    },
    "16dc5a77-5758-4d19-9801-6e9932d9fbc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "several patients in cohort 1 of the primary trial preferred oral tablets as a Method of Drug Administration.",
        "Label": "Contradiction",
        "entail": "The expert statement \"several patients in cohort 1 of the primary trial preferred oral tablets as a Method of Drug Administration\" cannot be directly entailed by the information in the CTRs since the CTRs only report data on SC and IV drug administration for Cohort 1. Therefore, there is no mention of oral tablet administration or preference for it in the CTR data. The expert statement contradicts the information provided in the CTRs.</s>",
        "contradict": "The statement \"several patients in cohort 1 of the primary trial preferred oral tablets as a Method of Drug Administration\" is contrary to the information presented in the CTRs since oral tablets were not mentioned as an option for administering Herceptin in the given trial. The trial only compared the preferences between SC (Subcutaneous) and IV (Intravenous) methods of Herceptin administration.</s>"
    },
    "2ed770a0-fe98-4029-9511-ad04a94a1a69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. In the primary trial, the proportion of patients with Leukopenia in cohort 2 (1/61 or 1.64%) is higher than that in cohort 1 (0/42 or 0.00%).\n2. In the secondary trial, the proportion of patients with Leukopenia in cohort 1 (2/145 or 1.38%) is higher than that in cohort 2 (0/144 or 0.00%).\n\nTherefore, the statement \"In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia\" is consistent with the data in the CTRs, as it accurately compares the proportions of participants in each cohort with Leukopenia within their respective trials.</s>",
        "contradict": "The statement asserts that cohort 1 in the primary trial had a higher proportion of patients with leukopenia than cohort 1 in the secondary trial. However, the data in the CTRs contradict this claim as both CTRs list the total number of patients with leukopenia in each cohort and neither indicates that cohort 1 in one trial had a higher number than cohort 1 in the other. The statement also asserts that cohort 2 in the primary trial had more patients with leukopenia than cohort 2 in the secondary trial, but there is no information in the given CTRs to support this claim. Therefore, the statement is not entailed by the information in the CTRs.</s>"
    },
    "b4c97206-66fd-468b-8388-fac076222c10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement entails that there is a difference in the frequency of anemia and disseminated intravascular coagulation between the two cohorts in the primary trial. This difference can be determined from the CTR data by observing the number of cases in each cohort for these adverse events. For anemia, there are 1.66% (8 cases) in cohort 1 and 0.84% (2 cases) in cohort 2 of the primary trial, resulting in a difference of 7 cases. For disseminated intravascular coagulation, there is 0.41% (2 cases) in cohort 1 and no cases in cohort 2 of the primary trial, resulting in a difference of 1 case. The statement does not contradict or exceed the information in the CTRs and is semantically entailed by it.</s>",
        "contradict": "The statement does not entail the information in the CTRs because it makes a comparative claim about the number of cases of Anaemia and Disseminated intravascular coagulation between the two cohorts, while the CTRs only report the absolute numbers of these adverse events for each cohort. The statement assumes that the total number of participants in each cohort is the same, which is not explicitly stated in the CTRs. Therefore, the statement can be contradicted if the total number of participants in each cohort is different, which would affect the relative numbers of adverse events.</s>"
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR information as follows: In the primary CTR, there are several conditions mentioned that restrict patients from participating in the trial, including prior thoracic or cardiac surgery, prior ipsilateral chest tube placement, prior neoadjuvant chemotherapy, and prior radiotherapy to the mediastinum. The secondary trial statement generalizes this information by mentioning \"several types of surgical and therapeutic treatments which are banned.\" Therefore, the expert's statement is an accurate reflection and a logical entailment of the information provided in the CTRs.</s>",
        "contradict": "The expert's statement does not provide sufficient detail to determine if it is contradictory to the CTRs' information. The CTRs outline specific procedures and treatments not allowed for patients in each trial, but the expert's statement mentions \"several types of surgical and therapeutic treatments\" without specifying which ones. Some of the treatments not allowed in the primary trial (such as prior neoadjuvant chemotherapy and radiotherapy to the mediastinum) may not be prohibited in the secondary trial. Thus, without more context, it's impossible to definitively determine entailment or contradiction.</s>"
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There aren't several types of surgical and therapeutic treatments which are banned for patients wanting to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not explicitly state which treatments are allowed or disallowed in the primary trial. However, based on the information in the CTR, there are certain conditions for patient inclusion and exclusion, as well as restrictions on prior therapies. These conditions and restrictions can be interpreted as implying that there are indeed some types of surgical and therapeutic treatments that are not allowed. However, the CTR itself does not provide an exhaustive list of all the treatments that are banned. Therefore, the statement does not contradict the CTR and can be considered entailed, as the CTR leaves open the possibility that there are treatments that are not allowed.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial's ELIGIBITY CRITERIA section clearly lists several types of treatments and conditions that are exclusionary for patient participation:\n- No prior thoracic or cardiac surgery\n- No prior ipsilateral chest tube placement\n- No prior neoadjuvant chemotherapy\n- No prior radiotherapy to the mediastinum\n\nThese restrictions contradict the statement, which asserts that there aren't several types of treatments which are banned for patients in the primary trial.</s>"
    },
    "6e22d118-af77-41bd-bd47-9385779f33aa_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "Patients wanting to take part in the primary trial have several types of surgical and therapeutic treatments banned.",
        "Label": "Entailment",
        "entail": "The statement that \"Patients wanting to take part in the primary trial have several types of surgical and therapeutic treatments banned\" is entailed by the CTR information, as follows:\n\n1. Surgical treatments banned:\n   a. No prior thoracic or cardiac surgery (implies no repeat surgeries on the thorax or heart)\n   b. No prior ipsilateral chest tube placement (implies no chest tube in the same side as the tumor)\n   c. Contralateral chest tube placement is allowed, but not banned, so this is not a contradiction.\n2. Therapeutic treatments banned:\n   a. No prior neoadjuvant chemotherapy\n   b. No prior radiotherapy to the mediastinum\n   c. No known allergy to methylene blue or isosulfan blue (implies no use of these drugs)\n\nThese prohibitions are explicitly stated in the CTRs. The expert's statement correctly summarizes these restrictions in a different but equivalent way, making it entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement \"Patients wanting to take part in the primary trial have several types of surgical and therapeutic treatments banned\" is contradicted by the information presented in the CTRs as follows:\n\n1. Contralateral chest tube placement is allowed.\n2. No prior neoadjuvant chemotherapy is specified as a ban, but it is not stated explicitly as allowed either.\n3. No information is provided about the use of radiotherapy to the mediastinum or other areas in the trials.\n\nTherefore, the expert's statement is not an entailed relationship based on the provided CTR data. The trials allow some types of surgical and therapeutic treatments, whereas the statement asserts that several types of treatments are banned.</s>"
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group.",
        "Label": "Entailment",
        "entail": "The statement \"The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group\" can be entailed by the information in the CTRs as follows: \n\nThe CTR provides the Median PFS for the Talazoparib group as 8.6 months (7.2 to 9.3), and the shortest PFS in this group is not explicitly mentioned in the text. However, since the time frame for treatment in the Talazoparib group was until radiographic disease progression or other specified conditions, and the shortest PFS cannot be shorter than the time frame, it must be longer than zero months. Additionally, the statement specifies that the shortest PFS in the Talazoparib group was \"over a month shorter\" than the Median PFS, so the shortest PFS must be between 0 and 7.2 months. Therefore, the existence and duration of a shortest PFS in the Talazoparib group that is over a month shorter than the Median PFS is consistent with the information provided in the CTRs.</s>",
        "contradict": "The statement \"The shortest PFS in the Talazoparib group of the primary trial was over a month shorter than the Median PFS for that group\" does not contradict the information presented in the CTRs, but it can be challenged based on the available data. The given statement assumes that there exists a participant in the Talazoparib arm with a PFS duration shorter than 8.6 months (median PFS), which is not explicitly stated in the CTR. However, the presence of such a participant cannot be ruled out based on the provided information, and it is possible for the shortest observed PFS to be less than the median. Hence, the statement is not an entailed consequence of the CTR data, but a valid inference within the given constraints.</s>"
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial wasn't over a month shorter than the Median PFS for that group.",
        "Label": "Contradiction",
        "entail": "The IRF assessment of PFS in the Talazoparib arm of the primary trial ranged from the reported median of 8.6 months (7.2 to 9.3) up to a maximum of 36.9 months. The shortest PFS value falls within this range and, therefore, cannot be over a month shorter than the median without contradicting the provided data. The statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"The shortest PFS in the Talazoparib group of the primary trial wasn't over a month shorter than the Median PFS for that group\" cannot be directly contradicted by the information presented in the CTRs. However, it may be possible to find a case where the shortest PFS in the Talazoparib group was indeed over a month shorter than the median if we look at individual patient data, which is not provided in the given data. The statement is based on the assumption that the range of PFS durations for the Talazoparib group is known, but the CTR does not provide that detailed information. Therefore, the statement is not necessarily false, but it also does not follow directly from the given information in the CTRs.</s>"
    },
    "ccc5362a-33d0-4f1b-be46-d31729ba9194_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The Median PFS in the Talazoparib group of the primary trial was over a month longer than the shortest PFS.",
        "Label": "Entailment",
        "entail": "The statement \"The Median PFS in the Talazoparib group of the primary trial was over a month longer than the shortest median PFS\" can be entailed by the information present in the CTRs as follows:\n\n1. According to the Primary Trial CTR, the Talazoparib group had a median PFS of 8.6 months (7.2 to 9.3).\n\n2. In the Secondary Trial CTR, the shortest reported median PFS was 5.6 months (4.2 to 6.7).\n\n3. A difference of over a month (approximately 30 days) exists between the two median PFS values [8.6 months vs. 5.6 months].\n\n4. The statement \"The Median PFS in the Talazoparib group of the primary trial was over a month longer than the shortest PFS\" is an accurate representation of this difference and can be derived from the provided data.\n\n5. This statement holds true for both individual trials and does not contradict the information in the CTRs.</s>",
        "contradict": "The statement \"The Median PFS in the Talazoparib group of the primary trial was over a month longer than the shortest PFS\" cannot be directly contradicted by the information provided in the CTRs. However, it is important to note that the shortest PFS mentioned in the statement is not explicitly stated in the CTRs. The CTRs only provide the median PFS for each arm, and the comparison between them does not mention a specific value for the shortest PFS. Therefore, while the statement is not a direct contradiction, it may not be entirely accurate without more context or specification of the value for the shortest PFS.</s>"
    },
    "fa530b28-9142-49f2-aa80-4d04fa532910": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive taping to anastomosis regions., but no  Complex Decongestive Physiotherapy.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR information as follows:\n\nIn the primary trial, group 2 received Complex Decongestive Physiotherapy plus taping to anastomosis regions (as stated in the CTR). However, the statement focuses on group 2 not receiving Complex Decongestive Physiotherapy. Although group 2 received Complex Decongestive Physiotherapy according to the CTR, the statement is true because it is stating that they did not receive this therapy \"exclusively\" or \"only,\" but rather in conjunction with taping to anastomosis regions. The absence of Complex Decongestive Physiotherapy alone in group 2's intervention, as stated in the expert's claim, is indeed a part of the comprehensive intervention described in the CTR for this group.</s>",
        "contradict": "The statement is contradictory to the CTR information because in the primary trial, group 2 participants did receive Complex Decongestive Physiotherapy, along with taping to anastomosis regions. According to the provided CTR descriptions, Complex Decongestive Physiotherapy includes MLD, short-stretch bandages, lymph-reducing exercises, and skin care (as stated for Intervention 1), which is not mentioned in the expert's statement. Therefore, the statement cannot hold true based on the given CTR information.</s>"
    },
    "7cbe445f-2df6-4a87-be6b-7ecc1e80b08b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 had Pyrexia.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the patients in cohort 1 of the primary trial had thrombocytopenia, and none of the patients in cohort 2 had Pyrexia\" is entailed by the data in the given CTRs because:\n\n1) The first condition is met, as no patient in Cohort 1 of the primary trial had thrombocytopenia, since the Adverse Events section reports 0/52 instances (0.00%) among this cohort.\n\n2) The second condition is also met, as no patient in Cohort 2 of the primary trial had Pyrexia, as per the Adverse Events section of the secondary trial reporting 0/21 instances (0.00%).\n\nTherefore, the statement is entailed by the provided CTR data and does not contradict the given descriptions.</s>",
        "contradict": "The statement \"None of the patients in cohort 1 of the primary trial had a thrombocytopenia, and none of the patients in cohort 2 had Pyrexia\" can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, there was one patient (1/52) in cohort 1 with thrombocytopenia (0.00% as stated in the statement, but 1.92% according to the data).\n2. In the primary trial, there were two patients (2/52) in cohort 1 with Pyrexia (3.85% as stated in the statement, but 3.85% according to the data).\n3. In the secondary trial, there were no occurrences of thrombocytopenia or Pyrexia according to the statement, but the CTR is not provided for comparison.\n\nTherefore, the statement's claim of no occurrence of thrombocytopenia in cohort 1 and no occurrence of Pyrexia in cohort 2 of the primary trial contradicts the data presented in the CTR for the primary trial.</s>"
    },
    "41cf791e-ed7a-48e5-af84-eefc9fa41ba7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event.",
        "Label": "Contradiction",
        "entail": "The statement asserts that the frequency of each adverse event in the primary trial was equal, while alcohol poisoning was the most common event in the secondary trial. This can be entailed by the information in the CTRs if we consider that the statement is comparing the prevalence of individual adverse events as proportions within each trial, rather than absolute numbers. In the primary trial, each named adverse event occurred in 3.45% of participants. The secondary trial, however, has a different distribution of adverse events, and alcohol poisoning occurs in 11.11% of participants. This difference in proportions does not contradict the statement that all adverse events in the primary trial were equally prevalent (as proportions) and that alcohol poisoning was more common in the secondary trial.</s>",
        "contradict": "The statement that \"The adverse events in the primary trial were all equally prevalent, whereas in the secondary trial, alcohol poisoning was reported as the most common event\" is contradicted by the provided Clinical Trial Reports (CTRs) data because the information in the primary CTR indicates that no single adverse event was more prevalent than any other (with each event occurring in 3.45% of participants), while the secondary CTR reports a different set of adverse events and identifies alcohol poisoning as occurring in 11.11% of participants, which is not equal in prevalence to the other events reported in the primary CTR.</s>"
    },
    "d417aa7b-6d2c-46f8-812c-426ea60e0328": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were only 3 adverse events in the primary trial which occurred more than twice.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There were only 3 adverse events in the primary trial which occurred more than twice\" can be entailed by the data in the CTRs if and only if \"ATRIAL FIBRILLATION\", \"CARDIAC TAMPONADE\", and \"MALIGNANT PLEURAL EFFUSION\" are considered as the three adverse events that occurred more than twice, since all of them appeared twice in the CTR. The statement does not contradict the CTR and is a valid inference based on the given data.</s>",
        "contradict": "The statement \"There were only 3 adverse events in the primary trial which occurred more than twice\" contradicts the information presented in the CTRs because none of the listed adverse events occurred more than twice in the primary trial. Each adverse event was reported to have occurred only once, with a total of 12 distinct adverse events listed in the CTR.</s>"
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months.",
        "Label": "Entailment",
        "entail": "The expert's statement \"Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months\" can be entailed by the information presented in the CTRs as follows:\n\n1. According to the primary trial CTR, Letrozole patients were exposed to Letrozole for 5 years.\n2. The outcome measurement in the trial was the percent change in Bone Mineral Density (BMD) of the Lumber Spine (L2-L4) measured by dual energy X-ray absorptiometry (DXA) every 6 months for the first 2 years and annually thereafter until 5 years after enrollment.\n3. The median percent change in BMD for the Letrozole group after 24 months was -4.63 (-14.21 to 4.32). This value indicates a decrease in BMD for most patients, as the median is the value that separates the data into two equal halves.\n4. The expert's statement that \"Most patients in the Letrozole group had a decreased BMD after 24 months\" is entailed by the CTR data as it aligns with the observed median percent change in BMD for the Letrozole group after 24 months.</s>",
        "contradict": "The expert's statement, \"Most patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 24 months,\" contradicts the information in the CTR, as the median percent change from baseline for the Letrozole group after 24 months was -4.63, which can be considered a decrease; however, the full range of the percent change was (-14.21 to 4.32). The presence of positive values within this range suggests that not all patients in the Letrozole group had a decreased BMD after 24 months. Consequently, the expert's statement is too generalizing, as it implies that almost all patients in the Letrozole group experienced a decrease in BMD, whereas the data shows that it was true for only some patients.\n\nTherefore, the statement does not entail the information in the CTRs, and it is a potential source of misinformation.</s>"
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "Most patients in the Letrozole group of the primary trial didn't have a decreased Bone Mineral Density of the Lumbar Spine after 24 months.",
        "Label": "Contradiction",
        "entail": "The statement \"Most patients in the Letrozole group of the primary trial didn't have a decreased Bone Mineral Density of the Lumbar Spine after 24 months\" can be entailed by the information in the CTR as follows:\n\nThe median percent change in BMD for the Letrozole group is -4.63 (-14.21 to 4.32). Since the median value represents the middle value of the dataset, this means that half of the participants had a greater percent change than -4.63, and the other half had a smaller percent change. Since percent change can be negative, having a smaller percent change than -4.63 does not necessarily mean a decreased BMD; it could also mean that the BMD remained stable or even increased. Therefore, most patients in the Letrozole group having a smaller percent change than -4.63 implies that most patients didn't have a decreased BMD.</s>",
        "contradict": "The statement \"Most patients in the Letrozole group of the primary trial didn't have a decreased Bone Mineral Density of the Lumbar Spine after 24 months\" is contradictory to the information in the CTRs because the median percent change from baseline for the Letrozole group was -4.63 (-14.11 to 4.32). A negative value for the percent change indicates that on average, patients in this group had a decreased bone mineral density compared to their baseline measurement.</s>"
    },
    "2744cc0a-86e9-4764-ae1c-f10f635dc283_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "A decreased Bone Mineral Density of the Lumbar Spine after 24 months was present in most patients in the Letrozole group of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs because the primary trial's results show that the Letrozole group experienced a median percent change of -4.63 in bone mineral density of the lumbar spine after 24 months. This value falls outside the range of 0, indicating a decrease from baseline. The expert's statement, which asserts that most patients in the Letrozole group had a decreased bone mineral density after 24 months, aligns with these findings. The Tamoxifen and Letrozole combination group's bone mineral density values in the secondary trial do not contradict this conclusion, either.</s>",
        "contradict": "The statement \"A decreased Bone Mineral Density of the Lumbar Spine after 24 months was present in most patients in the Letrozole group of the primary trial\" can be contradicted by the information present in the CTRs as follows:\n\n1. The CTR for the primary trial states that BMD measurements were performed every 6 months for the first 2 years and annually thereafter until 5 years after enrollment. Therefore, 24 months post-enrollment is not an available measurement timepoint for the Letrozole group in the primary trial.\n\n2. The statement claims that a decreased BMD was present in most patients, while the CTR provides the median percentage change and the full range for both the Letrozole and Tam-Let groups, which indicates that some patients in each group had an increase in BMD and others had a decrease. However, without further information, it's impossible to conclude that most patients in the Letrozole group experienced a decreased BMD at 24 months.\n\nThus, the statement cannot be conclusively determined to entail the information present in the CTRs based on the provided data.</s>"
    },
    "2e4717fd-b349-48a3-b751-88674dfaaa18": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy.",
        "Label": "Contradiction",
        "entail": "The statement entails that participants in Cohort 1 of the primary trial have failed or were intolerant to standard therapy, or had no standard therapy available. This aligns with the information in the CTR stating that participants received alobresib based on having failed or been intolerant to standard therapy, or for whom no standard therapy existed. Similarly, the statement entails that participants in Cohort 2 of the secondary trial respond well to standard therapy, which is not explicitly stated in the provided CTRs but is consistent with the common understanding of \"standard therapy\" as an effective treatment.</s>",
        "contradict": "The statement \"In the primary trial cohort 1 patients must have failed or be intolerant to standard therapy, or have no standard therapy available, and cohort 2 patients must respond well to standard therapy\" contradicts the information in the given CTRs because:\n\n1) There is no mention of a separate cohort 2 with good response to standard therapy in the provided primary trial data. Instead, both cohorts received alobresib monotherapy and had either failed or were intolerant to standard therapy or had no standard therapy available.\n\n2) The statement assumes different treatment responses for the two cohorts, whereas the CTRs do not provide any such evidence. In the CTRs, the only distinction is the different dose levels of alobresib administered to cohorts 1 and 2 for the purpose of MTD determination.\n\n3) Since there is no information about cohort 2 responding well to standard therapy in the provided CTRs, it contradicts the assumption made in the statement.</s>"
    },
    "b0c65cd7-8cad-404d-8704-ee074e480f57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the mimimum age limit of 18.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial do not have any overlapping inclusion criteria, apart from the minimum age limit of 18\" is entailed by the information in the CTRs because:\n\n1. In the Primary Trial: \n   - Inclusion: Participants must have previously participated in study 971-ONC-0028-080.\n   - Exclusion: Participants who have not previously participated in study 971-ONC-0028-080.\n\n2. In the Secondary Trial:\n   - Disease Characteristics: Patients must have various disease stages and hormone receptor status, but all have a diagnosis of breast cancer or are at high risk for recurrence.\n   - Patient Characteristics: Participants must be 18 years old and above, but other characteristics such as sex, menopausal status, and performance status are not identical for all patients.\n   - Prior Concurrent Therapy: Participants cannot have had prior immunotherapy or vaccines with specific antigens, prior chemotherapy or concurrent chemotherapy, endocrine therapy or concurrent endocrine therapy, radiotherapy or concurrent radiotherapy, and surgery or concurrent surgery (except for local recurrence), but the time frame since these interventions varies.\n\nThe only overlapping criterion is the minimum age limit of 18, as stated in the given expert statement. No other inclusion criteria overlap between the two trials.</s>",
        "contradict": "The statement can be contradicted by the CTR information because both trials do have overlapping inclusion criteria beyond the minimum age limit of 18. In the primary trial, participation in study 971-ONC-0028-080 is an inclusion criterion, and in the secondary trial, not having previously participated in study 971-ONC-0028-080 is an exclusion criterion. Consequently, these two conditions contradict each other, indicating that there is indeed an overlapping criterion between the two trials.</s>"
    },
    "28e20650-e100-4e30-a319-5eceb69a979d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "1 patient in the primary trial had toxic hepatitis.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial had toxic hepatitis\" can be entailed by the information in the CTR under the Adverse Events section of the Primary Trial, as there is a reported case of \"Hepatotoxicity\" (toxic liver damage), which is a type of hepatitis.</s>",
        "contradict": "The statement \"1 patient in the primary trial had toxic hepatitis\" cannot be definitively contradicted by the information in the CTRs, as the term \"toxic hepatitis\" is not explicitly mentioned. However, it is mentioned that one patient had hepatotoxicity. While hepatotoxicity and toxic hepatitis are related, they are not the same condition. Hepatotoxicity is a broader term that encompasses various types of liver damage, including toxic hepatitis. Therefore, the statement could be a valid inference from the data in the CTR, but it does not exactly match the information presented. It is essential to recognize that the expert's statement and the CTR's data may use slightly different terminologies for the same underlying concept. In this case, the expert's statement is not strictly contradicted but may require clarification.</s>"
    },
    "28e20650-e100-4e30-a319-5eceb69a979d_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "No patient in the primary trial had toxic hepatitis.",
        "Label": "Contradiction",
        "entail": "The statement \"No patient in the primary trial had toxic hepatitis\" can be entailed by the information in the CTR as none of the reported adverse events in the Primary Trial's Adverse Events section included the term \"toxic hepatitis.\" Therefore, the absence of toxic hepatitis cases in the trial data is a logical consequence of the presented information.</s>",
        "contradict": "The statement \"No patient in the primary trial had toxic hepatitis\" is contradicted by the data in the Adverse Events section of the Primary Trial report, which states that one patient (1/112) had Hepatotoxicity, a type of toxic liver injury.</s>"
    },
    "28e20650-e100-4e30-a319-5eceb69a979d_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "The primary trial registered 1 patient with toxic hepatitis.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial registered 1 patient with toxic hepatitis\" can be entailed by the information in the CTRs since the CTR for the primary trial reports an instance of hepatotoxicity (a form of toxic liver damage), which was experienced by 1/112 (0.89%) of the patients. Therefore, the presence of at least one case of hepatotoxicity in the primary trial is consistent with the expert's statement.</s>",
        "contradict": "The expert's statement that \"The primary trial registered 1 patient with toxic hepatitis\" contradicts the information in the CTR because the CTR reports only 1 instance of hepatotoxicity among the 112 participants in the primary trial, not toxic hepatitis specifically. The expert's statement implies a more severe form of hepatotoxicity, potentially leading to incorrect interpretations or conclusions.</s>"
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "The secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP. ",
        "Label": "Entailment",
        "entail": "The statement does not make any claims about the content of the primary or secondary trials that contradict or cannot be inferred from the information provided in their respective CTRs. The statement clarifies the different objectives and outcomes being measured in each trial, which aligns with the information that the CTRs provide regarding their outcome measurements and interventions. The primary trial focuses on the detection of lymph nodes using SentiMag and SiennaXP, while the secondary trial investigates the DLT of interventions with E7389 and different Trastuzumab dosing schedules. The statement neither asserts nor denies anything that contradicts the facts stated within the CTRs, making it an entailed statement.</s>",
        "contradict": "The statement does not provide sufficient information to establish entailment with the provided CTRs due to the following reasons:\n\n1. The primary trial's outcome measurement involves lymph node detection with SentiMag and SiennaXP, while the secondary trial is focused on DLT evaluation, which is not related to lymph node detection.\n2. The statement does not mention any semantic relationship between the outcome measurements or results of the primary and secondary trials. Thus, it is unclear whether there is any entailment relationship between the statements and the CTR information.\n\nAdditionally, it should be noted that the absence of any reported instances of DLTs in the secondary trial results does not necessarily imply that the trials are testing for different things, as the small sample size might not be sufficient to detect any DLTs. However, since the statement specifically mentions that the secondary trial is testing for DLTs while the primary trial is evaluating lymph node detection, it is contradictory based on the information provided in the CTRs.</s>"
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "The secondary trial isn't testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP.",
        "Label": "Contradiction",
        "entail": "The statement \"The secondary trial isn't testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP\" is entailed by the information present in the CTRs as follows: \n\n1. The secondary trial does not report any DLT evaluation. In both Results 1 and 2 of the secondary trial, the Measure Type is listed as 'Number' and the Unit of Measure is listed as 'Participants', but the value is 0. This implies that no DLT cases were observed in either arm during the study. \n\n2. The primary trial, on the other hand, focuses on evaluating the efficacy of lymph node detection by comparing the detection rates using SentiMag and SiennaXP with the standard of care. It does not report any information regarding DLT evaluation.</s>",
        "contradict": "The statement \"The secondary trial isn't testing for the DLT of its interventions, whereas the primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP\" is not directly contradicted by the provided CTRs. However, it does not entail any information derived from them either. The CTRs solely describe the study designs, interventions, and participant numbers for both trials without any mention of the DLT evaluation or comparison between them.</s>"
    },
    "8cf0c320-9486-4531-9212-bb3284b734f1_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "The primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP, whereas the secondary trial is testing for the DLT of its interventions.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial is evaluating the efficacy of lymph node detection through the use of SentiMag and SiennaXP, whereas the secondary trial is testing for the DLT of its interventions\" is entailed by the CTRs as follows:\n\n1. The primary trial is evaluating the efficacy of lymph node detection:\n   - The outcome measurement in the primary CTR is \"Number of Participants With Detected Lymph Nodes\", indicating that the trial aims to assess the effectiveness of the interventions (SentiMag and SiennaXP) in lymph node detection.\n\n2. The secondary trial is testing for DLT:\n   - The outcome measurement in the secondary CTR is \"Number of Participants With DLT\", implying that the trial focuses on safety assessments, specifically the detection and evaluation of adverse reactions to the treatments (E7389 and Trastuzumab).\n\n3. The use of SentiMag and SiennaXP in the primary trial:\n   - In the primary CTR, the Arm/Group Title is \"SiennaXP Injection\" and the description states \"SiennaXP: Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe\".\n\n4. The interventions and their administration in the secondary trial:\n   - In the secondary CTR, the Arm/Group Titles are \"E7389 With Weekly Trastuzumab\" and \"E7389 With Tri-weekly Trastuzumab\". The descriptions indicate that both trials involve the administration of Eribulin mesylate (E7389), but with differing schedules for Trastuzumab (weekly vs. tri-weekly).\n\nThus, the information in the statement can be entailed by the CTRs as it accurately reflects and summarizes the content, goals, and interventions of the two separate trials.</s>",
        "contradict": "The statement does not provide any specific information regarding the clinical trials or their sections, making it impossible to determine if there is any contradiction with the CTRs directly. However, it is mentioned that the primary trial is evaluating \"the efficacy of lymph node detection\" using SentiMag and SiennaXP, and the secondary trial is testing for \"DLT of its interventions.\" This implies that the primary trial is focusing on the effectiveness of the interventions for lymph node detection, while the secondary trial is assessing the safety of the interventions.\n\nThe contradiction arises when considering the sections provided in the CTRs. The primary CTR focuses on the results of a lymph node detection trial using SentiMag and SiennaXP, but it doesn't mention any information about the primary trial's objective or the evaluation of their efficacy. In contrast, the secondary CTR describes two different arms with different dosing schedules for a drug (E7389) and its combination with Trastuzumab, but it doesn't provide information on any lymph node detection trial or its relationship to the primary trial.\n\nThe statement assumes that the primary trial is evaluating the efficacy of the lymph node detection methods, while the secondary trial is assessing the DLT. However, the CTRs alone do not provide clear evidence to substantiate this claim, and the information provided is insufficient for establishing an entailment relationship.</s>"
    },
    "34a75478-e7cc-495e-86c3-d0accdaf1ddd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Entailment",
        "entail": "The statement's conditions are a subset of the inclusion criteria mentioned in the CTR. The statement requires participants to be older than 18, have histologically confirmed stage 4 breast cancer, and have an ECOG performance status of less than 2 (equivalent to 0 or 1) with a life expectancy greater than 6 months. These requirements are identical to or included within the CTR's inclusion criteria. The only difference is that the CTR includes additional details about other requirements, such as prior therapy, tumor size, and time since certain treatments. The statement, however, focuses only on age, histological diagnosis, ECOG, and life expectancy, and these requirements are entailed by the more specific inclusion criteria mentioned in the CTR.</s>",
        "contradict": "The statement \"Participants of the primary trial must be older than 18, have histologically confirmed stage 4 breast cancer, ECOG<2 and a life expectancy exceeding 6 months\" is generally consistent with the inclusion criteria of the primary CTR. However, it can be contradicted by the following specific aspects of the inclusion criteria:\n\n1. Age: The statement specifies that participants must be older than 18, which is already an inclusion criterion mentioned in the CTR. However, the CTR does not exclude participants based on age below 18, meaning that younger patients could potentially be included if they met all other criteria.\n2. ECOG Performance Status: The statement requires ECOG<2, but the CTR permits ECOG performance status 0 or 1.\n3. Life expectancy: The statement states that participants must have a life expectancy exceeding 6 months, but the CTR only requires an estimated life expectancy of greater than or equal to 6 months.\n\nTherefore, the statement is mostly consistent with the primary CTR but can be contradicted in the specific cases where younger patients, participants with ECOG 1, or patients with a borderline life expectancy meet all other inclusion criteria.</s>"
    },
    "47780450-1202-4934-8e50-b29416b124f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen.",
        "Label": "Contradiction",
        "entail": "The statement \"All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen\" can be entailed by the information in the CTRs as follows:\n\n1. The primary trial has two intervention groups: one receiving Letrozole 2.5 mg/day and another receiving Letrozole in combination with Zoledronic Acid. However, both intervention groups in the primary trial receive 2.5 mg/day of Letrozole.\n2. In the secondary trial, there are two intervention groups: one receiving Tamoxifen 20mg/day and another receiving a combination of Tamoxifen and OFS (Ovarian Function Suppression). Despite the differences in the second intervention, all patients in the secondary trial receive the same 20mg daily dose of Tamoxifen.\n\nHence, the statement that \"All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen\" is a semantically entailed statement given the information in the CTRs.</s>",
        "contradict": "The statement \"All the primary trial participants receive the same dose of Letrozole, and all patients in the secondary trial are administered the same dose of Tamoxifen\" is contradicted by the information present in the CTRs because the primary trial involves two interventions, one using Letrozole monotherapy with a dose of 2.5 mg/day, and the other combining Letrozole and Zoledronic Acid with the same dose of Letrozole (2.5mg/day), but different dosage and frequency for Zoledronic Acid (4mg every 6 months). \n\nIn the secondary trial, there are two interventions, one using Tamoxifen monotherapy with a dose of 20mg orally daily, and the other using Tamoxifen in combination with Ovarian Function Suppression (OFS), which could either be Triptorelin (3.75 mg by im injection q28 days for 5 years), surgical oophorectomy, or ovarian irradiation. This indicates that patients in the secondary trial receive different types and methods of interventions, making it incorrect to assert that they all receive the same dose of Tamoxifen.</s>"
    },
    "27421e64-e9f0-42a9-8070-bdfb0ce4ce7c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were 2 cases of severe back pain observed in the primary trial.",
        "Label": "Contradiction",
        "entail": "neither of the CTRs provides sufficient evidence to entail the statement about severe back pain as it is not mentioned in either of the Adverse Events sections. Therefore, the statement cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There were 2 cases of severe back pain observed in the primary trial\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not mention the occurrence or non-occurrence of severe back pain in the trial participants. Therefore, the statement is not contradictory but rather an additional claim that may or may not be entailed by the CTR data, depending on whether such cases were indeed present and reported in the primary trial.</s>"
    },
    "c5e6497a-2e2f-4663-97fd-e73ba8904b0c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis.",
        "Label": "Contradiction",
        "entail": "The statement \"Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Thrombosis\" is entailed by the information present in the CTRs because:\n\n1. Myocarditis was reported in only one participant in each trial, as stated in both Adverse Events 1 sections.\n2. Thrombosis/thrombus/embolism was reported in two participants in the secondary trial, but not in the primary trial. Since the statement refers to the occurrence across all cohorts of both trials, it aligns with the information in the primary trial, where Thrombosis was not reported. Therefore, the statement's assertion (single reported case of Myocarditis and Thrombosis across both trials) harmonizes with the clinical trial data, and there is no contradiction with the provided descriptions.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because:\n\n1. The primary CTR reports one case of Myocarditis (1.37% prevalence) out of 73 participants.\n2. The secondary CTR reports no cases of Myocarditis (0.00% prevalence) out of 43 participants.\n3. The statement asserts there was only one recorded case of Myocarditis across both trials.\n4. However, the primary CTR does report one case, while the secondary CTR reports no cases, leading to a contradiction.\n\nSimilarly, with regards to Thrombosis:\n\n1. The primary CTR does not provide information on Thrombosis occurrences.\n2. The secondary CTR reports two cases of Thrombosis (4.65% prevalence) out of 43 participants.\n3. The statement asserts there was only one recorded case of Thrombosis across both trials.\n4. However, the primary CTR does not provide data on Thrombosis, while the secondary CTR reports two cases, leading to a contradiction.</s>"
    },
    "c4dd814d-f525-465f-abe1-a7975771d57e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolone 3 times per week for 6 doses.",
        "Label": "Contradiction",
        "entail": "The CTR specifies that for Intervention 1 and Intervention 2 in the primary trial, both arms receive the same regimen of Fludarabine, Cyclophosphamide, Cyclosporine (CsA), Natural Killer cells, and Interleukin-2 (IL-2) treatments, with the exception of the IL-2 dosing for patients weighing less than 45 kg versus those weighing 45 kg or more. The statement asserts that participants in the first cohort (presumably the one with weights below 45 kg) receive 5 million units/m^2 less IL-2 than the second cohort, while both receive Methylprednisolone 3 times per week for 6 doses. The CTR's description of the IL-2 dosing for participants under 45 kg (5 million units/m^2) aligns with the statement's assertion regarding the reduced dosage for the lighter weight group. The CTR also states that all participants in both arms receive Methylprednisolone 3 times per week for 6 doses, which is confirmed through the statement's assertion. Therefore, the information in the statement is entailed by the CTRs' description of the trial interventions.</s>",
        "contradict": "The statement \"Participants in cohort 1 of the primary trial weighing less than 45 kg receive 5 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered Methylprednisolon 3 times per week for 6 doses\" cannot be directly contradicted by the information in the CTRs, as the CTRs do not provide information about the administration of Methylprednisolone to participants weighing less than 45 kg or over 45 kg in separate dosing groups. However, the statement can be considered contradictory if the context assumes that the Methylprednisolone administration is part of the Intervention for both cohorts and that the IL-2 dosage adjustment only applies to the IL-2 component of the Intervention. In this case, the CTRs do not support the dosing difference stated for Methylprednisolone.</s>"
    },
    "cfd93077-87c5-458b-8712-e1896929309d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.",
        "Label": "Entailment",
        "entail": "The statement \"One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets\" can be entailed by the information in the CTRs under the Adverse Events section of the Primary Trial for three distinct reasons:\n\n1) Pancytopenia: One patient in the Primary Trial experienced pancytopenia, a condition characterized by an abnormally low count of all three types of blood cells: red blood cells, white blood cells, and platelets.\n\n2) Neutropenia and Febrile Neutropenia: One patient each in the Primary Trial exhibited neutropenia and febrile neutropenia, which are conditions of decreased white blood cell count and febrile neutropenia being a subtype with a fever, respectively. While the statement doesn't explicitly mention white blood cells, it does imply abnormally low blood cells, which neutropenia entails.\n\n3) Platelets: While the given statement doesn't specifically mention platelets, one patient in the Primary Trial had a recorded event of thrombocytopenia, which is the term for low platelet count. The term \"abnormally low red blood cells, white blood cells, and platelets\" in the statement is a general term for pancytopenia, and the statement is an entailed statement given the information present in the Primary Trial.\n\nSo, the information contained in the statement can be entailed by the information present in the CTRs, as there is a clear correspondence between the statement and the Adverse Events data provided.</s>",
        "contradict": "The statement \"One patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets\" can be contradicted by the information present in the CTRs if the expert is implying that this condition is not accounted for in the reported adverse events. However, the CTRs clearly list three separate instances of neutropenia, pancytopenia, and one instance each of anemia (implied from the term \"abnormally low red blood cells\") and thrombocytopenia (implied from \"abnormally low platelets\"). Thus, the statement does not provide new information and may contradict the trial data if it is used to infer that an additional instance of these conditions occurred without being reported.</s>"
    },
    "cfd93077-87c5-458b-8712-e1896929309d_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "No patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets.",
        "Label": "Contradiction",
        "entail": "The statement \"No patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets\" can be entailed by the information present in the CTRs if we assume that \"abnormally low\" in the statement refers to conditions such as anemia (low red blood cells), neutropenia (low white blood cells), and thrombocytopenia (low platelets), as these are the only types of low blood cell count abnormalities listed in the Primary Trial's Adverse Events section. Since no patient in the trial experienced these conditions (as per the CTR), the statement is entailed.</s>",
        "contradict": "The statement \"No patient in the primary trial had abnormally low red blood cells, white blood cells, and platelets\" cannot be directly contradicted by the information present in the CTR as there is no clear mention of normal or abnormal ranges for red blood cells, white blood cells, and platelets in either trial report. However, it can be contradicted by the presence of adverse events such as Neutropenia, Pancytopenia, and Febrile Neutropenia reported in the primary trial which indicate low levels of neutrophils (a type of white blood cells) in some patients. Therefore, the statement is potentially misleading without further clarification of what constitutes \"abnormally low\" levels of these cells according to the trial's eligibility criteria or standard clinical definitions.</s>"
    },
    "cfd93077-87c5-458b-8712-e1896929309d_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "The primary trial registered a single patient with abnormally low red blood cells, white blood cells, and platelets.)",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial registered a single patient with abnormally low red blood cells, white blood cells, and platelets\" can be entailed by the information present in the CTRs under the \"Adverse Events\" section of the primary trial. Specifically, the statement refers to the conditions of having low red blood cells (anemia or pancytopenia), low white blood cells (neutropenia), and low platelets (thrombocytopenia), all of which are listed in the CTR with occurrences.</s>",
        "contradict": "The statement by the expert does not provide specific numbers or percentages, and the term \"abnormally low\" is subjective. The CTR, on the other hand, specifies the exact number of patients with Neutropenia (white blood cells) and Pancytopenia (all three types of cells) as 1/56 (1.79%). The expert's statement does not entail these figures and may contradict the CTR data depending on how the term \"abnormally low\" is defined.</s>"
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial where all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail the information in the CTRs as it makes a comparison between the prevalence of specific adverse events across two trials and the most common event in the secondary trial, which is not mentioned in the CTRs. However, it does not contradict or negate any information in the CTRs. The statement is an observation based on the prevalence numbers provided in the CTRs and does not conflict with them.</s>",
        "contradict": "The expert's statement is contradictory to the data presented in the CTRs because the primary trial's adverse events were not all equally prevalent. Leukopenia, Thrombocytopenia, Abscess, and several others were reported in only one instance each among the 29 participants (3.45% frequency each). In contrast, in the secondary trial, progression of disease occurred in four instances among the nine participants (44.44% frequency). Therefore, the expert's claim that the adverse events in the primary trial were all equally prevalent is not supported by the trial data.</s>"
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "The adverse events in the primary trial wheren't all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event.",
        "Label": "Contradiction",
        "entail": "The statement \"The adverse events in the primary trial weren't all equally prevalent, whereas in the secondary trial, progression of disease was reported as the most common event\" is entailed by the information in the CTRs because the CTRs report that the adverse event prevalence rates differ between the primary and secondary trials, and progression of disease is reported as a separate adverse event in the secondary trial with a higher prevalence rate (44.44%) compared to the adverse events in the primary trial, which do not have such uniformly low prevalence rates (ranging from 1.03% to 34.48%). The statement does not contradict the CTRs and is a valid observation based on the provided data.</s>",
        "contradict": "The expert's statement is inconsistent with the data in the CTRs due to a misinterpretation of the adverse event prevalence information. The expert's statement asserts that in the primary trial, \"not all adverse events were equally prevalent,\" while in the secondary trial, \"progression of disease was reported as the most common event.\"\n\nHowever, the provided data from the CTRs contradicts this statement. In the primary trial, the total number of adverse events is 8 (27.59%), but there is no mention of each adverse event having an equal prevalence. On the contrary, there are distinct adverse events listed with varying frequencies (e.g., Leukopenia, 1/29; Thrombocytopenia, 1/29; etc.).\n\nIn the secondary trial, the total number of adverse events is 7 (77.78%), and the most common event is \"Progressive Disease,\" which accounts for 44.44% of all reported adverse events. It is essential to recognize that having one adverse event be more prevalent than others does not imply that all other events were equally rare in this trial.\n\nTherefore, the expert's statement that \"not all adverse events were equally prevalent in the primary trial, whereas in the secondary trial, progression of disease was reported as the most common event\" is an incorrect summary based on the provided clinical trial data.</s>"
    },
    "a3faaf85-62c6-430f-acf2-9c5992ee5221_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00503906",
        "Secondary_id": "NCT01142661",
        "Statement": "In the secondary trial, progression of disease was reported as the most common event, whereas in the primary trial all where equally prevalent.",
        "Label": "Entailment",
        "entail": "The statement does not entail the information in the CTRs as the frequency and type of adverse events reported differently between the two trials. The expert's observation refers to the prevalence of \"progression of disease,\" which is not an adverse event mentioned explicitly in the provided data, and the comparison of \"all events being equally prevalent\" in the primary trial contradicts the data showing varying frequencies of different adverse events.</s>",
        "contradict": "The statement \"In the secondary trial, progression of disease was reported as the most common event, whereas in the primary trial all events were equally prevalent\" is contradicted by the CTRs data, as the frequency of the \"Progressive Disease\" event in the secondary trial (44.44%) is notably higher than the frequency of any single event in the primary trial (3.45%) where no event was reported as most common, and all events occurred with similar prevalence (27.59%).</s>"
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar\" is entailed by the CTRs as none of the adverse events sections report \"High blood sugar\" in either trial. Additionally, the frequency of reported adverse events, which includes hyperglycemia (high blood sugar), for both trials is less than 5% for the primary trial and 0% for the secondary trial. This aligns with the statement's claim that less than 5% of cohort 1 in the primary trial and no patients in the secondary trial had high blood sugar.</s>",
        "contradict": "The statement \"Less than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.\" conflicts with the CTR data because the CTRs mention one instance of hyperglycemia in each trial, which represents a form of high blood sugar, but the statement claims that no instances of high blood sugar were reported in the secondary trial.</s>"
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "More than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar\" is entailed by the information present in the CTRs, as:\n\n1. In the primary CTR, there is one instance of hyperglycemia reported in 22 patients (4.55%).\n2. Hyperglycemia is considered a condition indicative of high blood sugar.\n3. Therefore, more than 5% of the primary trial cohort had high blood sugar (as per the definition in the statement).\n4. In contrast, the secondary CTR does not report any instance of high blood sugar or hyperglycemia among its 101 patients.\n5. Thus, 0% of the secondary trial patients were recorded as having high blood sugar.</s>",
        "contradict": "The statement \"More than 5% of cohort 1 of the primary trial had High blood sugar, 0% of the secondary trial patients were recorded as having High blood sugar\" is contradictory to the information presented in the given CTRs because hyperglycemia, which is a manifestation of high blood sugar, is listed as an adverse event in the primary trial with an occurrence rate of 4.55%, but it is not mentioned at all in the secondary trial's adverse events sections.</s>"
    },
    "65e3afbb-70f6-4e1a-89e6-d819f8b95ab6_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "No patients in the secondary trial were recorded as having High blood sugar, and less than 5% of cohort 1 of the primary trial had High blood sugar.",
        "Label": "Entailment",
        "entail": "The statement that \"No patients in the secondary trial were recorded as having High blood sugar, and less than 5% of cohort 1 of the primary trial had High blood sugar\" can be entailed by the information present in the CTRs as follows: The primary trial's Adverse Events section mentions that only one patient (1/22, or 4.55%) in cohort 1 had hyperglycemia, which is a clinical manifestation of high blood sugar. The secondary trial's Adverse Events section does not list any occurrences of high blood sugar (hyperglycemia) at all. Thus, the statement that fewer than 5% of cohort 1 patients in the primary trial had high blood sugar, and no patients in the secondary trial had this condition, is consistent with the information provided in the CTRs.</s>",
        "contradict": "The statement does not entail with the information in the provided CTRs. Contrarily, the CTR for the primary trial indicates that one patient (1/22 or 4.55%) experienced hyperglycemia, which is a form of high blood sugar. This directly contradicts the expert's statement.</s>"
    },
    "335936e4-9eaa-43b3-84fe-6f112c0d0226": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, both Intervention 1 (A) and Intervention 2 (B) involve radiotherapy. The expert's statement is consistent with this since radiotherapy is a common factor in both interventions.\n   \n2. In the primary trial, Intervention 1 (A) includes healing touch therapy. The expert's statement is also consistent with this since it mentions healing touch therapy for all cohorts.\n\n3. In the secondary trial, all participants receive radiation therapy, as stated in the expert's statement and described in the CTR.\n\n4. The healing touch therapy in the secondary trial is not explicitly mentioned in the CTR, but since the statement asserts that \"Radiotherapy and healing touch therapy is used in all cohorts,\" the implication is that it applies to the secondary trial as well, given that radiotherapy is present in both trials.\n\nTherefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Radiotherapy and healing touch therapy is used in all cohorts of the primary trial and the secondary trial\" is contradicted by the information present in the CTRs because in the primary trial, patients in intervention 1 receive real healing touch therapy, while in intervention 2, patients receive sham healing touch therapy. Conversely, in the secondary trial, all patients receive radiotherapy, but only those in the intervention group receive healing touch therapy. Therefore, healing touch therapy is not used in all cohorts within each trial, and it is not used uniformly across the primary and secondary trials.</s>"
    },
    "19921113-538e-4fd2-81a6-6053f2dd6459": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1\" can be entailed by the information in the CTRs as follows:\n\n1. From the CTR of the primary trial, we learn that the number of participants with DLTs in Cohort A (KNp/KAC) is 2 out of 10, which is equivalent to 20.0%.\n2. In Cohort B (KNpCb) of the same trial, the number of participants with DLTs is 4 out of 10, which is equivalent to 40.0%.\n3. Therefore, there is a difference of 20.0% - 40.0% = -20.0% in percentage of participants with DLTs between the two cohorts if we consider Cohort A as the base or reference group.\n4. However, since the statement mentions that there is a 38% \"more\" DLTs in Cohort 2 than in Cohort 1, we need to find the absolute difference in the number of participants with DLTs and divide it by the number of participants in Cohort 1 to obtain the percentage difference relative to Cohort 1, as follows:\n   Absolute difference = 4 - 2 = 2\n   Percentage difference = 2 / 10 * 100 = 20%\n5. Then, to find the percentage increase in Cohort 2 compared to Cohort 1, we need to add the percentage difference to 100% (since Cohort 1 is the base), and finally subtract the result from 100% to obtain a percentage increase:\n   Percentage increase = 100% + 20% - 100% = 20%\n6. Finally, since the statement mentions a 38% \"more\" DLTs in Cohort 2 than in Cohort 1, we need to multiply the percentage increase by 2 to obtain the correct percentage difference:\n   Percentage difference = 2 * 20% = 40%\n7. Therefore, the percentage difference of 40% between the two cohorts is equivalent to a 38% \"more\" DLTs in Cohort 2 than in Cohort 1. Hence, the statement is entailed by the information in the CTRs.\n\nTherefore, the information in the statement can be entailed by the information present in the CTRs since the statement correctly reports a 40% difference in the proportion of participants with DLTs between the two cohorts, which is derived from the given data in the CTRs. However, the statement uses the term \"38% more\" instead of \"38% greater\" or \"40% difference\" which may be a source of confusion, as it implies an additive rather than a multiplicative effect.</s>",
        "contradict": "The statement \"There was 38% more patients with DLT in cohort 2 of the primary trial than in cohort 1\" is contradicted by the information presented in the CTRs because:\n\n1. The CTRs do not provide the exact number of participants in each cohort (Cohort A and Cohort B) who experienced DLTs. Therefore, we cannot definitively say that there is a 38% difference in the number of patients experiencing DLTs between the two cohorts. \n2. The CTRs only specify that there were 10 participants in each cohort for the analysis of the given measure. It does not provide enough information on the occurrence of DLTs for each participant to make an accurate comparison between the two cohorts based on the statement made by the expert.</s>"
    },
    "6a013bb4-0688-4f02-96c5-062f3ca67ae1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were 5x more adverse events in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs data as follows:\n\n1. The CTRs provide the number of participants and the corresponding number of adverse events for each cohort in both trials.\n2. In the primary trial, there were 26 participants in cohort 1 and 22 participants in cohort 2. The total number of adverse events in cohort 1 was 4, and in cohort 2, it was 1.\n3. Therefore, the difference in the number of adverse events between the two cohorts is 3 (4-1), and the ratio of adverse events in cohort 1 to cohort 2 is (4/26) / (1/22) = 5/1 (approximately).\n4. The statement asserts that there were 5 times more adverse events in cohort 1 of the primary trial, and the CTRs data shows that this is indeed the case (5/1 \u2248 5).\n5. The statement is consistent with the information provided in the CTRs and doesn't contradict it, so the entailment holds.</s>",
        "contradict": "The statement cannot be entailed by the CTR information, as the CTRs do not provide sufficient data to determine if there are indeed 5 times more adverse events in cohort 1 of the primary trial compared to cohort 2. While the CTRs provide information about the number of adverse events for each individual trial, they do not provide a comparison between the two trials or their respective cohorts.</s>"
    },
    "c103a786-0b1d-4124-aa5d-4945ded2c384": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying PFS, PBR or DLTs.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial are not studying PFS, PBR or DLTs\" cannot be directly entailed by the information present in the CTRs provided.\n\nExplanation:\n\nThe CTRs describe various aspects of their respective trials, including outcome measurements and results. However, they do not explicitly state that Progression-Free Survival (PFS), Patient Benefit Rate (PBR), or Drug-Related Toxicities (DLTs) were the primary endpoints being evaluated in these trials. The CTRs focus on different outcome measures, such as the proportion of lymph nodes detected by Lymphoseek and blue dye in the primary trial, and patient benefits and response rates in the secondary trial. Therefore, the statement about PFS, PBR, or DLTs not being studied can't be determined based on the information present in the CTRs alone.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because:\n\n1. In the Primary Trial, the outcome measurement is not explicitly stated as Progression-free Survival (PFS), but the detection of lymph nodes intraoperatively by blue dye and Lymphoseek indicates evaluation of the therapeutic effect on disease spread or progression.\n2. In the Secondary Trials, the outcome measurement is defined as the percentage of patients with patient benefit, which includes assessment of CNS disease progression, tumor-related worsening of neurological signs and symptoms, tumor-related increase in corticosteroid dosage, and progression of extra CNS disease according to RECIST version 1.1- a commonly used measure of PFS.\n\nTherefore, both trials are, in fact, evaluating aspects related to PFS, even if not explicitly stated as the primary endpoint. The statement is incorrect.</s>"
    },
    "2746a75c-7f01-4dc3-a05e-5c7499e75555": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary CTR, there is no explicit mention of a limitation on disease stage for eligibility, but the disease characteristics do include stage IV disease. However, this section also mentions that patients with measurable disease are eligible, which could potentially include stage III patients.\n\n2. In the secondary CTR, the disease characteristics state that patients must have measurable disease, defined as at least one lesion that can be accurately measured, and this is not limited to any particular stage of disease. Therefore, stage III patients could meet this requirement.\n\n3. Both trials have similar patient characteristics requirements, including ECOG performance status, age range, ANC, platelet count, creatinine clearance, fertility status, and exclusion of severe medical history, pregnancy, and certain medications. Therefore, patients meeting these criteria in both trials would be eligible for either trial.\n\n4. The statement does not conflict with any information in the CTRs, and all its conditions are met or can be inferred from the provided information. Thus, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial\" is contradicted by the information in the CTRs in several ways:\n\n1. Primary Trial: The eligibility criteria for the primary trial include metastatic involvement (stage IV disease), making it incompatible with the statement's condition of \"at most stage 3 cancer.\"\n\n2. Secondary Trial: The disease characteristics section of the secondary trial states that it is intended for patients with locally recurrent or metastatic disease. This implies a more advanced stage than stage 3.\n\nTherefore, the statement \"Patients with at most stage 3 cancer are eligible for the secondary trial and the primary trial\" is contradicted by the eligibility criteria outlined in the CTRs for both trials.</s>"
    },
    "df64a4c5-08f3-40c7-a4e7-2a6271bc9e53": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients with a prior malignancy of skin cancer are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with a prior malignancy of skin cancer are excluded from the primary trial\" is entailed by the CTR as follows:\n\n1. According to the CTR, the exclusion criteria for patient characteristics include \"Other prior malignancies except skin cancer.\" \n2. Therefore, any patient with a prior malignancy, including skin cancer, is excluded from participating in the primary trial according to the CTR.\n3. The expert statement \"Patients with a prior malignancy of skin cancer are excluded from the primary trial\" is entailed by the CTR as it correctly represents the exclusion criterion mentioned in the trial document.</s>",
        "contradict": "The provided statement is not directly contradictory to the CTR information as the statement excludes \"patients with a prior malignancy of skin cancer\" while the CTR explicitly mentions \"Other prior malignancies except skin cancer.\" However, the CTR and the statement have different scopes: the CTR describes the inclusion/exclusion criteria for the primary trial, while the statement is a general clinical trials principle. To establish entailment, it would be necessary to ensure that the statement applies specifically to the primary trial in question or to compare its applicability to both trials. If the secondary trial shares the same exclusion criteria, then there is no contradiction. However, if the secondary trial allows patients with skin cancer, the statement could potentially be contradictory to the CTRs if such patients are included in the secondary trial while being excluded from the primary trial.</s>"
    },
    "682f5e80-75c4-4a36-9bc1-b389a98ad160": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "None of the patients in Cohort 1 of the primary trial suffered from Hypotension.",
        "Label": "Entailment",
        "entail": "The statement that \"None of the patients in Cohort 1 of the primary trial suffered from Hypotension\" can be entailed by the information present in the CTRs as there are no instances of Hypotension reported in the Adverse Events section for Cohort 1 of the Primary trial (0.00% incidence rate). The CTRs provide explicit data that no patient in Cohort 1 experienced Hypotension during the trial. This statement is in alignment with the CTR data and avoids contradiction, making it entailed.</s>",
        "contradict": "The statement \"None of the patients in Cohort 1 of the primary trial suffered from Hypotension\" is contradicted by the CTR data in the given Primary Trial Adverse Events section, where it is stated that \"Hypotension 0/50 (0.00%)\". However, in Cohort 1 of the Secondary Trial, there is no data provided regarding the occurrence of hypotension.</s>"
    },
    "7028841e-28e6-4fd3-a27c-2ae2e7dc7b52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "Only White and Asian patients are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the CTRs information. The CTRs provide detailed eligibility criteria for each trial separately, but they do not mention any restrictions based on ethnicity for either trial.</s>",
        "contradict": "The statement \"Only White and Asian patients are eligible for both the primary trial and the secondary trial\" is contradicted by the information presented in the CTRs as they do not make any restrictions based on race or ethnic origin. The inclusion criteria for both trials specify that participants can be from any racial or ethnic origin. Therefore, the statement is not entailed by the information in the CTRs.</s>"
    },
    "348c9273-6aa1-43a8-840d-3cf080874669": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.",
        "Label": "Entailment",
        "entail": "The statement \"In total, across both cohorts of the primary trial, there were at least 2 patients with a fever\" can be entailed by the information present in the CTRs as follows:\n\n1. Each CTR reports the number of patients with febrile neutropenia in their respective cohorts.\n2. The total number of patients in both cohorts is 12 (6 in CTR 1 and 6 in CTR 2).\n3. The number of patients with febrile neutropenia in both cohorts is 1 in each (mentioned in the provided CTR data).\n4. Adding the number of patients with febrile neutropenia in both cohorts gives a total of 2 patients.\n5. Therefore, the statement \"In total, across both cohorts of the primary trial, there were at least 2 patients with a fever\" is true and can be entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement \"In total, across both cohorts of the primary trial, there were at least 2 patients with a fever\" is contradicted by the CTR information because the total number of cases with febrile neutropenia in both cohorts combined is equal to 2, but it's mentioned in each cohort separately, which sums up to 2 and not more than that. However, the expert's statement implies the existence of at least two distinct patients with a fever across both cohorts, which is not directly supported by the data given in the CTRs.</s>"
    },
    "348c9273-6aa1-43a8-840d-3cf080874669_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there were less than 2 patients with a fever.",
        "Label": "Contradiction",
        "entail": "The expert's statement, \"In total, across both cohorts of the primary trial, there were less than 2 patients with a fever,\" is entailed by the CTRs' data as follows:\n\nThe CTR for both trials provides the total number of patients with adverse events and the number of patients experiencing febrile neutropenia. Febrile neutropenia is defined as a fever (pyrexia) in the context of neutropenia. According to the CTRs, there was a total of 12 patients across the two cohorts (6 patients per cohort), and the number of patients with febrile neutropenia was 2 in Cohort 1 and 1 in Cohort 2, resulting in a total of 3 patients. Since the statement asserts that there were less than 2 patients across both cohorts with a fever, it is an entailed statement from the CTR information as the number of patients with febrile neutropenia, which includes a fever, falls below the stated threshold.</s>",
        "contradict": "The statement \"In total, across both cohorts of the primary trial, there were less than 2 patients with a fever\" contradicts the information in the CTRs because the CTRs report that there were a total of 2 patients with a fever in each cohort (1/6 or 16.67% of the total participants), which amounts to 4 patients in total (2 from each cohort). Therefore, there were not less than 2 patients with a fever across both cohorts according to the provided information in the CTRs.</s>"
    },
    "348c9273-6aa1-43a8-840d-3cf080874669_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "There were at least 2 patients with a fever in total, across both cohorts of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were at least 2 patients with a fever in total, across both cohorts of the primary trial\" is entailed by the information present in the CTRs as follows:\n\nFebrile neutropenia, a condition characterized by fever, occurred in a total of 2 patients across the two cohorts in both the Primary Trial Adverse Events 1 and Adverse Events 2. This satisfies the condition of at least 2 patients exhibiting a fever in both cohorts as stated in the expert's claim.</s>",
        "contradict": "The statement \"There were at least 2 patients with a fever in total, across both cohorts of the primary trial\" can be contradicted by the information present in the CTRs because the statement implies that there are at least two patients experiencing a fever in the combined data of both trial cohorts (1 and 2), while the data provided indicates that the total number of patients experiencing fever in each cohort was 1 (16.67%) out of 6. Therefore, the statement contradicts the data if we assume that there are no shared patients between the two cohorts, as no mention of such occurrences is present in the CTRs.</s>"
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1.",
        "Label": "Entailment",
        "entail": "The expert statement \"We cannot compare results between the two Arms of the primary trial as there were no patients in cohort 1\" is entailed by the information in the CTRs since, in Results 1, the \"Overall Number of Participants Analyzed\" in Arm 1 is stated as 0, meaning that there were no patients in this arm. This absence of patients in Arm 1 prevents any valid comparison from being made between the two arms as per the expert's claim.</s>",
        "contradict": "The expert's statement implies that no participants were analyzed in Arm 1 of the primary trial, making it impossible to make comparisons between the two arms. However, this contradicts the information in the CTR as there is a clear outline for the intervention and dose escalation scheme for Arm 1, which includes a definition and time frame for evaluating DLTs. Therefore, even though no results (participants experiencing DLTs) are provided for Arm 1, there is still data in the CTR suggesting that patients have been or will be enrolled and treated in this arm. This discrepancy between the expert's statement and the CTR information calls for a more thorough investigation of the primary trial data to resolve any potential inconsistencies.</s>"
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "We can compare results between the two Arms of the primary trial as there were no patients in cohort 1.",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the CTRs as there are no participants (zero) in Arm 1 of the primary trial, and the expert is suggesting making a comparison between the two arms. Therefore, the lack of data in Arm 1 does not hinder the comparison being made between the two arms according to the statement.</s>",
        "contradict": "The statement \"We can compare results between the two Arms of the primary trial as there were no patients in cohort 1\" is contradicted by the information in the CTRs because the comparison of results between arms requires a minimum participation of patients in each arm to establish valid findings. In this case, there were no patients analyzed in Arm 1, and the results section only includes information about Arm 2, which does not allow for a valid comparison between the arms.</s>"
    },
    "dfe6228e-6bfb-49d3-b0b4-397aab177bea_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "Since there were no patients in cohort 1., we cannot compare results between the two Arms of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert can be entailed by the information in the CTRs because:\n\n- The statement mentions that \"we cannot compare results between the two Arms of the primary trial\" due to \"no patients in cohort 1.\"\n- In the CTR for the primary trial, under the \"Results 1\" section for Arm 1, it is stated that \"Overall Number of Participants Analyzed: 0\". This indicates that there were no patients enrolled in this arm at the time the data was reported.\n- Therefore, the lack of data and inability to compare results between the two arms in the statement is consistent with the information provided in the CTRs.</s>",
        "contradict": "The statement \"Since there were no patients in cohort 1., we cannot compare results between the two Arms of the primary trial\" is contradictory to the information in the CTRs because the statement assumes there were no participants analyzed in Arm 1 of the primary trial based on the given Result 1 having an \"Overall Number of Participants Analyzed: 0.\" However, the statement does not take into account the absence of DLTs reported for Arm 2 in Result 2, which implies that at least 3 participants were treated in that arm. The CTRs themselves do not provide enough information to directly compare the results between the two arms, but they do show that participants were treated in both arms, contradicting the assumption of no participants in Arm 1.</s>"
    },
    "9f424ebb-63b8-4930-b2c1-cd46fff4d706": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Only one patient cohort of the primary trial had a positive median Insulin change from baseline.",
        "Label": "Contradiction",
        "entail": "Based on the information provided in the CTRs, the statement can be entailed as follows:\n\nFrom Results 1, the Metformin + Lifestyle Intervention arm had a Least Squares Mean (LSMean) of -21.8% (-29.7 to -13.0) for Insulin change from baseline, while for the Placebo + Lifestyle Intervention arm, the LSMean was -17.7% (-25.9 to -8.6). Since the absolute value of Insulin change from baseline for the Metformin group is greater than that of Placebo group, it implies that the Median Insulin change from baseline for the Metformin group is more positive than that of the Placebo group. Therefore, only one patient cohort, the Metformin + Lifestyle Intervention arm, had a positive median Insulin change from baseline.</s>",
        "contradict": "The expert's statement \"Only one patient cohort of the primary trial had a positive median Insulin change from baseline\" contradicts the information provided in the CTRs. While it's true that the Metformin + Lifestyle Intervention arm had a greater Insulin percentage change from baseline than the Placebo + Lifestyle Intervention arm (-21.8% versus -17.7%), it does not mean that only one cohort had a positive median change from baseline. The data in the CTRs indicates that both cohorts had negative median changes from baseline, but the Metformin + Lifestyle Intervention cohort had a more significant improvement. The confusion arises from the expert's use of the term \"positive\" to describe an improvement in insulin levels. In this context, a negative change from baseline can be considered as an improvement if compared to the placebo group.</s>"
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1\" can be entailed by the information present in the CTRs as follows:\n\nThe CTRs provide the number of patients with CR, PR, and SD for each arm (cohort). According to the CTRs, there is one more patient with SD in cohort 2 (Arm 2) compared to cohort 1 (Arm 1) - (7 SD in cohort 1) and (8 SD in cohort 2).</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial had one more patient with Stable disease than cohort 1\" contradicts the information in the CTRs if we assume that both trials have the same number of participants in each arm or group. However, the CTRs provide different numbers of participants for each arm (34 for Arm 1 and 32 for Arm 2). If we interpret the statement as comparing the number of participants with SD within the same size cohort, then the statement is not in contradiction with the CTRs since the number of participants in each cohort is different.\n\nTherefore, the statement is potentially contradictory depending on the interpretation of the term \"Cohort 2 of the primary trial.\" If we assume that both trials have the same number of participants in each arm, then the given statement is a contradiction. However, if we interpret the statement as referring to the same group or arm with the label \"Cohort 2,\" then the statement is not necessarily a contradiction, but it may need further clarification.</s>"
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial didn't have one more patient with Stable disease than cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial didn't have one more patient with Stable disease than cohort 1\" can be entailed by the information present in the CTRs as follows: \n\nThe number of patients with SD in Arm 1 (Cohort 1) is 7, and in Arm 2 (Cohort 2) is 8. The difference between the number of SD patients in these two arms is 1 (8-7). However, the statement asserts that the difference is 0, meaning Cohort 2 has the same or fewer number of patients with SD than Cohort 1. Since the number difference is actually 1, but the statement claims it's 0, it's a negative statement, which is equivalent to saying \"Cohort 2 didn't have one more patient with Stable disease than Cohort 1.\" Therefore, the statement is entailed by the information in the CTRs because the CTRs allow the derivation of the negation of the statement.</s>",
        "contradict": "The statement that \"Cohort 2 of the primary trial didn't have one more patient with Stable disease than cohort 1\" contradicts the information in the CTRs because the number of patients with Stable disease in Arm 2 (Cohort 2) of the primary trial is 8, which is indeed one more than the number of patients with Stable disease (7) in Arm 1 (Cohort 1).</s>"
    },
    "c1f8c7fb-22de-4501-af86-d9eb59542ae3_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": " One more patient with Stable disease was present in cohort 1. then cohort 2. of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement \"One more patient with Stable disease was present in cohort 1. then cohort 2. of the primary trial\" is entailed by the information in the CTRs since both cohorts had participants with Stable disease, as indicated in the Results sections: \n\nPrimary Trial - Results 1: \"Stable disease (SD): 7\"\nPrimary Trial - Results 2: \"Stable disease (SD): 8\"\n\nThis implies that the total number of participants with Stable disease across both cohorts is one more than stated in the expert statement, making it an entailed statement based on the CTR information.</s>",
        "contradict": "The statement \"One more patient with Stable disease was present in cohort 1. then cohort 2. of the primary trial\" contradicts the information presented in the CTRs if we assume the statement refers to the number of participants with Stable disease. According to the CTRs, there were 7 participants with Stable disease in Arm 1 (6 mg Estradiol) and 8 participants with Stable disease in Arm 2 (30 mg Estradiol). So, there is no evidence in the CTRs that one more participant with Stable disease was present in Cohort 1 compared to Cohort 2.</s>"
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Left ventricular ejection fraction > 50% is required for participation in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Left ventricular ejection fraction > 50% is required for participation in the primary trial\" is entailed by the information present in the CTR under the \"PRIOR CONCURRENT THERAPY: LVEF\" section where it specifies that \"LVEF 50% as measured by echocardiogram or MUGA scan\" is one of the inclusion criteria for the primary trial.</s>",
        "contradict": "The statement is consistent with the ELIGIBILITY CRITERIA section of the primary CTR regarding LVEF, as it requires a minimum LVEF of 50%. However, the secondary CTR does not provide any information regarding the LVEF requirement for participation in the secondary trial. The contradiction arises because the expert statement makes a blanket assumption about the LVEF requirement being the same for both trials, when in fact, it may not be the case. Therefore, the statement is not directly entailed by the information in the CTRs without additional context or confirmation.</s>"
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Left ventricular ejection fraction > 50% isn't required for participation in the primary trial.",
        "Label": "Contradiction",
        "entail": "The Primary CTR does not explicitly state that a left ventricular ejection fraction of greater than 50% is a requirement for participation in the trial. Instead, it specifies that a normal LVEF, as measured by echocardiogram or MUGA scan, is a inclusion criterion. Since an LVEF of 50% is considered within the normal range according to standard clinical practice, the statement that \"Left ventricular ejection fraction > 50% isn't required for participation in the primary trial\" can be inferred from the information in the CTR.</s>",
        "contradict": "The information contained in the statement is contradictory to the CTR as the primary trial explicitly requires a left ventricular ejection fraction (LVEF) of at least 50% as measured by echocardiogram or MUGA scan for patient eligibility.</s>"
    },
    "6630047b-7ebc-4435-8203-cf6bbe6b6ee7_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Participation in the primary trial requires a left ventricular ejection fraction > 50%.",
        "Label": "Entailment",
        "entail": "The statement \"Participation in the primary trial requires a left ventricular ejection fraction > 50%\" can be entailed by the information present in the CTRs as LVEF (Left Ventricular Ejection Fraction) is mentioned in the PRIMARY TRIAL: PRIOR CONCURRENT THERAPY section with a specified value of 50%.</s>",
        "contradict": "The statement \"Participation in the primary trial requires a left ventricular ejection fraction > 50%\" contradicts the information in the CTRs as LVEF (left ventricular ejection fraction) is listed among the inclusion criteria for the primary trial but its minimum value is not specified, allowing patients with a LVEF of 50% as measured by echocardiogram or MUGA scan to participate.</s>"
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with cancer in situ of the cervix are eligible for the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary CTR inclusion criteria list \"basal/squamous cell skin carcinoma in situ of the cervix\" as a condition that does not exclude patients from the trial. This implies that patients with this condition can meet the eligibility requirements, and therefore, are considered part of the potential study population.\n\nSimilarly, the secondary CTR exclusion criteria do not include \"basal cell cancer or cancer in situ of the cervix\" as reasons to reject patients. This also implies that patients with these conditions can potentially be included in the trial, as they do not meet any exclusion criteria.\n\nSince both trials allow the presence of \"basal cell cancer or cancer in situ of the cervix,\" this statement is entailed, as it correctly reflects that patients with this condition can be eligible for both primary and secondary trials according to the CTRs.</s>",
        "contradict": "The given statement is contradicted by the information present in the CTRs as follows:\n\nIn the Primary Trial CTR, the exclusion criteria state that \"Women with a history of cancer other than breast cancer within 5 years\" are not eligible for the study. Cancer in situ of the cervix is classified as a cancer, which contradicts the statement's claim that women with this condition are eligible for the trial.\n\nIn the Secondary Trial CTR, the exclusion criteria state that \"Any other malignancy in the last 5 years, except for basal cell cancer or cancer in situ of the cervix\" are eligible for the study. However, the Primary Trial CTR's exclusion criteria contradict this statement, as they do not allow women with a history of cancer other than breast cancer within 5 years to participate in the trial, including women with cancer in situ of the cervix.</s>"
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with cancer in situ of the cervix aren't eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with cancer in situ of the cervix aren't eligible for the primary trial and the secondary trial\" is entailed by the information present in the CTRs. In the primary CTR, cervical cancer in situ is listed under the exclusion criteria for both the primary and secondary trials. Therefore, the statement correctly reflects the clinical trial eligibility criteria as stated in the reports.</s>",
        "contradict": "The statement \"Patients with cancer in situ of the cervix aren't eligible for the primary trial and the secondary trial\" is not necessarily contradictory to the provided CTR information. However, it can be misleading as the CTRs do not explicitly state that patients with cervical cancer in situ are eligible for either trial. While the Primary Trial exclusion criteria include a history of cancer other than breast cancer within 5 years, it does not explicitly mention cervical cancer in situ. The Secondary Trial inclusion criteria do not mention cervical cancer in situ at all. Therefore, based on the provided CTRs alone, it cannot be definitively concluded that patients with cervical cancer in situ are ineligible for either trial. The expert statement is not an entailment of the CTR information as it goes beyond the explicit information provided in the CTRs.</s>"
    },
    "039c3fc2-f798-4d97-b904-9aa7d363eeef_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "To be eligible for the primary trial and the secondary trial, patients can have cancer in situ of the cervix.",
        "Label": "Entailment",
        "entail": "The primary CTR includes an exclusion criterion for patients with \"a history of cancer other than breast cancer within 5 years, except for basal/squamous cell skin carcinoma in situ of the cervix.\" The secondary CTR does not include this specific exclusion criterion but only mentions an exclusion for \"any other malignancy in the last 5 years, except for basal cell cancer.\" However, as both types of cancer - basal/squamous cell skin carcinoma in situ and other malignancy - are exceptions in their respective exclusion criteria and refer to cancers in the cervix, patients with such conditions can be considered eligible for both trials.</s>",
        "contradict": "The statement \"To be eligible for the primary trial and the secondary trial, patients can have cancer in situ of the cervix\" contradicts the information present in the CTRs because the primary trial explicitly lists \"cervical cancer\" as an exclusion criteria (not in situ). In contrast, the secondary trial includes no mention of cervical cancer, either in the inclusion or exclusion criteria. Consequently, the statement's assertion is not harmonious with clinical trial data in both CTRs and could lead to contradiction with their provided descriptions.</s>"
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have undergone PTR.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial requires participants to have undergone PTR\" can be entailed by the CTR information as follows: \n\n1. The CTR specifies that patients must have completed preoperative (neoadjuvant) chemotherapy with a standard regimen and no further chemotherapy is planned. \n2. Preoperative chemotherapy (neo-adjuvant therapy) is also referred to as Primary Tumor Response (PTR) therapy in clinical trials, as it aims to reduce the size of the primary tumor before surgery. \n3. Therefore, the CTR requirement that patients have undergone preoperative (neo-adjuvant) chemotherapy implies that the participants have undergone PTR (as per clinical trial terminology).</s>",
        "contradict": "The statement \"the primary trial requires participants to have undergone PTR\" is in contradiction with the information present in the CTRs as the term \"PTR\" is not mentioned anywhere in the inclusion or exclusion criteria of the primary trial. Therefore, it cannot be inferred from the provided information that the trial requires participants to have undergone PTR.</s>"
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "The primary trial doesn't require participants to have undergone PTR.",
        "Label": "Contradiction",
        "entail": "The statement that \"The primary trial doesn't require participants to have undergone PTR\" is entailed by the CTR as there is no mention of PTR (preoperative trastuzumab) as a mandatory requirement for patient inclusion in the primary trial. Instead, the CTR specifies that patients must have completed preoperative chemotherapy and have significant residual invasive disease on pathologic review following their preoperative chemotherapy for eligibility. Trastuzumab is not mentioned as a necessary component of the preoperative chemotherapy regimen or as a requirement for initiation of protocol-based treatment. Therefore, the statement is in harmony with the clinical trial data and avoids contradiction with the provided description, making it an entailed statement.</s>",
        "contradict": "The statement \"The primary trial doesn't require participants to have undergone PTR\" contradicts the inclusion criteria of the primary CTR which specifies that \"Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.\" PTR (Preoperative Therapy, such as chemotherapy or radiation) is a common procedure used in breast cancer treatment, and the requirement for patients to have completed this treatment prior to enrollment in the trial is a crucial inclusion criterion in the primary CTR.</s>"
    },
    "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "Undergoing PTR is a requirement to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs if we interpret \"PTR\" as referring to preoperative chemotherapy, as defined in the inclusion criteria of the primary trial. According to the CTR, patients in the primary trial must have undergone preoperative chemotherapy before enrolling and starting protocol-based treatment. Thus, the requirement of undergoing preoperative chemotherapy (PTR) is an inherent condition for trial participation as stated in the CTRs.</s>",
        "contradict": "The statement \"Undergoing PTR is a requirement to participate in the primary trial\" cannot be directly contradicted by the information in the CTRs as there is no explicit reference to PTR (Progressive Taxane Responses) in the inclusion/exclusion criteria of the Primary Trial CTR provided. Therefore, the statement is neither confirmed nor refuted based on the given information, as PTR-related requirements are not mentioned.</s>"
    },
    "f8028143-35d1-4cc3-895a-acb577db4715": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD.",
        "Label": "Contradiction",
        "entail": "The statement \"participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole and 40 milligrams of simvastatin PO QD\" is entailed by the information in the CTRs because:\n\n1. In the primary trial, intervention for cohort 1 includes anastrozole with a daily dose of 1 mg PO.\n2. In the secondary trial, intervention includes the coadministration of anastrozole and simvastatin, with anastrozole having a daily dose of 1 mg PO.\n3. In both trials, the stated dose of anastrozole is consistent.\n4. In the secondary trial, intervention also includes simvastatin with a daily dose of 40 mg PO.\n\nTherefore, the combined intake of 1 mg of anastrozole and 40 mg of simvastatin PO QD as stated in the expert's claim can be derived from the information in the CTRs. The provided statement neither contradicts nor goes beyond the information presented, ensuring entailment.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because, in the primary trial, the participants in cohort 1 received only Arimidex or anastrozole (1 mg once daily oral dose), and not simvastatin. In the secondary trial, both anastrozole and simvastatin were administered, but to different cohorts and not simultaneously. Therefore, the statement's assertion does not hold true for the data presented in the CTRs.</s>"
    },
    "907f7e56-b6ec-4a43-bf3a-14f93c644bc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from chronic viral hepatitis would be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The female patient's age (18 years or older) and the absence of any mention of hepatitis as an exclusion criterion in the primary CTR's inclusion/exclusion criteria make it compatible with her participation in the trial, according to the provided statement.</s>",
        "contradict": "The statement is contradicted by the CTRs as chronic viral hepatitis is listed in the exclusion criteria for the primary trial. The CTR specifies that patients with known chronic liver disease are not eligible for participation.</s>"
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial\" is entailed by the CTR inclusion criteria that state \"Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group.\" Therefore, this statement is consistent with the clinical trial data, finds substantiation in the CTR, and does not contradict the provided descriptions.</s>",
        "contradict": "The expert statement does not explicitly mention the specific inclusion criteria from the CTR, such as the required Gail risk percentage or the presence of certain risk factors. Consequently, it might include women who meet the high-risk criteria by the Gail model but do not fulfill all the trial's eligibility conditions mentioned in the CTR. Therefore, there is a potential for contradiction, as not all women satisfying the Gail model's criteria would be eligible for the trial based on the CTR's inclusion criteria.</s>"
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The Gail model is a mathematical formula used to estimate a woman's risk of developing breast cancer. The primary trial inclusion criteria specify that one condition for patient eligibility is having a Gail risk score of 1.7% or more and/or a relative risk three times that for the 5-year age group. Women whose risk, as assessed by the Gail model, falls into this high-risk category would not be able to participate in the trial according to this inclusion criterion. Therefore, the statement made by the clinical trial expert that \"Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model aren't eligible for the primary trial\" is entailed by the information presented in the CTR.</s>",
        "contradict": "The statement \"Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model aren't eligible for the primary trial\" can be contradicted by the information present in the CTRs as some high-risk women based on the Gail model criteria are included in the primary trial. The eligibility criteria for the primary trial includes \"Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group.\" This directly aligns with the Gail model, which classifies women as high-risk if their 5-year risk is greater than 1.7%, and their lifetime risk is greater than 20-30%. Therefore, not all women classified as high-risk by the Gail model are excluded from the primary trial.</s>"
    },
    "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "If a women is classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model, they are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR information as follows: \n\n1. The primary trial includes participants with a Gail risk >= 1.7% and/or relative risk >= 3 times that for the 5-year age group. The Gail model is a tool used to estimate a woman's risk of developing breast cancer within a specific timeframe (usually 5 years) and during her lifetime. Therefore, a woman who meets this criterion is considered to be at high risk of developing breast cancer.\n\n2. The CTR explicitly states that this is one of the inclusion criteria for the primary trial. Thus, the statement is a valid summary of the CTR and is entailed by the information presented in the CTR.</s>",
        "contradict": "The statement does not directly contradict the CTR information. However, the CTR specifies more precise and additional inclusion criteria that need to be met besides the Gail model risk classification to be eligible for the primary trial. The CTR includes criteria like age, menopausal status, breast density, family history, menstrual cycles, and various laboratory values. Therefore, a woman who meets the Gail model criteria but does not fulfill other trial-specific requirements would not actually be eligible for the study based on the CTR. The statement, on its own, does not capture the complete picture of eligibility as outlined in the CTR.</s>"
    },
    "a41bf7b0-9a09-4ce0-8832-f13758581f20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more optical adversse events than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the primary trial recorded more optical adverse events than cohort 2\" is entailed by the information present in the CTRs if we consider the number of cases of optic neuroopathy, which is 1 in cohort 1 and 0 in cohort 2. Therefore, cohort 1 had a higher incidence of this specific type of adverse event compared to cohort 2. This information is present in the CTRs and does not contradict any other information provided, making it an entailed statement.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the number of optic neuropathy events in cohort 1 is equal to that in cohort 2, according to the given data: 0/202 for cohort 1 and 1/201 for cohort 2, both occurring 0.50% of the time. However, the statement suggests that cohort 1 recorded more optic neuropathy events.</s>"
    },
    "5f2d2015-eaf9-45a8-9583-fddbc9807287": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia\" can be entailed by the CTR data, as the CTR reports that there was only 1 instance of Hyperbilirrubinemia out of 436 total participants in the primary trial, which equates to a frequency of approximately 0.23%. Since cohort 1 is the overall participant group in the primary trial, the statement is consistent with the CTR data and does not contradict any information presented.</s>",
        "contradict": "The statement \"Less than 0.25% of patients in cohort 1 of the primary trial suffered from Hyperbilirrubinemia\" is contradicted by the CTR information as there was 1 reported case of Hyperbilirrubinemia out of 436 participants (a rate of approximately 0.23%), which exceeds the 0.25% threshold stated in the expert's claim.</s>"
    },
    "609ddd08-ebd5-4661-be43-874b65dbfe52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not entail information from the CTRs directly as the CTRs provide no information regarding patients having dementia or schizophrenia. However, the statement is not contradictory to any information in the CTRs either. Eligibility criteria for the primary trial include having informed consent, which does not exclude patients with dementia or schizophrenia if they are capable of providing informed consent. Similarly, the secondary trial's eligibility criteria do not mention any exclusion related to dementia or schizophrenia unless stated explicitly. Therefore, the statement does not contradict nor entails the CTRs' data. The statement introduces new conditions (dementia and schizophrenia) not mentioned in the CTRs and does not provide sufficient evidence for either entailment or contradiction.</s>",
        "contradict": "The statement \"Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial\" cannot be confirmed based on the information provided in the CTRs. \n\nReason:\n\n1. In the primary trial, dementia and schizophrenia are not mentioned as inclusion or exclusion criteria.\n2. In the secondary trial, the inclusion criteria specify female patients, whereas dementia and schizophrenia are not gender-specific conditions.\n3. The secondary trial excludes patients with serious uncontrolled medical disorders, but it does not mention dementia or schizophrenia as specific disorders in this category.\n4. Therefore, the statement that \"Patients with dementia or schizophrenia may be eligible for the primary trial and the secondary trial\" is not directly supported by the available information in the CTRs.\n\nFurther investigation and consultation with clinical experts would be necessary to determine the potential eligibility of patients with dementia or schizophrenia for these trials, considering the complexities and nuances of these conditions in the context of clinical trial participation.</s>"
    },
    "b6ac985d-87ae-4e0f-83e1-38033c1db5cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status.",
        "Label": "Contradiction",
        "entail": "The ECOG (Eastern Cooperative Oncology Group) performance status scale is a widely used tool to evaluate the functional status and general health condition of patients with cancer (National Cancer Institute, 2022). In the primary CTR, the inclusion criterion specifies candidates having a WHO performance status of 0, 1, or 2. The WHO performance status scale is an older, yet similar assessment to ECOG, with 0-2 representing good performance status. In the secondary CTR, the inclusion criterion specifies candidates having a Zubrod performance status less than 2. The Zubrod performance status scale is another functional assessment scale, which is also equivalent to ECOG 0-2 (Zubrod, 1979). Thus, both primary and secondary trials are indeed using ECOG performance status to evaluate potential candidates, as stated.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial use ECOG to evaluate potential candidates' performance status\" can be contradicted by the information present in the CTRs because while the Primary Trial specifies the use of WHO performance status for evaluating candidates' performance status, the Secondary Trial employs Zubrod performance status instead. Therefore, the statement's assertion that both trials use the ECOG performance status system is not harmonious with the clinical trial data and is a contradiction to the descriptions provided within the CTRs.</s>"
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants achieved Objective Response (OR).",
        "Label": "Entailment",
        "entail": "The statement \"More than 5% of the primary trial participants achieved Objective Response (OR)\" can be entailed by the information present in the CTRs if at least 2 participants (more than 5% of 41 total participants) in the Afatinib 50 mg arm/group achieved OR (either complete response or partial response) during the study period (up to 34 months). The CTR indicates that the outcome measurement was Objective Response, and the type of measure is number of participants. Therefore, if the actual number of participants achieving OR meets or exceeds the stated threshold, then the statement is entailed by the CTR information.</s>",
        "contradict": "The expert statement \"More than 5% of the primary trial participants achieved Objective Response (OR)\" cannot be definitively determined from the provided CTR information as no explicit mention of the percentage of participants achieving OR (complete or partial response) is given in the CTR for the Afatinib 50 mg arm. The expert's claim contradicts the CTR if no, or less than 5%, of participants in the Afatinib 50 mg arm experienced OR, but there is currently insufficient information in the given CTR to validate this contradiction.</s>"
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "More than 5% of the primary trial participants didn't achieve Objective Response (OR).",
        "Label": "Contradiction",
        "entail": "The number of participants in the Afatinib 50 mg arm/group who didn't achieve Objective Response (OR) is not explicitly stated in the CTR. However, the CTR provides the number of total participants analyzed in this arm/group, which is 41. Assuming that OR consists of both Complete Response (CR) and Partial Response (PR), and no participant was classified as having stable disease or progressive disease, we can calculate the proportion of participants achieving OR as follows: OR participants = Total Number of Participants - Number of participants without OR. Since the CTR does not specify the number of participants without OR, it's not possible to determine an exact figure. However, if we assume that less than 5% of the participants didn't achieve OR, the total number of OR participants would be more than 95% of the 41 participants, which is 37 or more. As the given statement states that more than 5% of the participants didn't achieve OR, it contradicts this assumption. However, if we consider that the statement is not meant to describe the exact percentage but rather to convey that OR was not achieved by more than 5% of the primary trial participants, the given statement can be entailed by the CTR information, as the provided data does not contradict it. In summary, the statement \"More than 5% of the primary trial participants didn't achieve Objective Response (OR)\" is entailed by the information in the CTRs, as it does not contradict the available data and remains consistent with the possibility that less than 5% of the participants didn't achieve OR.</s>",
        "contradict": "The statement \"More than 5% of the primary trial participants didn't achieve Objective Response (OR)\" cannot be definitively determined to be true or false based on the information provided in the CTRs. The CTR for the primary trial only reports the number of participants in the Afatinib 50 mg arm and the number overall who were analyzed, but it does not provide specific data on the percentage of participants who achieved OR or the exact number of participants who did not achieve OR.</s>"
    },
    "43ff9425-5e6e-4a85-a8ca-0c0c67a96623_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00431067",
        "Statement": "In the primary trial, more than 5% of the participants achieved Objective Response (OR).",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, more than 5% of the participants achieved Objective Response (OR)\" can be entailed by the information in the CTRs as follows: \n\n1. The CTR specifies that Objective Response (OR), including Complete Response (CR) and Partial Response (PR), was measured according to RECIST criteria in the primary trial. \n2. The number of participants who achieved OR in the Afatinib 50 mg arm of the primary trial (Results 1) is stated as \"Overall Number of Participants Analyzed: 41\". \n3. To determine if more than 5% of the participants achieved OR, we calculate (41 x 0.05 =) 2.05, which rounds up to 3 when considering whole numbers of participants. \n4. Since the CTR reports that 3 participants achieved OR, this is within the range of more than 5% (as 3 represents 7.32% of 41). \n\nTherefore, the statement \"In the primary trial, more than 5% of the participants achieved Objective Response (OR)\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"In the primary trial, more than 5% of the participants achieved Objective Response (OR)\" cannot be definitively contradicted by the given CTR information. However, it can be questioned for accuracy without contradiction, as the CTR provides the number of participants analyzed and the response rate, but it does not state the exact percentage of participants achieving OR. Therefore, while the statement does not contradict the provided CTR data, it might not be accurate if other trials with different OR percentages exist.</s>"
    },
    "b3ccde30-cdfc-4e18-aee0-8b3a921dde39": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV, but only a subset of participants undergo axillary lymph node dissection.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR as tipifarnib is given orally to all patients in Arm I of the primary trial, while paclitaxel, doxorubicin hydrochloride, and cyclophosphamide are given intravenously. The statement also mentions axillary lymph node dissection being performed on a subset of participants, which is consistent with the correlative study mentioned in the primary CTR.</s>",
        "contradict": "The statement is not entirely consistent with the CTR information. While it correctly specifies that all patients in the primary trial receive tipifarnib PO, paclitaxel, doxorubicin hydrochloride, and cyclophosphamide IV, it incorrectly states that not all patients undergo axillary lymph node dissection. However, according to the provided CTR, axillary lymph node dissection is part of the conventional surgery mentioned under the Intervention 1 for the primary trial.</s>"
    },
    "8697a59e-0f1c-452a-b15a-6d24e2df387f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial or the secondary trial committed suicide.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the patients in the primary trial or the secondary trial committed suicide\" is entailed by the information in the CTRs because no instance of suicide is reported in the adverse events sections of either trial. In the primary trial, the adverse events include various conditions such as atrial fibrillation, ventricular fibrillation, gastrointestinal perforation, periproctitis, general physical health deterioration, Escherichia sepsis, pneumonia, renal failure acute, pleurisy, atrial fibrillation, and ventricular fibrillation, but none of them mentions suicide. Similarly, the adverse events section of the secondary trial lists leukopenia, neutropenia, cataract, infection, upper respiratory tract infection, but none of them indicates suicide. Consequently, the statement that no suicide occurred in either trial is consistent with the data provided in the CTRs.</s>",
        "contradict": "The statement \"None of the patients in the primary trial or the secondary trial committed suicide\" is contradicted by the information in the CTRs because, in the primary trial, there was one patient who experienced \"Completed suicide\" as an adverse event.</s>"
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, she is eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Stephanie's eligibility for the primary trial is determined by meeting the following inclusion criteria mentioned in the CTR: \n- Female\n- Age > 21 years\n- Has diagnosis of non-recurrent stage I-III breast cancer\n- Completed active treatment (chemotherapy, radiation therapy, surgery) 6 months-5 years ago (current use of endocrine therapy is acceptable)\n- Has a partner or spouse who is > 21\n- Lives with a romantic partner > 6 months\n- Score of > 3 on Patient Care Monitor Sexual Concerns screening item.\n\nThe given statement, \"Stephanie has been living with her husband for 31 years,\" is entailed by the inclusion criterion \"Has a partner or spouse who is > 21\" and \"Lives with a romantic partner > 6 months.\" Since Stephanie's 31-year marriage implies a long-term romantic relationship and her partner is her husband, who is undoubtedly older than 21, she is in accordance with these inclusion criteria.</s>",
        "contradict": "The statement that \"Stephanie is eligible for the primary trial\" is generally consistent with the inclusion criteria stated in the CTR, as Stephanie is a female with a diagnosis of non-recurrent stage I-III breast cancer, has a partner, and meets the sexual concerns criterion. However, there is no explicit age requirement mentioned in the statement, whereas the CTR states that patients must be between 21 and 5 years post-treatment, and the age of the patient is unknown from the provided statement. Thus, although the statement does not contradict any specific information, it is potentially misleading because it does not fully conform to the CTR inclusion criteria due to the missing age requirement.</s>"
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, she isn't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Stephanie has been living with her husband for 31 years, she isn't eligible for the primary trial,\" is entailed by the information in the CTRs because Stephanie's lengthy marriage duration exceeds the specified maximum of 5 years since completion of treatment (6 months - 5 years) as stated in the Inclusion Criteria of the primary trial. This discrepancy in eligibility renders her ineligible for the primary trial.</s>",
        "contradict": "Stephanie may not be eligible for the primary trial due to her lengthy marital duration exceeding the specified 6 months, which is a requirement stated in the inclusion criteria. Therefore, the statement's assertion contradicts the trial eligibility criteria mentioned in the CTR.</s>"
    },
    "4ab74186-5f4e-4139-af05-d4a9871a251d_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her husband for 31 years, so she isn't excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Stephanie isn't excluded from the primary trial because she has been living with her husband for 31 years\" is entailed by the information present in the CTR since there is no explicit exclusion criterion related to the length of marriage in either the primary or secondary trial's inclusion or exclusion criteria.</s>",
        "contradict": "The statement \"Stephanie isn't excluded from the primary trial because she has been living with her husband for 31 years\" is not directly related to any of the inclusion or exclusion criteria in the CTRs provided. The CTRs only state that the participant must have a romantic partner for over 6 months, and there is no mention of the length of the relationship. Therefore, the statement does not necessarily entail that Stephanie fulfills the trial eligibility criteria based on the information available in the CTRs.</s>"
    },
    "082ee581-f420-4892-b098-ce82c6ad0210": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial were cardiac related.",
        "Label": "Contradiction",
        "entail": "The statement \"All of the adverse events recorded in the primary trial were cardiac related\" cannot be entailed by the information present in the given CTRs, as the CTRs do not provide any evidence of cardiac adverse events occurring in either trial.</s>",
        "contradict": "The statement that \"All of the adverse events recorded in the primary trial were cardiac related\" is contradicted by the information present in the CTRs because the CTRs report various types of adverse events, including but not limited to diarrhea, mucositis/stomatitis, vomiting, diabetic decompensation, pancreatitis, febrile neutropenia, and infection pulmonary/ upper airway NOS. None of these events are specified as cardiac-related in the provided data.</s>"
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.",
        "Label": "Entailment",
        "entail": "The statement \"Pre and Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy\" is entailed by the information in the CTRs because both trials' inclusion criteria specify that women must not have used hormone replacement therapy within the past 6 months prior to eligibility screening. Therefore, the statement harmonizes with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement is not entirely contradictory to the information in the CTRs, but it is incomplete. While the statement correctly notes that pre and post-menopausal women can enter the primary trial, it incorrectly assumes that hormone replacement therapy is the sole condition for exclusion. The CTRs, however, list multiple exclusion criteria, including the use of hormone replacement therapy, tamoxifen, or raloxifene within the prior 6 months, as well as other conditions like active infection or inflammation and abnormal lab values. Thus, while the statement's assertion about hormone replacement therapy is correct, it fails to account for the complete set of exclusion criteria specified in the CTRs. Therefore, the statement may lead to incorrect assumptions if taken in isolation and not read in conjunction with the full information in the CTRs.</s>"
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Pre and Post menopausal women can enter the primary trial, as long as they have prior hormone replacement therapy.",
        "Label": "Contradiction",
        "entail": "The statement \"Pre and Post menopausal women can enter the primary trial, as long as they have prior hormone replacement therapy\" can be entailed by the information present in the CTRs as follows:\n\nInclusion Criteria of the primary trial states \"Pre or Post menopausal women reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months to eligibility screening.\" However, the statement allows for participation even with prior hormone replacement therapy use. This is a subtle difference in the inclusion criterion but doesn't contradict the data in the CTR since the trial doesn't explicitly state that prior use of hormone replacement therapy disqualifies a participant. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Pre and Post menopausal women can enter the primary trial, as long as they have prior hormone replacement therapy\" contradicts the inclusion criteria of the primary trial. According to the CTR, females who have used hormone replacement therapy within the prior 6 months to eligibility screening are excluded from the trial. Therefore, this statement cannot be entailed by the given CTR information.</s>"
    },
    "7bf084eb-873a-4011-9b98-3a899ee582ee_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "If a pre or post menopausal women has had prior hormone replacement therapy, they cannot enter the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"a pre or post menopausal women cannot enter the primary trial if they have had prior hormone replacement therapy\" is entailed by the CTR's inclusion criteria, specifically the exclusion of women who have used hormone replacement therapy within the past 6 months prior to eligibility screening.</s>",
        "contradict": "The statement is not an exact entailment of the CTR information because the CTR inclusion criteria specify that pre or post menopausal women reporting no use of hormone replacement therapy, tamoxifen or raloxifene within the prior 6 months to eligibility screening can enter the trial. The statement, however, asserts that women who have ever used hormone replacement therapy cannot enter the trial. Thus, there is a potential for overlap where individuals who were eligible according to the CTR criteria but not according to the statement could potentially be included in the trial.</s>"
    },
    "ef0406b4-34ad-4cbd-83a4-dd0f118c4d5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial are testing completely different modalities of interventions, but utilizing the same 21 day cycle\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial and the secondary trial both have a 21 day cycle: The statement mentions that both trials have the same 21 day cycle. This is true according to the provided information in the CTRs. In the primary trial, patients receive tivantinib PO BID on days 1-21 and courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. In the secondary trial, the nature of interventions is not mentioned in the provided information, but no explicit information suggests a different cycle duration.\n\n2. Different modalities of interventions: The statement also asserts that the trials are testing completely different modalities of interventions. This is entailed by the information in the CTRs as well. The primary trial involves the administration of Tivantinib, a drug, while the secondary trial mentions interventions in the form of Prone and Supine positions. These are distinctly different modalities of interventions.</s>",
        "contradict": "The statement is contradictory to the CTRs because the primary trial is testing an intervention using tivantinib, a pharmaceutical agent, while the secondary trial is testing interventions using different positions (prone and supine). The statement implies that both trials follow the same 21-day cycle, but the primary trial involves a drug administered in a particular dosing schedule within that cycle, whereas the secondary trial describes interventions as positions that do not involve any dosing schedule or medication. Consequently, the modalities of interventions being tested are fundamentally distinct in each trial despite the similar 21-day cycle length.</s>"
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that patients with ERBB2 positive tumors are eligible for the primary trial based on the following reasons:\n\n1. ERBB2 gene amplification or overexpression is an inclusion criterion for the primary trial (CTR, PART 2).\n2. The statement does not conflict with any exclusion criteria.\n\nTherefore, if a patient has an ERBB2 positive tumor, it implies that they meet the inclusion criteria, and hence are eligible for the trial.</s>",
        "contradict": "The expert statement \"Patients with ERBB2 positive tumors are eligible for the primary trial\" can be contradicted by the CTR in the following ways:\n\n1. The eligibility criteria for the primary trial state that \"erbB-2 gene amplified tumor (FISH or CISH)\" or \"erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)\" is required for patient inclusion. However, the expert statement only specifies \"ERBB2 positive tumors,\" and the methods for determining \"ERBB2 positivity\" are not explicitly stated. It is possible that the expert's statement could be interpreted to include only those patients with ERBB2 gene amplification or overexpression, as required by the trial, but it could also be interpreted more broadly to include any patient with any detectable ERBB2 protein expression, which may include patients who do not meet the trial's criteria.\n\n2. The expert statement does not mention any of the other inclusion criteria, such as the requirement for progressive disease following prior trastuzumab treatment, the requirement for prior taxane treatment, or the requirement of at least one measurable lesion. Therefore, the expert statement does not guarantee that the patients it refers to meet all of the trial's inclusion criteria.\n\n3. The expert statement does not mention any of the exclusion criteria. Therefore, it is possible that the patients it refers to may be excluded from the trial due to factors such as prior treatment with capecitabine, lapatinib, or anthracyclines, or the presence of bone-only disease or active CNS metastases.\n\n4. The expert statement does not specify which primary trial it is referring to. The eligibility criteria for different trials may vary, so it is possible that the statement is referring to a different trial with different eligibility criteria.\n\nOverall, the expert statement \"Patients with ERBB2 positive tumors are eligible for the primary trial\" is not an exact entailment of the CTR, as it omits some of the specific inclusion and exclusion criteria, and does not specify which trial it is referring to.</s>"
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with ERBB2 positive tumors aren't eligible for the primary trial\" is entailed by the CTR inclusion criteria in PART 2, which specifies that patients should have \"erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation)\". This condition explicitly requires patients to have ERBB2-positive tumors, meaning that those patients who do not meet this criterion are indeed ineligible for the trial.</s>",
        "contradict": "The statement can be contradicted by the CTR as some patients with ERBB2 positive tumors are eligible for the primary trial based on the specified inclusion criteria. The inclusion criteria state that patients should have erbB-2 gene amplification or overexpression. This is a definition of ERBB2 positivity as per clinical trial terminology. Therefore, the statement \"Patients with ERBB2 positive tumors aren't eligible for the primary trial\" does not hold true based on the information present in the CTR.</s>"
    },
    "06bc9cff-e9fc-42c7-a2a3-c01a036e04c6_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with ERBB2 positive tumors aren't excluded from the primary trial.)",
        "Label": "Entailment",
        "entail": "The statement \"Patients with ERBB2 positive tumors aren't excluded from the primary trial\" is entailed by the CTR information as follows:\n\n1. In the primary trial inclusion criteria, ERBB2 gene amplification or overexpression, which is a defining characteristic of ERBB2 positive tumors, is specified as a requirement for patient eligibility.\n2. The statement does not exclude patients based on having ERBB2 positive tumors.\n3. The exclusion criteria do not mention ERBB2 positive tumors as a reason for exclusion, either explicitly or implicitly.\n4. Therefore, the statement \"Patients with ERBB2 positive tumors aren't excluded from the primary trial\" is entailed by the CTR information.</s>",
        "contradict": "The statement, \"Patients with ERBB2 positive tumors aren't excluded from the primary trial,\" contradicts the information in the CTR because the CTR specifies that patients must have ERBB2 gene amplification or overexpression for inclusion in the trial. However, the statement implies that ERBB2 positivity is not a requirement for exclusion, which is not the case according to the CTR.</s>"
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Most patients in the primary trial treated with Eribulin Mesylate did not achieve complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "entail": "The ORR in the primary CTR was calculated as the sum of CR and PR, with ORR equal to 28.6% for the Eribulin Mesylate arm. Since CR and PR represent the number of participants who achieved complete response and partial response, respectively, and the total ORR is given as 28.6%, it follows that most participants (100% - 28.6%) did not achieve CR or PR.</s>",
        "contradict": "The statement made by the clinical trials expert can be contradicted by the information in the CTRs as follows: \n\nThe ORR in the primary trial, which is the sum of CR and PR, was 28.6%. While the exact number of patients achieving CR and PR is not mentioned, the ORR indicates that over a quarter of the participants did achieve a response (CR or PR), which contradicts the expert's assertion that \"Most\" patients did not achieve response.</s>"
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Most patients in the primary trial treated with Eribulin Mesylate achieved complete response (CR) or partial response (PR).",
        "Label": "Contradiction",
        "entail": "The expert's statement, \"Most patients in the primary trial treated with Eribulin Mesylate achieved complete response (CR) or partial response (PR),\" can be entailed by the information present in the CTRs because the ORR for the Eribulin Mesylate arm, as defined in the Primary Trial's Outcome Measurement section, is the sum of CR and PR. The Results 1 section for the Eribulin Mesylate arm indicates that 28.6% of participants experienced either CR or PR, which is equivalent to stating that most patients achieved a response (CR or PR) based on the expert's statement.</s>",
        "contradict": "The statement made by the clinical trial expert, \"Most patients in the primary trial treated with Eribulin Mesylate achieved complete response (CR) or partial response (PR),\" cannot be definitively confirmed or contradicted based on the information present in the CTRs alone. The ORR in the primary trial was 28.6%, which represents the percentage of patients with either CR or PR, but the statement goes beyond the data in the CTR by suggesting that \"most\" patients achieved these responses. Without more information, it's impossible to know whether \"most\" implies a majority or a simple plurality, nor can we be sure that the definition of \"most\" used by the expert is the same as the one used in the trial. Additionally, the CTR does not specify the exact number of patients in the Eribulin Mesylate arm who achieved CR or PR, only the ORR percentage. Consequently, we cannot directly compare the ORR percentage to the statement's claim that \"most\" patients achieved CR or PR, as the percentage alone does not provide enough detail to support a definitive conclusion regarding the individual responses of most patients. Therefore, the statement is not directly contradictory to the CTRs, but it does not follow directly from the data provided either.</s>"
    },
    "f6c85ce8-e0fc-4186-a961-6207dd4cacd2_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "Treament with Eribulin Mesylate did not make most patients in the primary trial achieve complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "entail": "The statement \"Treatment with Eribulin Mesylate did not make most patients in the primary trial achieve complete response (CR) or partial response (PR)\" can be entailed by the information in the CTRs as follows:\n\n1. According to the CTR for the primary trial, the Objective Response Rate (ORR) was calculated as the sum of CR and PR.\n2. The ORR for the Eribulin Mesylate arm was stated as 28.6%.\n3. Since ORR represents the percentage of patients with CR or PR, having an ORR of 28.6% implies that fewer than half (51.4%) of the patients achieved CR or PR.</s>",
        "contradict": "The statement \"Treatment with Eribulin Mesylate did not make most patients in the primary trial achieve complete response (CR) or partial response (PR)\" contradicts the information in the CTRs because the ORR (the percentage of participants with CR or PR) was reported as 28.6% in the Eribulin Mesylate arm. This means that nearly one-quarter of the participants in this arm did achieve either a CR or PR. Contrary to the statement, most participants in this arm did, in fact, achieve a response as defined by the trial's outcome measure.</s>"
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with invasive breast cancer with a diameter of less than 4 cm are included in the primary trial\" is entailed by the CTR inclusion criteria, specifically \"Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.\" As the maximal diameter of the breast cancer is stated to be less than 5 cm in this CTR, it falls under the category of patients with invasive breast cancer with a diameter of less than 4 cm mentioned in the statement. Therefore, the statement is harmonious with the clinical trial data, finds substantiation in the CTR, and does not contradict the provided descriptions, making it an entailed statement.</s>",
        "contradict": "The information contained in the expert statement can be contradicted by the information present in the CTRs because the statement only mentions the diameter criteria for patient inclusion in the primary trial being less than 4 cm, while the CTRs provide a more detailed list of inclusion and exclusion criteria, including age, breast cancer type, absence of axillary lymph node involvement, and various other conditions. The statement does not account for these other criteria and may not accurately reflect the patient population described in the CTRs.</s>"
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of less than 4 cm aren't included in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with invasive breast cancer with a diameter of less than 4 cm aren't included in the primary trial\" is entailed by the CTR's \"Inclusion Criteria: Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.\" The statement made by the expert is a specialization of the inclusion criteria's dimension requirement.</s>",
        "contradict": "The statement \"Patients with invasive breast cancer with a diameter of less than 4 cm aren't included in the primary trial\" cannot be directly contradicted by the information present in the CTRs, as the primary CTR does not explicitly state the maximum diameter limit for patient inclusion, instead specifying a limit of 5 cm. The statement, however, implies a stricter limitation, which may not necessarily be in contradiction with the actual data, but rather a potential narrower scope of the primary trial.</s>"
    },
    "5bdd61d9-aadf-4944-afe3-a04242d9c2b2_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "If a patient has invasive breast cancer with a diameter of less than 4 cm, they are included in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"If a patient has invasive breast cancer with a diameter of less than 4 cm, they are included in the primary trial\" is entailed by the CTR inclusion criteria which state \"Ipsilateral biopsy-proven invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography.\" Since the diameter of a breast cancer of less than 4 cm falls under the specified 5 cm limit, such patients meet the inclusion criteria and are eligible for the primary trial.</s>",
        "contradict": "The statement \"If a patient has invasive breast cancer with a diameter of less than 4 cm, they are included in the primary trial\" is contradicted by the information in the CTRs as the Primary Trial's Inclusion Criteria explicitly states that the breast cancer maximal dimension should be less than 5 cm, not less than 4 cm.</s>"
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore Fiona may be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Fiona's sister having ductal carcinoma makes Fiona a subject at increased risk for breast cancer according to the primary CTR inclusion criteria, as specified by the criteria B and H: having a first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer, and a history of a DCIS, atypical hyperplasia, or ER-positive DCIS by diagnostic biopsy. Therefore, Fiona may be eligible for the primary trial.</s>",
        "contradict": "Fiona's eligibility for the primary trial based on her sister having ductal carcinoma is contradicted by the CTR inclusion criteria. The criteria state that subjects must not have had a history of invasive breast cancer within the past five years.</s>"
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore Fiona may not be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Fiona's sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore Fiona may not be eligible for the primary trial\" is entailed by the following information in the CTRs: \n\n- \"Subjects who have had a DCIS, atypical hyperplasia (AH), lobular carcinoma in situ (LCIS), or invasive breast cancer by diagnostic biopsy are not eligible.\" \n\n- \"Women who have had a DCIS, atypical hyperplasia (AH), lobular carcinoma in situ (LCIS), or invasive breast cancer within the past five years are not eligible.\"</s>",
        "contradict": "The statement that \"Fiona may not be eligible for the primary trial because her sister was diagnosed with a ductal carcinoma\" contradicts the inclusion criteria of the primary trial which states that subjects with a history of ductal carcinoma in situ (DCIS) or atypical hyperplasia (AH) by diagnostic biopsy, but have not had appropriate local therapy (lumpectomy plus radiation or mastectomy), are eligible provided they meet other criteria. However, the statement does not specify whether Fiona has undergone any local therapy for her sister's DC, or if she meets any other eligibility criteria such as age, increased risk, or hormonal status. Consequently, the statement's assertion cannot be definitively confirmed or refuted based on the information presented in the CTRs alone.</s>"
    },
    "b8ce7d6a-d707-48e0-816c-de7ac3a63823_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Since Fiona's sister, is 34 years old and was diagnosed with a ductal carcinoma, Fiona may be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Fiona's sister having ductal carcinoma at the age of 34 makes Fiona eligible for the primary trial as she falls into the category of having a first degree relative with breast cancer under the age of 60, one of the inclusion criteria mentioned in the CTR.</s>",
        "contradict": "Fiona's eligibility for the primary trial as inferred from her sister's diagnosis is not directly specified in the CTR. While having a first-degree relative with breast cancer under the age of 60 is an inclusion criterion, it does not guarantee Fiona's eligibility, as there are additional requirements such as meeting certain risk assessment scores, having cytomorphologic evidence of hyperplasia with atypia, or having a menstrual cycle documented, which are not mentioned in the provided information. Therefore, the statement is not entailed by the CTR information.</s>"
    },
    "53d88010-e7d7-41c7-b20d-6328c8e507d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For some adverse event types in the primary trial, there were no recorded cases.",
        "Label": "Contradiction",
        "entail": "The statement \"For some adverse event types in the primary trial, there were no recorded cases,\" can be entailed by the information present in the CTR if the types of adverse events that are being referred to in the statement are not mentioned or reported as occurring in the primary trial's Adverse Events section. The CTR explicitly states the types and frequencies of adverse events observed in the primary trial. The absence of certain adverse events in the CTR implies that there were no recorded cases for those specific events.</s>",
        "contradict": "The expert's statement asserts that for some adverse event types in the primary trial, there were no recorded cases. However, according to the CTRs, there is a recorded case of Thrombocytopenia, Hypertension, and three recorded cases of Hepatotoxicity. This contradicts the expert's statement as it suggests that there were recorded cases of these adverse event types, contrary to the statement that there were no recorded cases for these types.</s>"
    },
    "8257bf5c-fae6-44c0-a86d-293746fdc468": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2\" can be entailed by the information present in the CTRs as follows:\n\n1. The total number of adverse events (AEs) in Cohort 1 of the primary trial was 5/26 (19.23%) and in Cohort 2 was 4/13 (30.77%), but this difference does not necessarily mean that one cohort had more cases of specific adverse events than the other without further examination.\n\n2. However, the CTRs do provide the number of specific AEs for several conditions in both cohorts. For Hepatic encephalopathy, there was 1 case in Cohort 1 (3.85%) and none in Cohort 2 (0.00%). For Pneumonia, there was 0 case in Cohort 1 (0.00%) and 1 case in Cohort 2 (7.69%).\n\n3. Thus, the statement \"Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2\" is entailed by the CTRs as the former had 1 case and the latter had none for Hepatic encephalopathy, and the reverse is true for Pneumonia.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial had more cases of Hepatic encephalopathy and Pneumonia than cohort 2\" cannot be directly contradicted by the information present in the CTRs as both trials report occurrences of Hepatic encephalopathy and Pneumonia in each cohort. However, based on the given data, it appears that cohort 1 had an equal number of cases for Hepatic encephalopathy (1) and more cases for Pneumonia (1 vs 0) compared to cohort 2. Therefore, the statement might not be accurate according to the information provided. The statement's potential contradiction stems from the assumption that \"more cases\" implies a higher absolute count, while the data in the CTRs only reveals the occurrence of these adverse events in each cohort. Further context or information, such as sample size, would be needed to validate the statement's claim accurately.</s>"
    },
    "7ea00c54-b4a1-427b-8ef7-a8b3cb96e8c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial, but excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n1. The primary trial includes patients with breast cancer and HER2 overexpression, while the secondary trial includes patients with stage IV breast cancer and HER2 positivity confirmed through FISH or IHC. Thus, patients with HER2 positive breast tumors satisfy the inclusion criteria for the primary trial but the specificity criteria for the secondary trial.\n\n2. In the primary trial, there is no explicit exclusion criterion related to HER2 status. However, in the secondary trial, there is no mention that HER2 positivity is a requirement for inclusion. Since there is no contradiction between the two sets of criteria, patients with HER2 positive breast tumors are eligible for the primary trial but excluded from the secondary trial due to the absence of an overlap in the inclusion criteria.</s>",
        "contradict": "The information contained in the statement can be contradicted by the information present in the CTRs because while the primary trial includes patients with HER2-positive breast cancer, the secondary trial excludes them. Therefore, the statement does not hold for all patients in the clinical domain as described by the trial reports.</s>"
    },
    "974225b7-9089-499c-9550-0a7207fd28b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "The intervention for the primary trial does not require patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy.",
        "Label": "Entailment",
        "entail": "In the primary trial, both intervention arms involve patients undergoing mastectomy or scheduling one, considering reconstruction, and interacting with decision tools or booklets during their consultations. No medical treatment is specified to be administered during the study as part of the interventions.\n\nIn the secondary trial, patients receive radiation therapy as part of the intervention but only the mode of administration varies between arms - daily boost versus weekly boost. However, the type of intervention in this trial (radiation therapy) is distinct from the interventions described in the primary trial where no medical treatment is involved.\n\nThe expert's statement that the intervention in the primary trial does not require patients to undergo any medical treatment during the study is entailed by the CTR information, as it aligns with the descriptions of the interventions in the primary trial and does not contradict them. In contrast, the statement about the secondary trial is not directly related to the information provided in the CTRs, as the type of intervention in the secondary trial is different from what was described in the primary trial.</s>",
        "contradict": "Despite the statement claiming that no medical treatment is required in the primary trial, the CTRs describe that patients in both arms interacted with intervention tools and were asked to answer surveys, which could be considered non-medical treatments. Furthermore, the statement's comparison to the secondary trial, which does involve medical treatment through radiation therapy, can create a misleading impression. Therefore, the statement's assertion contradicts the information present in the CTRs.</s>"
    },
    "974225b7-9089-499c-9550-0a7207fd28b2_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "The intervention for the primary trial requires patients to undergo any medical treatment during the study, whereas in the secondary trial, all patients receive Radiation Therapy.",
        "Label": "Contradiction",
        "entail": "In the primary trial, both Intervention 1 and Intervention 2 involve patient interactions with the study team, undergoing surveys and having information collected about consult durations and decision-making processes. There is no mention of any specific medical treatments given to patients beyond the study procedures.\n\nIn the secondary trial, both Intervention 1 and Intervention 2 involve Radiation Therapy. Therefore, the statement's requirement of patients receiving medical treatment during the study in the primary trial can be entailed by the fact that all patients in the secondary trial receive Radiation Therapy. This information doesn't contradict any information in the CTRs and finds substantiation in the description of the trials.</s>",
        "contradict": "The statement's claim that \"all patients receive Radiation Therapy\" in the secondary trial contradicts the information in the primary trial, where two different interventions (BREASTChoice Decision Tool vs Enhanced Usual Care) are compared, and none of them involve Radiation Therapy.</s>"
    },
    "974225b7-9089-499c-9550-0a7207fd28b2_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": " In the secondary trial, all patients receive Radiation Therapy, whereas the intervention for the primary trial does not require patients to undergo any medical treatment during the study.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail the information presented in the CTRs, as the CTRs describe interventions involving different types of treatments - a decision tool in the primary trial, and radiation therapy in the secondary trial. The statement focuses on the type of treatment received (radiation therapy) in the secondary trial, and the absence of a required medical treatment during the study in the primary trial. However, the statement is consistent with the information provided in the CTRs, as the primary trial does not involve any medical treatment as part of the intervention.</s>",
        "contradict": "The statement \"In the secondary trial, all patients receive Radiation Therapy, whereas the intervention for the primary trial does not require patients to undergo any medical treatment during the study\" is contradicted by the information present in the CTRs because, in the primary trial, patients were exposed to either the BREASTChoice decision tool or the Enhanced Usual Care booklet, neither of which involve undergoing medical treatment as part of the intervention. In contrast, in the secondary trial, patients in both arms received Radiation Therapy as the primary intervention.</s>"
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial\" is entailed by the Primary Trial's Inclusion Criteria, specifically the subcondition \"Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.\" This means that if the locally recurrent disease is amenable to radiation with curative intent, then the patient does not meet the inclusion criteria for the primary trial.</s>",
        "contradict": "The statement \"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the primary trial\" contradicts the information present in the CTR's Inclusion Criteria for the Primary Trial, which specifies that patients with locally recurrent disease that \"is not amenable to surgical resection or radiation with curative intent\" are eligible for the trial, provided all other inclusion criteria are met.</s>"
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are eligible for the primary trial\" is entailed by the primary trial's inclusion criteria stating \"Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent\" with the exception that the statement adds an additional condition that the locally recurrent disease should be amenable to radiation with curative intent for eligibility. This condition can be inferred as an implicit exclusion in the primary trial's inclusion criteria. Therefore, the statement does not contradict any information in the CTR, and it can be entailed from the primary trial's inclusion criteria.\n\nThe secondary trial's description was not provided to evaluate the potential entailment relationship with the given statement. The primary CTR's inclusion criteria are sufficient to determine the entailment relationship.</s>",
        "contradict": "The statement \"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are eligible for the primary trial\" contradicts the information in the CTR, as the Primary Trial's Inclusion Criteria explicitly states that \"Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent\".</s>"
    },
    "6f533f52-c8e4-4983-8968-69af03a9e34a_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Statement": "An exclusion criteria of the primary trial is having cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent.",
        "Label": "Entailment",
        "entail": "The statement excludes participants with locally recurrent breast cancer that is amenable to radiation with curative intent. The CTR specifies inclusion of patients with locally recurrent disease that is not amenable to surgical resection or radiation with curative intent. Since the statement excludes patients with locally recurrent disease that can be treated with radiation to achieve a cure, it is a subset of the condition stated in the CTR. Consequently, the statement is entailed by the CTR.</s>",
        "contradict": "The statement \"An exclusion criteria of the primary trial is having cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent\" contradicts the information in the CTR because, according to the primary trial's inclusion criteria, patients with locally recurrent breast cancer that is amenable to radiation with curative intent are specifically included in the trial, not excluded. Therefore, the statement's assertion is not harmonious with clinical trial data.</s>"
    },
    "690b8562-7d68-4642-bacb-601f227bb763": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial does not have an intervention section.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not have an intervention section\" is entailed by the information present in the CTR for the primary trial since the CTR explicitly states \"There are no arms or subgroups in this study.\" An intervention typically refers to the specific treatment or procedure under investigation in a clinical trial. Given that there are no distinct arms or subgroups in the primary trial, it logically follows that there is no intervention section in the report.</s>",
        "contradict": "The statement \"the primary trial does not have an intervention section\" is contradictory to the information provided in the CTR as the primary trial explicitly states that \"There are no arms or subgroups in this study,\" implying that the trial does indeed have an intervention, even if it's a single-arm study.</s>"
    },
    "690b8562-7d68-4642-bacb-601f227bb763_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "The primary trial has an intervention section.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial has an intervention section\" is entailed by the CTR of the primary trial as it explicitly states \"INTERVENTION:  Study Participants. There are no arms or subgroups in this study.\" Although the primary trial does not mention the term \"intervention section\" explicitly, the presence of the intervention details in the report fulfills the requirement for such a section.</s>",
        "contradict": "The statement \"The primary trial has an intervention section\" is not contradicted by the information provided in the CTR for the primary trial. However, it is contradicted by the statement in the CTR that \"There are no arms or subgroups in this study,\" as this implies that there is no intervention section in the primary trial. The secondary trial, which is not mentioned in the statement, may or may not have an intervention section.</s>"
    },
    "690b8562-7d68-4642-bacb-601f227bb763_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "An intervention section is not present in the primary trial.",
        "Label": "Entailment",
        "entail": "The absence of an intervention section in the primary CTR implies that no specific intervention or treatment was administered to the study participants. The statement made by the clinical trials expert accurately reflects this fact, as stated in the CTR under the Intervention section: \"There are no arms or subgroups in this study.\" Therefore, the statement's assertion harmonizes with the clinical trial data and is entailed by the provided information.</s>",
        "contradict": "The statement is not a contradiction but rather an observation based on the information provided in the CTRs. While it is true that the primary trial does not have an intervention section as explicitly stated in the given CTR snippet, it does not contradict the statement as the CTRs themselves confirm the absence of intervention details, which is what the expert statement is describing.</s>"
    },
    "75f94edd-dbde-4a19-be18-e67c767f6d8f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration for cohort 2, however cohort 1 receives placebo twice daily for two months.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR information because the primary trial's intervention section does not specify the dosage, frequency, or duration for cohort 2, as stated. Therefore, the absence of information regarding the intervention for cohort 2 in the primary CTR is in accordance with the expert's statement. Additionally, the expert's statement does not contradict the information in the CTR, as it only pertains to the intervention details for cohort 2, which is not mentioned in the CTR.</s>",
        "contradict": "The statement can be contradicted by the information present in the primary CTR because it only refers to the intervention details for cohort 1 (placebo group), while the secondary trial does not have an explicitly stated intervention for cohort 2. The primary CTR's intervention section does provide information about the intervention received by cohort 1, allowing for comparison and contrast with cohort 2 in the secondary trial if such information is available there. However, the statement's focus on cohort 2's absence of intervention dosage, frequency, and duration details is not directly contradictory to the information in the primary CTR, but rather a lack of information in the secondary CTR.</s>"
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. From the primary trial, the number of participants who had a partial tumor response in the Caelyx, Docetaxel, Trastuzumab arm was 13 out of 26 participants (50%).\n2. From the secondary trial, the percentage of patients with a partial response in the Abraxane + Tigatuzumab arm ranged from 14.9% to 45.0% (average: 28%), and for the Abraxane Alone arm the percentage ranged from 18% to 61.1% (average: 38%).\n\nComparing the percentages directly, the primary trial had a higher percentage of participants with at least a partial response (50%) than either arm of the secondary trial on average. Therefore, the statement \"the primary trial had a higher percentage of patients with at least partial response than either cohort of the secondary trial\" is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial reported 15 participants (53.8%) with either complete or partial response, while the secondary trial with Abraxane + Tigatuzumab reported 6 (15.4%) with partial response, and the secondary trial with Abraxane alone reported 8 (38.1%) with partial response. Therefore, neither cohort in the secondary trial had a higher percentage of participants with at least partial response compared to the primary trial.</s>"
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "The primary trial didn't have a higher percentage of patients with at least partial response than either cohort of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. From the primary trial results, the number of participants with partial response is 13 out of 26 analyzed, which is equivalent to 49.23% (13/26).\n2. From the first cohort of the secondary trial, the percentage of patients with a response (partial or complete) ranges from 14.9% to 45.0%, which includes 30% decrease in tumor size (partial response).\n3. From the second cohort of the secondary trial, the percentage of patients with a response is 38% (8 out of 21).\n4. Comparing the percentages from the primary and secondary trials, it's clear that the primary trial did not have a higher percentage of patients with at least partial response than either cohort of the secondary trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as follows:\n\n1. In the primary trial, the partial response rate is 46.2% (13/28), while in one of the secondary trials, the partial response rate is 45.0% (18/39). A direct comparison between the two trials suggests that the primary trial does not have a lower percentage of participants with at least partial response. However, this conclusion overlooks the difference in the overall number of participants analyzed and the measurement units used. In the primary trial, there were 28 participants with partial response out of a total of 104 participants (26 analyzed), whereas, in one of the secondary trials, there were 18 participants with partial response out of a total of 39 participants (39 analyzed). Therefore, the percentage of participants with partial response in the primary trial is higher when considering the total number of participants in the study.\n\n2. Additionally, the other secondary trial reports a partial response rate of 61.1% (13/21). Again, comparing the percentages directly can be misleading due to the different sample sizes. However, when comparing the number of participants with at least partial response between the primary and both secondary trials, the primary trial still has a higher number of participants with partial response (2 + 13 = 15) than the secondary trial with the lower partial response rate (18).\n\nTherefore, the expert's statement is incorrect as the primary trial had a higher number of participants with at least partial response when accounting for the total number of participants in both trials.</s>"
    },
    "e37ed9ee-b312-4ea3-a6eb-3785fa94ccc4_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "Either cohort of the secondary trial had a lower percentage of patients with at least partial response than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Either cohort of the secondary trial had a lower percentage of patients with at least partial response than the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. From the primary trial Results 1, we have the number of participants who had complete response, partial response, and no response for the Caelyx, Docetaxel, and Trastuzumab arm. We can calculate the percentage of patients who had at least partial response (complete and partial responses) by adding the number of patients with complete response and partial response and dividing by the total number of participants analyzed, which is 26. The calculation results in: percentage of patients with at least partial response = (2 + 13)/26 * 100%.\n\n2. From the secondary trial Results 1, we have the percentage of patients with at least partial response for both the Abraxane + Tigatuzumab and Abraxane Alone arms. We need to compare these percentages to the primary trial's percentage.\n\n3. To compare the percentages, we can observe that the percentage of patients with at least partial response in the primary trial was greater than 45.0% (the upper bound of the range for the secondary trial). Since the primary trial's percentage is higher than both the minimum and maximum percentage of patients with at least partial response in the secondary trial, it entails that neither cohort in the secondary trial had a higher percentage of patients with at least partial response than the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial reported 15 participants (53.8%) with at least partial response, whereas both cohorts in the secondary trial reported slightly higher percentage of patients with at least partial response: 28.2% (Arm A) and 38% (Arm B). Contradiction arises since the statement implies that neither cohort in the secondary trial had a higher or equal percentage of participants with at least partial response compared to the primary trial.</s>"
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Entailment",
        "entail": "The statement \"Both cohorts in the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study\" is entailed by the CTR information as follows:\n\n1. Both cohorts (Arm I and Arm II) in the primary trial use topical interventions (Curcumin-based Gel and HPR Plus\u2122, respectively).\n2. Application frequency for both interventions is \"approximately every 4-6 hours\".\n3. Application starts on the first day of radiation therapy and continues until 1 week after completion of radiation therapy.\n4. A week is the duration between the start and completion of the application for both interventions.\n\nGiven that both cohorts use the same application frequency and duration, the expert's statement is a valid conclusion based on the information present in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs. However, it is less specific than the CTRs and could potentially be misleading. The statement implies that the topical interventions are applied the same way for both cohorts, which is true according to the given information in the CTRs. however, the CTRs also specify different interventions for each arm (Curcumin-based Gel and HPR Plus) with possibly different effects on dermatologic complications management. Therefore, even though the application frequency is the same, the context and implications could differ between the cohorts. To avoid confusion, it is crucial to consider the specific details of the interventions when comparing and contrasting statements with trial data.</s>"
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial don't apply the topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Contradiction",
        "entail": "Both cohorts in the primary trial apply the topical intervention (curcumin-based gel or HPR Plus) approximately every 4-6 hours from the first day of radiation therapy until 1 week after completion. This frequency aligns with the statement's requirement that they don't apply the intervention \"approximately every 4-6 hours every day for a week.\" Thus, the statement is entailed by the CTRs as it correctly describes the interventions' application schedules without contradicting the provided information.</s>",
        "contradict": "The expert's statement \"Both cohorts in the primary trial don't apply the topical intervention for approximately every 4-6 hours every day for a week of the study\" contradicts the information present in the CTRs. According to the CTR descriptions, patients in both interventions (Arm I with curcumin-based gel and Arm II with HPR Plus) are instructed to apply the topical interventions TID (three times a day) beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy. This application frequency meets, or even exceeds, the expert's stated requirement of \"approximately every 4-6 hours every day for a week\" of the study.</s>"
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "The topical intervention for approximately every 4-6 hours every day for a week of the study is applied to both cohorts in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The topical intervention for approximately every 4-6 hours every day for a week of the study is applied to both cohorts in the primary trial\" is entailed by the information present in the CTRs because both Intervention 1 (Curcumin-based Gel) and Intervention 2 (HPR Plus) specify application of the topical interventions \"approximately every 4-6 hours\" starting on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy for both arms of the study.</s>",
        "contradict": "The expert's statement is contradicted by the information in the CTRs as the interventions in Arm I and Arm II have identical application schedules, but they differ in the substances applied: Curcumin-based Gel and HPR Plus\u2122, respectively. Therefore, the expert's statement, which refers only to the topical application schedule, does not capture this important distinction. Consequently, the expert's statement could potentially misrepresent or oversimplify the actual trial conditions.</s>"
    },
    "9b0451fe-f760-46d3-b555-0a9b83546e73": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded half as many patients vomiting as the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded half as many patients vomiting as the secondary trial\" can be entailed by the information present in the CTRs if we assume that the expert's reference to \"vomiting\" in the statement corresponds to the adverse event \"Nausea/vomiting\" reported in both trials. Based on the given data, the primary trial recorded 1/20 (5.00%) cases of Nausea/vomiting, while the secondary trial recorded 4/39 (10.26%) cases. Half of the secondary trial's reported cases would be: 10.26% * 0.5 = 5.13%. The primary trial's reported cases are less than half of this value, which aligns with the statement.</s>",
        "contradict": "The statement \"the primary trial recorded half as many patients vomiting as the secondary trial\" is contradicted by the information present in the CTRs because the primary trial recorded the same number of patients experiencing nausea/vomiting (4/20 or 20.00%) as the secondary trial recorded for this symptom (4/39 or 10.26%). However, the statement implies that only diarrhea is considered when comparing vomiting between the trials, but the statement's phrasing is ambiguous, leading to the potential for misunderstanding or misinterpretation.</s>"
    },
    "b9304415-073d-476e-a056-cb2a747d56fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial receives Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial receives Doxorubicin only during cycles 1-4, and then Doxorubicin, cyclophosphamide, Herceptin and docetaxel during Cycle 5 of the study\" can be entailed by the information present in the CTRs as follows:\n\nINTERVENTION 1 for cohort 2 in the primary trial: Doxorubicin 60 mg/m\u00b2 IV bolus injection on Day 1 of every 3 weeks for 4 cycles.\n\nINTERVENTION 2 for cohort 2 in Cycle 5: Doxorubicin 60 mg/m\u00b2 IV bolus injection, followed by cyclophosphamide, Herceptin, and docetaxel.\n\nTherefore, during Cycle 5 of the primary trial, cohort 2 receives Doxorubicin (60 mg/m\u00b2 IV bolus) followed by cyclophosphamide, Herceptin (2 mg/kg IV infusion from Day 8), and docetaxel (100 mg/m\u00b2 IV infusion). This sequence of treatments matches the description in the expert statement, thus establishing entailment.</s>",
        "contradict": "The statement asserts that Cohort 2 in the primary trial receives Doxorubicin only during cycles 1-4, followed by Doxorubicin, cyclophosphamide, Herceptin, and docetaxel in cycle 5. However, the CTR for the primary trial indicates that Cohort 2 receives Doxorubicin and cyclophosphamide during cycles 1-4, and then docetaxel during cycles 5-8. Herceptin is administered differently in the CTR, with a different dosing schedule (starting from Day 8 of cycle 5 and continuing every 3 weeks until 1 year from initial dose). Therefore, the information in the statement contradicts the CTR as it incorrectly implies that Herceptin is also given during cycles 5-8 when it is actually given after cycle 8.</s>"
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement \"Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial\" is entailed by the CTR inclusion criteria which state \"Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer. Unresectable, locally recurrent breast cancer or stage IV disease.\" Thus, the statement's assertion harmonizes with the CTR data, finds substantiation within the CTR, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement can be contradicted by the information in the CTR as it incorrectly states that only Chinese women with stage 4 or unresectable, locally recurrent breast cancer are eligible for the primary trial. Per the CTR, there are additional inclusion criteria that must be met: female patients of Chinese origin with histologically or cytologically proven breast cancer, performance status of 0 or 1 on the ECOG Scale, treatment with an anthracycline-based chemotherapy regimen in the adjuvant/neoadjuvant setting with subsequent disease relapse, and at least one measurable lesion. These additional conditions are not mentioned in the expert's statement, making it an incomplete and potentially incorrect representation of the trial eligibility criteria.</s>"
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails that only Chinese women with stage 4 or unresectable, locally recurrent breast cancer are ineligible for the primary trial, which is in agreement with the CTR's inclusion criteria, which specifies that only female patients of Chinese origin with unresectable, locally recurrent breast cancer or stage IV disease are eligible for the trial. This information is not contradictory to the CTR and is a direct consequence of the provided eligibility criteria.</s>",
        "contradict": "The statement \"Only Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer aren't eligible for the primary trial\" is contradicted by the CTR inclusion criteria because the primary trial also excludes Chinese women with stage 4 or Unresectable, locally recurrent breast cancer if they have undergone prior chemotherapy for these conditions or if they have concurrent administration of other tumor therapies. Therefore, it's not just the stage and the type of breast cancer that disqualifies the patients from the primary trial as per the statement, but an addition of conditions not mentioned in the statement.</s>"
    },
    "6e365e33-16b8-43e1-99b5-49dfed6f7b13_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "The primary trial is only eligible to Chinese women with stage 4 or Unresectable, locally recurrent cancer breast cancer.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial is only eligible to Chinese women with stage 4 or Unresectable, locally recurrent breast cancer\" is entailed by the CTR information under the \"Inclusion Criteria\" section, which specifies \"Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer. Unresectable, locally recurrent breast cancer or stage IV disease\" as the patient eligibility criteria.</s>",
        "contradict": "The statement is contradictory to the CTR information as it does not accurately reflect the full inclusion criteria. While the primary trial is indeed focused on Chinese women with stage 4 or unresectable, locally recurrent breast cancer, the CTR also includes patients with histologically or cytologically proven diagnosis of breast cancer who have received an anthracycline-based chemotherapy regimen with subsequent disease relapse, and have at least one measurable lesion as defined by RECIST criteria and a performance status of 0 or 1 on the ECOG Scale. Therefore, the statement's restriction to only stage 4 or unresectable, locally recurrent breast cancer does not entail the full set of conditions specified in the CTR.</s>"
    },
    "7c2dd3c3-8e72-451e-9fe7-c442f659bfc3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs because, in both cohorts, patients received trastuzumab 2 mg/kg IV weekly, paclitaxel 80 mg/m2 weekly for 3 weeks, and a 7-day rest period. However, the dosage of Dasatinib differs between cohorts, with cohort 1 receiving 100mg and cohort 2 receiving 140mg. Therefore, cohort 1 indeed received more Dasatinib per day (100mg vs 140mg/day) and, considering both Dasatinib and Paclitaxel are given on a daily basis in different dosages, they receive more Dasatinib and Paclitaxel overall during each 28-day cycle in cohort 1.</s>",
        "contradict": "Although cohort 1 in the primary trial received a higher dose of Dasatinib (100mg vs. 140mg), both cohorts received the same dose of Trastuzumab (2mg/kg) and Paclitaxel (80mg/m2). Therefore, the statement \"Participants of cohort 1 in the primary trial received more Dasatinib and Paclitaxel than those in cohort 2\" is not necessarily true based on the CTR information provided. Instead, cohort 1 participants received a different dose of Dasatinib but identical doses of Trastuzumab and Paclitaxel.</s>"
    },
    "27acc6d7-c12d-4a38-9133-a5c8429dd264": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial recorded 23 adverse events.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"the primary trial recorded 23 adverse events\" is entailed by the CTR data as the CTR reports a total of 23 adverse events across all the mentioned categories (0.00%) for the primary trial.</s>",
        "contradict": "The expert's statement \"the primary trial recorded 23 adverse events\" is in direct contrast with the data present in the CTR under the Adverse Events section for the primary trial, as the CTR states that \"Total: 0/23 (0.00%)\". This contradiction arises because the statement made by the expert implies that there were 23 adverse events reported, whereas the CTR indicates that there were no recorded adverse events.</s>"
    },
    "5919a080-2f0d-4c3b-9b03-10df80b2e680": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "There were no adverse event in the primary trial which affected more than 10% of a particular patient cohort.",
        "Label": "Contradiction",
        "entail": "None of the adverse events in the primary trial had a prevalence exceeding 10% within any patient cohort as per the reported data. This claim is entailed by the CTRs since the prevalence rates for each adverse event, such as anemia (3.57%), neutropenia (4.29%), thrombocytopenia (1.43%), and others, are all less than 10%. The same is true for the secondary trial with no reported adverse events exceeding 10%.</s>",
        "contradict": "The statement \"There were no adverse events in the primary trial which affected more than 10% of a particular patient cohort\" is contradicted by the data in the CTRs because the incidence rate of febrile neutropenia (10.71%) and total adverse events (43.57%) in the primary trial exceeds 10% for the respective patient cohorts.</s>"
    },
    "91f6e62a-97e7-49fa-8509-7ff8c1f0155e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) or Melanoma are eligible for both the secondary trial and the primary trial, and are able to participate in these trials alongside other drug trials, up to a maximum of 3.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs if we consider the following:\n\n1. The CTRs include patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma in the primary trial's eligibility criteria for breast cancer patients, provided that lymph node biopsy is part of the surgical plan.\n2. The CTR for the secondary trial specifies inclusion criteria for breast cancer patients, which includes patients with Ductal or Infiltrating Ductal Carcinoma, but does not explicitly mention pure DCIS in the inclusion criteria. However, the secondary trial's inclusion criteria do not contradict the primary trial's eligibility criteria for patients with DCIS, as the secondary trial requires lymph node biopsy.\n3. The statement does not contradict the exclusion criteria in either of the CTRs, as there is no explicit mention of a limit on concurrent drug trials for patients.</s>",
        "contradict": "The patients with pure ductal carcinoma in situ (DCIS) from the secondary trial are eligible to participate in the primary trial, but the primary trial explicitly excludes patients with a diagnosis of pure DCIS or non-invasive carcinoma unless lymph node biopsy is part of the surgical plan. \n\nAdditionally, melanoma patients are not explicitly mentioned as being eligible for the secondary trial according to the provided criteria, and there are several exclusion criteria for melanoma patients in the primary trial which make it unlikely for them to meet eligibility requirements.\n\nFurthermore, the statement asserts that these patients can participate in up to 3 trials, but the CTRs do not provide information about concomitant trial participation limitations.\n\nTherefore, the statement contains contradictory information with the inclusion and exclusion criteria in the CTRs, and its assertions cannot be entailed by the data presented.</s>"
    },
    "b351a091-d5fb-49f9-a864-5c89c6316b1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed PR+ invasive breast cancer, with Primary tumor > 2 cm in diameter TO PARTICIPATE in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert statement entails the primary trial's inclusion criteria, specifically the requirement for patients to have a histologically or cytologically confirmed invasive breast cancer and a primary tumor larger than 2 cm in diameter. This requirement aligns with the information presented in the CTR's inclusion criteria section. Therefore, the expert statement is entailed by the CTR data.</s>",
        "contradict": "The given statement can be contradicted by the CTRs as follows:\n\n1. The primary trial's inclusion criterion specifies that patients must have histologically or cytologically confirmed primary invasive breast cancer. However, the statement only mentions PR+ invasive breast cancer, which is a subset of invasive breast cancers. The CTRs do not necessarily only include patients with PR+ invasive breast cancer.\n\n2. While the statement mentions a tumor size requirement of > 2 cm in diameter for trial participation, the CTRs have multiple additional requirements for eligibility. Not all patients who meet the stated tumor size criterion may be eligible to participate due to the presence of other exclusionary criteria in the CTRs.\n\n3. The expert's statement does not include any mention of overexpression and/or amplification of HER2, Karnofsky percentage, or other eligibility criteria mentioned in the CTRs. The CTRs may include additional eligibility requirements that contradict the statement if those requirements are not met.\n\n4. The statement does not specify which trial it refers to, potentially implying the primary trial but not necessarily so. If the expert meant to refer to a different trial with different eligibility criteria, their statement could contradict the primary trial's CTRs even if the stated condition (PR+ invasive breast cancer with > 2 cm diameter tumor) is met.\n\nOverall, the given statement is too vague and incomplete compared to the comprehensive inclusion criteria presented in the CTRs, making it potentially contradictory to the CTRs in certain cases.</s>"
    },
    "d5ca2086-8404-42d1-bf45-5370f3d4e8e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows: In the primary CTR, there is a total of 15 participants with adverse events, out of which 1 participant (6.67%) experienced hemorrhage. In the secondary CTR, there are 258 participants with adverse events, out of which 1 participant (0.39%) experienced hemorrhage. The difference in the percentage of hemorrhaging cases between the trials is calculated as (|6.67% - 0.39%|) = 6.28%, which is less than the stated 16.67%. However, since the percentage difference mentioned in the statement is an error, the statement can still be considered entailed if we disregard the specific percentage mentioned and focus on the fact that there is a difference in the occurrence of hemorrhaging between the two trials.</s>",
        "contradict": "The statement \"There was 16.67% more cases of hemorrhaging in the primary trial than in the secondary trial\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not provide a clear definition of hemorrhaging, making it difficult to determine if the conditions leading to hemorrhage events in the primary trial are the same as those in the secondary trial. However, the statement is not entailed by the data provided, as there is no mention of hemorrhaging events in the secondary trial in the given Adverse Events sections.</s>"
    },
    "4c038972-20a9-4031-a1cd-ba00e9dd0908": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Secondary_id": "NCT00617539",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily. The opposite was true in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as follows: In the primary trial, the median PFS for Dasatinib, 70 mg, Twice Daily was 15.3 (8.7-20.1) weeks, which is longer than the median PFS for Dasatinib, 100 mg, Daily, which was 10.3 (8.4-16.7) weeks (Results 1 and 2 in the CTRs). However, in the secondary trial, the treatment with Irinotecan and Temozolomide had a lower response rate (6.7%) compared to Dasatinib, 100 mg, Daily in the primary trial, where the number of participants with objective treatment response (complete or partial) in the CNS was not provided (Results 1 in each CTR). But, the statement does not contradict the CTRs as it only compares the PFS between the two different doses of Dasatinib within each trial and does not involve the secondary trial results directly.</s>",
        "contradict": "The statement is not entailed by the provided information in the CTRs as it does not directly compare the median PFS between the same treatment groups across the trials. Instead, it compares different treatment groups between trials. The primary and secondary trials have different patient populations, outcome measurements, and assessment criteria for PFS, which makes a direct comparison of the treatment groups inaccurate. The statement contradicts the information in the CTRs as it oversimplifies the results and fails to consider the contextual differences between the trials.</s>"
    },
    "82d6275a-97e6-4d13-84eb-5f7c2585db8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorst of the primary trial and the secondary trial there was only a single patient who suffered heart failure.",
        "Label": "Contradiction",
        "entail": "The statement that \"between both of the patient cohorts of the primary trial and the secondary trial, there was only a single patient who suffered heart failure\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial reported 3 instances of heart failure in 199 patients (a rate of 1.51%).\n2. The secondary trial reported 4 instances of heart failure in 198 patients (a rate of 2.02%).\n3. The total number of patients in both trials is 397 (199 from the primary trial and 198 from the secondary trial).\n4. Subtracting the number of patients in each trial from the total, we have 5 patients with heart failure out of 397.\n5. Therefore, there was indeed only a single patient who suffered heart failure between the two cohorts (the sixth instance of heart failure could have belonged to either cohort).</s>",
        "contradict": "The statement \"Between both of the patient cohorts of the primary trial and the secondary trial, there was only a single patient who suffered heart failure\" contradicts the information present in the CTRs because:\n\n1. In the primary trial, there were three heart failures reported in the first Adverse Events section and one in the second section, making a total of four cases.\n2. In the secondary trial, there was only one reported heart failure in the second Adverse Events section.\n3. Therefore, according to the given data, there is a difference of at least three heart failure cases between the patient cohorts of both trials, which contradicts the statement that \"there was only a single patient who suffered heart failure\" across both trials.</s>"
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Entailment",
        "entail": "According to the CTR for the primary trial, the PFS was defined as the time from randomization to disease progression or death. The Afatinib + Vinorelbine (AV) arm participants received oral treatment of Afatinib at a median PFS of 5.49 months (3.55 to 9.07), which falls within the range of 9 months. Therefore, at least one AV arm participant experienced a PFS longer than 9 months, as stated in the expert's claim. Additionally, the CTR states that participants in the AV arm had the option to switch to Trastuzumab + Vinorelbine (TV) from 26 April 2013. However, since the expert's statement does not specify which arm the participant belonged to before or after the switch, it remains valid for either condition.</s>",
        "contradict": "The statement \"At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months\" can be contradicted by the information present in the CTRs because the median PFS for the Afatinib + Vinorelbine arm (AV) was 5.49 months [(3.55 to 9.07)], which is less than 9 months.</s>"
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least one participant in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) didn't have a PFS over 9 months.",
        "Label": "Contradiction",
        "entail": "Based on the CTR information, there were 339 participants in the Afatinib + Vinorelbine (AV) arm, and their median PFS was 5.49 months (3.55 to 9.07). This means that approximately 50% of the participants had a PFS shorter than 9 months, and some could have had a PFS even less than that. Therefore, it is plausible that at least one participant in this arm had a PFS under 9 months, as claimed by the statement.</s>",
        "contradict": "The statement cannot be directly contradicted by the information in the CTRs, as the statement only asserts that at least one participant in the Afatinib + Vinorelbine arm had a PFS under 9 months, but the CTRs do not provide specific information about the PFS duration of individual participants. However, it is important to note that the median PFS in the Avatinib + Vinorelbine arm was 5.49 months, which is slightly under the threshold of 9 months mentioned in the statement, but this doesn't necessarily mean that there were participants with a PFS under 9 months. The CTRs do not provide sufficient information to confirm or refute the statement with certainty.</s>"
    },
    "286e74e5-74ed-4d42-b32d-f1398c514d37_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "A PFS over 9 months was had by at least one participant in the primary trial that received an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m).",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: \n\n1. The CTR for the primary trial specifies that at least one participant in the Avatinib + Vinorelbine (AV) arm received a PFS greater than 9 months. \n2. The CTR for the primary trial also specifies that participants in the AV arm received oral treatment of film-coated Afatinib tablet at a starting dose of 40 mg once daily and weekly intravenous infusions of Vinorelbine 25 mg/m^2. \n3. The statement's condition for entailment (a PFS over 9 months for a participant in the AV arm) is satisfied by the information in the CTR (at least one participant in the AV arm had a PFS greater than 9 months). \n4. The statement does not contradict any information in the CTRs. \n5. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"at least one participant in the primary trial that received an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 had a Progression-Free Survival (PFS) over 9 months\" cannot be directly contradicted by the information present in the CTRs. However, without additional context or information, it is impossible to definitively establish entailment between the statement and the CTRs. The CTRs do provide the median PFS for participants in each arm, but they do not specify the distribution of PFS durations. It is possible, but not guaranteed, that some participants in the Afatinib + Vinorelbine arm had PFS longer than 9 months. The statement, therefore, does not contradict the CTRs but also does not definitively follow from them.</s>"
    },
    "634642da-db6d-49cc-a999-67f46e91dbca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria\" is entailed by the CTR information as follows:\n\nThe primary trial has inclusion criteria of subjects who had previously participated in study 971-ONC-0028-080. This is an explicit difference from the secondary trial, which has inclusion criteria related to breast cancer and its stages, age, and sex (among others). The primary trial excludes subjects who had not previously participated in study 971-ONC-0028-080, which is again distinct from the secondary trial's exclusion criteria (such as specific disease characteristics, laboratory values, and prior therapies).\n\nTherefore, the CTRs provide no evidence of any overlapping inclusion or exclusion criteria between the two trials.</s>",
        "contradict": "The statement that \"the primary trial and the secondary trial do not have any overlapping inclusion or exclusion criteria\" is contradicted by the information provided in the CTRs. In the primary trial, the inclusion criteria state that subjects had previously participated in study 971-ONC-0028-080, while in the secondary trial, the exclusion criteria state that subjects who had not previously participated in study 971-ONC-0028-080 were excluded. This means that there is an overlap in the exclusion criteria between the two trials, making the expert's statement incorrect.</s>"
    },
    "634642da-db6d-49cc-a999-67f46e91dbca_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "The primary trial and the secondary trial have any overlapping inclusion or exclusion criteria.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial have no overlapping inclusion or exclusion criteria\" cannot be entailed by the information present in the provided CTRs as both trials have distinct inclusion and exclusion criteria. The primary trial includes subjects with a previous participation in study 971-ONC-0028-080, and the secondary trial includes patients with breast cancer at high risk for recurrence based on various disease and patient characteristics. No commonalities exist between these criteria, hence there is no entailment relationship.</s>",
        "contradict": "The primary trial's inclusion criteria require previous participation in study 971-ONC-0028-080, while the secondary trial excludes those who had not previously participated in the same study. These criteria are contradictory, making the statement that the trials have no overlapping inclusion or exclusion criteria false.</s>"
    },
    "634642da-db6d-49cc-a999-67f46e91dbca_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01237327",
        "Secondary_id": "NCT00030823",
        "Statement": "The secondary trial and the primary trial do not have any overlapping inclusion or exclusion criteria.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial and the primary trial do not have any overlapping inclusion or exclusion criteria\" can be entailed by the information in the CTRs as follows:\n\n1. In the primary trial, inclusion criteria require previous participation in study 971-ONC-0028-080, which is an unique criterion not present in the secondary trial.\n2. In the primary trial, exclusion criteria state that subjects who had not previously participated in study 971-ONC-0028-080 were excluded, which is also not present in the secondary trial.\n3. The secondary trial includes various disease and patient characteristics, some of which have different criteria compared to the primary trial, indicating separate sets of inclusion and exclusion criteria.\n\nTherefore, the statement that the trials do not have any overlapping inclusion or exclusion criteria is inferred to be true based on the distinct criteria outlined in the CTRs for each trial.</s>",
        "contradict": "The statement \"The secondary trial and the primary trial do not have any overlapping inclusion or exclusion criteria\" is contradicted by the CTRs because the primary trial includes subjects who have previously participated in study 971-ONC-0028-080, while the secondary trial excludes subjects who have not previously participated in that study. Therefore, there is an overlap in exclusion criteria between the two trials.</s>"
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 2 weeks would be excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR's exclusion criteria as it specifies that investigational agents, including immunotherapies like T-cell transfer therapy, are excluded if administered within 4 weeks prior to study enrollment for the primary trial.</s>",
        "contradict": "The patient who underwent T-cell transfer therapy in the past 2 weeks would not be eligible for the primary trial according to the CTR inclusion criteria. However, the expert statement implies that this patient would be excluded, suggesting a contrary condition. The discrepancy lies in the interpretation of the same information, where the CTR indicates ineligibility, while the expert's statement implies exclusion.</s>"
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 2 weeks wouldn't be excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not entail information from the CTRs as it contradicts the exclusion criteria mentioned in the Primary Trial section which explicitly states, \"Exclusion Criteria: ... Immunosuppressive therapy including:... T-cell transfer therapy (within 4 weeks prior to study enrollment)...\"</s>",
        "contradict": "The statement is contradicted by the CTR as it specifies that patients should have no immunosuppressive therapy, including investigational agents, within 4 weeks prior to study enrollment. T-cell transfer therapy is considered an immunosuppressive therapy.</s>"
    },
    "a529e364-2da7-4067-acb6-9fb2f0adf08b_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "The primary trial excludes patients that underwent T-cell transfer therapy in the past 2 weeks.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria as it mentions the exclusion of patients who have received immunotherapy within 2 weeks of study enrollment, which includes T-cell transfer therapy as a type of immunotherapy. The CTR specifically states that patients must be 6 weeks free from immunotherapy to be eligible. Therefore, the statement is a valid implication of the information present in the CTRs.</s>",
        "contradict": "T-cell transfer therapy is not mentioned in the exclusion criteria of the primary CTR. Hence, the statement contradicts the information presented in the CTR.</s>"
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their bone marrow are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The patients in the primary trial are not allowed to have histologically proven bone marrow metastasis, as per the disease characteristics specified in the CTR. The expert's statement that patients with bone marrow metastases are excluded from the trial is a consequence of this criterion. Therefore, the statement is entailed by the CTR information.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTR as it does not explicitly exclude patients with bone marrow metastasis from the primary trial, but only those with histologically proven bone marrow metastasis.</s>"
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their bone marrow aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as it is not stated that patients with bone marrow metastasis are excluded in the Eligibility Criteria section of the primary trial. The CTR only specifies that there should be no histologically proven bone marrow metastasis. The absence of an exclusion does not necessarily mean inclusion, but the lack of an explicit exclusion implies that patients with bone marrow metastasis may still be eligible, as stated in the expert's claim.</s>",
        "contradict": "The statement \"Patients with Cancer that has spread to their bone marrow aren't excluded from the primary trial\" contradicts the CTR information under the Disease Characteristics section, where it explicitly states \"No histologically proven bone marrow metastasis\" as a condition for patient inclusion.</s>"
    },
    "317e00ae-9d17-4f85-8787-602cc2548fdb_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "The primary trial excludes patients with Cancer that has spread from a breast tumor to their bone marrow.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial excludes patients with Cancer that has spread from a breast tumor to their bone marrow\" is entailed by the CTR as the disease characteristics specify \"No histologically proven bone marrow metastasis.\"</s>",
        "contradict": "The provided CTR for the primary trial includes the eligibility criteria stating that \"No histologically proven bone marrow metastasis\" is a requirement for patient inclusion. The expert statement, however, asserts that the primary trial excludes patients with breast cancer that has spread to their bone marrow without explicitly mentioning the absence of bone marrow metastasis as an inclusion criteria. Although the statement's intent aligns with the data in the CTR, its wording may give rise to contradictory interpretations. It is essential to recognize that the statement does not explicitly mention that patients with no bone marrow metastasis are included, which may lead to confusion regarding the applicability of the statement to the primary trial's eligibility conditions.</s>"
    },
    "de955acc-ce0e-4416-9884-644a06971603": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial and the secondary trial are test groups.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial and the secondary trial are test groups\" can be entailed by the information present in the CTRs because both trials involve the comparison of two groups (intervention arms) receiving different treatments. In the primary trial, these groups are labeled as \"INTERVENTION 1: Glutamine\" and \"INTERVENTION 2: Placebo,\" while in the secondary trial they are labeled as \"INTERVENTION 1: Mammography Only\" and \"INTERVENTION 2: Gamma Imaging.\" In both trials, the researchers aim to evaluate the effects of each intervention against a control or comparison group. Therefore, the designation of these groups as test groups is inferred from the trial structure and objectives, which align with the information in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial and the secondary trial are test groups\" cannot be directly contradicted by the information in the provided CTRs. However, the statement is not entailed by the CTR information either, as it goes beyond the details given in the reports and makes an assumption not directly stated therein.\n\nThe CTRs only indicate that the trials involved cohorts or arms exposed to distinct interventions, but they do not explicitly state that these cohorts or arms functioned as test groups in a study comparing the interventions. Therefore, the statement is neither contradictory nor entailed by the provided information in the CTRs.</s>"
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has more patients cohorts than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial has more patient cohorts than the primary trial\" is entailed by the information in the CTRs as follows: \n\n1. The primary trial has one intervention with the use of Electronic Brachytherapy. \n2. The secondary trial has two interventions - one with the same Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine but with different dosages (300 micrograms for Initial Cohort and 500 micrograms for Escalation Cohort) for subcutaneous administration. \n3. Therefore, the secondary trial has more than one intervention, and subsequently, it has more than one cohort (one for each intervention), which satisfies the condition stated in the expert's claim.\n\nThis explanation illustrates that the information in the expert's statement can be inferred from the descriptions in the CTRs and does not contradict them, establishing entailment.</s>",
        "contradict": "The statement does not contradict the information in the CTRs. The primary trial describes the use of a specific type of radiation therapy, Electronic Brachytherapy, using the Xoft Axxent System. The secondary trial, on the other hand, describes two different cohorts receiving vaccinations with varying dosages. The number of cohorts in each trial does not depend on the type of intervention but on the number of groups in the study design. Therefore, it is possible for a trial with a different intervention to have more patient cohorts than another trial.</s>"
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "The secondary trial doesn't have more patients cohorts than the primary trial.",
        "Label": "Contradiction",
        "entail": "Both trials have only one intervention (Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG) with two different dosage groups: the Initial Cohort receiving 300 micrograms per dose, and the Escalation Cohort receiving 500 micrograms per dose. The number of distinct cohorts, regardless of their dosage groupings, remains the same in both trials, which aligns with the stated claim that the secondary trial does not have more patient cohorts than the primary trial.</s>",
        "contradict": "The statement does not provide information about the number of patient cohorts in each trial. However, based on the given information, the primary trial has only one Intervention arm (Electronic Brachytherapy), while the secondary trial has two Intervention arms (Initial Cohort with 300 micrograms dosage and Escalation Cohort with 500 micrograms dosage, both receiving the same vaccine). Therefore, the secondary trial indeed has more than one arm, contradicting the assumption made in the statement.</s>"
    },
    "4956f0d0-4df4-4de3-9a46-6073927485c3_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "The primary trial has less patients cohorts than the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial has fewer patient cohorts than the secondary trial\" can be entailed by the information present in the CTRs as both reports describe only one intervention (electronic brachytherapy for the primary trial and vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG for the secondary trial). The difference in the number of cohorts within each trial arises from the secondary trial having two distinct cohorts (Initial and Escalation), whereas the primary trial does not indicate multiple cohorts.</s>",
        "contradict": "The statement \"The primary trial has less patient cohorts than the secondary trial\" cannot be directly contradicted by the given information in the CTRs. The number of cohorts is not explicitly stated in either trial description. The statement only makes a comparison between the number of cohorts in the two trials, but the CTRs do not provide sufficient information to determine if this is true or false.</s>"
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Entailment",
        "entail": "The statement that \"Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial,\" is entailed by the information in the CTRs since it aligns with the inclusion criteria for both trials specifying the requirement of brain MR imaging for the primary trial and MR imaging for the secondary trial prior to study entry. Additionally, the statement does not contradict any information in the CTRs, as the primary trial also mandates PET imaging alongside the MR imaging, but the statement does not make a claim about PET scans. Thus, the statement is an entailed consequence based on the CTRs.</s>",
        "contradict": "The statement \"Patients will have to undergo an MRI scan for before entry for both the secondary trial and the primary trial\" is generally in agreement with the CTRs, as both trials require MR imaging for patient selection. However, the statement \"for the primary trial patients will also need to have a brain MR and PET imaging, after study entry\" contradicts the information present in the primary CTR. While the primary trial does require an MRI scan for eligibility, it does not state that an additional brain MRI and PET imaging will be conducted after study entry. Instead, the primary CTR specifies that these imaging modalities are required for eligibility determination and are performed prior to study entry.</s>"
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients won't have to undergo an MRI scan for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients won't have to undergo an MRI scan for before entry for both the secondary trial and the primary trial\" is not directly entailed by the CTRs. However, the statement \"for the primary trial patients will also need to have a brain MR and PET imaging, after study entry\" can be harmonized with the information in the CTRs. In the primary CTR, it is stated that subjects must undergo brain MR and PET imaging, but it does not specify whether this imaging must be done prior to entry or after. In the secondary CTR, no mention of imaging prior to entry is made, only that it is required after study entry for both trials. Therefore, the statement can be considered consistent with the CTRs, but it does not strictly follow the information in the CTRs, as it makes a stronger claim than what is stated in the CTRs.</s>",
        "contradict": "The statement that \"Patients won't have to undergo an MRI scan for before entry for both the secondary trial and the primary trial\" is contradicted by the information in the CTRs. For the primary trial, the inclusion criteria explicitly state that subjects must have the ability to undergo brain MR imaging. Additionally, for the primary trial, there is a requirement for PET imaging, which may also involve MRI. For the secondary trial, while the statement is true that MRI scans for entry are not explicitly mentioned in the provided inclusion criteria, the fact that it is a requirement for the primary trial suggests that it may still be necessary depending on the trial protocol. Overall, the statement is too general and does not account for the differences between the trials and their specific inclusion criteria.</s>"
    },
    "9ca0cc75-58b3-451d-abcc-378526744ca4_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "For the primary trial patients will need to have a brain MR and PET imaging, after study entry, and patients will have to undergo an MRI scan before entry for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that the primary trial patients undergo brain MR and PET imaging both before and after study entry, which is in agreement with the CTR's inclusion criteria for the primary trial specifying the requirement for study subjects to have normal organ and marrow function, which may include imaging assessments, and ability to undergo brain MR and PET imaging. Additionally, the statement does not contradict any information in the CTRs.\n\nFurthermore, the statement also mentions that patients will undergo an MRI scan before entry for the secondary trial, which is also consistent with the CTR's inclusion criteria for the secondary trial stating the requirement for participants to have a detectable lesion / clip marker on ultrasound and clinical and imaging complete or near-complete response on MRI.\n\nTherefore, the statement is entailed by the available CTR information, as it aligns with the stated inclusion criteria for both trials and does not contradict any provided information.</s>",
        "contradict": "The statement that \"patients will need to have a brain MR and PET imaging, after study entry, and patients will have to undergo an MRI scan before entry for both the secondary trial and the primary trial\" contradicts the information presented in the CTRs. In the primary CTR, it is stated that \"Study subjects must have normal organ and marrow function as defined below: Ability to undergo brain MR and PET imaging\" (imaging is a requirement for study entry). However, the statement suggests that the imaging is performed after study entry, which is not in accordance with the CTR. Additionally, for the secondary trial, it is stated that \"with informed consent\" is an inclusion criterion, but the statement implies that the imaging is performed before informed consent is obtained.</s>"
    },
    "6efb001b-5ed3-470b-a206-7768a1adf597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Statement": "histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs because, in the Primary Trial, the inclusion criteria explicitly state that only histologically confirmed invasive ductal breast cancer is eligible for participation. In contrast, the Secondary Trial does not have such a restriction. Therefore, a patient with histologically confirmed invasive ductal breast cancer would be excluded from the Primary Trial but not from the Secondary Trial. The statement correctly reflects the differences in the trials' inclusion criteria.</s>",
        "contradict": "The statement \"histologically confirmed invasive ductal breast cancer would result in exclusion from the primary trial, but not from the secondary trial\" is contradicted by the inclusion criteria of the primary trial which states that \"Primary diagnosis: histologically confirmed invasive ductal breast cancer or Grade I or II DCIS\" and the exclusion criteria of the secondary trial which is not provided in the description. According to the information in the CTRs, historically confirmed invasive ductal breast cancer results in inclusion in the primary trial but exclusion in the secondary trial based on the given information, while the statement suggests the opposite.</s>"
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial uses a 3-week cycle for SB-715992 administration\" is entailed by the CTR information as follows: The CTR specifies that the eligible participants in the primary trial were administered Ispinesib, which is SB-715992, via intravenous infusion for one hour, on Day 1 of every 21-day treatment cycle. This description implies a 21-day cycle length, which is equivalent to a 3-week cycle. Thus, the statement is consistent with the CTR information and does not contradict it.</s>",
        "contradict": "The statement \"the primary trial uses a 3-week cycle for SB-715992 administration\" contradicts the information in the CTR, as per the primary trial's Intervention 1 section, which mentions a 21-day treatment cycle (not 3 weeks) for the administration of SB-715992.</s>"
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "The primary trial doesn't use a 3 week cycle for SB-715992 administration.",
        "Label": "Contradiction",
        "entail": "The statement does not entail that there is a 3-week cycle for the administration of SB-715992 in the secondary trial. Instead, it only states that there is no such cycle in the primary trial. This difference is consistent with the CTR, which explicitly describes the administration of SB-715992 in the primary trial as a one-hour infusion on Day 1 of every 21-day treatment cycle. The statement does not contradict or challenge this description in any way. Therefore, the statement is entailed by the information in the CTR, given that it does not make any assertions beyond the scope of the CTR.</s>",
        "contradict": "The statement that \"The primary trial doesn't use a 3-week cycle for SB-7159992 administration\" is contradicted by the information in the CTR because the CTR specifies that SB-715992 is administered as a one-hour infusion on Day 1 of \"every 21-day treatment cycle.\" A 21-day cycle is longer than 3 weeks, so the administration schedule is not in accordance with a 3-week cycle as asserted by the statement.</s>"
    },
    "70dd1a42-6e40-4880-80a8-45dfd4941ce4_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "A 3 week cycle for SB-715992 administration is used for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"A 3 week cycle for SB-715992 administration is used for the primary trial\" can be entailed by the information in the CTR as follows: The CTR specifies that the one-hour infusion of SB-715992 is given on Day 1 of every 21-day treatment cycle. Therefore, the administration of SB-715992 occurs every 21 days, which is equivalent to a 3-week cycle.</s>",
        "contradict": "The statement \"A 3 week cycle for SB-715992 administration is used for the primary trial\" is contradicted by the information present in the CTR for the primary trial as the administration cycle specified is every 21 days, not every 3 weeks.</s>"
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "Not all subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi.",
        "Label": "Entailment",
        "entail": "The statement \"Not all subjects in the primary trial and the secondary trial will be administered 4-8 mCi Tc-99m sestamibi\" is entailed by the CTR information because the primary CTR states that \"Each subject served as her own control, with imaging of each mass by both the test and control modalities.\" This means that not all subjects received the same dosage of Tc-99m sestamibi in the primary trial, and therefore not all subjects were imaged with 4-8 mCi in both modalities. In the secondary trial, molecular breast imaging is performed after injection of both 4 mCi and 8 mCi of Tc-99m sestamibi, but it does not specify that all subjects receive both doses. Thus, it is possible that some subjects in the secondary trial received only one dosage. Consequently, the statement that not all subjects receive 4-8 mCi Tc-99m sestamibi in either trial is a valid entailment of the provided CTR information.</s>",
        "contradict": "The expert's statement contradicts the primary trial's description as it does not entail that all subjects in the primary trial were administered 4-8 mCi Tc-99m sestamibi. According to the primary trial's description, the subjects served as their own control by undergoing imaging with both the test and control modalities without mentioning a specific dose administration. In contrast, the secondary trial specifies the administration of 4 mCi Tc-99m sestamibi followed by 8 mCi Tc-99m sestamibi, implying that this is the case for subjects in the secondary trial but not for the primary trial. Thus, the expert's statement contradicts the primary trial's description by not entailing that all subjects in the primary trial received the specified dose of Tc-99m sestamibi.</s>"
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "All subjects in the primary trial and the secondary trial will be adminstered 4-8 mCi Tc-99m sestamibi.",
        "Label": "Contradiction",
        "entail": "In the primary trial, it is stated that \"Each subject served as her own control, with imaging of each mass by both the test and control modalities\" (CTR for Primary Trial, Intervention 1). While the method of sestamibi administration is not explicitly stated, it is implied that each subject undergoes imaging with both test and control modalities, implying that they receive some dose of Tc-99m sestamibi for each imaging session.\n\nIn the secondary trial, it is stated that \"Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi\" (CTR for Secondary Trial, Intervention 1). This directly indicates that subjects in the secondary trial receive both 4 mCi and 8 mCi doses of Tc-99m sestamibi.\n\nGiven that both trials involve the administration of Tc-99m sestamibi for molecular breast imaging, and that the primary trial implicitly includes a dose for each imaging session, the expert's statement that \"All subjects in the primary trial and the secondary trial will be administered 4-8 mCi Tc-99m sestamibi\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"All subjects in the primary trial and the secondary trial will be administered 4-8 mCi Tc-99m sestamibi\" is contradicted by the information in the CTRs because in the primary trial, each subject served as her own control and received different doses (4 mCi and 8 mCi) of Tc-99m sestamibi for imaging with separate modalities, whereas in the secondary trial, molecular breast imaging was performed only after the administration of 4 mCi and 8 mCi Tc-99m sestamibi. Thus, not all subjects received the same dose of the tracer during a single imaging session in either trial.</s>"
    },
    "85f43677-b680-4127-b1da-7e1cc966e4b2_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "4-8 mCi Tc-99m sestamibi won't will be adminstered to all subjects in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, the ITD population as a whole undergoes imaging using both the test and control modalities without mention of a specific dose of Tc-99m sestamibi administered. In contrast, the secondary trial specifies that molecular breast imaging is conducted after injections of 4 mCi and then 8 mCi Tc-99m sestamibi. Since the primary trial does not dictate administration of 4-8 mCi to all subjects, and the secondary trial only administers this dose during molecular breast imaging, it follows that \"4-8 mCi Tc-99m sestamibi won't be administered to all subjects in the primary trial and the secondary trial\" is an entailed statement.</s>",
        "contradict": "The statement that \"4-8 mCi Tc-99m sestamibi won't be administered to all subjects in the primary and secondary trials\" contradicts the information in the CTRs because in the primary trial, each subject served as her own control with imaging by both the test and control modalities, but the CTR does not specify that the same 4-8 mCi Tc-99m sestamibi dose was used for both modalities. In the secondary trial, molecular breast imaging was specifically performed after injection of 4 mCi Tc-99m sestamibi and then again after 8 mCi Tc-99m sestamibi, indicating that different doses were used for this trial. Therefore, it is not correct to assume that the same 4-8 mCi Tc-99m sestamibi dose was administered to all subjects in both trials.</s>"
    },
    "4cccea8a-22ae-4813-96df-b902850f4991": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03136367",
        "Statement": "Women of any age can participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information in the CTRs as both trials have specific age requirements (Primary Trial: Women with locally advanced, recurrent, or metastatic breast cancer; Secondary Trial: Assigned female at birth; 18 years and older) and other inclusion and exclusion criteria. The statement is too general to be an entailed consequence from the given CTRs.</s>",
        "contradict": "The statement \"Women of any age can participate in the primary trial or the secondary trial\" is contradicted by the provided CTRs as follows:\n\n1. The primary trial's eligibility criteria include \"Women with locally advanced, recurrent, or metastatic breast cancer\" (implying older women). There's no mention of age limit in this trial.\n\n2. The secondary trial's inclusion criteria state that participants \"must be assigned female at birth\" and \"18 years and older.\" This trial is for early stage breast cancer patients.\n\nThese trials have different eligibility criteria and the primary trial does not mention age as a limitation, yet it targets a specific population (women with advanced breast cancer). The secondary trial explicitly states an inclusion age range. Consequently, the statement is not entailed by the information given in the CTRs.</s>"
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. The first part of the statement, \"Nausea is a common adverse event,\" is entailed by the occurrence of one instance of Nausea in the 26 patients of cohort 1 of the primary trial, represented by the value \"1/26\" under the Nausea column in Adverse Events 1.\n2. The second part of the statement, \"Death is a common adverse event,\" is also entailed by the occurrence of one instance of Death - unknown cause in the same cohort, represented by the value \"1/26\" under this category in Adverse Events 1.\n3. The statement does not contradict any information in the CTRs, as it only makes a claim about the frequency of two specific adverse events within the primary trial's cohort 1.\n4. The statement also implies that these adverse events might be more common in cohort 1 as compared to cohort 2, but the CTRs do not provide data to verify or refute this implication.</s>",
        "contradict": "The statement \"Nausea and Death are two of the most common adverse events for patients in cohort 1 of the primary trial\" is contradictory to the information present in the CTR because, as per the given data, only one participant in cohort 1 experienced nausea (1/26) and one participant died of an unknown cause (1/26). Therefore, neither nausea nor death can be considered the \"most common\" adverse events based on the provided information.</s>"
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Nausea and Death aren't two of the most common adverse events for patients in cohort 1 of the primary trial",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n\n1. In the Primary Trial's Adverse Events 1 section, Nausea occurs only once in 26 patients, accounting for a frequency of 3.85%. \n\n2. In the Primary Trial's Adverse Events 1 section, Death - unknown cause occurs once in 26 patients, accounting for a frequency of 3.85%.\n\n3. The statement asserts that Nausea and Death aren't two of the most common adverse events for patients in cohort 1. Since the frequencies of these two events are lower than 50.00% (implying less common), the statement holds true based on the data provided.\n\nThere's no contradictory information in the CTRs, and the statement is harmonious with the clinical trial data.</s>",
        "contradict": "The expert's statement that \"Nausea and Death aren't two of the most common adverse events for patients in cohort 1 of the primary trial\" cannot be directly contradicted by the information provided in the CTRs. However, the statement can be misleading without further context. While neither nausea nor death are among the most frequent adverse events listed for cohort 1 in the primary trial, they both still occurred in 1/26 (3.85%) of participants. Thus, the expert's statement, which implies that these adverse events were uncommon or insignificant, might not accurately represent the data in the CTRs.</s>"
    },
    "8574ecd7-4da7-49b0-a273-de495bc1fee7_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": " The primary trial has Nausea and Death as two of the most common adverse events for patients in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial has Nausea and Death as two of the most common adverse events for patients in cohort 1\" can be entailed by the information present in the CTRs if we consider that:\n\n1. Nausea was reported as an adverse event in the primary trial, with a frequency of 1/26 (3.85%), which is a proportion smaller than 50.00% (implicitly stated in the expert's statement as \"two of the most common\"), but still a considerable presence within the cohort.\n\n2. Death - unknown cause was reported as an adverse event in the primary trial, with a frequency of 1/26 (3.85%), which meets the requirement of being one of the \"most common\" adverse events in cohort 1 according to the expert's statement. \n\nHence, the information in the expert's statement is an entailed outcome based on the information provided in the CTRs, as it is a valid inference that can be derived from the data presented.</s>",
        "contradict": "The expert's statement is contradicted by the CTR data as the frequency of Nausea in the primary trial is 1/26 (3.85%) which is not the most common adverse event and the frequency of Death, including deaths of unknown cause, is 1/26 (3.85%) as well, making it not the most common adverse event for patients in cohort 1 of the primary trial. Instead, the most common adverse event in the primary trial is Febrile neutropenia, which occurred in 1/26 (3.85%) of the patients. The expert's statement does not align with the clinical trial data presented in the CTRs.</s>"
    },
    "01b82c51-dd3d-430b-9523-0e93a9eb9c1a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a multitude of patients with chest pain, whereas the secondary trial observed only one patient with abdominal pain.",
        "Label": "Contradiction",
        "entail": "The expert's statement does not directly entail information from the CTRs based on the provided data. The CTRs report adverse events for each trial, including chest pain under the category of angina pectoris in the primary trial and no mention of chest pain in the secondary trial. However, the expert's statement compares occurrences of \"chest pain\" and \"abdominal pain\" across the studies, which are not directly equivalent adverse events as reported in the CTRs. Therefore, the information in the expert's statement does not follow directly from the data in the CTRs.</s>",
        "contradict": "The statement is not directly contradictory to the CTR data, but it mischaracterizes the types of adverse events reported in each trial. The primary trial reported on chest pain-related events under the categories of arrhythmia, angina pectoris, and myocardial infarction, whereas the secondary trial reported on abdominal pain. Therefore, a more accurate statement would be that the primary trial reported on chest pain-related adverse events and the secondary trial reported on an abdominal pain-related adverse event.</s>"
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events\" can be entailed by the information present in the CTRs because both cohorts have the same types of adverse events with identical frequencies. For instance, the number of anemia cases in Cohort 1 is 2/94 (2.13%), which is equivalent to the number of anemia cases in Cohort 2, 2/39 (5.13%). The same applies to other types of adverse events. Therefore, the statement is in agreement with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial recorded exactly the same number of each type of adverse events\" cannot be entailed by the information provided in the given CTRs as the number of occurrences for each adverse event is different between the two cohorts for several adverse events, such as Anemia (2 vs 5.13%), Haemorrhoids (1 vs 2.56%), and Vomiting (1 vs 2.56%).</s>"
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial didn't record exactly the same number of each type of adverse events.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs because the data provided in the Adverse Events sections of both trials shows that the frequency and types of adverse events are not identical for each cohort in the primary trial and for the entire secondary trial. This discrepancy in adverse event occurrence between the two trials or the two cohorts within the primary trial supports the statement made by the clinical trial expert.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial didn't record exactly the same number of each type of adverse events\" does not contradict the information presented in the CTRs. The CTRs report slightly varying frequencies of individual adverse events across Cohort 1 and Cohort 2 within the Primary Trial. However, the statement does not claim that the number of each type of adverse event is the same for every event category; it only states that the number is not identical between the two cohorts for at least one adverse event category. Therefore, the statement does not contradict the information provided in the CTRs.</s>"
    },
    "93149dfc-667b-48d3-a46d-ad48b15e701f_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "The same number of each type of adverse events was recorded in Cohort 1 and 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement does not hold true based on the provided CTRs as the number of occurrences of each type of adverse event varies between Cohort 1 and Cohort 2 in the primary trial. For instance, anaemia occurred 2 times in Cohort 1 and 5 times in Cohort 2; myocardial infarction occurred 1 time in Cohort 1 and 2 times in Cohort 2; and ischaemic cardiomyopathy did not occur in Cohort 1 but occurred once in Cohort 2. Therefore, the statement cannot be entailed by the CTR data.</s>",
        "contradict": "The statement that \"The same number of each type of adverse events was recorded in Cohort 1 and 2 of the primary trial\" directly contradicts the information in the CTRs since the number of adverse events of some types differs between the cohorts. For instance, the number of patients experiencing Myocardial infarction is 1 in Cohort 1 and 1 in Cohort 2, but the number of participants with Anaemia is 2 in Cohort 1 and 5 in Cohort 2. Therefore, the statement cannot be entailed by the CTR data.</s>"
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.",
        "Label": "Entailment",
        "entail": "Both the statement and the CTR describe a phase II trial involving topical application of fluocinonide 0.05% cream for genitalia. The statement specifies that the participants will apply the cream twice daily for the first two weeks, which aligns with the duration and frequency stated in the CTR. Consequently, the statement is entailed by the information in the CTR, as the statement's claim is a specific instance of the more comprehensive information provided in the CTR.</s>",
        "contradict": "The statement from the clinical trial expert is not a direct contradiction to the information present in the CTRs, but it is an oversimplification. The CTR states that the participants in the primary trial will apply topical fluocinonide 0.05% cream to their vagina, which is a part of the genitalia but not the same as applying it directly to the genitalia in general. Additionally, the statement in the CTR provides more detailed information about the application schedule and duration of treatment, which is not mentioned in the expert's statement.</s>"
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "The primary trial isn't a phase II trial in which all participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks.",
        "Label": "Contradiction",
        "entail": "The expert's statement implies that the primary trial is not a phase II trial with a specific application regimen for fluocinonide 0.05% cream. The primary trial described in the CTR is, indeed, a phase II trial with the exact application regimen specified as twice daily for the first two weeks and then once daily for the next two weeks. Therefore, the expert's statement, which does not contradict the provided information in the CTR, is entailed by it.</s>",
        "contradict": "The expert's statement is contradictory to the primary trial's Intervention 1 description in the CTR, as the trial is indeed identified as a Phase II trial and all participants are instructed to apply topical fluocinonide 0.05% cream to their genitalia twice daily for the first two weeks of treatment. However, the third and fourth weeks of treatment involve applying the cream once daily. The discrepancy between the expert's statement and the CTR lies in the misunderstanding or misinterpretation of the application frequency during the entire duration of the intervention. The expert's statement incorrectly states that all participants apply the fluocinonide cream twice daily for the whole 4-week treatment period.</s>"
    },
    "d080eec7-412f-4a44-8c56-91e0ec459acc_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "All participants will recieve topical fluocinonide 0.05% cream to apply to their genitalia twice daily for two weeks in a phase II trial, which is the primary trial.",
        "Label": "Entailment",
        "entail": "The statement entails the information in the primary CTR as both share identical details regarding the application frequency, dose, and length of treatment for topical fluocinonide 0.05% cream in a phase II trial.</s>",
        "contradict": "The expert's statement is not an accurate representation of the primary trial as specified in the CTR. The expert's statement incorrectly states that \"All participants\" will apply the cream to their \"genitalia,\" whereas the primary trial specifically mentions \"vagina.\" This discrepancy can lead to potential misinterpretations or misunderstandings. The CTR provides clear information regarding the body part to which the treatment should be administered.</s>"
    },
    "fd18a599-f94a-478a-975f-854a4210ccad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is only a single day after removal of the drains.",
        "Label": "Contradiction",
        "entail": "The primary trial's intervention duration is five years, whereas the secondary trial's intervention lasts only a day after removing the drains. Although the trials involve different interventions, the statement can be entailed by the information in the CTRs because the comparison is focused on the intervention duration post-surgery and not during the treatment period. In the primary trial, the participants received either Tamoxifen or Tamoxifen with OFS for 5 years, while in the secondary trial, participants had a drain inserted (either single or double) and underwent ultrasonography one day after drain removal. The statement's duration comparison does not contradict the information in the CTRs.</s>",
        "contradict": "The statement's duration claim about the primary trial being 5 years long for the intervention contradicts the secondary trial's duration claim of only a single day after drain removal. While the primary trial indeed involves 5-year interventions, the statement's assertion for the secondary trial is incorrect, as the information provided in the CTRs indicates no such requirement for the secondary trial's duration.</s>"
    },
    "ac9ca070-80b2-4913-97d8-06d1b90fcfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Secondary_id": "NCT02005887",
        "Statement": "the secondary trial and the primary trial both have a placebo arm and a test arm.",
        "Label": "Contradiction",
        "entail": "Both trials, the primary and secondary one, include a placebo arm and a test arm in their design. In the primary trial, Intervention 2 for both arms involves the administration of a placebo in addition to fulvestrant or everolimus, respectively. The secondary trial specifies separate interventions, Arm A and Arm B, where Arm A receives Triptorelin and Letrozol, and Arm B receives Degarelix and Letrozol. However, Arm B also involves the use of a placebo as part of Degarelix treatment in cycles 2 to 6. Consequently, the statement's claim that both trials have a placebo arm and a test arm is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial both have a placebo arm and a test arm\" is not contradicted by the information in the CTRs as both trials do indeed have a placebo arm (Arm B for the secondary trial and placebo for INTERVENTION 2 in the primary trial) and a test arm (Arm A for the secondary trial with the combination of Triptorelin and Letrozol, and INTERVENTION 1 with the combination of Fulvestrant and Everolimus in the primary trial). However, the statement does not specify if the placebo and test arms are being compared directly between the trials or not, and the CTRs do not provide any information regarding other trials or comparisons.</s>"
    },
    "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, participants receive increasing doses of Fulvestrant.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trials expert is not an entailed conclusion based on the provided CTR information. \n\nThe CTR for the primary trial specifies that patients receive fulvestrant intramuscularly at a dose of 250 mg on day 1. The statement, however, asserts that participants receive \"increasing doses\" of fulvestrant throughout the trial. This assertion contradicts the information in the CTR, which indicates a fixed dose of fulvestrant for all participants. Therefore, the statement is not an entailed consequence of the data in the CTRs.</s>",
        "contradict": "The information in the statement is contradicted by the data in the CTRs as the CTRs describe patients in the primary trial receiving a fixed dose of fulvestrant (250 mg intramuscularly) and a specific dose of tipifarnib (300 mg orally) throughout the trial, rather than increasing doses of fulvestrant.</s>"
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been treated with bevacizumab are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients that have previously been treated with bevacizumab are not eligible for the primary trial\" is entailed by the information present in the primary CTR's exclusion criteria, specifically \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab.\"</s>",
        "contradict": "The statement \"Patients that have previously been treated with bevacizumab are not eligible for the primary trial\" can be contradicted by the information present in the CTR as the primary trial specifically excludes patients who have received bevacizumab for metastatic breast cancer but does not mention anything about bevacizumab administration in the past for other indications.</s>"
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been treated with bevacizumab are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR states that \"Patients may have received 0 - 1 prior therapies (except taxanes in the metastatic setting). An interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy for metastatic disease; at least 6 months must have elapsed since prior adjuvant therapy.\" Bevacizumab is an anti-angiogenic monoclonal antibody, often used in conjunction with chemotherapy in the treatment of metastatic breast cancer. Since it is not explicitly mentioned as an exclusion criterion in the inclusion/exclusion criteria of the primary trial, it can be inferred that patients who have previously received bevacizumab treatment are potentially eligible for the study, provided they fulfill all other eligibility criteria. The expert's statement, \"Patients that have previously been treated with bevacizumab are eligible for the primary trial,\" is therefore entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"Patients that have previously been treated with bevacizumab are eligible for the primary trial\" cannot be true according to the CTR information. The Primary Trial's Exclusion Criteria explicitly state \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab.\" Therefore, patients who have undergone previous treatment with bevacizumab are not eligible to participate in the study based on the information provided in the CTRs.</s>"
    },
    "009d23bb-2179-4ce3-927d-4dedca6b32a8_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients must not have previously been treated with bevacizumab to be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must not have previously been treated with bevacizumab to be eligible for the primary trial\" is entailed by the CTR inclusion criteria that state \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab\" is an exclusion factor for the primary trial.</s>",
        "contradict": "The statement \"Patients must not have previously been treated with bevacizumab to be eligible for the primary trial\" can be contradicted by the information present in the CTR as the trial explicitly includes the exclusion criterion of \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab, or any taxane for metastatic breast cancer.\" This indicates that patients who have received bevacizumab are not eligible for the study. The expert's statement and the CTR information contradict each other regarding the eligibility criterion for bevacizumab.</s>"
    },
    "5152d810-7669-4fb2-a66b-a0a1d6026af5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame.",
        "Label": "Contradiction",
        "entail": "The statement that \"the secondary trial and the primary trial both use Pathologic complete response (pCR) as their outcome measure, and use a 6 month time frame\" is entailed by the information present in the CTRs because:\n\n1. Both trials report pCR as their outcome measurement:\n   Primary trial: \"Outcome Measurement: Clinical Benefit Rate (CR + PR + SD > 6 Months).\" - While clinical benefit rate is the measure reported, the pCR rate could be inferred as a subset of this measure, since pCR is a type of clinical benefit.\n   Secondary trial: \"Outcome Measurement: pCR Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort\"\n\n2. Both trials use a 6 month time frame:\n   Primary trial: \"Time frame: baseline through end of study, up to 3 years.\" - While this is the overall time frame, the pCR rate could be extracted from the 6 month period (after completion of treatment).\n   Secondary trial: \"Time frame: After 24 weeks of treatment.\" - This time frame directly corresponds to the 6 month mark.</s>",
        "contradict": "The statement is not entirely accurate as the primary and secondary trials have different outcome measurements and time frames. In the primary trial, the outcome measure is Clinical Benefit Rate using RECIST version 1.0 and the time frame is baseline through end of study, up to 3 years. In contrast, the secondary trial measures Pathological Complete Response by investigator assessment after 24 weeks of treatment. Therefore, the statement's claim about both trials using pCR as their outcome measure and a 6 month time frame is not accurate.</s>"
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with stage 3 Cervical carcinoma are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with stage 3 Cervical carcinoma are excluded from the primary trial\" is entailed by the CTR information as follows: \n\nThe primary trial's exclusion criteria state that no patient with a neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix, is eligible to participate in the study. Since cervical carcinoma, especially stage 3, is considered a malignancy, it falls under the category of neoplasm, and hence, patients with such conditions are excluded from the trial, as stated in the expert's claim.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because cervical carcinoma is not a type of cancer mentioned in the inclusion or exclusion criteria for the primary trial. The statement specifically refers to stage 3 cervical carcinoma, but the CTR focuses on breast cancer and does not provide any information regarding participation of patients with cervical cancer in the study.</s>"
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with stage 3 Cervical carcinoma aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial inclusion criteria state that patients with invasive breast cancer are eligible, and no specific exclusion is stated for patients with cervical carcinoma, provided it is not in situ or metastatic. The statement made by the clinical trials expert is consistent with this information as stage 3 cervical carcinoma, though it is a type of cancer, is not mentioned as an exclusion criterion within the given CTR sections.</s>",
        "contradict": "Patients with stage 3 Cervical carcinoma are excluded from the primary trial based on the given inclusion and exclusion criteria in the CTR. Inclusion Criteria states \"no distant disease/secondary cancer,\" and stage 3 Cervical carcinoma is considered as a distant disease.</s>"
    },
    "e8f4a600-0296-47d4-903b-2fa840ebcf28_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Stage 3 Cervical carcinoma excludes patients from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Stage 3 Cervical carcinoma excludes patients from the primary trial\" is entailed by the CTR information since cervical cancer, in any stage, is listed among the exclusion criteria for the primary trial.</s>",
        "contradict": "The statement \"Stage 3 Cervical carcinoma excludes patients from the primary trial\" is contradictory to the information present in the CTRs because the CTRs do not mention any exclusion of patients based on the presence of Stage 3 Cervical carcinoma. In the Primary Trial's Inclusion Criteria, no mention of exclusion based on cervical cancer stage is given. Therefore, the statement goes against the information presented in the CTRs.</s>"
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.",
        "Label": "Entailment",
        "entail": "The expert's statement \"2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTR reports that participants in the trial were evaluated for stomatitis, which includes symptoms such as difficulty swallowing and symptoms associated with life-threatening consequences.\n2. In the primary CTR, there were 86 participants analyzed, out of which 2 had stomatitis grade \u22652, meaning they either had symptoms that required a modified diet or were unable to eat or drink orally, or had symptoms associated with life-threatening consequences. \n\nSo, the expert's statement is entailed by the information present in the CTRs since it describes the same patient population and includes the subset of patients with stomatitis grade \u22652.</s>",
        "contradict": "The statement \"2 of the patients in the primary trial were either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences\" contradicts the information in the CTR as no participants in the trial had stomatitis Grade 3 or 4, and only two had stomatitis Grade 2. The statement implies that there were more than two participants with serious stomatitis symptoms, which contradicts the data in the CTR.</s>"
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in the primary trial weren't either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.",
        "Label": "Contradiction",
        "entail": "The statement \"2 of the patients in the primary trial weren't either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences\" can be entailed by the information in the CTRs as follows:\n\n1. The CTR for the primary trial provides the number of participants who experienced grade 3 or 4 stomatitis, which includes participants who were symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences. However, no participants in the primary trial were reported to have grade 4 stomatitis. Therefore, the statement implies that there were a maximum of two participants with grade 3 stomatitis, which aligns with the CTR reporting \"Stomatitis grade >=2: Yes: 2\".\n\n2. The CTR does not provide information about participants having grade 1 stomatitis, which is characterized as minimal symptoms but still allowing for a normal diet. The statement implies the absence of such participants, and this is neither contradictory nor in disagreement with the CTR. \n\nTherefore, the statement is entailed by the information provided in the CTR.</s>",
        "contradict": "The expert's statement asserts that \"2 of the patients in the primary trial weren't either symptomatic, but able to swallow a modified diet; symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences.\"\n\nThis claim contradicts the CTR's information, as it reports that all participants experiencing grade 3 or 4 stomatitis were not able to aliment or hydrate orally and that no participants had life-threatening consequences related to stomatitis. However, according to the expert's statement, there were 2 participants that did fall into these categories. Therefore, the expert's claim is inconsistent with the CTR data, making it contradictory.</s>"
    },
    "3fa8b747-b48d-4fb4-995d-38a23c64ccb3_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "2 of the patients in the primary trial were either symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences; symptomatic, but able to swallow a modified diet.",
        "Label": "Entailment",
        "entail": "The statement \"2 of the patients in the primary trial were either symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences; symptomatic, but able to swallow a modified diet\" can be entailed by the information in the CTR as follows:\n\nFrom Results 1 of the CTR, we observe that there were 2 participants with Stomatitis grade >=2. The description of Stomatitis grades in the CTR indicates that grade 2 is defined as \"symptomatic, but able to swallow a modified diet,\" whereas grade 3 and 4 represent \"symptomatic and unable to aliment or hydrate orally\" or \"symptoms associated with life-threatening consequences,\" respectively. Thus, the statement's assertion that \"2 of the patients were either symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences; symptomatic, but able to swallow a modified diet\" aligns with the reported Stomatitis grades in the CTR and does not contradict any provided descriptions.</s>",
        "contradict": "The expert's statement that \"2 of the patients in the primary trial were either symptomatic and unable to aliment or hydrate orally or had symptoms associated with life-threatening consequences; symptomatic, but able to swallow a modified diet\" contradicts the information presented in the CTR as no participant in the Dexamethasone Based Mouthwash arm/group experienced stomatitis grade 3 or 4. All participants with stomatitis were either grade 1 or grade 2 (symptomatic but able to swallow a modified diet), with only two participants having grade 2 stomatitis.</s>"
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids are only used in one cohort.",
        "Label": "Entailment",
        "entail": "The statement \"Between all cohorts in the primary trial and the secondary trial, Omega-3-fatty Acids are only used in one cohort\" can be entailed by the information present in the CTRs because: \n\n1. In the primary trial, radiation therapy is the only intervention mentioned for all participants in both arms (no mention of any omega-3-fatty acid usage).\n2. In the secondary trial, participants in one arm (Arm I) receive omega-3-fatty acids, while those in the other arm (Arm II) receive a placebo. Therefore, the use of omega-3-fatty acids is limited to one cohort (Arm I) across both trials.</s>",
        "contradict": "The expert's statement can be contradicted by the information in the CTRs because the primary trial involves the use of Omega-3-fatty Acids as part of Intervention 1 in the secondary trial. While the primary trial is for radiation therapy, the secondary trial tests the effect of Omega-3-fatty Acids on an unspecified outcome. Despite being in a separate trial, the cohort receiving Omega-3-fatty Acids (Arm I) exists within the secondary trial. Therefore, it is inaccurate to claim that Omega-3-fatty Acids are only used in one cohort across both trials, as stated by the clinical trial expert.</s>"
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Between all cohorts in the primary trial and the secondary trial Omega-3-fatty Acids aren't only used in one cohort.",
        "Label": "Contradiction",
        "entail": "The statement \"Between all cohorts in the primary trial and the secondary trial, Omega-3-fatty Acids aren't only used in one cohort\" is entailed by the information in the CTRs as follows:\n\nIn the primary trial, participants do not receive omega-3-fatty acids as part of their intervention. They receive radiotherapy treatment instead. Therefore, in this trial, omega-3-fatty acids are not used in any cohort.\n\nIn the secondary trial, omega-3-fatty acids are given to participants in Arm I, but they are not the only treatment or intervention provided; they are given in addition to the standard of care or placebo. Thus, in this trial also, omega-3-fatty acids are not used exclusively in one cohort.\n\nTherefore, the information in the statement is consistent with the information in the CTRs and is an entailed conclusion.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, in the primary trial, the term \"Omega-3-fatty Acids\" is not associated with any treatment or intervention provided to the participants. Instead, it is only mentioned in the secondary trial, where it is used in Intervention 1 for Arm I. Therefore, the statement's claim that \"Omega-3-fatty Acids aren't only used in one cohort\" across both primary and secondary trials is not entailed in the provided CTR information, as Omega-3-fatty Acids are not used in the primary trial at all.</s>"
    },
    "b9c294c3-93b7-4681-be02-285f9e5cd867_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Omega-3-fatty Acids are only used in one cohort between all cohorts in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial only involves the use of radiotherapy (Intervention 1), while the secondary trial involves the use of omega-3-fatty acids in Arm I and placebo in Arm II. The primary trial does not have an arm that involves the use of omega-3-fatty acids, so the statement that \"Omega-3-fatty Acids are only used in one cohort between all cohorts in the primary trial and the secondary trial\" is consistent with the CTR information.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as Omega-3-fatty Acids are not mentioned in the Intervention section of the primary trial. Instead, the primary trial involves the use of radiotherapy for breast cancer treatment. Hence, the statement's claim about Omega-3-fatty Acids being used in only one cohort between the primary and secondary trials is incorrect based on the information available in the CTRs.</s>"
    },
    "9df90d78-d857-4e1d-a650-e47f7b6b68d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone, at a higher frequency, than cohort 1, ",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial receives a higher dose of Ixabepilone, at a higher frequency, than cohort 1\" can be entailed by the information presented in the CTRs as follows:\n\nThe CTRs state that for Intervention 1 in the primary trial, participants received 25 mg/m^2 Ixabepilone, and for Intervention 2, participants received 30 mg/m^2 Ixabepilone. This directly implies that Cohort 2 receives a higher dose (30 mg/m^2 vs. 25 mg/m^2) of Ixabepilone.\n\nFurthermore, both interventions state that participants received the treatments every 21 days. Therefore, there is no difference in the frequency of Ixabepilone administration for cohorts 1 and 2. However, as mentioned earlier, Cohort 2 receives a higher dose of Ixabepilone. This higher dose constitutes the difference in the interventions and supports the statement that Cohort 2 receives a higher dose of Ixabepilone, at a higher (though not changed) frequency than Cohort 1.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs. However, it makes an assumption about the implications of the dose and frequency differences between cohorts 1 and 2 without explicit statements in the CTRs indicating that these differences translate to higher or lower overall doses per treatment cycle. The CTRs only state that cohort 2 receives a higher dose, but they do not provide sufficient data to establish if this translates to more Ixabepilone being administered over the course of the trial. Therefore, the statement is not strictly entailed by the CTRs but does not contradict them either.</s>"
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results section indicates there were no patients in the primary trial with 0 adverse events.",
        "Label": "Entailment",
        "entail": "Given the information in the CTRs, the statement \"There were no patients in the primary trial with 0 adverse events\" is entailed since none of the reported participant counts in Result 1 for the Nivolumab + Daratumumab (TNBC) arm nor in Result 2 for the Nivolumab + Daratumumab (NSCLC) arm indicate any participant experienced zero adverse events. Both trials report that 100.0% of participants had adverse events. Therefore, the lack of any participant reporting 0 adverse events is consistent with the CTR data.</s>",
        "contradict": "The statement is not entailed by the CTR information, as the CTRs do not provide details on the number of participants in the Nivolumab + Daratumumab (TNBC and NSCLC) arms who experienced no adverse events (AEs). The CTRs only state the total number of participants analyzed for each arm and the percentage of participants who experienced any grade of AEs. Therefore, it is unknown from the given CTR information if there were any participants in either arm who did not experience any AEs within the specified time frame.</s>"
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There result section indicates there were patients in the primary trial with 0 adverse events.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information in the CTRs. The CTRs specify the number of participants with any grade of adverse events, not the number of participants with 0 adverse events. Therefore, the statement goes beyond the information provided in the CTRs and cannot be directly inferred from them.</s>",
        "contradict": "The statement is incorrect as the CTRs do not indicate that all participants in the primary trial had 0 adverse events. The statement misinterprets the data provided in the Results 1 and Results 2 sections, which report the total number of participants in each arm of the trial, not the number of participants with 0 adverse events.</s>"
    },
    "4923ff4f-b2a8-48ad-bf4b-1e193deb0dfe_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There were no patients in the primary trial with 0 adverse events, as indicated by the results section.",
        "Label": "Entailment",
        "entail": "The statement \"There were no patients in the primary trial with 0 adverse events\" can be entailed by the information in the CTRs as follows:\n\n1. From the results section of the primary trial, we know that there were 41 participants in the Nivolumab + Daratumumab (TNBC) arm and 100.0% of them experienced adverse events.\n2. Similarly, in the secondary trial, we find that there were 21 participants in the Nivolumab + Daratumumumab (NSCLC) arm and 100.0% of them experienced adverse events.\n3. Based on this information, it can be logically deduced that no participant in either arm had 0 adverse events. This deduction aligns with the statement, making it entailed by the information in the CTRs.\n\nIn other words, given that every participant in both arms experienced adverse events, it is a logical conclusion that no participant experienced 0 adverse events.</s>",
        "contradict": "The expert's statement \"There were no patients in the primary trial with 0 adverse events, as indicated by the results section\" cannot be directly contradicted by the information present in the CTRs. However, it can be misinterpreted as a contradiction since the CTRs do not report the number of patients with no adverse events, but rather the number of patients experiencing any grade of adverse events. In this case, all participants in both trials had at least one adverse event recorded, but the absence of a reported number of patients without adverse events does not necessarily imply that there were no such patients. Therefore, while there is no direct contradiction, the expert's statement may create confusion or misunderstanding.</s>"
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them.",
        "Label": "Entailment",
        "entail": "The statement \"The interventions in the primary trial and the secondary trial are so different that it is not possible or useful to compare them\" can be entailed by the information present in the CTRs, as the trials' interventions differ in their nature and scope. In the primary trial, intervention 1 involves molecular breast imaging using Tc-99m sestamibi, whereas, in the secondary trial, intervention 1 is a control arm with a standard reminder postcard, and intervention 2 is an additional family physician reminder letter in the experimental arm. These interventions cannot be compared directly due to their inherent differences in methodology, purpose, and type. Thus, the statement is consistent with the information in the CTRs, as it acknowledges the disparity between the trials' interventions and the impracticability of a direct comparison.</s>",
        "contradict": "The statement made by the expert is contradicted by the CTR information because the interventions in the primary and secondary trials, while differing in their nature, are not necessarily incomparable. In the primary trial, intervention 1 refers to the use of molecular breast imaging with different doses of Tc-99m sestamibi, while in the secondary trial, intervention 1 for both arms involves mailing standard reminder postcards. The comparison could be made in terms of the use of reminder interventions in the secondary trial, which is a common component in many clinical trials. Therefore, the statement is overly categorical and ignores the potential for comparative analysis.</s>"
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are so different that it is possible and useful to compare them.",
        "Label": "Contradiction",
        "entail": "1. The statement acknowledges the difference between the interventions in the primary and secondary trials. This is consistent with the fact that in the primary trial, the intervention is molecular breast imaging using Tc-99m sestamibi, while in the secondary trial, there are two intervention arms: a control arm receiving a standard reminder postcard via mail, and an experimental arm receiving both a standard reminder postcard and a reminder letter from a family physician via mail. The statement does not contradict any information in the CTRs and is semantically entailed as the CTRs explicitly state the differences in interventions.</s>",
        "contradict": "The statement \"The interventions in the primary trial and the secondary trial are so different that it is possible and useful to compare them\" does not contradict the information present in the CTRs directly. However, it may be contradicted if the focus of the comparison is on the specific interventions mentioned in the statement, as they are indeed different in nature. Molecular breast imaging using Tc-99m sestamibi and mail-based reminders for participant follow-up are fundamentally distinct interventions. The usefulness of comparing these trials depends on the research question or clinical context at hand. The CTRs only provide a snapshot of the interventions used in each trial, but it's important to consider the overall study design and goals when assessing the value of comparison.</s>"
    },
    "92ac6e0c-8427-454d-9218-36eda1c580a7_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "Since the interventions in the primary trial and the secondary trial are so different, its not useful or possible to compare them.",
        "Label": "Entailment",
        "entail": "The statement \"Since the interventions in the primary trial and the secondary trial are so different, it's not useful or possible to compare them\" can be entailed by the information in the CTRs based on the following reasoning:\n\n1. The primary trial intervention involves molecular breast imaging with Tc-99m sestamibi injections.\n2. The secondary trial interventions consist of a control arm with mail reminders and a family physician reminder letter arm, also with mail reminders.\n3. The differences between the interventions are substantial, with molecular breast imaging being a diagnostic procedure and mail reminders being communications for patient follow-ups.\n4. Comparing these interventions would likely require direct evaluation of their clinical effects, which may not be feasible due to the disparities in their nature and purpose.\n5. The statement acknowledges this challenge and suggests that comparison would not be fruitful or practical.\n\nThus, the clinical trial expert's statement is entailed by the information in the CTRs, as it accurately reflects the significant differences between the trials' interventions and the resulting difficulty in making meaningful comparisons.</s>",
        "contradict": "The statement \"Since the interventions in the primary trial and the secondary trial are so different, it's not useful or possible to compare them\" is contradicted by the information in the CTRs because both trials do share a common intervention in the control arm, which is the use of a standard reminder postcard (INTERVENTION 1 in both trials). This shared intervention provides a basis for comparison, allowing for the evaluation of the effectiveness or difference in outcomes between the molecular breast imaging intervention in the primary trial and the family physician reminder letter intervention in the secondary trial for the control arm participants.</s>"
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial\" can be entailed by the information in the CTRs, as the CTR for the primary trial states that the lower bound of the 95% confidence interval for median PFS with Nab-Paclitaxel-bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy is 8 months, and the median PFS for the placebo arm is not provided in the given text. A difference greater than 14 weeks between the two treatments' PFS translates to a median PFS of less than 8 months for the placebo, implying that the difference is within the reported range of PFS values in the primary trial.</s>",
        "contradict": "The statement's assertion that there was over 14 weeks difference in Progression-free Survival (PFS) between the minimum and maximum values from the primary trial contradicts the CTR information because:\n\nThe CTR does not provide explicit values for the minimum and maximum PFS in the Tx (Chemo, MoAb, and Enzyme Inhibitor) arm of the trial. The statement assumes the existence of these values and asserts that their difference is over 14 weeks, while the CTR only reports the median PFS and its confidence interval. Therefore, the statement's assumption is unfounded based on the given CTR information.</s>"
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There wasn't over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There wasn't over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial\" can be entailed by the following information in the CTR:\n\n1. The minimum and maximum PFS values can be extracted from the median PFS (9.1 months) and the lower bound of the 95% confidence interval (7.2 months). The difference between these two values is approximately 1.9 months, which is less than 14 weeks.\n2. The statement does not require the specific comparison of two distinct therapies or arms within the trial, but rather a comparison of the overall PFS range. The CTR provides the required information for this comparison.</s>",
        "contradict": "The expert's statement \"There wasn't over 14 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial\" contradicts the information in the CTR as follows:\n\n1. The CTR specifies that the Kaplan-Meier survival curves will be used and a 95% confidence interval for the median PFS will be calculated, but it does not provide the exact minimum and maximum values of PFS within the trial.\n2. The CTR mentions that a lower bound greater than 8 months would be strong evidence of superiority for the Nab-Paclitaxel-bevacizumab induction therapy followed by bevacizumab-erlotinib hydrochloride maintenance therapy over paclitaxel and bevacizumab, but it does not specify an exact difference of 14 weeks between the minimum and maximum PFS. \n3. The expert's statement suggests a difference of less than 14 weeks, implying that the minimum and maximum PFS values are close to each other within the trial. However, the CTR does not support this claim with the provided data.</s>"
    },
    "f0aff1fc-4a67-4b28-a974-a4a67a5c930f_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "Between the minimum and maximum PFS in the primary trial there were over 14 weeks difference in Progression-free Survival.",
        "Label": "Entailment",
        "entail": "The statement \"Between the minimum and maximum PFS in the primary trial there were over 14 weeks difference in Progression-free Survival\" is entailed by the information in the CTRs as follows:\n\n1. From the Primary Trial CTR, the minimum bound of the 95% confidence interval for the median PFS is 7.2 months.\n2. The maximum bound of the 95% confidence interval for the median PFS is 11.1 months.\n3. The difference between the minimum and maximum bounds is (11.1-7.2 =) 3.9 months.\n4. The statement asserts that the difference is over 14 weeks, which is equivalent to 9.68 hours or approximately 11.6 days.\n5. The difference of 11.6 days is greater than the difference of 3.9 months, and thus, the statement is entailed by the CTR information.\n\nNote: This explanation assumes that the clinical expert's use of \"weeks\" in the statement implies 4 weeks in a month, which is consistent with the common usage in the field of clinical trials.</s>",
        "contradict": "The statement \"Between the minimum and maximum PFS in the primary trial there were over 14 weeks difference in Progression-free Survival\" cannot be directly contradicted by the information in the CTRs. However, it is not explicitly entailed. The CTRs provide the median PFS for the primary trial with a 95% confidence interval but they don't explicitly state the minimum and maximum PFS values. The expert's statement implies that these values are given in the CTR, but they are not.</s>"
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.",
        "Label": "Entailment",
        "entail": "The statement \"Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part\" is entailed by the CTRs as they both specify that all patients must be informed of the investigational nature of the study and must sign and give written informed consent in accordance with institutional and federal guidelines before participation (Primary Trial: Eligibility Criteria, last bullet; Secondary Trial: Eligibility Criteria, 13th bullet).</s>",
        "contradict": "The statement does not contradict the information provided in the CTRs regarding eligibility criteria since it only mentions the requirement of informed consent for trial participation, which is already stated in both primary and secondary CTRs. However, the statement potentially contradicts other exclusion criteria mentioned in the CTRs, such as those concerning prior treatment history, concurrent infections, and certain types of malignancies. The statement does not specify that only willing patients without the above-mentioned exclusion criteria can participate, potentially implying that unwilling patients with those criteria could be included.</s>"
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "Patients that are willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs because both primary and secondary trials require patients to give informed consent for participation. There are no mentions of coercion or mandatory participation in either CTR.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as they specify certain inclusion and exclusion criteria that must be met for trial participation, which is not mentioned in the expert's statement. Therefore, willingness to give informed consent alone does not determine eligibility for the trials.</s>"
    },
    "2e0c241f-0a3b-4b39-87fe-ee2e5c7768d6_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Secondary_id": "NCT00256243",
        "Statement": "To be able to be made take part in the primary trial or the secondary trial, patients need to be willing to sign and give written informed consent for participation.",
        "Label": "Entailment",
        "entail": "The primary and secondary CTRs both include the requirement for patients to provide written informed consent for participation in the trials. Thus, the statement's claim about informed consent is an entailed outcome from the information in the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs; it is a general requirement for clinical trials that patients must provide informed consent. The CTRs themselves do not explicitly mention this requirement but assume it since it's a standard procedure in clinical trials.</s>"
    },
    "96ab702d-cfe1-48fb-b348-a7c7b8db3f16": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"The Median length of time that a patient in Arm A of the primary trial survived after receiving a TNBC diagnosis was 6 months\" is entailed by the information in the CTRs because:\n\n1. The statement mentions that the patients were diagnosed with TNBC, which is consistent with the information in the CTR (type of cancer under investigation).\n2. The statement asserts that the median length of time survived for patients in Arm A is 6 months, which matches the reported median survival of 6.0 months (4.3 to 8.6) mentioned in the Results section of the CTR for Arm A.</s>",
        "contradict": "The expert statement asserts that the median survival time for patients in Arm A of the primary trial was 6 months. However, the CTR specifies that the median survival for Arm A is 6.0 months (with a 95% CI of 4.3 to 8.6 months). These two statements appear identical at first glance, but upon closer inspection, the expert statement incorrectly omits the unit of measurement, which is essential for comparison. The CTR explicitly states that the survival times are in months, but the expert statement does not make this clear. Consequently, the expert statement is not an entailed claim derived from the data in the CTR. The discrepancy arises due to the ambiguous wording in the expert statement.</s>"
    },
    "6224d2de-c62b-4b43-8517-475eaa565491": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial experienced at least one adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"The majority of patients in the primary trial experienced at least one adverse event\" is entailed by the information presented in the CTR. This is because the CTR specifies a total of 20 adverse events out of 88 participants (22.73%). Given that 22.73% represents more than half of the patient population, it follows logically that the majority of patients (more than 50%) experienced at least one adverse event. The statement does not contradict the provided data and finds substantiation within it.</s>",
        "contradict": "Despite the statement's assertion that \"The majority of patients in the primary trial experienced at least one adverse event,\" the information presented in the CTRs indicates that 22.73% of patients (or 20 out of 88) did experience an adverse event. The majority refers to more than 50%, which is not supported by these data. Thus, the statement can be contradicted by the information present in the CTRs.</s>"
    },
    "95154c62-9f79-4d80-90fd-2f61612285b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Secondary_id": "NCT01702571",
        "Statement": "In total more than 5 patients in the primary trial and the secondary trial experienced Earache.",
        "Label": "Contradiction",
        "entail": "None of the Adverse Events sections in the provided CTRs mention \"Earache\" as an observed condition. Therefore, the expert's statement cannot be entailed by the information present in the CTRs as there is no substantiation or harmonization of the assertion with clinical trial data. Contradiction is also absent.</s>",
        "contradict": "The statement \"In total more than 5 patients in the primary trial and the secondary trial experienced Earache\" cannot be established as true based on the provided CTR sections due to the absence of any reported cases of earache in either trial.</s>"
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the exact same number of cases of nausea.",
        "Label": "Entailment",
        "entail": "Both trials report the occurrence of nausea in 1 out of 23 participants (Primary Trial) and 1 out of 52 participants (Secondary Trial) respectively. The number of cases in each trial may vary due to differences in sample sizes, but the occurrence of an identical number of cases for the specific event of nausea in both trials aligns with the data provided in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial recorded the exact same number of cases of nausea\" is contradicted by the information in the CTRs because the primary trial reported 1 case of nausea in 23 participants (4.35%), whereas the secondary trial reported 0 cases of nausea in 20 participants (0.00%).</s>"
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "The primary trial and the secondary trial didn't record the exact same number of cases of nausea.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial didn't record the exact same number of cases of nausea\" is entailed by the CTR data because the number of nausea cases in the primary trial is 1 out of 23 participants (4.35%), while in the secondary trial, it is 1 out of 52 participants (1.92%). The discrepancy in the number of reported cases of nausea between the two trials indicates that the trials did not record the exact same number of cases.</s>",
        "contradict": "The information in the statement can be contradicted by the CTRs as the number of cases of nausea reported in the primary trial (1/23 or 4.35%) is different from the number of cases in the secondary trial (0/52 or 0.00% for the entire trial and 0/20 or 0.00% for the subset of data provided). However, it is important to note that the primary trial had 23 participants in the arm being assessed, while the secondary trial had 52 participants in total, with only 20 participants in the arm being compared to the primary trial. Thus, the difference in the number of cases could be due to the different sample sizes or other factors unrelated to the trials themselves. To determine if the statement entails the information within the CTRs, a more comprehensive analysis considering these factors is required.</s>"
    },
    "2f6243a9-af40-426d-9a6a-a5c5708cf1b4_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "The exact same number of cases of nausea was recorded in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "Both trials report occurrences of nausea in 1 out of every 23 (Primary Trial) and 1 out of every 52 (Secondary Trial) participants, respectively. The total number of participants in the primary trial is 23, and in the secondary trial it is 52. However, the number of instances of nausea reported is equal in both trials, which is 1. Therefore, the ratio of nausea cases per participant is the same in both trials (1/23 and 1/52, respectively), which when equated, results in a common value of 1/13. This implies that if we compare the number of cases of nausea to the total number of participants in each trial, we find the same proportion (1/23 or 1/52) of participants experiencing nausea. This proportion is consistent with the given statement that \"The exact same number of cases of nausea was recorded in the primary trial and the secondary trial.\" Hence, this statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"The exact same number of cases of nausea was recorded in the primary trial and the secondary trial\" is contradicted by the data presented in the CTRs because, while one trial reported one case of nausea out of 23 participants (a rate of 4.35%), the other trial reported no cases of nausea out of its respective 52 participants.</s>"
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial do not need to meet a specific life expectancy criteria.",
        "Label": "Entailment",
        "entail": "The CTR does not specify a life expectancy criteria for candidates of the primary trial, as indicated in the text. Therefore, the statement made by the clinical trials expert that \"Candidates for the primary trial do not need to meet a specific life expectancy criteria\" is entailed by the information in the CTR.</s>",
        "contradict": "The statement made by the clinical trial expert that \"Candidates for the primary trial do not need to meet a specific life expectancy criteria\" contradicts the information in the CTRs as they do not specify any life expectancy requirement for trial participation. However, the statement implies that there is no life expectancy criterion, which is not explicitly stated in the CTRs, and thus is not entailed by the provided information.</s>"
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "Candidates for the primary trial need to meet a specific life expectancy criteria.",
        "Label": "Contradiction",
        "entail": "The CTRs do not explicitly specify life expectancy as an eligibility criteria for the primary trial. However, there is no mention of any exclusion related to life expectancy being too short. Since the statement \"Candidates for the primary trial need to meet a specific life expectancy criteria\" does not contradict any information in the CTRs and is consistent with the general principle of clinical trials excluding severely ill or terminally ill patients, it can be inferred that this statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Candidates for the primary trial need to meet a specific life expectancy criteria\" is contradicted by the information in the CTRs as no life expectancy criteria are explicitly stated in either of the trial's eligibility criteria sections.</s>"
    },
    "837f0588-22fc-4069-b2bc-297b3f6aabf7_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00058058",
        "Statement": "A specific life expectancy criteria doesn't need to be met by candidates for the primary trial.",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial does not specify a life expectancy requirement for participants, while the statement asserts that no particular life expectancy criteria is necessary for candidates. This alignment in information implies entailment, as the statement's claim is a logical consequence of the information provided within the CTR. No contradiction exists between the two.</s>",
        "contradict": "The statement \"A specific life expectancy criteria doesn't need to be met by candidates for the primary trial\" contradicts the CTR information as it doesn't align with the statement \"Life expectancy Not specified\". Since the CTR does not mention any life expectancy criteria for the primary trial, the expert statement is inaccurate and contradictory to the provided information.</s>"
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial will not be made to take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Patients in the primary trial will not be made to take Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial\" is entailed by the information in the CTRs because in the primary trial, the intervention involves 18F-FLT PET/CT scans, whereas in the secondary trial, the intervention for both groups includes intravenous administration of either Herceptin\u00a9 or Myl 1401O trastuzumab in combination with paclitaxel or docetaxel. The statement does not contradict any information in the CTRs and is supported by the distinct interventions described in each trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as follows: \n\nIn the primary trial, Intervention 1 does not involve the administration of Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously. However, Intervention 1 in the secondary trial includes the use of Herceptin\u00a9 and paclitaxel as treatment options. Despite this difference between the two trials, the statement wrongly asserts that patients in the primary trial will be administered these drugs intravenously, which is not entailed by the information provided in the CTR for the primary trial.</s>"
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial will be made to take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the primary trial will be made to take Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial\" is entailed by the information in the CTRs because, in both trials, the interventions include the use of intravenous administration for Herceptin\u00a9 (trastuzumab) and paclitaxel. In the primary trial, Herceptin\u00a9 is given as Monotherapy in Part 2 and in combination with PET/CT scan in Intervention 1. Similarly, in the secondary trial, Herceptin\u00a9 is given in combination with Taxane in Part 1 and alone in Part 2. Paclitaxel is also given intravenously in both trials, as part of the combination therapy in Part 1 of both trials. Thus, the statement's assertion harmonizes with the clinical trial data and is substantiated by the CTR information, without contradiction.</s>",
        "contradict": "The statement that \"Patients in the primary trial will be made to take Herceptin\u2122 (trastuzumab) or paclitaxel intravenously like those in the secondary trial\" can be contradicted by the information present in the CTRs because the primary trial specifies the use of 18F-FLT PET/CT as the intervention, while the secondary trial describes Herceptin\u2122 (trastuzumab) and taxane being administered intravenously. These trials differ in their interventions, and the statement fails to acknowledge this distinction.</s>"
    },
    "01ef1af2-bac4-4ff9-9f0e-bb39276a9d78_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial won't be made to be taken by patients in the primary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, the intervention involves undergoing 18F-FLT PET/CT scans at multiple time points, whereas in the secondary trial, the interventions are Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously. The statement asserts that patients in the primary trial will not receive Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously like those in the secondary trial. The primary trial's intervention does not include intravenous Herceptin\u00a9 (trastuzumab) or paclitaxel administration. Consequently, the statement's assertion is harmonious with the clinical trial data and is entailed by it.</s>",
        "contradict": "The patients in the primary trial undergo 18F-FLT PET/CT scans throughout the trial, while the statement mentions Herceptin\u00a9 (trastuzumab) or paclitaxel being given intravenously like in the secondary trial but not specifying that it relates to the PET/CT procedure. Therefore, the information in the statement does not contradict the primary trial data if the mentioned intravenous administered drugs are for purposes other than the PET/CT scan. However, based on the given CTRs, there is no mention of Herceptin\u00a9 (trastuzumab) or paclitaxel being administered intravenously for purposes other than chemotherapy or biomarker analysis in the primary trial, which contradicts the statement if it's interpreted as a direct comparison between the primary and secondary trials regarding the administration of these drugs.</s>"
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over half a year to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have a life expectancy over half a year to participate in the primary trial\" is entailed by the CTR inclusion criteria that states \"Patient who have estimated life expectancy of more than six months.\"</s>",
        "contradict": "The statement \"Patients must have a life expectancy over half a year to participate in the primary trial\" can be contradicted by the inclusion criterion in the CTR that specifies \"Patient who have estimated life expectancy of more than six months\". While the statement is consistent with the minimum life expectancy requirement, it is more restrictive as it sets a stricter time frame (over half a year) which is not explicitly stated in the CTR.</s>"
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients mustn't have a life expectancy over half a year to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the CTR as the CTR specifies that patients have an estimated life expectancy of more than six months.</s>",
        "contradict": "The statement \"Patients mustn't have a life expectancy over half a year to participate in the primary trial\" contradicts the eligibility criterion stated in the CTR that \"Patients have an estimated life expectancy of more than six months.\"</s>"
    },
    "e7b47e19-9cd0-4121-a79a-ee223e7f3ab7_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "A life expectancy over half a year is required for patients to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The CTR specifies \"Patient who have estimated life expectancy of more than six months.\" This statement from the clinical trial expert is a less precise but entailed version, as six months is greater than half a year.</s>",
        "contradict": "The statement that \"A life expectancy over half a year is required for patients to participate in the primary trial\" is contradicted by the CTR's inclusion criteria stating that patients must have an estimated life expectancy of more than six months. However, the statement's requirement is less stringent, only asking for a life expectancy over \"half a year,\" which is less than the six months mentioned in the CTR.</s>"
    },
    "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if we interpret the term \"life-threatening reaction to an infection\" as covering \"sepsis,\" which appeared in both trials as a recorded adverse event with a combined occurrence of 5 cases out of 179 patients (2.80%). Thus, the statement's claim of 30% of patients having a life-threatening reaction to an infection can be inferred from the reported sepsis cases, which are a part of the adverse events in the CTRs.</s>",
        "contradict": "The statement \"A 30% of patients in the primary trial suffered a life-threatening reaction to an infection\" contradicts the information in the CTRs because the combined total of Sepsis cases in both trials (4/179, or 2.27%) does not reach the stated percentage of life-threatening reactions to infections.</s>"
    },
    "d72ecaae-c132-480c-af5e-87c58dd26082": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer.",
        "Label": "Contradiction",
        "entail": "The statement asserts that \"Endocervical cancer\" is the only adverse event observed in patients from both trials. The CTRs list zero occurrences of Endocervical cancer in the primary trial's Adverse Events 1 and 2 sections, and zero occurrences in the secondary trial's Adverse Events 1 and 2 sections. Since neither trial reported an occurrence of Endocervical cancer for any participant, and the expert statement claims that it's the only shared adverse event, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"The only adverse event observed in Patients from both the secondary trial and the primary trial, was Endocervical cancer\" is contradicted by the information in the CTRs because:\n\n1. In the primary trial, Endocervical cancer is not listed as an adverse event in either the first or second set of Adverse Events.\n2. In the secondary trial, only one case of Endocervical cancer is mentioned among Adverse Events 2, but it is not indicated that it was observed in patients from both trials.</s>"
    },
    "80245791-4a95-4682-bd5f-856694c9f52f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with HER2 negative tumours are eligible for the primary trial but not for the secondary trial\" can be entailed by the CTRs as follows:\n\nInclusion Criteria for Primary Trial: The primary trial includes patients with inoperable estrogen receptor positive and HER2 negative breast cancer.\n\nExclusion Criteria for Secondary Trial: The secondary trial excludes patients with HER2 positive tumours and defines HER-2 negativity according to current ASCO-CAP guidelines for HER testing. Since the primary trial includes HER2 negative patients and the secondary trial excludes them, this implies that HER2 negative patients are eligible for the primary trial but not for the secondary trial.</s>",
        "contradict": "The statement is not an entailment of the CTRs as the primary trial includes both HER2 negative and positive breast cancer patients, while the secondary trial specifically excludes HER2 negative tumors. The CTR for the secondary trial mentions \"HER-2 negativity will be based on the current ASCO-CAP guidelines for HER testing,\" but it does not mention anything about exclusivity for HER2 negative patients.</s>"
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold\" is entailed by the CTRs because neither of the provided CTRs include ethnicity, specific language proficiency, or height threshold among their inclusion or exclusion criteria.</s>",
        "contradict": "The statement made by the clinical trials expert can be contradicted by the CTRs due to their different inclusion criteria. While the statement mentions that neither trial specifies any ethnicity, language, or height threshold for participants, the primary trial includes patients with HER2-overexpressing breast cancer, a condition that may disproportionately affect certain ethnic groups. Additionally, the secondary trial has eligibility criteria related to breast cancer risk factors that may differ in prevalence across various populations. Therefore, the trials do not meet the exact conditions outlined in the statement.</s>"
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "The secondary trial and the primary trial require participants to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold.",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information in the CTRs as there is no mention regarding participant ethnicity, language, or height threshold in the provided inclusion or exclusion criteria for either the primary or secondary trial.</s>",
        "contradict": "The statement is not supported by the information provided in the CTRs as there is no mention of any requirements related to ethnicity, language, or height in either the primary or secondary trial inclusion criteria.</s>"
    },
    "be7a2ed3-49a3-45e0-ba0a-ee5ee95e6138_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "Participants are not required to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold to participate in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The given statement \"Participants are not required to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold to participate in the primary trial or the secondary trial\" is entailed by the information present in the CTRs. There is no mention of any specific ethnicity, language requirement, or height threshold in the inclusion or exclusion criteria of either trial.</s>",
        "contradict": "The statement that \"Participants are not required to be of a particular ethnicity, to be able to speak a specific language or to be above a certain height threshold to participate in the primary trial or the secondary trial\" contradicts the eligibility criteria present in the provided CTRs. \n\nIn the Primary Trial, there is no mention of any specific ethnicity, language requirement, or height threshold. However, the eligibility criteria do mention a specific diagnosis, age range, and disease state, which is different from the broad statement made by the expert. \n\nIn the Secondary Trial, there is a mention of postmenopausal status, but no specific ethnicity, language requirement, or height threshold is mentioned in the provided eligibility criteria. However, the exclusion criteria mention certain conditions that may impact eligibility based on medical history, which is not covered by the broad statement made by the expert. \n\nTherefore, the statement made by the expert is too broad and contradicts the specific eligibility criteria mentioned in the given CTRs.</s>"
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily.",
        "Label": "Entailment",
        "entail": "The expert's statement that \"Intervention 1 of the primary trial require participants to take 300 mg alpelisib once daily\" is entailed by the information in the CTR as stated, because the CTR specifies that \"Participants in Intervention 1 took alpelisib 300 mg once daily.\" Therefore, the statement made by the clinical trial expert aligns with the clinical trial data, finds substantiation in the CTR, and does not contradict the provided description.</s>",
        "contradict": "The statement made by the clinical trial expert is contradicted by the information in the CTR as participants in Intervention 1 of the primary trial took alpelisib 300 mg once daily, but the statement only mentions the requirement for alpelisib without specifying the exact dosage and frequency. In the CTR, it is also mentioned that Intervention 2 involved a placebo instead of alpelisib, which is not mentioned in the expert's statement. Therefore, the expert's statement is incomplete and could potentially misrepresent the actual information in the CTR.</s>"
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial don't require participants to take 300 mg alpelisib once daily.",
        "Label": "Contradiction",
        "entail": "The statement \"Intervention 1 of the primary trial doesn't require participants to take 300 mg alpelisib once daily\" can be entailed by the information in the CTR as follows:\n\nThe CTR specifies that \"Participants in Intervention 1 took alpelisib 300 mg once daily,\" not that they had to strictly adhere to this exact dosage throughout the trial. The statement made by the expert acknowledges that participants were given alpelisib, but not necessarily at the stated dosage of 300 mg once daily. This is still consistent with the information in the CTR.</s>",
        "contradict": "The information in the expert's statement contradicts the Intervention 1 description in the CTR. The CTR states that participants in Intervention 1 took alpelisib 300 mg once daily. The expert's statement asserts that the participants did not need to take this dose.</s>"
    },
    "f0da58e6-e937-41ac-b53a-d46ec8a28d11_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "300 mg alpelisib once daily is required to be taken by participants in Intervention 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"300 mg alpelisib once daily is required to be taken by participants in Intervention 1 of the primary trial\" is entailed by the information in the CTRs as both Intervention 1 and the statement explicitly mention that participants took alpelisib 300 mg once daily in the primary trial.</s>",
        "contradict": "The statement \"300 mg alpelisib once daily is required to be taken by participants in Intervention 1 of the primary trial\" can be contradicted by the information in the CTRs because the CTR for the primary trial specifies that participants took \"alpelisib 300 mg once daily\" but it does not explicitly mention that this dosage of alpelisib is a requirement. It's simply a fact about what was administered in the intervention. The statement makes an assumption that the requirement extends beyond just the administered dosage, potentially implying that no lower or higher doses are permissible, which may not be the case based on the information in the CTR.</s>"
    },
    "5a74a63a-3912-44f0-9e83-4e6b678cbe90": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, and are both testing the effectiveness of Full-Field Digital Mammography.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as both trials involve two study groups each. In the primary trial, there are two interventions: FFDM Plus DBT and FFDM, both utilizing the FujiFilm Aspire Cristalle System for Full-Field Digital Mammography. In the secondary trial, there are two study groups: an Active Control Group and the My Surgical Success Intervention Group, and while the interventions are not explicitly stated as Full-Field Digital Mammography in this section of the CTR, it is mentioned elsewhere in the report that this is the imaging modality used in the trial. Therefore, both trials are testing the effectiveness of Full-Field Digital Mammography, fulfilling the statement's condition.</s>",
        "contradict": "Although both trials involve the use of Full-Field Digital Mammography (FFDM), the number of study groups and interventions being compared in each trial are different. In the primary trial, there are two intervention groups - FFDM Plus DBT and FFDM alone. In contrast, the secondary trial has two distinct interventions - an Active Control Group and a My Surgical Success Intervention Group. Hence, the statement's claim about the trials having the same number of study groups and being solely focused on FFDM is contradicted by the available data in the CTRs.</s>"
    },
    "43f03ba4-ef03-4f57-b059-3d9267f0dcf8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients under the age of 18, wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment prior to study entry, and have a life expectancy of more than 3 months\" is entailed by the CTR inclusion criteria which state that \"Female participants of childbearing potential must discontinue antitumoral hormonal treatment prior to enrollment\" and \"Estimated life expectancy of at least 3 months\" for all participants. Therefore, the statement's conditions are a subset of the CTR's inclusion criteria, and its assertion harmonizes with the clinical trial data.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, while it requires patients in the primary trial to discontinue antitumoral hormonal treatment and have a life expectancy of more than 3 months for participation, the CTRs include eligibility criteria stating that participants must have antitumoral hormonal treatment discontinued prior to enrollment and have an estimated life expectancy of at least 3 months. However, the statement incorrectly implies that only age is a limitation for patients under 18, when in reality, antitumoral hormonal treatment and life expectancy are also requirements for the primary trial.</s>"
    },
    "6e106caf-2522-4022-898d-64b82093d77a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement's assertion harmonizes with the CTRs' eligibility criteria, which include females aged 18-70 (inclusive of ages over 20) with no prior chemotherapy, making the statement's entailment straightforward.</s>",
        "contradict": "The statement \"Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are eligible for the primary trial,\" contradicts the CTR's eligibility criteria in several ways:\n\n1. Age: The CTR specifies that female subjects must be between 18-70 years old.\n2. Prior Chemotherapy: The statement does not mention the requirement for hormonal receptor status, HER-2 status, or the specific chemotherapy agents allowed in the CTR. Thus, the statement does not account for all the exclusions related to prior chemotherapy.\n\n3. Eligibility for Specific Cancer Stages: The CTR states that the trial is for patients with stage I, II, or III triple negative breast cancer, while the statement does not mention any cancer stage restrictions.\n\nIn summary, while the age and lack of prior chemotherapy with therapeutic intent mentioned in the statement are requirements in the CTR, the statement fails to address other essential eligibility criteria and can therefore potentially contradict the information presented in the CTRs.</s>"
    },
    "6e106caf-2522-4022-898d-64b82093d77a_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, aren't eligible for the primary trial\" is entailed by the CTR as it includes the eligibility criterion \"Female subjects age 18 - 70 years\" but explicitly states \"No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer.\" Thus, individuals over the age of 20 who haven't undergone prior chemotherapy, endocrine therapy, or radiation therapy with therapeutic intent for their current cancer are not eligible for the primary trial.</s>",
        "contradict": "The statement \"Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, aren't eligible for the primary trial\" is contradicted by the inclusion criteria of the primary trial which states \"Female subjects age 18 - 70 years\" and \"No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer.\" This contradiction lies in the discrepancy of the age limit and the chemotherapy eligibility criterion. The primary trial includes females aged 18 to 70 without prior chemotherapy, while the statement implies females over 20 are not eligible if they have not had chemotherapy. The primary trial's inclusion criteria are more inclusive in terms of age and chemotherapy history than the expert statement.</s>"
    },
    "6e106caf-2522-4022-898d-64b82093d77a_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are not excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are not excluded from the primary trial,\" can be entailed by the information present in the CTRs because the CTR specifies that \"Female subjects age 18 - 70 years\" are eligible for inclusion in the trial, and one of the exclusion criteria is \"Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer.\" Since the statement mentions that females over 20 with no prior chemotherapy for the current cancer are not excluded, this condition falls within the eligible age range and does not violate any of the exclusion criteria stated in the CTR.</s>",
        "contradict": "The statement \"Females over the age of 20 with no prior chemotherapy with therapeutic intent for current cancer, are not excluded from the primary trial\" is contradicted by the CTR inclusion criteria which state \"No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer\" for the primary trial.</s>"
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial receives Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study.",
        "Label": "Entailment",
        "entail": "Cohort 2 of the primary trial receives Doxorubicin, cyclophosphamide, and docetaxel throughout the cycles of the study as per the following schedule:\n\n1. Doxorubicin and cyclophosphamide: Given in combination as AC regimen during the first 4 cycles every 3 weeks.\n\n2. Docetaxel: Given as monotherapy during cycles 5 to 8 every 3 weeks, starting from cycle 5.\n\nAdditionally, Cohort 2 in the primary trial also receives Herceptin as follows:\n\n1. Herceptin: Given as a single agent starting from cycle 5, initially at a dose of 4 mg/kg IV infusion on Day 1 of cycle 5, followed by a dose of 2 mg/kg by IV infusion weekly starting from Day 8.\n2. After completion of chemotherapy, Herceptin was continued every 3 weeks until 1 year from the initial Herceptin dose.\n\nHence, the statement that 'Cohort 2 of the primary trial receives Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study' is entailed by the information present in the CTRs since it accurately represents the given treatment schedules for the respective drugs in Cohort 2 of the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the treatment regimens for cohorts in the primary trial are different. In Intervention 1, cohorts receive Doxorubicin, cyclophosphamide, and docetaxel, but Herceptin is not part of their treatment plan. In Intervention 2, on the other hand, cohorts receive Doxorubicin, cyclophosphosphamide, Herceptin, and docetaxel, but the administration of Herceptin varies between cycles 5 and beyond the last cycle of chemotherapy.</s>"
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Cohort 2 of the primary trial doesn't recieve Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial doesn't receive Doxorubicin, cyclophosphamide, Herceptin and docetaxel throughout the cycles of the study\" is entailed by the information present in the CTRs because the interventions described differ between the two cohorts. In intervention 1 of the primary trial, Doxorubicin and cyclophosphamide are administered to all patients for the first four cycles, while in intervention 2, these drugs are only administered during the first four cycles, but Herceptin and docetaxel are added for an additional four cycles. However, the statement explicitly mentions that cohort 2 doesn't receive Doxorubicin, cyclophosphamide, Herceptin, and docetaxel \"throughout the cycles of the study,\" indicating that these drugs are not given to cohort 2 at any point during the trial.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs because, according to the primary trial's Intervention 2 description, Cohort 2 (represented as AC\u2192TH) does receive Doxorubicin, cyclophosphamide, Herceptin, and docetaxel throughout the study, but with differing dosage and administration schedules. Specifically, they receive Doxorubicin and cyclophosphamide for the first 4 cycles, Herceptin starting from Cycle 5, and docetaxel starting from Cycle 5 as well. This discrepancy between the statement and the CTR information indicates a contradiction.</s>"
    },
    "7f8a918c-fab8-4129-8178-0cda7d0441e1_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Doxorubicin, cyclophosphamide, Herceptin and docetaxel are recieved throughout the cycles of the study by Cohort 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Doxorubicin, cyclophosphamide, Herceptin, and docetaxel are received throughout the cycles of the study by Cohort 2 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Doxorubicin and cyclophosphamide are part of Intervention 1 (AC) and Intervention 2 (AC\u2192TH) given to Cohort 1 and Cohort 2 respectively in the primary trial throughout the cycles of the study.\n2. Herceptin is a part of Intervention 2 (AC\u2192TH) given to Cohort 2 of the primary trial throughout the specified cycles.\n3. Docetaxel is a part of Intervention 1 (AC\u2192T) and Intervention 2 (AC\u2192TH), given to Cohort 1 and Cohort 2 of the primary trial throughout the cycles of the study. \n\nHence, all the mentioned drugs (Doxorubicin, cyclophosphamide, Herceptin, and docetaxel) are indeed received by Cohort 2 throughout the cycles of the study in the primary trial as outlined in the statement.</s>",
        "contradict": "The statement \"Doxorubicin, cyclophosphamide, Herceptin and docetaxel are received throughout the cycles of the study by Cohort 2 of the primary trial\" is contradicted by the information present in the CTRs, as:\n\n1. Cohort 2 in the primary trial undergoes AC\u2192TH treatment regimen, meaning they receive Doxorubicin+Cyclophosphamide in Cycles 1-4, Herceptin+Docetaxel in Cycle 5, and Herceptin monotherapy from Cycle 6 until 1 year from initial Herceptin dose. \n2. The information in the statement suggests all drugs are received continuously throughout the entire study, while in reality, the drugs are administered in different combinations and sequences as specified by the trial's intervention design.</s>"
    },
    "84aa1194-c081-4acf-9ed6-8cf0d1a08f5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01125566",
        "Statement": "At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months.",
        "Label": "Contradiction",
        "entail": "The statement \"At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months,\" can be entailed by the CTRs as follows:\n\n1. In the primary trial, one arm/group (AV) involved participants receiving the mentioned Afginib and Vinorelbine treatment combination.\n2. According to the CTR, the overall number of participants analyzed in this arm was 339.\n3. The median PFS for this arm is 5.49 months (3.55 to 9.07), which implies that some participants had a PFS greater than 9 months since the median is an estimator representing the middle value.\n4. The CTR does not provide the exact number of participants with PFS over 9 months, but given that the overall number of participants was 339, it is plausible that at least 400 participants (assuming a few participants had multiple PFS measurements) with PFS over 9 months existed based on the given median and interquartile range.\n5. The expert's statement does not contradict the information in the CTRs.\n\nTherefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"At least 400 participants in the primary trial receiving an oral treatment of film-coated Afatinib tablet at a starting dose of 40 milligram (mg) once daily and weekly 10 minutes intravenous infusions of Vinorelbine 25 mg/meter^2 (meter=m) had a PFS over 9 months\" cannot be definitively contradicted by the information presented in the CTRs, as the number of participants fulfilling this condition is not explicitly stated. However, it is possible that this statement is incorrect based on the information provided, as the median PFS for the Afatinib + Vinorelbine (AV) arm was only 5.49 months (3.55 to 9.07), which is below the 9-month threshold mentioned in the statement. Therefore, the statement may be an overestimation of the number of participants who met the condition and could contradict the trial results if it was assumed that all participants in the AV arm had a PFS of at least 9 months.</s>"
    },
    "2bd65df6-4f1d-461c-93f5-f2ddbfde57b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial\" is entailed by the information present in the CTRs because:\n\n1. In the primary CTR, there is no explicit mention of unexplained fever as an exclusion criterion, and there is no temperature restriction mentioned for patient inclusion.\n2. In the secondary CTR, patients are eligible as long as they have acceptable organ function, which includes normal body temperature. The statement does not limit the acceptable temperature range, so it implicitly includes patients with unexplained fever below thirty eight degrees Celsius.</s>",
        "contradict": "The statement \"Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial\" is contradictory to the information present in the CTRs because:\n\n1. In the primary trial, an active infection or unexplained fever >38.5\u00b0C during screening is an exclusion criteria.\n2. In the secondary trial, there is no mention of fever as an inclusion or exclusion criteria. However, the presence of an active infection is an exclusion criteria.\n\nHence, the statement that \"Patients with unexplained fever below thirty eight degrees Celsius may be included in the secondary trial and the primary trial\" contradicts the information provided in the CTRs.</s>"
    },
    "0290bc2d-9cd3-44ab-9b04-385f19527c42": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have ductal carcinoma, that can be felt by touch to be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have ductal carcinoma, that can be felt by touch,\" can be entailed by the information in the Primary Trial's Inclusion Criteria as it specifies \"Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.\" This implies that the patients in the trial have a form of breast cancer, specifically ductal carcinoma that is palpable, which meets the expert's requirement.</s>",
        "contradict": "The statement \"Patients must have ductal carcinoma, that can be felt by touch,\" is contradictory to the inclusion criteria of the primary CTR, as it omits the requirement for cancer to enhance on breast MRI imaging.</s>"
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame\" can be entailed by the information in the CTRs because:\n\n1. The primary trial measures Clinical Benefit Rate using RECIST version 1.0 criteria, which includes Complete Response (CR), Partial Response (PR), and Stable Disease (SD) for a duration of more than 6 months. The secondary trial, however, measures Pathological Complete Response (pCR) by assessing the absence of any residual invasive cancer on hematoxylin and eosin evaluation after 24 weeks of treatment, which is not the same as Clinical Benefit Rate.\n2. The primary and secondary trials use different time frames for measuring outcomes. In the primary trial, the time frame for measuring Clinical Benefit Rate is baseline through end of study, up to 3 years. In contrast, in the secondary trial, the time frame for measuring pCR is after 24 weeks of treatment.\n\nTherefore, the statement \"the secondary trial and the primary trial do not both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame\" is a logically valid conclusion based on the information provided in the CTRs.</s>",
        "contradict": "The statement asserts that the primary and secondary trials do not use identical outcome measures (Clinical Benefit Rate with the same time frame). However, the primary trial reports the Clinical Benefit Rate using different durations of response (CR + PR + SD > 6 months) and the secondary trial reports pCR after 24 weeks of treatment, which are distinct measures. Consequently, the statement does not contradict the information provided in the CTRs, but instead highlights their differences.</s>"
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "The secondary trial and the primary trial do both use Clinical Benefit Rate as their outcome measure, and they do not use the same time frame.",
        "Label": "Contradiction",
        "entail": "The statement \"The secondary trial and the primary trial do both use Clinical Benefit Rate as their outcome measure\" can be entailed by the CTRs since the Primary Trial's outcome measurement is defined as \"Clinical Benefit Rate (CR + PR + SD > 6 Months)\" and the Secondary Trial's outcome measurement is defined as \"Pathological Complete Response (pCR) Per Investigator Assessment,\" which, though different in definition, can indirectly be related to the Clinical Benefit Rate. Although the time frames are not identical in the two trials, the Clinical Benefit Rate is assessed for the duration of the study in the Primary Trial, while in the Secondary Trial, it is implied to be assessed after 24 weeks of treatment, which is a part of the overall study duration. Thus, even if the time frames are not identical, both trials use the Clinical Benefit Rate as an outcome measure.</s>",
        "contradict": "The statement that \"The secondary trial and the primary trial do both use Clinical Benefit Rate as their outcome measure\" is generally correct, as both trials report the percentage of participants with Clinical Benefit (Complete Response, Partial Response, or Stable Disease) based on different response evaluation criteria and time frames. \n\nHowever, the statement's second part, \"and they do not use the same time frame,\" can be contradicted by the information presented in the CTRs. The primary trial's outcome measurement is assessed at baseline through end of study, up to 3 years, whereas the secondary trial measures Clinical Benefit after 24 weeks of treatment. Therefore, the Clinical Benefit Rates and their associated confidence intervals reported in the primary and secondary trials refer to different time points, which might result in different percentages and implications for clinical interpretation.</s>"
    },
    "505afbf8-b2b4-4b12-99c5-e0feef473248_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00577122",
        "Secondary_id": "NCT01923168",
        "Statement": "Clinical Benefit Rate is not used as an outcome measure by both the secondary trial and the primary trial, and they do not use the same time frame.",
        "Label": "Entailment",
        "entail": "The statement \"Clinical Benefit Rate is not used as an outcome measure by both the secondary trial and the primary trial, and they do not use the same time frame\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial specifies \"Outcome Measurement: Clinical Benefit Rate (CR + PR + SD > 6 Months)\" while the CTR for the secondary trial mentions \"Outcome Measurement: Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort,\" which is not equivalent to \"Clinical Benefit Rate.\"\n\nFurthermore, the time frames for measuring outcome in the two trials differ: \"Time frame: baseline through end of study, up to 3 years\" for the primary trial and \"After 24 weeks of treatment\" for the secondary trial, indicating that the trials employ dissimilar assessment methods and schedules, making it incomparable to determine a Clinical Benefit Rate between the trials.</s>",
        "contradict": "The statement \"Clinical Benefit Rate is not used as an outcome measure by both the secondary trial and the primary trial, and they do not use the same time frame\" is contradicted by the information present in the CTRs because:\n\n1. In the primary trial, the Clinical Benefit Rate is indeed used as an outcome measure.\n2. Although the secondary trial does not use the exact term \"Clinical Benefit Rate,\" it reports pCR (pathological complete response) rates for two arms in the trial. These rates can be related to the overall clinical benefit in the trial, as the pCR indicates that the disease has not progressed, and patients may continue to receive treatment beyond the 24-week mark.\n3. The primary and secondary trials do not use identical time frames for their outcome measures, but they don't necessarily contradict each other. In the primary trial, the time frame for Clinical Benefit Rate measurement is from baseline through the end of the study, which can be up to 3 years. In contrast, the secondary trial assesses pCR after 24 weeks of treatment. These time frames are different, but they serve separate purposes in their respective trials.</s>"
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0  bilateral  breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial, but may still be eligible for the secondary trial,\" can be entailed by the information present in the CTRs as follows:\n\nThe primary CTR explicitly includes histologically confirmed, newly diagnosed early breast cancer in the eligibility criteria, but specifies that it must be greater than 2cm by clinical examination and/or 1.5cm confirmed by ultrasound or MRI. Stage 0 breast cancer may not meet this size requirement. The primary CTR also excludes bilateral breast cancer, which includes both breasts. The secondary CTR includes survivors with histologically confirmed, newly diagnosed breast cancer, but it does not specify a size requirement or limit the cancer to unilateral occurrence. Therefore, patients with stage 0 bilateral breast cancer may still be eligible for the secondary trial, which is consistent with the statement.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the primary trial explicitly excludes patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer from participating. The secondary trial, however, does not provide any information related to the inclusion or exclusion criteria for breast cancer stage. Therefore, making a definitive statement about the eligibility of patients with stage 0 bilateral breast cancer for the secondary trial based on the provided information is not possible.</s>"
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer can take part in the primary trial, but may still be eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary CTR inclusion criteria include patients with histologically confirmed, newly diagnosed early breast cancer, which can encompass stage 0 cases. The statement does not contradict this requirement. Additionally, the primary CTR excludes patients with bilateral breast cancer, but the statement only mentions bilateral disease as a possible condition for the secondary trial and does not state that it is a criterion for exclusion from the primary trial. Therefore, the information in the statement is harmonious with the CTRs.</s>",
        "contradict": "The patients with histologically confirmed, newly diagnosed stage 0 bilateral breast cancer cannot take part in the primary trial as per its exclusion criteria which states \"Patient has bilateral breast cancer or metastatic disease or inflammatory breast cancer\" (Primary CTR). Therefore, the statement is contradictory to the information present in the CTRs.</s>"
    },
    "19e7469d-8a6f-4bbd-9c8c-ad6b127ce7a5_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Newly diagnosed stage 0 bilateral breast cancer patients may still be eligible for the secondary trial, but cannot take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Newly diagnosed stage 0 bilateral breast cancer patients may still be eligible for the secondary trial, but cannot take part in the primary trial\" is entailed by the information in the CTRs as follows:\n\n1. Primary Trial: The inclusion criteria state that the patient must have unilateral (not bilateral) breast cancer. Hence, patients with stage 0 bilateral breast cancer would not meet this requirement and would therefore be ineligible for the primary trial.\n\n2. Secondary Trial: The secondary trial includes patients with newly diagnosed breast cancer, but the statement does not specify that the cancer must be unilateral. Therefore, patients with stage 0 bilateral breast cancer could potentially meet the eligibility criteria for the secondary trial.\n\nHence, the statement does not contradict the information in the CTRs and is a valid inference based on the given eligibility criteria.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because:\n\n1. The primary trial does not include patients with stage 0 bilateral breast cancer as per the inclusion criteria which explicitly states that patient has a unilateral, histologically confirmed, early breast cancer >2cm by clinical examination and/or >1.5 cm confirmed by ultrasound or by MRI. \n\n2. The secondary trial does not mention anything about eligibility criteria related to the stage of breast cancer, it only includes Latina patients with breast cancer and their primary caregivers. Hence, the statement does not hold true for the information present in the CTRs.</s>"
    },
    "2e540abd-06e3-483d-bd69-6eb5d2275e9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial and the secondary trial are administered daily oral medication.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Usual Care does not involve any change in medication for patients. However, in the secondary trial, both Placebo and Vitamin D interventions involve administering oral medication daily for 12 months. Therefore, the statement that \"Patients in the primary trial and the secondary trial are administered daily oral medication\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial and the secondary trial are administered daily oral medication\" is not contradicted by the information present in the CTRs. However, it does not fully capture the details of the interventions in each trial. In the primary trial, some patients receive usual care which does not involve medication, while in the secondary trial, patients in the placebo arm do receive oral medication but it is not an active treatment. Therefore, while the statement is not incorrect, it is also not as specific or informative as the details provided in the CTRs regarding the nature of the interventions.</s>"
    },
    "d905f4cb-32aa-41b8-8f61-40578d8ea9ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No less than 2 patients from either cohorts of the primary trial felt nauseous.",
        "Label": "Contradiction",
        "entail": "The statement \"No less than 2 patients from either cohorts of the primary trial felt nauseous\" is entailed by the CTRs since the Adverse Events sections report at least one instance of nausea in each trial (1/101 and 0/103 for the primary and secondary trials, respectively). The total number of adverse events for each trial also includes patients with multiple adverse events, so it is possible for more than two patients to have experienced nausea across both trials. The statement does not contradict the given CTR information, and its assertion aligns with the reported adverse events.</s>",
        "contradict": "The statement \"No less than 2 patients from either cohorts of the primary trial felt nauseous\" cannot be directly contradicted by the provided CTR data. However, the statement is misaligned with the CTR data because no instances of nausea are reported in either CTR. Therefore, the statement cannot be entailed by the information presented in the CTRs. The discrepancy lies in the absence of reported nausea in the trials versus the statement's claim that \"no less than 2 patients\" experienced it.</s>"
    },
    "45510043-7931-493b-8251-41b0be9aabbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were 2 instances of patients with Atrial tachycardia in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 2 instances of patients with Atrial tachycardia in the primary trial\" is not entailed by the information present in the provided CTRs as there is no record of any patient having Atrial tachycardia in either Adverse Events 1 or Adverse Events 2 of the primary trial or the secondary trial.</s>",
        "contradict": "The statement that \"There were 2 instances of patients with Atrial tachycardia in the primary trial\" contradicts the information in the CTRs since no instances of Atrial tachycardia or Paroxysmal Atrial Tachycardia are reported in either Adverse Events section for the primary trial. (0/31 for Adverse Events 1, and 0/25 for Adverse Events 2).</s>"
    },
    "e7037f34-bd2e-402e-a19c-48073781885a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193037",
        "Statement": "10 of the patients in Cohort 1 of the primary trial suffered from Hypotension.",
        "Label": "Contradiction",
        "entail": "The statement that \"10 of the patients in Cohort 1 of the primary trial suffered from Hypotension\" is not entailed by the information presented in the CTRs, as no instances of Hypotension are reported in Cohort 1 of the primary trial according to the provided data.</s>",
        "contradict": "The information in the statement \"10 of the patients in Cohort 1 of the primary trial suffered from Hypotension\" contradicts the information in the CTRs because, according to the CTRs, there were zero cases of hypotension reported in both Cohort 1 of the primary trial (Adverse Events 1) and Cohort 1 of the secondary trial.</s>"
    },
    "5275a332-46c1-4941-8850-26a8033012e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial, as long as they are over the age of 20.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria, as it requires participants to have a history of cancer diagnosis and be cancer-free at the time of trial entry. Additionally, the statement's age restriction aligns with the CTR's minimum age requirement (20 years-old). The exclusion criteria in the CTR, such as signs of cancer recurrence, also support the statement's condition for having no active cancer. Therefore, the statement can be entailed by the information within the CTRs.</s>",
        "contradict": "The statement's assertion that \"Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eligible for the primary trial, as long as they are over the age of 20\" is not an exact entailment of the primary CTR's inclusion criteria. The CTR explicitly states that only breast cancer survivors who have undergone both surgery and chemotherapy and have newly developed dyspareunia after treatment are eligible. The age requirement is met by all patients in the trial, but the statement's eligibility condition is broader, as it doesn't mention the surgery, chemotherapy, or dyspareunia requirement. Therefore, while the statement does not contradict the information present in the CTRs, it is not an exact entailment because it is less specific and includes more potential participants.</s>"
    },
    "5275a332-46c1-4941-8850-26a8033012e3_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment aren't eliglbe for the primary trial, as long as they are over the age of 20.",
        "Label": "Contradiction",
        "entail": "The statement \"Only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment aren't eligible for the primary trial, as long as they are over the age of 20\" is entailed by the CTR's inclusion criteria stating \"breast cancer survivors over 20 years-old who are premenopausal at the time of diagnosis, treated with operation and chemotherapy, and have newly developed dyspareunia after cancer treatment\" and exclusion criteria stating \"evidence of cancer recurrence\". The statement also matches the age requirement stated in the CTR. Therefore, the statement is in line with the clinical trial data and does not contradict the provided descriptions, making it entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement can be contradicted by the information in the CTRs due to the following reasons: \n\n1. The CTR for the Primary Trial specifies that only breast cancer survivors who have developed dyspareunia after cancer treatment are eligible, regardless of the absence or presence of cancer signs at the time of trial enrollment. \n\n2. The expert's statement incorrectly assumes that the only condition for eligibility is the absence of cancer after treatment and the age requirement, while the CTR has additional eligibility conditions (i.e., having undergone surgery and chemotherapy, and experiencing dyspareunia post-treatment).\n\n3. Conversely, the expert's statement could be correct if we assume that the CTR only mentions cancer diagnosis as an exclusion criterion, but this is not actually the case, as per the provided information in the CTR.\n\nTherefore, the contradiction exists because of a misinterpretation or an oversight of the full eligibility conditions mentioned in the CTR by the clinical trials expert.</s>"
    },
    "5275a332-46c1-4941-8850-26a8033012e3_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "As long as they are over the age of 20, only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eliglbe for the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement \"As long as they are over the age of 20, only people who have previously been diagnosed with cancer and have no signs of cancer after finishing treatment are eligible for the primary trial\" is entailed by the CTR inclusion criteria that state, \"breast cancer survivors over 20 years-old, premenopausal at the time of diagnosis, treated with operation and chemotherapy, and newly developed dyspareunia after cancer treatment.\" The expert statement does not contradict or add additional information beyond the inclusion criteria, as it aligns with the requirement that participants have a history of cancer and be cancer-free at the time of enrollment. The expert statement does not directly reference the exclusion criteria, but since they do not contradict the inclusion criteria or the expert statement, the overall entailment relationship remains intact.</s>",
        "contradict": "The expert's statement is contradicted by the primary trial's eligibility criteria, which also require that study participants have undergone both surgery and chemotherapy for breast cancer. The statement implies that any cancer diagnosis and treatment, not just surgery and chemotherapy, is sufficient for eligibility. The CTR's eligibility criteria are more specific, and the expert's statement is less inclusive, making it a contradiction.</s>"
    },
    "1ec6aca8-6e67-4535-aeb7-a250e1d7b6c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI and Letrozole for their interventions.",
        "Label": "Contradiction",
        "entail": "Both trials involve the usage of Magnetic Resonance Imaging (MRI) in their interventions. The primary trial administers Letrozole to healthy postmenopausal women and has them undergo MRI scans, while the secondary trial screens patients (healthy volunteers and breast cancer patients) and subjects them to MRI scans. The statement's assertion is in accord with the information presented in the CTRs, as they both mention MRI utilization, and no contradiction is present since the trials differ in patient populations and intervention specifics. The primary trial employs Letrozole in conjunction with MRI, whereas the secondary trial incorporates MRI as an independent intervention.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial both used MRI and Letrozole for their interventions\" is not a contradiction to the information in the CTRs; however, it does not fully capture the differences in how these interventions are implemented in each trial.\n\nIn the primary trial, Letrozole intervention involves only healthy postmenopausal women, who receive Letrozole treatment (12.5 mg/day for three consecutive days) and undergo two breast MRIs (baseline and post-treatment). The MRI procedure in this trial is for evaluating breast enhancement and safety.\n\nIn contrast, in the secondary trial:\n\n1. The MRI intervention applies to both healthy volunteers and breast cancer patients.\n2. The volunteers and patients receive MRI scans for different purposes (SWIFT MRI workflow in both cases).\n3. The MRI procedure for volunteers includes screening, contrast injection, SWIFT acquisition, and late enhancement images.\n4. The MRI procedure for patients is similar but is performed before breast biopsy.\n\nSo, the statement is not contradictory to the CTRs but may lack necessary precision to fully convey the nuances of how MRI and Letrozole interventions are used in each trial.</s>"
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial\" is entailed by the information in the CTRs since the primary trial's inclusion criteria explicitly state that postmenopausal status is a requirement for patient eligibility, which is defined as \"cessation of menses for >1 year\" or \"FSH > 20 mIU/mL (within the past month)\".</s>",
        "contradict": "The statement can be contradicted by the information in the CTR because it only partially matches the inclusion criteria stated in the CTR. While postmenopausal status is a requirement in the primary trial, it is only one of the multiple inclusion criteria. The CTR also requires histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or DCIS, undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment, and be free of prior chemotherapy, radiation therapy, or surgery within 6 months of study entry, among other conditions. Consequently, not every patient meeting the postmenopausal requirement will be eligible for the trial as outlined in the CTR.</s>"
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients mustn't have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial inclusion criteria clearly state that postmenopausal status is defined as cessation of menses for more than one year. Therefore, patients who do not meet this condition are explicitly excluded from the primary trial. The expert's statement reiterates this requirement for postmenopausal status, making it entailed by the information in the CTRs.</s>",
        "contradict": "The statement contradicts the CTR because the CTR specifies that postmenopausal status is a requirement for patient eligibility in the primary trial. Contrarily, the statement asserts that patients cannot have a confirmed postmenopausal status to participate, which is not consistent with the CTR's inclusion criteria.</s>"
    },
    "b02f43d7-44bb-4219-9a08-fd70e7cc9b87_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "To take part in the primary trial, patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year.",
        "Label": "Entailment",
        "entail": "The expert's statement entails the CTR's inclusion criterion for postmenopausal status (cessation of menses for >1 year), as it reiterates the definition of postmenopausal status given in the CTR.</s>",
        "contradict": "The expert statement \"To take part in the primary trial, patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year\" is not directly contradicted by the CTR inclusion criteria, but it can be less precise since it omits an alternative definition of postmenopausal status using FSH levels. In the CTR, both the cessation of menses and an FSH level greater than 20 mIU/mL are acceptable methods to establish postmenopausal status.</s>"
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial\" is entailed by the CTR inclusion and exclusion criteria as follows:\n\n1. Inclusion Criteria: The CTR explicitly states that patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer are excluded, which encompasses the conditions stated in the clinical trial expert's claim.\n2. Exclusion Criteria: The CTR also includes patients with a history of a myocardial infarction within 12 months, high-risk uncontrolled arrhythmias, grade 3 QT prolongation, or subjects requiring drugs that may prolong the QT, which are not mentioned in the expert's claim, but it is reasonable to assume that radiation therapy or biotherapy might influence these conditions. Since the expert's claim only mentions radiation therapy and biotherapy as the exclusion criteria and the CTR covers a broader range of treatments, the expert's statement is still entailed by the CTR. \n\nTherefore, the information in the expert's statement is harmonious with the CTR data, is substantiated by the provided descriptions, and avoids contradiction. The expert's statement is entailed by the CTRs.</s>",
        "contradict": "The given statement can be contradicted by the information present in the CTRs because the primary trial's inclusion criteria do not exclude patients with stage IV breast cancer undergoing chemotherapy, radiation therapy, or biotherapy for current breast cancer. In contrast, the stated exclusion criterion only refers to patients currently receiving these treatments. The difference in the scope of patient exclusion between the statement and the CTRs creates the contradiction.</s>"
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial inclusion criteria state that patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer are excluded. However, the statement does not contradict this information. Instead, it specifically mentions that patients with breast cancer \"above stage\" are not excluded, which could be interpreted as patients with stage I, II, or III breast cancer. These stages are included in the primary trial, so the statement is entailed by the information in the CTRs. The statement also correctly notes that patients currently receiving radiation therapy or biotherapy are excluded, which is consistent with the primary trial exclusion criteria.</s>",
        "contradict": "The statement \"Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy aren't excluded from the primary trial\" contradicts the information presented in the primary CTR's exclusion criteria, as patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer are explicitly excluded from participating in the trial.</s>"
    },
    "1a6661e0-343f-4056-b568-611e7cc7750c_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Excluded from the primary trial are any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy.",
        "Label": "Entailment",
        "entail": "The statement \"Excluded from the primary trial are any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy\" can be entailed by the information in the CTRs as the primary trial explicitly states that patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer are excluded.</s>",
        "contradict": "The statement's assertion that \"Excluded from the primary trial are any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy,\" is contradicted by the information in the CTRs because the primary trial excludes patients with stage IV breast cancer but does not mention a specific requirement for patients not to be receiving radiation therapy or biotherapy beyond stating that they are ineligible if undergoing such therapies for their current breast cancer. This discrepancy could potentially lead to misinterpretations of the eligibility criteria for the clinical trial.</s>"
    },
    "ec97c90e-f904-4cf2-9567-8525edf747cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating patient assisted imaging interventions.",
        "Label": "Contradiction",
        "entail": "Both the primary and secondary trials involve evaluations of patient-assisted imaging interventions, aligning with the descriptions of Interventions 1 in each CTR. The primary trial assesses the acceptability of clinical image quality for patient-assisted compression image sets, while the secondary trial utilizes each subject as her own control and evaluates imaging using both test and control modalities for a broader, overall population. Despite their differences in methodology, the common theme is the application of patient-assisted imaging interventions, which is reflected in the statement. The statement's assertion is harmonious with the information in the CTRs and avoids contradiction, making it entailed.</s>",
        "contradict": "Although both trials are evaluating patient-assisted imaging interventions, the primary trial involves separate image sets being evaluated for overall clinical image quality by two readers for each intervention, while in the secondary trial, each subject serves as their own control and imaging is done with both test and control modalities. The statement does not contradict the interventions being patient-assisted; however, the evaluation methods and study designs differ significantly between the primary and secondary trials.</s>"
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial do not test the same modalities of cancer treatments.",
        "Label": "Entailment",
        "entail": "The statement that \"the secondary trial and the primary trial do not test the same modalities of cancer treatments\" is entailed by the information present in the CTRs because:\n\n1. In the primary trial, Intervention 1 involves Lapatinib Plus Capecitabine, while Intervention 2 involves Trastuzumab Plus Capecitabine. Lapatinib and Trastuzumab are different drugs used for treating breast cancer, making them distinct modalities of cancer treatment.\n2. In the secondary trial, Intervention 1 involves a Behavioral Dietary Intervention and Therapeutic Conventional Surgery, but it does not involve any form of chemotherapy, biologic therapy, or radiation therapy mentioned explicitly in the CTR.\n\nThus, the statement that \"the secondary trial and the primary trial do not test the same modalities of cancer treatments\" is a logical conclusion based on the information provided in the CTRs, as the trials investigate different combinations and types of interventions.</s>",
        "contradict": "Although the secondary trial does not involve lapatinib, capecitabine, or trastuzumab as its interventions, it does not mean that the trials test the same modalities of cancer treatments. The statement is not contradicted by the information present in the CTRs, but rather, it correctly reflects the differences in intervention modalities between the two trials.</s>"
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "The secondary trial and the primary trial test the same modalities of cancer treatments.",
        "Label": "Contradiction",
        "entail": "Both trials involve the use of capecitabine as a common modality in Intervention 2. In the primary trial, participants received capecitabine as part of Intervention 1 in combination with lapatinib or Intervention 2 with trastuzumab. In the secondary trial, capecitabine is a component of Intervention 1, which also includes a behavioral dietary intervention, therapeutic conventional surgery, radiation therapy, and counseling intervention. Since both trials utilize the same drug, capecitabine, in their interventions, the statement that they test the same modalities of cancer treatments is entailed by the provided CTR information.</s>",
        "contradict": "The statement \"The secondary trial and the primary trial test the same modalities of cancer treatments\" can be contradicted by the information present in the CTRs as follows:\n\nIn the primary trial, the interventions involve lapatinib plus capecitabine (for Intervention 1) and trastuzumab plus capecitabine (for Intervention 2), which consist of different combinations of drugs. \n\nIn contrast, the secondary trial only involves a behavioral dietary intervention, which is a different modality of treatment compared to the pharmacological interventions in the primary trial. Therefore, the statement is not an entailed relationship between the information in the CTRs and the expert statement.</s>"
    },
    "7a129a1e-20d9-4f5a-a921-d30957460e27_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "The same modalities of cancer treatments are not tested by the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, the interventions involve administering either lapatinib plus capecitabine or trastuzumab plus capecitabine. No information is provided in the primary trial regarding behavioral dietary interventions, therapeutic conventional surgery, radiation therapy, or counseling intervention. \n\nSimilarly, in the secondary trial, the intervention is a behavioral dietary intervention. There is no mention of any cancer treatments, such as lapatinib, capecitabine, or trastuzumab, being tested. \n\nThus, the statement that \"The same modalities of cancer treatments are not tested by the secondary trial and the primary trial\" is an entailed conclusion, as the CTRs themselves do not report the use of identical treatments in both trials.</s>",
        "contradict": "The statement \"The same modalities of cancer treatments are not tested by the secondary trial and the primary trial\" is contradicted by the information present in the CTRs as both trials include the use of Capecitabine as a common intervention.</s>"
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial is less than 1%.",
        "Label": "Entailment",
        "entail": "The difference in the reported percentage of participants with at least one adverse event between Cohort A (91.4% with SC Herceptin by needle/syringe) and Cohort B (90.0% with SC Herceptin by SID) in the secondary trial is 1.4%. The difference of 1.4% is less than 1%, as claimed in the statement. The percentages reported in the primary trial for both cohorts (88.6% for Cohort A and 89.0% for Cohort B) also support this finding, as the difference between them is less than 1%.</s>",
        "contradict": "The expert's statement cannot be definitively contradicted by the information in the CTRs, but it could be challenged based on the following points:\n\n1. The absolute difference in percentage (0.4%) between Cohort A and Cohort B may seem small, but it does not directly account for the total number of participants with at least one adverse event.\n2. The CTRs report percentages for the entire cohort, meaning that a difference less than 1% could still mean that there are significant differences in the number of participants experiencing adverse events within the respective cohorts.\n3. The eligibility criteria, intervention details, and adverse events in both trials might vary, leading to potential confounding factors that could influence the occurrence of adverse events.\n\nTo accurately determine the entailment relationship, a more comprehensive comparison of the trials, including the eligibility criteria, intervention methods, outcome measures, and adverse event profiles, would be necessary.</s>"
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial isn't less than 1%.",
        "Label": "Contradiction",
        "entail": "The statement \"The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial isn't less than 1%\" can be entailed by the information present in the CTRs as follows:\n\n1. The percentage of participants with at least one AE for Cohort A is 88.6%, and for Cohort B is 89.0%.\n2. The difference between the two percentages is 0.4%.\n3. The statement asserts that the difference between the percentages is not less than 1%.\n4. Therefore, the statement is entailed by the data in the CTRs because the difference in percentages of at least 1% is not reported, but the difference in percentages is actually greater than 1%.\n\nThe statement does not contradict the information in the CTRs, as the CTRs do not report a difference of less than 1% between the percentage of participants with at least one AE in the two cohorts.</s>",
        "contradict": "The statement \"The difference in Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period in both cohorts of the primary trial isn't less than 1%\" cannot be definitively contradicted by the information in the CTRs. However, it does not necessarily entail agreement as well. While the percentage differences between Cohorts A and B are similar (0.4 percentage points), the actual number of AEs and their severity or seriousness are not reported in the provided CTRs. Therefore, the statement is ambiguous as it does not specify the number of participants experiencing AEs of a particular severity or seriousness level. Further analysis would be required to establish entailment or contradiction between the statement and the CTRs.</s>"
    },
    "fa9bd6ab-bd69-43f9-a0c0-f8c80bad9da4_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "In the primary trial, during the Treatment Period in both cohorts the percentage of participants with at least 1 Adverse Event (AE) difference is less than 1%.",
        "Label": "Entailment",
        "entail": "The percentage difference between the two cohorts (A and B) in the number of participants with at least 1 adverse event during the treatment period is calculated as follows: |88.6 - 89.0| = 0.4%. This difference is less than 1%. The information in the CTRs indicates that both cohorts received SC Herceptin with similar dosing regimens (600 mg every 3 weeks for a total of 18 doses/cycles) and similar time frames for adverse events measurement (From Day 1 up to 19 cycles, approximately 1 year). As the trial definitions for adverse events are consistent between the two groups, the difference in adverse event occurrence between them is expected to be relatively small. Therefore, the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"In the primary trial, during the Treatment Period in both cohorts the percentage of participants with at least 1 Adverse Event (AE) difference is less than 1%\" is not directly contradictory to the information provided in the CTRs. However, it cannot be definitively established that the difference in AE percentage between the two cohorts is less than 1% based on the given data.\n\nThe CTRs provide the percentage of participants with at least 1 AE in each cohort (Cohort A: 88.6% and Cohort B: 89.0%). The difference between these percentages is approximately 0.4%. While this difference is relatively small, it is greater than 1%. Therefore, the statement by the expert is not directly contradictory to the information provided in the CTRs, but it does not accurately reflect the data presented.</s>"
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Entailment",
        "entail": "The statement \"Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes\" is entailed by the information present in the CTRs because:\n\n1. The statement correctly identifies that there is a higher percentage of Thrombocytopenia cases in the secondary trial (12.50%) compared to cohort 1 of the primary trial (1.01%).\n2. The statement acknowledges the difference in sample sizes between the two trials, and correctly points out that this difference hinders making robust comparisons.\n3. The statement does not contradict any information presented in the CTRs, as it only makes a statement about the comparability of the trials based on their size and the occurrence of Thrombocytopenia.\n4. The statement remains consistent with the data presented in the CTRs and does not make any false claims.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the comparison between the two trials focuses on the percentage of patients with Thrombocytopenia, but it fails to account for the overall adverse event counts and cohort sizes. While the secondary trial has a higher percentage of Thrombocytopenia cases per cohort, cohort 1 in the primary trial has a larger total number of patients and a lower overall percentage of Thrombocytopenia cases (1.01% vs 12.50%), which could potentially lead to a different conclusion if the comparison included these additional factors.</s>"
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can't be made due to the significant differences in cohort sizes.",
        "Label": "Contradiction",
        "entail": "The expert's statement infers the presence of a larger proportion of Thrombocytopenia cases in the secondary trial compared to cohort 1 of the primary trial, based on their respective adverse event percentages. This comparison aligns with the information presented in the CTRs, as the percentage of participants with Thrombocytopenia in the secondary trial (12.50%) is indeed greater than the percentage in cohort 1 of the primary trial (1.01%), while acknowledging the disparities in cohort sizes. Thus, the assertion made by the expert is a valid inference drawn from the data provided in the CTRs and entailed by it.</s>",
        "contradict": "The expert's statement implies that the difference in Thrombocytopenia rates between the two trials justifies caution against making robust comparisons between them. However, the CTRs provided show that the primary trial had 2/199 cases, while the secondary trial had 1/8 cases, which, despite the percentage difference, does not necessarily mean the secondary trial has a significantly higher absolute number of Thrombocytopenia cases due to their different participant sizes. Thus, the statement's implication that no robust comparisons can be made based on their Thrombocytopenia findings might be contradictory to a more comprehensive analysis taking cohort sizes into consideration.</s>"
    },
    "a1c99d5b-d53a-4195-ad5f-5e1b48c22078_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "No robust comparisons can be made due to the significant differences in cohort sizes, although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs because:\n\n1. The statement acknowledges the significant differences in cohort sizes, which is consistent with the different participant numbers in each trial's Adverse Events sections (59/199 for cohort 1 vs. 6/8 for cohort 2).\n\n2. The statement notes that no robust comparisons can be made regarding the percentage of patients with Thrombocytopenia due to these cohort size differences. This aligns with the CTRs, as the percentage of patients with Thrombocytopenia is 1.01% (2/199) in cohort 1 of the primary trial and 12.50% (1/8) in cohort 2 of the secondary trial. This percentage difference is mentioned explicitly in the statement.\n\n3. The statement's condition for no robust comparisons being made does not contradict any information in the CTRs, as the statement does not claim that the trials are comparable in other ways (e.g., treatments, baseline characteristics). Thus, there are no inconsistencies with the CTR descriptions.</s>",
        "contradict": "The statement \"No robust comparisons can be made due to the significant differences in cohort sizes, although there is a much higher percentage of patients with Thrombocytopenia in the secondary trial than in cohort 1 of the primary trial\" is not directly contradictory to the provided CTR information. However, it could be contradictory if it is assumed that the statement is referring specifically to the Thrombocytopenia data. However, the statement does not explicitly limit its comparison to Thrombocytopenia and instead mentions \"robust comparisons cannot be made due to significant differences in cohort sizes.\" Therefore, the statement's accuracy depends on the context of the comparison being made.\n\nThe CTRs provided do show a difference in the percentage of patients with Thrombocytopenia between the primary and secondary trials. However, this difference may not be significant enough to warrant the conclusion that \"No robust comparisons can be made\" based on the Thrombocytopenia data alone, especially when taking into account the significant differences in cohort sizes.\n\nTherefore, the statement can be seen as an overgeneralization, which may not hold up under closer examination of the specific data presented in the CTRs. While it is true that larger differences in cohort sizes can limit the validity of comparisons, it is important to consider whether such differences are sufficient to negate any meaningful comparisons, and the Thrombocytopenia data alone may not provide enough evidence to support that conclusion.\n\nAdditionally, it should be noted that there are other factors beyond cohort size that need to be considered when making comparisons between trials, such as baseline characteristics, treatment protocols, and outcome measures. Therefore, it may still be possible to make meaningful comparisons based on other data points, despite the differences in cohort sizes.\n\nIn summary, the statement \"No robust comparisons can be made due to the significant differences in cohort sizes\" is not necessarily contradictory to the CTR information provided, but it could be an overgeneralization that may not hold up under closer examination. The validity of the comparison ultimately depends on the context and specific data being considered.</s>"
    },
    "0203435e-03a0-4c41-afdf-6c497d8908c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00331630",
        "Statement": "Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial\" is entailed by the information in the Primary Trial's ELIGIBILITY CRITERIA and ADVERSE EVENTS sections:\n\n1. ELIGIBILITY CRITERIA:\nThe CTR specifies that LVEF should be 50% as measured by echocardiogram or MUGA scan. Since a value greater than 50% would exclude a patient from meeting this requirement, the statement that men with an LVEF > 50% are excluded is a direct consequence of this criterion.\n\n2. ADVERSE EVENTS:\nThe CTR also lists \"Cardiac arrhythmia\" and \"Symptomatic congestive heart failure\" as exclusion criteria. Both conditions can be associated with a decreased LVEF, but the statement focuses on an LVEF > 50%, which can be interpreted as a healthy LVEF value. The statement, therefore, can also be seen as a restatement of one of the exclusion criteria in the ADVERSE EVENTS section.</s>",
        "contradict": "The statement \"Men with Left ventricular ejection fraction > 50% are excluded from participating in the primary trial\" is contradicted by the information in the CTR as it states \"LVEF > 50%\" is an inclusion criterion for the primary trial.</s>"
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "Label": "Entailment",
        "entail": "The statement \"The highest number of occurrences for any adverse event in both the primary trial and the secondary trial was 2\" can be entailed by the information present in the CTRs because in the primary trial, the adverse event \"Colitis\" occurred 2 times, and in the secondary trial, the adverse events \"Anaemia\" and \"Neutropenia\" each occurred 2 times.</s>",
        "contradict": "The statement \"The highest number of occurrences for any adverse event in both the primary trial and the secondary trial was 2\" is in contradiction with the information present in the CTRs as follows:\n\n1. In the primary trial, the adverse event with the highest occurrence was diarrhea, with a total of 2 cases out of 2240 (0.09%).\n\n2. However, according to the statement, the highest number of occurrences for any adverse event in both trials was 2.\n\n3. This is not the case, as diarrhea occurred more often in the primary trial with 2 cases, whereas the highest number of occurrences for any adverse event in the secondary trial was for fatigue, with a total of 3 cases out of 103 (2.94%).\n\nThus, the statement is contradicted by the information present in the CTRs.</s>"
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial wasn't 2.",
        "Label": "Contradiction",
        "entail": "none of the adverse events in both trials had more than 2 occurrences. This is entailed by the data in the CTRs, as the highest number of occurrences for any adverse event in the primary trial was 2 (atrial fibrillation, colitis, and diarrhea), and the highest number of occurrences for any adverse event in the secondary trial was 2 (anaemia and neutropenia). Therefore, the statement is a logical consequence of the CTR data and can be entailed by it.</s>",
        "contradict": "The statement contradicts the information present in the CTRs because the adverse event with the highest number of occurrences for both trials is \"Febrile neutropenia,\" which occurred 2 times in the secondary trial. The statement asserts that no adverse event occurred more than twice in both trials, which is not true according to the provided CTR data.</s>"
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "2 was the highest number of occurences for any adverse event in both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"2 was the highest number of occurrences for any adverse event in both the primary trial and the secondary trial\" can be entailed by the information present in the CTRs. In the primary trial, the adverse event \"Colitis\" occurred 2 times out of 2240 participants (0.09%). In the secondary trial, the adverse events \"Anaemia\" and \"Neutropenia\" each occurred 2 times out of 61 participants (3.28% each). Since the statement does not compare the specific adverse events, but instead the number of occurrences, and the highest number of occurrences is indeed 2 in both trials for different adverse events, the statement can be entailed by the CTRs.</s>",
        "contradict": "The statement \"2 was the highest number of occurrences for any adverse event in both the primary trial and the secondary trial\" is contradicted by the data provided in the CTRs. In the primary trial, the adverse event \"Colitis\" occurred 2 times, while in the secondary trial, the adverse event \"Anaemia\" occurred 2 times and \"Febrile neutropenia\" occurred 1 time. Therefore, there are different adverse events with the highest occurrence number (2) in each trial.</s>"
    },
    "93511e52-1c12-4dee-858e-13b10793e2a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial exclusively uses radiotherapy in its intervention, whereas the primary trial gives its patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Contradiction",
        "entail": "The statement does not entail that the primary trial does not use radiotherapy or that the secondary trial does not involve Stem Cell Transplants, as the information in the CTRs indicates otherwise. Instead, the statement asserts false information regarding the exclusive use of certain interventions in each trial. The primary trial involves chemotherapy with High-dose Carboplatin, Cyclophosphamide, and Thiotepa, followed by Stem Cell Transplant. The secondary trial involves the use of radiotherapy with Samarium 153-EDTMP, followed by Stem Cell Transplant. Neither trial exclusively uses the stated intervention. Thus, the statement cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information present in both CTRs. Contrary to the statement, neither trial exclusively uses radiotherapy in its intervention, and neither trial gives Stem Cell Transplants on the first day of the study for all patient cohorts. Instead, in the primary trial, patient cohorts undergo high-dose chemotherapy (consisting of Carboplatin, Thiotepa, and Cyclophosphamide) prior to Stem Cell Transplant, while in the secondary trial, Stem Cell Transplant follows Samarium 153-EDTMP treatment.</s>"
    },
    "cb932dbf-4c98-4488-b189-1286442968b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02005549",
        "Statement": "Patients with Cervical carcinoma in situ are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Cervical carcinoma in situ are excluded from the primary trial\" is entailed by the information present in the CTRs as follows:\n\nThe primary CTR specifies \"no in situ cancer of the cervix\" among the exclusion criteria for patients. In situ carcinoma is a type of cancer that has not invaded deeper into the tissue compared to invasive carcinoma, like breast cancer. Therefore, the statement that patients with cervical carcinoma in situ are excluded from the trial aligns with the CTR information, as both refer to the exclusion of patients with this specific condition.</s>",
        "contradict": "The statement \"Patients with Cervical carcinoma in situ are excluded from the primary trial\" is not directly contradictory to the information present in the provided CTRs. However, it can be inferred that this statement is not entailed by the information in the CTRs as cervical carcinoma in situ is specifically mentioned as an exclusion for the primary trial in the given CTR, but the statement does not mention any inclusion or exclusion criteria for the secondary trial. Therefore, the statement does not necessarily hold true for both trials, and there is a potential for difference in patient populations between the two trials.</s>"
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions in the primary trial.",
        "Label": "Entailment",
        "entail": "Paranasal sinus reactions are not mentioned in either the primary or secondary CTRs. Therefore, the statement that \"There were no patients with paranasal sinus reactions in the primary trial\" is entailed by the CTRs, as the absence of a particular adverse event in the report implies that no such events were reported.</s>",
        "contradict": "The statement \"There were no patients with paranasal sinus reactions in the primary trial\" cannot be directly contradicted by the provided information in the CTRs, as this section does not mention any paranasal sinus reactions or their occurrence. Consequently, the CTR information is neutral with respect to the expert's statement.</s>"
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There weren't no patients with paranasal sinus reactions in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't no patients with paranasal sinus reactions in the primary trial\" is not entailed by the information in the provided CTRs as paranasal sinus reactions are not listed as reported adverse events in either the primary or secondary trials.</s>",
        "contradict": "The statement \"There weren't no patients with paranasal sinus reactions in the primary trial\" is contradicted by the information in the CTRs because paranasal sinus reactions are not listed among the adverse events in either the primary or secondary trials. Hence, the statement goes beyond what is entailed by the data provided in the CTRs.</s>"
    },
    "0b9aa7e8-5912-44db-b9b0-6a84df769e19_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "Paranasal sinus reactions were not observed in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Paranasal sinus reactions were not observed in the primary trial\" is entailed by the information present in the CTRs because neither Adverse Events 1 nor Adverse Events 2 mention paranasal sinus reactions as occurring in the trials. The absence of a specific adverse event in the CTRs implies that it was not observed in the trials, making the expert's statement an entailed conclusion from the provided data.</s>",
        "contradict": "The statement \"Paranasal sinus reactions were not observed in the primary trial\" contradicts the information presented in the CTRs because the CTRs do not mention any occurrence of paranasal sinus reactions in either the Adverse Events section of the Primary or the Secondary trial.</s>"
    },
    "570ab6bb-b23c-4955-b6b0-d756d1b69c0e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert statement \"Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial\" is entailed by the CTR inclusion criteria as follows: \"Patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3), invasive breast cancer.\" \n\nAlthough the statement adds \"metastatic\" and \"cytologically confirmed,\" these features do not contradict the information given in the CTR. The CTR includes patients with \"early stage\" cancer, but it does not explicitly state that patients must have histologically confirmed tumors. Therefore, the expert statement can be considered an extension of the original CTR that does not contradict or misrepresent the information provided. \n\nHowever, it is important to note that the primary trial does exclude patients with metastatic disease in its eligibility criteria, but it only applies to those who are not locally advanced by other criteria. Therefore, the expert statement's inclusion of \"metastatic\" patients may not be entirely accurate in all cases, although it is still entailed by the broader \"early stage\" criteria given in the CTR. \n\nOverall, the expert statement is entailed by the CTR because it falls within the scope of eligible patients specified in the CTR and does not contradict or misrepresent any information provided.</s>",
        "contradict": "The statement \"Patients with cytologically confirmed, metastatic, early stage invasive breast cancer with an Allred score of 3 are eligible for the primary trial\" is contradicted by the CTRs as the primary trial only includes patients with histologically or cytologically confirmed early stage, ER-positive invasive breast cancer that is not metastatic.</s>"
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR information as both interventions in the primary trial, Urea/Lactic Acid Cream and Placebo Cream, are applied to the palms and soles of patients with the same frequency, which is twice daily.</s>",
        "contradict": "The statement \"the primary trial administers the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin\" is contradicted by the information in the CTRs because, while the placebo cream and Urea/Lactic Acid Cream are both applied twice daily to the palms and soles, they are distinct interventions in the trials. The statement implies that the same intervention is being administered to the control and treatment groups, whereas the CTRs specify separate interventions for each group.</s>"
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "The primary trial doesn't administer the placebo and Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin.",
        "Label": "Contradiction",
        "entail": "In the primary CTR, the intervention specifies that patients in the Urea/Lactic Acid Cream group receive the treatment on their palms and soles twice daily. In contrast, the placebo group in the same CTR receives a placebo cream on the same areas but also twice daily. However, in the secondary statement, it is mentioned that the frequency and application areas of the placebo and Urea/Lactic Acid Cream are different in the primary trial. Since the statement is derived from this known difference in application frequency and areas, it can be considered entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement made by the expert contradicts the information in the CTRs because, in the primary trial, patients in the Urea/Lactic Acid Cream group receive the treatment on their palms and soles twice daily, while in the placebo group, patients receive placebo cream on the same body areas and also at the same frequency. Contrary to the statement, both groups receive their respective interventions on the same parts of the skin and at the same frequency.</s>"
    },
    "daf105f8-58e8-47d7-b0a2-5949620b0a2b_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin is administered by the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement entails that both trials involve the application of urea/lactic acid cream on the palms and soles of patients. This is consistent with the information presented in the primary trial's INTERVENTION 1 section, which specifies the application of the urea/lactic acid cream to the palms and soles twice daily. As the secondary trial's intervention does not specify a different method or frequency of application, it follows that the frequency and application areas are the same as those in the primary trial. Thus, the expert's statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Urea/Lactic Acid Cream in the same frequency and on the same areas of the skin is administered by the primary trial\" can be contradicted by the information present in the CTRs if Intervention 1 in the primary trial specifies a different frequency or application area compared to Intervention 2 (Placebo Cream) in the secondary trial. For instance, if the secondary trial involves a different dosing frequency or application site for Urea/Lactic Acid Cream, then the statement would contradict the respective details stated in the primary trial's CTR.</s>"
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must be aware of where they are, and what day it is.",
        "Label": "Entailment",
        "entail": "The statement \"In order to participate in the primary trial, participants must be cognitively oriented to time, place, and person\" is present in the inclusion criteria of the primary CTR. This implies that participants must be aware of where they are (place) and what day it is (time), as these concepts fall under the umbrella of cognitive orientation. Therefore, the expert's statement is entailed by the CTR information.</s>",
        "contradict": "The statement \"In order to participate in the primary trial, participants must be cognitively oriented to time, place, and person\" is present in the inclusion criteria of the primary trial. Therefore, the statement \"In order to participate in the primary trial, participants must be aware of where they are, and what day it is\" is not a contradiction but instead an implicit requirement already stated in the CTR. However, there is a potential for ambiguity since the expert's statement does not directly refer to the CTR. The statement in the CTR goes beyond just being aware of time, place, and person by specifically mentioning that this orientation is \"determined via nurse recruiter.\" Nonetheless, neither of the statements contradicts the other as the second statement is an implication of the first.</s>"
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must not be aware of where they are, and what day it is.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information in the CTRs, as the CTRs explicitly specify inclusion criteria related to cognitive orientation, which is the opposite of being unaware of one's time, place, and person.</s>",
        "contradict": "The statement is contradictory to the inclusion criteria in the CTR as it requires participants to be cognitively oriented to time, place, and person, which is determined via the nurse recruiter. This contradicts the statement's requirement for participants to not be aware of where they are and what day it is.</s>"
    },
    "c4b671ae-4701-43a3-ada1-659c265d1f3a_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "Participants must be aware of where they are, and what day it is in order to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Participants must be cognitively oriented to time, place, and person\" as per the inclusion criteria of the primary CTR implies that participants are capable of understanding their current location and time. This requirement aligns with the secondary statement \"Participants must be aware of where they are, and what day it is,\" as both statements address the cognitive ability of participants regarding their spatial and temporal orientation.</s>",
        "contradict": "The information contained in the statement can be contradicted by the information present in the CTRs, as the eligibility criteria for the primary trial include cognitive orientation to time and place, which is determined via a nurse recruiter, but the statement does not explicitly state that participants must be aware or able to communicate their awareness of their location and current day. Thus, the statement does not entail the conditions outlined in the primary trial's inclusion criteria but could still hold true for participants who meet the stated requirement in an implicit way. However, the CTRs do not provide evidence that contradicts the statement, but rather additional information that may narrow its scope. Therefore, the relationship between the statement and the CTRs is not one of semantic entailment but rather one of consistency with an additional constraint on the participants.</s>"
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There was a dental adverse event in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was a dental adverse event in the primary trial\" is entailed by the information in the CTR as there is one instance of \"Tooth loss\" listed in the Adverse Events section of the primary trial, which constitutes a dental adverse event.</s>",
        "contradict": "The statement \"There was a dental adverse event in the primary trial\" cannot be definitively contradicted by the information present in the provided CTR for the primary trial. However, it is also not explicitly stated in the CTR that there was a dental adverse event. The CTR lists \"Tooth loss\" as an adverse event, but it does not provide a number or percentage associated with it. Therefore, based on the information given, it is unknown if the dental adverse event referred to by the expert was the same one documented in the CTR or a separate incident. Contradiction would only arise if there was clear evidence to the contrary, such as the CTR explicitly stating that there were no dental adverse events.</s>"
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There wasn't a dental adverse event in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There wasn't a dental adverse event in the primary trial\" can be entailed by the CTR data if we consider that the term \"dental adverse event\" typically refers to tooth loss or other dental-related issues. In the primary trial's Adverse Events 1 section, there is only one instance of a tooth loss reported, which affected 1/52 (1.92%) of the study participants. Given this information, no dental adverse event occurred in more than 1 out of every 52 patients. Thus, the statement's assertion harmonizes with clinical trial data and finds substantiation in the CTR.</s>",
        "contradict": "The statement \"There wasn't a dental adverse event in the primary trial\" is contradicted by the information in the CTR as one participant reported Tooth loss in the Adverse Events section under the Primary Trial.</s>"
    },
    "0a17a404-ed1d-4c31-a192-509b68198ea8_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "In the primary trial there was a dental adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial there was a dental adverse event\" can be entailed by the information present in the CTR as there is a mention of a tooth loss event in the primary trial's Adverse Events section, which falls under the dental category.</s>",
        "contradict": "The statement can be contradicted by the CTR information if the dental adverse event mentioned by the expert is not present in the Primary Trial's Adverse Events section. The CTR only reports one dental adverse event (Tooth loss) in the Primary Trial's Adverse Events section, which occurred in 1 out of 52 trial participants (1.92%). If the expert's statement refers to a different dental adverse event, it could potentially contradict the CTR data.</s>"
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device.",
        "Label": "Entailment",
        "entail": "In the primary trial, Intervention 1 for Group I specifies the use of the SparkPeople web-based program and the Fitbit activity monitoring device for behavioral dietary intervention and exercise intervention, respectively. However, there is no mention of yoga intervention or wearing a Fitbit device while practicing yoga. Similarly, in Intervention 2, no yoga intervention is mentioned while wearing a Fitbit device. In the secondary trial, neither Intervention 1 (Yoga Intervention) nor Intervention 2 (Educational Wellness Group) involve wearing a Fitbit device while practicing yoga. Thus, the statement is entailed by the information present in the CTRs as it correctly reflects that neither trial requires participants to practice yoga while wearing a Fitbit activity monitoring device.</s>",
        "contradict": "In the primary trial, participants in Group I undergoing the SparkPeople Program are required to wear a Fitbit activity monitoring device as part of the exercise intervention. Therefore, the statement is contradicted by the primary CTR, as it fails to acknowledge the presence of yoga intervention in Group I, but incorrectly asserts that no trial requires yoga while wearing a Fitbit.</s>"
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Both the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device.",
        "Label": "Contradiction",
        "entail": "The primary trial's Intervention 1 specifies that participants in Group I use the SparkPeople web-based program and wear a Fitbit activity monitoring device for both behavioral dietary intervention and exercise monitoring. The secondary trial's Intervention 1 for Arm 1 also mentions that participants undergo a Yoga Intervention while wearing a Fitbit activity monitoring device. Therefore, the statement that \"both the primary trial or the secondary trial require participants to practice yoga while wearing a Fitbit activity monitoring device\" is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Both the primary trial or the secondary trial require participants to practice yoga while Wearing a Fitbit activity monitoring device\" is contradicted by the information in the CTRs because, in the primary trial, participants in Group I of Intervention 1 (SparkPeople Program) engage in yoga sessions and wear Fitbit activity monitoring devices, but there is no mention of yoga sessions in Intervention 2 (Wait List), where participants also wear Fitbit activity monitoring devices. In contrast, in the secondary trial, neither Intervention 1 nor Intervention 2 mentions participants practicing yoga while wearing Fitbit activity monitoring devices. Therefore, the statement does not hold true for both trials and contradicts the information presented in the CTRs.</s>"
    },
    "9661db11-0c91-48c6-a8e8-6cb7cc2b06fd_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Participants are not required to practice yoga while Wearing a Fitbit activity monitoring device in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs because:\n\n1. In the primary trial, Intervention 1 (SparkPeople Program) does not mention yoga practice. Participants use the SparkPeople website for diet tracking, receive motivational reminders, and wear a Fitbit for activity monitoring. There is no mention of yoga practice in the intervention description.\n2. In the primary trial, Intervention 2 (Wait List) also does not include yoga practice. Participants initially receive a weight loss handout and a Fitbit activity monitor before eventually receiving the SparkPeople treatment. Again, there is no mention of yoga practice within the intervention description.\n3. In the secondary trial, Intervention 1 (Yoga Intervention) explicitly states that participants receive yoga sessions. However, there is no mention of participants wearing a Fitbit activity monitoring device during yoga sessions, nor does the statement indicate that yoga requires wearing a Fitbit to practice effectively.\n4. Intervention 2 (Educational Wellness Group) in the secondary trial does not include yoga practice or the use of a Fitbit activity monitoring device.\n\nThus, the statement that \"Participants are not required to practice yoga while wearing a Fitbit activity monitoring device in either the primary trial or the secondary trial\" is in line with the information contained within the CTRs, as no CTR section indicates yoga practice and Fitbit use concurrently.</s>",
        "contradict": "The statement \"Participants are not required to practice yoga while Wearing a Fitbit activity monitoring device in either the primary trial or the secondary trial\" is contradicted by the information present in the CTRs because, in the primary trial:\n\n1. Intervention 1 (Group I): Participants receive the SparkPeople training and use the Fitbit activity monitoring device. There is no mention of yoga practice during the intervention. However, wearing the Fitbit device is a mandatory requirement.\n2. Intervention 2 (Group II): Participants do not receive the Yoga intervention initially but receive a Fitbit activity monitoring device. They wear the device for 6 months before receiving the SparkPeople intervention, so they wear it throughout the trial.\n\nIn the secondary trial:\n\n1. Intervention 1 (Arm 1): Participants undergo a Yoga intervention, but there is no mention of wearing a Fitbit activity monitoring device.\n2. Intervention 2 (Arm 2): Participants undergo the Educational Wellness Group intervention and receive no mention of Fitbit devices.\n\nThe statement incorrectly asserts that participants are not required to wear Fitbit devices while practicing yoga. However, in the primary trial, some participants use the Fitbit device without undergoing the yoga intervention. Therefore, it contradicts the information present in the CTRs.</s>"
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because it accurately reflects that the primary trial involves the administration of an infusion of Perflutren Lipid Microspheres (Definity), while the secondary trial involves the implantation of a different intervention, the Meso BioMatrix Acellular Peritoneum Matrix. The statement does not contradict the details provided in the respective CTR sections and is in line with the clinical trials' descriptions.</s>",
        "contradict": "The statement \"Patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix\" is not directly contradictory to the information in the provided CTRs. However, it does not entail the information in the CTRs, as the two trials involve distinct types of interventions: an infusion versus an implantation procedure. The statement is valid in the sense that it accurately describes the difference in interventions between the two trials. But it does not follow that one intervention entails the other. In other words, a patient receiving an infusion in the primary trial does not entail that they are implanted with a matrix in the secondary trial, and vice versa.</s>"
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial don't receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Contradiction",
        "entail": "In the primary trial, subjects do not receive an Infusion of Perflutren Lipid Microspheres, as stated in the CTR section for the Intervention of the primary trial. \n\nIn contrast, the secondary trial involves a different intervention, the implantation of the Meso BioMatrix Acellular Peritoneum Matrix, which does not entail the administration of Perflutren Lipid Microspheres through infusion, as described in the CTR section for the Intervention of the secondary trial. \n\nHence, the statement that \"Patients in the primary trial don't receive an Infusion of Perflutren Lipid Microspherides, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix\" is in agreement with the provided information in both CTRs, establishing entailment.</s>",
        "contradict": "The statement \"Patients in the primary trial don't receive an Infusion of Perflutren Lipid Microspheres, whereas in the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix\" is contradictory to the information presented in the CTRs. In the primary trial, an infusion of Definity (Perflutren Lipid Microspheres) is indeed described, while in the secondary trial, an implantation of Meso BioMatrix Acellular Peritoneum Matrix is reported. However, these interventions address different aspects of treatment in separate trials. Therefore, the statement's claim that \"Patients in the primary trial don't receive an Infusion of Perflutren Lipid Microspheres\" is in contradiction to the reality described in the CTR.</s>"
    },
    "e8b86ef4-3ce8-4d81-a632-f30672c80ff5_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "In the secondary trial subjects are implanted with a Meso BioMatrix Acellular Peritoneum Matrix, whereas patients in the primary trial receive an Infusion of Perflutren Lipid Microspheres.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trial expert can be entailed by the information in the CTRs due to the following reasons:\n\n1. In the primary trial, the intervention involves the infusion of Definity (Perflutren Lipid Microspheres), while in the secondary trial, a different intervention is used, which is the implantation of the Meso BioMatrix Acellular Peritoneum Matrix.\n\n2. There is no contradiction between the statements that participants in each trial receive different interventions. The trials are distinct from one another, and their interventions target unique therapeutic approaches.\n\n3. The statement does not contradict the information in the CTRs regarding the procedures and interventions used. In both trials, the interventions are clearly described and distinct from each other.\n\n4. The statement does harmonize with the CTRs since it correctly identifies that the interventions are different for the two trials.\n\nHence, the statement is entailed by the information in the CTRs as it accurately describes the differences in interventions used in the primary and secondary trials.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the interventions described in the CTRs of the two trials are inherently different in nature. The primary trial involves administering Definity (Perflutren Lipid Microspheres) through infusion, while the secondary trial describes implanting the Meso BioMatrix Acellular Peritoneum Matrix. These two interventions are distinct from each other, and the statement's comparison of \"implanted\" versus \"infusion\" oversimplifies their essential differences.</s>"
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of LA-EP2006.",
        "Label": "Entailment",
        "entail": "Cohort 1 in the primary trial receives Neratinib 40 mg qd (once daily), while cohort 2 receives Neratinib 80 mg qd. The dose for cohort 1 is 40 mg, which is 60% of the dose received by cohort 2, which is 80 mg. Therefore, the statement that \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinib\" is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of LA-EP2006\" contradicts the information presented in the CTRs because both cohorts receive Neratinib, not LA-EP2006. The CTRs specify the type and dosage of interventions as Neratinib 40 mg qd for cohort 1 and Neratinib 80 mg qd for cohort 2. Therefore, the comparison of dosages should be made based on Neratinib and not LA-EP2006, which is not even mentioned in the CTRs. Consequently, the statement cannot be entailed from the information given in the CTRs.</s>"
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial doesn't recieve less than 60% of cohort 2's dose of LA-EP2006.",
        "Label": "Contradiction",
        "entail": "To determine if the statement is entailed by the CTRs, let's compare the dosages of each cohort in the primary trial with the dosages in cohort 2 of the secondary trial, assuming it also uses LA-EP2006.\n\nIn the primary trial, the dosage for cohort 1 is 40 mg of Neratinib daily, and for cohort 2, it is 80 mg of Neratinib daily. \n\nThe statement asserts that cohort 1 receives no less than 60% of cohort 2's dose. \n\nCalculate 60% of cohort 2's dose: \n80 mg * 0.6 = 48 mg\n\nSince cohort 1 receives 40 mg of Neratinib daily in the primary trial which is more than 48 mg, the statement is entailed by the CTRs. This entailment relationship holds, as the statement is not contradictory and is supported by the provided information in the trial reports.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial doesn't receive less than 60% of cohort 2's dose of LA-EP2006\" cannot be directly contradicted by the provided CTR information. However, it can't be entailed either, since the statement makes a comparative claim about the doses received by cohorts 1 and 2 across trials, which is not explicitly mentioned in the CTRs. In the provided information, the doses for Cohort 1 and Cohort 2 of the primary trial are both Neratinib 40 mg qd and Neratinib 80 mg qd, respectively, but no comparison or relationship to each other is given in the CTR. In the absence of such explicit comparative data, it is not possible to definitively establish entailment or contradiction based on the information given in the CTRs alone.</s>"
    },
    "879f2f14-38a8-419a-bae0-e62ed81eb9dd_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Less than 60% of cohort 2's dose of LA-EP2006 is received by cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 60% of cohort 2's dose of LA-EP2006 is received by cohort 1 of the primary trial\" does not directly entail information from the provided CTRs as they involve the use of Neratinib instead of LA-EP2006, and the dose quantities are different between cohorts within each trial.\n\nHowever, we cannot definitively rule out the possibility that the statement holds if there exists an unstated assumption that Neratinib and LA-EP2006 are equivalent drugs, their doses are comparable, and the patient cohorts' characteristics are similar in the primary and secondary trials. In such a case, the entailment could potentially be derived by comparing the dose quantities, assuming that the 40 mg and 80 mg doses of Neratinib administered in the primary trial correspond to less than 60% of the dosage given to cohort 2 in the secondary trial using LA-EP2006.\n\nHowever, the CTRs do not provide sufficient evidence to support such an assumption, and without further context or information on the drugs' properties, patient populations, or trial conditions, it is impossible to definitively conclude entailment. Therefore, the statement may or may not be entailed by the information present in the CTRs, and the level of confidence in this assessment would be low.</s>",
        "contradict": "The statement cannot be entailed by the information in the CTRs as it does not provide any quantifiable comparison of the doses received by the cohorts in both trials. The statement mentions \"LA-EP2006\" without defining it, and it is assumed to be a reference to Neratinib based on the context of the CTRs. However, the CTRs only provide the dosage and frequency for each intervention in the trials, but they do not report the actual amount of Neratinib received by each individual participant in the cohorts. Therefore, there is no data in the CTRs to determine the percentage of dose received by one cohort compared to another.</s>"
    },
    "2ec46285-dd0c-4420-b9f6-e44a1ac74f20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Secondary_id": "NCT01940497",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The absence of Tibia or Fibula fractures in the statement is entailed by the data in the CTRs since neither Adverse Events 1 nor Adverse Events 2 of the primary trial, nor Adverse Events 1 of the secondary trial, report any occurrences of these conditions.</s>",
        "contradict": "The expert's statement asserts that \"there were 0 observed cases of Tibia or Fibula fractures in the primary trial or the secondary trial.\" However, the CTRs indicate that there was one observed case of Tibia fracture in the secondary trial for Adverse Events 1 (in the 1/95 participant) and one observed case of Fibula fracture in the secondary trial for Adverse Events 2 (in the 1/20 participant). This directly contradicts the expert's statement, making it an entailment violation.</s>"
    },
    "f8afffdc-649b-4921-942a-66b804a3717f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-4, N1 and M1 bilateral breast cancer.",
        "Label": "Contradiction",
        "entail": "The statement that \"patients must not have prior radiation, anthracycline or systemic anticancer therapy, and must have T1-4, N1 and M1 bilateral breast cancer\" can be entailed by the information present in the CTRs as follows:\n\nThe first condition, \"patients must not have prior radiation therapy for breast cancer,\" is in agreement with the CTR as it states \"Prior radiation therapy for breast cancer\" is an exclusion criterion.\n\nThe second condition, \"patients must not have prior anthracycline therapy or taxoids for any malignancy,\" is also in agreement with the CTR as it explicitly excludes patients who have received \"Prior systemic anticancer therapy for breast cancer\" and specifically mentions \"Prior anthracycline therapy or taxoids (paclitaxel, docetaxel)\" as a sub-exclusion criterion.\n\nThe third condition, \"patients must have T1-4, N1 and M1 bilateral breast cancer,\" is only partially entailed by the CTR. The CTR includes eligibility criteria for unilateral T1-3 breast cancer with negative axillary nodes (N0) and high risk criteria according to St. Gallen consensus criteria. The statement allows for bilateral disease with more advanced stages (T4, N1, and M1), and thus is a broader condition that includes the criteria in the CTR, but not all cases in the CTR meet the more advanced stage conditions specified by the statement. Therefore, not all patients eligible per the statement would be eligible per the CTR, but all patients eligible per the CTR would also be eligible per the statement.\n\nThe remaining exclusion criteria in the CTR such as prior systemic anticancer therapy for non-breast malignancies, concurrent treatment with other experimental drugs, and concurrent treatment with any other anti-cancer therapy are also not addressed in the statement. Therefore, the information in the statement cannot be directly entailed from the CTRs alone, and additional context or information might be required to determine the exact relationship between the two.</s>",
        "contradict": "The statement contradicts the CTR's inclusion criteria in several ways:\n\n1. The statement mentions that patients must have T1-4, N1 and M1 bilateral breast cancer to be eligible for the primary trial, whereas the CTR explicitly lists T1-T3 breast cancer with negative axillary lymph nodes and no M1 metastatic disease as the inclusion criteria.\n\n2. The statement states that there should be no prior radiation therapy, anthracycline, or systemic anticancer therapy for any malignancy, but the CTR excludes patients with a history of such treatments only for breast cancer.\n\nThese discrepancies make the statement contradictory to the information present in the provided CTRs.</s>"
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: In the primary trial, both the Ketorolac 30 mg and NaCl 0.9% 3mL arms have participant counts of 80 and 96, respectively, which sums to 176 participants. The percentage of participants achieving Recurrence-free Survival after 5 years in each arm is 83.3% for Ketorolac 30 mg and 89.7% for NaCl 0.9%. The average of these percentages is 86.5%, and given that there are 176 participants in total, over 82% of them (approximately 145) would have achieved Recurrence-free Survival after 5 years. This figure aligns with the statement.</s>",
        "contradict": "The statement \"In total Over 82% patient in the primary trial achieve Recurrence-free Survival after 5 years\" contradicts the CTR information because there is no data in the Results 1 and Results 2 sections provided in the CTRs indicating that over 82% of patients in the primary trial achieved Recurrence-free Survival after 5 years. Each CTR result only specifies the number and percentage of participants analyzed in each arm/group and their respective Recurrence-free Survival rates. The statement goes beyond the provided CTR data.</s>"
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 82% patient in the primary trial don't achieve Recurrence-free Survival after 5 years.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: In the Primary Trial, the Recurrence-free Survival was measured for a time frame of 5 years. The number of participants in the Ketorolac 30 mg arm who were analyzed was 80, out of which 83.3% did not achieve Recurrence-free Survival after 5 years. Similarly, in the NaCl 0.9% 3mL arm, 96 participants were analyzed, and 89.7% did not achieve Recurrence-free Survival. Since over 82% of patients in both arms did not achieve Recurrence-free Survival after 5 years, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"In total Over 82% patient in the primary trial don't achieve Recurrence-free Survival after 5 years\" cannot be directly contradicted by the information in the CTRs, but it might be misleading without proper context. Recurrence-free Survival is defined in the primary CTR as the time from randomization to the first documented progression or death from any cause. The statement does not consider the participants who are still alive and disease-free after the observation period, which is crucial for the interpretation of the Recurrence-free Survival rate.\n\nThe given CTRs only provide the percentage of participants analyzed in each arm that completed the study, but they do not specify whether or not these participants achieved Recurrence-free Survival after 5 years. To determine the percentage of patients who didn't achieve Recurrence-free Survival, one would need additional information from the CTR, such as the number of participants with recurrence or death during the follow-up period.\n\nIn summary, the statement might be misleading as it does not take into account the percentage of participants who achieved Recurrence-free Survival and are still alive after 5 years. To establish semantic entailment, a more accurate statement would include information regarding the number of participants who experienced recurrence or died during the follow-up period.</s>"
    },
    "65f22210-47dd-4865-99e2-ddd414dddb08_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In the primary trial, after 5 years, over 82% patient achieve Recurrence-free Survival.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, after 5 years, over 82% of patients achieve Recurrence-free Survival\" can be entailed by the information present in the CTRs as follows: \n\nThe CTR provides the time frame for Recurrence-free Survival measurement as 5 years. However, it does not directly provide the percentage of participants who achieved Recurrence-free Survival after 5 years. \n\nBut, Results 1 and Results 2 each provide the number of participants analyzed for the respective groups (Ketorolac 30 mg and NaCl 0.9% 3mL) and their percentage of total participants (80.0% and 89.7%, respectively). Since the total number of participants is the sum of the participants in both groups (96 + 107 = 203), and over 82% of them completed the 5-year follow-up, we can calculate the number of participants achieving the Recurrence-free Survival as 203 * 0.82 = 168.53, which can be rounded to 169 participants. Therefore, the statement is entailed by the information in the CTRs.\n\nThis explanation is based on the assumption that the Recurrence-free Survival rate provided by the statement refers to the percentage of all participants in the trial and not just for one of the groups, and that the statement is intended to be an accurate representation of the data in the CTRs.</s>",
        "contradict": "The expert's statement contradicts the information in the CTRs as there's no mention of Recurrence-free Survival rates for either the Ketorolac 30 mg or NaCl 0.9% 3mL arms in the Results section of the primary trial. The CTRs only provide the number of participants analyzed for each arm and their respective percentages.</s>"
    },
    "ff8a1e0d-d2ee-4687-b429-5b3b6081edc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR of 1.35 is enough for participation in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "There is no specific mention of INR requirements in the provided inclusion or exclusion criteria for both the primary and secondary trials in the CTRs. However, the inclusion criteria for the primary trial do mention adequate liver function and acceptable INR or PT/PTT values, but these values are not explicitly stated. The statement does not contradict the provided CTR information, as it only sets a lower threshold for INR, which could be acceptable based on the vague requirements in the CTRs. Therefore, the statement can be entailed by the information in the CTRs, given the lack of explicit contradiction or inconsistency.</s>",
        "contradict": "The statement \"INR of 1.35 is enough for participation in the primary trial and the secondary trial\" is contradictory to the information present in the CTRs. \n\nThe CTR for the primary trial specifies the following inclusion criteria for liver function: \"Adequate liver function, defined by: \u00b7 AST and ALT <=2.5 x the upper limit of normal (ULN) or <=5 x ULN in presence of liver metastases \u00b7 Total bilirubin <=1.5 x ULN\". It also includes the following statement under adequate lipid profile: \"Note: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.\" \n\nThe statement does not specify which ULN value corresponds to the INR value of 1.35 and does not take into account the other liver function and lipid profile requirements. Moreover, the CTR for the secondary trial states that subjects with unknown clinical status are not eligible. This statement does not relate to liver function at all and hence is not contradictory to the information provided in the CTRs. However, the statement regarding INR being sufficient for both trials is contradictory as it does not consider the specific ULN value or other eligibility criteria mentioned in the CTRs.</s>"
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial crashed their motorbike.",
        "Label": "Entailment",
        "entail": "The statement that \"One patient in cohort 2 of the primary trial crashed their motorbike\" is entailed by the information in the CTRs as there is one reported case of a motorcycle accident in cohort 2 of trial 1 under the Adverse Events section. Therefore, the statement is consistent with the trial data and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"One patient in cohort 2 of the primary trial crashed their motorbike\" cannot be directly determined as true or false based on the given CTR information. While one instance of a motorcycle accident is reported in the secondary trial's adverse events section, there is no such mention in the primary trial's adverse events section. Consequently, there is no information in the primary trial CTR that directly contradicts the statement, but the statement does not necessarily entail the information in the primary trial CTR either. The patient cohorts in the primary and secondary trials might be different, so the statement may refer to a patient in the secondary trial, which is not described in the primary trial CTR. However, without additional context, it is impossible to definitively establish the truth of the statement based on the provided CTR information alone.</s>"
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "No patient in cohort 2 of the primary trial crashed their motorbike.",
        "Label": "Contradiction",
        "entail": "The statement \"No patient in cohort 2 of the primary trial crashed their motorbike\" can be entailed by the information present in the CTRs because there is no instance of a motorcycle accident reported in the Adverse Events section for the secondary trial (0/537), and there is also no instance reported for the primary trial's cohort 2 (0/12). The absence of motorcycle accidents in both trials and their respective cohorts is consistent with the statement.</s>",
        "contradict": "The statement \"No patient in cohort 2 of the primary trial crashed their motorbike\" contradicts the CTR data as one patient in cohort 2 of the primary trial (Adverse Events 2) was recorded to have experienced a motorcycle accident (1/537).</s>"
    },
    "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "In the primary trial one patient in cohort 2 crashed their motorbike.",
        "Label": "Entailment",
        "entail": "In the given statement, the occurrence of a motorcycle accident in the primary trial is mentioned for cohort 2. In the CTRs, one instance of a motorcycle accident is reported under adverse events of the primary trial, with a frequency of 1/538 (0.19%). The frequency value implies that exactly one participant in the trial had a motorcycle accident. Therefore, the statement can be entailed by the information present in the CTRs, as it aligns with the trial data and avoids contradiction.</s>",
        "contradict": "The information in the statement that one patient in cohort 2 of the primary trial crashed their motorbike is contradicted by the CTR data as no cases of motorcycle accidents were reported in the Adverse Events sections of either the primary or secondary trials.</s>"
    },
    "0aa3c085-b9c6-4918-a5d0-eabc55bdd177": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"there was over 10 more cases of adverse events in cohort 2 than in cohort 1 of the primary trial\" is entailed by the CTRs since the number of adverse events in cohort 2 (11/35 = 0.3143 x 35 = 11.17) is indeed over 10 more than in cohort 1 (2/15 = 0.1333 x 15 = 2) of the primary trial.</s>",
        "contradict": "The statement cannot be determined to be entailed by the CTR data alone as it makes a comparative claim across two trials (primary and secondary) without specifying which adverse events were involved in the comparison. The provided Adverse Events sections do not indicate the number of cases for all adverse event types between cohorts 1 and 2 in the secondary trial. Therefore, it is impossible to verify if there were indeed over 10 more cases in cohort 2 or not. Without this additional information, the statement cannot be considered entailed by the given CTR data.</s>"
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.",
        "Label": "Entailment",
        "entail": "The statement that \"A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2\" can be entailed by the information present in the CTRs because the CTR for the primary trial indicates that 2/41 (4.88%) participants in cohort 1 had fever, whereas the CTR for the secondary trial states that 1/5 (20.00%) in cohort 2 showed signs of fever. Therefore, the percentage of participants with fever in cohort 1 is lower than that in cohort 2. The expert's statement correctly compares the frequency of fever in each cohort and is consistent with the information in the CTRs.</s>",
        "contradict": "The statement \"A higher percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2\" contradicts the data present in the CTRs as neither CTR reports the percentage of patients in each cohort who experienced fever. The CTRs only provide the absolute number of patients in each cohort who experienced fever (2 patients in cohort 1 vs 0 patients in cohort 2 for the primary trial and 1 patient in cohort 1 vs 1 patient in cohort 2 for the secondary trial). The percentage of patients with fever in each cohort cannot be determined directly from the information provided in the CTRs.</s>"
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A lower percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"A lower percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2\" can be entailed by the information present in the CTRs as follows:\n\nFever occurred in 2/41 (4.88%) patients in cohort 1 of the primary trial (Adverse Events 1), and in 1/5 (20.00%) patients in cohort 2 of the secondary trial (Adverse Events 2). The percentage of patients with fever is indeed lower for cohort 1 (4.88%) than in cohort 2 (20.00%).</s>",
        "contradict": "The statement \"A lower percentage of cohort 1 of the primary trial showed signs of fever, compared to cohort 2\" is contradicted by the CTR data because the percentage of participants experiencing fever is higher in cohort 1 (4.88%) compared to cohort 2 (0.00%).</s>"
    },
    "333c2723-e2e8-4c68-9591-36b7f169ff26_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "Compared to cohort 2 a higher percentage of cohort 1 of the primary trial showed signs of fever.",
        "Label": "Entailment",
        "entail": "The statement \"Compared to cohort 2 a higher percentage of cohort 1 of the primary trial showed signs of fever\" can be entailed by the information present in the CTRs as follows: \n\n1. The percentage of cohort 1 with fever is higher than that of cohort 2 in the primary trial: The statement \"Compared to cohort 2 a higher percentage of cohort 1 of the primary trial showed signs of fever\" implies that there is a difference in the prevalence of fever between the two cohorts in the primary trial. This is directly evident from the given data in the primary trial where cohort 1 has a higher number of participants with fever (2 out of 41 or 4.88%) compared to cohort 2 which has no reported cases (0 out of 5). Thus, the percentage of cohort 1 having fever is indeed higher than that of cohort 2. \n\n2. The CTRs provide accurate information about the number and types of adverse events for each cohort: The CTRs are reliable sources of information regarding the occurrence and frequency of adverse events in each cohort of the primary and secondary trials. The given data on the number of participants with fever in each cohort comes directly from the CTRs, ensuring the accuracy and completeness of the information.\n\nTherefore, the statement \"Compared to cohort 2 a higher percentage of cohort 1 of the primary trial showed signs of fever\" is entailed by the information present in the CTRs as it is a logical consequence of the given data on the number and types of adverse events for each cohort.</s>",
        "contradict": "The statement \"Compared to cohort 2 a higher percentage of cohort 1 of the primary trial showed signs of fever\" is contradicted by the CTRs, as the percentage of participants with fever in cohort 1 was 4.88%, while in cohort 2, no participant experienced fever. This contradiction exists since the statement implies that the percentage of participants with fever in cohort 1 is greater than in cohort 2, but the CTR data indicate the opposite.</s>"
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59% of Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Entailment",
        "entail": "The expert's statement asserts that 59% of Arm A participants from the primary trial achieved a clinical benefit response (CBR) lasting for at least 6 months. The CTR specifies that the CBR is defined as the percentage of participants with a complete or partial (confirmed) tumor response or stable disease for at least 6 months. The number of participants in Arm A is 51, and the results section of the CTR states that 59% of them were classified with a best overall response of complete or partial response or stable disease for at least 6 months. Consequently, the expert's statement harmonizes with the information in the CTR and is entailed by it.</s>",
        "contradict": "The statement does not directly contradict the information provided in the CTRs; however, it makes an assumption about Arm A of the primary trial without explicitly stating which arm it is. The CTR only provides information about one arm (Lapatinib 1250 mg and Capecitabine 2000 mg/m^2). Thus, while the percentage in the expert's statement (59%) may be correct for the mentioned arm, it cannot be universally applied to all arms within the primary trial without further context.</s>"
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59% of Arm A of the primary trial didn't achieve a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"59% of Arm A of the primary trial didn't achieve a best overall response\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTR specifies that the clinical benefit response (CBR) is defined as the percentage of participants receiving study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months (24 weeks).\n2. The CTR for Results 1 states that for the Arm/Group titled \"Lapatinib 1250 mg and Capecitabine 2000 mg/m^2,\" there were 51 participants analyzed and among this group, 59% didn't achieve a best overall response.\n\nThus, the statement is entailed by the CTRs as the percentage mentioned in the statement aligns with the definition of CBR from the Primary Trial and the number of participants not achieving a best overall response stated in the Results 1 for the specified Arm A.</s>",
        "contradict": "The statement \"59% of Arm A didn't achieve a best overall response for at least 6 months\" contradicts the CTR's definition of Clinical Benefit Response (CBR), which requires participants to achieve a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. The CTR reports that 59% of participants received the treatment, but it does not specify how many of those participants achieved the CBR. Therefore, it's impossible to know whether or not 59% of participants did not achieve the CBR based on the information provided in the CTR alone.</s>"
    },
    "1fa01b9a-1288-404c-ad58-8dcf3db3264c_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "Classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months, 59% of Arm A of the primary trial achieved a best overall response.",
        "Label": "Entailment",
        "entail": "The statement \"Classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months, 59% of Arm A of the primary trial achieved a best overall response\" can be entailed by the information in the CTR as follows:\n\nThe CTR defines Clinical Benefit Response (CBR) as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial response (confirmed) or stable disease for at least 6 months (24 weeks). It is given that 59% of participants in Arm A of the primary trial achieved this response based on the Results 1 section of the CTR. Thus, the given statement is a restatement of the information in the CTR.</s>",
        "contradict": "The statement made by the clinical trial expert does not directly contradict the information presented in the CTRs, but it may be considered misleading without additional context. The CTR provides the definition and time frame for the Clinical Benefit Response (CBR), but it does not specify which arm or group within the primary trial achieved this response rate of 59%. Therefore, without knowing which arm or group the statement refers to, it cannot be definitively determined if the statement is in agreement or contradiction with the CTR information. If the statement is referring to the same arm/group as the CTR results (Lapatinib 1250 mg and Capecitabine 2000 mg/m^2), then the statement is consistent with the CTR data. However, if the statement is referencing a different arm or group, it could potentially contradict the information provided in the CTR.</s>"
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is not entailed by the information provided in the CTRs as there are no cases of Diplopia reported in the primary trial and no cases of Anemia reported in the secondary trial.</s>",
        "contradict": "The statement \"There is the same number of cases of Diplopia in the primary trial as anemia in the secondary trial\" is contradicted by the information in the CTRs because there are no cases of Diplopia reported in either the primary or secondary trials, whereas Anemia is not listed as an adverse event in either trial.</s>"
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There isn't the same number of cases of Diplopia in the primary trial as anemia in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"There isn't the same number of cases of Diplopia in the primary trial as anemia in the secondary trial\" is entailed by the CTR data as the number of cases of Diplopia in the primary trial is zero for both Adverse Events 1 and 2, whereas anemia is not reported in the primary trial at all. Therefore, there cannot be the same number of cases of Diplopia as anemia because Diplopia is not present in the primary trial.</s>",
        "contradict": "The statement \"There isn't the same number of cases of Diplopia in the primary trial as anemia in the secondary trial\" cannot be contradicted by the information present in the CTRs because Diplopia is not mentioned in the secondary trial's Adverse Events sections. Therefore, there is no comparison possible between the number of cases of Diplopia and Anemia.</s>"
    },
    "ed272c3f-37a1-4db7-8990-bf226f8c9822_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "The primary trial has the same number of cases of Diplopia as anemia in the secondary trial.",
        "Label": "Entailment",
        "entail": "The given statement asserts that the number of cases of Diplopia in the primary trial is equal to the number of Anemia cases in the secondary trial. However, the CTRs do not report the occurrence of either Diplopia or Anemia in either trial. Consequently, this statement is false and cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The primary trial has the same number of cases of Diplopia as anemia in the secondary trial\" is contradicted by the information present in the CTRs because neither trial reports any cases of Diplopia, while the secondary trial reports no cases of anemia.</s>"
    },
    "b1497cf4-6b06-4227-b679-19e2ac5fb5c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and Epothilone on Central Nervous System (CNS) Progression-free Survival(PFS), 9 weeks after the start of treatment.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as both trials involve the use of radiation therapy (RT) and imiquimod (IMQ) in combination with different interventions (CTX in the primary trial and Epothilone in the unspecified secondary trial) within the same time frame (9 weeks after the start of treatment). Therefore, the secondary trial's focus on Central Nervous System (CNS) Progression-free Survival (PFS) does not contradict the provided CTR information. Additionally, the CTRs mention that patients may receive additional cycles of treatment, which leaves room for other interventions like Epothilone, as long as they follow the specified protocol and are beneficial in the opinion of the investigator.</s>",
        "contradict": "The statement does not directly contradict the information present in the CTRs. However, it goes beyond the scope of the provided data, as the CTRs do not report any information about Central Nervous System (CNS) Progression-free Survival (PFS) for the primary trial's arms, specifically for \"IMQ+RT\" and \"CTX/IMQ/RT,\" at 9 weeks after the start of treatment. Hence, the statement cannot be definitively proven or disproven based on the available trial data.</s>"
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients diagnosed with intradural tumors are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria of the primary trial. The CTR explicitly lists \"No metastatic disease to the Central Nervous System\" as a criterion, which covers intradural tumors as a subtype of central nervous system metastasis. Therefore, the expert's statement that \"Patients diagnosed with intradural tumors are excluded from the primary trial\" can be derived from the provided information.</s>",
        "contradict": "The statement \"Patients diagnosed with intradural tumors are excluded from the primary trial\" is inconsistent with the CTR inclusion criteria as intradural tumors are not explicitly mentioned as a condition for exclusion. The CTR only specifies exclusion for metastatic disease to the Central Nervous System, which is not equivalent to intradural tumors.</s>"
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients diagnosed with intradural tumors aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients diagnosed with intradural tumors aren't excluded from the primary trial\" can be entailed by the information present in the CTRs as there is no specific exclusion criterion mentioned for intradural tumors in either the Primary Trial's inclusion or exclusion criteria.</s>",
        "contradict": "The primary CTR specifies that one of the inclusion criteria is for patients to have \"localized breast cancer (adenocarcinoma) that is locally advanced or locally recurrent and not able to be surgically removed OR with measurable and/or evaluable disease.\" However, the term \"locally advanced\" can encompass tumors that have grown into nearby organs or tissues, and intradural tumors are growths located within the spinal cord or brain. Given that intradural tumors are not mentioned as an inclusion criterion and that the statement suggests that they are not explicitly excluded, it's possible that the statement is incorrect. In the primary trial, intradural tumors could potentially be considered an exclusion, as they could pose a risk that is not addressed or studied in the trial. Therefore, the statement can be contradicted by the CTR information, which does not definitively include or exclude intradural tumors.</s>"
    },
    "186d5a67-1309-4abc-b31a-de026c5b8bda_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "The primary trial excludes patients with intradural tumors.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial excludes patients with intradural tumors\" is entailed by the CTR inclusion criteria, specifically, \"No metastatic disease to the Central Nervous System.\" Intradural tumors are a type of central nervous system tumor, and the CTR excludes patients with such metastases.</s>",
        "contradict": "The statement \"The primary trial excludes patients with intradural tumors\" cannot be directly contradicted by the information present in the CTRs provided. The statement is specific to the exclusion of intradural tumors, which is not mentioned explicitly in the CTRs as a criterion for patient exclusion. The CTRs only specify the exclusion of metastatic disease to the Central Nervous System, which is not the same as having an intradural tumor. Intradural tumors refer to neoplasms located within the subarachnoid space of the spinal cord or the subpia mater of the brain, whereas metastatic disease to the Central Nervous System implies the presence of tumor cells in the brain parenchyma or leptomeninges.</s>"
    },
    "6b86f306-f989-4676-8f5e-c4c8a6aa4258": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will receive either Lapatinib, WBRT or Herceptin.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial participants will receive either Lapatinib, WBRT or Herceptin\" is entailed by the CTR information since the CTR for the primary trial specifies that participants will receive Lapatinib before and during WBRT, followed by Herceptin 4mg/kg IV weekly. Thus, every participant in the primary trial is subjected to at least one of the listed treatments: Lapatinib, WBRT, or Herceptin.</s>",
        "contradict": "The statement that \"the primary trial participants will receive either Lapatinib, WBRT or Herceptin\" is contradictory to the CTR information because, according to the CTR of the primary trial, participants will receive Lapatinib before and during WBRT, and then Herceptin 4mg/kg IV weekly, which is a combination of two interventions, not just one of Lapatinib, WBRT, or Herceptin.</s>"
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n- The primary trial measures clinical benefit rate in ER+/AR+ BC subjects with centrally confirmed AR+ status.\n- Two arms/groups were involved, each receiving a different dose of GTx-024: 9 mg and 18 mg.\n- The same outcome measure was used for both groups: clinical benefit rate according to RECIST 1.1.\n- The time frame for outcome measurement is 24 weeks.\n- The number of participants analyzed in each group is specified (50 for the 9 mg group and 52 for the 18 mg group).\n  \nFrom this information, the following can be inferred:\n\n1. Both groups underwent the same outcome measurement using the same criteria.\n2. The primary trial aimed to determine the acceptable clinical benefit rate for each dose.\n3. The results from both groups can be compared since they were assessed using the same methodology.\n\nThe statement \"There was less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial\" implies that the clinical benefit rate for the 9 mg group was close to the clinical benefit rate for the 18 mg group. This inference is consistent with the information provided in the CTRs, which indicates that the trials aimed to determine the acceptable clinical benefit rate for each dose and that the results from both groups can be compared. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"There was less than a 5% difference in the results from the 9 mg and 18 mg group\" is not directly contradictory to the information in the CTRs, but it can be misleading. The CTRs describe that the primary trial aimed to determine whether either dose (9 mg or 18 mg) results in an acceptable clinical benefit rate. However, they do not provide explicit data about the actual clinical benefit rates or their statistical comparison. Therefore, making a definitive statement about a less than 5% difference between the two groups based on the given information in the CTRs is not possible. Further analysis and comparison of clinical benefit rates or statistical analysis (such as p-values and confidence intervals) from both groups are required to validate or contradict this statement.</s>"
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There wasn't less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"there wasn't less than a 5% difference in the results from the 9 mg and 18 mg group in the primary trial\" can be entailed by the information in the CTRs as follows:\n\n1. According to the CTR, both the 9 mg and 18 mg arms had the same goal, which was to determine whether either or both doses result in an acceptable clinical benefit rate.\n2. Both arms used the same outcome measurement, i.e., Clinical Benefit Rate based on RECIST 1.1 criteria.\n3. The time frame for evaluating the clinical benefit rate is the same for both arms, i.e., 24 weeks.\n4. The number of participants analyzed in each arm is slightly different, with 50 participants in the 9 mg arm and 52 participants in the 18 mg arm.\n5. The statement implies that the difference in the number of participants between the two arms is not large enough to cause a significant difference in clinical benefit rates, which is in line with the trial design, where both arms aim to test the same clinical hypothesis with slightly different doses.\n6. Since the statement does not suggest that there was a difference in the clinical benefit rates that contradicts the provided information in the CTRs, it does not contradict the CTRs. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement can be contradicted by the information present in the CTRs because the statement implies that there is no significant difference between the clinical benefit rates of the 9 mg and 18 mg groups in the primary trial. However, the CTRs do not provide enough information to directly compare the clinical benefit rates between the two groups. Instead, they report the number of participants with clinical benefit in each group but do not explicitly state whether the difference in the number of participants is less than 5%. Therefore, the expert's statement goes beyond the information provided in the CTRs and assumes that the difference is not significant without sufficient evidence.</s>"
    },
    "0e8e4a92-b104-4192-ad36-33b683f94216_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "The primary trial registered less than a 5% difference in the results from the 9 mg and 18 mg group.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial registered less than a 5% difference in the results from the 9 mg and 18 mg group\" can be entailed by the information present in the CTRs as follows:\n\n1. According to the CTR of the primary trial, the outcome measure is the clinical benefit rate (CBR) for ER+/AR+ BC subjects with centrally confirmed AR+ status, assessed according to RECIST v1.1 criteria for target lesions at 24 weeks.\n2. Results 1 and 2 from the primary trial report on two different arms/groups receiving either 9 mg or 18 mg of GTx-024 daily. Both groups aim to determine an acceptable clinical benefit rate for the given treatment.\n3. The number of participants analyzed in each group are stated as 50 for 9 mg and 52 for 18 mg, with 16 and 15 participants achieving the clinical benefit rate, respectively.\n4. The statement \"The primary trial registered less than a 5% difference in the results\" implies that the difference between the percentage of participants achieving the clinical benefit rate in the two groups is less than 5%.\n5. To calculate this difference, we can find the percentage of participants with a clinical benefit in each group, and subtract the percentages: (15/52)*100% - (16/50)*100% = 3.77% - 32% \u2248 -28.23%.\n6. However, since the statement only claims that the difference is less than 5%, it does not necessarily need to be exact. Therefore, the difference being approximately -28.23% is not a contradiction, as long as it's still less than 5%.\n7. Thus, the statement \"The primary trial registered less than a 5% difference in the results from the 9 mg and 18 mg group\" is entailed by the information present in the CTRs, given the approximation and the less-than condition.</s>",
        "contradict": "The statement does not provide specific information about the clinical benefit rate (CBR) or the number of participants in each group who achieved a CBR. The CTRs specify that the study aimed to determine the acceptability of the two doses of GTx-024 based on the CBR according to RECIST v1.1. Without this data, it is not possible to directly compare the 9 mg and 18 mg groups in terms of CBR and ascertain a 5% difference.</s>"
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial has a topical intervention, whereas the secondary trial has both oral and IV interventions\" is entailed by the information present in the CTRs. In the primary trial, patients apply mometasone furoate cream once daily to the treatment area, which is an instance of a topical intervention. In the secondary trial, patients receive Afatinib monotherapy orally and Paclitaxel or Vinorelbine IV infusions, which are examples of oral and IV interventions, respectively. The statement accurately describes the nature of interventions used in each trial as stated in the CTRs.</s>",
        "contradict": "Although the statement does not contradict the information directly presented in the CTRs, it implies a distinction between the types of interventions between the two trials based on administration routes (topical vs oral/IV). However, the Primary Trial also mentions the use of a placebo as an intervention, which is also an inactive substance applied topically, making both trials include topical interventions as an option. The contradiction lies in the generalization made by the statement that the Primary Trial only has a topical intervention, whereas it actually has both a topical mometasone intervention and a placebo.</s>"
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "The primary trial doesn't have a topical intervention, whereas the secondary trial has both oral and IV interventions.",
        "Label": "Contradiction",
        "entail": "The statement does not directly reference the specific interventions mentioned in the CTRs, but it correctly distinguishes between a topical intervention (mometasone cream in the primary trial) and oral and IV interventions (Afatinib in both trials, with Paclitaxel or Vinorelbine in the secondary trial). The statement's assertion is consistent with the given CTR information. The absence of a topical intervention in the primary trial, as stated in the expert's comment, is indeed reflected in the CTR's description of Intervention 1 for the primary trial. The existence of oral and IV interventions in the secondary trial is also confirmed by the CTR information. Therefore, the statement is entailed by the information within the CTRs.</s>",
        "contradict": "The statement is not an entailed outcome from the information present in the CTRs. The primary trial does, in fact, include a topical intervention (mometasone furoate cream) in arm A, whereas the secondary trial includes oral and intravenous interventions (Afatinib and Paclitaxel or Vinorelbine) in addition to topical intervention (Afatinib monotherapy in the form of film-coated tablets). The statement contradicts the information in the CTRs by implying that the primary trial does not involve a topical intervention when, in fact, it does.</s>"
    },
    "47ea6e1a-c9dd-4fc6-82b6-7af46dec7a12_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "The secondary trial has both oral and IV interventions, whereas the primary trial has a topical intervention.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial has both oral and IV interventions, whereas the primary trial has a topical intervention\" is entailed by the information in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 involves mometasone furoate cream, which is applied topically to the treatment area, whereas Intervention 2 is a placebo cream with identical appearance applied to the treatment area.\n2. In the secondary trial, Intervention 1 refers to Afatinib monotherapy, which is an oral intervention, and Intervention 2 combines Afatinib with Paclitaxel or Vinorelbine, which are administered intravenously.\n\nThe statement accurately describes the differences in intervention modalities between the primary and secondary trials, which aligns with the information presented in the provided CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs based on interventions alone, as they describe different trials with distinct interventions. However, the statement makes a claim about the modalities of the interventions (oral and topical) without explicitly considering the sections or treatments within each intervention (tablets, cream, or infusions). The CTRs do not provide sufficient information to definitively establish entailment or contradiction based on this broad statement.</s>"
    },
    "03a8a787-2bf3-43e5-9c9e-7bd9c3278751": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171704",
        "Statement": "All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years.",
        "Label": "Contradiction",
        "entail": "The statement \"All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years\" is entailed by the CTR information as follows:\n\n1. The CTR states that the Letrozole group received 2.5 mg q.d. orally for 5 years, and the measurement of BMD of the Lumbar Spine (L2-L4) in the Results section for this group showed a median percent change of -4.63 (-14.21 to 4.32) at 3 years. Since the median value represents the central tendency and the range provides an idea about dispersion, this suggests that the majority of patients in the Letrozole group experienced a decrease in BMD after 3 years.\n2. The CTR does not provide data for the BMD changes of Letrozole group after 4 and 5 years. However, the absence of a rebound effect or improvement in BMD after 3 years would suggest that the decreased BMD persisted for these additional 2 years of the trial, as there is no information indicating a recovery from the bone loss.\n\nTherefore, the statement \"All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years\" is a logical conclusion derived from the information presented in the CTR. The statement is also consistent with the data in the Results section, as it accurately reflects the trend observed in the Letrozole group regarding BMD changes over time.</s>",
        "contradict": "The statement that \"All patients in the Letrozole group of the primary trial had a decreased Bone Mineral Density of the Lumbar Spine after 3 years\" can be contradicted by the information present in the CTRs, as per the given results, because the median percent change of Bone Mineral Density of the Lumbar Spine for the Letrozole group at 3 years is not explicitly stated as negative. In fact, the median percent change is given as -4.63 (-14.21 to 4.32), which includes negative as well as positive values. This ambiguity leaves room for the possibility that some patients in the Letrozole group may not have had a decreased BMD after 3 years. The expert's statement makes a stronger claim than what is supported by the data in the CTR.</s>"
    },
    "7d7a9a69-533a-4480-b2e7-aa59eb8a738b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the percentage of participants in Cohort 1 (HER2-positive group) achieving CR or PR (as measured by CNS ORR) ranges from 5% to 24%. (Results 1)\n2. In the primary trial, the percentage of participants in Cohort 2 (ER+ and/or PR+ group) achieving CR or PR (as measured by CNS ORR) ranges from 4% to 58%. (Results 2)\n3. According to the statement, the percentage of participants in Cohort 1 achieving CR or PR is 6x higher than that in Cohort 2.\n4. To find the difference in percentage points, we subtract the percentage of participants in Cohort 2 from the percentage in Cohort 1 and multiply the difference by 6: (24% - 4%) * 6 = 72%\n5. The statement's claim is that the percentage difference between the two groups is 72%. This difference is within the range of the reported percentages in the CTRs, and no contradiction is evident, which establishes entailment.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the percentage of participants achieving CR or PR is provided in Results 1 and Results 2, with different values for HER2-positive and ER+ and/or PR+ groups. However, no actual numerical data is given in the CTRs for the percentages of patients with CR or PR, only the number of analyzed participants and the measurement unit. Therefore, we cannot directly compare the percentage values mentioned in the statement with the data from the CTRs to confirm or refute the entailment relationship. Instead, to validate or falsify the statement, we would need access to the specific percentage values from the primary and secondary trials.</s>"
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Entailment",
        "entail": "The statement \"In total, less than 10% of patients in the primary trial either had a disease relapse or died\" can be entailed by the information present in the CTRs as follows:\n\nFrom the primary trial's Results 1, there were 352 events (disease relapse or death) out of 4898 participants in the Exemestane arm, which is equivalent to approximately 7.2% of the participants.\n\nFrom Results 2, there were 388 events (disease relapse or death) out of 4868 participants in the Tamoxifen followed by Exemestane arm, which is equivalent to approximately 8% of the participants. Since both percentages are below 10%, the statement that \"In total, less than 10% of patients in the primary trial either had a disease relapse or died\" harmonizes with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The expert's statement, \"In total Less than 10% of patients in the primary trial either had a disease relapse or died,\" contradicts the information presented in the CTRs because the provided data shows that there were 740 events (disease relapse or death) for the Exemestane arm (4898 analyzed participants) and 776 events for the Tamoxifen Followed by Exemestane arm (4868 analyzed participants). The percentage of patients who experienced an event is approximately 15.4% and 15.8% for the Exemestane and Tamoxifen Followed by Exemestane arms, respectively, which is greater than 10%.</s>"
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total more than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Contradiction",
        "entail": "The statement \"In total more than 10% of patients in the primary trial either had a disease relapse or died\" can be entailed by the information in the CTRs because:\n\n1. From Results 1, there were 352 events (disease relapse or death) in the exemestane arm out of a total of 4898 participants, which is equal to a proportion of approximately 7.2%.\n2. From Results 2, there were 388 events (disease relapse or death) in the tamoxifen followed by exemestane arm out of a total of 4868 participants, which is equal to a proportion of approximately 8%.\n3. The sum of events in both arms is 352 + 388 = 740, and the total number of participants in both arms is 4898 + 4868 = 9766. Therefore, the proportion of patients with a disease relapse or death in the combined trial is 740/9766 = 7.58%, which is above 10% when rounded up.\n\nTherefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"In total more than 10% of patients in the primary trial either had a disease relapse or died\" contradicts the information in the CTRs because the statement makes a claim about the percentage of patients experiencing disease relapse or death without specifying which treatment arm/group (Exemestane or Tamoxifen Followed by Exemestane) the data pertains to. However, the CTRs provide separate data for the number of events (disease relapse or death) in each arm, allowing us to calculate the respective percentages. According to the provided data, 7.2% of participants in the Exemestane arm and 7.9% of participants in the Tamoxifen Followed by Exemestane arm experienced disease relapse or death. The total percentage for both arms is 15.1%, which is below 10%. Therefore, the statement is not entailed by the provided CTR information.</s>"
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In the primary trial less than 10% of patients either had a disease relapse or died.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, less than 10% of patients either had a disease relapse or died\" can be entailed by the information present in the CTRs as follows:\n\n1. In both arms of the primary trial, the time frame for observation is up to 2.75 years, which covers the period for recording both disease relapse and death events.\n2. From Results 1, the number of disease relapse or death events for the Exemestane arm is 352 among 4898 participants, implying 7.2% incidence.\n3. From Results 2, the number of disease relapse or death events for the Tamoxifen followed by Exemestane arm is 388 among 4868 participants, implying 8.0% incidence.\n4. The total number of participants in both arms is 9766 (4898 + 4868), and the total number of participants who experienced a disease relapse or died is 740 (352 + 388).\n5. Thus, 7.5% (740/9766) of the total patients had a disease relapse or died during the trial, which is less than 10%.</s>",
        "contradict": "The statement \"In the primary trial less than 10% of patients either had a disease relapse or died\" is contradictory to the data presented in the CTRs because the number of disease relapse or death events for each arm is given explicitly. For the exemestane arm, there were 352 events out of 4898 participants, which amounts to approximately 7.2% (352/4898). Similarly, for the arm with tamoxifen followed by exemestane, there were 388 events out of 4868 participants, which is approximately 8.0% (388/4868). Both percentages are above the stated threshold of less than 10%. Therefore, the statement is not entailed by the information in the CTRs.</s>"
    },
    "9035000f-d87b-439f-882a-e6e30694e391": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed Diuretics are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs because the primary trial's exclusion criteria list \"medication(s) known to affect body fluid balance\" as a reason for exclusion. Diuretics function by increasing urine production and eliminating excess water and electrolytes from the body, thereby affecting body fluid balance. Consequently, their use would interfere with accurately evaluating the impact of the trial intervention on lymphedema progression or resolution. Thus, patients who are currently prescribed diuretics meet the exclusion criteria for the primary trial, as stated in the expert's remark.</s>",
        "contradict": "Contradiction exists because the primary CTR's Exclusion Criteria list medication(s) known to affect body fluid balance as a reason for exclusion. Diuretics, being a medication that influences body fluid balance, should technically fall under this category. However, the secondary statement specifically mentions Diuretics as a reason for exclusion independently, potentially implying a more restrictive set of inclusion/exclusion criteria for the primary trial within the study. The contradiction arises due to the ambiguity regarding whether the secondary statement refers to the primary trial's specific exclusion criteria or a more general exclusion criteria. To determine the semantic entailment, it would be necessary to have access to additional context or clarification from the clinical trials expert or the study itself.</s>"
    },
    "9035000f-d87b-439f-882a-e6e30694e391_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed Diuretics aren't excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients currently prescribed Diuretics aren't excluded from the primary trial\" is entailed by the information in the CTRs because diuretics are not mentioned in the exclusion criteria. The exclusion criteria in the primary CTR list conditions for patient exclusion, such as active cancer, pregnancy, and renal failure, among others. Diuretics are not explicitly mentioned as a reason for exclusion. Therefore, patients currently prescribed diuretics can be included in the trial according to the stated inclusion and exclusion criteria.</s>",
        "contradict": "The statement \"Patients currently prescribed Diuretics aren't excluded from the primary trial\" contradicts the CTR information since diuretics are mentioned among the exclusion criteria under medications known to affect body fluid balance.</s>"
    },
    "9035000f-d87b-439f-882a-e6e30694e391_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "The primary trial excludes Patients currently prescribed Diuretics.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial excludes Patients currently prescribed Diuretics\" is entailed by the CTR inclusion/exclusion criteria since \"medication(s) known to affect body fluid balance\" is listed in the exclusion criteria, and diuretics are a type of medication that affects body fluid balance.</s>",
        "contradict": "The statement that the primary trial excludes patients currently prescribed Diuretics is not directly contradicted by the information present in the CTRs. However, the CTRs do list medication(s) known to affect body fluid balance as part of the exclusion criteria. Diuretics are indeed a type of medication that can affect body fluid balance. Consequently, the CTRs' inclusion of this criterion can be considered to implicitly exclude patients currently prescribed diuretics. Yet, the primary trial's statement can be seen as a more specific application of the CTRs' broader criterion, focusing solely on diuretics, and not necessarily contradicting it. Nonetheless, both statements convey the same essential information.</s>"
    },
    "522ca0ec-aeb0-4083-a274-ab58c2cddb8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the CTRs as it makes a comparative claim between the two trials, focusing on the absence of a specific intervention (Gonadotrophin-releasing Hormone Analogues or medical devices) in the secondary trial. However, the statement is consistent with the information provided in the CTRs, as neither trial includes the use of Gonadotrophin-releasing Hormone Analogues or medical devices in the Intervention sections. Therefore, the statement does not contradict the CTR information and is semantically entailed given the context of the CTRs provided.</s>",
        "contradict": "The statement made by the clinical trial expert is contradicted by the primary CTR as it tests a different intervention in the primary trial compared to the one described in the statement for the secondary trial. The primary trial involves ultrasound guided pectoral nerve blocks using ropivacaine, while the secondary trial involves the use of tamoxifen or letrozole for treating ductal carcinoma in situ.</s>"
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial\" can be entailed by the information present in the CTRs if we consider the following:\n\nThe total number of adverse events for Dehydration in the primary trial was 1/25 (4.00%), and for Dyspnea was 2/25 (8.00%). The difference between their occurrences is one case, which represents a 4% difference in percentage terms (8% for Dyspnea and 4% for Dehydration). Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement asserts that there is a 4% difference in the number of cases (1 more case) of Dyspnea compared to Dehydration in the primary trial. However, the CTRs provide information that there were 2 cases of Dyspnea and 1 case of Dehydration, which is not a 4% difference but a 100% difference. Thus, the expert's statement is contradictory to the information in the CTRs.</s>"
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There weren't 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial\" is entailed by the CTR data as follows:\n\nThe primary trial reported a total of 5 adverse events for 25 participants, resulting in an overall rate of 20.00%. The rate for Dyspnea (Shortness Of Breath) was 8.00%, and for Dehydration it was 4.00%. The difference in the rates is 4.00% (8.00% - 4.00%), which is not equal to 4% more cases (1 more case). However, the statement asserts that there wasn't a 4% difference in the number of cases, which is true according to the data. Since the statement is harmonious with the clinical trial data, avoids contradiction, and is substantiated by the CTR, it is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There weren't 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial\" is contradicted by the information present in the CTRs as the number of cases of Dyspnea (2) is indeed 4.00% more than the number of cases of Dehydration (1).</s>"
    },
    "46d65581-7a0a-423b-907e-662c1f5843cc_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4% less cases (1 less case) of Dehydration than Dyspnea in the primary trial.)",
        "Label": "Entailment",
        "entail": "The statement \"There were 4% less cases (1 less case) of Dehydration than Dyspnea in the primary trial\" can be entailed by the information in the CTRs because the CTR for the primary trial reports 1 instance (4.00%) of Dehydration and 2 instances (8.00%) of Dyspnea, and the difference between these counts is exactly 1 instance, which represents a 4% difference in terms of the percentage of participants experiencing each adverse event. This relationship remains consistent with the CTR data and is not contradictory, thus establishing entailment.</s>",
        "contradict": "The expert's statement asserts that there were 4% less cases (1 less case) of Dehydration than Dyspnea in the primary trial. However, the CTRs indicate that there were equal numbers of participants who experienced both Dehydration (1/25) and Dyspnea (2/25). Contradictorily, the statement implies that there were fewer dehydration cases than dyspnea cases.</s>"
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.",
        "Label": "Entailment",
        "entail": "The statement entails that the interventions in the primary trial involve repeated administrations, which aligns with the dosage schedules specified in the CTR for interventions 1 and 2 (weekly applications for weeks 4-12). In contrast, the statement asserts that the interventions in the secondary trial are applied only once, which is consistent with the description of the interventions as placement procedures at the time of reconstruction. No contradiction or inconsistency with the provided CTR descriptions is evident.</s>",
        "contradict": "The statement \"The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only applied once\" is contradicted by the information present in the CTRs. Contradiction arises because both the primary and secondary trials' interventions involve repeated applications for certain periods. In the primary trial, patients receive estriol vaginal gel once a day for the first three weeks and twice weekly for the next nine weeks. Similarly, in the secondary trial, patients undergo tissue expander placement, which can be considered as a single application but involves multiple steps, including surgery, expansion, and possibly removal, spread over a longer period. Therefore, the statement does not hold true for all aspects of the trials' interventions as described in the CTRs.</s>"
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial aren't only apllied once.",
        "Label": "Contradiction",
        "entail": "In the primary trial, patients undergo vaginal application of Intervention 1 (0.005% Estriol Vaginal Gel) for weeks 1-3 with a daily application and weeks 4-12 with twice weekly applications. Intervention 2 (Placebo Vaginal Gel) follows the same schedule.\n\nIn the secondary trial, patients receive different types of interventions - one-port tissue expander placement for Intervention 1 and two-port tissue expander placement for Intervention 2 during breast reconstruction.\n\nThe expert's statement \"The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial aren't only applied once\" can be entailed by the CTR information as follows:\n\n1. The primary trial's interventions require multiple applications (weekly for both Estriol and Placebo) over a prolonged period (weeks 1-3 and 4-12).\n2. The secondary trial interventions are one-time procedures (tissue expander placements).\n\nThe statement is entailed by the CTR information because the expert's statement accurately describes a difference between treatments in the two trials, and the CTR data confirms that difference.</s>",
        "contradict": "The statement \"The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial aren't only applied once\" can be contradicted by the information in the CTRs because:\n\nFor the primary trial:\n- Intervention 1 for both groups (Estriol Vaginal Gel and Placebo Vaginal Gel) involves multiple applications over several weeks.\n\nFor the secondary trial:\n- Intervention 1 (one-port tissue expander placement) and Intervention 2 (two-port tissue expander placement) are both surgical procedures applied at the time of reconstruction, which can be considered as a single application, despite the ongoing process of tissue expansion after the initial procedure. \n\nSo, while the expert's statement suggests a difference in the number of applications between the primary and secondary trials, the actual information from the CTRs does not support this claim, as both primary trial interventions involve multiple applications, and the secondary trial interventions are also applied as surgical procedures.</s>"
    },
    "f4ea6e98-75e1-43a0-8202-548bb7ceb66c_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The interventions for the secondary trial are only apllied once, whereas the intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks.",
        "Label": "Entailment",
        "entail": "The statement \"The interventions for the secondary trial are only applied once, whereas the intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks\" is entailed by the information in the CTRs. In the primary trial, patients receive either Estriol Vaginal Gel or Placebo Vaginal Gel, with different dosage schedules (single daily application for Weeks 1-3 and twice weekly application for Weeks 4-12). This demonstrates that the intervention in the primary trial involves multiple applications over an extended period. In contrast, in the secondary trial, patients receive either one-port or two-port tissue expanders during breast reconstruction surgery, which is only a single application per patient. This aligns with the statement that interventions in the secondary trial are only applied once. Therefore, the statement is harmonious with the CTR information and avoids contradiction.</s>",
        "contradict": "The statement \"The interventions for the secondary trial are only applied once, whereas the intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks\" is contradicted by the information present in the CTRs because in the primary trial, both Intervention 1 (Estriol Vaginal Gel) and Intervention 2 (Placebo Vaginal Gel) require patients to receive the gel over a period of several weeks with different dosing schedules, not just a single application. Therefore, the statement does not hold true for both trials and is contradicted by the given CTR information.</s>"
    },
    "c3a618d6-2c2e-4ed6-bfe7-88d28ec18240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP for patients in cohort one of the primary trial is NA.",
        "Label": "Contradiction",
        "entail": "The statement \"The median TTP for patients in cohort one of the primary trial is NA\" can be entailed by the information present in the CTRs since the CTR for the primary trial indicates that the median TTP for the Capecitabine and Fulvestrant arm, which presumably corresponds to cohort one in this context, is not provided (denoted as \"NA\" in the Results 1 section). Therefore, the expert's statement does not contradict the information in the CTRs, as it acknowledges the absence of data for the median TTP in the primary trial's first cohort.</s>",
        "contradict": "The statement made by the clinical trial expert can be contradicted by the information in the CTR because the CTR reports a specific median TTP value of 26.94 months (7.26 to NA) for the Capecitabine and Fulvestrant arm, which is part of the primary trial and therefore has a defined cohort.</s>"
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"There were more cases of embolisms in cohort 2 of the primary trial than cohort 1\" can be entailed by the information present in the CTRs if the following conditions are met:\n\n1. Cohort 1 in the primary trial refers to the group of participants who did not experience the specified adverse event (i.e., thrombosis/embolism), as evidenced by a total of 0 instances in both cohort 1 adverse event sections.\n2. Cohort 2 in the primary trial refers to the group of participants who did experience the specified adverse event (i.e., thrombosis/embolism), as evidenced by a higher total number of instances, i.e., 1 instance in the first section of Adverse Events 1 and 2 instances in the first section of Adverse Events 2, and possibly more in other sections.\n3. Both CTRs represent valid data from distinct trials, ensuring that the comparison is meaningful.\n\nTherefore, the statement can be entailed by the information present in the CTRs as it accurately reflects the data presented in the reports.</s>",
        "contradict": "The statement \"There were more cases of embolisms in cohort 2 of the primary trial than cohort 1\" is contradicted by the information in the CTRs since the number of thrombosis/embolism cases is lower in cohort 2 (2/715) compared to cohort 1 (4/669).</s>"
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There weren't more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't more cases of embolisms in cohort 2 of the primary trial than cohort 1\" is entailed by the information in the CTRs since both reports indicate the same number of embolism cases in cohort 1 (1 case) and a lower number of embolism cases in cohort 2 (2 cases, compared to 3 cases in cohort 1 for Thrombosis/embolism [1] and 1 case in cohort 1 for Adverse Events 1). The statement is consistent with the CTR data without contradiction.</s>",
        "contradict": "The statement \"There weren't more cases of embolisms in cohort 2 of the primary trial than cohort 1\" can be contradicted by the information in the CTRs because the statement is not consistent with the actual data presented. In the CTR for the primary trial, there is one reported case of thrombosis/embolism in cohort 1 and a total of 2 cases in cohort 2. Thus, there is indeed a higher number of cases in cohort 2 than cohort 1, which contradicts the claim made in the statement.</s>"
    },
    "932728c5-2e7f-401f-be64-e90597ff2ce2_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were less cases of embolisms in cohort 1 of the primary trial than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"There were less cases of embolisms in cohort 1 of the primary trial than cohort 2\" can be entailed by the information present in the CTRs as follows:\n\n1. The total number of participants in cohort 1 was 669, and there were 0/669 (0.00%) reported cases of thrombosis/embolism in the Adverse Events 1 section.\n2. The total number of participants in cohort 2 was 715, and there were 2/715 (0.28%) reported cases of thrombosis/embolism in the Adverse Events 2 section.\n3. The statement's assertion that there were less cases of embolisms in cohort 1 is substantiated because the reported number of cases in cohort 1 (0) is lower than the reported number of cases in cohort 2 (2).\n4. The statement does not contradict the provided descriptions in the CTRs and is in harmony with the clinical trial data. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"There were less cases of embolisms in cohort 1 of the primary trial than cohort 2\" cannot be definitively concluded from the CTR data provided, as the number of embolisms in cohorts 1 and 2 is not the same in both trials. In the primary trial, there was 1 embolism in cohort 1 (total of 669 participants) and 3 embolisms in cohort 2 (total of 669 participants). In the secondary trial, there were 2 embolisms in cohort 2 (total of 715 participants), but no mention was made of embolisms in cohort 1. Therefore, the CTRs do not provide sufficient information to determine whether there were actually fewer cases of embolisms in cohort 1 than cohort 2.</s>"
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "Label": "Entailment",
        "entail": "The information in the statement can be entailed by the CTR data as follows:\n\nThe CTR states that the median Tmax for SU011248, SU012662, and the total drug (combined SU0111248 and SU012662) is 6.0 hours at both C1D2 and C2D3. None of the reported median Tmax values for individual components or the total drug exceed 16 hours. Additionally, the time frame for Tmax measurements in the trial is up to 24 hours postdose; hence, there is no observation recorded beyond 16 hours. Therefore, it is impossible for a participant in the primary trial to have a Tmax of 16, 17, or 20 hours.</s>",
        "contradict": "The statement cannot be definitively contradicted by the information in the CTRs as the CTRs only report median Tmax values for each timepoint, and do not provide enough data to establish that no individual participant in the primary trial had a Tmax of 16, 17, or 20 hours. While the reported range for some Tmax values includes these hours, it does not necessarily mean that all participants in the corresponding groups experienced these specific Tmax values. Therefore, the statement and the CTRs do not contradict each other directly, but the statement is not entailed by the information in the CTRs.</s>"
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours",
        "Label": "Contradiction",
        "entail": "The statement is consistent with the data presented in the CTRs as there are recorded instances of median Tmax values for individual drugs (SU011248 and SU012662) and the total drug being 6.0 hours, but with reported ranges extending up to 24 hours postdose. Consequently, a participant's individual Tmax value falling within the range of 16, 17, or 20 hours would not contradict the CTR data and can, therefore, be entailed.</s>",
        "contradict": "The statement \"It is possible for a participant of the primary trial to have a Time to Reach Maxima Plasma Concentration (Tmax) of 16, 17 or 20 hours\" conflicts with the information in the CTR since all the observed Tmax values for both Sunitinib (SU011248) and its metabolite (SU012662), as well as for the total drug, are within the range of 2 to 24 hours, with a median of 6 hours for all time points. No participant had a Tmax above 16 hours or below 2 hours. Therefore, the statement is not semantically entailed by the data provided in the CTRs.</s>"
    },
    "54ad9406-852c-40fc-bd0e-8e7e81eacc71_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "A Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours is not possible for a participant of the primary trial.",
        "Label": "Entailment",
        "entail": "The median Tmax for all drug concentrations (SU011248, SU012662, and total drug) in the primary trial is 6.0 hours with a range of 2.0 to 24.0 hours. The statement asserts that a time to reach maximum plasma concentration of 16, 17, or 20 hours is not possible for a participant of the primary trial. Since none of the observed median Tmax or even their ranges include the mentioned hours (16, 17, or 20), this statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"A Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours is not possible for a participant of the primary trial\" is contradicted by the CTR results because none of the reported Tmax values for SU011248, SU012662, or the total drug in the primary trial fall outside the range of 2.0 to 24.0 hours, which includes the mentioned hours (16, 17, and 20) within this range.</s>"
    },
    "7021a4a9-b474-4568-a3b8-015a50c9d9cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n1. In the primary CTR, under eligibility criteria, it states \"Must have invasive breast cancer,\" and \"Her 2/neu negative or positive by IHC or FISH,\" which implies that patients with triple negative breast cancer (Her 2/neu negative) are eligible.\n2. In the secondary CTR, it specifies \"infiltrating (invasive) HER2-neu-negative breast cancer\" as inclusion criteria, which is a subset of triple negative breast cancer.\n3. The statement does not contradict any information in the CTRs, making the entailment relationship valid.</s>",
        "contradict": "The statement \"Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial\" cannot be directly derived from the information presented in the CTRs for both trials. The primary trial specifies eligibility criteria for patients with invasive metastatic breast cancer, including those with Her2/neu positivity by IHC or FISH. The secondary trial, on the other hand, only mentions inclusion for women with either HER2-neu-negative or HER2-neu-positive infiltrating breast cancer without any mention of triple negative status. Therefore, the statement does not entail the information present in the CTRs and may contradict them depending on the specific patient cohorts within these trials.</s>"
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "There is no radiotherapy or educational part of the intervention used in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is no radiotherapy or educational part of the intervention used in the primary trial\" is entailed by the information present in the CTRs because:\n\n1. The CTR for the primary trial explicitly mentions \"neoadjuvant therapy,\" which is a form of systemic treatment and does not include radiotherapy.\n2. The CTR also mentions \"Tamoxifen or Letrozole,\" which are hormonal treatments and do not involve educational interventions as part of their application. Therefore, the statement's condition that neither radiotherapy nor educational interventions are present in the trial is consistent with the CTR's description of the intervention.</s>",
        "contradict": "The expert statement asserts that there is no radiotherapy or educational component in the intervention used in the primary trial. However, the CTRs do not provide explicit information regarding the absence or presence of radiotherapy or educational components. The statement's contradiction with the CTRs lies in the fact that radiotherapy and educational components are neither explicitly mentioned as being present nor explicitly mentioned as being absent in the CTRs. Therefore, the statement cannot be definitively confirmed or contradicted based on the given CTR information alone.</s>"
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "There is a radiotherapy or educational part of the intervention used in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trials expert is not entailed by the information in the provided CTRs as there is no mention of radiotherapy or an educational part of the intervention in the INTERVENTION sections of either the primary or secondary trials.</s>",
        "contradict": "The information contained in the expert's statement cannot be entailed by the data present in the CTRs. The CTRs do not mention any radiotherapy or educational part of the intervention used in the primary trial. Therefore, the expert's statement contradicts the information in the CTRs.</s>"
    },
    "24eced44-40b2-4365-abd3-42eb13220cf0_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "In the primary trial there is no radiotherapy or educational part of the intervention.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial there is no radiotherapy or educational part of the intervention\" is entailed by the information present in the CTR, as there is no mention of radiotherapy or educational interventions specified as part of the intervention in the CTR for the primary trial.</s>",
        "contradict": "The expert's statement asserts that there is no radiotherapy or educational part of the intervention in the primary trial. However, the CTRs do not provide explicit information about the absence of radiotherapy or educational interventions in the primary trial, but solely mention that the interventions consist of Tamoxifen or Letrozole, surgery (conventional or neoadjuvant), and do not mention any radiotherapy or educational interventions explicitly as being absent. Thus, based on the information present in the CTRs alone, it cannot be determined with certainty that there is no radiotherapy or educational part of the intervention. This means the expert's statement contradicts the CTRs only if it is assumed that the absence of explicit mention implies the absence, which may not be a valid assumption.</s>"
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device.",
        "Label": "Entailment",
        "entail": "The statement asserts that the primary trial is evaluating a radiotherapy intervention, which is entailed by the Intervention sections in the CTR, where it is clearly stated that patients in the primary trial will receive HDR brachytherapy using Mammosite ML as the sole method or as a boost technique for breast cancer or DCIS. Radiotherapy is a well-established cancer treatment method involving the use of radiation to destroy cancer cells. The CTRs describe HDR brachytherapy, a specific type of radiotherapy, as the intervention under investigation in the primary trial.\n\nFurthermore, the statement mentions that the secondary trial is testing a novel hand-held medical device. This claim is also entailed by the CTRs, as Intervention 1 in the secondary trial refers to Manual Lymph Drainage (MLD), which is a manual massage technique applied by practitioners, while Intervention 2 involves the use of a PhysioTouch, a handheld device that administers negative pressure. Both manual lymph drainage and negative pressure massage treatments are considered medical devices, as they require specialized tools and equipment to be administered effectively.\n\nIn summary, the expert's statement is entailed by the Clinical Trial Reports, as they both describe the primary trial as testing a radiotherapy intervention and the secondary trial as investigating novel hand-held medical devices.</s>",
        "contradict": "The statement does not directly contradict the information present in the CTRs. However, it misrepresents the nature of the interventions being tested in each trial. While it is true that the primary trial is testing a radiotherapy intervention using HDR brachytherapy with Mammosite ML, the secondary trial is also testing a medical device intervention, specifically manual lymph drainage (MLD), which is a hands-on manipulative therapy technique used to stimulate lymphatic drainage, rather than a hand-held device like the PhysioTouch used in the secondary trial. The statement's implication that the secondary trial is not testing an intervention related to radiotherapy is incorrect.</s>"
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "The primary trial isn't testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial isn't testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device\" is entailed by the information in the CTRs as follows:\n\nFor the primary trial, Intervention 1 describes patients being treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS. This is explicitly stated to not be a test of a hand-held medical device but a specific type of radiotherapy intervention.\n\nFor the secondary trial, Intervention 1 describes Manual Lymph Drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb. This intervention is not a radiotherapy intervention, but a manual massage technique for managing lymphedema. Intervention 2 in the secondary trial, \"Negative Pressure\" using PhysioTouch, is a separate intervention testing the effect of the hand-held negative pressure massage device on lymphedema. The statement, therefore, accurately reflects the information presented in the CTRs.</s>",
        "contradict": "The statement \"The primary trial isn't testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device\" is contradicted by the information presented in the CTRs as follows:\n\n1. The primary trial is, in fact, testing a radiotherapy intervention - HDR brachytherapy using Mammosite ML.\n2. The secondary trial is also testing a radiotherapy intervention, although in the context of lymphedema management. Manual lymph drainage (MLD) and PhysioTouch are techniques used to enhance lymphatic flow and facilitate the removal of interstitial fluid, which is a part of the lymphatic system.\n\nHowever, it's important to note that the primary and secondary trials are addressing different aspects of patient care for breast cancer and lymphedema, respectively. The first trial focuses on radiation therapy after lumpectomy, while the secondary trial deals with lymphedema management.</s>"
    },
    "3e2dda3a-815f-4681-a470-009d9f9b30d6_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "The secondary trial is testing a novel hand-held medical device whereas the primary trial is testing a radiotherapy intervention.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial is testing a novel hand-held medical device\" is entailed by the description of Intervention 2 in the Secondary Trial section because it mentions \"PhysioTouch,\" which is described as a \"hand-held device.\" Therefore, the statement aligns with the provided data and does not contradict it.\n\nThe statement \"whereas the primary trial is testing a radiotherapy intervention\" is also entailed by the descriptions in the Primary Trial section, specifically the information about Intervention 1 and Intervention 2, which both involve radiotherapy delivered using the Mammosite ML device.</s>",
        "contradict": "The statement made by the expert does not contradict the information in the CTRs directly, but it does oversimplify the trials' focuses, potentially leading to misinterpretation. While it is true that the primary trial is investigating HDR brachytherapy using Mammosite ML for breast cancer/DCIS treatment and the secondary trial is evaluating hand-held medical devices for managing lymphedema, the expert's description of the trials as solely focusing on a radiotherapy intervention vs. a novel hand-held device oversimplifies the complexities within each trial. Both trials incorporate specific intervention methods, delivery schedules, and patient populations, making it essential to examine each trial individually to gain a comprehensive understanding of the trials' goals and outcomes. The statement, while accurate in part, lacks the necessary detail to fully capture the intricacies of both trials, potentially leading to misunderstandings or incorrect assumptions.</s>"
    },
    "1a293e7c-691f-4f93-bab8-6bf5d9b3f904": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01653964",
        "Secondary_id": "NCT02660788",
        "Statement": "The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trial expert can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 refers to \"Molecular Breast Imaging,\" but it does not specify the name or dosage of the medication being tested.\n2. The expert's statement acknowledges that both trials test the same medication.\n3. In the secondary trial, Intervention 1 for both arms is listed as \"Mail\" and \"Standard Reminder Postcard,\" and Intervention 2 is a \"Family Physician Reminder Letter\" with an additional Standard Reminder Postcard. No medication dosage information is provided.\n4. The expert's statement focuses on the differences between interventions being the use of different doses of the same medication and not the methods of delivery or additional interventions.\n5. The CTRs do not contradict the expert's statement, as they do not provide information about the medication dosages used in the trials.\n\nTherefore, the expert's statement is entailed by the information in the CTRs since it does not contradict the available information and is consistent with the trials' testing the same medication with different doses.</s>",
        "contradict": "The statement \"The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication\" is not contradicted by the information in the CTRs. However, the statement \"they are not using the same doses\" can be contradicted. In the primary trial, molecular breast imaging is performed after injection of 4 mCi and then 8 mCi Tc-99m sestamibi, which can be considered as using different doses of the same medication. In contrast, the secondary trial has two interventions: the control arm receives a standard reminder postcard, while the family physician reminder letter arm also receives a standard reminder postcard in addition to a family physician reminder letter. These interventions do not involve the administration of the same medication with different doses as in the primary trial. Hence, the statement is not directly contradicted but incomplete in describing the differences between the trials' interventions.</s>"
    },
    "a87e6e20-c7d0-4941-9933-204fab99b299": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.",
        "Label": "Contradiction",
        "entail": "The statement \"Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment\" can be entailed by the information present in the CTRs as follows:\n\nThe primary CTR reports that the PFS rate after 12 weeks of treatment for the Lapatinib + Bevacizumab group is 69.2%, which is equivalent to 36 out of 52 participants. Since no information about the participants' status after 12 weeks is provided, it is unclear how many of them experienced disease progression or death between week 12 and week 6. However, we know there were 16 participants (30.8%) who did experience disease progression or death by week 12.\n\nAssuming that some participants in the primary trial experienced disease progression or death after week 12, the PFS rate at 6 months would be lower than 69.2%. Since the statement \"Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment\" implies that fewer than 17 participants (which is 1/3 of 52) did not experience disease progression or death by 6 months, this statement is consistent with the information in the CTRs, and the entailment relationship holds.</s>",
        "contradict": "The statement made by the clinical trial expert can be contradicted by the information presented in the CTRs because the outcome measurement and time frame specified in the expert's statement (Progression-free Survival Rate After 6 months) differ from those reported in the CTRs (Progression-free Survival Rate After 12 weeks). Therefore, the comparison between the expert's statement and CTR information is not directly comparable. To establish entailment, the comparison should be made between identical or equivalent outcome measures and time frames. In this case, it is not possible to determine if the expert's statement is entailed by the data in the CTRs due to the discrepancy in outcome measures and time frames.</s>"
    },
    "6c3427a8-27a1-459c-9fbc-175649210868": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" cannot be directly entailed by the given information in the Clinical Trial Reports (CTRs). Anaphylactic shock, which is a type of allergic reaction, was reported in one participant (1.05%) in cohort 1 of the primary trial and none in cohort 2 of the secondary trial. However, the CTRs do not provide information about the total number of allergic reactions (other than anaphylactic shock) in each cohort. Therefore, the statement goes beyond the data presented in the CTRs and lacks substantiation.</s>",
        "contradict": "The statement \"there were more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not explicitly report on allergic reactions occurring in each cohort. However, based on the given data, neither trial reports any allergic reactions. Therefore, the statement is false, not contradictory to the information in the CTRs.</s>"
    },
    "6c3427a8-27a1-459c-9fbc-175649210868_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There weren't more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" is entailed by the information from the CTRs as neither of them reported any occurrence of anaphylactic shock or other allergic reactions (besides one instance in cohort 1 of the primary trial) among participants in their respective adverse events sections. Thus, based on provided CTR data, there is no difference in the number of allergic reactions between both cohorts.</s>",
        "contradict": "The statement \"There weren't more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" is contradicted by the information in the CTRs because anaphylactic shock, which is a type of allergic reaction, occurred in 1 participant (1.05%) of cohort 1 of the primary trial, while it did not occur in any participant of cohort 2 of the secondary trial. This means that there was at least one more allergic reaction observed in cohort 1 than cohort 2.</s>"
    },
    "6c3427a8-27a1-459c-9fbc-175649210868_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were less allergic reactions observed in cohort 2 of the primary trial than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs because the term \"allergic reactions\" is not explicitly mentioned in either CTR. However, anaphylactic shock, which is a type of allergic reaction, is reported in only 1 instance (1.05%) in cohort 1 of the primary trial, while it is not reported in cohort 2 of the primary trial or in either cohort of the secondary trial. This difference in frequency supports the statement that \"there were less allergic reactions observed in cohort 2 of the primary trial than cohort 1.\"</s>",
        "contradict": "The expert's statement cannot be definitively determined to be entailed by the information present in the CTRs based on the provided data alone. While there are fewer instances of anaphylactic shock reported in cohort 2 compared to cohort 1, there is no information provided in the CTRs about the types of allergic reactions being compared. The CTRs only report specific adverse events and their corresponding frequencies in each cohort, but they do not provide a comprehensive list of all potential allergic reactions. Therefore, it is possible that there are other types of allergic reactions not reported in the CTRs or that the expert is using a broader definition of allergic reactions than what is specified in the CTRs. Consequently, the statement cannot be definitively contradicted or confirmed based on the information provided.</s>"
    },
    "883bec6a-bce2-4e60-9304-49a056e66df7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin < 1.2 x ULN are eligilbe for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that a female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l, and total bilirubin < 1.2 x ULN is eligible for the primary trial is entailed by the CTR inclusion criteria because the CTR states that the inclusion criteria include subjects with Hemoglobin > 9.0 g/dl, and the statement meets this requirement (Hemoglobin > 10.0 g/dl exceeds this minimum), as well as Absolute neutrophil count > 1,500/mm3, platelet count = 100,000/\u00b5l, and Total bilirubin = 1.5 x the upper limit of normal or < 1.2 x ULN. These requirements are stated separately in the CTR, but they all refer to the minimum health standards for participation in the study, which the statement fulfills. Additionally, no exclusion criteria in the CTR apply to this statement.</s>",
        "contradict": "The statement that a female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l, and total bilirubin < 1.2 x ULN are eligible for the primary trial contradicts the inclusion criteria in the CTR, specifically the hemoglobin level requirement (Hemoglobin > 9.0 g/dl).</s>"
    },
    "8720143a-2611-4502-a5ee-da4e641df918": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of extravasation in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no cases of extravasation in either the primary trial or the secondary trial.\" can be entailed by the information present in the CTRs as both trials report 0/10 (for primary) and 0/24 (for secondary) cases of extravasation under their respective Adverse Events sections.</s>",
        "contradict": "The expert's statement contradicts the primary trial CTR data, as there was 1 reported case of extravasation in the primary trial with a total of 10 participants (1/10 or 10.00%). This information can be found in the Adverse Events 1 section of the primary CTR.</s>"
    },
    "0fdda7a2-4119-40a7-84f3-6c5c6077df49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Contradiction",
        "entail": "In the primary trial, women with serum 25 (OH)D greater than or equal to 30 ng/ml were excluded from receiving cholecalciferol supplementation during the intervention phase as specified in Intervention 2. Therefore, these women were in the arm that received no intervention, aligning with the description in the expert statement regarding cohorts A and B in the primary trial. Thus, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "Women in cohort A from the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did receive weekly supplementation of cholecalciferol according to the INTERVENTION section of the CTR, which specifies that women in the control arm (no intervention) only had this condition applied if their serum 25 (OH)D levels were already above the threshold. Therefore, the statement contradicts the CTR information. However, for cohort B, the statement aligns with the CTR as they did not receive any cholecalciferol supplementation.</s>"
    },
    "e7eae332-6b6a-41e0-aa31-86a781fd373f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial\" is entailed by the CTR data as follows:\n\n1. The number of Cardiac adverse events in cohort 1 of the primary trial is 4.55% * 22 (patients) = 1 (event).\n2. The number of Dyspnea events in cohort 1 of the primary trial is 9.09% * 22 (patients) = 2 (events).\n3. Twice the number of Dyspnea events (2 * 2 = 4) is equal to the number of Cardiac adverse events (1), which fulfills the statement's condition.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the CTR for the primary trial indicates that there was only one case of Cardiac adverse event (4.55%) and two cases of Dyspnea (9.09%), which is not twice as many Cardiac events as cases of Dyspnea.</s>"
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide\" entails the following: The low dose of magnesium oxide used in the primary trial is 800 mg/week (2 tablets/day * 400 mg/tablet * 7 days/week), and the high dose used in the trial is 1200 mg/week (3 tablets/day * 400 mg/tablet * 7 days/week). Thus, the difference in dosage is 400 mg/day (1200 mg/week - 800 mg/week). The CTRs provide the information on the dosages of magnesium oxide for both the low dose (800 mg/day) and high dose (1200 mg/day) interventions, so this entailment holds true based on the facts presented.</s>",
        "contradict": "The statement \"In the primary trial, Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide\" can be contradicted by the information present in the CTRs as follows:\n\n1. The low dose magnesium oxide group in the primary trial takes 800 mg/Day (two 400 mg tablets) during Weeks 2-9 and high dose magnesium oxide group takes 1200 mg/Day (three 400 mg tablets) during Weeks 2-9.\n2. The difference between the dosages of low dose and high dose Magnesium Oxide (1200 mg/Day - 800 mg/Day = 400 mg/Day) is exactly the same as mentioned in the expert's statement. However, the contradiction lies in the timing of these doses.\n3. During Week 2, both groups take the same dosage (one 400 mg/tablet/day).\n4. During Week 3, both groups take a higher dosage compared to Week 2.\n   - Low Dose: 800 mg/day (two 400 mg tablets)\n   - High Dose: 1200 mg/day (three 400 mg tablets)\n5. Therefore, the expert's statement \"In the primary trial, Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide\" may technically hold true for the total daily dosage difference between Weeks 4-9, but it contradicts the CTRs in Weeks 2 and 3, where the dosages are equal despite the difference in the number of tablets taken.</s>"
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide isn't 400 mg/day less than high dose Magnesium Oxide.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial, Low Dose Magnesium Oxide isn't 400 mg/day less than High Dose Magnesium Oxide\" holds true according to the provided CTRs. This is because both the low dose (800 mg/Day) and the high dose (1200 mg/Day) of magnesium oxide given in the primary trial exceed 400 mg/day. Thus, the low dose is not less than the high dose in terms of the daily magnesium intake in the primary trial. Therefore, the statement is entailed by the CTRs as it is consistent with the data provided and does not contradict any information in the trial reports.</s>",
        "contradict": "The statement \"In the primary trial, Low Dose Magnesium Oxide isn't 400 mg/day less than high dose Magnesium Oxide\" is contradicted by the CTR data because:\n\n- In the primary trial, the low dose group receives 800 mg/day (2 tablets of 400 mg each), and the high dose group receives 1200 mg/day (3 tablets of 400 mg each)\n- Therefore, the high dose group is receiving 400 mg/day more magnesium oxide than the low dose group (1200 mg/day - 800 mg/day = 400 mg/day)\n- Hence, the statement is incorrect as stated, as the low dose is indeed less than the high dose in the primary trial.</s>"
    },
    "9a52d5d4-ff71-42ee-8672-ec4ac3cfd591_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial high dose Magnesium Oxide is 400 mg/day more than low dose Magnesium Oxide.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, high dose Magnesium Oxide is 400 mg/day more than low dose Magnesium Oxide\" can be entailed by the information present in the CTRs, as the dosage of Magnesium Oxide is higher in the high dose intervention (1200 mg/day) compared to the low dose intervention (800 mg/day), which is a difference of 400 mg/day.</s>",
        "contradict": "The statement \"In the primary trial, high dose Magnesium Oxide is 400 mg/day more than low dose Magnesium Oxide\" can be contradicted by the information present in the CTRs because the difference in dosage between the two interventions not only occurs in the number of tablets taken daily but also in the total dosage per week. The low dose group takes 800 mg/day (two 400 mg tablets) and the high dose group takes 1200 mg/day (three 400 mg tablets). Therefore, the total difference in dosage per week is 400 mg/day only for the daily dose difference, but if we consider the weekly dosage, the difference is greater (1200 mg/week for high dose vs 800 mg/week for low dose). Thus, the statement is partially true but insufficient as it fails to consider the weekly dosage difference.</s>"
    },
    "c09b9f7c-2d22-4c44-a79d-32929530dd9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial and the primary trial are both testing Biodesign interventions.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial and the primary trial are both testing Biodesign interventions\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 uses LA-EP2006, which is a Biodesign product (LA-EP2006 is not explicitly labeled as a Biodesign intervention but it is mentioned that it's a \"Biodesign\u00ae product\" in the secondary trial).\n2. In the primary trial, Intervention 2 uses Neulasta\u00ae, which is also a Biodesign product (Neulasta\u00ae is a trademarked name for pegfilgrastim, and pegfilgrastim is described as a \"Biodesign\u00ae product\" in the CTR for another trial).\n3. In the secondary trial, Intervention 1 is specified as the Biodesign\u00ae Nipple Reconstruction Cylinder.\n4. Since both primary and secondary trials are testing Biodesign interventions (LA-EP2006 and Neulasta\u00ae in the primary trial, and the Biodesign Nipple Reconstruction Cylinder in the secondary trial), the statement is a logical consequence of the information provided in the CTRs.</s>",
        "contradict": "The statement does not provide sufficient information to determine whether it entails the data in the CTRs. While it's true that both trials involve a Biodesign intervention, the statement neither explicitly mentions which section of the trials it refers to (ELIGIBILITY CRITERIA, INTERVENTION, RESULTS, or ADVERSE EVENTS), nor does it provide context about which intervention within each trial the expert is referring to (LA-EP2006 or Nipple Reconstruction Cylinder). Without further clarification, it is impossible to definitively establish semantic entailment or contradiction.</s>"
    },
    "6f143256-52e4-40b7-950c-5c892f8632b9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that Stage IIIB patients had a higher proportion of Event-free Survival (PFS) at 5 months compared to Stage IV Disease patients as per the primary trial findings. This relationship aligns with the data in the CTR, where the Event-free Survival time frame is given as 11 years, and the number of participants in each group with their respective percentages are stated as follows:\n\nStage IIIB: 18 participants, 61.1%\nStage IV: 32 participants, 28.1%\n\nThus, the expert's statement is entailed by the CTR information.</s>",
        "contradict": "The statement asserts that Stage IIIB patients had the highest percentage of Progression-Free Survival (PFS) at 5 months, while Stage IV Disease patients had the lowest. However, the CTR does not provide PFS data at 5 months for the different patient groups. Instead, it reports Event-free Survival (EFS) data over a time frame of 11 years. Therefore, it is not possible to directly compare PFS percentages between groups based on the given information. The statement is contradictory because it draws comparisons based on PFS at 5 months, while the CTR reports Event-free Survival data over a different time frame.</s>"
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.",
        "Label": "Entailment",
        "entail": "The given statement \"To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions\" is entailed by the CTR inclusion criteria stating \"Measurable disease, defined as >=1 unidimensionally measurable lesion\" and the detailed size conditions for measurable lesions mentioned under the inclusion criteria of the primary trial CTR.</s>",
        "contradict": "The expert's statement is incomplete as it does not specify which CTR or trials it refers to. The given CTR has more detailed inclusion criteria, including various size conditions for measurable lesions in addition to other eligibility criteria. The expert's statement might be contradictory to some patients in the CTR who meet the other inclusion conditions but may have measurable lesions smaller than the stated minimum size. Therefore, the expert's statement may not entail the information in the CTRs without further clarification or qualification.</s>"
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients mustn't have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.",
        "Label": "Contradiction",
        "entail": "The statement \"To be included in the primary trial, patients mustn't have at least 1 unidimensionally measurable lesion\" is contradictory to the CTR's inclusion criteria stating \"Measurable disease, defined as >=1 unidimensionally measurable lesion.\" Therefore, the expert statement cannot be directly entailed by the CTR information. \n\nHowever, the statement \"must meet some specific size conditions\" can be entailed by the CTR's inclusion criteria, as they specify the minimum size requirements for measurable lesions, such as a lesion >= 10 mm on CT scan, >= 10 mm on physical exam, >= 20 mm on CT scan or MRI, or >= 10 mm on bone disease assessments.</s>",
        "contradict": "The statement \"To be included in the primary trial, patients mustn't have at least 1 unidimensionally measurable lesion\" is contradictory to the CTR, as the primary trial in fact requires the presence of at least one unidimensionally measurable lesion for patient eligibility.</s>"
    },
    "d2718f05-1d35-4c84-a054-06a3fe4a0a9c_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "Patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions to be included in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTRs as the inclusion criteria in both trials specify that patients must have at least 1 unidimensionally measurable lesion. Additionally, the size conditions mentioned in the expert's statement are also outlined in the CTR for measuring lesion size using different imaging techniques. Therefore, these requirements align and are consistent with the information in the CTRs.</s>",
        "contradict": "The statement \"Patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions to be included in the primary trial\" is not a direct contradiction to the information in the CTRs. However, the statement is less specific and does not accurately convey all the inclusion criteria outlined in the CTRs. The CTRs specify that patients must have a measurable lesion, but also provide several options for what constitutes measurable disease, including specific size conditions for various types of lesions on different imaging modalities. Additionally, the statement does not mention the requirement that patients have received a prior aromatase inhibitor, have estrogen receptor-positive or progesterone receptor-positive tumors, and meet certain other eligibility criteria listed in the CTRs. Therefore, while the statement is not a contradiction, it does not fully capture the semantic entailment relationship with the information in the CTRs due to its less specific and incomplete nature.</s>"
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs because, in CTR 1 (Primary Trial), the frequency of Neutropenia (5.80%) is higher than the frequencies of all other adverse events listed in the \"Adverse Events 1\" section for cohort 1. Therefore, the expert's claim is consistent with the trial data and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial\" contradicts the information in the CTRs because the frequency of Neutropenia in cohort 1 of the primary trial (5.80%) is not higher than any other adverse event. The most common adverse event in cohort 1 of the primary trial is Anemia with a frequency of 2.90%. The statement is incorrect based on the available data in the CTRs.</s>"
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "Neutropenia wasn't the most common adverse event for patients in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Neutropenia wasn't the most common adverse event for patients in cohort 1 of the primary trial\" is entailed by the CTR data as follows: The total number of adverse events for cohort 1 in the primary trial was 26 out of 69 participants (37.68%), while the number of participants who experienced neutropenia was 4 out of 69 (5.80%). The percentage of participants with neutropenia (5.80%) is less than the percentage of participants with the most common adverse event, which is not explicitly stated in the given CTR data but can be inferred from the fact that the total percentage of adverse events is higher (37.68%). Therefore, based on the CTR data, the statement \"Neutropenia wasn't the most common adverse event for patients in cohort 1 of the primary trial\" can be entailed.</s>",
        "contradict": "Despite the statement, the primary CTR reports that Neutropenia was observed in 5.80% (or 4/69) of patients in the first cohort, which is higher than the occurrence rate of any other adverse event except for anemia (2.90%). Consequently, the statement contradicts the information present in the CTR.</s>"
    },
    "7f49cafd-3a27-4fc8-872d-914b9176442e_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01427933",
        "Statement": "For patients in cohort 1 of the primary trial Neutropenia was the most common adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"For patients in cohort 1 of the primary trial, Neutropenia was the most common adverse event\" can be entailed by the information present in the CTRs as follows:\n\n1. The frequency of Neutropenia in cohort 1 of the primary trial is 4/69 (5.80%), which is higher than the frequency of any other adverse event mentioned in the CTR.\n2. The statement does not contradict the information in the CTRs and only makes a claim based on data presented. Therefore, it is entailed by the CTR information.</s>",
        "contradict": "Although the statement implies that Neutropenia was the most frequent adverse event for patients in cohort 1 of the primary trial, the CTR data indicates otherwise. The CTR for the primary trial shows that the most common adverse event was Anemia, with an occurrence of 2.90% in 69 patients, while Neutropenia had a lower occurrence of 5.80%. Consequently, the expert's statement is contradictory to the information presented in the CTR.</s>"
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial\" can be entailed by the information in the CTRs since both CTRs report one instance (0.87%) of Pancytopenia and one instance (0.87%) of Neutropenia each, in the Adverse Events sections of their respective cohort 1 data.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs because there is only one instance of Pancytopenia reported in the primary trial (1/115), whereas there are two instances of Neutropenia (2/115). Therefore, the number of cases of Neutropenia is indeed greater than the number of cases of Pancytopenia in the primary trial. The statement, however, asserts that the number of cases is equal.</s>"
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia and Pancytopenia aren't observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"The same number of cases of Neutropenia and Pancytopenia aren't observed in patients from cohort 1 of the primary trial\" is entailed by the information present in the CTRs because:\n\nIn the primary trial's Adverse Events 1 section for cohort 1, there is one instance of each condition reported (Neutropenia: 1/115, Pancytopenia: 1/115). Therefore, the statement that \"The same number of cases of Neutropenia and Pancytopenia aren't observed in patients from cohort 1 of the primary trial\" is a correct observation based on the data provided. The statement doesn't contradict any information in the CTRs and is harmonious with the trial data.</s>",
        "contradict": "The statement \"The same number of cases of Neutropenia and Pancytopenia aren't observed in patients from cohort 1 of the primary trial\" is contradicted by the information present in the CTRs because cohort 1 of the primary trial reports one case (0.87%) of Pancytopenia but no cases (0.00%) of Neutropenia. Therefore, fewer cases of Neutropenia than Pancytopenia were observed in the patients from cohort 1 of the primary trial.</s>"
    },
    "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "Patients from cohort 1 of the primary trial have the same number of cases of Neutropenia and Pancytopenia.",
        "Label": "Entailment",
        "entail": "Both the primary and secondary trials report on different patient cohorts (115 in the primary trial and 112 in the secondary trial). However, the statement does not involve any comparative analysis between the two trials or their cohorts, but rather asserts that within the primary trial, there is the same number of cases of Neutropenia and Pancytopenia in cohort 1.\n\nThe information present in the CTRs for both trials, specifically the ELIGIBILITY CRITERIA and ADVERSE EVENTS sections, can be used to determine the number of cases of Neutropenia and Pancytopenia in the primary trial's cohort 1. Both conditions are listed in the Adverse Events sections for the primary trial, with 1 case each reported. Therefore, the statement that \"Patients from cohort 1 of the primary trial have the same number of cases of Neutropenia and Pancytopenia\" is entailed by the CTR information.</s>",
        "contradict": "The statement \"Patients from cohort 1 of the primary trial have the same number of cases of Neutropenia and Pancytopenia\" is contradicted by the CTR information because in the Adverse Events section of the primary trial, there is only one reported case of Pancytopenia (0.87%) while there are two reported cases of Neutropenia (1.79%). Therefore, the statement that both conditions have the same number of cases cannot be entailed by the given clinical trial data.</s>"
    },
    "3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as both trials share identical exclusion criteria regarding prior radiation therapy within the last 4 weeks. The expert's statement extends this criterion to include radiation therapy for the treatment of stage 4 cancer over 5 years ago, which aligns with the existing exclusion criteria in the CTRs. No contradiction arises as both trials exclude patients with prior radiation therapy in their eligibility criteria.</s>",
        "contradict": "The statement contradicts the eligibility criteria of both primary and secondary trials, which do not include any exclusion related to prior radiotherapy beyond a 4-week window for the primary trial and no exclusion for the secondary trial.</s>"
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "Label": "Entailment",
        "entail": "The statement entails that Black men who meet certain conditions specified in the primary trial's inclusion criteria, such as ECOG <=2, ANC >1.5 x 10^9/L, and PLT >100 x 10^9/L, and have no prior history of blood clots, are eligible for the primary trial but not the secondary trial. This information is entailed by the CTRs since the primary CTR's inclusion criteria include these conditions (ECOG <=2, ANC >1.5 x 10^9/L, PLT >100 x 10^9/L) without prior history of blood clots for patient eligibility, whereas the secondary trial excludes patients with a history of blood clots regardless of other inclusion criteria.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because:\n\nFor the Primary Trial:\n- Black men are eligible for the primary trial according to the given inclusion criteria.\n\nFor the Secondary Trial:\n- Black men with ECOG <=2 and normal ANC and PLT counts are excluded from the secondary trial.\n\nHowever, the information in the primary CTR does not specify any exclusion of black men in the trial. Therefore, the statement contradicts the information in both primary and secondary CTRs.</s>"
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots aren't eligible for the primary trial but excluded from the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots aren't eligible for the primary trial but excluded from the secondary trial\" is not directly entailed by the information present in either CTR. \n\nIn the primary trial CTR, there is no explicit mention of race as an eligibility criterion. The inclusion criteria for the primary trial state that patients must have ECOG performance status 0-2, and ANC and PLT must meet certain thresholds. The exclusion criteria for this trial mention having a history of blood clots as a reason for exclusion, but it does not state that Black men are excluded from the study.\n\nIn the secondary trial CTR, there is also no mention of race as an inclusion or exclusion criterion. The inclusion criteria include having an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and having a complete blood count (CBC) and basic metabolic panel within 6 months. The exclusion criteria mention having a history of liver or kidney failure, allergies to iodine containing products, and psychiatric or addictive disorders as reasons for exclusion, but it does not state that Black men are excluded from the study.\n\nTherefore, the statement that \"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots aren't eligible for the primary trial but excluded from the secondary trial\" is not directly entailed by the information present in either CTR.</s>",
        "contradict": "The statement that \"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots aren't eligible for the primary trial but excluded from the secondary trial\" is contradictory to the information presented in the CTRs. \n\nIn the primary CTR, Black men are specifically stated to be eligible for the trial, under the inclusion criteria. They do not appear in the exclusion criteria for the primary trial. \n\nIn the secondary CTR, no demographic information is provided regarding eligibility or exclusion of Black men. However, based on the provided inclusion criteria for the secondary trial (age >18 years, ECOG 0-2, and signed informed consent), it appears that Black men would be eligible for the secondary trial, assuming they meet the other requirements. \n\nTherefore, the statement that Black men with the specified characteristics are excluded from the secondary trial while ineligible for the primary trial is contradictory to the information in the CTRs.</s>"
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "The primary trial includes black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots, whereas the secondary trial excludes them.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial includes black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots, whereas the secondary trial excludes them\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial includes patients with cytologically/histologically documented locally advanced or metastatic breast cancer, who meet certain inclusion criteria, including having an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n2. The primary trial also states that patients must have acceptable organ function, as defined by specific laboratory parameters, including absolute neutrophil count (ANC) >1.5 x 10^9/L and platelets (PLT) >100 x 10^9/L.\n3. The primary trial excludes patients with a history of blood clots.\n4. The secondary trial excludes patients based on specific criteria, which includes having a history of \"blood clots\".\n5. The term \"black men\" is not mentioned in the primary trial inclusion criteria, but there is no information in the provided CTRs that would contradict the inclusion of black men in the trial.\n6. Therefore, the statement that the primary trial includes black men with an ECOG <=2, ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots, whereas the secondary trial excludes them, is entailed by the information in the CTRs, as the primary trial includes all the specified criteria for inclusion in the trial except for race, and the secondary trial explicitly states the exclusion of black men based on a different trial design.</s>",
        "contradict": "The primary trial allows inclusion of patients who are men and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2. However, the secondary trial explicitly excludes men. The statement, therefore, contradicts the information present in both CTRs. The primary trial also specifies certain laboratory parameters for inclusion, including ANC >1.5 x 10^9/L and PLT >100 x 10^9/L. The secondary trial does not mention these specific values, and it also excludes patients with a history of blood clots. The statement's claim about the absence of prior history of blood clots for men in the primary trial, thus, conflicts with the exclusion criterion in the secondary trial.</s>"
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in the primary trial were recorded as having heart related adverse events,\" is entailed by the data in the primary CTR's Adverse Events section since none of the listed adverse events include heart-related conditions such as myocardial infarction, atrial fibrillation, cardiac failure, cardiogenic shock, or pericardial effusion. The percentage of heart-related adverse events is also lower in the primary trial (2.47%) compared to the secondary trial (11.92% in total between Cardiac failure, Cardiogenic shock, Atrial fibrillation, and Pericardial effusion).\n\nThe statement \"whereas many patients in the secondary trial experienced several different heart related issues,\" is also entailed by the data in the secondary CTR's Adverse Events sections. This is indicated by the higher percentage of heart-related adverse events in the secondary trial, as mentioned in the statement, and the presence of multiple heart-related conditions (myocardial infarction, atrial fibrillation, cardiac failure, cardiogenic shock, and pericardial effusion).</s>",
        "contradict": "The statement \"None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues\" is contradicted by the information in the CTRs because in the primary trial, two patients did experience neurotoxicity, which is a known cardiac adverse event, and one patient experienced cardiac failure in the secondary trial. Therefore, both trials reported instances of heart related adverse events, contrary to the claim in the statement.</s>"
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "None of the patients in the primary trial weren't recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that there were no heart-related adverse events in the primary trial, as evidenced by the absence of such events in the provided list of adverse events for the primary trial, with a total of 6 events and none of them being heart-related.\n\nAdditionally, the expert's statement implies that there were heart-related adverse events in the secondary trial, as indicated by their statement that \"many patients in the secondary trial experienced several different heart related issues.\" This is confirmed in the CTRs, with a greater total number of adverse events (25) and multiple types of heart-related issues being reported (cardiac failure [1.92%], cardiogenic shock [1.92%], palpitations [2.04%], and pericardial effusion [8.16%]). \n\nTherefore, the statement is entailed by the information present in the CTRs as it accurately reflects the data provided and does not contradict it.</s>",
        "contradict": "The expert's statement asserts that no heart related adverse events were recorded for patients in the primary trial, while patients in the secondary trial experienced several heart related issues. However, the CTRs data reveals that in the primary trial, 1 patient (1.23%) had neurotoxicity, which is a condition that can involve cardiac symptoms, and 1 patient (1.23%) had cardiac failure and cardiogenic shock, which are clearly heart related adverse events. In the secondary trial, while several patients had heart related conditions such as cardiogenic shock, right ventricular failure, and pericardial effusion, the number of patients with heart related events is lower than stated in the expert's claim (11/81 in the primary trial vs 7/52 in the secondary trial, if we include patients with neurotoxicity in the primary trial). The contradiction arises from the misinterpretation or misstatement of the data in the CTRs by the expert.</s>"
    },
    "e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "Many patients in the secondary trial experienced several different heart related issues whereas none of the patients in the primary trial were recorded as having heart related adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Many patients in the secondary trial experienced several different heart related issues whereas none of the patients in the primary trial were recorded as having heart related adverse events\" is entailed by the CTRs as follows:\n\n1. The secondary trial had a higher total percentage of patients experiencing adverse events, 38.46% compared to 7.41% in the primary trial.\n2. The secondary trial had a higher number of patients who experienced different types of heart related adverse events, such as cardiac failure (1.92%), cardiogenic shock (1.92%), and pericardial effusion (8.16%).\n3. In contrast, the primary trial did not report any cases of cardiac failure, cardiogenic shock, or pericardial effusion.\n4. The primary trial did report cases of neurotoxicity (2.47%) and colitis (1.23%), but neither condition is considered heart related.\n\nThus, the statement's assertion that \"Many patients in the secondary trial experienced several different heart related issues whereas none of the patients in the primary trial were recorded as having heart related adverse events\" can be entailed by the CTRs as the secondary trial had more patients with heart related adverse events than the primary trial and none of the patients in the primary trial were recorded to have any heart related issues.</s>",
        "contradict": "The statement does not contradict the CTR information outright, but it may be misleading without additional context. While it is true that more patients in the secondary trial experienced heart-related adverse events, and no patients in the primary trial had heart-related events reported, the specific adverse events differed between the trials. The secondary trial included incidents of cardiac failure, cardiogenic shock, pericardial effusion, and right ventricular failure. In contrast, the primary trial reported neurotoxicity, colitis, multiple sclerosis relapse, community-acquired pneumonia, and local infection reservoir area as adverse events. Therefore, while some patients in the secondary trial did experience heart-related issues, it is not accurate to claim that \"many patients\" did, as the statement suggests. Furthermore, it is crucial to note that the absence of heart-related adverse events in the primary trial does not equate to an absence of risk; it only indicates that no such events were reported during that trial.</s>"
    },
    "407369fa-92ba-4994-8a0f-d372995f3241": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02699983",
        "Secondary_id": "NCT00994279",
        "Statement": "Neither the primary trial or the secondary trial require participants to practice yoga.",
        "Label": "Contradiction",
        "entail": "The primary trial involves two intervention groups: Group I receiving the SparkPeople Program and Fitbit monitoring device, and Group II receiving only a weight loss handout and a Fitbit activity monitor initially, with the SparkPeople treatment administered afterward. The yoga intervention is not mentioned in the primary trial's intervention sections for either group. \n\nThe secondary trial describes two separate interventions: Arm 1 with the yoga intervention and Arm 2 with the educational wellness group. Neither of these arms is part of the primary trial, and the statement is not about the secondary trial's interventions. \n\nTherefore, as neither the primary nor the secondary trial requires participants to practice yoga, the statement is entailed by the information contained in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because, in the primary trial, Group I (SparkPeople Program) includes a behavioral dietary intervention that does not specify yoga but uses the SparkPeople web-based program. In Intervention 1 of the secondary trial, Arm 1 (Yoga Intervention) clearly states that participants receive yoga sessions. Therefore, although neither the primary trial nor the statement explicitly requires participants in the primary trial to practice yoga, participants in one arm of the secondary trial do receive a yoga intervention.</s>"
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.",
        "Label": "Entailment",
        "entail": "The statement that the primary and secondary trials evaluate response rates but with a focus on different sites (CNS vs tumor) and using distinct treatments, is entailed by the information in the CTRs. \n\nIn the primary trial CTR, the outcome measurement is explicitly stated as the Central Nervous System (CNS) objective response rate. This measurement includes assessment of complete and partial responses related to measurable and non-measurable CNS lesions, as well as the absence of progression in extra-CNS disease. The treatment regimen involves Carboplatin, Bevacizumab, and Trastuzumab (if HER2+).\n\nIn the secondary trial CTR, the outcome measurement is stated as Objective Response Rate according to RECIST v1.0 for target lesions and assessed by MRI. This includes complete response, partial response, and overall response definitions based on the sum of the longest diameter of target lesions. The treatment regimen is NKTR-102 given on different schedules (q14 days or q21 days).\n\nThe statement's assertion that the trials evaluate response rates but differ in focus and treatment aligns with the information provided in these CTRs. The CNS response rate focus is evident in the primary trial, while the secondary trial focuses on tumor response. Additionally, the treatments used in the trials differ.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both evaluate response rates\" is consistent with the information in the CTRs. However, the statement \"however, the primary trial studies CNS response, whereas the secondary trial studies tumor response\" cannot be definitively determined from the given CTR information. \n\nThe reason being, the CTR for the primary trial specifies that the outcome measurement is \"Central Nervous System (CNS) Objective Response Rate,\" which does indeed imply CNS response. However, the CTR for the secondary trial only mentions \"Objective Response Rate (ORR)\" without further specification as to which type of response is being evaluated, be it CNS or tumor response. Therefore, the statement cannot be confirmed to be an entailed relationship based on the available CTR information alone. \n\nMoreover, \"the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments\" is an incomplete representation of the facts as presented in the CTRs. The statement is partially correct in that the trials do test different treatments, but it fails to acknowledge the specific type of response being evaluated in each trial. \n\nHence, the statement cannot be considered an entailed relationship based on the given CTR information, and it contains potential contradictions.</s>"
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "The primary trial and the secondary trial both don't evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial both don't evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments\" is entailed by the CTRs as follows:\n\n- The primary trial does not explicitly mention the term \"response rate,\" but it evaluates the percentage of participants who achieved CNS complete or partial response, which aligns with the statement's description of the primary trial assessing CNS response.\n\n- Similarly, the secondary trials do not mention the term \"response rate\" in their outcome measurement, but they measure the percentage of subjects with either complete response, partial response, or overall response according to RECIST v1.0 for target lesions, indicating that they are studying tumor response.\n\n- The statement correctly points out that the trials test different treatments. The primary trial investigates Carboplatin, Bevacizumab, and Trastuzumab (if HER2+), while the secondary trials test NKTR-102 under different dosing schedules.\n\nThus, the statement's content is a logical implication of the information presented in the CTRs.</s>",
        "contradict": "The statement asserts that both trials do not evaluate response rates. However, the primary trial explicitly states that it measures CNS objective response rate using the defined criteria. Therefore, the statement is contradictory to the information provided in the CTRs.</s>"
    },
    "05e50a3d-d5b2-4fe6-9709-c884c89c5f71_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "The primary trial studies CNS response, whereas the secondary trial studies tumor response and they both evaluate response rates, additionally, they test different treatments.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial studies CNS response, whereas the secondary trial studies tumor response and they both evaluate response rates, additionally, they test different treatments\" is entailed by the information in the CTRs as follows: \n\n1. Both trials evaluate response rates:\n   - The primary trial measures CNS objective response rate, which includes complete and partial responses.\n   - The secondary trial measures Objective Response Rate (ORR) according to RECIST v1.0 for target lesions. \n\n2. Different response types evaluated:\n   - The primary trial focuses on CNS response, while the secondary trial assesses overall tumor response, specifically target lesions.\n\n3. Different treatments tested:\n   - In the primary trial, participants received Carboplatin, Bevacizumab, and Trastuzumab.\n   - In the secondary trial, subjects received treatment with NKTR-102 with two different schedules (q14 days and q21 days). \n\nTherefore, the statement is in harmony with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement does not provide sufficient detail to definitively establish semantic entailment with the CTRs. While both trials evaluate response rates, the specific outcome measurements differ between CNS response in the primary trial and tumor response according to RECIST v1.0 in the secondary trial. The statement implies that the trials test different treatments, but the primary trial only specifies three treatments within one arm, whereas the secondary trial only mentions NKTR-102 without specifying any other treatments. Without further context or clarification, it's impossible to confirm that the statement is an entailed consequence of the CTRs.</s>"
    },
    "59fd53e4-b38c-4018-bafc-6fd7f7becebe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their blood vessels.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial suffered from a blood clot\" is entailed by the data in the CTR under the Adverse Events section for the primary trial, as there is one instance (1/31) of reported thrombosis (a type of blood clot) in the CTR.</s>",
        "contradict": "The statement \"1 patient in the primary trial suffered from a blood clot\" cannot be definitively contradicted by the provided CTR as thrombosis is listed as an adverse event in the report. However, the statement's specificity is not explicitly supported within the data presented in the CTR. It mentions one occurrence of thrombosis among 31 participants, but it does not provide enough context to determine which patient this applies to or whether the event caused any symptoms or complications that would align with the expert's statement about a \"blood clot blocking their blood vessels.\"\n\nIn summary, there is insufficient evidence to establish semantic entailment or contradiction between the statement and the provided CTR.</s>"
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Nausea or Anaemia in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"There were no cases of Cellulitis, Nausea or Anaemia in the primary trial\" is entailed by the information present in the CTRs as none of these adverse events are mentioned under the Adverse Events section of the primary trial. Therefore, the absence of these conditions in the primary trial is consistent with the clinical trial data and does not contradict the provided descriptions.</s>",
        "contradict": "The expert's statement \"There were no cases of Cellulitis, Nausea or Anaemia in the primary trial\" is contradicted by the information present in the CTRs because there is no mention of these conditions in the \"Adverse Events\" section of the primary CTR. However, the presence or absence of these conditions cannot be inferred directly from the given data. The expert's statement assumes that the absence of Cellulitis, Nausea, and Anaemia implies that these conditions did not occur in the trial; however, the CTR only reports the occurrence of specific adverse events that were recorded. The absence of reporting for certain adverse events does not necessarily imply their absence in the trial.</s>"
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There weren't no cases of Cellulitis, Nausea or Anaemia in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't no cases of Cellulitis, Nausea or Anaemia in the primary trial\" is entailed by the information in the CTRs because the CTR for the primary trial does not report any cases of Cellulitis, Nausea, or Anaemia under the Adverse Events section. The statement correctly reflects the absence of these adverse events from the primary trial based on the data provided in the CTR.</s>",
        "contradict": "The expert's statement \"There weren't no cases of Cellulitis, Nausea or Anaemia in the primary trial\" is contradicted by the CTR data because:\n\n1. Although there were no instances of Cellulitis recorded in the Adverse Events section of the primary trial, Nausea was mentioned in the secondary trial, not the primary one.\n2. Anemia was not listed as an adverse event in either the primary or secondary trials.\n3. Vertigo and Infected lymphocele, which were present in the primary trial, were not specifically excluded in the expert's statement.</s>"
    },
    "c17eaeab-4e99-4cc4-8681-ae6ccddba572_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "In the primary trial there were no cases of Cellulitis, Nausea or Anaemia.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial there were no cases of Cellulitis, Nausea or Anaemia\" can be entailed by the information present in the CTRs if there are no instances reported of these conditions under the Adverse Events section of the primary trial. The CTR provides specific information on adverse events in the primary trial, including the number and percentage of participants experiencing Vertigo, Infected lymphocele, Ejection fraction decreased, and Lymphoedema. The absence of Cellulitis, Nausea, or Anaemia is not explicitly stated, but since there are no reports of these conditions, the statement is entailed by the provided CTR information.</s>",
        "contradict": "The statement \"In the primary trial there were no cases of Cellulitis, Nausea or Anaemia\" contradicts the information present in the CTR for the Adverse Events section of the Primary Trial, as there is no mention of these conditions in the provided data (zero occurrences reported for Cellulitis and Nausea, and no specific mention of Anaemia in the listed adverse events). However, for the Intervention and Eligibility Criteria sections, the CTR does not provide sufficient information to determine whether the statement holds true or false. For instance, the absence of these conditions might not be directly related to the trial interventions, patient inclusion criteria, or other factors. Thus, the statement is contradictory to the information available in the Adverse Events section, but it cannot be definitively determined as true or false based on the given CTR information alone for the other sections.</s>"
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "Label": "Entailment",
        "entail": "The statement \"Candidates for the primary trial must not be currently receiving amiodarone or have received amiodarone in the 6 months preceding the first dose of study treatment\" is directly stated in the Exclusion Criteria section of the first CTR. Therefore, this statement is entailed by the information present in the CTRs.\n\nIn addition, the statement \"Candidates for the primary trial must have adequate renal and hepatic function\" is indirectly entailed by the Inclusion Criteria of both CTRs. Although not explicitly stated, adequate renal and hepatic function are prerequisites to meet the eligibility criteria as they are necessary for the patient's overall health and ability to participate in the trial.</s>",
        "contradict": "The given statement is not contradictory to the inclusion and exclusion criteria of the Primary Trial CTR as it only addresses two specific points: (1) renal and hepatic function, which matches the CTR, and (2) use of amiodarone, which is an exclusion criterion for this trial. However, the CTR also includes additional exclusion criteria for amiodarone, such as receiving it within 6 months prior to screening or receiving it concurrently. Therefore, the given statement is not a contradiction but an incomplete representation, as it does not include all the exclusion criteria related to amiodarone stated in the CTR.</s>"
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Candidates for the primary trial must have adequate renal and hepatic function, and must be currently receiving amiodarone or have received amiodarone in the 6 months",
        "Label": "Contradiction",
        "entail": "The CTR states that patients with \"acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormalities\" are excluded from the study. However, it also specifies an exception for patients with stable chronic liver disease, as determined by the investigator. The statement does not contradict the CTR, as it mentions that the candidates for the primary trial \"must have adequate renal and hepatic function\" while also acknowledging an exception for those currently receiving or previously having received amiodarone. The statement's requirement for candidates to currently be receiving or have received amiodarone within the past six months is not explicitly stated in the CTR as an exclusion criterion; however, it is an exclusion criterion mentioned in the CTR for the secondary trial. Since this statement does not contradict the information provided in the CTRs and is related to a separate trial, it can be considered entailed.</s>",
        "contradict": "The patients with amiodarone use are excluded from the primary trial according to the CTR. Therefore, the statement \"must be currently receiving amiodarone or have received amiodarone in the 6 months prior to screening\" contradicts the inclusion criteria stated in the CTR.</s>"
    },
    "621d06ac-12dd-42c2-a012-15c1d94a4f0b_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00952692",
        "Statement": "Adequate renal and hepatic function, is necessary for participants of the primary trial and they must not be currently receiving amiodarone or have received amiodarone in the 6 months",
        "Label": "Entailment",
        "entail": "The statement entails that participants in the primary trial must have adequate renal and hepatic function and should not currently be receiving or have received amiodarone within the past 6 months. The CTRs specify inclusion criteria that require patients to have adequate renal and hepatic function as evidenced by normal creatinine levels, serum bilirubin levels within the normal limits, and both AST and ALT levels below 1.5 times the ULN, unless the patient has liver metastasis in which case a serum bilirubin level within 1.5 times the ULN and both AST and ALT levels below 3 times the ULN are acceptable. Additionally, the CTRs exclude patients receiving amiodarone or having received it within the past 6 months. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Adequate renal and hepatic function, is necessary for participants of the primary trial and they must not be currently receiving amiodarone or have received amiodarone in the 6 months preceding study entry\" is generally in line with the CTR's exclusion criteria. However, it contradicts the CTR when it comes to patients with liver metastases, as the CTR accepts these patients with a serum bilirubin level <1.5 times the ULN and both AST and ALT levels <3 times the ULN. Additionally, the CTR does allow current use of amiodarone if it was initiated more than three weeks before the first ASCI administration.</s>"
    },
    "021e79d2-ce70-43cf-aac9-fa8d4c8d3770": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot\" can be entailed by the information present in the CTRs, although Athlete's foot is not explicitly mentioned, because:\n\n1. The statement correctly identifies that there are infections reported in the primary trial.\n2. The types of infections mentioned in the statement (pneumonia, urinary tract) are explicitly stated in the CTR.\n3. The presence of other infections not listed in the CTR does not contradict the information provided. The absence of Athlete's foot in the CTR does not negate the possibility that it might have been observed in the trial but not reported.\n\nTherefore, the statement can be considered entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot\" cannot be directly contradicted by the information present in the CTRs as Athlete's foot is not listed as an adverse event in either the primary or secondary trial CTRs. The statement does extend beyond the information provided in the CTRs, as it adds an additional type of infection not reported in the trials.</s>"
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.",
        "Label": "Entailment",
        "entail": "The statement \"The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga\" is entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, cohort 1 (Arm I) underwent Hatha yoga therapy with a duration of 90 minutes, twice weekly for 12 weeks and were encouraged to practice yoga at home, whereas cohort 2 (Arm II) was wait-listed and instructed not to begin any yoga practice during the study period.\n\nThus, the statement correctly conveys the difference between the two cohorts in terms of their participation in yoga practice as described in the provided CTR information.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs. However, it could be considered an oversimplification, as it fails to capture the full extent of the differences between the two intervention groups. While it's true that one group participated in Hatha yoga and the other did not, the CTRs also specify important details such as the duration, frequency, and encouragement for home practice that further distinguish the two groups. Thus, the statement does not fully capture the entailment relationship, as it lacks the specificity of the CTRs.</s>"
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial isn't that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.",
        "Label": "Contradiction",
        "entail": "The statement \"The difference between the two cohorts of the primary trial isn't that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga\" is entailed by the information present in the CTRs because:\n\n1. The statement acknowledges two cohorts in the primary trial, which correlates with the description in the CTR. \n2. The first cohort is described as receiving Hatha yoga therapy, which is explicitly stated in the CTR under Intervention 1 for Arm I.\n3. The second cohort is described as being wait-listed and instructed to refrain from yoga practice, which is detailed in the CTR under Intervention 2 for Arm II.\n4. The statement does not contradict the provided descriptions in the CTRs, as it accurately characterizes the differences between the arms without introducing any false information. \n5. The statement's assertion can be logically derived from the information within the CTRs since it correctly identifies the distinct interventions for each cohort.</s>",
        "contradict": "The statement \"The difference between the two cohorts of the primary trial isn't that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga\" can be contradicted by the information present in the CTRs because, although it's true that both cohorts differed in their participation of yoga, the statement oversimplifies this difference and neglects other significant differences between the groups - namely, the active intervention (yoga) versus the control group (wait-list). The statement fails to capture the essence of the clinical trial design, as it doesn't convey the experimental nature and the purpose of the wait-list group.</s>"
    },
    "06aa0fbc-fe49-4715-88cc-507646f6323f_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 2 abstained from yoga, whereas cohort 1  participated in Hatha yoga.",
        "Label": "Entailment",
        "entail": "The statement entails that in the primary trial, cohort 1 underwent Hatha yoga intervention while cohort 2 did not. The CTRs provide this information explicitly by stating that Arm I of the primary trial involved Hatha yoga therapy sessions, and participants were encouraged to practice yoga at home. In contrast, Arm II of the primary trial was a wait-list control, with patients instructed to refrain from practicing yoga during the study period. This difference aligns with the expert's statement. Additionally, there is no contradictory information present in the CTRs that would undermine the entailment.</s>",
        "contradict": "The statement is not directly contradictory to the information presented in the CTRs, but it may be considered incomplete or imprecise. While it is true that cohort 1 participated in Hatha yoga and cohort 2 did not, the statement does not capture important details such as the duration, frequency, and intensity of the yoga practice in cohort 1. Additionally, the statement does not mention that patients in cohort 1 were encouraged to practice at home, or that they recorded their practice time. These details are crucial for a thorough understanding of the difference between the two cohorts and may impact any potential entailments.</s>"
    },
    "21947261-bbef-4d3a-adda-02bb4a91a3ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.",
        "Label": "Contradiction",
        "entail": "The primary trial includes patients with histologically confirmed breast cancer that is hormone receptor positive (HR+), which includes those with both estrogen receptor (ER+) and/or progesterone receptors (PgR+), as stated in the inclusion criteria. Similarly, the secondary trial includes patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast, but also permits those with HR+ (ER+ and/or PgR+) disease. Therefore, both trials encompass PgR+ breast cancer cases, and this statement can be entailed by the data presented in the CTRs.</s>",
        "contradict": "The primary trial includes patients with HR+ (estrogen receptor and/or progesterone receptors positive) breast cancer. However, it does not specifically mention the requirement of PgR+ status in its inclusion criteria. The secondary trial accepts patients who have histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast and who are PgR+. The statement, thus, implies that both trials share this common criterion for PgR status. However, the discrepancy lies in the fact that the primary trial does not explicitly require PgR+ status, and the statement's assumption could be a potential contradiction to the information in the primary CTR.</s>"
    },
    "71daae7c-3ee5-4451-91e2-273d8ff55aae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial\" is entailed by the information in the CTRs since the secondary trial reported a lower total number of adverse events (25.91%) compared to the primary trial (25.84%). The specific adverse event counts for each trial, as presented in the CTRs, support this conclusion.</s>",
        "contradict": "The statement cannot be definitively determined to be true or false based on the provided information alone, as the severity and types of adverse events differ between the two trials, which could impact the overall comparison. The statement only mentions the total number of patients experiencing adverse events without specifying the severity or type, making a direct comparison problematic. Additionally, some adverse events are present in both trials but have different occurrence rates, which further complicates the comparison. Therefore, the statement's contradiction or entailment relationship to the CTR data cannot be definitively established without more context or additional information.</s>"
    },
    "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Every single patient in the primary trial experienced at least 1 adverse event.",
        "Label": "Entailment",
        "entail": "100.00% of patients in the primary trial experienced at least one adverse event, as indicated by the total number of adverse events reported (39) and the number of patients (39). The statement made by the expert is an inevitable conclusion from the data presented in the CTR.</s>",
        "contradict": "The statement \"Every single patient in the primary trial experienced at least 1 adverse event\" is not directly contradicted by the provided CTR data. However, the statement is not entailed by the data either because the statement applies to each individual patient having experienced any adverse event, whereas the data lists specific adverse events for each patient without indicating that every patient had only one adverse event. The data does not contradict the statement, but it does not provide enough information to definitively establish entailment.</s>"
    },
    "7d22937b-9823-45fa-a914-261f993e4d64": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient developed issues with their vision.",
        "Label": "Entailment",
        "entail": "The statement \"Throughout the primary trial, one patient developed issues with their vision\" can be entailed by the information present in the CTR under Adverse Events 1 for the Primary Trial, specifically the occurrence of \"Cataract\" in one patient out of 214. The term \"issues with their vision\" can be understood to include the condition of cataract and thus, the statement is consistent with the CTR information.</s>",
        "contradict": "The statement, \"Throughout the primary trial, one patient developed issues with their vision,\" contradicts the information in the CTRs if no cases of cataract, macular fibrosis, or other vision-related adverse events are reported in the sections on Adverse Events 1 and Adverse Events 2. In the provided information, no such events were reported. However, the expert's statement implies that a vision issue occurred for a patient, making it contradictory to the CTR data.</s>"
    },
    "507a4189-4905-4752-8348-d715a5ce3962": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01940497",
        "Statement": "There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" can be entailed by the information present in the CTRs if we interpret \"allergic reactions\" as an umbrella term that includes the reported adverse events of \"anaphylactic shock\" in both trials. Accordingly, the occurrence of 1 anaphylactic shock in cohort 1 (as per the Primary Trial's Adverse Events 1) and 2 anaphylactic shocks in cohort 2 (as per the Secondary Trial's Adverse Events) would imply a difference of 3 instances, which matches the statement.</s>",
        "contradict": "The statement \"There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2\" cannot be directly contradicted by the information provided in the CTRs, as the CTRs themselves do not mention the number of allergic reactions occurring in each cohort. However, the statement is contradictory if we assume that the expert meant to refer to anaphylactic shocks as the type of allergic reaction, since there was only 1 occurrence in both cohorts as stated in the CTRs.</s>"
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The statement's claim that \"CoQ10 reduces the level of fatigue\" aligns with the information in the CTR that Arm 1, which received CoQ10, had a lower mean fatigue score (6.96) compared to Arm 2, which received the placebo (8.33).\n\n2. The difference in fatigue scores between CoQ10 and placebo arms in the primary trial is statistically significant, as indicated by the lower standard error in the Least Squares Mean for Arm 1.\n\n3. Both trials used the same fatigue assessment measure, POMS-F, ensuring comparability between the primary trial results and the expert's statement.\n\n4. There is no contradictory information in the CTRs that would negate the entailment relationship between the expert's statement and the trial information.</s>",
        "contradict": "The statement made by the clinical trial expert appears to contradict the CTRs' information because the CTRs do not directly report a statistically significant difference in fatigue levels (as measured by POMS-F scale) between Arm 1 (CoQ10 & Vitamin E) and Arm 2 (Placebo-Vitamin E) groups. Although Arm 1's least squares mean value is lower than Arm 2's, the differences between the means do not meet the conventional threshold for significance (p < 0.05) based on reported standard errors. Therefore, the statement's implication that CoQ10 definitively reduces fatigue compared to a placebo is not supported by the CTRs.</s>"
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "The primary trial results don't indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial results don't indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo\" is entailed by the CTRs as follows:\n\n1. Both CTRs provide the Least Squares Mean (LSM) and Standard Error (SE) for each group (CoQ10 & Vitamin E, and Placebo-Vitamin E) in relation to the POMS-F fatigue scale, which ranges from 0 to 28, with higher values indicating greater fatigue.\n2. In the primary CTR, the LSM for Arm 1 (CoQ10 & Vitamin E) is 6.96 (0.71), while for Arm 2 (Placebo-Vitamin E) it is 8.33 (0.79).\n3. To evaluate if CoQ10 reduces the level of fatigue compared to the placebo, we would need to calculate and compare the difference between the LSMs and their 95% Confidence Intervals (CIs) or perform a statistical test (e.g., t-test or ANOVA).\n4. The CTRs do not provide sufficient information for these analyses, so the comparison cannot be directly determined from the data in the CTRs.\n5. The expert's statement \"The primary trial results don't indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo\" is a reasonable conclusion based on the available data in the CTRs, as no significant difference in fatigue levels has been proven between the two study arms.</s>",
        "contradict": "Despite the expert's statement suggesting no reduction in fatigue levels for the CoQ10 group compared to the placebo, the primary trial results do provide evidence of a difference in mean fatigue levels between the two arms. The CoQ10 group had a lower least squares mean (6.96) compared to the placebo group (8.33). This difference, even if not statistically significant at a certain threshold, indicates a trend towards lower fatigue levels in the CoQ10 group. Consequently, the statement contradicts the findings from the CTRs as presented.</s>"
    },
    "24001e83-6a8c-4f67-9c24-55dc285c4cc2_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "CoQ10 reduces the level of fatigue experienced by patients compared to a placebo according to the primary trial results.",
        "Label": "Entailment",
        "entail": "The statement \"CoQ10 reduces the level of fatigue experienced by patients compared to a placebo according to the primary trial results\" can be entailed by the information present in the CTRs because:\n\n1. The CTR specifies that the primary outcome measurement for the trial is the effect of CoQ10 on fatigue as measured by the POMS-F scale.\n2. The trial reports the least squares means and standard errors for Arm 1 (CoQ10 & Vitamin E) and Arm 2 (Placebo & Vitamin E) for the same time frame (24 weeks). The lower Least Squares Mean (6.96, SD 0.71) value in Arm 1 compared to Arm 2 (8.33, SD 0.79) indicates that patients in Arm 1 reported lower levels of fatigue on average, supporting the expert's statement.\n3. The CTR does not contain contradictory data, such as evidence of more severe adverse events or other factors that might offset the difference in fatigue levels between the groups.\n\nTherefore, the information in the CTRs supports the statement that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo based on the primary trial results.</s>",
        "contradict": "The statement \"CoQ10 reduces the level of fatigue experienced by patients compared to a placebo according to the primary trial results\" cannot be directly contradicted by the information present in the CTRs. However, it may be misleading without additional context. The CTRs only provide data on the least squares mean and standard error of POMS-F fatigue scores for the CoQ10 with Vitamin E and Placebo-Vitamin E groups. The statement implies that the difference in means between the two groups is statistically significant and clinically meaningful, but the CTRs do not directly indicate this information. To assess whether the statement is entailed by the CTRs, further analysis, such as statistical testing or interpretation of effect size, is required.</s>"
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "filgrastim is the only drug in the primary trial given by subcutaneous injection.",
        "Label": "Entailment",
        "entail": "The statement \"filgrastim is the only drug in the primary trial given by subcutaneous injection\" can be entailed by the information in the CTR as follows:\n\nThe CTR specifies that \"filgrastim is given SC on days 2-7 for 16 weeks.\" The term \"SC\" denotes subcutaneous injection, meaning that filgrastim is indeed given by subcutaneous injection in the trial. Furthermore, the CTR does not mention any other drug in the primary trial being given by subcutaneous injection. Therefore, the statement that \"filgrastim is the only drug in the primary trial given by subcutaneous injection\" is an accurate conclusion based on the information in the CTR and entails no contradiction or error.</s>",
        "contradict": "The expert statement \"filgrastim is the only drug in the primary trial given by subcutaneous injection\" can be contradicted by the CTR information as filgrastim is not the only drug given by subcutaneous injection in the primary trial. Paclitaxel, while given intravenously in the majority of the regimen, also has a requirement for subcutaneous administration for filgrastim support. Specifically, filgrastim is given SC on days 2-7 for 16 weeks.</s>"
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "Filgrastim isn't the only drug in the primary trial given by subcutaneous injection.",
        "Label": "Contradiction",
        "entail": "The statement \"Filgrastim isn't the only drug in the primary trial given by subcutaneous injection\" can be entailed by the information present in the CTR as follows: \n\nThe CTR for the primary trial specifies that filgrastim is given SC on days 2-7 for 16 weeks. However, it also mentions that sunitinib malate, a component of the chemotherapy regimen, is given PO (orally). Although the mode of administration (PO vs. SC) for sunitinib malate is different, it does not negate the fact that another drug (filgrastim) is administered by a subcutaneous injection in the primary trial in addition to the oral and intravenous administrations of the chemotherapies. Thus, the expert's statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"Filgrastim isn't the only drug in the primary trial given by subcutaneous injection\" can be contradicted by the information present in the CTR because filgrastim is explicitly mentioned as the only drug given by subcutaneous injection in the primary trial.</s>"
    },
    "d179396d-94fe-465f-a4f1-e7c3291a0a9a_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "The primary trial only gives filgrastim by subcutaneous injection.",
        "Label": "Entailment",
        "entail": "The expert's statement implies that filgrastim was not given through any means other than subcutaneous injection in the primary trial. The CTR specifies that filgrastim is indeed given subcutaneously in the primary trial (as indicated by the phrase \"filgrastim: Given SC\"). Therefore, the expert's statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement made by the expert contradicts the information in the CTR for the primary trial, as the CTR specifies that filgrastim is given by subcutaneous injection in the secondary phase of the trial following chemotherapy, but the expert's statement incorrectly states that filgrastim is only given in the primary trial.</s>"
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"More patients in the secondary trial suffered from edema in their limbs, compared to patients in the primary trial\" is entailed by the data presented in the CTRs since the secondary trial reported 1 instance of edema limbs in 56 total adverse events of the primary trial (1.79%), while the secondary trial reported 2 instances of edema limbs in 70 total adverse events (2.86%). Therefore, the frequency of edema limbs in the secondary trial is indeed greater than in the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the CTRs provide different frequencies of adverse events between the two trials, but they do not mention any specific information about edema in the limbs for either group. Therefore, we cannot directly compare the number of patients with edema in the primary and secondary trials based on the given CTR data alone. To determine whether the statement is entailed by the CTRs, we would need more specific information about the occurrence and frequency of edema in the trials.</s>"
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in the secondary trial didn't suffer from oedema in their limbs, compared to patients in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"More patients in the secondary trial didn't suffer from edema in their limbs, compared to patients in the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary trial, there was one patient (1.43%) who suffered from edema in the secondary trial, whereas in the primary trial, there was only one patient (1.79%) who suffered from this adverse event. Therefore, a smaller number of patients in the secondary trial (relative to the primary trial) experienced edema in their limbs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the statement makes a comparison between the number of patients experiencing edema (limbs) between the primary and secondary trials. However, the CTRs do not provide the number of patients in each trial who suffered from edema. The Adverse Events sections only list the total number of adverse events for each trial, including edema, but not the number of patients who experienced this condition. Therefore, it is impossible to determine if fewer patients in the secondary trial suffered from edema based on the provided information.</s>"
    },
    "4b893eeb-80a4-4a83-8df5-b5c668ce55b1_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "Less patients in the primary trial suffered from oedema in their limbs, compared to patients in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Less patients in the primary trial suffered from edema in their limbs, compared to patients in the secondary trial\" can be entailed by the information present in the CTRs if we assume that \"edema\" in the statement refers to the condition mentioned as \"Edema limbs\" in the secondary trial. The adverse event data in the CTRs indicate that 1.43% of patients in the secondary trial experienced edema in their limbs, while no cases were reported in the primary trial. Therefore, a lower incidence of edema in the primary trial compared to the secondary trial is evident from the data provided in the CTRs.</s>",
        "contradict": "The expert's statement is contradictory to the CTRs as neither trial reports adverse events related to edema in the limbs. Therefore, no valid comparison can be made regarding the incidence of limb edema between the primary and secondary trials based on the given information.</s>"
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2\" is entailed by the information in the CTRs because the number of total adverse events in Cohort 1 (4/26 or 15.38%) is greater than the number of total adverse events in Cohort 2 (1/28 or 3.57%).</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the number of adverse events in cohort 1 and cohort 2 varies for specific types of adverse events. According to the provided data, the percentage of adverse events in cohort 1 is higher than that in cohort 2, but the types of adverse events are different. In fact, cohort 1 had more cases of hospitalization for intrapleuric chemotherapy and thoracentesis, acute renal failure, general malaise, and febrile neutropenia. However, cohort 2 had more cases of gastric volvulus. Therefore, the overall count of adverse events is not the only relevant factor when assessing the comparison between the two trials. Instead, the types and their respective occurrences should also be taken into account. Hence, the statement is not an accurate reflection of the information presented in the CTRs.</s>"
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there weren't more adverse events in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that the total number of adverse events in cohort 1 of the primary trial is either equal to or less than the total number of adverse events in cohort 2 of the secondary trial. This is inferred from the CTRs provided, as the total number of adverse events in cohort 1 is 4/26 = 0.1538 * 26 = 3.85%, and the total number of adverse events in cohort 2 is 1/28 = 0.0357 * 28 = 3.57%. Since the percentage in cohort 1 is larger than that in cohort 2, it means that there are fewer actual adverse events in cohort 1 (3.85%) compared to cohort 2 (3.57%), which satisfies the statement's claim. The specific adverse events mentioned in the statement (Febrile neutropenia, Gastric volvulus, General Malaise, Hospitalisation for intrapleuric chemotherapy and thoracentesis, and Acute renal failure) are not directly referenced in the CTRs; however, the statement is only concerned with the total number of adverse events, which is consistent with the CTRs' information.</s>",
        "contradict": "The statement \"In total, there weren't more adverse events in cohort 1 of the primary trial, than in cohort 2\" is contradicted by the information in the CTRs because the total number of adverse events reported in the primary trial for cohort 1 is higher than that reported for cohort 2 (4/26 vs. 1/28). The contradiction lies within the numerical discrepancy in the total number of adverse events reported for each cohort, and the statement implying an equivalence.</s>"
    },
    "44cd16f5-6638-4d82-9121-1941eb8ce4b5_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448279",
        "Statement": "In total there were less adverse events in cohort 2 of the primary trial, than in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if the number of adverse events reported in the primary trial's cohort 1 is greater than in cohort 2. Based on the provided data, there are more adverse events in the primary trial's CTR (4/26 or 15.38%) compared to the secondary trial's CTR (1/28 or 3.57%). Therefore, the statement is entailed by the data in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR data as the number of adverse events in cohort 1 (4/26, or 15.38%) is greater than the number of adverse events in cohort 2 (1/28, or 3.57%). However, it's important to note that not all types of adverse events are listed for both trials, and the absence of certain adverse events in one trial but not the other could also impact the comparison. Inconsistencies like these should be resolved by consulting the full CTRs or contacting the trial authors for clarification.</s>"
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information presented in the CTRs because the first trial (Primary) does not mention the use of FEC in its intervention section, while the second trial (Secondary) explicitly details the usage of FEC in both cohorts, but only after the initial administration of paclitaxel and trastuzumab. Therefore, the assertion that FEC is used in the secondary trial, but not the primary trial, aligns with the provided data.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it may be contradictory depending on the context of the trials and the specific patient populations involved. In the primary trial, FEC is not listed in the intervention section, so according to the provided information, it was not used. In contrast, in the secondary trials, FEC is mentioned in both intervention sections as part of the treatment regimen for each cohort. However, the primary trial may still not contradict the statement, if the trials are distinct and involve different patient populations or disease conditions. Therefore, to definitively determine if the statement contradicts the CTRs, additional context or information is needed.</s>"
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "In the secondary trial, interventions for both cohorts involve the use of epirubicin hydrochloride and cyclophosphamide, which are administered IV as part of the FEC regimen. These agents are also mentioned in the primary trial intervention for cohort 1. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement asserts that \"FEC\" is used in the secondary trial in both cohorts. However, the CTRs indicate that in the primary trial, \"FEC\" is only mentioned in the context of the secondary trial and not as part of the interventions for the two cohorts. Therefore, the statement contradicts the information in the CTRs by implying incorrectly that the primary trial involves the use of FEC in both cohorts.</s>"
    },
    "50ac2c53-3b63-4507-8712-41f8c257b4da_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Both cohorts of the secondary trial used Fluorouracil, epirubicin, and cyclophosphamide (FEC), but not cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Both cohorts of the secondary trial used Fluorouracil, epirubicin, and cyclophosphamide (FEC), but not cohort 1 of the primary trial,\" can be entailed by the information present in the CTRs as follows:\n\n1. In the secondary trial, Intervention 1 states that FEC is used with paclitaxel and trastuzumab, and Intervention 2 states that FEC is used after paclitaxel and trastuzumab.\n\n2. In the primary trial, Intervention 1 does not mention FEC at all.\n\nTherefore, the statement that \"Both cohorts of the secondary trial used FEC, but not cohort 1 of the primary trial\" follows logically from the information provided in the CTRs, as it accurately describes the differences in treatment regimens between the two trials.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because, in the primary trial, the FEC regimen was not administered as an intervention, while in the secondary trial, the FEC regimen was used in both arms (cohort 1 and cohort 2) for four courses, each separated by the administration of paclitaxel and trastuzumab. In the primary trial, no mention of FEC was made as a part of the interventions, making the statement incorrect based on the provided CTR information.</s>"
    },
    "14607d45-9aef-458d-89cc-d47c62c23322": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The patient described in the statement - a patient with histologically confirmed triple-negative breast cancer, no brain metastases, no prior history of autoimmune disease, and no cardiac dysfunction - meets the inclusion criteria for the secondary trial, which involves women with early stage breast cancer (stage I-II) and an American Society of Anesthesiologists (ASA) score of I-II, with no mention of any specific exclusion criteria in the statement that would prevent the patient from being eligible for this trial.\n\nRegarding the primary trial, the patient also meets several of its inclusion criteria - histologically confirmed breast cancer, measurable disease according to RECIST, v1.1, and adequate hematologic and end organ function - without any contradiction. However, the patient does not meet the inclusion criteria for ER-negative, PR-negative, and HER2-negative breast cancer as stated in the primary trial, which is specific to triple-negative breast cancer but also requires the absence of ER, PR, and HER2 expression. Therefore, the patient cannot be conclusively said to be eligible for the primary trial based on the given information alone, but they could potentially still be eligible for the primary trial if they have other characteristics that meet its inclusion criteria and are not excluded by its exclusion criteria.\n\nOverall, the information in the statement can be entailed by the information present in the CTRs if we assume that the patient in question could still potentially meet the full inclusion criteria for the primary trial, even though the statement only explicitly mentions their eligibility for the secondary trial. However, based on the information provided, the patient's eligibility for the primary trial is not a definitive conclusion but rather an uncertainty.</s>",
        "contradict": "The statement cannot be directly contradicted by the primary CTR alone, since the patient's triple-negative breast cancer with no brain metastases and no prior history of autoimmune disease is consistent with the inclusion criteria of the primary trial. However, the patient's history of cardiac dysfunction, which is not specified in the statement but excluded in the primary trial, could make them ineligible. Therefore, the statement does not entail that this specific patient is eligible for both trials.\n\nThe secondary trial's inclusion criteria, however, contradict the statement, as the secondary trial only includes patients with early-stage breast cancer, whereas the patient in the statement is described as having histologically confirmed triple-negative breast cancer, which is a later-stage disease. Thus, based on the given information from the CTRs, the statement can be contradicted.</s>"
    },
    "14607d45-9aef-458d-89cc-d47c62c23322_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, couldn't be eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, couldn't be eligible for both the secondary trial and the primary trial,\" can be entailed by the information present in the CTRs as follows:\n\n1. Both trials require histologically confirmed breast cancer.\n2. Primary trial only includes patients with triple-negative breast cancer, whereas the secondary trial includes patients with any early stage breast cancer.\n3. Primary trial includes patients with measurable disease and locally advanced disease that is not amenable to resection with curative intent, whereas the secondary trial only includes patients with early stage (stage I-II) breast cancer.\n4. Primary trial excludes patients with Brain metastases, whereas the secondary trial does not mention anything about Brain metastases as an exclusion criterion.\n5. Primary trial includes patients with no prior history of autoimmune disease or cardiac dysfunction as exclusion criteria, whereas the secondary trial does not mention these specific conditions as inclusion or exclusion criteria.\n\nTherefore, a patient who meets the criteria stated in the expert's statement, i.e., histologically confirmed triple-negative breast cancer, with no known Brain metastases, and no prior history of autoimmune disease or cardiac dysfunction, cannot be eligible for both trials because they contradict each other in the inclusion and exclusion criteria, specifically the absence of cardiac dysfunction and autoimmune disease in the primary trial versus the lack of mention of these conditions in the secondary trial.</s>",
        "contradict": "The patient described in the statement - a patient with histologically confirmed triple-negative breast cancer, no known brain metastases, and no prior history of autoimmune disease or cardiac dysfunction - can potentially be eligible for the secondary trial, as per its inclusion criteria. However, the same patient would not be eligible for the primary trial due to several exclusion criteria, such as HER2-, ER-positive, or PR-positive breast cancer, prior chemotherapy, hormonal, or targeted therapy, and cobimetinib-specific exclusion criteria. Therefore, the statement is not an entailed outcome based on the information present in the CTRs.</s>"
    },
    "14607d45-9aef-458d-89cc-d47c62c23322_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "To be eligible for both the secondary trial and the primary trial, a patient can have Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction.",
        "Label": "Entailment",
        "entail": "The statement \"To be eligible for both the secondary trial and the primary trial, a patient can have Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction\" is entailed by the information present in both CTRs. \n\nIn the Primary CTR: \n- Histologically confirmed ER-negative, PR-negative, and HER2-negative adenocarcinoma of the breast is a requirement for inclusion. Triple-negative breast cancer meets these criteria.\n- Known Brain metastases are an exclusion criterion.\n- Prior autoimmune diseases and cardiac dysfunction are also exclusion criteria.\n\nIn the Secondary CTR:\n- The inclusion criteria only specify breast cancer with early stage and ASA score of I-II, which is a subset of triple-negative breast cancer.\n- Brain metastases, autoimmune diseases, and cardiac dysfunction are all exclusion criteria.\n\nTherefore, the statement that a patient can have histologically confirmed triple-negative breast cancer and meet all eligibility requirements for both trials if they have no known Brain metastases and no prior history of autoimmune disease or cardiac dysfunction is an entailment of the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs because the primary trial excludes patients with HER2-, ER-positive, or PR-positive breast cancer, as well as those with a history of autoimmune disease or cardiac dysfunction. The statement suggests that such patients could be eligible for both the primary and secondary trials, which is not consistent with the trial inclusion and exclusion criteria provided.</s>"
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in the primary trial showed signs of poor liver function.",
        "Label": "Entailment",
        "entail": "The statement \"At least 1 participant in the primary trial showed signs of poor liver function\" is entailed by the data in the primary CTR's Adverse Events section, specifically the occurrence of \"Hepatic function abnormal\" reported for 1 participant (1/109 or 0.92%). The term \"signs of poor liver function\" can be interpreted as synonymous with \"hepatic function abnormal,\" and thus, the statement is a logical consequence of the reported adverse event.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs if neither of the Adverse Events sections (in the Primary and Secondary trials) report \"Hepatic function abnormal\" as an adverse event, as both CTRs indicate no occurrence of this adverse effect in their respective trials. Despite one participant in the Primary trial having a decreased haemoglobin level, this does not necessarily mean that they showed signs of poor liver function.</s>"
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in the primary trial didn't show signs of poor liver function.",
        "Label": "Contradiction",
        "entail": "The statement \"At least 1 participant in the primary trial didn't show signs of poor liver function\" can be entailed by the information present in the CTRs since there is one participant (index 108 or 109, based on the total count in each CTR) in the primary trial with a normal hepatic function as indicated by the absence of \"Hepatic function abnormal\" under the Adverse Events section (occurrence: 0/109).</s>",
        "contradict": "Despite the expert statement suggesting that at least one participant in the primary trial didn't show signs of poor liver function, the CTR data contradicts this claim. Both CTRs list one participant with a hepatic function abnormal event in their respective adverse events sections. This indicates that at least one participant from each trial exhibited signs of impaired liver function. Therefore, the expert statement is not supported by the information provided in the CTRs.</s>"
    },
    "d2961e96-bd3b-4994-aa7e-2b310eb6204e_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "In the primary trial at least 1 patient showed signs of poor liver function.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial at least 1 patient showed signs of poor liver function\" can be entailed by the information present in the CTRs as there is a report of one participant in the primary trial (identified by the index 1/109 or 100th participant in the trial) experiencing \"Hepatic function abnormal.\" This term is commonly used to denote poor liver function. Therefore, the trial data substantiates that at least one patient in the primary trial did exhibit signs of poor liver function, making the expert's statement true and entailed by the CTR data.</s>",
        "contradict": "The statement \"In the primary trial at least 1 patient showed signs of poor liver function\" cannot be directly contradicted by the information present in the CTRs since both reports mention \"Hepatic function abnormal\" in their respective adverse events sections, indicating that at least one patient in the primary trial did experience poor liver function, as stated in the expert's claim. However, the frequency rates of such events differ between the trials.\n\nTo establish a contradiction, there should be clear evidence that the statement is inconsistent with the CTR information. In this case, there is no contradiction as the CTRs do contain the information that supports the expert's claim.</s>"
    },
    "8a5d7285-f4be-4e50-9057-19f74bcc410b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks\" can be entailed by the information in the CTRs because the Cohort A in the primary trial receives 6 mg/kg of IMGN853 by IV, and 6 mg/kg corresponds to approximately 198 mg per 62.3 kg average adult body weight (6 mg/kg \u00d7 62.3 = 385.86 mg \u2248 198 mg). Therefore, the total dose each patient receives in the primary trial within the given 3-week interval (Q3W) does not exceed 200 mg.</s>",
        "contradict": "The statement made by the clinical trial expert that \"Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks\" cannot be directly contradicted by the information in the CTR, but it is an oversimplification and can be misleading. The CTR states that \"Cohort A: Advanced Triple-Negative Breast Cancer (TNBC) receives 6 mg/kg IMGN853 IV Q3W.\" This implies that the dosage is calculated based on body weight, and thus individual patients may receive more than 200mg of IMGN853 depending on their weight. Therefore, the statement can be contradictory if taken in isolation without considering the weight-based dosing in the CTR.</s>"
    },
    "512990dd-45d2-4b31-b571-66735ff02308": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were 4 different adverse events, for which 0 cases were recorded in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"There were 4 different adverse events, for which 0 cases were recorded in cohort 1\" can be entailed by the information present in the CTRs as follows: The CTRs list 12 different adverse events in total, and for each cohort (1 and 2), they provide the number of cases (occurrences) for each adverse event. The statement states that 4 specific adverse events had no cases in cohort 1, which matches the information in the CTRs that 0 cases were recorded for those 4 adverse events in cohort 1. Therefore, the information in the statement is a logical consequence of the information in the CTRs.</s>",
        "contradict": "The statement that \"there were 4 different adverse events, for which 0 cases were recorded in cohort 1\" cannot be directly contradicted by the CTRs provided, as they do not mention all possible adverse events for each trial and only provide counts for specific adverse events in each cohort. However, the statement is incomplete and potentially misleading as it does not specify which of the 11 adverse events listed in the CTRs are the ones intended, making it impossible to determine if the statement and the CTRs are in agreement or not. To establish semantic entailment, the statement should be more precise, specifying the 4 adverse events and the trials to which they pertain.</s>"
    },
    "512990dd-45d2-4b31-b571-66735ff02308_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There weren't 4 different adverse events, for which 0 cases were recorded in cohort 1.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There weren't 4 different adverse events, for which 0 cases were recorded in cohort 1\" is entailed by the CTRs since none of the listed adverse events in either CTR (Coagulopathy, Febrile neutropenia, Cardiac failure, Cardiac failure congestive, Pericardial effusion, Appendicitis perforated, Colitis, Ileus, Abdominal pain upper, Gastrointestinal haemorrhage) had 4 different events with 0 cases recorded in the respective cohorts (CTRs 1 and 2).</s>",
        "contradict": "The expert's statement asserts that in both CTRs (Primary and Secondary), there were no recorded cases of 4 specific adverse events in cohort 1 (CTR 1 and CTR 2). However, this contradicts the information present in the CTRs, as there are instances of different adverse events being reported for cohort 1 in both trials (e.g., Coagulopathy in CTR 1 and Cardiac failure congestive in CTR 2). Therefore, the expert's statement is not entailed by the provided CTRs.</s>"
    },
    "512990dd-45d2-4b31-b571-66735ff02308_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "In cohort 1 there were 4 different adverse events, for which 0 cases were recorded.",
        "Label": "Entailment",
        "entail": "The expert's statement \"In cohort 1 there were 4 different adverse events, for which 0 cases were recorded.\", can be entailed by the information present in the CTRs as follows:\n\n1. According to CTR 1, there are 13 distinct adverse events mentioned under the section \"Adverse Events 1.\"\n2. The expert's statement specifies that \"there were 4 different adverse events.\" This matches with the 13 distinct adverse events in CTR 1.\n3. The expert's statement also asserts that \"for which 0 cases were recorded.\" For each of these 4 events, the CTR 1 states \"Cardiac failure,\" \"Cardiac failure congestive,\" \"Pericardial effusion,\" and \"Gastrointestinal haemorrhage\" with a recorded count of 0. Hence, the information in the statement is an entailed subset of the information in the CTR.\n\nSimilarly, the information from CTR 2 can also be used to demonstrate that the expert's statement is entailed. In CTR 2, there are 12 distinct adverse events mentioned, and 3 of them (\"Cardiac failure congestive,\" \"Pericardial effusion,\" and \"Gastrointestinal haemorrhage\") have a recorded count of 0.</s>",
        "contradict": "The statement \"In cohort 1 there were 4 different adverse events, for which 0 cases were recorded\" contradicts the information in the CTRs because there are several adverse events reported for both trials, but not all of them are present in the statement. The statement only mentions 4 adverse events, but the CTRs report a total of 13 different adverse events across both trials. Additionally, while the statement suggests that none of these events were recorded in cohort 1 of the primary trial, the CTRs report zero occurrences for some of the events in both cohorts of both trials. Therefore, the statement is too limited in scope and incorrectly assumes that the absence of reported adverse events in the statement implies the absence of those events in the CTRs.</s>"
    },
    "383db144-4bcd-4ebc-989c-b6ae7d282026": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial .",
        "Label": "Contradiction",
        "entail": "The statement \"Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial than in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs if we consider the following:\n\n1. The CTR for the primary trial reports one instance (1/83, or 1.20%) of Gastrointestinal haemorrhage in cohort 1.\n2. The CTR for the secondary trial reports no instances (0/26, or 0.00%) of Gastrointestinal haemorrhage in cohort 1.\n3. However, the CTR for the secondary trial does report one instance (1/10, or 10.00%) of Gastrointestinal haemorrhage in a separate cohort of 10 participants.\n4. Since the statement compares the frequencies of this adverse event between cohorts 1 and 2, and cohort 1 has no cases in the secondary trial, a higher frequency in cohort 2 is entailed if at least one case is present in cohort 2 and no cases are present in cohort 1.\n\nTherefore, the statement can be entailed by the information present in the CTRs, as long as we take into account the different cohorts and the separate reporting of adverse events for different subgroups in the secondary trial.</s>",
        "contradict": "The statement \"Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial than cohort 1 of the primary trial\" is contradicted by the information in the CTRs because both trials report 0 instances of gastrointestinal haemorrhage in cohort 1, whereas the secondary trial reports 0 instances of gastrointestinal haemorrhage in cohort 2. Hence, gastrointestinal haemorrhage was not more common in cohort 2, but rather, there were no instances reported in either cohort.</s>"
    },
    "bfa07fb7-f8cb-4215-9bca-ddee8b3bea73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00951665",
        "Statement": "Most patients in cohort 1 of the primary trial died of unknown causes.",
        "Label": "Contradiction",
        "entail": "The statement \"Most patients in cohort 1 of the primary trial died of unknown causes\" can be entailed by the information present in the CTR if there are more than three patients in cohort 1 who died of unknown causes (1/26 = 3.85%, and since the percentage of deaths due to unknown causes in cohort 1 is stated to be \"most,\" it implies that the number of such deaths is significantly higher than 3.85%). The CTR reports that one patient in cohort 1 died of an unknown cause, which, under the assumption of a sufficient sample size, could support the statement made by the expert.</s>",
        "contradict": "The statement \"Most patients in cohort 1 of the primary trial died of unknown causes\" cannot be directly inferred from the provided CTR data. The data indicates that there was one death of unknown cause in cohort 1 of the primary trial, which represents 3.85% of the total number of participants. However, the statement asserts that \"most\" patients died of unknown causes, which contradicts the data presented in the CTR. There isn't enough evidence in the CTR to support this claim.</s>"
    },
    "228e80ab-84d6-4b60-9960-dcdcbd78c03c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with an FEV1 of 80% to 120% are ineligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria specify that adequate pulmonary function is a requirement. However, the statement \"Patients with an FEV1 of 80% to 120% are ineligible for the primary trial\" suggests that a certain range of pulmonary function values (FEV1 between 80% and 120%) is sufficient to exclude patients. Since the CTR does not explicitly mention this range as a disqualifying factor for pulmonary function, it can be inferred that a lower value would lead to trial ineligibility. Therefore, the statement is entailed by the CTR as it adds a more specific condition to the inclusion criteria that harmonizes with the existing requirement of adequate pulmonary function.</s>",
        "contradict": "The statement that \"Patients with an FEV1 of 80% to 120% are ineligible for the primary trial\" contradicts the information present in the CTRs. The primary trial's eligibility criteria do not mention the requirement of a specific FEV1 (Forced Expiratory Volume in one second) value for patient inclusion. Therefore, the statement goes beyond the information presented in the CTRs, and there is no justification for it based on the provided data.</s>"
    },
    "b7caad28-5fb2-4eb6-845e-8315cff97318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background.",
        "Label": "Contradiction",
        "entail": "The statement \"prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial\" is consistent with the inclusion criteria of the CTR as no exclusion criteria specifies prior hormonal treatment(s) as a prerequisite.\n\nThe statement \"Adequate organ function or a particular racial or ethnic background is not necessary\" is also in line with the CTR information, since neither the inclusion nor the exclusion criteria mention adequate organ function as a requirement and the racial or ethnic backgrounds are explicitly listed as inclusion criteria.</s>",
        "contradict": "The statement contradicts the CTR information in several ways: \n\n1. Eligibility Criteria (Patient Characteristics) - The CTR specifies that patients in the primary trial must have one of the specified racial or ethnic backgrounds. The statement asserts that this is not a requirement.\n\n2. Eligibility Criteria (Prior Concurrent Therapy) - The statement asserts that prior hormonal treatment is not necessary for patients to be included in the primary trial. However, the CTR does not specify that it is required, but it does not exclude it either, leaving it unclear whether prior hormonal treatment is acceptable or not.\n\n3. Eligibility Criteria (Organ Function) - The statement asserts that there is no requirement for adequate organ function for patients in the primary trial. However, the CTR does not mention any requirement regarding organ function, but it does not exclude patients with impaired organ function either.\n\nTherefore, the statement contradicts the CTR in that it makes assertions about the eligibility criteria that are not explicitly stated or implied in the provided text, potentially limiting the pool of eligible patients and altering the trial's population characteristics.</s>"
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial\" can be entailed by the information present in the CTRs because: \n\n1. According to the primary CTR, patients with invasive carcinoma of the breast are eligible for the trial. \n2. T2 N1 M0 denotes T2 tumor size, N1 node involvement, and M0 absence of metastasis. This aligns with the eligibility criteria stating \"No evidence of T4, N2-3, or M1 disease prior to surgery.\"\n3. The primary CTR also states that node positive or high-risk node negative patients are eligible, which includes those with N1 node involvement.\n4. Therefore, patients with a T2 N1 M0 diagnosis of breast adenocarcinoma meet the eligibility criteria outlined in the CTR.</s>",
        "contradict": "The statement \"T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial\" can be contradicted by the information present in the CTRs if the patient with this staging also has one or more of the following conditions not meeting the eligibility criteria mentioned in the CTR:\n\n1. Evidence of T4, N2-3, or M1 disease prior to surgery\n2. No surgery or prior breast-conserving therapy (BCT) with axillary node dissection or sentinel node biopsy\n3. Microscopically positive resection margins without undergoing reexcision or receiving breast radiotherapy plus a boost to the lumpectomy site\n4. Prior sentinel node dissection with positive nodes or without meeting high-risk criteria\n5. Evidence of residual disease in axilla after dissection\n6. No treatment with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy\n7. High risk of regional and systemic recurrence without meeting the specified criteria\n\nThese factors can lead to ineligibility for the clinical trial despite having T2 N1 M0 adenocarcinoma of the breast.</s>"
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T2 N1 M0 adenocarcinoma of the breast aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"T2 N1 M0 adenocarcinoma of the breast aren't eligible for the primary trial\" can be entailed by the information present in the CTR as follows: According to the disease characteristics section of the CTR, patients with T2 tumors, N1 lymph nodes (positive nodes), or M1 (metastatic) disease are not eligible for participation in the trial. Therefore, a patient diagnosed with T2 N1 M0 breast adenocarcinoma would not meet the eligibility criteria specified in the CTR and, thus, cannot be part of the trial.</s>",
        "contradict": "The statement is contradicted by the information in the ELIGIBILITY CRITERIA section of the CTR as it specifies that node positive (N1) breast cancer is eligible for the trial, provided that other high-risk criteria are met. Therefore, T2 N1 M0 adenocarcinoma of the breast, which is a type of node positive breast cancer, can be eligible for the trial based on the information provided in the CTR.</s>"
    },
    "73c37b9c-e7ba-4c90-b26e-23b7a65509c4_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "The primary trial accepts T2 N1 M0 adenocarcinoma of the breast.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial accepts T2 N1 M0 adenocarcinoma of the breast\" can be entailed by the information present in the CTRs as follows:\n\n1. T2: The primary trial accepts patients with a T2 tumor, which is defined as a tumor larger than 2 cm but not greater than 5 cm in the primary disease characteristics section of the CTR.\n2. N1: The primary trial accepts patients with positive axillary lymph nodes, which is defined as N1 in the eligibility criteria section of the CTR.\n3. M0: The primary trial accepts patients without evidence of distant metastasis, which is defined as M0 in the eligibility criteria section of the CTR.\n\nThus, the statement \"The primary trial accepts T2 N1 M0 adenocarcinoma of the breast\" is entailed by the information present in the CTRs since T2, N1, and M0 fall within the accepted disease characteristics according to the trial eligibility criteria.</s>",
        "contradict": "The primary trial specified in the CTRs accepts patients with a diagnosis of histologically proven invasive carcinoma of the breast. T2 N1 M0 is a tumor staging classification, where T2 signifies a tumor size greater than 2 cm, N1 indicates the presence of axillary lymph node involvement, and M0 signifies no distant metastasis. The primary trial, however, has stricter eligibility criteria that exclude patients with T4, N2-3, or M1 disease prior to surgery. Therefore, accepting T2 N1 M0 patients contradicts the stated disease characteristics in the primary trial.</s>"
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is obligatory for entry in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Informed consent is obligatory for entry in the primary trial\" is entailed by the CTR inclusion criterion \"The subject must provide written informed consent with HIPAA authorization before participating in the study.\"</s>",
        "contradict": "The statement \"Informed consent is obligatory for entry in the primary trial\" is not contradictory to the CTR information as it is a general requirement for clinical trials and is explicitly stated in the primary CTR under the inclusion criteria: \"The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study.\" However, the following statement could potentially contradict the information in the CTR:\n\nIf the statement was \"Informed consent is not required for entry into the primary trial,\" it would contradict the CTR information because the trial explicitly states that informed consent is a requirement for participation.</s>"
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent isn't obligatory for entry in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Informed consent isn't obligatory for entry in the primary trial\" cannot be entailed by the information in the CTRs. The CTRs explicitly state that \"The subject must provide written informed consent with HIPAA authorization before participating in the study.\"</s>",
        "contradict": "The statement \"Informed consent isn't obligatory for entry in the primary trial\" is contradictory to the information present in the CTRs as per the following reasons: \n\n1. The CTR clearly states that \"The subject must provide written informed consent with HIPAA authorization before participating in the study.\" (Primary Trial: Inclusion Criteria) \n2. This requirement for informed consent is a standard procedure in clinical trials, and its absence would not align with typical clinical trial conduct.\n3. Therefore, the statement made by the clinical trials expert is incorrect as per the information available in the CTRs.</s>"
    },
    "d5b81f6c-821a-4db5-8810-9cc47a952913_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "In the primary trial informed consent is obligatory for entry.",
        "Label": "Entailment",
        "entail": "The primary CTR specifies that the subject must provide written informed consent with HIPAA authorization before participating in the study, thus satisfying the expert's statement that informed consent is obligatory for entry in the primary trial.</s>",
        "contradict": "Although the statement, \"In the primary trial informed consent is obligatory for entry,\" is generally true based on the standard practice in clinical trials, it does not directly contradict the information in the CTRs. However, the provided CTRs focus on the inclusion and exclusion criteria of the primary trial and do not directly mention informed consent being a requirement in those sections. The contradiction would only arise if the statement implied that the CTRs did not include a requirement for informed consent, which is not the case.</s>"
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered adverse events.",
        "Label": "Entailment",
        "entail": "Although the primary CTR does not directly report the number of participants who suffered adverse events for each arm/group, it does provide the number of participants analyzed for each group (Results 1 and 2) and indicates that the adverse events were recorded from patient screening to discontinuation plus 28 days safety follow-up (Outcome Measurement). Since the time frame for adverse event recording covers the entire study duration, including the screening phase, and there are 5 participants in each group, it can be inferred that all participants in both groups experienced some form of adverse event during the course of the trial, thus satisfying the condition stated in the expert's claim. Consequently, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"100% of patients in the primary trial suffered adverse events\" contradicts the information presented in the CTRs, as the number of participants experiencing adverse events in each arm was specified as 5, not all 5 participants in each arm experienced adverse events, hence 100% did not suffer from adverse events according to the provided data.</s>"
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial didn't suffer adverse events.",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information in the CTRs as it contradicts the provided data. The CTRs report that there were participants in both arms (AZD4547 80mg bd Cont + Ex 25mg and AZD4547 40mg Cont + Ex 25mg) who experienced adverse events, even though the overall number of participants analyzed is five for each arm. Thus, no patient in the trial experienced 100% freedom from adverse events as claimed in the statement.</s>",
        "contradict": "The expert's statement is contradicted by the information in the CTRs because:\n\n1. The statement claims that \"100% of patients in the primary trial didn't suffer adverse events,\" but the CTRs report the presence of adverse events for both the AZD4547 80mg bd Cont + Ex 25mg arm and the AZD4547 40mg Cont + Ex 25mg arm, with a total of 10 participants analyzed in both arms.\n2. Therefore, it is not possible for all patients in the trial to have experienced no adverse events as per the CTR data.</s>"
    },
    "cdba382e-894b-4f79-a8e2-ff818746adc5_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "In the primary trial 100% of patients suffered adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, 100% of patients suffered adverse events\" cannot be directly entailed from the provided CTRs as they do not indicate that all participants in the trials experienced adverse events. However, the statement is not contradictory to the CTR information since it only makes a claim about the primary trial and does not specify which arm or group of the trial the expert is referring to. The CTRs only report the number of participants in each arm that experienced adverse events, not the percentage of total participants. Therefore, the statement does not contradict the information in the CTRs, but it goes beyond what is stated in the CTRs by making a stronger claim.</s>",
        "contradict": "The statement \"In the primary trial 100% of patients suffered adverse events\" is contradictory to the information in the CTRs as the number of participants experiencing adverse events for each arm/group is given as 5, indicating that not all patients suffered adverse events. In fact, the statement asserts that every participant in the trial had an adverse event, which is not supported by the provided information.</s>"
    },
    "0093175a-38cb-4f63-b391-709ac48158b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial\" is entailed by the information in the CTRs because the primary trial explicitly states that patients must be HER-2/neu FISH negative or have IHC scores of 0, 1+, or 2+, thus excluding patients with HER-2 gene amplification and HER-2 overexpression. Conversely, the secondary trial includes patients with FISH+ HER2 gene amplified breast cancer, satisfying the condition of overexpression.</s>",
        "contradict": "The information contained in the statement can be contradicted by the information present in the CTRs because the primary trial specifically excludes patients whose tumors overexpress HER-2 (as defined by FISH positive or 3+ by IHC) from participation. Conversely, the secondary trial includes only patients with HER-2 gene amplified breast cancer, which is a subset of patients with HER-2 overexpression. However, the statement does not make this distinction, potentially leading to a contradiction.</s>"
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred more than once.",
        "Label": "Entailment",
        "entail": "In the primary trial, each adverse event was reported for exactly one participant, as indicated by the frequency value of 1/82 for each event. Therefore, the statement that \"none of the adverse events recorded for the primary trial occurred more than once\" is an entailed consequence of the information presented in the CTRs.</s>",
        "contradict": "The statement \"None of the adverse events recorded for the primary trial occurred more than once\" can be contradicted by the information present in the CTRs because, according to the provided data from the primary trial's Adverse Events section, several adverse events occurred more than once. Specifically, the following adverse events were reported multiple times: cardiac ischemia/infarction, left ventricular systolic dysfunction, hypertension, supraventricular and nodal arrhythmia, anorexia, gastrointestinal perforation, vomiting, dehydration, and diarrhea, each with an incidence of 1.22%. This directly contradicts the statement made by the clinical trial expert.</s>"
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial didn't occur more than once.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the adverse events recorded for the primary trial didn't occur more than once\" can be entailed by the information present in the CTRs because each adverse event is listed only once in the primary trial's Adverse Events section. The numbers given (e.g., \"1/82\" or \"1.22%\") indicate the occurrence of each event exactly once among the total participants. Therefore, the statement's assertion, which claims that all adverse events occurred only once, harmonizes with the clinical trial data and avoids contradiction.</s>",
        "contradict": "The statement \"None of the adverse events recorded for the primary trial didn't occur more than once\" can be contradicted by the CTR data since there are several adverse events, such as neutrophils count decreased, cardiac ischemia/infarction, left ventricular systolic dysfunction, hypertension, supraventricular and nodal arrhythmia, anorexia, gastrointestinal perforation, vomiting, dehydration, and diarrhea, that occurred more than once, each with a frequency of 1.22%.</s>"
    },
    "19106207-4fa2-4cc4-8e22-6e5330bf05ce_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "The primary trial recorded adverse event no more than once.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial recorded adverse event no more than once\" can be entailed by the information present in the CTRs because each adverse event listed under the Primary Trial's Adverse Events section is reported only once, with no repeated occurrences mentioned for any individual adverse event. Therefore, the statement is a valid summary of the data provided in the CTRs, as it accurately captures the absence of repeated adverse events within the given clinical trial.</s>",
        "contradict": "The statement \"The primary trial recorded adverse event no more than once\" is contradicted by the information present in the CTRs because, in the primary trial's Adverse Events section, multiple adverse events were recorded for each participant, with some participants experiencing more than one adverse event throughout the trial. For instance, there were participants who experienced both cardiac ischemia/infarction and left ventricular systolic dysfunction, or both anorexia and dehydration. Therefore, an adverse event was recorded more than once for each individual participant in the primary trial, contradicting the expert's statement.</s>"
    },
    "a015685e-f744-4bb2-a6d3-893f081d6dcc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.",
        "Label": "Contradiction",
        "entail": "The statement does not entail any information directly from the provided CTRs, as there's no mention of specific cycles or their duration in the CTR sections for the Primary or Secondary trials. Thus, no entailment relationship exists.</s>",
        "contradict": "The statement is not directly contradictory to the information in the CTRs, as there is no mention of the length of the intervention cycles in either trial's intervention section. The statement only specifies the number of cycles up to a maximum limit, but it does not necessarily mean that the intervention periods for each cycle are 21 days long. The length of a cycle in each trial may vary and is not explicitly stated. Therefore, the statement can co-exist with the information presented in the CTRs without contradiction. However, further analysis would be required to confirm the actual cycle lengths in each trial, as this information is not provided in the given descriptions.</s>"
    },
    "b9578bae-6640-4ef1-ba2c-899b45c602ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that all patients in the primary trial consumed 4 cups (32 ounces) of water. According to the provided CTRs, each patient drank 8 ounces of either alkaline or distilled water both before and after undergoing radiation therapy daily (5 days a week for 6 weeks). This amounts to a total of 16 ounces or 2 cups per radiation therapy session, and 32 ounces or 4 cups per day. Since all patients in the trial received radiation therapy, the expert's statement is an entailed conclusion from the data presented in the CTRs.</s>",
        "contradict": "The statement \"All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled\" contradicts the information in the CTRs as it implies that the patients consumed a total of 4 cups (32 oz) of water for each radiation session. However, the CTR specifies that patients drink 8 oz of water before and after each session, which amounts to 16 oz or half the volume stated in the expert's claim.</s>"
    },
    "405369ef-d216-4d81-a04f-46f36f466a19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement entails the following: \n\n1. The primary trial involved two cohorts, labeled as cohort 1 and cohort 2. \n2. In cohort 1 of the primary trial, there was a higher number of reported urinary tract infections (UTIs) and lumbar vertebral fractures than in cohort 2. \n\nThe CTRs provide the following information relevant to this statement:\n\nPrimary Trial:\nAdverse Events 1: (for cohort 1) - 1 UTI reported out of 26 participants.\n                Adverse Events 2: (for cohort 2) - 0 UTIs reported out of 13 participants.\n\nPrimary Trial:\nAdverse Events 1: (for cohort 1) - 1 lumbar vertebral fracture reported out of 26 participants.\n                Adverse Events 2: (for cohort 2) - 0 lumbar vertebral fractures reported out of 13 participants.\n\nFrom the given CTR data, it's evident that cohort 1 reported more cases of both UTIs (1 in cohort 1 vs 0 in cohort 2) and lumbar vertebral fractures (1 in cohort 1 vs 0 in cohort 2) than cohort 2. Therefore, the statement \"Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2\" is entailed by the provided CTR information.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2\" cannot be directly contradicted by the given CTR data since the CTRs do not provide the actual number of cases for each cohort regarding these specific adverse events. However, based on the provided information, it's evident that cohort 1 had 1 case of urinary tract infection and cohort 2 had 0 cases. Similarly, for lumbar vertebral fractures, cohort 1 had 1 case and cohort 2 had 0 cases. Contrary to the statement, cohort 2 had zero cases for both adverse events while there was at least one case in cohort 1.</s>"
    },
    "405369ef-d216-4d81-a04f-46f36f466a19_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 1 of the primary trial didn't have more cases of urinary infections and lumbar fractures than cohort 2.",
        "Label": "Contradiction",
        "entail": "The absence of a higher number of urinary infections and lumbar vertebral fractures in cohort 1 compared to cohort 2 is entailed by the data in the CTRs since both cohorts had the same number of reported cases for urinary tract infection (1/26 for cohort 1 and 0/13 for cohort 2) and lumbar vertebral fracture (1/26 for cohort 1 and 0/13 for cohort 2).</s>",
        "contradict": "The information in the statement can be contradicted by the CTR data as follows:\n- For urinary infections: cohort 1 had 1 case (3.85%) compared to cohort 2 which had 0 cases in the primary trial; and 0 cases in the secondary trial, whereas cohort 1 had no cases in the secondary trial.\n- For lumbar vertebral fractures: cohort 1 had 2 cases (7.69%) in the secondary trial, while cohort 2 had no cases reported in either trial.\n\nTherefore, the statement that \"Cohort 1 of the primary trial didn't have more cases of urinary infections and lumbar fractures than cohort 2\" is contradicted by the data provided in the two trials.</s>"
    },
    "405369ef-d216-4d81-a04f-46f36f466a19_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01416389",
        "Statement": "Cohort 2 of the primary trial had more less of urinary infections and lumbar fractures than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if there are fewer cases of urinary tract infection and lumbar vertebral fracture in Adverse Events 1 (cohort 1) compared to Adverse Events 2 (cohort 2). The given data shows that the number of reported urinary tract infections for cohort 1 was 1/26 (3.85%) and for cohort 2 was 0/13 (0.00%). The reported lumbar vertebral fractures for cohort 1 was 1/26 (3.85%) and for cohort 2 was 0/13 (0.00%). Therefore, the statement that \"Cohort 2 had fewer cases of urinary infections and lumbar fractures than cohort 1\" is entailed by the given information in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial had fewer urinary infections and lumbar fractures than cohort 1\" cannot be definitively contradicted based on the information given in the CTRs alone. However, it can be noted that the statement is not entailed by the data, as the data do not directly allow for a comparison of urinary infections and lumbar fractures between the two cohorts. In order to determine if the statement is true or false, additional data from the CTRs, such as the size of each cohort and the number of urinary infections and lumbar fractures in each cohort, would be necessary.</s>"
    },
    "e424c65e-7c6f-43a4-95e4-6beb705d9903": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n\n1. The statement makes a comparative claim about the frequency of stomatitis between two trials.\n2. The CTRs provide the frequency of stomatitis in both the primary and secondary trials.\n3. The primary trial reports 22 cases out of 72 participants (22/72 = 0.3056 or 30.56%) had stomatitis.\n4. The secondary trial reports 1 case out of 67 participants (1/67 = 0.0149 or 1.49%) had stomatitis.\n5. The statement's claim (higher percent in the secondary trial) is consistent with the data, as the percentage in the secondary trial is indeed higher than the percentage in the primary trial.\n\nTherefore, the information contained in the statement follows logically from the information presented in the CTRs.</s>",
        "contradict": "The statement cannot be entailed by the information in the CTRs, as no mention of stomatitis occurrences is provided in the Adverse Events sections of either trial. Consequently, no comparison regarding the percentage of patients experiencing stomatitis between cohorts 1 of the primary and secondary trials can be made based on the available data.</s>"
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because the CTR for the primary trial reports a higher mean retention rate for the placebo group (80.7% vs. 71.0% with a difference of 9.7%) despite both groups being treated for the same duration of 24 weeks. The statement, therefore, correctly reflects the data presented in the CTRs.</s>",
        "contradict": "The information in the statement contradicts the CTR data as the mean retention percentage for the placebo group (80.7, 7.2) was higher than that of the donepezil hydrochloride PO QD group (71.0, 8.3) according to the statement. However, the CTR results indicate the opposite, with the donepezil hydrochloride PO QD group having a higher retention percentage (71.0% vs 80.7%).</s>"
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The primary trial placebo group didn't have a better mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the CTR information as both trials measure retention percentage over a 24-week period for each arm. In the primary trial, the placebo group had a mean retention of 80.7 (7.2)%, while the donepezil hydrochloride PO QD group had a mean retention of 71.0 (8.3)%. Since the placebo group had a higher mean retention than the donepezil hydrochloride PO QD group, the expert's statement does not contradict the CTRs' descriptions. However, the expert's statement does not provide new information as the CTRs already report the retention data for each arm. The expert's statement simply draws a comparison between the two arms based on that data.</s>",
        "contradict": "Based on the CTR information provided, the statement can be contradicted because the mean retention percentage in Arm I (donepezil hydrochloride PO QD) is 71.0 (8.3), while the mean retention percentage in Arm II (placebo PO QD) is 80.7 (7.2). The placebo group had a higher mean retention percentage than the donepezil hydrochloride group, which contradicts the statement.</s>"
    },
    "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The primary trial donepezil hydrochloride PO QD group had a worse mean retention than the placebo group.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs as follows: \n\nThe mean retention rate for Arm I (donepezil hydrochloride PO QD) is lower than the mean retention rate for Arm II (placebo PO QD): \n\n71.0 (8.3) < 80.7 (7.2)\n\nTherefore, the expert's assertion that \"The primary trial donepezil hydrochloride PO QD group had a worse mean retention than the placebo group\" is entailed by the CTR data.</s>",
        "contradict": "The information in the statement contradicts the data presented in the CTRs as the mean retention percentage in Arm I (donepezil hydrochloride group) is 71.0 (8.3), which is lower than Arm II (placebo group) with a mean retention percentage of 80.7 (7.2). However, the statement asserts that the donepezil hydrochloride group had a worse retention than the placebo group. This statement is incorrect based on the information available in the given CTRs.</s>"
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial\" is entailed by the CTR information as follows:\n\n1. Nonpalpable breast lesion: The CTR specifies \"Palpable or nonpalpable breast lesion.\" Thus, patients with nonpalpable breast lesions meet the eligibility requirement according to the CTR.\n\n2. 0 palpable axillary lymph nodes: The CTR states \"No palpable axillary lymph node(s).\" Therefore, the absence of palpable axillary lymph nodes in patients is in accordance with the CTR's inclusion criterion.\n\nThus, the statement \"Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial\" follows directly from the eligibility criteria outlined in the CTR.</s>",
        "contradict": "The information in the expert statement does not directly contradict the information in the CTRs, however, it is less specific than the eligibility criteria stated in the primary trial CTR. The statement does not mention the requirement of a clinical or pathologic diagnosis of breast carcinoma, the largest tumor size, the presence or absence of hormone receptors, the need for sentinel node biopsy, or the absence of suspicious manifestations that cannot be ruled out by imaging, among others. Therefore, while the statement may apply to some patients who meet the eligibility criteria of the primary trial, it may also include patients who do not, depending on how broadly the term \"nonpalpable breast lesion\" is interpreted.</s>"
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes aren't eligible for the primary trial\" can be entailed by the information present in the CTRs since the CTR for the primary trial specifies \"No palpable axillary lymph node(s)\" as an eligibility criterion. Therefore, individuals with nonpalpable breast lesions and no palpable axillary lymph nodes would not meet this criterion and would be ineligible for the trial.</s>",
        "contradict": "The statement can be contradicted by the information in the CTR as patients with nonpalpable breast lesions and no palpable axillary lymp nodes are explicitly listed as eligible in the Primary Trial's ELIGIBILITY CRITERIA section.</s>"
    },
    "0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "For the primary trial patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible.",
        "Label": "Entailment",
        "entail": "The statement \"For the primary trial patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible\" can be entailed by the information present in the CTRs as follows:\n\nIn the CTR for the primary trial, the following eligibility criteria are listed:\n- Palpable or nonpalpable breast lesion\n- No palpable axillary lymph node(s)\n\nThe statement specifies that patients with a \"nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible.\" This is an entailed sub-set of the eligibility criteria provided in the CTR. The statement does not contradict or add anything beyond the information provided in the CTR, making the entailment relationship valid.</s>",
        "contradict": "The statement \"For the primary trial patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible\" can be contradicted by the following information present in the CTRs:\n\n- Nonpalpable breast lesions require localization for surgery (hook wire, radioactive occult lesion localization, etc.).\n- No palpable axillary lymph nodes is a criterion for eligibility.\n\nHowever, the CTR also states that \"prior (preoperative) or planned (intraoperative) sentinel node biopsy required\" for nonpalpable lesions. A sentinel lymph node biopsy is a surgical procedure used to assess the presence or absence of cancer in the lymph nodes. The presence of a palpable sentinel lymph node would make a patient ineligible for the trial, contradicting the statement's condition for 0 palpable axillary lymph nodes.\n\nAdditionally, the CTR states that \"no palpable axillary lymph node(s)\" is a criterion for eligibility, while the statement mentions only \"0 palpable axillary lymph nodes\", which can be interpreted as \"zero but possibly present axillary lymph nodes\" (as in the case of sentinel lymph nodes). The CTR, however, does not allow for the presence of palpable sentinel lymph nodes. Therefore, the statement can be contradicted by the CTR's eligibility criteria for axillary lymph nodes.</s>"
    },
    "6843daf8-8136-4973-9bf2-62a622d5a890": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the CTRs as the CTRs do not specify that participant assignment to interventions in the primary or secondary trials is based on HIV diagnosis. However, the statement could potentially be true depending on unstated details about the trials, as long as the trials allow for the specified procedures to be carried out as described in the CTRs for both intervention groups (Healthy Volunteers, Breast Cancer Patients, Hydrophor, MediHoney).</s>",
        "contradict": "The statement \"Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned\" is contradictory to the information present in the CTRs because the CTRs do not mention any relation between HIV diagnosis and intervention assignment in either the primary or secondary trials. In the provided CTRs, participants in both trials undergo the same MRI procedure and receive instructions for applying Hydrophor or MediHoney based on standard procedures without any reference to HIV diagnosis.</s>"
    },
    "2687b547-c225-4838-bbcd-99212a74d815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial and the secondary trial did not have any of the same adverse events\" can be entailed by the information in the CTRs if and only if none of the adverse events listed in the primary trial are present in the secondary trial, and vice versa. \n\nFrom the provided data, the adverse events in the primary trial are [supraventricular extrasystoles, ventricular extrasystoles, ascites, diarrhea, nausea, pancreatitis, small intestinal obstruction, vomiting, bile duct obstruction, portal hypertension]. \n\nThe adverse events in the secondary trial are [febrile neutropenia (occurring twice), fatigue, pyrexia, fracture, hip fracture, headache].\n\nNone of the adverse events in the primary trial are present in the secondary trial, and none of the adverse events in the secondary trial are present in the primary trial, therefore the statement \"Patients in the primary trial and the secondary trial did not have any of the same adverse events\" can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial and the secondary trial did not have any of the same adverse events\" is contradicted by the information in the CTRs because both trials reported the occurrence of headache in one patient each. However, the frequency and specific mention of this adverse event differed, with the primary trial mentioning \"1/25 (4.00%)\" and the secondary trial mentioning \"1/19 (5.26%)\" instances. Despite these differences, the presence of this adverse event in both trials contradicts the expert's claim of no shared adverse events.</s>"
    },
    "2687b547-c225-4838-bbcd-99212a74d815_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did have any of the same adverse events.",
        "Label": "Contradiction",
        "entail": "The absence of common adverse events between the two trials is entailed by the provided CTR data, as none of the listed adverse events from the secondary trial (febrile neutropenia, fatigue, pyrexia, fracture, hip fracture, headache) are present in the primary trial's adverse event section.</s>",
        "contradict": "Contradiction can occur if there is an adverse event present in both trials, but it is reported differently or its incidence is miscalculated in either one of them. For instance, in this scenario, there seems to be a headache reported once in the secondary trial, which is a common adverse event (reported twice with the same frequency in the provided information), but it is not mentioned in the primary trial's adverse events listing. Therefore, according to the information presented, the statement can be contradicted by the CTRs. However, this conclusion is based on the given information, and further investigation may be required to validate this observation.</s>"
    },
    "2687b547-c225-4838-bbcd-99212a74d815_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "The same adverse events were not observed in patients in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "none of the adverse events mentioned in the primary trial are identical to those in the secondary trial, as their sets differ in composition. The statement does not contradict any information in the CTRs and can be logically entailed based on the presented data.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the specified adverse events \"were not observed\" in both trials according to the expert's claim. However, there are differences in the types of adverse events reported in each trial. In the first trial, various types of extrasystoles, gastrointestinal events, and a few others are reported. In contrast, the secondary trial reports adverse events such as febrile neutropenia, fatigue, pyrexia, fracture, hip fracture, and headache. Since there are distinct adverse events reported in each trial, the statement cannot be said to hold true based on the given information in the CTRs.</s>"
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event is observed in patients from cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Only one adverse event is observed in patients from cohort 1 of the primary trial\" is entailed by the CTR data as follows: The CTR for the primary trial states that there was a total of 1 adverse event (syncope) in 25 patients (1/25) for cohort 1. This is consistent with the statement's assertion that only one adverse event was observed in patients from cohort 1. Additionally, the statement does not contradict any information in the CTRs and the CTR data provides substantiation for the statement.</s>",
        "contradict": "The statement \"Only one adverse event is observed in patients from cohort 1 of the primary trial\" is contradicted by the information present in the CTRs because, according to Adverse Events 1 of the Primary Trial, there is actually one adverse event observed in 1 out of 25 patients in cohort 1 (a 4.00% occurrence rate), which is a syncope event. Therefore, the statement is incorrect as it understates the number of observed adverse events in the primary trial's cohort 1.</s>"
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event isn't observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert statement \"Only one adverse event isn't observed in patients from cohort 1 of the primary trial\" can be entailed by the CTR information as follows:\n\n1. The expert's statement asserts that one adverse event is missing in the primary trial's cohort 1.\n2. In the primary CTR, we can find that no breast cellulitis was reported in cohort 1 (0/25, 0.00%).\n3. Since the expert statement does not specify which adverse event is missing and there is no contradiction between the statement and the CTR, this statement is entailed by the CTR information.\n4. The absence of breast cellulitis in the primary CTR for cohort 1 and the expert's statement that one adverse event is missing are consistent, and no contradiction exists between the two. Therefore, the expert statement can be entailed by the information in the primary CTR.</s>",
        "contradict": "The expert's statement does not provide enough information to determine which adverse event is not observed in patients from cohort 1 of the primary trial. The CTRs, however, list different adverse events for each cohort. In the primary trial, Syncope was observed in 1/25 (4.00%) patients from cohort 1, whereas in the secondary trial, Syncope was not reported for any patient. Therefore, the expert's statement contradicts the information in the CTRs if they are referring to Syncope as the adverse event not observed in patients from cohort 1 of the primary trial.</s>"
    },
    "fadf7710-6e4d-49d6-82fc-4f3137b5e26b_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Patients from cohort 1 of the primary trial only had one adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"Patients from cohort 1 of the primary trial only had one adverse event\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, there were a total of 25 patients in cohort 1.\n2. According to the Adverse Events 1 section of the primary CTR, there was only one instance of an adverse event recorded, and that was a case of syncope, which occurred in one patient.\n3. Therefore, the statement that \"Patients from cohort 1 of the primary trial only had one adverse event\" is an entailed result based on the information provided in the CTR.\n\nThis statement is consistent with the data in the CTR, finds substantiation in the provided descriptions, and does not contradict any information in the CTR, hence it can be considered as an entailed statement from the given CTRs.</s>",
        "contradict": "The statement that \"Patients from cohort 1 of the primary trial only had one adverse event\" cannot be directly inferred from the provided CTR data. The data shows that there was one patient in the primary trial cohort 1 who experienced Syncope as an adverse event. However, the data does not indicate that this was the only adverse event reported for any patient in that cohort. It is possible that there could have been other patients who experienced additional adverse events, but they were not specified in the provided CTR data. Similarly, in the secondary trial, one patient in cohort 1 had multiple adverse events (Diarrhoea and Breast cellulitis), yet the statement only refers to the number of adverse events per patient in the primary trial. Therefore, the statement is an incomplete representation of the available data and can be contradicted by the CTRs.</s>"
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "All of the adverse event cases in the primary trial occurred in patients from cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"All of the adverse event cases in the primary trial occurred in patients from cohort 2\" cannot be directly entailed from the provided CTR information as there is no information about the distribution of adverse events across cohorts in the primary or secondary trials. The CTRs only provide the total number of adverse events and the number of adverse events for specific types in each trial. Therefore, without additional information about the number of patients in each cohort and the number of adverse events in each cohort for the primary trial, it is not possible to establish entailment based on the given statements.</s>",
        "contradict": "The statement cannot be entailed by the information in the CTRs as there is no mention of patient cohorts or arm assignments in the provided data. The adverse events are reported only in aggregate numbers for each trial. Therefore, it is impossible to determine from the given information which patients experienced adverse events or which cohort they belonged to. Consequently, no valid conclusion can be drawn regarding the statement's accuracy based on the presented CTRs alone.</s>"
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "All of the adverse event cases in the primary trial didn't occur in patients from cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs if all the adverse events listed in the primary trial (0 in total) are not present in cohort 2 of the secondary trial (which has 12 adverse events in total). Since the list of adverse events in the primary trial is empty for each type, and the secondary trial has fewer instances of each adverse event than the primary trial for every type listed except for one type of neutropenia (which has one occurrence in the secondary trial and zero in the primary trial), the statement that none of the adverse events from the primary trial occurred in patients from cohort 2 is an logical consequence of the provided data.</s>",
        "contradict": "The statement \"All of the adverse event cases in the primary trial didn't occur in patients from cohort 2\" is contradicted by the CTRs because the CTRs do not provide enough information to support this claim. Although the frequency of adverse events is different between the primary and secondary trials, the statement does not consider the possibility that some adverse events might have occurred in cohort 2 but were not reported or counted differently. Without this context, it is impossible to determine if the statement is entailed by the CTRs.</s>"
    },
    "8c4e6f36-37b4-4bde-b518-08a6dc55f7a5_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "In the primary trial all of the adverse events occurred in patients from cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, all of the adverse events occurred in patients from cohort 2\" cannot be entailed by the information present in the provided CTRs, as none of them indicate which cohort experienced the adverse events. The CTRs only report the total number and percentage of occurrences for the entire trial participant population.</s>",
        "contradict": "The statement \"In the primary trial all of the adverse events occurred in patients from cohort 2\" contradicts the information in the provided CTRs, as neither trial indicates which cohort, if any, experienced an adverse event. The CTRs only report the total number of adverse events and the corresponding percentages within each trial. No information is given about which cohort, if any, experienced these adverse events.</s>"
    },
    "6c0896ac-db42-45b4-a6e2-620a27fd321a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01439945",
        "Statement": "In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial, Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide\" can be entailed by the information present in the CTRs through calculating the dose difference between intervention 1 and intervention 2.\n\nLow Dose Magnesium Oxide (weeks 2-9): 2 tablets/day * 400 mg/tablet = 800 mg/day\nHigh Dose Magnesium Oxide (weeks 2-9): 3 tablets/day * 400 mg/tablet = 1200 mg/day\n\nThe dose difference between low dose and high dose Magnesium Oxide is 1200 mg/day - 800 mg/day = 400 mg/day. A 5% difference would be 400 mg * 0.05 = 20 mg/day. Given that the difference in mg/day is 420 mg/day (400mg for the low dose increase and 20mg for the high dose exceeding), it is not a 5% difference, but rather a 10.5% difference. However since the statement only claims a 5% difference and not an exact amount, it is still considered entailed because 5% is a subset of 10.5%. This entailment relationship exists due to the statement being less specific than the information provided in the CTR.</s>",
        "contradict": "The statement \"In the primary trial, Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide\" contradicts the information in the CTRs because the CTRs do not provide enough data to determine that the low dose and high dose groups in the primary trial represent a 5% difference in Magnesium Oxide intake. The statements only mention the number of tablets taken per day and do not specify the exact amount (in mg) of Magnesium Oxide consumed in each group. Hence, it is not possible to determine if the dose difference is 5%, based on the information provided in the CTRs.</s>"
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial occurred in patients from cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"All of the adverse events recorded in the primary trial occurred in patients from cohort 1\" can be entailed by the information in the CTRs because the CTRs explicitly state that all the adverse events listed under the \"Adverse Events 1\" section for the primary trial occurred in a total of 45 patients, and there is no mention of any adverse events in the \"Adverse Events\" section for the secondary trial or its 46 patient cohort. Since the statement only refers to adverse events recorded in the primary trial, and the CTRs indicate that all such events occurred in the first cohort, the statement holds true and is entailed by the data presented.</s>",
        "contradict": "The statement can be contradicted by the CTR information as there are adverse events (e.g., febrile neutropenia) recorded in both cohorts 1 and 2 in the primary trial. However, the statement specifically claims that all adverse events occurred only in cohort 1. Therefore, the CTR data contradicts the assertion made by the clinical trials expert's statement.</s>"
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "All of the adverse events recorded in the primary trial didn't occur in patients from cohort 1.",
        "Label": "Contradiction",
        "entail": "According to the provided CTRs, all reported adverse events in the primary trial were absent in cohort 1 of both the primary and secondary trials (as indicated by the number of occurrences in brackets being zero for all adverse events and both trials). Therefore, the statement that \"all of the adverse events recorded in the primary trial didn't occur in patients from cohort 1\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the data in the Primary Trial Adverse Events section where ANC/AGC events [1] and [2], Diarrhea [2], Mucositis/stomatitis and Vomiting [3], Pancreatitis [4], and Febrile neutropenia [2] are recorded to have occurred in 0/45 or 0/46 patients, respectively, but the statement claims that none of these events occurred in any patient from the primary trial.</s>"
    },
    "3a80ba8a-265f-4931-a9a8-b7e00e372599_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00432172",
        "Statement": "In the primary trial all of the adverse events occurred in patients from cohort 1.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if all patients in cohort 1 of the primary trial are included in the count of the 45 patients in the first Adverse Events section of the primary CTR, and none of the patients in cohort 1 of the primary trial are included in the count of the 46 patients in the first Adverse Events section of the secondary CTR. This is because the statement asserts that all adverse events occurred in patients from cohort 1 of the primary trial, while the CTRs provide the number of adverse events for each cohort in both trials. Since the number of adverse events for cohort 1 in the primary trial is zero in the secondary CTR (as per the information given), this statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"In the primary trial all of the adverse events occurred in patients from cohort 1\" is contradicted by the data in the CTRs because there are adverse events listed in both trials, and some of them occurred in patients from cohort 2 as well. For instance, pancreatitis occurred in one patient of the primary trial and no patient of the secondary trial (CTRs provide the number of occurrences for each adverse event and trial). Also, febrile neutropenia occurred in three patients of the primary trial and none of the secondary trial. However, the statement implies that no adverse events occurred in patients from cohort 2 of the primary trial.</s>"
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial only has one test cohort whereas the secondary trial has both a test and control group.",
        "Label": "Entailment",
        "entail": "The primary trial and the secondary trial describe distinct interventions, with the primary trial involving the use of supine MRI in addition to conventional imaging (intervention 1 for the primary trial), while the secondary trial consists of a decision support workshop (intervention 1) and standard care (intervention 2) for separate groups. The statement asserts that the primary trial has only one test cohort, while the secondary trial has both a test and control group.\n\nThe information in the statement can be entailed by the CTRs as follows:\n\n1. The primary trial only includes a single intervention (supine MRI with intraoperative optical scanning and tracking) for its test cohort, and thus can be considered to have only one test cohort.\n2. The secondary trial includes two distinct interventions: a decision support workshop for the test group and routine pre-consultation education for the control group. This arrangement constitutes having both a test and a control group.\n\nTherefore, the statement's claim that the primary trial has only one test cohort, whereas the secondary trial has both a test and control group, is consistent with the information presented in the CTRs.</s>",
        "contradict": "The statement \"the primary trial only has one test cohort whereas the secondary trial has both a test and control group\" contradicts the information presented in the CTRs because the primary trial involves a group receiving MRI in addition to conventional imaging (group MRI), which can be considered as an intervention or treatment cohort. However, it does not explicitly state that there is a control group in the primary trial, but it is not stated that there isn't one, either. The secondary trial, on the other hand, does involve a control group receiving standard care. Therefore, the statement oversimplifies the trial designs presented in the CTRs and makes an incorrect assumption based on incomplete information.</s>"
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "The primary trial only doesn't have one test cohort whereas the secondary trial has both a test and control group.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial only has one test cohort whereas the secondary trial has both a test and control group\" is not directly entailed by the information presented in the CTRs. The Intervention section of the primary CTR mentions the addition of supine MRI to conventional imaging as the intervention, without specifying a control or comparison group. The Intervention section of the secondary CTR describes a Decision Support Workshop as one intervention and Standard Care as another. Therefore, the statement makes a comparison between the trial designs, which is not explicitly stated in the CTRs. However, the information in the CTRs is not contradictory to the statement and allows for the interpretation that the primary trial may not have a control group, while the secondary trial does.</s>",
        "contradict": "The statement \"The primary trial only doesn't have one test cohort whereas the secondary trial has both a test and control group\" contradicts the information in the CTRs because, in the primary trial, the use of supine MRI as an intervention in conjunction with conventional imaging is described, implying the presence of a study group receiving this intervention. However, the statement asserts that the primary trial does not have a test cohort, which is not consistent with the information provided in the CTR. In contrast, the secondary trial does indeed have a control group receiving standard care and a test group attending the decision support workshop, as stated in the description.</s>"
    },
    "df4b98f2-7ca9-4855-8d94-d62407ff8535_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "The secondary trial has both a test and control group wereas the primary trial only has one test cohort.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial has both a test and control group whereas the primary trial only has one test cohort\" does not directly entail any information present in the given CTRs. However, it is a valid observation based on the trial designs described. In the context of the CTRs, the primary trial is using an innovative imaging technique as an intervention, while the secondary trial includes a decision support workshop as well as standard care as interventions. The designation of these as a test group or control group for the secondary trial is not explicitly stated in the CTRs. Nonetheless, it is a common experimental design to compare a new intervention with a control or standard care group, which aligns with the information provided in the CTRs. Therefore, while the statement is not a direct entailment of the CTRs, it is a consistent and reasonable extension based on standard clinical trial design practices.</s>",
        "contradict": "The statement \"The secondary trial has both a test and control group where as the primary trial only has one test cohort\" is contradicted by the information in the CTRs because, based on the provided information, only the primary trial has a defined experimental intervention (supine MRI with intraoperative optical scanning and tracking, denoted as INTERVENTION 1 in the primary trial), and the secondary trial describes a decision support workshop (denoted as INTERVENTION 1 in the secondary trial) and standard care (denoted as INTERVENTION 2 in the secondary trial), but it doesn't specify that there are separate test and control groups in the secondary trial for these interventions. The CTRs do not provide sufficient information to determine if the secondary trial has a control group or if participants are randomly assigned to the intervention or control groups.</s>"
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages.",
        "Label": "Entailment",
        "entail": "The given statement is entailed by the CTRs since the primary trial reports an instance of rectal bleeding (a type of hemorrhage) in one patient out of 44 (2.27%), and the secondary trial reports an instance of vaginal hemorrhage in one patient out of 1634 (0.06%). Both reports document occurrences of hemorrhages, and the specific sites of bleeding differ. Therefore, the statement is a valid inference from the information contained in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial records instances of rectal bleeding (not hemorrhage), whereas the secondary trial does not report any vaginal hemorrhages at all. Therefore, the statement implies a comparison between two different types of hemorrhage events, while the CTRs only report on distinct types of bleeding events from each trial.</s>"
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "The primary trial doesn't record instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages.",
        "Label": "Contradiction",
        "entail": "The statement does not claim that the primary trial reports an instance of rectal hemorrhage, but rather states that it does not. Simultaneously, the secondary trial reports instances of vaginal hemorrhage, which is distinct from rectal hemorrhage. The absence of rectal hemorrhage in the primary trial and the presence of vaginal hemorrhage in the secondary trial do not contradict each other, and both can be true. Therefore, the statement is entailed by the information present in the CTRs, as the CTRs do not report any contradictory findings regarding hemorrhages in the respective trials.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the primary trial reports one instance of Rectal bleeding, which is a form of hemorrhage, but the statement specifically mentions \"Rectal Hemorrhage\" not being recorded in the primary trial while only reporting Vaginal hemorrhages from the secondary trial.</s>"
    },
    "5d2542fa-5482-4aff-af29-80875a0a9dcc_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "The secondary trial records Vaginal hemorrhages, whereas the primary trial records instances of Rectal Hemorrhage within its patient cohort.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail information from the provided CTRs as there is no mention of vaginal hemorrhages in the primary trial's adverse events, nor is there a mention of rectal hemorrhages in the secondary trial's adverse events. However, the statement is stating a difference in the type of hemorrhages between the two trials and not making an assertion based on the data within the trials themselves. Therefore, the statement may be considered inconsistent with the information in the CTRs but not directly entailing or contradicting it.</s>",
        "contradict": "The statement \"The secondary trial records Vaginal hemorrhages, whereas the primary trial records instances of Rectal Hemorrhage\" is contradicted by the information provided in the CTRs because the primary trial reports one instance of Rectal bleeding, which is not the same as Vaginal hemorrhage. Therefore, the statement asserts a difference between the two trials regarding adverse events, whereas the actual data indicates no such difference.</s>"
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ Patients are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"HIV+ Patients are excluded from both the secondary trial and the primary trial\" is entailed by the information present in the CTRs as HIV positive patients are specifically listed as an exclusion criterion in both the primary and secondary trial's inclusion/exclusion sections.</s>",
        "contradict": "The statement \"HIV+ Patients are excluded from both the secondary trial and the primary trial\" is contradicted by the information in the CTRs as HIV positive patients are explicitly included as an exclusion criterion in the primary trial, but there is no mention of HIV status in the secondary trial's inclusion or exclusion criteria.</s>"
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "HIV+ Patients aren't excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"HIV+ Patients aren't excluded from both the secondary trial and the primary trial\" is not directly entailed by the provided CTRs. In the Primary Trial CTR, HIV-positive patients are explicitly listed in the Exclusion Criteria. However, this statement does not apply to all trials or sections within the CTRs, as there may be other trials with different inclusion and exclusion criteria. Therefore, the statement cannot be definitively proven to be entailed based on the given information alone.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as HIV positive patients are explicitly excluded from both the primary and secondary trials according to their respective inclusion criteria.</s>"
    },
    "5deb8ebd-fbd2-4d84-8ad2-a1248426908b_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "The secondary trial and the primary trial excluded HIV+ Patients.",
        "Label": "Entailment",
        "entail": "Both clinical trials explicitly list \"HIV positive patients\" as a part of their exclusion criteria, hence, the statement's claim that the secondary trial and primary trial excluded HIV+ patients is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"The secondary trial and the primary trial excluded HIV+ Patients\" is in agreement with the information present in both CTRs as they both list HIV infection as an exclusion criterion. However, the contradiction lies in the context of the comparison between the two trials, as the statement does not specify that the exclusion is identical in both trials. It is possible for two clinical trials to have identical exclusion criteria for some factors, but differ in others. In this scenario, the statement does not provide sufficient information to definitively establish entailment.</s>"
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Entailment",
        "entail": "The statement \"To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL\" can be entailed by the information present in the CTRs because:\n\nFor the primary trial, the inclusion criteria specify that alkaline phosphatase must be less than 2.5 x ULN (and AST must also be less than 1.5 x ULN), and that hemoglobin must be greater than or equal to 10 g/dL. Thus, the more restrictive alkaline phosphatase criterion (< 2 x ULN) and the hemoglobin requirement (> 10 g/dL) in the statement are met by the primary trial's requirements.\n\nFor the secondary trial, the inclusion criteria specify that alkaline phosphatase, AST, and bilirubin must all be less than 2 times the ULN, and hemoglobin must be greater than 10 g/dL. Therefore, the statement's requirement that alkaline phosphatase be less than 2 x ULN and hemoglobin be greater than 10 g/dL are also satisfied by the secondary trial's criteria.\n\nThus, the statement that patients must satisfy the conditions of alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN, and Hemoglobin > 10 g/dL in order to be eligible for both trials is logically consistent with the eligibility criteria specified in the provided CTRs, and can be entailed by them.</s>",
        "contradict": "The statement implies that both the primary and secondary trials have the same requirements for alkaline phosphatase, aspartate aminotransferase, and hemoglobin levels for patient eligibility. However, this is not the case as the primary trial has additional conditions related to these laboratory values that are not mentioned in the statement. The primary trial specifies that alkaline phosphatase and aspartate aminotransferase may not both be greater than the ULN and that if one value is greater than ULN but less than 2.5 x ULN, the other value must be less than or equal to ULN. Additionally, patients with certain conditions, like skeletal pain or alkaline phosphatase greater than ULN but less than 2.5 x ULN, are still eligible for inclusion if specific imaging tests and results are met. These additional conditions contradict the statement and demonstrate that the requirements for these laboratory values are not identical in both trials.</s>"
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": "To be eligible for both the secondary trial and the primary trial patients must don't satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Contradiction",
        "entail": "The statement that a patient must not satisfy all the conditions of having alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN, and hemoglobin > 10 g/dL for eligibility in both trials, is entailed by the CTRs as follows:\n\n1. In the primary trial: The CTR explicitly states that patients with alkaline phosphatase or aspartate aminotransferase greater than ULN are eligible for inclusion, as long as imaging studies do not demonstrate metastatic disease and adequate hepatic or renal function is confirmed. Therefore, a patient with alkaline phosphatase or aspartate aminotransferase above ULN but below 2 x ULN could still be eligible. However, hemoglobin levels must be greater than 10 g/dL for eligibility. Hence, not all these conditions (alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN, and hemoglobin > 10 g/dL) must be satisfied for eligibility in the primary trial.\n\n2. In the secondary trial: The CTR does not specify a hemoglobin level requirement; however, it does state that patients must have their values for bilirubin, AST, and alkaline phosphatase within normal limits. These limits are not explicitly stated; thus, they may allow for slightly elevated values (i.e., below 2 x ULN for alkaline phosphatase and AST). Therefore, a patient with alkaline phosphatase or aspartate aminotransferase above normal limits but below 2 x ULN could still be eligible.\n\nSince both trials allow for some flexibility with respect to alkaline phosphatase and aspartate aminotransferase, but require hemoglobin above 10 g/dL (primary trial) or within normal limits (secondary trial), patients will not satisfy all the conditions in the statement (i.e., alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN, and hemoglobin > 10 g/dL) for eligibility in both trials.</s>",
        "contradict": "The statement that \"To be eligible for both the secondary trial and the primary trial patients must not satisfy all the following conditions: alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL\" is contradicted by the information present in the CTRs because:\n\n1. The primary trial inclusion criteria include patients having either alkaline phosphatase greater than ULN but less than/equal to 2.5 x ULN (if a bone scan or PET scan does not demonstrate metastatic disease), or AST greater than ULN but less than/equal to 1.5 x ULN (if liver imaging does not demonstrate metastatic disease and adequate hepatic function). These patients are eligible for inclusion in the study. Therefore, patients with alkaline phosphatase or AST levels between ULN and 2.5 x ULN are not necessarily excluded from the primary trial.\n\n2. The secondary trial inclusion criteria include patients who have alkaline phosphatase < 2 times ULN, but this is only one of several inclusion criteria for the secondary trial. The statement incorrectly implies that this is a requirement for being eligible for both trials, which is not the case.\n\n3. The primary trial also has specific inclusion criteria regarding hematological function (hemoglobin > 10 g/dL) which is in contradiction to the statement that \"patients must not satisfy all the following conditions: Hemoglobin > 10 g/dL\" for both trials.\n\nHence, the statement \"To be eligible for both the secondary trial and the primary trial patients must not satisfy all the following conditions: alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL\" is contradicted by the information present in the CTRs.</s>"
    },
    "5f4880ac-1ce2-4b89-841b-a9918720b6ea_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": "All the following conditions must be satisfied; alkaline phosphatase  < 2 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL, for patients to be eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The given condition for eligibility in both trials requires that alkaline phosphatase be less than 2 times the upper limit of normal (ULN), aspartate aminotransferase (AST) be less than or equal to 1.5 times ULN, and hemoglobin be greater than 10 g/dL. These conditions are present in the primary trial's inclusion criteria as follows:\n\n1. Alkaline phosphatase and AST: \"Patients must have the following criteria for evidence of adequate hepatic function: total bilirubin must be less than/equal to ULN for the lab unless the patient has a grade 1 bilirubin elevation, and alkaline phosphatase must be less than 2.5 x ULN for the lab; AST must be less than/equal to 1.5 x ULN for the lab. Alkaline phosphatase and AST may not both be greater than the ULN.\"\n2. Hemoglobin: \"Patients must have their blood counts meet the following criteria: hemoglobin must be greater than/equal to 10 g/dL.\"\n\nHence, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement's conditions for eligibility in both trials (secondary and primary) concerning alkaline phosphatase, aspartate aminotransferase, and hemoglobin can be contradicted by the CTR information as follows:\n\n1. In the primary CTR, patients with alkaline phosphatase or aspartate aminotransferase greater than upper limit of normal (ULN) but less than/equal to 2.5 x ULN are eligible, provided liver imaging (computed tomography [CT], MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function.\n2. In the primary CTR for inclusion in the secondary trial, alkaline phosphatase must be less than 2 times ULN.\n3. In the primary CTR for inclusion in the secondary trial, aspartate aminotransferase must be less than/equal to 1.5 x ULN.\n4. In the primary CTR, there is no explicit requirement for hemoglobin to be greater than 10 g/dL for both trials; only the primary trial states this condition for eligibility.\n\nTherefore, a patient with elevated alkaline phosphatase or aspartate aminotransferase, who meets all other inclusion criteria for both trials according to the primary CTR, would not satisfy the statement's conditions for both trials. This contradiction highlights the need for a thorough examination of individual CTR sections to ensure the accuracy and consistency of statements regarding clinical trial eligibility.</s>"
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO\" can be entailed by the information present in the CTRs because: \n\n1. The statement uses the term \"cohort 1 of the primary trial\", which matches the first intervention described in the CTR as \"Afatinib Mono\" under the primary trial section.\n2. The statement states that patients in this cohort may receive a gradually increasing dose of Afatinib monotherapy, which is consistent with the information in the CTR stating that if a patient is well-tolerated, the dose may be escalated from 40 mg to 50 mg.\n3. The statement uses the correct dose units and route of administration for Afatinib monotherapy, matching the information in the CTR that the dosage is in mg per day and the treatment is given orally.</s>",
        "contradict": "The information in the expert statement can be contradicted by the information in the CTRs if cohort 1 of the primary trial includes patients who received Afatinib+Vino instead of Afatinib Mono. The expert statement refers to \"patients in cohort 1 of the primary trial,\" but it does not specify that these patients are receiving monotherapy. However, according to the CTR, only cohort 1 of the primary trial receives Afatinib Mono, so the statement could be contradictory in this scenario.</s>"
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may not receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in cohort 1 of the primary trial may not receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO\" can be entailed by the information in the CTRs as follows:\n\nThe primary trial's Intervention 1 specifies that the starting dose of Afatinib monotherapy is 40 mg per day, and if the patient is well tolerated, the dose may be escalated to 50 mg. However, it does not state that all patients will receive a dose escalation. Hence, there is no entitlement for patients in cohort 1 to receive gradually increasing doses from 40mg PO to 50mg PO as stated in the expert's claim.</s>",
        "contradict": "The statement is contradicted by the information in the CTR as patients in Intervention 1 of the primary trial are explicitly allowed to escalate their Afatinib dosage from 40 mg to 50 mg if they are well tolerated.</s>"
    },
    "b3aabfaa-23cb-4a75-8416-761d8574f0a4_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO may be received by patients in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement \"Gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO may be received by patients in cohort 1 of the primary trial\" is entailed by the CTR information as follows:\n\n1. The CTR for the primary trial states that the starting dose of Afatinib monotherapy is 40 mg per day.\n2. If a patient is well tolerated at this dose, the dose may be escalated to 50 mg per day.\n3. The expert statement suggests that some patients in cohort 1 may receive the escalated dose of 50 mg per day, which aligns with the CTR description.\n\nTherefore, the expert statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"Gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO may be received by patients in cohort 1 of the primary trial\" is not directly contradictory to the information in the CTRs. However, it is not entailed either since the CTR only states that the dose may be escalated to 50 mg if the patient is well tolerated, without specifying that the dose increase must be gradual. Thus, the dose increase could potentially be immediate for some patients. Therefore, the statement is neither contradictory nor entailed based on the provided information in the CTRs.</s>"
    },
    "f697c2d8-e0dd-476e-8ff4-dffe053076f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the CTRs as the pCR rates stated in the CTRs for the Trastuzumab (54%) and Lapatinib (45%) arms can be directly compared to derive the stated conclusion. The CTRs provide the number of participants achieving pCR for each arm and the percentage calculation is consistent across both trials. The expert's statement is based on the presented data without contradicting or altering the information given in the CTRs.</s>",
        "contradict": "The statement is not directly contradictory to the information in the CTRs, but it makes a claim about the comparative pCR rates between the Trastuzumab and Lapatinib arms, which is not explicitly stated in the provided data. The CTRs only report the number and percentage of participants achieving pCR in each arm. The statement assumes that the trials had an adequate number of participants and similar designs to permit valid comparisons, but no such information is given in the provided CTRs. Therefore, the comparison made in the statement may not be accurate, as the trials' differences in sample size and other factors, such as baseline characteristics or compliance to treatments, could impact the pCR rates.</s>"
    },
    "f2c0f753-1775-42af-94f0-b87b20156e65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions ",
        "Label": "Contradiction",
        "entail": "The provided statement is entailed by the information presented in the CTRs as neither the Primary nor the Secondary trial employ Chemotherapy, Radiotherapy, or Mammography in their interventions. \n\nIn the Primary trial, Intervention 1 and Intervention 2 both utilize Digital Breast Tomosynthesis and Synthetic Mammography, which are non-invasive imaging techniques and not forms of Chemotherapy or Radiotherapy. In Intervention 1, DBT is used for screening, while in Intervention 2, both DBT and Synthetic Mammography are employed. The use of these techniques does not involve the application of Chemotherapy or Radiotherapy.\n\nIn the Secondary trial, Intervention 1 involves Yoga Therapy and Intervention 2 is a Wait-List control, neither of which entail the usage of Chemotherapy, Radiotherapy, or Mammography.\n\nTherefore, the statement that \"the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions\" is in accordance with the data presented in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions\" is contradicted by the following information in the CTRs:\n\nPrimary Trial:\nINTERVENTION 1 & 2: Both interventions involve the use of Synthetic Mammography in Digital Breast Tomosynthesis.\n\nSecondary Trial: \n(This trial does not involve mammography or chemotherapy in its interventions, as stated. However, it does not directly concern the primary trial and is not a contradiction in itself.)\n\nHowever, the contradiction lies in the fact that the statement generalizes to both trials, while the information in the CTRs only applies to the primary trial in regards to mammography (Digital Breast Tomosynthesis with Synthetic Mammography). Therefore, the statement is only partially incorrect for the secondary trial, but completely incorrect if the statement is intended to apply to both trials in its entirety.</s>"
    },
    "17b31c1d-db62-4628-b390-02da22512079": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with aromatestinib inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial\" is entailed by the information present in the CTRs because the CTR specifies that one of the inclusion criteria for the primary trial is the presence of aromatase inhibitor-associated musculoskeletal symptoms, as defined by the criteria provided in the text.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information in the CTRs as it aligns with the inclusion criteria mentioned in the primary trial section. However, the CTRs provide a more detailed description of the specific types and severity of musculoskeletal symptoms required for eligibility. The expert's statement is more general, only mentioning \"musculoskeletal symptoms,\" whereas the CTRs specify \"musculoskeletal pain that developed or worsened (6 or 7 on CGICS)\" and \"sensory neuropathy that developed or worsened (6 or 7 on CGICS)\" as the required symptoms. While the expert's statement is not contradictory, it may not fully capture the specificity of the CTRs' eligibility criteria.</s>"
    },
    "17b31c1d-db62-4628-b390-02da22512079_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, aren't eligible for the primary trial\" is entailed by the information present in the CTRs because the primary trial specifically excludes patients who have developed or worsened Grade 1 or higher musculoskeletal pain or sensory neuropathy during AI therapy (CTR, Inclusion Criteria). Therefore, individuals who experience these symptoms are not permitted to participate in the study.</s>",
        "contradict": "The information in the expert's statement is not an exact contradiction to the information in the CTRs, but it is not a complete reflection of the inclusion criteria in the CTRs either. The expert's statement focuses on the specific condition of \"aromatase inhibitor associated musculoskeletal symptoms\" as a reason for exclusion. However, the CTRs include multiple conditions for exclusion, one of which is the presence of AI-associated musculoskeletal symptoms, specifically those that meet the defined grade and pain level. Therefore, the expert's statement does not contradict the CTRs directly, but it could be seen as an oversimplification, as the CTRs also specify other exclusion criteria.</s>"
    },
    "17b31c1d-db62-4628-b390-02da22512079_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "The primary trial doesn't exclude patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy.",
        "Label": "Entailment",
        "entail": "The CTR's inclusion criteria state that patients with AI-associated musculoskeletal symptoms (Grade 1 or higher musculoskeletal pain and/or Grade 1 or higher sensory neuropathy) can participate in the study. Therefore, the expert statement, which acknowledges that the primary trial does not exclude patients with these symptoms, follows logically from the information in the CTR.</s>",
        "contradict": "The statement made by the clinical trial expert is not directly contradictory to the CTR information; however, it can be considered misleading. The CTR does include patients with AI-associated musculoskeletal symptoms (as stated in the inclusion criteria), but the expert statement could imply that the primary trial includes patients with any type of musculoskeletal symptoms, regardless of their association with AI therapy. This is not the case, and the CTR specifically mentions that the symptoms should be related to AI therapy to be included. Therefore, while not a contradiction, the expert statement could create a misunderstanding about the trial eligibility criteria.</s>"
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy is used in all cohorts of the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as both the primary and secondary trials involve the use of radiotherapy for all cohorts. In the primary trial, Intervention 1 (A) specifies that patients receive radiotherapy, and Intervention 2 (B) also includes radiotherapy for the control arm. In the secondary trial, all participants receive radiation for the treatment of breast cancer, regardless of the type of surgery. Hence, the statement \"Radiotherapy is used in all cohorts of the primary trial and the secondary trial\" is an entailed conclusion from the provided CTR data.</s>",
        "contradict": "although both trials involve radiotherapy as a common intervention, the healing touch therapy in the primary trial (INTERVENTION 1 of the primary trial) is not included in the secondary trial (INTERVENTION 1 of the secondary trial). Consequently, the statement is not entirely accurate since it does not distinguish between the specific interventions within the radiotherapy category.</s>"
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "Radiotherapy isn't used in all cohorts of the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Radiotherapy isn't used in all cohorts of the primary trial\" is entailed by the Intervention sections in the CTR as they specify different treatment arms: Intervention 1 of the primary trial involves the use of radiotherapy, while Intervention 2 (control arm) uses sham healing touch therapy instead. This means that not all cohorts receive radiotherapy.\n\nRegarding the secondary trial, the Intervention section clearly mentions Hypofractionated Simultaneous Integrated Boost Radiotherapy, indicating that radiotherapy is indeed used. However, the statement focuses on all cohorts of the primary trial, and since not all cohorts in the primary trial receive radiotherapy, the statement is entailed.\n\nTherefore, the statement that \"Radiotherapy isn't used in all cohorts of the primary trial\" harmonizes with the clinical trial data, finds substantiation in the CTR, and avoids contradiction with the provided descriptions. The same reasoning applies to the fact that radiotherapy isn't used in all cohorts of both trials.</s>",
        "contradict": "The statement \"Radiotherapy isn't used in all cohorts of the primary trial and the secondary trial\" is contradicted by the information in the CTRs, because radiotherapy is a common intervention across both trials. In the primary trial, both intervention groups (A and B) involve radiotherapy. In the secondary trial, all participants receive radiotherapy as part of their treatment.</s>"
    },
    "2e6e1044-8b4a-41f7-8319-85fc5bba4482_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00574145",
        "Secondary_id": "NCT03167359",
        "Statement": "The primary trial and the secondary trial uses radiotherapy in all cohorts.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial and the secondary trial use radiotherapy in all cohorts\" is entailed by the CTRs since both trials involve radiotherapy as a common intervention for participants in each trial. In the primary trial, patients in intervention 1 receive radiotherapy, and in the secondary trial, participants undergo hypofractionated simultaneous integrated boost radiotherapy. Therefore, the use of radiotherapy is present in both trials for all cohorts, satisfying the conditions outlined in the expert's statement.</s>",
        "contradict": "Although both primary and secondary trials involve the use of radiotherapy for all cohorts, the interventions differ in the additional therapies administered alongside radiotherapy. In the primary trial, patients receive healing touch therapy or sham healing touch therapy, which is not mentioned in the secondary trial. Therefore, the statement can be contradicted by the information in the CTRs.</s>"
    },
    "456c6011-52bb-4c8b-9e82-e5a85cbbe0e3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the provided CTRs, as there is no mention of MRSA infections in either Adverse Events 1 section. However, it's possible to infer that MRSA infections are types of infections, which are reported as adverse events in clinical trials. In the primary and secondary trials, various infections are listed as adverse events with differing frequencies. Therefore, the expert's statement does not contradict the information in the CTRs and could potentially be considered related, although it doesn't entail the exact information provided in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs. However, it does not follow semantically as there is no mention of MRSA infections in the provided Adverse Events sections. Therefore, the statement does not entail the information in the CTRs, but it also does not contradict them.</s>"
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "the primary trial's intervention section does not describe the intervention dosage, frequency or duration.",
        "Label": "Entailment",
        "entail": "The primary CTR only mentions the procedures for recruiting and enrolling the population into the trial without specifying the intervention dosage, frequency, or duration. The secondary statement asserts that the primary trial's intervention section does not provide this information. The two descriptions are consistent, as the primary CTR does not entail the presence or absence of intervention dosage, frequency, or duration details. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs if the primary trial's intervention section actually does describe the intervention dosage, frequency, or duration, either explicitly or implicitly. For example, if the CTR states that participants received a specific dose of a medication twice a day for six weeks, then the statement is contradictory to the facts presented in the CTR. The statement's generalization that the intervention section does not provide this information is not sufficient justification for entailment, given that the CTRs should be examined for specific trial details.</s>"
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "The primary trial's intervention section describes the intervention dosage, frequency or duration.",
        "Label": "Contradiction",
        "entail": "The primary trial's intervention section does not necessarily describe the intervention dosage, frequency, or duration in the provided quote. Instead, it describes the population recruitment and enrollment processes preceding randomization. In the secondary trial CTR, no intervention details are mentioned. Therefore, the expert's statement does not directly entail the information from the CTRs. However, this does not necessarily mean that there is no entailment relationship, as the expert's statement might be referring to a different trial or context. To establish entailment, more context would be required.</s>",
        "contradict": "The statement \"The primary trial's intervention section describes the intervention dosage, frequency or duration\" can be contradicted by the information present in the CTRs if the intervention section of the primary trial does not provide details on the intervention dosage, frequency, or duration. In this case of the provided CTR snippets, there is no mention of any specific dosage, frequency, or duration information for the interventions in either the primary or secondary trials. Therefore, the statement could be incorrect for these trials.</s>"
    },
    "0c0324d2-0672-45cb-b715-e51e48786afb_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03618017",
        "Statement": "The intervention dosage, frequency or duration is not described in the primary trial's intervention section.",
        "Label": "Entailment",
        "entail": "The primary trial's intervention section only provides information about the recruitment population and pre-randomization enrollment processes. It does not specify the intervention dosage, frequency, or duration. The statement made by the clinical trial expert is entailed by this information because the expert's claim aligns with the actual absence of dosage, frequency, and duration data in the primary trial's intervention section.</s>",
        "contradict": "The statement contradicts the information in the primary CTR because the intervention section in the primary trial does provide details regarding the treatment dosage, frequency, and duration for Intervention 1. The expert's statement erroneously assumes the absence of such information in the CTR.</s>"
    },
    "b3bd3522-8731-448a-bade-a5a350697a98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that in the primary trial, a certain number of patients experienced adverse events related to a low number of white blood cells in their bloodstream. The CTR reports that in Adverse Events 1 of the primary trial, 5 out of 67 patients (7.46%) suffered from Febrile Neutropenia, a condition characterized by fever and neutropenia (low number of white blood cells). This aligns with the expert's statement and is an entailed relationship.</s>",
        "contradict": "The expert's statement is incompatible with the CTR data as there is no evidence in the Primary Trial Adverse Events section indicating a low number of white blood cells in the majority of the patients (more than 9). The mentioned adverse events related to conditions like Febrile Neutropenia, Neutropenia, and Leukopenia which are related to low white blood cell count, but the number of patients with these conditions are 5/67 (7.46%), 0/67 (0.00%), and 0/67 (0.00%) respectively. Therefore, the statement contradicts the data in the CTR.</s>"
    },
    "8607e8c1-6e99-49be-a63e-e707856c805a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information in the CTRs as the treatments and interventions described in the CTRs are vastly different, and the statement makes an incorrect assumption about the treatments in the secondary trial being \"supportive-expressive group psychotherapy\" instead of the actual drugs mentioned, Afatinib and Lapatinib.</s>",
        "contradict": "The statement is not entailed in the information provided in the Clinical Trial Reports (CTRs) because the statement asserts that patients in the secondary trial receive \"supportive-expressive group psychotherapy instead\" of receiving drugs, which is not mentioned or implied in the CTRs. The CTRs describe the interventions given in each trial but do not suggest that patients in the secondary trial receive psychotherapy instead of drugs.</s>"
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time.",
        "Label": "Entailment",
        "entail": "The statement \"On average, patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time\" can be entailed by the information presented in the CTRs as follows:\n\n1. Both arms in the primary trial received treatment on Day 2 of each chemotherapy cycle.\n2. The length of Grade 4 Neutropenia for both F-627 and Neulasta arms is provided in the CTR under the 'Results' section.\n3. The means and standard deviations for the durations of Grade 4 Neutropenia for each arm are stated as 0.2 days (0.51) for F-627 and 0.2 days (0.45) for Neulasta, respectively.\n4. Since both treatments are given on the same day and for the same duration (up to 4 cycles), it is reasonable to assume that, on average, patients from both arms experienced the same duration of Grade 4 Neutropenia.</s>",
        "contradict": "The statement \"On average patients from both arms experienced Grade 4 Neutropenia for the same amount of time\" contradicts the CTR information because the mean durations of Grade 4 neutropenia for the F-627 arm (0.2 days with a standard deviation of 0.51 days) and the Neulasta arm (0.2 days with a standard deviation of 0.45 days) are provided in the CTRs. These means may not be equal, even though they are very close, which contradicts the assumption of the expert statement that the average duration is the same for both arms.</s>"
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "On average patients from both arms of the primary trial didn't experience Grade 4 Neutropenia for the same amount of time.",
        "Label": "Contradiction",
        "entail": "The statement \"On average, patients from both arms of the primary trial didn't experience Grade 4 Neutropenia for the same amount of time\" can be entailed by the information present in the CTRs as follows: \n\n1. Both F-627 and Neulasta groups in the primary trial had patients who were randomized in a 1:1 ratio and received their respective study drugs on Day 2 of each chemotherapy cycle.\n    (CTR: \"Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy on Day 2 of each chemotherapy cycle.\")\n\n2. The mean duration (in days) of Grade 4 neutropenia for each group is provided in the Results section.\n    (CTR: \"Results 1: Mean (SD) = 0.2 (0.51) days for F-627 group; Results 2: Mean (SD) = 0.2 (0.45) days for Neulasta group.\")\n\n3. The statement claims an average difference in the duration of Grade 4 neutropenia for both arms, which can be determined by calculating the absolute difference between the means and the standard deviations.\n    (Calculation: |0.2 (F-627) - 0.2 (Neulasta)| = |0.01|)\n\n4. The absolute difference between the means is smaller than the average standard deviation for both groups (0.51 for F-627 and 0.45 for Neulasta), indicating that the difference may not be statistically significant.\n    (Interpretation: The statement \"On average, patients from both arms didn't experience Grade 4 Neutropenia for the same amount of time\" is an approximation and is consistent with the given CTR data.)\n\nThus, the statement \"On average, patients from both arms of the primary trial didn't experience Grade 4 Neutropenia for the same amount of time\" can be entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement is contradictory to the CTR information because:\n\n1. The CTR specifies that the duration of Grade 4 Neutropenia for both F-627 and Neulasta arms is reported as 0.2 days for the mean with standard deviations of 0.51 and 0.45 respectively.\n2. The expert's statement implies that the average duration of Grade 4 Neutropenia for patients from both arms was not the same.\n\nHowever, the data from the CTR does not support this statement as they both report a mean duration of 0.2 days for both treatments, suggesting that the average duration for patients in the F-627 and Neulasta arms is, in fact, the same. This discrepancy arises from the expert's misinterpretation of the data presented in the CTR.</s>"
    },
    "1c26e1a7-9d77-46ff-b1c6-179ece7c190f_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "Grade 4 Neutropenia for the same amount of time is experienced on average by patients from both arms of the primary trial.",
        "Label": "Entailment",
        "entail": "both trials involved the same chemotherapy regimen and defined Grade 4 neutropenia as ANC <0.5 \u00d7 109/L within the first 12 days of chemotherapy; the primary CTRs reported that the mean duration of Grade 4 neutropenia for F-627 group was 0.2 days (0.51 standard deviation) and for Neulasta group was 0.2 days (0.45 standard deviation); these means are not significantly different (as evidenced by the small standard deviations), indicating that on average, patients from both arms experienced Grade 4 neutropenia for similar durations.</s>",
        "contradict": "The information in the statement \"Grade 4 Neutropenia for the same amount of time is experienced on average by patients from both arms of the primary trial\" cannot be directly inferred from the CTRs provided. The CTRs report different means (0.2 days with a standard deviation of 0.51 for F-627 arm and 0.2 days with a standard deviation of 0.45 for Neulasta arm) for the duration of Grade 4 neutropenia in chemotherapy cycle 1. Although the means are similar, the variances are not equal, which suggests that the distributions might be different. Thus, the statement could be contradicted by the data in the CTRs.</s>"
    },
    "0a156ee2-eb90-40d2-9802-27b9b4a42ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In cohort 2 and 3 of the primary trial there was only case 1 of jaundice.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because in the Primary Trial's Adverse Events section, there is only one instance (1/65 or 1.54%) of jaundice reported for all participants. In the cohorts 2 and 3, the number of participants is not provided, but since the statement specifically mentions that there was only one case of jaundice in these cohorts, it follows logically that the number of participants in these cohorts was less than or equal to 1. Therefore, the statement is consistent with the information provided in the CTRs and does not contradict it.</s>",
        "contradict": "The statement \"In cohort 2 and 3 of the primary trial there was only case 1 of jaundice\" contradicts the information in the CTR as there are two instances of jaundice reported in the primary trial, one in each of the sections labeled as \"Adverse Events 1\" under the primary and secondary trials. Therefore, the statement's claim that there was only one instance of jaundice in cohorts 2 and 3 is incorrect.</s>"
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event reports.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial have entirely different adverse event reports\" can be entailed by the information present in the CTRs based on the observation that the total number of adverse events, as well as the types of adverse events, differ significantly between the primary and secondary trials. In the primary trial, the total number of adverse events is 2 out of 17 participants (11.76%), whereas in the secondary trial, the total number is 19 out of 51 participants (37.25%). Additionally, there are distinct adverse event types present in each trial, such as nausea, pain-abdomen NOS, constipation in the primary trial versus anemia, leukopenia, neutropenia, thrombocytopenia, pericarditis, atrial flutter, cardiac failure congestive, visual impairment, dysphagia, abdominal pain, chills in the secondary trial. These observations directly correspond to the statement made by the clinical trial expert.</s>",
        "contradict": "Although the statement asserts that the primary and secondary trials have entirely different adverse event reports, this claim can be contradicted by the provided CTR data. Both trials report the occurrence of adverse events in their respective cohorts, including some similar events like nausea, pain, and constipation in the primary trial, and anemia, leukopenia, neutropenia, thrombocytopenia, and dysphagia in the secondary trial. However, the frequency and percentage of these events differ significantly between the trials. Therefore, while the types of adverse events may overlap, the statement only focuses on the difference in total adverse event count without accounting for this nuance, leading to an incomplete assessment of the semantic relationship between the CTRs and the expert statement.</s>"
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "The primary trial and the secondary trial don't have entirely different adverse event reports.",
        "Label": "Contradiction",
        "entail": "The given statement can be entailed by the information in the CTRs as the adverse event types mentioned in the statement (nausea, pain - Abdomen NOS, constipation, anaemia, leukopenia, neutropenia, thrombocytopenia, pericarditis, dysphagia, abdominal pain, chills) are present in both trials, even though their respective frequencies may differ. Additionally, the statement does not contradict any information provided in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as the frequency and types of adverse events differ significantly between the two trials. In the primary trial, the total number of adverse events is 2/17 or 11.76%, while in the secondary trial, the total number of adverse events is 19/51 or 37.25%. Moreover, while nausea, pain - Abdomen NOS, and constipation were reported in the primary trial, they are not mentioned in the secondary trial, and conversely, anemia, leukopenia, neutropenia, thrombocytopenia, pericarditis, atrial flutter, cardiac failure congestive, visual impairment, dysphagia, and chills were reported in at least one of the secondary trials but not in the primary trial. Therefore, the statement is not entailed by the provided CTR data.</s>"
    },
    "82895f11-37bf-4d03-8de2-84818d93cce0_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "Entirely different adverse event reports are observed in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"entirely different adverse event reports are observed in the primary trial and the secondary trial\" can be entailed by the information present in the CTRs because the frequency, type, and count of adverse events vary significantly between the two trials. In the primary trial, the total number of adverse events is 2/17, while in the secondary trial, it is 37.25% (19/51), indicating a marked difference in the prevalence and types of adverse events in each trial. The statement correctly reflects this observation. Additionally, none of the statements contradict the provided descriptions or assertions in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR information as the number and types of adverse events reported in the primary and secondary trials may differ in frequency or specificity, but this does not necessarily imply they are entirely different. The given statement oversimplifies the comparison, as some similarities and differences could exist between the two sets of data, and a more nuanced analysis is required to establish any entailment relationship.</s>"
    },
    "f94643de-7122-4a58-972d-b0bb7e59d441": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0\" does not directly relate to the provided Adverse Events data. However, the absence of Pancreatitis events in Adverse Events 2 of the secondary trial, and the presence of 2 Pancreatitis cases in Adverse Events 1 of the primary trial, can be taken as an indirect indication that there were no reported cases of Pancreatic Cancer in the secondary trial. This inference does not contradict any information in the CTRs and is consistent with the reported data. Therefore, the statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement does not contradict the information in the CTRs regarding adverse events directly. However, it can be contradicted in the context of the overall trial participant information. The statement mentions nothing about the number of patients with pancreatic cancer in the trials, and the CTRs do not provide this information. Therefore, the statement is not directly contradictory based on the given information about adverse events. However, if we consider the broader context of the trials, the statement is contradictory because the primary trial does not report any cases of pancreatic cancer amongst the adverse events, whereas the statement asserts that there were 3 patients with pancreatic cancer in the primary trial.</s>"
    },
    "1485315b-3169-42a3-a672-6f7963d49a51": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis.",
        "Label": "Entailment",
        "entail": "The statement \"Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis\" is entailed by the information present in the CTRs because both trials include the same type of analysis, \"Laboratory Biomarker Analysis,\" for all their respective treatment arms. In the primary trial, this analysis is mentioned in the interventions sections for both arms I and II, while in the secondary trial, it is explicitly stated for both arms I and II as well.</s>",
        "contradict": "The statement \"Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis\" is not contradicted by the information present in the CTRs, as both trials indeed involve Laboratory Biomarker Analysis for all participants according to the given information. However, the statement may be contradicted if further information in the CTRs revealed that not every participant actually underwent biomarker analysis despite the stated interventions.</s>"
    },
    "1485315b-3169-42a3-a672-6f7963d49a51_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial doesn't undergo Laboratory Biomarker Analysis.",
        "Label": "Contradiction",
        "entail": "The statement \"Every participant in the secondary trial and the primary trial doesn't undergo Laboratory Biomarker Analysis\" is not directly entailed by the provided CTR information because: \n\n1. While not every participant undergoes laboratory biomarker analysis in both trials, the CTRs do state that \"laboratory biomarker analysis: Correlative studies\" is included for both Intervention 1 (Omega-3 Fatty Acid and Curcumin-based Gel) and Intervention 2 (Placebo and HPR Plus\u2122) in both trials. It is crucial to differentiate between every participant undergoing the analysis and the analysis being a part of the study design.\n\n2. The statement is a universal negative claim (\"Every participant...\"), while the CTRs only provide information about specific aspects of each trial. The CTRs do not state that every participant in either trial undergoes laboratory biomarker analysis, but they do state that the analysis is part of the study design for all participants in both trials. \n\nHowever, it is important to note that the statement could still be true based on the provided CTRs, but additional information would be required to definitively determine its validity. For example, if there are reasons to believe that not every participant underwent laboratory biomarker analysis (such as a lack of funding, participant withdrawal, or ethical considerations), then the statement could be considered entailed by the CTRs.\n\nIn summary, while the statement \"Every participant in the secondary trial and the primary trial doesn't undergo Laboratory Biomarker Analysis\" is not directly entailed by the provided CTR information due to the difference between every participant having the analysis and the analysis being part of the study design, it could still be true, depending on additional context.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because all participants in both the primary and secondary trials undergo laboratory biomarker analysis as specified under the INTERVENTION sections. In the primary trial, patients in both arms receive omega-3 fatty acid or placebo and undergo correlative studies using laboratory biomarkers. Similarly, in the secondary trial, patients in both arms (Curcumin-based Gel and HPR Plus) undergo laboratory biomarker analysis as part of the correlative studies. Hence, the statement's assertion that 'Every participant in the secondary trial and the primary trial doesn't undergo Laboratory Biomarker Analysis' is incorrect.</s>"
    },
    "1485315b-3169-42a3-a672-6f7963d49a51_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Laboratory Biomarker Analysis is undergone by every participant in the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Laboratory Biomarker Analysis is undergone by every participant in the secondary trial and the primary trial\" is entailed by the information present in the CTRs due to the identical mention of \"Laboratory Biomarker Analysis: Correlative studies\" in both Intervention sections of both trials.</s>",
        "contradict": "The statement \"Laboratory Biomarker Analysis is undergone by every participant in the secondary trial and the primary trial\" is contradicted by the information in the CTRs because:\n\nIn the Primary Trial:\n1. Arm I (Omega-3 Fatty Acid): Patients undergo laboratory biomarker analysis, but it is specified as correlative studies.\n2. Arm II (Placebo): Patients undergo laboratory biomarker analysis, but it is also specified as correlative studies.\n\nIn the Secondary Trial:\n1. Arm I (Curcumin-based Gel): Patients undergo laboratory biomarker analysis as part of correlative studies.\n2. Arm II (HPR Plus): Patients undergo laboratory biomarker analysis as part of correlative studies.\n\nHowever, the statement claims that \"every participant\" undergoes \"Laboratory Biomarker Analysis.\" While all patients in both trials do undergo laboratory biomarker analysis as per the CTRs, the statement incorrectly assumes that this applies to every type of analysis mentioned in the trials, including ancillary studies (questionnaire administrations) which also occur in the trials but are not explicitly mentioned in the statement. Thus, the statement is not an exact entailment of the information in the CTRs and can be contradicted by the distinction between the types of studies mentioned in the CTRs and the generalization in the statement.</s>"
    },
    "b4ef27ca-52b4-4af3-9b60-e9e0285e0e86": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer.",
        "Label": "Contradiction",
        "entail": "Despite the primary trial excluding participants with HER2 positive BCS as a hormone receptivity subtype, it does not exclude participants based on hormone receptivity in general. Therefore, the statement that \"potential participants will be considered regardless of the hormone receptivity of their breast cancer\" can be entailed by the information presented in the primary trial's inclusion criteria. The secondary trial does not provide any information regarding hormone receptivity, and its statement is consistent with the primary trial's inclusive criterion for breast cancer patients, except for those with HER2 positive BCS.</s>",
        "contradict": "The information in the statement contradicts the inclusion criteria of the primary CTR, which specifies the exclusion of HER2 positive BCS patients. This implies that hormone receptivity is being taken into account for participant selection in the primary trial, contrary to the statement's claim that it will not be considered.</s>"
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "patients with Karnofsky Index  = 72 are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: Individuals with a Karnofsky Index (KI) of 72 are eligible for the primary trial because the inclusion criteria state that individuals are eligible if their Karnofsky Index is greater than 70 (KI > 70). Therefore, a KI of 72 falls within the permitted range.</s>",
        "contradict": "The statement \"patients with Karnofsky Index = 72 are eligible for the primary trial\" is contradictory to the information in the CTRs as the eligibility criteria in the primary trial explicitly states that only individuals with a Karnofsky Index >70 are eligible for participation.</s>"
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "Patients with Karnofsky Index = 72 aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's exclusion criteria state that patients with a Karnofsky index lower than 70 are not eligible for participation. The expert's statement, \"Patients with Karnofsky Index = 72 aren't eligible for the primary trial,\" is entailed by this information, as 72 falls below the permissible 70 for trial inclusion.</s>",
        "contradict": "The information in the expert's statement can be contradicted by the information in the CTRs because the primary trial explicitly states that individuals with a Karnofsky index between 70 and 80 are eligible for the trial, while the expert's statement asserts that patients with a Karnofsky index of exactly 72 are not. This discrepancy creates a contradiction as the expert's statement is not an entailment of the provided CTR information.</s>"
    },
    "769bb3b2-9d2d-4dad-bd59-0042c55ac1ee_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "The primary trial accepts patients with Karnofsky Index = 72.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criterion specifies that participants must have a Karnofsky Index >70 to be eligible. The expert statement that \"The primary trial accepts patients with Karnofsky Index = 72\" does not contradict this inclusion criterion. A Karnofsky Index of 72 falls within the acceptable range (>70) according to the primary trial's inclusion criteria. Thus, the expert statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement by the expert contradicts the CTRs as the primary trial explicitly states an inclusion criterion of Karnopy index >70 and an exclusion criterion of Karnofsky index <70. The expert's statement, claiming the primary trial accepts patients with Karnofsky Index = 72, is not entailed by the data in the CTRs as it contradicts the provided inclusion and exclusion criteria.</s>"
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts.",
        "Label": "Entailment",
        "entail": "The provided statement is entailed by the information in the CTRs because:\n\nIn the primary trial, the inclusion criteria specify that there are two cohorts, each with distinct eligibility requirements for concurrent systemic therapy (allowed or not). In contrast, the secondary trial only specifies one set of inclusion criteria without any mention of cohorts or different eligibility groups. However, the difference in inclusion criteria between the cohorts in the primary trial aligns with the statement's claim that the primary trial uses different inclusion criteria for its cohorts. \n\nFurthermore, the secondary trial's inclusion criteria do not contradict the statement, and they are consistent with the clinical trial context as a whole. Hence, the statement is an entailed consequence of the information in the CTRs.</s>",
        "contradict": "The provided statement can be contradicted by the CTRs as the Primary Trial does have multiple cohorts (Cohort 1 and Cohort 2) with distinct inclusion criteria. Despite having some shared criteria such as age, ECOG performance status, and having biopsy-accessible tumor, they differ significantly, with Cohort 1 permitting stable concurrent systemic therapy, whereas Cohort 2 allows any concurrent systemic therapy. This discrepancy directly contradicts the statement's assertion that both trials use identical inclusion criteria for all cohorts.</s>"
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "The primary trial uses different inclusion criteria for its cohorts, the secondary trial only doesn't use one set on inclusion criteria for all cohorts.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial specifies distinct inclusion criteria for its cohorts (as stated in the CTR), while the secondary trial allows different inclusion criteria for different cohorts (as indicated by \"Patients must have histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease\" for one cohort and \"Patients with biopsy-confirmed breast cancer\" for another cohort in the CTR). Therefore, the statement that \"the primary trial uses different inclusion criteria for its cohorts, the secondary trial only doesn't use one set on inclusion criteria for all cohorts\" correctly describes the information in the CTRs.</s>",
        "contradict": "The statement's assertion that \"the primary trial uses different inclusion criteria for its cohorts, the secondary trial only doesn't use one set on inclusion criteria for all cohorts\" can be contradicted by the CTRs information in the following ways:\n\n1. The primary trial indeed uses different inclusion criteria for its cohorts (Cohort 1 and Cohort 2), as outlined in the document. However, it is an incorrect assumption that the secondary trial does not use different inclusion criteria for its cohorts since the provided information only mentions one set of inclusion criteria. The CTR for the secondary trial also includes different inclusion criteria for patients receiving taxane therapy or not, as well as HER2+ or HER2- status.\n\n2. The statement overlooks the presence of different inclusion criteria for the secondary trial's cohorts, potentially leading to a misinterpretation of the trials' similarities and differences in terms of patient eligibility.</s>"
    },
    "426196d8-44ab-4c5c-8f81-5cb12345ad69_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00899574",
        "Secondary_id": "NCT01007942",
        "Statement": "The secondary trial only uses one set on inclusion criteria for all cohorts, whilst the primary trial uses different inclusion criteria for its cohorts.",
        "Label": "Entailment",
        "entail": "The statement reflects a distinction in the inclusion criteria design between the two trials. In the primary trial, there are separate inclusion criteria for each cohort, whereas, in the secondary trial, a uniform set of inclusion criteria is applied to all cohorts. This observation is consistent with the information provided in the CTRs, as they explicitly state the different inclusion criteria for each cohort in the primary trial, and the uniform inclusion criteria for the secondary trial.</s>",
        "contradict": "The statement does not contradict the information in the CTRs, but it makes a comparison between the inclusion criteria of the two trials. However, the statement is incorrect in implying that the secondary trial only uses one set of inclusion criteria for all cohorts, when in fact, it has different inclusion criteria for patients with HER2 negative breast cancer. The primary trial, as described in the provided CTR, indeed uses different inclusion criteria for its cohorts. Therefore, while the statement does not contradict the information, it contains an error in its assertion about the secondary trial's inclusion criteria.</s>"
    },
    "bcf433b6-4029-4d00-9ccf-d8d94f1722d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Secondary_id": "NCT00005908",
        "Statement": "the primary trial and the secondary trial only recorded one type of acute adverse event.",
        "Label": "Contradiction",
        "entail": "neither the primary nor the secondary trial recorded the exact same type of acute adverse event mentioned by the expert (acute adverse event of type \"acute coronary syndrome, cardiac failure congestive, myocardial infarction, or cardiomyopathy\" was not reported in Adverse Events 2 of the secondary trial); thus, the statement does not entail the information present in the CTRs. However, the statement is not contradictory to the provided data as it only claims that only one type of acute adverse event was recorded in both trials but doesn't specify which type.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial reported various types of acute adverse events including febrile neutropenia, neutropenia, thrombocytopenia, acute coronary syndrome, cardiac failure congestive, myocardial infarction, cardiomyopathy, abdominal pain, diarrhea, and upper gastrointestinal hemorrhage, among others. Similarly, the secondary trial reported several types of acute adverse events including febrile neutropenia, lymphatics, diarrhea (without colostomy), abdominal pain or cramping, colitis, dehydration, nausea, stomatitis/pharyngitis (oral/pharyngeal/mucositis), and vomiting. Therefore, the statement is an incorrect generalization based on insufficient data.</s>"
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.",
        "Label": "Entailment",
        "entail": "The statement \"The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months\" can be entailed by the information in the CTR as follows: The median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group, as reported in Results 1, is 23.29 weeks (8.71 to 38.43). Since 23.29 weeks is greater than 26 weeks (the midpoint of 5 months), the statement that their median PFS was over 5 months is a logical consequence of the provided data.</s>",
        "contradict": "The statement that \"The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months\" is contradicted by the CTR information because the median PFS for the arm titled \"Ridaforolimus + Dalotuzumab + Exemestane\" is reported as 23.29 weeks (8.71 to 38.43), which is less than 5 months.</s>"
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial didn't have a median PFS of over 5 months.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as the median PFS for the Ridaforolimus + Dalotuzumab + Exemestane arm, as reported in Results 1, was 23.29 weeks (8.71 to 38.43), which is less than 5 months.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group in the primary trial was reported as 23.29 weeks (8.71 to 38.43), which is less than, but not clearly under 5 months. Therefore, the statement's assertion that this group did not have a median PFS of over 5 months is not a direct consequence of the data provided.</s>"
    },
    "1268edfc-cce2-4f07-9fbb-392341b7f399_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The primary trial has a median PFS of over 5 months in the Ridaforolimus + Dalotuzumab + Exemestane group.",
        "Label": "Entailment",
        "entail": "The expert's statement that \"the primary trial has a median PFS of over 5 months in the Ridaforolimus + Dalotuzumab + Exemestane group\" can be entailed by the information present in the CTRs as follows:\n\n1. According to the CTRs for both the primary and secondary trials, the PFS was measured from randomization to disease progression or death.\n2. The CTR for the primary trial reports the median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group as 23.29 weeks (8.71 to 38.43), which is greater than 26 weeks (6 months). Hence, a median PFS of over 5 months (26 weeks) in the Ridaforolimus + Dalotuzumab + Exemestane group is a valid inference from the data reported in the CTR.\n\nTherefore, the expert's statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"The primary trial has a median PFS of over 5 months in the Ridaforolimus + Dalotuzumab + Exemestane group\" contradicts the information in the CTRs as follows:\n\n1. The reported median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group, according to the CTR, is 23.29 weeks, which is less than 5 months (26 weeks).\n2. The CTRs provide the exact data on the median PFS (with confidence intervals) from the clinical trial, while the statement does not, making it an incomplete representation of the data.\n3. The CTRs do not support a statement claiming a median PFS over 5 months for the Ridaforolimus + Dalotuzumab + Exemestane group, as the actual data contradicts it.</s>"
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "1 patient in the primary trial died in an event not associated with a specifc CTCAE term.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTR as it is a subcase of the Adverse Events section, where one patient (1.43%) experienced an unspecified death (Death NOS).</s>",
        "contradict": "The expert's statement that \"1 patient in the primary trial died in an event not associated with a specific CTCAE term\" is contradictory to the CTR data, as the CTR lists a death (1.43%) under the category of \"Death NOS\" (Death Not Otherwise Specified), which is a specific term from the Common Terminology Criteria for Adverse Events (CTCAE) used to describe adverse events. Therefore, the statement's assertion that the death was not associated with a specific CTCAE term contradicts the CTR information.</s>"
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "1 patient in the primary trial dieded in an event associated with a specifc CTCAE term.",
        "Label": "Contradiction",
        "entail": "The statement \"1 patient in the primary trial died in an event associated with a specific CTCAE term\" can be entailed by the CTR information as follows:\n\nThe CTR for the primary trial indicates that one patient experienced a \"Death NOS,\" which stands for Death of Unknown Cause. According to the Common Terminology Criteria for Adverse Events (CTCAE), \"Death NOS\" falls under the category of \"Deaths due to causes that are not otherwise classified (e.g., unspecified),\" and it can be considered a type of serious adverse event. This event was associated with a patient from the primary trial, thus fulfilling the requirement of the statement that \"1 patient in the primary trial died in an event associated with a specific CTCAE term.\"</s>",
        "contradict": "The expert's statement, \"1 patient in the primary trial died in an event associated with a specific CTCAE term,\" does not directly contradict the information in the CTRs as provided, as the CTRs do mention one death. However, without further information, it cannot be determined whether the cause of death mentioned in the CTRs falls under a CTCAE term, or which specific CTCAE term it refers to. Thus, the statement does not necessarily contradict the given information, but it may not be entirely accurate without additional context.</s>"
    },
    "58ccfd13-aa6d-4604-bf3d-c69270fe50d2_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Statement": "An event not associated with a specifc CTCAE term killed 1 patient in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"An event not associated with a specific CTCAE (Common Terminology Criteria for Adverse Events) term killed 1 patient in the primary trial\" is entailed by the information present in the CTRs because the given statement implies the occurrence of an unspecified death (Death NOS in CTR) in the primary trial, which is a fact stated in the CTR under the \"Adverse Events\" section. Therefore, the statement's assertion harmonizes with clinical trial data, is substantiated in the CTR, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"An event not associated with a specific CTCAE term killed 1 patient in the primary trial\" cannot be definitively contradicted by the information in the CTRs, as the statement does not specify which patient or event is being referred to. However, if the unspecified death is not accounted for in the given Adverse Events listed under \"Death NOS\" in the primary CTR, then it would contradict the information provided in the CTR. If the death was a result of an adverse event that is not listed under any specific CTCAE term, then the statement and the CTR would not be entailed, as the statement asserts the existence of such an event, but the CTR does not.</s>"
    },
    "a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00509769",
        "Statement": "The majority of patients in the primary trial and the secondary trial experienced an adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"The majority of patients in the primary trial and the secondary trial experienced an adverse event\" is entailed by the CTR data as follows: \n\nFor the primary trial, the CTR states that \"Total: 24/32 (75.00%)\" of the patients experienced an adverse event. \n\nFor the secondary trial, the CTR states that \"Total: 30/112 (26.79%)\" of the patients experienced an adverse event. \n\nThe combined total number of patients in both trials is 32 (primary) + 112 (secondary) = 144, and the total number of patients who experienced an adverse event is 24 (primary) + 30 (secondary) = 54. Therefore, the percentage of patients who experienced an adverse event across both trials is 54/144 = 0.38, which is greater than 50%. The statement \"The majority of patients in the primary trial and the secondary trial experienced an adverse event\" is true, since 50% is considered a majority when referring to more than half of the total number of patients.</s>",
        "contradict": "The statement \"The majority of patients in the primary trial and the secondary trial experienced an adverse event\" is contradicted by the data in the CTRs because the adverse event rates are not the same for both trials. The primary trial had an adverse event rate of 75.00%, while the secondary trial had an adverse event rate of 26.79%. Therefore, it cannot be said that the majority of patients in both trials experienced an adverse event, as the proportion of patients who experienced adverse events varies between the trials.</s>"
    },
    "8c84c96f-1635-40dc-839b-fc937ed566a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with measurable diseases are only eligible for phase 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with measurable diseases are only eligible for phase 2 of the primary trial\" is entailed by the information in the CTRs because the CTR specifies that \"Measurable disease only for phase II study\" and \"Measurable disease is a requirement for patient eligibility in phase 2\" (implied by the statement \"Measurable disease or non-measurable disease for phase I study\" and \"Measurable disease only for phase II study\"). Therefore, the statement that only patients with measurable diseases can participate in phase 2 of the trial is consistent with the CTR's eligibility criteria.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the phase I portion of the trial also allows patients with measurable diseases, but it does not exclude them from participation. The CTR states, \"Measurable disease only for phase II study,\" but it does not explicitly state that measurable disease is an exclusion criterion for phase I. Therefore, patients with measurable diseases can be eligible for both phase I and phase II of the primary trial.</s>"
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.",
        "Label": "Entailment",
        "entail": "None of the adverse events listed in the second cohort (CTR 2) of the primary trial occurred in more than 5% of the patients. This is evident from the data provided in the CTRs, as none of the listed adverse events in CTR 2 exceeded a frequency of 5%. The statement is in agreement with the data presented in the CTRs and does not contradict any of the provided descriptions. The information in the CTRs entails the statement made by the expert.</s>",
        "contradict": "The statement \"There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients\" is contradicted by the information present in the CTRs because in Adverse Events 1 for the Primary Trial, Atrial fibrillation occurred in 1/198 (0.51%) of patients which is more than 5% for the cohort if assuming it was exclusively for cohort 2 (1/396 > 5%). Similarly, for Adverse Events 2, Atrial fibrillation occurred in 1/202 (0.50%) of patients.</s>"
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There wasn't no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.",
        "Label": "Contradiction",
        "entail": "none of the adverse events in the second cohort of the primary trial had a prevalence of more than 5% according to both CTRs (1 and 2), as the totals of adverse events for each cohort were 0.51% (1/198) and 0.50% (1/202), respectively, which is lower than 5%. Therefore, the statement \"There wasn't no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients\" is entailed by the provided information in the CTRs.</s>",
        "contradict": "The statement \"There wasn't no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients\" is contradicted by the data in the given CTRs because, in both CTRs (Adverse Events 1 and Adverse Events 2), there is a patient (from each cohort) who experienced atrial fibrillation, an adverse event occurring in more than 0.5% of patients.</s>"
    },
    "7b48355e-3b9c-4cca-b7fa-1cbd612d1523_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "More than 5% of patients did not experience the same adverse event in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The frequency of specific adverse events varies between the two cohorts (1 and 2) in the primary trial. The expert's statement is entailed since the difference in adverse event frequency between cohorts does not result in more than 5% of patients having the same adverse event in cohort 2 as in cohort 1 having a frequency lower than 5%. The CTRs provide evidence of different rates of adverse events in each cohort.</s>",
        "contradict": "The statement \"More than 5% of patients did not experience the same adverse event in cohort 2 of the primary trial\" cannot be directly contradicted by the provided CTR data, as the CTR does not specify which adverse events were experienced by cohort 2 in the primary trial. Therefore, it's not possible to definitively establish entailment or contradiction based on the current data.</s>"
    },
    "3d188d93-13c6-48f3-b231-dcdeef81080e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Presence of Extracranial metastases is part of the exclusion critera for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Presence of Extracranial metastases is part of the exclusion criteria for the primary trial\" can be entailed by the information presented in the CTR as follows: The CTR states \"Extracranial metastases allowed\" for the primary trial under the Disease Characteristics section. However, it also specifies under the same section that \"Not a candidate for surgical resection and/or further stereotactic radiosurgery\" is a requirement. Surgical resection and stereotactic radiosurgery are often used to treat extracranial metastases. Given that a patient with extracranial metastases cannot undergo these treatments and is excluded from the trial, the presence of extracranial metastases indeed falls under the exclusion criteria.</s>",
        "contradict": "The statement \"Presence of extracranial metastases is part of the exclusion criteria for the primary trial\" contradicts the information in the CTR for the primary trial because, while it is true that extracranial metastases are mentioned as part of the disease characteristics and a potential reason for exclusion, they are not strictly excluded as the statement suggests. Instead, patients with extracranial metastases are included in the study if they meet all other eligibility criteria and have demonstrated progression of brain metastases.</s>"
    },
    "d7e81d80-5cbf-4969-be00-4fdf17aa4eb9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement entails that the doses of MM-121 in cohort 1 of the primary trial are lower than those in cohort 2, and similarly, the Paclitaxel doses in cohort 1 are also lower. This is indeed the case as per the CTR information, where MM-121 loading dose for cohort 1 is 20 mg/kg, and weekly dose is 12 mg/kg, whereas for cohort 2, the loading dose is 40 mg/kg and weekly dose remains the same at 20 mg/kg. Similarly, the weekly dose of Paclitaxel remains constant across both cohorts at 80mg/m2.\n\nTherefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "Despite the expert statement suggesting lower doses of MM-121 for cohort 1 compared to cohort 2, the information in the CTR reveals that the loading dose for cohort 1 is higher (20 mg/kg vs 40 mg/kg), and the weekly dose is lower only for MM-121 (12 mg/kg vs 20 mg/kg). The weekly Paclitaxel dose is the same for both cohorts (80mg/m2). This discrepancy between the expert statement and the CTR data invalidates the entailment relationship.</s>"
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin > 1.6 x ULN are eligilbe for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement implies that a female meeting the specified laboratory evaluation requirements, i.e., Hemoglobin > 10.0 g/dl, ANC 1,733/mm3, platelet count = 100,000/\u00b5l, and total bilirubin > 1.6 x ULN, is eligible for the primary trial. These requirements are consistent with the CTR's inclusion criteria, which list Hemoglobin > 9.0 g/dl, ANC > 1,500/mm3, and total bilirubin = 1.5 x the upper limit of normal as minimum requirements for eligibility. The difference in the bilirubin requirement between the statement and the CTR does not result in contradiction since the statement's requirement is a more stringent condition than the CTR's and is still within the permissible range. Thus, the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, and platelet count = 100,000/\u00b5l may be eligible for the trial based on the given hemoglobin level, but her eligibility cannot be determined definitively based on the provided information alone. The CTR specifies additional eligibility requirements, such as Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, and adequate bone marrow, liver, and renal function, which are not considered in the expert's statement. Additionally, total bilirubin is stated as > 1.6 x ULN, whereas the CTR specifies that it should not exceed 1.5 x the upper limit of normal. This discrepancy contradicts the statement and renders the eligibility determination incomplete and potentially inaccurate.</s>"
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin > 1.6 x ULN aren't eligilbe for the primary trial.",
        "Label": "Contradiction",
        "entail": "The provided statement excludes a female subject from the primary trial with specified laboratory values: Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u03bcl, and total bilirubin > 1.6 x ULN (Upper Limit of Normal).\n\nThe eligibility criteria in the primary CTR outline several laboratory evaluation requirements, among which are the hemoglobin > 9.0 g/dl, ANC > 1,500/mm3, and platelet count = 100,000/\u03bcl. However, the total bilirubin requirement stated in the trial's eligibility criteria is 1.5 x ULN, which is lower than the 1.6 x ULN in the expert's statement. Thus, the statement's assertion of the female subject's ineligibility due to laboratory values aligns with the CTR. The CTR does not entail this exact statement but allows for the inference of ineligibility given the more stringent bilirubin requirement in the expert's statement.</s>",
        "contradict": "The provided statement excludes a female subject from the primary trial based on the criteria that her hemoglobin level is higher than the required 9.0 g/dl, her neutrophil count is less than the required 1,500/mm3, and her total bilirubin is greater than 1.6 times the upper limit of normal (ULN), instead of the specified 1.5 times ULN in the CTR. Therefore, the statement contradicts the CTR eligibility criteria.</s>"
    },
    "2206dc2a-93da-4c11-b110-81f9c39af807_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00101400",
        "Statement": "The primary trial accepts a female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin > 1.6 x ULN.",
        "Label": "Entailment",
        "entail": "The statement that a female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00b5l, and total bilirubin > 1.6 x ULN is eligible for the primary trial, is entailed by the inclusion criteria of the CTR as follows:\n\n1. Age > 18 years: No explicit mention of age is given, but it is assumed that the statement refers to women, so age meets the requirement.\n2. Women with prior histologically documented diagnosis of breast cancer: This is given in the statement.\n3. Metastatic disease: The presence of metastasis is not explicitly stated in the given information, but it is known that women with metastatic breast cancer are included in the trial (from the primary inclusion criteria), and this statement refers to such women.\n4. Subjects have failed at least one chemotherapy regimen for metastatic disease: Since the statement refers to a woman with metastatic breast cancer, this inclusion criterion is met.\n5. Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy: The statement does not provide information about the timing relative to the last cytotoxic chemotherapy or progression on hormonal therapy. However, it can still be assumed that the woman meets this criterion because the statement does not mention any ongoing chemotherapy or evidence of progression.\n6. Subjects have at least one measurable lesion by CT scan or MRI: Not explicitly stated in the given information, but the presence of measurable lesions is a known criterion for inclusion in the primary trial. The statement does not provide enough specifics to contradict this criterion.\n7. Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2: The statement neither confirms nor denies the applicability of this inclusion criterion. However, the fact that the woman's condition is not explicitly stated to be worse than ECOG 2 supports this criterion.\n8. Adequate bone marrow, liver and renal function:\n   a. Hemoglobin: The given Hemoglobin value (> 10.0 g/dl) is above the CTR requirement (> 9.0 g/dl).\n   b. Absolute neutrophil count: The given value (1,733/mm3) is above the CTR requirement (> 1,500/mm3).\n   c. Platelet count: The given value (100,000/\u00b5l) is equal to the CTR requirement (100,000/\u00b5l).\n9. Total bilirubin: The given value (> 1.6 x ULN) exceeds the CTR requirement (<= 1.5 x ULN for subjects without liver involvement, or = 5 x ULN for subjects with liver involvement).\n\nTherefore, the information contained in the expert's statement can be entailed by the information in the CTRs, as it does not contradict any inclusion criteria. However, it should be noted that this statement does not necessarily mean that the woman meets all the other inclusion and exclusion criteria, but only the ones related to the given laboratory values.</s>",
        "contradict": "The female subject described in the expert's statement does not meet the inclusion criteria of the primary trial for hemoglobin level, as per the CTR, where the minimum requirement is 9.0 g/dl. Additionally, the platelet count of the subject falls below the lower limit for inclusion (100,000/\u00b5l). Furthermore, total bilirubin is stated to be more than 1.6 times the upper limit of normal, whereas the CTR specifies a limit of 1.5 x the upper limit of normal.</s>"
    },
    "6173faf3-f845-4cf1-94a9-756d1bff48bb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There was one patient in the primary trial who suffered from a significant decrease in the number of granulocytes in their blood\" is entailed by the CTR data under the \"Adverse Events 1\" section of the primary trial, as there is one recorded instance (1/403) of \"Granulocytopenia.\" This condition implies a significant decrease in the number of granulocytes in the patient's blood.</s>",
        "contradict": "Although the expert statement asserts that one patient in the primary trial experienced a \"significant decrease in the number of granulocytes in their blood,\" the CTR data for the primary trial does not indicate any patient with a diagnosis of granulocytopenia. In fact, the CTR reports one instance of granulocytopenia out of 403 participants, but it belongs to another trial (Trial 2). Therefore, the statement cannot be entailed by the information provided in the CTRs.</s>"
    },
    "512c72ab-f1b3-450d-8167-6e0d8d2bf5dd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the primary and secondary CTRs, as the CTRs do not provide information regarding manual lymph drainage being administered to any of the trial cohorts. Therefore, no entailment relationship exists between the statement and the information in the CTRs.</s>",
        "contradict": "The statement \"Only one cohort of the primary trial needs to receive manual lymph drainage prior to each cycle of anthracyclines\" contradicts the information in the CTRs because neither of the described interventions in the primary trial includes manual lymph drainage as a component before each cycle of anthracyclines. The primary trial's first intervention includes exercise, with specific timing before and after anthracycline administration, while the second intervention is defined as 'usual care,' which doesn't include manual lymph drainage.</s>"
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial states that there were 16 participants with pCR in the Breast and Nodes, which is a subset of the 93 participants who were analyzed in total. The expert's statement that \"more than a dozen\" primary trial participants had pCR is an overstatement, as it implies a number greater than 12, but it is consistent with the CTR's reported number of 16 participants with pCR. Additionally, the CTR provides the definition and criteria for pCR, which aligns with the expert's usage of the term. Therefore, the expert's statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"More than a dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes\" cannot be definitively contradicted by the information provided in the CTR, but it may be an overestimation. The CTR reports the number of participants with pCR as 16 out of 93 analyzed, which is less than a handful more than a dozen. However, the expert's statement leaves room for speculation, as \"more than a dozen\" could imply anywhere from thirteen to infinity participants, and the CTR only provides an exact number. Therefore, the expert's statement is not necessarily contradictory to the CTR, but may require clarification to ensure accurate interpretation.</s>"
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "More than a dozen the primary trial participants aren't classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Contradiction",
        "entail": "Based on the information provided in the CTRs, the statement \"More than a dozen the primary trial participants aren't classified as having Pathologic Complete Response (pCR) in the Breast and Nodes\" can be entailed as follows:\n\nThe CTR for the primary trial states that out of 93 participants analyzed, the number of participants with pCR was not explicitly provided. However, we know the definition of pCR as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy. The statement \"More than a dozen\" implies that more than 12 participants did not achieve pCR. Since we don't have the exact number of participants who did not achieve pCR, the statement is an overestimation. However, based on the information in the CTR, it is possible that more than a dozen participants did not achieve pCR. Therefore, the statement harmonizes with clinical trial data, finds substantiation in the absence of explicit data in the CTR, and avoids contradiction with the provided descriptions, making it entailed by the information present in the CTRs.</s>",
        "contradict": "The information in the statement contradicts the CTR data as it infers that more than a dozen participants did not achieve pCR, whereas the CTR reports that 16 of the 93 participants in the primary trial were classified as having pCR in the Breast and Nodes. Contradiction arises from the discrepancy between the number of participants with pCR as indicated by the expert statement and the reported number of such participants from the primary trial CTR.</s>"
    },
    "ee54ca2d-ccd9-4ceb-b6e7-c1ee10de8104_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "Pathologic Complete Response (pCR) in the Breast and Nodes is present in more than a dozen the primary trial participants.",
        "Label": "Entailment",
        "entail": "The statement \"Pathologic Complete Response (pCR) in the Breast and Nodes is present in more than a dozen the primary trial participants\" can be entailed by the information in the CTRs as follows:\n\n1. The CTR for the primary trial states that the outcome measure was the number of participants with pCR in the breast and nodes. \n\n2. The results section of the primary trial reports that there were 16 participants analyzed for this outcome measure in the AC, followed by weekly Paclitaxel and concurrent Pazopanib arm, with pCR defined as no detectable tumor in surgical specimens.\n\n3. The expert statement claims that more than a dozen participants had pCR. Since 12 is more than a dozen divided by 2 (for two groups), this implies that both groups (or more) have more than six participants with pCR each.\n\n4. Therefore, the expert statement is entailed by the information in the CTRs as it does not contradict the given data and is consistent with the reported number of participants with pCR in the primary trial.</s>",
        "contradict": "The statement made by the clinical trial expert that \"Pathologic Complete Response (pCR) in the Breast and Nodes is present in more than a dozen the primary trial participants\" cannot be directly contradicted by the data provided in the CTR, as the CTR does not specify an exact number of participants achieving pCR. However, it can be questioned if the statement is entailed by the CTR data due to the absence of an explicit statement confirming that there were over a dozen participants with pCR in the AC, follow-by weekly paclitaxel and concurrent Pazopanib arm.</s>"
    },
    "87987ebb-6799-4d1d-8529-d33c6b7799f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "64 of the study participants in the primary trial receiving lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that 64 participants in the primary trial experienced Near Complete Pathologic Response or better after 12 weeks of lapatinib and trastuzumab administration. This assertion is entailed by the information presented in the CTR, as:\n\n1. The CTR specifies that 64 participants were analyzed in the Lapatinib + Trastuzumab arm/group.\n2. The CTR reports that all participants in this arm received the same dosages of lapatinib and trastuzumab for 12 weeks as stated in the expert's statement.\n3. The CTR provides data on the number of participants who experienced Near Complete Pathologic Response, which is 16, and Complete Pathologic Response, which is 18. Since a Near Complete Pathologic Response implies residual disease less than 1 cm, it is a more inclusive condition compared to a Complete Pathologic Response. Therefore, the number of participants who experienced Near Complete Pathologic Response or better would be equal to or greater than those who had a Complete Pathologic Response.\n4. According to the CTR, the total number of participants who had a Complete Pathologic Response or Near Complete Pathologic Response is 34 (18 + 16). Given that this number is greater than or equal to the 64 participants stated in the expert's assertion, it follows that at least 64 participants had Near Complete Pathologic Response or better, as claimed in the statement.</s>",
        "contradict": "The expert's statement implies that all 64 participants in the specified arm of the primary trial achieved Near Complete Pathologic Response or better in 12 weeks. However, according to the CTR, there were 16 instances of Near Complete Pathologic Response. Therefore, the statement is contradictory as it asserts more instances of Near Complete Pathologic Response than reported in the CTR.</s>"
    },
    "bf94f208-a29b-4d8f-92a7-3cb8241ce344": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Secondary_id": "NCT00896649",
        "Statement": "Black women cannot take part in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Black women cannot take part in the secondary trial or the primary trial\" is not directly entailed by the information in the provided CTRs. The primary trial includes Black women as part of its patient population based on their diagnosis of carcinoma of the breast and meeting the specified inclusion and exclusion criteria. The secondary trial specifically includes Black women, Haitian Creole, Hispanic, and African American patients based on their racial or ethnic background. The statement in question contradicts the information in the CTRs by excluding Black women from both trials indiscriminately.</s>",
        "contradict": "The statement \"Black women cannot take part in the secondary trial or the primary trial\" is contradictory to the information present in the CTRs. The primary trial's inclusion criteria include \"Female patients\" with no specification regarding race. The secondary trial's inclusion criteria state that patients must be \"Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria: Dense breast tissue, At high-risk for breast cancer,\" without mentioning any race restriction. Therefore, the statement that \"Black women cannot take part in the secondary trial or the primary trial\" is not supported by the information provided in the CTRs.</s>"
    },
    "c68f6822-24fa-44b5-bf63-c272a8031fab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial\" can be entailed by the information present in the CTRs under the heading \"Hepatic status\" where it is specified that \"Serum total bilirubin 1 x ULN (in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase 1.5 x ULN\" is a requirement for eligibility in the trial. This implies that both AST and ALT values for patients should be below 1.5 times the upper limit of normal.</s>",
        "contradict": "The information in the statement is contradicted by the inclusion criteria of the primary trial, as patients with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 1.5 times the upper limit of normal (ULN) are still eligible for the trial if they have appropriate justifications and their hepatic status is still within acceptable range.</s>"
    },
    "54a459cf-f01a-4abc-a8cf-0efebc01c694": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded none of the same types of adverse events",
        "Label": "Contradiction",
        "entail": "none of the adverse events listed in the primary CTR are identical to those listed in the secondary CTR. The primary CTR reports 13 unique adverse events, and none of them appear in the secondary CTR. Conversely, the secondary CTR reports 11 unique adverse events, none of which appear in the primary CTR. Therefore, the statement \"the primary trial and the secondary trial recorded none of the same types of adverse events\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial recorded none of the same types of adverse events\" is contradicted by the information in the CTRs. \n\nExplanation:\n\nIn the primary trial, the adverse event \"Febrile neutropenia\" was recorded in 4/50 (8.00%) participants, while in the secondary trial, \"Febrile neutropenia\" was recorded in 21/482 (0.21%) and 21/238 (0.42%) participants in Adverse Events 1 and 2, respectively. \n\nTherefore, the primary and secondary trials both recorded the same type of adverse event, namely, \"Febrile neutropenia.\" Contrary to the claim in the statement, there is overlap in types of adverse events between the two trials.</s>"
    },
    "dd4b5a08-c033-4429-81d0-1ad59596edbd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial\" is not entailed by the information present in the CTRs as neither hyperthyroidism nor diabetes mellitus are explicitly mentioned as inclusion criteria in the provided CTR information. Additionally, there are exclusion criteria related to thyroid disorders and abnormal liver and kidney function which could potentially exclude patients with hyperthyroidism or diabetes mellitus depending on their specific cases, contradicting the statement.</s>",
        "contradict": "The statement \"sufferers of hyperthyroidism and diabetes mellitus are eligible for the primary trial\" is contradicted by the exclusion criteria present in the CTRs. Both hyperthyroidism and diabetes mellitus are listed as exclusion criteria for the primary trial under the category of patients with abnormal liver and kidney function, respectively. Therefore, the statement is not semantically entailed by the information provided in the CTRs.</s>"
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "Label": "Entailment",
        "entail": "In the primary trial, patients receive vorinostat PO QD (once daily) for 2 weeks, followed by AI therapy PO QD (once daily) for 6 weeks, creating a total treatment duration of 8 weeks per course. (Information from the CTR.)\n\nIn the secondary trial, 6-Mercaptopurine is given PO od (once daily) on a continuous schedule. (Information from the CTR.)\n\nThe statement asserts that patients in the primary trial receive vorinostat at the same frequency and through the same route of administration as the secondary trial receives 6-Mercaptopurine.\n\nSince both trials involve oral daily administration of vorinostat in the primary trial and 6-Mercaptopurine in the secondary trial, the statement's assertion is consistent with the information presented within the provided CTRs.\n\nTherefore, the statement is an entailed relationship between the CTR data and the clinical trial expert's statement.</s>",
        "contradict": "The statement is contradictory to the information presented in the CTRs because: \n\n1. In the primary trial, patients receive vorinostat PO QD for 2 weeks, followed by AI therapy PO for 6 weeks, with courses repeating every 8 weeks, while in the secondary trial, 6-Mercaptopurine is taken PO od, and Methotrexate PO once a week. These are significantly different dosing frequencies for each intervention.\n2. Vorinostat is given for a specific duration (2 weeks), while 6-Mercaptopurine and Methotrexate are given continuously until disease progression.\n3. The routes of administration are different; vorinostat is given orally (PO), while 6-Mercaptopurine and Methotrexate are also given orally but with different dosing schedules.\n\nTherefore, patients do not receive vorinostat in the primary trial at the same frequency and through the same route of administration as patients receive 6-Mercaptopurine in the secondary trial.</s>"
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial don't receive vorinostat at the same frequency and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "Label": "Contradiction",
        "entail": "In the primary trial, patients receive vorinostat PO QD (once daily) for 2 weeks, followed by AI therapy PO QD (once daily) for 6 weeks. In the secondary trial, 6-Mercaptopurine is administered PO OD (once daily) and Methotrexate PO QW (once a week), while the administration of vorinostat in the primary trial does not follow the same frequency or route (daily vs. weekly) as that of 6-Mercaptopurine in the secondary trial. This statement is entailed by the provided information from the CTRs.</s>",
        "contradict": "The statement is not directly contradicted by the information present in the CTRs, but rather highlights a difference in treatment regimens between the two trials. In the primary trial, patients receive vorinostat daily for the first 2 weeks followed by AI therapy three times a week for the remaining 6 weeks. In contrast, in the secondary trial, 6-Mercaptopurine and Methotrexate are administered daily and weekly, respectively. However, neither trial's description states that patients in the primary trial receive vorinostat via the same route of administration (oral) as the secondary trial's 6-Mercaptopurine or Methotrexate. Thus, the statement's contradiction is not an exact match to the data presented in the CTRs. Instead, the statement focuses on differences in treatment frequency and routes, which may not necessarily result in contradictions.</s>"
    },
    "d97ebc59-ab4b-462a-9057-12f4fc46df56_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the secondary trial receive 6-Mercaptopurine through the same route of administration as patients in the primary trial receive vorinostat.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the secondary trial receive 6-Mercaptopurine through the same route of administration as patients in the primary trial receive vorinostat\" is entailed by the information present in the CTRs because:\n\n1. Patients in both trials receive their interventions orally (PO).\n2. In the primary trial, vorinostat is given PO.\n3. In the secondary trial, 6-Mercaptopurine is given PO.</s>",
        "contradict": "The statement \"Patients in the secondary trial receive 6-Mercaptopurine through the same route of administration as patients in the primary trial receive vorinostat\" is contradictory to the information presented in the CTRs. In the primary trial, vorinostat is given orally (PO), while in the secondary trial, 6-Mercaptopurine and Methotrexate are also given orally, but the expert's statement does not specifically state that they are given through the same route as vorinostat. However, the statement implies a direct comparison between the two trials' interventions, suggesting that 6-Mercaptopurine's route of administration should be equivalent to that of vorinostat. This implication contradicts the fact that no such equivalence is stated or implied in the CTRs.</s>"
    },
    "2e4c7d0b-f1a2-4204-bac3-7445852fd916": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry ",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as both trials mention the use of scans in their intervention descriptions. In the primary trial, a dosimetry scan is performed using a post-implant dosimetry scanner. In the secondary trial, Zr89-trastuzumab PET/CT is used. Thus, the statement's claim about scans being involved in both trials is consistent with the provided information in the CTRs.</s>",
        "contradict": "The statement made by the expert that \"the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET, MRI and dosimetry\" is not directly contradicted by the CTR information provided. However, it is less specific than the details given in the CTRs. \n\nIn the primary trial, the intervention involves irradiation and partial accelerated breast brachytherapy using high dose rate, which does not explicitly mention any type of scan. However, it is stated that after treatment, a \"post-implant dosimetry scanner is used to analyze the dose distribution within the target volume and organs at risk.\" This implies the use of some kind of imaging modality, which could be considered a scan. Thus, the primary trial does involve a scan, but it is not mentioned in the expert's statement as specifically as it is in the CTR.\n\nIn the secondary trial, the intervention involves Zr89-trastuzumab PET/CT. Here, the use of PET/CT is explicitly stated. So, the expert's statement is consistent with the CTR information for the secondary trial. \n\nTherefore, although the statement made by the expert is not directly contradictory to the CTR information, it is less specific and does not fully capture the specific scans used in each trial as described in the CTRs.</s>"
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants and cohort 1 participants in the secondary trial do not receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these.",
        "Label": "Entailment",
        "entail": "The primary trial specifies the use of FLT PET scans with [F18] fluorothymidine as the tracer for patients with early stage, ER positive primary breast cancer, without mention of capecitabine, lapatinib ditosylate, or cixutumumab in the intervention section. The secondary trial's cohort 1 also does not have any reference to the mentioned medications in its intervention section. Therefore, the statement that the primary trial participants and cohort 1 in the secondary trial do not receive capecitabine, lapatinib ditosylate, or cixutumumab aligns with the information in the CTRs. In contrast, the cohort 2 in the secondary trial includes capecitabine and lapatinib ditosylate, as stated in its intervention section, and cixutumumab in a separate intervention, making the statement true for the difference between cohorts. The absence of a medication for a specific group in the CTRs entails the absence of that medication for those groups.</s>",
        "contradict": "The statement contradicts the information in the CTRs because the primary trial participants do receive oral capecitabine and oral lapatinib ditosylate according to the Intervention section in the primary CTR. Additionally, cohort 1 in the secondary trial also receives oral capecitabine and oral lapatinib ditosylate as stated in the Intervention sections for both arms (A and B) in the secondary CTR. Therefore, the assertion that no participants in the primary trial or cohort 1 in the secondary trial receive any of the listed treatments is incorrect.</s>"
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "All the primary trial participants and cohort 1 participants in the secondary trial do receive any oral capecitabine, oral lapatinib ditosylate or cixutumumab IV, however cohort 2 of the secondary trial receive all of these.",
        "Label": "Contradiction",
        "entail": "In the primary trial, patients undergo FLT PET scanning using [F18] fluorothymidine, and there is a laboratory biomarker analysis involving Ki67 staining of the tumor tissue. No explicit information regarding the use of capecitabine, lapatinib ditosylate, or cixutumumab is provided in the Intervention section. However, the statement does not contradict the primary trial's information since it does not claim that all primary trial participants receive these specific treatments.\n\nIn the secondary trial, both arms A and B receive capecitabine and lapatinib ditosylate orally. Arm A does not involve cixutumumab IV, while Arm B does. The statement correctly captures this distinction by acknowledging that cohort 1 in the secondary trial receives only PO capecitabine and PO lapatinib ditosylate, while cohort 2 receives all three interventions (PO capecitabine, PO lapatinib ditosylate, and IV cixutumumab).\n\nTherefore, the statement is entailed by the CTRs, as it does not contradict their content and correctly reflects the information provided.</s>",
        "contradict": "The statement \"All the primary trial participants and cohort 1 participants in the secondary trial do receive any oral capecitabine, or oral lapatinib ditosylate, but cohort 2 of the secondary trial receives all of these\" is contradictory to the information in the CTRs as follows:\n\n1. In the primary trial, only FLT PET scan participants receive F18 fluorothymidine, and no mention is made of oral capecitabine, oral lapatinib ditosylate, or cixutumumab administration.\n2. In the secondary trial, participants in arm A receive oral capecitabine and oral lapatinib ditosylate, but there is no mention of them receiving cixutumumab. Cohort 1 in arm B receives oral capecitabine and oral lapatinib ditosylate, but they do not receive cixutumumab. Conversely, cohort 2 in arm B receives oral capecitabine, oral lapatinib ditosylate, and cixutumumab.\n\nTherefore, not all primary trial participants and cohort 1 participants in the secondary trial receive the same medications, as stated in the expert's claim. Instead, participants in the primary trial receive FLT-PET scans with F18 fluorothymidine, and participants in arms A and B of the secondary trial each receive different combinations of oral capecitabine, oral lapatinib ditosylate, and cixutumumab.</s>"
    },
    "fafac1e0-1eaa-4a99-8f3f-72b3f71c4691_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT00684983",
        "Statement": "Cohort 2 of the secondary trial receives oral capecitabine, oral lapatinib ditosylate and cixutumumab IV, however all the primary trial participants and cohort 1 participants in the secondary trial do not receive any of these.",
        "Label": "Entailment",
        "entail": "The statement asserts that cohort 2 of the secondary trial receives oral capecitabine, oral lapatinib ditosylate, and cixutumumab IV, while no interventions mentioned in the statement are given to participants in the primary trial or cohort 1 of the secondary trial. \n\nThe primary trial specifies the use of F18 fluorothymidine in FLT PET scanning for ER positive primary breast cancer patients and does not mention any use of capecitabine, lapatinib ditosylate, or cixutumumab. \n\nIn the secondary trial, cohort 1 receives the same regimen of oral capecitabine and oral lapatinib ditosylate as cohort 2 but without cixutumumab. Therefore, the participants in cohort 1 and the primary trial do not receive any of the interventions mentioned in the statement. \n\nHence, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the secondary trial receives oral capecitabine, oral lapatinib ditosylate and cixutumumab IV, however all the primary trial participants and cohort 1 participants in the secondary trial do not receive any of these\" is contradictory to the information in the CTRs because:\n\nIn the primary trial, patients undergo FLT PET scan with F18 fluorothymidine, and there is no mention of oral capecitabine, oral lapatinib ditosylate, or cixutumumab being administered.\n\nIn the secondary trial, cohort A receives oral capecitabine and oral lapatinib ditosylate, while cohort B receives these drugs along with cixutumumab IV. However, the statement asserts that \"all the primary trial participants and cohort 1 participants in the secondary trial do not receive any of these,\" which is incorrect. Cohort A in the secondary trial does receive oral capecitabine and oral lapatinib ditosylate.</s>"
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records cardiovasuclar adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial only records cardiovascular adverse events\" can be entailed by the information present in the CTRs as follows: The primary CTR lists adverse events including cardiac arrest (2/349), cardio-respiratory arrest (2/349), cardiac failure (0/349, 0/349 for acute), cardiovascular insufficiency (0/349), and atrial fibrillation (2/349). All these conditions belong to the cardiovascular category. The secondary CTR also lists adverse events, among which are cardiac failure (4/353), cardiac failure acute (1/353), and cardiovascular insufficiency (1/353), further confirming that the primary trial indeed records cardiovascular adverse events.</s>",
        "contradict": "The statement \"the primary trial only records cardiovascular adverse events\" can be contradicted by the CTR information as the primary trial's Adverse Events section (Section 1) reports instances of anemia (which is not a cardiovascular condition) in addition to cardiovascular conditions. Therefore, the statement is not entailed by the CTR information.</s>"
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "The primary trial only doesn't record cardiovasuclar adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial does not record cardiovascular adverse events.\" can be entailed by the information in the CTRs if we define \"cardiovascular adverse events\" as adverse events related to the heart or blood vessels that are not explicitly mentioned in the reported data. In both the primary and secondary CTRs, no instances of \"cardiac failure,\" \"cardiac failure acute,\" or \"cardiovascular insufficiency\" are reported in the primary trial's adverse events section. Additionally, there are no mentions of other cardiovascular events, such as myocardial infarction or angina, within the sections provided. Therefore, the statement can be entailed based on the absence of these specific cardiovascular adverse events in the primary trial's reported data.</s>",
        "contradict": "The statement \"The primary trial only doesn't record cardiovascular adverse events\" is contradicted by the information in the CTRs as both reports list adverse events related to cardiovascular conditions such as atrial fibrillation, cardiac arrest, cardiac failure, cardiac failure acute, cardio-respiratory arrest, and cardiovascular insufficiency. These events were recorded in the primary trial, and their occurrence rates are specified in the provided data. Therefore, the statement is incorrect.</s>"
    },
    "4546c169-cc5c-4e03-bcce-31d491ed18e0_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "Cardiovasuclar adverse events are the only adverse events recorded in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Cardiovascular adverse events are the only adverse events recorded in the primary trial\" can be entailed by the information present in the CTRs if we define \"cardiovascular adverse events\" as events related to the cardiovascular system. Based on the CTRs provided, the following cardiovascular adverse events are recorded in the primary trial: atrial fibrillation (in 2/349 subjects), cardiac arrest (in 2/349 subjects), cardio-respiratory arrest (in 2/349 subjects), cardiac failure (in 0/349 subjects), cardiac failure acute (in 0/349 subjects), and cardiovascular insufficiency (in 0/349 subjects). Therefore, all the mentioned cardiovascular adverse events are recorded in the primary trial, and there are no other types of adverse events mentioned in the section. This aligns with the statement made by the expert.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because both trials report occurrences of adverse events other than cardiovascular events in their respective sections, specifically anemia, leukopenia, neutropenia, thrombocytopenia, and atrial fibrillation.</s>"
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are not able to take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"children and illiterate adults are not able to take part in the primary trial\" is entailed by the CTR inclusion criteria stating that participants must be willing and able to provide informed consent, and able to read and write English. Children are not able to provide informed consent, and illiterate adults cannot read the trial documents necessary for informed consent. Therefore, both groups are excluded by the CTR's inclusion criteria, entailing the stated expert claim.</s>",
        "contradict": "The statement \"children and illiterate adults are not able to take part in the primary trial\" cannot be directly contradicted by the information present in the CTRs as the provided CTRs do not include eligibility criteria related to children or illiterate adults.</s>"
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "Children and illiterate adults are able to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Children and illiterate adults are able to take part in the primary trial\" is not entailed by the information in the provided CTRs. \n\nExplanation:\n\nThe primary trial's inclusion criteria specify that participants must be postmenopausal with no menstrual cycle in the past 12 months, aged 18-85 years, newly diagnosed with specific breast cancer stages, have an ECOG performance status of 1 or less, and must be willing and able to comply with study guidelines and provide informed consent. The CTRs make no mention of children, illiterate adults, or any other specific age or literacy requirements. Furthermore, the exclusion criteria explicitly mention several conditions that would preclude trial participation, but none of them are related to age or literacy level. Therefore, the statement that children and illiterate adults are able to take part in the primary trial contradicts the provided CTR information.</s>",
        "contradict": "The statement contradicts the inclusion criteria in the CTR for the primary trial. The criteria explicitly state that participants must be able to read and write English. Therefore, children and illiterate adults cannot meet this requirement and are, in fact, excluded from the trial according to the provided information.</s>"
    },
    "1bb3badf-41c6-4741-90f0-367473ce254d_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "The primary trial excludes children and illiterate adults.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criteria specify that participants must be aged 18 and above. The statement does not contradict this condition and, thus, does not exclude children. Furthermore, the inclusion criteria list \"willingness to provide informed consent\" as a requirement, implying the ability to read and write English. The statement does not contradict this either, as it simply excludes illiterate adults and does not mention children who may or may not be literate. Consequently, the expert's statement is entailed by the provided CTRs.</s>",
        "contradict": "The statement contradicts the information in the primary trial's inclusion criteria, as the CTR explicitly states that the inclusion criteria include individuals aged 18 and above. Additionally, there is no mention of excluding illiterate adults in the provided inclusion and exclusion criteria of the primary trial.</s>"
    },
    "87953ba3-3e94-421c-b426-b716562b8b5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed PR positive breast cancer is elgible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The patient described in the statement matches the inclusion criteria of both trials in several aspects:\n- Stage 2B breast cancer: The primary trial includes patients with clinical locally advance breast cancer, which includes Stage IIB.\n- Pathologically confirmed PR-positive breast cancer: Both trials specify ER-positive or PR-positive breast cancer, and the primary trial requires an Allred Score > 4, which is typically indicative of positive receptor status.\n\nHowever, the patient's eligibility also depends on satisfying the remaining inclusion criteria and not meeting any exclusion criteria for each trial. Let's examine this:\n\nPrimary Trial: The patient must meet the remaining inclusion criteria:\n- Treated at INCAN: Not explicitly stated in the patient description but not explicitly excluded either.\n- Provided informed consent: Explicitly stated in the patient description.\n- Age: The patient meets the requirement of being at least 18 years old.\n- Life expectancy: The patient's life expectancy is not specified but is not a criterion for exclusion in the primary trial.\n\nSecondary Trial: The patient must meet all inclusion criteria:\n- Premenopausal: Not explicitly stated in the patient description but not explicitly excluded either, and is a requirement for the secondary trial.\n- Estrogen receptor positive breast cancer: The patient meets the requirement.\n- Aged 20 years or older: The patient meets the requirement.\n- Operable and measurable breast cancer: Not explicitly stated in the patient description but not explicitly excluded either, and is a requirement for the secondary trial.\n\nExclusion Criteria: The patient must not meet any exclusion criteria for either trial:\n- Prior chemotherapy, radiation therapy, and biologic therapy for invasive breast cancer: The patient's history is not specified in the patient description.\n- Not pregnant or nursing: The patient description does not mention pregnancy or breastfeeding.\n- Prior malignancy: No prior malignancy except for basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for five years is mentioned in the patient description, so this criterion is not violated.\n- Women of childbearing age unable or unwilling to use contraception: The patient's reproductive and contraceptive status is not mentioned in the patient description.\n\nThus, the information in the expert statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The patient with stage 2B PR-positive breast cancer is not eligible for both trials according to the provided CTRs. The primary trial explicitly states that the patient must have a clinical locally advance breast cancer (Stage IIB or III) and a life expectancy of 6 months, while the secondary trial only requires operable and measurable breast cancer and no prior chemotherapy or radiation therapy for breast cancer. Thus, the primary trial's more stringent inclusion criteria make it incompatible with the secondary trial for a patient with Stage 2B disease. Additionally, the patient in the primary trial must have an ECOG Performance Status of 0-2, while no such requirement exists in the secondary trial. This further distinguishes the two trials, and a patient could not meet both sets of eligibility criteria simultaneously.</s>"
    },
    "847b4dbe-428f-431c-8916-2a9c0c80cce4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial and the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"dosages are specified in the intervention section of the secondary trial and the primary trial\" is entailed by the information present in the CTRs because both CTRs contain a section titled \"INTERVENTION,\" in which specific dosage information for each intervention is mentioned. In the primary trial, the intervention is a lidocaine patch applied topically for 12 hours each day, with no further dosage information given. In the secondary trial, letrozole is given in a dose of 12.5 mg/day for three successive days. The statement's assertion that dosages are specified in the intervention sections is in accordance with the facts stated in the CTRs. There is no contradiction in this respect.</s>",
        "contradict": "The statement is not directly contradicted by the given CTRs. However, the meaning of \"dosages\" in the expert's statement can be interpreted differently in the context of each trial. In the context of the primary trial, the dosage refers to the amount of Lidocaine or placebo contained within each patch. In contrast, for the secondary trial, the dosage refers to the amount of Letrozole taken orally (12.5 mg/day) over a specific number of days (three). While the concept of dosages is present, the type of dosages (topical vs. oral) and the units (percentage vs. milligrams) differ in the primary and secondary trials. Thus, the statement does not explicitly contradict the CTRs, but the meaning of dosages in the statement might need clarification to ensure accurate entailment analysis.</s>"
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There were no instances of patients with abnormal heart rates in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"There were no instances of patients with abnormal heart rates in the primary trial\" can be entailed by the information in the CTRs if we interpret \"abnormal heart rates\" as referring specifically to supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia, as there were no occurrences of this condition recorded in either Adverse Events 1 or 2 (both having 0/31 and 0/25 instances, respectively). Furthermore, no instances of cardiac general - Other were specified to involve heart rate abnormalities in the provided CTRs. Hence, the statement is in agreement with the clinical trial data and does not contradict the given descriptions.</s>",
        "contradict": "Despite the assertion in the expert statement that there were no instances of patients with abnormal heart rates in the primary trial, there is a mention of \"Cardiac General - Other (Specify, __)\" with a total occurrence of 2 in the Adverse Events section of the primary CTR. One of these instances [1] is not further specified, allowing for the possibility that it could refer to an abnormal heart rate condition. Therefore, the expert statement contradicts the information present in the primary CTR.</s>"
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "There weren't no instances of patients with abnormal heart rates in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There weren't no instances of patients with abnormal heart rates in the primary trial\" is entailed by the information in the CTRs as there are no reported cases of supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia (abnormal heart rates) in the Adverse Events sections of both the primary (0/31) and secondary (0/N) trials.</s>",
        "contradict": "The statement can be contradicted by the presence of zero instances of \"supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia\" in the primary trial's adverse events section, even though atrial tachycardia and paroxysmal atrial tachycardia are types of abnormal heart rates.</s>"
    },
    "9c00b318-0a3a-43c9-a6cd-2983c07be393_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00232505",
        "Statement": "The primary trial has no instances of patients with abnormal heart rates.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial has no instances of patients with abnormal heart rates\" entails the absence of \"Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia\" events in Section 1 and Sections 2 of the Adverse Events sections in both primary and secondary trials. The CTRs confirm that there are no instances (0/31 and 0/25) of \"Supraventricular and nodal arrhythmia - Atrial tachycardia/Paroxysmal Atrial Tachycardia\" reported in the primary and secondary trials respectively. Therefore, the statement harmonizes with clinical trial data, has substantiation in the CTRs, and avoids contradiction with the provided descriptions, making it an entailed statement based on the information presented in the CTRs.</s>",
        "contradict": "The expert's statement is contradicted by the CTRs because, in both trials, there are no instances of patients exhibiting atrial tachycardia or paroxysmal atrial tachycardia which are types of supraventricular and nodal arrhythmias, but it does not explicitly mention the absence of abnormal heart rates in general. However, the CTRs list normal heart rates for both trials under the \"Cardiac General - Other\" category with the label \"Specify, __\", indicating the presence of heart rates that were not specified as abnormal or normal in the provided data. Therefore, the expert's statement, while technically correct for the specific type of arrhythmias mentioned, is not an accurate representation of the entire CTR data.</s>"
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "the primary trial and the secondary trial do not use cyclical interventions.",
        "Label": "Entailment",
        "entail": "neither trial involves interventions that repeat or cycle over time, as stated in the primary and secondary trials, the intervention described for both trials specifies a one-time procedure (iBE exam or pre-operative supine MRI) with no mention of recurrence or cyclical application. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not use cyclical interventions\" is contradicted by the information present in the CTRs because the primary trial's iBE intervention involves two consecutive iBE exams performed by different individuals during the same visit, which can be considered as a cyclical intervention for the participant. In contrast, the secondary trial's intervention with supine MRI and intraoperative optical scanning and tracking is not a cyclical intervention. The discrepancy between the statement and the CTRs lies in the misunderstanding of the term \"cyclical intervention\" and the specific details of the interventions in each trial.</s>"
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "The primary trial and the secondary trial use cyclical interventions.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial use cyclical interventions\" does not directly entail the information present in the CTRs, as no mention of cyclical interventions is made in the provided sections of either trial. Cyclical interventions refer to interventions that repeat or cycle through a sequence over a period of time, such as alternating between two different treatments or procedures in each trial visit. However, the information provided in the CTRs only describes the specific interventions used in each trial (i.e., iBE and clinical breast exam in the primary trial, and supine MRI with intraoperative optical scanning and tracking in the secondary trial) without any information regarding whether these interventions are cyclical or repeated in a particular order. Therefore, the statement does not harmonize with the clinical trial data, find substantiation in the CTRs, or avoid contradiction with the provided descriptions, and thus cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that the primary and secondary trials use cyclical interventions is contradicted by the information provided in the CTRs because the interventions described in each trial are not cyclical in nature. In the primary trial, patients receive an iBE exam followed by a clinical breast exam during their scheduled appointment, and those in the inter-rater reliability portion undergo both exams sequentially by two different individuals during the same visit. In the secondary trial, patients in group MRI receive a supine MRI with intraoperative optical scanning and tracking as an additional imaging modality alongside conventional imaging. Neither trial description suggests that interventions are repeated in a cyclical manner.</s>"
    },
    "cbfe14a5-5169-4de3-b69f-13b489be949a_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02597452",
        "Secondary_id": "NCT01929395",
        "Statement": "Cyclical interventions are not used by both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Cyclical interventions are not used by both the primary trial and the secondary trial\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, the iBE intervention is a one-time event performed during the scheduled breast screening appointment with no requirement for a return visit. This is consistent with the definition of a non-cyclical intervention.\n2. In the secondary trial, the addition of Supine MRI to conventional imaging is also a one-time intervention before the surgery, which is performed during the same visit as the conventional imaging. Hence, neither trial involves cyclical interventions.</s>",
        "contradict": "The statement \"Cyclical interventions are not used by both the primary trial and the secondary trial\" is contradicted by the information in the CTRs because:\n\n1. In the primary trial, the iBE exams are performed during a scheduled breast screening appointment, which does involve a return visit if the patient is part of the inter-rater reliability study, meaning there could be a cyclical nature to the intervention for those patients.\n2. In the secondary trial, patients undergo pre-operative supine MRI with intraoperative optical scanning and tracking, which is not explicitly stated as a cyclical intervention, but the nature of the MRI scan could potentially involve repeat scans, making it a possibility that cyclical interventions are utilized in this study as well.\n\nThus, while the primary statement may generally be true based on the provided information, it does not hold for both trials specifically. This highlights the importance of examining individual trial details when evaluating statements about clinical trials.</s>"
    },
    "bd6bf811-e9a8-4e1e-ace1-703aa8f5374b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect.",
        "Label": "Contradiction",
        "entail": "The statement \"There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect.\" can be entailed by the information present in the CTRs as follows:\n\n1. Both CTRs report on Partial Breast Irradiation (PBI) trials with identical overall number of participants (50 each) for cohorts 1 and 2.\n2. Cohort 1 received a lower dose of 36 Gy in 18 fractions per day for 4.5 treatment days, while Cohort 2 received a higher dose of 40 Gy in 20 fractions per day over 5 treatment days.\n3. The outcome measure in both CTRs is the same: Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan.\n4. The time frame for the trial is within 1 year of protocol registration for both trials.\n5. Based on the information provided, it is reasonable to infer that the higher dose in Cohort 2 might lead to a lower percentage of participants achieving a dosimetrically satisfactory treatment plan due to increased toxicity.\n6. The expert's statement suggests a significant difference and impact of the increased dose on the percentage of participants, which aligns with the potential differences in treatment outcomes between cohorts 1 and 2 based on the reported doses.</s>",
        "contradict": "The statement \"There is a significant difference in the Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan between cohort 1 and 2 of the primary trial, the increase in Gy has a huge effect.\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not provide sufficient data about the percentage of participants in each cohort who achieved a dosimetrically satisfactory treatment plan. However, the statement makes a causal claim (\"the increase in Gy has a huge effect\") that cannot be definitively concluded from the given information in the CTRs. The CTRs only report the number of participants and the treatment details for each cohort, and do not mention the specific percentage of participants who achieved a dosimetrically satisfactory treatment plan or any statistical analysis comparing the percentages between the cohorts. Therefore, while the statement is not contradictory to the CTRs, it goes beyond the information provided and makes an unsubstantiated assumption.</s>"
    },
    "3c4d9ab0-5e16-48b3-96d4-ae9d337b2822": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were more patients with hypotension in cohort 1 of the primary trial, than in cohort 1 of the secondary trial\" is not entailed by the information present in the CTRs. \n\nExplanation: \nThe statement asserts that there are more patients with hypotension in the primary trial's cohort 1, while the CTRs report the number of patients with hypotension for each trial separately. There is no direct comparison of the number of patients with hypotension between the two trials or their respective cohorts in the provided CTRs.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as there were no reports of hypotension in either cohort 1 of the primary trial or cohort 1 of the secondary trial, according to the provided data.</s>"
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial\" can be entailed by the information present in the CTRs, as follows:\n\n1. In the primary trial CTR, the inclusion criteria state \"Any\" as the condition for the presence or absence of smoking history. Although the criteria specifically exclude individuals with \"Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel,\" this exclusion does not mention heavy smoking as a cause. Thus, heavy smokers can meet the eligibility criteria for the primary trial if they satisfy all other conditions.\n\n2. In the secondary trial CTR, the inclusion criteria mention \"Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index >70)\" and \"An AUDIT-C score >1 or more than one cigarette smoked per day.\" The AUDIT-C score, which measures alcohol consumption, is not mentioned as a requirement for the primary trial. However, smoking more than one cigarette per day is a prerequisite for eligibility in the secondary trial. Since the statement under examination allows for \"Heavy smokers (more than 5 cigarettes smoked per day)\" to participate in the secondary trial, it can be inferred that they are also eligible for the primary trial if they meet all its other criteria.</s>",
        "contradict": "The statement \"Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial\" is contradicted by the eligibility criteria of the primary trial. The primary trial explicitly excludes individuals with a smoking history of more than one cigarette per day for the invasive breast cancer arm. Therefore, heavy smokers (more than 5 cigarettes per day) are not eligible for the primary trial as per the provided information. The secondary trial includes individuals with an AUDIT-C score >1 or more than one cigarette smoked per day, but the statement extends the smoking eligibility criteria beyond this requirement, making it inconsistent with the primary trial information.</s>"
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) aren't eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n- For the secondary trial, the inclusion criterion is \"An AUDIT-C score >1 or more than one cigarette smoked per day,\" which means smoking one cigarette per day or less is acceptable. The statement \"Heavy smokers (more than 5 cigarettes smoked per day) aren't eligible for the secondary trial\" goes beyond the inclusion criteria and excludes heavy smokers. Since the CTR does not specify eligibility criteria for smokers in the secondary trial beyond those stated, the expert's statement is an additional constraint that goes beyond the given information. Thus, the statement isn't an exact entailment, but it is consistent with the CTR since it is a more restrictive condition that does not contradict the CTR.\n\n- Regarding the primary trial, there is no explicit mention of smoking in the inclusion or exclusion criteria. However, the expert's statement implies that heavy smokers (those smoking more than 5 cigarettes per day) are not eligible for this trial as well. While the CTR does not exclude heavy smokers, it does specify certain hepatic, cardiovascular, and general health conditions that could potentially make individuals inappropriate for study participation. The absence of explicit smoking restrictions in the CTR does not contradict the expert's statement, but it also does not directly entail it. The expert's statement is a separate piece of information that could potentially impact the study population if adopted as an additional inclusion or exclusion criterion.</s>",
        "contradict": "The statement \"Heavy smokers (more than 5 cigarettes smoked per day) aren't eligible for the secondary trial and the primary trial\" contradicts the information present in the primary CTR, as heavy smokers (more than 5 cigarettes smoked per day) are eligible for the primary trial as stated in the inclusion criteria \"No smoking history or current smoker with less than or equal to 10 cigarettes per day\". The secondary CTR does not provide smoking-related eligibility criteria.</s>"
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "The secondary trial and the primary trial accept Heavy smokers (more than 5 cigarettes smoked per day).",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial and the primary trial accept Heavy smokers (more than 5 cigarettes smoked per day)\" is not directly entailed by the information given in the CTRs. The primary trial includes individuals with \"Any N\" but excludes those with \"Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel,\" but it does not explicitly state smoking status as an inclusion or exclusion criterion. The secondary trial includes individuals with an AUDIT-C score >1 or more than one cigarette smoked per day, which is considered heavy smoking according to some standards. However, the statement goes beyond the information given in the CTRs by combining data from both trials and making an assumption about the smoking status in the primary trial based on indirect evidence. Therefore, the statement cannot be definitively said to be entailed by the CTRs alone.</s>",
        "contradict": "The statement, \"The secondary trial and the primary trial accept Heavy smokers (more than 5 cigarettes smoked per day),\" contradicts the information presented in the inclusion criteria section of the primary CTR. In the primary trial, patients with \"over 1 cigarette smoked per day\" are excluded.</s>"
    },
    "6cf7d10e-902e-4f78-85f6-e06d63e1cd0e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that less than 50% of participants in the primary trial treated with Lapatinib 1500 mg had no progressive disease (PD) at Week 12. \n\nIn the primary trial's CTR, the percentage of participants with PD in Cohort 1 treated with Lapatinib 1500 mg, as determined both by an independent radiologist and an investigator, are stated as 38.9% and 43.1% respectively. \n\nSince these percentages represent the proportion of participants with PD, it follows that the difference between 100% and these percentages represents the proportion of participants without PD. Calculating this difference, we find that 61.1% (100% - 38.9%) and 56.9% (100% - 43.1%) of participants in the primary trial treated with Lapatinib 1500 mg had no PD at Week 12, according to the independent and investigator evaluations, respectively.\n\nThese percentages are both above the expert's stated threshold of 50%. Therefore, the expert's statement is entailed by the information present in the CTRs, as it is a logical consequence of the reported data.</s>",
        "contradict": "The statement less than 50% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at Week 12 directly contradicts the results presented in the CTR for Cohort 1. According to the results in the CTR, the percentage of participants with no progressive disease, or a response other than PD, for the Lapatinib 1500 mg group was 51.1% (the difference between 100% - 43.1% - 38.9%). Hence, more than 50% of participants had no progressive disease at Week 12 as per investigator evaluation. Similarly, for the independently evaluated data, more than 50% of participants (56.1%) had no progressive disease at Week 12. Therefore, the expert's statement contradicts the findings reported in the CTR.</s>"
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a bilateral mastectomy would be excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR information as female patients with a history of bilateral mastectomy do not meet the inclusion criterion of the primary trial. Specifically, one of the eligibility criteria states that \"Each participant must have at least 1 healthy intact breast.\" A bilateral mastectomy involves removal of both breasts, making the participant ineligible for the trial based on this criteria. Therefore, the statement \"A Female patients with a bilateral mastectomy would be excluded from the primary trial\" is a semantically entailed statement given the information provided in the CTRs.</s>",
        "contradict": "The statement is not entailed by the CTR information, as the CTR specifies that female patients with at least one healthy intact breast are eligible for the primary trial, and a bilateral mastectomy involves the removal of both breasts, leaving no intact breast. However, the CTR allows for prior biopsies, suggesting that some women may have undergone a bilateral breast conservation therapy (e.g., lumpectomy followed by radiation) and are still eligible for the trial. The CTR does not explicitly exclude patients with a history of bilateral mastectomy. Consequently, the statement made by the expert contradicts the CTR's inclusion criteria for the patient population.</s>"
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a bilateral mastectomy wouldn't be excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs, as the CTRs explicitly state, \"No prior radiotherapy or mastectomy.\" Therefore, a female patient with a bilateral mastectomy history would not meet the inclusion criteria for the primary trial.</s>",
        "contradict": "The statement is contradicted by the primary CTR's ELIGIBILITY CRITERIA section, which specifies \"No prior radiotherapy or mastectomy\" as an inclusion criterion. A bilateral mastectomy is considered a form of radiotherapy (radiation therapy following surgical resection) and thus would disqualify patients from the primary trial, according to the given CTR.</s>"
    },
    "91ad45ae-6714-4c27-ac1a-d8ff8e89684f_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "The primary trial excludes female patients with a bilateral mastectomy.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial excludes female patients with a bilateral mastectomy\" is entailed by the CTR information under \"Primary Trial: DISEASE CHARACTERISTICS,\" which states \"No prior radiotherapy or mastectomy.\" A bilateral mastectomy is a type of surgery that involves removing both breasts. Therefore, a female patient who has undergone a bilateral mastectomy has had both breasts removed, making her ineligible for the trial according to the provided exclusion criteria.</s>",
        "contradict": "The statement that the primary trial excludes female patients with a bilateral mestectomy contradicts the information in the CTR because the CTR specifies that \"At least 1 healthy intact breast\" is a requirement for participation in the study, but it does not exclude patients with a history of bilateral mastectomy as long as they have one healthy breast remaining. Therefore, the statement made by the clinical trial expert is incorrect, as the CTR does not entail the specified exclusion of patients with a bilateral mastectomy.</s>"
    },
    "91cf53f9-7233-49ee-a619-c027f6db67ac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Only men can be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Only men can be eligible for the primary trial\" is not entailed by the provided CTRs information. The primary trial's inclusion criteria state that it is for premenopausal, estrogen receptor positive women, and the exclusion criteria state that individuals who have undergone chemotherapy or endocrine therapy for breast cancer, have received radiotherapy, or are unwilling to stop taking any drug known to affect sex hormone status are ineligible. The statement does not align with these inclusion and exclusion criteria as it only mentions men as not being eligible for the trial, which contradicts the stated criteria for the primary trial being for women.</s>",
        "contradict": "The statement \"Only men can be eligible for the primary trial\" contradicts the information in the CTR as the primary trial includes women who meet specific eligibility criteria, and the exclusion criteria do not mention anything about gender. The CTR explicitly states that premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent are eligible for the trial.</s>"
    },
    "78894316-fc7d-4d61-a2d4-9ea369bfce20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea.",
        "Label": "Entailment",
        "entail": "In the primary trial, the frequency of Erysipelas in cohort 1 is 2/167 or 1.20%, while the frequency of Bacterial diarrhoea is 1/167 or 0.60%. A ratio of 2:1 implies that for every instance of Bacterial diarrhoea, there are two instances of Erysipelas. Therefore, the statement \"Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea\" is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea\" is contradicted by the information present in the CTRs because the number of participants who experienced Erysipelas in both trials was equal (0.60% in each), whereas the number of patients who experienced Bacterial diarrhea in the primary trial was lesser (0.00% in the secondary trial and 0.60% in the primary trial). Therefore, the statement that \"Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than Bacterial diarrhoea\" does not harmonize with the clinical trial data provided and, thus, cannot be entailed from the CTRs.</s>"
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia\" can be entailed by the data in the Adverse Events sections of the CTR since both sections report the same number of cases for anaemia (1) and Neutropenia (1).\n\nThe statement also implies that the total number of patients in each cohort is identical, which can be deduced from the given information since the percentage of patients with adverse events is stated for each cohort. Therefore, with the known number of patients affected by anaemia and Neutropenia in each cohort, we can calculate the total number of patients in each cohort based on the percentage of adverse events reported.\n\nThe statement \"but Cohort 1 had 1 more case of Leukopenia than cohort 2\" can also be entailed by the data in the CTRs as both sections report a different number of Leukopenia cases (1 for cohort 1 and 0 for cohort 2). This difference in Leukopenia cases between the two cohorts is in line with the statement.</s>",
        "contradict": "The statement does not entail the information in the CTRs because the CTRs indicate different numbers of patients in each cohort. The statement assumes that the number of patients in Cohort 1 and 2 are the same, whereas the primary trial CTR reports 51 patients in Cohort 1 and 50 patients in Cohort 2. Contradiction arises due to the discrepancy in patient numbers between what is asserted in the statement and the information provided in the CTRs.</s>"
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial didn't have the same number of patients with anaemia and Neutropenia, but Cohort 1 had 1 more case of Leukopenia than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement asserts that there is a difference in the number of cases of anaemia and Neutropenia between Cohort 1 and Cohort 2 of the primary trial, with Cohort 1 having one more case of Leukopenia. \n\nThe CTRs report that Cohort 1 had 1 anaemia case (1.96%) out of 51 patients, and 1 Neutropenia case (1.96%) and 1 Leukopenia case (1.96%). Cohort 2 had 1 anaemia case (2.00%) and 1 Neutropenia case (2.00%) but no Leukopenia cases.\n\nThus, the statement that Cohort 1 and 2 of the primary trial didn't have the same number of patients with anaemia and Neutropenia, and that Cohort 1 had 1 more case of Leukopenia, is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR data as the number of participants with anaemia and neutropenia is different between cohorts, but there is no mention of leukopenia in the statement or the CTRs that indicates a difference of one case between them.</s>"
    },
    "889e6622-1614-4f6c-a47c-e7caad6e154f_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 had 1 more case of Leukopenia than cohort 2, but Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: \n\n1. The number of patients with leukopenia in cohort 1 is given as 1/51 in the primary CTR, and in cohort 2 it is 0/50 in the secondary CTR. A difference of 1 case can be calculated, implying cohort 1 had one more case of leukopenia.\n\n2. The number of patients with anaemia and neutropenia in both cohorts of the primary trial are stated to be the same in the expert's statement. This aligns with the information provided in the CTRs, where both anaemia and neutropenia cases are identical for each cohort (1/51 for cohort 1 and 1/50 for cohort 2 in the respective CTRs).</s>",
        "contradict": "The statement \"Cohort 1 had 1 more case of Leukopenia than cohort 2, but Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia\" is contradicted by the information in the CTRs because, while cohort 1 had 1 more case of Leukopenia than cohort 2 (1 vs. 0), there were the same number of patients with anaemia (1) and Neutropenia (1) in each cohort. However, the overall number of patients differed between the cohorts (51 in Cohort 1 vs. 50 in Cohort 2), which may have influenced the occurrence of these adverse events but is not mentioned in the statement.</s>"
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial accept patients in the same age range.",
        "Label": "Entailment",
        "entail": "Both trials include the age criterion for patient inclusion, with no specified minimum or maximum age limit stated in either CTR beyond the general requirement of being over 18 years old. Therefore, the statement that the secondary trial and the primary trial accept patients in the same age range is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial accept patients in the same age range\" is generally true, as both trials state that patients must be 18 years old or older. However, the primary CTR provides more detailed inclusion criteria specifying only breast cancer patients. The secondary trial, on the other hand, includes a broader range of diseases, specifically breast cancer, but with additional conditions such as stage I-III, post-surgery or chemotherapy within a certain time frame, and receiving or planning to receive standard adjuvant therapy. These conditions may limit or expand the age range in practice. Therefore, although the minimum age requirement is the same, the age range in each trial could potentially be different depending on the specific patient population. This discrepancy in patient population could lead to a contradiction between the statement and the CTRs if the statement is interpreted too strictly without considering the additional conditions specified in the trials.</s>"
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "The secondary trial and the primary trial don't accept patients in the same age range.",
        "Label": "Contradiction",
        "entail": "The primary trial states that patients must be over 18 years old, while the secondary trial specifies a minimum age of 18 for eligibility. However, there is no maximum age mentioned in the primary trial, whereas the secondary trial includes a broader age range (18 and over) for its patients. Therefore, the primary trial does not explicitly exclude patients in the same age range as the secondary trial, but it also does not accept patients beyond the lower age limit specified in the secondary trial. However, the statement can still be entailed by stating that the primary trial may accept older patients, but the secondary trial has a stricter age limit, and thus does not accept patients who are younger than the primary trial's lower age limit.</s>",
        "contradict": "The statement that \"The secondary trial and the primary trial don't accept patients in the same age range\" is contradicted by the information presented in the CTRs since both studies accept female patients over the age of 18.</s>"
    },
    "4577d986-d7e5-4b5d-9852-b944a6f7f252_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the primary trial and the secondary trial accept patients in the same age range.",
        "Label": "Entailment",
        "entail": "both trials involve patients who are 18 and over (Primary Trial: \"Female breast cancer patients over the age of 18 will be recruited,\" Secondary Trial: \"Age 18 and over\").</s>",
        "contradict": "The primary trial specifies that patients must be over the age of 18, while the secondary trial only states that the age is 18 and over without further specification. Although the age ranges overlap, the primary trial has a more explicit inclusion criterion, meaning the statement that both trials accept patients in the same age range can be contradicted if we consider the stricter inclusion criteria of the primary trial. In other words, the primary trial might exclude individuals just at the border of the overlapping age range who would be eligible in the secondary trial.</s>"
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies tumours response, whereas the secondary trial investigates changes in Bone Mineral Density.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert that \"the primary trial studies tumor response, whereas the secondary trial investigates changes in Bone Mineral Density\" is entailed by the information presented in the CTRs as follows:\n\nThe primary trial (CTRs 1 and 2) focuses on the efficacy of different treatments on tumor response, as evident from the description of the primary endpoint in both trials which measures the overall response rate of participants based on RECIST 1.1 criteria.\n\nSimultaneously, the secondary trial (CTR 3) examines changes in bone mineral density, which is indicated by the description of the outcome measurement as the percent change in bone mineral density from baseline at month 12. The two trials address distinct aspects of treatment effects, with the primary trial investigating tumor response, and the secondary trial exploring bone mineral density changes.</s>",
        "contradict": "The statement \"the primary trial studies tumors response, whereas the secondary trial investigates changes in Bone Mineral Density\" is not directly contradicted by the information present in the CTRs. However, it makes some implicit assumptions which could potentially be contradicted by the CTRs. The statement assumes that the two trials are entirely independent of each other, but the CTRs do not provide enough information to confirm or deny this assumption. For instance, it's not clear whether any of the participants in the primary trial were also participants in the secondary trial, or if they were part of the same study population. Additionally, it is not mentioned whether there is any correlation or interaction between the treatments given in the primary trial and the bone mineral density changes observed in the secondary trial. Therefore, while the statement is not contradictory on its face, it is important to note that the assumptions it relies upon may not be valid based on the information provided in the CTRs alone.</s>"
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "The primary trial studies tumours response, whereas the secondary trial doesn't investigate changes in Bone Mineral Density.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial studies tumors response, whereas the secondary trial doesn't investigate changes in Bone Mineral Density\" is entailed by the information in the CTRs because:\n\n1. The CTR for the primary trial explicitly states \"Outcome Measurement: Primary Endpoint : Compare Best Overall Response Rate (ORR) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin\u00ae Plus Taxane in the ITT1 Population.\" This shows that the primary trial focuses on tumor responses.\n\n2. The CTR for the secondary trial states \"Outcome Measurement: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12.\" This indicates that the secondary trial investigates changes in Bone Mineral Density and not tumor responses.\n\nTherefore, the statement's claim that the primary trial studies tumor responses and the secondary trial doesn't investigate changes in Bone Mineral Density is consistent with the information given in the CTRs and is entailed by them.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the CTR for the primary trial provides details regarding the measurement of the primary endpoint, which is the comparison of Best Overall Response Rate (ORR) at Week 24 using RECIST 1.1 Criteria for MYL-1401O Plus Taxane versus Herceptin\u00ae Plus Taxane in the ITT1 Population. In contrast, the secondary trial does not involve tumour response assessment as its outcome measurement, but instead investigates the change in Lumbar Spine Bone Mineral Density at Month 12 using Dual Energy X-Ray Absorptiometry. The two trials focus on distinct clinical objectives.</s>"
    },
    "e83b56ba-d129-4cde-976d-2865e67ef4a3_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the secondary trial investigates changes in Bone Mineral Density, whereas the primary trial studies tumours response.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial investigates changes in Bone Mineral Density, whereas the primary trial studies tumors response\" is entailed by the information in the CTRs as the secondary trial's outcome measurement is explicitly stated as \"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12,\" while the primary trial's outcome measurement is \"Compare Best Overall Response Rate (ORR) (According to RECIST 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin\u00ae Plus Taxane in the ITT1 Population.\" These measurements pertain to different aspects of the trials (bone mineral density in the secondary trial, tumor response in the primary trial). Therefore, the statement accurately describes the difference between the trials based on the information in the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs, as it accurately describes the different outcomes measures and focus of each trial. However, it does not provide any entailment relationship between the two trials. The primary and secondary trials address distinct aspects of patient care - tumor response and bone mineral density, respectively. The statement does not claim that the results of one trial entail or depend on the results of the other.</s>"
    },
    "eee75423-9a61-4a57-8baf-8f91b9562486": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "The majority of patients in the primary trial suffered from Kidney stones.",
        "Label": "Contradiction",
        "entail": "The statement \"The majority of patients in the primary trial suffered from Kidney stones\" cannot be entailed by the information present in the CTRs as neither trial reports any instance of Nephrolithiasis (Kidney stones) among the adverse events.</s>",
        "contradict": "The statement cannot be entailed by the information present in the CTRs as there is no mention of Kidney stones or Nephrolithiasis in the ELIGIBILITY CRITERIA or ADVERSE EVENTS sections of the primary or secondary trials provided. The statement asserts a condition not supported by the data within the CTRs.</s>"
    },
    "9e046221-7d4b-4681-a374-96793350927d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort.",
        "Label": "Contradiction",
        "entail": "The statement \"Group 1 of the secondary trial has a higher ORR than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort\" cannot be directly entailed by the provided information in the CTRs. \n\nTo establish entailment, the statement should harmonize with clinical trial data and avoid contradiction with the provided descriptions. However, the statement makes a comparative claim between ORRs of different trials that is not directly stated in the CTRs. The CTRs only provide ORR percentages for specific arms/groups within each trial but do not provide a comparison of ORRs between trials.\n\nTherefore, the entailment relationship cannot be established based on the information in the CTRs alone. Further information, such as the ORR percentages of the trastuzabum cohort or a statistical comparison of the ORRs between the trials, would be needed to evaluate the truthfulness of the expert's statement.</s>",
        "contradict": "The statement cannot be definitively contradicted by the information present in the CTRs, but it can be questioned due to the lack of comparative data. The statement implies that the ORR of Group 1 in the secondary trial is higher than both the Everolimus + Letrozole cohort of the primary trial and the trastuzumab cohort. However, there is no information provided in the CTRs about the ORR of the trastuzumab cohort, making a direct comparison impossible. Moreover, the ORR definitions, assessment methods, and time frames are not identical across the trials. Thus, while the statement might be true, it cannot be definitively established based on the given data.</s>"
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial\" is entailed by the CTRs because:\n\n1. The statement accurately reflects that Cyclophosphamide, Doxil, and Trastuzumab are used in the secondary trial intervention. This aligns with the CTR description stating \"Some patients with HER2/neu 3+ disease may also receive trastuzumab IV\" and \"Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1.\"\n\n2. The statement also accurately reflects that these drugs were not used in the primary trial intervention. The CTR description for the primary trial specifies that only Cabozantinib was used, and no mention of Cyclophosphamide, Doxil, or Trastuzumab is provided.\n\nTherefore, the statement \"Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but not in the primary trial\" is entailed by the information contained within the CTRs as it correctly identifies the differences in interventions between the two trials.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because, while it is true that Intervention 1 in the secondary trial involves cyclophosphamide, pegylated doxorubicin hydrochloride, and trastuzumab, it does not accurately convey that these agents were not used in the primary trial. In the primary trial, only cabozantinib was used for Intervention 1.</s>"
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Doxil and Trastuzumab were used in the secondary trial intervention, but in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs if the expert meant to imply that the interventions for the secondary trial involved the use of cyclophosphamide, doxorubicin hydrochloride, and trastuzumab similar to the primary trial, but in different combinations or dosages. The primary trial administered cabozantinib alone, whereas the secondary trial used a combination of cyclophosphamide, doxorubicin hydrochloride, and trastuzumab. However, each trial included these medications as part of their respective interventions.</s>",
        "contradict": "The statement asserts that \"Cyclophamide, Doxil and Trastuzumab were used in the secondary trial intervention, but in the primary trial,\" which contradicts the information in the CTRs since:\n\n- In the primary trial (INTERVENTION 1), Cabozantinib was given as a single treatment, whereas the statement suggests the use of a combination therapy (Cyclophamide, Doxil, and Trastuzumab).\n- In the secondary trial (INTERVENTION 1), a different combination therapy was used compared to the primary trial, with cyclophosphamide being administered orally and pegylated doxorubicin hydrochloride and trastuzumab given IV, whereas the statement does not mention the administration routes.</s>"
    },
    "5448c6b8-244c-4a42-bbef-e1a1a2e254e2_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "The primary trial does not use Cyclophosphamide, Doxil and Trastuzumab in its intervention, but the secondary trial does.",
        "Label": "Entailment",
        "entail": "The primary trial and the secondary trial report different interventions. The primary trial uses Cabozantinib as the intervention, specified as 60 mg orally once daily for 21-day cycles, while the secondary trial reports the use of a combination therapy comprising Cyclophosphamide, Doxil, and Trastuzumab. \n\nThe provided statement correctly asserts that the primary trial does not employ Cyclophosphamide, Doxil, and Trastuzumab in its treatment plan, whereas the secondary trial does. This statement is entailed by the information present in the provided CTRs because the CTRs explicitly describe the interventions used in each trial, and the statement accurately reflects the differences between those interventions.</s>",
        "contradict": "The statement asserts that the primary trial does not use Cyclophosphamide, Doxil, and Trastuzumab in its intervention, while the secondary trial does. However, this information contradicts the CTRs provided because they describe the interventions for each trial separately, and there is no mention of similar treatments being used in both. The statement's comparison of interventions between the two trials is an invalid assumption, as each trial has distinct interventions.</s>"
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as the secondary trial explicitly states that pre-menopausal patients are ineligible, while the primary trial includes eligibility criteria for pre-menopausal patients who meet certain conditions, such as those undergoing estradiol treatment or ovarian suppression. Therefore, the statement does not contradict the provided descriptions and is harmonious with the clinical trial data.</s>",
        "contradict": "The statement \"pre-menopausal patients are excluded from the secondary trial, but eligible for the primary trial\" is contradictory to the information in the CTRs. \n\nThe primary trial includes pre-menopausal patients as long as they meet the inclusion criteria, which include having recurrent or residual metastatic breast carcinoma, Zubrod performance status less than 2, being 18-60 years old, related or unrelated HLA-compatible for allogeneic transplantation or unrelated HLA-compatible donor, and no major organ dysfunction or active infection. The secondary trial, however, explicitly excludes pre-menopausal patients unless they fall under certain conditions such as being postmenopausal or planning for estradiol treatment with ovarian suppression. The contradiction lies in the exclusion of pre-menopausal patients from the secondary trial, while they are eligible for the primary trial according to the statement.</s>"
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "Pre-menopausal patients aren't excluded from the secondary trial, but eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The pre-menopausal patients can be eligible for the primary trial as it states \"Patient must be pre-menopausal for whom standard estradiol treatment (ET) is planned with ovarian suppression\" under its inclusion criteria. This condition is not mentioned as an exclusion factor in the secondary trial. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as the secondary trial explicitly includes postmenopausal patients only, whereas pre-menopausal patients are eligible for the primary trial but have additional inclusion criteria.</s>"
    },
    "135a7d7b-b5d1-4fe6-9a41-4b303d6fb9b2_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "The primary trial accepts pre-menopausal patients, but the secondary trial excludes them.",
        "Label": "Entailment",
        "entail": "The primary trial includes pre-menopausal patients as a part of its eligibility criteria, specified as \"unrelated HLA-compatible donor for allogeneic transplantation or related donor for allogeneic transplantation\" without any age or menopausal status limitations mentioned explicitly. However, the secondary trial excludes pre-menopausal patients, stating \"Patient must be postmenopausal\" and defining it through various conditions such as age, amenorrhea, surgical sterilization, or FSH level. Although the primary trial does not explicitly exclude pre-menopausal women, its focus is on transplantation and does not include specific age or menopausal status requirements. In contrast, the secondary trial specifically targets hormonal therapy (ET) and sets clear criteria for patient eligibility. The discrepancy between the two trials lies in their objectives and targeted treatments. The statement that the primary trial accepts pre-menopausal patients but the secondary trial excludes them is entailed by the information present in the CTRs as they describe distinct trials with different objectives and inclusion/exclusion criteria.</s>",
        "contradict": "The primary trial includes pre-menopausal patients as long as they meet certain conditions, such as having a plan for hormonal treatment with ovarian suppression or falling into specific breast cancer categories. The secondary trial, however, excludes pre-menopausal patients unless they are postmenopausal or have a plan for estrogen treatment and ovarian suppression. \n\nThis statement is contradictory to the CTRs because the primary trial does accept pre-menopausal patients under specific circumstances, while the secondary trial explicitly excludes them, unless specific conditions are met.</s>"
    },
    "8d450d42-4eb1-4edb-be76-b2885964aa90": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01506609",
        "Secondary_id": "NCT00656019",
        "Statement": "Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial includes patients with histologically or cytologically confirmed breast cancer, but only those with locally recurrent disease that is not amenable to surgical resection or radiation with curative intent. The secondary trial excludes patients whose locally recurrent disease is amenable to radiation with curative intent.\n2. Therefore, patients with cytologically confirmed breast cancer, whose locally recurrent disease is amenable to radiation with curative intent, fall under the exclusion criteria of the primary trial and are not eligible for it.\n3. However, such patients are not explicitly mentioned in the inclusion or exclusion criteria of the secondary trial. But, since they meet the inclusion criteria of the secondary trial, i.e., having cytologically confirmed breast cancer, they are eligible for that trial by default, as per the given statement.\n4. Thus, the statement \"Patients with cytologically confirmed breast cancer, who's Locally recurrent disease is amenable to radiation with curative intent are not eligible for the secondary trial, but are eligible for the primary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTR information as the primary trial's inclusion criteria explicitly states that patients with locally recurrent disease must not be amenable to surgical resection or radiation with curative intent to be eligible. Therefore, patients with locally recurrent disease amenable to radiation with curative intent would not be eligible for the primary trial, but they are mentioned as ineligible for the secondary trial in the statement. Thus, the statement is not entailed by the CTR information.</s>"
    },
    "2674e194-3113-4a11-b2cc-f089d960d194": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention\" is entailed by the information in the CTRs because the INTERVENTION section of the primary trial does not mention the usage of these drugs. The statement does not contradict any information in the CTRs and is in harmony with the trial data.</s>",
        "contradict": "The statement made by the expert that \"the primary trial does not use trastuzumab, Tamoxifen or Exemestane in its intervention\" can be contradicted by the CTR if it turns out that the primary trial actually does use one or more of these drugs in the CMRM or UMRM arms. The CTR would need to be consulted to determine if this is the case, but simply stating that these drugs are not mentioned in the provided Intervention description is not enough to conclusively entail that they are not being used in the trial.</s>"
    },
    "2674e194-3113-4a11-b2cc-f089d960d194_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "The primary trial uses trastuzumab, Tamoxifen or Exemestane in its intervention.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the CTRs since the statement mentions specific drugs (trastuzumab, Tamoxifen, and Exemestane), whereas the CTRs describe Intervention 1 as using CMRM (Chemotherapy, Monoclonal Antibody, and Radiotherapy) versus UMRM (Chemotherapy, Monoclobulin, and Radiotherapy). However, there is a potential for entailment if it is known or assumed that trastuzumab, Tamoxifen, or Exemestane are treatments within the CMRM or UMRM arms. If this assumption holds true in the context of the trials, the statement can be derived from the information in the CTRs. In other words, if trastuzumab, Tamoxifen, and Exemestane are valid treatments within either CMRM or UMRM, then the statement is entailed by the CTRs.</s>",
        "contradict": "The statement made by the expert is contradicted by the information in the CTRs if the specified primary trial does not involve the use of trastuzumab, Tamoxifen, or Exemestane in its intervention. This contradiction arises because the expert's statement asserts the use of these specific medications, while the CTRs do not support this claim for the given primary trial.</s>"
    },
    "2674e194-3113-4a11-b2cc-f089d960d194_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "trastuzumab, Tamoxifen or Exemestane are not used in the primary trial intervention.",
        "Label": "Entailment",
        "entail": "The statement \"trastuzumab, Tamoxifen or Exemestane are not used in the primary trial intervention\" can be entailed by the information present in the CTRs if the interventions specified in the primary trial do not mention or involve the use of trastuzumab, Tamoxifen, or Exemestane. Since the CTR for the primary trial does not provide any information about the specific interventions used, it does not contradict the statement and thus can be entailed by it. However, if the primary trial CTR does mention the use of any of these drugs, the statement would not be entailed.</s>",
        "contradict": "The statement \"trastuzumab, Tamoxifen or Exemestane are not used in the primary trial intervention\" is contradicted by the given CTR if the unspecified interventions in the primary trial are, in fact, CMRM (trastuzumab-based therapy) or UMRM (Tamoxifen or Exemestane-based therapy). The CTR does not provide sufficient information to confirm or refute the statement definitively, but it does not necessarily entail that trastuzumab, Tamoxifen, or Exemestane are excluded from the primary trial intervention based on the current evidence.</s>"
    },
    "a7232387-b266-4bfb-8df8-ca9789188500": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing adverse events than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if the number of patients experiencing adverse events in cohort 1 of the primary trial is indeed 25% more than the number in cohort 2. This can be determined by adding the total number of adverse events in cohort 1 (13) and finding the difference with the total number of adverse events in cohort 2 (6), then calculating 25% of the difference and adding it to the total number of adverse events in cohort 2. If the result equals the total number of adverse events in cohort 1, then the statement can be entailed by the CTR data.\n\nThe calculation would be: (13 - 6) * 0.25 + 6 = 10.25. Since there cannot be a fractional participant, the statement cannot be exactly entailed from the data. However, if we round the number of adverse events up or down, the statement can be approximately entailed:\n- If we round down the number in cohort 1 to 13, then the statement is approximately entailed: (13 - 6) * 0.25 + 6 = 10.25 \u2248 11.\n- If we round up the number in cohort 2 to 7, then the statement is approximately entailed: (13 - 7) * 0.25 + 7 = 11.\n\nSo, if the number of participants in each cohort is adjusted to round the numbers of adverse events up or down, then the statement can be approximately entailed by the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs as the percentages of patients experiencing adverse events are not equivalent between the cohorts, with cohort 1 having a higher rate (54.17% vs 25.00%), and certain types of adverse events differing in occurrence between the two cohorts.</s>"
    },
    "a7232387-b266-4bfb-8df8-ca9789188500_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial didn't have 25% more patients experiencing adverse events than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if the total number of adverse events in cohort 1 of the primary trial is not 25% greater than that of cohort 2 in trial 2. Based on the provided data, the total number of adverse events in cohort 1 and cohort 2 of the primary trial are 13 (54.17%) and 6 (25.00%) respectively. A 25% difference would mean 1.25 times as many adverse events in cohort 1 as in cohort 2. However, the number of adverse events in cohort 1 is 13 and 1.25 * 6 = 7.81, which is not an integer number of events, indicating there is no 25% difference. Consequently, the statement is entailed by the data in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial didn't have 25% more patients experiencing adverse events than cohort 2\" cannot be directly contradicted by the information in the CTRs since the CTRs do not provide the exact number of participants in each cohort or a comparison of their adverse event rates. However, based on the provided adverse event data, it can be observed that cohort 1 had a slightly higher percentage (54.17%) of participants experiencing adverse events than cohort 2 (25.00%). This difference is not 25% but is within the range of 29.17%. Consequently, the statement is not entirely contradicted by the CTR data, but it is not entirely accurate either.</s>"
    },
    "a7232387-b266-4bfb-8df8-ca9789188500_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 2 of the primary trial had 25% less patients experiencing adverse events than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR data as follows:\n\n1. Calculate the difference in adverse event rates between cohorts 1 and 2: 54.17% (CTR 1) and 25.00% (CTR 2). The difference is a relative reduction of 54.17% - 25.00% = 29.17%.\n2. Determine the factor by which Cohort 2's rate is less than Cohort 1's: 1 - (CTR 2/CTR 1) = 1 - (25.00%/54.17%) \u2248 0.536.\n3. Find the percentage decrease: 100% * (1-0.536) \u2248 46.4%, which is approximately 25% less than Cohort 1.\n\nThis analysis shows that Cohort 2 having 25% fewer adverse events than Cohort 1 is an entailed statement given the data in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial had 25% less patients experiencing adverse events than cohort 1\" contradicts the information present in the CTRs because, based on the data provided, the number of adverse events in cohort 2 is equal to that of cohort 1, with both having a total of 6 adverse events each. However, cohort 1 had 24 patients while cohort 2 had 24 patients as well. Therefore, the percentage of patients experiencing adverse events is actually identical between the two cohorts (25.00% for each), not 25% less in cohort 2. The statement's contradiction with the CTR data stems from an incorrect assumption regarding the difference in the number of patients experiencing adverse events between the cohorts, rather than the actual percentage of patients affected.</s>"
    },
    "2e317381-2704-4d06-a793-1d2b29139969": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only one participant of the primary trial did not achieve Pathological Complete Response.",
        "Label": "Entailment",
        "entail": "The statement \"In total only one participant of the primary trial did not achieve Pathological Complete Response\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTRs specify the outcome measurement as \"Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative).\"\n\n2. In both Cohort 1P and Cohort 1T of the primary trial, all participants with HER2-positive molecular subtypes were administered trastuzumab and pertuzumab, in addition to chemotherapy.\n\n3. Results 1 and 2 report the number of participants in each cohort who achieved pCR, which were 4 out of 5 in Cohort 1P and all 6 participants in Cohort 1T.\n\n4. Since there were a total of 5 + 6 = 11 participants in these two cohorts, the statement \"In total only one participant of the primary trial did not achieve Pathological Complete Response\" can be derived by subtracting the total number of pCRs (4 + 6 = 10) from the total number of participants.</s>",
        "contradict": "The statement \"In total only one participant of the primary trial did not achieve Pathological Complete Response\" cannot be directly contradicted by the information present in the CTRs. However, it may be misinterpreted as contradictory based on a lack of clarity regarding which Cohort (1P or 1T) and molecular subtype (HER2 Positive) the statement refers to. The CTRs provide separate results for each Cohort (Cohort 1P and Cohort 1T) and different molecular subtypes (HER2 Positive), but the statement does not specify which one is being referenced. Therefore, the statement could potentially hold true for one of the Cohorts and molecular subtypes, but not for the others, without directly contradicting the CTRs. However, if the expert meant to assert that \"only one participant in the entire primary trial did not achieve a pCR across all Cohorts and molecular subtypes,\" then the statement would indeed contradict the CTRs, as the provided information indicates that there were 5 participants in Cohort 1P (1 non-pCR) and 6 participants in Cohort 1T (all achieved pCR).</s>"
    },
    "2e317381-2704-4d06-a793-1d2b29139969_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only one participant of the primary trial achieved Pathological Complete Response.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. The statement claims that only one participant achieved pCR in the primary trial.\n2. According to Results 1 and 2 in the CTRs, a total of 5 participants were analyzed in Cohort 1P (HER2 Positive) and 6 participants were analyzed in Cohort 1T (HER2 Positive).\n3. Therefore, the total number of participants in both cohorts combined is 11.\n4. Since only one participant achieved pCR (as stated in the expert statement), the remaining 10 participants did not achieve pCR.\n5. The information in the CTRs, specifically the Results sections, reports the number of participants who did not achieve pCR in each cohort, and the total number of participants in each cohort. However, the CTRs do not explicitly state that only one participant achieved pCR.\n6. The expert statement is a logical conclusion based on the data presented in the CTRs.\n7. The statement does not contradict any information in the CTRs.\n8. The statement harmonizes with the clinical trial data by accurately summarizing the number of participants who achieved pCR in the trial.</s>",
        "contradict": "The statement \"In total only one participant of the primary trial achieved Pathological Complete Response\" contradicts the information in the CTRs because:\n\n1. The statement implies that only one participant across both Cohorts 1P and 1T in the primary trial achieved pCR.\n2. However, the CTRs provide separate information for pCR in each cohort, which shows that 4 out of 5 participants in Cohort 1P and all 6 participants in Cohort 1T achieved pCR.\n3. Thus, the statement's assertion that \"only one participant\" achieved pCR is inconsistent with the data presented in the CTRs.</s>"
    },
    "2e317381-2704-4d06-a793-1d2b29139969_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "Pathological Complete Response was achieved by all but one participant of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Pathological Complete Response was achieved by all but one participant of the primary trial\" can be entailed by the information in the CTRs as follows: \n\nIn the primary trial, there were two cohorts (Cohort 1P and Cohort 1T) consisting of HER2 positive patients. The results indicate that in Cohort 1P, 4 out of 5 participants achieved pCR, while in Cohort 1T, all 6 participants achieved pCR. Therefore, a total of 10 participants out of 11 (90.9%) achieved pCR in the primary trial. Since the statement asserts that all but one participant achieved pCR, this is consistent with the data in the CTRs.</s>",
        "contradict": "The statement \"Pathological Complete Response was achieved by all but one participant of the primary trial\" cannot be directly contradicted by the information present in the CTRs as the statement does not provide enough detail to determine which Cohort or Group from the Primary Trial or the Secondary Trial it refers to. The CTRs only provide data for two different cohorts within the Primary Trial, but it is unknown if there is a third cohort or if the statement is combining data from both cohorts. Without this context, it is impossible to definitively establish entailment or contradiction between the statement and the CTRs.</s>"
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO every single day of the study duration.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert can be entailed by the information in the CTRs as follows: In the primary trial, patients receive saracatinib PO on days 1-28, and treatment repeats every 28 days. Since the statement claims that participants are given saracatinib every day of the study duration, it harmonizes with the CTR information by capturing the frequency of the treatment administration, which is indeed every day during each treatment cycle. This interpretation is also supported by the absence of any contradictory information in the CTRs regarding the administration schedule. Therefore, the expert statement is entailed by the CTRs.</s>",
        "contradict": "The expert's statement is contradicted by the CTR information as the participants in the primary trial do not receive saracatinib PO every single day of the study duration. According to the CTR, patients receive saracatinib PO on days 1-28, and then treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Therefore, there are intervals during the study in which patients are not receiving the treatment.</s>"
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "The primary trial participants aren't given saracatinib PO every single day of the study duration.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial participants aren't given saracatinib PO every single day of the study duration\" is entailed by the information in the CTRs because the CTR for the primary trial indicates that patients receive saracatinib PO on days 1-28, and the treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. This implies that patients are not on treatment every single day of the study duration since there are intervals between treatment cycles.</s>",
        "contradict": "The statement \"The primary trial participants aren't given saracatinib PO every single day of the study duration\" is contradicted by the information present in the CTR as patients in the primary trial receive saracatinib PO on days 1-28 and the treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity, which implies that they do receive saracatinib on most days of the study duration.</s>"
    },
    "030316a2-fb48-469d-9c55-04cdc9a37fb6_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "saracatinib PO was given to the primary trial participants every single day of the study duration.",
        "Label": "Entailment",
        "entail": "The statement \"saracatinib PO was given to the primary trial participants every single day of the study duration\" can be entailed by the information present in the CTRs as follows: \n\n1. Saracatinib is the specified treatment in Intervention 1 of the primary trial. \n2. Participants receive saracatinib PO (orally) on days 1-28 of each cycle. \n3. Each cycle repeats every 28 days in the absence of disease progression or unacceptable toxicity. \n\nFrom the above information, it can be inferred that participants in the primary trial receive saracatinib PO every day during each 28-day cycle and, given the absence of progression or toxicity, for the entire study duration. Thus, the statement is an entailed consequence of the CTR information.</s>",
        "contradict": "The expert's statement is contradictory to the CTR because the CTR specifies that saracatinib is given to participants every 28 days, repeating the treatment in the absence of disease progression or unacceptable toxicity. The expert's statement, however, asserts that patients received the drug every single day of the study duration, which is not consistent with the repeated-dose schedule described in the CTR.</s>"
    },
    "2c723e02-14d8-4a80-a95f-517e904bbbad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month.",
        "Label": "Contradiction",
        "entail": "The expert's statement that \"no participants of the primary trial had a Progression Free Survival over 1 year, but several patients had a PFS of less than 1 month\" can be entailed by the information presented in the CTRs as follows:\n\n1. According to the Primary Trial's description, progression-free survival was calculated from the date of randomization to the date of disease progression (PD) or death, whichever occurred first.\n2. The Results 1 and Results 2 sections in the Primary Trial provide the median PFS for the SOC and Epoetin Alfa arms, respectively. Both medians are less than 12 months, which implies that no patient had a PFS exceeding 1 year.\n3. The Primary Trial's description also mentions that participants who had a missing interval immediately preceding an event (PD or death) were censored at the last disease assessment prior to the missing interval. However, there is no information in the CTRs about any participants having a PD or death with a missing interval greater than 1 month, so all such events should be considered to have occurred within 1 month of the last disease assessment. Thus, some patients had a PFS of less than 1 month.\n\nTherefore, the expert's statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the data in the CTRs, but it may be incomplete or misleading without additional context. The statement suggests that all participants in the primary trial had a PFS of less than 1 year, but the CTR provides median PFS values for each arm that are greater than 1 year. The statement also mentions that some participants had a PFS of less than 1 month, but it does not indicate which arm or arms this applied to. The CTR does report the number of participants who were censored at the time of last disease assessment prior to the clinical cutoff, which could potentially include some participants with very short PFS durations. However, it's important to note that the CTR does not explicitly state that no participants had a PFS greater than 1 year, so the statement could be considered an overgeneralization rather than an outright contradiction.</s>"
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary trial, the Adverse Events section does not report any instances of \"Appetite Decreased,\" while in the secondary trial, there is one instance (1/53) of \"Appetite Decreased\" reported. Therefore, the statement correctly infers that there were no reports of appetite reduction in the primary trial, but there was at least one instance in the secondary trial. This inference is consistent with and can be derived from the information provided in the CTRs.</s>",
        "contradict": "The given statement \"Patients' appetites were not affected in the primary trial, but at least one was affected in the secondary trial\" is contradictory to the information in the CTRs because in the primary trial, there were no adverse events reported related to appetite decrease (0/33, 0.00%), while in the secondary trial, there was one participant who experienced a decrease in appetite (1/53, 1.89%).</s>"
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were affected in the primary trial, but at least one was affected in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients' appetites were affected in the primary trial, but at least one was affected in the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, there is a mention of an adverse event named \"Appetite Decreased,\" which occurred in 0/33 (0.00%) cases in Adverse Events 1 and 1/53 (1.89%) cases in Adverse Events 2 for the primary and secondary trials, respectively. Although the number of affected patients differs between trials, the statement does not specify a particular trial. Therefore, it can be entailed from the information in the CTRs that at least one patient experienced a decreased appetite in both trials.</s>",
        "contradict": "The statement \"Patients' appetites were affected in the primary trial, but at least one was affected in the secondary trial\" is not directly contradicted by the provided CTR data, but it can be misleading. The statement is true if we consider the number of trials with reported appetite decreased events, but it overlooks the number of participants affected within each trial. In the primary trial, 3 participants (9.09%) out of the 33 total had appetite decreased, while in the secondary trial, only 1 participant (1.89%) out of 53 total had this adverse event. The statement does not convey this nuanced difference in frequencies between the trials and may lead to an incorrect interpretation if taken at face value.</s>"
    },
    "8befa03f-c3da-4950-8d27-491ea06b51ed_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "The secondary trial affected patients' appetites, but the primary trial did not.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial affected patients' appetites, but the primary trial did not\" can be entailed by the information present in the CTRs as follows:\n\nIn the secondary trial, the Adverse Events section lists \"Appetite Decreased\" with a frequency of 1/48 (2.08%). However, in the primary trial, this particular adverse event is absent from the Adverse Events section. Since the absence of an event in one trial implies that it did not affect the patients in that trial, this statement is entailed by the data present in the CTRs.</s>",
        "contradict": "The statement \"The secondary trial affected patients' appetites, but the primary trial did not\" is contradicted by the information present in the CTRs because in the secondary trial, there were reports of appetite decreased occurring in 1/48 (2.08%) of the participants, whereas in the primary trial, there were no mentions of any appetite-related adverse events (0/33, 0.00%).</s>"
    },
    "32424458-a3e2-440a-9693-6a2f8d4aaddb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Capecitabine group of the primary trial has 61 more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Contradiction",
        "entail": "The statement asserts that the Abraxane + Capecitabine group of the primary trial contains 61 more patients who achieve CR or PR compared to the Abraxane Alone group. \n\nTo establish entailment, we need to show that this statement is harmonious with the data in the CTRs, substantiated by the information provided, and avoids contradiction.\n\nFirst, let us determine the number of patients in each group with CR and PR in the primary trial based on the given data in Results 1 and 2.\n\nFrom Results 1, the percentage of patients with CR or PR in the Abraxane + Tigatuzumab group is between 14.9 and 45.0, with a total number of participants analyzed of 39.\n\nFrom Results 2, the percentage of patients with CR or PR in the Abraxane Alone group is between 18 and 61.1, with a total number of participants analyzed of 21.\n\nTo compute the number of patients in each group with CR or PR, we can convert the percentage ranges into absolute numbers:\n\nFor the Abraxane + Tigatuzumab group:\nMinimum: 39 * 0.149 \u2248 5.75 \u2192 6 patients\nMaximum: 39 * 0.45 \u2248 17.61 \u2192 18 patients\nTotal: 6 to 18 patients\n\nFor the Abraxane Alone group:\nMinimum: 21 * 0.18 \u2192 3.78 \u2248 4 patients\nMaximum: 21 * 0.611 \u2192 12.79 \u2248 13 patients\nTotal: 4 to 13 patients\n\nNow, the statement asserts that the Abraxane + Capecitabine group has 61 more patients with CR or PR. This translates to a difference of 48 to 108. Since the minimum number of participants with CR or PR in the Abraxane Alone group is 4, this difference is not feasible for the given data. However, if we consider the maximum number of 13 patients with CR or PR in the Abraxane Alone group, the difference of 101-121 is still not possible. \n\nTherefore, based on the provided information, the statement is not directly entailed by the information presented in the CTRs. However, it's worth noting that the statement could still be potentially correct, as more data or additional information about the trial may not be presented in the provided CTR snippets. Inaccuracies or errors in statement could also arise due to misinterpretations or misunderstandings of the trial data, rounding errors or other factors.\n\nIn order to definitively determine if the statement is entailed by the CTRs, a more complete analysis of the entire CTRs is required. This could include examining other relevant sections such as eligibility criteria, intervention specifics, and adverse events, in addition to the provided results sections, to ensure that the statement does not contradict any information in these sections.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the information presented in the CTRs, as the CTRs do not provide data on the number of participants with CR or PR in each arm of the primary trial. Therefore, it's impossible to determine if the expert's statement is contradictory without more information.</s>"
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial did not record any skin infections in their patients.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial did not record any skin infections in their patients\" can be entailed by the information present in the CTRs as both report zero occurrences of skin infection in their respective adverse events sections.</s>",
        "contradict": "The statement \"the primary trial did not record any skin infections in their patients\" is contradicted by the information present in the CTRs since in the Primary Trial under Adverse Events 1 section, one out of four patients (25.00%) had a skin infection, but it was not specified as a hand-foot skin reaction.</s>"
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "The primary trial recorded any skin infections in their patients.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial recorded any skin infections in their patients\" is entailed by the CTR data as both trials report no instances (0/4 and 0/3, respectively) of skin infections (Skin infection in the CTR) in their cohorts. No contradictory evidence exists to dispute this claim.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as neither of them reported any skin infections (0/4 for the primary trial and 0/3 for the secondary trial).</s>"
    },
    "a2b25229-c003-49c3-8b0b-94b68f756d3c_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "No skin infections were recorded in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"No skin infections were recorded in the primary trial\" entails the absence of skin infections in the Adverse Events section of the primary CTR, as both state that no instances of skin infections occurred in the primary trial. This alignment in information, with no contradiction, supports the entailment relationship.</s>",
        "contradict": "The expert statement, \"No skin infections were recorded in the primary trial,\" is contradicted by the CTR data since zero skin infections were reported in Adverse Events 1, but the statement implies that no skin infections occurred in the entire trial, including Adverse Events 2 which is not mentioned in the given statement.</s>"
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy is only used in cohort 1 of the primary trial,  neither cohort of the secondary trial make use of this.",
        "Label": "Entailment",
        "entail": "The statement \"Laser Therapy is only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this\" is entailed by the CTRs as follows: \n\n1. In the primary trial, the Intervention section states that Laser Therapy is used in Intervention 1, and there is no mention of Laser Therapy in Intervention 2 of the secondary trial. \n2. Intervention 1 of the primary trial and Intervention 1 of the secondary trial have different treatments, with Laser Therapy in the former and Abemaciclib in the latter. \n3. Intervention 2 of the primary trial and both Interventions of the secondary trial involve different diseases, HR+, HER2+ Breast Cancer in the former (for Intervention 1) and HR+, HER2- Breast Cancer in Intervention 1 of the secondary trial and HR+, HER2- Breast Cancer in Intervention 2 of the secondary trial. \n4. The expert's statement that \"Laser Therapy is only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this\" is consistent with these facts, as it correctly describes that Laser Therapy is not found in the secondary trial at all, let alone in both cohorts. \n5. No contradiction exists between the statement and the CTRs.</s>",
        "contradict": "The statement asserts that laser therapy is not used in the secondary trial. However, the CTRs do not explicitly state that laser therapy is absent in the secondary trial. The statement makes an assumption based on the primary trial's information and fails to consider the possibility of laser therapy being used in the secondary trial but in a different cohort or context not mentioned in the provided descriptions. The absence of such information in the primary trial does not entail the absence of laser therapy in the secondary trial.</s>"
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Laser Therapy isn't only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this.",
        "Label": "Contradiction",
        "entail": "The primary trial specifies Intervention 1 as Laser Therapy, administered by a therapist without any mention of the cohorts using this intervention. The secondary trial, on the other hand, mentions two cohorts (A and B) for Intervention 1, both of which receive abemaciclib therapy instead of laser therapy. Therefore, the statement that \"Laser Therapy isn't only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this\" is entailed by the information in the CTRs since the trials do not involve laser therapy in the specified cohorts as stated.</s>",
        "contradict": "The statement \"Laser Therapy isn't only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this\" contradicts the information present in the CTRs because: \n\n- In the primary trial, there is only one intervention that involves laser therapy, which is specified in Intervention 1 of the primary trial.\n- In the secondary trial, there are no interventions that involve laser therapy. Both interventions, Intervention 1 and Intervention 2, involve the use of Abemaciclib with or without endocrine therapy for HR+, HER2- or HR+, HER2+ breast cancer patients, respectively.\n- Therefore, the statement that \"Laser Therapy isn't only used in cohort 1 of the primary trial, neither cohort of the secondary trial make use of this\" is not harmonized with the clinical trial data, and it contradicts the CTRs as it asserts the use of laser therapy in both primary and secondary trials when, in fact, it is not mentioned at all in the secondary trial.</s>"
    },
    "728721c4-6376-4ab8-9e4a-af8596bd1ab3_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02308020",
        "Statement": "Neither cohort of the secondary trial uses Laser Therapy, but cohort 1 of the primary trial does.",
        "Label": "Entailment",
        "entail": "The statement neither refers to specific sections in the CTRs labeled as \"ELIGIBILITY CRITERIA\" nor makes any direct mention of interventions being compared in terms of their type. However, it does state that none of the cohorts in the secondary trial uses Laser Therapy, while cohort 1 in the primary trial does. This information can be entailed by the CTRs as:\n\n1. In the primary trial, intervention 1 (Laser Therapy Alone) uses therapist administered laser treatment.\n2. In the secondary trial, no such laser therapy intervention is mentioned, and the focus is on the Abemaciclib intervention for different subgroups of HR+, HER2+ and HR+, HER2- breast cancer patients.\n\nTherefore, it can be inferred that since the secondary trial does not have a laser therapy intervention, and the primary trial's intervention 1 does, the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Neither cohort of the secondary trial uses Laser Therapy, but cohort 1 of the primary trial does\" is contradicted by the CTRs because the CTRs do not describe any use of Laser Therapy in either the primary or secondary trials. The primary trial mentions the use of therapist-administered laser treatment in Intervention 1, but not in Intervention 2. In contrast, the secondary trial mentions the use of Abemaciclib in both Intervention 1 and Intervention 2, without any mention of Laser Therapy. Therefore, the statement is not semantically entailed in the CTRs.</s>"
    },
    "c7151ad6-bcac-48e1-ba1e-e6f56a043804": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial both record cases of Cholecystitis.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both record cases of Cholecystitis\" can be entailed by the CTRs information as follows: In the primary CTR, an adverse event \"Acute Cholecystitis\" occurred once in 22 patients of the secondary trial, represented by the value 1 in the second CTR. Similarly, in the primary CTR, there is no mention of Disseminated intravascular coagulation (DIC), Death NOS, Edema limbs, Fatigue, Hepatic failure, Alanine aminotransferase increased, Aspartate aminotransferase Increased, or Blood bilirubin increased, but these conditions are not mentioned in the expert's statement. Therefore, no contradiction exists between the expert's statement and the CTRs. Since both trials report an occurrence of Cholecystitis, the statement is a semantically entailed result from the CTR data.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both record cases of Cholecystitis\" may be contradicted by the information present in the CTRs because the specific instances of Cholecystitis, as described in each trial, are not directly comparable due to the absence of Cholecystitis cases in the same section of the same trials. In the first trial, Cholecystitis is listed as an adverse event in the secondary trial, while in the primary trial, it is not mentioned as an adverse event in either trial section provided.</s>"
    },
    "4f71e33c-4f0f-4952-bb03-52402be5f9f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There is 1 case (1.45%) of thrombocytopenia in the primary trial.",
        "Label": "Contradiction",
        "entail": "Thrombocytopenia is a condition characterized by a decrease in platelet count, which can be inferred as a type of anemia or hematological adverse event. In the primary CTR, there are two cases of anemia (1.45% each) mentioned \u2013 one of which is anemia NOS (without further specification). Moreover, there is a single case (1.45%) of thrombophlebitis, which could potentially include thrombocytopenia as a symptom. Therefore, based on these observations, it can be inferred that the statement \"There is 1 case (1.45%) of thrombocytopenia in the primary trial\" is entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"There is 1 case (1.45%) of thrombocytopenia in the primary trial\" is not explicitly stated in the given CTR. However, it can be contradicted based on the information provided. The CTR lists \"Thrombophlebitis\" and \"Anaemia NOS\" as separate Adverse Events. Neither of these terms synonymously represents Thrombocytopenia, which is defined as a decrease in platelet count. Thus, the statement's assertion contradicts the CTR as it incorrectly interprets the listed conditions as thrombocytopenia cases.</s>"
    },
    "ef675459-a7d9-4ea1-8963-c95682c38d15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial\" can be entailed by the information present in the CTR under the following conditions:\n\n1. T4: The statement does not directly contradict the exclusion criteria that mention T3 as the maximum T-stage for eligible participants. However, it is important to note that T4 tumors are considered locally advanced and are excluded in the CTR only if they have invaded the chest wall, or are mammary or skin involvement, or have metastases to the chest wall or skin. The CTR does not explicitly exclude T4 tumors that only invade the breast itself, as long as all other inclusion criteria are met. Therefore, the statement can be entailed by the CTR under this interpretation.\n2. N1: The statement does not contradict the inclusion criteria for clinically positive axillary nodes (N1).\n3. M0: The statement is consistent with the inclusion criteria for M0 (no distant metastases) status.\n\nTherefore, the statement \"Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial\" can be entailed by the information present in the CTR, as long as we interpret the T4 criterion in a specific way. However, it should be noted that the CTR may not intend to include patients with T4 tumors that only invade the breast itself, and thus the study authors may have excluded such patients for a reason. Therefore, the entailment relationship may not be perfect and requires some interpretation.</s>",
        "contradict": "The statement \"Participants with T4 N1 M0 breast carcinoma are eligible for the primary trial\" contradicts the CTR inclusion criteria as T4 is an exclusion criterion. Therefore, participants with T4 breast carcinoma are not eligible for the trial.</s>"
    },
    "f9df9e45-eb68-4257-801e-b086a89374b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The given statement entails that female patients with LVEF > 50% who have previously undergone treatment with specific drugs are eligible for the primary trial but excluded from the secondary trial. \n\nThis statement can be derived from the information present in the CTRs as follows:\n\n1. The primary CTR includes LVEF > 50% as an inclusion criterion, which makes it clear that female patients with LVEF greater than 50% are eligible for the primary trial.\n2. The primary CTR lists trastuzumab emtansine, paclitaxel, abraxane, and lapatinib as exclusion criteria for the secondary trial. This implies that patients who have undergone treatment with any of these drugs are not eligible for the secondary trial. \n3. There is no contradiction between the given statement and the information present in the CTRs. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"Female Patients with LVEF > 50%, who have previously undergone treatment with any of the following drugs; trastuzumab emtansine, paclitaxel, abraxane or lapatinib are still eligible for the primary trial but are excluded from the secondary trial\" is contradictory to the information present in the CTRs as:\n\n1. For the primary trial, patients with a history of prior treatment with trastuzumab emtansine, lapatinib or lapatinib with capecitabine, or non-comparable biologic or biosimilar of trastuzumab are excluded (Inclusion Criteria).\n2. For the secondary trial, patients with a history of prior treatment with paclitaxel, abraxane, trastuzumab, or lapatinib are excluded (Exclusion Criteria). \n\nTherefore, according to the information provided in the CTRs, female patients with LVEF > 50% who have previously undergone treatment with trastuzumab emtansine, paclitaxel, abraxane, or lapatinib would be ineligible for both trials, not just the secondary trial as stated in the expert's statement.</s>"
    },
    "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement\" can be entailed by the information in the CTRs because the CTR for the primary trial explicitly states that the outcome measurement used for that trial was \"Progression-Free Survival (PFS).\" Neither overall response rate nor tumour response rate are mentioned as the outcome measures for the primary trial.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs because the primary trial's outcome measurement was, in fact, Progression-Free Survival (PFS), as detailed in the CTRs. The statement incorrectly claims that PFS, as well as overall response rate and tumor response rate, were not used as outcome measurements.</s>"
    },
    "958721dc-e374-4fd1-abb9-071add70bde3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of paclitaxel is approximately is 120 mg.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information present in the CTRs. The statement asserts that the MTD of paclitaxel is approximately 120 mg, whereas the CTR does not provide this specific information. However, the CTR states that weekly paclitaxel is given as a fixed dose of 80mg/m2, and the statement does not contradict this information. Thus, the statement does not contradict the CTR and is therefore not explicitly falsified. However, it is important to note that the CTR only reports on the Phase I portion of the trial where the MTD of dasatinib in combination with paclitaxel is being determined and no definitive statement about the MTD of paclitaxel is provided.</s>",
        "contradict": "The expert's statement is not contradictory to the CTR information. However, it is incorrect. The CTR states that the weekly paclitaxel dose given is 80 mg/m2, which is not equivalent to 120 mg as stated in the expert's claim. The units are different, and the expert's statement should have referenced MTD in terms of mg/m2 to match the CTR information. The contradiction is merely apparent due to the misunderstanding of the units in the expert's statement.</s>"
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia.",
        "Label": "Entailment",
        "entail": "The term \"thrombocytopenia\" refers to a medical condition characterized by low platelet counts. In the CTRs provided, there is no explicit mention of the number of participants who experienced thrombocytopenia in the primary trial's cohort 2. However, the CTR for Adverse Events 1 of the primary trial indicates that zero incidents of anemia with trombocytopenia were recorded among 113 participants (0.00%). Although anemia and thrombocytopenia are separate conditions, they can occur together. Therefore, the absence of reported cases of anemia with thrombocytopenia does not rule out the occurrence of isolated thrombocytopenia. Thus, since one incident of thrombocytopenia is within the range of what could have been reported under the category of anemia with thrombocytopenia (given that the CTR does not explicitly separate the number of cases for each condition), the expert's statement can be entailed by the information in the CTR.</s>",
        "contradict": "The statement that \"Cohort 2 of the primary trial recorded 1 incident of thrombocytopenia\" cannot be directly contradicted by the information present in the CTRs. However, the CTRs do not support this statement as there is no mention of thrombocytopenia in the adverse events section for Cohort 2 (or any other cohort) in either the Primary or Secondary trial. Hence, while the statement itself is not contradictory, it lacks substantiation from the provided data.</s>"
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial didn't record 1 incident of thrombocytopenia.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial didn't record 1 incident of thrombocytopenia\" is entailed by the information present in the CTRs because the Adverse Events section for Cohort 2 of the primary trial reports 0 instances of anemia with trombocytopenia. Thrombocytopenia is a type of anemia characterized by a deficiency of platelets. Thus, the absence of this type of anemia in Cohort 2 is a necessary condition for the statement that Cohort 2 didn't record 1 incident of thrombocytopenia to be true.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as neither cohort of the primary trial (1 or 2) reported an incident of anemia with trombocytopenia. Therefore, neither cohort recorded \"0\" incidents of thrombocytopenia. Consequently, the statement's assumption that only cohort 2 didn't record a thrombocytopenia event is not in line with the facts stated in the CTRs.</s>"
    },
    "19c0b2c7-e45c-4740-b25d-f6e738b59893_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "1 incident of thrombocytopenia was recorded in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"1 incident of thrombocytopenia was recorded in cohort 2 of the primary trial\" can be entailed by the information present in Adverse Events 1 of the CTRs because:\n\n1. An adverse event of thrombocytopenia (0.00% in the first cohort but non-zero in the second cohort) is mentioned in the first CTR.\n2. The statement refers to the primary trial, which is consistent with the origin of the data in the CTRs.\n3. The statement indicates that the incident occurred in cohort 2.\n4. According to Adverse Events 1 of CTR 1, there is one occurrence of thrombocytopenia (0.88%) among 113 participants in the trial (cohort 1 and 2 combined).\n5. The statement does not contradict any information in the CTRs, and its claims are supported by the data provided.</s>",
        "contradict": "The statement \"1 incident of thrombocytopenia was recorded in cohort 2 of the primary trial\" is contradictory to the information in the CTRs as no case of thrombocytopenia was reported in cohort 2 of the primary trial according to the provided data. The Adverse Events section for cohort 2 of the primary trial indicates a total of 13 adverse events with 1 event being anemia with trombocytopenia, but there's no record of thrombocytopenia occurring independently.</s>"
    },
    "7bcfca9e-1b09-45d4-8165-cb6ac96b8815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of gastrointestinal adverse events than the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial recorded more total occurrences of gastrointestinal adverse events than the primary trial\" cannot be directly entailed from the provided CTR data. \n\nExplanation: \n\nThe CTRs do not report the number of participants experiencing gastrointestinal adverse events, such as esophagitis or large intestine polyp, in both trials. Therefore, without specific information on the occurrence of gastrointestinal adverse events, it is impossible to determine whether the secondary trial did indeed record more instances than the primary trial.</s>",
        "contradict": "The information contained in the statement cannot be directly contradicted by the given CTRs as they do not include data on gastrointestinal adverse events for either trial.</s>"
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Less than 5 patients in the primary trial experienced Earache.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 5 patients in the primary trial experienced Earache\" is entailed by the CTR data as follows: Neither Adverse Events 1 nor Adverse Events 2 lists Ear pain as an observed adverse event with a frequency higher than 0.26%, which represents fewer than 5 patients out of the total 383 patients in each trial.</s>",
        "contradict": "The expert's statement is incongruous with the CTR data as there is no mention of \"Earache\" or \"Otalgia\" as an adverse event in either the Primary or Secondary trials. The provided information in the CTRs pertains only to Anemia, Febrile neutropenia, Haemoytique anemia, Leukopenia, Neutropenia, Thrombocytopenia, Anginal pectoris, Cardiomyopathy, Abdominal distension, and Abdominal pain.</s>"
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Less than 5 patients in the primary trial didn't experience Earache.",
        "Label": "Contradiction",
        "entail": "The statement \"Less than 5 patients in the primary trial didn't experience Earache\" is entailed by the CTR data since neither of the provided Adverse Events sections reports ear pain for more than 5 patients in each trial. The absence of ear pain in the majority of patients is inferred from the reported numbers.</s>",
        "contradict": "The expert statement \"Less than 5 patients in the primary trial didn't experience Earache\" cannot be directly contradicted by the information present in the CTRs as the CTRs do not provide data on earache as an adverse event in the listed sections for either the primary or secondary trials.</s>"
    },
    "e3a8be03-20e4-460d-9ebc-f958a515ac45_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01095003",
        "Statement": "Earache was experienced by less than 5 patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Earache was experienced by less than 5 patients in the primary trial\" is entailed by the data in the Adverse Events section of the CTR for the primary trial since the reported instance of ear pain is only 1/383 (0.26%), which is less than 5 patients.</s>",
        "contradict": "The statement \"Earache was experienced by less than 5 patients in the primary trial\" cannot be directly contradicted by the provided data from the CTRs, as earache is not listed as an adverse event in either the Primary Trial's Adverse Events 1 or Adverse Events 2 sections.</s>"
    },
    "f1096271-3160-4483-9246-ba0d96735efb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "Less than 5% of the primary trial participants achieved CR or PR.",
        "Label": "Entailment",
        "entail": "The RECIST 1.0 criteria used in the primary trial specifies that a response includes achieving a complete response (CR) or partial response (PR). The Results 1 section of the primary trial reports that out of 22 participants in the Pralatrexate arm/group, the number achieving CR or PR is not explicitly stated. However, it can be inferred from the ORR measurement that the response assessment was based on CR and PR. Thus, if less than 5% of the participants (or 1 participant in this case, given the number reported) achieved CR or PR, that information is consistent with the data in the Results 1 section. This statement does not contradict the CTR and is entailed by the information provided.</s>",
        "contradict": "The information in the statement \"Less than 5% of the primary trial participants achieved CR or PR\" cannot be directly contradicted by the information provided in the CTRs. However, it could contradict the actual outcomes of the trial if the data in the CTRs shows that more than 5% of the participants in the Pralatrexate arm achieved complete or partial response, which is not indicated by the given CTR excerpt. Therefore, to determine entailment or contradiction, the full data from both trials needs to be compared.</s>"
    },
    "f1096271-3160-4483-9246-ba0d96735efb_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "Less than 5% of the primary trial participants didn't achieve CR or PR.",
        "Label": "Contradiction",
        "entail": "The statement less than 5% of the primary trial participants didn't achieve CR or PR can be entailed by the information present in the CTRs as follows: \n\n1. The outcome measure in the primary trial is Objective Response Rate (ORR), which is determined by the proportion of patients achieving a CR or PR.\n2. According to the results section of the primary CTR, the number of participants in the Pralatrexate arm who achieved either a CR or PR is not explicitly stated. However, we know that there were 22 participants in total in this arm.\n3. Since ORR is the proportion of patients with a CR or PR, and since no participants in the Pralatrexate arm are reported to have had progression, the assumption is that all or almost all participants in this arm had a CR or PR. \n4. To calculate the proportion of participants who did not achieve a CR or PR, we subtract the proportion of participants who did from 1.\n5. Given that there are 22 participants in total, and assuming that the majority, if not all, achieved a CR or PR, it is reasonable to estimate that fewer than 5% of the participants did not achieve a CR or PR.</s>",
        "contradict": "The expert statement that \"Less than 5% of the primary trial participants didn't achieve CR or PR\" cannot be definitively contradicted by the information provided in the CTRs. However, it does not entail the information from the CTRs either, because the CTR only provides the number of participants who achieved CR or PR, but not the total number of participants in the trial. Thus, the expert statement could be true if the total number of participants in the primary trial is less than 101, but it is an assumption and not directly stated or proven by the CTR information.</s>"
    },
    "f1096271-3160-4483-9246-ba0d96735efb_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "CR or PR was achieved by less than 5% of the primary trial participants.",
        "Label": "Entailment",
        "entail": "Based on the given CTR information, the ORR (Objective Response Rate) for the Pralatrexate arm was not provided. However, we know that ORR is defined as the proportion of patients achieving CR (Complete Response) or PR (Partial Response). In the primary trial, no CRs were reported, and the statement suggests that PRs were achieved by less than 5% of the participants. The time frame for response assessment in both trials is consistent, allowing for valid comparison. Therefore, the statement is entailed by the CTR information as it implies a lower response rate for the Pralatrexate arm than what would be expected for an effective treatment, aligning with the data not explicitly stated in the CTR.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the information present in the primary CTR, but it contradicts the information inferred from the given outcome measure in the results section (ORR of more than 5% for Pralatrexate arm/group). However, the expert's statement only pertains to CR and PR, and the CTR outcome measure includes both CR and PR for the calculation of ORR, which is above 5%. This difference in scope between the statement and the CTR might lead to apparent contradiction. Nonetheless, the expert's statement does not necessarily contradict the primary CTR as a whole.</s>"
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.",
        "Label": "Entailment",
        "entail": "The statement \"More participants in the primary trial suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is entailed by the information present in the CTRs because the data shows that there were more instances of Grade 1 cardiotoxicity events (Arm I: 8 in total, with 4 occurring after Cycle 8) compared to Grade 3 events (Arm I: no instances after Cycle 8). Additionally, no Grade 3 cardiotoxicity events were reported from the secondary trial (Arm II) after Cycle 8. Therefore, the statement is consistent with the data provided in the CTRs and does not contradict any information presented.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as follows:\n\n1. In the primary trial, the number of participants with Grade 1 cardiotoxicity events after Cycle 8 (Arm I: 8) is less than the number of participants with Grade 3 cardiotoxicity events (Arm I: 0).\n\n2. In the secondary trial, there were no participants with Grade 3 cardiotoxicity events for any time frame (Arm II: 0 for all grades and cycles).\n\nThus, the statement's assertion that \"More the primary trial participants suffered Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is not harmonious with the clinical trial data and contradicts the provided descriptions.</s>"
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "More the primary trial participants didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events.",
        "Label": "Contradiction",
        "entail": "The statement \"More participants in the primary trial didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" can be entailed by the information in the CTRs as follows:\n\n1. According to Results 1 of the primary trial, the number of patients with Grade 1 events after Cycle 8 was 8, while the number with Grade 3 events was 0.\n   - For Arm I: 8 (Grade 1) vs 0 (Grade 3)\n2. According to Results 2 of the primary trial, the number of patients with Grade 1 events after Cycle 8 was 8, while the number with Grade 3 events remained 0.\n   - For Arm II: 8 (Grade 1) vs 0 (Grade 3)\n3. The statement \"More participants in the primary trial didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is equivalent to stating \"The number of participants in the primary trial with Grade 1 Cardiotoxicity Events After Cycle 8 is greater than the number of participants with Grade 3 Cardiotoxicity Events After Cycle 8\".\n4. This condition is satisfied as shown in points 1 and 2 above (8 > 0).\n\nHence, the statement \"More participants in the primary trial didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" can be entailed by the data in the CTRs.\n\nAdditionally, this statement can be generalized to apply to both trials (primary and secondary) since both trials reported no Grade 3 events after Cycle 8.</s>",
        "contradict": "The statement \"More participants in the primary trial didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is contradicted by the CTR data as follows:\n\n1. In the primary trial (Results 1 and 2 combined), the total number of patients who experienced Grade 1 events after Cycle 8 is 8 (from Arm I) + 8 (from Arm II) = 16.\n2. The total number of patients who experienced Grade 3 events after Cycle 8 is 0 (from both arms).\n3. Therefore, the statement \"More participants didn't suffer Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events\" is not true according to the given data.</s>"
    },
    "329b6871-2edc-4142-a4af-e7f8cef118ee_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "Grade 1 Cardiotoxicity Events After Cycle 8 than Grade 3 events were suffered by more the primary trial participants.",
        "Label": "Entailment",
        "entail": "The statement \"Grade 1 Cardiotoxicity Events After Cycle 8 were suffered by more participants than Grade 3 events in the primary trial\" can be entailed by the data presented in the CTRs as follows:\n\n- The data in the CTRs specifies the number of participants suffering from each grade of cardiotoxicity events (Grade 1, 2, and 3) for both arms of the primary trial at three different time points: after cycle 4, after cycle 8, and 30 or more days after the last cycle.\n- According to the CTRs, there were 16 participants in Arm I and 37 participants in Arm II. The data in Results 1 and Results 2 shows that there were a total of 4 Grade 3 events (2 in Arm I and 0 in Arm II) across both arms, and 10 Grade 3 events (0 in Arm I and 10 in Arm II) if considering the time frame 30 days or more after the last cycle.\n- In contrast, the data in Results 1 and Results 2 indicates that the number of participants suffering from Grade 1 cardiotoxicity events after cycle 8 was 8 in Arm I and 2 in Arm II, and the number of participants suffering from Grade 1 cardiotoxicity events 30 days or more after the last cycle was 1 in Arm I and 5 in Arm II.\n- Therefore, the statement that \"Grade 1 Cardiotoxicity Events After Cycle 8 were suffered by more participants than Grade 3 events in the primary trial\" can be entailed by the data presented in the CTRs as the total number of participants experiencing Grade 1 cardiotoxicity events after cycle 8 (8 in Arm I and 2 in Arm II) is indeed greater than the total number of participants experiencing Grade 3 cardiotoxicity events (2 in Arm I and 0 or 10 in Arm II depending on the time frame considered).</s>",
        "contradict": "The statement \"Grade 1 Cardiotoxicity Events After Cycle 8 were suffered by more participants than Grade 3 events\" is contradicted by the information presented in the CTRs, as the number of Grade 3 cardiotoxicity events was zero for both primary trial arms (Arm I and II) at Cycle 8.</s>"
    },
    "67522762-9423-4e3d-bf75-247f84ba7f05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365417",
        "Secondary_id": "NCT00853996",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Contradiction",
        "entail": "Both the primary and secondary trials share the condition that alkaline phosphatase must be less than 2.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) must be or be less than 1.5 times the ULN, and hemoglobin must be greater than 10 grams per deciliter (g/dL). These requirements are present in the inclusion criteria of the primary trial under \"evidence of adequate hepatic function\" and \"evidence of adequate renal function,\" respectively. Therefore, the statements in the CTRs entail that patients meeting these hepatic and renal function criteria are eligible for both trials.</s>",
        "contradict": "The statement that \"to be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions: alkaline phosphatase < 2.5 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL\" can be contradicted by the information present in the CTRs as follows:\n\n1. In the primary trial, the condition for alkaline phosphatase and AST is not that they must both be less than ULN, but rather they may not both be greater than ULN (one can be less than ULN and the other can be less than or equal to ULN). This contradicts the statement that both must be less than 1.5 x ULN.\n\n2. In the primary trial, patients with a history of alkaline phosphatase or AST greater than ULN but less than 2.5 x ULN and no evidence of metastatic disease are eligible for inclusion if bone scan, PET scan, or liver imaging (CT, MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function is confirmed. This implies that some patients with alkaline phosphatase or AST greater than ULN but less than 2.5 x ULN may still be eligible, contradicting the statement that both must be less than 1.5 x ULN.\n\n3. In the secondary trial, the condition for total bilirubin is that it must be less than or equal to the upper limit of normal (ULN) for the lab, but the statement does not specify this requirement. This is important because some patients with Gilbert's disease or similar syndromes involving slow conjugation of bilirubin can have total bilirubin levels greater than ULN but not greater than 1.5 x ULN. If these patients are not considered eligible under the statement, they would be excluded erroneously.\n\nTherefore, the statement is not an entailed consequence of the information presented in the CTRs, and there are discrepancies between the two.</s>"
    },
    "efd37946-54f3-4813-b63d-6d7df6123677": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection.",
        "Label": "Entailment",
        "entail": "The statement \"A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection\" can be entailed by the information presented in the CTRs if we assume that \"life-threatening reaction to an infection\" encompasses the conditions described as \"sepsis\" and \"death NOS\" (death of unknown cause). According to the CTRs, there were 2 cases of sepsis (1 in the primary trial and 1 in the secondary trial) and 1 death NOS in the primary trial. Thus, a total of 3 patients experienced life-threatening reactions to infections based on the expert's definition.</s>",
        "contradict": "The statement \"A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection\" cannot be directly contradicted by the information in the CTRs as given since the CTRs do not explicitly indicate whether the deaths classified as \"Death NOS\" were due to life-threatening reactions to infections. However, the number of patients who experienced sepsis (a potentially life-threatening condition) is 4 in the primary trial and 2 in the secondary trial. This discrepancy, if significant, might require further investigation as it could impact the interpretation of the data. The statement itself does not contradict the information in the CTRs, but it may be subject to additional analysis to determine its validity with respect to the clinical trial findings.</s>"
    },
    "efd37946-54f3-4813-b63d-6d7df6123677_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A total of 3 patients in the primary trial didn't suffer a life-threatening reaction to an infection.",
        "Label": "Contradiction",
        "entail": "The statement \"A total of 3 patients in the primary trial didn't suffer a life-threatening reaction to an infection\" can be entailed by the information present in the CTRs as follows:\n\nThe CTRs provide the number of participants who experienced specific adverse events, including infections resulting in sepsis or lung infection, which are considered life-threatening. The CTR for the primary trial reports that 2 patients experienced sepsis and 2 patients had lung infection, making a total of 4 patients with life-threatening infections out of 90 participants.\n\nHowever, the statement suggests that there were 3 patients who didn't suffer a life-threatening reaction to an infection, meaning that 1 more participant didn't experience any life-threatening infections beyond the reported sepsis or lung infections. The CTR for the secondary trial reports 1 additional patient with a non-specific infection-related adverse event (Other hepatobiliary disorders), but it is not mentioned whether this event was life-threatening or not. Assuming this event was not life-threatening, the statement can be entailed from the provided CTR information.\n\nTherefore, the statement's assertion harmonizes with the clinical trial data, is substantiated by the CTR, and avoids contradiction with the descriptions.</s>",
        "contradict": "The statement \"A total of 3 patients in the primary trial didn't suffer a life-threatening reaction to an infection\" is contradicted by the CTR data in the following ways:\n\n1. No mention of non-life-threatening infections: The CTR reports the occurrence and number of various types of infections, including febrile neutropenia, lung infection, and sepsis, but it does not specify whether they were life-threatening or not. The statement assumes that the infections referred to are life-threatening, which is not indicated in the CTR.\n\n2. Number discrepancy: According to the CTR, a total of five patients in the primary trial (1/90 in Adverse Event 1 and 2/90 in Adverse Event 2) experienced deaths due to infections or infection-related causes (sepsis). The statement claims that three patients did not suffer a life-threatening reaction to an infection, while the remaining six patients suffered life-threatening infections. If we assume that these six patients survived, that would mean nine patients experienced life-threatening infections, leaving only one patient without such an event. However, based on the CTR data, there are ten patients without life-threatening infections. This inconsistency further contradicts the statement.</s>"
    },
    "efd37946-54f3-4813-b63d-6d7df6123677_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02630693",
        "Statement": "A life-threatening reaction to an infection was suffered by a total of 3 patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A life-threatening reaction to an infection was suffered by a total of 3 patients in the primary trial\" can be entailed by the information present in the CTRs as follows: \n\n1. The statement mentions 3 patients who experienced a life-threatening reaction to an infection. \n2. The primary CTR reports 2 cases of sepsis, which is a potentially life-threatening condition caused by an infection. \n3. The primary CTR also reports 1 case of death NOS, which can be considered a life-threatening event and might be related to infections based on the context of the trial.\n4. Therefore, the statement's claim of 3 patients experiencing a life-threatening reaction to an infection is entailed by the reported cases of sepsis and death NOS from the primary CTR.</s>",
        "contradict": "The statement \"A life-threatening reaction to an infection was suffered by a total of 3 patients in the primary trial\" cannot be directly contradicted by the information present in the CTRs as there is no mention of the exact nature or number of life-threatening reactions caused by an infection in either CTR. However, the statement is less specific than the information provided in the CTRs, as the CTRs specify the exact number of patients experiencing specific types of adverse events, including sepsis which is a type of life-threatening reaction to an infection. The statement could possibly be entailed if it is clarified to specify that it is referring to the sepsis events reported in the CTRs.</s>"
    },
    "dcf62f43-04b7-4acb-b444-2d805238a8b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR information as follows:\n\n1. The outcome measure in both trials is the percentage of patients achieving pathological response, which is defined as the absence of invasion tumor cells in the breast and axillary lymph nodes, regardless of DCIS.\n2. Both the Herceptin and CT-P6 groups received the same neoadjuvant treatment regimen, consisting of docetaxel and FEC, for a total of 8 cycles. The only difference between the two groups is the addition of Herceptin for the Herceptin group.\n3. The time frame for surgery and assessing the primary endpoint is the same for both groups (within 3 to 6 weeks from the last dose of study).\n4. The herceptin group had a higher percentage of responders, 50.39 (44.10 to 56.68), compared to the CT-P6 group, 46.77 (40.43 to 53.19), as stated in the results.\n\nTherefore, the statement is entailed by the CTRs since it reflects a finding from the data presented in the trials.</s>",
        "contradict": "The statement \"The Herceptin group in the primary trial had a higher percentage of Patients Achieving partial Pathological Response than the CT-P6 and ZA group\" cannot be directly contradicted by the information provided in the CTRs. However, no information regarding partial Pathological Response is given in the CTRs for either Arm/Group (CT-P6 or Herceptin), making it impossible to compare percentages of partial pathological response between the two groups based on the provided data.</s>"
    },
    "83dc7b9a-b863-4f81-88fb-763afc3b79e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, and half the subjects in the secondary trial must take a weekly tablet.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the subjects in the primary trial are required to ingest any pills, and half the subjects in the secondary trial must take a weekly tablet\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the interventions specified do not include any mention of the use of pills for either intervention 1 (Manual Lymph Drainage) or intervention 2 (Negative Pressure).\n2. In the secondary trial, intervention 1 (No Exercise) does not involve the use of pills, as stated in the description.\n3. However, intervention 2 (Exercise) includes an additional component of a weekly Calcitriol pill, but only for the Calcitriol+ Exercise Arm. Therefore, half the subjects in this trial are required to take a weekly tablet. \n\nHence, the statement is entailed by the CTRs as it accurately reflects the information provided regarding the use or non-use of pills in both trials.</s>",
        "contradict": "In the primary trial, subjects in Intervention 1 undergo Manual Lymph Drainage, which does not involve any pill intake. Meanwhile, subjects in Intervention 2 of the primary trial receive PhysioTouch treatment, which is administered through a hand-held device and does not involve any pill intake as well. In the secondary trial, subjects in Intervention 1 receive no exercise but take a weekly tablet of Calcitriol. In contrast, subjects in Intervention 2 receive weekly exercises and also take a Calcitriol pill. Contrary to the expert's statement, both primary and secondary trials do have subjects taking pills, and the number of subjects taking pills is not the same across trials or intervention arms within a trial.</s>"
    },
    "d446920a-2b8e-4452-b9f2-17d2771dbb07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is Neutropenia.",
        "Label": "Contradiction",
        "entail": "The statement \"The most common adverse event in cohort 1 of the primary trial is Neutropenia\" can be entailed by the information present in the CTRs as follows:\n\nThe CTRs provide the number of occurrences for various adverse events in both the primary and secondary trials. In the primary trial, the total number of adverse events for cohort 1 is 21, and Neutropenia is one of the listed adverse events with an occurrence of 0/337 (0.00%) for the first cohort in Adverse Events 1 and 1/337 (0.30%) for all cohorts in Adverse Events 2. Since the occurrence of Neutropenia is reported in both sets (Adverse Events 1 and Adverse Events 2), the total number of occurrences for Neutropenia across all sections in the primary trial is 1/337 + 1/337 = 2/337.\n\nIn the primary trial, there are 337 participants, which makes the overall percentage of occurrence of Neutropenia 2/337 * 100 = 0.6% (or 0.62% when considering the total number of participants from Adverse Events 1 and Adverse Events 2). The statement \"The most common adverse event in cohort 1 of the primary trial is Neutropenia,\" implies that Neutropenia is the adverse event that occurred most frequently in the primary trial for cohort 1. Since the percentage of occurrence for Neutropenia (0.6%) is greater than any other listed adverse event, and the statement specifically refers to cohort 1, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The most common adverse event in cohort 1 of the primary trial is Neutropenia\" is contradicted by the CTR data because, according to the provided information, the frequency of Neutropenia in cohort 1 of the primary trial is 0/337 (0.00%).</s>"
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events.",
        "Label": "Entailment",
        "entail": "The statement that \"Cohort 1 of the primary trial and Cohort 1 of the secondary trial both have less than 30% occurrence of adverse events\" can be entailed by the information present in the CTRs because:\n\n1. The primary trial's Adverse Events section reports a total of 15 adverse events out of 52 participants, which equals 28.85%. The percentage for Cohort 1, which is not explicitly stated but can be determined from the given data since all the adverse events are listed, is therefore also less than 30%.\n\n2. Similarly, the secondary trial's Adverse Events section reports a total of 2 adverse events out of 15 participants, which equals 13.33%, but since the statement uses the round figure of less than 30%, this condition is still met.\n\nThe statement is consistent with the provided CTR data, and there is no contradiction between the statement and the given information.</s>",
        "contradict": "The statement does not contradict the information present in the CTRs, as both trials have adverse event occurrence rates below 30%. However, the statement does not specify which particular adverse events were included in the calculation. The CTRs provide separate lists of adverse events, and some of them occur in different frequencies between the two trials. Therefore, it's possible for the total adverse events percentage for each cohort to be below 30%, while some individual adverse events might differ significantly in occurrence between the trials.</s>"
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial both don't have less than 30% occurrence of adverse events.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because, in the primary CTR, the total adverse events in Cohort 1 is 15/52 (28.85%), and in the secondary CTR, the total adverse events in Cohort 1 is 1/8 (12.50%), and in Cohort 2 of the secondary trial, there are no adverse event occurrences reported. Since neither of the cohorts in the primary trial nor in the secondary trial has less than 30% occurrence of adverse events, the statement holds true.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial and Cohort 1 of the secondary trial both don't have less than 30% occurrence of adverse events\" is contradicted by the information presented in the CTRs because the primary trial's Cohort 1 had a 28.85% occurrence of adverse events while the secondary trial's Cohort 1 had a 28.57% occurrence, both below 30%. The statement implies that they both have more than 30%, making it contradictory to the provided data.</s>"
    },
    "aa710138-bf2a-4a7f-8014-4513fa1f448b_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the secondary trial and Cohort 1 of the primary trial both have less than 30% occurrence of adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the secondary trial and Cohort 1 of the primary trial both have less than 30% occurrence of adverse events\" is entailed by the information in the CTRs as follows:\n\nThe primary trial has a total of 52 participants, with a total of 15 adverse events, resulting in an adverse event occurrence rate of 28.85% for Cohort 1.\n\nThe secondary trial has a total of 15 participants in Cohort 1, with a total of 1 adverse event, resulting in an adverse event occurrence rate of 12.50%. This rate is less than 30%.\n\nTherefore, both Cohort 1 of the primary trial and Cohort 1 of the secondary trial have an adverse event occurrence rate less than 30%.</s>",
        "contradict": "The statement does not provide sufficient information to determine if it can be contradicted by the CTRs, as it makes a comparative claim between two trials without specifying which adverse events are being compared. The CTRs only report different sets of adverse events for each trial and do not mention the total number of participants. Therefore, it is impossible to determine if the occurrence of adverse events is less than 30% for the same types and same cohorts in both trials.</s>"
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criteria state that participants must have less than 120 minutes of exercise per week, while the secondary trial does not specify any exercise requirements. However, the statement is entailed by the primary CTR since the primary requirement for exercise in the primary trial (less than 2 hours per week) is a stricter version of the requirement in the CTR (less than 120 minutes per week). The secondary trial's lack of an exercise requirement does not contradict the primary trial's requirement, and both trials' inclusion criteria are consistent with the stated expert claim.</s>",
        "contradict": "The statement \"Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is not a requirement for the secondary trial\" is contradicted by the following information in the CTRs:\n\nPrimary Trial: \"Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.\" (This may include physical activities prescribed as part of endocrine therapy.)\n\nAdditionally, there is no mention of any exercise requirement or restriction in the Primary Trial's inclusion/exclusion criteria.\n\nTherefore, the statement made by the expert contradicts the CTR information by suggesting a less than 2 hours of exercise per week requirement in the Primary Trial, whereas the CTR does not impose such a requirement.</s>"
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is a requirement for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria state that participants must have less than 120 minutes (2 hours) of exercise per week. This requirement is explicitly mentioned in the CTR, and thus, the expert's statement is an entailed consequence of the primary trial's eligibility criteria. However, the expert's statement also mentions the secondary trial's requirement, which is not directly related to the CTR provided. This discrepancy between the statement and the CTR limits the scope of the entailment relationship, as the expert's statement goes beyond the information presented in the primary CTR.</s>",
        "contradict": "The statement that \"Patients must be doing less than 2 hours of physical exercise per week to participate in the primary trial, however, this is a requirement for the secondary trial,\" is contradictory to the inclusion criteria in the primary CTR which states that \"Less than 120 minutes of exercise per week\" is an eligibility criterion. This means that patients in the primary trial are allowed to have less than 120 minutes of exercise per week, not less than 2 hours as stated in the expert's claim. In contrast, the secondary CTR does not mention any specific exercise requirement in the provided inclusion criteria. Therefore, the statement is not entailed by the information presented in the CTRs.</s>"
    },
    "aa38a1cc-35d6-4194-9e9e-3bcc0298a95c_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "The secondary trial does not require patients to be doing less than 2 hours of physical exercise per week, but the primary trial does.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information presented in the CTRs as the primary trial specifies a weekly exercise limit of less than 120 minutes (2 hours), while the secondary trial does not mention any exercise requirements. The statement does not contradict any information in the CTRs.</s>",
        "contradict": "The statement is contradictory to the inclusion criteria of the primary trial stating that participants have to do less than 120 minutes (2 hours) of exercise per week. The secondary trial does not have such a requirement.</s>"
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure.",
        "Label": "Entailment",
        "entail": "The statement \"There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure\" can be entailed by the information present in the CTRs as follows:\n\n1. The statement mentions \"cohort 1 of the primary trial,\" which matches the context of the CTRs as they also refer to a primary trial.\n2. The statement mentions \"4 cases\" of Febrile neutropenia in cohort 1, which is consistent with the data in the first CTR under Adverse Events 1, where 4 cases of Febrile neutropenia are reported out of 127 participants in total for the primary trial.\n3. The statement claims \"0 cases of heart failure,\" which is consistent with the data in the first CTR under Adverse Events 1, where there are 0 cases of heart failure reported out of 127 participants. Therefore, the information in the statement is entailed by the data presented in the CTRs.</s>",
        "contradict": "The statement \"There were 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure\" contradicts the CTR data as the number of cases of Febrile neutropenia stated in the expert's claim (4) does not match the reported number in the CTR for cohort 1 of the primary trial (3), and the CTR for both primary and secondary trials indicates the absence of heart failure cases.</s>"
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There weren't 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure.",
        "Label": "Contradiction",
        "entail": "The statement that \"There weren't 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure\" is entailed by the CTR data as follows:\n\n1. In the Adverse Events 1 section of the Primary Trial, there are only 3 cases of Febrile neutropenia reported, and none in the specific mention of cohort 1.\n2. The statement explicitly states that there weren't 4 cases of Febrile neutropenia, meaning it allows for the possibility of fewer than 4 cases, making the reported 3 cases a valid entailment of the statement.\n3. In the Adverse Events 1 section of the Primary Trial, there is no mention of heart failure, and the statement also accurately reflects this absence of reported cases.\n\nTherefore, the statement is a valid entailment of the information presented in the CTRs.</s>",
        "contradict": "The statement \"There weren't 4 cases of Febrile neutropenia in cohort 1 of the primary trial, and 0 cases of heart failure\" contradicts the information present in the CTR as follows:\n\n1. The statement claims \"There weren't 4 cases of Febrile neutropenia in cohort 1 of the primary trial,\" which contradicts the information provided in the CTR where there were indeed 4 cases of Febrile neutropenia out of 127 total participants.\n\n2. The statement also claims \"and 0 cases of heart failure,\" whereas the CTR reports 0 cases of heart failure in both trials, Primary and Secondary. However, this part of the statement does not contradict the CTR information, as both the statement and the CTR agree on the absence of heart failure in the trials.\n\nTherefore, the main contradiction lies in the incorrect claim about the number of cases of Febrile neutropenia in the primary trial.</s>"
    },
    "6a71c114-2e38-4d57-8f8b-8252d9c62cbe_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 0 cases of heart failure in cohort 1 of the primary trial, and 4 cases of Febrile neutropenia.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail information from the CTRs as it makes a comparison between two different conditions (heart failure and Febrile neutropenia) within the same cohort of the primary trial, which is not explicitly stated in the provided CTR data. However, there is no contradiction between the statement and the CTR data, as both report the absence of heart failure in cohort 1 of the primary trial and the occurrence of 4 cases of Febrile neutropenia.</s>",
        "contradict": "The statement \"There were 0 cases of heart failure in cohort 1 of the primary trial, and 4 cases of Febrile neutropenia\" contradicts the information in the CTR because the CTR reports 3 cases of heart failure under the Left Ventricular Dysfunction subsection in the Adverse Events section of the primary trial for all participants, and there is no mention of cohort 1 in the provided information. Therefore, it is incorrect to state that there were 0 cases of heart failure in cohort 1 specifically.</s>"
    },
    "4333aaa3-dbe4-4275-a982-881fe25c96c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 2 of the primary trial receive dose-intensive chemotherapy on a21 day cycle up to 3 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "entail": "The statement \"Arm 2 of the primary trial receive dose-intensive chemotherapy on a 21-day cycle up to 3 times in the absence of disease progression or unacceptable toxicity\" is entailed by the following details from the CTR:\n\n1. Arm I of the primary trial receives dose-intensive chemotherapy every 7 days.\n2. The first phase of chemotherapy for Arm I lasts for up to 12 weeks, and it consists of dose-intensive chemotherapy followed by paclitaxel.\n3. In the absence of disease progression or unacceptable toxicity, patients undergo both phases of treatment in one course, and then repeat the entire course.\n\nGiven that the statement refers to Arm 2, it implies that the chemotherapy in Arm 2 follows the same pattern as Arm I, but with a different cycle length. Since the number of treatment courses is limited by disease progression or unacceptable toxicity, the statement's condition of \"up to 3 times\" aligns with the CTR's requirement that patients receive both phases of treatment a maximum number of times.\n\nTherefore, the statement that \"Arm 2 of the primary trial receive dose-intensive chemotherapy on a 21-day cycle up to 3 times in the absence of disease progression or unacceptable toxicity\" is entailed by the information provided in the CTRs.</s>",
        "contradict": "The information in the statement contradicts the CTR by specifying a 21-day cycle for dose-intensive chemotherapy in Arm 2 of the primary trial, whereas the CTR describes a 7-day cycle for chemotherapy courses with a repeat every 7 days for up to 12 weeks.</s>"
    },
    "d605b820-2915-4b19-b9cd-ca7850645f83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Only 6 patients in cohort 1 of the primary trial had Varicose Veins.",
        "Label": "Contradiction",
        "entail": "The statement \"Only 6 patients in cohort 1 of the primary trial had Varicose Veins\" is entailed by the CTR data as the number of patients with Varicose Veins in cohort 1 of the primary trial, according to Adverse Events 1, is 1 out of 6 patients (16.67%). Therefore, six patients represent the total number of patients in cohort 1, and one of those patients had Varicose Veins, which aligns with the expert's claim.</s>",
        "contradict": "The expert's statement that \"Only 6 patients in cohort 1 of the primary trial had Varicose Veins\" is contradictory to the CTR data because in the CTR for the primary trial in the Adverse Events 1 section, it is stated that \"Varicose Vein 1/6 (16.67%)\" which indicates that one out of six patients (or 16.67%) had Varicose Veins in cohort 1. Therefore, there were more than six patients with Varicose Veins in the primary trial, which conflicts with the expert's claim.</s>"
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial\" is entailed by the CTR inclusion criteria for Cohorts A and A1, which specifically state, \"Known deleterious germline mutation of BRCA1/2.\" Thus, the statement is harmonious with clinical trial data in the CTR, and there is no contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial\" can be contradicted by the CTRs in several ways:\n\n1. Not all patients with BRCA1/2 mutations are included: The CTR states that patients in cohorts A and A1 must have a proven diagnosis of MBC and a known deleterious germline mutation of BRCA1/2 for inclusion. However, not every person with a BRCA1/2 mutation has MBC.\n\n2. Other inclusion criteria must also be met: Patients with a BRCA1/2 mutation are only eligible if they meet all other inclusion criteria, such as age, voluntary signed informed consent form, disease evaluability, adequate organ function, washout periods, and no ongoing toxicity. \n\n3. Prior treatment with PARP inhibitors is also required for some patients: Patients in Cohort A1 must have failed prior chemotherapy for metastatic disease and have a proven BRCA1/2 mutation, but they are also required to have prior treatment with PARP inhibitors for inclusion. This contradicts the statement which only mentions the requirement for a BRCA1/2 mutation.\n\nTherefore, the statement \"People who inherit harmful variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial\" is not an entailed consequence of the information present in the CTRs.</s>"
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit harmful variants of the BReast CAncer gene 1 or 2 aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"People who inherit harmful variants of the BReast CAncer gene 1 or 2 aren't eligible for the primary trial\" is entailed by the CTR inclusion criteria for Cohorts A and A1, which specify that patients with known deleterious germline mutation of BRCA1/2 are ineligible for the trial.</s>",
        "contradict": "The statement \"People who inherit harmful variants of the BReast CAncer gene 1 or 2 aren't eligible for the primary trial\" can be contradicted by the information present in the CTRs because the CTRs specify that individuals with \"known deleterious germline mutation of BRCA1/2\" are indeed eligible for the primary trial, specifically in cohorts A and A1.</s>"
    },
    "d6de70df-d113-4bc8-9d3b-b71f31937ebe_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "The primary trial accepts people who inherit harmful variants of the BReast CAncer gene 1 or 2.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria for Cohorts A and A1, which explicitly list \"known deleterious germline mutation of BRCA1/2\" as a requirement for patient eligibility.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because not all patients in the primary trial are required to have a deleterious germline mutation of BRCA1/2. The inclusion criteria specify that patients in Cohorts A and A1 must have such mutations, but patients in other cohorts are not necessarily required to meet this condition. Therefore, the statement oversimplifies the eligibility criteria by focusing only on one subset of patients and ignoring the diversity of patient populations in the trial.</s>"
    },
    "9f897b29-7cfa-414c-8cf6-212a68ec2216": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03346161",
        "Secondary_id": "NCT01000662",
        "Statement": "Neither the secondary trial or the primary trial require patients to undergo any kind of medical treatment during their interventions, they are only testing effectiveness of consultations.",
        "Label": "Contradiction",
        "entail": "The provided statement does not directly entail information from the CTRs as the CTRs do describe interventions involving interactions with decision tools, a surgical care booklet, and radiation therapy. However, the statement is consistent with the information in the CTRs in that no active medical treatment beyond consultations or booklets is mentioned in the trials' interventions. The focus of both trials is on the testing of consultation effectiveness, as stated in the expert's claim.</s>",
        "contradict": "The statement contradicts the information in the CTRs because both the primary and secondary trials involve medical treatments as part of their interventions. In the primary trial, patients undergo a mastectomy and are randomly assigned to either use a decision tool (Intervention 1) or a surgical care booklet (Intervention 2). In the secondary trial, patients undergo radiation therapy with different schedules for the tumor bed boost (Intervention 1: daily boost; Intervention 2: weekly boost). The statement's claim that neither trial requires patients to undergo any medical treatment is incorrect.</s>"
    },
    "0d0deba5-c7bd-489b-a49d-c6af9a5cd92a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed much better than the test group, as a lower PFS is ideal.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial placebo group performed much better than the test group, as a lower PFS is ideal\" cannot be directly entailed by the information in the CTRs as the CTRs do not provide sufficient data to make this comparison. However, a contradictory statement to the expert's claim, \"The test group had a significantly longer PFS than the placebo group,\" could be derived from the CTR data. The median PFS of the Exemestane + Placebo group was 2.27 months (1.81 to 3.68), while the Exemestane + Entinostat group had a median PFS of 4.28 months (3.26 to 5.36). This indicates that the Exemestane + Entinostat group had a longer PFS, which goes against the expert's claim that a lower PFS is ideal for the placebo group to perform better. However, it's important to note that PFS might not always be the primary goal in all trials, and the statement may hold true in certain contexts where a lower PFS is desired for the control group, such as for certain palliative care trials or in certain patient populations. In the absence of such contextual information, the given statement cannot be entailed by the CTR data alone.</s>",
        "contradict": "The statement contradicts the information in the CTRs as the PFS is defined as the number of months from randomization to disease progression or death, with a shorter PFS indicating a less favorable outcome. However, the statement suggests that a lower PFS in the placebo group is desirable, implying the opposite of what is typically sought in clinical trials.</s>"
    },
    "4606f64f-64cc-4d73-a8be-75701c97008d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Plasma transfusion.",
        "Label": "Contradiction",
        "entail": "The statement \"A patient in cohort 2 of the primary trial received a Plasma transfusion\" cannot be entailed by the information present in the CTRs, as there is no mention of plasma transfusions in either of the Adverse Events sections for the primary or secondary trials.</s>",
        "contradict": "The statement \"A patient in cohort 2 of the primary trial received a Plasma transfusion\" is inconsistent with the data presented in the Adverse Events sections of the CTRs because there is no record of any plasma transfusion (pRBCs or otherwise) in either the primary or secondary CTRs.</s>"
    },
    "40bef815-18ed-4db5-8108-9a1cdbdd0a13": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial. However, being pregnant is required.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs. The primary trial's inclusion criteria explicitly exclude pregnancy, whereas the secondary statement requires it. Additionally, the statement's first part contradicts the primary trial's eligibility criteria, as adequate hematologic, hepatic, and renal function are essential requirements for trial participation. Therefore, the statement does not hold true for the provided CTR information.</s>",
        "contradict": "The statement is contradicted by the CTR information because the primary trial inclusion criteria explicitly exclude pregnancy as a condition for participation.</s>"
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement\" is entailed by the information present in the CTRs as neither the primary trial nor the Results 1 section mention any details related to overall response rate, tumour response rate, or preference score. Instead, the primary trial's outcome measurement was Progression-Free Survival (PFS).</s>",
        "contradict": "The statement \"the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement\" can be contradicted by the information present in the CTRs because the primary trial did in fact use Progression-Free Survival (PFS) as its outcome measurement, which is not explicitly mentioned as one of the named measures (Overall Response Rate, Tumor Response Rate, or Preference Score) in the statement. However, PFS is a commonly used measure in clinical trials for assessing the effectiveness of cancer treatments.</s>"
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "The primary trial used overall response rate, tumour response rate or preference score as its outcome measurement.",
        "Label": "Contradiction",
        "entail": "The expert statement \"The primary trial used overall response rate, tumour response rate or preference score as its outcome measurement\" cannot be directly entailed by the information in the provided CTRs, as neither the primary nor the secondary trial's outcome measurement was stated as overall response rate, tumour response rate, or preference score. However, if it is known that these outcome measures are interchangeable or related to the Progression-Free Survival (PFS) measure used in the CTRs, the statement could be indirectly entailed. For instance, if it is established that a high Progression-Free Survival rate often implies a high overall response rate or tumour response rate, the expert statement could be considered to hold true based on that relationship. Nonetheless, without additional context, the expert statement cannot be definitively entailed by the given CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert can be contradicted by the information present in the CTRs as the primary trial reported Progression-Free Survival (PFS) as the outcome measurement instead of overall response rate, tumor response rate, or preference score as suggested in the expert's statement.</s>"
    },
    "5c676007-9ea4-4f80-82dd-89293237cb07_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00319254",
        "Statement": "Overall response rate, tumour response rate or preference score were not used as the outcome measurement in the primary trial.",
        "Label": "Entailment",
        "entail": "The outcome measurement in the primary trial was Progression-Free Survival (PFS), not overall response rate, tumor response rate, or preference score. This information is explicitly stated in the CTR under the \"Outcome Measurement\" section, and therefore the expert's statement is entailed by the information presented in the CTR, as it aligns with the facts stated and does not contradict any of the provided information.</s>",
        "contradict": "The statement made by the expert contradicts the information in the CTR as the outcome measurement in the primary trial was Progression-Free Survival (PFS) rate, not overall response rate, tumor response rate, or preference score.</s>"
    },
    "a6682883-ace7-4d83-a35c-956928fdc75a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01325428",
        "Secondary_id": "NCT00073073",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language.",
        "Label": "Contradiction",
        "entail": "The statement does not entail any specific requirement regarding ethnicity, sex, height, or language in either the primary or secondary trial inclusion criteria, which aligns with the information provided in the CTRs.</s>",
        "contradict": "The information stated by the expert is contradicted by the inclusion criteria in both the primary and secondary trials. The primary trial explicitly states that it includes \"female patients,\" while the secondary trial includes postmenopausal females specifically. The secondary trial also mentions certain exclusion criteria based on hormonal therapy use and menopausal status, implying that the trial is targeted towards females. Additionally, there are no statements in either CTR indicating that participation is not restricted based on ethnicity, height, or language.</s>"
    },
    "1a271e29-477b-4819-a472-5c7c7df99e70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "2 cases of hematolysis were recorded in the primary trial, none in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"2 cases of hematolysis were recorded in the primary trial, none in the secondary trial\" does not directly entail any specific information from the Adverse Events sections of the provided Clinical Trial Reports (CTRs). However, it can be deduced as an entailed statement based on the information present in those sections.\n\nThe Adverse Events sections of the primary and secondary trial CTRs both list \"hemolysis\" as a possible adverse event. The primary trial reports 1 occurrence of hemolysis in a total of 157 participants (0.64%). The secondary trial reports 0 occurrences of hemolysis in a total of 168 participants (0.00%).\n\nGiven this information, it follows logically that the number of recorded cases of hemolysis is higher (2) in the primary trial than in the secondary trial (0). Therefore, the statement \"2 cases of hematolysis were recorded in the primary trial, none in the secondary trial\" can be considered entailed by the data presented in the CTRs.\n\nHowever, this inference relies on the assumption that the data in the CTRs is complete and accurate, and that the reported cases of hemolysis are not underreported or misclassified. Additionally, it is important to consider other possible causes for the absence of hemolysis cases in the secondary trial, such as differences in patient populations, trial designs, or interventions between the primary and secondary trials.</s>",
        "contradict": "The statement \"2 cases of hematolysis were recorded in the primary trial, none in the secondary trial\" is contradictory to the information in the CTRs because the Adverse Events section of the primary trial reports 1 case of hematolysis out of 157 participants (0.64%), not 2 cases. Therefore, the statement exceeds the number of reported cases of hematolysis in the primary trial.</s>"
    },
    "060e833e-384f-48f0-8e56-ebd95f55f221": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01926886",
        "Statement": "There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert statement \"There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial\" is entailed by the information in the CTRs as follows:\n\n1. The CTR for the primary trial lists Vertigo as an adverse event occurring in 1/101 participants (0.99%). However, the expert statement indicates that there were no cases of Vertigo. This might seem contradictory at first glance. However, the expert statement could be interpreted as referring to the absence of Vertigo as a significant finding or a major safety concern in the primary trial. In the given CTR, Vertigo is mentioned only as an adverse event with a low frequency. It does not seem to have affected a substantial number of participants or led to any serious consequences, making it less noteworthy as a safety issue. The expert statement, which focuses on the absence of major safety concerns, is thus consistent with the CTR.\n\n2. The CTR for the primary trial does not mention Cellulitis or Anaemia as adverse events. Therefore, the expert statement \"There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial\" is entailed by the CTR as it accurately reflects the absence of these conditions in the trial data. \n\nIn summary, the expert statement \"There were no cases of Cellulitis, Vertigo or Anaemia in the primary trial\" is entailed by the CTR, as it accurately reflects the absence of these conditions as major safety concerns or significant findings in the trial, or the absence of reports of these conditions in the trial data.</s>",
        "contradict": "The expert's statement asserts that there were no cases of Cellulitis, Vertigo, or Anaemia in the primary trial. However, the CTR reports that there was one case (0.99%) of Vertigo. Therefore, the expert's statement contradicts the information in the CTR.</s>"
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial only recorded three types of adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial only recorded three types of adverse events\" is entailed by the given CTRs since the information in the primary CTR lists three distinct adverse events (cholecystitis, increase in diarrhea, and flank pain), and there is no mention or implication of any other adverse events. Therefore, the statement correctly reflects the data in the CTR.</s>",
        "contradict": "The statement \"the primary trial only recorded three types of adverse events\" is contradicted by the information present in the CTRs because the CTR for the primary trial lists four distinct types of adverse events: cholecystitis, increase in diarrhea, flank pain, and an unspecified number of other adverse events (implicitly mentioned since there was a \"Total\" adverse event count given).</s>"
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "The primary trial only didn't record three types of adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial only didn't record three types of adverse events\" can be entailed by the CTR information as follows: The CTR for the primary trial lists three types of adverse events that occurred in 3 out of 30 participants (10.00%). However, it is possible that there could be other types of adverse events not listed in the provided data. The expert's statement acknowledges this possibility and does not claim that all types of adverse events were recorded in the primary trial, but rather that three specific types were not mentioned. This is in line with the information in the CTR, which does not claim to provide an exhaustive list of all adverse events. Therefore, the statement is entailed by the CTR.</s>",
        "contradict": "The expert's statement \"The primary trial only didn't record three types of adverse events\" contradicts the CTR information because the CTRs do record those three types of adverse events (cholecystitis, increase in diarrhea, and flank pain) in the primary trial. The expert's statement implies that those events were not reported, while the CTR evidence shows they were indeed recorded.</s>"
    },
    "ac193d32-156e-48bf-bc6b-d613691f869c_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "Three types of adverse events were the only ones recorded by the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Three types of adverse events were the only ones recorded by the primary trial\" is entailed by the information in the CTRs since the statement only makes a claim about the number and types of adverse events that were reported in the primary trial. The CTRs explicitly list three distinct types of adverse events - cholecystitis, increase in diarrhea, and flank pain - that were observed in the trial, with each type having a count of one occurrence. Therefore, the statement made by the clinical trial expert is consistent with the CTR data and does not contradict any information provided.</s>",
        "contradict": "The statement \"Three types of adverse events were the only ones recorded by the primary trial\" is contradicted by the information in the CTRs as there were, in fact, four types of adverse events reported in the primary trial, namely cholecystitis [1], increase in diarrhea [2], flank pain [3], and an unknown type of adverse event (implicitly mentioned in the ELIGIBILITY CRITERIA section for another arm of the trial). Therefore, the statement does not entail the information present in the CTRs.</s>"
    },
    "d79173da-5e59-4150-99bd-f1c20118dddc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography.",
        "Label": "Contradiction",
        "entail": "The statement \"All participants of the primary trial must have undergone either an echocardiography\" is entailed by the inclusion criteria of the primary CTR that requires \"Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography\" as a condition for eligibility. The expert's statement implies that all participants have had an echocardiography to ensure they meet this requirement.</s>",
        "contradict": "The statement that \"All participants of the primary trial must have recently undergone either an echocardiography\" is contradicted by the CTR inclusion criteria, as normal left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography is one of the inclusion criteria. However, the statement implies that all participants have undergone a recent echocardiography for checking their LVEF, which is not necessarily true for all participants based on the CTR information.</s>"
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women are eligible for the primary trial, and Premenopausal women are eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as follows:\n\n1. Postmenopausal women are eligible for the primary trial: This is evident from the inclusion criteria of the primary trial that specifies the patients must be postmenopausal women.\n2. Premenopausal women are eligible for the secondary trial: The secondary trial includes premenopausal women as a part of its eligibility criteria. While the primary trial does not include premenopausal women, that does not mean they are excluded, as different trials can cater to different patient populations. The premenopausal status in the secondary trial is defined by various criteria, which include last menstrual period within 3 months, post-hysterectomy without bilateral oophorectomy and with FSH in the premenopausal range, or plasma estradiol in the premenopausal range if tamoxifen administered within the past 3 months. These conditions are not present in the primary trial's eligibility criteria but do not contradict it either. Therefore, the statement is in line with the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs due to a discrepancy in the eligibility criteria for women's menopausal status. While postmenopausal women are eligible for the primary trial, premenopausal women are excluded from it. Conversely, premenopausal women are eligible for the secondary trial. However, the statement does not account for this distinction between the trials.</s>"
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "Postmenopausal women are eligible for the primary trial, and Premenopausal women aren't eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Postmenopausal women are eligible for the primary trial, and Premenopausal women aren't eligible for the secondary trial\" is entailed by the information in the CTRs as follows: \n\n1. Primary Trial: The inclusion criteria for the primary trial specify that patients must be postmenopausal women. \n2. Secondary Trial: The inclusion criteria for the secondary trial exclude premenopausal women (last menstrual period within 3 months, or post-hysterectomy without bilateral oophorectomy and with FSH in the premenopausal range, or if tamoxifen administered within the past 3 months, plasma estradiol must be in the premenopausal range). \n\nTherefore, the statement that postmenopausal women are eligible for the primary trial and premenopausal women aren't eligible for the secondary trial is consistent with the information in both CTRs, and the statement finds substantiation in the CTRs. The statement does not contradict any descriptions in the provided CTRs.</s>",
        "contradict": "The statement \"Postmenopausal women are eligible for the primary trial, and Premenopausal women aren't eligible for the secondary trial\" is contradicted by the CTRs due to the following reasons: \n\n1. Primary Trial: The inclusion criteria for the primary trial specify that patients must be postmenopausal women. However, the eligibility criteria for the secondary trial allow for premenopausal women to be included if they meet certain conditions, such as having a premenopausal ECOG performance status or being post-hysterectomy without bilateral oophorectomy and having FSH in the premenopausal range. Thus, premenopausal women can be included in trials other than the primary trial mentioned in the statement.\n\n2. Secondary Trial: The statement incorrectly asserts that premenopausal women are excluded from the secondary trial. However, the inclusion criteria for the secondary trial specify that women can be included if they meet certain conditions related to menopausal status (as mentioned above). Thus, the statement is inconsistent with the information provided in the CTRs.\n\nTherefore, the statement \"Postmenopausal women are eligible for the primary trial, and Premenopausal women aren't eligible for the secondary trial\" is not entailed by the information in the provided CTRs, and there is a contradiction between the statement and the clinical trial data.</s>"
    },
    "50559f15-636d-4265-8f8c-4aad016c6c50_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "Premenopausal women are eligible for the secondary trial, and postmenopausal women are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Premenopausal women are eligible for the secondary trial, and postmenopausal women are eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe primary trial's inclusion criteria specify that patients must be postmenopausal women, while the secondary trial's inclusion criteria state that premmenopausal women are eligible for the study. Since these criteria apply to different trials, the statement does not contradict the provided descriptions.\n\nIn the primary CTR, postmenopausal women are explicitly stated as eligible, whereas, in the secondary CTR, premenopausal women are mentioned as eligible. This difference in eligibility criteria for distinct trials does not contradict the provided information and, therefore, the statement can be entailed.</s>",
        "contradict": "The statement \"Premenopausal women are eligible for the secondary trial, and postmenopausal women are eligible for the primary trial\" is contradicted by the information present in the CTRs because the primary trial specifically includes only postmenopausal women, while the secondary trial only includes premenopausal women.</s>"
    },
    "a5af6d2b-4cea-40aa-acdc-59fab5362b3e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are included in the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial inclusion criteria specify that patients must have documented ER (estrogen receptor) status for eligibility. Therefore, the statement that \"Patients with Breast cancers that have estrogen receptors are included in the primary trial\" is entailed by the information presented in the CTR.</s>",
        "contradict": "Although the statement mentions that patients with breast cancers that have estrogen receptors are included in the primary trial, the CTRs provide more detailed eligibility criteria which include, among others, ER or PR-positive tumors. However, the statement does not explicitly mention this requirement for ER or PR positivity, making it potentially contradictory to the more comprehensive information provided in the CTRs.</s>"
    },
    "7e89b190-b8f7-4281-b0f1-0e65dcebf402": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan.",
        "Label": "Contradiction",
        "entail": "Exemestane in Intervention 1 of the primary trial is prescribed at a frequency of 25 mg daily, which translates to 750 mg (25 mg x 30 days) monthly. In contrast, Cytoxan in Intervention 2 of the primary trial is given at a frequency of 600 mg/m\u00b2 every 3 weeks. To find out how many doses Cytoxan administers in a month, we need to determine the number of cycles and the frequency of administration within a cycle. Since there are 6 cycles in 24 weeks (\u224884 days), each cycle lasts approximately 14 days. Cytoxan is given once every 3 weeks, which means each cycle consists of 2 doses. Therefore, patients in the secondary trial's cohort 2 receive approximately 2 doses of Cytoxan per month. The statement that patients in cohort 1 receive Exemestane twice as often as cohort 2 receives Cytoxan is entailed by the information in the CTRs because patients in cohort 1 receive one dose of Exemestane daily (750 mg monthly), while patients in cohort 2 receive about 2 doses of Cytoxan monthly (\u2248720 mg or 2 x 360 mg). The difference in the total monthly dose between the two cohorts (750 mg vs. 720 mg) is within the acceptable margin of error due to the rounding of the Cytoxan dose to the nearest mg in the statement and the potential variability in the actual dosage given to patients.</s>",
        "contradict": "The statement \"Patients in cohort 1 of the primary trial receive Exemestane twice as often as cohort 2 patients receive Cytoxan\" cannot be directly derived from the provided information in the CTRs, as the number of treatments or dosages each patient receives within their respective cohorts is not explicitly stated. The statement assumes a relationship between the frequency of Exemestane and Cytoxan administration that is not directly mentioned in the CTRs, which can be contradicted by various possible dosing schedules that could fulfill the conditions set by the trial.</s>"
    },
    "6036d341-9c6a-49fc-a2f4-19c0e2399f4c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement cannot be directly entailed by the information in the CTRs, as neither trial reports any occurrence of ventricular tachycardia or supraventricular tachycardia in their adverse event sections.</s>",
        "contradict": "The expert's statement \"There were significantly more cases of ventricular tachycardia than Supraventricular tachycardia in cohort 2 of the primary trial\" contradicts the information presented in the CTRs because neither cohort 1 nor cohort 2 of the primary trial reported any cases of ventricular tachycardia. The CTRs only mentioned tachycardia in general but did not specify whether it was ventricular or supraventricular. Additionally, the CTRs only reported data for adverse events in cohorts 1 and 106, not for cohort 2.</s>"
    },
    "a84afa25-2741-4a08-9e6c-4049f5feca48": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior.",
        "Label": "Contradiction",
        "entail": "The exclusion criteria for the primary trial state that patients cannot have received previous treatment with PI3K inhibitors (CTR, Inclusion/Exclusion Criteria, line 13). However, the statement does not contradict this, as it specifies that the treatment with PI3K inhibitor must have ended over 5 years prior to trial enrollment (statement, \"if this treatment ended over 5 years prior\"). Thus, this statement can be entailed by the information present in the CTR, as it does not include any patients who have received PI3K inhibitor treatment within the 5-year window.</s>",
        "contradict": "The statement \"patients with Phosphoinositide 3-kinase inhibitor based treatments are eligible for the primary trial, if this treatment ended over 5 years prior\" contradicts the CTR inclusion criteria, which explicitly states that individuals who have received previous treatment with PI3K inhibitors are not eligible for participation.</s>"
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "the primary trial and the secondary trial do not have the same duration of intervention administration.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial do not have the same duration of intervention administration\" is entailed by the information present in the CTRs as follows: \n\nIn the primary trial, the letrozole intervention lasts for two separate periods (Part A and Part B) with a duration of 28 days for each period. \n\nIn contrast, in the secondary trial, the neratinib intervention lasts for a single period with a fixed dosage of 40 mg and 80 mg administered once daily, but no specific duration is mentioned in the provided information. \n\nSince the length of time that participants in each trial are exposed to intervention is not equivalent, the statement that they do not have the same duration of intervention administration is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not have the same duration of intervention administration\" is not contradicted by the information present in the CTRs. In the primary trial, the letrozole administration lasts for 28 days whether in the standard of care or double dose group. In contrast, in the secondary trial, both neratinib interventions last for 28 days, but their doses differ (40 mg and 80 mg, respectively). The discrepancy between the trials lies in the type of intervention, not the duration.</s>"
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "The primary trial and the secondary trial have the same duration of intervention administration.",
        "Label": "Contradiction",
        "entail": "In the primary CTR, Letrozole administration in both Part A and Part B lasts for 28 days. In the secondary CTR, Neratinib is given at two different dosages (40 mg and 80 mg) each day, and the duration of administration is not explicitly stated. However, since both trials have identical intervention duration (28 days), it can be inferred that the secondary trial also administers Neratinib for 28 days. Thus, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the duration of intervention administration is not the same in both trials. In the primary trial, letrozole is administered for 28 days in both Part A and Part B. However, in the secondary trial, neratinib is administered once daily for 28 days in Intervention 1 and once daily for 28 days in Intervention 2. Thus, the number of doses taken during the 28-day period differs between the two trials, as the doses of neratinib are higher in Intervention 2, and therefore, the actual duration of administration may also differ depending on individual participant needs.</s>"
    },
    "09e4c746-642a-4a5d-a267-25258a3f2ec0_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01669343",
        "Secondary_id": "NCT00146172",
        "Statement": "The secondary trial and the primary trial have different durations of intervention administration.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial and the primary trial have different durations of intervention administration\" is entailed by the information present in the CTRs as follows: In the primary trial, letrozole is administered for 28 days in Part A for routine care and 28 days in Part B for overweight/obese participants. In contrast, the secondary trial administers neratinib at a dose of 40 mg qd for an unspecified duration (implied to be different from the primary trial since it is a separate study) and also administers a higher dose of 80 mg qd for an identical 28-day period. Therefore, the durations of intervention administration are distinct between the two trials.</s>",
        "contradict": "The statement can be contradicted by the CTRs because the primary trial involves letrozole administration for 28 days in both Part A and Part B, while the secondary trial involves the administration of neratinib 40 mg or 80 mg qd for an undisclosed duration, for which no specific duration is provided in the statement. The length of interventions in the two trials is not directly comparable due to the different treatments and lack of duration specification for the secondary trial.</s>"
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "the primary trial recorded the same number of occurences for every type of adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial recorded the same number of occurrences for every type of adverse event\" is not entailed by the information in the CTRs. The CTRs list the number of occurrences for each specific type of adverse event separately in the primary trial, which shows that the number of occurrences varies for different types of adverse events, and they are not the same. Therefore, the statement does not follow from or harmonize with the data presented in the CTRs and contradicts the provided descriptions.</s>",
        "contradict": "The information in the statement that \"the primary trial recorded the same number of occurrences for every type of adverse event\" is contradicted by the CTR data as the numbers of reported adverse events for each type differ. For instance, Fatigue, Non-cardiac chest pain, Sepsis, Urinary tract infection, Syncope, Anxiety, Thromboembolic event each occurred in 1/9 of the participants, but their frequency is not the same (33.33% for all types combined). Therefore, the statement is contradictory to the data presented in the CTRs.</s>"
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The primary trial didn't record the same number of occurences for every type of adverse event.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial reported different numbers of occurrences for each type of adverse event (3, 1 for Fatigue, Non-cardiac chest pain, Sepsis, Urinary tract infection, Syncope, Anxiety, Thromboembolic event respectively). The statement correctly acknowledges this discrepancy and does not contradict the information in the CTRs.</s>",
        "contradict": "The statement that \"The primary trial didn't record the same number of occurrences for every type of adverse event\" does not contradict the CTR information, as the CTR data clearly shows that the number of occurrences varies among different types of adverse events in the primary trial (i.e., 1 occurrence each for Fatigue, Non-cardiac chest pain, Sepsis, Urinary tract infection, Syncope, Anxiety, and Thromboembolic event). Therefore, the statement is consistent with the CTR data, and no contradiction exists. However, the statement implies an expectation of equal occurrences for all adverse events, but the CTR shows that is not the case. This discrepancy may lead to confusion or misinterpretation but does not contradict the facts presented.</s>"
    },
    "99855d11-e2e4-4a0e-b40e-2264ff128ac5_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The same number of occurences for every type of adverse event were recorded by the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The same number of occurrences for every type of adverse event were recorded by the primary trial\" is entailed by the CTRs if we consider the following:\n\nIn the CTR for the primary trial, we have the number of occurrences (i.e., frequency) of each type of adverse event. Each adverse event type is mentioned with the same number of occurrences (i.e., 1/9 or 11.11% of the total participants).\n\nThus, the statement that \"The same number of occurrences for every type of adverse event were recorded by the primary trial\" can be entailed by the data provided in the CTRs for the primary trial. This entailment holds because the statement's assertion harmonizes with the clinical trial data, finds substantiation in the CTR, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"The same number of occurrences for every type of adverse event were recorded by the primary trial\" contradicts the information present in the CTRs since the primary trial report indicates that each adverse event occurred in a differing number of instances: fatigue occurred 1/9 times, non-cardiac chest pain occurred 1/9 times, sepsis occurred 1/9 times, urinary tract infection occurred 1/9 times, syncope occurred 1/9 times, anxiety occurred 1/9 times, thromboembolic event occurred 1/9 times. Thus, the number of occurrences for each adverse event is not the same.</s>"
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzabemtansine\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, Zoledronic Acid 5 mg IV is given once as a one-time dose, whereas,\n2. In the secondary trials, ado-trastuzumab emtansine 3.6mg/kg IV is given on day 1 and repeatedly every 21 days, which is a higher dose and more frequent administration compared to the primary trial's Zoledronic Acid dose.\n\nTherefore, the statement is entailed as it accurately describes the difference in the amount and frequency of the administered IV drugs between the two trials.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because:\n- In the primary trial, Zoledronic Acid (Zometa) is given as a one-time IV dose of 5 mg, while in the secondary trial, ado-trastuzumab emtansine is given as a repeated IV dose of 3.6mg/kg every 21 days.\n- Therefore, comparing the dosage of Zometa and ado-trastuzumab emtansine directly does not make a fair comparison, as they are two distinct treatments used for different purposes and administered differently.\n\nHowever, the statement could be made true by changing it to:\n- Primary trial patients receive a lower cumulative dose of IV Zoledronic Acid (5 mg) compared to secondary trial patients who receive a cumulative dose of IV ado-trastuzumab emtansine over a longer period.\n- Or, the statement could be made true by comparing the dosage per body weight unit, in which case the secondary trial patients would indeed receive a lower dose of ado-trastuzumab emtansine compared to the primary trial patients receiving Zoledronic Acid.\n\nSo, without further context or clarification from the expert, the statement as written could be contradicted by the information present in the CTRs.</s>"
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial don't receive a lower dose of Zometa by IV than the secondary trial patients receive of ado-trastuzumab emtansine.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Zoledronic Acid (Zometa) is given as a one-time dose of 5 mg IV. In the secondary trials, ado-trastuzumab emtansine (T-DM1) is given as a dose of 3.6mg/kg IV. The statement asserts that the primary trial patients do not receive a \"lower dose\" of Zometa compared to the secondary trial patients receiving T-DM1. Since the dosages of Zoledronic Acid and T-DM1 are not directly comparable due to their differing roles in the trials (one is a single dose vs. multiple courses), a more precise comparison would be in terms of the total amount of active substance administered. The amount of active Zoledronic Acid administered is 5 mg, whereas the amount of active T-DM1 administered over the same time frame (as a single dose comparison) would be much greater due to its repeated dosing in every 21-day course. However, the statement does not claim a direct comparison between the total amounts of active substances, but rather that no primary trial patient receives a \"lower dose\" of Zometa (as a single IV dose) than any secondary trial patient receives of T-DM1. Since both Zometa and T-DM1 are administered intravenously, and the primary trial patients do not receive a smaller amount of Zometa as a single IV dose than the secondary trial patients receive of T-DM1, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTRs because the primary trial involves the administration of Zoledronic Acid (Zometa) as a one-time dose of 5 mg IV, while the secondary trial includes the use of ado-trastuzumab emtansine, which is given as a 3.6mg/kg IV dose. The statement fails to consider the different drugs being used in each trial and focuses only on the mode of delivery (IV) and the absence of a lower dose mention in the secondary trial for the specific drug mentioned in the statement (Zometa). The statement is misleading as it does not accurately compare the dosages of the interventions being administered in the trials.</s>"
    },
    "54fe69c7-5a67-49b1-8bc5-c975133e2bb7_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Secondary trial patients received a higher dose of ado-trastuzumab emtansine than patients in the primary trial received of Zometa by IV.",
        "Label": "Entailment",
        "entail": "The statement \"Secondary trial patients received a higher dose of ado-trastuzumab emtansine than patients in the primary trial received of Zometa by IV\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, patients received Zoledronic Acid 5 mg IV as the intervention.\n2. In the secondary trial, patients received ado-trastuzumab emtansine which is different from Zoledronic Acid.\n3. The dose of ado-trastuzumab emtansine given in the secondary trial is 3.6mg/kg, which is higher than the dose of Zoledronic Acid given in the primary trial.\n\nTherefore, the given statement is entailed by the information present in the CTRs as it correctly describes the differences in dosing between the primary and secondary trials for the respective drugs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the treatments in the two trials differ not only in the type and route of administration of ado-trastuzumab emtansine but also in the type of intervention and dosing regimen of the other components of the treatment. Therefore, comparing the dosages of ado-trastuzumab emtansine alone without taking into account the differences in the overall interventions is misleading. In the primary trial, patients received a single dose of Zoledronic Acid 5 mg IV, while in the secondary trials, patients received multiple doses of ado-trastuzumab emtansine, in addition to daily doses of the PI3K inhibitor BYL719. The statement does not provide the necessary context to determine the comparability of the treatments, making it contradictory to the information in the CTRs.</s>"
    },
    "76362fd3-3a07-4aa3-a072-b9075d2ea791": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment).",
        "Label": "Entailment",
        "entail": "The Primary CTR does not report any instance of Congestive Heart Failure (CHF) during active treatment in the AC/PTL arm among the 109 participants. Thus, the expert's statement that \"Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment)\" entails the truth according to the CTR data.</s>",
        "contradict": "The expert's statement that \"Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment)\" cannot be directly contradicted by the information present in the CTRs. However, it can be misleading since the CTR does not explicitly report on the occurrence or absence of Congestive Heart Failure during active treatment for the AC/PTL arm. The expert's statement is based on an assumption that if it were reported, it would indicate the occurrence of CHF, which is not necessarily true. It's essential to note the distinction between absence of information (in this case, no explicit reporting of CHF) and negative information (explicit reporting of no CHF during active treatment). The absence of explicit reporting of CHF during active treatment in the CTR doesn't allow for a definitive contradiction of the expert's statement. However, it does not support the expert's claim either. To determine if the expert's statement is accurate, one would need access to more comprehensive information, such as data from other sources, case reports, or additional analyses, which may include information on CHF during active treatment.</s>"
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0\" is entailed by the information present in the CTRs as follows:\n\n- The primary trial had 2 patients with pancreatitis mentioned under Adverse Events 1, making the total number of patients with pancreas-related adverse events in the primary trial 2.\n- The secondary trial had no mention of pancreas-related adverse events in either Adverse Events 1 or Adverse Events 2.\n\nHence, the statement that the primary trial had a total of 3 patients with pancreas-related adverse events is not directly mentioned in the CTRs but is an entailed conclusion based on the data presented. However, the statement that the secondary trial had no patients with pancreas-related adverse events is directly entailed by the absence of such events mentioned in the CTR.</s>",
        "contradict": "The statement \"the primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial had 0\" is contradicted by the information present in the CTRs as follows:\n\n1. In Adverse Events 1 of the primary trial, there are 2 instances of pancreatitis reported out of a total of 1408 participants.\n2. In Adverse Events 1 of the secondary trial, there is 1 instance of pancreatitis reported out of a total of 170 participants.\n\nTherefore, the statement's assertion of 3 cases in the primary trial and none in the secondary trial is in contradiction with the actual data presented in the CTRs.</s>"
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "The primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial didn't have 0.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial didn't have 0.\" is entailed by the CTRs because the primary CTR reports 2 cases of pancreatitis out of 1408 participants (0.14%), and the secondary CTR does not report any cases of pancreas related adverse events (as per the provided data). The sum of the reported pancreas related adverse events in the primary trial (2) and the absence of such events in the secondary trial (0) equals 3, which corresponds to the number stated in the expert's claim.</s>",
        "contradict": "The statement \"The primary trial had a total of 3 patients experiencing pancreas related adverse events, the secondary trial didn't have 0\" contradicts the information in the CTRs because:\n\n1. The primary trial had 2 cases of pancreatitis in Adverse Events 1 and none in Adverse Events 2.\n2. The secondary trial had 0 cases of pancreas-related adverse events in both Adverse Events 1 and 2. \n\nTherefore, the primary trial reported 2 cases, not 3 cases, and the secondary trial did have adverse events data, but it didn't involve pancreatitis. Consequently, the expert's statement is incorrect.</s>"
    },
    "064b39e9-e9d8-4c51-a76a-ad150bb127f1_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00878709",
        "Secondary_id": "NCT02447003",
        "Statement": "The secondary trial had 0 patients experiencing pancreas related adverse events, the primary trial had a total of 3.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial had 0 patients experiencing pancreas related adverse events, the primary trial had a total of 3\" can be entailed by the information present in the CTRs since:\n\n1. In both trials (primary and secondary), the adverse events sections report on pancreatitis as a potential event.\n2. The primary trial reports a total of 2 cases of pancreatitis (Adverse Events 1: 2/1408, Adverse Events 2: 1/1408) which sums up to 3 cases.\n3. The secondary trial reports 0 cases of pancreatitis (Adverse Events 1: 0/170, Adverse Events 2: 0/170) in its adverse events sections.\n\nHence, the statement does not contradict the data in the provided CTRs, and the statement's assertion harmonizes with the clinical trial data.</s>",
        "contradict": "The statement \"The secondary trial had 0 patients experiencing pancreas related adverse events, the primary trial had a total of 3.\" is contradicted by the information present in the CTRs because, in the primary trial, there were 2 cases of pancreatitis reported in Adverse Events 1 and none in Adverse Events 2 of the secondary trial, but the statement suggests that there were no pancreas related adverse events in the secondary trial at all.</s>"
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "the secondary trial and the primary trial give their patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Entailment",
        "entail": "In the primary trial, the Stem Cell Transplant is given on Day 0, whereas in the secondary trial, the Stem Cell Transplant occurs around Day 0, specifically \"about 14-21 days\" after the Samarium 153-EDTMP administration. Although the exact timing of the transplant may differ slightly between the trials, the essential similarity lies in the fact that both trials administer the Stem Cell Transplant on or near the first day of the study, which is consistent with the stated expert claim.</s>",
        "contradict": "In the primary trial Intervention 1, the Stem Cell Transplant is given on Day 0. In contrast, in the secondary trial, Intervention 1, the Stem Cell Transplant occurs about 14-21 days after the administration of Samarium 153-EDTMP. These schedules do not align, contradicting the statement that both trials give their patient cohorts Stem Cell Transplants on the first day of the study.</s>"
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "The secondary trial and the primary trial don't give their patient cohorts Stem Cell Transplants on the first day of the study.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Stem Cell Transplant is given on Day 0, which is not the first day of the study as the interventions start on Days -6 through -3. \n\nIn the secondary trial, Stem Cell Transplant is performed about 14-21 days after Samarium 153-EDTMP administration, clearly not on the first day of the study. \n\nTherefore, the statement is entailed by the information present in both CTRs, as neither trial administers Stem Cell Transplants on the first day of the study.</s>",
        "contradict": "The expert's statement contradicts the information in the primary trial CTR, as it explicitly states that the Stem Cell Transplant in the primary trial occurs on Day 0, which is the first day of the study for that patient cohort. However, the secondary trial CTR describes that the Stem Cell Transplant occurs about 14-21 days after the Samarium 153-EDTMP administration, implying that it is not on the first day of the study for that patient cohort. This discrepancy between the two trials leads to the contradiction.</s>"
    },
    "67a628d7-d883-44b9-b351-901f20fd5d0a_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429182",
        "Secondary_id": "NCT00429507",
        "Statement": "Stem Cell Transplants on the first day of the study were given to the patient cohorts of the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "In both trials, the stem cell transplant is administered on Day 0. (Primary Trial: \"Stem Cell Transplant on Day 0.\") (Secondary Trial: \"Stem Cell Transplant Day 0,\" about 14-21 days after Samarium 153-EDTMP.) Therefore, the statement that \"Stem Cell Transplants on the first day of the study were given to the patient cohorts of the secondary trial and the primary trial\" is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Stem Cell Transplants on the first day of the study were given to the patient cohorts of the secondary trial and the primary trial\" is contradicted by the information present in the CTRs because, in the primary trial, stem cell transplant is given on Day 0 which is after the administration of the chemotherapy drugs (Carboplatin, Thiotepa, and Cyclophoshamide) on days -6 to -3, while in the secondary trial, stem cell transplant is given about 14-21 days after the administration of Samarium 153-EDTMP on Day 1.</s>"
    },
    "78c60212-28f7-4306-9f63-549be04687b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patients in cohort 1 of the primary trial\" can be entailed by the information in the CTRs since the data shows that Leukopenia occurred in 0.35% (8/2264) of patients and Anaemia occurred in 0.35% (8/2264) of patients, which individually exceeds the 1% threshold when considering each adverse event separately.</s>",
        "contradict": "The statement \"Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patient in cohort 1 of the primary trial\" contradicts the information present in the CTR for the following reasons:\n\n1. The statement claims that only Leukopenia and Anaemia occurred in more than 1% of patients, while the CTR states that Febrile neutropenia and Neutropenia also occurred in more than 1% of patients (5.17% and 4.33%, respectively).\n2. The statement implies that the adverse events were limited to the patients in cohort 1 of the primary trial, but the CTR reports the adverse events for the entire cohort of 2264 patients.</s>"
    },
    "a72e1259-50be-48e5-bdf8-296040cbf7ce": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the primary CTR's exclusion criteria, which include AST > 2.5 times ULN as an exclusion factor. However, the secondary CTR does not specify a limit for AST in its inclusion criteria. Therefore, patients with elevated AST levels, more than 2 times the upper limit of normal, are excluded from the secondary trial but could potentially meet other inclusion criteria of the primary trial, making the statement consistent with the information present in both CTRs.</s>",
        "contradict": "The statement that \"Patients with aspartate aminotransferase (AST) more than 2 times the upper limit of normal are excluded from both the secondary trial but eligible for the primary trial\" is contradictory to the information provided in the CTRs as follows:\n\nFor the primary trial: The exclusion criteria state \"AST > 2.5 times the upper limit of normal (ULN)\", which is more stringent than the statement that \"AST more than 2 times the ULN\" is an exclusion criterion for the secondary trial but not the primary trial.\n\nFor the secondary trial: The inclusion and exclusion criteria for AST are clearly defined as \"AST 2.5 times ULN (5 times ULN in the presence of liver or bone metastases)\" for inclusion, and \"AST > 2.5 times ULN\" for exclusion. This directly contradicts the statement that \"AST more than 2 times the ULN\" is an exclusion criterion for the secondary trial but not the primary trial.\n\nTherefore, the provided statement is inconsistent with the information present in the CTRs.</s>"
    },
    "19cfd511-8582-4116-8d51-7ec4a6221022": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "0/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"0/49 the primary trial Participants had a Maximum change from baseline in QTcF of <60ms\" is entailed by the CTR's statement \"Maximum change from baseline in QTcF: >60 ms: 0 % (0 participants)\" in the DS-8201a arm. Since there were no participants in the primary trial who experienced a maximum change in QTcF exceeding 60 ms, it follows that all participants had a maximum change below 60 ms, as stated in the expert's claim.</s>",
        "contradict": "The statement \"0/49 the primary trial Participants With HER2-expressing Metastastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of <60ms\" contradicts the information in the CTR, as stated in Results 1, which reports that 0 participants had a maximum change from baseline in QTcF greater than 60 ms. However, no data is presented concerning maximum changes from baseline in QTcF less than 60 ms. Therefore, the statement goes beyond the information provided in the CTR by making a claim that no participants had changes greater than 60 ms, while the CTR only reports that no participants had changes greater than 60 ms among those with maximum changes. The statement is not an entailment of the information in the CTR.</s>"
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.",
        "Label": "Entailment",
        "entail": "The expert's statement \"According to the results of the primary trial, the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary CTR, it is mentioned that the phase I portion of the trial aims to determine the Maximum Tolerated Dose (MTD) of dasatinib in combination with weekly paclitaxel.\n2. The results section of the primary CTR indicates that the phase II portion of the trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel, but it does not specify the MTD.\n3. However, the results section states that the phase I portion used a dose escalation schedule, and the next cohort tested dasatinib with a different schedule when 2 DLTs occurred in the first cohort. This indicates that the MTD was determined and exceeded in at least one cohort.\n4. The results section further states that the overall number of participants analyzed was 15. Given that the trial followed a standard 3-patient per cohort scheme, and the first cohort had 0 DLTs, it can be inferred that the MTD was likely determined in the second or subsequent cohorts.\n5. The statement by the expert that \"the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg\" falls within the range of doses tested in the trial, as the dosage of dasatinib given was 120 mg.\n\nThus, the expert's statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"According to the results of the primary trial, the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg\" contradicts the CTR information in several ways:\n\n1. The CTR does not explicitly state the MTD of dasatinib in combination with weekly paclitaxel as being 120 mg.\n2. The CTR states that the phase I portion of the study is to determine the MTD, and no definitive statement about the MTD has been made yet.\n3. The CTR describes a dose escalation schedule and mentions that a dose level might need to be altered if dose-limiting toxicities occur.\n\nTherefore, the expert's statement is premature and contradicts the information provided by the CTR.</s>"
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately isn't 120 mg.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the CTRs, as it asserts that the MTD of dasatinib is approximately not 120 mg, while the CTRs describe the testing of the MTD of dasatinib at 120 mg in combination with weekly paclitaxel. However, the expert statement could be considered entailed if it is interpreted as expressing an expectation or prediction about the outcome of further trials or data analysis, based on the information provided in the CTRs about the occurrence of dose-limiting toxicities and the potential for testing alternative dosing schedules. In this case, the expert statement implies that the MTD of dasatinib in combination with weekly paclitaxel may be determined to be different from 120 mg based on the results of the ongoing or future phases of the trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTR as it asserts that the MTD of dasatinib in combination with weekly paclitaxel is not 120 mg, while the CTR clearly states that the dosage of dasatinib used in the trial is 120 mg.</s>"
    },
    "3f012bd3-bb89-414b-9dd9-35cef524a69a_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820170",
        "Statement": "The MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg according to the results of the primary trial.",
        "Label": "Entailment",
        "entail": "The MTD of dasatinib in the primary trial was determined through a dose escalation schedule in which the maximum dose at which no more than two dose-limiting toxicities (DLTs) were observed was identified. The statement that \"The MTD of dasatinib in combination with weekly paclitaxel is approximately 120 mg\" is consistent with this finding, as the results section of the primary CTR indicates that the maximum tolerated dose was 120 mg of dasatinib when given in combination with weekly paclitaxel. This information can be entailed by the CTR, as the CTR provides the specific details of the dose escalation schedule and its outcomes, leading to the determination of the MTD.</s>",
        "contradict": "The statement made by the clinical trials expert is not contradictory to the CTR information, but it is important to note that the statement only approximates the MTD based on the results of the primary trial, whereas the CTR specifies the initial dose level tested for the determination of the MTD. The statement does not explicitly mention that it is referring to the initial dose level in the trial, leading to a potential ambiguity. However, the statement is harmonious with the CTR as both suggest that the MTD of dasatinib in combination with weekly paclitaxel is in the range of 120 mg.</s>"
    },
    "5eafb3a1-473a-4270-848d-173e5dca9466": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial\" is not directly entailed by the information present in the CTRs. The exclusion criteria mentioned in the CTRs do not include Leukemia, Hepatitis, or Cataracts as specific exclusion criteria. The CTR only lists specific conditions related to letrozole therapy, laboratory tests, cardiovascular conditions, and other medical or psychiatric conditions as exclusion criteria. Hence, the statement goes beyond the information provided in the CTRs.</s>",
        "contradict": "The statement \"Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial\" is contradicted by the information present in the CTRs because none of these conditions are explicitly listed as exclusion criteria. Although Hepatitis is mentioned as a criterion for adequate liver function evaluation, it doesn't mean that patients with a history of Hepatitis are excluded from the study. Similarly, Leukemia and Cataracts are not mentioned as exclusion criteria in the provided CTRs.</s>"
    },
    "ed956644-5228-4915-b706-1cedb0462577": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial\" is entailed by the information presented in the CTRs. This is because the CTR for the primary trial explicitly states that \"Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist\" (INTERVENTION 1 in the primary CTR), while there is no mention or implication of hypnotherapy in the secondary CTR (INTERVENTION 1 in the secondary CTR). Consequently, the assertion that hypnosis is used exclusively in the primary trial and not in the secondary trial aligns with the given information.</s>",
        "contradict": "The statement \"the primary trial participants are treated with hypnosis, this is not used at all in the secondary trial\" is contradicted by the information in the CTRs because the primary trial uses hypnotherapy as an intervention, while the secondary trial uses Digital Breast Tomosynthesis (DBT) and Digital Mammography as interventions, and there is no mention or indication of the use of hypnosis in the secondary trial.</s>"
    },
    "ed956644-5228-4915-b706-1cedb0462577_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "The primary trial participants are treated with hypnosis, this is used at all in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial participants are treated with hypnosis, this is used at all in the secondary trial\" is not entailed by the provided CTRs information. The primary trial involves patients undergoing hypnotherapy sessions, while the secondary trial focuses on different interventions: Digital Breast Tomosynthesis and Digital Mammography. No mention of hypnosis being used in the secondary trial is present in the given CTRs.</s>",
        "contradict": "The statement \"The primary trial participants are treated with hypnosis, this is used at all in the secondary trial\" is contradicted by the information present in the CTRs because the secondary trial does not involve the use of hypnosis as an intervention. Instead, it employs Digital Breast Tomosynthesis and Digital Mammography as interventions.</s>"
    },
    "ed956644-5228-4915-b706-1cedb0462577_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "The secondary trial does not use hypnosis, but the primary trial does.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial does not use hypnosis, but the primary trial does\" is entailed by the information present in the CTRs because the primary trial explicitly states that patients in the hypnotherapy arm will undergo three one-hour sessions with a certified hypnotherapist, while the secondary trial does not mention the use of hypnotherapy in its intervention section.</s>",
        "contradict": "The statement \"The secondary trial does not use hypnosis, but the primary trial does\" is contradictory to the information provided in the CTRs. The first CTR states that Intervention 1 in the primary trial involves the use of hypnotherapy. The second CTR, on the other hand, does not mention the use of hypnosis in the secondary trial, but it does not explicitly state that hypnosis is not used. The absence of information on hypnosis usage in the secondary trial does not necessarily entail its absence. Therefore, the expert's statement contradicts the information in the CTRs by implying that no hypnosis was used in the secondary trial without definitive proof to support that claim.</s>"
    },
    "02158762-9490-46a1-b494-0589885fd4ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any cardiac related adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial does not record any cardiac related adverse events\" is entailed by the CTR data as none of the listed cardiac adverse events (myocardial infarction, pericardial effusion, tachycardia, acute myocardial infarction, and atrial fibrillation) are reported with frequencies greater than zero in the \"Primary Trial: Adverse Events 1\" section. Similarly, the absence of these events in \"Secondary Trial: Adverse Events 2\" section further supports the statement. The frequency of all other adverse events, including non-cardiac ones (such as febrile neutropenia, neutropenia, anemia, and thrombocytopenia), is present and accounted for in the CTRs, making the statement true based on the given information.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as the primary trial report records at least one instance of acute myocardial infarction (0.22%) and atrial fibrillation (0.45%) under adverse events.</s>"
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial had a higher occurrence rate of fistula enterovesical than the secondary trial\" is not directly entailed by the information provided in the CTRs. While the primary trial had one instance of fistula enterovesical out of 74 participants (1.35%), the secondary trial had none. Therefore, the primary trial had a higher occurrence rate of this adverse event. However, it's essential to note that a single occurrence in one trial and no occurrences in another doesn't necessarily indicate that the first trial had a higher occurrence rate, as the number of participants in each trial differed significantly. To establish entailment, a more robust comparative analysis considering the sample sizes and statistical significance would be required.</s>",
        "contradict": "The statement is contradicted by the CTR information as the primary trial report does not show a higher occurrence rate of fistula enterovesical compared to the secondary trial. In the primary trial report, the occurrence rate of fistula enterovesical is 1/74 (1.35%), and in the secondary trial report, it is 2/50 (4.00%). However, the statement suggests that the primary trial has a higher occurrence rate of this adverse event than the secondary trial.</s>"
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "The primary trial didn't have a higher occurrence rate of fistula enterovesical than the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial didn't have a higher occurrence rate of fistula enterovesicular than the secondary trial\" can be entailed by the information present in the CTRs because the number of cases of fistula enterovesicular reported in the primary trial (1/74, or roughly 1.35%) is not higher than the number reported in the secondary trial (2/50, or roughly 4.00%). In other words, the secondary trial had a higher incidence of this adverse event. Therefore, the statement that the primary trial did not have a higher occurrence rate is consistent with the data in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR information due to the following: \n\n1. The primary trial reported one (1.35%) instance of fistula enterovesical, while the secondary trial reported two (4.00%) instances of this adverse event. Therefore, the secondary trial has a higher occurrence rate of fistula enterovesical than the primary trial.\n\n2. The statement asserts that the primary trial didn't have a higher occurrence rate of fistula enterovesical than the secondary trial, which contradicts the CTR data.</s>"
    },
    "c0a8e1a0-cbe6-4240-b578-59afa4d6cf23_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "The secondary trial has a lower occurrence rate of fistula enterovesical than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial has a lower occurrence rate of fistula enterovesical than the primary trial\" is entailed by the information present in the CTRs, as the primary trial reports one occurrence of fistula enterovesical out of 74 participants (1.35%) and the secondary trial does not report any occurrence of this adverse event out of its 50 participants (0%). Therefore, the secondary trial having a lower occurrence rate of fistula enterovesical than the primary trial can be logically inferred from the presented data.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs because neither trial reports an instance of fistula enterovesical in the secondary trial. Thus, the statement makes an unwarranted comparison between the occurrence rates of this specific adverse event between the two trials.</s>"
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear.",
        "Label": "Entailment",
        "entail": "The statement \"dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are not made clear\" is entailed by the information in the CTRs because:\n\n1. The CTR for the primary trial provides the type of intervention for each arm but does not specify the exact dosages.\n2. The CTR for the secondary trial also mentions the intervention type (Letrozole), but in addition, it explicitly states that \"Letrozole of 12.5 mg/day is given for three successive days.\"\n3. The statement is harmonious with the CTRs, as it points out a difference between the level of detail regarding dosages in the two trials.\n4. The statement does not contradict the descriptions given in the CTRs, as it only makes an observation about the difference in the level of detail between the two trials.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because for the primary trial, where two interventions are involved (Lidocaine Patch and Placebo Patch), the dosage information is not provided in the given text. Hence, it cannot be directly compared or contrasted with the dosage information in the secondary trial regarding Letrozole.</s>"
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "Dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are made clear.",
        "Label": "Contradiction",
        "entail": "The statement \"Dosages are specified in the intervention section of the secondary trial, whereas for the primary trial these are made clear\" is entailed by the information in the CTRs because:\n\n1. In both the primary and secondary trials, the intervention sections explicitly state that one patch is applied topically for 12 hours each day. This detail does not concern dosage in the conventional sense, as it refers to the application of a patch rather than the intake of a substance. However, it indicates that both trials involve consistent application regimens, which sets the stage for further dosage discussion.\n\n2. The expert's statement acknowledges that dosages are specified for the secondary trial, which is accurate as per the CTR for the secondary trial, where Letrozole, a specific drug, is mentioned and its dosage is stated.\n\n3. The expert's statement also mentions that dosages are made clear for the primary trial, which is true based on the information given in the CTR for the primary trial, where the type of patch (Lidocaine), as well as the duration and frequency of application, are stated. Although not explicitly labeled as a \"dosage,\" the consistent and detailed instructions for the application of the Lidocaine patch can be inferred as specifying an effective dose.\n\n4. Overall, the expert's statement is consistent with the information in the CTRs, as both trials include intervention sections with clear application instructions. The expert's statement does not contradict the CTRs and adds no new information, thus it is entailed by the given data.</s>",
        "contradict": "The expert's statement does not directly contradict the information provided in the CTRs. However, it can be misleading since the statement implies a comparison between dosages in the primary and secondary trials. Yet, the primary trial involves the use of a lidocaine patch and doesn't mention any specific dosage. This lack of information makes it impossible to make a direct comparison with the stated dosage information from the secondary trial. Therefore, while the statement is not contradictory, it may lead to erroneous interpretations if taken out of context.</s>"
    },
    "7ec286e9-f519-41da-848d-a0bc5a50c0ee_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT01129622",
        "Statement": "The primary trial does not make dosages clear in the intervention section, whereas the secondary trial does.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial does not make dosages clear in the intervention section, whereas the secondary trial does\" is entailed by the information present in the CTRs since:\n\n1. The primary trial states: \"Lidocaine patch 5% (Lidoderm\u00ae, Endo Pharmaceuticals Inc.): 1 patch was applied topically to the affected site(s) for 12 hours each day,\" but it does not explicitly mention the dosage of Lidocaine in the patch.\n2. The secondary trial states: \"Letrozole of 12.5 mg/day is given for three successive days.\" This statement makes it clear that the dosage of Letrozole is 12.5 mg/day.\n3. The statement \"The primary trial does not make dosages clear in the intervention section, whereas the secondary trial does\" is a comparison of the two trials, implying that the primary trial does not provide explicit dosage information while the secondary trial does. This comparison is entailed by the information in the CTRs.</s>",
        "contradict": "The statement implies that the primary trial lacks clear dosage information in its intervention section, while the secondary trial specifies dosages for its intervention. However, this is not a contradiction as the primary trial is about the use of a Lidocaine patch, which is applied topically without specifying an exact dosage, whereas the secondary trial does not involve a Lidocaine patch but rather administers Letrozole with a specific dosage. The two trials focus on different interventions, making the statement non-contradictory to the CTRs.</s>"
    },
    "d0af59a9-04ae-4922-97eb-dc29f5bc44e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions, however they both require trained Radiologists on site for evaluation.",
        "Label": "Contradiction",
        "entail": "The statement \"both trials require trained Radiologists on site for evaluation\" is entailed by the CTRs as follow:\n\n1. Primary Trial: No explicit mention of a radiologist evaluation in the provided INTERVENTION 1 description. However, there is a RESULTS section that mentions \"MRI scans were conducted at baseline and every 12 weeks for all participants\" (implicitly requiring radiologist participation for MRI scan interpretation). Thus, trained radiologists are implied to be involved in the primary trial.\n\n2. Secondary Trial: The provided INTERVENTION 1 specifies \"Prone to Supine MRI Evaluated by Radiologist A\" and \"Prone to Supine MRI Evaluated by Radiologist B,\" making it clear that trained radiologists are an integral part of this trial's interventions.\n\nBoth trials require radiologist involvement for MRI scan evaluations as per their respective descriptions in the CTRs, aligning with the statement.</s>",
        "contradict": "The statement \"they both require trained Radiologists on site for evaluation\" is not directly contradicted by the information present in the CTRs. However, it may be considered an oversimplification, as the specific roles and functions of Radiologists in both trials differ. In the primary trial, Radiologists are involved in evaluating MRI scans (prone to supine), but the CTR does not explicitly state that this evaluation is part of the intervention or that the Radiologists play the same role in both the Fulvestrant + Anastrozole and Anastrozole arms. In the secondary trial, the involvement of Radiologists also concerns MRI evaluation, but this trial compares the performance of two different Radiologists. Therefore, although the involvement of Radiologists in both trials is a commonality, the statement's broad interpretation may not accurately reflect the precise functions and contexts of their involvement. The statement can coexist with the information from the CTRs, but it may lack the necessary detail to fully capture the nuances of the trials' designs.</s>"
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert is entailed by the primary trial CTR information because the statement's assertion of oral pazopanib administration aligns with the CTR, specifying pazopanib hydrochloride as an orally administered treatment. Additionally, the statement's description of patients receiving pazopanib daily until disease progression or intolerable toxicity mirrors the CTR's statement that patients take pazopanib daily in 28-day courses without interruption for disease progression or unacceptable toxicity. Thus, the statement is substantiated by the provided CTR and does not contradict its content.</s>",
        "contradict": "The statement made by the clinical trials expert can be contradicted by the information present in the CTRs because, in the primary trial, patients do not receive oral pazopanib once daily every day. Instead, they receive it once daily on days 1-28, with courses repeating every 28 days in the absence of disease progression or unacceptable toxicity.</s>"
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": "Patients in the primary trial don't receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the primary trial don't receive oral pazopanib once daily every day, continuing until disease progression or unacceptable toxicity\" can be entailed by the information present in the CTR as follows:\n\nThe CTR indicates that patients receive oral pazopanib once daily, but only on days 1-28. The courses of treatment repeat every 28 days. This means that patients do not take pazopanib every day continuously; instead, they take it for 28 days, then have a 28-day break before starting the next cycle. Therefore, the statement that patients do not receive oral pazopanib once daily every day is consistent with the information in the CTR.\n\nAdditionally, the CTR states that the courses of pazopanib treatment continue only in the absence of disease progression or unacceptable toxicity. This means that if either condition occurs, the treatment is discontinued. The statement that the treatment doesn't continue \"until disease progression or unacceptable toxicity\" is also consistent with this aspect of the CTR.\n\nThus, both aspects of the expert's statement - that patients do not receive daily pazopanib indefinitely and that the treatment is discontinued upon disease progression or unacceptable toxicity - are entailed by the information in the CTR.</s>",
        "contradict": "The statement contradicts the information in the primary CTR because it asserts that patients do not receive oral pazopanib every day continuously until disease progression or unacceptable toxicity, whereas the CTR clearly specifies that patients receive oral pazopanib once daily on days 1-28, and courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The statement's assertion contradicts the dosing schedule detailed in the CTR.</s>"
    },
    "5d4cbb15-ea50-4394-b1b9-ab4553b5b275_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": "Oral pazopanib is given once daily every day in the primary trial, continuing until disease progression or unacceptable toxicity",
        "Label": "Entailment",
        "entail": "The expert's statement \"Oral pazopanib is given once daily every day in the primary trial, continuing until disease progression or unacceptable toxicity\" is entailed by the CTR information as follows:\n\n1. The CTR for the primary trial explicitly states, \"Patients receive oral pazopanib once daily\" (INTERVENTION 1: Treatment).\n2. There is no mention of any particular dosing schedule that deviates from 'once daily' in the CTR.\n3. The CTR also states, \"Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity\" (INTERVENTION 1: Duration). This implies that patients continue receiving pazopanib daily as long as they don't experience disease progression or unacceptable toxicity, making the expert's statement \"continuing until disease progression or unacceptable toxicity\" consistent with the CTR information.</s>",
        "contradict": "The expert's statement that \"Oral pazopanib is given once daily every day in the primary trial, continuing until disease progression or unacceptable toxicity\" is contradicted by the CTR information as follows:\n\n1. In the primary trial's intervention section, it is mentioned that patients receive oral pazopanib once daily on days 1-28, with courses repeating every 28 days in the absence of disease progression or unacceptable toxicity.\n2. This means that the treatment cycle lasts 28 days, and patients restart the treatment after completion, not continuing it daily without interruption as stated in the expert's comment.\n\nHence, the information in the expert's statement contradicts the information in the CTR.</s>"
    },
    "bd51e2f7-05a6-4d1a-b6eb-4f6426eec3d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777049",
        "Statement": "All 4 of the CHF cases in the primary trial, were in cohort 1.",
        "Label": "Contradiction",
        "entail": "The given statement can be entailed by the information in the CTRs as follows: \n\n1. According to the primary CTR, there are a total of 32 participants, and one case of Cardiac Failure Congestive (CHF) is reported. \n2. The CTR further specifies that all adverse events, including CHF, are distributed across cohorts, but the primary CTR does not mention the cohort of the CHF patient.\n3. In the secondary CTR, it is stated that there are 20 participants in total, and no case of CHF is reported. \n4. Therefore, based on the information provided in the primary CTR, it can be inferred that the single CHF case occurred in cohort 1, as the total number of adverse events (12) in the primary trial is greater than the total number of participants (32), implying that some participants had more than one adverse event.\n5. Since the secondary CTR reports no CHF cases, the statement that \"All 4 of the CHF cases in the primary trial, were in cohort 1\" is a reasonable inference from the available data, given that the primary CTR does not contradict this claim.</s>",
        "contradict": "The statement that \"All 4 of the CHF cases in the primary trial, were in cohort 1\" cannot be definitively confirmed or contradicted based on the given CTR information alone. The CTR does not provide enough detail to determine which cohort the specific patients with CHF (Cardiac Failure Congestive) belong to. Therefore, it's not possible to determine if the statement is entailed, inconsistent, or inconclusive based on this data alone.</s>"
    },
    "78a5162d-140a-4631-b776-5c284446b5ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial and the secondary trial have entirely different adverse event profiles.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial have entirely different adverse event profiles\" can be entailed by the information present in the CTRs as the frequency and types of adverse events in the primary trial are notably disparate from those observed in the secondary trial. In the CTR for the primary trial, adverse events were reported in 77.78% of the participants and included various types such as Lymphocytopenia, Neutropenia, Anemia, Thrombocytopenia, Hyperglycemia, Nausea, Diarrhea, Fatigue, Flu-like symptoms, Hot Flashes, AST/ALT elevation, and Arthralgia. In contrast, the secondary trial reported only one case (4.55%) of increased blood bilirubin and one case (4.55%) of increased alkaline phosphatase. These differences in frequency and types of adverse events support the statement that the primary and secondary trials possess distinct adverse event profiles.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have entirely different adverse event profiles\" can be contradicted by the information present in the CTRs if the frequencies or types of specific adverse events are not the only factors considered in determining the adverse event profiles being comparable or different.\n\nFor instance, the primary trial has a larger cohort size compared to the secondary trial, which could result in a higher overall occurrence of adverse events despite the individual frequencies being lower for some adverse events in the primary trial. Additionally, the types of adverse events observed in the primary trial may differ in severity or clinical impact, making a direct comparison more complex.\n\nMoreover, the presence of similar adverse events, albeit at different frequencies, does not necessarily indicate identical adverse event profiles. The clinical significance and implications of these events could still vary between trials.\n\nTherefore, the statement should be evaluated in the context of the complete clinical trial data and the relevant background knowledge of the specific clinical conditions and treatment interventions.</s>"
    },
    "78a5162d-140a-4631-b776-5c284446b5ec_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "The primary trial and the secondary trial don't have entirely different adverse event profiles.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial don't have entirely different adverse event profiles\" can be entailed by the provided CTRs if we consider the following:\n\n1. The term \"entirely different\" suggests that there is no overlap or commonality whatsoever between the adverse event profiles of the two trials.\n2. In the primary trial, several common adverse events were reported, such as gastrointestinal symptoms (nausea, diarrhea), fatigue, and hematologic events (lymphocytopenia, neutropenia, anemia, thrombocytopenia).\n3. In the secondary trial, only two specific adverse events were observed: bilirubin elevation and alkaline phosphatase increase.\n4. The statement is still entailed because none of the adverse events from the primary trial are entirely absent in the secondary trial, even though new adverse events have been reported.\n\nTherefore, the statement can be considered entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"The primary trial and the secondary trial don't have entirely different adverse event profiles\" is contradicted by the information in the CTRs because the types and frequencies of adverse events reported in the primary trial are significantly different from those in the secondary trial. In the primary trial, there are multiple types of adverse events with high occurrence rates (up to 77.78%), such as Lymphocytopenia, Neutropenia, Anemia, Thrombocytopenia, Hyperglycemia, Nausea, Diarrhea, Fatigue, Flu-like symptoms, Hot Flashes, AST/ALT elevation, and Arthralgia. In stark contrast, the secondary trial reports only two types of adverse events, both occurring only once (4.55% each) - Blood bilirubin increased and Alkaline phosphatase increased. This substantial discrepancy in the types and frequencies of adverse events renders the statement \"The primary trial and the secondary trial don't have entirely different adverse event profiles\" as false.</s>"
    },
    "78a5162d-140a-4631-b776-5c284446b5ec_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "The secondary trial and the primary trials have entirely different adverse event profiles",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial and the primary trials have entirely different adverse event profiles\" is entailed by the information present in the CTRs due to the following reasons:\n\n1. The CTRs provide specifics about the adverse events observed in each trial, with different frequencies for various types of adverse events.\n2. The primary trial reports a much higher total number of adverse events (28/36) compared to the secondary trial (1/22).\n3. The types of adverse events differ significantly in the two trials; while the primary trial reports adverse events such as Lymphocytopenia, Neutropenia, Anemia, Thrombocytopenia, Hyperglycemia, Nausea, Diarrhea, Fatigue, Flu-like symptoms, Hot Flashes, AST/ALT elevation, and Arthralgia, the secondary trial only reports Blood bilirubin increased and Alkaline phosphatase increased.\n4. No adverse event mentioned in the secondary trial appears in the primary trial with a frequency above chance level (1/36 or 2.78% for any given adverse event), and vice versa.\n\nTherefore, the statement is a valid conclusion based on the information presented in the CTRs, as the adverse event profiles of the two trials do indeed appear to be entirely different.</s>",
        "contradict": "The information in the statement \"The secondary trial and the primary trials have entirely different adverse event profiles\" can be contradicted by the information present in the CTRs because the frequencies of adverse events differ significantly between the trials. However, having different frequencies of individual adverse events does not necessarily equate to entirely different profiles. The primary trial exhibits a high frequency of several adverse events (77.78% total), while the secondary trial has a very low frequency for all adverse events (4.55% total). Nevertheless, they share some adverse events, such as AST/ALT elevation (present in both). Thus, a more nuanced comparison is required to assess the true implications of the statement.</s>"
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe number of patients with Left ventricular systolic dysfunction in the primary trial is 4, and in the secondary trial is 1. A ratio of 4:1 = 4, and multiplying by 10 gives 40. The number of patients with Left ventricular systolic dysfunction in the primary trial is not 10 times the number in the secondary trial; however, the difference is only one order of magnitude. Since the statement is close enough to the actual difference in patient numbers and does not contradict the information in the CTRs, it can be entailed.</s>",
        "contradict": "The statement \"There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial\" cannot be entailed by the information present in the CTRs because the number of patients with Left ventricular systolic dysfunction in the primary trial was 4/218 (1.83%) and in the secondary trial it was 1/82 (1.22%). A difference of 3 cases is not equivalent to a tenfold difference.</s>"
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There weren't 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial\" can be entailed by the information in the CTRs as follows:\n\nGiven: The frequency of Left ventricular systolic dysfunction in the primary trial is 1.83% (4/218) and in the secondary trial is 1.22% (1/82).\n\nTo prove that there aren't 10x more patients in the primary trial with Left ventricular systolic dysfunction than in the secondary trial, we simply need to check if the ratio of the frequency is less than 10:1.\n\nCalculation: 1.83% \u00f7 1.22% = 1.51 (rounded)\n\nSince 1.51 < 10, this means that there aren't 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial, and the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There weren't 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial\" cannot be definitively determined from the provided Adverse Events data alone. However, it is clear that there is a discrepancy between the occurrence of Left ventricular systolic dysfunction in the two trials: 13 cases in the primary trial (5.70%) compared to 1 case in the secondary trial (1.22%). However, the total number of participants in the two trials is not given in the provided information, making it impossible to determine if there are indeed 10 times more patients in the primary trial overall. Thus, the statement cannot be definitively confirmed or contradicted based on the given Adverse Events data.</s>"
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "The secondary trial has 10x less patients with Left ventricular systolic dysfunction than the primary trial.",
        "Label": "Entailment",
        "entail": "The frequency of Left ventricular systolic dysfunction reported in Adverse Events 1 of the primary trial is 1.83% (4 out of 218), while in the secondary trial it is reported as 1.22% (1 out of 82). The difference in the frequency between the two trials is (1.83% - 1.22%) = 0.61%, which is not equivalent to a factor of 10. Therefore, the statement that \"The secondary trial has 10x less patients with Left ventricular systolic dysfunction than the primary trial\" is not entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The secondary trial has 10x less patients with Left ventricular systolic dysfunction than the primary trial\" cannot be definitively concluded based on the given information from the CTRs. \n\nThe CTRs provide the number of patients with Left ventricular systolic dysfunction in each trial, but they don't give the total number of patients in the secondary trial. Without knowing the total number of patients in the secondary trial, it's impossible to determine if it has 10 times fewer patients with Left ventricular systolic dysfunction than the primary trial.</s>"
    },
    "7c5b29bc-ac37-48bb-abb1-a102174f79ef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21 ",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Cohort 1 and 2 of the primary trial receive 50mg of different drugs, administered orally from Day 1 to Day 21\" is entailed by the CTRs' Intervention sections as follows:\n\n1. Afatinib cohort: \"Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course.\"\n2. Lapatinib cohort: \"Patients received continuous daily dosing with Lapatinib 1500 mg, which is equivalent to 50 mg when considering the difference in molecular weights between Afatinib (507.6 g/mol) and Lapatinib (872.8 g/mol), from Day 1 to Day 21 of each treatment course.\"\n\nThe expert's statement and the CTR data both agree on the drugs being administered orally, the dosages of 50 mg, and the treatment duration from Day 1 to Day 21 for each cohort. Although the drugs are different, the administration method, dosage, and duration match. The only discrepancy is in the drug names, which does not contradict the information in the CTRs and instead only adds additional specificity.</s>",
        "contradict": "Although the statement implies that Cohort 1 and 2 of the primary trial receive different drugs, the information in the CTRs specifies that Cohort 1 receives Afatinib 50 mg and Cohort 2 receives Lapatinib 1500 mg, which are indeed different drugs. However, the contradiction lies in the dosages mentioned - the statement states that each cohort receives 50 mg, while the CTRs detail distinct dosages for each drug.</s>"
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Entailment",
        "entail": "Based on the CTRs, all participants in the Afatinib 50 mg With Letrozole group were progression-free after 16 weeks as indicated by a percentage of 28.57 (3.67-70.96). This group had a total of 7 participants analyzed, and no participants in this group were reported to have disease progression. In contrast, the Afatinib 40 mg With Letrozole group, which had 13 participants analyzed, had no progression-free participants after 16 weeks, as indicated by a percentage of 0.00 (0.00-24.71). Therefore, the statement that \"All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group\" is contradicted by the information in the CTRs as the statement implies that every participant in the Afatinib 50 mg With Letrozole group experienced progression-free status for 16 weeks, while the CTR results show that only a percentage of participants in that group (specifically 28.57%) had progression-free status within the timeframe.</s>"
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a_neg": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Progression Free Participants (After 16 Weeks of Treatment) in the primary trial weren't in the Afatinib 50 mg With Letrozole group.",
        "Label": "Contradiction",
        "entail": "none of the progression-free participants in the primary trial were in the Afatinib 50 mg With Letrozole group based on the information provided in the CTRs because none of the participants in that group were reported as progression-free, with a percentage of 0.00 (0.00-24.71), while all the participants in the other arm, Afatinib 40 mg With Letrozole, had some degree of progression or were withdrawn due to clinical deterioration. Therefore, no progression-free participants were identified in the Afatinib 50 mg With Letrozole group according to the CTR results.</s>",
        "contradict": "The expert's statement contradicts the information presented in the CTR, as there were progression-free participants (2 out of 7 or around 28.57%) in the Afatinib 50 mg With Letrozole group according to Results 1, contrary to the expert's claim that none were progression-free.</s>"
    },
    "b8881e2e-ca25-4c1b-bbd2-281ebdb7514a_rephrase": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "Afatinib 50 mg With Letrozole group were all the Progression Free Participants (After 16 Weeks of Treatment) in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if all participants in the Afatinib 50 mg With Letrozole group in the primary trial were progression-free after 16 weeks of treatment. This is consistent with the results in CTR 1, where 7 out of 7 participants (100%) were reported to have been progression-free with the given percentage of 28.57% (3.67-70.96). Thus, the statement is entailed by the information in CTR 1.</s>",
        "contradict": "The statement \"Afatinib 50 mg With Letrozole group were all the Progression Free Participants (After 16 Weeks of Treatment) in the primary trial\" cannot be definitively concluded from the CTR information. While the Afatinib 50 mg With Letrozole group had a higher percentage of progression-free participants (28.57% or 2 out of 7) compared to the Afatinib 40 mg With Letrozole group (0.00% or 0 out of 13) after 16 weeks, it does not imply that this group consisted entirely of progression-free participants. The statement contradicts the CTR information by implying a stronger entailment than the data supports, potentially oversimplifying the complex nature of clinical trials and their results.</s>"
    },
    "a70cc8e5-0ef5-4045-8fec-d9e7503b5e6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded many more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the CTRs information as follows: The primary trial reported 1 seizure in 38 patients (2.63%), while the secondary trial recorded 0 seizures in 490 patients. The expert's observation is correct, as the primary trial reported more seizures despite having a smaller patient cohort.</s>",
        "contradict": "The statement that \"the primary trial recorded many more seizures despite having less than one tenth the number of patients in its total cohort\" contradicts the information in the CTRs because the CTRs report only one seizure in the primary trial (1/38) and no seizures in the secondary trial (0/490 and 0/488). Therefore, the statement implies a discrepancy in the number of seizures between the two trials without any supporting evidence from the provided data.</s>"
    },
    "e852619c-312a-470f-8b77-149e79f69a3f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts produced better results than the control groups.",
        "Label": "Entailment",
        "entail": "In the primary trial, Arm I (Lapatinib) had a median PFS of 4.7 months (3.7-5.7) compared to 3.8 months (3.8-5.6) in Arm II (Placebo), indicating longer PFS duration in the Lapatinib group.\n\nIn the secondary trial, Cohort 1 receiving Lapatinib + Placebo had 11 participants with Overall Response (OR), while Cohort 1 receiving Lapatinib + Pazopanib 800 mg had 17 participants with OR. Though numbers are not directly comparable due to different measurement scales, both Lapatinib combinations showed a larger number of participants with OR compared to the respective control groups.\n\nTherefore, the claim that \"In both the secondary trial and the primary trial the test cohorts produced better results than the control groups\" can be entailed by the data present in the CTRs.</s>",
        "contradict": "The statement \"In both the secondary trial and the primary trial, the test cohorts produced better results than the control groups\" cannot be definitively concluded from the provided information in the CTRs. The primary trial compares an arm with a combination of lapatinib and fulvestrant to an arm with placebo and fulvestrant, and the secondary trial compares two cohorts with different dosages of lapatinib plus pazopanib. The statement does not specify which trials or arms are being compared, nor does it provide sufficient information to determine if the \"better results\" refer to PFS, OR, or any other outcome measure. Additionally, the CTRs only report medians and confidence intervals for PFS, and numbers of participants with OR, without providing information about the statistical significance or p-values of the differences between the groups. Therefore, based on the provided data, it is not possible to conclude that the test cohorts produced better results in both trials.</s>"
    },
    "e852619c-312a-470f-8b77-149e79f69a3f_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts didn't produce better results than the control groups.",
        "Label": "Contradiction",
        "entail": "Both trials compare two cohorts or arms - one receiving an intervention (Lapatinib in both trials) and another receiving a control (Placebo in the primary trial, and Placebo vs different doses of Pazopanib in the secondary trial). In both trials, the results section provides the median PFS for each arm. In the primary trial, the median PFS for Arm I with Lapatinib is longer (4.7 months [3.7-5.7] vs 3.8 months [3.8-5.6] for Arm II with placebo). Although there is a difference in median PFS, it does not indicate that the Lapatinib cohort produced significantly better results than the placebo group in terms of overall outcome. Instead, the difference in PFS might suggest a trend towards benefit with Lapatinib but not a definitive improvement.\n\nSimilarly, in the secondary trial, the OR results for each cohort (Lapatinib + placebo and Lapatinib + Pazopanib 800 mg) are given, with no significant difference observed in the number of participants achieving OR between the two cohorts (11 vs 17 participants, respectively).\n\nThe expert's statement, \"In both the secondary trial and the primary trial, the test cohorts didn't produce better results than the control groups,\" holds, as the trials did not find statistically significant differences between the Lapatinib (or Lapatinib + Pazopanib 800 mg) and the placebo (or Pazopanib 800 mg alone) arms regarding either PFS or OR.</s>",
        "contradict": "The statement does not take into account the specific outcomes being measured and compared between the test and control groups in each trial. In the primary trial, Arm I (Lapatinib) had a longer median PFS than Arm II (Placebo), suggesting that Lapatinib was effective in delaying disease progression or death. Conversely, in the secondary trial, both Cohort 1 groups had a smaller number of participants achieving overall response (OR) than expected, with no significant difference between the two groups. This does not indicate that neither test cohort produced better results than the control groups, as different outcome measures were used in each trial.</s>"
    },
    "e852619c-312a-470f-8b77-149e79f69a3f_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "the test cohorts produced better results than the control groups in both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR information as follows:\n\n1. In the primary trial, Arm I (Lapatinib) showed a median PFS of 4.7 months (3.7 to 5.7) compared to Arm II (Placebo) with a median PFS of 3.8 months (3.8 to 5.6). A longer PFS indicates better disease control, suggesting that Arm I produced better results than Arm II.\n2. In the secondary trial, the number of participants with OR (CR or PR) in Cohort 1: Lapatinib 1500 mg + Placebo was 11, and in Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg was 17. The larger number of participants with OR in Cohort 1: Lapatinib 1500 mg+Pazopanib 800 mg compared to Cohort 1: Lapatinib 1500 mg+Placebo suggests that the combination therapy yielded better results than the placebo in this secondary trial.\n\nTherefore, the statement \"the test cohorts produced better results than the control groups in both the secondary trial and the primary trial\" can be entailed by the given CTR data.</s>",
        "contradict": "The statement \"the test cohorts produced better results than the control groups in both the secondary trial and the primary trial\" cannot be definitively contradicted by the information presented in the CTRs without further context as the CTRs do not provide sufficient data to compare the results of the test and control groups directly within each trial, let alone across both trials. However, a direct comparison of the median (95% confidence interval) PFS between Arm I (Lapatinib) and Arm II (Placebo) in the primary trial, and Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo and Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg in the secondary trial, would be necessary to evaluate the accuracy of the expert's statement.</s>"
    },
    "27160f45-e4cb-48be-8cf2-c23ced4578c0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total\" is entailed by the CTR data as follows:\n\n1. The CTRs provide the number of adverse events for each category in both the primary and secondary trials.\n2. According to the given CTR data, there are 5 instances of Anaphylaxis in the primary trial for a total of 2788 participants, and 5 instances of Anaphylaxis in the secondary trial for a total of 2800 participants.\n3. The expert's statement asserts that Anaphylaxis was the most common adverse event and that it occurred more than 10 times in total across both trials, which aligns with the CTR data as there are a total of 10 Anaphylaxis cases (5 each from primary and secondary trials).\n\nHence, the expert's statement is an entailment of the CTR data.</s>",
        "contradict": "The statement that \"The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected more than 10 patients in total\" is contradicted by the CTRs as neither CTR reports that Anaphylaxis was the most common adverse event in both cohorts, nor does it indicate that more than 10 patients in total experienced this adverse event across both cohorts. According to the CTRs, the incidence of Anaphylaxis was 5 cases each in Cohort 1 and Cohort 2, totaling 10 cases for the primary trial. However, this does not make it the \"most common\" adverse event, as other categories such as Infections and Infestations, Nervous system disorders, and Thromboembolic events also occurred and had a similar or even higher number of instances.</s>"
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "the secondary trial and the primary trial both accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.",
        "Label": "Entailment",
        "entail": "Both trials include \"HER-2/neu-overexpressing adenocarcinoma of the breast\" as a requirement for patient inclusion. Therefore, the statement is an entailed subset of the information presented in both CTRs.</s>",
        "contradict": "The statement is not entirely contradictory to the CTRs, but it may be misleading because it focuses solely on the acceptance of patients with HER-2/neu-overexpressing breast cancer without specifying the identical HER-2+ status by IHC or FISH, or the absence of prior HER-2-targeted therapy in both trials. The primary trial includes patients with HER-2-negative breast cancer, making it not an exact match for the stated comparison.</s>"
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "The secondary trial and the primary trial both don't accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast.",
        "Label": "Contradiction",
        "entail": "Both trials include the condition of having histologically confirmed HER-2/neu-overexpressing breast cancer as one of their inclusion criteria. Therefore, the statement that the secondary trial and the primary trial both don't accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial does indeed accept patients with HER-2/neu-overexpressing adenocarcinoma of the breast, as stated in their inclusion criteria, contrary to the assertion in the expert's statement.</s>"
    },
    "e4b65e9f-10f6-4424-95d2-837e29587a63_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754325",
        "Secondary_id": "NCT00399529",
        "Statement": "Patients with HER-2/neu-overexpressing adenocarcinoma of the breast are accepted by the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "Both trials include HER-2/neu-overexpressing adenocarcinoma of the breast as an inclusion criterion. In the primary trial, this is defined as HER-2+ by IHC 3+ staining or FISH. In the secondary trial, it is defined as HER-2+ by IHC 3+ staining or FISH. Thus, patients who meet this criterion for the secondary trial also meet it for the primary trial.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because the primary trial only accepts patients with HER-2/neu-overexpressing breast cancer who have progressed during or within 12 months of adjuvant AI treatment or in the advanced setting. The secondary trial also accepts patients with HER-2/neu-overexpressing breast cancer, but it has additional inclusion criteria such as prior adjuvant Trastuzumab therapy and no eligibility for therapy of known curative potential for metastatic breast cancer, among others. The primary trial does not mention these additional criteria and has specific exclusion criteria for HER-2/neu-negative breast cancer that are not present in the secondary trial. Therefore, the statement oversimplifies the acceptance criteria for patients with HER-2/neu-overexpressing breast cancer in the two trials and is contradictory to the more detailed information provided in the CTRs.</s>"
    },
    "68f6f3db-0bfb-4e03-8e2f-92ae5d0f55a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eliglbe for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eligible for the primary trial\" is entailed by the CTR inclusion criteria because the CTR states that \"Any T stage is allowed as long as the N stage is 1 and M stage is 0.\" Thus, patients with the specified T and N stages (T1N2, T2N1, T3N1) meet the N stage requirement and are therefore eligible for the trial according to the CTR.</s>",
        "contradict": "The statement that \"Patients with T1N2M0, T2N1M0, T3N1M1 and TxN1M0 tumors are eligible for the primary trial\" contradicts the inclusion criteria in the CTR as it does not specify that the patients must have pathologic confirmation of metastatic disease in at least one regional lymph node, which is a requirement for eligibility in the primary trial.</s>"
    },
    "7796fe1b-1952-4339-90f3-47b051ebe927": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days.",
        "Label": "Contradiction",
        "entail": "The statement that \"One of the patients in cohort 2 of the primary trial experienced neutropenia persisting for more than 7 days\" can be entailed by the information present in the CTRs as follows:\n\n- In the primary trial, DLTs were defined as grade 4 neutropenia persisting for more than 7 days.\n- The statement indicates that one patient in cohort 2 experienced neutropenia that lasted for more than 7 days, which matches the definition of DLT in the trial.\n- The CTRs do not provide specific information about which patient in either cohort experienced neutropenia lasting more than 7 days, but the statement does not contradict any information in the CTRs. Therefore, the statement is consistent with the CTRs and can be entailed by them.</s>",
        "contradict": "The statement does not provide sufficient information to establish a contradiction with the CTRs. While it mentions neutropenia persisting for more than 7 days in one patient from cohort 2 in the primary trial, it does not specify which arm of the trial (E7389 with weekly Trastuzumab or E7389 with tri-weekly Trastuzumab) the patient belonged to. The CTRs provide separate data for both arms, and without further context, it's impossible to determine if the patient's experience contradicts the information in the CTRs, as the DLT definitions and evaluation timelines are the same for both arms according to the given information.</s>"
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "the primary trial and the secondary trial do not record any of the same adverse events.",
        "Label": "Entailment",
        "entail": "None of the listed adverse events in Trial 1 (Disseminated intravascular coagulation, Death NOS, Edema limbs, Fatigue, Hepatic failure, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood bilirubin increased, Ejection fraction decreased) appear in Trial 2, and vice versa. The stated condition of no common adverse events is a logical consequence of the given data in Adverse Events 1 for both trials.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not record any of the same adverse events\" can be contradicted by the information present in the CTRs because the primary trial recorded one instance each of Alanine aminotransferase increased, Aspartate aminotransferase increased, and ejection fraction decreased as adverse events, while the secondary trial recorded one instance each of Alanine aminotransferase increased, Aspartate aminotransferase increased, and renal failure as adverse events. These are three adverse events that are recorded in both trials, despite the statement implying that no common adverse events are recorded between the two trials.</s>"
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "The primary trial and the secondary trial do record any of the same adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial and the secondary trial do not record the same adverse events\" is entailed by the information present in the CTRs if none of the adverse events from the Primary Trial are recorded in the Secondary Trial. The absence of any shared adverse events between the two trials in the provided CTRs supports this claim.</s>",
        "contradict": "Despite the statement's assertion that the primary and secondary trials do not record any of the same adverse events, this claim is contradicted by the presence of shared adverse events in both trials. In the primary trial, there is one instance each of \"Ejection fraction decreased\" and \"Alanine aminotransferase increased,\" which also appear in the secondary trial with the same description. Therefore, the trials do record at least two of the same adverse events, rendering the statement false.</s>"
    },
    "c7df7b38-068b-48a8-b805-b8ebb3e854e6_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Secondary_id": "NCT00570921",
        "Statement": "None of the same adverse events are recorded by the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The given statement does not directly entail information from the CTRs as it makes a comparison between thetwo trials and requires additional information not explicitly provided. However, the statement can be entailed indirectly if we assume that the trials involve the same treatments and patient populations. In this context, the absence of identical adverse events in both trials implies that none of the adverse events listed in the primary trial are present in the secondary trial, which is consistent with the information in the CTRs. Therefore, the statement is entailed if we make this assumptions.\n\nHowever, it is important to note that without further information, it cannot be definitively established whether the assumption is valid or not. For example, if the trials involve different treatments or patient populations, the statement may not hold true. Thus, while the assumption makes the statement entailed given the information in the CTRs, it does not follow directly from the provided data.</s>",
        "contradict": "The statement \"None of the same adverse events are recorded by the primary trial and the secondary trial\" can be contradicted by the information present in the CTRs if there are common adverse events, but they have different frequencies or occur in different participants between the two trials. For instance, if the same adverse event is present in both trials, but its frequency or incidence is different (e.g., edema limbs with 0.00% in the primary trial and 4.55% in the secondary trial), or if it affects different participants (e.g., Disseminated intravascular coagulation occurred in one patient in the primary trial and another patient in the secondary trial), then the statement would not hold.</s>"
    },
    "39227bbb-0e26-4ba0-94a7-762376541889": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multi-focal breast cancer cannot be accepted for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"patients with Multi-focal breast cancer cannot be accepted for the primary trial\" is entailed by the information in the CTRs because the CTRs explicitly list multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm) as an exclusion criterion for the primary trial. Therefore, the statement that multifocal breast cancer patients cannot participate in the trial is a logical consequence of the given criteria.</s>",
        "contradict": "The statement \"patients with Multi-focal breast cancer cannot be accepted for the primary trial\" contradicts the CTR inclusion criteria as multi-focal breast cancer is not listed as an exclusion criterion. The CTR states that patients with breast cancer in different quadrants or tumors separated by less than 4 cm are excluded, but it does not specify that patients with multi-focal breast cancer, defined as having cancer in multiple areas of the same breast, are excluded.</s>"
    },
    "39227bbb-0e26-4ba0-94a7-762376541889_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "Patients with Multi-focal breast cancer can be accepted for the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement does not follow from the information in the CTRs as the CTRs explicitly exclude patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Multifocal breast cancer refers to the presence of two or more discrete foci of cancer in the same quadrant, whereas multicentric cancer refers to the presence of multiple distinct primary tumors in different quadrants or locations within the same breast. Therefore, the statement contradicts the CTR's exclusion criteria. Consequently, there's no entailment relationship between the statement and the given information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTR inclusion criteria which explicitly states that patients with multicentric carcinoma, defined as tumors in different quadrants of the breast or tumors separated by at least 4 cm, are excluded from the primary trial. Therefore, patients with multi-focal breast cancer (which can also be considered as a form of multicentric carcinoma) are not eligible for participation in the primary trial according to the provided CTR.</s>"
    },
    "39227bbb-0e26-4ba0-94a7-762376541889_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "The primary trial excludes patients with multi-focal breast cancer.",
        "Label": "Entailment",
        "entail": "The term \"multicentric carcinoma\" in the CTR refers to tumors in different quadrants of the breast or tumors separated by at least 4 cm. Therefore, the statement that the primary trial excludes patients with multi-focal breast cancer is entailed by the information present in the CTR, which explicitly lists multicentric carcinoma as an exclusion criterion.</s>",
        "contradict": "The statement \"The primary trial excludes patients with multi-focal breast cancer\" can be contradicted by the information in the CTR as the CTR explicitly lists \"multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm\" in the exclusion criteria. However, this does not necessarily mean that all forms of multi-focal breast cancer are excluded, as this statement only mentions tumors in different quadrants or separated by at least 4 cm, which might not capture all instances of multi-focal breast cancer.</s>"
    },
    "fdb7afc0-ef7e-44bf-bfe3-5252fa8b0106": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Secondary_id": "NCT02679755",
        "Statement": "the primary trial and the secondary trial have a different number of cohorts.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as both reports describe separate trials with distinct cohorts for each intervention arm. In the primary trial, there are two intervention groups: Intervention 1 and Intervention 2, while in the secondary trial, there are also two intervention groups: Palbociclib+Letrozole India Cohort and Palbociclib+Letrozole Australia Cohort. The number of cohorts is different in each trial, with the primary trial having two intervention groups and the secondary trial having two distinct cohorts within each intervention group.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have a different number of cohorts\" is contradictory to the information present in the CTRs because both the primary and secondary trials have only one intervention arm each. The primary trial consists of two interventions, an agenda setting checklist and usual care, but it still has only one cohort receiving these interventions. Similarly, both the Palbociclib+Letrozole India and Palbociclib+Letrozole Australia cohorts in the secondary trial represent a single cohort receiving the same interventions (Palbociclib and Letrozole) with minor differences in dosing information. Therefore, the statement is incorrect as the trials do not have different numbers of cohorts, but rather different intervention details within a single cohort for each trial.</s>"
    },
    "fd15ddaf-1abc-4551-a5b3-08217b975e36": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02321527",
        "Statement": "Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial\" can be entailed by the information present in the CTR, as there is no explicit maximum diameter limit mentioned in the inclusion criteria. However, the minimum diameter limit is stated as \"invasive breast cancer <5 cm in maximal dimension by Ultrasound or Mammography,\" implying that larger diameters (greater than 5 cm) are also within the scope of the trial. Thus, the statement does not contradict the information in the CTR and is a valid inference based on the given criteria.</s>",
        "contradict": "The statement \"Patients with invasive breast cancer with a diameter of more than 70mm are included in the primary trial\" is contradicted by the CTRs' Eligibility Criteria, which specify a maximal diameter of 5 cm for invasive breast cancer in order to participate in the study.</s>"
    },
    "067f4671-0720-4980-a0fa-8d01d31daa9a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Secondary_id": "NCT01421017",
        "Statement": "As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results.",
        "Label": "Contradiction",
        "entail": "The statement \"As the primary trial and the secondary trial use very similar outcome metrics, we can easily compare and contrast across their results\" can be entailed by the information present in the CTRs since both trials utilize the same type of outcome measurements - systemic tumor response rates for the primary trial and proportion of tumors responding for the secondary trial. The primary trial measures EGFR expression, while the secondary trial measures response rates in the context of specific treatments (RT, IMQ, and CTX/IMQ/RT), but both trials provide enough information for comparison by stating the number of participants and response proportions. The similarities in outcome metrics and reporting formats allow for the comparison and contrast stated by the expert.</s>",
        "contradict": "The expert's statement assumes similarity in the outcome metrics between the primary and secondary trials based on the mentioned outcome measurements: EGFR expression levels and systemic tumor response rates. However, the primary trial's outcome measurement is focused on EGFR expression levels, while the secondary trial measures systemic tumor response rates. Though both trials may report response rates, they assess different aspects of treatment efficacy. Therefore, a direct comparison between their results would not provide valid insights.</s>"
    },
    "026e7eb7-37fd-4aae-b74f-dacf905db262": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02366130",
        "Secondary_id": "NCT01262027",
        "Statement": "the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial .",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if we compute the ratio of the total adverse events in the Primary Trial to those in the Secondary Trial: \n\n28/36 (77.78%) vs. 1/22 (4.55%)\n\nThe ratio is approximately 16.78:1. Given that the number 10 is greater than 16.78, the statement \"the primary trial reported more than 10 times the number of patients experiencing adverse events as the secondary trial\" is a stronger claim than the actual data. However, since there is no contradiction with the data, the statement is still entailed by the information in the CTRs.</s>",
        "contradict": "The given statement can be contradicted by the CTR information due to the significant difference in the total number of patients between the two trials (36 in the primary trial and 22 in the secondary trial) and the composition of adverse events. The statement implies that the number of patients with adverse events in the primary trial was at least 10 times that in the secondary trial, which is not the case based on the data provided. Instead, the proportion of patients with adverse events is much higher in the primary trial compared to the secondary trial, but the absolute number of affected patients in the primary trial is not 10 times larger than that in the secondary trial.</s>"
    },
    "a79fc503-215f-40d4-9cc1-e101cec3a9c9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criterion of an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 indicates that patients have the ability to carry on all pre-disease activities without restriction. Thus, the statement that patients who are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial is entailed by the information in the CTR.</s>",
        "contradict": "The expert's statement is contradictory to the CTR as it fails to consider patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, who can still carry on all pre-disease activities with some restrictions. The primary trial inclusion criteria explicitly state this condition.</s>"
    },
    "ee5f95d0-3824-4ce4-bf58-1ecd3ce4e7ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial measured the Number of Participants With Disease Progression (PD) or Death, to evaluate the performance of its interventions.",
        "Label": "Contradiction",
        "entail": "Both trials measure number of participants with progressive disease (PD) as an outcome, which is explicitly stated in the primary trial's outcome measurement section and can be inferred from the results section where participants with PD are identified. The expert's statement also mentions \"death,\" but the CTRs do not provide information about it, so the entailment only holds for the number of participants with PD.</s>",
        "contradict": "The statement made by the clinical trial expert does not directly contradict the information presented in the CTRs. However, it does not fully capture the complexity of the data provided. While it is true that the primary trial evaluated the number of participants with disease progression or death, the CTRs also report other outcomes such as Complete Response (CR), Partial Response (PR), Long Stable Disease (SD), and Stable Disease (SD). These outcomes are important for understanding the efficacy and safety of the interventions being tested in the trials. The statement does not acknowledge the presence of these additional outcomes, and therefore, is not a complete representation of the information contained in the CTRs.</s>"
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of cardiac tamponade in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were no cases of cardiac tamponade in the primary trial or the secondary trial\" is entailed by the information in the CTRs because the number of cases of cardiac tamponade reported in both trials is zero in each Adverse Events section.</s>",
        "contradict": "The statement \"There were no cases of cardiac tamponade in the primary trial or the secondary trial\" is contradicted by the information present in the CTRs because, in the primary trial, the number of cases of cardiac tamponade is reported as 0 out of 3 (0.00%) in Adverse Events 1, and in the secondary trial, it is reported as 0 out of 23 (0.00%) in Adverse Events 1. However, the statement asserts that there were no cases of cardiac tamponade in both trials, which contradicts the reported data.</s>"
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were cases of cardiac tamponade in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were cases of cardiac tamponade in the primary trial or the secondary trial\" can be entailed by the information present in the CTRs as neither trial reported any cases of cardiac tamponade with a total of 58 participants in each trial (3 in Primary and 23 in Secondary). However, the statement does not provide information about which trial had these cases, so it only entails that there is a possibility of cardiac tamponade occurring in either trial, but not that it definitively did. The CTRs do not contradict this statement as they do not report that there were absolutely no cases of cardiac tamponade across both trials.</s>",
        "contradict": "The statement \"There were cases of cardiac tamponade in the primary trial or the secondary trial\" contradicts the information in the CTRs since neither trial reported any cases of cardiac tamponade in their respective adverse event sections.</s>"
    },
    "7a9fa9d8-8b71-4df3-918f-0f8e8ecb4b0a_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "Both tirals have no cases of cardiac tamponade.",
        "Label": "Entailment",
        "entail": "The statement \"Both trials have no cases of cardiac tamponade\" can be entailed by the information present in the CTRs because the Adverse Events sections of both trials report zero instances of cardiac tamponade for each trial. Thus, the statement aligns with the clinical trial data, finds substantiation in the CTRs, and does not contradict the provided descriptions.</s>",
        "contradict": "While the statement that \"both trials have no cases of cardiac tamponade\" is true when comparing the number of reported instances of cardiac tamponade in Adverse Events 1 and 2 across both trials, it overlooks the fact that the total number of participants differs between the trials (3 for the first trial and 23 for the second, 32 for the second trial). The percentage of participants experiencing adverse events in each trial is not the same. Therefore, even though neither trial reports any instances of cardiac tamponade for the sections provided, the statement can be misleading if taken out of context without considering the differing sample sizes.</s>"
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial does not specify a specific dosage or frequency for its intervention\" is entailed by the information present in the CTRs because both INTERVENTION 1 (AB-101) and INTERVENTION 2 (Placebo) in the primary trial only mention the application time, without specifying dosage or frequency details. Similarly, the statement is also consistent with the information in the secondary trial's INTERVENTION 1 (Letrozole), which mentions the dosage (2.5 mg/day) but not the application frequency. Therefore, the given statement does not contradict the provided descriptions and is harmonious with the clinical trial data.</s>",
        "contradict": "The statement \"Unlike the secondary trial, the primary trial does not specify a specific dosage or frequency for its intervention\" is contradictory to the information present in the CTRs because, for the primary trial, it is stated in the INTERVENTION section that AB-101 is to be applied to both nipple/areola regions approximately 1 hour prior to sexual activity, without any specification of dosage or frequency. However, this does not mean that the primary trial doesn't have any dosage or frequency information, it simply isn't stated in the provided text. Therefore, the statement is not an entailed consequence of the CTR information.</s>"
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "Unlike the secondary trial, the primary trial specifies a specific dosage or frequency for its intervention.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial specifies a specific dosage or frequency for its intervention\" entails that the primary trial provides detailed information about how AB-101 (INTERVENTION 1) is to be administered, namely \"Apply to both nipple/areola regions approximately 1 hour prior to sexual activity.\" This level of detail regarding application time frames for the intervention aligns with the definition of specifying a \"specific dosage or frequency.\" \n\nHowever, in the CTRs, this level of detail is present not only for Intervention 1 (AB-101), but also for Intervention 2 (Placebo): \"Apply to both nipple/areola regions approximately 1 hour prior to sexual activity\" and \"Placebo: Apply approximately 1 hour prior to sexual activity.\" \n\nGiven that both interventions share the same application instructions, the primary trial's requirement for specifying a \"specific dosage or frequency\" is met, and it is entailed in the information provided in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information present in the CTRs. However, it makes a comparison between the primary and secondary trials, implying that the primary trial has a more detailed intervention specification than the secondary trial. However, the primary trial does specify a timeframe for the application of AB-101 and placebo, but it does not provide detailed information about the dosage or frequency of application. Therefore, while the statement is not strictly contradictory, it may be considered misleading as it overstates the level of detail in the intervention specification of the primary trial.</s>"
    },
    "ccb703ea-df18-451b-8db8-ed0e510a4c0f_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "The primary trial does not specify a specific dosage or frequency for its intervention, unlike the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's statement \"AB-101: Apply approximately 1 hour prior to sexual activity\" regarding Intervention 1 does not provide specifications on dosage or frequency, while the secondary trial's statement about Intervention 1 \"Letrozole + MRI: Protocol Therapy will consist of 6 months of letrozole, administered orally at a dose of 2.5 mg/day\" includes a dosage and frequency specification for letrozole. However, neither CTR mentions any discrepancy or contradiction concerning the application time of interventions, which is identical for both trials (applying to both nipple/areola regions approximately 1 hour prior to sexual activity). The statement made by the expert is an observation of a difference in information detail between the two trials and does not contradict or misrepresent any information present in the CTRs. Therefore, the statement can be entailed by the information present in the CTRs since it does not contradict or misrepresent it.</s>",
        "contradict": "The expert's statement misrepresents the Intervention section of the primary trial. Contrary to their claim, the primary trial does specify the application of AB-101 approximately 1 hour prior to sexual activity. No discrepancy exists for the application timing between AB-101 and Placebo. The statement's focus on dosage or frequency, however, is not addressed in the provided CTR sections.</s>"
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across both cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Entailment",
        "entail": "The statement \"Across both cohorts of the primary trial a total of two patients had hypoxia\" is entailed by the information present in the CTRs. In the first CTR under Adverse Events 1 for the Primary Trial, there is one occurrence of hypoxia reported (1/11). In Adverse Events 1 for the Secondary Trial, there is also one occurrence of hypoxia reported (1/21). Combining the data from both trials, a total of two patients (1+1) had hypoxia across both cohorts, which matches the statement's assertion.</s>",
        "contradict": "The statement \"Across both cohorts of the primary trial a total of two patients had hypoxia\" contradicts the information present in the CTRs because the CTRs report a total of three patients with hypoxia in the primary trial (1/11 in Adverse Events 1 and 2/11 in Adverse Events 2) and no mention of hypoxia in the secondary trial. The expert's statement incorrectly assumes that the number of patients with hypoxia is the same across both trials and in both cohorts, which is not true based on the information provided.</s>"
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across both cohorts of the primary trial a total of two patients didn't have low levels of oxygen in their body tissues.",
        "Label": "Contradiction",
        "entail": "The statement asserts that \"across both cohorts of the primary trial, a total of two patients didn't have hypoxia.\" Hypoxia is listed as an adverse event in both CTRs with a occurrence rate of 9.09% in each cohort. However, as stated, two patients in total across both cohorts didn't experience hypoxia. Since the CTRs indicate that there is a total of 11 patients in the first cohort and 21 patients in the second cohort, and the number of patients with hypoxia (1 in each cohort) is accounted for in the CTRs, it can be inferred that the remaining 2 patients (1 from each cohort) did not experience hypoxia. This aligns with the expert statement, thus establishing entailment.</s>",
        "contradict": "The statement \"Across both cohorts of the primary trial a total of two patients didn't have hypoxia\" contradicts the information in the CTRs because the CTRs report that one patient in each cohort experienced hypoxia, resulting in a total of two patients with hypoxia across both cohorts, contrary to the statement's claim that no such patients were present.</s>"
    },
    "56cd4492-3884-4b2a-a000-7c859d86f6f5_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "A total of two patients had low levels of oxygen in their body tissues across both cohorts of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"A total of two patients had low levels of oxygen in their body tissues across both cohorts of the primary trial\" is entailed by the information in the provided CTRs. This is because the CTRs report one instance of Hypoxia in each cohort (Total: 1/11 + 1/21 = 2/22), which implies low levels of oxygen in the body tissues.</s>",
        "contradict": "The statement \"A total of two patients had low levels of oxygen in their body tissues across both cohorts of the primary trial\" cannot be directly contradicted by the information in the CTRs as there is one reported case each of Hypoxia (low oxygen levels) in Cohort 1 and Cohort 2. However, the statement's assertion is not entailed by the CTR data since the statement refers to \"low levels of oxygen in their body tissues across both cohorts,\" whereas the reported cases are specific instances of Hypoxia in individual patients.</s>"
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy.",
        "Label": "Entailment",
        "entail": "The statement \"less than 1% of either cohort of the primary trial was affected by either Pancytopenia or Coagulopathy\" can be entailed by the CTR data as follows: The total number of participants in the primary trial was 425, and the number of participants with Pancytopenia was 2, and the number of participants with Coagulopathy was 1. Therefore, the total number of participants affected by either Pancytopenia or Coagulopathy is 3 (2+1), which is less than 1% of the primary trial cohort (3<0.01*425). Similarly, in the secondary trial with 406 participants, there were no instances of both Pancytopenia and Coagulopathy. Hence, none of the trials reported more than 1% of participants with either Pancytopenia or Coagulopathy.</s>",
        "contradict": "The expert's statement is contradicted by the CTR data because, although the overall occurrence of Pancytopenia and Coagulopathy in both trials is low (0.47% for each condition in Cohort 1 of the primary trial and 0% in Cohort 2 of the secondary trial), the occurrence in individual trials is higher than less than 1%. Specifically, two participants in Cohort 1 of the primary trial experienced Pancytopenia and one participant had Coagulopathy. Thus, more than 1% of the participants in Cohort 1 of the primary trial experienced either Pancytopenia or Coagulopathy, contradicting the expert's statement.</s>"
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "Less than 1% of either cohort of the primary trial wasn't effect by either Pancytopenia or Coagulopathy.",
        "Label": "Contradiction",
        "entail": "The statement \"Less than 1% of either cohort of the primary trial wasn't affected by either Pancytopenia or Coagulopathy\" can be entailed by the data presented in the CTRs as follows:\n\nThe total number of participants in each cohort (Primary Trial: 425, Secondary Trial: 406) is subtracted from the number of participants affected by Pancytopenia or Coagulopathy in each cohort (Primary Trial: 2 for each condition, Secondary Trial: 0 for both conditions). \n\nFor Primary Trial: 425 - (2 for Pancytopenia + 2 for Coagulopathy) = 421\n\nFor Secondary Trial: 406 - (0 for Pancytopenia + 0 for Coagulopathy) = 406\n\nNow, we calculate the percentage of participants in each cohort unaffected by these conditions:\n\nFor Primary Trial: Unaffected / Total = 421 / 425 = 0.9929 or approximately 99.3%\n\nFor Secondary Trial: Unaffected / Total = 406 / 406 = 100.0%\n\nSince the statement claims that \"Less than 1% of either cohort of the primary trial wasn't affected by either Pancytopenia or Coagulopathy,\" it is an underestimation of the actual percentage (99.3%) found in the CTR of the primary trial. However, it still falls within the range of the reported percentage, making it an entailed statement based on the provided CTR data.\n\nIn summary, the statement \"Less than 1% of either cohort of the primary trial wasn't affected by either Pancytopenia or Coagulopathy\" is entailed by the CTR data because it accurately represents the fact that the percentage of participants affected by these conditions is below 1% for each cohort, as reported in the data.</s>",
        "contradict": "The statement \"Less than 1% of either cohort of the primary trial wasn't affected by either Pancytopenia or Coagulopathy\" is contradicted by the CTR data because, in the primary trial, there were a total of 425 participants and two participants (0.47%) each experienced Pancytopenia and Coagulopathy. Therefore, the statement incorrectly implies that fewer than 1% of participants experienced either condition, while the reality is that more than 0.5% did.</s>"
    },
    "08b79e0d-5e97-45fb-ac83-0096b56f714b_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "Pancytopenia or Coagulopathy affected less than 1% of either cohort of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as neither Pancytopenia nor Coagulopathy affected more than 1% of participants in either cohort of the primary trial according to the given data:\n\n- In CTR 1 (Primary Trial): Pancytopenia: 2/425 (0.47%) and Coagulopathy: 1/425 (0.24%).\n- In CTR 2 (Primary Trial): Pancytopenia: 0/425 (0.00%) and Coagulopathy: 0/425 (0.00%).\n- Therefore, the combined prevalence of Pancytopenia and Coagulopathy in both cohorts of the primary trial is less than 1%: 1/425 (0.24%) + 0/425 (0.00%) = 0.24% < 1%.\n\nThe statement does not contradict the provided descriptions, and all the assumptions made are based on the information within the CTR.</s>",
        "contradict": "Despite the expert's claim, the data from the primary CTR reveals that a total of 4/425 participants (0.94%) experienced either pancytopenia or coagulopathy. This figure contradicts the statement that less than 1% of the cohort was affected.</s>"
    },
    "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01466270",
        "Statement": "The the primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR information as follows: The mean retention percentage for Arm II (placebo) is 80.7 (%), which is over 10% higher than the mean retention percentage for Arm I (donepezil hydrochloride PO QD), which is 71.0 (%).</s>",
        "contradict": "The statement \"The primary trial placebo group had a over 10% higher mean retention than the donepezil hydrochloride PO QD group\" contradicts the information present in the CTRs because the mean retention for Arm I (donepezil hydrochloride) is 71.0 (8.3) %, which is less than the mean retention for Arm II (placebo) which is 80.7 (7.2) %. Therefore, the claim of a more than 10% higher mean retention for the placebo group is not in line with the data provided in the CTRs.</s>"
    },
    "6d549a9b-47bf-4369-962b-2759cfd7051e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial both investigate Pharmacokinetics Itraconazole 500mg QD.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both investigate Itraconazole 500mg QD\" cannot be directly entailed from the provided CTRs, as the primary trial reports on the pharmacokinetics of 200mg itraconazole taken orally daily, while the statement mentions a dose of 500mg taken QD (once a day) without specifying the route of administration. The secondary trial does not provide any information on Itraconazole dosing. Hence, the statement does not harmonize with the clinical trial data, and its assertion cannot be entailed from the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both investigate Itraconazole 500mg QD\" is contradicted by the information present in the CTRs as follows:\n\n1. In the primary trial, patients received oral itraconazole 200mg a day (equivalent to 500 mg/day if taken as a single dose), not Itraconazole 500mg QD as stated in the expert's claim.\n2. The secondary trial does not investigate Itraconazole 500mg QD at all, as it focuses on the safety and tolerability of escalating doses of the MM-121 plus Paclitaxel combination. Itraconazole is only a component of the secondary trial, and its dosing regimen is different from the one specified in the statement.</s>"
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nInclusively, the primary trial specifies that participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast and that their primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative. The secondary trial also requires a histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast but does not explicitly mention HER2 status. However, the HER2-negative condition is inferred from the requirement that participants have measurable disease and at least one measurable lesion, as measurable lesions are defined by RECIST as lesions that can be accurately measured with imaging techniques, and RECIST is the standard for evaluating response to systemic therapy in solid tumors, including breast cancer. Additionally, HER2 status is an essential biomarker in breast cancer, and the lack of its mention in the secondary trial does not exclude the possibility that HER2 testing will be performed as part of the diagnostic workup. Therefore, the requirement of HER2 negativity is implied and can be inferred from the given trial criteria. \n\nFurthermore, both trials use the same diagnostic method, fluorescence in-situ hybridization (FISH), to confirm HER2 status. Thus, participants with a HER2-negative status confirmed by FISH are eligible for both trials.</s>",
        "contradict": "The statement \"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.\" can be contradicted by the information present in the CTRs due to the following reasons:\n\n1. The primary trial has strict inclusion criteria specifying that participants must have HER2-negative primary and/or metastatic breast tumors by FISH, CISH, or IHC. The statement does not mention this requirement for HER2-negativity in the metastatic setting. Thus, a participant with HER2-positive metastatic breast cancer would be ineligible for the primary trial but might be eligible for the secondary trial based on the expert statement.\n\n2. The secondary trial also has HER2-negative inclusion criteria. However, the statement does not specify whether HER2 status should be negative only in the primary tumor or both the primary and metastatic tumors. If the latter is the case, then participants eligible for the secondary trial according to the expert statement would also be eligible for the primary trial. But, if only primary HER2-negativity is required in the secondary trial, then participants with HER2-positive metastatic breast cancer would be ineligible for the secondary trial. In this context, the primary and secondary trials have slightly different HER2 requirements, making it possible for a participant to be eligible for one trial but not the other, even with HER2-negative primary tumors confirmed by FISH.</s>"
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization aren't eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization aren't eligible for the secondary trial and the primary trial\" is entailed by the information present in the CTRs because both primary and secondary trials explicitly exclude participants with HER2-positive breast cancer. In the primary trial, this exclusion is stated as \"Participant's primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC)\" while in the secondary trial, HER2 status is not specified. However, considering the general context of the trials being focused on breast cancer and the importance of HER2 status in treatment decisions, it is reasonable to assume that both trials intend to exclude HER2-positive cases, even if not mentioned explicitly in the secondary trial. Therefore, the expert's statement correctly reflects this common eligibility requirement across both trials.</s>",
        "contradict": "The statement \"Participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization aren't eligible for the secondary trial and the primary trial\" can be contradicted by the information present in the CTRs, as the primary trial explicitly includes participants with HER2-negative breast tumors using various methods for confirmation, including FISH and IHC, while the secondary trial does not specify HER2 status as a criterion for inclusion.</s>"
    },
    "596f20cf-299d-40a3-881a-cdd49bcb21f6_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "The secondary trial and the primary trial both accept participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization.",
        "Label": "Entailment",
        "entail": "The statement that both trials accept participants with HER2-positive primary breast tumors confirmed by FISH is entailed by the information in the CTRs as follows:\n\n1) Primary Trial: Inclusion Criteria: Participants must have histologically or cytologically confirmed adenocarcinoma of the breast that is HER2-negative by FISH or CISH or 0, 1+ overexpression by IHC. However, the statement specifically focuses on the HER2-negative status confirmed by FISH, which meets this requirement.\n\n2) Secondary Trial: Disease Characteristics: Participants must have a histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast. No explicit information about HER2 status is given, but the statement from the expert assures HER2-negativity confirmed by FISH, which is not contradicted by the information in the trial.\n\nThus, the statement can be entailed by the information present in the CTRs, as it does not contradict any information and harmonizes with the HER2-negative status confirmed by FISH in both trials.</s>",
        "contradict": "The statement \"The secondary trial and the primary trial both accept participants with HER2- primary breast tumors, confirmed by fluorescence in-situ hybridization\" is generally correct for the given information. However, there are some differences in the inclusion criteria regarding HER2 negativity between the two trials. While both trials accept participants with HER2- primary breast tumors confirmed by FISH, the primary trial specifies additional methods, such as CISH or IHC, for determining HER2 negativity. Additionally, the primary trial accepts participants with hormone receptor-positive breast cancer, while the secondary trial does not mention hormone receptor status as a requirement. Therefore, the statement could be considered an approximation, as it does not capture the full complexity of the inclusion criteria in both trials. However, it does not directly contradict the information in the CTRs.</s>"
    },
    "78ae19aa-6e26-4f9a-b381-cd77d92e4ecb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03066947",
        "Statement": "At least one patient in the primary trial suffered from Gastroesophageal reflux disease.",
        "Label": "Entailment",
        "entail": "The statement \"At least one patient in the primary trial suffered from Gastroesophageal reflux disease (GERD)\" can be entailed by the information present in the CTR as follows:\n\nIn the Primary Trial Adverse Events section, we have 21 reported cases of GERD out of a total of 24 participants (33.33%). This indicates that at least one participant in the primary trial (1 out of 24) experienced GERD during the trial.</s>",
        "contradict": "The given statement \"At least one patient in the primary trial suffered from Gastroesophageal reflux disease\" is not directly contradictory to the information provided in the CTRs. However, the CTRs mention \"GERD\" as an adverse event occurring in all patients, which is equivalent to saying every patient suffered from it. The expert's statement, on the other hand, only asserts that \"at least one\" patient in the trial experienced GERD. These two statements may seem similar but differ slightly in meaning. While they do not necessarily contradict each other, they do not fully entail each other either.\n\nThe CTRs state that all patients in both trials experienced GERD as an adverse event, whereas the statement made by the clinical trial expert only asserts that at least one patient in the primary trial experienced this condition. The CTRs contain more precise information, and the expert's statement can be seen as a generalization or a simplification of the CTR data. The statement does not contradict the information in the CTR, but it does not fully entail it either, making their relationship ambiguous.</s>"
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Sam has recently received a liver transplant, he is not eligible for the primary trial, but is eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "Sam's ineligibility for the primary trial is due to his liver transplant, which is listed as an exclusion criterion in the primary CTR. However, the statement also mentions his eligibility for the secondary trial. The secondary CTR only includes criteria related to breast cancer, estrogen receptor or progesterone receptor status, and menstrual cycle regularity. None of these criteria have any mention of liver transplantation, making it an irrelevant factor for the secondary trial. Thus, the statement is entailed by the CTRs as it correctly reflects that Sam is ineligible for the primary trial due to his liver transplant, and that he is eligible for the secondary trial as it does not exclude him based on that criterion.</s>",
        "contradict": "Sam's eligibility for the secondary trial contradicts the information in the primary CTR, as Sam is excluded from the primary trial due to having received a liver transplant.</s>"
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Sam has recently received a liver transplant, he is eligible for the primary trial, but is eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "Sam's eligibility for the primary trial is established as he is diagnosed with metastatic breast cancer and meets other criteria, such as ambulatory status, life expectancy, and agreement to protocol requirements. The presence of a liver transplant is an exclusion criterion in the primary trial, but not mentioned in the secondary trial inclusion criteria. Therefore, the statement \"Sam is eligible for the primary trial, but is eligible for the secondary trial\" contradicts the information in the CTRs, and it is not entailed by the provided clinical trial data.\n\nSam's eligibility for the secondary trial is given as having estrogen receptor or progesterone receptor positive breast cancer and being premenopausal with regular menstrual cycles. The information about Sam's liver transplant is not mentioned as an exclusion criterion in the secondary trial, so the statement is not directly contradictory and could be potentially entailed by the secondary trial's inclusion criteria. However, further information about the specific clinical trials would be necessary to definitively establish entailment.</s>",
        "contradict": "The statement that \"Sam has recently received a liver transplant, he is eligible for the primary trial, but is eligible for the secondary trial\" is contradicted by the information present in the CTRs. According to the primary CTR, one of the exclusion criteria is \"Patients with organ transplants.\" Therefore, Sam is not eligible for the primary trial based on this information. In contrast, the secondary CTR does not list organ transplants as an exclusion criterion, but Sam's eligibility for this trial is based on having estrogen receptor or progesterone receptor positive breast cancer and being premenopausal with regular menstrual cycles, which are the inclusion criteria for the secondary trial. However, his ineligibility for the primary trial due to the organ transplant exclusion criterion contradicts his eligibility for the primary trial as stated in the expert's statement.</s>"
    },
    "1d4f9f95-6f97-4054-9dd8-fe78aa5fc685_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "The secondary trial accepts Sam that has recently received a liver transplant, but the primary trial doesn't.",
        "Label": "Entailment",
        "entail": "The secondary trial's inclusion of patients who have undergone a liver transplant contradicts the primary trial's exclusion of such patients (as mentioned in the primary trial's exclusion criteria). Therefore, the statement that the secondary trial accepts a patient with a liver transplant, but the primary trial does not, is not entailed by the information presented in the CTRs as they are conflicting statements.</s>",
        "contradict": "The statement contradicts the exclusion criteria listed in the primary CTR which mentions patients with organ transplants as being ineligible for the trial.</s>"
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must undergo a minor surgery.",
        "Label": "Entailment",
        "entail": "Both the primary and secondary trial interventions involve tissue expander placement procedures, which inherently include minor surgeries for implantation of the specified acellular dermal matrices, AlloDerm RTU or SurgiMend PRS. The statement, therefore, is in alignment with the procedures outlined in the CTRs. The participants' undergoing a minor surgery in the trial is a logical entailment of the intervention specifications provided.</s>",
        "contradict": "The statement \"all subjects in the primary trial must undergo a minor surgery\" is contradictory to the information in the CTRs as it goes beyond the details provided. While both arms of the primary trial involve implantation of an acellular dermal matrix during tissue expander placement, which can be considered a minor surgery, the statement implies that all surgeries are identical and of a minor nature, which is not necessarily the case based on the available information. The CTRs do not specify the extent or details of the surgeries beyond the implantation of the matrices.</s>"
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "All subjects in the primary trial mustn't undergo a minor surgery.",
        "Label": "Contradiction",
        "entail": "The statement \"All subjects in the primary trial mustn't undergo a minor surgery\" is entailed by the information in the CTRs because neither the Intervention 1 nor Intervention 2 descriptions indicate any minor surgeries being performed at the time of tissue expander placement, where the implantation of the acellular dermal matrices occurs.</s>",
        "contradict": "The statement \"All subjects in the primary trial mustn't undergo a minor surgery\" contradicts the information in the CTRs because the CTRs describe a surgical procedure (implantation of acellular dermal matrices) that is a part of the intervention for both arms in the primary trial.</s>"
    },
    "d4b2d877-34af-4944-84f7-046e22c2854e_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "A minor surgery is a requirement for all subjects in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A minor surgery is a requirement for all subjects in the primary trial\" is entailed by the information present in the CTRs because both INTERVENTION 1 and INTERVENTION 2 specify that the acellular dermal matrices (AlloDerm RTU and SurgiMend PRS) are implanted \"at the time of tissue expander placement.\" A tissue expander is a medical device used for breast reconstruction, which involves a surgical procedure. Hence, a surgery is an inherent part of both interventions, implying that all subjects undergo a minor surgery as required by the statement.</s>",
        "contradict": "The information in the expert statement \"A minor surgery is a requirement for all subjects in the primary trial\" cannot be contradicted directly by the CTRs provided. However, it could be contradicted depending on the context and specific definitions of the term \"minor surgery.\" \n\nThe CTRs only mention the implantation of acellular dermal matrices (AlloDerm RTU and SurgiMend PRS) at the time of tissue expander placement, but they do not explicitly state that this procedure is a minor surgery. According to the Merriam-Webster dictionary, a minor surgery is a surgical procedure that is less invasive than major surgery and usually causes fewer complications. Depending on the context and specific definition of \"minor surgery,\" the expert statement might not be contradicted by the CTRs if the implantation of the matrices is considered a minor surgery. However, if the definition of minor surgery implies minimal tissue dissection, anesthesia requirements, or recovery time, then the CTRs do not provide enough information to confirm or deny this statement.</s>"
    },
    "d3ca3729-2795-4cd5-9968-666781d17fac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as the number of participants in each arm/group who experienced Congestive Heart Failure is explicitly stated: 2.9% (0.6-8.3%) in Arm A and 2.5% (0.5-7.1%) in Arm B. The difference in these percentages indicates that the number of patients experiencing Congestive Heart Failure was indeed different between the two cohorts.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs if there is no mention or no clear indication of Congestive Heart Failure cases in both arms (A and B) of the primary trial in the provided data. The statement only states that the number of patients with Congestive Heart Failure was different between the two cohorts, but it does not specify whether this difference is due to more incidents in one arm or fewer incidents in the other arm. The CTRs, however, only provide the percentage of participants with Congestive Heart Failure for each arm. To establish whether the statement is entailed by the CTRs, it would be necessary to have access to the raw data or additional information regarding the number of participants who experienced Congestive Heart Failure in each arm.</s>"
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "There were 0 observed cases of Tibia or Fibula fractures in the primary trial.",
        "Label": "Entailment",
        "entail": "The absence of Tibia or Fibula fractures in the primary trial is not explicitly mentioned in the provided adverse events sections. However, the lack of such cases can be inferred from the data presented, as none of the reported adverse events include Tibia or Fibula fractures. Additionally, the number of total adverse events in the primary trial (16/149) is lower than that of the secondary trial (20/151), suggesting that any rare or uncommon adverse events, including Tibia or Fibula fractures, would also be less frequent in the primary trial if they occurred at all. Thus, the statement can be entailed by the CTRs.</s>",
        "contradict": "The statement \"There were 0 observed cases of Tibia or Fibula fractures in the primary trial\" contradicts the information present in the CTRs, as the CTRs do not report any data on Tibia or Fibula fractures for the given adverse events sections.</s>"
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "There weren't 0 observed cases of Tibia or Fibula fractures in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There weren't 0 observed cases of Tibia or Fibula fractures in the primary trial\" does not directly entail any information from the provided CTRs since the CTRs do not report the occurrence or non-occurrence of Tibia or Fibula fractures. However, since the provided CTRs only report Adverse Events and none of them include Tibia or Fibula fractures, it can be inferred that there were no observed cases of these fractures based on the absence of such reports. Thus, while the statement is entailed by the information in the CTRs, it is not directly stated in them.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs as they do not mention Tibia or Fibula fractures among the reported adverse events. However, the statement makes an assumption about the absence of certain adverse events based on the CTR data, which might not be entirely accurate. The CTRs only report specific adverse events observed during the trials, and the absence of an adverse event is not explicitly stated unless it is mentioned as having a count of 0. Therefore, while the statement is not directly contradictory, it may be misleading if used to make broad assumptions about the safety of the trials without considering all relevant information.</s>"
    },
    "fb85a3a5-b9a1-48f4-84f3-2e2307e2f104_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01752907",
        "Statement": "Tibia or Fibula fractures had no observed cases in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Tibia or Fibula fractures had no observed cases in the primary trial\" is entailed by the information in the CTRs as neither Adverse Events 1 nor Adverse Events 2 report any cases of Tibia or Fibula fractures.</s>",
        "contradict": "The statement \"Tibia or Fibula fractures had no observed cases in the primary trial\" cannot be directly contradicted by the provided CTR information, as the CTRs do not report any occurrences of Tibia or Fibula fractures. However, it is important to note that the CTRs only report a subset of possible adverse events and do not guarantee an exhaustive list. The lack of reporting does not necessarily mean the absence of events. Therefore, while the statement does not contradict the given CTRs, it is also not entailed by them.</s>"
    },
    "b98c7a50-ed79-41ff-9733-fff143f630be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the primary trial recorded the same number of instances of Neutropenic fever as Cohort 1 of the secondary trial\" cannot be directly entailed by the provided information in the CTRs as neither of the trials report the number of instances of Neutropenic fever in their respective Cohort 1. The provided CTRs only report the total number of adverse events for each trial, but they do not specify how many of those events were instances of Neutropenic fever, nor do they distinguish between different cohorts within each trial regarding this particular adverse event. Therefore, the statement cannot be determined to be either true or false based on the information provided in the CTRs alone.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs because, according to the provided information, there were no instances of febrile neutropenia reported in Cohort 1 of the primary trial, whereas Cohort 1 of the secondary trial had no instances of neutropenic fever explicitly mentioned.</s>"
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis is used in the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"laboratory biomarker analysis is used in the secondary trial and the primary trial\" is entailed by the information in the CTRs because both primary and secondary trials mention the use of \"laboratory biomarker analysis\" as an optional correlative study. In the primary trial, it is stated that \"laboratory biomarker analysis: Optional correlative studies\" for the Intervention 1 of the primary trial. In the secondary trial, it is stated that \"laboratory biomarker analysis: Correlative studies\" for several interventions (doxorubicin hydrochloride, methotrexate, vinorelbine tartrate, letrozole). Therefore, the statement that \"laboratory biomarker analysis is used in the secondary trial and the primary trial\" follows logically from the information provided in the CTRs.</s>",
        "contradict": "While both trials use laboratory biomarker analysis, the primary trial only mentions it as an optional correlative study, whereas in the secondary trial, it is a required component for several interventions (needle biopsy, immunohistochemistry staining method, and potentially others, although not explicitly stated for all). This difference in the extent and required nature of laboratory biomarker analysis can contradict the statement, as the statement assumes an identical use of this analysis in both trials.</s>"
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "Laboratory biomarker analysis isn't used in the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary CTR explicitly mentions \"laboratory biomarker analysis: Optional correlative studies\" under the Intervention 1 section. However, it is not explicitly stated in the secondary CTR that laboratory biomarker analysis is used. Based on the given information, it can be inferred that laboratory biomarker analysis is not mentioned as a required or integral part of Intervention 1 in the secondary trial. Since the statement \"Laboratory biomarker analysis isn't used in the secondary trial and the primary trial\" is a logical deduction from the provided CTRs, it can be considered entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTRs because the primary trial includes optional laboratory biomarker analysis, while the secondary trial includes correlative laboratory biomarker analyses.</s>"
    },
    "47aa5686-75af-4ed8-b4ff-715b458ce40a_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "The secondary trial and the primary trial used laboratory biomarker analysis.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial and the primary trial used laboratory biomarker analysis\" is entailed by the information present in the CTRs because both trials mention \"laboratory biomarker analysis\" as an optional correlative study in the RESULTS sections of their respective INTERVENTION 1 parts. In the primary CTR, it is described as a part of ancillary studies, while in the secondary CTR, it is mentioned for multiple types of chemotherapy treatments. Therefore, the statement's assertion that both trials used laboratory biomarker analysis aligns with the data provided in the CTRs and avoids contradiction.</s>",
        "contradict": "While both trials mention the use of laboratory biomarker analysis as an optional correlative study in the primary trial and a required component in the secondary trial, the nature and timing of the biomarker analysis differ between the trials. In the primary trial, the biomarker analysis is optional and can be conducted in ancillary studies, while in the secondary trial, it is a required component of the treatment interventions and is performed in conjunction with therapeutic surgery, immunohistochemistry staining method, or needle biopsy. Therefore, the statement does not precisely convey the entailment relationship between the trials regarding the use and context of laboratory biomarker analysis.\n\nThe statement is not contradictory to the CTR information, but it is not a precise representation of their relationship. To establish entailment, it would be necessary to examine the specifics of the biomarker analysis, such as the markers used and the timing in relation to other interventions, to determine if the statement accurately captures the semantic relationship between the trials.</s>"
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the interventions include Trastuzumab/Ixabepilone/Carboplatin, which are identified as chemotherapy drugs.\n2. In the secondary trial, Intervention 1 refers to clinical management, which is a psychological therapy.\n3. Therefore, the statement's assertion that one trial investigates chemotherapy and the other investigates psychological therapy aligns with the information presented in the CTRs.\n\nThe statement also avoids contradicting the CTRs as neither trial reports any conflicting information about treatment types. Thus, the entailment relationship is established based on the harmony of the statement with the clinical trial data and the absence of contradiction.</s>",
        "contradict": "The statement \"the primary trial investigates a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy\" is not contradictory to the CTR information. \n\nExplanation: \n\nThe statement accurately describes the nature of the interventions being tested in each trial according to their respective CTRs. The primary trial involves the use of a combination of chemotherapies (Trastuzumab, Ixabepilone, and Carboplatin), whereas the secondary trial investigates the efficacy of a psychological therapy (clinical management and CBT). No contradiction exists between the statement and the provided CTRs.</s>"
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "The primary trial doesn't investigate a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial doesn't investigate a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary trial, the intervention consists of Trastuzumab/Ixabepilone/Carboplatin, which are known and recognized treatments in the clinical setting, with Trastuzumab being an established targeted therapy for HER2-positive breast cancer. Therefore, the primary trial does not investigate a novel chemotherapy treatment.\n\nIn contrast, the secondary trial investigates a different type of intervention, specifically Clinical Management and CBT, which are distinct from the chemotherapy regimen in the primary trial. These interventions are psychological therapies and are not related to novel chemotherapy treatments. Therefore, the secondary trial is testing a type of psychological therapy.\n\nThus, the statement that \"the primary trial doesn't investigate a novel chemotherapy treatment, whereas the secondary trial is testing a type of psychological therapy\" is a correct and entailed interpretation of the provided information in the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs based on the provided Intervention sections alone. The first part of the statement correctly identifies that the primary trial is not investigating a novel chemotherapy treatment, as Ixabepilone, Carboplatin, and Trastuzumab are named in the trial's Intervention section. \n\nHowever, the secondary trial is indeed testing a type of psychological therapy (CBT). While it is not a new therapy in a broader sense, it is a distinct therapeutic intervention from the pharmacologic treatments used in the primary trial.\n\nThus, the statement is correct regarding the nature of the interventions being tested in each trial but could be misleading without context, as it does not mention the difference in intervention types (chemotherapy vs. psychology).\n\nHowever, it's essential to note that the statement is based solely on the presented Intervention sections. Other sections in the CTRs, such as Eligibility Criteria, Results, and Adverse Events, might provide additional information that could potentially contradict or add context to the expert's statement. A more comprehensive comparison of the two trials would be needed to fully assess any semantic entailment relationship.</s>"
    },
    "e89fdc93-d624-4ba7-aa64-574a278e982b_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "The secondary trial is testing a type of psychological therapy whereas the primary trial investigates a novel chemotherapy treatment.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as the trials clearly differ in their interventions: while the primary trial examines a chemotherapy combination of Trastuzumab/Ixabepilone/Carboplatin, the secondary trial focuses on psychological therapies, specifically Clinical Management and Cognitive Behavioral Therapy (CBT). The statement's claim that the secondary trial tests a type of psychological therapy while the primary trial investigates a novel chemotherapy treatment aligns with the distinct nature of the interventions in each CTR.</s>",
        "contradict": "The statement \"The secondary trial is testing a type of psychological therapy whereas the primary trial investigates a novel chemotherapy treatment\" is not directly contradicted by the provided CTRs. However, it can be contradicted if we consider other information not presented in the excerpts. The contradiction lies in the trials' focus on different types of interventions. The primary trial focuses on a novel chemotherapy treatment with Trastuzumab, Ixabepilone, and Carboplatin. Meanwhile, the secondary trial focuses on psychological therapy, specifically clinical management and Cognitive-Behavioral Therapy (CBT), as interventions. The trials are different in their therapeutic approach, but the statement is correct in that they are testing distinct interventions. No contradiction is found within the provided CTR excerpts alone.</s>"
    },
    "1739541a-2d3f-4a13-b956-769a1cbed4d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Contradiction",
        "entail": "The statement \"1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma\" is entailed by the information present in the CTRs, as one occurrence of Clear cell kidney cancer is reported in the Adverse Events section of the Primary Trial, with a count of 1 out of 60 patients (0.00% if expressed as a percentage). This implies that at least one patient in the primary trial cohort did experience this condition, which fulfills the statement's requirement.</s>",
        "contradict": "The statement \"1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma\" contradicts the information present in the CTRs because no cases of Clear cell kidney cancer were reported in either the primary or secondary trial's adverse events sections. The CTRs specify that no cases of Clear cell kidney cancer occurred among the 60 and 58 participants in the primary and secondary trials, respectively.</s>"
    },
    "c8f401a0-5e7d-4fd9-b31e-0866c9bee6a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "One patient in the primary trial suffered from sepsis, due to the presence of an implanted device.",
        "Label": "Entailment",
        "entail": "The statement \"One patient in the primary trial suffered from sepsis, due to the presence of an implanted device\" can be entailed by the CTR data as both trials report an instance of \"Device related sepsis\" in the Adverse Events sections. In the primary trial, this event occurred in one patient out of 113 (1/113 or 0.88%), and in the secondary trial, it occurred in one patient out of 112 (1/112 or 0.89%). Therefore, the statement is harmonious with the clinical trial data, substantiated in the CTRs, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"One patient in the primary trial suffered from sepsis, due to the presence of an implanted device\" contradicts the given CTR data because, according to the CTRs, there is only one instance of device related sepsis reported in each of the primary and secondary trials (1/113 in primary and 0/112 in secondary). Thus, the statement implies the existence of an additional occurrence of device-related sepsis, which is not supported by the CTRs.</s>"
    },
    "206fc00c-2c34-42bc-8fca-44be696e03c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days , the differences between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC and the number of cycles for each cohort, 1 for cohort 1 and 4 for cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement's assertion harmonizes with the CTR data since both cohorts indeed receive identical interventions: pegylated irinotecan administered intravenously (IV) at 145 mg/m\u00b2 as monotherapy once every 21 days. The differences mentioned in the statement, namely the types of cancers (NSCLC for cohort 1 and mBC for cohort 2) and the number of cycles (1 for cohort 1 and 4 for cohort 2), are also described in the CTRs for each cohort, respectively. Therefore, the statement is entailed by the information in the CTRs and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly. However, it contains an additional claim about the number of cycles that each cohort receives, which is not mentioned in the provided CTRs. According to the CTRs, the pegylated irinotecan intervention is administered every 21 days, but it does not specify the number of cycles for either cohort. Hence, the discrepancy lies in the extra detail provided in the statement, not in the core entailed information. To establish semantic entailment, the statement should only focus on the identical interventions and the types of cancers in the two cohorts.</s>"
    },
    "4a6d7f07-27b5-4281-b59c-f1c77dbd6e2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows: \n\n1. PFS values in months were 8.6 (8.2-10.3) for the Docetaxel + Sunitinib group and 6.9 (6.5-7.3) for the Docetaxel group, according to investigator's assessments. \n2. Independent radiology assessments showed 8.3 (7.7-9.6) months for Docetaxel and 8.6 (8.2-10.3) months for Docetaxel + Sunitinib. \n3. The difference in median (95% Confidence Interval) PFS between the two groups is calculated as |(8.6 - 6.9)| = 1.7, which is greater than 12 months (1 year), as claimed in the statement.\n\nTherefore, the statement's assertion is consistent with and can be derived from the data presented in the CTRs.</s>",
        "contradict": "The statement \"Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a year higher for patients in the Trastuzumab + Sunitinib group of the primary trial than for the Docetaxel group\" is contradicted by the information in the CTRs because the primary trial does not involve Trastuzumab in any of its arms. The statement asserts a comparison between Trastuzumab + Sunitinib and Docetaxel, but the provided CTR data is only for Docetaxel and Sunitinib used in combination with or without each other.</s>"
    },
    "83cef795-d4a8-486c-8ac1-34a9acee9672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial\" is entailed by the CTR inclusion criteria as the CTR specifies that \"Performance status should be 0-2 by ECOG criteria.\" Therefore, patients with an ECOG of 1-2 are excluded from the study according to the CTR.</s>",
        "contradict": "The statement \"Patients with left-sided breast cancer and an ECOG between 1-2 are excluded from the primary trial\" can be contradicted by the information present in the CTRs, specifically the Eligibility Criteria section, because the CTR includes patients with an ECOG performance status of 1 or 2. Therefore, the statement is not an entailed condition based on the CTR information.\n\nHowever, it's important to note that the CTR and the statement may both be valid in different contexts, and the statement might reflect the inclusion/exclusion criteria of a different trial or analysis. In this context, the discrepancy exists between them, making it impossible for the statement to be entailed by the CTR without modification.</s>"
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded one patient with a catheter-related complication, whereas in the secondary trial none where observed.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information in the CTRs because, according to Adverse Events 1 in the primary trial, there was one case (1/122, or 0.82%) of catheter site cellulitis, which is a type of catheter-related complication. In contrast, Adverse Events 1 in the secondary trial does not report any cases (0.00%) of catheter site cellulitis or any other specific catheter-related complications. Therefore, the expert's statement that \"in the primary trial one patient had a catheter-related complication, whereas the secondary trial recorded none\" is consistent with the data provided in the CTRs.</s>",
        "contradict": "The information in the statement is contradictory to the Adverse Events sections of both trials, as the primary trial reported one case of catheter site cellulitis, while the secondary trial reported none.</s>"
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919_neg": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "The primary trial didn't record one patient with a catheter-related complication, whereas in the secondary trial none where observed.",
        "Label": "Contradiction",
        "entail": "The statement \"The primary trial didn't record one patient with a catheter-related complication, whereas in the secondary trial none were observed\" can be entailed by the information present in the CTRs because both trials report zero instances of catheter site cellulitis for each respective cohort. The absence of an adverse event in the CTR implies that no patient in the trial experienced that specific event. As both trials report zero occurrences of catheter site cellulitis for their respective cohorts, the expert's statement is a correct summary of the CTR information.</s>",
        "contradict": "The statement \"The primary trial didn't record one patient with a catheter-related complication, whereas in the secondary trial none were observed\" is contradictory to the information present in the CTRs because:\n\n1. In the primary CTR under Adverse Events 1, one patient experienced catheter site cellulitis.\n2. Neither of the CTRs indicate that no patients experienced catheter-related complications in absolute terms, only that the number of occurrences differed between the trials.</s>"
    },
    "b3cee7a6-cec1-4676-974d-7cfb3ccd9919_rephrase": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "The secondary trial did not record any patient with a catheter-related complication, whereas in the primary trial one was observed.",
        "Label": "Entailment",
        "entail": "The statement that \"The secondary trial did not record any patient with a catheter site cellulitis\" is entailed by the information present in the CTRs, as there is no occurrence of catheter site cellulitis reported in the secondary trial (Adverse Events 2: 0/34), while one case was observed in the primary trial (Adverse Events 1: 1/122).</s>",
        "contradict": "The expert's statement does not entail with the information in the CTRs due to the absence of a matching term between them. The expert's statement is comparing \"catheter-related complications\" in the trials, while the CTRs list specific complications, such as \"catheter site cellulitis,\" which is not an exact match to \"catheter-related complications.\" Consequently, the statement's assertion may not be definitively determined as either true or false based solely on the information presented.</s>"
    },
    "007de11b-4265-4695-b18e-e0d6909a347a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with HER2 positive tumors are excluded from the primary trial, but may be included in the secondary trial\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the exclusion criteria state that patients with HER2 FISH amplified tumors (FISH ratio >2.2) or those who are HER-2 neu 0+ or 3+ by immunohistochemistry are not eligible for participation. Thus, patients with HER2 positive tumors are indeed excluded from this trial.\n2. In contrast, the secondary trial does not have specific inclusion criteria pertaining to HER2 status. Therefore, it does not exclude patients based on HER2 status explicitly, meaning patients with HER2 positive tumors may still be eligible for inclusion in this study, provided they meet other inclusion criteria.\n\nHence, the statement is consistent with the information in the CTRs and is entailed by the exclusion and inclusion criteria of the primary and secondary trials, respectively.</s>",
        "contradict": "The information in the statement is contradictory to the inclusion criteria of the primary trial as stated in the CTR. The primary trial explicitly excludes patients with HER2 positive tumors. In contrast, the statement suggests that these patients may be included in the secondary trial.</s>"
    },
    "ce621235-b584-439b-bb11-ab2fa04c3195": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01869764",
        "Secondary_id": "NCT02556632",
        "Statement": "Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis and completes a Questionnaire.",
        "Label": "Contradiction",
        "entail": "The provided statement is entailed by the CTRs as both the primary and secondary trials involve Laboratory Biomarker Analysis and Questionnaire Administration. In the primary trial, this information is mentioned in the INTERVENTION sections for both Arm I and Arm II. In the secondary trial, it is explicitly stated for both INTERVENTION 1 and INtervention 2.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it may be misleading as it implies that all participants undergo the same types of analyses (laboratory biomarker analysis and questionnaire administration) for both interventions in both trials. However, the CTRs specify that the laboratory biomarker analysis is a correlative study for the Omega-3 Fatty Acid intervention in the primary trial and for both interventions in the secondary trial. Similarly, the questionnaire administration is an ancillary study in the secondary trial for both interventions. Therefore, the statement is not a strict entailment of the CTRs, as it does not specify which analysis or questionnaire is related to which intervention and trial.</s>"
    },
    "f358f023-2393-44eb-9535-3f0e1851318d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial both use irradiation techniques in their studies.",
        "Label": "Contradiction",
        "entail": "The primary trial utilizes External beam partial breast radiation as its intervention method, which is a type of irradiation technique. The secondary trial involves a multicomponent intervention where one component is education on access to doctor's electronic visit notes which could include information related to radiotherapy. Although the primary focus of the secondary trial is not irradiation, its presence as a component in the multicomponent intervention implies the use of irradiation techniques in the study. Therefore, the statement \"the secondary trial and the primary trial both use irradiation techniques in their studies\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is not an entailed relationship between the clinical trial reports. The primary trial utilizes 4D Conformal Image-Guided Partial Breast RT, a specific type of irradiation therapy, while the secondary trial employs a multicomponent intervention that includes usual care with a medical oncologist, and does not explicitly mention irradiation in Intervention 1. Therefore, the statement's assertion of using irradiation techniques in both trials does not harmonize with the clinical trial data and can be contradicted by the provided descriptions.</s>"
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.",
        "Label": "Entailment",
        "entail": "The statement \"Every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclopharmamide IV\" is entailed by the information present in the CTRs because the CTR for the primary trial explicitly states that \"tipifarnib: Given orally,\" \"paclitaxel: Given IV,\" \"doxorubicin hydrochloride: Given IV,\" and \"cyclophosphamide: Given IV\" for Arm I. Although cyclophosphamide is listed under the Intervention section as \"cyclophosphamide,\" it is a known fact that cyclophosphamide is an IV formulation when used in the context of this clinical trial, as stated in the CTR. Therefore, the statement is an accurate summary of the treatment interventions described in the CTRs.</s>",
        "contradict": "The expert's statement asserts that \"every patient in the primary trial is given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.\" However, according to the CTRs provided, not all patients received the exact combination mentioned in the statement. While tipifarnib was given orally to all patients, the other mentioned drugs (paclitaxel, doxorubicin hydrochloride, and cyclophosphamide) were given IV to some patients and conventional surgery with axillary lymph node dissection was performed on others. Hence, the statement is contradictory to the information presented in the CTRs.</s>"
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Every patient in the primary trial isn't given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV.",
        "Label": "Contradiction",
        "entail": "The statement \"Every patient in the primary trial isn't given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV\" can be entailed by the information present in the CTRs because the intervention for Arm I in the primary trial specifies that tipifarnib is given orally (PO), while paclitaxel, doxorubicin hydrochloride, and cyclophosphamide are given intravenously (IV). Acyclophosphamide is also given IV, as stated, but the expert's statement doesn't mention it in conjunction with the other three agents, so its inclusion or exclusion doesn't contradict the statement. Therefore, every patient isn't given tipifarnib PO with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide IV as per the expert's statement, which is an entailed relationship to the information in the CTRs.</s>",
        "contradict": "The statement \"Every patient in the primary trial isn't given tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV\" is contradicted by the information provided in the CTRs. The CTR for the primary trial indicates that Arm I of the trial includes patients receiving tipifarnib PO, paclitaxel IV, doxorubicin hydrochloride IV, and cyclophosphamide IV as part of their intervention, which contradicts the expert's statement that \"Every patient in the primary trial isn't given\" these specific drugs via the stated routes. Additionally, the absence of acyclovir (mentioned inexplicably in the expert's statement instead of acyclophosphamide) in the CTR does not impact the contradiction.</s>"
    },
    "0e963b25-0d2b-4fc6-89c6-1eb068bc092e_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470301",
        "Statement": "Tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV is given to every patient in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV is given to every patient in the primary trial\" is entailed by the information present in the CTRs as follows: In the primary trial, Tipifarnib is given orally (PO), paclitaxel is given intravenously (IV), doxorubicin hydrochloride is given intravenously (IV), and acyclophosphamide is given intravenously (IV) to specific arms of the trial. However, the statement does not contradict the information that conventional surgery is also performed on patients (surgical procedures are not specified in the expert's statement) and that axillary lymph node dissection is part of a correlative study, which does not affect the administration of these medications to all patients. Therefore, the statement is entailed by the data provided in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTRs because, while tipifarnib, paclitaxel, doxorubicin hydrochloride, and acyclophosmide IV are administered to patients in the primary trial, they are not given to every patient in the same arm. Instead, patients are assigned to different treatment groups, with the specific combinations of treatments varying between these groups. Therefore, the statement's generalization that \"Tipifarnib PO, along with paclitaxel, doxorubicin hydrochloride and acyclophosphamide IV is given to every patient in the primary trial\" contradicts the detailed information present in the CTRs.</s>"
    },
    "390b08d3-e147-47f9-82d7-0643b8d5c8ae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00733408",
        "Statement": "There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement asserts that there was a 8-week difference in Progression-free Survival (PFS) in the primary trial. According to the CTR, the lower bound of the 95% confidence interval for the median PFS of the treatment arm was 8 months, which translates to approximately 24 weeks. The upper bound of the confidence interval was 11.1 months, or around 37.4 weeks. Thus, the difference in PFS between the minimum and maximum lies within this range, and hence is entailed by the data in the CTR.</s>",
        "contradict": "The statement \"There was just under 8 weeks difference in Progression-free Survival between the minimum and maximum PFS in the primary trial\" cannot be directly contradicted by the information in the CTRs provided. However, the statement does not entail the information in the CTRs. \n\nThe statement only mentions the difference between the minimum and maximum PFS, but it doesn't specify the actual values. The CTRs, on the other hand, provide the median PFS, which is 9.1 months (7.2 to 11.1) for the Tx arm/group, but no mention of the minimum or maximum PFS values.\n\nTo establish entailment, the statement would need to explicitly state or be able to be logically deduced from the information in the CTRs. In this case, without the actual minimum and maximum PFS values, there is no entailment relationship between the statement and the CTRs.</s>"
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Between both the primary trial and the secondary trial Bevacizumab is only administered to patients in cohort 2 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Between both the primary trial and the secondary trial, Bevacizumab is only administered to patients in cohort 2 of the secondary trial\" is entailed by the following facts from the CTRs:\n\n1. In the primary trial, Bevacizumab is not mentioned in any intervention arm.\n2. In the secondary trial, Bevacizumab is mentioned only in intervention arm B (ET-B), and it is given in combination with endocrine therapy.\n3. No patient from the primary trial receives both endocrine therapy and Bevacizumab.\n\nHence, the statement is a correct summary of the information in the CTRs.</s>",
        "contradict": "In the primary trial, Bevacizumab is not mentioned as being administered to any arm, neither in Intervention 1 nor in Intervention 2. However, in the secondary trial, Bevacizumab is mentioned as being administered to cohort 2 of Intervention 2 (ET-B). The statement implies that Bevacizumab is exclusive to the secondary trial and only given to patients in cohort 2 of that trial. Since the primary trial does not include Bevacizumab, the statement contradicts the information present in the CTRs.</s>"
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Between both the primary trial and the secondary trial Bevacizumab isn't only administered to patients in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Bevacizumab is mentioned as part of the intervention for Arm 2, the Educational Wellness Group arm, but it is not directly administered to the patients, rather it is given in combination with endocrine treatment. \n\nIn the secondary trial, Bevacizumab is mentioned as part of the intervention for Arm B, the ET-B arm, which is a separate trial with distinct patient population and intervention from the primary trial. Here, Bevacizumab is administered in combination with endocrine treatment similarly to Arm 2 in the primary trial. \n\nThe expert's statement is entailed by the CTRs as it correctly identifies that Bevacizumab isn't only administered to patients in cohort 2 of the secondary trial, but also to patients in a different trial, the secondary trial, and in a different cohort, Arm B.</s>",
        "contradict": "The statement \"Between both the primary trial and the secondary trial Bevacizumab isn't only administered to patients in cohort 2 of the secondary trial\" is contradicted by the information present in the CTRs because:\n\n1. In the primary trial, Bevacizumab is administered as an intervention on its own, not in association with any other intervention.\n2. In the secondary trial, Bevacizumab is only administered in combination with Endocrine Therapy (ET) to patients in cohort B (ET-B). There is no evidence in the CTR that Bevacizumab is administered to patients in Arm A (ET) without ET.\n\nTherefore, the statement is incorrect as per the information provided in the CTRs.</s>"
    },
    "2570cb04-4edd-48c9-b634-9f2e086469de_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00994279",
        "Secondary_id": "NCT00545077",
        "Statement": "Bevacizumab is only administered to patients in cohort 2 of the secondary trial between both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement asserts that bevacizumab is only administered to patients in the second trial (secondary trial) and not in the first trial (primary trial). This assertion is entailed by the CTRs as follows:\n\n1. In the primary trial, there are two treatment arms - Arm 1 for Yoga Intervention and Arm 2 for Educational Wellness Group. Neither of these arms receives any form of pharmacological therapy, including bevacizumab.\n2. In the secondary trial, there are also two treatment arms - Arm A for Endocrine Therapy (ET) without bevacizumab and Arm B for Endocrine Therapy (ET) with bevacizumab. Therefore, the statement that bevacizumab is only administered to patients in cohort 2 (Arm B) of the secondary trial is consistent with the provided CTRs, as it is not administered to patients in the primary trial at all.</s>",
        "contradict": "The statement \"Bevacizumab is only administered to patients in cohort 2 of the secondary trial between both the primary and the secondary trial\" is contradicted by the information present in the CTRs. In the primary trial, Bevacizumab is mentioned as part of the intervention for cohort 2 in the secondary trial. However, in the primary trial, Bevacizumab is not mentioned as being given between the two trials, but rather as a component of the intervention for Arm 2 in the secondary trial. Therefore, the statement incorrectly implies that Bevacizumab is given only in the gap between the primary and secondary trials when it is actually given as part of the intervention in the secondary trial.</s>"
    },
    "f6a7e279-b923-45e3-8ad5-e81e17c0a682": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Contradiction",
        "entail": "The statement \"60 patients in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule\" can be entailed by the information in the CTRs as follows:\n\n1. The outcome measurement in the primary CTR specifies that feasibility will be evaluated by determining the percentage of subjects able to complete the neoadjuvant portion of the study with > 85% of the protocol-specified dose.\n2. The results of the primary CTR provide the number of participants (60) who underwent neoadjuvant therapy and were able to complete at least 85% of the planned dose. \n3. The information in the statement aligns with this result since it also reports that 60 patients completed at least 85% of the planned dose.\n4. The statement does not contradict any details in the CTRs, and it finds substantiation in the provided data.\n\nHence, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTR directly. However, the CTR does not provide an explicit confirmation that exactly 60 out of 30 participants (or 200% of the participants) completed at least 85% of the planned dose on schedule. While the percentage in the statement aligns with the percentage mentioned in the CTR's outcome measurement, the CTR does not state an exact number of participants achieving this outcome.</s>"
    },
    "3d82851c-f302-4988-bd78-232583e04e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial\" is entailed by the information present in the CTRs because:\n\n1. The primary CTR states that there are no exclusion criteria specifically mentioning \"prior chemotherapy\" for patients in the inclusion criteria. However, it does mention that only \"female subjects participating in FMSU004A protocol with known clinical status\" are eligible, which does not directly exclude patients with prior chemotherapy. Therefore, patients with prior chemotherapy could theoretically meet other inclusion criteria and be included in the primary trial.\n\n2. The secondary CTR explicitly lists \"No prior chemotherapy for breast cancer\" as an inclusion criterion, and \"Adequate bone marrow, liver and kidney function\" as a potential exclusion criterion for which prior chemotherapy could potentially disqualify a patient. Therefore, patients with prior chemotherapy are not eligible for the secondary trial.\n\nThus, the statement that \"Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial\" is consistent with both sets of CTR data. The statement is entailed by the CTRs because it correctly captures the distinction in eligibility criteria between the two trials.</s>",
        "contradict": "The statement \"Patients with prior chemotherapy are eligible for the primary trial, but excluded from the secondary trial\" is contradicted by the information in the CTRs. In the primary trial, patients with known clinical status and a history of chemotherapy are explicitly excluded in the Exclusion Criteria. In contrast, the secondary trial includes the statement \"No prior chemotherapy for breast cancer\" as a requirement for participation, thereby excluding patients with prior chemotherapy treatment.</s>"
    },
    "3d82851c-f302-4988-bd78-232583e04e96_neg": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy aren't eligible for the primary trial, but excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with prior chemotherapy aren't eligible for the primary trial, but excluded from the secondary trial\" is entailed by the CTR information as follows:\n\nIn the primary CTR, patients with \"unknown clinical status not participating in FMSU004A protocol\" are excluded, and those participating in FMSU004A protocol are included regardless of prior chemotherapy history. Since patients with prior chemotherapy have a known clinical status (they are not eligible for the trial), they fall under the category of \"unknown clinical status not participating in FMSU004A protocol,\" thereby fulfilling the exclusion criteria for the primary trial.\n\nIn the secondary CTR, patients with \"prior chemotherapy for breast cancer\" are explicitly listed as exclusion criteria. This directly supports the inclusion of \"Patients with prior chemotherapy aren't eligible for the primary trial, but excluded from the secondary trial\" statement.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs because the primary trial's exclusion criteria include patients with unknown clinical status not participating in FMSU004A protocol, whereas the secondary trial specifically excludes patients with prior chemotherapy, but there is no mention of patients with unknown clinical status in its exclusion criteria. Therefore, the statement's claim about patients with prior chemotherapy being excluded from both trials is only true for the secondary trial, not the primary trial.</s>"
    },
    "3d82851c-f302-4988-bd78-232583e04e96_rephrase": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "The secondary trial excludes patients with prior chemotherapy, but the primary trial doesn't.",
        "Label": "Entailment",
        "entail": "The statement \"The secondary trial excludes patients with prior chemotherapy, but the primary trial doesn't\" is entailed by the information present in the CTRs. The primary trial's inclusion criteria do not mention the exclusion of patients with prior chemotherapy, while the secondary trial's exclusion criteria state that participants cannot have prior chemotherapy. The absence of prior chemotherapy exclusion in the primary trial doesn't contradict the secondary trial's requirement, allowing the statement to be considered entailed within the CTR data.</s>",
        "contradict": "The statement \"The secondary trial excludes patients with prior chemotherapy, but the primary trial doesn't\" is contradicted by the information presented in the CTRs as follows:\n\nPrimary Trial: The exclusion criteria specify \"Subjects with unknown clinical status not participating in FMSU004A protocol\" but there is no mention of previous chemotherapy as an exclusion criterion.\n\nSecondary Trial: The exclusion criteria list \"No prior chemotherapy for breast cancer.\"\n\nTherefore, the statement contradicts the information in the CTRs since the primary trial does have an exclusion criterion related to trial participation (FMSU004A protocol), but it does not explicitly mention chemotherapy as a reason for exclusion. In contrast, in the secondary trial, there is an explicit exclusion criterion regarding prior chemotherapy.</s>"
    },
    "5c9f5916-37d3-4f6f-977b-be70204cf57c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants have the same number of calories in their diets throughout the duration of the study.",
        "Label": "Contradiction",
        "entail": "The statement \"All the primary trial participants have the same number of calories in their diets throughout the duration of the study\" is entailed by the CTR as follows:\n\n1. The CTR specifies that patients in the primary trial receive dietary counseling for dietary modifications to reduce caloric intake by a consistent percentage of their normal diet (25%).\n2. Patients follow the caloric restricted diet for a consistent duration of 10 weeks, starting 2-4 weeks after lumpectomy, continuing during radiation therapy, and lasting at least 2 weeks post radiation therapy.\n\nGiven that the counseling intervention aims to reduce caloric intake uniformly for all patients and that patients adhere to this caloric restriction for an identical duration, it follows that all participants have the same number of calories in their diets throughout the course of the primary trial.</s>",
        "contradict": "The statement \"All the primary trial participants have the same number of calories in their diets throughout the duration of the study\" is contradictory to the information present in the CTRs because the CTRs describe participants in the primary trial receiving a caloric restricted diet for a specific period (2 weeks before radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy), which implies that their diets do not maintain a consistent calorie count throughout the study.</s>"
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned.",
        "Label": "Entailment",
        "entail": "In the primary trial, both intervention groups involve the use of specific instructions for patients regarding applying certain substances (Hydrophor or MediHoney) on their skin during and after radiation therapy. The method of intervention assignment is based on cancer diagnosis. In contrast, the secondary trial assigns interventions randomly to patients (Group A for Hydrophor and Group B for MediHoney).\n\nThe provided statement is consistent with the information presented in the CTRs. The CTRs outline the application instructions and duration for both interventions (Hydrophor and MediHoney), which are assigned based on cancer diagnosis in the primary trial and randomly in the secondary trial. The statement does not contradict any information found in the CTRs and only builds upon the given details by specifying the differences in intervention assignment methods between the primary and secondary trials.</s>",
        "contradict": "The statement that \"Participants in the primary trial are assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned\" contradicts the information in the CTRs because in both the primary and secondary trials, the interventions (SWIFT MRI with Hydrophor or MediHoney) are not randomly assigned to participants, but rather, participants in the primary trial are assigned an intervention based on their status as healthy volunteers or breast cancer patients, and participants in the secondary trial are assigned an intervention of either Hydrophor or MediHoney.</s>"
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Participants in the primary trial aren't assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants in the primary trial aren't assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned\" can be entailed by the information in the CTRs as follows:\n\n1. In the primary trial, the intervention (Hydrophor and SWIFT MRI) does not differ based on cancer diagnosis. The trial description states that both healthy volunteers and breast cancer patients with suspected breast lesions undergo the same MRI screening process and SWIFT acquisition procedure. Therefore, the interventions are not assigned based on diagnosis.\n2. In the secondary trial, the interventions (Hydrophor and MediHoney) are applied to patients irrespective of their cancer diagnosis. The instructions provided in the trial description state that both groups (Group A and Group B) will consist of patients, and the interventions are to be applied starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed. The statement that interventions are randomly assigned in this trial is not directly indicated in the provided information. However, the fact that interventions are not assigned based on cancer diagnosis is an indirect implication from the information present in the CTRs.</s>",
        "contradict": "The statement that \"Participants in the primary trial aren't assigned an intervention depending on their cancer diagnosis, whereas in the secondary trial the interventions are randomly assigned\" is contradicted by the information in the CTRs because:\n\n1) In the primary trial, healthy volunteers and breast cancer patients both undergo the same MRI procedure with SWIFT acquisition and contrast injection. Although they are not assigned interventions based on cancer diagnosis in the context of MRI, this does not hold true for the overall trial as they are part of different cohorts (INTERVENTION 1 for healthy volunteers and INTERVENTION 2 for breast cancer patients).\n\n2) In the secondary trial, Group A (Hydrophor) and Group B (MediHoney) interventions are assigned to patients regardless of cancer diagnosis. The contradiction lies in the statement that interventions are randomly assigned in the secondary trial, when in reality, patients are assigned to either Group A or Group B based on the intervention being tested.</s>"
    },
    "0c5f2498-4c10-4e51-8915-d86b37b08156_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "In the secondary trial the interventions are randomly assigned, whereas participants in the primary trial are assigned an intervention depending on their cancer diagnosis.",
        "Label": "Entailment",
        "entail": "The statement \"In the secondary trial, the interventions are randomly assigned, whereas participants in the primary trial are assigned an intervention depending on their cancer diagnosis\" can be entailed by the information in the CTRs as follows:\n\nThe CTRs do not specify how the study participants for each intervention (Hydrophor or MediHoney) were assigned in the secondary trial. However, the statement explicitly states that the interventions are randomly assigned in this trial. Therefore, this assignment method is consistent with the information in the CTRs since they do not disclose any specifics about the assignment process.\n\nFor the primary trial, the CTRs indicate that the intervention assignment is contingent on the participants' diagnosis (healthy volunteers or breast cancer patients) in the primary trial. Hence, this assignment method differs from the one stated in the expert's comment for the secondary trial, which is randomized. Therefore, these two statements describe different trials and do not contradict one another.</s>",
        "contradict": "The statement that \"in the secondary trial, the interventions are randomly assigned, whereas participants in the primary trial are assigned an intervention depending on their cancer diagnosis\" cannot be directly contradicted by the information present in the CTRs, as the trials' design details beyond the provided intervention sections are not mentioned. However, the information in the statement can be considered inconsistent if we make an assumptions that the trials are comparable beyond the given sections. In the provided CTRs, the interventions are not randomly assigned but depend on the participants' cancer diagnosis and type of treatment they receive.</s>"
    },
    "c54dc963-671a-4384-8b1f-d8058a832131": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00545688",
        "Statement": "There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial\" is entailed by the CTR data because both conditions, paranasal sinus reactions and left ventricular dysfunction, are explicitly stated as having no occurrences (0/107) in both the Adverse Events 1 and Adverse Events 2 sections for the primary trial. Therefore, no patients in the primary trial experienced these conditions, as per the CTR reports.</s>",
        "contradict": "The statement \"There were no patients with paranasal sinus reactions, or Left ventricular dysfunction in the primary trial\" can be contradicted by the information present in the CTRs because:\n\n- Paranasal sinus reactions are not listed as an adverse event in the provided CTRs for either the primary or secondary trials. Therefore, the statement's assertion about no paranasal sinus reactions cannot be confirmed or denied based on the available data.\n\n- Concerning Left ventricular dysfunction, the CTR for the primary trial states \"Left ventricular dysfunction * 0/107 (0.00%)\". This means that no cases of left ventricular dysfunction were reported in the primary trial, which directly contradicts the statement's claim that \"there were no patients with (Left ventricular dysfunction) in the primary trial.\"\n\nThus, based on the provided CTRs, the statement contains an inaccuracy regarding Left ventricular dysfunction in the primary trial.</s>"
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 32 patients in the primary trial had Diarrhoea.",
        "Label": "Entailment",
        "entail": "The statement \"A total of 32 patients in the primary trial had Diarrhea\" can be entailed by the CTR data as follows:\n\nThe CTR provides the number of patients with Diarrhea in Adverse Events 1 and Adverse Events 2 for the primary and secondary trials, respectively. For the primary trial, the number of patients with Diarrhea is given as 0/213 (0.00%) initially but later in the text as 1/213 (0.47%) due to an error. However, the corrected value of 1/213 (0.47%) can be used to determine the total number of patients with Diarrhea across both trials.\n\nTotal number of patients in the Primary trial = 213\nNumber of patients with Diarrhea in the Primary trial = 1 (0.47%)\nTotal number of patients in the Secondary trial = 416\n\nTo find the total number of patients with Diarrhea in both trials, we can calculate:\n\nTotal number of patients with Diarrhea = (Total number of patients in the Primary trial * Percentage of participants with Diarrhea in the Primary trial) + (Total number of patients in the Secondary trial * Percentage of participants with Diarrhea in the Secondary trial)\nTotal number of patients with Diarrhea = (213 * 0.47) + (416 * 0.0769)\nTotal number of patients with Diarrhea = 213 * 0.47 + 317.54\nTotal number of patients with Diarrhea = 213 * 0.47 + 317 (Rounding up to the nearest whole number)\nTotal number of patients with Diarrhea = 213 * 0.47 + 316 - 1 (Subtracting one to account for double-counting of the Diarrhea case in the Primary trial)\nTotal number of patients with Diarrhea = 321 - 1\nTotal number of patients with Diarrhea = 320\n\nThe statement \"A total of 32 patients in the primary trial had Diarrhea\" is entailed since 32 is equal to 320 - 288, where 288 is the total number of patients without Diarrhea mentioned in the statement above, as calculated from the given CTR data.</s>",
        "contradict": "The statement \"A total of 32 patients in the primary trial had Diarrhoea\" contradicts the information in the CTR as the number of patients reported with Diarrhea in the primary trial was 0/213 (0.00%).</s>"
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 32 patients in the primary trial didn't have Diarrhoea.",
        "Label": "Contradiction",
        "entail": "The statement \"A total of 32 patients in the primary trial didn't have Diarrhoea\" is entailed by the primary CTR Adverse Events data since the total number of participants without Diarrhea in the primary trial is 181 (213 total participants - 32 with Diarrhea). This information is consistent with the data provided in the CTR and does not contradict it. Similarly, the absence of Diarrhea in the secondary trial's Adverse Events data (0/213) also supports this statement.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because, in the Primary Trial, no cases of Diarrhoea were reported out of the 213 total patients, while in the Secondary Trial, 32 out of the 416 patients did not have Diarrhoea. Therefore, the statement suggests a different patient population and a different number of cases without Diarrhoea than what is reported in the CTRs.</s>"
    },
    "a4c62782-9f4c-4cf5-96b3-eb8e9098a3b4_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "The primary trial had a total of 32 patients with Diarrhoea.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial had a total of 32 patients with Diarrhoea\" can be entailed by the information present in the CTR under Adverse Events 1 of the primary trial, as 32 patients represent 7.69% of the total 416 patients in the secondary trial, and 7.69% is the percentage of patients who experienced Diarrhea as listed in Adverse Events 2 of the secondary trial, and 0 cases of Diarrhoea were reported in Adverse Events 1 of the primary trial. Therefore, the difference in patient numbers between the primary and secondary trials can account for the 32 patients with Diarrhoea mentioned in the statement.</s>",
        "contradict": "The statement \"The primary trial had a total of 32 patients with Diarrhoea\" contradicts the information in the CTR as the total number of patients with Diarrhea mentioned in the primary trial's Adverse Events section is 0/213 (0.00%).</s>"
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none.",
        "Label": "Entailment",
        "entail": "The statement that \"cohort one of the primary trial reported 2/680 patients experiencing eye-related adverse events, whereas cohort two recorded none\" is entailed by the information in the CTRs if the eye-related adverse events refer to either Keratitis (occurred in 1 patient out of 680 in the primary trial) or Double vision (occurred in 1 patient out of 680 in the primary trial). This is because the CTRs explicitly list these events under the Adverse Events section for the primary trial. Since cohort one represents the entire participant population in the primary trial, and the CTRs report these specific adverse events for this cohort, the statement is an accurate representation of the data provided. Additionally, the CTRs do not mention any eye-related adverse events for cohort two in the secondary trial, which supports the statement's claim of \"none\" for that group.</s>",
        "contradict": "The information in the statement can be contradicted by the CTR data because both trials reported a total of one patient each with an eye-related adverse event (keratitis), yet the statement asserts that cohort two reported none.</s>"
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2_neg": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial didn't report 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded none.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that cohort one of the primary trial reported fewer eye-related adverse events (none) compared to cohort two. According to the provided CTRs, the number of eye-related adverse events in cohort one is 1 (Keratitis and Double vision), and in cohort two, there was no recorded occurrence of any eye-related adverse event. Therefore, cohort one reporting fewer eye-related adverse events than cohort two harmonizes with the data in the CTRs, is substantiated, and avoids contradiction with the provided descriptions, thus entailed.</s>",
        "contradict": "The expert's statement can be contradicted by the CTR data because the statement makes a comparison between the number of eye-related adverse events (keratitis and double vision) in cohorts one and two, while the CTRs do not provide this information separately for each cohort within the given adverse event categories. Instead, the CTRs provide the total number of patients experiencing each adverse event across both cohorts. In this case, there is a difference in the total number of patients in each cohort, making direct comparison of adverse event rates without further information misleading. Additionally, there are other adverse events not mentioned in the expert's statement which could impact the overall comparison as well.</s>"
    },
    "91adb350-ab20-41a6-944d-c13b55cf33f2_rephrase": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort two recorded no patients experiecing eye-related adverse events, whereas cohort one of the primary trial reported 2/680.",
        "Label": "Entailment",
        "entail": "The expert's statement that \"cohort two recorded no patients experiencing eye-related adverse events, whereas cohort one of the primary trial reported 2/680\" can be entailed by the CTR information as follows:\n\n1. The CTR for the primary trial states that \"Keratitis 1/680 (0.15%)\" and \"Double vision 1/680 (0.15%)\" were reported as adverse events in cohort one. These two events are classified as eye-related adverse events.\n2. The expert's statement claims that cohort one reported 2 instances of eye-related adverse events among 680 patients (2/680).\n3. Therefore, the expert's statement is a valid summary of the CTR information and is not contradictory to it.\n4. The expert's statement further claims that cohort two reported no instances of eye-related adverse events.\n5. The CTR for the secondary trial does not provide data on any eye-related adverse events in cohort two.\n6. However, the absence of eye-related events in cohort two is not contradictory to the CTR information, as it only confirms that the specific data on eye-related events was not reported for cohort two in the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the CTR data because it misrepresents the number of participants in each cohort who experienced eye-related adverse events. According to the CTRs, there was one instance of keratitis in cohort one (out of 680 participants), but no instances of double vision or colitis reported in either cohort. Therefore, cohort two did not record \"no patients experiencing eye-related adverse events.\"</s>"
    },
    "78949f1f-6738-4220-a233-e7831902e6f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Dose Limiting Toxicity of BYL719 in Combination With T-DM1.",
        "Label": "Contradiction",
        "entail": "The primary trial describes the assessment of Dose Limiting Toxicity (DLT) of BYL719 in combination with T-DM1 using the National Cancer Institute's Common Toxicity Criteria for adverse events version 4.0, excluding hyperglycemia. However, the trial does not report any specific DLT occurrences or results. \n\nThe secondary trial does not report information about DLTs for BYL719 in combination with T-DM1. Instead, it focuses on measuring endoxifen concentrations in participants receiving tamoxifen citrate dose of 20 mg or 40 mg stratified by the metabolizing CYP2D6 genotypes. \n\nTherefore, neither trial directly measures or reports DLTs of BYL719 in combination with T-DM1, as stated in the expert's claim. The CTRs do not entail the statement that both trials are measuring DLTs for this combination, as they do not provide data or results on this topic.</s>",
        "contradict": "The primary trial described in the CTR focuses on evaluating Dose Limiting Toxicity (DLT) of BYL719 in combination with T-DM1 using National Cancer Institute's Common Toxicity Criteria. However, the statement made by the clinical trial expert asserts that neither the primary nor the secondary trial are measuring Dose Limiting Toxicity of BYL719 in combination with T-DM1.\n\nThe contradiction arises due to the following reasons:\n1. The primary trial explicitly mentions evaluating DLTs in the outcome measurement description.\n2. The CTR provides information on the assessment methods for DLTs, the time frame, and the types and number of participants involved in the study.\n3. The secondary trial is not mentioned in the provided CTRs. The expert's statement is incorrect as both the primary and secondary trials do not have to be mentioned in the CTR for the statement to be false.\n\nHence, the clinical trial expert's statement can be contradicted by the information present in the provided Clinical Trial Reports.</s>"
    },
    "135311d8-c579-4568-913e-937be00dde7e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00390455",
        "Secondary_id": "NCT00558103",
        "Statement": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: \n1. In the primary trial, Arm I (Lapatinib) had a median PFS of 4.7 (3.7 to 5.7) months compared to 3.8 (3.8 to 5.6) months in Arm II (Placebo). A longer PFS in Arm I implies a better overall response in terms of disease control, supporting the statement that the test cohort achieved better overall response than the control group. \n\n2. In the secondary trial, Cohort 1 (Lapatinib + Placebo) had 11 participants with OR, and Cohort 1 (Lapatinib + Pazopanib) had 17 participants with OR. The larger number of participants with OR in the Lapatinib + Pazopanib group indicates a better overall response in this cohort compared to the Lapatinib + Placebo group.</s>",
        "contradict": "The statement is contradicted by the CTRs as the results for the primary trial show that Arm I (Lapatinib) had a longer median PFS compared to Arm II (Placebo), but the secondary trial does not directly compare Lapatinib to a placebo group. Instead, it compares two different dosage combinations of Lapatinib with Pazopanib. Therefore, it is not valid to make a direct comparison of overall response between the test and control groups in both trials, as the trials are studying different combinations of interventions.</s>"
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some.",
        "Label": "Entailment",
        "entail": "The statement that \"Cohort 1 of the primary trial does not receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some,\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary trial, Cohort 1 received a combination of Eribulin Mesylate and Trastuzumab with or without filgrastim for neutropenia. However, the CTR does not specify that filgrastim was used in a prophylactic manner with Eribulin Mesylate for this Cohort. In contrast, the secondary trial had two separate Cohorts receiving different regimens. In Cohort 1, Eribulin Mesylate was given following doxorubicin and cyclophosphamide, with filgrastim used as needed for neutropenia. In Cohort 2, Eribulin Mesylate was also given following doxorubicin and cyclophosphamide, but filgrastim was used prophylactically. This difference in the usage of filgrastim between the trials confirms the statement that Cohort 1 of the primary trial did not receive Eribulin Mesylate with prophylactic filgrastim, whereas both Cohorts in the secondary trial received some form of filgrastim with their Eribulin Mesylate treatment.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as Cohort 1 in the primary trial receives Eribulin Mesylate but not with prophylactic Filgrastim, whereas in the secondary trial, Cohort 1 receives Eribulin Mesylate with Filgrastim given on-demand based on neutropenia, not as prophylaxis. Therefore, the statements about Cohort 1 in both trials do not exactly match.</s>"
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa_neg": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does receive any Eribulin Mesylate With Prophylactic Filgrastim, whereas both cohorts in the secondary trial receive some.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Intervention 1 for Cohort 1 specifies the administration of eribulin mesylate and filgrastim only in case of neutropenia. Filgrastim use is discretionary and not a routine part of the intervention. In contrast, in the secondary trial, there are two cohorts, and Intervention 1 for both Cohort 1 and Cohort 2 specifies the administration of eribulin mesylate and filgrastim, with different dosing regimens but as consistent components of each intervention. Therefore, it is entailed that Cohort 1 of the primary trial does not receive Eribulin Mesylate With Prophylactic Filgrastim as a standard treatment, whereas both cohorts in the secondary trial do.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as Cohort 1 in the primary trial does receive filgrastim, but only as need arises due to neutropenia, while in the secondary trial, Cohort 1 receives filgrastim prophylactically and Cohort 2 also receives filgrastim along with eribulin. However, the statement fails to distinguish between reactive and prophylactic use, leading to a potential misrepresentation of the facts.</s>"
    },
    "0984431d-4997-41dc-9ba4-07134568c3fa_rephrase": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Both cohorts in the secondary trial receive some Eribulin Mesylate With Prophylactic Filgrastim, whereas cohort 1 of the primary trial does not.",
        "Label": "Entailment",
        "entail": "The statement \"Both cohorts in the secondary trial receive some Eribulin Mesylate With Prophylactic Filgrastim, whereas cohort 1 of the primary trial does not,\" is entailed by the CTR information because:\n\n1. In the secondary trial, Cohort 1 and Cohort 2 both receive Eribulin Mesylate as a part of their intervention, but the manner in which Filgrastim is administered differs between the two cohorts.\n\n2. In Cohort 1, Filgrastim is used at the discretion of the physician if neutropenia occurs and recovers to Grade 2. This is not considered prophylactic use.\n\n3. In Cohort 2, Filgrastim is used prophylactically at different doses based on participant weight.\n\n4. The primary trial does not mention any use of Filgrastim in conjunction with Eribulin Mesylate for Cohort 1.\n\n5. Therefore, it's true that both cohorts in the secondary trial receive Eribulin Mesylate With Filgrastim, but in different ways, while Cohort 1 of the primary trial does not receive Filgrastim prophylactically with Eribulin Mesylate.</s>",
        "contradict": "The statement \"Both cohorts in the secondary trial receive some Eribulin Mesylate With Prophylactic Filgrastim, whereas cohort 1 of the primary trial does not\" is contradictory to the information in the CTRs for the following reasons:\n\n1. In the primary trial, there is no information about the use of prophylactic filgrastim with eribulin mesylate for Cohort 1.\n2. In the secondary trial, Cohort 1 received filgrastim as needed for neutropenia recovery to Grade 2 while Cohort 2 received filgrastim as a prophylactic measure. These are different uses of filgrastim.\n\nTherefore, the statement does not hold true given the information provided by the CTRs.</s>"
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC <  1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 11 to 18 grams per deciliter are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement specifies eligibility criteria for the primary trial based on platelet count, ANC (absolute neutrophil count), and hemoglobin levels. The provided CTR details the patient characteristics section of the primary trial, which includes the specified laboratory values for platelet count (>100,000/mm\u00b3), ANC (>1,500/mm\u00b3), and hemoglobin (\u22659.0 g/dL). However, the expert statement allows for ANC to be lower than the specified value in the CTR. Since ANC is a measure of the number of neutrophils in the blood, and a lower count indicates a weaker immune response, it is reasonable that the trial may consider patients with lower ANC values, provided their platelet count and hemoglobin levels meet the other requirements. Therefore, the expert statement's conditions are a subset of those stated in the CTR and are, thus, entailed.</s>",
        "contradict": "The statement contradicts the CTR by expanding the patient eligibility criteria for the primary trial to include patients with platelet counts above 100,000/mm\u00b3 but lower than the specified 1,500/mm\u00b3 in the CTR, and by accepting hemoglobin levels between 11 grams per deciliter and the minimum of 9.0 g/dL mentioned in the CTR. Additionally, the ANC level specified in the statement is lower than the requirement in the CTR, which may exclude some patients.</s>"
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "Patients with Platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC < 1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 11 to 18 grams per deciliter aren't eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Platelet count over 100,000/mm\u00b3, ANC < 1,700/mm\u00b3 and Hemoglobin between 11 to 18 grams per deciliter aren't eligible for the primary trial\" can be entailed by the information present in the CTR as follows: \n\nThe CTR specifies \"Platelet count 100,000/mm\u00b3\" as an inclusion criterion and \"ANC < 1,500/mm\u00b3\" and \"Hemoglobin 9.0 g/dL\" as lower limits, respectively, for these lab values. Since the statement's platelet count requirement is higher than the CTR's, and both the ANC and Hemoglobin values in the statement fall below the corresponding CTR limits, it follows that patients meeting the conditions stated in the expert's claim would not meet the CTR's eligibility requirements, making the statement an entailed one.</s>",
        "contradict": "The statement \"Patients with Platelet count over 100,000/mm\u00b3, ANC < 1,700/mm\u00b3 and Hemoglobin between 11 to 18 grams per deciliter aren't eligible for the primary trial\" is inconsistent with the eligibility criteria in the CTR for the following reasons:\n\n1. Platelet count: The CTR specifies \"Platelet count 100,000/mm\u00b3\" as a requirement for patient eligibility.\n2. ANC: The CTR specifies \"ANC 1,500/mm\u00b3\" as a requirement for patient eligibility.\n3. Hemoglobin: The CTR specifies \"Hemoglobin 9.0 g/dL\" as the lower limit for Hemoglobin, and there is no upper limit mentioned. However, the statement asserts patients with Hemoglobin levels between 11 to 18 grams per deciliter aren't eligible.\n\nTherefore, according to the information provided in the CTR, the expert statement cannot be logically entailed from the trial eligibility conditions.</s>"
    },
    "d9dc4a6d-a913-46ac-b0aa-d50823ff2305_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00662129",
        "Statement": "The primary trial accepts patients with platelet count over 100,000/mm\u00ac\u00a8\u201a\u00e2\u2022, ANC < 1,700/mm\u00ac\u00a8\u201a\u00e2\u2022 and Hemoglobin between 11 to 18 grams per deciliter.",
        "Label": "Entailment",
        "entail": "The expert's statement that \"The primary trial accepts patients with platelet count over 100,000/mm\u00b3, ANC < 1,700/mm\u00b3 and Hemoglobin between 11 to 18 grams per deciliter\" is entailed by the information present in the CTRs as follows:\n- The CTR specifies that \"Platelet count 100,000/mm\u00b3\" is a requirement for patient enrollment.\n- The expert's statement that \"ANC < 1,700/mm\u00b3\" is within the acceptable range as per the CTR, which does not explicitly state a lower limit for ANC but does mention \"ANC 1,500/mm\u00b3\" as a requirement, and thus ANC < 1,700/mm\u00b3 would still meet this requirement.\n- The CTR specifies that \"Hemoglobin 9.0 g/dL\" is a requirement for patient enrollment. The expert's statement expands this requirement slightly, specifying a range of \"Hemoglobin between 11 to 18 grams per deciliter\", which is still consistent with the requirement stated in the CTR, as Hemoglobin 9.0 g/dL falls within this range.\n\nTherefore, the expert's statement is entailed by the CTRs, as it does not contradict or go beyond the information provided in the CTRs.</s>",
        "contradict": "The statement \"The primary trial accepts patients with platelet count over 100,000/mm\u00b3, ANC < 1,700/mm\u00b3 and Hemoglobin between 11 to 18 grams per deciliter\" can be contradicted by the information present in the CTRs as the primary trial in the first CTR specifies a minimum platelet count of 100,000/mm\u00b3, while the secondary trial's statement allows for lower platelet counts. Additionally, the primary trial does not provide any information about ANC or hemoglobin levels. The discrepancy lies in the specifications given about the patient characteristics.</s>"
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use non comparable evaluation metrics, and significantly different time frames.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial use non-comparable evaluation metrics, and significantly different time frames\" is entailed by the information in the CTRs because:\n\n1. In the primary trial, the outcome measurement is Progression Free Survival (PFS) presented in months, while in the secondary trial, the outcome measurement is Overall Response Rate (ORR) with Best Overall Response (CR, PR, SD, and PD) categorized. These metrics are non-comparable as they assess different aspects of treatment efficacy and patient response.\n\n2. The primary trial has a time frame of 4 years for presenting PFS results, in contrast, the secondary trial measures response rates at 48 weeks. These significantly different time frames prevent a direct comparison between the two trials.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial use non-comparable evaluation metrics, and significantly different time frames\" can be contradicted by the information present in the CTRs because the primary trial measures Progression Free Survival (PFS) over a period of 4 years, while the secondary trial assesses the Best Overall Response of patients at week 48. The metrics of measuring treatment effectiveness between the trials are not directly comparable (PFS vs Best Overall Response) and the time frames for evaluation are also distinct. This does not necessarily imply contradiction, but rather the lack of comparability between the trials.</s>"
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9_neg": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "The secondary trial and the primary trial don't use non comparable evaluation metrics, and significantly different time frames.",
        "Label": "Contradiction",
        "entail": "The statement \"The secondary trial and the primary trial don't use comparable evaluation metrics, and significantly different time frames\" can be entailed by the following observations from the CTRs:\n\n1. In the primary trial, Progression Free Survival (PFS) is used as the outcome measurement, while in the secondary trial, the Best Overall Response (OR) of Everolimus and Exemestane treatment is evaluated. These metrics are not directly comparable as PFS measures the time until disease progression, whereas ORR measures the proportion of patients with a best response of CR or PR by week 48.\n\n2. The primary trial has a time frame of 4 years, while the secondary trial has a time frame of 48 weeks. These time frames are significantly different, with the primary trial measuring a much longer duration than the secondary trial.\n\n3. The primary trial reports median PFS with 90% confidence intervals, while the secondary trial reports number of participants with different response types at week 48. These reporting methods are also not directly comparable.\n\nThus, the statement that \"The primary trial and the secondary trial don't use comparable evaluation metrics, and significantly different time frames\" is an accurate observation based on the information presented in the CTRs.</s>",
        "contradict": "The statement \"The secondary trial and the primary trial don't use comparable evaluation metrics, and significantly different time frames\" can be contradicted by the information present in the CTRs as follows:\n\n1. Comparability of Evaluation Metrics: \nThe primary trial uses Progression Free Survival (PFS) as the outcome measure under RECIST v1.1 by local assessor. The secondary trial utilizes the best Overall Response (OR) determined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.), with CR and PR defined as per the trial protocol. Although different, PFS and ORR are related as PFS is often considered a surrogate endpoint for survival and ORR is an indicator of treatment effectiveness. Thus, the evaluation metrics can be considered somewhat comparable, as both assess treatment response and efficacy.\n\n2. Similarities in the Use of Response Evaluation Criteria:\nBoth trials follow Response Evaluation Criteria in Solid Tumors (RECIST 1.1.), which is a widely accepted standard for assessing tumor response and progression.\n\n3. Different Time Frames:\nWhile the primary trial reports median PFS at 4 years and the secondary trial reports OR at 48 weeks, the different time frames are not necessarily a contradiction, as the primary trial's longer-term follow-up provides a more comprehensive understanding of disease progression, while the secondary trial assesses treatment effect within a shorter time frame. However, a direct comparison between the two studies may require adjusting for the different time frames.\n\nTherefore, while there are differences between the trials in their primary endpoints and time frames, they do share some similarities. The statement \"The secondary trial and the primary trial don't use comparable evaluation metrics, and significantly different time frames\" can be contradicted by the information present in the CTRs in the sense that the statement overlooks these similarities.</s>"
    },
    "9d9ab190-cdcf-4320-b69a-12f2dad9dba9_rephrase": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "Significantly different time frames and non comparable evaluation metrics are used in the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs because both trials report different outcome measures (Progression Free Survival in the primary trial and Best Overall Response in the secondary trial) and different time frames for evaluating those outcomes (4 years in the primary trial and 48 weeks in the secondary trial). This difference in evaluation metrics and time frames is explicitly mentioned in the text, and the statement accurately reflects that fact. No contradiction is present, as the statement does not claim that the trials are directly comparable or that the same metric and time frame should be applied to both trials.</s>",
        "contradict": "The statement \"Significantly different time frames and non-comparable evaluation metrics are used in the secondary trial and the primary trial\" is not directly contradicted by the information present in the CTRs. However, it implies that the trials cannot be compared directly, which may not necessarily be the case based on the provided information. While there are differences in the trial designs - with different outcomes measured and time frames considered - it doesn't necessarily mean the trials are non-comparable. For example, they could still be compared in terms of specific outcomes or subgroups, depending on the research question. The contradiction arises when assuming the trials are completely non-comparable based on the provided information alone, while the CTRs do not definitively state that.</s>"
    },
    "89fdf182-7474-4e70-baf7-03c8920c4ff3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial.",
        "Label": "Contradiction",
        "entail": "In the secondary trial, Intervention 2 specifies the use of a placebo for cohort 2, while the primary trial does not have a separate placebo group. The absence of a placebo arm in the primary trial does not affect the statement's entailment with the CTR, as the statement only focuses on the presence of placebo in the secondary trial. The CTRs provide sufficient information to support the statement, making it semantically entailed.</s>",
        "contradict": "The statement \"Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial\" is contradicted by the information present in the CTRs because, in the primary trial, there is a control arm receiving placebo (INTERVENTION 2), whereas in the secondary trial, the term \"cohort 2\" is not explicitly stated to be a placebo arm.</s>"
    },
    "9f2fd0cc-af87-433d-9d2f-6235591d6cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2\" can be entailed by the information present in the CTRs as follows:\n\nThe CTRs provide the cOR data for each cohort:\nCTR1: Letrozole + Placebo: CR = 2, PR = 58 (total = 60)\nCTR2: Letrozole + Lapatinib: CR = 12, PR = 54 (total = 66)\n\nTo determine which cohort has the highest cOR percentage, the total percentage for each cohort needs to be calculated:\nLetrozole + Placebo: (CR + PR) / total number of participants = (2 + 58) / 48 = 0.625 * 100% = 62.5%\nLetrozole + Lapatinib: (CR + PR) / total number of participants = (12 + 54) / 41 = 0.732 * 100% = 73.2%\n\nBased on the calculation, cohort 2 (Letrozole + Lapatinib) has the highest cOR percentage (73.2% > 62.5%). The expert's statement is consistent with the data in the CTRs.</s>",
        "contradict": "The statement \"Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2\" contradicts the provided CTR information, as cohort 2 (Letrozole + Lapatinib) had a lower percentage of participants with CR (12%) compared to cohort 1 (Letrozole + Placebo) with a CR percentage of 2%. Additionally, while the percentage of participants with PR was higher in cohort 2 (54% versus 58% in cohort 1), the absolute number of participants with PR was smaller in cohort 2. Consequently, the statement is not consistent with the data presented in the CTRs.</s>"
    },
    "90364098-7e9a-47be-ab2e-f66958cfb09d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02725801",
        "Statement": "The interventions in the primary trial and the secondary trial are applied daily for a period of several months.",
        "Label": "Contradiction",
        "entail": "The statement \"The interventions in the primary trial and the secondary trial are applied daily for a period of several months\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 (Estriol Vaginal Gel) is administered weekly, with a single application per week during weeks 1-3 and twice weekly applications during weeks 4-12. A month contains four weeks, so the gel is administered daily for approximately three months during the dosage schedule in the primary trial.\n2. In the primary trial, Intervention 2 (Placebo Vaginal Gel) follows the same dosage schedule as Intervention 1 and is also applied daily for approximately three months.\n3. In the secondary trial, Intervention 1 and Intervention 2 (one-port and two-port tissue expanders, respectively) are both surgical interventions performed at the time of breast reconstruction. The reconstruction procedure and subsequent tissue expander placements occur over several months, and there's no information specifying a different frequency for tissue expander placements.\n\nTherefore, given that tissue expander placements are performed over several months, and the vaginal gel applications in the primary trial are also daily for approximately three months, the statement \"The interventions in the primary trial and the secondary trial are applied daily for a period of several months\" holds true for both trials and is entailed by the information within their respective CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert is contradicted by the information in the CTRs because:\n\n1. In the primary trial, both Intervention 1 (Estriol Vaginal Gel) and Intervention 2 (Placebo Vaginal Gel) follow different dosing schedules: single daily application during Weeks 1-3 and twice weekly application during Weeks 4-12.\n\n2. In the secondary trial, both Intervention 1 (one-port tissue expander) and Intervention 2 (two-port tissue expander) are surgical interventions applied at the time of breast reconstruction, which does not involve daily application as stated in the expert's claim.</s>"
    },
    "021c3f62-8067-49e3-9d4b-c7641feb2548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "Both trials involve the use of trastuzumab for participants. In the primary trial, trastuzumab is given IV weekly or every 3 weeks in combination with cyclophosphamide and pegylated doxorubicin hydrochloride for HER2/neu 3+ disease patients at a dose of 2 mg/kg. In the secondary trial, trastuzumab is administered IV weekly at a dose of 2 mg/kg in combination with dasatinib and paclitaxel for all participants. Both dosages are equivalent, and the method of administration is consistent between trials, thus satisfying the statement.</s>",
        "contradict": "The statement \"The same dose of trastuzumab was used for the interventions in the primary trial and the secondary trial\" can be contradicted by the information present in the CTRs because the primary trial uses a dose of 2mg/kg in the second and subsequent cycles and the secondary trials use a dose of 2mg/kg for the loading dose and 4mg/kg in the first cycle for the cohorts with different dasatinib doses (100mg and 140mg). The contradiction arises due to the difference in the dosing regimens of trastuzumab between the trials, even though the statement claims the same dose was used for both trials.</s>"
    },
    "6893c9b4-d3a3-47a8-ada9-8aef67de2375": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR inclusion criteria as follows: (1) \"HER2-positive disease determined locally\" and \"Histologically or cytologically confirmed invasive breast cancer\" imply incurable and unresectable disease, (2) \"Documented progression of incurable, unresectable, LABC, or mBC\" also indicates incurable and unresectable status, (3) the statement does not contradict the exclusion criteria for metastatic disease in the primary CTR. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with incurable and unresectable Breast Cancer are eligible for the primary trial, unless it is metastatic\" can be contradicted by the inclusion criteria of the primary CTR that explicitly states \"Metastatic central nervous system (CNS) disease only\" and \"Brain metastases which are symptomatic\" as exclusion criteria. Therefore, patients with metastatic breast cancer are not eligible for the primary trial, contradicting the expert's statement.</s>"
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "Helen's stage III ovarian cancer history falls under the \"Other prior malignancy\" exclusion criterion stated in the Primary Trial's Eligibility Criteria section, thus her entitlement to participate in the trial is negated as per the CTR information.</s>",
        "contradict": "Helen's exclusion from the primary trial based on her previous history of stage III ovarian cancer contradicts the statement in the CTR that \"other prior malignancy is an exclusion criterion, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, stage I or II cancer from which the participant is currently in complete remission, or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years.\" Since Helen's ovarian cancer is still active and she is not in complete remission, she does not meet the specified criteria for allowed prior malignancies.</s>"
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30_neg": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 2 years prior, from which she is still recovering, she is included in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Helen, with a history of stage III ovarian cancer 2 years prior, is included in the primary trial,\" can be entailed by the CTR inclusion criteria, as long as Helen's other inclusion criteria are met. The CTR includes \"no other prior malignancy\" in the exclusion criteria. However, the statement \"from which she is still recovering\" implies that Helen's ovarian cancer is being adequately treated, allowing her to be included under the allowed exceptions for \"any other cancer (including breast cancer) for which the participant has been disease-free for 5 years.\" The CTR does not provide information on Helen's medical condition beyond what is stated about her eligibility, so the statement about her still recovering from ovarian cancer does not contradict any information in the CTR.</s>",
        "contradict": "Helen's inclusion in the primary trial, as stated, contradicts the CTR's exclusion criteria which list \"other prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or any other cancer (including breast cancer) for which the participant has been disease-free for 5 years\" as reasons for exclusion. Since Helen had stage III ovarian cancer only 2 years prior, she does not meet the criteria for being adequately treated or disease-free from cancer.</s>"
    },
    "b88cde11-ae29-48e8-832b-4b9cb2596c30_rephrase": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "The primary trial excludes Helend because she had stage III ovarian cancer 2 years prior, from which she is still recovering.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial excludes Helend because she had stage III ovarian cancer 2 years prior, from which she is still recovering\" is entailed by the CTR's exclusion criteria which states \"other prior malignancy\" except for \"any other cancer (including breast cancer) for which the participant has been disease-free for 5 years.\" Since Helend has a prior malignancy of ovarian cancer, which is not covered by the exception, she is excluded from the trial as stated in the expert's observation.</s>",
        "contradict": "The statement contradicts the inclusion criteria of the primary trial, which permits participation for individuals with a history of in situ cervical cancer or any other cancer for which they have been disease-free for 5 years. The statement mentions a participant named Helend with a history of stage III ovarian cancer, which is not an allowed condition according to the trial's exclusion criteria. However, the statement contradicts the primary CTR by stating that Helend is excluded, whereas she should have been eligible based on the given inclusion criteria.</s>"
    },
    "ebe7078c-fd8b-439a-b1f5-7bd482071ead": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02472964",
        "Secondary_id": "NCT00089661",
        "Statement": "the primary trial studies changes in tumour diameter, whereas the secondary trial investigates changes in heart failure rate.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trial expert does not entail any information directly related to the given CTRs as they describe different trials investigating distinct outcomes: the primary trial evaluates the effect of different treatments on tumor diameter using RECIST 1.1 criteria, whereas the secondary trial investigates the effect of Denosumab versus placebo on bone mineral density percentage change at Month 12. The expert's statement does not mention any semantic relationship to the outcome measurements or results provided in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert is not contradictory to the information present in the CTRs, as they pertain to different trials investigating distinct outcomes. The first CTR focuses on changes in tumor diameter using RECIST criteria, while the second CTR examines bone mineral density percent change. The expert's statement acknowledges this difference and does not attempt to make a claim about the data within the same trial.</s>"
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.",
        "Label": "Entailment",
        "entail": "The statement \"Both cohorts of the primary trial receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00b2 as monotherapy once every 21 days (1 cycle)\" is entailed by the information present in the CTRs since both the NSCLC and mBC cohorts are specified to receive pegylated irinotecan via the same intravenous dosing regimen of 145 mg/m\u00b2 once every 21 days. The difference mentioned in the statement, regarding the types of cancer in each cohort, does not contradict or alter the stated intervention details.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly. However, it may be inconsistent if additional information from the CTRs, such as different dosing regimens, schedules, or eligibility criteria for the two cohorts, exists but was not included in the given descriptions. The given statement assumes identical interventions based on the pegylated irinotecan administration method and dose. If there are no such differences, then the statement is entailed by the information in the CTRs. However, if the actual interventions have differences not accounted for in the given statement, then the statement would not be entailed by the CTRs.</s>"
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36_neg": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "Both cohorts of the primary trial don't receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days (1 cycle), the difference between the cohorts is the type of cancers that patients are diagnosed with, cohort 1 is NSCLC, whereas cohort 2 is mBC.",
        "Label": "Contradiction",
        "entail": "The statement entails that the interventions for each cohort in the primary trial differ only in the type of cancer being treated (NSCLC for Cohort A and mBC for Cohort C), not in the administration details of Pegylated Irinotecan, which is given intravenously at 145 mg/m\u00b2 as monotherapy once every 21 days (1 cycle) in both cohorts, as described in the CTRs. Therefore, the statement is consistent with the information presented in the CTRs.</s>",
        "contradict": "Although the statement acknowledges the different types of cancers in each cohort, it fails to consider potential variations in intervention details beyond the Pegylated Irinotecan dosage and frequency. For instance, the CTR doesn't mention any additional treatments or modifications that could be unique to each cohort, potentially leading to contradictory interpretations if the statement is taken to imply that all intervention details are identical between cohorts. The CTR does not provide enough information to conclusively determine if there are any other differences between the interventions beyond the cancer types and Pegylated Irinotecan administration. Therefore, while the statement correctly identifies the distinction in patient populations, it may not capture the full entailment relationship between the statement and the CTR information.</s>"
    },
    "d0b9c11c-50f2-4803-a96c-fff3ca90cf36_rephrase": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02312622",
        "Statement": "The types of cancer patients are diagnosed with differs between cohorts in the primary trial cohort 1 is NSCLC, whereas cohort 2 is mBC, however both cohorts receive identical interventions; Pegylated Irinotecan Administered intravenously (IV) at 145 mg/m\u00ac\u00a8\u201a\u00e2\u00a7 as monotherapy once every 21 days (1 cycle).",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR information since:\n 1. The statement correctly mentions the types of cancer patients in each cohort of the primary trial - NSCLC for Cohort 1 and mBC for Cohort 2. \n 2. The statement accurately identifies that both cohorts receive the identical intervention - pegylated irinotecan administered intravenously at 145 mg/m\u00b2 as monotherapy once every 21 days.\n 3. The CTRs confirm these details in their respective interventions sections, with no contradictory information.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly. However, it makes an assumption that the identical intervention in each cohort implies no difference in the types of cancer patients. This is not guaranteed based on the given information in the CTRs alone. While the interventions are identical, the patient populations and types of cancer are different in each cohort. Therefore, the statement is not an entailed conclusion based on the data in the CTRs, but rather an additional contextual observation.</s>"
    },
    "b620e1c5-69c4-4c30-9006-faa346200b60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Trastuzumab, a type of chemotherapy.",
        "Label": "Contradiction",
        "entail": "The primary trial's Intervention 1 section describes the use of Clinical Management, which is a form of psychological therapy involving half-structured interviews lasting 20-25 minutes per session. In contrast, Intervention 2 in the primary trial introduces Cognitive Behavioural Therapy (CBT), which is another psychological therapy that involves standardized treatment for a defined period.\n\nThe secondary trial, on the other hand, focuses on two groups with different interventions - Neratinib with prior trastuzumab treatment and Neratinib with no prior trastuzumab treatment. The intervention for both groups consists of taking Neratinib in a prescribed dose orally, which is not related to the type of psychotherapy discussed in the primary trial.\n\nThe statement by the clinical trials expert is entailed by the information in the CTRs as it correctly identifies the distinct types of interventions in the two trials - CBT, a type of psychological therapy in the primary trial, and Neratinib, a chemotherapeutic agent in the secondary trial. The statement does not contradict the given information in the CTRs and is harmonious with the clinical trial data.</s>",
        "contradict": "The statement is not contradictory to the CTR information, but it does not directly entail it either. While the primary trial does involve cognitive behavioral therapy (CBT), the secondary trial does not. The statement correctly identifies the difference in interventions between the two trials, but it does not address the specific details of the interventions within each trial, which is where potential semantic entailment or contradiction would be determined. Therefore, the statement can coexist with the CTR information without contradiction but also without entailment.</s>"
    },
    "0900325b-6ecd-46f1-b3f1-a2ce1605d151": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00325598",
        "Statement": "There is no difference in results or cohort size between cohort 1 and 2 of the primary trial, the increase in Gy has no notable effect.",
        "Label": "Entailment",
        "entail": "The expert's statement entails that there is no variation in the number of participants or trial outcomes between Cohort 1 (36 Gy) and Cohort 2 (40 Gy) from the primary trial. This claim is in accordance with the information given in the CTRs, where both cohorts have an identical overall number of participants analyzed, 50 each. Moreover, the statement does not contradict the CTRs, as they do not indicate any disparity in outcomes between the two cohorts. Thus, the expert's statement is entailed by the data presented in the CTRs.</s>",
        "contradict": "The expert's statement is contradictory to the information in the CTRs because the CTRs report different interventions (36 Gy in 9 fractions versus 40 Gy in 10 fractions), and the number of participants analyzed is equal for each cohort. However, the expert's statement implies that the results and cohort sizes are identical, suggesting the interventions are the same. This contradicts the given information.</s>"
    },
    "6f10e1f3-1197-464e-b574-d697fb49331d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer are eligible for both the primary trial and the secondary trial. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligilbe for the secondary trial. ",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n1. Patients with HER2+ breast cancer are eligible for both trials:\n   - Primary trial: Inclusion Criteria mention participants with a confirmed diagnosis of breast cancer, which includes HER2+ subtype.\n   - Secondary trial: Inclusion Criteria explicitly lists HER2 positive breast cancer as a requirement.\n\n2. Only patients with stage 1-2 breast cancer are eligible for the primary trial:\n   - Primary trial: Inclusion Criteria specifies participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer.\n\n3. Only patients with stage 3-4 breast cancer are eligible for the secondary trial:\n   - Secondary trial: Inclusion Criteria states participants must have stage IIIB, IIIC, or IV breast cancer.\n\nTherefore, the statement \"Patients with HER2+ breast cancer are eligible for both trials. However, only patients with stage 1-2 breast cancer are eligible for the primary trial, and patients with stage 3-4 are eligible for the secondary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradictory to the CTRs as the primary trial only includes patients with clinical stage 1 or 2 breast cancer, whereas the secondary trial includes patients with stage IIIB, IIIC, and IV erbB2 (HER2) positive breast cancer. Therefore, patients with stages 1-2 disease are eligible for the primary trial, but not for the secondary trial, and patients with stages 3-4 disease are eligible for the secondary trial, but not for the primary trial. The statement incorrectly suggests that patients with HER2+ breast cancer are eligible for both trials, regardless of stage.</s>"
    },
    "cbf91beb-829b-488f-8e80-3b08b891a181": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03592121",
        "Secondary_id": "NCT01439711",
        "Statement": "the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis.",
        "Label": "Contradiction",
        "entail": "In the primary trial, AB-101 and placebo are applied to the nipple/areola regions of patients approximately 1 hour prior to sexual activity on a daily basis, as stated by \"Apply to both nipple/areola regions approximately 1 hour prior to sexual activity\" for both Intervention 1 (AB-101) and Intervention 2 (Placebo).\n\nIn the secondary trial, letrozole is administered orally to patients at a daily dose of 2.5 mg/day. MRI procedures are scheduled at months 3 and 6, but the frequency of letrozole administration is not limited to these evaluation points. Therefore, letrozole is still being given to patients daily throughout the 6-month treatment period.\n\nThus, the statement that \"the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis\" is an entailed claim based on the information provided in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial both require their patients to receive their respective interventions on a daily basis\" is not directly contradicted by the information in the CTRs. However, it is an oversimplification, as the nature of the daily intervention differs between the trials. In the primary trial, the intervention for both the AB-101 and placebo groups is application to the nipple/areola regions approximately 1 hour prior to sexual activity (daily sexual activity implies daily application). In contrast, the secondary trial involves daily administration of letrozole orally (at a dose of 2.5 mg) and periodic MRI evaluations. While daily interventions, the modalities are distinct.</s>"
    },
    "985df98b-b397-4dbc-8fad-43ada30927d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients needing active supportive care can participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR states that there are no exclusion criteria based on the need for active supportive care. Therefore, the statement \"Patients needing active supportive care can participate in the primary trial\" is entailed by the CTR.</s>",
        "contradict": "The statement \"Patients needing active supportive care can participate in the primary trial\" contradicts the CTR information as the primary trial's eligibility criteria exclude patients with a clinical diagnosis of congestive heart failure or angina pectoris, which are conditions requiring active supportive care.</s>"
    },
    "0d4fdeef-89b2-463b-8252-66fa51d9ce8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication on the skin of the hands or feet, but rather onto the breast or chest wall.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information in the CTRs as there is a clear contradiction. The primary trial involves oral and IV administration of lapatinib and paclitaxel to the whole body, and no mention of skin applications. The secondary trial, on the other hand, involves topical application of urea/lactic acid cream to the palms and soles, and a placebo cream to a similar area for the control group. There is no overlap in terms of medication application sites between the two trials.</s>",
        "contradict": "The statement contradicts the primary CTR as the primary trial participants received interventions through different routes - oral administration for lapatinib and intravenous infusion for paclitaxel, neither of which involve application to the skin of the hands or feet. The secondary trial, however, involves topical application of creams to the palms and soles, which is distinct from the interventions used in the primary trial.</s>"
    },
    "2c270b8f-d1a4-4686-a75c-bb3ac4b0c6fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response.",
        "Label": "Contradiction",
        "entail": "The statement \"27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with Minocycline Hydrochloride did not have Pathological Complete Response\" is entailed by the given CTRs as follows:\n\nIn the primary trial, the outcome measurement defines FASN expression as having a positivity level of >= 15% at the baseline or after 4-7 days of Omeprazole monotherapy. It is evaluated using immunohistochemistry in core biopsy samples, and the percentage of patients with FASN expression that have pCR is calculated.\n\nThe secondary trial does not provide information regarding the FASN expression level of its cohort. However, it can be inferred that if a patient has FASN expression, they were included in the primary trial and thus, their FASN expression level could be >= 15% or >= 15% after 4-7 days of Omeprazole monotherapy.\n\nIn the primary trial, the results section indicates that 27.56 of the 29 patients (or 91.1%) in the High Dose Omeprazole Treatment group with FASN expression had pCR (percentage of 72.4 [52.8 to 87.3]). This implies that 8.84 of the 29 patients (or 29.6%) did not have pCR while still having FASN expression.\n\nSince the expert's statement refers to patients with FASN expression and does not contradict the given information from the primary trial, it is entailed by the information presented in the CTRs.</s>",
        "contradict": "The given statement asserts that 27.6% of patients who have FASN expression and were treated with Minocycline Hydrochloride did not achieve pCR in the primary trial. However, the information from the CTRs indicates that no data on FASN expression or pCR was provided for the secondary trial with Minocycline Hydrochloride treatment. Therefore, it is contradictory for the statement to make a claim based on the secondary trial when no such data exists in the provided CTR. Additionally, the statement refers to the primary trial, yet it is comparing a different treatment (Minocycline Hydrochloride instead of Omeprazole) which further contradicts the information from the CTRs.</s>"
    },
    "494c1f01-5a2d-409e-b614-5871f408fbe6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. ",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial, group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B\" can be entailed by the information present in the CTRs as follows:\n\n1. From the Primary Trial CTR, we know that group A and group B both received the same dosage and frequency of Patupilone administration (10 mg/m2, q3weeks), which is a potential therapeutic intervention.\n\n2. In Results 1 of the Primary Trial, it is stated that there were 45 participants in group A and 12 of them had a >25% increase in tumor area at 3 months after treatment.\n\n3. In Results 2 of the Primary Trial, it is stated that there were 10 participants in group B and no explicit information about the number of patients with >25% increase in tumor area at 3 months after treatment is provided.\n\n4. Since there's no information about group B patients having >25% increase in tumor area at 3 months after treatment in the Primary TTR, it can be inferred that this percentage is lower than that of group A based on the given information.\n\n5. In the Secondary Trial expert statement, it asserts that group A has a higher percentage of patients with >25% increase in tumor area at 3 months after treatment than group B. This is entailed by the information in the Primary Trial CTRs, as group A has a documented higher number of patients (12) with this condition compared to group B, which has no explicitly stated number.</s>",
        "contradict": "The expert's statement is based on a percentage change in tumor area greater than 25%, which is inconsistent with the PFS definition in the primary trial. Progression-free survival is defined as less than 25% increase in tumor area. Therefore, the statement contradicts the information in the primary trial CTR, which states that patients in group A with documented progression-free survival at 3 months after treatment are those who have not experienced a 25% increase in tumor area.</s>"
    },
    "17881072-2517-483f-9c03-1edad21a58cf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial\" can be entailed by the information present in the CTRs because:\n\n1. The statement asserts that there is a difference of 3 cases between the total number of Pyrexia incidents in the two trials.\n2. The CTRs provide the total number of Pyrexia incidents in both trials. In the primary trial, there are 0/42 (0.00%) instances out of a total of 42 participants. In the secondary trial, there are 2/216 (0.93%) instances out of a total of 216 participants.\n3. By subtracting the number of Pyrexia incidents in the primary trial from the number of Pyrexia incidents in the secondary trial, we get a difference of 3 cases.\n4. The statement does not contradict any information in the CTRs and only makes a comparison between the two trials based on their reported data.</s>",
        "contradict": "The statement \"In total the secondary trial recorded only 3 more cases of Pyrexia than the primary trial\" is contradicted by the information present in the CTRs because the primary trial recorded no cases of Pyrexia, while the secondary trial recorded 2 cases. Therefore, there is a discrepancy of more than 3 cases between the trials regarding Pyrexia cases.</s>"
    },
    "58ba5dfd-3d8d-42e4-8cff-3c179fcd43a7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells that have metastasised into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with cancer cells that have metastasized into less than 3 lymph nodes, with at least one larger than 2mm, cannot enter the primary trial\" is an implication of the clinical trial inclusion criteria for the node evaluation. Specifically, the statement entails the condition that ipsilateral nodes must be pN1, pN2a, or pN3a, and that pN1 nodes must not be greater than pN1c (which includes micrometastases). These conditions imply that the largest metastasis cannot be larger than 2mm and there cannot be more than 2-3 involved nodes. The statement is also consistent with the exclusion criteria for patients with suspicious nodes in the contralateral axilla or supraclavicular nodes, which would require biopsy evidence to confirm they are not involved with tumor, as well as the exclusion of patients with clinical or radiologic evidence of metastatic disease.</s>",
        "contradict": "The statement contradicts the inclusion criteria in the CTR for the primary trial, specifically regarding the node involvement. The CTR states that patients with ipsilateral nodes that are pN1 or pN2 (with or without positive internal mammary nodes) are eligible if other criteria are met. The statement, however, excludes such patients if they have more than two nodes involved and at least one is larger than 2mm. Therefore, the statement is not entailed by the information present in the CTRs.</s>"
    },
    "da6ce3a9-b653-47b2-9271-f831e4de3f19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1\" can be entailed by the CTR data as follows: The CTRs provide the number of adverse events of pleural effusion, which is an unusual amount of fluid around the lungs. The CTR for the primary trial reports zero occurrences in cohort 1, whereas cohort 2 of the primary trial has only one occurrence in 30 participants (a rate of 3.33%), which is indeed lower than the rate in cohort 1. The statement does not contradict the information given, and the provided data supports the claim. Therefore, the statement is entailed by the given CTR information.</s>",
        "contradict": "The statement \"Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1,\" can be contradicted by the information present in the CTRs because the number of participants with pleural effusion, which is a type of unusual fluid accumulation around the lungs, is higher in cohort 2 (6.67%) than in cohort 1 (0.00%).</s>"
    },
    "66979ae5-a709-4adf-9067-287f0f92b9e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00828074",
        "Statement": "A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1.",
        "Label": "Contradiction",
        "entail": "Although the statement does not directly quote adverse event percentages from the CTRs, it implicitly compares the frequency of a specific adverse event (fever) between two cohorts (cohort 1 and cohort 2). The CTRs provide the information needed to determine whether this statement is entailed. In the primary trial, 2/41 (4.88%) of participants from cohort 1 and 1/5 (20.00%) of participants from cohort 2 experienced fever. The higher percentage in cohort 2 (20.00%) does indeed indicate that a higher number of cohort 2 participants experienced fever compared to cohort 1. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"A higher number of cohort 2 participants from the primary trial experienced fever, compared to cohort 1\" is contradicted by the information present in the CTRs because the frequency of fever in both cohorts is the same: 2 participants out of 41 in cohort 1 (4.88%) and 1 participant out of 5 in cohort 2 (20.00%). The statement implies that there is a larger number of participants with fever in cohort 2, which is not true based on the data provided in the CTRs.</s>"
    },
    "0af6799b-655f-4b8b-a192-ce8dcbb2fcff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Only Black women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Entailment",
        "entail": "The expert statement is entailed by the CTR inclusion criteria, which specify that only Black women who do not have uncontrolled or symptomatic brain metastases are eligible for the trial.</s>",
        "contradict": "The statement is not an exact entailment of the information provided in the CTRs as it introduces an additional requirement - the absence of uncontrolled or symptomatic brain metastases is applicable only to Black women, whereas the CTR explicitly states that \"previously treated and clinically stable, as per Investigator's judgment, brain metastases are permitted.\"</s>"
    },
    "3a3e2387-c4c7-48e6-b3ca-1257de7019c2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00072293",
        "Statement": "Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with a palpable breast lesion and axillary lymph nodes are eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nAccording to the Primary Trial's Disease Characteristics section, patients with palpable breast lesions are eligible for the trial. Additionally, the CTR specifies that prior or planned sentinel node biopsy is required, which may uncover axillary lymph nodes with metastases. However, the CTR excludes patients with clinically evident axillary lymph nodes, meaning those with palpable axillary lymph nodes would be ineligible per the stated criteria. Therefore, the statement's condition of having both palpable breast lesions and axillary lymph nodes is an incorrect combination of eligibility factors from the CTR.\n\nHowever, it is important to notice that the provided statement does not directly contradict the CTR, as the statement's condition of having palpable breast lesions is indeed present in the trial's eligibility criteria (as mentioned earlier). Thus, the statement's first part is entailed by the CTR.\n\nTherefore, the statement is only partially entailed by the information in the CTRs. It correctly asserts that patients with palpable breast lesions are eligible for the trial, but incorrectly combines eligibility factors in stating that they can also have palpable axillary lymph nodes.</s>",
        "contradict": "The statement \"Patients with a palpable breast lesions and axillary lymph nodes are eligible for the primary trial\" is contradicted by the information in the CTRs because the CTRs specify that \"No palpable axillary lymph node(s)\" is an eligibility criterion for the primary trial. Thus, patients with palpable axillary lymph nodes do not meet the inclusion criteria for the primary trial.</s>"
    },
    "46ac8a9f-77ab-40cf-9421-64aad4ae6976": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00537771",
        "Secondary_id": "NCT00354640",
        "Statement": "participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD.",
        "Label": "Entailment",
        "entail": "In the primary trial, participants in Intervention 1 receive Anastrozole in a dose of 1 mg PO QD. In the secondary trial, participants in Intervention 1 receive both Anastrozole and Simvastatin, with Anastrozole still being administered at a dose of 1 mg PO QD. Thus, the statement that \"participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD\" is entailed by the information in the CTRs, as Anastrozole dosing remains consistent across trials for the specified cohort.</s>",
        "contradict": "The statement \"participants of cohort 1 in the primary trial and all participants of the secondary trial take 1 milligram of anastrozole PO QD\" is contradicted by the information in the CTRs because in the primary trial, cohort 1 received a daily oral dose of Arimidex (anastrozole) of 1 mg, while in the secondary trial, anastrozole was given in combination with simvastatin and the dose of anastrozole was still 1 mg PO QD, but it was part of a combination therapy instead of a monotherapy. Therefore, the statement implies that all participants are receiving monotherapy with anastrozole 1 mg PO QD, while the CTRs indicate that some participants are receiving combination therapy with anastrozole and simvastatin.</s>"
    },
    "d2b7253b-0654-4bb1-a9a4-b203714d64f9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame.",
        "Label": "Entailment",
        "entail": "Both the primary and secondary trials report on the incidence of dose limiting toxicities (DLT) within a 28-day time frame. The primary trial details the DLT incidence for subjects with solid tumors receiving Neratinib in combination with Paclitaxel, while the secondary trial reports on the number of participants with DLTs for those receiving Afatinib and Herceptin. Despite the differences in interventions, the time frame for measuring DLTs is identical between the two trials. This statement is entailed by the CTRs as they both explicitly state the time frame of 28 days for determining DLTs, making the expert's claim a logical consequence of the data presented.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame\" can be contradicted by the information present in the CTRs because the primary trial specifies the time frame for DLT measurement as \"from first dose date through day 28,\" while the secondary trial specifies the time frame for DLT measurement as \"28 days.\" Although both trials assess DLT, the different time frames for measurement in each trial prevent a direct comparison of results without further context.</s>"
    },
    "9a896e4a-ae6b-468c-a7c0-32c1514c0b48": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and more than 30% of those in cohort 2 of the secondary trial had adverse events.",
        "Label": "Entailment",
        "entail": "The expert's statement entails that the percentage of patients with adverse events in the primary trial was less than 5%, and the percentages in cohort 1 and 2 of the secondary trial were 9.68% and 32.00%, respectively. This is consistent with the CTRs provided. In the primary CTR, 4.21% of patients had adverse events, which is under 5%. In the secondary CTR, cohort 1 had 9.68% adverse events, and cohort 2 had 32.00%, which are the figures the expert used in their statement. The expert's statement does not contradict the CTRs and is a valid comparison based on the data within.</s>",
        "contradict": "The statement can be contradicted by the CTRs if there are differences in the types of adverse events or the patient populations between the primary and secondary trials that are not taken into account. Although the statement suggests higher adverse event rates in the secondary trials, it does not specify whether the same types of adverse events were present in both trials. The absence of Neutrophils/granulocytes (ANC/AGC) adverse events in the secondary trial could result in lower overall adverse event rates, but this does not necessarily mean the interventions themselves were safer in the secondary trial if other, more severe adverse events were present. Additionally, the differences in patient populations, such as demographics or baseline characteristics, could impact the incidence of adverse events. Therefore, direct comparison of adverse event percentages without considering these factors may not accurately reflect the safety profiles of the interventions in the trials.</s>"
    },
    "41eb4b9a-3b8f-4895-9aa3-cb43dbe27dd4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00356811",
        "Secondary_id": "NCT00296036",
        "Statement": "The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically.",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial specifies the administration of lapatinib orally and paclitaxel intravenously, and does not mention the application of any topical medications to the participants. Similarly, the CTR for the secondary trial explicitly states that participants receive either a urea/lactic acid-based cream or placebo cream topically, but no other interventions. Thus, the statement that \"the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically\" is entailed by the information in the CTRs, as there is no contradiction or inconsistency in this claim with the trial data.</s>",
        "contradict": "The primary trial describes the use of lapatinib and paclitaxel, which are administered orally and intravenously respectively, and do not involve the application of topical creams to the palms and soles. Therefore, the statement that \"the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically\" is contradicted by the information present in the CTRs.</s>"
    },
    "0931065d-35e4-4f82-8ef6-ac6db900127a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast cancer has spread into both the skin and the chest wall are eligible for the secondary trial, but not the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. Patients with inflammatory breast cancer or T4 features, which include cancer spreading into both the skin and the chest wall, are not eligible for the primary trial according to its disease characteristics section. However, they are explicitly stated to be eligible for the secondary trial in its inclusion criteria. This discrepancy in eligibility criteria between the two trials establishes the entailment relationship.\n\n2. Furthermore, the primary trial's patient characteristics do not include any specifications related to the presence or absence of skin involvement or involvement into the chest wall, allowing for the entailment of the given statement.</s>",
        "contradict": "The primary trial inclusion criteria specify that patients must not have inflammatory breast cancer or other T4 features, which is a type of breast cancer that can present with cancer involvement in the skin and chest wall. Thus, according to the primary trial CTR, patients with cancer spreading into both the skin and chest wall are not eligible for that trial. However, the secondary trial inclusion criteria do allow for patients with advanced and/or metastatic breast cancer, including those with inflammatory breast cancer or T4 features. This discrepancy between the trials' inclusion criteria contradicts the statement that patients with cancer spreading into both the skin and chest wall are eligible for the secondary trial but not the primary trial.</s>"
    },
    "70912726-ba1b-47ef-9005-9584c8caf559": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00853996",
        "Statement": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model , and no Family history consistent with hereditary breast cancer, are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model, and no Family history consistent with hereditary breast cancer, are eligible for the primary trial\" is entailed by the CTR inclusion criteria as follows:\n\n- Gail risk < 1.7% implies low risk of developing breast cancer within the next 5 years according to the Gail model (as specified in the primary trial's inclusion criteria).\n- The absence of any family history consistent with hereditary breast cancer as per the criteria in the primary trial (>= 4 relatives with breast cancer, >= 2 relatives diagnosed with breast cancer at 50 years of age, breast and ovarian cancer diagnosed in the same relative, or no suspicion for breast cancer on the baseline mammogram) indicates that women are not eligible for the high-risk breast cancer category.\n\nTherefore, the statement \"Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model and no Family history consistent with hereditary breast cancer\" is a logical subset of the inclusion criteria stated in the CTR for the primary trial.</s>",
        "contradict": "The statement \"Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model, and no Family history consistent with hereditary breast cancer, are eligible for the primary trial\" conflicts with the CTR's inclusion criteria as follows:\n1. The primary trial's inclusion criteria include women who have a Gail risk of 1.7% and/or a relative risk of 3 times that for their 5-year age group, regardless of whether they are considered low-risk by the Gail model or not.\n2. The statement excludes women with a family history consistent with hereditary breast cancer, whereas the CTR allows for inclusion if the family history meets certain specified criteria.\n\nIn summary, the CTR's inclusion criteria do not entail the statement made by the clinical trial expert, and there is a contradiction between them.</s>"
    },
    "6743f85c-8318-49cc-acba-94aeb1f57130": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer PFS than cohort 2. However the patient with the longest PFS was in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement that \"Cohort 1 of the primary trial had a longer median PFS than cohort 2\" is entailed by the data presented in the CTRs since the median PFS for cohort A (Sorafenib + Gemcitabine or Capecitabine) is 103 days (83 to 128 days) and the median PFS for cohort B (Placebo + Gemcitabine or Capecitabine) is 81 days (48 to 95 days). \n\nThe statement that \"there was a patient in cohort 2 with the longest PFS\" is also compatible with the CTR data, as it does not contradict any information provided in the CTRs and does not necessitate any additional assumptions. \n\nTherefore, the statement \"Cohort 1 of the primary trial had a longer PFS than cohort 2. However, the patient with the longest PFS was in cohort 2\" can be considered entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial had a longer median PFS than cohort 2. However, the patient with the longest PFS was in cohort 2\" is not directly contradicted by the information in the CTRs. However, it does not follow logically from the provided information as median PFS for each group and the individual PFS data for the longest survivor are not mentioned in the same context. The lengths of PFS for individual participants within each cohort, including the longest survivor, are not stated in the given CTRs.</s>"
    },
    "ddffa26d-2581-477a-955c-ebf0c2ab0f97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Accelerated partial Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement asserts that Accelerated Partial Breast Irradiation (APBI) is used in the secondary trial for both cohorts, but not in the primary trial. This statement is entailed by the information in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 is Sentinel Lymph Node Biopsy with radiolabeled Methylene Blue, which does not involve breast irradiation at all.\n2. In the secondary trial, there are two intervention arms: Conventional Whole Breast Irradiation (WBI) and Accelerated Partial Breast Irradiation (APBI). Both arms use APBI, but only in the second intervention arm. The first arm utilizes conventional WBI.\n\nThus, the statement's assertion that APBI is used in the secondary trial but not at all in the primary trial is in agreement with the provided information and avoids contradiction, making it a semantically entailed statement according to the CTRs.</s>",
        "contradict": "The information in the statement contradicts the CTRs because the primary trial does not involve a partial breast irradiation intervention at all, whereas the secondary trial has two arms, one using conventional whole breast irradiation and the other using accelerated partial breast irradiation. The statement's claim about the presence of accelerated partial breast irradiation in both arms of the secondary trial is not entailed by the information provided in the CTRs.</s>"
    },
    "f1a45b47-498d-45c8-b6d9-6c8f035da30b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Statement": "1 patient in the primary trial was affected by Sepsis.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial was affected by Sepsis\" is entailed by the data in the CTR as one of the adverse events recorded was \"Septic Shock,\" which is a known complication of Sepsis.</s>",
        "contradict": "The statement \"1 patient in the primary trial was affected by Sepsis\" cannot be definitively contradicted or confirmed by the information given in the CTRs without additional context. Although Septic Shock, a severe form of sepsis, is mentioned in the CTR for the primary trial with an incidence rate of 2.5%, the CTR does not specify if this case was the same individual who experienced anaemia, febrile neutropenia, neutropenia, or thrombocytopenia, which can be contributing factors to sepsis. Therefore, the statement is ambiguous and may or may not be in agreement with the data in the CTRs depending on which patient is being referred to. To establish entailment, more precise information about which patient(s) in the trial experienced sepsis is required.</s>"
    },
    "a5272c37-0e32-42db-a44a-d17df7bd70ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00179309",
        "Statement": "There were no pain related adverse events observed in the primary trial.",
        "Label": "Entailment",
        "entail": "None of the adverse events listed in the primary and secondary CTRs include \"pain\" as a symptom, thus there were no pain related adverse events observed in the primary trial as stated. The CTR information does not entail, contradict, or contradict the statement.</s>",
        "contradict": "The statement \"There were no pain related adverse events observed in the primary trial\" contradicts the information present in the CTRs as there are mentions of injection site reactions, which are classified as adverse events and can involve pain. Therefore, the presence of injection site reactions in both primary and secondary trials (as indicated in the CTRs) contradicts the statement's claim of no pain-related adverse events in the primary trial.</s>"
    },
    "4c67a7b4-36fa-4c20-a15a-122609550973": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201773",
        "Statement": "Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Adele is an 85 year old woman with Stage IV histologically confirmed ER+ breast cancer with an ECOG of 0, she has a life expectancy below 6 months and a history of thrombotic events. She is eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Adele is a female with histologically confirmed breast cancer (primary trial: inclusion criteria)\n2. Adele's breast cancer is Stage IV (primary trial: inclusion criteria)\n3. Adele's breast cancer is ER+ (primary trial: inclusion criteria)\n4. Adele's ECOG Performance Status is 0 (primary trial: inclusion criteria)\n5. Adele is over 50 years old (implicit in the term \"postmenopausal\" from primary trial: inclusion criteria), thus she is 85 years old\n6. Adele is eligible for the trial despite having a life expectancy below 6 months (not explicitly mentioned in primary trial: inclusion criteria, but the exclusion criteria do not state that a patient with a life expectancy below 6 months is ineligible)\n7. Adele's history of thrombotic events does not necessarily exclude her from the trial, as the primary trial does not list it as an exclusion criteria and only certain specific types of NSAIDs are excluded (primary trial: exclusion criteria)</s>",
        "contradict": "The information stated about Adele being eligible for the primary trial despite having a history of thrombotic events contradicts the trial's exclusion criteria, which specify that patients with a history of myocardial infarction or other thrombotic events are not eligible for participation.</s>"
    },
    "120c6aa7-fcaa-4eaa-b520-6382968a6724": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different dental imaging modalities, namely Mammography and gamma imaging.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the information in the CTRs because both trials described in the reports involve different imaging modalities, namely Mammography and gamma imaging, for the interpretation and analysis of their respective reporting arms.</s>",
        "contradict": "Although the expert statement acknowledges the use of two different imaging modalities in the primary trial, it incorrectly identifies their applications. The CTRs specify that the interpretation and analysis were done with mammography only for one arm and with gamma imaging only for the other arm. Contradictorily, the expert statement infers that both modalities were used for the same trial participants, rather than recognizing that each modality was used for distinct reporting arms within the primary trial.</s>"
    },
    "e35ebcea-f1ca-4c26-aa3b-2dc5de1a8645": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for preventing any change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Contradiction",
        "entail": "The expert's statement infers that the Zoledronic Acid Upfront arm exhibits a greater prevention of L1-L4 BMD change compared to the Zoledronic Acid Delayed-start arm based on the reported mean percentage BMD changes. According to the CTRs, the mean percentage change in BMD for the Zoledronic Acid Upfront arm is 1.955%, while the mean percentage change for the Zoledronic Acid Delayed-start arm is -2.325%. The negative value for the Delayed-start arm implies a greater loss or decrease in BMD. Given that the Upfront arm has a positive value and a smaller absolute value compared to the Delayed-start arm, it can be inferred that the Upfront arm results in a smaller change in L1-L4 BMD than the Delayed-start arm, as stated in the expert's claim.\n\nAdditionally, both arms received the same interventions for Letrozole, calcium, and vitamin D, ensuring a consistent comparison. The eligibility criteria for both arms are not explicitly stated in the information given but are presumed to be equivalent as they both involve participants at risk of lumbar spine fracture. The trial designs and analysis methods also appear to be comparable. Thus, the expert's statement is a logical conclusion based on the information provided in the CTRs.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the information present in the CTRs. However, the CTRs do not definitively prove that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start. The statement makes a causal claim, implying that Zoledronic Acid Upfront results in a greater BMD preservation effect. While the CTRs show different mean percent changes in BMD, they do not provide sufficient information to establish causation or determine which treatment is better. Additionally, other factors like standard deviations, p-values, and statistical significance tests are required to assess the clinical relevance and significance of these differences. Therefore, the expert's statement goes beyond the information in the CTRs, and further analysis and interpretation are needed to determine if it is accurate or not.</s>"
    },
    "ac997ae1-7e48-48e2-af9e-f7e289622250": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00798135",
        "Secondary_id": "NCT01209195",
        "Statement": "the primary trial and the secondary trial investigate different outcome measures for different interventions.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial investigate different outcome measures for different interventions\" can be entailed by the following facts drawn from the CTRs:\n\n1. In the primary trial, the outcome measure is the determination of the pharmacokinetics (PK) of oral itraconazole in patients with MBC.\n2. In the secondary trial, the outcome measure is the evaluation of the safety and tolerability of escalating doses of MM-121 in combination with paclitaxel to determine the recommended phase 2 dose.\n3. The two trials use different interventions:\n   a. In the primary trial, itraconazole is given orally at a dose of 200mg a day until disease progression or unacceptable toxicities.\n   b. In the secondary trial, MM-121 is administered intravenously as a loading dose of 20 mg/kg or 40 mg/kg, followed by a weekly dose of 12 mg/kg or 20 mg/kg, while paclitaxel is given intravenously at a dose of 80mg/m2 weekly.\n4. The primary trial focuses on measuring trough plasma levels of itraconazole and its metabolite 6-OH itraconazole at steady state in week 2 and 4.\n5. The secondary trial uses the 3+3 model to determine the maximum tolerated dose (MTD) based on reports of dose-limiting toxicities (DLTs).\n6. The primary and secondary trials do not share the same intervention, nor do they measure the same outcome.</s>",
        "contradict": "The statement does not contradict the information in the CTRs as both trials indeed investigate different outcome measures for different interventions. However, the statement does not provide enough detail to directly entail or infer any specific information from the CTRs. It only states that the trials have different outcome measures for different interventions, which is an observable fact based on the provided descriptions.</s>"
    },
    "59328f44-6755-4dcb-b04c-4e0ce2ba3ac8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month, the patient with the longest OS was in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement that \"the difference in median Overall Survival (OS) of Patients between the two cohorts of the primary trial was less than one month, and the patient with the longest OS was in cohort 1\" can be entailed by the following facts from the CTRs:\n\n1. The primary trial compares the OS of patients receiving NKTR-102 (Group A) with the OS of patients receiving TPC (Group B).\n2. The medians (95% CI) of OS for Group A and Group B are 7.8 (6.1-10.2) months and 7.5 (5.8-10.4) months, respectively.\n3. The difference between these medians is less than one month (0.3 months, to be precise).\n4. The CTRs do not provide information on the longest OS observed in each cohort, but the statement does not contradict the given data.\n\nThus, the statement can be entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs; however, it fails to provide sufficient context to establish semantic entailment. The statement mentions \"the difference in median Overall Survival (OS) of Patients\" but it does not clarify which trial or cohort the statement is comparing. Moreover, the statement does not indicate which patient had the longest OS or which cohort that patient belonged to. The CTRs, on the other hand, provide clear information on the median OS for each cohort and the number of participants analyzed. To establish entailment, the statement would need to explicitly compare the median OS of the \"NKTR-102\" and \"TPC\" groups and include the relevant patient information (i.e., longest OS and its corresponding cohort) to harmonize with the data in the CTRs.</s>"
    },
    "441c0760-ca4a-4f1d-864e-a77395fd1f18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Lapatinib group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Contradiction",
        "entail": "The statement entails that the Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen for the Lapatinib group in the primary trial is smaller than that of the Odanacatib 5 mg group in the same trial. This can be derived from the information in the CTRs as follows:\n\nResults 1 and 2 report the percentage change in u-NTx levels for the ZA 4 mg and Odanacatib 5 mg groups, respectively, at Week 4 compared to baseline. According to the data, the mean percentage change for the ZA 4 mg group is -73% (95% CI: -80% to -62%) and for the Odanacatib 5 mg group is -77% (95% CI: -82% to -71%). Since -73% < -77%, the statement is entailed by the information in the CTRs, indicating that the Lapatinib group had a smaller percentage change in u-NTx compared to the Odanacatib 5 mg group.</s>",
        "contradict": "The statement cannot be directly contradicted by the information present in the CTRs, as they do not provide data on the Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen for the Lapatinib group in the primary trial. To make an accurate determination of entailment or contradiction, both the statement and the CTR information must pertain to the same trial and the same outcome measure. In this case, only the Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen for the ZA 4 mg and Odanacatib 5 mg groups are provided in the CTRs. To evaluate the statement, data on the Lapatinib group would be required.</s>"
    },
    "fbe60029-8944-4e12-b4b2-3413037a10cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery.",
        "Label": "Entailment",
        "entail": "The statement that \"57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery\" can be entailed by the information present in the CTRs because the CTRs provide the number of participants (16) who achieved Pathological Complete Response Rates at Surgery in Cohort 1. Dividing this number by the overall number of participants analyzed in Cohort 1 (28) results in a percentage of 57.14%. This percentage is close enough to 57% for the statement to be considered entailed by the information in the CTRs. Additionally, the statement does not contradict any information in the CTRs.</s>",
        "contradict": "The statement \"57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery\" contradicts the information in the CTR because there is no mention of the percentage of participants in Cohort 1 achieving a Pathological Complete Response in the provided Results 1 section. The statement's assertion goes beyond the information available in the CTR, as the CTR only reports the number of participants achieving a Pathological Complete Response in Cohort 1 (which is 16).</s>"
    },
    "fe1782aa-a871-4608-a7cb-8f83b7f76d8a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the intervention section does not mention the use of Gemcitabine.\n2. In the secondary trial, there are two interventions mentioned. The use of Gemcitabine is specifically stated in the description of intervention 1 for cohort 2.\n3. The statement correctly specifies the trials and the interventions where Gemcitabine is or isn't used, based on the provided information in the CTRs.</s>",
        "contradict": "The statement \"Gemcitabine is not used in the primary trial, and used only in cohort 2 of the secondary trial\" can be contradicted by the information in the CTRs as follows:\n\n1. In the primary trial, gemcitabine is explicitly stated in the Intervention 1 description as \"gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration of each 21-day treatment cycle,\" which means it is indeed used in the primary trial, not only in cohort 2 of the secondary trial.\n\nHowever, it's worth noting that the primary trial includes other chemotherapy agents such as cyclophosphamide, doxorubicin hydrochloride, and radiation therapy along with gemcitabine. The statement's focus on gemcitabine alone may lead to a misunderstanding that it wasn't used in the primary trial.\n\nTherefore, while technically the expert's statement contradicts the CTR, the context of their claim can lead to confusion, which highlights the importance of considering the full context when evaluating the relationship between statements and clinical trial reports.</s>"
    },
    "a153ecbf-11ac-4c40-a3af-9dbb0e12c49b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "There is no overlap in treatments used in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is no overlap in treatments used in the primary trial and the secondary trial\" is entailed by the information present in the CTRs because, in the primary trial, the intervention is MAESTRO and there is no mention of any breast tissue expansion or use of carbon dioxide or saline. In the secondary trial, there are two interventions, AeroForm Tissue Expansion and Saline Tissue Expansion. However, since the MAESTRO intervention is not present in this trial and the first interventions of both trials are distinct (AeroForm vs. Saline), the statement is an accurate reflection of the information in the CTRs.</s>",
        "contradict": "The statement \"There is no overlap in treatments used in the primary trial and the secondary trial\" can be contradicted by the information present in the CTRs because both trials involve the use of tissue expansion as an intervention, but the methods of tissue expansion differ. In the primary trial, MAESTRO is used, which is not explicitly stated to be a type of tissue expander. However, in the secondary trial, two different types of tissue expanders are mentioned: AeroForm Tissue Expansion (inflated by carbon dioxide through remote control) and Saline Tissue Expansion (inflated by needle injections of saline). Although the primary trial is not using the exact same type of tissue expander as in the secondary trial, they both share the common intervention of tissue expansion.</s>"
    },
    "bcd48c1e-bfeb-4f1e-993f-cbbe4fadbf6e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients intracranial metastasis may be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with intracranial metastasis may be eligible for the primary trial\" cannot be directly entailed by the information present in the CTRs. The CTRs clearly state that \"No metastatic disease to the Central Nervous System\" is an exclusion criterion for the primary trial. Therefore, according to the information provided, patients with intracranial metastasis would not meet the eligibility criteria.</s>",
        "contradict": "The statement \"Patients intracranial metastasis may be eligible for the primary trial\" is contradicted by the CTR inclusion criteria that \"exclude patients with metastatic disease to the Central Nervous System.\" Therefore, patients with intracranial metastasis would not meet the eligibility criteria for the primary trial.</s>"
    },
    "4dc22366-3ff3-41c8-aa4c-7342d7b7085d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate.",
        "Label": "Entailment",
        "entail": "The statement \"The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate\" can be entailed by the information presented in the CTRs as follows:\n\n1. The sum of participants with PD in both Cohort A and Cohort B is 80 (40 from Cohort A and 40 from Cohort B).\n2. The number of participants with an unknown CNS objective response rate is 26 (8 from Cohort A and 18 from Cohort B).\n3. The total number of participants analyzed in both Cohort A and Cohort B is 237 (94 from Cohort A and 143 from Cohort B).\n4. Therefore, the majority of the participants, which is over 50%, have either Progressive disease or an undetermined CNS objective response rate.</s>",
        "contradict": "The statement \"The majority of the primary trial subjects either had Progressive disease or undetermined CNS objective response rate\" contradicts the information in the CTRs because it goes beyond the provided data. The CTRs explicitly report the numbers and percentages of participants in each response category: Complete response (CR), Partial response (PR), Stable disease (SD), Progressive disease (PD), and Unknown for both cohorts. \n\nHowever, the statement makes a general assertion about \"the majority\" of subjects, which is not directly supported by the CTR data. It is true that the majority of participants had either PD or unknown CNS response rate, according to the given CTRs for cohorts A and B. But, the statement incorrectly implies that this is the case for all subjects in the primary trial. The CTRs do not report the total number of participants or the exact percentage that experienced Progressive disease or had undetermined CNS response rate across both cohorts. Therefore, the statement is not semantically entailed by the information in the CTRs.</s>"
    },
    "196c2132-c735-4b79-bf03-3a830fcaf0fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial records several central nervous system related adverse events in its patients, whereas the secondary trial does not\" can be entailed by the information present in the CTRs as follows: \n\nIn the primary CTR, under Adverse Events 1, there is one instance (1/30, or 3.33%) of a \"seizure,\" a central nervous system disorder. There are no explicit mentions of central nervous system disorders in the secondary CTR. However, the absence of specific central nervous system disorders listed in the secondary CTR does not contradict the statement if we consider \"several\" central nervous system related adverse events as a minimum of one event. The primary trial's recording of one such event is sufficient to satisfy the statement's claim, as the secondary trial does not report any central nervous system disorders at all.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because neither of the trials records any central nervous system related adverse events in their respective sections, as per the provided descriptions. In the primary trial, the section on Adverse Events 1 lists one instance of seizure under the category of Nervous system disorders - Other, specify, but this does not equate to a \"central nervous system related adverse event\" as claimed in the statement for the primary trial. Similarly, in the secondary trial, there is no mention of any central nervous system related adverse event in either section of Adverse Events. Therefore, the statement's assertion is contradicted by the data in the CTRs.</s>"
    },
    "72619b0a-57c2-465c-8428-72019b59f8ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Cardiac failure occurred in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as none of the cases of Enteritis, Vertigo, or Cardiac failure were reported in the Adverse Events section of cohort 1 in the Primary Trial, whereas all these adverse events were reported in cohort 2 according to the CTR data. Therefore, the statement accurately conveys information that is present and not contradictory within the CTRs.</s>",
        "contradict": "The statement that \"In the primary trial, all cases of Enteritis, Vertigo and Cardiac failure occurred in cohort 2\" contradicts the CTRs as there are reports of Enteritis, Vertigo, and no cases of Cardiac failure in cohort 1 of the primary trial, according to the Adverse Events 1 data. Therefore, the statement does not hold semantic entailment with the information present in the CTRs.</s>"
    },
    "b8663fa7-585a-4cd9-afd2-89e8e1a58b82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark complained he had a racing heart twice in the last month and he is therefore excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "Mark's statement that \"he had a racing heart twice in the last month\" is entailed by the Primary CTR's Exclusion Criteria, specifically \"Clinically significant, uncontrolled heart disease and/or recent cardiac events.\" This condition excludes patients with such conditions, thereby implying that individuals with a racing heart would not be eligible for the trial.</s>",
        "contradict": "Mark's exclusion based on his self-reported racing heart is not contradicted by the information in the CTRs, as the CTRs do not provide information regarding cardiac events or cardiac function as eligibility criteria. However, if Mark had a history of clinically significant, uncontrolled heart disease and/or recent cardiac events, he would be excluded according to the Primary Trial's Exclusion Criteria. The statement by the expert does not necessarily contradict the CTRs, but it might not apply to the trial population based on the given information.</s>"
    },
    "7c92d075-ba9d-45b5-9834-83b09d2753bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer treatments to their patients through IV.",
        "Label": "Entailment",
        "entail": "Both trials describe intravenous (IV) administration of treatments. In the primary trial, patients receive MEDI4736 and tremelimumab IV, while in the secondary trial, patients receive IV zoledronic acid. The method of administration is consistent between the trials.</s>",
        "contradict": "Although both trials involve intravenous (IV) administration of treatments, the Primary Trial and the Secondary Trial differ significantly in their intervention details. In the Primary Trial, patients receive two separate IV treatments (MEDI4736 and tremelimumab) in combination initially and then sequentially for different durations. In contrast, the Secondary Trial administers a single IV dose of Zoledronic Acid. The statement's generality, \"both administer treatments to their patients through IV,\" is contradicted by the specific intervention details outlined in the CTRs.</s>"
    },
    "0e8d1b4f-d6f6-455a-a7e3-07f67a8fbcc8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday.",
        "Label": "Contradiction",
        "entail": "Ketoconazole, a medication listed in the secondary trial's exclusion criteria, is mentioned as a medication that Hannah has been taking for 6 weeks prior to her intended participation in the primary trial. The primary trial excludes participants who have used ketoconazole within 4 weeks of enrollment. Since Hannah has discontinued the use of ketoconazole at least 4 weeks before her planned trial participation, her eligibility for the primary trial is consistent with the provided CTR data. Therefore, the statement \"If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will be eligible for the primary trial next Tuesday\" is entailed by the information in the primary trial CTR.</s>",
        "contradict": "The statement that \"Hannah will be eligible for the primary trial next Tuesday\" is contradicted by the information in the CTR because she is excluded from the trial if she has used ketoconazole within 4 weeks prior to enrollment.</s>"
    },
    "9a346aac-46c2-4a50-8f3a-309b3b7bc295": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention.",
        "Label": "Contradiction",
        "entail": "The statement \"Neither the primary trial nor the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention\" is entailed by the information present in the CTRs because:\n\n1. The CTRs explicitly mention the interventions used in the trials for both the primary and secondary studies.\n2. The statement asserts that \"Neither\" of the trials uses \"Low Dose Magnesium Oxide, Biopsies or Mometasone\".\n3. The primary trial interventions are an online support group led by a healthcare provider and another in a peer-led format online. Neither of these interventions involves \"Low Dose Magnesium Oxide, Biopsies or Mometasone\".\n4. The secondary trial intervention is a diagnostic procedure using radiolabeled Methylene blue for sentinel lymph node biopsy. Again, this intervention does not involve \"Low Dose Magnesium Oxide, Biopsies or Mometasone\".\n5. Therefore, since the CTRs do not list \"Low Dose Magnesium Oxide, Biopsies or Mometasone\" as interventions for either trial, the statement \"Neither the primary trial nor the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Neither the primary trial nor the secondary trial use Low Dose Magnesium Oxide, Biopsies or Mometasone in their intervention\" can be contradicted by the information present in the CTRs as neither of them explicitly states the absence or inclusion of Low Dose Magnesium Oxide, Biopsies, or Mometasone in their interventions. The CTRs only provide details about the specific interventions used in each trial, as mentioned in the descriptions above. Therefore, the absence of Low Dose Magnesium Oxide, Biopsies, or Mometasone in the interventions is not entailed by the information presented in the CTRs.</s>"
    },
    "949d79e0-95db-47a2-802a-6280c0255923": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02132949",
        "Secondary_id": "NCT01111825",
        "Statement": "Between both of the patient cohorts of the primary trial and the secondary trial there was only a single patient with a deficiency of granulocytes in the blood.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information in the CTRs because, in the primary trial, there was one patient (out of 199) who experienced agranulocytosis (a deficiency of granulocytes) in Adverse Event 1, with a total of 56 adverse events reported. In the secondary trial, there were no reported cases of aganulocytosis, as stated in Adverse Event 1. Therefore, the expert's statement is correct as it describes the occurrence of only one case of agranulocytosis across both trials.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial report indicates that there were two patients with granulocytopenia (agranulocytosis and neutropenia), whereas the secondary trial reported no cases of this condition. The expert's statement implies that only one patient from the two trials had a granulocyte deficiency, but that is not consistent with the data in the CTRs.</s>"
    },
    "6e080a1e-a03e-4547-a7c4-c9d5a80de977": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced serious eye disorders.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients participating in the primary trial and the secondary trial experienced serious eye disorders\" cannot be entailed by the information present in the CTRs as there is no mention of any serious eye disorders reported as adverse events in either CTR.</s>",
        "contradict": "The statement that \"Patients participating in the primary trial and the secondary trial experienced serious eye disorders\" is contradicted by the information in the CTRs as there is no mention of any eye disorders being reported as adverse events in either of the trials. The CTRs provide details of adverse events experienced by the patients, and none of them include eye disorders.</s>"
    },
    "63218fb2-3f5b-4738-bea8-11fbbc560949": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with severe malabsorption disorders are ineligible for the primary trial, unless they are able to receive intravenous (IV) alimentation\" is entailed by the CTR's exclusion criteria for the following reason:\n\nThe primary trial's exclusion criteria state that patients with \"requir[e] intravenous (IV) alimentation\" are excluded. Malabsorption syndrome, a type of severe GI tract disease that results in an inability to take oral medication, is listed among the exclusion criteria. Therefore, if a patient has severe malabsorption disorder, they are generally ineligible for the primary trial unless they can receive IV alimentation, as stated in the expert's statement. This is an entailment because the statement does not contradict the CTR information and is a logical conclusion based on it.</s>",
        "contradict": "The statement is contradicted by the CTRs as the exclusion criteria explicitly list malabsorption syndrome as a condition that disqualifies patients from participating in the primary trial, and there is no mention of an exception for those able to receive IV alimentation.</s>"
    },
    "d7fa4f81-e108-491f-9b08-c147a33863e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information present in the CTRs as follows:\n\n- In the primary trial's Intervention 1 for Arm A, Vinflunine is administered intraveinously on day 1 of each cycle, and Capecitabine is administered orally for 14 days.\n- Therefore, patients in Arm A receive both intraveinous and oral medication.\n- Although the statement in the CTRs does not exactly replicate the expert's statement (\"patients receiving intervention 1 will be administered medication orally AND intraveinously\"), it does entail this statement since the CTRs' description of the administration methods for each drug in Intervention 1 implies that patients receive both types of medication.</s>",
        "contradict": "The statement \"Patients receiving intervention 1 of the primary trial, will be administered medication orally and intraveinously\" is contradicted by the information present in the CTRs because the intervention described in the CTRs for Arm A of the primary trial specifies intravenous administration of vinflunine on day 1 of each cycle and oral administration of Capecitabine for 14 days. Therefore, the statement's assertion that patients would be administered medication orally and intraveinously for the same intervention contradicts the specifications provided in the CTR.</s>"
    },
    "f24afb09-ea65-457f-9f9b-0db3cc3101ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00849472",
        "Statement": "Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes.",
        "Label": "Contradiction",
        "entail": "The statement \"Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR specifies that the primary outcome measurement was the number of participants with pCR in the Breast and Nodes. It also states that there were 93 participants analyzed in total within the study. Given that \"two dozen\" is equal to 24, if we assume that approximately 24 participants achieved pCR, the number stated in the expert's claim would be consistent with the information presented within the CTR. The claim does not contradict any information in the CTR and aligns with the stated outcome measurement and total number of participants, making it entailed by the CTR.</s>",
        "contradict": "The statement made by the clinical trials expert, \"Two dozen the primary trial participants are classified as having Pathologic Complete Response (pCR) in the Breast and Nodes,\" contradicts the information presented in the CTRs because the statement suggests that there were 24 participants with pCR, whereas the CTR indicates that there were 16 participants analyzed for pCR in the primary trial. The number of participants with pCR according to the expert's statement is higher than the reported number in the primary CTR.</s>"
    },
    "3cd79df2-e6dd-41dd-b819-4d993b5f7aed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial\" is entailed by the information present in the CTRs as none of these conditions are mentioned as adverse events in the Primary Trial's Adverse Events section. The provided CTR mentions the occurrence of various other adverse events, but none of them include Leukopenia, Epitasis, or Arrhythmia.</s>",
        "contradict": "The statement \"There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial\" contradicts the information presented in the CTRs because:\n\n1. Leukopenia: Though no specific number is mentioned for leukopenia in the CTR, it is stated that Neutropenia, a form of leukopenia, was present in 3/26 (11.54%) participants.\n   Therefore, the statement is not accurate, as it implies that no cases of leukopenia, including neutropenia, were reported in the trial.\n\n2. Epitasis: The primary CTR mentions one case (1/26 or 3.85%) of Epitasis. The statement claims that there were no cases observed.\n\n3. Arrhythmia: No mention of arrhythmia is made in either the primary or secondary CTRs. However, the statement implies that there were no occurrences of arrhythmia in the primary trial, which cannot be definitively confirmed or contradicted based on the provided CTR information.\n\nIn summary, the expert's statement contradicts the information presented in the CTRs regarding Leukopenia (Neutropenia) and Epitasis.</s>"
    },
    "d2d6f646-5881-42a2-b965-0c6f79e89463": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR as it aligns with the eligibility criteria section specifying that a bone density scan within 2 standard deviations from normal within the past 30 days is required, and if the results are 2 standard deviations below normal, it is allowed if approved by the study physician.</s>",
        "contradict": "The statement \"Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, the study physician can still decide to let them participate\" is contradictory to the CTR information in the following aspects:\n\n1. Timing of bone density scan: The CTR states that a bone density scan must be done within 30 days before or after randomization, not exactly one month prior to study entry.\n2. Allowance for bone density scan results: The CTR indicates that if the bone density scan is 2 standard deviations below normal but approved by the study physician, candidates are still eligible for the study. However, the statement implies that only those who have a bone density scan result more than 2 standard deviations below normal and are still allowed by the study physician can participate. This is a potential contradiction because the CTR does not specify that only those who are approved by the study physician despite having results more than 2 standard deviations below normal can participate.</s>"
    },
    "428d5165-560b-4783-8c4b-5fd3a3289cab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding one year.",
        "Label": "Entailment",
        "entail": "The absence of patients with a PFS greater than one year in either cohort is an implication of the reported data. In the first cohort (Trastuzumab + Anastrozole), the median PFS was 4.8 months (3.7 to 7) for the 24-month period and 5.8 months (4.6 to 8.3) for the entire study. None of the values exceeded 12 months. Similarly, in the second cohort (Anastrozole), the median PFS was 2.4 months (2 to 4.6) for the 24-month period and 2.9 months (2.1 to 4.5) for the entire study, none of which surpassed one year. Therefore, the expert's statement is an entailed consequence of the information presented in the CTRs.</s>",
        "contradict": "The statement \"There were no patients in either cohort of the primary trial with a PFS exceeding one year\" is contradicted by the data in the CTRs, as evidenced by the following reasons:\n\n1. In Results 1, for the Trastuzumab + Anastrozole group, the median PFS in the End of Study was 5.8 months (4.6 to 8.3), indicating that some patients had a PFS greater than one year.\n2. In Results 2, for the Anastrozole group, the median PFS in the End of Study was 2.9 months (2.1 to 4.5), and while it's shorter than in the Trastuzumab + Anastrozole group, it still implies that some patients had a PFS greater than one year, albeit a smaller percentage.\n\nHence, the statement is contradicted by the CTR data.</s>"
    },
    "6e7df2e4-11b3-4183-aefc-760f85809515": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02536794",
        "Secondary_id": "NCT00712985",
        "Statement": "the primary trial and the secondary trial both administer Zometa to their patients through IV, although in different doses.",
        "Label": "Contradiction",
        "entail": "Both trials involve intravenous (IV) administration of Zometa (Zoledronic Acid) to their respective patient cohorts, albeit with differing dosing regimens. In the primary trial, MEDI4736 and tremelimumab are the primary interventions; however, anti-B7H1 monoclonal antibody MEDI4736 is continued to be administered IV every 2 weeks for up to 18 additional doses as part of the treatment regimen. The secondary trial specifically mentions that Zometa (Zoledronic Acid) 5 mg IV is given over 15 minutes as a one-time dose. The statement's assertion that both trials administer Zometa to their patients through IV aligns with this information in the CTRs, as it acknowledges the IV administration of Zometa in both trials.</s>",
        "contradict": "While it is true that both trials involve administering Zometa (Zoledronic Acid) to their patients via IV, the statement does not correctly reflect the information provided in the CTRs. In the primary trial, Zometa is not mentioned as a part of the intervention; it is only mentioned as a component of correlative studies related to a different treatment (Zoledronic Acid is not the same as MEDI4736). In contrast, the secondary trial is specifically focused on Zoledronic Acid as the intervention, administered as a one-time dose, which is different from the continuous dosing regimen in the primary trial. Therefore, the statement can be contradicted by the details in the CTRs.</s>"
    },
    "45e6b4b6-ca31-4318-936e-5b27cbca47a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR information because:\n\n1. The expert's statement refers to a patient from the primary trial with a 2.87 cm3 decrease in Total MRI FTV over 3 months.\n2. The primary trial's CTR specifies that Mean Total MRI FTV change from baseline to month 3 (V3) is calculated by subtracting the total MRI FTV measured at 3 months from the total MRI FTV measured at baseline, and that the raw change in volume is calculated for each patient.\n3. The CTR also states that for V3, a mean and 95% confidence interval are constructed using two-sided t-tests, and the time frame for this measurement is up to 3 months from the start of treatment.\n4. Given that the expert's statement describes a patient with a 2.87 cm3 change in Total MRI FTV between baseline and month 3, it falls within the specified time frame and aligns with the calculation method described in the CTR. This means that the expert's statement can be inferred from, or is an entailed consequence of, the information provided in the CTR.</s>",
        "contradict": "The statement \"One patient in the primary trial had a 2.87 cm3 decrease in Total MRI Functional Tumor Volume (FTV) over 3 months\" cannot be directly contradicted by the information in the CTRs since it doesn't involve a specific patient from the trial. However, the statement cannot be definitively confirmed from the CTRs either. The CTR reports the mean change in FTV for the entire cohort treated with letrozole and MRI, which was -1.93 cm3 (-2.87 to -0.98) over 3 months. The statement mentions a decrease of 2.87 cm3 for an individual patient, which is larger than the reported mean change but falls within the reported 95% confidence interval. However, the CTR does not provide enough information to definitively confirm that this specific patient was included in the reported results. Therefore, while the statement does not contradict the CTR, it cannot be definitively verified either based on the information provided.</s>"
    },
    "22a6d10e-55c5-4a8c-8010-3e8252bcb279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have recently undergone External beam radiation therapy are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial includes \"Patients may have received prior radiation therapy\" under the inclusion criteria. This implies that patients who have recently undergone external beam radiation therapy are included in the trial per the CTR information. Therefore, the statement made by the expert is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patient who have recently undergone External beam radiation therapy are eligible for the primary trial\" is contradicted by the CTR's Exclusion Criteria, specifically \"Major surgery within 2 weeks before study entry.\" External beam radiation therapy is considered a major surgery, making patients who have undergone it ineligible for the trial according to the provided information.</s>"
    },
    "7fd1ae1e-bfdb-4c37-aaea-ed97663758e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment, but is administered much more often.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial treatment lasts for a shorter period of time than the secondary trial treatment, but is administered much more frequently\" is entailed by the information in the CTRs as follows: \n\n1. The primary trial treatment involves accelerated partial breast brachytherapy, which is delivered over 5-7 days with a minimum of 6 hours separation between fractions, totaling around 12-14 days.\n2. The secondary trial treatments involve Cranial Microcurrent Electrical Stimulation (CES), which is administered once daily for 18 weeks, equivalent to 126 days.\n\nTherefore, although the duration of the primary treatment (in terms of number of days spent at the clinic) is shorter than the secondary treatment, the primary treatment is administered more frequently (with multiple daily fractions) than the secondary treatment, which entails the expert's statement.</s>",
        "contradict": "The statement is contradicted by the CTRs as the primary trial treatment (accelerated partial breast brachytherapy) actually lasts longer in terms of total dose delivery (3400 cGy in 10 fractions) compared to the secondary trial treatments (each lasting for 1 hour of CES usage daily for 18 weeks). However, the primary treatment is indeed administered more frequently with a shorter separation between fractions (5-7 days). But the statement focuses on the total duration of treatment and the number of administrations, which do not align with the information provided in the CTRs.</s>"
    },
    "50d119f6-a657-4619-918e-7617ac57f052": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 1 of the primary trial reported one case of AML.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial reported one case of AML\" is entailed by the information in the CTRs since both reports indicate that \"Acute myeloid leukaemia\" appeared in one participant in the respective cohorts: 1/26 (3.85%) in the primary trial and 0/24 (0.00%) in the secondary trial. The statement's assertion is a specialization of the reported data, making it entailed.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial reported one case of AML\" can be contradicted by the information present in the CTR as the number of cases reporting Acute Myeloid Leukaemia (AML) in the Primary Trial's Adverse Events Section 1 is given as 1/26 (3.85%), not 1/1. The statement suggests that there was one case in the entire cohort, while the CTR indicates that there was one case among 26 participants.</s>"
    },
    "e436827b-10db-4179-bf8f-07786ee6145b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Statement": "There are no racial criteria for entry into the primary trial, however there are gender criteria.",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria state that both males and females are eligible for participation. While there is a gender distinction, there is no mention of racial criteria. Therefore, the absence of racial criteria in the expert's statement is consistent with the information provided in the CTR.</s>",
        "contradict": "The statement \"There are no racial criteria for entry into the primary trial, however there are gender criteria\" can be contradicted by the information present in the CTRs because the CTRs explicitly state that the trial includes both males and females. However, the statement implies that there are no gender criteria, which is not consistent with the information provided in the CTRs.</s>"
    },
    "fcc6708a-b0fc-4215-a45f-02b1e0e2d30a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Statement": "Patients with hemophilia are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Patients with hemophilia are excluded from the primary trial\" is entailed by the information in the CTRs as there is no mention or inclusion of patients with hemophilia in the primary trial's Eligibility Criteria section.</s>",
        "contradict": "The statement \"Patients with hemophilia are excluded from the primary trial\" cannot be directly contradicted by the information present in the given CTRs as hemophilia is not listed in the exclusion criteria specified for the primary trial. However, it can be inferred that the primary trial may exclude patients with hemophilia based on the general exclusion criteria related to bleeding risk or coagulation disorders, which are not explicitly mentioned but can be implied from the exclusion of patients with \"any swallowing dysfunction\" or \"active bleeding or a pathological condition that carries a high risk of bleeding.\" Nonetheless, the absence of an explicit exclusion for hemophilia does not contradict the statement but rather leaves room for interpretation and further investigation.</s>"
    },
    "d63706f1-4fb8-488d-8f86-c1a19df341d4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00944047",
        "Secondary_id": "NCT00228943",
        "Statement": "Patients with tumors underexpressing HER2 are excluded from the primary trial, but may be included in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial explicitly excludes patients with HER-2 neu 0+ or 3+ tumors (CTR of primary trial: EXCLUSION CRITERIA), while the secondary trial includes patients with HER-2 neu underexpressed tumors (statement). The CTR of the secondary trial does not provide information regarding HER-2 neu status as an inclusion or exclusion criterion.</s>",
        "contradict": "The statement is contradictory to the CTR information since the primary trial excludes patients with HER2 neu 0+ or 3+ by immunohistochemistry, and FISH amplified tumors (FISH ratio >2.2) from participation, while the secondary trial makes no mention of HER2 status as an inclusion or exclusion criterion.</s>"
    },
    "ab357056-67a7-4227-966d-8c96eb1640fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath for half a minute.",
        "Label": "Entailment",
        "entail": "The CTR specifies that patients in the primary trial must be able to maintain a 30 second breath hold as an inclusion criteria. The statement made by the expert falls within this requirement, as 30 seconds is longer than half a minute (30 seconds < 60 seconds). Therefore, every candidate meeting the trial's inclusion criteria also satisfies the expert's statement.</s>",
        "contradict": "The statement that \"Candidates for the primary trial are expected to be capable of holding their breath for half a minute\" is contradicted by the CTR as it does not mention the requirement for breast cancer patients to hold their breath during the trial. Therefore, the statement goes beyond the information provided in the CTR and cannot be considered entailed. The CTR explicitly states the inclusion criterion as a patient's ability to maintain a 30 second breath hold, but it does not indicate that this ability is related to the trial procedure or treatment, only to the eligibility requirement.</s>"
    },
    "0359eef3-6339-485e-95bc-0cb6fa7bcd12": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00635050",
        "Statement": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial excludes patients with node-negative, ER or PR-positive tumors whose tumors are low risk (score of 0-17) on an Oncotype DX profile. ER and PR receptors are markers for estrogen dependence in breast cancer, and low-risk Oncotype DX profiles often indicate a lower probability of hormone receptor positivity. Therefore, the statement about patients with breast cancers that have estrogen receptors being excluded from the primary trial is entailed by the CTR inclusion criteria.</s>",
        "contradict": "The statement \"Patients with Breast cancers that have estrogen receptors are excluded from the primary trial\" is contradicted by the information in the CTR as follows:\n\n* Inclusion Criteria: Patients must have known ER, PR, and HER-2 status. ER, PR positive tumors with a score of 0-17 on Oncotype DX profile are not eligible only if they are node-negative and 4 cm in size with a low-risk score. This implies that patients with ER, PR positive tumors can be included in the trial if they are node-positive, have larger tumors, or have high-risk Oncotype DX scores.\n\nTherefore, the statement \"Patients with Breast cancers that have estrogen receptors are excluded from the primary trial\" is not entailed by the information in the CTR.</s>"
    },
    "57ef3c6c-b4e1-4302-b423-aa9faca21200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial do not use the same route of administration for their interventions.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial do not use the same route of administration for their interventions\" is entailed by the CTRs as follows:\n\n1. In the primary trial, the HER2/neu peptide vaccine and the ex vivo-expanded HER2-specific T cells are given intravenously (IV), while sargramostim is given intradermally (ID). These are different routes of administration.\n2. In the secondary trial, the PET-guided biopsy itself does not involve administration of any intervention; it is a diagnostic procedure and not a treatment, so it does not have an associated route of administration.\n\nTherefore, the statement that the primary and secondary trials do not use the same route of administration for their interventions is an accurate description of the differences in the trials and is entailed by the information provided in the CTRs.</s>",
        "contradict": "Contrary to the statement, the primary and secondary trials both employ intravenous (IV) administration for certain interventions. The primary trial uses IV administration for cyclophosphamide, ex vivo-expanded HER2-specific T cells, and HER2/neu peptide vaccine (booster doses). The secondary trial uses IV administration for the PET guided biopsy procedure, although this is not a therapeutic intervention but rather a diagnostic one.</s>"
    },
    "29d5779b-c228-4b82-9ca8-075beadae879": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than eukopenia observed in the primary trial, but less cases of Febrile neutropenia than Neutropenia.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTRs as follows: \n\n1. The primary trial reported 10 cases of Febrile neutropenia and 15.82% total cases of adverse events.\n2. The secondary trial reported 10 cases of Febrile neutropenia and 18.30% total cases of adverse events.\n3. The primary trial reported 14 cases of Neutropenia and 3.75% of total cases of adverse events.\n4. There were more cases of Febrile neutropenia than eukopenia (normal neutrophil count) in the primary trial because 10 cases of Febrile neutropenia is greater than 0 cases of eukopenia.\n5. The statement \"There were more cases of Febrile neutropenia than eukopenia observed in the primary trial,\" is an accurate summary of the CTR data.\n6. The statement \"but less cases of Febrile neutropenia than Neutropenia,\" can also be derived from the CTRs, as 10 cases of Febrile neutropenia are less than 14 cases of Neutropenia.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because it asserts that there were fewer cases of Febrile neutropenia than Neutropenia in the primary trial, but according to the data provided, there were fewer cases of Febrile neutropenia than Neutropenia in both trials (10 vs 14 in the primary trial and 10 vs 17 in the secondary trial), which means the statement is not entailed by the data in the CTRs.</s>"
    },
    "4e124d90-68d7-40bd-a8b1-27cb49d64c64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00591864",
        "Statement": "the primary trial patients receive Trametinib, Akt Inhibitor GSK2141795 PO QD on days 1-28, up to a maximum of 8 cycles.",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information present in the CTRs as there is no mention of any treatment intervention, including Trametinib or Akt Inhibitor GSK2141795, in the provided Intervention section of the primary CTR.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the primary CTR as it does not provide any information about the interventions used in the trial. However, the statement refers to the patients in the primary trial receiving a specific intervention - Trametinib and Akt Inhibitor GSK2141795 - which is not mentioned in the primary CTR. Therefore, the statement goes beyond the information provided in the CTR and cannot be considered entailed by it.</s>"
    },
    "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the route of administration for both interventions in the primary trial is a topical skin cream.",
        "Label": "Contradiction",
        "entail": "The expert's statement is not entailed by the information present in the CTRs, as the CTRs do not mention the route of administration for either intervention being a topical skin cream. The information in the CTRs is inconsistent with the expert's statement as they describe the interventions as celecoxib and placebo, respectively, without specifying the route of administration.</s>",
        "contradict": "The statement made by the clinical trial expert is contradictory to the information in the CTRs as the provided descriptions indicate that the interventions in the primary trial involve oral administration of celecoxib and placebo, not topical skin creams.</s>"
    },
    "f4c7dae5-012f-4f05-b5ba-da072fe1359c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed suffering from Enteritis.",
        "Label": "Contradiction",
        "entail": "The term \"Enteritis\" encompasses various inflammatory conditions of the small intestine or colon. While \"Haematemesis\" is a symptom of gastrointestinal bleeding, it does not necessarily mean Enteritis; however, Enteritis can lead to Haematemesis. Since the CTR for the primary trial reports one incidence of Haematemesis, it does not contradict the expert's statement about one patient experiencing Enteritis. The CTR does not mention Enteritis explicitly, but its presence does not conflict with the available information in the trial. Therefore, the expert's statement can be entailed by the data in the CTR.</s>",
        "contradict": "The statement \"One patient in the primary trial was observed suffering from Enteritis\" is contradicted by the information in the CTR if no case of Enteritis is reported in the primary trial's Adverse Events section. The CTR indicates no occurrences of Enteritis among the 66 participants.</s>"
    },
    "927bbb75-37da-4b75-9483-252d31a0fd98": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section.",
        "Label": "Entailment",
        "entail": "The statement \"The primary trial does not provide a duration of cycles or any dosages in the intervention section\" is entailed by the information present in the CTRs since the primary trial's intervention section is not specified to include such details.</s>",
        "contradict": "The statement \"Unlike the secondary trial, the primary trial does not provide a duration of cycles or any dosages in the intervention section\" does not directly contradict the information in the CTRs. However, it implies that the primary trial lacks essential intervention details that are present in the secondary trial. This inference may not be accurate, as the provided CTR snippet for the primary trial does not include any details about the intervention duration or dosages, but it is possible that such information exists elsewhere in the full CTR. The discrepancy lies in the assumption that the primary trial's lack of explicit intervention information equates to a contradiction with the secondary trial.</s>"
    },
    "80a5cdbc-0721-41b6-af1a-28e3f46557ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had a cardiac related adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"1 patient in the primary trial had a cardiac related adverse event\" is entailed by the data in the CTRs. The CTR for the primary trial reports 2 adverse events related to the cardiovascular system: acute coronary syndrome (1 occurrence) and cardiac arrest (1 occurrence). Therefore, one patient in the primary trial experienced a cardiac related adverse event, which matches the statement.</s>",
        "contradict": "The statement \"1 patient in the primary trial had a cardiac related adverse event\" can be contradicted by the information presented in the CTRs because the total number of cardiac related adverse events in the primary trial is reported as 2 (atrial fibrillation and cardiac arrest, each occurring in one patient). However, the statement only mentions one patient, potentially creating a contradiction with the reported data. Similarly, in the secondary trial, there is one reported instance of atrial flutter, another cardiac related adverse event. Therefore, the statement may not hold true if referring to both trials.</s>"
    },
    "af710d36-8062-4412-8d11-1c57a14b5e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00217672",
        "Secondary_id": "NCT00110084",
        "Statement": "the primary trial had three times the occurence rate of fistula enterovesical as the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial reported one occurrence of fistula enterovesical in 74 participants, corresponding to a rate of 1.35%. The secondary trial reported one occurrence in 50 participants, corresponding to a rate of 2.00%. For the statement to be entailed by the CTRs, it must hold true that the rate of occurrence in the primary trial is three times the rate in the secondary trial. To verify this, we calculate the ratio of the occurrence rates:\n\n1.35% (primary) / 2.00% (secondary) = 0.675\n\nWe need to find three times the rate of occurrence in the secondary trial, which is 3 * 2.00% = 6.00%. The ratio of the occurrence rates is less than this value.\n\nTherefore, the statement is not entailed by the information present in the CTRs. The statement claims that the occurrence rate of fistula enterovesical in the primary trial is three times the occurrence rate in the secondary trial, while the data in the CTRs shows otherwise.</s>",
        "contradict": "The statement that \"the primary trial had three times the occurrence rate of fistula enterovesical as the secondary trial\" is contradicted by the information present in the CTRs because the occurrence rate of fistula enterovesical in the primary trial is 1.35%, while in the secondary trial it is 0.4%, which is less than one third of the primary trial's rate.</s>"
    },
    "c91c7dc1-17b7-4475-9aec-38999a18a306": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00717405",
        "Statement": "There were several patients who contracted Pneumonia in the primary trial.",
        "Label": "Contradiction",
        "entail": "Pneumonia is not explicitly mentioned in the provided CTRs as an adverse event. however, some of the mentioned adverse events like Fevers (Febrile bone marrow aplasia, Febrile neutropenia, Pyrexia) and Respiratory symptoms (Impaired healing, Inflammation) can be potential symptoms of Pneumonia. Therefore, while the statement does not directly entail any information from the CTRs, it is plausible based on the implied relationships between the mentioned adverse events and Pneumonia, making it entailed up to a certain degree.</s>",
        "contradict": "The statement \"There were several patients who contracted Pneumonia in the primary trial\" cannot be conclusively determined from the information present in the CTRs as pneumonia is not listed as an adverse event in either the primary or secondary CTRs provided.</s>"
    },
    "5357ce66-7f7b-4ffd-926c-f6116f5a2e20": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial observed a different number of adverse events in their patients.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial observed a different number of adverse events in their patients\" can be entailed by the information in the CTRs as the primary trial reported a total of 25 adverse events in 60 patients (41.67%), whereas the secondary trial reported a total of 4 adverse events in 26 patients (15.38%). Additionally, the specific adverse events listed for each trial vary. The primary trial reported several different types of adverse events, including anemia, cardiac failure, and thrombocytopenia, while the secondary trial reported gastric volvulus, hospitalization for intrapleuric chemotherapy and thoracentesis, and acute renal failure. The differing numbers and types of adverse events between the trials support the statement that they observed a different number of adverse events in their patients.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because it does not provide sufficient specificity regarding the types of adverse events being compared between the primary and secondary trials. The statement mentions \"different number of adverse events,\" but the CTRs provide information on specific types of adverse events (e.g., anemia, febrile neutropenia, cardiac failure, etc.) which can vary in frequency between trials. To determine if the statement is entailed or contradicted by the CTRs, it would be necessary to compare the frequency of specific types of adverse events across the trials.</s>"
    },
    "3c7ecca8-5397-41f5-b72b-84217bf3acd2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial,\" is entailed by the information present in the CTRs since the CTRs explicitly state \"No systemic oral steroids administered within 28 days prior to initiating treatment on protocol.\" Chronic obstructive pulmonary disease that does not require daily systemic corticosteroids falls under the category of topical, ocular, and nasal steroids and those applied to mucus membranes, as per the CTR's eligibility criteria. Therefore, women with chronic obstructive pulmonary disease who do not require systemic corticosteroids are eligible for the trial as per the CTRs.</s>",
        "contradict": "The statement that \"Women with chronic obstructive pulmonary disease that do not require systemic corticosteroids, are eligible for the primary trial\" can be contradicted by the CTR information because the CTR explicitly states that \"No topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes. No systemic oral steroids administered within 28 days prior to initiating treatment on protocol.\" This means that regardless of the requirement for systemic steroids for managing chronic obstructive pulmonary disease, such steroids are still excluded from participation in the trial.</s>"
    },
    "2c53e14a-719c-4994-9090-73f9bddb60ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00615901",
        "Secondary_id": "NCT00829166",
        "Statement": "the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTRs because the primary trial reported one seizure (1/38) and the secondary trial reported no seizures (0/490 and 0/488 in both sets of Adverse Events data). The primary trial had fewer patients (38), but the presence of a seizure event in the primary trial (a higher rate of 2.63%) contrasts with the absence of seizure events in the secondary trials (a rate of 0% in both sets of Adverse Events data). This contrast is consistent with the statement that the primary trial recorded more seizures than the secondary trial, despite having fewer patients.</s>",
        "contradict": "The statement \"the primary trial recorded more seizures despite having less than one tenth the number of patients in its total cohort compared to the secondary trial\" contradicts the information in the CTRs because:\n\n1. The statement infers that there were more seizure cases in the primary trial, whereas the actual numbers of seizure cases are given as 1 in the primary trial and 0 in the secondary trial.\n2. The statement implies that the primary trial has a higher seizure rate (5.26%) than the secondary trial (18.78%). However, the seizure rate in the primary trial is lower.\n3. The statement does not account for the overall number of adverse events, which is less in the primary trial (5.26%) compared to the secondary trial (20.29%).\n\nTherefore, the statement contradicts the information provided in the CTRs.</s>"
    },
    "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response.",
        "Label": "Contradiction",
        "entail": "The statement that \"In total, more participants in the primary trial had no tumor response, than partial response, and only 3 patients had a complete response\" is entailed by the CTRs, as follows:\n\n1. The CTRs provide the number of participants having a confirmed CR and PR for both Lapatinib 1500 mg QD and 500 mg BID arms.\n2. From Results 1 and 2, we can determine that:\n   - For Arm/Group 1 (Lapatinib 1500mg QD), there were 0 confirmed CRs and 15 confirmed PRs in a total of 69 participants.\n   - For Arm/Group 2 (Lapatinib 500mg BID), there were 0 confirmed CRs and 18 confirmed PRs in a total of 69 participants.\n3. The total number of participants in both arms is 138 (69 + 69), and the total number of confirmed CRs is 0 (0 + 0), while the total number of confirmed PRs is 33 (15 + 18).\n4. Therefore, the number of participants with no tumor response (neither CR nor PR) is 105 (138 - 33).\n5. The statement that \"In total, more participants in the primary trial had no tumor response, than partial response, and only 3 patients had a complete response\" is true, as per the CTRs.</s>",
        "contradict": "The expert's statement contradicts the CTR data because, based on the provided information, more participants had a partial response (PR) than no response in both the Lapatinib 1500 mg QD (15 participants) and Lapatinib 500 mg BID (18 participants) arms. Therefore, the statement is not entailed by the CTR data.</s>"
    },
    "bfb617c8-51ae-4ab2-be05-6346daad5437": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00820222",
        "Secondary_id": "NCT01819233",
        "Statement": "the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial and the primary trial interventions both require subjects to follow caloric restricted diets or gluten free diets, while completing food diaries\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial for Intervention 1 (Lapatinib Plus Capecitabine), the text mentions that \"no special dietary instructions were given to the patients\" (implying a standard diet). However, for Intervention 2 (Trastuzumab Plus Capecitabine), no such mention is made and both medications have no known requirement for specific diets. Thus, the participants in both interventions are free to follow their regular diets, which could potentially include caloric restriction or other modifications.\n\n2. For the secondary trial, the intervention clearly states that patients \"receive guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet.\"\n\n3. Neither of the CTRs mention anything about a requirement for gluten-free diets in either intervention. However, the statement does not contradict the CTRs on this point, so the lack of explicit mention does not preclude the possibility that some participants may be following gluten-free diets.\n\nTherefore, the statement is entailed by the CTRs because it accurately describes a shared element (caloric restriction) in the diets for the subjects in both trials, and does not contradict the information provided in the CTRs about dietary requirements.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial interventions do not require subjects to follow gluten-free diets, only caloric restricted diets. The secondary trial intervention mentions neither caloric restriction nor gluten-free diets in the exact same context as the primary trial interventions (i.e., as part of the intervention itself). Instead, it mentions a caloric restricted diet as part of a broader context that includes dietary counseling and radiation therapy. Therefore, the statement is not an accurate reflection of the interventions as described in the primary CTRs.</s>"
    },
    "dcc5c3b0-848b-4ef4-afe6-e9c9933e33af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines.",
        "Label": "Contradiction",
        "entail": "The statement \"Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial, unless treated with herbal medicines\" is entailed by the CTRs because:\n\n1. In the primary trial's exclusion criteria, having an abnormal LVEF (Left Ventricular Ejection Fraction) is mentioned as a reason for exclusion (section: PRIMARY TRIAL: EXCLUSION CRITERIA, item: Congestive heart failure, abnormal left ventricular ejection fraction, or other significant heart disease, or who have had a myocardial infarction within the past year).\n\n2. Pregnancy or lactating is also listed among the exclusion criteria in the primary trial (section: PRIMARY TRIAL: EXCLUSION CRITERIA, item: Pregnant or lactating).\n\n3. The statement introduces an exception for pregnancy and lactating women if they are using herbal medicines, but this is not mentioned in the provided CTRs. Thus, the statement is not directly entailed by the information in the CTRs. However, the statement is not contradictory to the CTRs either. It is a more general statement about eligibility criteria in clinical trials. The CTRs provide the specific exclusion criteria for the primary trial, while the statement could potentially apply to other trials with different inclusion/exclusion criteria.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the inclusion criteria of the primary trial as stated in the CTR because the statement makes an additional assumption that is not explicitly stated in the given trial's criteria - that herbal medicines can reverse the exclusion of patients with abnormal LVEF or pregnancy/lactating status. However, according to the primary trial's exclusion criteria, there's no mention that herbal medicines can override these exclusions. Therefore, the statement's assumption is not entailed by the information in the CTR.</s>"
    },
    "18fcd396-cb03-4e80-bb2d-ee03c12ba32a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of pregnancy, in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Throughout both the secondary trial and the primary trial, there was only one case of pregnancy, in cohort 1 of the secondary trial,\" does not directly entail information from the provided Adverse Events sections in the CTRs. The statement pertains to demographic information not mentioned in the Adverse Events sections, which focuses on the occurrence of specific health conditions. The CTRs only mention the number of participants, their conditions, and the number of instances of certain adverse events. The statement does not contradict any information in the CTRs, but it does not entail any specific details regarding adverse events or their relationship to pregnancy.</s>",
        "contradict": "The statement does not provide information on the number of pregnancies in the CTRs, only that one occurred in cohort 1 of the secondary trial. The CTRs, however, do not mention the number of pregnancies or pregnancy status of the participants. Therefore, the statement does not contradict or entail the information present in the CTRs, as the two datasets address different aspects.</s>"
    },
    "694c5820-ebb6-4271-8685-a0b51c637f7f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no significant difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.",
        "Label": "Entailment",
        "entail": "Both trials use the same outcome measure, \"Number of Subjects With Clinical Benefit,\" based on the RECIST system. The time frames for assessing clinical benefit in the primary trial (every 12 weeks beyond 24 weeks up to Week 108 and every 24 weeks thereafter) are long enough to capture the effect of the interventions in both trial arms (Exemestane alone and Exemestane + Celecoxib) until 9 months following the last subject's last visit. \n\nThe primary trial provides the overall number of participants analyzed for each arm (49 in the Exemestane alone arm and 51 in the Exemestane + Celecoxib arm). The expert's statement implies that the number of participants with clinical benefit was compared between the two arms, and no significant difference was found. This conclusion aligns with the CTR information as both trials used the same outcome measurement and time frames, and the number of participants analyzed for each arm is available to compare. Therefore, the expert statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs if the absolute number of participants experiencing clinical benefit differs significantly between the two cohorts despite similar proportions. Since the number of participants analyzed in each cohort and the measurement unit are the same, a difference in the number of participants experiencing clinical benefit, even with similar proportions, would lead to a statistical significance in the analysis, contradicting the expert's statement.</s>"
    },
    "b87abb47-13b6-4dbe-9cfd-e63075b676aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Contradiction",
        "entail": "The expert statement asserts that on assessment 0 (Day 1 of Cycle 2), the participants in the primary trial experienced a confirmed disappearance of all target and non-target lesions, which is equivalent to having a complete response (CR) as per the definition provided in the CTR. However, the CTR indicates that there were no participants in the SUNITINIB+CAPECITABINE arm who achieved a CR (based on the RECIST criteria). Therefore, the expert statement is not directly entailed by the CTR data.\n\nHowever, it's essential to note that the expert statement might be based on an erroneous assumption or incomplete knowledge of the trial data, as the CTR only indicates the total number of participants with CR+PR, not their individual response status at every assessment point. To accurately evaluate the expert statement's entailment with the CTR, it's necessary to access more comprehensive data, such as individual participant response trajectories or additional information on the assessment methodology.</s>",
        "contradict": "The statement made by the clinical trial expert contradicts the information in the primary CTR since no participant in the trial had a confirmed disappearance of all target and non-target lesions based on the provided data. According to the CTR, there were 19 participants with confirmed PR but none with CR, which does not meet the definition of \"disappearance of all target and non-target lesions\" in the statement.</s>"
    },
    "eb025223-1b4a-4df7-a85e-2eeeb62a6bf5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed under a year ago, are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement implies that patients eligible for the primary trial have received anastrozole therapy for more than 5 years and completed it within the past year. According to the CTR, patients must have received aromatase inhibitor therapy for 4\u00bd - 6 years, which includes anastrozole. Therefore, the expert's statement falls within the scope of the CTR's eligibility criteria, making the statement entailed by the information presented in the CTR.</s>",
        "contradict": "The statement is contradicted by the CTR information as it includes patients with hormone receptor status of the primary tumor unknown, whereas the statement specifies only those with ER+ and/or PR+ tumors. Therefore, the CTR may contain eligible patients who do not meet this requirement stated in the expert's claim.</s>"
    },
    "23df2cc2-6aae-4251-a8a7-e2f5a65f176a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "None of the adverse events which occurred in the primary trial were not GI related.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the adverse events which occurred in the primary trial were not GI related\" cannot be definitively entailed by the provided CTR data alone. The CTRs do not report any adverse events related to the gastrointestinal system for either trial. However, absence of evidence for a particular condition in the CTRs does not necessarily imply that the condition did not occur during the trial; it merely indicates that it was not reported. The statement would be entailed if, in addition to the given data, there was evidence in the CTRs that all adverse events for both trials were GI-related. Without this additional information, it is impossible to determine if the statement is true or false based on the provided CTR data alone.</s>",
        "contradict": "The statement \"None of the adverse events which occurred in the primary trial were not GI related\" is contradictory to the information in the CTRs because the CTRs list several adverse events that are not related to the gastrointestinal system, such as cardiac failure congestive, supraventricular tachycardia, thrombocytopenia, myocardial infarction, and haemolytic anaemia.</s>"
    },
    "1bd51c93-d7a8-4da4-825d-ada625033c34": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00293540",
        "Statement": "Samantha has recently received a liver transplant, and is taking the combined oral contraceptive pill, she is not eligible for the primary trial, but is eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "Samantha's ineligibility for the primary trial is due to her having received a liver transplant, which is listed as an exclusion criterion for that trial (CTR: Exclusion criteria: Patients with organ transplants). Her eligibility for the secondary trial is based on her having estrogen receptor or progesterone receptor positive breast cancer and being premenopausal with regular menstrual cycles, which meet the inclusion criteria for that trial (CTR: Secondary Trial: Inclusion Criteria). The statement does not contradict any information in the CTRs.</s>",
        "contradict": "The statement is contradictory to the CTRs as Samantha, having a liver transplant, is explicitly excluded from the primary trial according to the CTR. However, the statement implies that she is not eligible for the primary trial but is eligible for the secondary trial. The secondary trial, as described, includes no such exclusion criteria related to liver transplant.</s>"
    },
    "58c58b68-fc9a-438c-8a85-9233dde714c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.",
        "Label": "Entailment",
        "entail": "The statement \"The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort\" is entailed by the information in the CTRs as follows:\n\n1) Both CTRs state that the outcome measure for ORR was defined using the same criteria (RECIST 1.1) and time frame (radiological evaluation every 9 weeks on treatment and maximum treatment duration specified).\n\n2) Results 1 and 2 provide the ORR percentage for Cohort 1 (HR+/HER2-) and Cohort 2 (TNBC), respectively.\n\n3) The stated difference in ORR percentages between the two cohorts (35.6% for HR+/HER2- vs. 13.2% for TNBC) directly supports the expert's claim that the Triple-Negative Breast Cancer cohort had a much lower ORR than the HR+/HER2- cohort.</s>",
        "contradict": "The information in the expert statement cannot be directly contradicted by the data in the CTRs as they both report different ORR percentages for Cohorts 1 (HR+/HER2-) and 2 (TNBC). However, the statement implies a greater difference between the ORRs than what is explicitly stated in the CTRs (35.6% vs 13.2%), which does not contradict the data but may not be fully supported by it. A more nuanced comparison, considering confidence intervals or effect sizes, might be necessary to establish a definitive semantic relationship.</s>"
    },
    "843778c6-a320-49a1-93a0-5dc6239b822a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis.",
        "Label": "Entailment",
        "entail": "The statement \"The most common adverse events in the primary trial were Infection and Stomatitis\" is entailed by the information present in the CTRs since the CTR for the primary trial reports a total number of Adverse Events as 81, out of which Infection occurred 2 times (2.47%) and Stomatitis occurred 2 times (2.47%). Therefore, Infection and Stomatitis have the highest frequency of occurrence among all the reported adverse events in the primary trial.</s>",
        "contradict": "The statement \"The most common adverse events in the primary trial were Infection and Stomatitis\" is inconsistent with the CTR data provided, as the frequencies of these events are not the highest among all reported adverse events in the primary trial. According to the data, the most frequent adverse events were Nausea and Stomatitis, occurring in 1.23% of patients each. Infection had a frequency of 2.47%.</s>"
    },
    "a5486f80-69e5-4a5a-8435-f82f39cddf85": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR data if there are two additional instances of Gastrointestinal Haemorrhage reported in Adverse Events section of cohort 2 of the Primary Trial, compared to cohort 1, without any mention of these events in the Adverse Events section of the Secondary Trial. Since the CTRs do not mention any adverse event related to Gastrointestinal Haemorrhage for the Secondary Trial, the statement's claim about the difference in occurrence between the two cohorts in the Primary Trial can be inferred based on the provided data in the Primary Trial's Adverse Events sections alone.\n\nAdditional Information:\n\nTo establish entailment, it would be necessary to verify that the statement's assertion harmonizes with clinical trial data, find substantiation in the CTRs, and avoid contradiction with the descriptions. In this case, the provided statement does not contradict the data in the CTRs. It is important to note that, based on the given CTRs, it is unknown whether there were any cases of Gastrointestinal Haemorrhage in the Secondary Trial's Adverse Events section. Therefore, the statement only relies on the information available in the Primary Trial's Adverse Events sections and makes a comparison between the two cohorts within the same trial. This comparison is consistent with the CTRs, as they do not report any discrepancies in the treatment or cohort composition between the Primary and Secondary Trials that could invalidate the comparison.</s>",
        "contradict": "The statement \"There were 2 more cases of Gastrointestinal Haemorrhage in cohort 2 of the primary trial, than in cohort 1\" cannot be determined to be either entailed or contradictory based on the provided information from the CTRs alone. The reason for this is that the CTRs do not include data on the occurrence of Gastrointestinal Haemorrhage in either cohort 1 or 2 of the primary trial.</s>"
    },
    "c2c60b25-f255-48ba-bcb7-2bcd2de4315d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which no occurences are recorded.",
        "Label": "Entailment",
        "entail": "The statement asserts that there are four types of adverse events mentioned in the primary CTR but no occurrences were recorded. The CTRs list several types of adverse events and their respective occurrences. Among them, the primary CTR does not report any occurrences for angina unstable, bundle branch block left, coronary artery disease, and coronary artery stenosis. Since the statement is consistent with the given CTR data and does not contradict any information within, it can be entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement contradicts the CTR information as it asserts that there are four adverse events not recorded in the primary trial, namely angina unstable, coronary artery disease, and coronary artery stenosis. However, the CTR data clearly indicates the occurrence of these adverse events in the primary trial (1/254 each for angina unstable and coronary artery disease, and 1/254 for coronary artery stenosis). Therefore, the expert's statement does not entail the information in the CTRs.</s>"
    },
    "a8167a90-8ccf-4024-a4cc-8c1b047fd548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial do not employ the same route of administration for their interventions.",
        "Label": "Entailment",
        "entail": "In the primary trial, Intervention 1 specifies cyclophosphamide as being given intravenously as part of the planned chemotherapy regimen, while in Intervention 2 of the secondary trial, goserelin acetate is given subcutaneously. PD-0332991 in Intervention 1 and Intervention 2 of the secondary trial is given orally. The statement, \"the primary trial and the secondary trial do not employ the same route of administration for their interventions,\" can be entailed by the CTRs as the primary trial uses intravenous cyclophosphamide and the secondary trial uses subcutaneous goserelin acetide and oral PD-0332991.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs because both the primary and secondary trials involve oral administration of PD-0332991 in addition to cyclophosphamide in the primary trial given intravenously or subcutaneously. Therefore, while the routes of administration for PD-0332991 may differ slightly in the two trials (oral vs. not explicitly mentioned), they both involve oral administration as part of the interventions. Hence, the statement is contradictory to the CTRs.</s>"
    },
    "bdca0fa1-a3fa-4dcf-8f58-15d130dbfa75": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial participants are treated with 600 mg of Pemetrexed orally twice a month until complete response or disease progression\" is not entailed by the given CTR. The statement specifies an oral administration of Pemetrexed with a different dosing schedule compared to the one stated in the CTR (intravenous infusion every 14 days). Thus, the statement contradicts the provided CTR information and does not follow harmoniously with the clinical trial data.</s>",
        "contradict": "The statement made by the clinical trial expert contradicts the information in the CTR because the primary trial participants were treated with intravenous (IV) Pemetrexed at a dose of 600 mg/m2, every 14 days, not orally and not twice a month.</s>"
    },
    "277f5d17-36cc-44c5-9b94-7e052f2bdb2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01067976",
        "Secondary_id": "NCT00941330",
        "Statement": "Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section.",
        "Label": "Contradiction",
        "entail": "The statement \"Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section\" is entailed by the information in the CTRs. In the CTR for the primary trial, the intervention section is stated as \"CMRM vs UMRM\", but no specifications about the drug types, doses, or administration frequency are given. On the other hand, for the secondary trial, the intervention sections clearly state the drugs (Exemestane, Docetaxel, and Cytoxan), their respective doses and administration schedules. However, the statement points out that the primary trial only provides the duration of cycles and drug doses in its intervention section, which aligns with the information present in the primary CTR. Hence, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement implies that the primary trial only specifies the duration of drug administration cycles and doses, similar to the secondary trial. However, the CTR for the primary trial does not mention the type or name of the interventions being compared (CMRM vs UMRM), which is crucial for assessing the potential contradiction between statements. Therefore, based on the available information, the expert's statement can be contradicted by the primary CTR.</s>"
    },
    "fcb195de-2143-44d8-8c46-136104554e2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01492101",
        "Statement": "There less than 1% of either cohort of the primary trial was effect by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy.",
        "Label": "Contradiction",
        "entail": "The statement \"There is less than 1% of either cohort of the primary trial was affected by Pancytopenia, but just over 5% of cohort 1 patients suffered from Coagulopathy\" can be entailed by the information present in the CTRs as follows: The total number of patients in the primary trial for both cohorts is 850 (425+425). From the Adverse Events section of the primary trial, we find that 128/425 (0.3012) or 0.3012*425 = 131.35 affected patients for cohort 1 and 129/406 (0.3177) or 0.3177*425 = 138.55 affected patients for cohort 2. The number of patients affected by Pancytopenia is 2 in each cohort, which is equal to 0.0047*425 = 2.03 for cohort 1 and 0 for cohort 2. So, less than 1% of each cohort was affected by Pancytopenia (0.0047 < 1%). The number of patients affected by Coagulopathy is 1 for cohort 1 and 0 for cohort 2, so 0.0024*425 = 1.05 for cohort 1, which is more than 5% of 21.11 (the percentage of cohort 1 patients, calculated as 2/425*100) but less than 6% of the total number of patients in the primary trial. Therefore, just over 5% of cohort 1 patients suffered from Coagulopathy.</s>",
        "contradict": "The statement asserts that less than 1% of patients in both cohorts had Pancytopenia, but more than 5% of cohort 1 patients had Coagulopathy. This contradicts the information in the CTRs as the primary trial report states that 0.47% (2/425) of patients experienced Pancytopenia and 0.24% (1/425) had Coagulopathy. In the secondary trial report, there is no occurrence of Pancytopenia or Coagulopathy reported, so the comparison in the statement cannot be drawn from this data. Therefore, the expert's statement contradicts the CTR data.</s>"
    },
    "70337af9-3d4a-44bc-bbfa-0d97ea88553c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial\" is not explicitly stated in the given CTR. However, it can be implied and entailed as a consequence of the following conditions in the CTR:\n\n1. Patients must have a history of trastuzumab resistance.\n2. Patients may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen.\n\nGiven these criteria, it follows logically that patients have received a minimum of 3 prior trastuzumab treatments (two regimens of trastuzumab-based therapies, with each regimen likely comprising multiple cycles or courses). This inference is valid as long as the trial does not consider partial trastuzumab treatments (e.g., a partial course of therapy) as a single treatment.\n\nAdditionally, the secondary trial description doesn't provide any conflicting information regarding eligibility criteria, further supporting the entailment relationship.</s>",
        "contradict": "The statement \"Patients must have at least 3 prior treatments with trastuzumab to be eligible for the primary trial\" contradicts the inclusion criteria in the CTR for the primary trial, which stipulates that patients may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen for metastatic breast cancer.</s>"
    },
    "9cf89221-5801-4709-a098-de763b6e702e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334542",
        "Statement": "A Female patients with a mastectomy would be excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"A Female patient with a mastectomy would be excluded from the primary trial\" is entailed by the information present in the CTRs as stated under Disease Characteristics, where it specifies \"No prior radiotherapy or mastectomy\" as a requirement for inclusion. A mastectomy is a type of surgical treatment for breast cancer which involves removal of the entire breast tissue including the nipple and areola, hence, it falls under the category of \"prior radiotherapy or mastectomy\" and is excluded in the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTR for the primary trial, as it does not explicitly exclude female patients with a history of mastectomy. Instead, the CTR specifies that at least one intact breast is required. Therefore, patients who have undergone a mastectomy on one breast and still have another intact breast would meet the inclusion criteria and should not be excluded based on the statement provided.</s>"
    },
    "f89883ea-dd60-4d5f-9354-13fbca2aeec8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This will not prevent her from participating in the primary trial.",
        "Label": "Contradiction",
        "entail": "Sarah's eligibility for the clinical trial is not explicitly stated in the provided CTR. However, the CTR specifies that patients with symptomatic brain metastases are not eligible, while those with stable, asymptomatic brain metastases are eligible, provided certain conditions are met (no prophylactic anticonvulsants that are CYP3A4 modifiers and no recent use of steroids or radiation therapy). The statement does not contradict the CTR information and implies that Sarah's seizures, being a result of a brain tumor, do not prevent her from participating in the trial, as long as she meets the other eligibility criteria. Therefore, the expert's statement is entailed by the information in the CTR.</s>",
        "contradict": "Sarah's participation in the primary trial is contingent on being clinically stable for > 3 weeks after completion of radiotherapy and not taking steroids or therapeutic anticonvulsants that are CYP3A4 modifiers if she has a history of brain metastases. The statement mentions Sarah's epileptic seizures from a brain tumor but does not specify her current clinical status or medication use. Therefore, it is unclear whether she fulfills the eligibility requirements outlined in the CTR and the statement's assumption contradicts the CTR's conditions.</s>"
    },
    "a289f67c-ff56-44a9-b3da-152fb0d20271": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "Across both trials, there is one instance of an upper respiratory tract infection reported in the primary trial (1/32) and one instance of vertigo reported in the secondary trial (1/6). The total number of participants in the primary trial was 32 and in the secondary trial was 6. Therefore, the total number of participants across both trials is 38 (32 + 6). The total number of adverse respiratory events across both trials is also 2 (1 upper respiratory tract infection from the primary trial and 1 vertigo from the secondary trial). Since 2 is less than or equal to 1.16 (38 * 0.0313, the proportion of respiratory adverse events across all participants in both trials), the statement that only 1 respiratory adverse event was recorded across the duration of both trials is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Only 1 respiratory adverse event was recorded across the duration of both the secondary trial and the primary trial\" cannot be directly contradicted by the information presented in the CTRs. However, it is important to note that the primary trial reported an upper respiratory tract infection as an adverse event, which is a type of respiratory infection. Conversely, the secondary trial did not explicitly mention a respiratory infection event. Therefore, while the statement is technically correct based on the information available, it may be misleading, as the primary trial did report a respiratory adverse event, which was not explicitly identified as such in the statement.</s>"
    },
    "10ed1242-c6ab-4ad0-b93c-4738857f543a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with ICDs may be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with ICDs may be eligible for the primary trial\" can be entailed by the information present in the CTRs, as \"ICDs\" (Implantable CardioDefibrillators) are not mentioned in the exclusion criteria for both the primary and secondary trials. Thus, patients with ICDs do not contradict the inclusion criteria for the primary trial, and therefore, may be eligible.</s>",
        "contradict": "Patients with Implantable CardioDefibrillators (ICDs) are excluded from the primary trial based on the CTR's eligibility criteria. Therefore, the expert's statement, suggesting that patients with ICDs could be eligible for the trial, is contradictory to the information provided in the CTR.</s>"
    },
    "683b9885-4027-4108-b37e-61255611538a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02692755",
        "Statement": "Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases.",
        "Label": "Contradiction",
        "entail": "The statement \"Asian, white british and white irish women are eligible for the primary trial, as long as they do not have uncontrolled or symptomatic brain metastases\" is entailed by the primary CTR's Inclusion Criteria if we make the assumption that the terms \"Black, African or African American\" in the CTR are synonymous with \"Asian, white british, and white irish\" in the statement, which implies inclusion of all three ethnicities in the trial. The statement does not contradict the CTR as it explicitly states the exclusion of individuals with uncontrolled or symptomatic brain metastases, which aligns with the CTR's Exclusion Criteria.</s>",
        "contradict": "The statement can be contradicted by the CTRs because they specifically state that only self-identified Black, African or African American women are eligible for the primary trial. Therefore, the statement that Asian, white British, and white Irish women are eligible is not in line with the information provided in the CTRs.</s>"
    },
    "a47e048a-56aa-49e0-9903-563f53797b6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial receives Bevacizumab at a higher frequency and dose than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement that \"Cohorts 1 of the primary trial receives Bevacizumab at a higher frequency\" is entailed by the information in the CTR, as cohort 1 receives Bevacizumab every 3 weeks, while cohort 2 receives Bevacizumab every 4 weeks. \n\nThe statement that \"Cohorts 1 of the primary trial receives Bevacizumab at a higher dose\" is also entailed by the information in the CTR, as cohort 1 receives Bevacizumab at 15 mg/kg, which is higher than the 10 mg/kg dose given to cohort 2.</s>",
        "contradict": "Although Cohort 1 of the primary trial receives Bevacizumab at a higher dose (10 mg/kg versus 15 mg/kg), the frequency of Bevacizumab administration is the same in both cohorts (every 3 weeks in the secondary trial and every 4 weeks in the primary trial). The statement is contradicted because it combines the elements of dose and frequency without specifying that the frequency difference is the source of the contradiction.</s>"
    },
    "690de5e2-3d7f-407e-8eb9-783adf58841b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. In the primary CTR, women of any age are included in the trial for early stage breast cancer.\n2. In the secondary CTR, women are included in the trial for stage 1-4 invasive breast cancer, and there is no age restriction stated.\n\nHence, both trials include women of any age as participants. The other differences in inclusion criteria, such as cancer stage and treatments received, do not contradict this statement as it only refers to age eligibility.</s>",
        "contradict": "The statement \"Women of any age can participate in the primary trial and the secondary trial\" is contradictory to the information in the CTRs because:\n\n1. In the primary trial, the inclusion criteria state women \"at any age\" with early stage breast cancer and an ASA score of I-II can participate, but women with DCIS, advanced or metastatic stage breast cancer, receiving any neoadjuvant therapy, antibiotics within the past 3 months, history of immunodeficiency, having a remote infection, or a reaction to study antibiotics are excluded.\n\n2. In the secondary trial, the inclusion criteria state women aged 18 years with stage 1-4 invasive breast cancer, post mastectomy with axillary exploration, and an ECOG Performance Status of 0 or 1 can participate, but men, pregnant or breastfeeding women, patients with clinical evidence of gross disease, prior radiation therapy to the ipsilateral chest wall or thorax, patients requiring a chest wall boost, concurrent chemotherapy (except biologic agents), psychiatric illness that would prevent informed consent, inability or unwillingness to comply with skin care instructions and follow-up, allergy to either Eucerin or MF, residual grade >1 skin toxicity, cellulitis, or incompletely healed wound(s) at the time of study drug application, uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases are excluded.\n\nThese exclusion criteria in both trials directly contradict the statement that \"Women of any age can participate in the primary trial and the secondary trial.\"</s>"
    },
    "f5477a02-dde7-44c8-80b5-2cdb9fa66f23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 2 cases of Anaphylaxis occurred in either the primary trial or the secondary trial\" cannot be entailed by the provided information in the Clinical Trial Reports (CTRs) since there is no mention of Anaphylaxis as an adverse event in either trial.</s>",
        "contradict": "Anaphylaxis is not listed as an adverse event in the provided CTRs for either the primary or secondary trials. The stated condition is distinct from the reported events of anaemia, febrile neutropenia, neutropenia, thrombocytopenia, bundle branch block right, pericardial effusion, cardiopulmonary failure, aplasia, eye symptom, abdominal discomfort, left ventricular dysfunction, fistula enterovesical, constipation and hypokalemia, nausea, vomiting and burning abdominal pain, speech impairment, dyspnea, pain, hemorrhage/bleeding, and infection.</s>"
    },
    "dc184dcb-a22d-4cac-bee1-6c182692e522": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03511378",
        "Statement": "Patients must have a life expectancy over a year to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have a life expectancy over a year to participate in the primary trial\" is entailed by the CTR inclusion criteria stating \"Patient who have estimated life expectancy of more than six months.\" Although the exact number of months is different, the statement implies a longer life expectancy requirement, which is satisfied by the CTR's inclusion criteria.</s>",
        "contradict": "The statement \"Patients must have a life expectancy over a year to participate in the primary trial\" is contradictory to the inclusion criterion stated in the CTR that patients have an estimated life expectancy of more than six months.</s>"
    },
    "4dfbdeba-cae0-48b2-a38d-07338512904e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions.",
        "Label": "Entailment",
        "entail": "The statement \"Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions\" can be entailed by the information in the CTRs because:\n\n1. In the primary trial, Intervention 1 is a Health Education Active Control Group and Intervention 2 is a My Surgical Success Treatment Group. There is no mention of Molecular Breast Imaging in either intervention.\n2. In the secondary trial, Intervention 1 is about the evaluation of PA Compression Image Sets and Intervention 2 is about the evaluation of TC Compression Image Sets. There is no mention of Molecular Breast Imaging in either intervention.</s>",
        "contradict": "The statement \"Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions\" is contradicted by the CTR information as neither the CTR of the primary trial nor the secondary trial mentions anything about the application or non-application of Molecular Breast Imaging in their interventions. The CTRs provide details only about the Health Education Active Control Group, My Surgical Success Treatment Group, All Study Participants with PA Compression Image Sets, and All Study Participants with TC Compression Image Sets, but they do not specify the use or non-use of Molecular Breast Imaging.</s>"
    },
    "62489179-bb30-4b96-a904-ea907dd05e23": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Secondary_id": "NCT01009918",
        "Statement": "Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Contradiction",
        "entail": "The statement \"Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years\" can be entailed by the information present in the CTRs as follows:\n\nFor the Primary Trial:\n- The outcome measurement specifies an incidence of treatment-emergent adverse events for a time frame of 2 years.\n- The results section reports that all 16 participants in the MM-111 + Herceptin arm experienced treatment-emergent adverse events since they are part of the study.\n\nFor the Secondary Trial:\n- The outcome measurement also specifies an incidence of treatment-emergent adverse events for a time frame of 2 years.\n- The results sections report that 45 out of 152 patients in Arm I and 43 out of 147 patients in Arm II experienced treatment-emergent adverse events, which means all patients in both arms suffered at least one adverse event.</s>",
        "contradict": "The statement \"Every patient in the primary trial and the secondary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years\" cannot be directly deduced from the provided CTRs due to insufficient data. The CTRs only report the number of participants in each arm who experienced adverse events specific to their respective treatments, without specifying that every participant experienced at least one event. Additionally, the CTR for the primary trial does not explicitly state the time frame for all treatment-emergent adverse events, only for those related to MM-111 and Herceptin combination. Therefore, it is impossible to confirm the statement with certainty based on the available information in the CTRs.</s>"
    },
    "45891239-bb78-4f83-8306-8edceb8247fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast mammography prior to study entry.",
        "Label": "Contradiction",
        "entail": "The statement \"All patients in the primary trial must have a bilateral breast mammography prior to study entry\" is entailed by the CTRs if we assume that a standard of care bilateral breast MRI, which is a prerequisite for PEM in the secondary trial, includes a bilateral breast mammography. Since the CTR for the primary trial does not exclude patients based on their history of breast mammography, it is reasonable to infer that patients have undergone this procedure as part of the standard of care. This inference is consistent with the statement that all patients in the primary trial must have a bilateral breast mammography prior to study entry.</s>",
        "contradict": "The statement contradicts the information in the CTRs as some patients are excluded from the primary trial based on not having undergone a \"standard of care bilateral breast MRI at UC\" prior to study entry. Therefore, it cannot be the case that all patients had a bilateral breast mammography prior to study entry.</s>"
    },
    "9ec1e3f0-64a2-4629-aee8-cdb516fd27f3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00258349",
        "Secondary_id": "NCT01328249",
        "Statement": "Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, whereas both cohorts in the secondary trial receive some of both.",
        "Label": "Contradiction",
        "entail": "The primary trial specifies Intervention 1 as a combination of Vorinostat and Trastuzumab, with no mention of Eribulin Mesylate. In the secondary trial, Intervention 1 in Cohort 1 includes the administration of Eribulin Mesylate following the doxorubicin and cyclophosphamide regimen, but it doesn't overlap with the primary trial's Intervention 1. Therefore, Cohort 1 of the primary trial indeed doesn't receive any Eribulin Mesylate. The statement also mentions that both cohorts in the secondary trial receive some Vorinostat (as it is a component of Intervention 1), which is in line with the information in the CTRs.</s>",
        "contradict": "The statement asserts that Cohort 1 of the primary trial does not receive any Eribulin Mesylate or Vorinostat, while both cohorts in the secondary trial receive some of both. However, this contradicts the information provided in the CTRs.\n\nIn the primary trial, Cohort 1 is given Vorinostat + Trastuzumab combination therapy. While Trastuzumab is not mentioned in the statement, the statement is incorrect about Cohort 1 of the primary trial not receiving Eribulin Mesylate or Vorinostat.\n\nIn the secondary trial, Cohort 1 receives Eribulin Mesylate, but only following the initial cycles with doxorubicin plus cyclophosphamide. The statement is correct that both cohorts in the secondary trial receive Eribulin Mesylate, but it overlooks the fact that only Cohort 2 receives Vorinostat.\n\nTherefore, the statement is partially correct but overlooks important differences between the trials, making it misleading. A more accurate statement would be: \"In the primary trial, only Cohort 1 receives Vorinostat + Trastuzumab without Eribulin Mesylate. In the secondary trial, both Cohorts receive Eribulin Mesylate, with Cohort 1 receiving it following initial cycles of doxorubicin plus cyclophosphamide and Cohort 2 receiving it concurrently with Filgrastim as prophylaxis.\"</s>"
    },
    "91f23b55-38b6-41c4-af30-baa15e989aa7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - non metastatic breast cancer, aswell as not having Dysphagia.",
        "Label": "Contradiction",
        "entail": "The statement entails that the patients in the secondary trial have breast cancer with specific receptor statuses (-ER, -PR, and -HER2) and do not have Dysphagia. This can be inferred from the primary CTR's inclusion criteria which states that patients must have locally advanced, or 'triple negative' metastatic breast cancer, and the exclusion of patients with metastatic disease confined to bone only. The 'triple negative' term indicates that the cancer cells do not express ER, PR, and HER2 receptors. The primary CTR's exclusion criteria also states that patients with uncontrollable nausea and vomiting or difficulty swallowing (dysphagia) are not eligible for the trial. Thus, the statement's requirement of ER-, PR- and HER2- non metastatic breast cancer and absence of dysphagia is a special case within the conditions specified by the primary CTR. The secondary trial, therefore, falls under the scope of the eligibility criteria set forth in the primary CTR.</s>",
        "contradict": "The statement contradicts the Primary Trial inclusion criteria, which permits patients with recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer. 'Triple negative' refers to cancer cells that do not express ER, PR, or HER2 receptors, but the statement specifically excludes these receptor types. Additionally, the Primary Trial includes patients with measurable disease and a history of prior chemotherapy, which is not mentioned in the expert's statement.</s>"
    },
    "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that lapatinib 1500 mg treatment is associated with a lower risk of disease recurrence or death (implying longer DFS) compared to placebo, based on the trial data. The CTRs indicate that in the primary trial, there were 1318 participants in the lapatinib group who were censored (i.e., not experiencing an event or death) at the last visit date, out of a total of 1571 analyzed participants (Result 1). Similarly, there were 1285 participants in the placebo group who were censored, out of a total of 1576 analyzed participants (Result 2). The expert's statement that participants receiving lapatinib had a 5-year DFS rate twice as high as placebo patients translates to a relative risk reduction of 50% for the lapatinib group. The difference in the number of recurrences or deaths between the groups (252 in the lapatinib group versus 290 in the placebo group) can be interpreted as the absolute risk reduction of 38 events for lapatinib over placebo. With a total follow-up of 5 years and 1 year of treatment for each participant (as per the provided information), and assuming a constant hazard ratio, the expected number of events in the lapatinib group can be calculated as 1571 * (38/1191) * 5.3 = 249.2, and in the placebo group as 1576 * (38/1195) * 5.3 = 253.8. This means that the observed difference of 38 fewer events in the lapatinib group is consistent with a 50% relative risk reduction and, thus, the expert's statement is entailed by the data provided in the CTRs.</s>",
        "contradict": "The statement \"the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients\" cannot be definitively confirmed or contradicted with the information provided in the CTRs. Although the statement infers a difference in DFS between the two groups, it does not mention any specific data or statistical test to support this claim, making it speculative. The CTRs provide the number of participants with recurrence or death for each group, but they do not directly compare the 5-year DFS rates between the lapatinib 1500 mg and placebo arms. Additionally, the time frame for follow-up in the primary trial is up to 6 years, so it is not possible to definitively determine the 5-year DFS rates based on the available data.</s>"
    },
    "a2d489d5-3677-43ef-b03a-33d571c0c3b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, as long as they do not have uncontrolled Hypertension.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as follows: In the primary CTR, Class III obesity (BMI > 40 kg/m^2) is listed as an exclusion criterion due to potential risks associated with the study treatment. However, the secondary CTR does not mention a BMI limitation, and it specifically includes patients with adequate organ function as defined in the protocol. Obesity itself, without mention of uncontrolled hypertension, is not an exclusion criterion in the secondary trial. Thus, patients with Class III obesity who do not have uncontrolled hypertension can be eligible for the secondary trial according to the given inclusion criteria. This statement correctly reflects the information in the CTRs.</s>",
        "contradict": "The patients with Class III obesity (BMI > 40 kg/m^2) are explicitly excluded from the primary trial due to the inclusion criteria specifying a BMI between 19 and 40 kg/m^2, inclusive. However, the secondary trial does not have a similar explicit exclusion for Class III obesity. Yet, an additional requirement exists, stating that patients must have adequate organ function. Uncontrolled hypertension could potentially impair organ function and, thus, be a reason for exclusion. However, this statement does not entail that all patients with Class III obesity but without uncontrolled hypertension can be included in the secondary trial, as it does not account for other potential exclusionary factors that may be present in the protocol. Therefore, the information contained in the statement can be contradicted by the information present in the CTRs if a patient with Class III obesity and uncontrolled hypertension, or other exclusionary factors, is encountered.</s>"
    },
    "943ff737-4edd-4dbd-a3c9-213e3e0234d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in their patient cohorts.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial and the secondary trial both report cases of confusion in their patient cohorts\" is entailed by the information present in the CTRs because in the Primary Trial's Adverse Events Section 1, there is a reported case of confusion (1/33 or 3.03%). In the Secondary Trial, there are two reported cases of confusion, one in Adverse Events Section 1 (1/11 or 9.09%) and another in Adverse Events Section 2 (1/12 or 8.33%). Both trials report cases of confusion, which aligns with the statement.</s>",
        "contradict": "The statement is not contradicted by the CTRs, as both trials report instances of confusion among their patient cohorts, as indicated in the statement and in the CTRs respectively. However, there are differences in the overall adverse event rates and specific adverse events between the two trials. This information is complementary and not contradictory. The statement focuses on the shared occurrence of confusion, while the CTRs provide more detailed information on the incidence and other adverse events in each trial.</s>"
    },
    "be50c45f-ec51-40c8-904f-ffc200d39d9d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Only patients capable of understanding english are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The primary CTR specifies \"Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English)\" which aligns with the expert's statement \"Only patients capable of understanding english are eligible for the primary trial.\" This indicates that the entailment relationship between the statement and the information in the CTR is valid.</s>",
        "contradict": "The statement \"Only patients capable of understanding English are eligible for the primary trial\" contradicts the information in the CTR as it incorrectly implies that only English-speaking patients are eligible for the trial. However, the inclusion criteria in the CTR state that participants must be able to understand English and able to complete assessment forms (all assessment forms are in English), not that they must only be English speakers. Therefore, the statement can be contradicted by the CTR as it oversimplifies and incorrectly interprets the eligibility criteria.</s>"
    },
    "f53c8212-6da8-470f-a392-1bb037ed90e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial either include no treatment at all, or a placebo.",
        "Label": "Contradiction",
        "entail": "The statement asserts that Intervention 1 in both the secondary and primary trials either involves no treatment or a placebo. This can be entailed by the information present in the CTRs because, in the primary trial, Intervention 1 specifies \"IUS Alone\" which can be considered no active treatment, and in the secondary trial, Intervention 1 consists of \"Subjects will be randomly selected to receive saline (placebo), administered to the breast area during surgery.\"</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs due to a misinterpretation of the terms \"no treatment\" and \"placebo.\" While it's correct that Intervention 1 in both trials includes a placebo arm, the primary trial also has an Intervention 1 with IUS Alone that isn't a placebo. The secondary trial's statement incorrectly asserts that Intervention 1 is always a placebo across both trials.</s>"
    },
    "7b7e6e8b-aa62-4fcd-af1e-c243995243d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02622074",
        "Statement": "There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the following information from the CTRs:\n\n1. The DLT criteria and time frame for both cohorts are identical (as described in the Primary Trial section under Outcome Measurement).\n2. The number of participants analyzed in each cohort is given (as described in Results 1 and Results 2).\n3. Based on the provided data, there were 2 participants with DLTs in Cohort A (as inferred from 20.0% having a DLT), while there were 4 participants with DLTs in Cohort B (as inferred from 40.0% having a DLT).\n\nTherefore, the statement \"There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1\" can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"There were twice as many patients with DLT in cohort 2 of the primary trial than in cohort 1\" contradicts the data provided in the CTRs if there is no substantiated evidence of such a discrepancy. The given information from the CTRs states that there were 10 participants analyzed in both cohorts A and B, with 2 participants experiencing DLTs in cohort A (20.0%) and 4 participants experiencing DLTs in cohort B (40.0%). These numbers do not meet the criteria for being \"twice as many\" in cohort B as in cohort A. Therefore, the statement cannot be entailed by the provided data in the CTRs.</s>"
    },
    "74a53536-bb9d-4c64-9280-679d7b660cdd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Statement": "the primary trial does not investigate the effects of its intervention on patient tpCR.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not investigate the effects of its intervention on patient tpCR\" is entailed by the information present in the CTRs since neither the Primary nor the Secondary trial results sections provide any data on \"tpCR\" (tumor progression-free response) for either of the arms/groups. The outcome measure for the primary trial is defined as \"Progression Free Survival (PFS)\" and is described in detail. Therefore, the absence of data on \"tpCR\" in the CTRs implies that the primary trial does not investigate its intervention's effects on this measure.</s>",
        "contradict": "The statement \"the primary trial does not investigate the effects of its intervention on patient tpCR\" cannot be directly contradicted by the information provided in the CTRs, as the CTRs do not contain any data related to patient tpCR (tumor response based on the response assessment criteria defined as the complete or partial disappearance of target lesions, with no new lesions, according to RECIST, v1.1 or WHO). Therefore, it would be an incorrect assumption to make a definitive contradiction based on the absence of such data in the provided CTRs.</s>"
    },
    "6b35c306-a699-44f2-8606-a58d58fc18f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTRs provide the number of occurrences for each adverse event within the specified cohort (Adverse Events 1 for the primary trial).\n2. The statement seeks categories with at least three occurrences.\n3. From the given CTR, the following adverse event categories meet this condition for cohort 1 of the primary trial: Abdominal pain (3 occurrences), Diarrhoea (2 occurrences), Disease progression (3 occurrences), Infusion related reaction (1 occurrence), Pain (1 occurrence), and Pancytopenia or Pericarditis (each with 0 occurrences, but not explicitly stated in the statement).\n4. However, the statement does not require an exact count of occurrences for each category, just that there are at least three. Since the CTR data supports this condition for six different adverse event categories, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement \"There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least three cases\" contradicts the information in the CTR if the expert intended this statement to apply to both Adverse Events 1 and 2, but the CTRs do not provide enough information to establish that there are exactly 6 categories with at least three cases in both sets of adverse events. The CTRs only specify the number of occurrences for each individual adverse event, but do not group them into categories.</s>"
    },
    "62f50fe5-a83d-4f07-9dc7-8f495254d398": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00784849",
        "Secondary_id": "NCT02104895",
        "Statement": "Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial\" is entailed by the information in the CTRs as follows:\n\nThe primary trial's Intervention 1 involves sentinel lymph node biopsy with radiolabeled methylene blue and does not mention any form of breast irradiation.\n\nIn the secondary trial, there are two Interventions 1: conventional whole breast irradiation (WBI) and accelerated partial breast irradiation (APBI). The former is a type of WBI and the latter is a type of APBI. Both types of interventions for the secondary trial involve breast irradiation. Therefore, breast irradiation is used for both cohorts of the secondary trial.\n\nOn the other hand, the primary trial does not include any breast irradiation in its Intervention 1. Thus, breast irradiation is not used at all in the primary trial.\n\nSo, the statement \"Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial\" is in agreement with the information present in the CTRs and does not contradict them.</s>",
        "contradict": "The statement \"Breast breast irradiation is used in some form for both cohorts of the secondary trial, but not at all in the primary trial\" is contradicted by the CTRs because the primary trial uses Sentinel Lymph Node Biopsy With Radiolabeled Methylene Blue, which is not a form of breast irradiation, while the secondary trial employs both conventional whole breast irradiation (WBI) and accelerated partial breast irradiation (APBI) as interventions.</s>"
    },
    "edcae553-8a0a-45d2-a0fa-4db68608ef03": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Statement": "the primary trial requires participants to have a primary tumor > 5cm in longest dimension. ",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria state that patients must have histologically or cytologically confirmed invasive breast cancer. There is no specific mention of a size limitation for the primary tumor in the provided criteria. However, in the context of breast cancer, having a primary tumor larger than 5cm in its longest dimension is typically considered a part of advanced or locally extensive disease, which falls under the eligibility criteria as patients with histologically or cytologically confirmed invasive breast cancer in stages II-III per AJCC 6th edition are eligible for the trial. Therefore, there might not be an explicit statement regarding the tumor size limitation in the trial, but the information about tumor size larger than 5cm being a part of the inclusion criteria for advanced breast cancer is an entailed relationship given the existing information in the CTRs.</s>",
        "contradict": "The statement \"the primary trial requires participants to have a primary tumor > 5cm in longest dimension\" is contradicted by the inclusion criteria of the primary CTR which states \"Histologically or cytologically confirmed invasive breast cancer\" without any specifications regarding tumor size.</s>"
    },
    "a1b3667f-bfa5-426a-975a-20ed350c12c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month\" is entailed by the information present in the CTRs because:\n1. Azacitidine (Vidaza) is administered daily for 5 days in each 4-week cycle, which translates to 5 doses in a 4-week period.\n2. Azacitidine is given in 3 different dosages: 50mg/m2, 75mg/m2, and 100mg/m2, but the expert statement does not specify which dosage is being referred to. Regardless, the total number of doses per month remains consistent with the information in the CTR.\n3. Nab-paclitaxel (Abraxane) is given weekly for 3 weeks of each 4-week cycle, which translates to 3 doses in a month.\n\nHence, the expert statement that \"Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month\" is a correct representation of the dosing regimens outlined in the CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial receive 5 doses of Azacitidine (Vidaza) every month and 3 doses of Nab-paclitaxel (Abraxane) per month\" is not an accurate reflection of the Intervention sections provided in the CTRs. According to the CTRs, the Azacitidine doses are given in cycles of 5 days every 4 weeks, meaning patients receive a total of 20 doses of Azacitidine per month. Similarly, Nab-paclitaxel is given as 3 weekly doses each 4-week cycle, which equals 12 doses per month. Therefore, the statement's claim of 5 doses of Azacitidine and 3 doses of Nab-paclitaxel per month is contradictory to the actual Intervention details given in the CTRs.</s>"
    },
    "903617fa-7c40-45ac-a03c-498f51879408": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02915744",
        "Statement": "The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohort of the primary trial was less than one month.",
        "Label": "Entailment",
        "entail": "The statement asserts that the difference in median, maximum, and minimum OS between the two cohorts (NKTR-102 and TPC) in the primary trial is less than one month. This can be entailed by the information in the CTRs as follows:\n\n1. The difference in median OS is already given in the CTRs, with a difference of 0.3 months (7.8 vs. 7.5 months).\n2. The maximum and minimum OS values for each group are included in the (95% Confidence Interval) provided, which also supports the statement as they fall within one month apart (from 6.1 to 10.2 months for the NKTR-102 group, and from 5.8 to 10.4 months for the TPC group).</s>",
        "contradict": "The statement \"The difference in median, maximum and minimum Overall Survival (OS) of Patients between the two cohorts of the primary trial was less than one month\" contradicts the information in the CTRs because the provided CTRs state that the median OS for Group A (NKTR-102) was 7.8 months (6.1 to 10.2) and for Group B (TPC) was 7.5 months (5.8 to 10.4). A difference of 0.3 months (7.8-7.5) is not less than one month.</s>"
    },
    "9436e18a-a055-41c3-980f-bf451b4da7ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00171314",
        "Statement": "There are four types of adverse events in the primary trial, for which one occurence is recorded.",
        "Label": "Contradiction",
        "entail": "The statement \"There are four types of adverse events in the primary trial, for which one occurrence is recorded\" is entailed by the CTR data as follows: \n\n1. Four types of adverse events are mentioned in the statement: anaemia, febrile neutropenia, lymphadenopathy, and acute myocardial infarction.\n2. These conditions are indeed present in the CTR as adverse events for the primary trial.\n3. Each of these events occurred at least once in the primary trial as reported in the adverse events section.\n\nFurthermore, there is no contradiction between the statement and the provided CTRs, ensuring the entailment relation.</s>",
        "contradict": "The statement that \"There are four types of adverse events in the primary trial, for which one occurence is recorded\" is in contradiction with the CTR information if the four types referred to by the expert do not exactly match the ones presented in the CTR. The CTR specifies the types of adverse events as Anaemia, Febrile neutropenia, Lymphadenopathy, Acute myocardial infarction, Angina pectoris (unstable and pectoris), Bundle branch block left, Cardiac failure, Coronary artery disease, and Coronary artery stenosis, with occurrences ranging from 0.39% to 18.50%. The expert's statement only mentions four types but does not list them. Therefore, if the expert meant any four types different from those mentioned in the CTR, then the statement contradicts the CTR.</s>"
    },
    "f57403d9-7278-481e-bcb9-066bf31b6158": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01201265",
        "Secondary_id": "NCT00932373",
        "Statement": "1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails that at least one patient from the primary trial experienced Sepsis (a type of Septic Shock), which is listed as an adverse event in the primary trial with an incidence of 1/40 (2.50%). No exact number of patients from the secondary trial experienced Sepsis; however, the statement does not contradict the information in the CTRs as Sepsis is not listed as an adverse event in the secondary trial. The statement does not make any claims beyond the available data in the CTRs.</s>",
        "contradict": "The statement \"1 patient in the primary trial was affected by Sepsis, and several were affected in the secondary trial\" cannot be directly contradicted by the provided CTR data. However, it is important to note that none of the adverse events listed for either trial explicitly mention the condition \"Sepsis.\" While Septic Shock and Septicemia are related conditions, they are not synonymous with Sepsis. Additionally, the statement implies that more than one patient in the secondary trial experienced this condition, which is not supported by the data as there are no occurrences of Septic Shock or Septicemia reported. Thus, the statement may be an overgeneralization or an error in terminology, but it is not an outright contradiction to the information presented in the CTRs.</s>"
    },
    "ec601f6b-6ce3-4df7-b7b3-fbde1a241e93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events.",
        "Label": "Entailment",
        "entail": "none of the adverse events mentioned in the primary trial are identical to those in the secondary trial. The primary trial lists adverse events with frequencies and unique names (cholecystitis, post procedural bile leak, spinal column stenosis, depression, mania, pulmonary embolism), while the secondary trial lists different adverse events with their respective frequencies and names (febrile neutropenia, congestive heart failure, cardiac-ischemia/infarction, acute pharyngitis, infection, neutrophil count decreased, pneumonitis/pulmonary infiltrates). Since none of the adverse events are identical between the two trials, the statement is entailed by the information present in the CTRs. The statement's assertion that \"Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events\" can be derived from the given CTR information.</s>",
        "contradict": "The statement \"Patients in the primary trial and the secondary trial did not suffer from any of the same adverse events\" is contradicted by the information in the CTRs because the primary trial reported cases of cholecystitis chronic (0.38%), post procedural bile leak (0.38%), depression (0.38%), mania (0.38%), pulmonary embolism (0.38%), and the secondary trial reported cases of febrile neutropenia (6.35%), congestive heart failure (1.59%), cardiac-ischemia/infarction (1.59%), neutrophil count decreased (1.59%), pneumonitis/pulmonary infiltrates (1.59%), and vomiting (1.59%).\n\nFebrile neutropenia, neutrophil count decreased, and vomiting are shared adverse events between the two trials, which makes the statement incorrect.\n\nTherefore, the information contained in the statement contradicts the information present in the CTRs.</s>"
    },
    "0f0e5a8e-3972-46c2-84dd-7436e82a9787": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent.",
        "Label": "Contradiction",
        "entail": "The statement \"The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, letrozole is given at a dosage of 2.5 mg daily for a total duration of six months.\n2. In the secondary trial, there are two treatment arms: one receiving celecoxib at an unspecified dosage daily for a total duration of 12 months; another receiving placebo daily for the same duration of 12 months.\n\nComparing the two trials, we observe that:\n\n- The primary trial has a shorter total duration, with letrozole being administered for six months, whereas the secondary trial has a longer total duration, with both celecoxib and placebo arms lasting for 12 months.\n- In the primary trial, treatment is given daily for half the duration compared to the secondary trial, but since letrozole is given daily, we can say it is administered twice as frequently in the primary trial compared to celecoxib or placebo in the secondary trial (as each month in the secondary trial contains more days than in the primary trial).\n\nTherefore, the statement \"The duration of treatment in the primary trial is half as long as in the secondary trial, but twice as frequent\" is entailed by the information present in the CTRs.</s>",
        "contradict": "Despite the statement suggesting that the primary trial's treatment duration is half as long but twice as frequent as the secondary trial, the CTRs do not support this conclusion. The primary trial involves Letrozole administration of 2.5 mg daily for six months, while the secondary trial includes two arms: celecoxib at an undefined daily dosage for 12 months and placebo at an undefined daily dosage also for 12 months. There is no mention in the provided information indicating that the Letrozole treatment frequency in the primary trial is twice as frequent as that of the secondary trial. Thus, the statement can be contradicted by the information presented in the CTRs.</s>"
    },
    "420e4977-ce75-4fab-99e0-3e7db837d521": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 21 days  in the Docetaxel Plus Capecitabine group.",
        "Label": "Contradiction",
        "entail": "The statement \"The longest Time to Disease Progression in the primary trial was over 21 days in the Docetaxel Plus Capecitabine group\" is entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial specifies in the RESULTS section for the Docetaxel Plus Capecitabine arm that the median Time to Disease Progression is 8.88 months (7.37 to 11.05). Since the term \"longest\" in the statement refers to the maximal value within the group, and the given median value is above 21 days (when converted to months: 21 days * 30.43 = 676.865 days), the statement is a logical consequence of the data presented in the CTR.\n\nThe fact that both the CTR and the statement are referring to the same trial and the same arm, and the statement does not contradict any information in the CTR, further supports the semantic entailment of the statement with respect to the information contained in the CTR.</s>",
        "contradict": "The statement \"The longest Time to Disease Progression in the primary trial was over 21 days in the Docetaxel Plus Capecitabine group\" is contradicted by the information in the CTRs because the median Time to Disease Progression (TTDP) for the Docetaxel Plus Capecitabine group, as reported in Results 2, is specifically stated to be 8.88 months (7.37 to 11.05) with no mention of any TTDP exceeding 21 days.</s>"
    },
    "d07b4a30-e74f-468a-8420-7ade791d372d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00096356",
        "Statement": "the primary trial results indicate that CoQ10 reduces the PFS of breast cancer patients compared to a placebo by about 8%",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial results indicate that CoQ10 reduces the PFS (Progression-Free Survival) of breast cancer patients compared to a placebo by about 8%\" cannot be directly entailed by the given CTR information. However, the CTR data does not contradict this statement, either. The statement goes beyond the provided information, as the CTRs do not report PFS as an outcome measure. Additionally, there is no mention of breast cancer patients specifically in the CTRs. Therefore, while the statement does not contradict the CTRs, it is not a direct implication from the data presented.</s>",
        "contradict": "The statement made by the clinical trial expert contradicts the information in the CTRs because the primary trial results do not entail the reduction of Progression-Free Survival (PFS) in breast cancer patients by CoQ10. Rather, the CTRs report data on the effects of CoQ10 on fatigue levels as measured by the POMS-F scale, and no information about PFS reduction for breast cancer patients is presented.</s>"
    },
    "412b2743-8f76-494a-af97-f7bf9541a890": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial\" is entailed by the information present in the CTRs since the primary trial reports an instance of pneumonia (1/70 in the secondary trial) and the secondary trial reports an instance of lobar pneumonia (1/70). This finding satisfies the requirement stated in the expert's claim.</s>",
        "contradict": "The statement \"At least one type of respiratory illness was observed in patients from both the primary trial and the secondary trial\" can be contradicted by the information present in the CTRs because:\n\nNeither the primary nor the secondary CTR explicitly mentions any cases of respiratory illnesses (such as sinusitis, pneumonia, or lobar pneumonia) in common between the two trials. While the primary trial reports cases of gastroenteritis viral and parainfluenzae virus infection that might be considered respiratory in nature, these infections do not necessarily imply the presence of respiratory illnesses as commonly understood. Additionally, no respiratory illnesses are reported in the secondary trial. Therefore, the statement is not an entailed conclusion based on the given data.</s>"
    },
    "fd43feb6-4a55-4de6-b21d-25ff723b0959": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00631852",
        "Secondary_id": "NCT00193037",
        "Statement": "Patients may be forced to take part in the secondary trial and the primary trial, even against their consent, as long as it is in their best interests.",
        "Label": "Contradiction",
        "entail": "The statement cannot be directly entailed by the information present in the CTRs as they do not provide any information about patients being forced to participate in multiple trials against their consent. The CTRs only detail the inclusion and exclusion criteria for each specific trial.</s>",
        "contradict": "The statement is contradicted by the CTRs as they both include specific eligibility criteria that patients must meet in order to participate, including the requirement for patients to be willing and able to sign written consent. The statement implies that patients may be involuntarily included in the trials against their consent, which conflicts with the informed consent process described in the CTRs.</s>"
    },
    "e1fa68ac-42b4-4223-a362-a89c43562e06": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "Label": "Contradiction",
        "entail": "The expert's statement \"The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%)\" is entailed by the provided CTRs information because the statement accurately reflects the adverse event frequencies mentioned in each trial's section (14.29% for Febrile neutropenia in the primary trial and 4.95% for Ejection fraction decrease in the secondary trial). The statement does not introduce any new or contradictory information and is derived directly from the CTR data.</s>",
        "contradict": "The statement \"The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%)\" is contradictory to the information presented in the CTRs because, according to the data provided, the most common adverse event in the primary trial was indeed Febrile neutropenia (14.29%), but in the secondary trial, the most frequent adverse event, in terms of absolute number, was Pleural effusion, which occurred in 2 out of 101 participants (1.98%). However, the expert's statement incorrectly identified Ejection fraction decrease (4.95%) as the most common adverse event in the secondary trial.</s>"
    },
    "6f5570c0-4114-47ee-9611-b2e4be91cf9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "2 patients in the primary trial suffer from DVT, 0 in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"2 patients in the primary trial suffer from DVT, 0 in the secondary trial\" is entailed by the CTR information as follows:\n\n1. The statement specifies that there are two patients with DVT in the primary trial, which aligns with the reported 1/28 (3.57%) occurrence of deep vein thrombosis in the primary trial.\n2. The statement also asserts that there are no patients with DVT in the secondary trial, which is consistent with the reported 0/30 (0.00%) occurrence of deep vein thrombosis in the secondary trial.\n\nTherefore, the statement's assertions are based on the information present in the CTRs and do not contradict them.</s>",
        "contradict": "The statement \"2 patients in the primary trial suffer from DVT, 0 in the secondary trial\" is contradictory to the given CTRs as per the following reasons:\n\n1. The first trial reports that 1 patient experienced Deep Vein Thrombosis (DVT) as an adverse event out of 28 participants.\n2. The second trial does not report any occurrence of Deep Vein Thrombosis as an adverse event among 30 participants.\n3. However, the statement claims that '2 patients in the primary trial suffer from DVT, 0 in the secondary trial'.\n4. This discrepancy between the statement and the reported data indicates a contradiction.\n5. The statement does not align with the clinical trial data, as presented in the CTRs.</s>"
    },
    "13b4a3c5-cf6e-4f65-9f94-be927c3ce5ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: \n\n1. From the primary trial's CTR, we know that the outcome measurement is the change in percent mammographic density after one year of intervention in premenopausal women.\n\n2. The results section of the primary trial reports the mean percentage change and its standard deviation for both the placebo and vitamin D arms. \n\n3. The mean percentage change in the placebo arm (-3.4% with a standard deviation of 7.1%) is greater in magnitude than the mean percentage change in the vitamin D arm (-1.4% with a standard deviation of 11.9%), indicating that the vitamin D arm had a smaller decrease (or less increase in density) than the placebo group.\n\n4. The statement made by the clinical trial expert refers to \"intervention 2\" and does not explicitly mention the trial, but the primary trial is the only trial provided in the context of the CTRs, making it a reasonable assumption that the expert is discussing the vitamin D intervention from the primary trial.\n\n5. The expert's statement \"Intervention 2 of the primary trial resulted in a lower percentage change in tumor diameter than intervention 1\" can be entailed by the data provided in the CTR since the percentage change in density is a measure related to breast tissue, and smaller density changes in the vitamin D arm suggest a less pronounced effect on the tissue compared to the placebo arm. The expert's statement is consistent with these findings.\n\nTherefore, the expert's statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert cannot be directly contradicted by the information in the CTRs as they do not provide data on tumor diameter or any other relevant measurements. The CTRs only report on the change in mammographic density using the Boyd method for two different arms of the primary trial. Hence, the statement and the CTRs address different outcomes, and no direct contradiction exists. However, the expert's statement implies a comparison between interventions, which could potentially be evaluated using data from future or related trials focusing on tumor diameter.</s>"
    },
    "6495c223-f7d9-459f-8c57-66a2caac5ee4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as the text specifies that a Kaplan-Meier curve of CNS PFS and its 95% CI will be estimated at 12 weeks, with most subjects expected to not have CNS progression at this time. The provided result (Measure Type: percentage, Unit of Measure: percentage of participants) shows that 88.9% of participants had CNS PFS greater than or equal to 12 weeks (3 months), which is more than the required 16 weeks mentioned in the statement but still within its range. Thus, the statement is entailed by the CTR information.</s>",
        "contradict": "The statement \"All participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 16 weeks\" cannot be definitively contradicted by the provided CTR information. However, it is important to note that the CTR only reports that \"Most subjects will begin eribulin mesylate at 3 months without CNS progression\" and provides the percentage of participants without CNS progression at 3 months (88.9%, 51.0% to 99.7%). This does not necessarily mean that all participants had a PFS >= 16 weeks. The statement made by the clinical trial expert goes beyond the reported data and makes a stronger claim. Therefore, although the CTR information does not directly contradict the statement, it does not provide enough evidence to support it either.</s>"
    },
    "eb61fee2-30fc-42f9-80bd-4d73d6af592c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating interventions associated with breast reconstruction for patients that have had mastectomies.",
        "Label": "Entailment",
        "entail": "Both trials involve evaluating interventions related to breast reconstruction for patients who have undergone mastectomies. In the primary trial, the intervention is the use of Biodesign\u00ae Nipple Reconstruction Cylinder. In the secondary trial, the interventions are the use of a decision tool (BREASTChoice) in Arm 1 and the use of an enhanced usual care intervention (Surgical Care Booklet from the American Society of Plastic Surgeons) in Arm 2. Both trials target similar patient populations: those who have had or are scheduled for mastectomies and are considering breast reconstruction. The studies follow comparable procedures for recruiting, randomizing, and collecting data, and the patient participation time is approximately equal (30 minutes). Therefore, this expert statement is entailed by the information present in the Clinical Trial Reports, as it accurately reflects the trial designs and objectives.</s>",
        "contradict": "While the statement correctly identifies that both trials are evaluating interventions related to breast reconstruction for patients who have had mastectomies, it does not explicitly acknowledge the differences in the interventions being tested in each trial.\n\nIn the primary trial, the intervention is the use of Biodesign\u00ae Nipple Reconstruction Cylinder for breast reconstruction. In contrast, interventions in the secondary trial are:\n\n1. Arm 1: Use of the BREASTChoice (Decision Tool)\n2. Arm 2: Enhanced Usual Care (use of a surgical care booklet)\n\nThe statement does not mention these distinct interventions, potentially leading to a misunderstanding of the trials' objectives or results. Therefore, the statement's information could be contradicted by the CTRs, as they provide more detailed information on the specific interventions and their respective methods.</s>"
    },
    "79c698bf-a756-4a73-8075-38c3c5eb7a04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "Both cohorts of the primary trial in a negative (mean) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr).",
        "Label": "Entailment",
        "entail": "Both cohorts of the primary trial exhibited negative (decrease) in Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr). This statement is entailed by the information presented in the CTRs, as shown below:\n\n1. Both cohorts (Bisphosphonate IV Q4W and Denosumab 30 mg Q4W) in the primary trial underwent uNTx/Cr measurement from Baseline to Week 13.\n2. The statement asserts that both cohorts had negative Percent Change From Baseline of uNTx/Cr.\n3. The Results sections of the CTRs provide the Mean (Standard Deviation) and Unit of Measure for each cohort. \n   a. Bisphosphonate IV Q4W: Mean (-10.19, 208.84), Unit of Measure: Percent change\n   b. Denosumab 30 mg Q4W: Mean (-52.87, 95.14), Unit of Measure: Percent change\n4. Since both Means are negative numbers and represent a decrease in percentage, this statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the cohorts in the primary trial had negative (decreasing) Percent Change From Baseline of Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr), but the magnitudes of the changes were significantly different. While the bisphosphonate IV Q4W group had a smaller decrease of -10.19% (208.84), the Denosumab 30 mg Q4W group had a larger decrease of -52.87% (95.14). Therefore, stating both cohorts had the same negative change, without specifying the degree, is not accurate according to the CTRs.</s>"
    },
    "f7be0a6e-6c63-473e-af00-df009f3d7d46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTRs do not explicitly list breast implants and diffuse microcalcifications as exclusion criteria within the provided sections. Therefore, the statement that these factors will not disqualify a patient from entry to the primary trial aligns with the information in the CTRs.</s>",
        "contradict": "The statement \"Breast implants and Diffuse microcalcifications will not disqualify a patient from entry to the primary trial\" contradicts the CTR inclusion criteria as breast implants are explicitly listed as an exclusion criterion and diffuse microcalcifications may be determined as a reason for exclusion by the investigator according to the CTR.</s>"
    },
    "6f686de9-f110-4be0-9cd8-1ceb0ce6f073": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain receives Duloxetine 30 mg daily.",
        "Label": "Contradiction",
        "entail": "In the primary trial, the Intervention 1 for Cohort I uses a low dose (3.25 mg) of vaginal DHEA gel applied QD, while Intervention 2 for Cohort II uses a higher dose (6.5 mg) of vaginal DHEA gel also applied QD. Therefore, Cohort II subjects indeed receive 3.25 mg more of vaginal DHEA gel daily than Cohort I subjects.\n\nIn the secondary trial, Intervention 1 for Arm 1 involves Duloxetine treatment with a dosage schedule of 30 mg daily for a week, 60 mg daily for four weeks, and then 30 mg daily for 14 days. Arm 2 (without pain) only undergoes patient reported pain and symptom assessment, meaning they do not receive any medication like Duloxetine during the trial. This information supports the statement that only Arm 2 in the secondary trial receives Duloxetine 30 mg daily.\n\nThus, the statement is entailed by the information in the CTRs since it accurately summarizes the differences in interventions between Cohorts I and II of the primary trial, as well as the medication regimens for each arm in the secondary trial.</s>",
        "contradict": "The statement \"Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only the cohort without pain receives Duloxetine 30 mg daily\" is contradictory to the information in the CTRs because the primary trial involves two arms with different treatments (low dose and high dose of vaginal DHEA), whereas the secondary trial comprises two distinct cohorts (one with pain and one without pain), but they do not correspond directly to arms in the primary trial. Therefore, making a direct comparison between the doses of DHEA received by cohorts in the primary trial and the medication received by cohorts in the secondary trial is invalid, making the statement contradictory to the provided data. Additionally, the statement incorrectly assumes that cohort 2 from the secondary trial is part of the primary trial. This misconception leads to an incorrect comparison of the interventions, making the statement contradictory.</s>"
    },
    "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01004744",
        "Statement": "Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement cannot be entailed by the information present in the provided CTRs. The reason being that the CTRs do not mention any requirements related to pregnancy testing or status for the trial participation.</s>",
        "contradict": "The statement contradicts the information in the CTRs since the CTRs do not specify pregnancy as an inclusion criterion for the primary trial. The inclusion criteria mentioned in the CTRs only include histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or DCIS, postmenopausal status, age 21 years, no prior chemotherapy, radiation therapy, or surgery within 6 months of study entry, and signed informed consent. No mention of pregnancy is made in the CTRs as a requirement for participating in the trial.</s>"
    },
    "ffa913b7-9875-458e-8a28-476f9e788bb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02463032",
        "Statement": "There was less than a 5% difference in the Percentage of Participants With Objective Response in the GTx-024 9 mg and GTx-024 18 mg group in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails that the difference in the percentage of participants with objective response between the two GTx-024 dose groups in the primary trial is less than 5%. The CTRs indicate that the clinical benefit rate, defined as complete response, partial response, or stable disease according to RECIST 1.1, was assessed for both the 9 mg and 18 mg dose groups of GTx-024 in the primary trial. The Results sections report the number of participants in each group, allowing calculation of the percentage of participants with objective response (complete response or partial response) for each group. The differences in these percentages can be calculated and directly compared to ascertain if they are less than 5%.</s>",
        "contradict": "The given statement does not directly contradict the information in the CTRs, but it can be contradictory depending on the definition of \"Objective Response\" and the specific data presented in the CTRs. If \"Objective Response\" is defined according to RECIST 1.1 as complete response (CR) or partial response (PR), then the statement does not contradict the results (Results 1 and 2) in the CTRs. However, if \"Objective Response\" includes other types of responses (such as stable disease), then the statement might contradict the clinical benefit rate (CBR) results, as the difference in CBR between the two groups may be greater than 5%. The statement does not provide enough information to definitively establish entailment or contradiction.</s>"
    },
    "5a4018ea-5d00-4d44-bfa3-a1dfb341b9e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 different types of infections.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"the primary trial records a total of 7 different types of infections\" is entailed by the information in the CTR, as follows:\n\n1. The statement \"7 different types of infections\" can be inferred from the CTR data, since there are a total of 5 infection types explicitly mentioned (skin, gastrointestinal, vein, pneumonia), and cardiac ischemia/infarction could be considered as a type of infection given its nature as a vascular event potentially related to infections.\n2. The statement does not contradict any information in the provided CTR, as it does not claim the number of occurrences or the specific patients who experienced these infections. It merely asserts the existence of different types.\n3. Thus, the expert's statement entails the information present in the CTR and is semantically consistent with it.</s>",
        "contradict": "The statement \"the primary trial records a total of 7 different types of infections\" contradicts the information presented in the CTR as there are only 5 distinct types of infections mentioned: infection - skin, gastrointestinal, vein, pneumonia, and liver.</s>"
    },
    "d8e47fe7-be41-4f74-881b-a80cd3a1e95f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial",
        "Label": "Entailment",
        "entail": "The statement \"There are no details concerning the duration or frequency of administration in the intervention sections of the primary trial and the secondary trial\" is entailed by the information present in the CTRs since neither CTR specifies explicit duration or frequency for the interventions described. Instead, they focus on the types of compression techniques used (Patient-Assisted and Technologist-Controlled for the primary trial, and FFDM and FFDM Plus DBT for the secondary trial). Therefore, the absence of information about the duration or frequency of administration in the statement is consistent with the information provided in the CTRs, and the statement can be considered entailed.</s>",
        "contradict": "The given statement does not directly contradict the information in the CTRs. However, it could be contradicted by additional details in the CTRs if they specify different durations or frequencies for the interventions. Based on the provided CTR sections alone, the statement is generally accurate.</s>"
    },
    "e77e15a3-d851-4174-80c3-7b5156e7f987": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial do not use any of the same drugs in their interventions.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial and the secondary trial do not use any of the same drugs in their interventions\" is entailed by the information presented in the CTRs because:\n\n1. In the primary trial, Intervention 1 and Intervention 2 utilize different drugs for each arm: Docetaxel vs Paclitaxel for Arm C and D respectively; Gemcitabine is a common drug used in both Interventions 1 and 2 but in different schedules.\n   - Arm C: Docetaxel + Gemcitabine\n   - Arm D: Paclitaxel + Gemcitabine\n2. In the secondary trial, the intervention consists of Vorinostat followed by Anastrozole, Letrozole, or Exemestane. None of these drugs are present in the primary trial.\n\nThus, the statement is an accurate reflection of the information presented in the CTRs, and it follows that the primary trial and the secondary trial do not utilize any of the same drugs in their interventions.</s>",
        "contradict": "Despite the statement that the primary and secondary trials do not use the same drugs in their interventions, the primary trial involves the use of Docetaxel and Gemcitabine in both Arm C and Arm D, and the secondary trial employs Gemcitabine in combination with Anastrozole or Letrozole or Exemestane as AI sensitization therapy. Thus, the statement is contradicted by the provided CTRs.</s>"
    },
    "c003dd08-af3b-44cc-b31c-6fbdadfa1d83": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "In total Over 85% patient in the primary trial achieve Recurrence-free Survival after 3 years.",
        "Label": "Contradiction",
        "entail": "Based on the information in the CTRs, we know that the primary analysis of the Recurrence-free Survival outcome measure in the primary trial was conducted up to 2 years after randomization, while the secondary analysis extended this time frame up to 5 years. However, neither CTR provides exact data on the number of participants in each arm achieving Recurrence-free Survival beyond 3 years.\n\nNevertheless, the statement made by the clinical trials expert asserts an overall percentage of over 85% of patients in the primary trial achieving Recurrence-free Survival after 3 years. Since we don't have access to specific data beyond what's presented in the CTRs, it is reasonable to assume the expert's statement is based on an extrapolation from the given data or from the secondary analysis of the same trial (if published elsewhere). Therefore, the statement can be entailed by the information present in the CTRs if the assumption of the expert's statement being based on the available data is correct.\n\nAdditionally, there's no contradictory information in the given CTRs that would disprove the expert's statement, so it aligns harmoniously with the available data. Hence, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The expert statement does not provide information directly from the CTRs. Recurrence-free Survival data for over 85% of patients in the primary trial after 3 years is not explicitly stated in either Results 1 or Results 2. The CTRs only provide information on the number of participants analyzed, the treatment interventions, and the percentage of participants achieving Recurrence-free Survival up to 5 years. The statement contradicts the CTRs since it makes a claim beyond the data presented without substantiation.</s>"
    },
    "8ddf49c7-316e-4c7c-b2dd-423182a37612": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00455533",
        "Secondary_id": "NCT00767520",
        "Statement": "Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Throughout both the secondary trial and the primary trial there was only one case of sudden and unexpected death, in cohort 1 of the secondary trial\" entails the following conditions:\n\n1. Both trials had instances of sudden and unexpected deaths.\n2. The number of occurrences of sudden and unexpected deaths was equal in both trials (one).\n3. The occurrence of sudden and unexpected death was present in the secondary trial, specifically in cohort 1.\n\nThe CTRs provide data on adverse events for each trial, including the number of occurrences and corresponding cohorts. In the primary trial, the adverse event \"Sudden death\" was observed once in 145 participants (in cohort not mentioned). In the secondary trial, the same adverse event was observed once in 79 participants (in cohort 1).\n\nThus, the statement can be entailed by the information in the CTRs since it aligns with the trial data, and there is no contradiction.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly. However, it does not entail the information present in the CTRs either. While the statement mentions only one sudden and unexpected death in both trials, the CTRs provide separate adverse event tables for each trial. According to the given CTRs, there was one sudden death in primary trial and none in the secondary trial. Thus, the statement is not an entailed result from the given CTRs.</s>"
    },
    "d9e41be5-1e37-4dff-b51a-166576f351d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "For all adverse event types in the primary trial, at least one case was recorded.",
        "Label": "Entailment",
        "entail": "The statement \"For all adverse event types in the primary trial, at least one case was recorded\" can be entailed by the information in the CTRs as each adverse event type (Thrombocytopenia, Hypertension, Hepatotoxicity, and Pancreatectomy) is reported to have occurred in at least one patient (1/8) within the primary trial. Therefore, the statement's assertion is harmonious with clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.\n\nConfidence: 95%.</s>",
        "contradict": "The statement \"For all adverse event types in the primary trial, at least one case was recorded\" contradicts the information in the CTRs if we assume that the expert's statement refers to the unique occurrences of each adverse event type, rather than the total number recorded. In the given CTRs, Thrombocytopenia, Hypertension, Hepatotoxicity, and Pancreatectomy each occurred in one case, but Thrombocytopenia and Hypertension were recorded as having a prevalence of 12.50% each. Therefore, according to the CTRs, there was only one unique instance of Thrombocytopenia and Hypertension each, but these conditions were reported in more than one participant. The expert's statement would hold if each unique instance of an adverse event type was counted only once, but this interpretation is not consistent with the CTR's reporting of percentages. The expert's statement, as stated, implies that at least one unique instance of each adverse event type was recorded, which is inconsistent with the reported data in the CTRs.</s>"
    },
    "ee2287bd-af76-4232-9575-d371fe3257dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred once.",
        "Label": "Entailment",
        "entail": "The given statement \"Every adverse event in the primary trial occurred once\" can be entailed by the information present in the CTRs because each adverse event (Febrile neutropenia, Cardiac ischemia/infarction, Ventricular arrhythmia - left ventricular systolic dysfunction, Hemorrhage - GI, Pancreatitis, Infection - pneumonia, Infection - Streptococcus, and Abscess of Bartholin's cyst) is reported only once in the Adverse Events section of the primary CTR. Therefore, the statement's claim that every adverse event occurred once is consistent with and substantiated by the provided CTR data.</s>",
        "contradict": "The given statement can be contradicted by the information in the CTRs since there are multiple occurrences of some adverse events in the primary trial. For instance, Febrile neutropenia, Cardiac ischemia/infarction, Ventricular arrhythmia - left ventricular systolic dysfunction, Hemorrhage - GI, Pneumonia, and Streptococcus infection each occurred once in 45 participants, but Hemorrhage and Infection (without specification) both occurred twice (once in GI hemorrhage and once in Bartholin's cyst abscess).</s>"
    },
    "e5495b51-5f42-4e97-80ec-c215652bd3ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement excludes patients with an IHC test result of 3+ from both primary and secondary trials. However, the CTRs provide the following exclusion criteria for IHC positivity in the primary trial: \"HER-2 neu overexpression either by IHC 3+ or FISH+.\" Therefore, the statement can be entailed by the information present in the CTRs, as both IHC 3+ and HER-2 neu overexpression by IHC are considered equivalent exclusion criteria in the primary trial. In the secondary trial, the statement's condition aligns directly with the specified IHC 3+ inclusion criterion for HER-2 positive breast cancer. Thus, it is also entailed by the secondary trial's CTR information.</s>",
        "contradict": "The statement that \"Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial and the secondary trial\" is contradictory to the inclusion criteria in the CTRs. In the primary trial, the inclusion criterion for breast cancer is \"Histologically confirmed breast cancer with HER-2 neu overexpression either by IHC 3+ or FISH+\". This means that patients with HER-2 neu overexpression by IHC 3+ are indeed included in the primary trial. Similarly, in the secondary trial, the inclusion criterion for breast cancer is \"Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are: IHC 3+ (>10% of tumor cells with complete and intense membrane staining)\". Therefore, the statement is incorrect and conflicts with the given CTRs.</s>"
    },
    "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00612560",
        "Statement": "children and illiterate adults are able to take part in the primary trial, unless they are can read and write in italian. ",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information in the CTRs as it introduces a new criterion, namely language proficiency being limited to English, which is not mentioned in the provided inclusion and exclusion criteria for the primary trial.</s>",
        "contradict": "The statement that \"children and illiterate adults are able to take part in the primary trial, unless they are unable to read and write in Italian\" is contradicted by the CTR's inclusion criteria that specify \"Willingness to comply with study guidelines and procedures,\" which includes the ability to read and write English for informed consent. The CTR does not mention the requirement for Italian literacy, making the statement inconsistent with the information provided.</s>"
    },
    "9ae51f9c-8544-4764-b731-e4efe9ae0ba6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.",
        "Label": "Entailment",
        "entail": "The statement \"1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" can be entailed by the information present in the CTRs as follows:\n\n1. In the first CTR, the description of DLTs states that \"If 1 DLT was observed in the first 3 participants in a cohort, then 3 additional participants were studied.\" This implies that a minimum of 6 participants were enrolled in cohort 1.\n2. The results of the first CTR indicate that \"1 DLT in 6 subjects at the DL\" occurred. This means that 1 DLT was observed in 1 out of the 6 participants in cohort 1 (i.e., 1 out of 7 when considering the initial 3 participants).\n\nThus, the statement is a logical consequence of the data in the CTRs.</s>",
        "contradict": "The statement \"1/7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" could be contradicted by the information present in the CTRs because the number of participants who experienced dose-limiting toxicities at a specific dose level (DL) in the first cohort was not specified in the provided results (Results 1). According to the CTR, the number of participants in cohort 1 who experienced dose-limiting toxicities is not explicitly stated; only the overall number of participants analyzed in that dose level is given. Additionally, the statement refers to \"cohort 1,\" but the CTR provides information for the \"Arm/Group Title\" and \"Arm/Group Description\" of each dose level, not for the specific cohorts. Consequently, the accuracy of the expert's statement depends on the availability of additional information that is not provided in the CTRs.</s>"
    },
    "5b1915da-1819-4504-81bd-3f44a83b5e95": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1\" is entailed by the CTRs if we interpret the statement to mean that the proportion of participants with Leukopenia in cohort 2 was approximately threefold that of cohort 1. This interpretation is supported by the data in the CTRs, as cohort 2 had 4 instances of Leukopenia, whereas cohort 1 had 1 instance. This represents a ratio of approximately 4:1. Thus, the statement harmonizes with trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1\" cannot be directly contradicted by the provided CTRs because the CTRs do not specify the number of participants in each cohort or the total number of cases of Leukopenia in each cohort. The information in the statement goes beyond what is provided in the CTRs, so it is not a semantic entailment. However, the statement can be tested for consistency by checking if the total number of Leukopenia cases in cohort 2 is three times the number in cohort 1 based on the available data. From the given data, cohort 1 has 3 cases of Leukopenia and cohort 2 has 4 cases. Three times the number of cases in cohort 1 would be 9, which is not equal to 4, so the statement is inconsistent with the provided data if we take it literally. However, it's important to note that the statement might be true if we make certain assumptions, such as the total number of participants or the total number of cases of Leukopenia being the same in both cohorts but with a different distribution, or if we consider that the statement is a rough estimation and not an exact statement. Therefore, the information in the statement can be inconsistent with the CTRs depending on how we interpret the statement and the assumptions we make.</s>"
    },
    "edb1e4c0-7669-4b8c-878b-ea8ca060c350": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00074152",
        "Statement": "Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1\" can be entailed by the information present in the CTRs as follows: \n\nThe CTR for the primary trial provides the number of adverse events for each type and for the total count. By comparing these counts in both trials, we can determine that there are only two types of adverse events that occurred in both trials, and their occurrence is mentioned in the primary trial for cohort 1: Neutropenia [1] (occurred once in both trials) and Cardiac ischemia (occurred twice in the primary trial, one instance was in cohort 1). Therefore, the expert's statement \"Only 2 of the adverse event cases in the primary trial occurred in patients from cohort 1\" is a logical conclusion drawn from the data in the CTRs.</s>",
        "contradict": "The statement cannot be directly contradicted by the provided data from the CTRs alone. However, it could be contradicted if further information about the distribution of adverse events across cohorts in the primary trial is not consistent with the statement. The CTRs provided do not indicate which patients experienced adverse events in cohort 1 or cohort 2. If additional information contradicts the statement, it would be based on such information, not on the CTRs alone.</s>"
    },
    "915939cf-7813-43e7-b503-e14a7eb4e568": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2.",
        "Label": "Contradiction",
        "entail": "The statement \"Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2\" is not entailed by the information present in the CTRs. \n\nThe primary trial includes two interventions, Intervention 1 and Intervention 2. Intervention 1 involves the administration of trastuzumab at 2 mg/kg IV per week, which does not equal 600 mg/m^2. Intervention 2 does not involve the administration of 600 mg/m^2 trastuzumab as stated in the expert's statement.\n\nTherefore, the statement made by the expert is not entailed by the information present in the CTRs and contradicts the provided data.</s>",
        "contradict": "The statement \"Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2\" is contradictory to the information in the CTRs. In the Primary Trial, the description for Intervention 1 clearly states that \"Trastuzumab was administered throughout the course of the CT and for two weeks after the last CT administration,\" but the dose of trastuzumab given is 4 mg/kg on the first day followed by 2 mg/kg weekly. No information is provided that indicates the dose of trastuzumab was ever increased to 600 mg/m^2^. In Intervention 2, participants did receive lapatinib 1500 mg, which is higher than 600 mg/m^2^ (equivalent to 1000 mg), but it is not trastuzumab that is being administered at that dose in Intervention 2. Therefore, the statement that \"Only one cohort in the primary trial is administered trastuzumab 600 mg/m^2^\" cannot be true based on the information provided in the CTRs.</s>"
    },
    "126c1169-b375-4f89-95b2-52e971d19565": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial recorded no deaths and no cases of Enterocolitis infectious\" is entailed by the CTRs as the data in the Adverse Events sections of both trials show:\n\n1. No deaths were reported in Cohort 1 of the primary trial (Death NOS: 0/96).\n2. No cases of Enterocolitis infectious were reported in the primary trial for any cohort or arm (Enterocolitis infectious: 0/96).\n\nTherefore, the information in the expert statement harmonizes with the clinical trial data presented, is substantiated in the provided CTRs, and does not contradict the descriptions.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information present in the CTRs; however, it is incomplete. While cohort 1 in the primary trial did not record any deaths and no cases of Enterocolitis infectious, it's important to note that the CTRs themselves only report the incidence of adverse events for different cohorts, not the total number of participants in each cohort. Without knowing the total number of participants in each cohort, it's impossible to determine if the statement is accurate or not. Therefore, while the statement isn't contradictory in a strict sense, it may not be fully accurate due to the missing context. \n\nHowever, if we assume that the total number of participants in Cohort 1 of the primary trial is 60 based on the information provided for Adverse Events 2, then the expert's statement is indeed accurate. In this case, the absence of deaths and Enterocolitis infectious is consistent with the reported incidences. But if the total number of participants in Cohort 1 was larger than 60, then the statement would not be entirely correct.</s>"
    },
    "11235250-3627-427e-aae9-099507484456": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00284180",
        "Statement": "Across all three cohorts of the primary trial a total of two patients had low levels of oxygen in their body tissues.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as it correctly identifies that one patient in each of the two trials (Primary and Secondary) experienced Hypoxia, which is a condition characterized by low levels of oxygen in the body tissues. This information aligns with the CTR data without contradicting it.</s>",
        "contradict": "The statement \"Across all three cohorts of the primary trial a total of two patients had hypoxia\" contradicts the information present in the CTRs as the number of patients with Hypoxia mentioned in the CTRs is different for each cohort. In Adverse Events 1, there is one case of Hypoxia reported out of 11 participants. In Adverse Events 2, there is also one case reported out of 21 participants. Therefore, the total number of patients with hypoxia across the two cohorts is 2, which does not match the assertion in the expert's statement that there are a total of two patients with low levels of oxygen in all three cohorts.</s>"
    },
    "8a9f2247-7c51-44be-910b-5091d9abb2ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00236899",
        "Secondary_id": "NCT01153672",
        "Statement": "the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both administer Paclitaxel and Gemcitabine to their patients cohorts, but only the secondary trial utilises positron emission tomography\" can be entailed by the information present in the CTRs as follows:\n\nBoth trials have sections describing Intervention for Arm C and Arm D in the primary trial and intervention for the study in the secondary trial, which all involve the administration of Paclitaxel and Gemcitabine to their participants. The CTRs clearly state the drug names, dosages, frequency, and schedules for these drugs in both trials. The secondary trial, in addition to the mentioned interventions, also includes positron emission tomography in their correlative studies. This information is not contradictory to the primary trial and is an additional component to the secondary trial, thus the statement can be entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the CTRs, but it is incomplete and may be misleading. While it's true that both primary and secondary trials use Paclitaxel and Gemcitabine, the statement only mentions positron emission tomography (PET) in relation to the secondary trial. However, there is no information in the provided CTRs about PET scans being used in the trials. Thus, the statement leaves out crucial context about the primary trial regarding the use of PET.</s>"
    },
    "7e283897-4d9e-4353-8331-00f8db16cc7e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Entailment",
        "entail": "The statement entails that there are two distinct patient groups in the primary trial, each receiving a different oral medication, namely Tamoxifen or Exemestane. This assertion is in line with the information in the CTRs as each trial arm specifies a different intervention: Intervention 1 describes participants receiving exemestane and Intervention 2 describes those receiving tamoxifen. Therefore, no contradiction arises and the statement is entailed by the CTR information.</s>",
        "contradict": "The statement \"The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane\" is not contradicted by the information present in the CTRs. However, it does not fully capture the semantic entailment relationship as it only mentions the medications, without specifying the intervention details such as dosage, frequency, and duration. The CTRs indeed state that the patient groups do receive different medications, but the statement does not contradict the CTRs because it does not explicitly contradict any information in the CTRs. The statement is accurate within the scope of the provided information, but it may not convey the full complexity of the trial. To establish entailment with the CTRs, a more precise statement would be required that reflects the intervention details.</s>"
    },
    "54b15068-023b-4e60-bb82-2a22512fda62": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Male patients with Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs due to the following reasons:\n\n1. In the primary trial, male sex is explicitly listed as an exclusion criterion under the \"PATIENT CHARACTERISTICS\" section.\n2. In the secondary trial, the list of autoimmune diseases requiring management with systemic immunosuppression includes Systemic lupus erythematosis but does not exclude males.\n\nThe statement is consistent with the CTRs, as it acknowledges that male Systemic lupus erythematosus patients are excluded from the primary trial but may be eligible for the secondary trial due to the different inclusion criteria.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial explicitly states that male patients with systemic lupus erythematosis are excluded, while the secondary trial lists systemic lupus erythematosis as an exclusion criterion for females.</s>"
    },
    "78764961-52be-4235-a2b7-e581497d0099": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but different doses.",
        "Label": "Entailment",
        "entail": "Both Intervention 1 and Intervention 2 in the primary trial involve the administration of AZD8931, and the difference lies only in the dose: 160 mg bd for Intervention 1 versus 120 mg bd for Intervention 2. The statement that \"the two groups in the primary trial receive the same drug treatment, but different doses\" is an accurate description of the information in the CTRs. This statement is entailed by the given CTRs as it correctly reflects the details presented in the INTERVENTION sections.</s>",
        "contradict": "Although both groups in the primary trial receive the same drug (AZD8931), they do not receive the same dose regimen. The first intervention arm receives 160 mg twice daily (bd), while the second intervention arm receives 120 mg bd. Consequently, the doses of AZD8931 differ between the groups, contradicting the statement's assertion that they receive the same drug treatment.</s>"
    },
    "e09fe98c-ec5c-49cf-9f49-92ba8824e82e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Intervention 1 for both arms specifies \"IUS Alone\" and \"IUS alone imaging,\" implying no active involvement of the patient in the application of the intervention or imaging process. However, in Intervention 2, patients are required to apply compression during the imaging process using Patient-Assisted Compression (PAC). This constitutes active participation from the patient in applying the treatment.\n\nIn the secondary trial, Intervention 1 for both arms involves Patient-Assisted Compression (PAC) in addition to standard imaging. The process of PAC requires the patient to apply compression, thus actively participating in the application of the intervention. Intervention 2 follows the same procedure as in the primary trial for one breast, but for the other breast, patients undergo Technologist-controlled (TC) Compression, which does not necessitate active patient involvement.\n\nThe statement by the clinical trial expert is entailed by the CTRs as they both indicate that the interventions in the trials involve active participation from the patient in applying the treatment in certain cases, as described in the primary and secondary Interventions using Patient-Assisted Compression.</s>",
        "contradict": "The statement \"The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment\" is not directly contradicted by the CTRs provided. However, it is an oversimplification and does not accurately reflect the specifics of the interventions described. \n\nIn the primary trial, Intervention 1 involves the use of Intrauterine Systems (IUS) alone. Intervention 2 involves the use of Imagio (IUS with Osteoanabolic Agent), and the imaging is performed with both Patient-Assisted Compression (PAC) and Technologist-controlled Compression (TC). The patient's role in the primary trial is limited to being imaged with different compression methods. There is no mention of the patient applying the treatment itself in the primary trial CTR.\n\nIn the secondary trial, both patient-assisted and technologist-controlled compression are used for breast imaging, but it is the technologist who ensures the breast tissue is in position and guides the patient to apply compression. Thus, while the patient's cooperation is required, they are not applying the actual treatment.\n\nTherefore, the statement that \"The interventions in the primary trial and the secondary trial require active participation from the patient to apply the treatment\" can be considered a misinterpretation or an oversimplification of the information provided in the CTRs. However, it does not contradict the information presented directly.</s>"
    },
    "a83d98c9-e3da-4449-878b-5fa2f3bee8cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or radiotherapy intervention.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial is not testing a novel Physiotherapy or radiotherapy intervention\" is entailed by the information present in the CTRs because neither the INTERVENTION section of the primary trial nor the INTERVENTION section of the secondary trial mention Physiotherapy or radiotherapy as the treatment intervention. The primary trial only involves the use of Akt Inhibitor MK-2206, and the secondary trial's information is not provided in the given text. Therefore, the absence of Physiotherapy or radiotherapy interventions in both trials implies that the statement about not testing a novel Physiotherapy or radiotherapy intervention in the primary trial is an entailed conclusion based on the available information from the CTRs.</s>",
        "contradict": "The statement \"the primary trial is not testing a novel Physiotherapy or radiotherapy intervention\" is contradicted by the lack of information about Physiotherapy or radiotherapy interventions in the provided CTRs. The CTRs only describe an intervention using Akt Inhibitor MK-2206. Therefore, the statement makes an assumption about the absence of certain interventions that is not supported by the available data.</s>"
    },
    "41db854e-1565-4eda-8236-550556043b47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Contradiction",
        "entail": "The statement's assertion is entailed by the CTR as both trials require a definitive diagnosis of invasive carcinoma through core biopsy and exclude pregnant or lactating women, who would undergo pregnancy tests for screening purposes. The secondary trial's additional requirement of a negative human chorionic gonadotropin urine test further aligns with the CTR's pregnancy screening criteria.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because it only mentions the requirements of invasive carcinoma confirmed by core biopsy and a negative human chorionic gonadotropin urine test for eligibility in the primary trial. However, the CTRs provide additional inclusion and exclusion criteria that need to be met, such as ER-alpha receptor positivity, age, ECOG score, and consent to participate in DBBR, among others. Additionally, there are exclusion criteria mentioned, such as male gender, certain stages of breast cancer, prior therapy for breast cancer, and use of certain medications or herbal therapies, that are not mentioned in the expert's statement. Therefore, the statement's assertion does not harmonize with the complete set of clinical trial eligibility criteria outlined in the CTRs and may be contradictory to some of them.</s>"
    },
    "f559cacb-30e7-47cf-9ac6-5929c1a508f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00493649",
        "Secondary_id": "NCT01201265",
        "Statement": "There were no MRSA infections in either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"there were no MRSA infections in either the secondary trial or the primary trial\" is entailed by the information in the CTRs since neither CTR mentions any cases of Methicillin-resistant Staphylococcus aureus (MRSA) infections under their respective adverse events sections. MRSA infection is not mentioned as an adverse event in either the primary or secondary trial, which aligns with the statement.</s>",
        "contradict": "The statement \"There were no MRSA infections in either the secondary trial or the primary trial\" cannot be definitively contradicted by the provided information in the CTRs as MRSA infections are not mentioned in the given adverse event data for both trials. However, the absence of information regarding MRSA infections does not necessarily mean that they did not occur in the trials. Therefore, the statement is neither entailed nor contradicted by the CTRs.</s>"
    },
    "79362f6d-ef2c-4b93-8719-be361d0b5acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Contradiction",
        "entail": "The statement that \"Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english\" is entailed by the information in the CTRs as follows:\n\nThe primary trial excludes patients who have received a mTOR inhibitor, which includes Rapamycin, making them ineligible for that trial. (CTR for Primary Trial: Exclusion Criteria - \"Patient has received > 1 chemotherapy for the treatment of advanced/metastatic breast cancer which includes mTOR inhibitors\").\n\nThe secondary trial includes patients with invasive breast cancer and DCIS diagnoses, which can be in the stage 1 to 2 range, as well as patients who can read English. It does not list Rapamycin as an exclusion criterion. (CTR for Secondary Trial: Inclusion Criteria - \"Stage 1-2 invasive breast cancer diagnosis,\" and \"DCIS,\" and Exclusion Criteria - \"Male\").\n\nTherefore, the statement is entailed by the information provided in the CTRs as it correctly conveys the conditions under which a female patient, who is a Rapamycin user, can or cannot participate in either the primary or secondary trials based on their diagnosis and eligibility criteria.</s>",
        "contradict": "The statement that \"Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english,\" contradicts the information in the CTRs because:\n\n1. The primary trial has specific inclusion criteria that include having not received any mTOR inhibitor before, including Rapamycin. This directly contradicts the statement that \"Female Patients recently prescribed Rapamycin are eligible for the secondary trial.\"\n\n2. The secondary trial has no information provided regarding any exclusions related to previous treatments, specifically Rapamycin, making it unclear whether patients who have been prescribed Rapamycin would be eligible or not. Thus, the statement's condition about being \"unless they have a stage 1 to 2 Ductal carcinoma in situ and can speak english\" cannot be determined from the secondary CTR.\n\nTherefore, based on the information provided in the CTRs, the statement can be contradicted as the eligibility criteria for the primary and secondary trials are not in agreement.</s>"
    },
    "54918996-1b4d-48bd-a0ca-13d8e259767b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02650193",
        "Secondary_id": "NCT00656669",
        "Statement": "Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension.",
        "Label": "Contradiction",
        "entail": "The primary trial includes an exclusion criterion of BMI > 40 kg/m^2, which is the diagnostic definition of Class III obesity. However, this criterion is not present in the secondary trial's inclusion or exclusion criteria for obesity, which allows for inclusion of patients with a BMI of any value if they meet other requirements. Regarding hypertension, the primary trial includes it as part of the assessment of adequate organ function and sets a threshold for eligibility (systolic blood pressure \u2264 150 mmHg or diastolic blood pressure \u2264 90 mmHg). The secondary trial also considers adequate organ function, but it does not have a specified threshold for hypertension and leaves room for patients to be included despite uncontrolled hypertension, according to the investigator's judgment. Therefore, patients with Class III obesity and uncontrolled hypertension can be entered into the secondary trial but not the primary trial, which aligns with the provided statement.</s>",
        "contradict": "The statement that \"Patients with Class III obesity cannot be included in the primary trial, but can be entered into the secondary trial, even if they have uncontrolled Hypertension\" is contradicted by the information in the CTRs because the primary trial's eligibility criteria explicitly states that patients with a BMI of more than 40 kg/m^2 (Class III obesity) are excluded, whereas the secondary trial's eligibility criteria does not have a specific mention about BMI. However, the secondary trial does state that adequate organ function must be present for participation, but it does not specify any restrictions based on BMI. Thus, the statement is not entailed by the information in the CTRs. Additionally, the secondary trial's exclusion criteria do mention uncontrolled hypertension as a reason for exclusion, which contradicts the statement's assertion that patients with Class III obesity and uncontrolled hypertension can be included in the secondary trial.</s>"
    },
    "a5a1c7f1-92f4-4436-9dcb-ab222ff1c8a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679341",
        "Secondary_id": "NCT00201851",
        "Statement": "Patients in the secondary trial and those in the primary trial did not share any of the same adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the secondary trial and those in the primary trial did not share any of the same adverse events\" is entailed by the provided Clinical Trial Reports data as follows:\n\nIn the primary trial, no adverse event was reported for both trials in common among the mentioned events. The secondary trial reported no occurrence of febrile neutropenia, anaemia, atrial fibrillation, cardiopulmonary failure, supraventricular extrasystoles, abdominal pain, intestinal obstruction, vomiting, chills, oedema peripheral, and pyrexia. Also, the secondary trial did not mention any cases of pregnancy, endocervical cancer, nosocomial pneumonia, or venous thrombosis reported in the primary trial. Therefore, the statement is a consequence of the data in the CTRs, as there is no overlap in reported adverse events between the two trials.</s>",
        "contradict": "Contradiction arises due to differences in adverse event types and occurrences between the primary and secondary trials. The primary trial reports adverse events such as febrile neutropenia, anaemia, atrial fibrillation, etc., whereas the secondary trial lists adverse events including pregnancy, endocervical cancer, nosocomial pneumonia, venous thrombosis. Although no common adverse events are shared between the trials based on the provided data, the statement does not hold for all possible adverse events, as the trials investigate distinct treatments and patient populations.</s>"
    },
    "52c8361f-75dc-45f1-a35c-79180a22b931": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02015676",
        "Statement": "There are no recorded cases of thrombocytopenia in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no recorded cases of thrombocytopenia in the primary trial\" is entailed by the information in the CTRs as there is no mention or occurrence of thrombocytopenia in the primary trial's Adverse Events section. The statement's claim that no cases were recorded is consistent with the data in the CTRs and does not contradict any information presented.</s>",
        "contradict": "The information in the statement can be contradicted by the information present in the CTRs because thrombocytopenia (a condition characterized by decreased platelet count) is not listed as an adverse event in the primary trial. The CTR provides specific information about the types of adverse events observed in the trial, and thrombocytopenia is not among them. Therefore, the statement's assertion that \"there are no recorded cases of thrombocytopenia in the primary trial\" is contradicted by the available data.</s>"
    },
    "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year\" can be entailed by the information present in the CTRs as follows: In the primary trial, the control group's (arm B) median overall survival was given as 9.3 (7.5 to 10.9) months, which is less than one year but some patients survived beyond that period.</s>",
        "contradict": "The statement \"Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in arm B survived longer than a year\" is contradicted by the information present in the CTRs because the stated median overall survival for the control group in the primary trial was 9.3 months (7.5 to 10.9), which is more than one year. The statement implies that no or very few patients in arm B survived beyond one year, while the actual data reveals that there were participants who did survive beyond that time frame.</s>"
    },
    "db8ffa86-bf52-47bb-89f7-42e7ae47b84d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. The percentage of participants with OR for Afatinib Monotherapy is presented as 18% in Results 1, and for Afatinib and Paclitaxel or Vinorelbine Combination Therapy as 31% in Results 2.\n2. The time frame for measuring OR in both trials is the same (from initial dose of study drug until 28 days after treatment period, up to 1562 days).\n3. Both trials use the same criteria for defining OR according to RECIST v1.1.\n4. The participant numbers in both trials are given, allowing calculation of the difference in percentages.</s>",
        "contradict": "The statement's assertion that \"The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group\" cannot be directly derived from the information in the CTRs, and it contradicts the data given. According to the CTRs, the percentages of participants with Objective Response (OR) for Afatinib Monotherapy were 10% to 28% and for Afatinib and Paclitaxel or Vinorelbine Combination Therapy were 17% to 48%. A direct comparison between these ranges does not show a consistent 18% difference.</s>"
    },
    "5a01d00f-8601-4c17-b814-be87e63b0d8a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02392611",
        "Statement": "the primary trial cohorts are not seperated based on patient characteristics.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial cohorts are not separated based on patient characteristics\" cannot be directly entailed by the provided CTR information. The given CTR sections describe the patient population for each arm of the primary trial (INTERVENTION 1 and INTERVENTION 2) as having advanced solid tumors and lymphomas who had failed or were intolerant to standard therapy, or for whom no standard therapy existed. This information does not exclude the possibility of patient characterizations within each arm, such as demographics (age, sex, race), disease stage, or comorbidities. The expert's statement implies that there is no separation of cohorts based on such patient characteristics. However, the provided CTR information alone does not confirm this assertion as it does not specify whether the patient groups in INTERVENTION 1 and INTERVENTION 2 are identical in all characteristics beyond their eligibility for the trial and the intervention administered.</s>",
        "contradict": "The statement contradicts the information in the CTRs because the primary trial participants are indeed separated based on patient characteristics - specifically, they are separated into two different dosing groups, receiving either 0.6 mg or 1.4 mg of alobresib daily. This separation is clearly indicated in the provided CTR information for each trial intervention.</s>"
    },
    "7577f05f-04e9-44de-9e00-b7411ff4010f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients currently prescribed laxatives are not excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's exclusion criteria do not specify laxative use as a reason for exclusion. Therefore, patients currently prescribed laxatives can meet the eligibility requirements as long as they fulfill the other conditions stated, such as having unilateral breast cancer, upper extremity lymphedema, a commitment to long-term follow-up, and no other exclusionary factors, like active cancer, pregnancy, or renal failure. Consequently, the expert's statement is entailed by the information within the CTRs.</s>",
        "contradict": "The primary trial exclusion criteria include \"medication(s) known to affect body fluid balance.\" Laxatives can influence body fluid balance and potentially lead to fluid loss or retention, making them a possible exclusion under this criterion. Thus, the expert's statement contradicts the information provided in the CTRs.</s>"
    },
    "3b0440e6-cf85-4236-8a1d-2e3572143946": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a only one type of Oesophageal adverse events and several types of cardiac adverse events.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the information in the CTRs because it aligns with the data present. In the primary CTR, one instance of Oesophageal spasm is reported out of 50 participants (2.00%). No other types of Oesophageal adverse events, such as Oesophagitis or Oesophageal obstruction, are mentioned. For cardiac adverse events, the primary CTR reports instances of Tachycardia (2.00%) and Diastolic dysfunction (0.00%). In the secondary CTR, one instance of Oesophageal spasm and one instance of cardiac Tachycardia are reported out of 48 participants (2.08% and 2.08% respectively), while Diastolic dysfunction is reported in one participant (2.08%). The expert's statement correctly reflects this information without contradicting the details in the CTRs.</s>",
        "contradict": "The expert's statement is contradictory to the information in the CTRs as none of the trials reported any instances of oesophageal adverse events, except for a single instance of oesophageal spasm in the first trial. The expert's statement suggests that patients in the primary trial experienced multiple types of oesophageal adverse events, which is not supported by the data provided. Regarding cardiac adverse events, both trials reported occurrences; however, the statement does not provide enough information to establish a contradiction as it only mentions \"several types\" without specifying the types in question.</s>"
    },
    "6f342205-ef33-482a-b74a-74644537538b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have one or more target lesions and more than 2 regiments of chemotherapy to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR as it accurately reflects the inclusion criteria stated in the Primary Trial section: women, age >=18; >=1 target lesion, locally advanced or metastatic breast cancer, demonstrated resistance to anthracyline, and >=2 regimens of chemotherapy for advanced/metastatic disease. These conditions align with the statement requiring patients to be older than 18, female, have one or more target lesions, and have undergone more than 2 regiments of chemotherapy.\n\nAdditionally, there is no contradictory information in the statement, and it finds substantiation in the CTR's provided inclusion criteria. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement is consistent with the inclusion criteria of the primary trial regarding age, gender, having one or more target lesions, and having more than 2 regiments of chemotherapy. However, the expert's statement contradicts the exclusion criteria present in the primary CTR, specifically regarding previous treatment with Xeloda or other oral fluoropyrimidines and previous treatment with paclitaxel or docetaxel for advanced/metastatic disease. These conditions should not be present for patients to be eligible for the primary trial, but the expert's statement does not mention these conditions as exclusionary factors.</s>"
    },
    "5b63fffb-0a75-414f-8744-5fea78395f28": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.",
        "Label": "Contradiction",
        "entail": "The statement \"100 participants in the Afatinib 20mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTR for the primary trial reports the number of participants with DLTs for each arm, including the Afatinib 20mg + Herceptin group.\n2. Results 1 in the CTR states that there are 13 participants in the Afatinib 20mg + Herceptin group.\n3. Since the statement claims that 100 participants experience DLTs, it can be inferred that this number includes the 13 participants mentioned in Results 1, along with additional participants from the same group.\n4. However, Results 1 only mentions the overall number of participants analyzed in the Afatinib 20mg + Herceptin group, but it does not provide the number of participants experiencing DLTs.\n5. Therefore, the statement goes beyond the information directly stated in the CTR, but it remains an entailed claim because it is based on the information provided and does not contradict any statements in the CTR.\n\nAdditionally, it is important to note that while the CTR mentions that the DLT data is from the first cycle, there is no information about the number of participants experiencing DLTs in the first cycle specifically. The statement does not make this distinction and instead refers to all DLTs in the Afatinib 20mg + Herceptin group, which might include those that occurred later than the first cycle. This could introduce some uncertainty or ambiguity into the statement, but it does not negate the entailment relationship with the CTR.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the data in the CTRs, but it is an overestimation of the number of participants experiencing DLTs in the Afatinib 20mg + Herceptin group. The CTR reports a total of 13 participants in this group (Result 1), which contradicts the assumption of having 100 participants with DLTs.</s>"
    },
    "9e655973-7d1d-4528-8394-a9cbcf0b978f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Secondary_id": "NCT00943670",
        "Statement": "Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Adult Patients with Histologically proven HER2- infiltrating breast cancer that have had a Previous lumpectomy or same side mammary reduction are excluded from both the secondary trial and the primary trial\" is entailed by the information present in the CTRs because:\n\n1. For the primary trial, \"Previous lumpectomy\" and \"Previously reduced breast (mammary reduction)\" are listed as exclusion criteria (CTR: Inclusion Criteria: None; Exclusion Criteria: Previous lumpectomy, Previous mammary reduction).\n2. For the secondary trial, \"Previous lumpectomy\" is also listed as an exclusion criteria (CTR: Inclusion Criteria: None; Exclusion Criteria: Previous lumpectomy). \n\nSince the statement is consistent with the exclusion criteria listed in both CTRs, the information in the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradictory to the inclusion and exclusion criteria presented in the Primary and Secondary CTRs. In the Primary CTR, \"Previous lumpectomy\" is listed as an exclusion criterion. However, in the Secondary CTR, there is no explicit mention of \"Previous lumpectomy\" among the exclusion criteria. Although patients with a history of lumpectomy are excluded from the Primary trial due to the presence of breast cancer and previous intervention on the affected breast, the Secondary trial's inclusion criteria do not have this restriction. Consequently, it is incorrect to assert that adult patients with histologically proven HER2-infiltrating breast cancer who have had a previous lumpectomy are excluded from both primary and secondary trials.</s>"
    },
    "ea62355f-aab9-4796-8658-746c0b669ca7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There is no placebo or control group in the primary trial, in the secondary trial, Suramin acts as placebo.",
        "Label": "Contradiction",
        "entail": "The statement \"In the secondary trial, Suramin acts as a placebo\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, there is no mention of a placebo or control group.\n2. In the secondary trial, Suramin is administered weekly and acts as a pre-medication to Paclitaxel, which is infused one hour afterwards. There is no information indicating that Paclitaxel is being compared to another treatment or a placebo in this trial.\n\nTherefore, since there is no placebo or control group in the primary trial, and no clear evidence of a comparative study in the secondary trial, it can be inferred that Suramin, acting as a pre-medication in the secondary trial, may serve a similar role as a placebo in the absence of any other comparative treatment.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as the primary trial does have a treatment arm (exemestane, calcium carbonate, and vitamin D) which cannot be considered as a placebo or control group. In contrast, the secondary trial involves an intervention with Suramin and Paclitaxel, but there is no mention of a placebo or control group either. The statement's claim that Suramin acts as a placebo in the secondary trial is not supported by the information provided in the CTRs.</s>"
    },
    "55eaae8d-611c-4dbb-b162-de664902e059": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2.",
        "Label": "Contradiction",
        "entail": "In the provided CTRs, there is no mention of the number of cases of intestinal obstruction in each cohort of the primary trial. However, based on the given statement, we can infer that there were more cases in cohort 1. \n\nThe statement does not contradict the information in the CTRs, as it only makes a comparison between the two cohorts based on the data provided for one adverse event (intestinal obstruction). Therefore, the statement can be entailed by the information present in the CTRs through an inference based on the provided data.</s>",
        "contradict": "The statement \"In the primary trial, there were more cases of Intestinal Obstruction in cohort 1 than in cohort 2\" cannot be determined to be true or false solely based on the provided information in the CTRs. The CTRs report that there was one case of Small Intestinal Obstruction in cohort 1 (3.23%) and none in cohort 2. Therefore, the statement is contradicted by the available data if it asserts that there were more than one case in cohort 1 and none in cohort 2. However, if the statement is meant to imply that the incidence of Intestinal Obstruction was higher (but not necessarily more than one case) in cohort 1, then the statement is not directly contradicted by the CTRs, but additional information would be needed to make a definitive judgment on entailment.</s>"
    },
    "c3438bb2-4a49-4f14-ae50-a46fb48d0208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial and the Placebo dose in the primary trial are not specified.",
        "Label": "Entailment",
        "entail": "The statement does not require the exact dosages of cyclophosphamide or placebo for entailment. It only notes the absence of specified dosages in the CTRs for the given sections. This observation is in line with the information provided in the CTRs, as neither the primary nor the secondary trial explicitly mention the cyclophosphamide dose in the Intervention section for their respective placebo groups. Therefore, the statement can be entailed by the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information presented in the CTRs because:\n\n1. In the primary trial, the Intervention for Group 1 specifies the dose of risedronate as 35 mg weekly, while for Group 2, it mentions placebo medication once weekly. No information about cyclophosphamide or its dose is mentioned for this trial, making the statement incorrect with respect to the primary trial.\n\n2. In the secondary trial, the Intervention for Group 1 states that patients receive cyclophosphamide as part of their planned chemotherapy regimen without specifying its exact dose. However, the Intervention for Group 2 clearly indicates the use of goserelin acetate given subcutaneously once every 4 weeks in addition to cyclophosphamide in the chemotherapy regimen. The statement, on the other hand, only focuses on the absence of a mentioned dose for the cyclophosphamide in the secondary trial. This omission in the statement doesn't contradict the information in the CTR but doesn't tell the entire story, making it an incomplete comparison.\n\n3. To accurately assess semantic entailment between the statement and the CTRs in context, it is important to consider the entirety of the information available, including the missing pieces. In this case, the missing pieces (cyclophosphamide doses in both trials) are crucial to determining if the statement entails or is entailed by the CTRs. Without this information, a direct comparison of the doses cannot be made, and thus, the statement is incomplete or misleading.</s>"
    },
    "8f505cec-6ad4-4142-a861-1771e3ae5cdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: In the primary trial, patients apply topical imiquimod for a total of 13 application days in each 28-day cycle (on days 1-4, 8-11, 15-18, and 22-25). Therefore, the total number of application days matches the statement's assertion that participants apply topical imiquimod for a total of 13 days every 28 days. This entailment is based on the given information in the CTRs without contradiction.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the CTRs. However, the statement does not entail the information in the CTRs because it does not specify the exact number of applications of topical imiquimod within each 28-day cycle as outlined in the primary CTR (days 1-4, 8-11, 15-18, and 22-25). Therefore, the statement falls short of entailing the precise details of imiquimod administration in the primary trial.</s>"
    },
    "8f4f9793-041d-448b-9da8-b0c787a875bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00478257",
        "Statement": "Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial\" is not directly stated in the provided CTR inclusion or exclusion criteria. However, the statement does not contradict the given information and can be inferred as an implication based on the absence of specific hematologic, hepatic, and renal function criteria as prerequisites for trial participation. The CTR focuses on breast cancer and its treatment, without mentioning any functional requirements beyond age and specific cancer-related conditions.</s>",
        "contradict": "The statement \"Adequate Hematologic, Hepatic and renal function is not necessary for participating in the primary trial\" contradicts the CTR as there are explicit exclusion criteria for participants with confounding underlying medical illnesses, including hematologic, hepatic, and renal impairments.</s>"
    },
    "d13e5689-2a9e-4295-b3f8-e4a18fe42bf1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01735175",
        "Secondary_id": "NCT01216319",
        "Statement": "the secondary trial is testing a surgical intervention, unlike the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial is testing a surgical intervention, unlike the primary trial\" entails that the secondary trial involves a treatment modality different from chemotherapy with pegfilgrastim injections used in the primary trial. The information in the CTRs indicates that the primary trials use LA-EP2006 or Neulasta\u00ae, which are both forms of pegfilgrastim injections. In contrast, the secondary trial uses a Nipple Reconstruction Cylinder, which is a surgical intervention, thereby fulfilling the condition of being different from the primary trial. The statement's assertion harmonizes with the clinical trial data and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The expert's statement that \"the secondary trial is testing a surgical intervention, unlike the primary trial\" contradicts the information in the CTRs as both primary and secondary trials involve the use of subcutaneous post-chemotherapy injections (LA-EP2006 or Neulasta\u00ae in the primary trial and Biodesign\u00ae Nipple Reconstruction Cylinder not being explicitly mentioned as a surgical intervention in the secondary trial). Injections are considered a medical intervention, but not surgical interventions, as they do not entail invasive procedures under anesthesia to alter body structure or function.</s>"
    },
    "61d56c2a-089f-4fa3-9e97-3a9007576077": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial do not receive any intervention by IV, orally or by surgery during the study.",
        "Label": "Entailment",
        "entail": "The statement does not entail any direct intervention with Intravenous (IV) infusions, oral medication, or surgery for patients in the primary trial as per the CTR information provided. Both Intervention 1 and Intervention 2 involve educational and assessment components but no mention of IV infusions, oral medications, or surgery for any of the patients in either intervention arm. Therefore, the statement is consistent with, and entailed by, the information present in the CTRs.</s>",
        "contradict": "The expert's statement that \"the primary trial do not receive any intervention by IV, orally or by surgery during the study\" is contradicted by the information present in the CTRs, as the statements describe interventions that include oral instruction, written materials, and telephone calls, which can be considered forms of oral communication. However, the CTRs do not mention any interventions involving intravenous procedures or surgery.</s>"
    },
    "5b90b8de-97b9-4ed7-b5a4-e3724fd38c41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00411788",
        "Statement": "If Hannah has been taking ketoconazole to treat athlete's foot for 6 weeks, until today, she will not be eligible for the primary trial for the next month.",
        "Label": "Entailment",
        "entail": "The statement entails that Hannah is currently taking ketoconazole, an excluded medication listed in the Primary Trial's Exclusion Criteria. The CTR specifies that patients are ineligible for the study if they have used any of the listed medications within 4 weeks of enrollment. Therefore, Hannah's ineligibility for the trial due to recent ketoconazole use is entailed by the CTR information.</s>",
        "contradict": "The statement that Hannah will not be eligible for the primary trial for the next month due to ketoconazole use is contradictory to the CTR's exclusion criteria because the CTR specifies that patients must not use ketoconazole within 4 weeks of enrollment. This contradiction renders the statement non-entailing with respect to the CTR.</s>"
    },
    "bad4d3e7-a05a-44fd-937a-c94a23655c03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency and dosage as cohort 2 patients in the secondary trial receive Pilocarpine.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, cohort 2 patients receive naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.\n2. In the secondary trial, cohort 2 patients receive 1 capsule of placebo 2 times per day for 6 weeks.\n\nThe statement asserts that the frequency and dosage of naproxen in the primary trial for cohort 2 is the same as the frequency of Pilocarpine in the secondary trial for any cohort. \n\nThe frequency of naproxen in the primary trial is BID (twice a day), and the number of doses per 6 weeks is 5 cycles * 5 days/cycle * 2 doses/day = 5 * 5 * 2 = 50 doses.\n\nThe statement does not specify a dosage for Pilocarpine, but we know the frequency is 2 times per day. Since the number of doses per day for both agents is the same (2), and the number of doses per 6 weeks is the same for both cohorts (50 doses), it follows that the dosages must also be equivalent on a per-dose basis to maintain the same total dose per 6 weeks. \n\nThus, the daily dose of Pilocarpine must be equivalent to naproxen 500mg/dose to ensure that the total dose over 6 weeks is the same for both cohorts.\n\nTherefore, the statement can be entailed by the information in the CTRs, assuming that the equivalent daily dosage of Pilocarpine that would result in the same total dose of 50 doses/6 weeks is 500mg.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the frequency and dosage of naproxen in the primary trial (500 mg BID, which translates to 2 doses per day) and the frequency of Pilocarpine in the secondary trial (2 times per day) are different. Although the daily dose is similar (500 mg for naproxen and 5mg for Pilocarpine), the administration frequency is distinct, preventing a direct entailment relationship between the statement and the CTRs.</s>"
    },
    "b88eaf78-957d-4b3d-bcb2-d029b7d7b7e2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "Multi-Organ Failure is mentioned in the Adverse Events section of the primary trial with a frequency of 1/41 (3.23%). Although not explicitly stated in the secondary trial's Adverse Events 1 section, it is mentioned in Adverse Events 2 with a frequency of 1/31 (3.23%). Therefore, the statement \"There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial\" can be entailed by the data provided in the CTRs, as the occurrence of Multi-Organ Failty in both trials is in line with the reported frequencies.</s>",
        "contradict": "The statement \"There were several cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 2 of the primary trial\" cannot be entailed by the information present in the CTRs, as there are no instances of Multi-Organ Failure reported in either trial's Adverse Events sections.</s>"
    },
    "0c435231-a09c-4424-924a-13840c6b7068": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Statement": "In the primary trial there was 1 case of jaundice.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, there was 1 case of jaundice\" entails the information in the CTR under Adverse Events for the primary trial since both the statement and the CTR agree that there was one instance (case) of jaundice reported in the primary trial.</s>",
        "contradict": "The statement \"In the primary trial there was 1 case of jaundice\" is contradictory to the information in the CTR because it asserts that there was only one instance of jaundice in the primary trial, while the CTR reports that there was actually two cases of jaundice among the study participants.</s>"
    },
    "0812dcc1-eab5-4d5f-9d51-934f9b1f05ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not allowed for patients in the secondary trial, however, the primary trial may accept patients despite this.",
        "Label": "Entailment",
        "entail": "The statement entails that the secondary clinical trial does not allow inclusion of patients with prior exposure to exemestane, while the primary clinical trial may include patients with such exposure. This relationship is entailed by the information in the CTRs, as the primary trial's inclusion criteria explicitly state \"No contraindications for primary chemotherapy,\" allowing chemotherapy drugs such as exemestane, while the secondary trial explicitly excludes patients with prior exposure to exemestane as part of its eligibility criteria.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because, according to the Primary Trial inclusion criteria, patients are permitted to have prior exposure to exemestane.</s>"
    },
    "a29e6a86-65f3-4565-93e2-81f49fa837e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression.",
        "Label": "Contradiction",
        "entail": "The statement \"Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression\" is entailed by the CTR information, as none of these conditions are reported in the ELIGIBILITY CRITERIA or ADVERSE EVENTS section of the primary trial. Similarly, these conditions are not mentioned in the secondary trial ADVERSE EVENTS section as having occurred more frequently or exclusively in that trial.</s>",
        "contradict": "The statement \"Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or depression\" contradicts the information in the CTRs because the primary trial report states that there was one case (1/35) of Gastroesophageal reflux disease, which can present with symptoms similar to Dyspepsia, Nausea, and Anemia. However, the statement explicitly denies the presence of Anemia, Dyspepsia, and Nausea in the primary trial.</s>"
    },
    "2470d8d1-27cd-41a5-9e5d-f62d4bbdd049": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial\" is entailed by the CTRs as the following reasons explain:\n\n1. The primary CTR does not explicitly state that scheduled flap reconstruction is an exclusion criterion.\n2. The primary CTR does not mention any restrictions concerning the timing of flap reconstruction in relation to the trial commencement.\n3. The secondary CTR does not contain any information related to inclusion or exclusion criteria regarding scheduled flap reconstruction within 10 days prior to the beginning.\n\nTherefore, the CTRs are silent on this specific topic, leaving it an open question for the trial investigators to make a judgement. The expert statement provides such a judgement, stating that it is acceptable for patients to undergo flap reconstruction within 10 days prior to beginning the trial. Since this statement aligns with the information present in the CTRs, it is semantically entailed by them.</s>",
        "contradict": "The statement \"Scheduled flap reconstruction within 10 days prior to beginning is acceptable for patients entering the primary trial\" contradicts the CTR's exclusion criteria, specifically \"Scheduled free flap reconstruction.\" Therefore, this statement cannot hold true according to the information provided in the CTRs.</s>"
    },
    "34bb7f09-3b2b-464f-96df-c8d80b1206fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Secondary_id": "NCT01805089",
        "Statement": "All cancer stages are accepted for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"All cancer stages are accepted for the primary trial and the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nFor the primary trial: \n- The inclusion criteria state that patients with a new diagnosis of breast cancer are accepted, which includes all stages of breast cancer.\n\nFor the secondary trial: \n- The inclusion criteria state that patients with a history of ductal carcinoma in situ, lobular carcinoma in situ or stages 1-3 breast cancer are accepted, which covers stages 1-3 of breast cancer and is a subset of all cancer stages.\n\nThus, both trials accept patients with all cancer stages, as stated in the expert's claim, since the primary trial includes stage 4 breast cancer patients with negative surgical margins and the secondary trial includes stages 1-3 breast cancer patients.</s>",
        "contradict": "The statement \"All cancer stages are accepted for the primary trial and the secondary trial\" is contradicted by the information in the CTRs, as the primary trial only includes patients with a new diagnosis of breast cancer or a previous breast cancer patient with negative surgical margins, while the secondary trial includes patients with stages 1-3 breast cancer only. Thus, the statement goes beyond the information in the CTRs and contradicts their specific inclusion criteria.</s>"
    },
    "e9824c27-bb70-4707-9599-ff20281f873e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00357110",
        "Statement": "Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR data as follows: The total number of participants with Varicose Veins in the primary trial's cohort 1 is 1 out of 6, representing a percentage of 16.67%. Since this percentage is less than 20%, the statement that \"less than 20% of patients in cohort 1 of the primary trial had Varicose Veins\" is an entailed statement.</s>",
        "contradict": "The statement \"Less than 20% of patients in cohort 1 of the primary trial had Varicose Veins\" is contradicted by the information in Adverse Events 1 of the CTR for the primary trial, as 16.67% of patients (1 out of 6) in the trial experienced Varicose Veins. This percentage exceeds the threshold specified in the expert's statement.</s>"
    },
    "43fcba9b-4edd-433d-86a7-370cbbf56853": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as follows:\n\n1. In the primary trial, the median PFS, which represents the time from randomization until the first documented sign of disease progression or death due to any cause, for the Trastuzumab + Lapatinib arm was 12.0 (8.1 to 16.0) weeks.\n2. In the primary trial, the median PFS for the Lapatinib arm was 8.1 (7.6 to 9.0) weeks.\n3. In the secondary trial, the median TTP (Time to Progression), which also represents the time from randomization until the first documented sign of disease progression or death due to breast cancer, for the Lapatinib With Paclitaxel arm was 29.0 (13.9 to 46.9) weeks.\n4. In the secondary trial, the median TTP for the Placebo With Paclitaxel arm was 22.9 (12.0 to 38.3) weeks.\n\nGiven that the statement \"The median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial, was lower than the median time for patients in the secondary trial,\" is logically equivalent to \"The median PFS in the primary trial was less than the median TTP in the secondary trial,\" it can be entailed by the information present in the CTRs. Specifically, the median PFS in the primary trial (12.0 weeks for Trastuzumab + Lapatinib and 8.1 weeks for Lapatinib) is less than the median TTP in the secondary trial (29.0 weeks for Lapatinib With Paclitaxel and 22.9 weeks for Placebo With Paclitaxel).</s>",
        "contradict": "The primary trial measured Progression-Free Survival (PFS), defined as the time from randomization until the first documented sign of disease progression or death due to any cause. In contrast, the secondary trial measured Time to Progression (TTP), defined as the interval between the date of randomization and the earliest date of progression of disease or death due to breast cancer, assessed using imaging data and clinical symptomatic progress. The two outcome measures are not directly comparable as they measure different aspects of disease progression. Additionally, the primary trial's time frame for measuring PFS is from baseline to disease progression or death or 30 days after the last dose, while the secondary trial's time frame for measuring TTP is from randomization until the date of disease progression or death. Therefore, the statement that the median time from randomization until the first documented sign of disease progression or death due to any cause for all participants in the primary trial was lower than the median time for patients in the secondary trial can be contradicted by the information present in the CTRs.</s>"
    },
    "196c7a35-58a0-4d2d-a0a6-e9e3de077fb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause was higher in cohort 1 of the primary trial, compared to cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR data as follows: \n\nThe median time from randomization to death in Cohort 1 (Pembrolizumab) is 12.7 (9.9 to 16.3) months, and in Cohort 2 (Treatment of Physician's Choice, TPC) is 11.6 (8.3 to 13.7) months. Comparing these median survival times directly, the median survival time in Cohort 1 is higher than in Cohort 2. This difference is in line with the statement's claim of a higher median time to death in Cohort 1 compared to Cohort 2. This conclusion is based on the information provided in both the Primary Trial Results sections and the statement made by the clinical trial expert. There is no contradiction with the descriptions given in the provided CTR sections.</s>",
        "contradict": "The statement cannot be definitively contradicted by the information in the CTRs, as no information regarding the median time from randomization to death for each cohort (Pembrolizumab and Chemotherapy) in the primary trial is explicitly provided in the text. However, the statement can be neither confirmed nor disproven based on the available data. The median survival data for each group (Pembrolizumab: 12.7 months; Chemotherapy: 11.6 months) can be used to calculate the difference and compare the survival outcomes between the two cohorts, but the statement's assumption of \"cohort 1\" is not explicitly identified or defined in the text.</s>"
    },
    "27e0b995-b3d1-46a6-900a-d6e513504ff3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "3/4 patients in the primary trial did not suffer any adverse events.",
        "Label": "Entailment",
        "entail": "Given the data in the primary trial CTR, 3 out of 4 patients (75.00%) did not experience any adverse event as listed. These events are a subset of those listed in the CTR, and the absence of these events for 3 out of 4 patients does not contradict the information provided. Thus, the statement can be entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"3/4 patients in the primary trial did not suffer any adverse events\" contradicts the information presented in the CTRs, as the CTR for the primary trial indicates that 1 out of 4 patients (25.00%) experienced an adverse event of some kind. The statement oversimplifies the data and overlooks the fact that adverse events were indeed reported in the trial, albeit for only one patient. The statement's assertion, therefore, is not semantically entailed by the data in the CTRs.</s>"
    },
    "36a5357f-0c5f-4c64-a56a-a84aab165a16": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01727011",
        "Secondary_id": "NCT01420146",
        "Statement": "the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry ",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry\" is entailed by the information present in the CTRs because:\n\n1. In the primary CTR, the intervention involves the use of a post-implant dosimetry scanner which is a type of scan (dosimetry scan).\n2. In the secondary CTR, the intervention involves Zr89-trastuzumab PET/CT, which comprises of both PET and CT scans.\n\nTherefore, the statement that \"the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry\" can be entailed by the information present in the CTRs as both CT and dosimetry scans are mentioned explicitly in the primary CTR, and PET/CT scan, which includes both PET and CT scans, is mentioned in the secondary CTR.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial interventions involve a variety of scans, such as CT, PET and dosimetry\" is not contradicted by the information present in the CTRs. However, the information in the statement goes beyond the specific interventions described in the CTRs by implying that both trials involve multiple types of scans, including CT, PET, and dosimetry. However, while the primary trial does involve dosimetry scans, it does not mention the use of CT or PET scans. Conversely, the secondary trial specifically mentions only the use of PET/CT. Therefore, the statement does not contradict the CTRs, but it may be less precise in describing the exact interventions used in each trial.</s>"
    },
    "c876167f-fe1e-4c3b-9183-dd3c1069ed0b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00024102",
        "Statement": "A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion.",
        "Label": "Entailment",
        "entail": "The statement \"A patient in cohort 2 of the primary trial received a Packed red blood cell transfusion\" cannot be entailed by the information present in the CTRs as there is no record of a transfusion event (pRBCs) in the Adverse Events section of cohort 2 in the primary trial. The CTR only indicates that the total number of adverse events in cohort 2 was 1, but it does not specify the nature of this event. Therefore, the statement does not harmonize with clinical trial data and does not find substantiation in the CTR, and there is contradiction with the provided description of no transfusion event recorded in the CTR for cohort 2 of the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as there is no mention of a patient in cohort 2 of the primary trial receiving a transfusion of packed red blood cells (pRBCs) in the provided Adverse Events 1 or Adverse Events 2 sections. The total number of pRBC transfusions in the primary trial is reported as 0/131 (0.00%). Similarly, there is no mention of pRBC transfusions in the secondary trial.</s>"
    },
    "d6989b67-ae99-4c2a-a67d-c2285cc57058": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191152",
        "Statement": "The longest Time to Disease Progression the primary trial was over 11 months  in the Docetaxel Plus Capecitabine group.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR information as follows: In the Docetaxel Plus Capecitabine arm of the primary trial (Results 2), the median Time to Disease Progression is 8.88 (7.37 to 11.05) months. This means that there were participants in the arm who experienced progression beyond the median time, and some may have experienced progression beyond 11 months. This information aligns with the expert's statement, and there is no contradiction in the provided CTR descriptions.</s>",
        "contradict": "The statement \"The longest Time to Disease Progression in the primary trial was over 11 months in the Docetaxel Plus Capecitabine group\" contradicts the information presented in the CTRs because the median Time to Disease Progression for the Docetaxel Plus Capecitabine group, according to the results section, is 8.88 months (7.37 to 11.05). Although it's possible for individual participants to have a time to disease progression longer than the median, the statement does not provide any evidence that such a long TTP occurred in the trial or which participant it might be related to, making the claim an overgeneralization and potentially misleading without additional context.</s>"
    },
    "90dfb0bd-e0a0-47a9-945b-fd8ec8faaaa1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00320385",
        "Secondary_id": "NCT00075270",
        "Statement": "Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n1. The median PFS of Trastuzumab + Lapatinib cohort in the primary trial is 12.0 weeks (8.1-16.0), and the median PFS of Lapatinib cohort in the primary trial is 8.1 weeks (7.6-9.0).\n2. In the secondary trial, the median TTP of the Lapatinib with Paclitaxel cohort is 29.0 weeks (13.9-46.9), and the median TTP of the Placebo with Paclitaxel cohort is 22.9 weeks (12.0-38.3).\nSince PFS and TTP are related outcome measures, measuring disease progression, it's important to note that they aren't exactly interchangeable as PFS is defined as the time to the first documented sign of disease progression or death from any cause, whereas TTP considers progression based on the investigator's assessment and the average timeframe is shorter (26 weeks) for the secondary trial.\n\nTo evaluate the entailment, we can compare the median PFS of the two primary trial cohorts to the median TTP of the secondary trial's Lapatinib cohort:\n1. 12.0 weeks (8.1-16.0) > 8.1 weeks (7.6-9.0)\n2. 12.0 weeks (8.1-16.0) > 22.9 weeks (12.0-38.3)\n\nBoth of these comparisons demonstrate that the primary trial cohorts indeed had a longer median time to progression/event, implying that the statement \"Both cohorts in the primary trial outperformed cohort 1 of the secondary trial in median PFS\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement cannot be definitively concluded from the information provided in the CTRs, as the primary trial reports PFS in weeks, whereas the secondary trial reports TTP. Direct comparison between the two trial's outcomes is not meaningful due to the different outcome measurements used.</s>"
    },
    "886d3280-bc44-4a58-a5ba-66b018210332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year.",
        "Label": "Contradiction",
        "entail": "The statement that \"the minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year\" is entailed by the information in the CTRs, as the Median Time to Tumor Progression (TTP) for both arms of the trial exceeded 1 year (247 days for Axitinib + Docetaxel and 215 days for Docetaxel + Placebo).</s>",
        "contradict": "The expert's statement \"The minimum period of time from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was just over a year\" can be contradicted by the information in the CTRs because the provided data represents the medians of TTP for each treatment arm (Axitinib + Docetaxel and Docetaxel + Placebo), not the minimum TTP observed for any patient in the study.</s>"
    },
    "03dcb6d9-efae-40ec-87ee-68ef89424498": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of deteriorating mental health in the primary trial than the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were more cases of deteriorating mental health in the primary trial than the secondary trial\" cannot be directly entailed from the information provided in the CTRs, as neither trial reports an adverse event of mental health deterioration. However, it could be possible to derive this statement by comparing the types of adverse events between the two trials, but without that additional information, the statement does not follow directly from the data presented.</s>",
        "contradict": "The statement \"There were more cases of deteriorating mental health in the primary trial than the secondary trial\" cannot be definitively established or contradicted based on the information provided in the CTRs. The term \"deteriorating mental health\" is not mentioned in the Adverse Events sections of either CTR. Therefore, it cannot be directly inferred from the data if there were actually more cases of mental health deterioration in the primary trial compared to the secondary trial.</s>"
    },
    "b881b717-1c8a-41b8-9554-6ed9e8ee7c77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193206",
        "Statement": "the primary trial records a total of 7 patients suffering from various infections.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information in the CTRs because the term \"various infections\" in the expert's statement corresponds to the types of infections listed in the CTRs under the Adverse Events section for both trials. The number of patients suffering from infections in the primary trial, 7, can be calculated by summing up the reported cases of Infection - Skin [3], Infection - Gastrointestinal [1], Infection - Vein [2], and Infection - Pneumonia [1] in the provided CTR data. Therefore, the expert's claim is a valid conclusion drawn from the data presented in the CTRs, and no contradictory evidence is present.</s>",
        "contradict": "The information in the statement \"the primary trial records a total of 7 patients suffering from various infections\" is contradictory to the CTR data, as the total number of patients reported to have experienced infections in the Primary Trial is 6 (3 for skin, 1 for gastrointestinal, 1 for vein, and 1 for pneumonia), not 7.</s>"
    },
    "20530faf-addb-47bf-896d-b9666e149223": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2\" is entailed by the information in the CTRs as follows:\n1. The number of adverse events in the primary trial's cohort 1 is 14/67*100 = 20.90%*100 = 143.48.\n2. The number of adverse events in the primary trial's cohort 2 is 1/10*100 = 10.00%*118.8 = 11.88.\n3. The difference in number of adverse events between cohort 1 and cohort 2 is 143.48 - 11.88 = 131.56.\n4. The percentage difference in number of adverse events is (131.56 / 143.48) * 100% \u2248 20.38% > 20%.\n\nHence, the statement \"In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2\" can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs as the total number of adverse events in cohort 1 was 14/67 (20.90%), while the total number of adverse events in cohort 2 was 1/10 (10.00%), which is not a 20% difference but a 99% difference in terms of event frequency.</s>"
    },
    "52557c9f-f771-4f31-bb71-01f87f9f5821": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\nIn the primary CTR, the inclusion criteria state \"Hormone receptor status: Not specified.\" However, patients with ER and/or PR+ disease are included in the secondary trial. In the context of cancer research, ER+ and PR+ typically refer to hormone receptor status.\n\nIn the secondary CTR, the inclusion criteria state \"Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy.\" The primary CTR mentions \"Prior hormonal therapy as adjuvant therapy or for metastatic breast cancer allowed.\"\n\nThe statement also mentions \"HER2 positive stage 4 tumors may be eligible for the secondary trial or the primary trial.\" The primary CTR includes \"HER2-positive by fluorescence in situ hybridization (FISH) or immunohistochemistry 3+ staining,\" confirming the presence of HER2+ tumors as eligible for both trials. \n\nTherefore, the expert's statement is an entailed subset of the information presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial does not specify hormone receptor (HR) status, and the secondary trial includes strict requirements for HR status, limiting eligibility only to those with ER and/or PR+ disease. Therefore, patients with HER2 positive stage 4 tumors who are not ER and/or PR positive would not meet the inclusion criteria for the secondary trial. Additionally, the primary trial does not have any exclusion criteria regarding HR status, allowing patients with various HR profiles to be eligible. Consequently, the statement's assertion that patients with ER+, PR+, or HER2+ stage 4 tumors may be eligible for both trials can be inconsistent with the specific eligibility requirements outlined in the CTRs.</s>"
    },
    "11472413-533f-45f9-9aac-c46bca318aab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months\" can be entailed by the information present in the CTRs as follows:\n\n- Over 200 patients (242 total, specifically those in Arm/Group 1) were included in the primary trial and were treated with Sunitinib and Paclitaxel.\n- Treatment duration for Sunitinib and Paclitaxel is stated as \"From date of randomization through Day 1 and every 8 weeks thereafter up to 18 months or death.\"\n- The median PFS for Arm/Group 1 is reported as \"Median (95% Confidence Interval) = 7.4 (6.9 to 8.5)\" which is less than 7.5 months.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial included over 200 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the median PFS for this group was just under 7 and a half months\" contradicts the information in the CTRs for several reasons:\n\n1. The CTRs do not provide the total number of patients in the Sunitinib + Paclitaxel arm who underwent treatment for a duration of 18 months or until death.\n2. The CTRs specify a maximum follow-up period of 18 months or until death for measuring PFS; however, there is no information suggesting that all 242 patients in the Sunitinib + Paclitaxel arm were followed up for the complete 18 months.\n3. The median PFS value given in the CTRs for the Sunitinib + Paclitaxel arm is 7.4 months (6.9 to 8.5), which is lower than the 7.5 months mentioned in the statement.\n\nTherefore, the statement's assertion cannot be harmonized with the information in the CTRs and contradicts the provided descriptions.</s>"
    },
    "3b8f5ef2-b0bb-42e8-a165-45a2d35780e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial\" is entailed by the information present in the CTRs because the primary trial's inclusion criteria do not specify the requirement of Her2neu positive tumours or measurable indicator lesions. Only patients with breast cancer and Stage IV disease, a Performance Status of 0 or 1, who have previously received anthracycline based regimens as adjuvant therapy or neo-adjuvant chemotherapy and progressed, and have adequate organ function are eligible for the trial. The exclusion criteria do not mention Her2neu positive tumours or measurable indicator lesions as a requirement for exclusion.</s>",
        "contradict": "The statement that \"Patients do not need to have a Her2neu positive tumours or a measurable indicator lesion to be included in the primary trial\" is contradicted by the information present in the CTRs because the eligibility criteria for the primary trial explicitly state that patients must have a histological or cytological proven diagnosis of breast cancer. There is no mention that the cancer needs to be Her2neu positive or that there needs to be a measurable indicator lesion for patients to be included. However, the exclusion criteria do mention that concurrent administration of Herceptin is not allowed. Therefore, it appears that the statement made by the clinical trial expert might not accurately reflect the criteria for patient inclusion in the trial.</s>"
    },
    "6446f085-c6b0-43ce-82ed-16d6952b549e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Secondary_id": "NCT00916578",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression. However all patients in the secondary trial are treated with Trunk compression.",
        "Label": "Contradiction",
        "entail": "The statement \"Only patients in cohort 2 of the primary trial undergo Trunk compression. However, all patients in the secondary trial are treated with Trunk compression\" is entailed by the following information in the CTRs:\n\nIn the primary trial, Intervention 2 involves Trunk compression but there's no mention of cohort-specific details. In the secondary trial, all patients undergo Trunk compression. Therefore, since the statement restricts the Trunk compression to a specific cohort in the primary trial and extends it to all patients in the secondary trial, it is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement contradicts the information in the CTRs because:\n\n1. In the primary trial, there is no mention of trunk compression being exclusive to cohort 2 or any cohort for Intervention 1. In fact, there is no information regarding trunk compression in the primary CTR at all.\n \n2. In the secondary trial, Intervention 1 specifies arm, trunk, and chest compression for all patients receiving treatment, contradicting the claim that only cohort 2 in the primary trial undergoes trunk compression.</s>"
    },
    "7348c2e8-9eb5-4ed6-9a5d-bcb02a5c3a0a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01104584",
        "Statement": "the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the CTRs if the trials involve arms where participants receive trastuzumab at a dose of 50mg/m2, Tamoxifen, or Exemestane as specified interventions. The expert's statement does not directly contradict any information in the provided CTRs, as the trial descriptions do not state that the participants in the CMRM or UMRM arms receive these specific interventions. However, if the CTRs indicate that such arms exist, then the expert's statement would be entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"the primary trial participants receive either 50mg/m2 trastuzumab, Tamoxifen or Exemestane\" cannot be directly contradicted by the information present in the provided CTRs as they lack specificity regarding the type and dosage of interventions given in the primary trial. However, the statement is incomplete, as it does not mention which trial (Primary or Secondary) the information is referring to or whether this combination of treatments is even used in either trial. Thus, the statement itself does not contradict the CTRs but is potentially inconsistent with the actual clinical trials.</s>"
    },
    "db90c9d8-b289-48e2-a7df-f41620b3feab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of sepsis in their patients.",
        "Label": "Entailment",
        "entail": "The statements \"the primary trial reported cases of sepsis in its patients\" and \"the secondary trial reported cases of sepsis in its patients\" are entailed by the respective adverse event sections of the Primary and Secondary CTRs, as both sections report occurrences of sepsis (1/50 and 1/101, respectively).</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs if the cases of sepsis reported in the primary and secondary trials involve different patients, as the total number of participants and the number of sepsis cases differ between the trials. The statement implies that there is overlap in patients experiencing sepsis between the trials, but the CTRs do not provide enough evidence to support this claim.</s>"
    },
    "f2533676-1e72-444e-8aef-1fa826ceb804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01419197",
        "Statement": "There are no cases of agranulocytosis in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no cases of agranulocytosis in the primary trial\" is entailed by the information in the CTRs because the CTR for the primary trial reports zero cases (0/403) of agranulocytosis in Section Adverse Events 1. The statement accurately reflects the data presented in the CTR, making it a semantically entailed relationship.</s>",
        "contradict": "Although the statement claims there are no cases of agranulocytosis in the primary trial (0/403), the CTR data reveals that granulocytopenia, a potential precursor or indication of agranulocytosis, occurred in 1/403 cases. While granulocytopenia itself is different from agranulocytosis, the latter is a severe form of the former characterized by an absolute granulocyte count of less than 0. Therefore, the statement contradicts the CTR data since the CTR does report a case with potential signs of agranulocytosis (granulocytopenia).</s>"
    },
    "c15309b3-eb08-4d46-94ef-e4a504a111db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03708393",
        "Secondary_id": "NCT03456427",
        "Statement": "The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient.",
        "Label": "Entailment",
        "entail": "The statement \"The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient\" is entailed by the information present in the CTRs as follows:\n\n1. In both trials, there are two interventions: IUS Alone in the primary trial and Patient-Assisted Compression (PAC) and Technologist-Controlled (TC) Compression in the secondary trial.\n2. In the primary trial, the intervention is described as \"IUS Alone\" and \"IUS alone imaging,\" implying that no active patient participation is required for this intervention. The performers are mentioned as either a doctor, radiographer, or sonographer.\n3. In the secondary trial, the first intervention (PAC) is described as \"Patient-Assisted Compression.\" This intervention explicitly involves the patient, who applies compression under the technologist's guidance. The second intervention (TC Compression) is performed as per standard of care practices at the site, likely by a radiologist or a radiographer.\n4. Therefore, the statement \"The intervention in the primary trial is carried out by either a doctor, radiographer or a sonographer, whereas one of the interventions in the secondary trial requires active participation from the patient\" is a valid inference drawn from the information provided in the CTRs.</s>",
        "contradict": "The statement asserts that in the primary trial, the intervention is carried out by a doctor, radiographer, or sonographer. However, the CTR explicitly states that for IUS Alone intervention, there is no mention of medical personnel involved in the imaging process. Instead, it indicates that IUS alone imaging is performed. Similarly, for the Intervention 1 in the secondary trial, the patient is instructed to apply compression with assistance from the technologist, which contradicts the statement's assertion that the intervention in the primary trial is carried out only by doctors, radiographers, or sonographers.</s>"
    },
    "4885cd77-628c-4b8f-8345-6bce2165938c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02964234",
        "Secondary_id": "NCT00246090",
        "Statement": "Patients eligible for the primary trial and the secondary trial must live in the USA.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients eligible for the primary trial and the secondary trial must live in the USA\" does not directly entail any information present in the primary or secondary CTRs regarding patient eligibility. The statement only adds a geographical requirement not mentioned in the CTRs. However, the information in the CTRs is sufficient to determine patient eligibility based on age, ethnicity, residence, health history, and various other factors. Therefore, the USA residency condition is an additional requirement imposed by the statement, but it does not directly follow from the CTR information. Consequently, the statement cannot be considered entailed by the given CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTRs because the primary trial includes patients who reside in specific Chicago neighborhoods (Pilsen, Little Village, East Side or South Chicago), while the secondary trial does not have a residency requirement mentioned in its inclusion criteria.</s>"
    },
    "8809cc5e-36d5-4f7e-b06d-b1915a421f71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00759785",
        "Statement": "Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Only one adverse event, a Breast abscess, is observed in patients from cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. The statement asserts the occurrence of a single Breast abscess event in cohort 1 of the primary trial.\n2. The CTR for the primary trial specifies the number of events for each adverse reaction in cohort 1, including a Breast abscess event with a frequency of 1/25 (0.04%).\n3. The CTR's data does not contradict the statement, as the occurrence of a single Breast abscess event within cohort 1 is a logical implication of the given data.</s>",
        "contradict": "The statement is contradicted by the CTR information as both primary trial cohorts 1 and 2 reported zero occurrences of breast abscesses (0/25 and 0/20, respectively) despite the statement suggesting a single occurrence in cohort 1.</s>"
    },
    "f0f7241c-0c2d-47cb-8b42-6e5d7494b2b1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial, unless they have an ECOG>2.",
        "Label": "Contradiction",
        "entail": "The statement entails that female patients with histologically confirmed breast cancer and advanced Alzheimer's disease over the age of 60 are ineligible for both trials, unless their Eastern Cooperative Oncology Group (ECOG) performance status is greater than 2. This is in line with the CTRs' eligibility criteria as:\n\n1. In the Primary Trial, there is a condition that all patients must have an ECOG of 2.\n2. In the Secondary Trial, the inclusion of patients with advanced Alzheimer's disease is contingent on having an ECOG of 2 or less, but the statement specifies ECOG > 2, hence they do not meet the inclusion criteria for both trials.\n3. The age restriction for both trials aligns with the given statement.\n\nTherefore, the information in the statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The given statement contradicts the inclusion criteria of both trials. For the primary trial, the statement excludes females over 60 with breast cancer and Alzheimer's disease, regardless of the ECOG status. However, the primary trial inclusion criteria specifically states that patients with dementia or significantly altered mental status are excluded. Therefore, Alzheimer's disease, being a type of dementia, is an exclusion criterion for the primary trial irrespective of the ECOG status.\n\nFor the secondary trial, the statement excludes females over 60 with breast cancer and Alzheimer's disease, but the inclusion criteria for the secondary trial state that patients with dementia or significantly altered mental status are excluded as well. Again, Alzheimer's disease being a type of dementia is already an exclusion criterion, regardless of the ECOG status.\n\nTherefore, the statement contradicts the information present in the CTRs as it incorrectly suggests that patients with histologically confirmed breast cancer and Alzheimer's disease are eligible for both trials, only if they have an ECOG>2, while this is not the case as per the inclusion criteria provided in the CTRs.</s>"
    },
    "ca27db58-14c4-4889-95b1-69be9c10a07a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "More patients with a Low Platelet Count where found in the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"More patients with a Low Platelet Count were found in the primary trial than in the secondary trial\" can be entailed by the information present in the CTRs if we assume that the term \"Low Platelet Count\" refers to Thrombocytopenia, as the two terms are synonymous in clinical contexts.\n\nIn the primary CTR:\n1. Total number of participants: 52\n2. Number of participants with Thrombocytopenia: 1/52 (1.92%)\n\nIn the secondary CTR:\n1. Total number of participants: 54\n2. Number of participants with Thrombocytopenia: 6/54 (11.11%)\n\nComparing the two CTRs, it is observed that a smaller percentage (1.92%) of participants in the primary trial experienced Thrombocytopenia compared to the secondary trial (11.11%). Therefore, fewer patients with Thrombocytopenia were found in the primary trial than in the secondary trial, which contradicts the statement. However, upon further examination, the statement is not stating that fewer participants in the primary trial had Thrombocytopenia, but rather that more participants with a \"Low Platelet Count\" were found in the primary trial. The term \"Low Platelet Count\" can imply a broader spectrum of platelet counts below the normal range, not just the severe Thrombocytopenia cases.\n\nNow, let's calculate the number of participants with platelet counts below but close to the lower limit of the normal range in both trials:\n\nIn the primary CTR:\n1. Total number of participants: 52\n2. Number of participants with platelet counts below normal: 9/52 (17.31%)\n3. Number of participants with Thrombocytopenia (platelet counts <50,000/\u00b5L): 1/52 (1.92%)\n\nIn the secondary CTR:\n1. Total number of participants: 54\n2. Number of participants with platelet counts below normal: 11/54 (20.37%)\n3. Number of participants with Thrombocytopenia (platelet counts <50,000/\u00b5L): 6/54 (11.11%)\n\nSince the statement refers to a \"Low Platelet Count,\" which could include participants with platelet counts just below the normal range, the number of participants with such counts should be considered in the comparison. In this case, the primary trial actually has a larger percentage (17.31%) of participants with platelet counts below the normal range compared to the secondary trial (20.37%). Therefore, the statement \"More patients with a Low Platelet Count were found in the primary trial than in the secondary trial\" is indeed entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the provided CTRs data, as the CTRs do not mention the number of patients with a low platelet count in each trial, and the statement does not specify what is meant by \"more patients\" or a \"Low Platelet Count\". The statement only makes a comparison between the presence or absence of certain adverse events in the two trials, and the given data does not contain sufficient information to draw a conclusion on the platelet count distribution or the total number of patients in each trial.</s>"
    },
    "5147b171-b5dc-46d6-a153-1a6d9a062ef1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03190083",
        "Statement": "All cancer stages are accepted for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"All cancer stages are accepted for the primary trial\" is entailed by the primary CTR inclusion criteria, which states \"New diagnosis of breast cancer\" without specifying any particular cancer stage. Therefore, the broader implication of accepting all cancer stages is harmonious with the given inclusion criteria, and no contradiction is presented in the CTR descriptions.</s>",
        "contradict": "The statement \"All cancer stages are accepted for the primary trial\" is contradicted by the information present in the primary CTR's inclusion criteria as it explicitly states that \"new diagnosis of breast cancer\" is a requirement for enrollment. This condition does not include advanced or metastatic stages of breast cancer, which would contradict the expert's statement.</s>"
    },
    "a5ed3500-1ea1-40b6-b1cb-3d5ae776f713": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656669",
        "Statement": "the primary trial did not record any adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial did not record any adverse events\" is entailed by the information present in the CTRs as both reports confirm that there were no instances of any adverse event mentioned in the primary trial, including LEFT VENTRICULAR SYSTOLIC DYSFUNCTION, NAUSEA, VOMITING, BILIRUBIN (HYPERBILIRUBINEMIA), INFECTION with grade 3 or 4 NEUTROPHILS, and NEUTROPHILS/GRANULOCYTES (ANC/AGC). The number of instances for each adverse event is listed as 0/23 (0.00%) in the primary trial CTR. Therefore, the expert's statement is a valid conclusion drawn from the CTR data.</s>",
        "contradict": "The statement \"the primary trial did not record any adverse events\" can be contradicted by the information present in the CTR because the CTR reports specific adverse events occurring in the primary trial with a total count of 0 for each event. The absence of adverse events is not the same as not recording them. The CTR provides data on the occurrence of adverse events, even though the number of occurrences is zero.</s>"
    },
    "3c482d5e-bfad-4a46-9e98-ba9967f2d900": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00903162",
        "Secondary_id": "NCT01674062",
        "Statement": "Patients with BCC are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with BCC (basal cell carcinoma) are excluded from the primary trial and the secondary trial\" can be entailed by the information present in the CTRs because neither of the trials lists basal cell carcinoma as a permitted condition in their inclusion criteria and explicitly mentions breast cancer as the target disease. Therefore, by definition, patients with a diagnosis other than breast cancer, including those with basal cell carcinoma, are excluded.</s>",
        "contradict": "The statement \"Patients with BCC are excluded from the primary trial and the secondary trial\" is not directly contradicted by the information in the CTRs. However, it is important to note that BCC stands for Basal Cell Carcinoma, which is a type of skin cancer. Neither the primary nor the secondary trial mentions Basal Cell Carcinoma explicitly as an exclusion criterion; they only exclude pregnant and nursing women and those with a history of other types of cancer within certain timeframes or specific cancers (e.g., BRCA1 or BRCA2 mutation). Therefore, the statement does not directly contradict the information in the CTRs, but it does not harmonize with the trials as described, because Basal Cell Carcinoma is not mentioned as an exclusion criterion for these trials.</s>"
    },
    "48ccd744-abf1-4e98-bc86-8ecd625e6279": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The given statement entails that patients with HER-2-negative metastatic breast adenocarcinoma are potential candidates for the primary trial. According to the CTR, the inclusion criteria state that patients with locally recurrent or metastatic disease and HER-2-negative breast cancer are eligible for the trial, as long as they meet other inclusion and exclusion criteria. Therefore, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"Patients with metastatic HER-2-negative adenocarcinoma of the breast may be eligible for the primary trial\" can be contradicted by the following information present in the CTRs:\n\nThe primary CTR states: \"Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab or have previously received trastuzumab in the past.\"\n\nTherefore, the statement does not accurately capture the full eligibility criteria for the trial as outlined in the CTR. Patients with metastatic HER-2-negative breast cancer are indeed eligible, but those who have previously received or are unable to receive trastuzumab are excluded, even if their breast cancer is HER-2-negative.</s>"
    },
    "dce5d9c8-7da6-4732-b969-c492c876cdca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Statement": "Women of any age can participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criteria state that there are no age restrictions specified for women with ER+ locally advanced, recurrent, or metastatic breast cancer with measurable disease or bone metastases. Therefore, the statement \"Women of any age can participate in the primary trial\" is entailed by the information present in the CTR.</s>",
        "contradict": "The key inclusion criteria in the primary CTR state that \"Women with locally advanced, recurrent, or metastatic breast cancer along with confirmation of estrogen-receptor positive (ER+)\" can participate in the trial. The statement, however, asserts that \"Women of any age can participate in the primary trial.\" This contradicts the CTR as it does not mention any age restriction for the trial participants.</s>"
    },
    "1882de62-2df2-4b73-a3d2-81811f85f661": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy.",
        "Label": "Contradiction",
        "entail": "The statement \"2% of the primary trial patients were diagnosed with Fatty Liver Disease after 3 years of Treatment with Chemotherapy or Maintenance Therapy\" does not entail any information directly from the provided CTRs, as there is no mention of patients being diagnosed with Fatty Liver Disease in either the primary or secondary CTRs. Therefore, the statement cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not provide specificity regarding which trial's cohort (Primary or Secondary) the fatty liver disease cases belong to. The CTR for the Primary Trial does not report any occurrences of fatty liver disease among its participants. Consequently, the statement cannot be entailed by the information in the CTRs.</s>"
    },
    "161c852e-a42c-47c2-ab6a-2b7bd6a4b934": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Statement": "Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months.",
        "Label": "Entailment",
        "entail": "The statement \"Patients wanting to participate in the primary trial, must discontinue any Antitumoral hormonal treatment, and must have a life expectancy of more than 3 months\" can be entailed by the CTR inclusion criteria. The CTR explicitly states that \"Antitumoral hormonal treatment must be discontinued prior to enrollment\" (Primary Trial: Inclusion Criteria). Regarding the life expectancy criterion, the CTR requires that participants have an \"Estimated life expectancy of at least 3 months\" (Primary Trial: Inclusion Criteria). Therefore, the statement made by the clinical trial expert aligns with the provided information in the CTRs and does not contradict the given inclusion criteria.</s>",
        "contradict": "The statement can be contradicted by the CTR information in several ways:\n\n1. Antitumoral hormonal treatment need not be discontinued for all participants: According to the Primary Trial's Inclusion Criteria, participants who have undergone antitumoral hormonal treatment prior to enrollment must discontinue it. However, the Secondary Trial's statement does not mention this requirement and could be interpreted as applicable to all potential study participants, including those who have not received hormonal therapy. \n\n2. Life expectancy requirement is different: The Secondary Trial's statement sets the life expectancy requirement as \"more than 3 months,\" which is identical to the Primary Trial's Inclusion Criteria. However, the CTRs might include participants with life expectancies below this threshold but still meeting other inclusion criteria. Therefore, the Secondary Trial's statement could potentially exclude some eligible participants based on this criterion alone.\n\n3. The statement does not mention the other inclusion and exclusion criteria from the Primary Trial. These could also potentially lead to contradictions if not taken into account. For instance, participants with prior malignancies other than breast cancer or with serious concomitant systemic disorders would not meet the inclusion criteria for the Primary Trial and should not be considered for the trial despite the life expectancy and hormonal treatment conditions being met.\n\n4. The statement does not provide enough context to determine if it is referring to the primary or secondary trial. If the expert meant to refer specifically to the primary trial, they should clarify that to avoid potential confusion with other trials.</s>"
    },
    "eb152d1b-a0d6-428c-8d1d-eb5d862a8147": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder.",
        "Label": "Contradiction",
        "entail": "The statement \"At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia\" does not directly entail information present in the CTRs. However, it can be inferred to be consistent with the data, as the term \"cohort 1\" implies a group of patients within the primary trial, and the CTRs do not provide information about the medical histories or diagnoses of individual patients, only the number of occurrences of certain adverse events. The absence of any mention of Hemophilia in the CTRs does not contradict the expert statement, as this condition was neither reported as a common adverse event nor mentioned in the eligibility criteria as an exclusion factor. Thus, the statement is consistent with the given CTR data.</s>",
        "contradict": "The statement \"At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder\" cannot be definitively determined to be either true or false based on the provided information in the CTRs. The CTRs do not mention anything about the presence or absence of Hemophilia in the participants of the trials. Therefore, there is no substantiation for the statement in the CTRs, and it could either be true or false depending on the actual participant data not presented in the excerpts. However, the statement contradicts neither the provided data nor each other, as both CTRs report on different trials with different participant populations.</s>"
    },
    "0701ac32-45b3-4199-aa20-a71080ce9bf6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo in the primary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no cases of Vertigo in the primary or secondary trial\" is entailed by the information in the CTRs since Vertigo is explicitly stated as having a count of 0 (zero) occurrences in Adverse Events 1 for both the primary and secondary trials.</s>",
        "contradict": "The statement \"There are no cases of Vertigo in the primary trial or the secondary trial\" is contradicted by the information in the CTRs because the statement asserts that there are no instances of Vertigo in both trials, while the Primary Trial's Adverse Events 1 list includes no cases of Vertigo for that trial; however, the statement does not address the absence or presence of Vertigo in the Secondary Trial's Adverse Events 1 section, which is provided in the text. Therefore, the statement does not accurately represent the information in the CTRs.</s>"
    },
    "866876f5-68de-44bd-b58a-e4b590aa4b39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a fitbit.",
        "Label": "Entailment",
        "entail": "In the primary CTR, both Intervention 1 and 2 involve MRI evaluations by different radiologists, indicating that participants undergo an MRI scan during the intervention. However, the CTR does not specify whether the MRIs are performed more than once or if there is a requirement for participants to use a Fitbit device.\n\nThe secondary CTR outlines the multi-component physical activity intervention, which includes the use of a Fitbit device for subjects. While the statement does not exactly mirror any single section in the CTR, it can be entailed by combining the information from both trials:\n\n1. The primary trial states that participants undergo MRI scans during the interventions.\n2. The secondary trial states that subjects are required to use a Fitbit device.\n3. There is no contradiction in the information, as the MRI evaluations in the primary trial do not necessarily conflict with the use of Fitbit devices in the secondary trial.\n\nTherefore, the statement \"Participants of the primary trial must undergo at least one MRI during the intervention, in the secondary trial patients must use a Fitbit\" can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, MRI evaluation by Radiologist A and B is part of the intervention, but it does not specify that every participant undergoes MRI at least once.\n2. In the secondary trial, while participants are provided with a Fitbit as part of the intervention, MRI evaluation is not mentioned.\n\nTherefore, it cannot be entailed that participants of the primary trial must undergo at least one MRI during the intervention and that patients of the secondary trial must use a Fitbit, as stated in the given expert's claim, based on the information provided in the CTRs.</s>"
    },
    "b4304362-1cb4-4606-9de4-03935ad509f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. The number of participants with PR or CR in Cohort 1 (Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg) is given by the percentage stated: 47.8% (32.9-63.1). With the overall number of participants Analyzed as 46, we can calculate the actual number as: 46 * 0.478 \u2248 21.8. Since we cannot have a fraction of a participant, we will round it to the nearest whole number: 22 participants.\n\n2. The number of participants with PR or CR in Cohort 2 (Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg) is given by the percentage stated: 71.1% (55.7-83.6). With the overall number of participants Analyzed as 45, we can calculate the actual number as: 45 * 0.711 \u2248 32.25. Rounding it up to the nearest whole number: 33 participants.\n\n3. The difference between the number of participants with PR or CR in Cohort 1 and Cohort 2 is 33 - 22 = 11 participants.\n\nThe expert's statement that \"There are 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 than in cohort 1\" can be derived from the CTRs data by calculating the difference between the actual number of participants with PR or CR in both cohorts. Since the difference calculated (11) is less than the difference stated in the expert's claim (55), the claim is an overestimate. However, as long as the difference stated remains within the plausible range of the data, there is entailment between the expert's claim and the CTRs, despite the slight discrepancy in numbers.</s>",
        "contradict": "The statement cannot be directly contradicted by the information in the CTRs, but it does require careful scrutiny. The percentage of participants with partial response or complete response in each cohort (results 1 and 2) can be calculated from the provided data. However, the statement only mentions a difference in the number of participants, not the percentage itself. To determine if the statement is true, one would need to calculate the percentage difference between the two cohorts based on the provided data, and then verify if that percentage difference matches the stated difference of 55 participants. Without performing these calculations, it is not possible to definitively say whether the statement is contradictory or not based on the information in the CTRs alone.</s>"
    },
    "9cddd86a-4340-4918-b000-7e6e593a3f7f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with stable angina cannot be included in either the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information present in the CTRs as the CTRs do not include females aged between 18-25 as potential participants. The primary trial includes women aged 45-69, and the secondary trial specifically mentions women with infiltrating breast cancer, cytologically or histologically confirmed. No age restriction is provided for this secondary trial, but the statement excludes females within the age range of 18-25, which is not consistent with the age range stated in the CTRs. Hence, the statement cannot be inferred from the information given in the CTRs.</s>",
        "contradict": "The information contained in the statement is contradictory to the inclusion criteria of both the primary and secondary trials as stated in the CTRs. The primary trial includes women aged 45-69 and has no age restriction for the secondary trial, and there is no mention of stable angina as an exclusion criterion in either trial.</s>"
    },
    "c3f01101-2259-4677-add1-1b1f48a0202b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial is more than 1000.",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information in the CTRs, as the total number of patients with adverse events in cohort 2 of the primary trial is 15 (not over 1000).</s>",
        "contradict": "The statement \"The total number of patients affected by adverse events in cohort 2 of the primary trial is more than 1000\" is contradicted by the CTR data as the total number of patients with adverse events in cohort 2 of the primary trial, according to the provided information, is 250, which is not more than 1000.</s>"
    },
    "33b827a0-ada5-4204-abb8-d5239ea16f0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial, there was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group\" can be entailed by the information in the CTRs as follows:\n\nGiven that both trials report the use of expert evaluation committee assessment for determining tumor progression (Outcome Measurement, Primary Trial) and the same timeframe for measuring TTP (up to 2008 days, Outcome Measurement, Primary Trial), the comparison between TTP maxima in the Exemestane and Anastrozole groups from the expert's perspective can be derived.\n\nFrom the Results 1 and 2 sections of the CTRs, we find the median TTP for the Exemestane group is 13.8 months (10.8 to 16.5) and for the Anastrozole group is 11.1 months (10.8 to 16.6). To calculate the maximum TTP in each group, one can find the highest recorded TTP value for each group from the given data. Since the 95% confidence interval for both medians covers the range of 16.6 months, the maximum TTPs could potentially exceed this value. Therefore, the maximum TTP for the Exemestane group could be higher than 16 months, and the maximum TTP for the Anastrozole group could be higher than 16.6 months.\n\nNow let's calculate the difference between these hypothetical maximum values:\n\nMaximum TTP (Exemestane) > 16 months\nMaximum TTP (Anastrozole) > 16.6 months\n\nDifference = Maximum TTP (Exemestane) - Maximum TTP (Anastrozole)\n\nSince both maximum TTP values are greater than 16 months, we can calculate the difference as:\n\nDifference = Maximum TTP (Exemestane) - Maximum TTP (Anastrozole)\n           = (Maximum TTP (Exemestane) - 16) - (Maximum TTP (Anastrozole) - 16)\n\nTo ensure that the difference is less than 3 days, we need to find a value for the Maximum TTP (Exemestane) and Maximum TTP (Anastrozole) such that their difference is less than 3 days (approximately 72 hours, or 0.002555 months).\n\nLet's assume that Maximum TTP (Anastrozole) = 17 months and Maximum TTP (Exemestane) = 17.01 months. Then, the difference would be:\n\nDifference = Maximum TTP (Exemestane) - Maximum TTP (Anastrozole)\n           = (17.01 months) - (17 months)\n\nDifference = 0.01 months\n\nSince 0.01 months is less than 0.002555 months (or 3 days), the statement \"In the primary trial, there was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"In the primary trial, there was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group\" is contradicted by the CTR information as follows:\n\nIn the primary CTR, the median TTP (Time to Progression) for the Exemestane group was 13.8 months (10.8 to 16.5), and for the Anastrozole group was 11.1 months (10.8 to 16.6). A difference of approximately 2.7 months exists between the TTP of the two groups. Therefore, the claim of less than 3 days difference is inaccurate and inconsistent with the data presented in the CTRs.</s>"
    },
    "40f1d3ce-2ff8-4177-9b11-0bf10b7f6591": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score.",
        "Label": "Entailment",
        "entail": "The given expert statement, \"the primary trial studies the impact of Fulvestrant, Anastrozole on Oestrogen Receptor H-score,\" is entailed by the Clinical Trial Reports (CTRs) as follows:\n\n1. The CTRs describe the Primary Trial as examining the \"Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score\" (CTR - Outcome Measurement).\n2. The ER H-score is stated to be calculated based on changes in ER receptor expression, with a greater change from baseline indicating more ER blocking and potential anti-tumour activity (CTR - Outcome Measurement).\n3. The first arm of the Primary Trial involves Fulvestrant treatment (CTR - Results 1), and the second arm involves a combination of Fulvestrant and Anastrozole (CTR - Results 2).\n4. The impact of the treatments on the ER H-score is reported in both arms (CTR - Results 1 and 2) and can, therefore, be inferred to be a focus of the study. \n\nTherefore, the expert statement is entailed by the provided CTR information.</s>",
        "contradict": "The statement can be contradicted by the information presented in the CTRs as the CTRs do not report the impact of Anastrozole on the Oestrogen Receptor H-score in the second trial. The statement asserts that the primary trial studies the impact of Fulvestrant and Anastrozole on the Oestrogen Receptor H-score, however, the second trial only reports the results for the group receiving both Fulvestrant and Anastrozole, but not the separate impact of Anastrozole.</s>"
    },
    "22bff413-a1bd-419b-b19b-2157dedc9948": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00802945",
        "Secondary_id": "NCT01231659",
        "Statement": "Group 1 of the secondary trial has a higher ORR than both the NKTR-102 14 Day cohort of the primary trial and the NKTR-102 21 Days cohort.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the CTRs' information if the ORR in the secondary trial, specifically in Group 1, exceeds the ORR in both NKTR-102 cohorts (14 Day and 21 Days) of the primary trial. This can be inferred by comparing the percentage values reported in the ORR definitions of both trials. In the primary trial, the ORR is defined as the proportion of subjects with CR or PR according to RECIST v1.0 for target lesions and MRI assessment, while in the secondary trial, the ORR is defined as the proportion of participants with either CR or PR according to RECIST 1.0 for target lesions and CT assessment. The ORR in the secondary trial is 37.2%, which is higher than both 28.6% (95% CI: 14.6-46.3%) in the NKTR-102 14 Day cohort and 35% (95% CI: 14.6-46.3%) in the NKTR-102 21 Days cohort. Therefore, the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information presented in the CTRs due to the following reasons: \n\n1. Different patient populations: The two trials involved different patient cohorts, and it is not directly comparable as the patient characteristics might have influenced the outcomes. \n\n2. Different outcome measurements: The primary and secondary trials used different outcome measurements. The primary trial reported the Objective Response Rate (ORR) measured by RECIST v1.0 using MRI, whereas the secondary trial reported the percentage of participants with ORR, assessed by CT using RECIST 1.0. The discrepancies in assessment methods, imaging modalities, and time frames for follow-up can influence the results.\n\n3. Different time frames: The secondary trial assessed overall response for approximately 15 months, whereas the primary trial reported response rates up to 2 years. The difference in assessment durations could potentially lead to varying outcomes.</s>"
    },
    "b64d6e41-7ec7-4e62-beda-c28559a6cee7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00880022",
        "Statement": "Only patients in cohort 2 of the primary trial undergo Trunk compression.",
        "Label": "Entailment",
        "entail": "The statement \"Only patients in cohort 2 of the primary trial undergo Trunk compression\" is entailed by the information in the CTR if cohort 2 of the primary trial is the one that received Intervention 2, which specifies Arm, Trunk and Chest Compression.</s>",
        "contradict": "The statement \"Only patients in cohort 2 of the primary trial undergo Trunk compression\" is contradictory to the information in the CTRs since the CTRs do not provide any information specifying that cohort 2 of the primary trial undergoes trunk compression specifically. Both cohorts 1 and 2 in the primary trial are described as undergoing either arm compression only or arm, trunk, and chest compression, and no distinct information is given regarding which cohort receives trunk compression alone.</s>"
    },
    "2ea80a50-0db3-4ff2-8ca0-71eb048649f7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "More than 3 patients in the primary trial had a common cold.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 3 patients in the primary trial had a common cold\" cannot be entailed by the information present in the CTRs, as no instances of the common cold are reported in the Adverse Events section for either the primary or secondary trials.</s>",
        "contradict": "The statement \"More than 3 patients in the primary trial had a common cold\" is contradicted by the information in the CTRs because no cases of a common cold (0/81 in the first CTR and 0/85 in the second CTR) were reported among the trial participants.</s>"
    },
    "20545360-b2a1-4be9-997a-97040866b239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00880464",
        "Secondary_id": "NCT00458237",
        "Statement": "Patients with AIDS are eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the provided Clinical Trial Reports (CTRs) as the CTRs explicitly state that HIV positive patients are excluded from participation in both trials. The statement suggests inclusion, contrary to the stated exclusion in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as patients with HIV infection, which is a component of AIDS, are explicitly listed as an exclusion criterion for both the primary and secondary trials.</s>"
    },
    "3b1bdc19-62cd-4ff1-9e30-424e124342f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial and the primary trial both measure PFS of their patient cohorts and use the same time frame\" can be entailed by the information present in the CTRs as follows:\n\nIn both trials, the outcome measurement is Progression Free Survival (PFS). The time frame for measuring PFS is from the date of randomization up to a specific point in time - approximately 34 months in the primary trial and up to 6 months in the secondary trial. Therefore, both trials are measuring PFS within the same time frame.</s>",
        "contradict": "While both trials measure Progression-Free Survival (PFS), the primary trial reports median PFS (time to progression or death) in months, while the secondary trial reports the PFS rate at 6 months (proportion of participants progression-free at 6 months). These measurements are not equivalent, hence the trials are not directly comparable based on this statement alone. In the primary trial, PFS is measured as a continuous variable, while in the secondary trial, it is measured as a categorical variable. Therefore, the statement's assertion can be contradicted by the information present in the CTRs as they report different types of PFS measures.</s>"
    },
    "a44cd0d1-92b3-4add-badf-b8dd5a324138": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive heart failure, the secondary trial did not record any.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because the primary CTR reports one instance of congestive heart failure (1/30 or 3.33% incidence), whereas the secondary CTR does not report any instances of congestive heart failure (0/3 or 0.00% incidence). The statement accurately summarizes this difference in adverse event occurrence between the two trials.</s>",
        "contradict": "Although the statement asserts that the primary trial recorded one patient with congestive heart failure and the secondary trial did not record any, it is contradictory to the CTRs. In the primary CTR, congestive heart failure was reported as an adverse event with an occurrence rate of 3.33% (1/30) among the patients. However, the secondary CTR does not provide any mention of congestive heart failure as an adverse event. The statement's claim that no cases were observed in the secondary trial contradicts the data presented in the CTR, as it does not reflect the accurate information regarding the occurrence of this event in the secondary trial.</s>"
    },
    "291bb67e-f02f-49d4-b967-29cc9f5098c4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01738438",
        "Secondary_id": "NCT00331552",
        "Statement": "Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial\" is entailed by the information in the CTRs as follows:\n\nThe statement asserts that these drugs were used in the secondary trial intervention, which is correct according to the CTR (INTERVENTION 1 in the secondary trial specifies the use of cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, and trastuzumab). \n\nThe statement also asserts that they were not used in the primary trial, which is also correct according to the CTR (INTERVENTION 1 in the primary trial specifies the use of cabozantinib, and no mention of cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, or trastuzumab is found). \n\nTherefore, the statement is harmonious with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction, making it entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cyclophosphamide, Cabozantinib and Trastuzumab were used in the secondary trial intervention, but not in the primary trial\" contradicts the CTRs because, for the Primary Trial, Cabozantinib was used as the sole intervention, while for the Secondary Trial, Cyclophosphamide, Doxil, and Trastuzumab were used together but not Cabozantinib alone. Therefore, the statement incorrectly suggests that none of the named drugs were used in the Primary Trial, whereas they were indeed used, just not in combination like the Secondary Trial.</s>"
    },
    "55704a1f-eab2-44ea-a6de-8df508a28066": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274768",
        "Secondary_id": "NCT00654836",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with stage 4 cancer are eligible for the secondary trial and the primary trial\" is entailed by the information present in both CTRs based on the following reasoning:\n\n1. Both CTRs include \"DISEASE CHARACTERISTICS\" sections that specify the diagnosis of adenocarcinoma of the breast as the requirement for participation in the trials.\n2. Both CTRs include \"DISEASE CHARACTERISTICS\" sections that state \"Patients must have measurable disease,\" which includes patients with metastatic involvement (stage IV disease, as per the primary CTR).\n3. Neither CTR explicitly states or denies eligibility based on cancer stage (IV or any other stage), so the statement does not contradict any specific information within the CTRs.\n\nTherefore, since the statement does not contradict the information in the CTRs and is consistent with it (patients with stage 4 cancer meet the inclusion criteria for measurable disease, as specified in both CTRs), the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial explicitly states that patients with leptomeningeal disease are ineligible, which is a type of metastatic disease (stage IV) and thus, would make them ineligible for the primary trial. Contrarily, the secondary trial includes metastatic disease (stage IV) as a requirement for participation. Therefore, patients with stage 4 cancer can be eligible for the secondary trial but cannot participate in the primary trial.</s>"
    },
    "6e1955b8-e6fa-42b2-a498-7ada9e733304": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01593020",
        "Secondary_id": "NCT00834678",
        "Statement": "Patients with aspartate aminotransferase more than 3 times the upper limit of normal are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "Both trials exclude patients with an aspartate aminotransferase (AST) level greater than 3 times the upper limit of normal (ULN). This criterion can be found directly in the secondary trial's inclusion/exclusion criteria under \"Liver Function Tests\" with ALT and AST specified as 2.5 times ULN (5 times ULN in the presence of documented liver metastases), but AST is also mentioned as > 3 times ULN in the present statement, which falls within the scope of the given criterion. In the primary trial, the exclusion criteria list AST > 2.5 times ULN without specifying a limit for liver metastases. However, since AST being more than 3 times ULN implies a more severe liver dysfunction than 2.5 times ULN, it logically follows that patients with AST levels more than 3 times ULN are excluded according to the primary trial as well. Consequently, the statement is entailed by the information provided in both CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs since the primary trial explicitly states that the AST (alanine aminotransferase) value should not exceed 2.5 times the upper limit of normal (ULN), not 3 times the ULN as stated in the expert's claim. The secondary trial also sets the limit to 2.5 times the ULN, except for the presence of liver metastases where the limit is 5 times the ULN. Thus, the expert's statement is inconsistent with the CTRs' inclusion criteria.</s>"
    },
    "52337e14-7f51-40c1-b965-fb6aba8ae4e7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial\" is entailed by the following conditions in the CTR:\n\n1. No history of significant cardiac disease or cardiac risk factors, unless controlled or well-compensated:\n   The statement implies that patients have a diagnosed condition of CHF, which falls under this category with the specified treatments.\n\n2. No clinically significant valvular heart disease:\n   The statement does not mention any valvular heart disease as an exclusion.\n\n3. No uncontrolled arrhythmias and no use of medications that alter cardiac conduction, if administered for cardiac arrhythmia, angina, or CHF:\n   Bisoprolol and labetalol are both beta blockers, which can be used to manage arrhythmias and angina, but they are not mentioned to be used for these specific indications in the statement. Therefore, the patients are assumed to be using these medications under control and for CHF only.\n\n4. No cardiomegaly on chest X-ray or ventricular hypertrophy on ECG unless echocardiogram or MUGA scan shows LVEF within the institutional lower limit of normal:\n   Since the statement does not mention cardiomegaly or ventricular hypertrophy, it is assumed that these conditions do not apply to the eligible patients.\n\nThus, the information in the statement \"Patients prescribed with bisoprolol or labetalol to treat CHF are eligible for the primary trial\" is entailed by the information in the CTRs, as it only adds a specific treatment condition for CHF patients that falls under the existing eligibility criteria.</s>",
        "contradict": "The patients with cardiac history, specifically those with a history of congestive heart failure (CHF), are excluded from the primary trial as per the CTRs. Bisoprolol and labetalol are commonly used drugs to manage symptoms of CHF. Therefore, the statement contradicts the inclusion criteria stated in the CTRs.</s>"
    },
    "8a6397e9-84cd-4a2e-ac6a-b56ee355d862": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00004092",
        "Statement": "Patients with Cancer that has spread from a breast tumor to their CNS are able to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the provided CTRs as the CTRs do not specify any conditions related to CNS metastasis. However, the primary CTR does not exclude patients with CNS metastasis as a condition for eligibility. Therefore, the statement does not contradict the provided information and can be considered neutral towards it.\n\nExplanation:\n\n1. The statement asserts that patients with CNS metastases can participate in the trial.\n2. The CTRs provide eligibility criteria for the primary and secondary trials, which include conditions for patient inclusion and exclusion.\n3. The primary CTR includes the condition \"No CNS metastasis\" under disease characteristics but it does not explicitly state that patients with CNS metastases are ineligible for the trial.\n4. Since the primary CTR does not exclude patients with CNS metastases based on the provided information, the statement does not contradict any statements in the CTRs and can be considered neutral towards them.\n5. The statement, however, does not follow directly from the information in the CTRs as it makes an additional claim beyond what is explicitly stated in the provided data.</s>",
        "contradict": "The statement \"Patients with Cancer that has spread to their CNS are able to take part in the primary trial\" is contradicted by the following eligibility criteria in the CTR: \"No CNS metastasis.\"</s>"
    },
    "8b5f946c-71d9-42cd-aa9a-1d3a4845c460": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their hormone status, Cohort A is TNBC patients and cohort B is ER/PR +HER2- BC Patients, in contrast the secondary trial assigns interventions randomly.",
        "Label": "Entailment",
        "entail": "The statement asserts that the primary trial assigns interventions based on hormone status, with distinct cohorts for triple-negative breast cancer (TNBC) and hormone receptor positive/HER2-negative breast cancer (ER/PR+ HER2-), in contrast to the secondary trial, which assigns interventions randomly. This claim can be entailed by the information in the CTRs since:\n\n1. The primary trial's cohort designations clearly indicate patient selection based on hormone status.\n2. The secondary trial description mentions the absence of randomized intervention assignment, as stated in the expert's claim.\n\nThe expert's statement does not contradict or misrepresent the information presented in the trial descriptions. Therefore, it can be considered semantically entailed by the provided CTR data.</s>",
        "contradict": "The expert's statement implies that the interventions in the secondary trial are assigned randomly without regard for patients' hormone status. However, the CTRs provided specify distinct interventions for Cohort A (triple-negative breast cancer) and Cohort B (hormone receptor positive/HER2-negative breast cancer) in the primary trial based on patients' hormone status. This contradicts the statement's assertion regarding the random assignment of interventions in the secondary trial.</s>"
    },
    "8f0aff7f-0d9e-498b-bcb6-05e6d309724c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information present in the CTRs as there is no explicit mention of placebo administration or dosage comparison in the provided CTRs. However, based on the context and general understanding of clinical trials, it's plausible that placebo tablets are used in the secondary trial. The statement claims that the placebo is administered at a \"twice the rate\" of the primary trial but \"less than half the dose\" of the study drug. Since the primary trial involves breast cancer patients undergoing tomosynthesis and breast CT scanning, the intervention is non-pharmacological in nature. In contrast, the secondary trial mentions a study drug, Pralatrexate, which is administered for 2 to 4 weeks.\n\nGiven that clinical trials often compare experimental treatments to placebo controls, it's reasonable to infer that a placebo arm existed in both trials. Based on the expert's statement, the placebo is administered more frequently in the secondary trial but with a lower dose, which could be a common strategy to ensure blindness and minimize potential adverse effects. This strategy could also allow for the comparison of the efficacy of the study drug and the placebo, as the patients in the placebo arm will receive more placebo tablets but with smaller doses overall. However, without access to the actual CTRs, it's crucial to acknowledge the limitations and possibilities for ambiguity in drawing definitive conclusions based on the given information.\n\nTherefore, although there isn't a direct entailment between the CTRs and the statement, the statement can be consistent with the general principles of clinical trials design based on the context provided.</s>",
        "contradict": "The statement \"the secondary trial administers placebo tablets at twice the rate of the primary trial, but less than half the dose\" is contradictory to the information in the CTRs because:\n\n1. The primary trial describes two interventions, Tomosynthesis Breast Scanning and Breast CT Scanning, which are procedures and not interventions involving drugs or dosages. The statement refers to a secondary trial and its interventions, but it mentions neither Tomosynthesis Breast Scanning nor Breast CT Scanning.\n\n2. The statement claims that the secondary trial administers placebo tablets at a higher rate but a lower dose, but there is no mention of placebo tablets or dosages in any of the CTR sections for either trial.</s>"
    },
    "b7936bbc-f0c0-444c-a199-2db323c30396": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Secondary_id": "NCT00305448",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a 33% higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if we calculate the percentage point difference between the Objective Response Rates (ORR) in the Fulvestrant 250 mg and Fulvestrant 250 mg + Loading Dose arms in both trials. \n\nPrimary Trial: \nORR for Fulvestrant 250 mg: 8.5% (2.4-20.4)\nORR for Fulvestrant 250 mg + Loading Dose: 5.9% (1.2-16.2)\n\nPercentage point difference: 2.6%\n\nSecondary Trial:\nORR for Fulvestrant 250 mg: 11.1% (N/A)\nORR for Fulvestrant 250 mg + Loading Dose: 17.6% (N/A)\n\nPercentage point difference: 6.5%\n\nThe expert's statement asserts a 33% difference, which is not exactly the calculated percentage point difference from either trial alone. However, if we take an average of the percentage point differences from both trials and double it, we get a 13.2% difference. This is closer to the 33% stated by the expert, and it is within the confidence interval of both trials' results. \n\nGiven the similarity in trial designs, patient population, and outcome measurement, the trials' results can be reasonably combined and compared, allowing the statement made by the expert to be entailed by the information in the CTRs.\n\nHowever, it's important to note that combining data from two separate trials for comparison comes with some inherent limitations and uncertainties, and the expert's statement should be considered with caution. The 33% difference stated by the expert might not be statistically significant, and further analysis and validation would be needed to confirm this conclusion.</s>",
        "contradict": "The statement cannot be directly deduced from the provided information in the CTRs due to discrepancies in the analyzed participant populations, outcome measurement time frames, and measurement units. The statement compares the Objective Response Rates (ORR) between two arms of the primary trial, but the secondary trial data includes an additional arm treatment and different participant analysis time frames. Additionally, the primary trial reports the ORR as a percentage of patients, whereas the secondary trial reports it as a percentage of participants. Consequently, a meaningful comparison of the ORR percentages between trials requires adjustment for these differences. Without such adjustments, the statement may be incorrect or misleading.</s>"
    },
    "6d6625ec-26b7-4157-a38c-87c770201323": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial\" can be entailed by the information present in the CTRs. In the primary trial, FFDM and DBT are used in intervention arm 1 with FFDM exam conducted on a Siemens MAMMOMAT Inspiration machine. In the secondary trial, a lidocaine patch (Lidoderm) is used in intervention arm 1, and a placebo patch is used in intervention arm 2. Although the specific interventions vary, Siemens and Lidoderm are mentioned as components of their respective trials, fulfilling the statement.</s>",
        "contradict": "The statement \"Lidoderm products are used in intervention arm 1 of the secondary trial, and a Siemens product is used in arm 1 of the primary trial\" can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, Intervention 1 uses FFDM and DBT (Full-Field Digital Mammography and Digital Breast Tomosynthesis) on a Siemens MAMMOMAT Inspiration machine. This information is not related to the use of Lidoderm products.\n\n2. In the secondary trial, Intervention 1 is the application of a Lidocaine patch and Intervention 2 is the application of a placebo patch. There is no mention of Siemens products in either intervention, and the trial does not involve imaging technologies like mammography.</s>"
    },
    "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive\" is entailed by the CTR's inclusion criteria that \"Inclusion Criteria... Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified)\" and \"Patients with at least one progressive and/or new metastatic brain lesion (>/=5 mm on radiographic imaging) after receipt of intracranial radiation therapy.\" The statement is consistent with the CTR's requirement of histologically-confirmed HER2-positive breast adenocarcinoma as a prerequisite for trial participation. The expert's statement further specifies that HER2 positivity should be confirmed through IHC 3+ or FISH amplification, which is consistent with the CTR's inclusion criteria. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR as it restricts eligibility to patients with IHC 3+ or FISH amplified HER2-positive breast cancer, not specifically triple-positive breast cancer. Triple-positivity refers to the presence of HER2 positivity, estrogen receptor (ER) positivity, and progesterone receptor (PR) positivity, whereas the CTR's eligibility criteria only requires HER2 positivity.</s>"
    },
    "7e0259a3-073b-45f5-8e08-2cfaceecef0b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests MRI scanning as a technique for guiding biopsies.",
        "Label": "Contradiction",
        "entail": "The expert's statement is not entailed by the information present in the CTRs, as the primary trial does not compare MRI scanning to any other method for guiding biopsies, but instead uses PET guided biopsy for all participants.</s>",
        "contradict": "The statement contradicts the primary trial CTR as the primary trial does not involve the usage of MRI scanning for guiding biopsies but instead uses PET scanning exclusively.</s>"
    },
    "c94ad26b-1f5e-4446-a4fe-bb949c5dc561": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients must have BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients must have BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial\" is entailed by the CTRs as follows:\n\n1. Primary Trial: The CTR states that one of the inclusion criteria is \"Creatinine: within a normal upper value in the institution\". Since a normal range for BUN is usually within the normal range for creatinine, the statement about BUN being below 20 mg/dL is implicitly included. Furthermore, the CTR lists Platelet count and Leukocyte count as inclusion criteria with the specified ranges.\n2. Secondary Trial: The CTR does not explicitly list a BUN criterion, but there is no exclusion criterion for BUN in either trial. Therefore, having a BUN below 20 mg/dL is an implicit requirement for both trials. The CTR also states that one of the inclusion criteria for the secondary trial is \"Platelet count: <100,000/mm3 or more\" and \"Leukocyte count: 4,000/mm3 to 12,000/mm3.\" The statement about Leukocyte count being between 5,000/mm3 and 8,000/mm3 is within the range provided in the CTR.\n\nThus, the statement \"Patients must have BUN < 20 mg/dL, Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 to be eligible for either the primary trial or the secondary trial\" is a logical consequence of the information presented in the CTRs.</s>",
        "contradict": "The statement's inclusion criteria for platelet count (<90,000/mm3) and leukocyte count (5,000/mm3 to 8,000/mm3) contradict the CTRs. In the primary trial CTR, the inclusion criteria for platelet count is >100,000/mm3 or more, and for leukocytes, it's 4,000/mm3 to 12,000/mm3. In the secondary trial CTR, there is no mention of a specific requirement related to platelet count or leukocytes. Therefore, the statement cannot be entailed by the information in the CTRs.</s>"
    },
    "4e31e4f8-a6da-49fc-8bfe-1309674ec2ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 42 days of treatment.",
        "Label": "Contradiction",
        "entail": "The statement entails the information in the CTRs as follows:\n\n1. The statement's claim of a 30% increased level of CECs in the primary trial corresponds to the Results 1 data, where 30% of participants in the Cediranib Maleate arm had an increased level of CECs.\n2. The statement's time frame, 42 days of treatment, aligns with the information in the Primary Trial Outcome Measurement, where the CEC response rate is measured after 3 weeks (21 days) of treatment followed by another 21 days. Since the treatment courses repeat every 42 days, the statement's 42-day time frame remains valid. \n\nHence, the expert's statement is entailed by the information within the provided CTRs.</s>",
        "contradict": "The statement \"30% of the primary trial participants had an increased level of CECs after 42 days of treatment\" cannot be directly contradicted by the information present in the CTRs since the CTR only provides the percentage response rate (30%) but not the specific number of participants with increased CECs after 42 days. However, there's a potential discrepancy regarding the time frame for the measurement of CECs. The expert's statement mentions \"after 42 days of treatment,\" while the CTR specifies \"after 3 weeks of treatment.\" Therefore, the expert's statement might not accurately reflect the timing of the outcome measurement, and further investigation would be required to establish semantic entailment.</s>"
    },
    "5c00f992-5066-42f2-88d7-566b8b9104b5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Rate of Acute Toxicity , whereas those in cohort 2  did not experience any Acute Toxicities.",
        "Label": "Contradiction",
        "entail": "The statement \"On average, cohort 1 participants in the primary trial had an increased rate of Acute Toxicity, whereas those in cohort 2 did not experience any Acute Toxicities\" does not directly relate to the given CTRs as the term \"Acute Toxicity\" is not explicitly mentioned in the provided information. However, we can infer entailment by making the reasonable assumption that adverse events, which include acute toxicities, are reported in the ADVERSE EVENTS section of the CTRs. Since the CTRs do not provide such data, the statement does not have a definitive entailment relationship with the given data. However, if additional information from the ADVERSE EVENTS sections of the CTRs confirmed the expert's statement, then it would be entailed by the data in the CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert cannot be directly contradicted by the information in the provided CTRs as there is no mention of \"Acute Toxicities\" or their occurrence in either the primary or secondary trials. The CTRs only provide information about bone mineral density percentage change at month 12 for the Denosumab and Placebo groups in the primary trial.</s>"
    },
    "4c0ffc50-5cb2-4574-b954-335d142edbe4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial\" is entailed by the information present in the CTRs under the \"Exclusion Criteria\" section. Specifically, it is mentioned that \"Patients receiving investigational drugs, including but not limited to, other anti-cancer drugs, antidepressants, or antipsychotics, are excluded from the study.\" While Citalopram is an antidepressant, it can be inferred that patients currently taking this medication are not eligible for the primary trial based on the provided CTR information.</s>",
        "contradict": "The statement \"Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial\" contradicts the CTR inclusion criteria as Citalopram is not mentioned as an exclusion criterion for the trial. The statement incorrectly assumes that Citalopram is an exclusion criterion based on the assumption that it may interact with the study drugs (eribulin, cyclophosphamide, and docetaxel). However, there is no explicit mention of Citalopram in the exclusion criteria of the CTR.</s>"
    },
    "4e3379b9-f971-4ab6-8846-c395f1162bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Skin infections were more common in patients in cohort 1 of the secondary trial, than in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n- The primary trial reports 1 skin infection in cohort 1 out of 36 patients (2.78%).\n- The secondary trial reports 2 skin infections in cohort 1 out of 41 patients (4.88%).\n- The percentage of patients with skin infections is higher in the secondary trial (4.88%) than in the primary trial (2.78%).\n\nThus, the statement is entailed by the CTR data.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the frequency of skin infections in cohort 1 is the same in both trials, with each having one reported incident among 36 and 41 participants respectively (both 2.78%). Therefore, the statement implies a higher rate of skin infections in the secondary trial, but the data in the CTRs do not support that conclusion.</s>"
    },
    "9872394c-18b7-4f88-849e-0e2831e6ebf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving for treatment rheumatoid arthritis, experiencing poorly controlled migraines, receiving hormone replacement therapy or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Contradiction",
        "entail": "The participants of the primary trial are excluded if they are currently receiving treatment for rheumatoid arthritis or fibromyalgia (CTR: Exclusion Criteria). The statement does not add any new information regarding rheumatoid arthritis or fibromyalgia.\n\nThe participants of the primary trial are excluded if they have a current history of poorly controlled migraines (CTR: Exclusion Criteria). The statement agrees with this exclusion criterion.\n\nThe participants of the primary trial are included if they are post-menopausal women and are on a stable dose of hormone replacement therapy, but the statement excludes participants currently receiving hormone replacement therapy, which contradicts the CTR.\n\nThe participants of the primary trial are excluded if they have any prior history of invasive breast cancer in the last 5 years (CTR: Exclusion Criteria). The statement modifies the criterion to \"in the last 3 years,\" which is a narrower exclusion than stated in the CTR.\n\nSince the statement excludes participants currently receiving hormone replacement therapy but the CTR allows it for some participants, the statement does not entail the information in the CTR. The statement's criterion for invasive breast cancer history is narrower, so it can be seen as a subset of the information in the CTR. However, the disagreement on hormone replacement therapy makes the statement and the CTR incompatible.</s>",
        "contradict": "The statement contradicts the information in the primary trial's Eligibility Criteria section. The CTR specifies that women on a stable dose of hormone replacement therapy are eligible for the study, whereas the statement excludes participants currently receiving hormone replacement therapy. Additionally, the CTR includes women with a history of breast cancer, but the statement excludes those with a prior history of invasive breast cancer within the last 3 years, which is narrower than the 5-year window stated in the CTR. Furthermore, the statement does not mention the eligibility criteria regarding Ki-67 expression, vitamin D levels, and RPFNA procedures, which are present in the primary trial's Eligibility Criteria. Therefore, the expert's statement contradicts the CTR in several respects.</s>"
    },
    "adf3bb50-ec36-467a-987a-f33c10380c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. For the Primary Trial: In the inclusion criteria, there is a condition stating that \"Women of 18 years of age or older with Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status of 0,1,2 are eligible.\" ECOG 2 is included under this criterion, making Japanese participants who have an ECOG score of 2 eligible for the Primary Trial.\n\n2. For the Secondary Trial: In the inclusion criteria, there is a condition stating that \"The participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\" ECOG 2 corresponds to a performance status of 2 under the Karnofsky scale which is equivalent to ECOG 0-1 under the ECOG scale. Therefore, a Japanese participant with an ECOG score of 2 can still be considered as having an ECOG performance status of 0 or 1, making them eligible for the Secondary Trial.</s>",
        "contradict": "The statement \"Japanese participants with an ECOG of 2 are eligible for the secondary trial and the primary trial\" is contradictory to the information in the CTRs as per the following reasons:\n\n1. Inclusion Criteria for Primary Trial: The ECOG performance status for primary trial participants must be 0,1, or 2. Japanese participants with an ECOG of 2 do not meet this requirement.\n2. Inclusion Criteria for Secondary Trial: The ECOG performance status for secondary trial participants can only be 0 or 1. Japanese participants with an ECOG of 2 do not meet this requirement.</s>"
    },
    "2ef37a06-a1ed-47eb-b8f4-2f97f46293d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01875367",
        "Statement": "One patient in the primary trial suffered a cerebral infarction.",
        "Label": "Entailment",
        "entail": "The statement \"One patient in the primary trial suffered a cerebral infarction\" can be entailed by the information in the CTR under the Adverse Events section of the Primary Trial, specifically the instance of \"Stroke\" reported, which is a type of cerebral infarction.</s>",
        "contradict": "The statement \"One patient in the primary trial suffered a cerebral infarction\" is contradicted by the information present in the CTRs since neither Adverse Events 1 nor Adverse Events 2 report an instance of stroke (cerebral infarction) among the 81 and 85 participants, respectively.</s>"
    },
    "03cb39e4-1d21-47e5-9b09-ebe508eb2a17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00477464",
        "Statement": "59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"59 patients from Arm A of the primary trial achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months\" can be entailed by the information in the CTRs as follows: \n\nAccording to the Primary Trial's CTR, the outcome measurement is Clinical Benefit Response (CBR). CBR is defined as the percentage of participants receiving at least one dose of study medication who achieved a best overall response classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months. The Primary Trial reports that 51 participants were analyzed in Arm A, and the Measure Type and Unit of Measure for CBR is percentage of participants. Thus, since 59 out of the 51 participants (or 114.3%, which cannot be achieved in reality) achieved the specified best overall response, the statement is an overestimation or typographical error, but it does not contradict with the CTR's information. If the intended statement is that \"at least 59 patients (out of 51 analyzed) in Arm A achieved a best overall response, classified as a complete or partial (confirmed) tumor response or stable disease for at least 6 months,\" then the statement is entailed by the data in the CTR.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it may be contradicted depending on the specific outcomes achieved by the patients in Arm A of the primary trial. The CTR specifies that the clinical benefit response (CBR) was measured every 6 weeks until Week 24 and then every 12 weeks until disease progression. If the statement refers to the 59 participants achieving a CBR of at least 6 months without specifying the exact duration, it could potentially include responses that were initially stable for 6 months but subsequently progressed, which would not meet the definition of a CBR as stated in the CTR. This discrepancy arises from the lack of clarity regarding the exact duration of the responses in the statement. To ensure entailment, the statement should explicitly indicate that all of the 59 participants maintained a CBR of at least 6 months with no subsequent disease progression.</s>"
    },
    "dca6ba74-441e-482f-b667-6c45800ed8c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs .",
        "Label": "Contradiction",
        "entail": "The statement \"Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs\" is entailed by the information presented in the CTR as follows: According to the CTR, patients in arm I of the primary trial receive ONTAK IV over the course of 1 hour on days 1-5. This treatment cycle repeats every 21 days for up to 6 courses, as specified by the phrase \"in the absence of disease progression or unacceptable toxicity\". The statement by the clinical trial expert resembles this information, as it also describes a 21-day treatment cycle repeating for 6 courses, with the addition that the treatment may be continued until death. While the CTR does not explicitly mention death, the expert's statement does not contradict the CTR. In fact, the addition of death as a condition for discontinuation is a more general and comprehensive statement, as it covers the possibility of death due to causes other than disease progression or unacceptable toxicity. Therefore, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"Patients receiving intervention 1 of the primary trial must undergo a 21 day treatment cycle, for a total of 6 courses, unless death occurs\" can be contradicted by the information in the CTR because the CTR also specifies that treatment stops in the absence of disease progression or unacceptable toxicity. This condition for stopping treatment is not explicitly stated in the expert's statement, potentially implying a different set of circumstances for discontinuation.</s>"
    },
    "aeecc244-13a9-4944-858e-27ef49585e90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01702571",
        "Statement": "Patients with incurable and  unresectable Locally Advanced Breast Cancer are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria, as the trial specifically states that patients must have documented progression of incurable, unresectable LABC or mBC, defined by the investigator. The CTR further stipulates that patients should not have a history of treatment with curative intent or be suffering from metastatic CNS disease or symptomatic brain metastases, which aligns with the concept of incurable and unresectable cancer as mentioned in the expert statement. Therefore, the patient population described in the expert statement falls within the scope of patients eligible for the primary trial according to the CTRs.</s>",
        "contradict": "The statement is not necessarily contradictory to the information in the CTRs, but it is less specific and may include patients who do not meet all the inclusion criteria of the primary trial. For example, the CTRs specify that patients must have documented progression of incurable, unresectable, locally advanced or metastatic breast cancer, and this condition is not explicitly mentioned in the expert statement. Additionally, the CTRs have several other inclusion and exclusion criteria that the expert statement does not address. Therefore, while the statement is not contradictory, it is not identical to the information in the CTRs and may not capture all nuances of the eligibility criteria for the trial.</s>"
    },
    "741ca5eb-4737-4a35-a9fd-4235d6552b4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01256008",
        "Secondary_id": "NCT00300781",
        "Statement": "the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy.",
        "Label": "Entailment",
        "entail": "The statement asserts that the primary trial investigates cognitive behavioral therapy (CBT), a type of psychotherapy, whereas the secondary trial studies Neratinib, a type of chemotherapy. \n\nThis statement can be entailed by the CTR information as follows:\n\n1. In the primary trial, Intervention 1 involves clinical management, which is explicitly stated to be a half-structured interview method of psychological therapy, distinct from the chemotherapy intervention.\n2. Intervention 2 in the primary trial, however, refers to CBT as a separate intervention, which is confirmed to be distinct from clinical management and also a form of psychotherapy.\n3. In contrast, the secondary trials both involve Neratinib, a drug treatment, and do not include any reference to psychotherapy or counseling interventions.</s>",
        "contradict": "The statement \"the primary trial is investigating Cognitive behavioural therapy, a type of psychotherapy, in contrast the secondary trial studies Neratinib, a type of chemotherapy\" can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, both experimental and controlled groups receive clinical management which involves a psychotherapy component, but the expert in clinical trials mistakenly states that only the primary trial investigates a type of psychotherapy.\n2. In the secondary trials, participants receive Neratinib, a type of chemotherapy, regardless of their prior trastuzumab treatment status. The expert in clinical trials correctly identifies that the secondary trials study Neratinib, but incorrectly assumes that it is in contrast to the primary trial which investigates a type of psychotherapy. However, the primary trial also has an intervention involving a psychotherapy component.</s>"
    },
    "b8e0458c-b834-42b5-b5fd-8791f89b0853": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
        "Label": "Entailment",
        "entail": "The expert's statement \"The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group\" can be entailed by the information in the CTRs as follows:\n\n1. The CTRs provide the median (95% Confidence Interval) of Progression-Free Survival (PFS) in months for both the Gemcitabine and Carboplatin groups.\n2. The median PFS for the Gemcitabine group is 5.5 months (4.1 to 7.0), while the median PFS for the Carboplatin group is 8.3 months (5.7 to 10.6).\n3. To meet the expert's statement, a difference of more than 2 months between the median PFS of the two groups must be demonstrated.\n4. The given data shows that the median PFS of the Gemcitabine group is 2.8 months (3.6-0.4) shorter than the median PFS of the Carboplatin group (i.e., 8.3 months - 5.5 months = 2.8 months). This difference meets the expert's requirement of \"more than 2 months\" and is consistent with the statement.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the median PFS for Arm A (Nab-Paclitaxel + Gemcitabine) is 5.5 months (4.1 to 7.0), which is not more than 2 months shorter than the median PFS for Arm B (Nab-Paclitaxel + Carboplatin) of 8.3 months (5.7 to 10.6). Instead, Arm B has a longer median PFS compared to Arm A.</s>"
    },
    "1a112ed3-8318-493b-8973-10de01794892": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis.",
        "Label": "Entailment",
        "entail": "The statement \"Between the patients in the primary trial and the secondary trial, only a single one suffered from sepsis\" can be entailed by the information present in the CTRs because, according to Adverse Events 1 in the secondary trial, there is one case of sepsis reported out of a total of 34 participants (2.94%). There is no mention of sepsis in the Adverse Events section of the primary trial, which indicates that none of the 161 participants in the primary trial experienced this condition. Therefore, the statement is a valid comparison of the two trials based on the data provided in their respective CTRs.</s>",
        "contradict": "Although the statement mentions that only one patient in the two trials suffered from sepsis, the frequency of this adverse event varies significantly between the primary and secondary trials. In the primary trial, no cases of sepsis were reported, as indicated by the \"0/161 (0.00%)\" value under the total adverse events and sepsis categories. Conversely, in the secondary trial, one case of sepsis was reported with a frequency of \"1/34 (2.94%)\". Therefore, the statement contradicts the information provided in the CTRs.</s>"
    },
    "6044590d-0f89-4a6e-8be7-54ca0c0327d9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00003404",
        "Secondary_id": "NCT00711529",
        "Statement": "the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not have a Hypnotherapy based intervention, and the secondary trial does not have a Radiotherapy intervention\" is entailed by the information present in the CTRs because neither trial Intervention 1 of the Primary Trial, nor Intervention 1 of the Secondary Trial, mentions Hypnotherapy, and neither Intervention 1 nor Intervention 2 of the Primary Trial mentions Radiotherapy. Therefore, the trials do not include interventions that contradict the statement's assertions.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, while it is true that the primary trial does not include a hypnotherapy intervention and the secondary trial does not include a radiotherapy intervention, the CTRs do not necessarily rule out the possibility of multiple trials being compared or discussed. The statement's assertion, however, assumes that only one trial is being considered at a time in each section. The statement is contradictory to the information in the CTRs if taken in isolation, but it may be consistent with a more complex analysis that takes into account multiple trials and their comparative analysis.</s>"
    },
    "8d3378f7-caaf-4654-b12a-382a0e911eb1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50 x 109/l are not eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a platelet count of 50 x 109/l are not eligible for the primary trial\" can be entailed by the inclusion criteria of the CTR which stipulates that \"Platelets greater or equal to 100 x 109/l\" is a requirement for study entry. Thus, patients with platelet counts below the specified threshold are excluded from the trial according to the CTR.</s>",
        "contradict": "The statement \"Patients with a platelet count of 50 x 109/l are not eligible for the primary trial\" contradicts the information presented in the inclusion criteria of the CTR, where it specifies that patients must have a platelet count of greater than or equal to 100 x 109/l for trial eligibility.</s>"
    },
    "f701473d-e034-4a06-9829-d20cc483162c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the different in cohort size is too significant.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as the trials involve different cohort sizes. The statement acknowledges that the trial results may not be comparable due to the significant difference in the number of participants. This observation aligns with the information provided in both CTRS, which report distinct numbers of participants for each arm/group. Therefore, the statement's assertion harmonizes with the clinical trial data and is substantiated by the data presented in the CTRs.</s>",
        "contradict": "The statement that \"the primary trial and the secondary trial have non-comparable results due to the significant difference in cohort size\" is contradicted by the CTRs because the comparison intended by the clinical trial expert goes beyond just cohort size. The primary and secondary trials investigate different treatments and outcomes. The primary trial examines the mean duration of severe neutropenia in response to LA-EP2006 or Neulasta treatments during chemotherapy cycles. In contrast, the secondary trial evaluates progression-free survival (PFS) following different therapeutic regimens, including chemotherapy, monoclonal antibody, and enzyme inhibitor combinations. While the difference in cohort size could impact the statistical significance of the findings, it is not sufficient to establish non-comparability without considering the trial designs and outcomes being investigated.</s>"
    },
    "3889cecd-aa2d-4f58-857e-11d7209f9cf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00450866",
        "Statement": "In the primary trial a cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2. ",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs if the percentage of patients with progression-free survival (PFS) at 3 months after treatment is higher in Group A (cohort 1) compared to Group B (cohort 2), given that:\n\n1. The outcome measurement in the primary trial is PFS, defined as the number of patients who are progression-free at 3 months after treatment.\n2. The number of participants with PFS in each group can be calculated based on the information provided in the Results sections of the CTRs.\n3. Group A has 12 patients with PFS at 3 months, while Group B has only 2.\n4. Percentage of patients with PFS at 3 months in each group can be calculated as (number of patients with PFS / total number of participants) x 100%.\n5. Therefore, the percentage of patients with PFS at 3 months in Group A will be higher than that in Group B.\n\nHence, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"In the primary trial, cohort 1 has a higher percentage of patients with progression free survival at 3 months after treatment, than cohort 2\" contradicts the information in the CTRs because neither the CTRs report the percentage of participants with progression free survival, nor do they directly compare the progression free survival between the two cohorts. The information provided only mentions the number of participants with progression free survival at 3 months after treatment in each group. Therefore, no definitive statements about percentages or comparisons can be made based on the data given.</s>"
    },
    "19d0c9de-02ad-4a8e-937b-e9d0f0cc8051": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00338286",
        "Statement": "No participants of the primary trial had a Progression Free Survival over 1 year.",
        "Label": "Entailment",
        "entail": "The statement \"No participants of the primary trial had a Progression Free Survival over 1 year\" can be entailed by the information present in the CTRs as follows:\n\n1. The Progression Free Survival in both the Standard of Care (SOC) and Epoetin Alfa arms of the primary trial were reported as 7.4 months (95% CI: 7.1-7.6 months) and 7.4 months (95% CI: 6.9-7.6 months), respectively, which are below 12 months.\n2. The Progression Free Survival time frame in the CTR for the primary trial is stated to be from the date of randomization to the date of disease progression (PD) or death, whichever came first, which may extend beyond one year for some participants, but no participant's Progression Free Survival exceeded 12 months.\n3. The CTR reports the median (95% CI) of Progression Free Survival for both treatment arms, and since the data indicates that all participants in the trial had Progression Free Survival below 13.5 months (1 year plus a 95% confidence interval), the statement \"No participants of the primary trial had a Progression Free Survival over 1 year\" is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"No participants of the primary trial had a Progression Free Survival over 1 year\" is contradicted by the data in the CTR as the median Progression Free Survival for both the Standard of Care and Epoetin Alfa groups are reported to be over 1 year (7.4 months and 7.4 months, respectively).</s>"
    },
    "cb023dbc-3e99-4c32-a857-7f8d49ef5a96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.",
        "Label": "Entailment",
        "entail": "The statement that \"the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION\" is entailed by the information present in the CTRs because:\n\n1. The secondary trial reported more cases of Haematemesis: This is evident from the CTR data of Adverse Events 1 for the secondary trial, which states \"Haematemesis 1/52 (1.92%)\".\n2. The primary trial had more total cases of DIASTOLIC DYSFUNCTION: This is evident from the CTR data of Adverse Events 1 for both the primary and secondary trials. In the primary trial, there is a total of 3 cases of Dysfunction (DIASTOLIC and SINUS TACHYCARDIA), whereas in the secondary trial, there is only 1 case reported (DIASTOLIC DYSFUNCTION). However, the primary trial has a larger total number of participants (305 compared to 52 in the secondary trial), hence having more instances of Dysfunction (1.02% in the primary trial vs 1.92% in the secondary trial). Therefore, the primary trial had more total cases of DIASTOLIC DYSFUNCTION despite reporting fewer cases of it specifically.\n\nSo, the statement that \"the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION\" harmonizes with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions, making the statement entailed by the information within the CTRs.</s>",
        "contradict": "The expert's statement implies that both trials reported instances of haematemesis and diastolic dysfunction. However, the CTRs provided do not report haematemesis for the primary trial and only one case of diastolic dysfunction in each trial. This discrepancy makes the statement contradictory to the information given in the CTRs.</s>"
    },
    "1d0ce237-70eb-45b4-9c77-f0b70d410387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193180",
        "Statement": "A female patient over the age of 18 suffering from Cirrhosis cannot take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The patient's ineligibility for the primary trial due to known chronic liver disease (mentioned under Exclusion Criteria in the CTR) entails that a female patient with cirrhosis cannot participate in the trial.</s>",
        "contradict": "The statement is contradictory to the information in the primary trial's inclusion criteria as cirrhosis is not listed as an exclusion criterion for that trial. The CTR states that \"there are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria.\" This suggests that cirrhosis may not be an automatic disqualifier, and the female patient in question could potentially participate in the primary trial if she meets the other criteria.</s>"
    },
    "93290529-38b1-444b-9ac8-fa32b98821c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "Patients wanting to take part in the secondary trial must be at a specific location, this is not necessary for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients wanting to take part in the secondary trial must be at a specific location\" does not entail any information directly from the CTRs provided, as the CTRs do not include details about the location requirements for participating in the trials.</s>",
        "contradict": "The primary trial's eligibility criteria section states, \"All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines,\" indicating no geographical restrictions for patient participation (implicitly meaning that patients can participate from various locations). In contrast, the secondary trial's inclusion criteria section includes no such statement, which could lead to the assumption that there is a specific location requirement. However, other inclusion criteria in the secondary trial, such as histological diagnosis and HER2 overexpression/amplification, do not necessitate a specific location for patient identification or assessment. Thus, the statement made by the clinical trials expert can be contradicted by the information in the CTRs.</s>"
    },
    "dad5ecc6-afcf-496c-8193-778a100c0318": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these constitute contraindications to spine dual energy x-ray absorptiometry (DXA).",
        "Label": "Entailment",
        "entail": "The statement entails that individuals with a Cobb angle greater than 20 degrees at the lumbar spine or a prior surgery at the lumbosacral spine cannot undergo DXA scans in the primary trial. This is entailed by the CTR, as patients with a Cobb angle > 15 degrees at the lumbar spine, immobility, hyperostosis, or sclerotic changes at the lumbar spine, evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan, or disease of the spine that would preclude the proper acquisition of a lumbar spine DXA are listed as having a contraindication to spine DXA. Additionally, those with a history of surgery at the lumbosacral spine, with or without implantable devices are also excluded from the trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTR as patients with a Cobb angle greater than 15 degrees at the lumbar spine are excluded from the primary trial based on the CTR, but the statement specifies a threshold of 20 degrees. Additionally, the statement includes patients with a prior surgery at the lumbosacral spine as a contraindication, whereas the CTR specifies various types of spinal diseases that would preclude DXA scans, not just surgery.</s>"
    },
    "d0efe29c-1d76-4129-9cf5-2955564d1370": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF greater than or equal to 60% are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criterion states that participants must have a baseline left ventricular ejection fraction (LVEF) of greater than or equal to 55%. The statement from the clinical trials expert can be entailed by this inclusion criterion, as it sets a higher threshold for LVEF eligibility (60%), which is still greater than or equal to the criterion stated in the CTR. This means that all patients who meet the inclusion criteria in the CTR, i.e., those with LVEF of 55% or higher, will also satisfy the statement's condition of having an LVEF greater than or equal to 60%.</s>",
        "contradict": "The expert's statement that \"Patients with LVEF greater than or equal to 60% are eligible for the primary trial\" contradicts the information provided in the CTRs because the inclusion criteria for the primary trial state that \"baseline left ventricular ejection fraction (LVEF) >/=55%\" and not \"LVEF >/=60%\". The discrepancy in the specified LVEF threshold for eligibility creates a contradiction.</s>"
    },
    "63ec91be-7e12-431e-84b0-ca401bfb157b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2.38% more total adverse events than the secondary trial",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial recorded 2.38% more total adverse events than the secondary trial\" is entailed by the CTR data if we calculate the difference in the percentage of total adverse events between the two trials: 35.71% (primary) and 33.33% (secondary), resulting in a difference of 2.38%.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the percentage of total adverse events in the primary trial (35.71%) is significantly higher than that in the secondary trial (33.33%). Contrary to the assertion that the primary trial recorded a 2.38% greater number of total adverse events than the secondary trial, the data in the CTRs shows the reverse.</s>"
    },
    "fd5af11f-7270-49d5-924a-755ff399c463": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00373256",
        "Statement": "Cohort 1 of the primary trial included 250 patients being treated with Sunitinib and Paclitaxel for a duration of 18 months or until death, and the mean PFS for this group was just under 7 and a half months.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows: \n\n1. The statement mentions that Cohort 1 of the primary trial comprised 250 patients being treated with Sunitinib and Paclitaxel. The CTR specifies that Arm/Group 1 in the primary trial had 242 participants analyzed. Although the number of participants in the statement and the CTR is slightly different, they are close enough to be considered equivalent, as the discrepancy is not significant.\n\n2. The statement states that these patients were treated for a duration of 18 months or until death. According to the CTR, the time frame for assessing PFS is from randomization through Day 1 and every 8 weeks thereafter up to 18 months or death. This aligns with the statement's claim of 18 months or until death.\n\n3. The statement provides the mean PFS for this group as 'just under 7 and a half months'. The CTR for Sunitinib and Paclitaxel in Arm/Group 1 reports a median PFS of 7.4 months. Although the mean and median are different statistics, they both provide information about the distribution of PFS durations within the cohort. A median value can be considered representative of the central tendency of the data, while the mean represents the average. As the median value (7.4 months) lies below the 'mean of 7 and a half months' reported in the statement, the statement is entailed by the CTR.\n\n4. The statement does not contradict any information in the CTR. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement's assertion that \"the mean PFS for Cohort 1 was just under 7 and a half months\" contradicts the information in the CTRs because the median (not mean) PFS for the Sunitinib + Paclitaxel arm was 7.4 months (6.9-8.5), not the mean.</s>"
    },
    "f07e932e-1d79-4e1f-9ac2-ed9e2db1c276": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02186015",
        "Statement": "Women in cohort B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.",
        "Label": "Entailment",
        "entail": "In the primary trial, according to the intervention section, women with serum 25 (OH)D levels greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol (INTERVENTION 2). Therefore, the statement made by the clinical trial expert is entailed by the information present in the CTR as it aligns with the stated intervention for this group of women.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, in the primary trial, women with serum 25 (OH)D greater than or equal to 30 ng/ml were included in the arm that received no intervention, but they were not explicitly stated to have not received weekly supplementation of cholecalciferol. According to the CTR, only participants in the intervention 2 arm (with serum 25 (OH)D greater than or equal to 30 ng/ml) did not receive any cholecalciferol supplementation. The statement, however, implies that these women deliberately did not receive the weekly supplementation, which is not directly stated in the CTR.</s>"
    },
    "6a5ee728-7db9-4ec0-b98c-0500e9a6187e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "One patient in the primary trial had abnormally low levels of AST, ALT and ANC.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the CTR, as it mentions \"abnormally low levels of AST, ALT and ANC\" without specifying whether these abnormalities are listed as adverse events or baseline characteristics. However, the CTR for the primary trial does mention the occurrence of one patient with Neutropenia, which is a condition characterized by an abnormally low number of neutrophils (ANC) in the blood. Therefore, the expert's statement could potentially be true for this specific patient based on the information in the CTR. However, without more context or information about the statement, it is unclear whether it is a general statement about all patients in the trial or specifically about this one patient. Thus, the entailment relationship is not straightforward based on the provided information alone.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly. However, it does not follow that one patient in the primary trial had abnormally low levels of AST, ALT (Alanine Transaminase), and ANC (Absolute Neutrophil Count), based on the data provided. The CTR lists specific adverse events observed in the trial, including one instance each of pancytopenia (a condition involving decreased numbers of multiple types of blood cells, including neutrophils, platelets, and red cells). However, the statement mentions \"abnormally low levels\" of AST, ALT, and ANC without explicitly stating that these levels were observed as adverse events in the trial. It is possible that these laboratory values were part of the baseline characteristics for the study, or they could have been measured during follow-up assessments, but the information provided does not allow us to determine this definitively. Therefore, while the statement does not contradict the CTRs, it also does not follow directly from the information given.</s>"
    },
    "a495df61-260d-479c-8d5f-d586f295c672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID\" is entailed by the information in the CTRs because:\n\n1. In the primary trial, the control arm (INTERVENTION 2) receives a placebo PO BID.\n2. In the secondary trial, the control arm (INTERVENTION 2) also receives a placebo PO BID.\n\nThus, both trial control groups receive identical placebo treatments as specified in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the secondary trial and the primary trial are control groups, receiving a placebo tablet PO BID\" can be contradicted by the information present in the CTRs because, while both trials have control groups receiving placebo, the nature and duration of interventions differ between the trials. In the primary trial, placebo is given PO BID for 7 days, followed by a 7-day break and repeat every 7 days for up to 12 courses. Conversely, in the secondary trial, the control group receives only web-based resource lists and study adherence reminders throughout the 24-week study period, without mention of receiving a placebo tablet PO BID. Hence, the statement's generalization of both control groups receiving identical placebo tablet regimens is not in agreement with the CTRs' specifications.</s>"
    },
    "917afeec-5152-4424-89e3-7f3ffad6378f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01105650",
        "Statement": "Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.",
        "Label": "Entailment",
        "entail": "Participants in the primary trial's cohort 1, who weigh less than 45 kg, are to receive IL-2 at 5 million units/m^2 3 times per week for 6 doses, according to the CTR. The statement asserts that participants in this weight group receive 4 million units/m^2 less IL-2 than those over 45 kg. This can be derived from the difference between the stated dosages: 9 million units (for participants over 45 kg) and 5 million units/m^2 (for participants under 45 kg). The difference, 4 million units/m^2, is the amount less that the lighter weight participants receive, as stated in the clinical trial expert's comment. Since the CTR provides the information on the IL-2 dosages for the two groups and the expert's statement is a logical deduction of that information, it can be considered entailed by the data presented in the CTRs.</s>",
        "contradict": "The statement \"Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses\" can be contradicted by the information present in the CTRs because the CTR specifies that for patients who weigh less than 45 kilograms in both arms (1 and 2) of the primary trial, they will receive 5 million units/m^2 instead of 9 million units, but it does not state that they will receive 4 million units/m^2 less than patients weighing over 45 kilograms. Therefore, the statement contains an incorrect assertion about the amount of IL-2 given to participants based on weight.</s>"
    },
    "19f84eca-6bb1-4d32-a9b0-b2dd7c3f22e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial\" can be entailed by the CTR inclusion criteria stating \"Adequate renal function,\" \"Adequate liver function and serum transaminases,\" and \"Adequate bone marrow function.\"</s>",
        "contradict": "The statement \"Patients must have healthy kidneys, liver and bone marrow to participate in the primary trial\" is contradicted by the inclusion criteria in the CTR, which specify that adequate renal function, adequate liver function and adequate bone marrow function are required for patient inclusion in the primary trial. However, the statement is overly restrictive as it implies that only \"healthy\" kidneys, liver, and bone marrow are acceptable, which goes beyond the requirements stated in the CTR. The CTR only demands adequate function, not a state of perfect health.</s>"
    },
    "f5aa1aa3-7be3-4518-8cc5-df2394e70e96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined estrogen receptor status can be accepted by both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "Neither of the CTRs explicitly mentions estrogen receptor (ER) status as an inclusion or exclusion criterion for patients. However, both trials include ER assessment as a requirement within their eligibility criteria. Since ER status is determined before trial participation, patients with undetermined ER status would not meet the inclusion criteria for either trial. However, the statement's assertion that such patients \"can be accepted\" by both trials is not directly contradictory to the information provided in the CTRs. It could be interpreted that the expert's statement refers to a hypothetical situation where patients with undetermined ER status could potentially be included in the trials if they were to be determined eligible based on other inclusion criteria and not explicitly excluded. Thus, while the statement is not an exact entailment of the CTRs' information, it can be considered harmonious with it given the context of the clinical trial domain expert's perspective on trial eligibility.</s>",
        "contradict": "The primary trial explicitly lists \"Estrogen receptor (ER) expression has been determined\" as an inclusion criterion, meaning patients with undetermined ER status are not eligible. In contrast, the secondary trial does not list ER status as an inclusion or exclusion criterion. However, it does mention \"known estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry\" as a requirement. Although it does not explicitly state that undefined ER status is an exclusion, it's reasonable to assume that a requirement for known hormone receptor status implies that patients with undetermined ER status are not accepted. Therefore, the statement is not semantically entailed by the information in the CTRs.</s>"
    },
    "45338f7c-5aaa-40fb-8503-7c943e1f3a29": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 800mg of Venetoclax orally.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the following information from the CTRs:\n\n1. The definition of clinical benefit as CR, PR or SD lasting \u2265 24 weeks from randomization, as determined by the investigator according to RECIST v1.1.\n2. The percentage of clinical benefit in the Fulvestrant only group was 13.7 (5.70 to 26.26).\n3. The percentage of clinical benefit in the Venetoclax + Fulvestrant group was 11.8 (4.44 to 23.87).\n\nThe expert's statement is consistent with these data as the percentage of clinical benefit was higher, not lower in the Fulvestrant only group.</s>",
        "contradict": "The expert's statement cannot be confirmed based on the information in the CTRs. While the percentages of clinical benefit in the Fulvestrant-only group and the Venetoclax + Fulvestrant group differ, the CTRs do not directly provide sufficient evidence to establish that the Fulvestrant-only group had a higher % of clinical benefit overall. The CTRs only report the percentage of participants experiencing clinical benefit (CR, PR, or SD lasting more than 24 weeks), but they do not provide information on the absolute numbers or the statistical significance of the difference between the two groups. Additionally, no information is provided regarding the baseline characteristics or disease status of the participants in the two arms, which could potentially influence the observed difference in clinical benefit. Therefore, the expert's statement goes beyond the available data in the CTRs and cannot be definitively confirmed or contradicted with the provided information.</s>"
    },
    "0964be32-f9e7-49ec-ad22-b030d483702a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally.",
        "Label": "Entailment",
        "entail": "The statement \"Unlike the secondary trial, the primary trial does not administer any medication orally\" can be entailed by the information present in the CTRs as neither the Intervention 1 of Primary Trial nor Intervention 2 of Secondary Trial involve oral administration of medications, only intravenous administration of Samarium 153-EDTMP and oral administration of Exemestane and Tamoxifen.</s>",
        "contradict": "The statement \"Unlike the secondary trial, the primary trial does not administer any medication orally\" is contradicted by the information present in the CTRs because the primary trial describes the administration of Samarium 153-EDTMP intravenously, which is not mentioned in the statement. The secondary trial indeed only mentions oral administration of Exemestane and Tamoxifen, but the primary trial includes an intervention that does not involve oral medication.</s>"
    },
    "73cfc4ea-afc0-465b-a403-c1bd771ded33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01527487",
        "Statement": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial\" can be entailed by the information in the CTRs because the CTRs list \"no psychological or psychiatric disorder\" (implied by \"Willingness and ability to comply with trial and follow-up procedures\") as an inclusion criterion for the primary trial. Since Citalopram is a selective serotonin reuptake inhibitor used primarily for the treatment of depression, patients currently taking this medication cannot meet this inclusion criterion and are therefore not eligible for the trial.</s>",
        "contradict": "The statement \"Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial\" is contradicted by the information present in the CTRs, as psychological conditions, specifically Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2, are not explicitly listed as exclusion criteria in the CTRs. Citalopram is a selective serotonin reuptake inhibitor (SSRI) used for the treatment of depression, which falls under the category of psychological conditions. However, the CTR eligibility criteria allow participation of patients with ECOG Performance Status scores of 0-2, indicating that the study includes patients with various health conditions, including psychological ones. Therefore, the statement is inconsistent with the CTRs.</s>"
    },
    "75b67d63-9727-418d-afd5-c0fb867417b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "Patients suffering from Ulcerative colitis are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients suffering from Ulcerative colitis are excluded from the primary trial\" is entailed by the information in the CTRs as Ulcerative colitis is not mentioned in the inclusion criteria of the primary trial and is listed in the exclusion criteria of the secondary trial, which indicates that patients with this condition are not eligible to participate in the trial.</s>",
        "contradict": "The statement that \"Patients suffering from Ulcerative colitis are excluded from the primary trial\" contradicts the information in the CTR as it does not list Ulcerative colitis in the exclusion criteria.</s>"
    },
    "94cd9451-35a4-4035-a7de-2d385f771607": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 2 of the primary trial fainted.",
        "Label": "Contradiction",
        "entail": "The statement \"1/42 patients in cohort 2 of the primary trial fainted\" can be entailed by the information present in the CTRs as follows: The CTR for the primary trial specifies that 1/42 patients in the trial experienced syncope (fainting). Therefore, the statement made by the clinical trial expert, stating that \"1/42 patients in cohort 2 of the primary trial fainted,\" is an accurate reflection of the data presented in the CTRs.</s>",
        "contradict": "The information in the statement that \"1/42 patients in cohort 2 of the primary trial fainted\" is not explicitly mentioned in the CTR. While syncope (fainting) is listed as an adverse event in the primary trial, the statement does not specify which cohort experienced syncope or how many individuals experienced this adverse event. Therefore, based on the information provided in the CTRs, it is possible that the statement could be contradicted if cohort 2 did not experience any syncope events.</s>"
    },
    "18310f83-54ca-4530-92f1-7c41419ab69e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2\" is entailed by the information present in the CTRs, as there are three cases of febrile neutropenia reported in cohort 1 (3/15) and only two cases in cohort 2 (2/14). This indicates that a higher proportion of patients in cohort 1 experienced febrile neutropenia compared to cohort 2.</s>",
        "contradict": "The statement \"More patients in cohort 1 of the primary trial experienced febrile neutropenia than in cohort 2\" contradicts the available information in the CTRs. According to the Adverse Events sections, 20.00% of patients in cohort 1 and 14.29% of patients in cohort 2 experienced febrile neutropenia. Thus, fewer patients in cohort 1 (15) experienced this adverse event than in cohort 2 (4 out of 14). Therefore, the statement's assertion is not entailed by the data presented in the CTRs.</s>"
    },
    "4fa6b99e-0e70-465d-8b24-b728979b3689": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was the same number of anemic patinets in both cohorts of the primary trial.",
        "Label": "Entailment",
        "entail": "Both the primary and secondary trial CTRs list the number and percentage of participants experiencing anemia in their respective cohorts. The primary trial reports 3 anemic patients out of 396 participants (0.76%), and the secondary trial reports 3 anemic patients out of 408 participants (0.74%). The difference in total number of participants between the trials does not affect the comparison of anemic patients' count, as both trials have an identical number of such cases. Therefore, the expert's statement that \"there was the same number of anemic patients in both cohorts\" is a semantically valid conclusion based on the information in the CTRs.</s>",
        "contradict": "The statement \"There was the same number of anemic patients in both cohorts of the primary trial\" contradicts the data presented in the CTRs because the number of anemic patients in each cohort, as stated in the given text, is different: 0.76% (3/396) in Cohort 1 and 0.74% (3/408) in Cohort 2.</s>"
    },
    "e0fac0a4-a5ab-4089-8986-f601586506af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry.",
        "Label": "Contradiction",
        "entail": "The statement entails that women with leptomeningeal metastases are excluded from the primary trial based on the CTR's exclusion criteria. The CTR explicitly mentions that patients with known and active brain and/or leptomeningeal metastases should be excluded from the trial due to their poor prognosis and potential confounding effects on adverse event evaluation.</s>",
        "contradict": "The statement that \"Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as it would prevent them from giving informed consent to study entry\" is contradicted by the inclusion criteria in the CTR which states that patients with \"known and active brain and/or leptomeningeal metastases should be excluded from this clinical trial.\" This contradiction arises from the misconception that the exclusion is due to the inability of these patients to give informed consent, when in fact, it is based on their poor prognosis and potential confounding of adverse event evaluations.</s>"
    },
    "85210693-996a-4ab9-92f4-62060571da21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR specifies inclusion criteria for women age 18 or above with a heart rate of more than 60 beats per minute. The statement asserts that Spanish women with a heart rate of at most 50 beats per minute are eligible for the trial. Although this statement appears to contradict the CTR, it does not. The CTR's inclusion criteria state a minimum heart rate, but it does not explicitly exclude those with a lower heart rate. Therefore, the statement can be seen as a special case of the CTR, as it only applies to Spanish women. Since the statement does not contradict any other details in the CTR and finds support by interpreting inclusion criteria, it can be considered entailed by the information in the CTR, given the additional information about Spanish women.</s>",
        "contradict": "The statement \"Spanish women with a heart rate of at most 50 beats per minute are eligible for the primary trial\" contradicts the inclusion criteria mentioned in the CTR, as it specifies a heart rate requirement of \"Heart Rate > 60 bpm\" for trial eligibility.</s>"
    },
    "f0fbdbf4-af12-4cde-a5f1-a56cc60658f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia.",
        "Label": "Entailment",
        "entail": "Both CTRs provide information about the number of patients with Neutropenia in each cohort. The primary trial reports 4 cases in cohort 1 and 4 cases in cohort 2, resulting in an equal total number of patients with Neutropenia in both trials. This statement is entailed by the data present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial recorded the same number of patients with Neutropenia\" is contradicted by the information in the CTRs because the number of patients with Neutropenia in Cohort 1 is 4, and in Cohort 2 of the secondary trial it is 40. Although the proportion of patients with Neutropenia in both cohorts is the same (10.00%), the raw numbers differ.</s>"
    },
    "6a37e999-4b7e-4654-b9ac-7776a0720040": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "1 patient in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the secondary trial developed an anorexia, there were no cases of this happening in the primary trial\" is entailed by the CTRs if we assume that \"eating disorder\" is used interchangeably with \"anorexia\" throughout the discussion. \n\nThe CTR for the primary trial does not report any cases of anorexia (0/22 or 0.00%), and the CTR for the secondary trial reports 1 case of anorexia (1/46 or 2.17%). This implies that the secondary trial had at least one instance of anorexia that was not present in the primary trial. Therefore, the statement is consistent with the data in the CTRs.</s>",
        "contradict": "The statement cannot be entailed by the information presented in the CTRs, as there is no mention of an \"eating disorder\" in either CTR. The listed adverse events include conditions such as anorexia, which refers to loss of appetite, and dyspnoea, which can be a symptom of various conditions including respiratory distress, but the term \"eating disorder\" as specifically used in the expert's statement is not present. Consequently, the statement cannot be directly derived from the provided clinical trial data.</s>"
    },
    "a625ff4b-9c91-4ab8-a78b-df833d15759a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00423917",
        "Secondary_id": "NCT00082641",
        "Statement": "the primary trial and the secondary trial both report cases of confusion in all their patient cohorts.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both report cases of confusion in all their patient cohorts\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary and secondary trials both have a section on Adverse Events where cases of confusion are reported.\n2. The CTR of the primary trial reports 1 case of confusion out of 33 participants (1.09% when converted to a percentage), while the CTR of the secondary trial reports 2 cases of confusion in total across both sections, with 1 case reported in Section 1 (9.09% when converted to a percentage for the section) and 0 cases reported in Section 2.\n3. The percentage of participants with confusion in each trial might differ, but the occurrence of confusion in both trials for at least some of their participants is evident.\n4. The statement does not contradict the information presented in the CTRs; hence, the entailment relation holds.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, although both trials report instances of confusion, the prevalence of confusion among the patient cohorts differs significantly between the primary and secondary trials. In the primary trial, confusion occurred in 1/33 (3.03%) of the patients, whereas in the secondary trial, it occurred in 2/23 (8.33% and 9.09% for Adverse Events 1 and 2, respectively). Therefore, while both trials report occurrences of confusion, the primary trial has a much lower prevalence rate than the statement suggests for both trials combined.</s>"
    },
    "b25e7c40-a1db-4ae7-9613-0f65ddb4c040": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from a life threatening bone fracture.",
        "Label": "Contradiction",
        "entail": "The statement \"At least one patient in the primary trial suffered from a life threatening bone fracture\" can be entailed by the information in the CTR if the bone fracture listed in the Adverse Events section of the primary trial is considered life-threatening. The term \"life threatening\" is not explicitly stated in the provided CTR data, but the occurrence of a hip fracture in the primary trial, which is listed as an Adverse Event, can be considered life threatening based on clinical knowledge and context. This event occurred in one patient out of 11, which matches the frequency stated in the expert's claim. Therefore, the statement can be entailed by the data in the CTR. The fact that the same type of Adverse Event did not appear in the secondary trial does not contradict the statement, as the trials may have different cohorts, treatments, or baseline characteristics.</s>",
        "contradict": "The statement \"At least one patient in the primary trial suffered from a life threatening bone fracture\" cannot be directly entailed from the information provided in the CTRs, as no such bone fracture is mentioned to be life-threatening in either the primary or secondary trials. The secondary trial does report one instance of hip fracture, but no severity level is given for it. Therefore, the statement is contradictory to the CTRs if it implies that a life-threatening bone fracture occurred in the primary trial, without specifying that the reported hip fracture in the secondary trial was also life-threatening.</s>"
    },
    "25f1f3b8-15ed-4339-bf56-1cf1e0c2909f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00856492",
        "Statement": "Cohort 1 of the primary trial recorded no deaths and no cases of Anemia.",
        "Label": "Contradiction",
        "entail": "The absence of deaths and anemia cases in Cohort 1 of the primary trial is entailed by the data in the CTRs because:\n\n1. There were 0 deaths reported in Cohort 1 of the primary trial according to Adverse Events 1.\n2. Similarly, there was 0 case of Anemia reported in Cohort 1 of the primary trial according to Adverse Events 1.\n\nTherefore, the statement made by the clinical trial expert is a logical consequence of the information provided in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial recorded no deaths and no cases of Anemia\" is contradicted by the CTR data as follows:\n\n- For cohort 1 in the primary trial, the total adverse events were 0/60 (0.00%). However, the statement asserts that there were no deaths and no cases of Anemia, which is an additional assertion beyond the reported data.\n- Anemia was reported in cohort 1 of the primary trial with an occurrence of 1/96 (1.04%) across the entire trial. This contradicts the statement that there were no cases of Anemia in cohort 1.</s>"
    },
    "c0ddffa9-4a88-4ee1-8525-a77e887c3d85": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01268150",
        "Statement": "The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n\n1. In the primary CTR, the definition of Objective Response Rate (ORR) includes CR and PR as its components.\n2. The primary CTR provides data on the ORR for the Eribulin Mesylate group, specifically a percentage of 28.6.\n3. No information is provided in the primary CTR regarding the ORR for the control group, but the expert statement compares the Eribulin Mesylate group with a control group.\n4. The secondary trial is not mentioned in the primary CTR, so no comparison between the trials is stated or implied in the primary CTR.\n5. However, if we assume that the secondary trial is a different trial comparing the Eribulin Mesylate group from the primary trial with a control group, and if the secondary trial also reports higher CR+PR percentage for the Eribulin Mesylate group than the control group, then the expert statement is entailed by the CTRs, since the ORR percentage for the Eribulin Mesylate group is higher according to the data provided in the primary CTR.\n\nTherefore, the expert statement \"The Eribulin Mesylate group in the primary trial had a higher proportion of patients with complete response (CR) or partial response (PR) than the control group\" can be entailed by the information present in both the primary and (assumed) secondary CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert cannot be definitively contradicted by the information present in the CTRs based on the given information. However, it cannot be confirmed either without access to the data regarding the control group's ORR, CR, and PR. The CTR only provides the ORR value for the Eribulin Mesylate group (28.6%). Therefore, without the corresponding ORR data for the control group, it's impossible to establish whether the statement is entailed by the data or not.</s>"
    },
    "64ea58e5-e28f-42bc-818e-31bbf347080c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement excluding patients with permanent sensory loss from the primary trial aligns with the exclusion criteria listed under \"Neurological or psychiatric disorders, which could preclude the patients to free informed consent\" in the primary CTR. However, this criterion does not explicitly mention sensory loss as a reason for exclusion. Yet, the statement does not contradict the CTR as it acknowledges the potential eligibility of such patients for the secondary trial. The secondary CTR does include \"No history of neurological or psychiatric disorders,\" but it does not exclude patients with sensory loss specifically. Thus, the statement is entailed by the CTRs, as it adheres to the clinical trial data while expanding the eligibility criteria comparison.</s>",
        "contradict": "The statement that \"Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial, but may still be eligible for the secondary trial\" is contradicted by the CTRs as neither trial includes a criterion specifically addressing permanent sensory loss as a inclusion or exclusion factor. Thus, no definitive conclusion can be drawn regarding the eligibility of such patients for either trial based on the provided CTR information alone.</s>"
    },
    "7a0f4365-9775-4f1d-a1c7-4630b41b43ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "the primary trial only defines intervention dosage for cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial only defines intervention dosage for cohort 2\" can be entailed by the information present in the CTRs because, in the primary trial, Intervention 2 specifically mentions the dosage of niraparib as \"Niraparab 300 mg (3x100 mg capsules) once daily,\" while Intervention 1, the Physician's Choice, does not specify a particular dosage for each chemotherapy. Therefore, the statement correctly highlights that only Intervention 2 in the primary trial has a defined dosage.</s>",
        "contradict": "The statement can be contradicted by the CTR information because the primary trial's intervention section does not only refer to cohort 2 but includes the physician's choice for intervention 1. This means that the dosage information provided for intervention 2 in the statement is not the only dosage defined in the primary trial. Instead, the primary trial outlines different treatment options for cohort 1, which is subject to a physician's choice and does not come with a fixed dosage.</s>"
    },
    "64dcb690-ef14-4cf2-85e5-670eb0645d7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial\" can be entailed by the CTR inclusion criteria in the following ways: \n\n1. The statement specifies that females must be over the age of 18, which is consistent with the CTR's requirement of \"Female 20 years and pre-menopausal\" (implicitly stating that pre-menopausal women are older than 18). \n\n2. The statement uses \"whose last period was 2 weeks prior\" as a proxy for the definition of pre-menopausal status provided in the CTR (\"last menses within 1 year of randomisation\"). This definition allows for some flexibility in the timing of last menstruation and is consistent with the 2-week window stated in the expert's statement. \n\n3. The statement does not explicitly reference hormone sensitivity or histological/cytological confirmation of breast cancer, but these requirements are not contradictory to the given statement and do not negate the entailment.\n\n4. The statement does not mention any exclusion criteria, so it does not contradict any information provided in the CTRs.\n\nTherefore, the information in the expert's statement is entailed by the inclusion criteria in the CTRs. However, it is essential to note that the expert's statement may not capture the full scope of the actual eligibility criteria as stated in the CTR. This example highlights the importance of careful consideration when making statements that rely on clinical trial data, as even seemingly minor differences in phrasing or interpretation can lead to potential misunderstandings or inconsistencies.</s>",
        "contradict": "The statement that \"Females over the age of 18, whose last period was 2 weeks prior are eligible for the primary trial\" is contradictory to the inclusion criteria in the CTR, which states that females must have had their last menstruation within 1 year of randomisation and meet certain hormonal criteria (E2 10 pg/mL and FSH 30 mIU/mL). Thus, a female who last menstruated 2 weeks before randomisation does not meet the inclusion criteria.</s>"
    },
    "cacd1b1b-510e-421b-9adb-c5715f281794": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01566721",
        "Statement": "More patients in cohort 2 of the primary trial had At Least 1 Adverse Event (AE) During the Treatment Period than in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follow: \n\nIn the Primary Trial, the percentage of participants in cohort A (SC Herceptin by needle/syringe) with at least 1 AE during the treatment period was 88.6%, and in cohort B (SC Herceptin by SID), it was 89.0%. The difference, although minor, indicates that more participants in cohort B had at least 1 AE than in cohort A. \n\nThe statement does not contradict the information in the CTRs, as both CTRs report a high percentage of participants with AEs. This difference could be due to factors such as the self-administration of Herceptin in cohort B, which might have led to different reporting or recognition of AEs by participants. Therefore, the statement is semantically entailed by the information in the Primary Trial CTRs.</s>",
        "contradict": "The statement cannot be directly contradicted by the information provided in the CTRs, as there is no clear evidence that the percentage of participants with at least one adverse event (AE) is higher in cohort 2 compared to cohort 1. The CTRs only report the percentage of participants with at least one AE for each cohort (88.6% for cohort A and 89.0% for cohort B), but they do not provide information about the number or severity of specific AEs, nor a comparison between the two cohorts. Therefore, it is impossible to establish entailment or contradiction based on the provided information alone.</s>"
    },
    "c3e5a015-e8b5-4281-828c-deb1f7fc7e3a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02502864",
        "Statement": "The maximum number of occurences for an adverse event in the primary trial was 3.",
        "Label": "Contradiction",
        "entail": "The statement \"The maximum number of occurrences for an adverse event in the primary trial was 3\" is entailed by the data in the CTRs as there were a total of 3 distinct adverse events reported for the primary trial, each occurring in 1/9 (11.11%) of the patients.</s>",
        "contradict": "The expert's statement does not contradict the information in the CTR directly. However, it fails to acknowledge the unique occurrence of each adverse event for each participant. While the maximum number of occurrences was 3 in total across all adverse events and participants in the primary trial, each event was experienced by only one participant (33.33% of total participants), resulting in a different interpretation of the data.</s>"
    },
    "7926bfa3-cf49-4589-8143-0a0826336b67": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01401166",
        "Statement": "All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration.",
        "Label": "Entailment",
        "entail": "The statement \"All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration\" can be entailed by the information in the CTRs as follows:\n\n1. According to the CTR descriptions, both Cohort 1: SC (SID) Then IV Herceptin and Cohort 1: IV Then SC (SID) Herceptin participants received a preferred method of drug administration during the trial.\n    a. In Cohort 1: SC (SID) Then IV Herceptin, 95.7% of participants preferred SC Herceptin and 4.3% preferred IV Herceptin.\n    b. In Cohort 1: IV Then SC (SID) Herceptin, 87.4% of participants preferred IV Herceptin and 9.2% preferred SC Herceptin.\n2. The preferred method of administration was determined through trial-specific telephone interviews with each study participant at Week 24.\n\nThus, since all participants in Cohort 1 of the primary trial underwent the preferred method of drug administration assessment and were classified as preferring either SC or IV Herceptin, the statement \"All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"All patients in cohort 1 of the primary trial had a Preferred Method of Drug Administration\" cannot be directly contradicted by the information in the CTRs based on the provided data. However, it is important to note that the CTRs do not explicitly state that every participant within Cohort 1 had a definitive preferred method of administration after completing the crossover period. The percentage values provided represent the distribution of preferences among participants at Week 24, and it is possible that there could be individuals who did not express a preference or had a preference that was not recorded. Therefore, while the CTRs do not directly contradict the expert's statement, they do not fully confirm it either, as there is no conclusive evidence that all patients in Cohort 1 had a preferred method of administration.\n\nAdditional context and data from the CTRs or other sources would be required to definitively evaluate the entailment relationship between the expert's statement and the provided trial information.</s>"
    },
    "1e0da2b7-b91e-4b83-bcb6-7bfafff7e39b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib.",
        "Label": "Entailment",
        "entail": "The statement does not require the exact dosage of triptorelin mentioned in the primary trial for entailment. The entailment exists because the CTR sections provide sufficient information for the expert's statement to hold. The statement focuses on the absence of explicit dosage information for triptorelin in the primary trial and the presence of it in the secondary trial for other treatments. This observation holds true for both CTRs. The expert's statement is consistent with the CTRs, as they indeed do not provide explicit dosage information for triptorelin. The absence of this information in the primary trial does not contradict the information in the secondary trial, as they pertain to different trials. Therefore, the expert's statement is entailed by the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs outright but focuses on a difference in detail provided regarding the dosage of Triptorelin in the primary and secondary trials. The statement does not claim that any dosage information for Triptorelin is incorrect in the CTRs, only that it is not explicitly stated in the primary trial. The secondary trial, however, provides details of doses used for other interventions, but not Triptorelin. Thus, the statement and CTRs can coexist without contradiction, as they address different aspects of the clinical trials.</s>"
    },
    "a81e4dbe-e9cf-4f2b-b2f7-b1bf6d630c42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial\" does not directly entail information from the CTRs provided. The CTRs list the number and types of adverse events in each cohort. The statement does not make a claim about the number or types of adverse events, but rather the total number of patients in each cohort. Therefore, this statement cannot be directly entailed by the information in the CTRs, as they do not provide the required information to substantiate the claim.</s>",
        "contradict": "The statement \"Cohort 1 of the secondary trial had more than 50x the number of patients as cohort 1 of the primary trial\" does not contradict the information in the CTRs directly. However, it cannot be determined to be an entailed statement based on the provided data. The Adverse Events sections of the CTRs do not mention the number of patients in each cohort, only the number of instances of each adverse event. Therefore, the statement's assertion regarding the size of the cohorts is outside the scope of the given CTR information.</s>"
    },
    "36957dd8-fe28-4b70-b651-8f6ea7d1d0e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01269346",
        "Secondary_id": "NCT01597193",
        "Statement": "Cohort 1 of the primary trial and Cohort 1 of the secondary trial  have the same total number of adverse events.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail any information from the CTRs, as the number of adverse events does not equalize when considering individual event types in each cohort. However, it does not contradict the data either. Hence, the statement is neither entailed nor contradictory based on the given Adverse Events sections in the CTRs.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs because, although both cohorts have the same total number of participants, the number and types of adverse events are different. In the primary trial, there are a total of 15 adverse events in cohort 1, while in the secondary trial, there are only 1 adverse event in cohort 1. The types of adverse events also differ, with anaemia being present in both trials but having different frequencies, and other adverse events being absent in one trial but present in the other. Thus, the statement is not an entailed relationship given the information provided in the CTRs.</s>"
    },
    "1aee22c7-96f2-4ea6-909a-48741f87ba07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement's assertion \"There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial\" harmonizes with the clinical trial data in the provided CTRs since both reports indicate the absence of Constipation, Diarrhoea, Nausea, and Febrile neutropenia in the specified patient cohorts as shown below:\n\nPrimary Trial: (Adverse Events 1 and 2)\nTotal number of participants: 14 (8 in Cohort 1 and 6 in Cohort 2)\nNumber of participants experiencing Constipation, Diarrhoea, Nausea, or Febrile neutropenia: 0\n\nTherefore, the statement is a valid entailment as the clinical trial data in the CTRs substantiate its truth and avoid any contradictions.</s>",
        "contradict": "The statement \"There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial\" is contradicted by the information present in the CTRs as follows:\n\nIn the Primary Trial Adverse Events 1 section, there is one instance of Eyelid oedema reported out of eight participants, while there are no reports of Constipation, Diarrhoea, Nausea or Febrile neutropenia. However, in Adverse Events 2 section of the same trial, there are no reports of these conditions out of six participants. \n\nIn the secondary trial, there is no information provided in the Adverse Events section regarding patient cohorts 1 and 2 for comparison with the primary trial. Hence, the statement cannot be directly verified or disproved using the given CTRs alone. However, based on the information in the primary trial CTR, the statement can be contradicted for Constipation, Diarrhoea and Nausea since there are no instances reported in the given trial. Febrile neutropenia is not reported in either trial.</s>"
    },
    "d677707e-9ca9-4801-8fcd-7960a9f4f30a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00513695",
        "Statement": "paclitaxel is the only drug in the primary trial given by IV.",
        "Label": "Contradiction",
        "entail": "The statement \"paclitaxel is the only drug in the primary trial given by IV\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTR for the primary trial specifies that paclitaxel is given IV (intravenously) for 1 hour once weekly during the neoadjuvant phase, and no other drug in the primary trial is mentioned to be given intravenously except paclitaxel.\n2. Therefore, the statement's assertion that \"paclitaxel is the only drug in the primary trial given by IV\" finds substantiation in the CTR and does not contradict it. \n\nHence, this statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"paclitaxel is the only drug in the primary trial given by IV\" is contradicted by the information in the CTR as both paclitaxel and doxorubicin are administered intravenously in the primary trial.</s>"
    },
    "5335a9c9-bae1-42e9-9428-eb0eded62d7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03252145",
        "Secondary_id": "NCT00904033",
        "Statement": "None of the subjects in the primary trial are required to injest any pills, whereas both cohorts of the secondary trial must take a weekly tablet.",
        "Label": "Entailment",
        "entail": "The statement \"None of the subjects in the primary trial are required to ingest any pills, whereas both cohorts of the secondary trial must take a weekly tablet\" is entailed by the information in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 and Intervention 2 both involve manual therapies, Manual Lymph Drainage (MLD) and PhysioTouch, respectively, which are applied directly to the lymphedematous upper limb. There is no mention of any oral medication or pills in either intervention.\n\n2. In the secondary trial, Intervention 1 consists of Calcitriol pill taken once per week, while Intervention 2 includes exercise only. However, the statement in question compares both cohorts of the secondary trial, implying that both groups take a weekly tablet. This is true, as Intervention 1 indeed requires weekly Calcitriol intake.\n\nTherefore, the statement \"None of the subjects in the primary trial are required to ingest any pills, whereas both cohorts of the secondary trial must take a weekly tablet\" is a valid observation based on the information provided in the CTRs.</s>",
        "contradict": "The statement \"None of the subjects in the primary trial are required to ingest any pills, whereas both cohorts of the secondary trial must take a weekly tablet\" is contradicted by the information present in the CTRs. \n\nIn the primary trial, Intervention 1 of Cohort 1 undergoes Manual Lymph Drainage, which is described as a \"manual massage technique,\" not involving ingestion of any pills or supplements. However, Intervention 2 of the same trial involves the use of Calcitriol pills taken once a week. \n\nIn the secondary trial, both Intervention 1 (No Exercise) and Intervention 2 (Exercise) arms have a common component where Calcitriol pills are taken once a week. Therefore, both cohorts are indeed required to take pills in this trial.\n\nContrary to the statement provided, the primary trial does have an intervention involving ingestion of pills, making the statement an incorrect representation of the facts presented in the CTRs.</s>"
    },
    "e6c0f7af-b549-4aad-8f3c-15f367a04a50": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01307891",
        "Statement": "Abraxane + Tigatuzumab group of the primary trial has 10% more patients with either Complete Response (CR) disappearance of all target lesions; Partial Response (PR) at least a 30% decrease in the sum of the longest diameter of target lesions than the Abraxane Alone group.",
        "Label": "Entailment",
        "entail": "The expert's statement infers that the Abraxane + Tigatuzumab group has a higher response rate (sum of CR and PR) compared to the Abraxane Alone group, which is supported by the CTR data. The CTR for the Abraxane + Tigatuzumab group indicates that patients in this arm will receive two different treatments, Abraxane and Tigatuzumab, with potentially synergistic effects. The CTR for the Abraxane Alone group specifies that patients will only receive Abraxane. The expert's statement, based on the given data, is a valid entailment as the response rates from the CTR confirm a higher percentage of responses (CR + PR) in the Abraxane + Tigatuzumab group.</s>",
        "contradict": "There is no information in the CTRs that directly supports the stated claim about a 10% difference in response rates between the Abraxane + Tigatuzumab and Abraxane Alone groups. The CTRs provide the response rates for each group but do not provide sufficient data for making a comparative statement. Additionally, the time frames for response assessments differ between the two groups, which further complicates any direct comparison. Thus, the statement cannot be conclusively established as entailed by the provided CTR information.</s>"
    },
    "1fc3aeac-3bc0-4a47-8222-ea267a822804": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile bone marrow aplasia in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no cases of Febrile bone marrow aplasia in the primary trial\" is entailed by the CTR data since febrile bone marrow aplasia is not listed under the Adverse Events section for either the primary or secondary trial. Therefore, the absence of this condition in the primary trial is consistent with the CTR information.</s>",
        "contradict": "Febrile bone marrow aplasia is not explicitly mentioned in the given CTRs. Instead, the reported adverse events include Febrile neutropenia which can be a symptom of bone marrow aplasia. However, the statement asserts the absence of \"Febrile bone marrow aplasia\" in the primary trial. Since the CTR does not provide definitive evidence to support or refute this claim, the statement is not entailed by the information in the CTR, and can be considered contradictory if it is taken as an absolute truth.</s>"
    },
    "9e664bcb-38cc-4ca6-9738-28d96248b7f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily\" is entailed by the information present in the CTRs as follow:\n\nThe CTR for the primary trial specifies that the Intervention is Lapatinib Monotherapy, with a dosage of 1500 mg taken orally once daily. It also mentions that six 250 mg tablets are needed to achieve this dosage. Therefore, the statement that the primary trial participants \"must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily\" is a direct consequence of the dosing instructions in the CTR.</s>",
        "contradict": "The given expert statement \"the primary trial participants must take 6 tablets of Lapatinib Monotherapy (1500g) PO once daily\" is not contradictory to the information presented in the CTR regarding the primary trial's intervention, as both statements indicate that the participants take six 250mg tablets (totaling 1500mg) of Lapatinib once daily. However, the expert statement includes an additional unit of measurement for the total Lapatinib intake, with grams (g) instead of milligrams (mg) as used in the CTR. This variation in units is not contradictory but may cause potential confusion, and it does not negate the semantic entailment between the expert statement and the CTR.</s>"
    },
    "1b8403ac-7eb3-41cb-8b7e-a89af3492805": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02924883",
        "Statement": "In the primary trial, all cases of  Enteritis, Vertigo and Anaemia occurred in cohort 2.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that all cases of Enteritis, Vertigo, and Anaemia in the primary trial belonged to cohort 2. This claim can be entailed by the information present in the CTRs if and only if there is no case of Enteritis, Vertigo, and Anaemia reported in cohort 1 in both trials. According to the provided CTRs, the number of cases for Enteritis, Vertigo, and Anaemia in cohort 1 is zero for both trials in the case of Vertigo and Anaemia, and there is only one case for Enteritis in the primary trial (but not in the secondary trial), which does not contradict the expert's claim. Therefore, the expert's statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"In the primary trial, all cases of Enteritis, Vertigo and Anaemia occurred in cohort 2\" is contradicted by the information present in the CTRs because:\n\n- For Enteritis, there was 1 reported case in cohort 1 of the primary trial, while there was none reported in cohort 2.\n- For Vertigo, there were no reported cases in either cohort of the primary trial.\n- For Anaemia, there was 1 reported case in the primary trial (in cohort 1, not cohort 2). \n\nTherefore, the expert's statement contradicts the information in the primary trial's Adverse Events section.</s>"
    },
    "ad853675-40ed-4a65-a401-d09ac3153570": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03004534",
        "Statement": "Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Participants with T2 N1 M0 breast carcinoma are eligible for the primary trial\" is entailed by the information in the CTR as it aligns with the stated eligibility criteria of T2 or T3 breast carcinoma with clinically positive (N1 only) or clinically negative (N0) axillary nodes (axilla involvement is indicated by N1), and M0 (no metastases).</s>",
        "contradict": "The statement can be contradicted by the CTR as it only includes participants with T2 breast carcinoma, whereas the CTR specifies that participants must have either T1 (with T1.0cm), T2, or T3 tumors, as per the given inclusion criteria.</s>"
    },
    "b43bee02-cc3f-4dc8-b13f-8a93de5dc422": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00493636",
        "Statement": "Cohort 1 of the primary trial had a longer median, maximum and minimum pfs than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as the duration of Progression Free Survival (PFS) for cohort A (Sorafenib + Gemcitabine or Capecitabine) is longer than cohort B (Placebo + Gemcitabine or Capecitabine), as evidenced by the longer median PFS in days (103 vs 81), and the upper limit of the 95% confidence interval for cohort A's median PFS (128 days) being greater than that of cohort B (95 days). The statement also does not contradict any information in the CTRs, and all the claims are based on data within the reports.</s>",
        "contradict": "The statement cannot be definitively contradicted by the information in the CTRs, as the CTRs do not directly provide data on the maximum and minimum Progression Free Survival (PFS) values for each cohort. However, based on the available information, it is not possible to conclude that cohort 1 had a longer median PFS than cohort 2, as the median PFS for each cohort is given as a range rather than a precise value (103 days for cohort A vs. 81 days for cohort B). Therefore, it is possible that cohort 2 had a longer median PFS than cohort 1 based on the given information. Additionally, the statement does not address the inter-trial comparability of the PFS data, as the primary and secondary trials may have differing patient populations, treatments, or other factors that could influence the PFS outcomes. Therefore, while the statement is not explicitly contradicted by the CTRs, it also does not find substantiation within their scope.</s>"
    },
    "62258901-8207-413d-913f-a04682635add": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00050011",
        "Statement": "the primary trial results show that Zoledronic Acid Upfront is a better treatment than Zoledronic Acid Delayed-start for increasing Lumbar Spine (L1-L4) Bone Mineral Density (BMD).",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. Both trials assessed change in Lumbar Spine (L1-L4) Bone Mineral Density (BMD) using the same measurement method with DXA devices cross-calibrated and analyzed by a central reader.\n2. The Zoledronic Acid Upfront arm involved treatment administration at an earlier time point (day 1 and every 6 months until disease progression), while the Delayed-start arm involved treatment initiation only upon meeting specific clinical criteria or fracture events.\n3. The results of the Upfront arm show a positive average percentage change in BMD (1.955%), while the Delayed-start arm shows a negative average percentage change in BMD (-2.325%).\n\nHence, the statement can be inferred as the Upfront treatment leading to a larger average change in BMD, and therefore, considered a better treatment compared to the Delayed-start treatment, as per the trial results presented.\n\nIn essence, the expert's statement is consistent with the CTRs, as the trial results clearly indicate that the Zoledronic Acid Upfront treatment results in a greater increase in Lumbar Spine BMD on average compared to the Zoledronic Acid Delayed-start treatment, as per the provided information.</s>",
        "contradict": "The expert's statement contradicts the CTRs due to the absence of directly comparable data between the two arms regarding the same time frame. The CTRs provide data on percent change in Lumbar Spine (L1-L4) BMD for the Zoledronic Acid Upfront and Delayed-start arms separately, but they are not measured under identical conditions. The Upfront arm receives the Zoledronic Acid treatment at the trial start, whereas the Delayed-start arm begins the treatment based on certain clinical criteria, leading to a potential difference in baseline characteristics and treatment duration. Thus, a direct comparison of the two arms' results without adjusting for these differences may lead to erroneous conclusions.</s>"
    },
    "d23aee47-e80f-42fe-b095-9cd81f9e0ed3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "Both the primary trial cohorts reported identical results.",
        "Label": "Entailment",
        "entail": "The statement \"Both the primary trial cohorts reported identical results\" can be entailed by the information present in the CTRs if we consider the following points:\n\n1. Both the primary trial cohorts have the same number of participants analyzed (6 participants each).\n2. Both trials involve the same two treatments - Niraparib and Pembrolizumab.\n3. The administration of Niraparib and Pembrolizumab is the same for both cohorts.\n4. The time frame for observation is the same - during Cycle 1.\n5. Both trials report the percentage of participants experiencing certain events - DLTs, in this case.\n\nGiven these similarities, it is reasonable to conclude that the results in terms of the occurrence of DLTs could be identical between the two trial arms. However, it is important to note that this conclusion would require further investigation to confirm, as the CTRs do not directly provide this information. The statement only entails that the trials were similar in design and had an identical number of participants with the same treatments and observation period. The actual results (DLTs or otherwise) need to be compared for equivalence.</s>",
        "contradict": "The statement \"Both the primary trial cohorts reported identical results\" contradicts the information in the CTRs as the results section (Results 1 and Results 2) presents the number of participants in each arm/group, which is the same (6 participants for each arm), but it does not provide any information about the occurrence or frequency of DLTs, which can differ between the two groups based on the different doses of Niraparib (200mg and 300mg). Therefore, even though the number of participants is identical, the outcomes and safety of the treatments in each group could be different due to dose-related differences, and thus, the statement is contradictory to the CTR information.</s>"
    },
    "d23eb56e-c232-4754-94aa-903bc174cb35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00524303",
        "Statement": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm.",
        "Label": "Entailment",
        "entail": "The statement \"The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm\" can be entailed by the information present in the CTRs if we calculate the difference between the percentage of participants achieving pCR in the Trastuzumab arm (54.0%) and the percentage of participants achieving pCR in the Lapatinib arm (45.0%). This difference is 9%, which aligns with the expert's statement.</s>",
        "contradict": "The percentage of participants achieving pCR after 26 weeks of therapy in the Trastuzumab arm was 54.0% compared to 45.0% in the Lapatinib arm in the primary trial. A 9% difference in favor of Trastuzumab would correspond to a percentage point difference of 4.5 (54.0% - 50.5% = 3.5%, and 3.5% x 2 = 7%, which is more than 9%, suggesting a misinterpretation of the data). However, the actual difference is only 9 percentage points, not 9%. Therefore, the expert's statement cannot be directly derived from the CTRs provided.</s>"
    },
    "1c0dcd29-4a04-4b78-abbf-b047d4c29597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with breast implants are always excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with breast implants are always excluded from the primary trial\" is entailed by the information in the CTRs because the CTR explicitly states that \"Patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion,\" but it does not mention anything about patients having active breast implants during the trial. This means that patients with breast implants are generally excluded from the trial, as stated in the expert's claim.</s>",
        "contradict": "The information contained in the statement is not entirely accurate according to the CTR. The CTR specifies that patients having tissue expanders or implants placed prior to radiation may be enrolled at the physician's discretion, indicating some patients with breast implants may be included in the trial.</s>"
    },
    "b1a17048-dfe8-4173-ae80-6ec273244848": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 20% of  patients in cohort 1 of the primary trial experienced adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 20% of patients in cohort 1 of the primary trial experienced adverse events\" can be entailed by the information present in the CTR as follows: The total number of adverse events reported across all patients in the primary trial was 31, and there were 185 participants. Thus, the percentage of patients experiencing at least one adverse event is (31/185) x 100% = 16.76%. Since the statement only concerns cohort 1 of the primary trial, the minimum number of patients in this cohort would be the total number of participants divided by the number of cohorts. Therefore, the minimum number of patients in cohort 1 is 185 / 1 = 185. If more than 20% of these patients experienced adverse events, the total number of patients with adverse events should be greater than 0.2 x 185 = 37. However, based on the information in the CTR, this is not the case since there were only 16 adverse events (1/185, 13/185, 2/185, 1/185, 1/185, 2/185, 2/185, 2/185, 1/185) reported for cohort 1. Nonetheless, the percentage of patients in cohort 1 who experienced adverse events (16/185) x 100% = 8.62% is close to, but less than, 20%. However, the statement does not specify which adverse events are being counted towards the 20% threshold, allowing the possibility that some adverse events may be more severe or impactful than others. Thus, based on the available information in the CTR, it can be argued that the statement is plausible but not strictly entailed.</s>",
        "contradict": "The statement that \"more than 20% of patients in cohort 1 of the primary trial experienced adverse events\" is contradicted by the CTR data because the total number of adverse events recorded in the primary trial was 31/185 (16.76%). This percentage is less than 20%.</s>"
    },
    "33652443-0bb4-493e-adfe-f5032b96b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS  much longer than the study time frame of 38 months.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial reports the restricted mean survival time for PFS for patients in the Neratinib Plus Capecitabine arm as 8.8 months with a 95% confidence interval of 7.8 to 9.8 months. Since the restricted mean survival time represents the area under the curve of the survival function up to a certain time point, it indicates that some patients had PFS greater than 38 months. The CTR does not provide information on the exact proportion or number of patients with PFS exceeding 38 months, but it does show that the mean PFS is longer than 38 months. \n\nTherefore, the expert's statement, which asserts that \"Patients receiving Neratinib Plus Capecitabine had a PFS much longer than the study time frame of 38 months,\" is consistent with the information reported in the CTR and does not contradict it.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as the reported restricted mean survival time for PFS in the Neratinib Plus Capecitabine arm is 8.8 months (within the study time frame of 38 months).</s>"
    },
    "74dba58a-8f5d-478b-a886-0e9758847fe3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically anxious patients are not able to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"clinically anxious patients are not able to participate in the primary trial\" cannot be entailed by the information present in the CTRs. The primary trial includes the inclusion criterion that participants must be willing and able to provide informed consent. However, there is no mention of anxiety as an explicit exclusion criterion. The CTR only states exclusion criteria related to depression and specific medical conditions.</s>",
        "contradict": "The statement \"Clinically anxious patients are not able to participate in the primary trial\" is contradicted by the CTR's eligibility criteria, which do not explicitly exclude patients with anxiety. The CTR mentions only depression, migraines, hepatitis, abnormal chemistry profile, or a positive urine drug screen for illegal substances as exclusion criteria.</s>"
    },
    "5344044c-127d-4a39-80dc-277538b5ad33": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Contradiction",
        "entail": "The information in the statement can be entailed by the information present in the CTRs as follows:\n\n1. The percentage of participants with tpCR in the TCH + P group is 56.1% (49.29% to 62.76%).\n2. The total number of participants in the TCH + P group is 221.\n3. Therefore, less than 60 participants in the TCH + P group can be calculated as 221 * (56.1% / 100%) * 60 = 56.1 * 60 = 336.6, which is approximately 336 participants. Since we cannot have a fractional participant, it's clear that fewer than 60 participants achieved tpCR based on the reported data.</s>",
        "contradict": "The statement \"less than 60 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR)\" is contradicted by the information in the CTR. According to the Results 1 section of the CTR, the percentage of participants in the TCH + P group who achieved tpCR is given as 56.1% (49.29% to 62.76%), which is higher than 50% and therefore, more than 110 participants (given the overall number of participants analyzed is 221) would have achieved tpCR if we extrapolate the percentage to the entire group.</s>"
    },
    "ed43519d-9954-4e0f-9d42-39a3ed81e4a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Hyperglycemia was the most common adverse event in cohort 1 of the primary trial\" cannot be entailed by the information present in the CTRs, as there is no mention of hyperglycemia or its frequency in either the primary or secondary CTRs provided.</s>",
        "contradict": "The statement that \"Hyperglycemia was the most common adverse event in cohort 1 of the primary trial\" cannot be definitively contradicted by the provided information in the CTRs. However, the statement is in error because the CTR for the primary trial does not list hyperglycemia as an adverse event. The listed adverse events for cohort 1 of the primary trial include hemoglobin decreased, abdominal pain, colitis, diarrhea, nausea, rectal hemorrhage, fatigue, skin infection, neutrophil count decreased, platelet count decreased, and dehydration. Thus, the statement is incorrect based on the information given in the CTRs.</s>"
    },
    "8d2fde27-a5e8-40ee-a35d-3d4697198a4e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00929240",
        "Statement": "There are no cases of Febrile neutropenia in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There are no cases of Febrile neutropenia in the primary trial\" is entailed by the information in the CTRs since the primary trial's Adverse Events section reports a total of 78 adverse events out of 284 participants (27.46%), but no cases of Febrile neutropenia are listed among them (9.86% was reported for the whole population but none is explicitly stated for the primary trial). Therefore, the statement's assertion harmonizes with the clinical trial data, is substantiated in the CTR, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"There are no cases of Febrile neutropenia in the primary trial\" is contradictory to the information present in the CTR, specifically in the Adverse Events section of the primary trial, where it is stated that there are 28 cases of Febrile neutropenia out of 284 participants (9.86%).</s>"
    },
    "fc0da76b-e5b5-44e3-abaf-6231fff493c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00676663",
        "Statement": "The the primary trial placebo group performed worse than the test group.",
        "Label": "Entailment",
        "entail": "To determine if the statement \"The placebo group in the primary trial performed worse than the test group\" is entailed by the information present in the CTRs, we can compare the median PFS values of the placebo group and the test group in both trials. In the primary trial, the median PFS of the placebo group was 1.81-3.68 months and in the secondary trial, the median PFS of the placebo group is not provided. However, we can infer that the placebo group in the secondary trial had a longer median PFS (3.26-5.36 months) compared to the Exemestane 25 mg + Placebo arm in the primary trial. Therefore, it is reasonable to conclude that the statement \"The placebo group in the primary trial performed worse than the test group\" can be entailed by the information present in the CTRs, given that a shorter median PFS indicates poorer outcomes.</s>",
        "contradict": "The statement \"The primary trial placebo group performed worse than the test group\" cannot be definitively concluded based on the provided information from the CTRs. The CTRs only provide the median PFS for each treatment group in the primary trial, but they do not offer direct comparisons of the two groups' outcomes. Additionally, the statement assumes that a worse outcome is indicated by a shorter PFS, which is not necessarily the case as it depends on the context and the study's objectives. In the absence of further context or additional data supporting the statement, it cannot be considered an entailed claim based on the presented information in the CTRs alone.</s>"
    },
    "1a32e1c1-31b1-40e5-bbb6-84041ef796fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00119262",
        "Statement": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure.",
        "Label": "Entailment",
        "entail": "Given the information in the CTRs, it can be determined that both Arm A and Arm B included patients with Congestive Heart Failure. From Results 1 and 2, the percentage of participants with Congestive Heart Failure in Arm A and Arm B are stated to be 2.9% (0.6-8.3%) and 2.5% (0.5-7.1%), respectively. Although the exact number of patients with Congestive Heart Failms in each arm is not directly mentioned, we can calculate this value based on the overall Number of Participants Analyzed and the stated percentage. In Arm A, this amounts to 3 participants (103 total * 2.9%). Similarly, in Arm B, there are 3 participants (120 total * 2.5%). Therefore, the statement that 'cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure' can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert that \"cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure\" cannot be directly derived from the information presented in the CTRs. The CTRs provide data on the percentage of participants in each arm (cohort) of the trial who experienced Congestive Heart Failure, but they do not specify the exact number of patients who experienced this condition. Therefore, while it's possible that each cohort had some participants with Congestive Heart Failure, it is not possible to determine if exactly 3 participants in each cohort experienced this condition based on the information provided in the CTRs.</s>"
    },
    "9a31db67-e28a-4114-a308-e899f9c22813": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the esophagus.",
        "Label": "Entailment",
        "entail": "The statement \"One patient in the primary trial suffered from an inflammation of the esophagus\" is entailed by the information in the CTR, specifically in the \"Adverse Events 1\" section under the primary trial, where the occurrence of esophagitis - an inflammation of the esophagus - is reported as an adverse event, with a frequency of 1/48 (2.08%).</s>",
        "contradict": "The statement \"One patient in the primary trial suffered from an inflammation of the esophagus\" cannot be directly contradicted by the information present in the CTRs as the primary trial Adverse Events section mentions one instance of esophagitis. However, the statement does not specify if it refers to the same trial or patient as the CTR data. If it is assumed the statement pertains to the primary trial, then there is no contradiction. If, however, the statement implies a second trial or a different patient within the primary trial, then it could potentially contradict the CTR data if no such instance is reported in the secondary trial or the patient in question was not included in the primary trial.</s>"
    },
    "f948a2d1-2e22-47c8-9345-0eb68569bd3f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "Emily's inoperable breast cancer meets the inclusion criteria of the primary trial, as it is specified in the primary CTR. However, it does not meet the exclusion criteria of the primary trial, as her breast cancer being inoperable is not listed. Therefore, Emily's eligibility for the primary trial is not explicitly stated in the CTR, but it is not contradicted either.\n\nEmily's eligibility for the secondary trial is determined by her histologically confirmed metastatic or recurrent breast cancer, her written informed consent, and her age (20 to 74 years old). These criteria are explicitly stated in the secondary CTR, and they are not contradicted by the primary CTR. Therefore, Emily is also eligible for the secondary trial according to the information provided in the CTRs.\n\nThus, the statement that \"Emily has an Inoperable breast cancer, she is eligible for both the secondary trial and the primary trial\" is entailed by the information present in the CTRs, as it does not contradict any information in the CTRs and follows logically from the stated inclusion and exclusion criteria.</s>",
        "contradict": "Emily having inoperable breast cancer contradicts her eligibility for the primary trial, as inoperable breast cancer is an exclusion criterion for that trial, according to its CTR.</s>"
    },
    "e3265040-8316-4f62-969c-27af396ba18c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00479674",
        "Statement": "Patients that have previously been treated with bevacizumab are not eligible for the primary trial, unless they have also received carboplatin 2 weeks prior to study entry.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR inclusion criteria since the CTR explicitly lists \"Prior treatment with bevacizumab\" as an exclusion criterion. The statement adds an additional condition that patients who have been treated with bevacizumab can still participate if they have received carboplatin 2 weeks prior to study entry. This condition aligns with the CTR's exclusion criterion for \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab,\" as long as carboplatin is given before study entry. Thus, the statement does not contradict the information in the CTR and is entailed by it.</s>",
        "contradict": "The statement contradicts the CTR inclusion criteria as it allows patients who have previously received bevacizumab to enter the trial if they have also received carboplatin 2 weeks prior to study entry. However, the CTR explicitly states that \"Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab, or any taxane for metastatic breast cancer\" is an exclusion criteria. Therefore, the statement contradicts the provided CTR information.</s>"
    },
    "6c25e195-47cd-48af-bb51-5b5c44772baa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "hyperparathyroidism is a condition listed under EXCLUSION CRITERIA in the primary trial. Therefore, individuals with this condition cannot participate in the trial, which entails that the statement \"Candidates with hyperparathyroidism are automatically excluded from the primary trial\" is consistent with the provided CTR information.</s>",
        "contradict": "The statement is contradictory to the CTR information as hyperparathyroidism is listed under the exclusion criteria in the primary trial but is not explicitly mentioned in the given statement. Therefore, the statement's assertion goes beyond what is stated in the CTRs and could potentially include individuals with hyperparathyroidism who do meet the other inclusion criteria.</s>"
    },
    "382747d3-69df-41be-a771-4218407ce5d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR data as follows: In the primary trial, the Zoledronic Acid 4 mg Upfront group shows a mean percentage change in BMD of 2.208 with a standard deviation of 3.4194, indicating a positive change in BMD. Conversely, the Zoledronic Acid 4 mg Delayed group in the same trial demonstrates a mean percentage change in BMD of -3.617 with a standard deviation of 4.2151, suggesting a loss in BMD. These results are consistent with the expert's statement that Zoledronic Acid 4 mg Upfront causes a positive change, while Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density, within the context of the specified clinical trial conditions.</s>",
        "contradict": "The statement \"the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a positive Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a loss in Bone Mineral Density (within a certain patient demographic)\" is contradictory to the information in the CTRs because the primary trial results show that the mean percentage change in BMD for Zoledronic Acid 4 mg Upfront was 2.208 (3.4194) and for Zoledronic Acid 4 mg Delayed was -3.617 (4.2151). A positive change indicates an increase in BMD, while a negative change indicates a decrease. Therefore, the statement suggests that Zoledronic Acid 4 mg Upfront causes an increase and Zoledronic Acid 4 mg Delayed causes a decrease in BMD, but the data in the CTRs shows that Zoledronic Acid 4 mg Upfront caused a smaller increase and Zoledronic Acid 4 mg Delayed caused a larger decrease in BMD. This discrepancy makes the statement inconsistent with the CTRs.</s>"
    },
    "d05ec90a-f267-44be-aaa6-3be960a0d50c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Contradiction",
        "entail": "The statement \"Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks\" can be entailed by the information in the CTRs as follows:\n\n1. The primary trial outcome measure was defined as the clinical benefit rate, which includes CR, PR, and SD.\n2. The time frame for evaluating clinical benefit rate is up to 24 months (as per the CTR).\n3. The CTR for the Temsirolimus arm indicates that 9.7 percentage of 31 participants experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks, implying that most participants in the trial experienced CR, PR, or SD for the minimum period stated in the expert's claim.\n\nTherefore, the statement can be entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Most the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks\" cannot be definitively contradicted by the information in the CTRs alone. However, the CTRs do not support this statement either, as they provide information on the response evaluation criteria and the number of participants with a clinical benefit rate, but do not explicitly state that \"most\" participants experienced a CR, PR, or SD for at least 24 weeks. The statement could potentially be correct, but it would require additional data or context beyond that presented in the CTRs to be confirmed.</s>"
    },
    "37301690-9b68-48de-b280-6307e632043e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains .",
        "Label": "Entailment",
        "entail": "The statement \"The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains\" can be entailed by the information present in the CTRs as follows: In the primary CTR, the types of adverse events recorded under Adverse Events 1 are \"Diarrhoea\" (1.32%) and \"Pain\" (1.32%). In Adverse Events 2, the types of adverse events recorded are \"Diarrhoea\" (1.33%) and \"Pain\" (1.33%). In the secondary CTR, the types of adverse events recorded under Adverse Events 1 are \"Diarrhoea\" (1.79%) and \"Pain\" (0.00%). In Adverse Events 2, the types of adverse events recorded are \"Diarrhoea\" (2.70%), \"Oesophageal pain\" (2.70%), and \"Pain\" (2.70%). Both trials have \"Diarrhoea\" as a common adverse event, and while the primary trial reports only \"Pain\" (1.32% + 1.32% = 2.64%), the secondary trial reports \"Oesophageal pain\" and \"Pain\" (2.70% + 2.70% = 5.40%), which can be considered as a subtype or variation of \"Pain\". Therefore, the expert's statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"The only types of adverse events recorded by both the secondary trial and the primary trial is Diarrhoea and various pains\" is contradicted by the information present in the CTRs because:\n\n1. The statement does not account for the differences in the types and frequencies of adverse events between the two trials, such as the absence of Sickle cell anemia with crisis, Pyrexia, Chest pain, Complication associated with device, General physical health deterioration, Pneumonia, Atypical pneumonia, Dehydration, Disease progression, Infusion related reaction, and Pain in the primary trial that were not reported in the secondary trial.\n2. The statement incorrectly assumes that only Diarrhoea and various pains are the common adverse events between the two trials without specifying that Diarrhoea is the only gastrointestinal adverse event that is common.\n3. The statement does not acknowledge the discrepancy in the total frequency of adverse events between the two trials. The primary trial had a higher frequency of adverse events (13.16%) compared to the secondary trial (4.00% or 29.73% depending on the adverse event type). Therefore, the statement oversimplifies the comparison of adverse events between the two trials.\n\nThus, the statement is contradicted by the more detailed information presented in the CTRs, which highlights the importance of considering the specific types and frequencies of adverse events when comparing trials or making generalizations about their findings.</s>"
    },
    "b61e798c-d38f-4c72-91bb-4d3e28b6184c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00356148",
        "Secondary_id": "NCT01856543",
        "Statement": "Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial includes women of any age as long as they meet certain criteria, while the secondary trial specifically targets adults (18 years and above). The difference lies in the age restriction in the secondary trial. Therefore, the statement \"Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial\" is entailed by the information present in the CTRs because the primary trial's inclusion criteria do not have an upper age limit, and the secondary trial's inclusion criteria have an age limit of 18 years and above.</s>",
        "contradict": "The statement \"Women of any age can participate in the primary trial, but only adults can be eligible for the secondary trial\" contradicts the CTR information due to the following reasons:\n\n1. Age Restriction in Primary Trial: Women of any age can participate in the primary trial, but the CTR states that the trial only includes women with early stage breast cancer (stage I-II) and an ASA score of I-II. While age is not explicitly stated as an inclusion criterion, it is implicitly limited by the conditions mentioned.\n\n2. Age Restriction in Secondary Trial: The CTR for the secondary trial states that participants must be 18 years or older. Therefore, the statement \"but only adults can be eligible for the secondary trial\" aligns with the information present in the CTR. However, it contradicts the statement \"Women of any age can participate in the primary trial,\" which does not apply to the secondary trial.\n\nOverall, the statement is misleading because it incorrectly applies the age eligibility condition to both trials. The primary trial indeed accepts women of all ages, but only under certain conditions, while the secondary trial specifically excludes women under 18 years old.</s>"
    },
    "3ca27248-0728-4b10-b940-6e2603acef30": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00201760",
        "Secondary_id": "NCT00127933",
        "Statement": "Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have an infiltrating breast carcinoma to participate in the secondary trial or the primary trial\" is entailed by the information present in the CTRs because:\n\nPrimary CTR: Eligibility Criteria - Must have histological confirmation of invasive breast cancer either from the original diagnosis and/or diagnosis of metastatic disease.\n\nSecondary CTR: Inclusion Criteria - Must have infiltrating (invasive) breast cancer.\n\nBoth the primary and secondary trials require participants to have an invasive or infiltrating breast cancer, as stated in their respective eligibility/inclusion criteria. Therefore, the expert's statement is a logical consequence of the given information, and no contradiction or additional assumptions are needed to establish entailment.</s>",
        "contradict": "The statement is not an entailed consequence of the information in the CTRs as it overlooks several essential distinctions. The eligibility criteria for the primary trial specify that patients must have either invasive breast cancer (Section 1) or metastatic breast cancer (Section 1) with the required Her2/neu status and other conditions. In contrast, the secondary trial includes only patients with newly diagnosed, infiltrating (invasive) breast cancer (Section 2) without specifying metastatic status. Thus, the statement is too vague and can potentially include patients who may not meet the eligibility criteria of either trial, leading to a possible contradiction.</s>"
    },
    "c2da6504-96a1-4669-b609-16731a5330d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is ineligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "Ae-Cha is ineligible for both trials due to her ethnicity (Korean origin), age (younger than 50 years old in the primary trial), and cancer type (inoperable breast cancer, which is metastatic and not specified as hormone receptor positive in the primary trial or as early stage in the secondary trial).\n\nIn the primary trial, she does not meet the criteria for postmenopausal status and hormone receptor positivity, and she is too young. Additionally, she has a contraindication for the primary trial due to having an inoperable breast cancer, which is not specified as an exclusion criterion but would likely render her ineligible due to the nature of the study.\n\nIn the secondary trial, she does not meet the age requirement and is not hormone receptor positive. Furthermore, she has inoperable breast cancer (metastatic disease), which is an exclusion criterion for the secondary trial.\n\nTherefore, the statement that \"Ae-Cha is ineligible for both the secondary trial and the primary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "Ae-Cha being a 32-year-old Korean woman with inoperable breast cancer makes her ineligible for the primary trial due to her age, non-postmenopausal status, and inoperable cancer, which violate its inclusion criteria. Additionally, she is also ineligible for the secondary trial since she is of Asian descent (Korean) and has inoperable breast cancer, which contradicts its inclusion criteria. However, the primary CTR does include the exclusion of Asian descent as a criterion for the secondary trial, but it does not explicitly state that as a requirement for the primary trial. Hence, the statement does not contradict the information in the CTRs but highlights the differences in criteria between the two trials, making Ae-Cha an ineligible candidate for both.</s>"
    },
    "646959e4-25d0-4eb1-b7b0-2d7b1e02e132": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "Less than 5% of patients in the primary trial suffered an adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 5% of patients in the primary trial suffered an adverse event\" is entailed by the information in the CTR as the CTR reports that 4.55% of patients (1/22) in the primary trial experienced adverse events. The percentage in the statement and the percentage in the CTR are close enough that they convey the same general information. Additionally, the statement does not contradict or add anything new to the information presented in the CTR, making it entailed.</s>",
        "contradict": "The expert statement is not a contradiction of the CTR information, as they both make the same claim using different phrasing. The expert statement asserts that less than 5% of patients in the primary trial experienced an adverse event, which aligns with the CTR data that states 4.55% of patients had an adverse event. The contradiction would arise if, for example, the expert statement claimed that more than 5% of patients had an adverse event.</s>"
    },
    "0e6eebe9-46c2-4fa5-b9ed-e0997044960b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or surgery\" is entailed by the CTRs since:\n\n1. In the primary trial Intervention 1, there is no mention of radiotherapy or surgery as part of the treatment regimen for either Arm 1 or Arm 2.\n2. Similarly, in the secondary trial Intervention 1 of the AC, WP, and Pazopanib regimen, there is no mention of radiotherapy or surgery as part of the treatment protocol. The trial only specifies the sequence and dosing information for the given drugs.\n\nTherefore, based on the provided data, the statement does not contradict any information in the CTRs and is an allowable entailment.</s>",
        "contradict": "The primary trial involves the use of neoadjuvant hormonal therapy and neoadjuvant chemotherapy, neither of which include radiotherapy or surgery in their interventions. However, the secondary trial does involve chemotherapy (AC) and surgery in its intervention. While none of the patients in the primary trial are required to undergo radiotherapy or surgery, this is not the case for all patients in the secondary trial. Thus, the statement cannot be universally applied to both trials based on the provided CTR information and is contradictory for the secondary trial.</s>"
    },
    "a781374c-99e1-47ee-a266-bff9267c2ed1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00950742",
        "Statement": "100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities.",
        "Label": "Entailment",
        "entail": "The expert's statement that \"100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities (DLT)\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR specifies that the Afatinib 30mg + Herceptin group consisted of two participants (Results 2) and states that there are no details regarding DLTs mentioned for this arm in the provided information (Important Limitations and Caveats). However, it is mentioned in the same section that \"Important Limitations and Caveats\" for the Afatinib 20mg + Herceptin group include the observation of DLTs in 3/13 participants within the first 28-day cycle (Results 1). Since the trial did not report any DLTs for the Afatinib 30mg + Herceptin group but only reported that the participants were analyzed, it can be inferred that the absence of reported DLTs for this group does not necessarily mean that no DLTs occurred. Instead, the absence of reported DLTs might mean that either no DLTs occurred or that they were not explicitly mentioned in the given text. However, given the limited sample size of the Afatinib 30mg + Herceptin group, it is statistically possible that all participants experienced DLTs but they were not reported. The expert's statement, therefore, is a logical possibility based on the provided CTR data and does not contradict the information within.\n\nTherefore, the expert's statement \"100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities\" can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"100% of participants in the Afatinib 30mg + Herceptin group of the primary trial suffer Dose Limiting Toxicities (DLT)\" is contradicted by the information in the CTR because the stated percentage does not correspond to the reported number of participants with DLT (which is given as 2 in the Afatinib 30mg + Herceptin group). This discrepancy between the claim and the data in the CTRs implies that the statement cannot be considered entailed by the provided information from the CTRs.</s>"
    },
    "9aea5a84-bced-4441-b8b8-154c307f5a03": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Contradiction",
        "entail": "The placebo group in the primary trial had a significantly lower median PFS (10.7 weeks, 95% CI: 8.1-16.1) compared to the MM-121 cohort (15.9 weeks, 95% CI: 9.3-30.3), as evident from the reported data in the CTRs.</s>",
        "contradict": "The statement \"The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort\" cannot be definitively concluded from the given CTR information. The CTRs provide the median PFS values for both the MM-121 + exemestane arm and the placebo + exemestane arm. However, they do not directly compare the difference between the medians or their statistical significance. The expert's statement implies a significant difference, but the CTR data alone does not provide sufficient evidence to support this claim.</s>"
    },
    "deb77d34-76a5-4e6e-bc9d-176cc30eca07": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00917735",
        "Statement": "One patient in cohort 2 of the primary trial died in a motorcycle crash.",
        "Label": "Contradiction",
        "entail": "The statement \"One patient in cohort 2 of the primary trial died in a motorcycle crash\" can be entailed by the information in the CTRs since there is one instance of a motorcycle accident reported in the Adverse Events section of the primary trial for cohort 2, with a total count of 1 occurrence out of 538 participants. Therefore, the occurrence of a motorcycle accident resulting in death for one patient falls within the possible outcomes reported in the CTR.</s>",
        "contradict": "The statement \"One patient in cohort 2 of the primary trial died in a motorcycle crash\" contradicts the information present in the CTRs since no instances of motorcycle accidents were reported as adverse events among the participants of both trials. In the provided data, none of the participants in the primary trial's cohort 2, nor any participant in the secondary trial, had motorcycle accidents recorded. Consequently, the expert's statement cannot be entailed by the information given in the CTRs.</s>"
    },
    "bfe97430-fcec-4c4a-9621-51f6ec05d8d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00068341",
        "Statement": "More patients in cohort 1 of the primary trial experienced death progressive disease  than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2\" is entailed by the information present in the CTRs, as the CTR for the primary trial reports zero occurrences of death progressive disease in cohort 2, while one occurrence is reported in cohort 1.</s>",
        "contradict": "The statement that \"More patients in cohort 1 of the primary trial experienced death progressive disease than in cohort 2\" is contradicted by the information present in the CTRs because neither cohort 1 nor cohort 2 reported any deaths due to progressive disease in their respective adverse events sections (both reported 0/15 for cohort 1 and 0/14 for cohort 2).</s>"
    },
    "568beebd-b350-4ba1-b8fc-c43f4d6ed517": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01421017",
        "Statement": "the primary trial studies the effects of CTX/IMQ/RT and IMQ+RT on Systemic Tumor Response Rates 9 weeks after the start of treatment.",
        "Label": "Entailment",
        "entail": "The expert's statement entails the information present in the CTRs as both trials evaluate the effect of different treatment regimens, CTX/IMQ/RT and IMQ+RT, on Systemic Tumor Response Rates, specifically 9 weeks after the start of treatment. This aligns with the outcome measurement in the CTRs, and the treatment details provided in each arm (CTX/IMQ/RT and IMQ+RT) enable comparison between the two interventions.</s>",
        "contradict": "The statement does not contradict the CTRs directly, as it accurately reflects the content of both trials. However, it makes a broader claim about the trials that could potentially be contradicted by unseen data. Specifically, the statement implies that the data for both trials covers a 9-week time frame and that they both investigate Systemic Tumor Response Rates. While this is true based on the provided CTR information, it is possible that there could be additional data or variations in how Systemic Tumor Response Rates were measured or analyzed between the trials that could lead to differences in their outcomes. Without access to this additional information, the statement's claim cannot be definitively verified or contradicted based on the provided CTRs alone.</s>"
    },
    "6bcc18b7-b063-49a1-8ab7-773636c02f1d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00076024",
        "Statement": "The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191.",
        "Label": "Entailment",
        "entail": "The minimum number of days for tumor progression or death in the Docetaxel + Placebo arm of the primary trial is 191 (191 to 247), as stated in Result 2. This value can be considered the lower bound for TTP in the primary trial. Consequently, the statement made by the clinical trial expert is entailed by the CTRs, as it is a consequence of the reported data.</s>",
        "contradict": "The statement's assertion, \"The minimum number of days from start of study treatment to first documentation of objective tumor progression or death due to cancer for any patient in the primary trial, was 191,\" is contradictory to the information presented in the CTRs because:\n\n1. The median TTP for the Docetaxel + Placebo arm of the primary trial was reported to be 191 days (191 to 247 days) in the given CTR, however,\n2. The statement asserts that it is the \"minimum\" number of days, which cannot be true based on the data provided since there were patients in the trial with longer TTP.</s>"
    },
    "dfa2ecee-96cf-4551-875e-aedd8aac5df9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial\" is entailed by the CTR data as follows: The difference between the mean durations of Grade 4 neutropenia for the EP2006 + EP2006 & Neupogen arm and the Neupogen + Neupogen & EP2006 arm is calculated as |1.17 - 1.2| = 0.03 days. Since 0.03 days is less than 24 hours (0.03 * 24 = 0.072 hours, which is less than 24 hours), the expert's statement is an entailed conclusion given the CTR data.</s>",
        "contradict": "The expert's statement can be contradicted by the data in the CTRs as the means of Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms (EP2006 + EP2006 & Neupogen vs Neupogen + Neupogen & EP2006) have a significant difference (1.17 days vs 1.2 days, p-value < 0.05). This difference is greater than 24 hours, implying that the expert's statement is incorrect.</s>"
    },
    "81c85a29-d449-4f79-a3b3-682ba5f288ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00190671",
        "Secondary_id": "NCT00455533",
        "Statement": "In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 2 of the primary trial had the highest proportion of patients with leukopenia.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, there were 2 cases of Leukopenia in cohort 2 out of 42 patients (1.38%), and 0 cases in cohort 1 out of 42 patients (0.00%). Thus, cohort 2 had more patients with Leukopenia than cohort 1.\n\n2. In the secondary trial, there were 2 cases of Leukopenia in cohort 1 out of 145 patients (1.38%), and 1 case in cohort 2 out of 145 patients (0.69%). Despite having fewer cases in cohort 2, the statement still asserts that cohort 2 had the highest proportion of patients with Leukopenia because the proportion of affected patients was higher than cohort 1, given the different total patient count in each trial. \n\nTherefore, the statement can be entailed since it follows logically from the data provided in the CTRs without contradicting any information.</s>",
        "contradict": "The statement can be contradicted by the CTRs as the number of patients with leukopenia is not higher in cohort 2 of the primary trial, but instead, both cohorts have the same number of patients with this condition. Contrarily, in the secondary trial, cohort 1 has a higher number of patients with leukopenia than cohort 2. Consequently, the statement's claim that cohort 2 of the primary trial had the highest proportion of patients with leukopenia is not accurate according to the information in the CTRs.</s>"
    },
    "9c48c5d6-83fd-42cc-aacc-2e888099bcdb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial more Imatinib mesylate than Letrozole on a daily basis.",
        "Label": "Entailment",
        "entail": "The statement \"Participants of the primary trial received more Imatinib mesylate than Letrozole on a daily basis\" is entailed by the information in the CTRs because, in the primary trial, participants received Imatinib mesylate 400 mg twice a day (which equals 800 mg per day), while they received Letrozole 2.5 mg once a day (which equals 2.5 mg per day). Therefore, participants indeed took more Imatinib mesylate (800 mg) than Letrozole (2.5 mg) on a daily basis.</s>",
        "contradict": "Although the statement asserts that participants in the primary trial take more Imatinib mesylate than Letrozole on a daily basis, the CTR specifies that participants receive Imatinib mesylate 400 mg twice a day and Letrozole 2.5 mg once a day. This means that while the total daily dose of Imatinib mesylate is higher than Letrozole, each individual dose of Imatinib mesylate is still smaller than two doses of Letrozole. Therefore, the statement is contradicted by the CTR information, as it fails to acknowledge the difference in dosing frequency.</s>"
    },
    "79a3bb0d-315f-4c39-8786-2aa98e2e3f6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Males are not eligible for the primary trial\" is entailed by the CTR as the Primary Trial's Inclusion Criteria explicitly specifies \"Estrogen receptor or progesterone receptor positive breast cancer,\" implying that participants must have female sex organs to meet the criteria. The Exclusion Criteria also mention \"no use of current oral contraceptives,\" which is not relevant to the eligibility of males. Therefore, the absence of male participants in the trial is an expected implication based on the stated criteria.</s>",
        "contradict": "The statement \"Males are not eligible for the primary trial\" is contradictory to the information present in the CTRs because the Primary Trial's Inclusion Criteria explicitly state \"Estrogen receptor or progesterone receptor positive breast cancer,\" which applies to females and not males. The Exclusion Criteria also mention \"no current oral contraceptives,\" which is not applicable to males. Hence, the statement contradicts the information in the CTRs by including a population (males) that is explicitly excluded from the trial according to its inclusion and exclusion criteria.</s>"
    },
    "cea17554-6736-4b52-b76c-b3c5dc9ecb77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00503750",
        "Statement": "All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan.",
        "Label": "Entailment",
        "entail": "The statement \"All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan\" can be entailed by the primary CTR inclusion criteria, specifically: \"Normal (greater than 50%) left ventricular ejection fraction (LVEF) by MUGA scan or echocardiography.\" This statement from the CTR implies that participants must have undergone one of these tests to verify their LVEF. The expert's statement is more explicit, but the implication is the same.</s>",
        "contradict": "The expert's statement that \"All participants of the primary trial must have recently undergone either an echocardiography or a MUGA scan\" cannot be directly contradicted by the CTR inclusion criteria, as those criteria specify that a normal LVEF (by MUGA scan or echocardiography) is a requirement for participation. However, it can be inferred from the CTR that only those patients who are amenable to having an echocardiography or MUGA scan are included in the trial, but it does not state that all participants have actually undergone these tests prior to entry. Thus, while the statement does not contradict the CTR in a strict sense, it goes beyond what the data in the CTR implies.</s>"
    },
    "b250a17c-9d4d-405d-ba64-40f7eda16707": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2 .",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial results indicate that the Recommended Phase II Dose for paclitaxel, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 90 mg/m2\" can be entailed by the information present in the CTRs because the CTR for the primary trial explicitly states that paclitaxel was administered at a dose of 90 mg/m2 (Results 1: Arm/Group Description: \"paclitaxel at 90 mg/m2 as 1-hour infusion on days 2, 9, and 16 of every 28-day cycle\"). The statement made by the expert is consistent with the data from the CTR and does not contradict it. Therefore, the statement can be considered entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTR. However, it only mentions the recommended Phase II dose for paclitaxel based on adverse events criteria, but the CTR also provides details about the dose administration schedule. Therefore, while the statement is not contradictory, it may not fully convey the complexity of the trial design involving paclitaxel dosing in combination with vorinostat and bevacizumab.</s>"
    },
    "698849c5-78fa-4c15-a1dc-f44eb9c970c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00082641",
        "Statement": "At least one patient in the primary trial suffered from impaired mobility.",
        "Label": "Entailment",
        "entail": "The statement \"At least one patient in the primary trial suffered from impaired mobility\" can be entailed by the information present in the CTRs through the following reasoning: The term \"impaired mobility\" can be considered a broader category that includes conditions such as hip fractures. In the Primary Trial Adverse Events section, one patient (1/11 or 9.09%) experienced a hip fracture, which is a form of impaired mobility. This observation aligns with the claim in the expert's statement, harmonizes with the clinical trial data, and finds substantiation in the CTR. The statement does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"At least one patient in the primary trial suffered from impaired mobility\" cannot be definitively contradicted or entailed by the information present in the provided CTRs, as the CTRs do not contain any explicit mention of impaired mobility among the adverse events or participant characteristics. However, the statement could be investigated further by examining other sections of the CTRs or additional trial data to potentially find entailment or contradiction. In the current context, neither entailment nor contradiction can be established based on the given information alone.</s>"
    },
    "4b4e6ac7-107c-46f4-adbb-c77c01f51935": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00075764",
        "Statement": "The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels.",
        "Label": "Entailment",
        "entail": "The statement, \"The most common adverse event in cohort 1 of the primary trial is low Hemoglobin levels,\" is entailed by the information in the CTRs if we define \"the most common adverse event\" as having the highest frequency in the given cohort. In the primary CTR, the frequency of low Hemoglobin levels (2 occurrences out of 337 participants) is greater than the frequency of any other adverse event in cohort 1, including all those mentioned in the statement. In the absence of any additional information that might contradict this conclusion, the statement holds true and can be inferred from the data provided in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTRs because the data does not support the claim that \"low Hemoglobin levels\" is the most common adverse event in cohort 1 of the primary trial. The data in the CTRs shows that the number of participants experiencing Hemoglobin-related adverse events is 2/337 for the primary trial and 1/348 for the secondary trial. Neither of these numbers is the most common adverse event for their respective cohorts based on the provided information. Instead, the most common adverse event for both cohorts, according to the data, is an overall adverse event rate of 6.23% (primary trial) and 13.79% (secondary trial).</s>"
    },
    "6b73dee4-0291-455e-90c2-786f0c2371d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00579826",
        "Statement": "Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years.",
        "Label": "Entailment",
        "entail": "The statement \"Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis, experiencing poorly controlled migraines or have any prior history of invasive breast cancer in the last 3 years\" is entailed by the information presented in the CTRs since:\n\n1. The CTR for the primary trial lists \"current history of rheumatoid arthritis\" as an exclusion criterion.\n2. The statement \"Participants of the primary trial cannot be currently receiving treatment for rheumatoid arthritis\" directly follows the CTR's exclusion criteria.\n3. The CTR for the primary trial lists \"prior history of invasive breast cancer within five years from the date of study entry\" as an exclusion criterion.\n4. The statement \"Participants of the primary trial cannot have any prior history of invasive breast cancer in the last 3 years\" implies a more restrictive criterion compared to the CTR, but it doesn't contradict it since 3 years is less than 5 years.\n5. The CTR for the primary trial does not provide information about migraines, but the statement \"Participants of the primary trial cannot be experiencing poorly controlled migraines\" is not a contradiction to the information present in the CTR.</s>",
        "contradict": "The statement can be contradicted by the CTRs as the primary trial's Inclusion Criteria state that participants have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells, and some women with these conditions might also have a history of rheumatoid arthritis or be experiencing poorly controlled migraines. Therefore, the statement is more restrictive than the actual inclusion criteria in the CTRs.</s>"
    },
    "2a1d9064-fde9-4645-95ab-7ddaea4ad322": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00324259",
        "Statement": "Cohort 2 of the primary trial 3 had more patients with Complete response than cohort 1.",
        "Label": "Contradiction",
        "entail": "To evaluate the statement \"Cohort 2 of the primary trial had more participants with Complete response than cohort 1,\" we need to compare the number of complete responses in each cohort from the CTRs provided. According to the data, in Cohort 1 (Arm 1), there were 0 complete responses, whereas in Cohort 2 (Arm 2), there was 1 complete response. Therefore, the statement is entailed by the CTR information as Cohort 2 indeed had one more complete response than Cohort 1.</s>",
        "contradict": "The statement that \"Cohort 2 of the primary trial had more patients with Complete response than cohort 1\" cannot be directly contradicted by the information present in the CTRs as the number of patients with complete response is not provided for both cohorts within the given CTRs. However, it can be determined from the information provided that cohort 1 (Arm 1, 6 mg Estradiol) had 0 complete responses and cohort 2 (Arm 2, 30 mg Estradiol) had 0 complete responses as well. Therefore, the statement cannot be confirmed or contradicted based on the provided information.</s>"
    },
    "847de3fe-b584-4d43-b82d-93263ce88830": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00509587",
        "Statement": " Patients in the primary trial receive 300 mg pazopanib once daily intravenously every day, continuing until disease progression or unacceptable toxicity.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs as the mode of administration (intravenous vs. oral), dosage, and frequency specified in the statement are different from those described in the CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert contradicts the information presented in the CTRs as the primary trial specifies that pazopanib hydrochloride is given orally once daily, not intravenously. The dosage, route of administration, and frequency are different between the statement and the provided CTR information.</s>"
    },
    "3c798991-6366-43e2-94ca-0523629930c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Secondary_id": "NCT01004744",
        "Statement": "Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibted for patients in the primary trial, but not for patients in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial excludes patients with prior anthracyclines as part of prior anticancer therapy (CTR for Primary Trial, Exclusion Criteria), while the secondary trial allows patients who have not received anthracyclines within 6 months of study entry (CTR for Secondary Trial, Exclusion Criteria). Consequently, the statement that anthracycline use within 6 months is prohibited in the primary trial but not in the secondary trial accurately reflects the differences in patient selection criteria between the two trials.</s>",
        "contradict": "The statement \"Prior use of Anthracycline drugs in the last 6 months for anticancer therapy is prohibited for patients in the primary trial, but not for patients in the secondary trial\" is contradicted by the information present in the CTRs as follows:\n\n1. In the primary trial, the exclusion criteria include \"prior anthracyclines as part of prior anticancer therapy,\" indicating that prior use of anthracycline drugs is a reason for exclusion in this trial.\n2. In contrast, in the secondary trial, there is no mention of such exclusion regarding prior use of anthracyclines. However, there is an exclusion criterion that states \"no prior chemotherapy within 6 months of study entry,\" which might lead to the misconception that anthracyclines are permitted, as they are a specific subset of chemotherapy.\n\nTherefore, the statement is contradicted by the information contained in the CTRs.</s>"
    },
    "64fe54a2-8897-4324-af88-f627c1c208ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01764022",
        "Statement": "Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia\" can be entailed by the information present in the CTRs since both trials share similar eligibility criteria and intervention procedures. Therefore, the participants in Cohort 2 are part of the same trial as those in the provided adverse events sections. Moreover, the CTR for the primary trial indicates the occurrence of thrombocytopenia, which is reported as having happened \"0.91%\" of times in Cohort 2 (Adverse Events 2). Thus, the expert's statement, which suggests multiple incidents, harmonizes with the trial data without contradiction.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial recorded multiple incidents of thrombocytopenia\" does not conform to the data presented in the given Adverse Events sections of both trials, as neither cohort reports a case of thrombocytopenia (defined as trombocytopenia with zero occurrences in the provided data). The data shows no instances of thrombocytopenia in either the primary trial's Adverse Events 1 or 2.</s>"
    },
    "4eac6a2d-64cd-4289-a545-211eb835f0e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 70% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The percentage difference in feasibility rates between cohorts 1 and 2 can be calculated by subtracting the percentage in Cohort 2 from that in Cohort 1: 70.4% - 60.0% = 10.4%. To establish semantic entailment, we need to ensure that the difference is within the 90% CI of each cohort. Here, the 90% CI for cohort 1 is (58.5-80.4)% and for cohort 2 is (41.7-76.4)%. Since 10.4% falls within this range, the statement can be entailed from the information in the CTRs. This difference may be due to the use of growth factor support in a discretionary manner in Cohort 1, while in Cohort 2, filgrastim use was mandatory.</s>",
        "contradict": "The percentage difference between the two cohorts cannot be directly determined from the given information, as the feasibility rates are presented as percentages with confidence intervals instead of raw numbers. Additionally, the methods for administering filgrastim and the definition of feasibility differ slightly between the cohorts. Therefore, it is impossible to accurately determine if the difference is 70% based on the provided CTR information.</s>"
    },
    "3ee1c60e-46ce-4f25-af52-31d5c6d8eba1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02435680",
        "Secondary_id": "NCT01743560",
        "Statement": "the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial and the primary trial use best Overall Response (OR) as their evaluation metrics, however they use significantly different time frames\" is entailed by the information in the CTRs, as follows:\n\n1. Both trials use Best Overall Response (OR) as their evaluation metric, as stated in the secondary trial's description.\n2. The primary trial reports the Median PFS for each arm at 4 years, which indicates the assessment of long term outcomes and response to treatment.\n3. The secondary trial measures the ORR at 48 weeks, which is a specific time point for assessing response to treatment.\n\nTherefore, the difference in time frames for measuring OR in both trials does not contradict the information present in the CTRs and is a reasonable variation in the trial designs.</s>",
        "contradict": "The information contained in the statement can be contradicted by the CTRs because the primary trial evaluates Progression Free Survival (PFS) over a time frame of 4 years, while the secondary trial assesses the Best Overall Response (OR) at 48 weeks. These two evaluation metrics do not directly compare as PFS is a time-to-event endpoint while OR is a categorical endpoint. The statement's focus on the similarity between the two trials in terms of OR as evaluation metric overlooks the substantial difference in their time frames.</s>"
    },
    "da1e1019-adb5-47bf-8093-e03352ca9e51": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01340300",
        "Secondary_id": "NCT00671918",
        "Statement": "Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's eligibility criteria state that participants should have \"less than 120 minutes of exercise per week.\" Half an hour of physical exercise is less than 120 minutes, which satisfies the primary trial's inclusion criteria regarding exercise limitations. The secondary trial does not specify any exercise limitations, allowing participants to engage in more than half an hour of exercise per day. Therefore, the statement \"Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial\" is entailed by the primary trial's eligibility criteria.\n\nThe secondary trial does not conflict with this statement as it does not set a requirement for exercise duration. Thus, the statement is consistent with the information in both primary and secondary CTRs.</s>",
        "contradict": "The statement \"Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial\" is contradictory to the CTR as the primary trial's inclusion criteria specify \"Less than 120 minutes of exercise per week\" as an eligibility requirement, which is more than half an hour of physical exercise per day. Consequently, the statement does not hold true for the information presented in the primary CTR. \n\nFor the secondary trial, however, no such requirement is stated regarding weekly exercise limitations. Therefore, the statement does not directly contradict the information in the secondary trial's CTR.</s>"
    },
    "e7fb6490-1ec7-48ff-95b1-715d79faec92": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01042938",
        "Statement": "Patients must be english to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR states that participants must be able to understand English and able to complete assessment forms (which are in English), thus implying that English proficiency is a requirement for participation in the trial. Consequently, the expert's statement \"Patients must be english to participate in the primary trial\" is an entailed statement given the information present in the CTR.</s>",
        "contradict": "The statement \"Patients must be English to participate in the primary trial\" is contradicted by the CTR inclusion criteria that state \"Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).\" However, this does not imply that only English-speaking patients are eligible for the trial. The ability to understand and complete assessment forms in English is a requirement for participation, not a limiting eligibility criterion based on language.</s>"
    },
    "d5ea3443-103f-4d29-9be3-522210b84152": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 2 of the same adverse events.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs if the two shared adverse events are among those listed in the primary trial's Adverse Events section (e.g., Fatigue with occurrences in both trials, or Diarrhea in primary and Mucositis oral in secondary).</s>",
        "contradict": "The statement \"the primary trial and the secondary trial only record 2 of the same adverse events\" is contradicted by the information present in the CTRs due to the following reasons:\n\n1. Different types of adverse events are recorded in each trial: While both trials report instances of fatigue, they document different types of adverse events in addition. In the primary trial, there is an occurrence of hemoglobin decrease, cardiac ischemia/infarction, and rigors/chills, none of which are mentioned in the secondary trial. Conversely, in the secondary trial, there are reports of breast infections, soft tissue infections, and lymphocyte and neutrophil count decreases, which do not appear in the primary trial.\n\n2. Different frequencies of identical adverse events: Though both trials report occurrences of fatigue, the number of instances differs significantly, with 2 occurrences out of 14 participants in the primary trial and 6 instances out of 162 participants in the secondary trial. Thus, the statement that only 2 identical adverse events occur in both trials is not supported by the provided CTR information.\n\nTherefore, the statement made by the expert is contradicted by the information present in the Clinical Trial Reports.</s>"
    },
    "d54cae08-3ac9-4460-bf6d-7338b45d8cd7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial\" is entailed by the information present in the CTRs as both inclusion criteria (age > 18) and exclusion criteria (life expectancy < 6 months) are explicitly mentioned in the Primary Trial's Inclusion and Exclusion Criteria sections. This statement does not contradict any other information provided in the CTRs and finds substantiation within them. Therefore, the statement is entailed by the Clinical Trial Reports.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the primary trial's inclusion criteria specify that patients must have a \"life expectancy of greater than 6 months,\" but the CTRs also list \"Life expectancy of less than 6 months\" as an exclusion criterion for the study. This discrepancy creates a contradiction between the statement and the clinical trial data.</s>"
    },
    "608c5521-c9a6-47de-9ebf-791ce317a02d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"All of the patients in cohort 1 of the primary trial experienced an adverse event\" is entailed by the information present in the CTR as follows: \n\n1. The number of patients in cohort 1 of the primary trial is 2. \n2. The CTR states that 100.00% (i.e., both patients) experienced an adverse event in the Primary Trial under the Adverse Events 1 section. \n\nTherefore, since every patient in the primary trial's cohort 1 had an adverse event, the statement \"All of the patients in cohort 1 of the primary trial experienced an adverse event\" is a valid and entailed conclusion from the CTR data.</s>",
        "contradict": "The information in the statement \"All of the patients in cohort 1 of the primary trial experienced an adverse event\" contradicts the information in the CTRs because only 100.00% of patients in cohort 1 of the primary trial experienced an adverse event, according to the provided information in the Adverse Events 1 section. However, the expert's statement implies that each individual patient experienced an adverse event, which goes beyond the reported data.</s>"
    },
    "14a8e9e9-0a46-4537-bc07-53c786bcbe97": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "Both trials include the condition that participants have Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Therefore, patients meeting this requirement can be eligible for participation in both trials as described in their inclusion criteria.</s>",
        "contradict": "The statement \"Patients with HER2 negative MBC are eligible for both the primary trial and the secondary trial\" is contradicted by the information present in the CTRs because the primary trial excludes patients with HER2 positive disease. Therefore, patients with HER2 negative MBC are not universally eligible for both trials.</s>"
    },
    "2d97bfa0-336f-4976-95e5-1262327a730b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Secondary_id": "NCT02502864",
        "Statement": "the primary trial recorded 2 more total adverse events than the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded 2 more total adverse events than the secondary trial\" can be entailed by the given CTRs as follows:\n\n1. Count the total number of adverse events in both trials:\n   Primary Trial: Total = 5\n   Secondary Trial: Total = 3\n\n2. Calculate the difference between the number of adverse events in the primary and secondary trials:\n   Difference = Primary Total - Secondary Total\n   Difference = 5 - 3 = 2.\n\n3. The statement \"the primary trial recorded 2 more total adverse events than the secondary trial\" is entailed by the provided CTRs because the difference in the total number of adverse events between the trials (2) is a logical consequence of the data presented in the reports.</s>",
        "contradict": "Despite the statement's apparent assertion that there is a discrepancy in the total number of adverse events between the primary and secondary trials, the CTRs provide contradictory information. The primary trial reported 5 adverse events in total, while the secondary trial reported 3. Therefore, the statement is incorrect, as it asserts a difference in the number of adverse events when none exists based on the provided CTR data.</s>"
    },
    "e68dddc8-ea04-49b2-ae91-ff7b4fcb1240": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00003199",
        "Statement": "The patient group with the highest percent of Event-free Survival in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs as follows:\n\n1. Event-free Survival percentage data is presented for both Stage IIIB and Stage IV patients in the Primary Trial Results section.\n2. The percentage values for both groups (i.e., 61.1% for IIIB and 28.1% for IV) are explicitly stated in the CTR.\n3. The statement by the clinical trials expert is a logical conclusion derived from the data in the CTR; it does not contradict or add any new information that goes beyond the scope of the provided data.\n4. The expert's statement is in harmony with the clinical trial findings as described in the CTR.</s>",
        "contradict": "Although the expert's statement suggests that Stage IIIB patients had the highest percentage of Event-free Survival, the CTR data shows a different percentage (61.1%) compared to Stage IV patients (28.1%), indicating the opposite. Consequently, the expert's statement contradicts the findings from the CTR.</s>"
    },
    "8c83330f-f2f3-48e1-9905-dc2ba1970c54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03765996",
        "Statement": "Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions.",
        "Label": "Entailment",
        "entail": "The statement that participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions, is entailed by the CTR information because:\n\n1. Both groups 1 and 2 receive Complex Decongestive Physiotherapy according to the CTR.\n2. The taping application to anastomosis regions is specified in the Intervention 2 section for group 2 in the CTR.\n\nTherefore, the statement's assertion is harmonious with the clinical trial data, substantiated within the CTR, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"Participants in group 2 of the primary trial receive the same Complex Decongestive Physiotherapy as those in group 1, with the addition of applying taping to anastomosis regions\" cannot be strictly contradicted by the information present in the CTRs. However, it may be considered misleading without further context. According to the CTRs provided, both groups receive the same Complex Decongestive Physiotherapy (CDP), but the application of taping in group 2 is not explicitly stated in the intervention description for group 1. Therefore, while it is technically correct that both groups receive the same CDP protocol, the statement does not fully capture the additional intervention of taping in group 2 as described in the CTR. Thus, the statement may create an inaccurate impression if taken at face value without further context or clarification.</s>"
    },
    "4613834d-c178-475c-b9fd-c9c66d5681eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.",
        "Label": "Entailment",
        "entail": "The primary trial's Intervention 2 involves administering 200 mg Q-122 daily, which is a dosage of 50 mg more than Intervention 1. Given that each capsule contains 50 mg Q-122, participants in Intervention 2 are indeed receiving a higher dose of Q-122 in terms of the total amount of Q-122 administered over the trial period.\n\nIn the secondary trial, both cohorts receive the same variant (AZD9496) and the same dosage of 100 mg daily. Although the names of the interventions differ between the trials, the actual amount and frequency of AZD9496 administered is the same.\n\nThus, the statement can be entailed by the CTR information, as the primary trial's Intervention 2 (100 mg Q-122) involves a higher total amount of Q-122 administered than both cohorts in the secondary trial (100 mg AZD9496).</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial receives higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants\" is not necessarily true based on the provided information in the CTRs. While it is true that Cohort 2 in the primary trial received a higher total dose of Q-122 (200 mg) compared to the total dose administered to each participant in the secondary trial (100 mg), it does not directly follow that Cohort 2 received a higher dose per day or per body weight than the participants in the secondary trial, especially since the active substance in the secondary trial, AZD9496, is not directly comparable to Q-122 in terms of dosing. The statement is contradictory only when the assumption that AZD9496 and Q-122 have equivalent therapeutic equivalence and dosing regimens is made, which is not supported by the provided CTR information.</s>"
    },
    "b4555685-6e25-4797-8616-bcab5b06a135": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00259090",
        "Statement": "the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score.",
        "Label": "Contradiction",
        "entail": "Although the expert statement mentions \"Fulvestrant, Docetaxel\" instead of \"Fulvestrant, Anastrozole\" in the primary trial, the information in the CTR about the antitumour effects of Fulvestrant alone or in combination can imply a comparison of these treatments. Since both trials measure the effect of Fulvestrant on the ER H-score using the same methodology, the expert statement's claim about the primary trial's focus on Fulvestrant's impact on the Oestrogen Receptor H-score can be entailed by the data in the CTRs.</s>",
        "contradict": "The statement \"the primary trial studies the impact of Fulvestrant, Docetaxel on Oestrogen Receptor H-score\" is contradicted by the information in the CTRs as there is no mention of Docetaxel being used in the primary trial. The trials only involve Fulvestrant, either alone or in combination with Anastrozole.</s>"
    },
    "c1b90c18-45f4-4e28-b50a-a00b0eadc523": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT02748213",
        "Statement": "Patients whose breast tumour is 0.1 cm across or less are eligible for the secondary trial, but not the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as follows:\n\nIn the primary CTR, there is no explicit mention of minimum tumor size for patient eligibility. Therefore, the statement about a specific tumor size being eligible for one trial but not the other does not contradict or directly follow from the information in the primary CTR. \n\nIn the secondary CTR, the minimum tumor size is not stated, but the disease characteristic mentions \"histologically confirmed, HER2-positive advanced and/or metastatic breast cancer not amenable to curative therapy\" and \"at least one measurable lesion according to RECIST\". These conditions imply that the patients have advanced or metastatic disease, which is likely to have larger tumors than those eligible for the primary trial that focuses on breast carcinoma with T1-3 stages. \n\nTherefore, the statement about patients with smaller tumors not being eligible for the primary trial but eligible for the secondary trial can be inferred from the difference in the disease characteristics between the two trials.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because the primary trial's eligibility criteria do not specify a lower limit for tumor size. In contrast, the secondary trial's inclusion criteria state that patients must have measurable lesions according to RECIST, which implies a larger tumor size than 0.1 cm. Thus, it cannot be inferred that patients with a tumor size of 0.1 cm or less are eligible for the primary trial based on the information provided in the CTRs.</s>"
    },
    "33ef3abf-97c0-4d15-909d-258fb47ac54a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Only patients with HER2 positive breast carcinoma are eligible for the primary trial\" is entailed by the information present in the CTRs because the primary trial's inclusion criteria explicitly states that the patients must have HER2 overexpressing breast cancer.</s>",
        "contradict": "The expert's statement is not a contradiction but rather a special case of the information presented in the CTRs. While it is true that only HER2 overexpressing breast cancer patients are eligible for the primary trial, the CTRs also specify clinical stage 2-3B as another inclusion criterion. Therefore, not all HER2 positive breast cancer patients would meet the eligibility criteria of the primary trial, as those with clinical stage 1 or 4 disease would be excluded.</s>"
    },
    "a381e340-18b1-4baa-91ce-0c420bcb411c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial results indicate that the PFS of participants is partially linked to age, cancer grade and ethnicity.",
        "Label": "Contradiction",
        "entail": "The given statement does not directly entail the information in the CTRs as the CTRs do not provide sufficient data to determine the Partial Filed Survival (PFS) of participants based on age, cancer grade, and ethnicity. However, the information from the CTRs can be used to infer potential factors influencing the occurrence of dose-limiting toxicities in the primary trial. These factors could include age, cancer grade, and ethnicity, but the trial results do not explicitly state this relationship. Therefore, while the statement does not directly entail the information in the CTRs, it does not contradict them either, and they can be considered contextually related.</s>",
        "contradict": "The statement by the clinical trial expert makes a claim about the primary trial results implying that there is data available concerning Progression-Free Survival (PFS) and its relationship to age, cancer grade, and ethnicity. However, none of the provided CTRs in the primary trial mention anything about PFS or its correlation to age, cancer grade, and ethnicity. Therefore, this statement contradicts the information in the CTRs, as there is no harmonization or substantiation of this claim within the provided data.</s>"
    },
    "15e6b2b9-ba8f-4ca5-99d7-a1bbf9497b4b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called Manual Lymphatic Drainage.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that the primary CTR is not reporting on a drug-based intervention but instead focuses on a medical device. This information is entailed by the INTERVENTION sections of the primary CTR, which explicitly state that INTERVENTION 1 involves the use of the Flexitouch Device, an intermittent pneumatic compression device, and INTERVENTION 2 involves self-administered manual lymphatic drainage therapy. Neither of these interventions involves the administration of a drug.</s>",
        "contradict": "The statement made by the clinical trial expert is contradictory to the information presented in the CTRs because the primary trial does indeed involve a medical device intervention (Flexitouch Device), not Manual Lymphatic Drainage as incorrectly stated by the expert. The secondary trial, in contrast, mentions Manual Lymphatic Drainage as an intervention. However, the statement's assertion that both trials are testing Manual Lymphatic Drainage contradicts the primary trial's actual intervention as reported in its CTR.</s>"
    },
    "8e246d8f-e063-4f2e-a382-5d201a946b87": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00436566",
        "Statement": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
        "Label": "Contradiction",
        "entail": "The statement that \"Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001\" can be entailed by the CTR information as follows:\n\n1. In the primary trial, there is an arm/group titled \"TL\" that administers trastuzumab and lapatinib without RAD001.\n2. The \"Results 1\" section states that no participant suffered from Congestive Heart Failure while on active treatment during the 12-month study period in the TL arm.\n3. The statement made by the clinical expert is about the TL arm, which matches the arm described in the CTR.\n4. The statement does not contradict any information in the CTR, as it aligns with the reported absence of Congestive Heart Failure in the TL arm. \n5. The statement does not go beyond what the CTR implies, as it only refers to the specific arm of the trial, not making any assumptions about the other arms or the overall study population.</s>",
        "contradict": "The statement contradicts the information in the primary CTR because the CTR does not provide data regarding the occurrence or non-occurrence of Congestive Heart Failure specifically during the administration of trastuzumab. The CTR only mentions the overall number of patients with CHF while on active treatment for 6 months, but it does not specify whether this condition occurred during trastuzumab administration or not. Therefore, it is impossible to conclude based on the provided CTR that no patient in the primary trial suffered from CHF during trastuzabhan and RAD001 treatment.</s>"
    },
    "8154bd8c-90a2-4b2f-8090-fcc89aeae30c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00097721",
        "Statement": "Patients of any ethnicity can participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients of any ethnicity can participate in the primary trial\" is entailed by the CTR inclusion criteria which do not specify any ethnicity restriction for patient eligibility.</s>",
        "contradict": "The statement \"Patients of any ethnicity can participate in the primary trial\" is contradicted by the CTR inclusion criteria which specify \"Female patients\" only. Therefore, the statement is not entailed by the information in the CTRs.</s>"
    },
    "537781f9-3693-479e-af22-824cdd827b9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02657889",
        "Statement": "the primary trial indicates that varying Pembrolizumab dosage has no effect on the Number of Subjects Reporting Dose-Limiting Toxicities (DLTs).",
        "Label": "Contradiction",
        "entail": "The primary trial defines DLTs as certain Grade 3 or 4 non-hematologic clinical or lab abnormalities that require medical intervention, hospitalization, or persist for a specified duration, and as any treatment-related AE leading to interruption or dose modification. The results sections report the same DLT definition and time frame for both Phase 1 arms, with identical eligibility criteria, intervention particulars, and participant counts for each arm. Since both arms receive Pembrolizumab with different Niraparib dosages, but identical Pembrolizumab dosing and identical trial conditions, the lack of a difference in the reported Number of Subjects experiencing DLTs between the two arms suggests that varying Pembrolizabus dosages has no effect on DLTs in this trial. This conclusion aligns with the data from the CTRs, making the statement entailed.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information in the CTRs, but it is not entailed by them either, as the trials presented do not test the effect of different Pembrolizumab dosages on DLTs within the same cohort of participants. In the primary trial, participants were split into two arms, one receiving a Niraparib dose of 200mg and Pembrolizumab 200mg, and the other receiving a Niraparib dose of 300mg and Pembrolizumab 200mg, so any comparison of DLTs between the arms is confounded by the difference in Niraparib dose. To assess the effect of Pembrolizumab dosage on DLTs directly, a separate clinical trial testing the same Pembrolizumab dosages in identical cohorts would be necessary.</s>"
    },
    "5feefe8b-ddca-4eb8-af68-d1e211963d1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland.",
        "Label": "Contradiction",
        "entail": "The statement \"2 patients, in cohort 1 of the primary trial, were recorded as having an overactive pituitary gland\" is not explicitly mentioned in the provided CTRs. However, the term \"Hyperthyroidism\" is listed under the Adverse Events section in the primary trial, which can be an outcome of an overactive pituitary gland. Since the statement mentions \"in cohort 1,\" it is assumed that it refers to the same trial. Thus, the occurrence of Hyperthyroidism in 1/112 participants (0.89%) can entail the existence of two patients (as stated in the expert's claim) with an overactive pituitary gland.</s>",
        "contradict": "The statement does not contradict the information in the CTRs directly, as the statement does not mention any adverse events related to the primary trial's cohort 1 patients or any specific condition like hyperthyroidism, which is present in the CTRs. However, if we consider the context, the statement implies that the presence of 2 patients with an overactive pituitary gland in cohort 1 of the primary trial might influence the occurrence of adverse events, such as hyperthyroidism, mentioned in the CTRs. Since the CTRs report only one instance of hyperthyroidism in the entire primary trial, the statement, as it stands, contradicts the relatively low occurrence of hyperthyroidism (0.89%) reported in the CTRs, if we assume that both patients with an overactive pituitary gland have hyperthyroidism. However, it is essential to consider that having an overactive pituitary gland is not synonymous with having hyperthyroidism, and the two conditions do not necessarily occur together. Thus, the statement's contradiction with the CTRs is based on an incorrect assumption rather than a direct contradiction, as stated.</s>"
    },
    "2a5d8ca7-1608-4607-b996-490fc447b593": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention tablet PO daily.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"All the primary trial subjects are required to take the intervention tablet PO daily\" cannot be entailed by the information present in the CTRs. \n\nThe CTRs specify that the interventions in the primary trial are not tablets but rather Nutrigrad\u2122 flaxseed bars with specific amounts of flaxseed and lignans. The expert's statement refers to \"intervention tablet,\" which contradicts the information provided in the CTRs.</s>",
        "contradict": "The statement is contradictory to the CTR information because the CTRs describe the interventions as \"Nutrigrad\u2122 flaxseed bars,\" not \"intervention tablets.\" The expert's statement assumes that the interventions are given in tablet form, while the CTRs specify the form as a bar.</s>"
    },
    "178c50cc-49ee-4083-bc8e-b5832037498a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "4 patients in the primary trial experienced a grade 3 or above adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"4 patients in the primary trial experienced a grade 3 or above adverse event\" can be entailed by the information in the CTR as follows. From the provided CTR data in the primary trial, a total of 16 adverse events were reported, and 7 out of these 16 events were of grade 3 or above (3/48 = 6.25% for febrrile neutropenia grade 3, 1/48 = 2.08% for neutropenia grade 3, 2/48 = 4.17% for hypersensitivity reaction grade 3, 1/48 = 2.08% for palmoplantar erythrodysesthesia grade 3 and stomatitis grade 3, 1/48 = 2.08% for neutropenia grade 4, fever grade 1, oral mucositis grade 3, and 1/48 = 2.08% for catheter-related infection grade 3). In total, there are 7 adverse events with a grade 3 or above severity. Since there were 48 patients in the trial, this means that 7 adverse events were experienced by 7 individual patients. Therefore, the statement \"4 patients in the primary trial experienced a grade 3 or above adverse event\" follows from the information presented in the CTR.</s>",
        "contradict": "The statement \"4 patients in the primary trial experienced a grade 3 or above adverse event.\" can be contradicted by the information presented in the primary trial's Adverse Events section if the number of patients with grade 3 or above adverse events is less than 4, as stated in the CTR. The CTR reports 6 patients with grade 3 or above adverse events out of 48 participants (12.5%), which is higher than 4 patients. However, it is essential to note that the statement does not necessarily contradict the information in the CTR, as long as there are at least 4 patients with grade 3 or above adverse events according to the CTR.</s>"
    },
    "92ace4fa-4426-4f34-af52-ee62913e60aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01026142",
        "Secondary_id": "NCT00846027",
        "Statement": "There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Count the number of patients with Left Ventricular Systolic Dysfunction in each trial:\n   - Primary Trial Adverse Events 1: 4/218 = 0.0183 * 218 = 4.0144 \u2248 4\n   - Secondary Trial Adverse Events 1: 1/82 = 0.0122 * 82 = 1\n\n2. Calculate the difference: 4 - 1 = 3.\n\n3. Find the percentage difference: (3 / (4 + 1)) * 100 = 0.1818 * 100 = 18.18%.\n\n4. Since the statement claims that there were \"10% more\" patients, the closest approximation would be to round up to the nearest 10% increment, which is 20%. However, since 20% is not an exact match with the calculated difference (18.18%), it is important to consider if there's any reasonable explanation for the discrepancy.\n\n5. The difference in the number of patients is less than 10%, so a plausible explanation for the expert's statement could be a slight error or rounding in their estimation, or an oversimplification of the data for ease of communication.\n\nTherefore, the statement can be considered to be entailed by the CTRs, with a small approximation or error in the percentage value.</s>",
        "contradict": "The statement \"There were 10% more patients with Left ventricular systolic dysfunction in cohort 1 of the primary trial than in the secondary trial\" cannot be directly contradicted by the information present in the CTRs because the CTRs do not provide the number of patients with Left ventricular systolic dysfunction for each cohort or arm in the primary and secondary trials. Therefore, it is impossible to determine if this statement is true or false based on the given CTR data alone.</s>"
    },
    "7dbde84d-f1c9-4197-9d44-500fd337bebd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events.",
        "Label": "Entailment",
        "entail": "The statement \"At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events\" is entailed by the information in the CTRs since the CTR for the Primary Trial indicates that there were 12 reconstructed breasts affected by breast related adverse events amongst the 25 participants who received the Meso BioMatrix Acellular Peritoneum Matrix. The statement's assertion harmonizes with the clinical trial data, as both mention 12 patients experiencing breast related adverse events, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The expert's statement \"At most 12 Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events\" is not contradicted but rather is in agreement with the data provided in the CTR, as 12 out of 25 participants (or 48%) in the Meso BioMatrix Acellular Peritoneum Matrix treatment arm experienced a breast related adverse event. However, the statement does not necessarily entail that no more than 12 patients suffered such events since the CTR does not provide information about the number of patients without adverse events.</s>"
    },
    "824da29f-b2ff-440e-8b78-7a8291cbd6d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02340221",
        "Statement": "A total of 89 patients in the primary trial had Supraventricular tachycardia.",
        "Label": "Contradiction",
        "entail": "The statement \"A total of 89 patients in the primary trial had Supraventricular tachycardia\" cannot be entailed by the provided CTR information.\n\nReasoning: \n\nThe CTRs do not report the total number of patients with Supraventricular tachycardia in the primary trial. The CTRs only provide the number of occurrences of Supraventricular tachycardia as an adverse event, which is zero in the primary trial. Therefore, the information in the expert's statement contradicts the CTR data. Hence, the statement cannot be entailed by the CTR information.</s>",
        "contradict": "The statement that \"A total of 89 patients in the primary trial had Supraventricular tachycardia\" contradicts the information present in the CTRs because there were no reports of Supraventricular tachycardia (0/213) in the primary trial's Adverse Events section.</s>"
    },
    "6cbac938-baf2-4f0b-b67b-9caeb7ea4fe1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02748213",
        "Statement": "1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland\" can be entailed by the information present in the CTRs if we consider the section on Adverse Events 1 of the primary trial. There is one instance of \"Hyperthyroidism\" reported with a frequency of 1/112 (0.89%). Since the statement mentions one patient in cohort 1, it is within the scope of the reported 112 patients. Thus, the statement harmonizes with the data and avoids contradiction, implying entailment.</s>",
        "contradict": "The statement that \"1 patient, in cohort 1 of the primary trial was recorded as having an overactive thyroid gland\" cannot be directly contradicted by the information present in the CTRs, as hyperthyroidism is listed in the adverse events section for cohort 1 of the primary trial. However, the statement does not specify the number of patients in cohort 1 who experienced hyperthyroidia, making it possible for the statement and CTR to differ in the number of affected individuals. Therefore, the contradiction lies in the quantitative aspect of the statement and not the qualitative one.</s>"
    },
    "052ee533-7daa-4cbf-a64c-bc9a50444173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not monitor the occurrence of Hemoglobin C Disease in its adverse events\" is entailed by the CTR data as there is no mention or reporting of Hemoglobin C Disease in the adverse events section of the primary trial.</s>",
        "contradict": "The statement is contradicted by the primary trial's adverse events section, where Hemoglobin (Hgb) is reported as an adverse event experienced by 1/19 (5.26%) of the participants. This observation implies that at least one participant in the trial has Hemoglobin-related condition, which is not explicitly stated as Hemoglobin C Disease but still pertains to a Hemoglobin abnormality.</s>"
    },
    "1d7dbb44-049d-4887-8bd6-6aefc77aa1e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Entailment",
        "entail": "The expert's statement \"A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea\" can be entailed by the information present in the CTRs as follows:\n\n1. We know from Primary Trial's Adverse Events section that the number of patients with Leukopenia is 2, Cardiopulmonary failure is 2, and Diarrhoea is 3.\n2. Therefore, in total, there are 7 patients in the Primary Trial with either Leukopenia, Cardiopulmonary failure, or Diarrhoea.\n3. This number is consistent with the expert's statement.\n4. No contradiction is present, as the statement is in line with the given CTR data.\n\nHence, the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement \"A total of 7 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea\" cannot be directly contradicted by the CTR data, as there are indeed instances of Leukopenia (2 patients), Cardiopulmonary failure (2 patients), and Diarrhoea (3 patients) reported in the primary trial's Adverse Events. However, it is important to note that the expert's statement does not specify how many patients had each individual adverse event. The CTR data indicates distinct numbers for each adverse event, so the expert's statement can appear to contradict these specific numbers if taken out of context. However, the statement does not directly contradict the CTR data in terms of the occurrence of these adverse events, only the specific numbers provided in the CTR.</s>"
    },
    "9b622b9b-3ad3-4cff-acb3-4127d0304de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00571987",
        "Statement": "occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial.",
        "Label": "Entailment",
        "entail": "There is no explicit mention of ionizing irradiation as an exclusion criterion in the primary trial's inclusion/exclusion criteria section. Therefore, the statement about occupational exposure to ionizing irradiation not disqualifying a patient from the primary trial is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"occupational exposure to ionizing irradiation will not disqualify a patient from entry to the primary trial\" is contradicted by the CTR inclusion criteria which explicitly state \"Previous radiation to the breast\" as an exclusion criterion. While the statement is discussing occupational exposure, it falls under the broader category of \"previous radiation to the breast\" which is listed as an exclusion criteria in the CTR.</s>"
    },
    "825ba6fd-8c08-49d2-941b-3338ef01e7fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02673918",
        "Secondary_id": "NCT01042938",
        "Statement": "African American patients are eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "Both trials do not have any explicit exclusion criteria based on race or ethnicity. Therefore, the statement \"African American patients are eligible for both the primary trial and the secondary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"African American patients are eligible for both the primary trial and the secondary trial\" is contradicted by the information in the CTRs due to the presence of exclusion criteria for African Americans in each trial. The primary trial excludes patients with \"severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol,\" which could potentially apply to some African American patients depending on the prevalence of such conditions in this population. The secondary trial excludes patients with breast cancer of inflammatory type, which disproportionately affects African American women. Consequently, the statement is not entailed by the information in the CTRs.</s>"
    },
    "0421750d-66c6-47be-bde7-0c41ee43a28b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01730729",
        "Statement": "Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with severe malabsorption disorders are ineligible for the primary trial, even if they are able to receive intravenous (IV) alimentation\" can be entailed by the CTR inclusion criteria as follows: \n\nThe CTR explicitly lists \"Malabsorption syndrome\" as an exclusion criterion for the primary trial. This condition implies an inability to absorb nutrients effectively through the gastrointestinal tract. The expert's statement goes beyond this criterion by specifically mentioning \"severe malabsorption disorders,\" yet it still falls within the scope of the CTR's exclusion. The addition of \"even if they are able to receive intravenous (IV) alimentation\" does not contradict the information in the CTR, as the CTR does not mention any exception for this scenario in its exclusion criteria.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the CTR for the primary trial explicitly lists malabsorption syndrome as an exclusion criterion, but it does not specify that IV alimentation is a requirement for ineligibility. Therefore, patients with severe malabsorption disorders who are able to receive IV alimentation could still potentially be eligible for the primary trial according to the provided CTR information.</s>"
    },
    "95345dbe-446f-4999-8f3e-a429b77ea554": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that the primary trial requires specific renal, hepatic, and blood work criteria for inclusion, which includes hemoglobin at 11.5 g/dL and certain liver function tests (ALT, AST, alkaline phosphatase, total bilirubin) and serum creatinine being below specified upper limit thresholds. This information is explicitly stated in the primary CTR's inclusion criteria. The statement does not contradict any information in the CTRs and is harmonious as it emphasizes the requirements for renal, hepatic, and blood work for the primary trial. The secondary trial's inclusion process does not explicitly state these same requirements, but that does not contradict the primary trial's criteria as each trial may have varying inclusion criteria.</s>",
        "contradict": "The statement that \"Adequate renal, hepatic and blood work is required for entry to the primary trial, this includes the following criteria; hemoglobin 11.5 g/dL, as well as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN. These conditions are not explicitly required for the secondary trial\" can be contradicted by the CTRs in the following ways:\n\n1. The primary CTR explicitly mentions these laboratory values and their requirements for inclusion in the study. However, the secondary CTR does not explicitly state that these values are not required.\n\n2. The statement that these conditions \"are not explicitly required for the secondary trial\" contradicts the information in the primary CTR.\n\n3. The CTR for the primary trial specifies that these laboratory values are necessary for inclusion, while the statement suggests that they are not necessary for the secondary trial.\n\n4. The discrepancy between the information in the CTR and the statement creates a contradiction.</s>"
    },
    "b05fde86-4004-427f-8baf-2ea4a0a535c7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00376597",
        "Statement": "the primary trial all undergo surgery twice, first at 2 weeks and then again a month later.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial all undergo surgery twice, first at 2 weeks and then again a month later\" is not entailed by the information present in the CTRs. The CTRs provide details of the intervention received by patients in Arm I and Arm II of the primary trial. However, the statement suggests that all patients in the primary trial undergo surgery twice, which contradicts the information in the CTRs. The CTRs do not report any surgery occurring at 2 weeks or a month later for patients in either arm. Therefore, the statement is not entailed by the given CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as there is no mention of patients undergoing surgery twice within six weeks in either Arm I or Arm II of the primary trial, or in the secondary trial. The statement implies that all patients in the primary trial undergo multiple surgeries within a short timeframe, whereas the provided details specify post-operative care and follow-up assessments occurring at specific time points after the initial surgery.</s>"
    },
    "21e24c6c-d282-48fb-8d68-3e723458794e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with any of the following conditions will be excluded from the primary trial; grade 3 infection, unstable angina or a grade 4 hemorrhage within the last month\" is entailed by the information in the CTR's Exclusion Criteria section, specifically under the cardiac and bleeding events categories. In the primary trial's CTR, patients with uncontrolled hypertension, thrombolic or embolic events, and pulmonary hemorrhage or bleeding events of grade 2 or higher within certain periods prior to study treatment are excluded. These conditions include unstable angina, which is a type of ischemia that can lead to myocardial infarction, and hemorrhage events, which can be grade 3 or higher. Additionally, patients with serious non-healing wounds, ulcers, or bone fractures are excluded, which can be considered a type of infection or hemorrhage event, depending on the severity. The statement, therefore, is a more specific version of the exclusion criteria mentioned in the CTR.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because:\n\n1. Regarding grade 3 infection: According to the primary trial's inclusion criteria, there are no specific exclusions related to grade 3 infection. However, it is mentioned that patients must recover to < grade 1 toxicity due to prior therapy before joining the study. This might imply that severe (grade 3) infections are not immediately disqualifying but should have resolved before study entry.\n\n2. Regarding unstable angina: The primary trial's inclusion criteria list unstable angina (anginal symptoms at rest or new onset angina) as an exclusion criterion. However, there is no specific mention of angina being limited to grade 3 or 4. It's possible that grade 1 and 2 angina are also excluded, depending on the trial's specific definitions and considerations.\n\n3. Regarding a grade 4 hemorrhage: The primary trial's inclusion criteria list a pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment as an exclusion criterion. There is no mention of a grade 4 hemorrhage as an exclusion criterion. However, the statement could potentially be interpreted to include both grade 3 and 4 hemorrhages, as it uses the term \"grade 3 or 4 hemorrhage.\" This is not explicitly stated in the primary trial's eligibility criteria.\n\nTherefore, the expert statement may not fully entail the information in the primary trial's CTRs due to potential differences in interpretation or specificity of criteria.</s>"
    },
    "d1e579e2-b057-43da-8a2f-64dad964b789": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00821964",
        "Statement": "the primary trial participants apply topical imiquimod to cutaneous lesions once daily every other day for a total of 14 days every 28 day cycle.",
        "Label": "Contradiction",
        "entail": "In the primary trial's intervention section, it is stated that participantsapply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25, repeating the cycle every 28 days. This translates to applying imiquimod once per day for approximately 12 out of the 28 days within a cycle. In the expert statement, participants apply topical imiquimod once daily every other day for a total of 14 days every 28-day cycle, which is equivalent to applying imiquimod once per day for slightly more than half of the days in the primary trial's cycle. The expert statement is entailed by the primary CTR because it implies the application frequency is once daily but not necessarily daily throughout the entire cycle. The primary CTR does not contradict the expert statement.</s>",
        "contradict": "The information in the statement that primary trial participants apply topical imiquimod once daily every other day for a total of 14 days every 28 day cycle is contradictory to the CTR information as the CTR specifies that primary trial participants apply topical imiquimod QD on days 1-4, 8-11, 15-18, and 22-25 of each 28-day cycle.</s>"
    },
    "5ac83a45-db7d-44d1-bf37-9cbf3c8fabb6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093145",
        "Secondary_id": "NCT00703326",
        "Statement": "Heart-related adverse events were recorded in the secondary trial, but not  the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because the statement \"Heart-related adverse events were recorded in the secondary trial, but not in the primary trial\" is consistent with the data provided. In the primary CTR, no heart-related adverse events such as atrial fibrillation, atrial flutter, cardiac failure congestive, or left ventricular dysfunction were reported. In contrast, the secondary CTR reports occurrences of atrial fibrillation and cardiac failure congestive. The primary CTR does include adverse events related to the heart, albeit different conditions than those mentioned in the statement. However, the statement focuses specifically on heart-related conditions, which aligns with the data in the secondary CTR but not in the primary CTR, making the statement entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the term \"heart-related adverse events\" is not explicitly defined. The primary trial's Adverse Events section includes \"supraventricular tachycardia\" and \"confusional state,\" which could be considered heart-related, while the secondary trial's Adverse Events section includes \"atrial fibrillation\" and \"atrial flutter,\" also heart-related. However, neither trial mentions heart failure, which is a more obvious heart-related adverse event. Additionally, the primary trial does not report any heart-related adverse events, while the secondary trial reports fewer instances of heart-related events (2/752) compared to non-heart-related events (361/752). Therefore, the statement's broad and vague definition of \"heart-related adverse events\" can lead to contradictions with the specific adverse events listed in the CTRs.</s>"
    },
    "d130c981-f602-4f17-b1cb-11a7ad632b92": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial more than 6 different types of cardiac related adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial reported more than 6 different types of cardiac related adverse events\" is entailed by the information in the CTR as follows: In the primary trial, there are a total of 12 distinct cardiac related adverse events reported (Anemia, Pancytopenia, Acute myocardial infarction, Atrial fibrillation, Cardiac failure, Cardiogenic shock, Palpitations, Pericardial effusion, Right ventricular failure, Abdominal pain,ASCites, and Pericardial effusion), which is more than the stated 6. Hence, the CTR data substantiates the expert statement and no contradiction exists.</s>",
        "contradict": "The statement can be contradicted by the CTR information because the primary trial report only lists eight cardiac-related adverse events (cardiac failure, cardiogenic shock, palpitations, pericardial effusion, right ventricular failure, atrial fibrillation, acute myocardial infarction, and anemia), while the statement asserts that there were more than six cardiac related adverse events. The statement is not entailed by the information in the given CTRs.</s>"
    },
    "c1f9982f-c4c9-48dc-887a-7ae05f508c21": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles",
        "Label": "Entailment",
        "entail": "The expert statement is entailed by the CTR as it accurately reflects the dosage and treatment cycle length for intervention 1 in the primary trial. The statement does not contradict any information in the CTR and provides a precise description of the intervention.</s>",
        "contradict": "The statement \"the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 2 cycles\" can be contradicted by the information present in the CTRs because, although all participants did receive niraparib 200 mg PO once daily for a 28-day cycle for the first two cycles, they did not necessarily stop there. Some participants went on to receive additional cycles, while others underwent surgery or neoadjuvant chemotherapy. Therefore, the statement oversimplifies the intervention details and does not account for the variation in treatment duration beyond the initial two cycles.</s>"
    },
    "e966302f-9378-4681-b2c6-9d8b5b5f709f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Statement": "The majority of patients in the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"The majority of patients in the primary trial experienced an adverse event\" can be entailed by the information present in the CTRs as 75.00% of the patients in the primary trial (32 out of 44) experienced at least one adverse event (Total: 24/32 or 75.00%), as reported in the Adverse Events section of the Primary Trial.</s>",
        "contradict": "The statement \"The majority of patients in the primary trial experienced an adverse event\" does not directly contradict the information in the CTRs, as stated. However, the statement is less precise than the CTR, which specifies the exact number of patients who experienced an adverse event (24 out of 32 or 75.00%). The statement could be contradicted if the context shifts to a different trial or if new information emerges indicating that a different majority was intended (e.g., a majority of patients did not experience an adverse event). The CTRs and the statement share the commonality that a significant number of patients experienced adverse events, but the CTRs provide more detailed and accurate information.</s>"
    },
    "75130da8-77be-45d1-bc32-dfc97c1a1dae": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial has a much longer duration than the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's total treatment duration is 16 weeks for both arms, whereas the secondary trial's treatment schedules differ in their delivery (9 fractions BID x 4 1/2 treatment days for Cohort 1 and 10 fractions BID over 5 treatment days for Cohort 2). Although the primary trial treatment duration is the same for both arms, the duration of individual treatment sessions and the overall treatment course in the secondary trial are longer due to the fractionation schedule. Therefore, the statement \"the secondary trial has a much longer duration than the primary trial\" is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial has a much longer duration than the primary trial\" is contradicted by the information in the CTRs as both trials have identical treatment durations of 16 weeks.</s>"
    },
    "c71cbcd6-3786-4b90-8991-b3c6e159ae77": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00975676",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib.",
        "Label": "Contradiction",
        "entail": "The primary trial and the secondary trial involve different interventions. In the primary trial, triptorelin is used in combination with tamoxifen or exemestane. The dosage and duration of triptorelin administration are identical in both combinations (5 years). In the secondary trial, triptorelin is used in combination with LBH589 and either capecitabine or lapatinib. Although the dosage and duration of triptorelin in the secondary trial are not explicitly stated, it is mentioned that the triptorelin regimen will follow the same schedule as in the primary trial (twice weekly). \n\nThe statement \"the primary trial uses the same dosage of Triptorelin as the secondary trial uses for Capecitabine and Lapatinib\" can be entailed because:\n\n1. The dosage and duration of triptorelin are identical in the primary trial for both combinations of interventions (triptorelin + tamoxifen and triptorelin + exemestane).\n2. In the secondary trial, the triptorelin regimen follows the same schedule as in the primary trial (twice weekly), but no explicit dosage is mentioned.\n3. The statement focuses on the comparison of the dosage of triptorelin between the two trials, and it is true that the same dosage and schedule are used, regardless of the different partner medications in each trial. Therefore, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the triptorelin dosage is not the same in both trials: In the primary trial, triptorelin is used in combination with tamoxifen or exemestane, while in the secondary trial, triptorelin is used in combination with capecitabine or lapatinib, but their dosages and administration schedules are different from those of the primary trial. Therefore, the statement's assumption that they are using the same dosage of triptorelin in both trials does not hold true.</s>"
    },
    "ed48936e-4933-437b-a7ba-e65b4c1fd276": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03167359",
        "Secondary_id": "NCT01385137",
        "Statement": "Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in  the secondary trial. but not the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR information as follows: \n\n1. Hypofractionated Simultaneous Integrated Boost Radiotherapy is not mentioned in the Primary Trial's Intervention section.\n2. However, it is explicitly stated in the Primary Trial's Intervention section that radiotherapy treatments are given for breast cancer patients with clear margins, but the details of the radiotherapy technique are not specified.\n3. In contrast, the Secondary Trial has a separate Intervention for radiotherapy, which explicitly mentions Hypofractionated Simultaneous Integrated Boost Radiotherapy. \n4. The statement correctly identifies the presence of Hypofractionated Simultaneous Integrated Boost Radiotherapy in the Secondary Trial and its absence in the Primary Trial.</s>",
        "contradict": "The statement \"Hypofractionated Simultaneous Integrated Boost Radiotherapy is used in the secondary trial. but not the primary trial\" is contradicted by the CTRs as follows:\n\n1. In the primary trial, Hypofractionated Simultaneous Integrated Boost Radiotherapy is used for the Intervention 1 in the treatment of breast cancer, but it is not explicitly mentioned that it is not used in the secondary trial.\n2. In the secondary trial, no such treatment as Hypofractionated Simultaneous Integrated Boost Radiotherapy is mentioned in either Intervention 1 or Intervention 2.\n\nTherefore, based on the information provided in the CTRs, the statement cannot be considered true without additional context or evidence.</s>"
    },
    "b01e966e-6624-4740-b477-a8bbbd8eec50": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock.",
        "Label": "Entailment",
        "entail": "The statement's assertion \"In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock\" is entailed by the information present in the CTRs because the CTR for the primary trial reports zero occurrences of Skin lymphangitis, Bone marrow suppression, and Allergic shock, while the CTR for the secondary trial reports at least one occurrence for each of these adverse events.</s>",
        "contradict": "The statement \"In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression or Allergic shock\" is contradicted by the information present in the CTRs as follows:\n\n1. Skin lymphangitis: The primary trial reported 1 case out of 132 participants (0.76%), while the secondary trial reported 2 cases in total, one out of 50 participants (2.00%) for Adverse Events 1, and none in Adverse Events 2. The statement incorrectly claims that the primary trial did not record any cases of Skin lymphangitis.\n\n2. Bone marrow suppression: The primary trial reported 1 case out of 132 participants (0.76%), while the secondary trial reported 0 cases in any of its Adverse Events sections. The statement incorrectly infers that the primary trial did not encounter any cases of Bone marrow suppression when the CTR indicates otherwise.\n\n3. Allergic shock: The primary trial reported 1 case out of 132 participants (0.76%). The secondary trial reported 1 case out of 50 participants (2.00%) in Adverse Events 1, and none in Advers Events 2. The statement incorrectly claims that the primary trial did not record any cases of Allergic shock.\n\nTherefore, the statement \"In contrast to the secondary trial, the primary trial did not record any cases of Skin lymphangitis, Bone marrow suppression, or Allergic shock\" contradicts the information provided in the CTRs.</s>"
    },
    "92acd36d-ea44-4b98-acbc-e51382233089": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Statement": "Diarrhea was the most common adverse event in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Diarrhea was the most common adverse event in cohort 1 of the primary trial.\" can be entailed by the information presented in the CTRs as follows:\n\n1. The CTR for the primary trial provides the number and percentage of patients who experienced each adverse event (in this case, Diarrhea occurred in 7 out of 30 patients, accounting for 23.33% of the cohort).\n2. The statement identifies Diarrhea as the most common adverse event, meaning it occurred more frequently than any other adverse event.\n3. Comparing the frequency of Diarrhea with other adverse events as stated in the primary CTR, it is indeed the most common adverse event.\n\nThus, the statement is a logical implication or consequence of the information provided in the CTRs.</s>",
        "contradict": "Although the statement \"Diarrhea was the most common adverse event in cohort 1 of the primary trial\" is not directly contradicted by the data presented in the CTRs, it is not entailed either. The CTR for the primary trial indicates that diarrhea was the third most common adverse event, preceded by decreased platelet count and decreased neutrophil count. Therefore, the statement made by the domain expert is not an entailed consequence of the data provided.</s>"
    },
    "01280892-ca31-4e46-831b-a076426f65e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01401062",
        "Statement": "A patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"a patient who underwent T-cell transfer therapy in the past 6 months prior, and has fully recovered from the associated toxicities, would be excluded from the primary trial\" entails the exclusion criteria in the CTR, specifically \"Investigational agents within 4 weeks prior to study enrollment (6 weeks if treatment was long-acting agent such as monoclonal antibody\". The statement further implies that the patient has fully recovered from the toxicities, which aligns with the requirement of being recovered from all prior treatments (including investigational agents) with the exception of alopecia, to meet the inclusion criteria. Therefore, the information contained in the statement is entailed by the information present in the CTR.</s>",
        "contradict": "The statement contradicts the CTR inclusion criteria as it excludes patients who underwent T-cell transfer therapy within 6 months, while the CTR allows participants who have recovered from immunotherapy or targeted therapies within the specified recovery periods, which may include T-cell transfer therapy.</s>"
    },
    "959bd67a-1b2a-48da-ae44-211cbab4b665": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00393939",
        "Statement": "Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group.",
        "Label": "Entailment",
        "entail": "The statement entails that there is a difference in median PFS of over a month between the two groups. This difference can be inferred from the data presented in the CTRs. According to the information in the primary trial, the median (95% Confidence Interval) PFS for the Docetaxel + Sunitinib group is 8.6 (8.2-10.3), and for the Docetaxel group, it is 6.9 (6.5-7.3). The difference between these two median values is over a month (1.7 months). Thus, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement's assertion that \"Median (95% Confidence Interval) Progression-Free Survival (PFS) was over a month higher for patients in the Docetaxel + Sunitinib group of the primary trial than for the Docetaxel group\" contradicts the CTR data. The median PFS for the Docetaxel + Sunitinib group was 8.6 (8.2-10.3) months and for the Docetaxel group was 6.9 (6.5-7.3) months. A one month difference does not exist between the two groups according to the provided data.</s>"
    },
    "92923765-76d4-4a27-a240-101690d9fea4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered cyclophosphamide more often and in higher dosages than Methotrexate and 6-Mercaptopurine.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because in the primary trial, 6MP is administered orally at a dose of 75mg/m2 body surface area once a day, and Methotrexate is administered orally at a dose of 20mg/m2 once a week. These doses have been reduced to 55mg/m2 of 6MP and 15mg/m2 of Methotrexate following an Urgent Safety Measure. In contrast, the secondary trial does not provide details about the dosages or frequencies of cyclophosphamide administration. However, the statement asserts that patients in the primary trial are administered cyclophosphamide \"more often\" and in \"higher dosages\" than Methotrexate and 6-M Mercaptopurine. Based on the original dosages before the reduction in the primary trial, this is true as both 6MP and Methotrexate have lower dosages and less frequent administration than cyclophosphamide (which is not specified in the secondary trial but is implied to have more frequent and higher dosages). Although the reduced dosages in the primary trial no longer hold this comparison true, the original dosages and frequencies as stated before the safety measure do entail the expert's statement.</s>",
        "contradict": "The information in the statement is contradictory to the CTRs because in the primary trial, patients are administered 6-Mercaptopurine and Methotrexate (which are not cyclophosphamide) and the dosage frequency and dosages for 6-Mercaptopurine and Methotrexate as stated in the CTRs are less frequent and lower compared to the stated frequency and dosages for cyclophosphamide in the expert's statement.</s>"
    },
    "437cb2c2-63e8-4d9b-a501-4b6a35db8d2b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429507",
        "Secondary_id": "NCT00038467",
        "Statement": "Unlike the secondary trial, the primary trial does not administer any medication orally or intravenously.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial does not administer any medication orally or intravenously\" is entailed by the information present in the CTRs, as neither of the interventions specified in the primary trial involves oral or intravenous administration of medications. In the primary trial, the intervention involves the use of Samarium 153-EDTMP, which is given intravenously on Day 1 and, if required, a higher therapy dose is given to the bones 7-14 days later. However, Samarium 153-EDTMP is not classified as a medication, but rather as a tracer. The other component of the intervention is a Stem Cell Transplant given about 14-21 days after the Samarium 153-EDTMP administration. Stem Cell Transplant is not given as a medication orally or intravenously, but involves the infusion of stem cells into the patient's body through a catheter. In contrast, in the secondary trial, the interventions consist of exemestane and tamoxifen, which are given orally as described in the statement, whereas neither intervention in the primary trial follows that administration route. Therefore, the statement that \"the primary trial does not administer any medication orally or intravenously\" is consistent with, and can be inferred from, the information present in the CTRs.</s>",
        "contradict": "The expert statement is contradicted by the information in the CTRs because the primary trial involves the administration of Samarium 153-EDTMP intravenously and stem cell transplant, which is not mentioned as oral or intravenous medication by the expert statement. However, the secondary trial only involves the administration of oral medications (exemestane and tamoxifen), which matches the description in the expert statement.</s>"
    },
    "5a5695e8-9b84-42ad-9f34-6dd043153943": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02872103",
        "Secondary_id": "NCT02995980",
        "Statement": "Adequate renal, hepatic and blood work is required for entry to the primary trial and the secondary trial, this includes the following criteria; hemoglobin  11.5 g/dL, aswell as ALT, AST, alkaline phosphatase and total bilirubin < 2.5xULN, and Serum creatinine should be less than 1.7x ULN.",
        "Label": "Contradiction",
        "entail": "The statement's assertion is harmonious with the information in both CTRs as it mirrors the inclusion criteria regarding renal, hepatic function, and hemoglobin levels for both trials. This entails that these conditions must be met for trial entry, ensuring alignment between the statement and data from the CTRs.</s>",
        "contradict": "The statement does not contradict the information in the CTRs, as both trials do require adequate renal, hepatic, and blood work with hemoglobin, ALT, AST, alkaline phosphatase, total bilirubin, and Serum creatinine meeting the stated thresholds. However, the primary trial has additional inclusion criteria regarding informed consent, age, breast cancer diagnosis, and chemotherapy regimen that are not mentioned in the statement. Additionally, the primary trial has more extensive exclusion criteria, including conditions related to medical history, contraception, and other treatments. The secondary trial has different inclusion criteria regarding age and breast density, as well as exclusion criteria related to breast history and iodinated contrast allergy. Therefore, the statement is not contradictory to the CTRs, but it also does not provide a complete picture of the inclusion and exclusion criteria for both trials.</s>"
    },
    "33634c51-0fb9-4de1-966d-14784bca93f8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01847001",
        "Statement": "Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial\" is entailed by the CTR information as follows:\n\nInclusion Criteria for the Primary Trial:\n- Spanish speaking women\n- Heart Rate > 60 bpm\n\nThe statement specifically mentions Spanish women with a heart rate of at least 60 beats per minute and is therefore a direct consequence of the inclusion criteria mentioned in the CTR.</s>",
        "contradict": "The statement \"Spanish women with a heart rate of at least 60 beats per minute are eligible for the primary trial\" can be contradicted by the information presented in the CTRs as the eligibility criteria also include several other conditions such as systolic blood pressure > 100 mm/Hg, ejection fraction > 50%, eligibility for neoadjuvant chemotherapy, HER2 status, invasive breast cancer, and agreement to research blood collection, among others. Thus, the statement only mentions one eligibility criterion and does not reflect the comprehensive eligibility criteria outlined in the CTRs.</s>"
    },
    "8e46dc77-fa36-4231-a124-0ff6392891a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02297412",
        "Secondary_id": "NCT02667626",
        "Statement": "Cohort 2 of the secondary trial and the primary trial are control groups.",
        "Label": "Entailment",
        "entail": "In the secondary trial, Intervention 2 is labeled as the \"Control,\" which implies a comparison group in the context of a clinical trial. Similarly, in the primary trial, both Arm I and Arm II are identified as control groups due to the administration of placebos. Therefore, Cohort 2 of the secondary trial and Arm II of the primary trial can be considered equivalent control groups in their respective trials. The statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"Cohort 2 of the secondary trial and the primary trial are control groups\" can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, both intervention groups (Arm I and Arm II) receive a treatment: minocycline hydrochloride for Arm I and a placebo for Arm II. Neither group can be considered a true control group in this trial design as both groups receive some form of intervention.\n\n2. In the secondary trial, the intervention for Cohort 2 (the waitlist control arm) is not identical to the intervention in Cohort 1 (SCPR Intervention). Although they both have access to web-based resources, Cohort 1 receives the SCPR intervention earlier and more extensively. Therefore, it's not accurate to call them both control groups based on the information given.</s>"
    },
    "d11b0673-42a9-46c0-887f-d5a9b038264f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00407888",
        "Statement": "Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity.",
        "Label": "Entailment",
        "entail": "The statement \"Arm 1 of the primary trial receive dose-intensive chemotherapy on a week long cycle up to 12 times in the absence of disease progression or unacceptable toxicity\" can be entailed by the CTR information as follows: \n\n1. Dose-intensive chemotherapy is specified as the intervention for Arm I in the primary trial (as described in the CTR).\n2. The chemotherapy regimen consists of a 7-day cycle (doxorubicin hydrochloride, oral cyclophosphamide, and filgrastim), which is repeated every week up to 12 times (as stated in the CTR). \n3. The continuation of the chemotherapy cycle is contingent on the absence of disease progression or unacceptable toxicity as per the CTR. \n\nThus, the statement is an accurate reflection of the CTR information.</s>",
        "contradict": "The statement does not specify the exact treatments constituting the dose-intensive chemotherapy received by Arm 1 in the primary trial. The CTR, however, provides a detailed account of the treatments given during each week of the chemotherapy cycle, which includes doxorubicin hydrochloride IV, oral cyclophosphamide, and filgrastim SC. Thus, while the statement is generally correct in mentioning a week-long cycle of dose-intensive chemotherapy, it fails to accurately represent the specific treatments given during each cycle as described in the CTR. Consequently, the statement is contradictory to the CTR in this respect.</s>"
    },
    "e08c196a-e3f0-420b-a252-7e2818949038": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"All women (regardless of Reproductive status) must use adequate methods of contraception to be eligible for the primary trial\" is entailed by the CTR's eligibility criteria for both male and female subjects. The CTR explicitly states that female subjects must agree to use an adequate method of contraception throughout the study (Sections 5.7.2 for those of childbearing potential and 5.7.1 for those not of childbearing potential). While the CTR does not use the term \"adequate methods\" for male subjects, it does state that they must agree to use an adequate method of contraception as outlined in Section 5.7.1. Therefore, the statement is a logical deduction from the CTR's eligibility criteria for both genders.</s>",
        "contradict": "The statement is contradicted by the CTR as it includes a distinction between women of childbearing potential and those who are not, regarding the contraceptive requirements. The CTR specifies that only female subjects of childbearing potential are required to use adequate methods of contraception, while those who are not are not explicitly mentioned to have this requirement. Therefore, the expert's statement is not in line with the CTR's inclusion criteria.</s>"
    },
    "83511f04-e07c-438d-bf1e-f680fa49b384": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01901146",
        "Secondary_id": "NCT00209092",
        "Statement": "Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial\" can be entailed by the information present in the CTRs because, in Adverse Events 1 of the primary trial, the number of cases for Febrile Neutropenia is 3/364 (0.82%), and for Cohort 1, there are 364 participants. Thus, the actual number of cases in Cohort 1 is 3. In Adverse Events 1 of the secondary trial, the number of cases for Febrile Neutropenia is 0/361 (0.00%) for the entire trial, and there are 25 participants in Cohort 1. Therefore, the statement holds true as there are more cases (3) of Febrile Neutropenia in the primary trial's Cohort 1 than in the secondary trial's Cohort 1 (0 cases).</s>",
        "contradict": "The statement that \"Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial\" cannot be directly derived from the provided information in the CTRs. While the primary trial reported 3 cases of Febrile neutropenia in Cohort 1, the secondary trial reported 0 cases of Febrile neutropenia in Cohort 1. Neutropenic fever is a specific type of febrile neutropenia, where neutropenia (a condition characterized by a low absolute neutrophil count) is also present. However, the primary trial does not explicitly report the neutropenia status of the patients experiencing febrile neutropenia. Therefore, it is impossible to definitively conclude that Cohort 1 of the primary trial recorded more instances of Neutropenic fever than Cohort 1 of the secondary trial based on the available information.</s>"
    },
    "c06a6571-6bc9-4bc1-b4f5-3e7aa71c8c94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one genitourinary adverse events recorded in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was one genitourinary adverse event recorded in the primary trial\" is entailed by the CTR data as there is a reported event of \"Obstruction, GU: Uterus\" in the primary trial under the Adverse Events section, which falls under the category of genitourinary adverse events.</s>",
        "contradict": "The statement \"There was one genitourinary adverse event recorded in the primary trial\" is contradicted by the CTR as no genitourinary adverse event was reported under the category \"Obstruction, GU: Uterus\" for the primary trial (it was reported for one participant out of 62). The statement oversimplifies the information in the CTR by ignoring the specification of the type of genitourinary event.</s>"
    },
    "72bb3c6e-66b0-4380-9da2-5a5867d715fd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Entailment",
        "entail": "The statement \"compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2\" can be entailed by the information in the CTRs based on the following reasoning: \n\n1. The CTRs provide the number of occurrences for each adverse event in cohorts 1 and 2 of both trials. \n2. The number of occurrences for each adverse event is higher in cohort 2 than in cohort 1 for every adverse event specified in the statement. \n3. The statement's assertion harmonizes with clinical trial data and is substantiated by the CTRs. \n4. The statement doesn't contradict any information in the provided CTRs. \n\nTherefore, the statement can be considered entailed by the information presented in the Clinical Trial Reports.</s>",
        "contradict": "The statement cannot be directly entailed by the provided CTR information because the CTRs do not indicate that cohort 2 of the secondary trial has more cases of each adverse event than cohort 1 of the primary trial. The CTRs merely report the total number of occurrences for each cohort without providing a comparison between them. Thus, the statement's assertion goes beyond the provided data and contradicts the CTRs if assumed to be factual without additional information.</s>"
    },
    "1b433096-f36a-4205-b16e-f9a370be3d05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "More than 18 participants in the primary trial had radiation dermatitis.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 18 participants in the primary trial had radiation dermatitis\" is entailed by the information in the CTRs since the CTR for the primary trial indicates that \"Radiation dermatitis 2 [1]4/18 (22.22%)\". Given that a proportion of 22.22% corresponds to more than 18 participants with radiation dermatitis in the trial with 18 subjects, the statement is entailed by the CTR data.</s>",
        "contradict": "The statement \"More than 18 participants in the primary trial had radiation dermatitis\" contradicts the information in CTR Adverse Events 1, as it asserts that more than half of the trial participants (19 or more) experienced radiation dermatitis, while the reported data indicates that only 4 participants had this condition.</s>"
    },
    "076ead15-ce03-4c33-9050-1f6eb13764a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section.",
        "Label": "Entailment",
        "entail": "The statement \"The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial provides almost no details in the intervention section\" implies that the intervention in the secondary trial does not involve an injection and only one imaging modality. However, the CTRs provide information that the intervention in the primary trial consists of an injection (Perflutren) followed by two distinct imaging modalities: Harmonic imaging (HI) and subharmonic imaging (SHI). \n\nAlthough the secondary trial does not specify the details of its intervention like the primary trial does, the lack of such details does not necessarily mean that it does not involve an injection or two different imaging modalities. The secondary trial's intervention might include other procedures or methods that may not require explicit mention in the CTR. \n\nHowever, the statement can be entailed by the CTRs if we assume that the intervention in the secondary trial is different from the one in the primary trial. In that context, the statement is accurate, as the primary trial's intervention indeed involves an injection and two different imaging modalities, whereas the secondary trial's intervention is not detailed in the provided CTR.</s>",
        "contradict": "The statement \"The secondary trial provides almost no details in the intervention section\" contradicts the CTR information as the primary trial also only mentions the intervention as \"3D HI and SHI of UCA,\" without explicitly stating the specific agent used for the injection and the exact procedure for the imaging modalities. Both CTRs are similar in their level of detail regarding the intervention section.</s>"
    },
    "0d76e3b7-c6ed-48b2-a3c2-4857a9c02f76": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00323479",
        "Secondary_id": "NCT03078751",
        "Statement": "There were more cases of Pulmonary embolisms in the primary trial than the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were more cases of Pulmonary embolisms in the primary trial than the secondary trial\" can be entailed by the information present in the CTRs because the primary trial had one reported case of Pulmonary embolism (1/110, or 0.91%), while the secondary trial had zero reported cases (0/26 or 0.00%, and also 0/24 or 0.00%). Hence, the primary trial had at least one more case than the secondary trial.</s>",
        "contradict": "Despite the statement suggesting that there are more cases of pulmonary embolisms in the primary trial compared to the secondary trial, the information from the Adverse Events sections of both CTRs contradicts this. According to the provided data, there is only one reported case of pulmonary embolism in the primary trial (1/110) and none in the secondary trial (0/26 for each Adverse Events section). Consequently, the statement does not hold true, and it cannot be entailed from the information presented in the CTRs.</s>"
    },
    "3e1037fd-cc1e-4229-892f-95d0987d9a68": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg.",
        "Label": "Entailment",
        "entail": "The statement that \"The Maximum Tolerated Dose (MTD) of of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg\" can be entailed by the information present in the primary CTR as follows:\n\n1. In the primary CTR, the MTD of indoximod for the 3+3 design was 800 mg PO QD, the fifth dose level listed in the description.\n2. According to the CTR, the MTD is the highest dose level below the maximally administered dose (MAD) that is safely tolerated among 6 treated patients. Since the statement mentions that this was the MTD observed in the trial, it follows that no more than 1 out of the 6 patients experienced a DLT at this dose level.\n3. The statement does not contradict the information in the primary CTR regarding the time frame of the study or the method of assessing toxicity.\n\nHence, the statement is entailed by the information present in the CTR.</s>",
        "contradict": "The statement that \"The Maximum Tolerated Dose (MTD) of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg\" cannot be directly contradicted by the CTRs provided, as both the primary and the secondary trials list 800 mg as a dosage level that was administered and evaluated. However, the primary trial specifies that 0 or 1 out of 6 patients experienced dose-limiting toxicity (DLT) at this dosage level, indicating that it might not be the MTD. The secondary trial does not provide such information. Thus, while the statements do not contradict each other, they do not fully align in providing the full MTD determination, with the primary trial providing more detailed information.</s>"
    },
    "f25adbc7-c0a0-44ed-af93-02f4bced7208": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial receives the same dose of Pilocarpine as cohort 2 of the secondary trial receives of oral itraconazole.",
        "Label": "Contradiction",
        "entail": "The statement entails that that the dose of Pilocarpine received by cohort 2 in the primary trial is equivalent to the dose of itraconazole received by cohorts in the secondary trial. \n\nFrom the primary CTR: The dose of Pilocarpine given to cohort 2 is 5mg twice a day for 6 weeks.\n\nFrom the secondary CTR: The dose of itraconazole given is 200mg a day. \n\nTo calculate the daily dose for cohort 2 in the secondary trial, we need to determine their total daily dose: \n\nTotal daily dose = dose per capsule \u00d7 number of capsules taken per day \n\nFrom the primary CTR, we know that cohort 2 takes 5mg of Pilocarpine twice a day. \n\nSo, total daily dose for cohort 2 in the primary trial = 5mg \u00d72 = 10mg per day.\n\nFrom the secondary CTR, we know that patients receive oral itraconazole 200mg a day.\n\nTo check if the dose of Pilocarpine in the primary trial entails the dose of itraconazole in the secondary trial, we can compare the total daily doses:\n\n10mg (for Pilocarpine in the primary trial) < 200mg (for itraconazole in the secondary trial)\n\nSince the Pilocarpine dose in the primary trial is less than the itraconazole dose in the secondary trial, the statement cannot be entailed directly from the CTR information. \n\nHowever, since the expert specified that it's cohort 2 that receives the same dose in both trials, we need to check cohort 2 in the CTRs:\n\nFrom the primary CTR: Cohort 2 receives Pilocarpine 5mg twice a day.\n\nFrom the secondary CTR: Cohort 2 receives oral itraconazole 200mg a day.\n\nCalculate the weekly dose for each trial:\n\nWeekly dose Pilocarpine = 5mg\u00d72 (twice a day)\u00d76 (weeks) = 60mg/week\n\nWeekly dose itraconazole = 200mg/day\u00d77(days) = 1400mg/week\n\nNow, we need to find the equivalent weekly dose for Pilocarpine:\n\nEquivalent weekly dose Pilocarpine = weekly dose Pilocarpine / number of days in a week\n\n= 60mg/week / 7 = 8.57mg/day\n\nSince the expert stated that cohort 2 receives the same dose of Pilocarpine as the dose of Itraconazole, the equivalent weekly dose of Pilocarpine (8.57mg) must equal the weekly dose of Itraconazole (1400mg):\n\n8.57mg/week = 1400mg/week\n\nSolve for Pilocarpine:\n\n8.57mg/week \u00d7 (1400mg/1mg) = 117.8mg/week\n\nNow let's calculate the daily Pilocarpine dose needed to reach this weekly dose:\n\nDaily Pilocarpine dose = weekly Pilocarpine dose / number of days in a week\n\n= 117.8mg/week / 7 = 16.8mg/day\n\nSo, the daily dose of Pilocarpine that cohort 2 receives in the primary trial that would be equivalent to the dose of itraconazole in the secondary trial is 16.8mg/day.\n\nNow let's check if the statement is entailed:\n\nStatement: \"Cohort 2 of the primary trial receives the same dose of Pilocarpine as cohort 2 of the secondary trial receives of oral itraconazole.\"\n\nExplanation: \"The weekly equivalent dose of Pilocarpine (8.57mg) for cohort 2 in the primary trial is equal to the weekly dose of itraconazole (1400mg) for cohort 2 in the secondary trial.\"\n\nFrom the primary CTR, cohort 2 receives Pilocarpine 5mg twice a day for 6 weeks.\n\nFrom the secondary CTR, cohort 2 receives itracon",
        "contradict": "The statement \"Cohort 2 of the primary trial receives the same dose of Pilocarpine as cohort 2 of the secondary trial receives of oral itraconazole\" is contradictory to the information presented in the CTRs. \n\nIn the primary trial, cohort 2 received 2 doses of Pilocarpine per day, with each dose containing 5mg. So, the total dose of Pilocarpine received by the patients in cohort 2 was 10mg per day (5mg x 2 doses). \n\nIn the secondary trial, patients received oral itraconazole at a dose of 200mg per day. These doses are not equivalent. Therefore, cohort 2 of the primary trial did not receive the same dose of Pilocarpine as cohort 2 of the secondary trial received of oral itraconazole.</s>"
    },
    "99951bae-37c8-4299-8ec1-4577a97d0b81": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded cases of pleural effusion and Spinal compression fracture, neither of these were observed in the secondary trial\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, under the Adverse Events section, there is a mention of \"PLEURAL EFFUSION 1/50 (2.00%)\" and \"SPINAL COMPRESSION FRACTURE 1/50 (2.00%)\", implying that these adverse events occurred in the primary trial.\n2. In the secondary trial, under the Adverse Events section, there is no mention of \"Pleural effusion\" or \"Spinal compression fracture\", indicating that these adverse events were not observed in the secondary trial. \n\nHence, the statement is entailed by the CTRs as it accurately reflects the data presented in those reports.</s>",
        "contradict": "The statement does not account for the differences in adverse events between the two trials in terms of patient populations and treatments. The absence of pleural effusion and spinal compression fracture in the secondary trial does not necessarily contradict the findings of the primary trial, as the trials involve different cohorts of patients and might have employed distinct interventions. Therefore, the statement's claim cannot be definitively established or refuted based on the provided information alone.</s>"
    },
    "b66b62c4-902d-4e19-929e-2086b349bd93": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00149214",
        "Statement": "Prior use of Anthracycline drugs for anticancer therapy is prohibted for patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that patients in the primary trial are excluded if they have previously received anthracyclines as part of their anticancer therapy. This is in accordance with the CTR's inclusion criteria, which specifies \"Prior anthracyclines as part of prior anticancer therapy\" as an exclusion criterion.</s>",
        "contradict": "The statement \"Prior use of Anthracycline drugs for anticancer therapy is prohibited for patients in the primary trial\" is contradicted by the information present in the CTRs since the CTRs explicitly state \"Exclusion Criteria: Prior anthracyclines as part of prior anticancer therapy.\" However, the statement is not contradictory to the information if it is interpreted as stating that Anthracycline drugs cannot be used as an intervention in the primary trial, rather than being a patient eligibility criterion.</s>"
    },
    "c789e79c-a254-4bb1-9d15-73d1726da8a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial. Patients simply need to be diagnosed with interstitial pneumonia or pulmonary fibrosis to be eligible.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information presented in the CTRs as it contradicts the exclusion criteria for both trials. While there is no age limit specified in the secondary trial, there are several conditions (interstitial pneumonia or pulmonary fibrosis, within specific time frames after chemotherapy/radiotherapy/hormonal therapy or surgery, brain metastases with symptoms, severe complications, technical inability to receive radiation, pregnancy, and failure to meet inclusion criteria) that make a patient ineligible. Similarly, the inclusion criteria for the primary trial list specific conditions for patient inclusion (histologically and/or cytologically confirmed breast cancer, received adjuvant/neo-adjuvant chemotherapy, measurable region, ECOG Performance Status 0-1, adequate organ function) and exclusion (interstitial pneumonia or pulmonary fibrosis within specific time frames after treatment, brain metastases with symptoms, severe complication, within 28 days after surgery, and failure to meet inclusion criteria). Therefore, having interstitial pneumonia or pulmonary fibrosia makes a patient ineligible for both trials, making the statement false according to the information provided in the CTRs.</s>",
        "contradict": "The statement \"There is no age limit for either the secondary trial or the primary trial. Patients simply need to have interstitial pneumonia or pulmonary fibrosis to be eligible\" is contradictory to the information present in the CTRs as follows:\n\nFor the Primary Trial, the Exclusion Criteria state that \"To have interstitial pneumonia or pulmonary fibrosis\" is a reason to exclude a patient. \n\nFor the Secondary Trial, although there is no mention of age limit or interstitial pneumonia or pulmonary fibrosis as an inclusion criterion, they are explicitly mentioned as exclusion criteria under \"Exclusion Criteria: Contraindications to radiation.\" \n\nTherefore, according to the information present in the CTRs, having interstitial pneumonia or pulmonary fibrosis is a reason to exclude a patient from both the Primary and Secondary Trials, and the statement that these conditions make one eligible for the trials contradicts the information provided in the CTRs.</s>"
    },
    "2b182323-9357-486a-87aa-09ddc6230bf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There is only 1 adverse event in the primary trial that occurred more than once.",
        "Label": "Entailment",
        "entail": "The statement \"There is only 1 adverse event in the primary trial that occurred more than once\" is entailed by the CTR information as follows: The CTR for the primary trial lists out 13 unique adverse events occurring more than once (Sepsis occurring twice). However, the statement only requires identification of one adverse event with multiple occurrences. Therefore, the statement is a valid deduction from the data presented in the CTR, as the existence of only one such adverse event is confirmed by the information provided.</s>",
        "contradict": "The statement that \"there is only 1 adverse event in the primary trial that occurred more than once\" cannot be directly contradicted by the information presented in the CTRs as given. However, it can be challenged based on the data provided since the statement assumes that the adverse events from both trials are directly comparable. \n\nThe CTRs only provide data for the occurrence of adverse events in each trial. They do not indicate if any particular adverse event occurred in both trials or not. Hence, based on the given information, it is not possible to definitively say that there is only one adverse event that occurred more than once across both trials or that such an event was unique to the primary trial alone. Further information or context is required to assess the entailment relationship between the statement and the CTR data.</s>"
    },
    "9681ec15-7545-455e-ac8c-1052fc199b11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02162667",
        "Statement": "The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group.",
        "Label": "Entailment",
        "entail": "The Herceptin group had a higher percentage of patients achieving pathological complete response (50.39% vs 46.77%) as stated in Results 1 and Results 2 of the CTR. Both groups underwent the same neoadjuvant treatment regimen consisting of docetaxel, FEC, and either CT-P6 or Herceptin. This statement is entailed by the data presented in the CTRs, as it directly compares the percentage of responders in each arm and does not contradict any information provided.</s>",
        "contradict": "The statement \"The Herceptin group in the primary trial had a higher number of Patients Achieving Pathological Complete Response than the CT-P6 group\" contradicts the information in the CTRs if the actual percentages of patients achieving pathological complete response in each arm (CT-P6: 46.77%, Herceptin: 50.39%) do not significantly differ. The CTRs do not provide sufficient information to determine if the difference in response rates is statistically significant, and therefore the statement could be a false claim based on the given data.</s>"
    },
    "8ca512c3-72d8-4179-a63e-51d83d76445f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00256243",
        "Secondary_id": "NCT00721630",
        "Statement": "the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center.",
        "Label": "Contradiction",
        "entail": "The Memorial Sloan Kettering Cancer Center (MSKCC) is a specific institution mentioned in both CTRs, and therefore, it's a common factor for both trials. The statement that \"the secondary trial and the primary trial are both taking place at the Memorial Sloan Kettering Cancer Center\" can be directly inferred from the provided information in the CTRs without any further assumptions.</s>",
        "contradict": "The statement does not provide sufficient information to determine semantic entailment or contradiction with the CTRs. While both trials take place at the Memorial Sloan Kettering Cancer Center, the eligibility criteria for each trial vary significantly. The primary trial specifically focuses on patients with locally advanced or inflammatory breast carcinoma, while the secondary trial includes patients with invasive adenocarcinoma of the breast, metastatic disease, HER2 overexpression/amplification, and progressive disease following treatment with trastuzumab. These differences in patient selection and inclusion/exclusion criteria could potentially lead to contradictory results or conclusions.</s>"
    },
    "171d0a20-8943-4994-a48a-7dff124e62ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial receives 60 mg of Ginkgo Biloba twice daily.",
        "Label": "Entailment",
        "entail": "The statement \"cohort 1 of the primary trial receives 60 mg of Ginkgo Biloba twice daily\" can be entailed by the information present in the CTR as follows: In the primary trial's Intervention 1 section, it is stated that \"Ginkgo Biloba: Patients will take 120 mg per day (60 mg BID)\". This implies that each patient in cohort 1 will receive 60 mg twice daily as part of their treatment with Ginkgo Biloba. The statement made by the expert aligns with this detail from the CTR.</s>",
        "contradict": "The statement \"cohort 1 of the primary trial receives 60 mg of Ginkgo Biloba twice daily\" contradicts the information present in the CTRs because the CTR for the primary trial indicates that patients in intervention 1 will take 120 mg of Ginkgo Biloba per day, not 60 mg twice daily.</s>"
    },
    "25cc9a6e-656d-44ee-a301-93f5879407a0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01923168",
        "Statement": "Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days.",
        "Label": "Contradiction",
        "entail": "The statement \"Intervention 1 of the primary trial require participants to take a total of 150 mg alpelisib every two days\" is entailed by the information in the CTR since the CTR states that participants took 300 mg of alpelisib once daily. Therefore, in two days, they would have taken a total of 300 mg x 2 = 600 mg, which is double the stated amount in the expert's claim, or 150 mg every two days.</s>",
        "contradict": "The statement made by the expert that Intervention 1 of the primary trial requires participants to take a total of 150 mg alpelisib every two days contradicts the information presented in the CTR. According to the CTR, participants in Intervention 1 took alpelisib 300 mg once daily, not 150 mg every two days. This discrepancy between the expert's statement and the CTR information undermines the entailment between them.</s>"
    },
    "d9b4d4aa-0094-405e-83a3-cf2978cfda38": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00347919",
        "Statement": "56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12.",
        "Label": "Entailment",
        "entail": "The statement \"56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at Week 12\" can be entailed by the data in the CTRs as follows:\n\nThe CTRs state that the percentage of participants with PD (progressive disease) in Cohort 1, treated with Lapatinib 1500 mg, was 38.9% when evaluated independently and 43.1% when evaluated by the investigator. Since the complement of PD is no PD, and the percentage of participants without PD is given by subtracting the percentage with PD from 100%, we can calculate that the percentage of participants without PD was 100% - 38.9% = 61.1%, independently evaluated and 100% - 43.1% = 56.9%, investigator evaluated.\n\nThus, the expert's statement \"56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive disease at Week 12\" is an entailed conclusion based on the information in the CTRs.</s>",
        "contradict": "The expert's statement \"56.9% of the primary trial subjects treated with Lapatinib 1500 mg had no progressive Disease at Week 12\" contradicts the information present in the CTR as follows:\n\n1. The CTR reports the percentage of participants with PD at Week 12 for Cohort 1 (Lapatinib 1500 mg) as 38.9% (Independently Evaluated) and 43.1% (Investigator Evaluated). \n2. The expert's statement implies that 56.9% did not have PD.\n3. However, the percentage of participants with no PD is the opposite of those with PD (i.e., 100% - PD%).\n4. According to the CTR, 38.9% (Independently Evaluated) and 43.1% (Investigator Evaluated) have PD at Week 12.\n5. Hence, it is impossible for 56.9% of the participants to have had no PD at Week 12 based on the provided data in the CTR.</s>"
    },
    "caa55802-329d-4a1f-a9a7-b99afc44fd67": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00038467",
        "Statement": "The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.",
        "Label": "Contradiction",
        "entail": "The statement \"The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane\" is entailed by the information present in the CTRs as follows:\n\n- Both trials specify that participants have previously received Tamoxifen for 2 to 3 years and are disease-free.\n- In the first intervention of the primary trial, patients receive Exemestane, which is a different medication than Tamoxifen given in the second intervention.\n- Both interventions in the primary trial involve the same dosages: for Tamoxifen, it is 20 mg or 30 mg tablet-in-capsule orally once daily, and for Exemestane, it is 25 mg tablet-in-capsule orally once daily.\n- Therefore, the statement that \"The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane\" is an accurate description of the information provided in the CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert can be contradicted by the information in the CTRs because, although the patient groups in the primary trial receive the same doses, they receive different medications (Tamoxifen vs. Exemestane) throughout the 5-year period.</s>"
    },
    "6df9ec3b-43ba-442a-a4f5-4ce3cdb7a2a0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02525718",
        "Secondary_id": "NCT02606708",
        "Statement": "Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo.",
        "Label": "Contradiction",
        "entail": "The primary trial's placebo group description specifies that subjects receive an intraoperative injection of saline with a concentration of 2.5 mg/ml. There are no mentions of oral placebos in the primary trial.\n\nThe secondary trial's statement asserts that patients in group 1 receive the same dosage of oral placebo as in the primary trial. Since there is no oral placebo mentioned in the primary trial, this statement does not entail a relationship with the primary CTR.\n\nTherefore, this statement is not entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Patients in group 1 of the secondary trial and the primary trial receive the same dosage of oral placebo\" is not supported by the given information in the CTRs. The primary trial involves the administration of intravenous placebo (saline) during surgery, whereas the secondary trial does not mention anything about oral placebo or the administration of placebo in any form. Thus, there is no evidence to suggest that patients in the two trials receive the same dosage of oral placebo.</s>"
    },
    "0880bb0b-9e8d-4fce-8795-2ec6526d9bfb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients. Whereas all the primary trial participants receive the same treatment.",
        "Label": "Entailment",
        "entail": "The statement \"In the secondary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients. While all the primary trial participants receive the same treatment\" can be entailed by the information present in the CTRs as follows:\n\n1. The secondary trial involves patients with Her-2 neu positive breast cancer who receive maintenance therapy in addition to systemic chemotherapy (trastuzumab), while the primary trial only specifies the intervention for all participants as vorinostat.\n   Entailment: \"Additional maintenance therapy\" for Her-2 neu positive patients > \"All primary trial participants receive the same treatment\" (which is vorinostat, not maintenance therapy).\n\n2. The statement does not contradict the information provided in the CTRs, as it only makes a comparative statement between two separate trials.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information provided in the CTRs, but it does contain an imprecision that could result in contradictory interpretations in certain contexts. The statement asserts that \"Her-2 neu positive breast cancer patients receive additional maintenance therapy\" in the secondary trial, which is true. However, it fails to mention that the primary trial does not have a maintenance therapy component. Thus, a reader might mistakenly assume that the primary trial involves the same intervention as the secondary trial but with a difference in maintenance therapy, leading to a contradictory interpretation. To avoid confusion, it's essential to clarify that the primary trial does not involve any maintenance therapy.</s>"
    },
    "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same drugs in different doses .",
        "Label": "Contradiction",
        "entail": "The statement \"Both cohorts of the primary trial are administered the same drugs in different doses\" can be entailed by the information present in the CTRs because:\n\n1. According to the information in the primary trial's INTERVENTION section, both cohorts are given AZD9496.\n2. The first cohort receives a variant A dose of 100 mg, and the second cohort receives a reference dose of 100 mg. Since both doses involve the same drug (AZD9496) given to different cohorts, the statement holds true.\n\nTherefore, the information in the statement is a logical consequence of the data presented in the CTR, and no contradiction exists.</s>",
        "contradict": "The statement \"Both cohorts of the primary trial are administered the same drugs in different doses\" can be contradicted by the information present in the CTRs because the statement assumes that both treatment periods in the primary trial use the same drug, whereas the CTRs explicitly state that participants in the first treatment period received AZD9496 - Variant A (100 mg) and those in the second treatment period received AZD9496 - Reference (100 mg). Although both groups received the same dose, the statement's ambiguity regarding which specific drug (Variant A or Reference) is administered in each period can lead to confusion or contradiction.</s>"
    },
    "01f89936-1621-4dd5-93b7-8b0c64b397fd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial\" is entailed by the information in the CTRs because the CTRs explicitly exclude patients with symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia (conditions which could potentially be indicative of severe anginal syndrome), regardless of their angiographic findings. Therefore, a patient presenting with severe anginal syndrome and normal coronary arteries would still not meet the inclusion criteria of the primary trial.</s>",
        "contradict": "The statement \"A patient with severe anginal syndrome but angiographically normal coronary arteries would be unable to participate in the primary trial\" is inconsistent with the CTR as the CTR does not include \"severe anginal syndrome\" as an exclusion criteria. Therefore, a patient with such condition could potentially participate in the trial as per the eligibility criteria specified in the CTR.</s>"
    },
    "ee7fe82e-de91-45c7-bd12-bff5d6c887a3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00320411",
        "Statement": "the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily\" is entailed by the information present in the CTRs because the CTR for the primary trial specifies that Lapatinib Monotherapy for participants consists of six 250mg tablets taken orally once daily.</s>",
        "contradict": "The statement that \"the primary trial participants must take 6 tablets of Lapatinib Monotherapy (250mg) PO once daily\" contradicts the information in the CTR as the CTR specifies that each participant should take \"six 250 mg tablets\" once daily, implying that they take a total of six tablets but not individual tablets, as stated in the expert's comment.</s>"
    },
    "888a8d39-3ad6-401e-acf2-cf5e01a73bf2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266110",
        "Secondary_id": "NCT00879086",
        "Statement": "the primary trial had a much higher rate of adverse events than the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial had a much higher rate of adverse events than the secondary trial\" is entailed by the information in the CTRs as the primary trial had an adverse event rate of 11.76% (total: 2/17) compared to the secondary trial's adverse event rate of 34.00% (total: 17/50).</s>",
        "contradict": "Despite the statement that the primary trial had a \"much higher\" rate of adverse events than the secondary trial based on the stated percentage of 37.25% for the secondary trial being apparently lower than 11.76% for the primary trial; however, the raw number of adverse events in the secondary trial (19/51 or 37.25%) is actually greater than the number of adverse events in the primary trial (2/17 or 11.76%). This discrepancy exists due to the difference in total participant counts between the two trials. The percentage alone, without considering the total number of participants, can be misleading and contradicts the actual number of adverse events reported in the CTRs.</s>"
    },
    "13466cbb-9f78-46ff-a983-09e2e9ad5a2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial presented a fever, in addition to either a cough or a sore throat\" can be entailed by the data in the CTRs as follows: One of the adverse events reported in the primary trial under the category \"Pyrexia\" has a count of 3 (2.73%). This indicates that three patients (including the one mentioned in the statement) had a fever. Additionally, the category \"Influenza like illness\" under the same trial has one count (0.91%), and this condition includes symptoms of fever, cough, and sore throat. Therefore, it is possible for one of the patients with a fever to also have had a cough or a sore throat. The information in the statement is not contrary to the CTR data.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the provided CTR data. However, it does not entail the CTR information exactly, as the statement mentions a \"fever, in addition to either a cough or a sore throat,\" while the CTRs list \"Pyrexia\" separately as an adverse event without specifying the presence or absence of cough or sore throat. The CTR information is more specific and detailed, but the statement is still within the scope of the CTR data, as it mentions a fever, which is listed in the CTR. However, for a stronger entailment relationship, the statement should explicitly reference the CTR data, such as \"One patient in the primary trial, as reported in the Adverse Events section, had a fever (Pyrexia) and either a cough or a sore throat.\"</s>"
    },
    "0beaef44-a39a-462c-a084-d3f824857673": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00374322",
        "Statement": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as it correctly infers the DFS rates comparison between the Lapatinib 1500 mg and Placebo groups based on the provided data in Results 1 and Results 2. \n\nFirstly, the statement correctly identifies that the primary trial results demonstrate a higher DFS rate for the Lapatinib 1500 mg group compared to the Placebo group. This conclusion can be drawn from the difference in the number of participants with any recurrence or death in each group. In the Lapatinib arm, there were 1318 censored participants and 252 participants with an event (recurrence or death), making a total of 1560 participants. In contrast, in the Placebo arm, there were 1285 censored participants and 290 participants with an event, making a total of 1375 participants. Thus, a lower number of events (252 vs. 290) in the Lapatinib arm indicates a better DFS outcome for this group.\n\nSecondly, the statement also correctly specifies that there was less than a 30% difference in DFS rates between the two cohorts. This can be confirmed by calculating the DFS rate percentage for both groups and comparing their difference:\n\nLapatinib DFS rate = (Total number of censored + Total number of participants with event) / Total number of participants * 100%\nLapatinib DFS rate = (1318 + 252) / 1571 * 100% \u2248 83.9%\n\nPlacebo DFS rate = (1285 + 290) / 1576 * 100% \u2248 81.5%\n\nThe difference between the DFS rate percentages of Lapatinib (83.9%) and Placebo (81.5%) is approximately 2.4 percentage points, which is less than a 30% difference.\n\nTherefore, the information in the statement is entailed by the provided data in the CTRs.</s>",
        "contradict": "The expert's statement infers that the difference in DFS rates between the lapatinib 1500 mg and placebo groups is less than 30%, based on the primary trial results. However, the CTRs do not provide sufficient information for this determination. The DFS rates are not explicitly stated; instead, the number of participants experiencing a recurrence or death is mentioned. The statement's conclusion relies on an assumption about the relationship between these number data and DFS rates, which is not warranted by the provided information.</s>"
    },
    "8e45da73-f016-4ca0-b106-a3fabc960b36": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01432145",
        "Statement": "the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial patients are administered 6-Mercaptopurine more often and in higher dosages than Methotrexate\" is entailed by the CTR information as follows:\n\n1. More often: The primary trial patients receive 6-Mercaptopurine daily (od), whereas they receive Methotrexate once a week.\n2. Higher dosages: The initial 6-Mercaptopurine dose is 75mg/m2, which is higher than the initial Methotrexate dose of 20mg/m2. However, due to safety concerns, the doses were subsequently reduced to 55mg/m2 for 6-Mercaptopurine and 15mg/m2 for Methotrexate, but the difference in dosages still holds.</s>",
        "contradict": "Despite the initial impression that patients in the primary trial receive more frequent and higher dosages of 6-Mercaptopurine compared to Methotrexate, the actual administration schedules and dosages contradict this statement. The primary trial patients take 6-Mercaptopurine once a day at a dose of 55mg/m2, while they receive Methotrexate once a week at a dose of 15mg/m2. This means that, in reality, Methotrexate is administered less frequently and with a lower dose compared to 6-Mercaptopurine. Therefore, the statement is not entailed by the information presented in the CTRs.</s>"
    },
    "37dc56a4-4756-4ab0-8055-7637bf579740": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial are both single arm clinical trials.",
        "Label": "Entailment",
        "entail": "Both trials are single arm clinical trials is entailed by the information in the CTRs as both trials involve the administration of interventions to a single treatment group without a control group for comparison. In the primary trial, Zr89-trastuzumab is administered as a single-arm intervention for PET/CT, while in the secondary trial, patients receive Ixabepilone, carboplatin, and trastuzumab as a single-arm combination therapy.</s>",
        "contradict": "While both trials are single-arm trials, they involve different interventions with distinct dosing regimens and schedules for the same drug, trastuzumab. The primary trial employs Zr89-trastuzumab for PET/CT imaging, while the secondary trial utilizes trastuzumab in combination with Ixabepilone and Carboplatin. The contradiction stems from the differences in interventions despite having the same drug, trastuzumab, in both trials.</s>"
    },
    "65e370b7-7726-477e-8730-8cea734d1609": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT01823107",
        "Statement": "Patients in the primary trial receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, whereas in the secondary trial subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.",
        "Label": "Contradiction",
        "entail": "The statement's assertion is that in the primary trial, patients receive an Infusion of 3 ml Perflutren Lipid Microspheres at a rate of approximately 3ml/min, while in the secondary trial, subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix.\n\nThe first part of this statement can be entailed by the information in the primary CTR's Intervention section. Although the infusion rate stated in the expert's statement is slightly different from the one provided in the CTR (3 ml/min instead of approximately 4 ml/min), this discrepancy is inconsequential and does not affect the entailment.\n\nThe second part of the statement, stating that in the secondary trial, subjects are implanted with a permanent Meso BioMatrix Acellular Peritoneum Matrix, can also be entailed by the information in the secondary CTR's Intervention section. Although the primary CTR does not mention the permanence of the matrix, it does not contradict this statement as long as it's understood that the matrix remains in place after tissue expansion.\n\nThe statement does not contradict any information in the CTRs and is harmonious with the provided descriptions. Therefore, it can be considered an entailed statement.</s>",
        "contradict": "The statement contains an error in the rate of infusion for patients in the primary trial. The rate mentioned in the statement is \"approximately 3ml/min,\" while the correct rate from the CTR is \"approximately 4ml/min.\" This discrepancy contradicts the information in the CTR. The rest of the statement regarding the type of intervention in each trial is consistent with the information in the CTRs.</s>"
    },
    "affdd551-15e2-4a47-8c20-209cc01570ec": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR data as it correctly mentions the occurrence of a thromboembolic event in one patient in the primary trial (as stated in the adverse events section) and identifies diarrhea as the most common adverse event based on the provided data (with a frequency of 20.59% in the primary trial).</s>",
        "contradict": "The statement that \"One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Diarrhea\" is contradictory to the information present in the CTRs because the most common adverse event in the primary trial was Diarrhea, not a thromboembolic event.</s>"
    },
    "2152f503-4fa4-4f32-b766-a05a4c69742f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02176083",
        "Secondary_id": "NCT03061175",
        "Statement": "Neither the primary trial or NCT0306117 use chemotherapy, adverse event management courses or radiotherapy in their intervention.",
        "Label": "Contradiction",
        "entail": "neither statement contradicts nor goes beyond the information presented in the CTRs. In the primary trial, both intervention groups (INTERVENTION 1 and INTERVENTION 2) do not involve the use of chemotherapy, adverse event management courses, or radiotherapy. Likewise, in the secondary trial, neither INTERVENTION 1 (Arm I) nor INTERVENTION 2 (Arm II) mentions chemotherapy, adverse event management courses, or radiotherapy in their interventions. Thus, the statement is semantically entailed by the CTRs.</s>",
        "contradict": "Despite the statement's claim about the absence of chemotherapy, adverse event management courses, or radiotherapy in the interventions of both trials, this is not entirely accurate based on the CTRs provided.\n\n1. In the primary trial, both interventions (text message management for Intervention 1 and control for Intervention 2) do not specifically mention chemotherapy, adverse event management courses, or radiotherapy as part of the intervention. However, the trials do not exclude these treatments as a possibility for the participants. It is essential to note that the absence of such information in the CTRs does not necessarily mean they were not used.\n\n2. In contrast, the secondary trial involves two arms: Arm I (Web-Based CPM-DA) and Arm II (Usual Care). In Arm II, patients undergo 'usual care available to patients considering CPM and receive information from a medical oncologist about CPM.' While it doesn't explicitly state that chemotherapy, adverse event management courses, or radiotherapy are part of the usual care provided, they could be included as these treatments are commonly used in managing CPM.\n\nTherefore, the statement's contradiction with the CTRs lies in the oversimplification that neither trial uses chemotherapy, adverse event management courses, or radiotherapy in their interventions, while the CTRs suggest that these treatments might still be part of the care received by some trial participants.</s>"
    },
    "a7903e59-9620-457a-8d83-eb6eb5dd8a2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01300351",
        "Statement": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function.",
        "Label": "Contradiction",
        "entail": "The statement \"At least 1 participant in each cohort of the primary trial showed signs of poor liver function\" can be entailed by the information in the CTRs because there is at least one instance of a participant in both cohorts (1/109 and 1/110) with reported hepatic function abnormalities, which is a known sign of poor liver function.</s>",
        "contradict": "The statement \"At least 1 participant in each cohort of the primary trial showed signs of poor liver function\" cannot be directly contradicted by the provided CTRs, as there is one instance of a participant in the primary trial having a hepatic function abnormal event. However, the statement is not entailed by the CTR data since it goes beyond the information given, implying that both cohorts had at least one participant with liver function issues, while the CTR data only reports one instance for the entire primary trial.</s>"
    },
    "dc7e7fbe-eed9-4307-b584-30ecaeb77c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" is entailed by the CTR inclusion criteria which specify that plasma estradiol must be in the premenopausal range for patients defined as premenopausal or for those who have received tamoxifen within the past 3 months.</s>",
        "contradict": "The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" contradicts the CTR information because the CTR does not explicitly state that E2 (estradiol) levels are among the inclusion criteria. While the CTR mentions the importance of estrogen/progesterone receptor determination, it does not limit the eligibility based on E2 levels alone.</s>"
    },
    "a34c6194-b6d9-49c3-8ddb-72de10c8a18c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02006979",
        "Statement": "Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines.",
        "Label": "Entailment",
        "entail": "The statement \"Neither cohort of the primary trial need to perform low intensity exercise prior to each cycle of anthracyclines\" is entailed by the information in the CTRs because:\n\nIn the primary trial, Intervention 1 specifies an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post exercise. \"Low intensity exercise\" is not mentioned in Intervention 1, but it can be inferred that no exercise is permitted for 48 hours post exercise, which would include low intensity exercise. Therefore, the statement does not require the performance of low intensity exercise prior to each cycle of anthracyclines by either cohort.\n\nIntervention 2 in the primary trial specifies no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines. This also implies that no low intensity exercise is required prior to each cycle of anthracyclines for either cohort.\n\nThe secondary trial's statement is consistent with the information provided in the CTRs, as it does not entail the requirement of low intensity exercise before each cycle of anthracyclines for either cohort, making it entailed by the CTRs.</s>",
        "contradict": "The expert's statement contradicts the information provided in the CTRs as Intervention 1 for the primary trial specifies an acute bout of exercise performed 24 hours prior to each cycle of anthracyclines, which is not consistent with the expert's claim that neither cohort needs to perform low intensity exercise prior to the cycles of anthracyclines.</s>"
    },
    "da00532d-57a8-4fe2-a2de-acc525161fd9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01120184",
        "Statement": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder.",
        "Label": "Entailment",
        "entail": "The statement \"At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder\" is entailed by the CTR data as one patient in the primary trial experienced Hypercoagulation, a type of coagulation disorder. This is evident in the Adverse Events section of the primary trial with a count of 21 cases (0.28%) out of 353 participants.</s>",
        "contradict": "The statement \"At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder\" cannot be directly contradicted by the information present in the CTRs, as no mention of coagulation disorders is made in either the Adverse Events section of the primary trial. However, the statement is not entailed by the given data, as there is no evidence that any patient in the primary trial's cohort 1 experienced a coagulation disorder.</s>"
    },
    "f90364e9-caee-4075-b444-2db1bf846d3a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02511730",
        "Secondary_id": "NCT00193206",
        "Statement": "Patients with prior chemotherapy are excluded from the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with prior chemotherapy are excluded from the secondary trial and the primary trial\" is entailed by the information in the CTRs as follows:\n\n1. For the primary trial, the exclusion criteria state that \"Subjects with unknown clinical status not participating in FMSU004A protocol\" are excluded. Since the statement does not mention any subjects with unknown clinical status or not participating in FMSU004A protocol having prior chemotherapy, it does not contradict the primary trial's exclusion criteria. However, the inclusion criteria for the primary trial do not mention anything related to prior chemotherapy, and the statement does not add any new information regarding this trial, thus, it is neutral with respect to the primary trial's CTR.\n\n2. For the secondary trial, the exclusion criteria state that \"You cannot participate in this study if any of the following apply to you: Prior chemotherapy or hormone therapy for breast cancer.\" The statement directly matches this part of the secondary trial's exclusion criteria. Hence, the statement's assertion is entailed by the secondary trial's CTR.\n\nTherefore, the statement that \"Patients with prior chemotherapy are excluded from the secondary trial and the primary trial\" can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with prior chemotherapy are excluded from the secondary trial and the primary trial\" is not a direct contradiction of the information in the CTRs, as the primary trial's eligibility criterion only mentions patients with \"known clinical status,\" without specifying if that includes a prior history of chemotherapy. However, since the secondary trial explicitly states that \"No prior chemotherapy for breast cancer\" is an inclusion criterion, the statement can be considered contradictory to the secondary trial's criteria but not to the primary trial's.</s>"
    },
    "deb78676-8f04-44c4-a5f6-389740d8a268": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to doxatel is obligatory for patients in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Prior exposure to doxorubicin is obligatory for patients in the primary trial\" is entailed by the information present in the CTR under the \"Inclusion Criteria\" section, specifically the statement \"Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting\". Doxorubicin is a commonly used taxane-based chemotherapeutic drug. Therefore, the requirement for prior exposure to a taxane drug in the primary trial logically implies prior exposure to doxorubicin, which is the specific drug mentioned in the expert's statement.</s>",
        "contradict": "The statement \"Prior exposure to doxorubicin is obligatory for patients in the primary trial\" is contradictory to the information present in the CTRs, as doxorubicin and eribulin are different drugs. The CTR specifies that prior treatment with eribulin is an exclusion criterion for the primary trial.</s>"
    },
    "a06d1ca5-c890-4157-b1d2-0b70fd0092bd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows: \n\n1. Sinus bradycardia (1.43%) and Pericarditis (1.43%) are distinct cardiac adverse events mentioned in the primary trial with occurrence rates of 1.43% each.\n2. Febrile Neutropenia (5.71%) includes fever (5.71%) as one of its possible adverse effects. While not explicitly stated as a cardiac adverse event, it's reasonable to assume that cardiac complications could arise in the context of severe infections like Febrile Neutropenia.\n3. Non-Cardiac chest pain (2.86%) may or may not be cardiac in origin. However, the presence of cardiac adverse events, such as Pericarditis and Sinus bradycardia, implies that some cases of Non-Cardiac chest pain may have had cardiac etiology.\n4. The occurrence of 21 participants with Diarrhea (1.43%) does not seem directly related to cardiac events. However, diarrhea can potentially lead to dehydration and subsequent cardiac complications such as arrhythmias.\n\nTherefore, the statement \"There were 4 different cardiac adverse events recorded in cohort 1 of the primary trial\" can be entailed by mentioning Sinus bradycardia, Pericarditis, Febrile Neutropenia/Fever, and potential cardiac complications from Diarrhea in CTR data. These cardiac adverse events collectively account for 4 distinct cardiac events in cohort 1.</s>",
        "contradict": "The statement made by the clinical expert can be contradicted by the information present in the CTRs because the statement claims that there were 4 different cardiac adverse events recorded in cohort 1 of the primary trial, while the CTR reports only 2 instances of Non Cardiac-Chest pain and Sinus bradycardia as cardiac adverse events. The other reported events, such as Pericarditis and Fever, are not specifically categorized as cardiac adverse events in the CTRs.</s>"
    },
    "5bc0d21d-a040-4d30-b0c7-8793cba6aba8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091168",
        "Statement": "Patients in the control group of the primary trial had a median Overall Survival of less than a year.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the control group of the primary trial had a median Overall Survivals of less than a year\" can be entailed by the information presented in the CTRs as follows:\n\n- In the primary CTR, the median Overall Survival for the control group (Arm B) was 9.3 (7.5 to 10.9) months.\n- Since 9.3 months is greater than 12 months but less than 13 months, the claim that the median Overall Survival for the control group was \"less than a year\" holds true.\n\nTherefore, there is entailment between the expert statement and the information contained in the CTRs.</s>",
        "contradict": "The statement \"Patients in the control group of the primary trial had a median Overall Survival of less than a year\" cannot be definitively contradicted by the information in the CTRs as it is not explicitly stated that the median overall survival for the control group was less than 12 months. However, the CTR states that the median overall survival for the control group was 9.3 months (7.5 to 10.9), which is above 12 months when considering the range of the 95% confidence interval. The statement could be potentially misleading without specifying that the median overall survival falls below the lower bound of the reported confidence interval.</s>"
    },
    "9bcbadcc-ae56-4254-ac8b-ab5d35e80eba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses.",
        "Label": "Entailment",
        "entail": "The cohort in the primary trial receiving placebo gel applied to the breasts daily, and in the secondary trial, patients are given an identical-looking placebo bar without flaxseed or lignans once daily, both scenarios represent receiving daily placebo doses. The information in the CTRs indicates that the placebo group in the primary trial receives a placebo gel applied daily, and the secondary trial placebo group receives a placebo bar identical in appearance and caloric/fat content, but without the active substance (flaxseed/lignans). The statement's assertion aligns with the provided clinical trial data and avoids contradiction.</s>",
        "contradict": "The statement \"Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses\" cannot be directly contradicted by the information present in the CTRs. However, the statement may be contradicted depending on the specific definition of \"Cohort 2\" in each trial. \n\nIn the primary trial, Cohort 2 corresponds to the group that received the Placebo Gel + Oral Treatment. According to the Intervention 2 section in the primary trial report, patients in Cohort 2 received placebo gel applied to their breasts daily and 20mg of oral tamoxifen taken daily. Therefore, they did receive daily doses but not of placebo only, but rather a combination of placebo gel and oral tamoxifen.\n\nIn the secondary trial, Cohort 2 corresponds to the group that received the Placebo intervention. The Intervention 2 section in the secondary trial report indicates that patients in Cohort 2 received an identical looking bar with the same calorie and total fat content but without flaxseed or lignans once daily. This does not necessarily mean that they received a daily dose of placebo only since there is no clear mention of placebo doses or pills being administered separately.\n\nSo, the potential contradiction arises from the ambiguity around what exactly constitutes \"daily placebo doses\" in the statement for Cohort 2 in the secondary trial. If the statement refers to daily placebo pills or doses, then it may contradict the secondary trial CTR as no such information is mentioned. However, if the statement is intended to refer to the absence of any active treatment or intervention (i.e., placebo in the form of inert substance or control condition), then the statement is consistent with the information in both primary and secondary trials.\n\nTherefore, it is essential to clarify the meaning of \"daily placebo doses\" in the context of the statement before determining entailment or contradiction with the CTRs.</s>"
    },
    "5a1358af-f51b-49f8-b1c0-99a0b108b0a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Statement": "There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia.",
        "Label": "Contradiction",
        "entail": "The statement asserts that in the primary trial, there were more instances of Febrile neutropenia than leukopenia, but fewer instances of neutropenia than leukopenia. This relationship can be derived from the data in the CTRs. In the primary trial, there were 10 instances of Febrile neutropenia and 1 instance of Leukopenia. The number of instances for Febrile neutropenia is indeed greater than that of Leukopenia. However, the number of instances for Neutropenia (14) is greater than that for Leukopenia. To reconcile this, it is necessary to recall that Febrile neutropenia is a type of neutropenia, where the neutropenia is accompanied by a fever. Therefore, every instance of Febrile neutropenia includes an instance of Neutropenia, but not all instances of Neutropenia result in Febrile neutropenia. Hence, it holds that there are fewer instances of Neutropenia than the total instances of both Neutropenia and Febrile neutropenia. This relationship is entailed by the data provided in the CTRs.</s>",
        "contradict": "The statement \"There were more cases of Febrile neutropenia than leukopenia observed in the primary trial, but less cases of neutropenia than leukopenia\" can be contradicted by the information present in the CTRs because the number of cases for febrile neutropenia (10) is less than that for leukopenia (1/373 for primary trial and 4/377 for secondary trial). However, the statement suggests the opposite, that there were more cases of febrile neutropenia than leukopenia. Additionally, the statement mentions fewer cases of neutropenia than leukopenia, which is also not consistent with the CTRs, as the number of cases for neutropenia is higher than that for leukopenia in both trials.</s>"
    },
    "ed0e1b04-aea7-4da0-922f-2be69c768c09": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02635737",
        "Statement": "Patients with implantable cardioverter defibrillators are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "Patients with implantable cardioverter defibrillators (ICDs) are excluded from the primary trial as per the given CTR. The exclusion criteria in the CTR list patients with a Pacemaker or implanted device as being ineligible for participation in the study. Although the statement specifically mentions ICDs, the CTR's inclusion criteria and exclusion criteria cover this scenario by encompassing all implanted devices, including ICDs. Therefore, the expert statement is entailed by the CTR.</s>",
        "contradict": "The statement \"Patients with implantable cardioverter defibrillators are excluded from the primary trial\" contradicts the information in the CTR because the CTR explicitly lists \"Patients with a Pacemaker or implanted device\" as an exclusion criterion, which is a broader category including implantable cardioverter defibrillators but not limited to them. Thus, the statement, if taken at face value, could be considered an overgeneralization or misinterpretation of the CTR's eligibility criteria.</s>"
    },
    "73d323e7-1a38-49d4-97f4-a15f1664fb3e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01439711",
        "Statement": "One patient in the primary trial had a 0.98 cm3 increase in Total MRI Functional Tumor Volume (FTV) over 3 months, almost 1cm3 less than average.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The statement mentions a patient from the primary trial with an increase of 0.98 cm3 in Total MRI Functional Tumor Volume (FTV) over 3 months.\n2. According to the CTR, the Mean Total MRI FTV change from baseline to month 3 (V3) for the Letrozole + MRI arm was calculated by subtracting the total MRI FTV measured at 3 months from the total MRI FTV measured at baseline for individual patients, and the mean change and 95% confidence interval were computed using two-sided t-tests.\n3. The CTR also states that for patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point.\n4. The given statement describes a patient who experienced a 0.98 cm3 increase in FTV, which is the raw change calculated for this specific patient. This value is within the range of the mean change (-1.93 to -0.98) and its 95% confidence interval mentioned in the CTR. Therefore, the statement does not contradict the data presented and can be considered entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement asserts that one patient in the Letrozole + MRI arm experienced an increase in Total MRI Functional Tumor Volume (FTV) of 0.98 cm3 over 3 months, which is nearly 1 cm3 less than the average change. However, this contradicts the information given in the CTR for the Letrozole + MRI arm, which states that patients will undergo MRI scans at months 3 and 6 and the mean change over 3 months (V3) was calculated by subtracting the total MRI FTV at 3 months from the total MRI FTV at baseline. Therefore, no individual patient's FTV change was specified, making it impossible for one patient to have been observed with a decrease in FTV change of 0.98 cm3. Instead, the average change for all patients was reported as -1.93 cm3 (-2.87 to -0.98).</s>"
    },
    "02dea6a3-d94f-4650-bf4f-be8fdb0a382f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02010021",
        "Statement": "A patient has recently had an oophorectomy,they are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The patient being an oophorectomy recipient falls under the exclusion criteria in the primary trial, as stated by the CTR: \"Women must be either post-menopausal, or pre-menopausal having undergone oophorectomy.\" Thus, the expert's statement is entailed by the CTR's inclusion and exclusion conditions.</s>",
        "contradict": "The patient being excluded from the primary trial due to having undergone oophorectomy is not directly contradictory to the CTR information. However, the CTR states that women with oophorectomy are eligible for the study. Thus, the statement's applicability to a specific individual can be contradictory depending on other contextual factors not provided in the given CTRs.</s>"
    },
    "4c8a124b-f015-42e2-8ad3-6168f21fe705": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows: \n\nThe Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial is given in the provided results for the T-DM1 arm at Cycle 3, Day 1, 15 minutes pre-dose, 15 minutes and 60 minutes post-dose. Among these, the highest value (4.7 milliseconds) is observed at 15 minutes post-dose, which is before T-DM1 infusion in the third cycle. This finding aligns with the expert's statement.</s>",
        "contradict": "The statement \"The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, before T-DM1 intravenous (IV) infusion\" contradicts the CTR information as follows:\n\n1. The CTR does not provide the baseline-adjusted average QTcF intervals for Cycle 3, Day 1, pre-dose. Therefore, it is impossible to make a statement about the highest change from baseline before the T-DM1 infusion.\n\n2. The statement implies that the highest change in QTcF interval occurred before the T-DM1 administration. However, the CTR data indicates that the highest mean change in QTcF interval was observed on Cycle 3, Day 1, 15 minutes post-dose (4.7 milliseconds).\n\nThe expert's statement contradicts the CTR data because it misrepresents the timing and magnitude of the highest change in QTcF interval.</s>"
    },
    "fb43432d-6c1b-4ff7-aea8-72bc2519a12d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00130533",
        "Statement": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.",
        "Label": "Contradiction",
        "entail": "The statement \"Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia\" is entailed by the information present in the CTR as neither the Adverse Events section of the primary trial reports an instance of Hyperbilirrubinemia for cohort 1. In the provided CTR, the section \"Adverse Events 1\" for the primary trial states that there was 0 (0.00%) instance of Hyperbilirrubinemia reported in cohort 1. Therefore, the statement is entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia\" contradicts the information in the CTR as there is a report of one case (1/436) of Hyperbilirrubinemia in cohort 1 of the primary trial.</s>"
    },
    "d6df95f5-472f-4b14-9cd4-5d5ef238175a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Statement": "There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs because:\n\n1. The primary CTR specifies conditions related to PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS, and DISEASE CHARACTERISTICS for eligibility to the trial.\n2. The statement correctly acknowledges the presence of these eligibility criteria in the clinical trial.\n\nTherefore, the statement's assertion that \"there are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial\" is harmonious with and substantiated by the information within the provided CTRs.</s>",
        "contradict": "The statement \"There are criteria for PRIOR CONCURRENT THERAPY, PATIENT CHARACTERISTICS and DISEASE CHARACTERISTICS for entry to the primary trial\" is not contradictory to the information in the CTRs provided. However, it is not an exact semantic entailment either as the CTRs contain more detailed criteria for each of these sections. For instance, the DISEASE CHARACTERISTICS section specifies the exact conditions for breast lesions, menstrual cycle, and imaging studies, while the PATIENT CHARACTERISTICS section includes additional information such as hormone receptor status and performance status. The statement only mentions that there are criteria, but not the specifics of what those criteria entail. Therefore, the statement does not contradict the information in the CTRs, but also does not capture the full extent of the details provided. However, the information in the statement does not contradict or contradict any statements made in the CTRs.</s>"
    },
    "bd8c39c6-96a3-40f8-80e6-6cbb6bdaecb5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to her age.",
        "Label": "Contradiction",
        "entail": "The statement \"A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial\" is entailed by the CTR information as follows:\n\n1. The patient must be postmenopausal: The statement specifies the patient is postmenopausal, which is a requirement for eligibility in the primary trial.\n2. Eligibility criteria for postmenopausal status: According to the CTR, a woman is considered postmenopausal if she meets certain age criteria and has definite biochemical evidence of postmenopausal status. In this case, a 55-year-old patient is within the age range for postmenopausal eligibility, but she would need to provide biochemical evidence of definite postmenopausal status as defined by the CTR to be considered eligible.\n3. Patient with sarcoidosis: Sarcoidosis is not mentioned as an exclusion criterion in the CTR. However, the CTR specifies that patients must have no other nonmalignant systemic diseases that would prevent prolonged follow-up. Sarcoidosis could potentially fall under this category if it causes significant morbidity or requires ongoing treatment. Therefore, a patient with sarcoidosis might not be eligible due to this unrelated exclusion criteria. However, the statement directly addresses the patient's postmenopausal status and her sarcoidosis as separate issues. Based on the given information, it seems reasonable to assume that the statement is addressing her postmenopausal status specifically and that the presence of sarcoidosis is irrelevant in this context.\n\nSince the patient's postmenopausal status is a requirement for eligibility as outlined in the CTR, and the statement directly addresses her postmenopausal status, it can be entailed that the stated patient would be excluded from the primary trial due to her age.</s>",
        "contradict": "The patient described in the expert statement, being 55 years old, falls within the eligible age group according to the CTR as long as she fulfills the postmenopausal status criteria defined in the document. Therefore, her exclusion based solely on age cannot be entailed from the information provided in the CTRs.</s>"
    },
    "52ae415a-d8ab-48f5-abcb-9e8c5bb4fc83": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00982319",
        "Statement": "Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy.",
        "Label": "Contradiction",
        "entail": "The statement \"Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy\" is entailed by the CTR as follows:\n\nThe inclusion criteria for the primary trial specify that female participants must be 18 years of age or older and have a confirmed diagnosis of DCIS on core or excisional/incisional biopsy, scheduled for definite surgery. The statement does not contradict this. However, it adds an additional condition that the females must be postmenopausal, which is also included in the CTR's eligibility criteria. The CTR states that pre and postmenopausal women are eligible, but the statement explicitly restricts the eligibility to postmenopausal women only. Furthermore, the CTR excludes females who have used hormone replacement therapy (HRT), tamoxifen or raloxifene within six months prior to eligibility screening. The statement also aligns with this condition by requiring that postmenopausal women cannot have prior hormone replacement therapy. Therefore, the statement is entailed by the CTR information.</s>",
        "contradict": "The statement \"Only Post menopausal women can enter the primary trial, as long as they do not have prior hormone replacement therapy\" is contradicted by the inclusion criteria of the primary CTR that states \"Female 18 + years of age\" and \"Pre or Post menopausal women,\" meaning both pre and postmenopausal women are eligible for the trial. Furthermore, the exclusion criteria states \"Used hormone replacement therapy, tamoxifen or raloxifene within the past 6 months prior to eligibility screening,\" but it doesn't specify that only postmenopausal women who have not used hormone replacement therapy in the past 6 months are eligible, allowing for premenopausal women who have not used hormone replacement therapy to still be eligible for the trial.</s>"
    },
    "3bb3f3d5-e2e8-4cde-9d4f-dfc4b25c0b70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01425268",
        "Secondary_id": "NCT01373671",
        "Statement": "CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"CO2 is utilised as part of the intervention in a single one of the study groups in the primary trial, and saline is used in both of the study groups in the secondary trial\" is entailed by the information present in the CTRs due to the following reasons:\n\n1. In the primary trial, Intervention 1 describes the use of AeroForm Tissue Expansion, which involves the use of carbon dioxide to inflate the tissue expander. This meets the requirement that CO2 is used in a single study group in the primary trial.\n2. In the primary trial, Intervention 2 does not mention any specific gas used for saline tissue expansion. However, the absence of information does not contradict the statement that saline is used in both study groups in the secondary trial as saline is a commonly used fluid for tissue expansion and its use is often assumed when not explicitly stated.\n3. In the secondary trial, Intervention 1 specifies the use of FFDM (Digital Mammographic Densitometry) and DBT (Digital Breast Tomosynthesis) scans, but no mention of gases or other interventions. Intervention 2 specifies the use of FFDM exam only, again without mention of any additional interventions or gases. This meets the requirement that saline is used in both study groups in the secondary trial as no other interventions or gases are mentioned.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because:\n\n1. In the primary trial, CO2 is utilized for inflation of the AeroForm Tissue Expander in Intervention 1, whereas saline is used in Intervention 2. Contradicting the statement, neither CO2 nor saline is used in both study groups.\n\n2. In contrast, the secondary trial involves Intervention 1 with FFDM and DBT (Full Field Digital Mammography and Digital Breast Tomosynthesis) on Siemens MAMMOMAT Inspiration for one study group, while Intervention 2 consists of FFDM only for the other group. No tissue expansion is involved, and neither CO2 nor saline are utilized as interventions in this trial. Therefore, the statement is not an entailment of the information provided in the CTRs.</s>"
    },
    "f820384b-0bf5-4f2e-96fd-2c8b13a4646c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial share at least one drug in their chemotherapy regiment.",
        "Label": "Entailment",
        "entail": "Both trials utilize Carboplatin as part of their chemotherapy regimens. In the primary trial, Carboplatin is given intravenously (IV) weekly for 6 weeks, with an AUC of 2.0. In the secondary trial, Carboplatin is given intravenously (IV) in four doses prior to stem cell infusion, targeting an AUC of 20. Therefore, the statement that the primary and secondary trials share at least one drug in their chemotherapy regimen is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not necessarily contradict the information in the CTRs, but it can be misleading without further context. The Primary Trial and the Secondary Trial do indeed share the use of Carboplatin as part of their chemotherapy regimens. However, the use, dosage, and timing of Carboplatin differ significantly between the two trials. In the Primary Trial, Carboplatin is used concurrently with Radiotherapy, whereas in the Secondary Trial, it is part of a high-dose chemotherapy regimen prior to a Stem Cell Transplant. Therefore, while the statement is technically correct, it does not convey the full complexity of the drug's role or the differences between the trials. To assess entailment, it's important to consider how the statement aligns with all details within the provided CTRs. In this case, the simple statement about sharing one drug does not fully capture the intricacies of the trials' designs and interventions.</s>"
    },
    "f7410166-82a7-4d15-8a04-47287ef6884c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00448591",
        "Statement": "Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Only two types of adverse events occurred in more than 1% of patients in cohort 1 of the primary trial\" is entailed by the CTR data as follows: From the given CTR of the primary trial, the total number of adverse events is 672, which amounts to 29.68% of the total number of patients (2264). Among these adverse events, febrile neutropenia and neutropenia are the only two types that occur in more than 1% of patients, each with a prevalence of 5.17% and 4.33%, respectively. Therefore, the statement is a logical conclusion based on the given CTR information.</s>",
        "contradict": "The statement \"Only two types of adverse events occurred in more than 1% of patient in cohort 1 of the primary trial\" contradicts the information provided in the CTRs because, based on the data given, there are four types of adverse events (Febrile neutropenia and Neutropenia, each with a frequency above 1%) in the primary trial that contradict this statement.</s>"
    },
    "80726ab0-e8e4-4c42-860b-fdedad407517": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121836",
        "Statement": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the CTRs as it pertains to the consent process, which is not explicitly mentioned or related to the inclusion or exclusion criteria in either CTR. While the primary trial CTR specifies that patients must sign informed consent to participate, the secondary statement allows for patients who do not consent to still be included, which does not contradict the information in the CTRs but rather pertains to a separate aspect of trial procedure.</s>",
        "contradict": "The statement contradicts the primary trial's inclusion criteria since signed informed consent is a prerequisite for participation, as per the CTR.</s>"
    },
    "f2e1c4f6-2f62-4a5e-b033-d798ba781d1d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have placebo groups.",
        "Label": "Entailment",
        "entail": "The statement \"Neither the primary trial nor the secondary trial have placebo groups\" is entailed by the CTR information as there is no mention of placebo groups in either trial's intervention descriptions. In the primary trial, patients are randomized to receive either a one-port or two-port tissue expander, and in the secondary trial, patients are randomized to receive either IUS alone or IUS+OA. No group is specified as a placebo group in either trial.</s>",
        "contradict": "The statement does not contradict the information in the CTRs as such, as the absence of placebo groups is not directly mentioned in the provided Intervention descriptions. However, it's essential to consider that the presence or absence of placebo groups is a fundamental characteristic of clinical trials. If placebo groups were included in the trials, it would have been mentioned in the CTRs under the ELIGIBILITY CRITERIA or other applicable sections. Since the CTRs do not provide evidence of placebo groups in either trial, the statement holds, as the trials indeed do not have placebo groups. However, the statement's generality, applying to both primary and secondary trials, might lead to confusion, as it doesn't explicitly refer to the specific trials mentioned in the description. To avoid ambiguity, it is recommended to specify that the statement applies to the trials provided or to refer explicitly to the absence of placebo groups in those trials in the CTRs.</s>"
    },
    "d42054cd-deb6-4436-941c-9e3a06c713cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00036270",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Contradiction",
        "entail": "The statement \"In total, less than 10% of patients in the primary trial either had a disease relapse or died\" can be entailed by the information presented in the CTRs as follows. The number of events (disease relapse or death) for the Exemestane arm is 352, and the total number of participants analyzed is 4898. Therefore, the percentage of patients with an event (disease relapse or death) is 352 / 4898 * 100% = 7.2%, which is less than 10%. Similarly, for the Tamoxifen followed by Exemestane arm, the number of events is 388, and the total number of participants analyzed is 4868. The percentage of patients with an event is 388 / 4868 * 100% = 7.9%, which is also less than 10%. Since both percentages are less than 10%, the statement is entailed by the data in the CTRs.</s>",
        "contradict": "The given statement \"In total Less than 10% of patients in the primary trial either had a disease relapse or died\" cannot be directly contradicted by the provided CTRs data. However, it can be noted that the CTRs only report the number of events (disease relapse or death) for each arm, but they do not provide the total number of participants who experienced neither disease relapse nor death up to the observation time. Based on the data given, it is not possible to definitively determine if less than 10% of patients in the primary trial had a disease relapse or died. This statement is an approximation and not an entailed statement based on the provided clinical trial data.</s>"
    },
    "0507fbf8-3557-4ace-b015-5e106b96f6a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use Maximum Tolerated Dose Determined by Dose-limiting Toxicities as their outcome measurements.",
        "Label": "Entailment",
        "entail": "Both trials determine the Maximum Tolerated Dose (MTD) based on the occurrence of dose-limiting toxicities (DLTs). The primary trial uses this measurement to identify the MTD for ruxolitinib in combination with paclitaxel. The secondary trial determines the MTD for Capecitabine and GTI-2040 in combination. Both trials define DLT as any grade III or IV non-hematologic toxicity or grade IV hematologic toxicity, based on the NCI CTC v 2.0, and the assessment for DLT occurs during the first course of treatment. Therefore, the information in the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement is not contradictory to the information in the CTRs, as both trials are indeed measuring the Maximum Tolerated Dose Determined by Dose-limiting Toxicities. However, there are some differences in the details of the dose escalation schedules and DLT definitions between the two trials, which should be taken into consideration when evaluating their semantic entailment relationships.</s>"
    },
    "49ecc5a6-89be-48b6-85c5-c809c83f5baf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00825734",
        "Statement": "Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month\" can be entailed by the information in the CTRs as follows:\n\n1. Grade 1 infection: The CTR specifies that patients with uncontrolled intercurrent illness including ongoing or active infection greater than grade 2 are excluded from the trial. Since grade 1 infection is a lesser degree of infection, it logically follows that patients with grade 1 infection would also be excluded based on the CTR inclusion/exclusion criteria.\n\n2. Unstable angina or a grade 4 hemorrhage within the last month: The CTR specifies that patients with a history of cardiac disease such as unstable angina, new onset angina, myocardial infarction within the past 6 months, and cardiac ventricular arrhythmias requiring anti-arrhythmic therapy are excluded from the trial. Additionally, the CTR specifies that patients with serious non-healing wounds, ulcers, or bone fractures, evidence or history of bleeding diathesis or coagulopathy, or major surgery, open biopsy, or significant traumatic injury within 4 weeks of study treatment are also excluded. These conditions include unstable angina (a type of angina), hemorrhage (a type of bleeding), and major surgery. The statement about a grade 4 hemorrhage within the last month is more specific to bleeding events, but it can still be logically inferred from the CTR's exclusion criteria for serious bleeding events.</s>",
        "contradict": "The statement \"Patients with any of the following conditions will be excluded from the primary trial; grade 1 infection, unstable angina or a grade 4 hemorrhage within the last month\" conflicts with the information in the CTR as it mentions different exclusion criteria. According to the CTR, the following exclusion criteria apply to the primary trial:\n1. More than one (>1) prior chemotherapy regimen.\n2. Treatment with chemotherapy, biologic agents, or targeted agents within the previous 4 weeks.\n3. Previous treatment with sorafenib or ixabepilone.\n4. Cardiac disease: Congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.\n5. Pulmonary hemorrhage or bleeding event grade 2 within 4 weeks of the first dose of study treatment, or any other hemorrhage or bleeding event grade 3 within 4 weeks of the first dose of study treatment.\n\nThe statement, however, contradicts the CTR by including the conditions of grade 1 infection, unstable angina, and grade 4 hemorrhage within the last month as exclusion criteria, while these conditions are not mentioned in the CTR. Therefore, the statement cannot be harmonized with the clinical trial data and is contradictory.</s>"
    },
    "68792f63-d7b5-4570-bf8e-95e4cb8094e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343382",
        "Secondary_id": "NCT00798135",
        "Statement": "Cohort 2 of the primary trial receives a lower dose of Pilocarpine than cohort 2 of the secondary trial receives of oral itraconazole.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The statement compares the dosages of Pilocarpine in cohort 2 of the primary trial and oral itraconazole in cohort 2 of the secondary trial. \n2. In the primary trial, cohort 2 receives 2 times per day of Pilocarpine, which equates to 5mg per day (as mentioned earlier, 1 capsule of 5mg Pilocarpine is given 2 times per day).\n3. In contrast, in the secondary trial, cohort 2 receives oral itraconazole 200mg a day.\n4. The statement is entailed because the dose of Pilocarpine (5mg a day) given in cohort 2 of the primary trial is lower than the dose of oral itraconazole (200mg a day) given in cohort 2 of the secondary trial.</s>",
        "contradict": "The statement cannot be directly compared as the units of measurement and durations are different between the two interventions. Cohort 2 of the primary trial receives Pilocarpine 5mg twice daily for 12 weeks (total dose 30mg/day), while cohort 2 of the secondary trial receives Itraconazole 200mg once daily, with no specified duration. To establish a valid comparison, the dosage and duration should be expressed in a consistent manner. Without this comparison, the statement does not directly follow from the information provided in the CTRs.</s>"
    },
    "2ddd64c7-98ef-4b06-9f01-e59d3731e8ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Erysipelas and Pneumonia in the secondary trial than in the primary trial",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR information as follows: In the secondary trial, there is 1 instance of Intestinal perforation, 1 instance of Chest pain, 1 instance of death, 1 instance of Erysipelas, and 1 instance of Pneumonia. In comparison, in the primary trial, there is 1 instance of Intestinal perforation, 1 instance of chest pain, no instances of death, no instances of Erysipelas, and no instances of Pneumonia. The statement that there are more cases of these specific adverse events in the secondary trial than in the primary trial is an accurate reflection of the data presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the statement asserts that there are more cases of specific adverse events in the secondary trial compared to the primary trial. However, the provided CTRs only present the total number of adverse events for each trial and do not specify the number of occurrences for each individual adverse event besides Intestinal perforation, Chest pain, and Death. Based on the given data, it appears that there is one instance of Intestinal perforation, Chest pain, and Death in the secondary trial, whereas the primary trial had none of these events listed. Therefore, it is unclear from the provided information if the statement is entailed by the data in the CTRs or not. To establish entailment, the expert's statement would need to be more specific, citing the exact number of occurrences for each adverse event in both trials or comparing the percentage of participants experiencing each event between the trials while taking into account the total number of participants in each trial.</s>"
    },
    "a1a5767f-07e7-4a33-a26f-586cf71a208d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01118624",
        "Statement": "We cannot compare the doses and frequencies provided in the intervention sections of the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The primary CTR mentions the use of Tomosynthesis Breast Scanning and breast CT Scanning without specifying any particular dose or frequency for these interventions. In contrast, the secondary CTR describes the administration of Pralatrexate at a dose of 190 mg/m^2 for 2 to 4 weeks. The two intervention descriptions differ significantly in their level of detail regarding the interventions used. Therefore, it is not feasible to make direct comparisons between the doses and frequencies mentioned in each trial, as stated in the expert's claim. Consequently, the expert's statement follows logically from the given CTR data.</s>",
        "contradict": "The statement does not contradict the information in the CTRs as they address different aspects of intervention sections. The primary trial's intervention involves procedures (Tomosynthesis Breast Scanning and breast CT Scanning), while the secondary trial's intervention describes the study drug (Pralatrexate) with its dose (190 mg/m^2) and duration (2 to 4 weeks). There is no mention of dose or frequency in the primary trial's intervention section, allowing the statement to hold true.</s>"
    },
    "9c80fb61-66dc-4b3d-82b9-4fb62db89422": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR exclusion criteria as Myocardial Infarction and Deep vein thrombosis within the last 3 months are listed as reasons for exclusion in the CTR.</s>",
        "contradict": "The statement \"Patients with Myocardial Infarction or Deep vein thrombosis within the last 3 months are excluded from the primary trial\" is contradicted by the exclusion criteria in the CTR. The CTR states that \"Cardiac dysrhythmias of NCI CTCAE Grade 2 within the last month\" and \"Hemorrhage within 28 days of starting study treatment\" are exclusion criteria. However, it does not specifically mention Myocardial Infarction or Deep vein thrombosis as exclusion criteria within the given time frame. Therefore, the expert's statement contradicts the CTR by implying a more restrictive exclusion for cardiovascular conditions than what is stated in the CTR.</s>"
    },
    "6755a378-08bf-4e9b-a6de-166733d0307b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients location.",
        "Label": "Contradiction",
        "entail": "The statement entails that the interventions in the primary trial differ only in the position of the patients (prone vs. supine), which aligns directly with the description of Interventions 1 and 2 in the CTRs. There is no contradiction or additional claim made in the statement.</s>",
        "contradict": "Although the statement \"The only difference between the interventions used in the primary trial is the patients location\" is consistent with the given information that the interventions in the primary trial involve prone and supine positions, it does not fully capture the entirety of the information in the CTRs. This is because the CTRs do not necessarily imply that there is no other difference between the interventions beyond patient positioning. For instance, there might be variations in dosage, frequency, duration, or treatment modalities. Thus, the statement is too restrictive and may be contradicted if it is discovered that there are indeed further differences not mentioned in the given descriptions.</s>"
    },
    "b7f3e657-638b-4463-9639-4fb0da2be042": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT01106898",
        "Statement": "In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy  compared to other patients.",
        "Label": "Contradiction",
        "entail": "In the secondary trial, Her-2 neu positive patients receive maintenance therapy (trastuzumab) that is not present in the primary trial (vorinostat). Therefore, the statement that \"Her-2 neu positive breast cancer patients receive additional maintenance therapy in the secondary trial compared to other patients\" is an accurate description of the data presented in the CTRs.</s>",
        "contradict": "The statement \"In the secondary trial and the primary trial Her-2 neu positive breast cancer patients receive additional maintenance therapy compared to other patients\" is not explicitly contradicted by the information present in the CTRs. However, it contains an implicit assumption that is contradicted. The assumption is that all patients in the primary trial receive no maintenance therapy, which is not indicated in the provided Intervention 1 information. In reality, the statement only holds if we consider that the primary trial does not have any maintenance therapy component. Thus, the statement is not semantically entailed by the CTRs but may still be true depending on the context of additional trial information.</s>"
    },
    "5498a85b-a086-4d5d-b677-9ae44646a382": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546156",
        "Secondary_id": "NCT00398567",
        "Statement": "There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial\" is entailed by the CTR data as follows: \n\n- For Vertigo: The secondary trial does not report any cases, and the primary trial also does not report any cases, as stated in the CTR under Adverse Events 1 for both trials.\n- For Abdominal distension: The secondary trial does not report any cases, and the primary trial reports a total of 0 cases out of 104 (0.00%).\n- For Neutropenia: The secondary trial does not report any cases, and the primary trial reports a total of 1 case out of 104 (0.96%). However, since the expert's statement mentions \"no cases\" instead of \"no reports of cases,\" the CTR's report of one occurrence does not contradict the statement.\n\nTherefore, the CTR data supports the statement that \"There are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the secondary trial\" by showing that neither trial reports any cases of Vertigo or Abdominal distension and that the primary trial reports only one case of Neutropenia, which is within the range of expected occurrence based on the trial's total participants (0.96%). The statement also holds true for the secondary trial, as it reports no cases for any of the three conditions.</s>",
        "contradict": "The statement that \"there are no cases of Vertigo, Abdominal distension or Neutropenia in the primary trial or the secondary trial\" is contradicted by the information present in the CTRs because, in the primary CTR, one participant experienced paranasal sinus reaction which can present as vertigo, and there was one instance of Neutropenia reported. These facts contradict the statement as it asserts the absence of Vertigo and Neutropenia for both trials.</s>"
    },
    "f3d2337e-6cd9-4e8c-b327-cbc48557b8dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00418457",
        "Statement": "antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial.",
        "Label": "Entailment",
        "entail": "The inclusion criteria in the primary CTR do not mention any specific restriction against the use of antibiotics within 10 days prior to the trial. Therefore, the statement made by the clinical trial expert is in harmony with the provided information and can be entailed by the CTRs.</s>",
        "contradict": "The given statement \"antibiotics within 10 days prior to beginning is acceptable for patients entering the primary trial\" contradicts the information present in the CTR inclusion criteria. The CTR explicitly states, among other exclusion criteria, a contraindication to participation if a patient has \"any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy, abnormal anatomy)\" (primary CTR). Antibiotics can interact with anesthetics and affect clotting times, making it a potential contraindication for patients participating in the trial. Since the given expert statement allows for antibiotic use within 10 days prior to the trial, it contradicts the CTR by potentially including patients with increased risk of anesthesia complications.</s>"
    },
    "f25d63c8-9033-4db6-9c15-2151d82e2a6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00068588",
        "Statement": "between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response.",
        "Label": "Contradiction",
        "entail": "The statement \"between the two Arms of the primary trial, cohort 1 vastly outperformed cohort 2 in terms of the number of patients with complete tumor response\" cannot be directly entailed from the provided CTRs since no data regarding tumor response, let alone comparisons between different cohorts, are present in the CTRs. The information in the statement is not found, substantiated nor harmonizes with the clinical trial data in the provided CTRs.</s>",
        "contradict": "The expert's statement contradicts the information in the CTRs since:\n\n1. There is no mention of the number of patients with complete tumor response in either of the primary trial's arms (Results 1 and 2). \n\n2. The expert's claim is about a comparison between the two arms, but the CTRs only provide data on the maximum tolerated doses (MTD) and the occurrence of dose-limiting toxicities (DLTs) for each arm. \n\nTherefore, there is insufficient information in the CTRs to establish semantic entailment with the expert's statement.</s>"
    },
    "5ab5f2e8-d1cf-4789-86b4-e2f6dbf443ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The patient described in the statement, having histologically confirmed breast cancer, meets the inclusion criteria of both trials. In the primary trial, breast carcinoma is a specified inclusion criterion, while in the secondary trial, cytologically confirmed breast cancer is mentioned. Since histologically confirmed breast cancer is a more stringent condition, it falls under the umbrella of cytologically confirmed breast cancer.\n\nTherefore, the statement \"A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial\" can be entailed by the information present in the CTRs.</s>",
        "contradict": "The given statement is contradicted by the CTRs as follows: A patient with a histologically confirmed breast cancer would not meet the eligibility criteria for both the primary trial and the secondary trial due to various discrepancies.\n\nIn the primary trial:\n1. The patient must have an early stage breast cancer (stage 1, 2, 3), and the cancer cannot have spread outside the breast or chest wall except for ipsilateral axillary lymph nodes. However, the statement does not provide this information.\n2. The patient is not allowed to have any prior therapy for breast cancer, while the given statement does not mention whether the patient had prior treatment or not.\n3. The patient must be 18 years of age or older, and the given statement does not mention the age.\n\nIn the secondary trial:\n1. The patient should undergo surgery (lumpectomy, subtotal or total mastectomy), while the given statement does not mention if the patient will undergo any surgery.\n2. The patient is not allowed to have any evidence of distant metastatic disease, while the given statement does not mention if the patient has metastases or not.\n3. The patient must be willing to forego surgery for a minimum of 5 days, but the given statement does not mention if the patient is willing to do so.\n4. The patient must have a negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal, while the given statement does not mention the patient's pregnancy status or menopausal status.\n5. The patient's HbA1C and fasting blood glucose levels are specified for the secondary trial, but the given statement does not mention any information regarding the patient's diabetic status.\n6. The patient must be able to sign a written consent, but the given statement does not mention if the patient is able or willing to do so.\n7. The patient's ECOG status and Karnofsky performance score are not mentioned in the given statement, while these are requirements for the secondary trial.\n8. The given statement does not mention any information regarding the patient's history of chronic inflammatory processes, swallowing dysfunction, uncontrolled intercurrent illness, poorly controlled diabetes, uncontrolled hypertension, or current investigational medications or treatments.\n\nTherefore, based on the provided CTRs, the given statement is contradicted as it does not account for all the specified eligibility criteria for both trials.</s>"
    },
    "4fd10abc-81d1-44f4-825a-26e2eaeae979": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were 23 participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as follows: In the primary trial, the outcome measurement section describes that the Objective Intracranial Response Rate (OIRR) is the percentage of participants with a CR or PR based on RANO-BM response criteria. Results 1 of the primary trial indicates that there were 23 participants analyzed in cohort A with breast cancer types HR+, HER2+, and received Abemaciclib 200 mg orally once every 12 hours on days 1-21 of a 21-day cycle as a single agent or in combination with endocrine therapy. According to the given RANO-BM response criteria, a CR is defined as measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is defined as at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Therefore, based on the given definition of CR and PR and the number of participants in cohort A with these responses as stated in Result 1, the statement made by the expert is entailed by the CTRs.</s>",
        "contradict": "The statement is in contradiction to the CTRs since the CTRs report that the outcome measurement was based on OIRR, which includes the percentage of participants with CR or PR, but they do not provide specific data on the number of participants in each arm achieving these responses. Consequently, we cannot validate the statement's claim of having 23 participants in cohort 1 of the primary trial with a CR or PR.</s>"
    },
    "a12a46de-9d3e-4c6a-becb-d43653040bf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00089973",
        "Statement": "the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles.",
        "Label": "Contradiction",
        "entail": "The primary trial's intervention cycle duration is stated as 21 days, which is equivalent to 3 weeks. The statement in the clinical trial expert's assertion that the primary trial uses a 3-week cycle for SB-715992 administration is consistent with the 21-day cycle described in the CTR. Additionally, the statement that the study lasts for 21 cycles aligns with the CTR's information that participants received SB-715992 for multiple cycles until disease progression, unacceptable toxicity, or withdrawal of consent. Therefore, the statement's assertions are entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"the primary trial uses a 3 week cycle for SB-715992 administration, and the study lasts for 21 cycles\" can be contradicted by the information present in the CTRs because, according to the CTR, SB-715992 was administered intravenously as a one-hour infusion on Day 1 of every 21-day treatment cycle. This means that the treatment cycle is indeed 21 days long, but the statement incorrectly states that the administration is done every 3 weeks, which is not consistent with the information in the CTRs.</s>"
    },
    "66ee10ac-1bfe-44d6-9b91-8a2bb1983606": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01017549",
        "Secondary_id": "NCT01390064",
        "Statement": "the secondary trial has 5 more patients cohorts than the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial has 5 more patient cohorts than the primary trial\" does not directly entail information from the provided CTRs. However, it is possible to infer this information from the given CTRs. \n\nThe primary trial only mentions one intervention, which has one arm or cohort of patients receiving electronic brachytherapy. The secondary trial also mentions one intervention, but it has two distinct cohorts: an initial cohort and an escalation cohort, each having 5 doses of the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous injection, but with different dosages (300 micrograms and 500 micrograms, respectively). \n\nSince each cohort represents a distinct group of patients in the clinical trial, the secondary trial has a total of 3 arms/cohorts (initial and escalation for intervention 1), while the primary trial has only 1 arm/cohort. Therefore, the difference in the number of patient cohorts between the primary and secondary trials is exactly 2, not 5 as stated in the expert's claim. However, since the expert's statement can be inferred from the information in the CTRs and the statement's assertion is not contradictory to the CTRs, we can still consider it entailed by the CTRs under a broad interpretation of semantic entailment.</s>",
        "contradict": "The statement that \"the secondary trial has 5 more patient cohorts than the primary trial\" is not directly contradicted by the information presented in the CTRs. However, the statement does not follow logically from the information presented in the CTRs either, since the number of cohorts is not specified in the provided information for either trial. The focus of the CTR sections provided is mainly on the interventions used in each trial rather than the number of cohorts. Thus, the statement's claim cannot be determined to be entailed or contradicted based on the given CTR information alone.</s>"
    },
    "714c540c-1fa1-47c7-ac13-1e8f056d1e31": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event\" can be entailed by the CTR data as follows:\n1. From the Adverse Events section of the primary trial, we find that 3/33 (0.091) of the patients had Herpetic eruptions in Cohort 1.\n2. However, the statement speaks of 'a total of 3 patients,' which is equivalent to 3/1 (300.0%) if we consider one patient as one unit.\n3. To reconcile this inconsistency, we assume the statement refers to the total number of Herpes related adverse events across both trials, as 'cohort 1 of the primary trial' could be interpreted ambiguously.\n4. According to the CTR data for the secondary trial, 3/11 (27.27%) patients experienced Herpetic eruptions.\n5. Thus, in total, 3 (from the primary trial) + 3 (from the secondary trial) = 6 patients experienced Herpetic eruptions.\n6. Since the statement claims there were a total of 3 patients in the primary trial with Herpes related adverse events, the statement is entailed by the CTR data as the number given in the CTR (3 Herpetic eruptions in the primary trial) is a subset of the statement's claim (3 or fewer Herpes related adverse events in the primary trial).</s>",
        "contradict": "The statement \"A total of 3 patients in cohort 1 of the primary trial experience a Herpes related adverse event\" is contradictory to the information presented in the CTR as no Herpes related adverse events are reported in cohort 1 of the Primary Trial according to the given data.</s>"
    },
    "3948b30d-934d-485c-b324-b3571e2957a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Entailment",
        "entail": "The statement \"The most common adverse event in both the primary and secondary trials is Neutropenia, with a total of 3 cases across all cohorts\" can be entailed by the information present in the CTRs since:\n\n1. In the primary trial, Neutropenia occurred 2 times in Cohort 1 (Adverse Events 1) and once in Cohort 2 (Adverse Events 2), resulting in a total of 3 cases across the two trials.\n2. The CTRs provide an explicit listing of Adverse Events for each cohort, and the number of occurrences for each type of Adverse Event is stated.\n\nTherefore, the statement's assertion is in agreement with the clinical trial data, is substantiated within the CTRs, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement's assertion that \"The most common adverse event in both primary and secondary trials is Neutropenia with a total of 3 cases\" is contradicted by the clinical trial data presented, as the total number of Neutropenia cases across all cohorts in the primary trial is 2, not 3, and in the secondary trial, Neutropenia is not the most common adverse event, with no instances reported in either trial having more occurrences.</s>"
    },
    "45cf29ce-25f5-4719-8468-69d94893c9e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01166763",
        "Statement": "the primary trial recorded 4 life-threatening adverse events.",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information in the CTRs. The CTRs report a total of six adverse events in the primary trial (three unique events with one participant experiencing more than one event). None of these events are identified as life-threatening in the provided data. Therefore, the statement is not entailed by the given CTR information.</s>",
        "contradict": "The statement \"the primary trial recorded 4 life-threatening adverse events\" contradicts the information in the CTR as there is no record of any life-threatening adverse events mentioned under the Adverse Events section of the primary trial. The CTR only documents three adverse events, none of which are identified as life-threatening. Therefore, the statement is not entailed by the information in the CTR.</s>"
    },
    "7502090d-1bcb-4be9-9358-81afb9440a17": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with metallic vascular clips placed to prevent bleeding from conditions such as intracranial aneurysms, are elligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The eligibility criteria for the primary trial include no evidence of dementia as a condition for participation. Metallic vascular clips for preventing bleeding from intracranial aneurysms do not affect cognitive function or indicate dementia, thus patients with such clips still meet the cognitive requirement and are eligible for the trial, as stated.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because patients with a medical history of metallic vascular clips are listed as an exclusion criteria in the primary trial. Specifically, under metabolic abnormalities, the CTR states that patients with known claustrophobia, presence of pacemaker and/or ferromagnetic material in their body that would prohibit MRI imaging, or a medical history of concussions are excluded from the study. Metallic vascular clips, used to prevent bleeding from intracranial aneurysms, are often made of magnetic materials and can interfere with MRI imaging, thus making patients with these clips ineligible for the trial, according to the CTR. Therefore, the statement made by the clinical trial expert contradicts the information provided in the CTR.</s>"
    },
    "89f84928-82a9-413e-ab25-400657002c55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs. \n\nExplanation:\n\nThe primary trial's exclusion criteria state that \"no prior or current systemic antitumor therapy\" is allowed. The secondary trial's exclusion criteria also state that \"no prior or concurrent systemic antitumor therapy\" is a condition for patient ineligibility. Both trials exclude patients with prior or current systemic antitumor therapy. The statement, which claims that neither trial excludes patients with concurrent systemic antitumor therapy, contradicts the information provided in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not exclude patients with concurrent systemic antitumor therapy\" contradicts the information present in the CTRs as follows:\n\nPrimary Trial Exclusion Criteria: \"no prior or current neoplasm except for non-melanoma skin cancer, or in situ cancer of the cervix.\" (implies no concurrent systemic antitumor therapy)\n\nSecondary Trial Exclusion Criteria: \"prior or concurrent systemic antitumor therapy.\" (explicitly states exclusion of patients with concurrent systemic antitumor therapy)\n\nThus, the statement is contradictory to the information presented in the CTRs.</s>"
    },
    "79dbf7bf-e08d-4eae-a804-0daeb83d6f01": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia.",
        "Label": "Contradiction",
        "entail": "The statement \"The most frequent adverse event in cohort 1 of the primary trial was lymphopenia\" can be entailed by the information in the CTRs because, in the Primary Trial's Adverse Events 1 section, there is one instance of lymphopenia reported among 96 participants (a frequency of 1.04%), which is higher than the frequency of any other adverse event mentioned in that same section. Since the expert's statement specifies cohort 1 of the primary trial, and the CTR provides the frequency of each adverse event for that cohort, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"The most frequent adverse event in cohort 1 of the primary trial was lymphopenia\" is contradictory to the information presented in the CTR, as the frequency of adverse events in the CTR does not indicate that lymphopenia was the most frequent event in cohort 1. The CTR states that the total number of adverse events in cohort 1 was 22, and lymphopenia occurred only once. Therefore, it is not possible for lymphopenia to be the most frequent adverse event based on the data in the CTR.</s>"
    },
    "c9ff5b91-cec7-4da7-b1cd-f08f3874e8ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Entailment",
        "entail": "The Expert's statement can be entailed by the information present in the CTRs as follows:\n\nGiven the primary trial results, Exemestane had a median PFS of 3.68 (1.94 to 5.26) months, while Abiraterone Acetate + Prednisone had a median PFS of 3.65 (2.73 to 5.59) months. Therefore, the Exemestane group had a better median PFS than the Abirateraterone Acetate + Prednisone group. \n\nHowever, the statement also mentions that the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group. Although the median PFS was longer in the Exemestane group, there is no contradiction with the statement as it's possible for individual patients in the Abiraterone Acetate + Prednisone group to have a longer PFS than patients in the Exemestane group, which is consistent with the CTR.\n\nIn summary, the Expert's statement is entailed by the data presented in the CTRs, as it correctly infers the comparison of group median PFS while acknowledging the existence of individual cases with longer PFS in both groups.</s>",
        "contradict": "The expert's statement does not entail the information in the CTRs because the median PFS for the Exemestane group is indeed longer than that of the Abiraterone Acetate + Prednisone group, as stated. However, the presence of a single patient with longer PFS in the Abiraterone Acetate + Prednisone group does not negate the overall finding of shorter median PFS in this group. Therefore, the expert's statement does not contradict the data in the CTRs, but it is not a complete representation of the information contained within. It focuses on two specific data points without considering the overall distribution of the data.</s>"
    },
    "23040754-d1ad-4660-aacf-3298aefa5dae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00777101",
        "Secondary_id": "NCT00559845",
        "Statement": "There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no depressed patients in either the primary trial or the secondary trial, however there was one suicide attempt in cohort 2 of the secondary trial\" is entailed by the given CTRs as:\n\n1. The CTRs do not report any instances of depression as an adverse event in either trial.\n2. The statement asserts the absence of depressed patients in both trials, which aligns with the CTR information.\n3. The statement acknowledges the occurrence of a suicide attempt in the secondary trial, which is an adverse event reported in the CTR of the secondary trial (Suicide Attempt: 1/54).\n4. No contradictory information is present in the CTRs, ensuring the validity of the statement's entailment.</s>",
        "contradict": "The statement \"There were no depressed patients in either the primary trial or the secondary trial\" is contradicted by the information present in the CTRs because the CTRs do not report information on depression as an adverse event. However, the statement does not contradict the data on other adverse events presented in the CTRs. The presence of a suicide attempt in the secondary trial does not contradict the information in the CTRs since it is a different adverse event from depression.</s>"
    },
    "e3be834c-c311-4132-8529-d354b9e620b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of pleural effusion.",
        "Label": "Entailment",
        "entail": "The statement \"The only adverse event recorded in the primary trial was one single case of pleural effusion\" is entailed by the information present in the CTRs, as the CTR for the primary trial reports \"PLEURAL EFFUSION 1/3 (33.33%)\". This number implies that one out of the three trial participants experienced pleural effusion. Therefore, the statement made by the clinical trial expert correctly reflects this finding from the CTR data.</s>",
        "contradict": "The statement made by the clinical trials expert is not directly contradictory to the information in the CTRs. However, the statement does not fully capture the complexity of the adverse events data presented. The CTR reports that out of three trial participants, one experienced pleural effusion, which represents a 33.33% incidence rate of this adverse event. Contrary to the expert's claim, there were other adverse events recorded but no instances for each of them. Therefore, while the statement is not contradictory, it is incomplete and lacks the precision required to accurately capture the data presented in the CTRs.</s>"
    },
    "8115b5e3-e178-433b-b114-09d97daaa8d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01326481",
        "Statement": "Patients with Myocardial Infarction,percutaneous transluminal coronary angioplasty or Deep vein thrombosis within the last 2 - 6 months are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if we consider the following:\n\n1. The primary trial includes patients with \"histologically proven advanced solid cancer for which curative therapy is not available\" (Part 1) or \"histologically proven metastatic Her-2-negative breast cancer with measurable disease by RECIST 1.1 criteria\" (Part 2). Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, and Deep Vein Thrombosis are not exclusionary conditions mentioned in the CTRs for either part. Hence, patients with these conditions can still meet the eligibility criteria for the trial.\n\n2. The statement specifies that these patients are eligible for the primary trial. The inclusion criteria for the primary trial, as mentioned in the CTRs, do not contradict this statement. Therefore, the statement is entailed by the information present in the CTRs.\n\n3. The statement does not mention any incompatibility with the intervention, results, or adverse events sections of the CTR, so it does not contradict any information in those sections.\n\nTherefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement contradicts the eligibility criteria in the Primary CTR, which excludes patients with a history of myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA), or deep vein thrombosis (DVT) within 6 months of starting study treatment. Therefore, the statement cannot be entailed by the information in the CTR.</s>"
    },
    "bbcfc019-2d60-413f-88f9-04cacec55e30": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that there is no mention of cardiac adverse events in the secondary trial's adverse events section. This is consistent with the information in the CTRs as none of the cardiac adverse events mentioned in the primary trial, such as atrial fibrillation, arrhythmia, arteriospasm coronary, atrioventricular block first degree, or cardiac failure, are present in the adverse events section of the secondary trial.</s>",
        "contradict": "The statement \"There are several cardiac adverse events recorded in the primary trial, but not a single one in the secondary trial\" is contradicted by the information in the CTRs because there are no cardiac adverse events reported in either the primary or secondary trials, according to the provided data. The primary trial reports incidents of arrhythmia and atrioventricular block first degree in the adverse events section, but these conditions cannot be considered cardiac adverse events per se, as they do not specifically relate to the heart structure or functioning, but rather to electrical activity. Thus, the statement's assumption that there are cardiac adverse events in the primary trial and none in the secondary trial is incorrect, given the data in the provided CTRs.</s>"
    },
    "e7899445-9b80-4429-b4c3-d47bd36a2347": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232479",
        "Statement": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR information because \"HER2 overexpressing breast cancer\" is an inclusion criterion for the primary trial as stated in the CTR. Therefore, individuals with HER2 positive breast cancer meet the eligibility requirements for participation in the trial, as specified in the CTR. The statement regarding colon carcinoma is not explicitly mentioned in the provided CTRs, but if this trial also includes patients with HER2 positive colon cancer and the other stated criteria are met, those patients would also be eligible. The statement does not contradict any information in the CTRs, so it is entailed.</s>",
        "contradict": "The statement made by the clinical trials expert is contradicted by the information in the primary CTR because it extends the eligibility criteria beyond what is stated in the CTR. The CTR specifies that only HER2 overexpressing breast cancer patients are eligible, whereas the statement includes HER2 positive colon carcinoma patients as well, which are not specified in the CTR.</s>"
    },
    "2a50cc2a-281b-4bc6-9f18-6bd9686c682d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00754845",
        "Statement": "Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial,\" can be entailed by the information present in the CTRs as follows: \n\n1. According to the primary trial's eligibility criteria, patients must have received aromatase inhibitor therapy, including anastrozole, for a minimum of 4\u00bd - 6 years. \n2. The statement specifies that patients have received over 5 years of anastrozole therapy. This condition falls within the minimum duration requirement stated in the CTR.\n3. The statement also mentions that the aromatase inhibitor therapy must be completed at least 2 years prior to the trial enrollment. This aligns with the information in the CTR, where no specific time limit is imposed regarding the duration between the completion of aromatase inhibitor therapy and the trial participation. \n4. The statement does not contradict any of the conditions mentioned in the CTR, ensuring semantic entailment.</s>",
        "contradict": "The statement \"Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial\" can be contradicted by the information present in the CTRs in several ways:\n\n1. Duration of anastrozole therapy: The CTR specifies that patients must have received 4\u00bd - 6 years of aromatase inhibitor therapy, but it does not necessarily mean that they must have taken anastrozole for that exact duration. Thus, patients who took anastrozole for more than 5 years but not exactly 4\u00bd - 6 years would not meet the primary trial's eligibility criteria.\n\n2. Timing of aromatase inhibitor completion: The statement suggests that patients must have completed aromatase inhibitor therapy 2 years prior to entering the primary trial, but the CTR allows for patients whose aromatase inhibitor therapy completion was 2 years ago (which could be more or less than 2 years before trial entry).\n\n3. Hormone receptor status: While patients with hormone receptor-positive breast cancer are eligible for the primary trial, the statement does not mention hormone receptor status as a requirement. This means it could potentially include patients with hormone receptor-negative breast cancer, which would not be eligible according to the CTR.\n\n4. Concurrent therapy: Patients with no concurrent anticancer therapy are eligible for the primary trial, but the statement does not mention anything about concurrent medications. If these patients are taking concurrent medications that interact with anastrozole or other aromatase inhibitors, they may not meet the trial's eligibility criteria.\n\nTherefore, the statement \"Patients who received over 5 years of anastrozole therapy, completed 2 years prior, are eligible for the primary trial\" can be contradicted by the information present in the CTRs based on differences in aromatase inhibitor duration, timing of completion, hormone receptor status, and concurrent therapy eligibility criteria.</s>"
    },
    "26419cec-e256-46a7-9026-94dbe026c63d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01151046",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Entailment",
        "entail": "The statement \"The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.\" can be entailed by the information present in the CTRs because:\n\n1. The CTR for the primary trial clearly states that progression-free survival (PFS) was measured in both the MM-121 + exemestane and placebo + exemestane groups.\n2. The CTR provides the Median PFS for both groups: 15.9 (9.3 to 30.3) weeks for MM-121 + exemestane and 10.7 (8.1 to 16.1) weeks for placebo + exemestane.\n3. The difference between the two Median PFS values, 5.2 weeks, represents a significant difference between the two groups, as stated by the expert in the given statement.</s>",
        "contradict": "The statement \"The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort\" is contradicted by the information in the CTRs because the CTRs provide the median PFS values, which are 10.7 weeks for the placebo group and 15.9 weeks for the MM-121 group, indicating that the MM-121 group had a longer median PFS than the placebo group, the opposite of the statement's claim.</s>"
    },
    "8ef93fe0-0a12-4a7e-93aa-c40af7154a57": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02336737",
        "Secondary_id": "NCT01432886",
        "Statement": "the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP. ",
        "Label": "Contradiction",
        "entail": "The statement that \"the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP\" is entailed by the provided CTRs as follows:\n\n1. The primary trial's outcome measurement section states that it investigates the proportion of lymph nodes detected by SentiMag and SiennaXP compared to Technetium Sulfur Colloid and Isosulfan blue dye. While it does not explicitly mention the term \"dose limiting toxicity\" or \"DLT,\" it can be inferred that the trial is evaluating safety since the document mentions \"adverse events\" and provides information related to their classification using the CTCAE v4.0. The primary trial also mentions \"SentiMag handheld magnetic probe\" which could potentially have dosing requirements or limitations, making it a relevant topic for dose-limiting toxicity testing.\n\n2. The secondary trial's outcome measurement section explicitly states that it investigates DLTs using CTCAE v4.0 criteria. Therefore, it is testing for dose limiting toxicity in line with the statement. \n\nThus, the statement is entailed by the provided Clinical Trial Reports as it correctly characterizes the nature of the safety evaluations conducted in both trials.</s>",
        "contradict": "The statement \"the secondary trial is testing for the DLT of its interventions, whereas the primary trial is evaluating the dose limiting toxicity for SentiMag and SiennaXP\" can be contradicted by the information present in the CTRs because:\n\n1. The primary trial is not evaluating the dose limiting toxicity for SentiMag and SiennaXP specifically, as the provided CTR only mentions the outcome measurement being the number of participants with detected lymph nodes and the comparison between SentiMag and SiennaXP in relation to the standard of care.\n\n2. The secondary trial is testing for dose limiting toxicity in general, but the CTRs do not provide any information about the interventions being tested in the secondary trial, so it cannot be confirmed that they are the same as SentiMag and SiennaXP.\n\nTherefore, the statement is contradictory to the information presented in the CTRs as it incorrectly assumes that the primary trial is evaluating the dose limiting toxicity of SentiMag and SiennaXP and that the secondary trial is testing for the dose limiting toxicity of different interventions.</s>"
    },
    "f5d50d87-b419-4537-87ec-7c9d23b765db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00171340",
        "Statement": "the primary trial results imply that Zoledronic Acid 4 mg Upfront causes a +ve Change in Bone Mineral Density, whereas Zoledronic Acid 4 mg Delayed causes a smaller, but still positive change in Bone Mineral Density (within a certain patient demographic).",
        "Label": "Contradiction",
        "entail": "The statement entails the following semantic relationships with the CTR data:\n\n1. The statement correctly identifies that Zoledronic Acid 4 mg Upfront and Zoledronic Acid 4 mg Delayed are two different arms in the primary trial.\n2. The statement correctly infers that the primary trial measures the Percentage Change in BMD at the lumbar spine (L2-L4) at 12 months.\n3. The statement correctly interprets the results as implying a positive change in BMD for the Zoledronic Acid 4 mg Upfront group (mean change: 2.208%, SD: 3.4194%).\n4. The statement correctly infers that the Zoledronic Acid 4 mg Delayed group exhibits a smaller, but still positive change in BMD (mean change: -3.617%, SD: 4.2151%), which may be considered positive within a certain patient demographic depending on the context.\n\nTherefore, the statement is entailed by the CTR information, as it draws valid conclusions from the presented data without contradicting or misrepresenting it.</s>",
        "contradict": "The statement implies that both Zoledronic Acid 4 mg Upfront and Zoledronic Acid 4 mg Delayed groups have positive changes in Bone Mineral Density. However, the CTRs indicate that the mean percentage change in BMD for Zoledronic Acid 4 mg Upfront group is 2.208 with a standard deviation of 3.4194, while the mean percentage change in BMD for Zoledronic Acid 4 mg Delayed group is -3.617 with a standard deviation of 4.2151. The negative value for the delayed group clearly contradicts the positive change claimed in the expert's statement.</s>"
    },
    "f52ab54b-7a78-4449-9dfe-5fc67323e5c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01797120",
        "Statement": "Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications\" is entailed by the information present in the CTRs since Intervention 2 for the primary trial specifies \"Placebo for Everolimus (2 tablets) daily x 12 cycles.\" Thus, the statement is in alignment with the CTR and does not contradict any details provided.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial is only receiving placebo tablets, and no other medications,\" contradicts the information present in the CTRs because Intervention 2 of the primary trial specifies that cohort 2 is receiving fulfilvestrant tablets along with placebo tablets for everolimus. Therefore, the statement oversimplifies the intervention in Intervention 2 and fails to mention the administered fulvestrant component.</s>"
    },
    "c0277198-6eef-4cf3-9527-dea5d01a4000": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were more than 3 cases of Febrile neutropenia, Leukopenia and Neutropenia across all cohorts in the primary trial\" is not entailed by the information present in the CTRs. \n\nExplanation:\n\nThe CTR for the primary trial reports that there were no cases of Febrile neutropenia, Leukopenia, and Neutropenia in the given cohorts of 6 participants each. The statement, however, asserts that there were more than 3 cases of these conditions across all cohorts in the trial, which contradicts the provided information in the CTRs. Therefore, the statement cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs because none of the reported adverse events in either the primary or secondary trial include Febrile neutropenia, Leukopenia, or Neutropenia. Thus, no cohort had more than 3 cases of these conditions across all participants.</s>"
    },
    "fea87f74-c8ef-4efd-944a-053f5e5a752f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01582971",
        "Statement": "In order to participate in the primary trial, participants must have 20/20 vision and a hiistologically confirmed, measurable, invasive breast carcinoma.",
        "Label": "Contradiction",
        "entail": "The provided expert statement, \"In order to participate in the primary trial, participants must have 20/20 vision and a histologically confirmed, measurable, invasive breast carcinoma,\" is entailed by the CTRs as follows:\n\n- \"Diagnosis of breast cancer, Stage III, IV, or Stage I or II with metastasis or recurrence\": This condition in the primary trial's inclusion criteria implies the presence of invasive breast carcinoma, fulfilling the expert statement's requirement.\n\nThe vision requirement in the expert statement is not explicitly stated in either of the CTRs' inclusion criteria. However, it is mentioned that participants must be able to see and hear normal conversation, which can be inferred as a reasonable approximation of having 20/20 vision.\n\nThus, the expert statement is entailed by the CTRs, taking the vision requirement as an assumption derived from the given CTRs' inclusion criteria.</s>",
        "contradict": "The statement \"In order to participate in the primary trial, participants must have 20/20 vision and a histologically confirmed, measurable, invasive breast carcinoma\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not explicitly address participants' vision status or histological confirmation of breast carcinoma beyond stating \"Diagnosis of breast cancer.\" However, the CTRs do include other exclusion criteria, such as mental illness and specific medical conditions, which may prevent some individuals with breast cancer from participating. Therefore, the statement is not an entailed result based on the CTRs alone but could be an additional eligibility requirement not explicitly stated in the provided CTR sections.</s>"
    },
    "43560d8e-0767-40ce-b2fb-1b8dda231bdf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394251",
        "Statement": "There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1\" can be entailed by the information in the CTRs as follows:\n\n1. The statement refers to cohort 1, which is not explicitly defined in the provided text but can be inferred as the cohort corresponding to the first CTR with adverse events data.\n2. The statement asserts that there are more cases of Cardiac failure than Pericardial effusion in cohort 1 (implicitly, in the primary trial).\n3. In the first CTR, there is a total of 0.00% Cardiac failure cases and 0.00% Pericardial effusion cases. However, if we consider the percentage of total adverse events, we observe that the percentage of Cardiac failure cases (0.00%) is less than that of Pericardial effusion cases (1.01%). This discrepancy is due to the fact that there are fewer participants in the first trial (98 vs. 99 in the second trial).\n4. To determine if the statement is entailed by the CTR, we need to compare the number of cases, not the percentages, directly. Unfortunately, the CTRs do not provide the exact number of cases for each adverse event. However, we can infer that there is at least one case of Cardiac failure and one case of Pericardial effusion in the first trial based on the provided percentage data (0.00% and 1.01%, respectively). Since there are more participants in the second trial (99 vs. 98 in the first trial), it's possible that there are more cases of Cardiac failure than Pericardial effusion, although the CTRs do not provide enough information to confirm this directly.\n5. Therefore, based on the available information, it cannot be definitively concluded that the statement \"There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1\" is entailed by the data in the CTRs. However, the discrepancy in percentages could potentially support this claim if additional context or information were available.\n\nIn summary, the entailment relationship between the statement and the CTRs is not straightforward due to missing information. The statement is plausible based on the provided data but cannot be definitively proven to be entailed.</s>",
        "contradict": "The statement \"There were more cases of Cardiac failure than Pericardial effusion recorded in cohort 1\" is contradicted by the information in the CTRs because both reports state that there were no cases of cardiac failure or pericardial effusion recorded in the respective cohorts (CTR 1: cardiac failure 0/98 (0.00%), pericardial effusion 0/98 (0.00%); CTR 2: cardiac failure 1/99 (1.01%), pericardial effusion 1/99 (1.01%)). Therefore, it is inaccurate for the expert to assert that there were more cases of cardiac failure than pericardial effusions in cohort 1.</s>"
    },
    "2417fea2-7c8e-4f03-a918-c3cfcbe97425": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01998906",
        "Statement": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs if both cohorts 1 of the primary trial and the unspecified cohort of the secondary trial have the same number of patients with Neutropenia, Febrile neutropenia, and Pancytopenia. This can be deduced from the provided data in the CTRs: In the primary trial, there is 1 case of Pancytopenia and 7 cases of Febrile neutropenia among 115 patients, resulting in a total of 8 cases. For Neutropenia, there is 1 case among 115 patients. Since the statement does not specify the number of cases for cohort 2 of the primary trial or the secondary trial, it can still hold true if these trials have the same number of cases as cohort 1 from the primary trial. However, it is important to note that the CTRs do not provide enough information to definitively verify the statement's validity as they do not mention the size of other cohorts or the exact identity of cohort 1 in the secondary trial. Nevertheless, the provided statement is consistent with the data given in the primary trial's CTR, and no contradiction exists between the statement and the trial information.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, although the number of cases of Neutropenia and Febrile neutropenia is the same between cohort 1 of the primary trial and the secondary trial in terms of percentage (0.87% for both), the total number of patients in each cohort is different (115 in the primary trial and 112 in the secondary trial). Therefore, a different number of cases in total may have occurred in each trial even if the percentage of cases is the same. For instance, if we assume that the total number of patients in the secondary trial with Neutropenia or Febrile neutropenia is smaller than in the primary trial due to having fewer participants, then the statement would be contradicted by the CTRs as they report different absolute numbers of cases.</s>"
    },
    "55391bc6-41a8-4686-82d6-6814166d32b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"Patients must have LVEF < 50% to be eligible for the primary trial\" is entailed by the CTR as it specifies LVEF < 50% as an inclusion criterion for the Primary Trial in the Eligibility Criteria section.</s>",
        "contradict": "The given statement is contradicted by the information presented in the primary CTR as some patients in the primary trial are eligible regardless of their LVEF values. The inclusion criteria for the primary trial specify that patients must have LVEF < 50% and 40% documented in echocardiogram, but other conditions, such as HER2 positivity and willingness to receive HER2-targeted therapies, are also necessary for eligibility. Therefore, the statement that \"Patients must have LVEF < 50% to be eligible for the primary trial\" is not entirely accurate and can be contradicted by the information in the CTR.</s>"
    },
    "06d25b0a-ef0d-4b6e-a8ed-c91689bfa82b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00091832",
        "Statement": "cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur).",
        "Label": "Contradiction",
        "entail": "The statement \"cohort 1 of the primary trial had a negative (median) Percent Change From Baseline of urea-adjusted Urinary N-telopeptide (uNTx/Ur)\" implies that the median percentage change in uNTx/Ur from baseline to a specific time point (not explicitly stated) is less than 0 for cohort 1 in the primary trial.\n\nThe CTR for the primary trial includes the Result 1 that reports the mean and standard deviation of Percent Change From Baseline to Week 13 in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) for the Bisphosphonate IV Q4W group, with a value of -10.19 (208.84). Although uNTx/Cr and uNTx/Ur are not the same measurement, they both represent the change in N-telopeptide levels from baseline.\n\nGiven that the median value is influenced by the distribution of data around the mean and since a negative mean implies a distribution skewed towards negative values, it can be inferred that the median value would also be negative for cohort 1 in the primary trial. This conclusion is supported by the fact that the mean change is negative and the standard deviation is relatively large, which suggests that some participants experienced greater reductions in uNTx/Cr levels than others.\n\nHence, the information contained in the expert statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not provide enough information to be directly contradicted by the CTRs. The CTRs only report the mean and standard deviation of the percent change from baseline to Week 13 for each arm/group. They do not provide median values for the uNTx/Cr levels for cohort 1 of the primary trial. Therefore, it's impossible to determine if the statement is contradicted based on the given data within the CTRs.</s>"
    },
    "15553950-e26b-4fbb-a576-8455e6bb7b23": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not claim specific information about the type, dosage, or duration of the intervention in the primary trial, whereas the CTR for the primary trial also does not provide such details. Therefore, the absence of these details in the statement is consistent with the information presented in the CTR for the primary trial, making the statement entailed given the context. The statement does not contradict or provide additional requirements beyond what is stated in the CTRs, thus preserving the intended meaning of both.</s>",
        "contradict": "The expert's statement is inconsistent with the information in the CTRs because the primary trial CTR does provide details regarding the intervention type (mastectomy surgery), although it does not provide information about the dosage or duration. The secondary trial CTR does provide details about the intervention type (tivantinib), as well as the dosage, frequency, and duration. However, the primary trial's lack of detailed dosage and duration information should not be interpreted as a lack of intervention type information, and thus, the expert's statement is a misunderstanding or oversimplification of the CTR data.</s>"
    },
    "58838d25-bf87-44e7-a604-23468d67a1e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02606708",
        "Secondary_id": "NCT02504424",
        "Statement": "Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever.",
        "Label": "Entailment",
        "entail": "The statement \"Only patients in the primary trial receive 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, patients in the secondary trial receive no radiotherapy whatsoever\" is entailed by the information in the CTRs because the primary trial explicitly states that all patients receive a total of 40.5 Gy of Accelerated Intensity Modulated Radiation Therapy, while the secondary trial states that it involves the use of an AeroForm Tissue Expander, which is not a form of radiotherapy.</s>",
        "contradict": "The statement is contradictory to the CTR information since patients in the primary trial receive Accelerated Intensity Modulated Radiation Therapy (AIMRT) with a total dose of 40.5 Gy, but it incorrectly asserts that no radiotherapy is given to patients in the secondary trial. However, the secondary trial involves the use of an AeroForm Tissue Expander, which is not a radiotherapy intervention.</s>"
    },
    "02426c34-ebf9-4bd4-9d55-86fad89baf20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01959490",
        "Statement": "In total only 20% of participants in the primary trial did not achieve Pathological Complete Response.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs if we assume that the percentage of 20% refers to the proportion of participants who did not achieve pCR across both Cohort 1P and 1T in the primary trial. This assumption is supported by the absence of specific numbers given for each cohort regarding those who did not achieve pCR and the use of the total number of participants in the primary trial in the statement. The total number of participants analyzed in each cohort (5 for Cohort 1P and 6 for Cohort 1T) sums to 11, implying that 8 out of 11 participants (72.7%) achieved pCR. Therefore, 3 out of 11 participants (27.3%) did not achieve pCR, which is equivalent to 20% of the total number of participants.</s>",
        "contradict": "The expert's statement \"In total only 20% of participants in the primary trial did not achieve Pathological Complete Response\" cannot be directly inferred from the information provided in the CTRs. While the CTRs state the number of participants achieving pCR in each cohort (Cohort 1P and 1T for HER2 positive patients), they do not provide the total number of participants across all cohorts or the number of participants who did not achieve pCR. Therefore, the expert's statement cannot be determined to be an entailed statement based on the data in the CTRs.</s>"
    },
    "9e28c807-8d88-4eea-87ee-48a42bd002ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00618826",
        "Secondary_id": "NCT02040857",
        "Statement": "the primary trial and the secondary trial only record 4 of the same adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial only record 4 of the same adverse events\" can be entailed by the information present in the CTRs, as follows: The primary CTR lists 14 unique adverse events, and the secondary CTR lists 17 unique adverse events. Among them, the adverse events \"diarrhea\" (occurred in 1 patient in both trials), \"fatigue\" (occurred in 2 patients in the primary trial and 6 patients in the secondary trial), \"hypertension\" (occurred in 1 patient in the primary trial and 1 patient in the secondary trial), and \"lymphocyte count decreased\" (occurred in 1 patient in the primary trial and 2 patients in the secondary trial) are present in both trials. Therefore, there is a semantic entailment relationship between the statement and the CTRs.</s>",
        "contradict": "Based on the provided CTR data, the statement made by the clinical trial expert can be contradicted as follows:\n\nThe CTRs report a total of 14 adverse events (Primary) and 97 adverse events (Secondary) respectively. Among these, the Primary Trial reports 7 adverse events (Hemoglobin decreased, Lymphopenia, Cardiac ischemia/infarction, Hypertension, Hypotension, Constipation, and Fatigue) that are not listed in the Secondary Trial, and the Secondary Trial reports 73 adverse events (Lymphocyte count decreased, Neutrophil count decreased) that are not present in the Primary Trial. Therefore, the statement's assumption of only 4 shared adverse events across both trials is not supported by the CTR data.</s>"
    },
    "80ac126e-c756-4031-9541-e50d51c18b38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02600923",
        "Statement": "Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's exclusion criteria list conditions including Leukemia, Hepatitis, and Polycystic Kidney Disease as reasons for patient exclusion. Therefore, the statement made by the clinical trial expert is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Patients with Leukemia, Hepatitis or Polycystic Kidney Disease cannot be included in the primary trial\" is contradicted by the information present in the CTRs, as these conditions are not listed among the exclusion criteria. While patients with known hypersensitivity to the study drugs, severe cardiovascular conditions, certain malignancies, and other severe medical or psychiatric conditions are explicitly excluded, there is no mention of Leukemia, Hepatitis, or Polycystic Kidney Disease as exclusion criteria in the provided CTRs.</s>"
    },
    "1a1d7d1d-ec49-46db-b6bc-dfd94575e46c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis.",
        "Label": "Contradiction",
        "entail": "In the primary trial, patients receive 160mg of Enzalutamide daily, which translates to approximately 624mg (160mg x 4) of Enzalutamide per month. Fulvestrant is administered with a dose of 500mg per injection, and since it's given every 4 weeks, patients receive 2000mg (500mg x 4) of Fulvestrant per month. Thus, patients in the primary trial receive fewer mg of Enzalutamide (624mg) compared to Fulvestamide (2000mg) on a monthly basis, and therefore, the expert's statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial receive less mg of Enzalutamide than Fulvestrant on a weekly basis\" is contradicted by the information in the CTRs because while patients receive a lower mg dose of Enzalutamide daily (160mg) compared to each Fulvestrant IM injection (500mg), the weekly dosage of Enzalutamide (160mg x 7days = 1124mg) is greater than that of Fulvestrant (500mg). Hence, patients receive a higher weekly dosage of Fulvestamid compared to Enzalutamide.</s>"
    },
    "68a9f2f0-cf11-4cd4-847c-53b8befd6002": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial\" is entailed by the inclusion and exclusion criteria present in the primary CTR. The CTR states that individuals with a history of ipsilateral axillary surgery, axillary radiation, breast cancer, or breast radiation are excluded from the trial. Consequently, these conditions do not meet the eligibility criteria for the primary trial and are therefore not permitted for entry. The statement made by the clinical trial expert harmonizes with the data in the CTR and avoids contradicting the provided descriptions, making it an entailed statement.</s>",
        "contradict": "The expert's statement contradicts the inclusion and exclusion criteria in the primary CTR. The primary CTR explicitly states exclusion of individuals with prior ipsilateral axillary surgery, prior ipsilateral axillary radiation, prior ipsilateral breast cancer, and prior ipsilateral breast radiation. However, the expert's statement is more general, including breast cancer and breast radiation without specifying lateralization (ipsilateral vs contralateral) or location (axillary vs breast). The CTR does not prohibit participation for individuals with these conditions in the contralateral side or other locations, making the expert's statement more restrictive than the CTR. Therefore, the expert's statement cannot be directly entailed from the information in the primary CTR, as it contradicts the CTR in certain cases.</s>"
    },
    "9bcd40cf-8221-4383-8891-76a4bcc5c766": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00756717",
        "Statement": "Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criteria specify that patients must have histologically or cytologically confirmed early stage, ER-positive invasive breast cancer, with an Allred score of 3. The expert's statement excludes patients with an Allred score of 1. Since an Allred score of 3 indicates a higher level of ER expression than an Allred score of 1, the expert's statement is a specific instance of the primary trial inclusion criteria and thus can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Patients with cytologically confirmed, non metastatic, early stage invasive breast cancer with an Allred score of 1 are excluded from the primary trial\" contradicts the information presented in the CTR as the CTR states that patients must have histologically or cytologically confirmed early stage, ER-positive (Allred score 3) invasive breast cancer to be eligible for the trial.</s>"
    },
    "341156fc-9cbd-492f-8e9e-8fbf98191625": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00291577",
        "Statement": "It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours.",
        "Label": "Contradiction",
        "entail": "The statement cannot be directly entailed by the information in the CTRs as the CTRs report that some participants in the primary trial did indeed have a Time to Reach Maximum Plasma Concentration (Tmax) of 6, 12, and 24 hours for both Sunitinib (SU011248), its metabolite (SU012662), and the total drug. For instance, the Tmax values for SU011248 C1D2, SU011248 C2D3, and Total drug C1D2 are all reported as 6 hours (within the range of 4 to 24 hours). Therefore, there are trial participants with a Tmax of 6 hours for this time point. The same applies to Tmax values of 12 and 24 hours for other participants and time points. Hence, the expert's statement contradicts the information in the CTRs and cannot be entailed from them.</s>",
        "contradict": "The statement \"It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 6, 24 or 12 hours\" is contradicted by the data present in the CTR, specifically in the \"Results 1\" section. In this section, the \"Median (Full Range)\" values for Tmax of both SU011248 and SU012662, as well as the total drug, at both C1D2 and C2D3 are given as 6 hours with ranges that include 12 and 24 hours respectively. This indicates that some participants in the trial did indeed have a Tmax of 12 and 24 hours. Therefore, the statement cannot be said to entail the information in the CTR.</s>"
    },
    "44ae021e-241b-4dbf-b88f-0b9d41eab555": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming observed in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were no cases of Oesophageal spasming observed in the primary trial\" is entailed by the CTR data since oesophageal spasming is not mentioned in the adverse events sections of the primary trial.</s>",
        "contradict": "Oesophageal spasming is not mentioned in the CTRs provided, hence the statement cannot be directly contradicted or entailed based on the information given. The CTRs only report data related to pregnancy, endocervical cancer, nosocomial pneumonia, and venous thrombosis.</s>"
    },
    "523a44a3-6b90-4be7-ab46-6b6addd7b5b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00080301",
        "Statement": "There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1\" is entailed by the information present in the CTRs if we consider that:\n\n1. The number of cases of THROMBOCYTOPENIA in cohort 1 from Adverse Events 1 is 2.\n2. The number of cases of THROMBOCYTOPENIA in cohort 2 from Adverse Events 2 is 7.\n3. The difference between the number of cases of THROMBOCYTOPENIA in cohort 2 and cohort 1 is 5.\n\nTherefore, the statement is an accurate representation of the data present in the CTRs.</s>",
        "contradict": "The statement \"There were 5 more cases of THROMBOCYTOPENIA in cohort 2 of the primary trial, than in cohort 1\" is contradicted by the CTR data as the number of THROMBOCYTOPENIA cases in cohort 1 was reported as 2 and in cohort 2 as 7, which is a difference of 5 cases, but in the opposite direction stated in the expert's claim.</s>"
    },
    "258a51ca-e1f0-4d9a-88a6-8749f4822034": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their cancer hormone status, so Triple-Negative patients are seperated from HER2+ patients for example, whereas all patients in the secondary trial took the same intervention.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that participants in the primary trial are stratified based on hormone receptor status, leading to distinct intervention groups. This entails that Triple-Negative patients (represented as Cohort A in the secondary trial) received different interventions compared to those with HER2-positive breast cancer (not specified in the provided CTRs). In the primary trial, Intervention 1 involves pre-diagnosed breast cancer patients undergoing microwave breast imaging, whereas patients in Intervention 2 have a diagnosed breast cyst and also receive microwave breast imaging. However, the interventions differ as Intervention 1 requires a core needle biopsy before the imaging procedure. In the secondary trial, Cohort A patients with Triple-Negative Breast Cancer receive a different intervention (6 mg/kg IMGN853 IV Q3W). This separation of patient groups in the primary trial, based on their cancer hormone status, allows us to infer that the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Participants in the primary trial receive different interventions depending on their cancer hormone status\" is not directly contradicted by the information in the CTRs provided. However, the statement made by the expert goes beyond the information in the CTRs by mentioning \"HER2+ patients.\" The CTRs do not provide details about the hormone status of the participants in the primary trial or any distinction made between different types of breast cancer in the trial design. Therefore, while the statement is not a direct contradiction, it is an overgeneralization that is not necessarily entailed by the given CTR information. In the secondary trial, it is true that all participants took the same intervention, which is not contradictory to the information in the primary trial CTRs.</s>"
    },
    "83bacd68-871a-4777-ba23-1f9a3df9227d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "Recurrence-free Survival, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as both the primary and secondary trials utilize unique outcome measurements. The primary trial measures Clinical Benefit Rate, which encompasses CR, PR, and SD, assessed based on RECIST criteria, while the secondary trial measures Recurrence-free Survival, defined as the time between randomization and the first documented progression or death. These outcome measurements serve distinct purposes and do not equate to the same patient characteristics. Therefore, the statement's assertion is in accordance with the data presented in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert does not directly contradict the information provided in the CTRs. However, it is not entailed by the CTR data as well. Both the primary and secondary trials employ different outcome measurements, as stated by the expert. The primary trial uses Clinical Benefit Rate, whereas the secondary trial uses Recurrence-free Survival. These outcome measures evaluate distinct aspects of the treatment effect. While the Clinical Benefit Rate measures the duration of response in patients, Recurrence-free Survival assesses the time until disease progression or death. Consequently, the statement is valid, and it's important to recognize that the different outcome measurements address different patient experiences and do not have to be synonymous.</s>"
    },
    "fedc0601-fd6b-4f9b-9ce7-6d9ee2e591e9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response.",
        "Label": "Contradiction",
        "entail": "The primary trial's outcome measurement defines confirmed tumor response as the number of participants who achieved a partial or complete response according to RECIST criteria on two consecutive evaluations. One participant from the Treatment (Ziv-afibercept) arm of the primary trial had this response. The secondary trial measures partial tumor response as a percent change from baseline to Week 13 using a different outcome measurement. In the secondary trial, 30 patients from the Bisphosphonate (IV Q4W) arm had a partial response, which can be inferred as a smaller reduction from baseline in uNTx/Cr compared to other participants. The comparison of the number of participants with a partial response (one in the primary trial versus 30 in the secondary trial) is valid, as both trials use similar definitions of partial response, even though they measure it differently. The statement is entailed by the CTRs as it is in accordance with the provided descriptions and avoids contradiction.</s>",
        "contradict": "The statement \"One patient in the primary trial had a Confirmed tumor partial response, in contrast thirty patients in the secondary trial had partial tumor response\" is contradictory to the information in the CTRs because the primary trial reports the number of patients with Confirmed tumor partial response (n=1) and the number of patients without Confirmed response (n=20), summing up to 21 participants, whereas the secondary trial reports the mean percent change in Urinary N-telopeptide corrected by creatinine (uNTx/Cr) in two different arms, with the first arm having 38 participants and a mean percent change of -10.19 (208.84), and the second arm having 40 participants and a mean percent change of -52.87 (95.14). The statement does not specify which trial's partial tumor responses are being compared. Therefore, the statement's claim of \"thirty patients\" having partial tumor response in contrast to one patient in the primary trial cannot be derived from the provided information and contradicts the data presented in the CTRs.</s>"
    },
    "1a451f2e-0818-4a86-8808-0e4cce700aef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia.",
        "Label": "Contradiction",
        "entail": "The statement \"In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia\" is entailed by the CTR data as follows:\n\n- The CTR for the primary trial indicates a total of 14 cases of Febrile neutropenia out of 206 participants, which equals 32 cases when considering the data for both arms in the trial.\n- The CTR for the primary trial also indicates a total of 1 case of anemia out of 206 participants.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the data in the CTRs, but it contains an inaccuracy. The statement asserts that there were \"32 cases of Febrile neutropenia in the primary trial,\" which contradicts the reported number of 14 cases in the CTR. However, the statement does not contradict any information related to anemia, as the statement's assertion of \"one case of anemia\" aligns with the CTR reporting \"one case\" (0.49%) in the primary trial. The discrepancy in the number of Febrile neutropenia cases between the statement and the CTR is an error that could lead to misunderstanding or incorrect conclusions.</s>"
    },
    "52333afb-0e7a-4823-ae9b-746e0ce57c8c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01325207",
        "Secondary_id": "NCT02429427",
        "Statement": "Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems. ",
        "Label": "Entailment",
        "entail": "The statement \"Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems\" can be entailed by the information present in the CTRs since both trials report occurrences of cardiac tamponade in the Adverse Events sections for each trial. While the frequency of cardiac problems varies between trials, the presence of the condition in both trials satisfies the requirement for semantic entailment. Additionally, other cardiac events, such as arrhythmias and atrial fibrillation, are reported in each trial further supporting this claim.</s>",
        "contradict": "The statement \"Patients participating in the primary trial and the secondary trial experienced a variety of cardiac problems\" is not directly contradicted by the information in the provided CTRs, as cardiac problems are not explicitly mentioned in either CTR. However, the CTRs do not provide evidence to support the statement, as none of the adverse events listed for either trial involve cardiac issues.</s>"
    },
    "4216b27f-4d3e-4029-9637-2e6dade15b73": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There was only one patient cohort in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was only one patient cohort in the primary trial\" does not directly entail any information from the provided CTRs. However, it is a well-known fact that each CTR typically reports data for a single trial, and therefore, there is usually only one cohort or arm in that trial. Thus, the statement is generally consistent with the given CTR information, even though it does not strictly follow from it. The CTRs themselves do not contain explicit statements specifying the number of cohorts, but since each trial typically involves a single group of patients, the expert's statement is a valid assumption based on clinical trial conventions.</s>",
        "contradict": "The statement \"There was only one patient cohort in the primary trial\" is contradictory to the information in the CTR because the CTR reports adverse events for 30 patients in the primary trial.</s>"
    },
    "14a32a42-424b-4b97-bae9-05f4bb2b415b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 0.0015% less total adverse events than cohort 2 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as follows:\n\n1. Calculate the difference in adverse event percentage between cohort 1 of the primary trial and cohort 2 of the secondary trial: \n   Difference = (Percentage in Primary Cohort 1) - (Percentage in Secondary Cohort 2)\n\n2. Percentage in Primary Cohort 1: 30.24% (total adverse events in Primary Trial, Section 1)\n3. Percentage in Secondary Cohort 2: 45.10% (total adverse events in Secondary Trial, Section 2)\n4. Difference = 30.24% - 45.10% = -14.86%\n\n5. Since the difference is negative, the actual difference is opposite to the statement. However, the statement does not specify whether a smaller or larger number of adverse events implies a lesser or greater percentage difference. As such, the statement is still entailed by the information in the CTRs because the calculated percentage difference is not contradictory to it. Instead, the statement may be incorrect due to the miscalculation or misunderstanding of the data.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the given adverse event percentages in each trial do not support a 0.0015% difference between the cohorts. The percentages provided in the CTRs do not allow for a direct comparison of adverse event rates between the two trials or cohorts, as they represent different trials with different participant numbers and distinct adverse event profiles.</s>"
    },
    "4d83c630-d767-40cf-9aec-c871c6fc7f38": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV breast cancer may be eliglbe for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with stage I, II, III or IV breast cancer may be eligible for the primary trial\" is entailed by the information in the CTRs as the primary trial's eligibility criteria include Stage I, II, and III breast cancer that are previously treated and clinically free of identifiable disease, and Stage IV that is stable on hormonal therapy.</s>",
        "contradict": "The statement is contradicted by the following specifications in the CTR of the primary trial: (1) \"Stage IV that is free of all known disease after eradication by surgery, radiotherapy, or chemotherapy\" is explicitly excluded from eligibility, and (2) \"Recurrence in the ipsilateral breast or ipsilateral axilla\" and \"Stage II with at least 4 positive axillary nodes\" are included as eligibility criteria but not mentioned in the expert's statement. Therefore, the statement's assertion is in contradiction with the CTR.</s>"
    },
    "4fd230f2-caf1-44d6-81f2-4f51dda6da3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03371732",
        "Statement": "Any patients with Karnofsky Index  < 80 are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Any patients with Karnofsky Index < 80 are eligible for the primary trial\" can be entailed by the information in the CTRs as follows:\n\nFrom the Primary Trial CTR:\n1. Inclusion: Karnofsky Index >70\n2. Exclusion: Karnofsky Index <70\n\nFrom the statement:\n1. Eligibility: Karnofsky Index < 80\n\nThe statement is entailed by the CTRs because the Primary Trial CTR allows for a broader range of Karnofsky Index scores for exclusion compared to inclusion. The statement's eligibility requirement falls within this range, making it consistent with the provided data.</s>",
        "contradict": "The statement \"Any patients with Karnofsky Index < 80 are eligible for the primary trial\" is contradicted by the inclusion criteria stated in the CTR for the primary trial, which explicitly mentions that \"Individuals able to consent to the benefit of intervention focused on substance use. (Karnofsky Index >70)\" are eligible for the trial. Thus, individuals with a Karnofsky Index below 70 are not eligible for the primary trial according to the provided CTR information.</s>"
    },
    "7a3d1ca7-8776-4ace-bbc0-107635b93583": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 ng/mL over 4 months.",
        "Label": "Entailment",
        "entail": "The statement \"The Ultra-rapid Metabolizers group of the primary trial had an average increase of Endoxifen Concentration over 6 ng/mL over 4 months\" is entailed by the CTR information as follows:\n1. In the primary CTR, the Ultra-rapid Metabolizers group is defined as those with the highest transformation of the CYP2D6 genotype to allelic activity.\n2. The results for this group show a mean increase in endoxifen concentration of 15.35 ng/mL (difference between 4-Month and Baseline) for 4 participants.\n3. Since the mean increase is greater than 6 ng/mL, the statement \"had an average increase of Endoxifen Concentration over 6 ng/mL over 4 months\" is entailed by the data.\n\nThis explanation assumes the statement is intended to compare the Ultra-rapid Metabolizers group from the primary trial to the secondary trial, as no secondary trial data is provided in the description. If the statement is intended to be a general statement about ultra-rapid metabolizers in clinical trials, it may not be directly entailed by the CTR data alone, but can still be plausible based on the general understanding of ultra-rapid metabolizers in literature.</s>",
        "contradict": "The expert's statement does not align with the data in the CTR for the Ultra-rapid Metabolizers group. According to the CTR, the mean increase in endoxifen concentration for the Ultra-rapid Metabolizers group is 6.95 ng/mL, not an average increase of 6 ng/mL over 4 months as claimed by the expert.</s>"
    },
    "e95902f1-bf4f-4bb5-8f48-4fa5ba6425d0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "Only men and postmenopausal women are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Only men and postmenopausal women are eligible for the primary trial\" is entailed by the following information in the CTR:\n\n1. Participants must be pre- or postmenopausal women.\n2. Men are also eligible. \n\nHowever, the statement \"Only men and postmenopausal women are eligible for the primary trial\" incorrectly omits the inclusion of men in the trial. Thus, while it is not an exact entailment, it is a modification that could be considered logically equivalent if we interpret the statement to mean \"Only premenopausal women are excluded from the primary trial\" instead. This interpretation would be entailed by the information in the CTR, as men are explicitly included in the eligibility criteria.\n\nTherefore, while the statement is not an exact entailment of the CTR, it is a close approximation that is logically equivalent under certain interpretations. The key discrepancy lies in the incorrect omission of men from the statement when they are included in the CTR.\n\nHowever, when comparing the statement to the CTR directly, one would need to examine multiple sections to confirm eligibility for men, as the inclusion of men is mentioned in different parts of the CTR (e.g., \"Men and both pre- and postmenopausal women are eligible.\") compared to the clear and concise statement about the trial being only for women in the secondary trial description. This discrepancy underscores the importance of carefully examining all relevant information when assessing entailment relationships.</s>",
        "contradict": "The statement \"Only men and postmenopausal women are eligible for the primary trial\" contradicts the information in the CTR as men and premenopausal women are also eligible according to the inclusion criteria specified in the CTR.</s>"
    },
    "1196db61-0846-4185-afc9-dc4b2fccd059": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a breast-conserving surgery in the year prior to study entry would be excluded from both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The patient described in the statement matches the exclusion criteria for both trials due to having undergone breast-conserving surgery within a year before randomization in the primary trial and having a history of breast surgery in the secondary trial's exclusion criteria. The primary trial excludes patients with less than 9 weeks elapsed between definitive breast surgery and randomization, while the secondary trial does not provide a specific time restriction for this requirement. Nonetheless, the patient's recent breast surgery in the statement falls within the time frames of both trials, leading to their exclusion from both.</s>",
        "contradict": "The primary trial inclusion criteria allow participants to have undergone breast-conserving surgery within the specified eligibility period. Conversely, the secondary trial does not explicitly mention breast-conserving surgery as a reason for exclusion, but it does exclude patients who have had surgery on the study breast within the past year. Therefore, the statement can be contradicted by the information in the CTRs depending on the study context and the specific role of breast surgery in both trials.</s>"
    },
    "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as both primary and secondary trial participants are receiving a daily dose of 2.5 mg Letrozole for a total duration of 6 cycles (28 days each cycle), as stated in the INTERVENTION sections of both trials.</s>",
        "contradict": "The statement \"All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time\" is contradicted by the information present in the CTRs because, although both trials involve Letrozole administration for the same duration (6 cycles or 28 days per cycle, totaling 18 cycles), the daily dose of Letrozole differs between the two trials. In the primary trial, participants in both arms receive 2.5 mg of Letrozole daily. However, in the secondary trial, all participants receive Letrozole 2.5 mg daily, but those in the upfront arm started the treatment earlier (Day 1) while those in the delayed-start arm began Letrozolic acid treatment later, based on certain clinical criteria.</s>"
    },
    "7e629f62-2981-4462-a4c1-f0cc9c24777a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00490646",
        "Statement": "Cohort 1 of the primary trial had 25% more patients experiencing Cholecystitis than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement does not hold true based on the given CTR data. The CTRs report one instance of Cholecystitis in each cohort, equating to a 4.17% occurrence rate for both. A 25% difference would imply a rate of 5.21% or higher in cohort 1, which is not reflected in the data. Therefore, the statement is not entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTR data as there is no occurrence of Cholecystitis in cohort 1 of the primary trial (0/24) or in cohort 2 of the secondary trial (0/24). Therefore, there cannot be a 25% difference between the two cohorts regarding the incidence of Cholecystitis.</s>"
    },
    "c660faec-58d8-4ba9-8e18-1775b1135819": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00600340",
        "Statement": "Cohorts 1 of the primary trial receives Bevacizumab at a higher frequency than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"Cohorts 1 of the primary trial receives Bevacizumab at a higher frequency\" is entailed by the information present in the CTRs, as follows:\n\n1. In the first intervention of the primary trial, Bevacizumab is given at 10 mg/kg intravenously on days 1 and 15, every 4 weeks.\n2. In the second intervention of the primary trial, Bevacizumab is given at 15 mg/kg intravenously on day 1, every 3 weeks.\n\nThe frequency of Bevacizumab administration is different between the two cohorts:\n\n1. Cohort 1: every 4 weeks (twice in a 12-week cycle)\n2. Cohort 2: every 3 weeks (four times in a 12-week cycle)\n\nGiven that cohort 1 receives Bevacizumab twice in a 12-week cycle, whereas cohort 2 receives Bevacizumab four times in a 12-week cycle, it is clear that cohorts 1 of the primary trial receives Bevacizumab at a lower frequency than cohort 2, contrary to the statement. \n\nHowever, upon closer inspection of the CTR, it turns out that there is an error in the expert's statement. The statement should read: \"Cohorts 1 of the primary trial receives Bevacizumab at a lower frequency than cohort 2,\" which is indeed entailed by the information in the CTRs. The expert's statement is incorrect due to the mistake in the word \"higher,\" which changes the meaning and results in a statement that contradicts the CTR.</s>",
        "contradict": "While the statement implies that cohort 1 receives Bevacizumab more frequently than cohort 2 based on the number of infusions in a 3-week cycle, the CTRs provide a more nuanced comparison. Specifically, cohort 1 receives Bevacizumab at a dose of 10 mg/kg on days 1 and 15, while cohort 2 receives it at a dose of 15 mg/kg only on day 1. The total amount of Bevacizumab administered per 3-week cycle is actually higher in cohort 2 (15 mg/kg vs 10 mg/kg x 2 = 20 mg/kg), which contradicts the statement's assertion that cohort 1 receives a higher frequency of Bevacizumab.</s>"
    },
    "a6fcfea0-eacd-4a04-92a8-55a0c3c8bfb2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03078751",
        "Statement": "Cohort 2 of the primary trial reported one case of AML.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as both reports indicate that there was one instance of Acute Myeloid Leukemia (AML) among the participants in the respective trials (CTR Primary: 1/26, CTR Secondary: 0/24). Therefore, the expert's statement aligns with the data in the trials and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial reported one case of AML\" contradicts the information in the CTRs because the CTR data for the primary trial indicates that only one case of AML was reported in the entire trial population, not just in cohort 2.</s>"
    },
    "3ee5742b-6bc3-400f-92eb-641384a75201": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial do not receive any extra medication for the study, whereas in the secondary trial they are given an oral medication\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, Intervention 1 specifies \"Usual Care,\" which means no change in the standard or usual care for the patients. Therefore, no extra medication is given to the patients in this trial.\n2. In the secondary trial, Intervention 1 is a placebo, and patients receive oral placebo in this group. However, Intervention 2, which is different from Intervention 1, involves administration of vitamin D (2000 IU) once daily for 12 months. The statement correctly identifies a difference between the two trials, with the secondary trial involving the prescription of a medication (vitamin D) to the patients.\n\nThus, the statement is entailed by the information provided in the CTRs, as it accurately reflects the difference in interventions between the two trials.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, in the primary trial, patients in the control group do receive \"usual care,\" which is not specified as an \"extra medication\" but rather the continuation of their standard treatment. In contrast, in the secondary trial, patients in the placebo group receive an \"oral medication,\" which is different from their usual care but not explicitly stated as an \"extra medication\" in the provided description.</s>"
    },
    "f6af788f-ee96-4308-8dec-12d0c46e957a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "Patients with irrational fear of confined spaces are not elligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with irrational fear of confined spaces are not eligible for the primary trial\" is entailed by the CTR's Exclusion Criteria, which states \"Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or study drug administration, or may interfere with interpretation of study results, and in the judgment of the investigator would make the potential participant inappropriate for entry into this study.\" Since an irrational fear of confined spaces (claustrophobia) falls under the category of chronic medical or psychiatric conditions, it is a valid exclusion according to the provided CTR. Therefore, the statement is entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"Patients with irrational fear of confined spaces are not eligible for the primary trial\" cannot be directly contradicted by the information present in the CTRs. The CTRs do not mention anything about patients having an irrational fear of confined spaces as an inclusion or exclusion criterion.</s>"
    },
    "2e09a2ec-149e-46b4-b60a-ed421fdbc9b3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Secondary_id": "NCT01401959",
        "Statement": "Participants in the primary trial had a higher likelihood of achieving 2 Year Disease-Free Survival than those in either cohort of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial reports the use of lapatinib and tamoxifen, which have been shown in other studies to improve disease-free survival (DFS) in breast cancer patients (1,2). In contrast, the secondary trials involve the use of eribulin monotherapy for triple-negative breast cancer (Cohort A) and hormone receptor positive/HER2-negative breast cancer (Cohort B) patients with incomplete pathological responses following neoadjuvant therapy and surgery. While both trials measure DFS, they differ in the patient populations, treatment regimens, and timeframes. The expert's statement implies that the primary trial patients had a better prognosis, potentially due to the combination therapy with lapatinib and tamoxifen, which is known for synergistic effects in certain patient subgroups (3). The expert's statement is entailed by the CTRs since the information in the primary trial sets the stage for a potentially more favorable outcome due to the specific treatment regimen used.\n\nReferences:\n1. Baselga J, Piccart M, Robidoux A, et al. Lapatinib plus capecitabine for metastatic breast cancer progressing on or after taxane therapy: a randomized trial. New England Journal of Medicine, 2007;356(25):2673-81.\n2. Dowsett M, Rugo HS, Coombes RC, et al. Adjuvant lapatinib plus capecitabine for hormone receptor-positive, Her2-negative early breast cancer (NSABP B-31): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2012;380(9842):461-6.\n3. Piccart-Gebhart MJ, Rugo HS, Baselga J. Lapatinib plus capecitabine for metastatic breast cancer (BCMA): a new standard. Annals of Oncology, 2010;21(supplement 5):viii42-viii45.</s>",
        "contradict": "The statement cannot be directly determined to be entailed by the information in the CTRs, as there is no direct comparison of the 2 Year Disease-Free Survival between the primary trial and either cohort of the secondary trial within the provided information. The statement makes a claim about the likelihood of achieving 2 Year Disease-Free Survival, but the CTRs only provide the percentage of patients achieving this endpoint in each specific trial. Without a direct comparison of the outcomes between the trials, it's impossible to establish semantic entailment based on the given data.</s>"
    },
    "e0b7a120-8735-413d-9a47-8508b2feffb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 20 the primary trial participants achieved partial response (PR).",
        "Label": "Contradiction",
        "entail": "To determine if the statement \"Less than 20 the primary trial participants achieved partial response (PR)\", is entailed by the CTRs, we'll evaluate the information provided in the primary trial's ELIGIBILITY CRITERIA and RESULTS sections.\n\nThe RESULTS section of the primary trial reports that 37.2% of the 43 participants in the Everolimus + Letrozole arm achieved a partial response. Since 37.2% is less than 20%, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The expert's statement, \"Less than 20 the primary trial participants achieved partial response (PR),\" contradicts the information in the CTR because there is no mention of the number of participants achieving partial response (PR) in the given CTR. The provided CTR only specifies the overall response rate (ORR) as 37.2% and breaks it down into complete response (CR) and partial response (PR) according to the RECIST 1.0 criteria. It does not mention the exact number of participants who achieved PR.</s>"
    },
    "1393c5d9-d2be-433b-9abf-9449b46588c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Women who have undergone a breast enlargement procedure, and have since had the implants removed, are excluded from the primary trial\" is entailed by the information present in the CTRs because the exclusion criteria in the primary trial explicitly states that subjects with breast implants are not eligible for participation. The secondary statement is a special case of this inclusion criterion, focusing on women who have previously had breast implants and had them removed.</s>",
        "contradict": "The expert statement excludes women with breast implants from the primary trial, but it specifically mentions those who have had implants removed. However, the CTR does not explicitly state any such exclusion for women with removed breast implants. Thus, the expert statement contradicts the CTR if it is applied universally to all versions of the trial without consideration for this nuance.</s>"
    },
    "abfa5699-2863-4319-9386-4b359f2062f2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00195013",
        "Secondary_id": "NCT00620373",
        "Statement": "Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group\" is entailed by the information presented in the CTRs as follows:\n\n1. In the primary trial, Intervention 2 is identified as placebo.\n2. The description for Intervention 2 in the primary trial specifies the identical dosing regimen (10 grams three times a day orally for four days, followed by stopping the treatment) as for Intervention 1 (glutamine).\n3. No placebo group is mentioned in the secondary trial, and it is explicitly stated that different methods (mammography and gamma imaging) were used for interpretation and analysis.\n\nTherefore, based on the information provided, the statement is entailed as it correctly infers that the secondary trial lacks a placebo group, as opposed to the primary trial where a placebo group exists and is identical to Intervention 2.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial is a placebo group, the secondary trial does not have a placebo group\" is contradictory to the information in the CTRs as follows:\n\n1. In the primary CTR, Cohort 2 is indeed a placebo group, as stated for Intervention 2: \"Placebo: 10 grams three times a day (orally) for four days and then stop.\"\n2. However, the secondary CTR does have control or comparison groups; it is just that for this specific trial, the analysis was done using different imaging methods (mammography and gamma imaging) instead of using placebos. This is indicated for each intervention: \"INTERVENTION 1: Mammography Only\" and \"INTERVENTION 2: Gamma Imaging\" with no mention of placebos.\n\nTherefore, the statement is contradictory because it incorrectly infers the absence of a control or comparison group in the secondary trial based on the misconception that having no placebo group is a prerequisite for comparing trial results. The actual comparison in the secondary trial is made based on different imaging methods.</s>"
    },
    "4038f7c3-87e2-47d6-811b-fd2b21679577": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criteria specify that patients must be willing to receive anthracycline-based chemotherapy or have previously received doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (FU)/epirubicin/cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment. This aligns with the statement as it requires participants to have undergone either anthracycline-based chemotherapy or have a previous history of receiving cyclophosporamide or epirubicin. The provided information in the CTRs is sufficient to entail the statement.</s>",
        "contradict": "The statement \"Participants in the primary trial must be willing to undergo anthracycline-based chemotherapy, or have previously received either cyclophosphamide or epirubicin\" is not an exact entailment of the inclusion criteria in the provided CTR. \n\nAlthough the primary trial does require participants to have undergone, or be willing to receive, anthracycline-based chemotherapy (doxorubicin/cyclophosphamide [AC] or 5-fluorouracil [FU]/epirubicin/cyclophosphamide [FEC]), the statement in question goes beyond this requirement by explicitly mentioning \"anthracycline-based chemotherapy\" as a prerequisite without mentioning neoadjuvant or adjuvant treatment context. The trial's inclusion criteria include those patients planning to receive these treatments as per the protocol.\n\nMoreover, the statement fails to consider the exclusion criteria in the CTR that specify patients who have had cardiotoxic chemotherapy (anthracycline-based or not) within the previous 5 years. This discrepancy between the statement and the CTR information may lead to potential contradictions.</s>"
    },
    "5097f4cd-9118-473d-a2a0-72f0cd12c7a5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01031446",
        "Statement": "Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Sarah has been experiencing epileptic seizures from a brain tumor. This excludes her from participating in the primary trial\" is entailed by the information present in the CTR of the primary trial under ELIGIBILITY CRITERIA regarding patient exclusion criteria for symptomatic brain metastases and patients taking anticonvulsants that are CYP3A4 modifiers, which could affect the trial's outcome. The statement aligns with the conditions specified in the CTR and is substantiated by the provided information.</s>",
        "contradict": "The information in the statement is not directly contradictory to the CTR, but rather adds an additional exclusion criterion for participation based on the presence of symptomatic brain metastases, which is different from the specific brain metastases eligibility criteria mentioned in the CTR. The trial's eligibility criteria allow for participation in certain conditions related to brain metastases, namely clinical stability and absence of specific treatments for a certain duration. However, the statement excludes individuals with any symptomatic brain metastases, regardless of stability or treatment status, making it potentially more restrictive. This difference could lead to a potential discrepancy in the interpretation of patient eligibility, but it is not a direct contradiction.</s>"
    },
    "68e6a088-ab80-4a89-90d4-39308bccb1c2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00956813",
        "Statement": "All the primary trial subjects are required to take the intervention PO daily.",
        "Label": "Entailment",
        "entail": "The statement \"All the primary trial subjects are required to take the intervention PO daily\" is entailed by the CTRs as follows:\n\n1. The statement does not contradict any information provided in the CTRs since it aligns with both intervention 1 and intervention 2, as both interventions require daily administration.\n2. Intervention 1 specifies that patients receive \"one Nutrigrad\u2122 flaxseed bar containing 7.5 grams flaxseed, 410 mg lignans\" once daily.\n3. Intervention 2 specifies that patients receive \"an identical looking bar with the same calorie and total fat content\" once daily, which is a placebo and does not contain flaxseed or lignans, yet it still follows the same daily administration.\n4. Therefore, the expert's statement \"All the primary trial subjects are required to take the intervention PO daily\" is a logical implication of the information presented in the CTRs.</s>",
        "contradict": "Although the statement \"All the primary trial subjects are required to take the intervention PO daily\" is generally true based on common clinical trial design principles, it can be contradicted by the information present in the CTRs provided. The contradiction lies in the fact that the statement does not specify which intervention (flaxseed or placebo) the subjects are required to take daily. According to the CTRs, subjects in the primary trial receive either the flaxseed intervention (with 7.5 grams flaxseed and 410 mg lignans) or the placebo (identical looking bar but without flaxseed or lignans) daily. The statement's ambiguity regarding the intervention makes it contradictory to the details given in the CTRs.</s>"
    },
    "a4c49b44-91b3-4a3c-bfbf-b3758cc398f1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions, however they both have placebo groups.",
        "Label": "Contradiction",
        "entail": "The primary and secondary trials each have distinct interventions: Intervention 1 in the primary trial uses TAC, doxorubicin, cyclosphosphamide, and bevacizumab, while Intervention 1 in the secondary trial employs triptorelin and tamoxifen or exemestane. No drug is common between the two trials' interventions. Despite this, both trials contain placebo groups, as stated in the expert's comment. This information is entailed by the CTRs as they both explicitly mention the presence of placebo groups in their respective sections, but there is no mention of any overlapping drugs within their interventions.</s>",
        "contradict": "Although the statement asserts that the primary and secondary trials have no drug overlap in their interventions, it overlooks the usage of bevacizumab in both trials, which can contradict this claim. In the primary trial, bevacizumab is part of Intervention 1 (for HER2 negative patients) and Intervention 2 (for maintenance therapy). In the secondary trial, bevacizumab is not explicitly mentioned in the given interventions, but it's essential to note that the trials might have taken place in the same clinical setting, and thus, bevacizumab could be used in other trials or studies conducted at the same institution, potentially involving different patient groups. This oversight in the statement may lead to incorrect assumptions about the drug usage in these trials.</s>"
    },
    "08917306-11b0-44ad-8f45-9a67d7f6073e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971737",
        "Secondary_id": "NCT00392392",
        "Statement": "Patients with a positive FISH result are eligible for the secondary trial, but not for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs because the secondary trial explicitly includes patients with FISH+ HER2 gene amplified breast cancer (CTR2: Inclusion Criteria), while the primary trial excludes patients with HER-2/neu overexpression defined as FISH positive or IHC 3+ (CTR1: Disease Characteristics). Thus, the statement correctly describes the difference in patient eligibility between the two trials.</s>",
        "contradict": "The primary trial explicitly states that patients must be FISH negative or have a 0, 1+, or 2+ IHC score to be eligible. The secondary trial, on the other hand, specifies that patients must have FISH+ HER2 gene amplified breast cancer. These requirements contradict each other, implying the statement made by the expert can't be entailed by the information present in the CTRs.</s>"
    },
    "9702cb6a-bdb1-415f-bb99-3b740728a4ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00073073",
        "Secondary_id": "NCT00054028",
        "Statement": "There are no placebo or control groups in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no placebo or control groups in the primary trial or the secondary trial\" can be entailed by the information present in the CTRs because:\n\nPrimary Trial: \nThe CTR does not provide any mention or description of a placebo or control group in the Intervention section.\n\nSecondary Trial: \nAlthough the statement does not directly appear in the CTR, the lack of mention or description of a placebo or control group in the Intervention section for both trials implies that none are being used. The presence of an active intervention for each trial further supports this conclusion.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as both trials do include a comparative element. In the primary trial, patients were initially intended to receive Celecoxib but it was never administered, implying the presence of a comparative arm. In the secondary trial, Suramin and Paclitaxel are administered together as a combination therapy, suggesting a comparison between the two interventions.</s>"
    },
    "7afa2d1f-7922-4b09-b52a-43bd9a4788a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The CTRs do not provide information on CNS Objective Response Rates for the participants in the primary or secondary trials. Therefore, the statement that \"participants from both cohorts of the primary trial had a drastically lower CNS Objective Response Rate than those in the secondary trial\" cannot be directly entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information presented in the CTRs, as neither the primary nor the secondary trials report CNS Objective Response Rates. The expert's statement refers to a concept (CNS Objective Response Rate) that is not explicitly mentioned or measured in either trial. Therefore, it cannot be definitively determined if the statement is entailed or contradicted based on the information provided in the CTRs alone.</s>"
    },
    "dfd5acc2-6824-4b63-93ad-34e6a0a4c621": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial\" is entailed by the information present in the CTRs if we assume that \"Cirrhosis\" is considered as a condition predisposing to renal failure secondary to rhabdomyolysis. \n\nThe primary CTR includes the exclusion criterion \"Recent history of heavy alcohol use as judged by the treating physician\" and \"History of rhabdomyolysis on statin therapy\" which may imply that heavy alcohol use and rhabdomyolysis are related conditions. Additionally, the secondary CTR mentions \"Conditions predisposing to renal failure secondary to rhabdomyolysis\" as an exclusion criterion.\n\nSince Joe has had an alcohol addiction for 15 years which has resulted in Cirrhosis, he falls under the category of \"heavy alcohol use\" that is excluded as per the primary CTR. Furthermore, Cirrhosis is a condition that may predispose to renal failure and rhabdomyolysis (as per the secondary CTR), making Joe a likely candidate for this exclusion as well.\n\nTherefore, the statement made by the clinical trial expert is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Joe has had an alcohol addiction for 15 years, resulting in Cirrhosis therefore he is likely to be excluded from the primary trial\" is contradicted by the information present in the CTRs because it mentions an exclusion criterion for \"recent history of heavy alcohol use as judged by the treating physician,\" but it does not specifically exclude patients with a history of alcohol addiction or cirrhosis. Therefore, Joe, with a history of alcohol addiction and cirrhosis, may or may not meet the eligibility criteria for the primary trial depending on the assessment of his current alcohol use by the treating physician.</s>"
    },
    "97e9967e-6525-4082-bd11-8c30e14d23fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03273426",
        "Secondary_id": "NCT01091168",
        "Statement": "Patients with Concurrent serious uncontrolled medical disorder may be eligible for the primary trial, but are always excluded from the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as follows:\n\nIn the primary trial CTR, there is no direct exclusion of patients with concurrent serious uncontrolled medical disorders. However, such patients may not meet other inclusion criteria, such as having unilateral primary cancer, cT1-T3 tumors, and clinical and imaging complete or near-complete response on MRI. Therefore, they might be ineligible for the primary trial despite not being explicitly mentioned in the exclusion criteria.\n\nIn the secondary trial CTR, concurrent serious uncontrolled medical disorder is explicitly stated as an exclusion criteria. Thus, patients with this condition cannot participate in the secondary trial according to the CTR.\n\nSince patients with concurrent serious uncontrolled medical disorders can be ineligible for the primary trial but are always excluded from the secondary trial, the statement holds true based on the given information from the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs due to the following:\n\nThe primary trial exclusion criteria explicitly lists \"concurrent serious uncontrolled medical disorder\" as a reason for exclusion. However, the statement asserts that such patients \"may be eligible\" for the primary trial.\n\nMeanwhile, the statement correctly notes that this condition is an exclusion criterion for the secondary trial. However, the discrepancy lies in the primary trial's exclusion, where the statement suggests a potential eligibility, which contradicts the trial data.</s>"
    },
    "d11dd4ae-28be-4ad2-a452-4374c48f08d1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, may increase OS, compared to Capecitabine alone.",
        "Label": "Entailment",
        "entail": "The expert's statement asserts that the combination of Ixabepilone (40 mg/m2 IV infusion on Day 1 + Capecitabine) may increase OS compared to Capecitabine alone, based on the primary trial results. \n\nThe CTRs provide the following information regarding OS in the primary trial: \n1. For Ixabepilone + Capecitabine, the median OS is 16.39 (14.95 to 17.91) months.\n2. For Capecitabine alone, the median OS is 15.64 (13.86 to 17.02) months.\n\nComparing these values, we can see that the Ixabepilone + Capecitabine group had a longer median OS compared to the Capecitabine alone group. This difference is consistent with the expert's statement that \"the combination may increase OS\" and is directly derived from the information presented in the CTRs. Therefore, the expert's statement is entailed by the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, as it does not provide specific numerical values or statistical analysis to support the claim that \"Ixabepilone + Capecitabine may increase OS, compared to Capecitabine alone.\" However, the statement is not entailed by the data in the CTRs, as the CTRs do not report a comparison of OS between the two arms, only their separate median values with confidence intervals.</s>"
    },
    "3b6229a9-00a1-4d26-9285-6d9f6a25fd77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Statement": "Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea.",
        "Label": "Contradiction",
        "entail": "The statement \"Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea\" can be entailed by the information present in the CTRs if we consider the number of participants who experienced each adverse event in each trial. According to the CTR, there were 2 occurrences of Erysipelas in cohort 1 of the primary trial. The occurrences of diarrhoea in cohort 1 were 1. In line with the statement, the number of Erysipelas cases (2) is indeed twice the number of diarrhoea cases (1). Therefore, the statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Twice as many patients in cohort 1 of the primary trial suffered from Erysipelas than diarrhoea\" contradicts the information present in the CTRs because, according to the provided data, the same number of patients (2) had Erysipelas anddiarrhoea in both trials. Therefore, it is not true that twice as many patients in cohort 1 had Erysipelas than diarrhoea.</s>"
    },
    "9eab20ad-ffc6-473f-8087-c6c3f06f356f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322348",
        "Secondary_id": "NCT00429572",
        "Statement": "the primary trial and the secondary trial use different metrics to evaluate potential candidates' performance status.",
        "Label": "Entailment",
        "entail": "The primary trial utilizes the World Health Organization (WHO) performance status scale with scores of 0, 1, or 2, while the secondary trial employs the Zubrod performance status with scores less than 2. These performance status scales are not interchangeable, as they assess and categorize patient functioning and well-being differently. The primary trial's inclusion criteria explicitly list WHO performance status, while the secondary trial's criteria specify the Zubrod performance status. This difference in performance status assessment metrics implies distinct evaluation of candidates' conditions between the two trials. The statement is entailed by the provided CTR information since it correctly reflects the documented differences in the inclusion criteria of the respective trials.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it can be misleading. The primary trial's inclusion criteria specify World Health Organization (WHO) performance status of 0, 1, or 2, while the secondary trial uses Zubrod performance status with a threshold of less than 2. Both scales assess a patient's overall health status, but they are not interchangeable. Therefore, the statement does not necessarily imply that the trials use different metrics to evaluate performance status in a contradictory manner, but rather, that they employ different performance status scales.</s>"
    },
    "92680a4c-a1e0-47d2-9b7f-cacb20cd1fde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00368875",
        "Statement": "the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg\" can be entailed by the information present in the CTRs as follows:\n\n1. The CTR specifies that in the Phase I trial, the participants received Vorinostat at a dose of 200 mg or 300 mg BID.\n2. Furthermore, the CTR indicates that in the primary trial, dose escalation was carried out based on toxicity observed during the first cycle.\n3. The CTR defines dose-limiting toxicities (DLTs) for the trial, which include grade 3-4 febrile neutropenia, thrombocytopenia and non-hematological toxicity attributed to therapy such as nausea, vomiting, and diarrhea.\n4. The CTR mentions that any toxicity occurring during cycle 1 that resulted in dose reduction of Vorinostat or paclitaxel or failure to complete all protocol-specified doses in the first cycle was also considered a DLT.\n5. The CTR reports that out of the 6 participants analyzed, none experienced DLTs at the 300 mg dose of Vorinostat.\n\nHence, based on the trial design described in the CTR, a recommended Phase II dose for Vorinostat of 300 mg can be inferred, as this was the highest dose level tested in the trial that did not result in any DLTs. This inference is entailed by the information provided in the CTR.</s>",
        "contradict": "The statement \"the primary trial results indicate that the Recommended Phase II Dose for Vorinostat, as Assessed by NCI Common Terminology Criteria for Adverse Events, is 300 mg\" is not directly contradicted by the information present in the CTRs, as both the statement and the CTR indicate that the Recommended Phase II Dose for Vorinostat is 300 mg based on NCI Common Terminology Criteria for Adverse Events. However, the statement does not provide enough context to determine if it applies to the same trial or if it is a separate trial. The CTRs only provide information for one primary trial, but the expert's statement could be referring to a different trial or a combination of trials. Therefore, the statement is not necessarily contradictory, but it is important to ensure that the context of the statement matches the context of the CTRs before drawing conclusions about entailment.</s>"
    },
    "b3dd4e23-f78c-4bf9-9268-d1018c966980": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02550210",
        "Statement": "Patients must have cancer that can be felt by touch to be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have cancer that can be felt by touch to be eligible for the primary trial\" is entailed by the CTR inclusion criteria that state \"Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ.\" This is because the terms \"palpable\" and \"can be felt by touch\" describe the same characteristic for the cancer in the statement and the CTR.</s>",
        "contradict": "The statement \"Patients must have cancer that can be felt by touch to be eligible for the primary trial\" is contradicted by the CTRs as some patients may be diagnosed with ductal carcinoma in situ, a type of breast cancer that cannot be felt by touch. Therefore, not all eligible patients in the primary trial meet the condition of having palpable cancer.</s>"
    },
    "553d7721-289e-4ab1-a9b9-7b2c939f47c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year.",
        "Label": "Contradiction",
        "entail": "The statement \"The maximum Progression Free Survival for patients in cohort 1 of the primary trial was 1 year\" cannot be directly derived from the provided CTRs since the CTRs only report medians (not maximums) and no specific information about individual patient data or cohort definitions is given. \n\nHowever, the statement could be entailed if additional evidence is available that indicates the existence of patients in cohort 1 with a Progression Free Survival of 1 year, and that these patients' data are included in the calculation of the reported median PFS of 2.8 months (95% CI 1.6 to 3.2). This would require access to more detailed participant-level data, which is not provided in the excerpt from the CTR.</s>",
        "contradict": "The statement \"The maximum Progression Free Survival for patients in cohort 1 the primary trial was 1 year\" cannot be directly contradicted by the information presented in the CTRs. However, it can be misleading. The given information from the CTR only provides the median PFS for each arm, not the maximum. Based on the presented data, there is no evidence to support that a patient in cohort 1 had a PFS of exactly 1 year. The CTRs do not contradict the statement, but they do not provide enough information to definitively confirm it either.</s>"
    },
    "01c6f82e-710d-4fa4-aa62-2d26e72f4533": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00894504",
        "Statement": "There were no adverse event in the primary trial which occurred more than 71 times.",
        "Label": "Entailment",
        "entail": "The statement \"There were no adverse events in the primary trial which occurred more than 71 times\" is entailed by the information in the CTRs because none of the adverse events listed in the Primary Trial's Adverse Events section occurred more than 71 times. Each listed adverse event (atrial fibrillation, cardiac tamponade, pericardial effusion, supraventricular tachycardia, diarrhea, nausea, vomiting, chest pain, pneumonia, malignant pleural effusion, and hepatic encephalopathy) occurred exactly once in the trial involving 71 participants. Thus, no adverse event exceeded the frequency of 71 occurrences.</s>",
        "contradict": "The statement \"There were no adverse events in the primary trial which occurred more than 71 times\" is in contradiction with the CTR data as there are several adverse events reported in the primary trial, each occurring only once in 71 participants, thus violating the condition that no event occurred more than 71 times.</s>"
    },
    "2e588ede-0ab8-4cb0-b03b-2c68a68bc5fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02018458",
        "Secondary_id": "NCT00895414",
        "Statement": "Patients with unexplained fever exceeding 39\u00ac\u00a8\u201a\u00e0\u00fbC are excluded from the primary trial but may be included in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs as follows:\n\nIn the primary CTR: \"Active infection or unexplained fever >38.5\u00b0C during screening\" is an exclusion criterion. This criterion states unequivocally that patients with a fever above 38.5\u00b0C during screening are ineligible for the study. However, the statement by the expert mentions unexplained fever exceeding 39\u00b0C, which is a slightly higher temperature threshold than specified in the CTR. Nonetheless, the implication is clear: fever that has not been explained and is greater than 38.5\u00b0C (as per the CTR) or 39\u00b0C (as per the expert's statement) is a reason for exclusion. Thus, patients with such a fever cannot participate in the primary trial, but they might still be considered for the secondary trial if they meet other inclusion criteria. This situation is perfectly reasonable, as different trials can have varying eligibility standards. The only discrepancy between the expert's statement and the CTR lies in the exact temperature threshold for unexplained fever, and it is a minor one that does not alter the entailment relationship.\n\nIn the secondary CTR: There is no mention of a temperature threshold for excluding patients based on fever. The expert's statement does not contradict the secondary CTR, as the secondary CTR is silent on the issue of fever.\n\nHence, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with unexplained fever exceeding 39\u00b0C are excluded from the primary trial but may be included in the secondary trial\" contradicts the CTRs because the primary trial explicitly lists \"Active infections including viral hepatitis and HIV. Active infection or unexplained fever >38.5\u00b0C during screening\" as an exclusion criterion (CTR 1). Additionally, for the secondary trial, the exclusion criterion includes \"active infections\" as a reason for ineligibility. Thus, patients with unexplained fever exceeding 38.5\u00b0C are not eligible for either trial according to the information presented in the CTRs, contradicting the statement.</s>"
    },
    "862c0bfe-10a6-453c-9ada-929dd00141a0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial employ non comparable outcome measures.",
        "Label": "Entailment",
        "entail": "The statement that \"the secondary trial and the primary trial employ non-comparable outcome measures\" is entailed by the information in the CTRs, as the primary trial measures disease-free survival in years, while the secondary trial measures changes in QTcF as a continuous variable using the unit of measurement \"ms\" and reports it as a count of participants with maximum changes exceeding certain thresholds. These measures cannot be directly compared due to their distinct units and types.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial employ non-comparable outcome measures\" does not contradict the information in the CTRs. However, it does not entail it either as the CTRs do not provide sufficient details about the nature of the outcome measures in the secondary trial beyond the measurement of changes in QTcF and the time frame for measurement. The statement only highlights that the outcome measures are different between the two trials (disease-free survival vs QTcF), which is evident from the CTR information alone. Therefore, neither the statement's assertion is contradicted nor is it substantiated by the provided CTR data. However, the trials are indeed not directly comparable due to their different outcome measures, as stated in the expert's comment.</s>"
    },
    "9ed5feb5-ab82-4f90-a6e4-5172dcd4d20f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had an oophorectomy in the last month would not be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A patient who had an oophorectomy in the last month would not be eligible for the primary trial\" is entailed by the information present in the CTRs as follows:\n\nThe patient's eligibility for the primary trial is determined by the inclusion criteria that specify \"no previous chemotherapy for metastatic breast cancer.\" An oophorectomy, which is a major surgical intervention, is a standard form of chemotherapy for breast cancer. Therefore, a patient who underwent an oophorectomy within the last month would not meet the eligibility criteria for the primary trial. This is consistent with the exclusion criteria in the primary trial that exclude participants who have undergone major surgery within 28 days prior to enrollment.</s>",
        "contradict": "The CTR states that there are no exclusion criteria related to recent major surgeries, except for those undergoing major surgery during study treatment. An oophorectomy is not explicitly mentioned as a major surgery in the exclusion criteria within the provided CTR sections for the primary trial. Therefore, a patient who underwent an oophorectomy within the last month may still be eligible for the trial according to the provided information. However, the actual eligibility would depend on the investigator's discretion as stated in the primary trial's inclusion criteria. The expert statement is contradictory to the CTR as it assumes an oophorectomy is an automatic exclusion, whereas the CTR only provides guidelines and not an absolute exclusion.</s>"
    },
    "5501dae3-0d3c-4812-96c2-35ca863e24a5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On day 1 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Entailment",
        "entail": "The statement entails the information from the CTRs as both trials' Intervention 1 and Intervention 2 specify that all patients in the primary trial receive doxorubicin hydrochloride IV and oral cyclophosphamide on specified days. Furthermore, both interventions state that patients receive dexamethasone (either IV or orally) and a specific antiemetic (ondansetron for Intervention 1 or palonosetron for Intervention 2) on day 1, prior to each dose of doxorubicin hydrochloride. Therefore, the statement's assertion of Cohort 1 receiving these treatments aligns with the CTR data, and there is no contradiction.</s>",
        "contradict": "Cohort 1 in the primary trial indeed receives doxorubicin hydrochloride IV, oral cyclophosphamide, and dexamethasone IV or orally on day 1 as stated. However, the contradiction lies in the mention of ondansetron IV, as ondansetron is only mentioned as being administered to patients in Intervention 1 and not Intervention 2 of the primary trial. Consequently, it is inaccurate to assert that all patients in Cohort 1 receive ondansetron IV on day 1 according to the information presented in the CTRs.</s>"
    },
    "ece8e7df-790d-4e26-9c34-40cf66d2abf5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02005887",
        "Secondary_id": "NCT00050011",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time.",
        "Label": "Contradiction",
        "entail": "The statement \"All Participants in the primary trial and the secondary trial are receiving the same daily dose of Degarelix injected into the muscle, for the same duration of time\" can be entailed by the information presented in the CTRs because:\n\n1. In the primary trial, Arm A of Intervention 1 receives Degarelix injected under the skin as two initial doses of 120 mg each (total 240 mg) on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6, making it 12 injections in total over 6 cycles. Since each cycle lasts 28 days, the daily dose of Degarelix in this arm is calculated as 240 mg / (12 injections * 28 days) = 2.5 mg/day.\n\n2. In the secondary trial, both Intervention 1 and Intervention 2 participants are receiving Degarelix 2.5 mg daily.\n\nHence, participants in both the primary and secondary trials are receiving Degarelix with the same daily dose (2.5 mg) and for the same duration (6 cycles).</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as follows:\n\nIn the primary trial, Arm A of Intervention 1 received Triptorelin 3.75 mg i.m. every 28 days and Degarelix 240 mg followed by 80 mg on day 1 of cycles 2 to 6, which is not the same as Degarelix being given daily as stated in the expert's statement.\n\nIn the secondary trial, both arms received Letrozole 2.5 mg orally daily. However, participants in the upfront arm received Zoledronic Acid 4 mg IV every 6 months, while participants in the delayed-start arm received Zoledronic Acid only when meeting certain conditions. Neither arm received daily Degarelix injections as stated in the expert's statement.</s>"
    },
    "550a36e2-43bb-40af-b0c8-49498fbe2c8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00077376",
        "Secondary_id": "NCT01256008",
        "Statement": "the primary trial investigates a novel radiotherapy treatment, whereas the secondary trial is testing a type of psychological therapy.",
        "Label": "Contradiction",
        "entail": "The statement does not entail any information directly from the CTRs as both trials described in the reports investigate interventions different from what is mentioned in the statement. The primary trial investigates a combination chemotherapy regimen using Ixabepilone, carboplatin, and Trastuzumab, while the secondary trial tests two different interventions: clinical management and cognitive-behavioral therapy (CBT). Therefore, the statement does not follow from the given CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because neither trial investigates a \"novel radiotherapy treatment.\" Instead, the primary trial focuses on a combination of chemotherapies (Trastuzumab/Ixabepilone/Carboplatin), and the secondary trial tests a psychological therapy called Clinical Management and CBT.</s>"
    },
    "95869347-6c3d-4de8-a325-a9a652f11edf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02102490",
        "Secondary_id": "NCT00768222",
        "Statement": "In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation .",
        "Label": "Contradiction",
        "entail": "The statement \"In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation\" is entailed by the information in the CTRs as there are no instances of Sinus bradycardia (0.76%), Bone marrow suppression (0.00% for both trials), or Constipation (0.76% in the primary trial and 0.00% in the secondary trial) reported in the Adverse Events section of the primary trial.</s>",
        "contradict": "The statement \"In contrast to the secondary trial, the primary trial did not record any cases of Sinus bradycardia, Bone marrow suppression or Constipation\" can be contradicted by the information present in the provided CTRs because the statement claims that there were no instances of these conditions in the primary trial, while the data in the CTRs shows that there were indeed instances of Sinus bradycardia (1 case out of 132), Bone marrow suppression (1 case out of 132), and Constipation (1 case out of 132) recorded in the primary trial.</s>"
    },
    "8df8e2c0-a0ca-4ea2-ba83-494f250c4bef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00509769",
        "Statement": "3/112 patients (2.68%) in the primary trial had Diabetes insipidus  ",
        "Label": "Contradiction",
        "entail": "The statement \"3/112 patients (2.68%) in the primary trial had Diabetes insipidus\" cannot be directly entailed from the provided information in the CTRs as there is no mention of \"Diabetes insipidus\" as an adverse event in either the primary or secondary trials.</s>",
        "contradict": "The statement \"3/112 patients (2.68%) in the primary trial had Diabetes insipidus\" is contradicted by the information in the CTRs as there is no mention of \"Diabetes insipidus\" as an adverse event in either the primary or the secondary trial.</s>"
    },
    "1d4a385f-1c72-4c61-8d49-9ada0e3b716a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02556632",
        "Statement": "Both cohorts the primary trial apply the same topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Contradiction",
        "entail": "both cohorts in the primary trial apply the same topical intervention (Curcumin-based Gel and HPR Plus\u2122) with the same frequency, approximately every 4-6 hours, for the same duration, a week. This aligns with the information in the CTRs, as the Curcumin-based Gel and HPR Plus\u2122 interventions, respectively in Arm I and Arm II, specify application TID approximately every 4-6 hours, from the first day of radiation therapy until 1 week after completion.</s>",
        "contradict": "The statement does not take into account the differences in the topical interventions applied in Arm I and Arm II of the primary trial. While both cohorts apply the topical intervention approximately every 4-6 hours every day for a week, the specific interventions differ: curcumin-based gel in Arm I and HPR Plus\u2122 in Arm II. This discrepancy contradicts the statement's assumption of identical interventions for both cohorts.</s>"
    },
    "b15aa13a-fbd9-4b2e-9dd2-b16628084d07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by results from cohort 2 of the primary trial, is 40 mg/m^2 orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Contradiction",
        "entail": "The expert's statement is in accord with the CTR's MTD definition in the primary trial, stating that the MTD is the dose range at which one of six evaluable participants experiences DLT, and that DLT includes grade 4 neutropenia and thrombocytopenia, or any other grade 3 nonhematologic toxicity requiring a dose reduction or discontinuation, with the exceptions of specific grade 3 toxicities listed. The expert's statement specifies a dose of 40 mg/m^2 BID on certain days, which corresponds to the maximum dose (40 mg) in the primary trial, and mentions the dosing schedule, which matches the one described in the primary trial. Additionally, the expert refers to cohort 2 of the primary trial, which further aligns with the provided CTR information.</s>",
        "contradict": "The statement's MTD value (40 mg/m^2) is inconsistent with the definition of MTD in the CTR, which is based on the occurrence of DLTs in 1 of 6 evaluable participants, not the total number of participants or their dose per m^2. The statement also does not align with the provided details about the dosage regimens for Alisertib and Paclitaxel in the primary trial.</s>"
    },
    "c9214d06-2733-4c78-99e5-a42015908eae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment.",
        "Label": "Contradiction",
        "entail": "The statement that \"Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment\" is entailed by the information in the CTRs as follows:\n\n1. The median PFS for patients receiving Standard of Care in the primary trial is mentioned in the Results 2 section with a value of 2.5 months (1.4 to 2.9) by Core radiology laboratory assessment.\n2. The statement made by the expert only mentions the median PFS for patients receiving the Standard of Care from the primary trial using the same measurement method and the same population as in the CTR.\n3. The values and uncertainty intervals in the CTR and the statement agree with each other, making the statement an entailed conclusion from the information presented in the CTRs.</s>",
        "contradict": "The statement \"Renal cancer Patients from the primary trial receiving Standard of Care had a median PFS of 2.5 months by Core radiology laboratory assessment\" cannot be directly contradicted by the information in the CTRs, but it is not a perfect match. The statement implies that the median PFS for patients receiving Standard of Care was exactly 2.5 months, whereas the CTR reports a range for the median PFS, which is 1.7 to 2.9 months. This discrepancy may seem minor, but it is important to note that precise numerical values can sometimes lead to misunderstandings or incorrect interpretations, especially when dealing with clinical trial data. It is crucial to be clear and specific when communicating such information to avoid confusion and maintain accuracy.</s>"
    },
    "a318fc31-4f28-4356-b09a-59741bb7c97a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is not.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs because: \n\n1. In the primary trial, there are two intervention arms: one with a standard mail reminder postcard and the other with a family physician reminder letter in addition to a mail reminder postcard. The statement correctly identifies that both interventions involve communication methods, and the communication methods in the control arm (mail reminder postcard) are the same as in the experimental arm (mail reminder postcard and family physician reminder letter). \n2. In the secondary trial, there are also two intervention arms, but they differ significantly from those in the primary trial. One arm receives standard Perflutren injections followed by Harmonic and subharmonic imaging, while the other arm receives only the standard Perflutren injections. The statement, however, does not make any claims about this trial's intervention methods or their communication aspects. Therefore, the statement's claim about the primary trial not investigating different ways of communication for the secondary trial applies since the information in the two CTRs does not contradict this assertion.</s>",
        "contradict": "The discrepancy between the statement and the CTR information lies in the inference drawn from the Intervention section. While it is true that the Primary Trial involves different communication methods for women in the specified age range (mail vs family physician letter), this observation does not imply that both trials are not investigating different ways to communicate with the same population. The Secondary Trial's Intervention indeed involves an additional communication method (3D Harmonic imaging and subharmonic imaging), but it is not explicitly stated as a method of communication between researchers and study participants. Therefore, the statement is a hasty generalization and does not accurately reflect the entailment relationships between the statement and the CTRs.</s>"
    },
    "70ec4bc8-f8fa-4901-aa7a-2388b53960c6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C.",
        "Label": "Entailment",
        "entail": "The statement \"The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C\" can be entailed by the information present in the CTRs because:\n\n1. Chevalier grades are mentioned in the Primary Trial's Outcome Measurement section as the method for assessing the patients' pathological response to neoadjuvant chemotherapy (Taxotere and AC).\n2. Results 1 from the Primary Trial provides the distribution of Chevalier grades for the Arm/Group A patients receiving Taxotere/Docetaxel (3A: 18, 3C: 18).\n\nTherefore, the information in the statement that the most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C is a valid conclusion that can be drawn based on the information provided in the CTRs.</s>",
        "contradict": "The statement \"The most common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 3A and 3C\" cannot be directly contradicted by the information present in the CTRs. However, the statement is not a semantically entailed conclusion from the CTR data. The CTRs provide the distribution of Chevalier grades for patients in Arm A receiving Taxotere/Docetaxel as 18 for grade 3A, 15 for grade 3B, 18 for grade 3C, 10 for grade 3D, and 3 for grade 4, with 14 participants having no assessment (NA). Therefore, the statement oversimplifies the distribution and does not specify the exact number of participants in each Chevalier grade. The CTR data does not contradict the statement, but it does not completely entail it either.</s>"
    },
    "00dc0e37-1d0b-4f53-a037-86bf9799dae6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients with a womb cannot take part in either the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not directly entailed by the information in the CTRs, as the CTRs do not explicitly mention the presence or absence of a womb for trial participants. However, the primary CTR does specify inclusion of patients with \"intact uterus\" among those who may be postmenopausal. This implies that some female patients with a womb could be enrolled in the trial. The secondary CTR does not mention the uterus or its status at all.</s>",
        "contradict": "The statement \"Female patients with a womb cannot take part in either the secondary trial or the primary trial\" is contradicted by the information present in the CTRs. In the primary trial, the inclusion criteria state that postmenopausal females with an intact uterus are eligible for participation. In the secondary trial, the inclusion criteria do not mention anything about having a womb as a requirement for exclusion. Therefore, the statement is not entailed by the information present in the CTRs.</s>"
    },
    "a1a421cc-01c9-4afb-8f09-6b10b0ff5094": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial\" does not directly appear in the provided CTRs. However, the statement can be entailed by the information present in the ELIGIBILITY CRITERIA sections of both CTRs since they do not specify an age limitation within the given range, allowing patients from ages 13 to 76 to satisfy the age inclusion criteria.</s>",
        "contradict": "The statement \"Patients must be between the ages of 13 and 76 to participate in the primary trial or the secondary trial\" is contradictory to the CTRs as the Primary Trial's inclusion criterion for patient age is not explicitly stated within the provided text, but it does state that there are no such age restrictions specified for the Secondary Trial. Therefore, the statement's assertion does not hold for both trials and contradicts the information in the CTRs.</s>"
    },
    "9316ef0d-55b0-4547-88ae-887e0132a263": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00246571",
        "Statement": "Patients from the primary trial receiving Standard of Care had a median PFS of 2.7months by Core radiology laboratory assessment.",
        "Label": "Entailment",
        "entail": "The statement \"Patients from the primary trial receiving Standard of Care had a median PFS of 2.7 months by Core radiology laboratory assessment\" is entailed by the CTR data as follows: \n\n1. The CTR reports that in the Standard of Care arm, participants were administered various regimens at the discretion of the investigator, including capecitabine, vinorelbine, docetaxel, paclitaxel, and gemcitabine, with different dose schedules and treatment intervals. \n2. The CTR also states that if RECIST-defined progression was met, participants could receive sunitinib. However, there is no information provided on how many or which participants switched to sunitinib, nor is there a clear indication of whether these participants' data were included in the median PFS calculation for the Standard of Care arm.\n3. Therefore, the median PFS value reported for patients receiving Standard of Care in the statement refers to those who did not receive sunitinib at any point during the trial.\n4. In the CTR, the median PFS for the Standard of Care arm was reported as 2.7 (1.7 to 2.8) months by Core radiology laboratory assessment, and as 2.5 (1.4 to 2.9) months by investigator assessment, respectively. While the range of the investigator assessment is wider, both values overlap and fall below 2.7 months, indicating that the statement's value is within the range reported in the CTR.</s>",
        "contradict": "The information in the expert's statement does not directly contradict the CTRs; however, it is less precise and potentially misleading. The statement only mentions the median PFS for patients from the standard of care arm in the primary trial by Core radiology laboratory assessment. It does not specify which group of patients within the standard of care arm the median belongs to. The CTRs provide separate median PFS estimates for different subgroups within the standard of care arm, such as those receiving capecitabine, vinorelbine, docetaxel, paclitaxel, or gemcitabine. These subgroups may have different median PFS, and the statement does not account for this variability. Thus, while not contradicting the CTR, the expert's statement is less specific and potentially less accurate.</s>"
    },
    "5d815fac-c66c-43fe-9ac8-a352b6e47a5b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01929395",
        "Secondary_id": "NCT01857882",
        "Statement": "the primary trial and the secondary trial are both utilising test and control groups in their interventions.",
        "Label": "Contradiction",
        "entail": "Both the primary and secondary trials involve distinct intervention groups: group MRI (test group) in the primary trial, and the decision support workshop and standard care (control group) in the secondary trial. The use of test and control groups in clinical trials signifies comparison and assessment of a novel intervention (test group) against the existing standard or current practice (control group). This design enables researchers to evaluate the efficacy and safety of the novel intervention. In both trials, the implementation of intervention groups corresponds to this design. Therefore, the statement's assertion that both trials are utilizing test and control groups in their interventions is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not provide sufficient information to determine if both trials are using a test and control group design directly within their intervention sections. The primary trial describes the use of supine MRI in addition to conventional imaging for one group, and standard care for the other. It does not specify if these groups are designated as test and control groups. The secondary trial outlines a decision support workshop and standard care as two separate interventions, but it also does not mention a specific test and control group design. Based on the available information, it cannot be definitively concluded that both trials are utilizing test and control groups within their intervention sections.</s>"
    },
    "7b9fdeaa-5cb7-4453-b174-07b44bb58234": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.",
        "Label": "Entailment",
        "entail": "The statement \"More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations\" cannot be directly entailed by the information present in the CTRs as no data about ventricular contractions or relaxations is provided. The CTRs only report specific adverse events related to heart functions, such as cardiac-ischemia/infarction, conduction abnormalities/AV block, and left ventricular diastolic and systolic dysfunctions. These terms refer to distinct aspects of heart functions and do not equate to ventricular contractions or relaxations. Therefore, the statement goes beyond the information presented in the CTRs and cannot be considered entailed.</s>",
        "contradict": "The statement is contradicted by the information presented in the CTRs as there is no mention or evidence of any dysfunctions related to ventricular contractions or relaxations in either trial's adverse events sections. The sections only report the occurrence of various adverse events, such as cardiac ischemia/infarction and conduction abnormalities, but they do not specify whether these events are related to contractions or relaxations of the left ventricle. Therefore, it is an incorrect assumption to claim that more patients suffered from dysfunctions with ventricular contractions based on the given CTRs alone.</s>"
    },
    "c330f152-c64e-47ab-8568-5129a1a2099e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 60+ patients in cohort 2 the primary trial experienced any adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the 60+ patients in cohort 2 the primary trial experienced any adverse events\" is entailed by the CTR data if we assume that \"cohort 2\" refers to the group of 64 patients from the Adverse Events Section 2 of the primary trial. The statement is in agreement with the CTR data, which indicates a total of 22 adverse events reported among 64 patients, but none of these events were observed in the three patients from the Adverse Events 1 section, who are assumed to be part of cohort 2 based on the context of the statement. Therefore, the statement is substantiated by the CTR data and avoids contradiction with it, making it entailed.</s>",
        "contradict": "The statement \"None of the 60+ patients in cohort 2 the primary trial experienced any adverse events\" is contradicted by the information present in the Adverse Events sections of the CTR. Specifically, there are reported adverse events for cohort 2 of the primary trial, with a total of 22 adverse events observed in 64 patients, representing a rate of 34.38%. The named adverse events include Pericardial effusion, Tachycardia, Nausea, Vomiting, Abdominal pain, Colitis, Diarrhea, Gastritis, Ileus, Fatigue, Pyrexia, Pain, Hepatic cirrhosis, and Cellulitis.</s>"
    },
    "e3b88c8c-241d-4ead-8573-534a46210707": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00811135",
        "Statement": "The majority of patients in the primary trial did not experience Left ventricular dysfunction.",
        "Label": "Entailment",
        "entail": "The statement \"The majority of patients in the primary trial did not experience Left ventricular dysfunction\" does not contain a direct mention of adverse events or specific conditions from the CTRs. However, it can be inferred that Left ventricular dysfunction is not a common adverse event based on the information provided in the CTRs, as no cases of this condition were reported in the primary trial. Therefore, the statement is entailed by the information in the CTR, as it does not contradict the given data and is consistent with the absence of reported Left ventricular dysfunction.</s>",
        "contradict": "The expert's statement that \"The majority of patients in the primary trial did not experience Left ventricular dysfunction\" is contradictory to the information in the CTR if \"Left ventricular dysfunction\" is considered synonymous with \"Cardiac Failure,\" which occurred in 2/88 (2.27%) of the patients in the primary trial. The statement's assertion, suggesting that the majority of patients did not experience this issue, is inconsistent with the trial findings.</s>"
    },
    "e621f354-dea0-4d0f-a252-5480028c1712": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event.",
        "Label": "Entailment",
        "entail": "In the primary trial Adverse Events section 1, all adverse event counts are listed as 0/0. However, in section 2, there is one instance (1/473) of radiation dermatitis. Since radiation dermatitis is a known type of radiation-induced adverse event, the statement that at least one patient in the primary trial suffered from a radiotherapy-induced adverse event is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"At least 1 patient in the primary trial suffered from a radiotherapy induced adverse event\" is contradicted by the information present in the CTRs as there is no reported instance of \"radiation dermatitis\" or any other radiation-induced adverse event in either of the trials. The CTRs only document adverse events related to leukopenia, neutropenia, ocular-other, elevated SGPT, arthralgia, CNS hemorrhage, neurologic-other, and radiation dermatitis. Since none of the documented adverse events were radiation-induced, the expert's statement contradicts the CTRs.</s>"
    },
    "ee209156-74dc-475e-87af-ae51160982ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00244881",
        "Statement": "30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trial expert is entailed by the information presented in the CTRs because:\n\n1. The statement and the CTR agree on the outcome measure, which is the level of circulating endothelial cells (CECs).\n2. The time frame of the statement (after 3 weeks of treatment) matches the time frame in the CTR (CEC response rate measured after 3 weeks of treatment).\n3. The statement's assertion of a 30% response rate for the primary trial participants is within the 95% confidence interval calculated in the CTR (no wider than 40%).\n4. The statement refers to the specific treatment in the primary trial, which is Cediranib Maleate, and the administration schedule in the statement aligns with the intervention described in the CTR.</s>",
        "contradict": "The expert's statement, \"30% of the primary trial participants had an increased level of CECs after 3 weeks of Cediranib Maleate treatment,\" does not contradict the information in the CTR directly. However, the CTR states that an exact 95% confidence interval (CI) for the CEC response rate will be calculated with a maximum width of 40%. Since 30% falls within this range, the statement is semantically entailed by the CTR.\n\nHowever, a closer examination reveals that the expert's statement goes beyond the scope of the CTR. Although there is no contradiction, the expert's statement is not an exact reproduction of the trial result, as it does not include the uncertainty range (confidence interval) specified in the CTR. The expert's statement is more definitive than what the CTR provides, potentially leading to misinterpretations of trial results.\n\nTherefore, while there is no contradiction between the statement and the CTR, it is essential to understand that the expert's statement is more specific than the information presented in the CTR, and that the uncertainty range associated with the outcome measurement is missing.</s>"
    },
    "edf813c0-2271-49ca-a040-a355bf71d8b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01519700",
        "Statement": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
        "Label": "Contradiction",
        "entail": "To evaluate the entailment relationship between the expert's statement and the information in the CTRs, we need to compute the median durations of Grade 4 neutropenia and find the difference between the two arms.\n\nFirst, let's calculate the median duration of Grade 4 neutropenia for each arm using the given mean durations and standard deviations:\n\nArm 1 (EP2006 + EP2006 & Neupogen): \nMedian = Mean - (Standard Deviation / 2)\nMedian = 1.17 - (1.11 / 2)\nMedian \u2248 1.12 days\n\nArm 2 (Neupogen + Neupogen & EP2006):\nMedian = Mean - (Standard Deviation / 2)\nMedian = 1.2 - (1.02 / 2)\nMedian \u2248 1.16 days \n\nThe difference between the two medians is 0.04 days. However, since the expert's statement refers to median duration being \"just over 36 hours,\" we need to convert 36 hours to days to compare it with the computed medians. 36 hours equals to approximately 1.3 days. \n\nThe difference between the two medians (0.04 days) is much smaller than the 0.3 days difference that would correspond to \"just over 36 hours.\"\n\nTherefore, the expert's statement is not entailed by the information present in the CTRs, as the stated difference is greater than the actual difference.\n\nExplanation:\n\nThe expert's statement claims that there was \"just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1\" between the two arms of the trial. However, the actual difference in median durations calculated from the given CTR data is smaller (approximately 0.04 days). The statement is not an exact entailment of the CTR data because the stated difference is greater than the actual difference.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because while it claims a difference in median duration of Grade 4 neutropenia between the two arms, the CTRs only provide mean duration data. Additionally, the mean durations in the CTRs are not directly comparable to a median duration mentioned in the statement. The statement also does not specify which CTR it is referring to, potentially causing confusion between the primary and secondary trial data.</s>"
    },
    "352475ea-1b17-4d1a-a5e3-71f1b87cffd8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01827163",
        "Statement": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement's conditions - histologically confirmed stage 4 adenocarcinoma HER2/neu IHC 3+, ECOG performance status <2, and negative HCG pregnancy test - are all subsets of the CTR's inclusion criteria. The CTR includes patients with histologically confirmed adenocarcinoma and HER2/neu IHC 3+ or FISH-amplified status (meeting the first two conditions). It also includes patients with an ECOG performance status of 0 or 1, which is a less restrictive condition than the statement's requirement of <2 (meeting the third condition). The CTR's negative HCG pregnancy test requirement also aligns with the statement. Therefore, the information in the statement entails the information in the primary CTR.\n\nHowever, it's worth noting that the primary CTR excludes patients with stage IV breast cancer, which is included in the statement. However, the statement refers to the \"primary trial,\" which may imply that it's a different trial from the one described in the CTR with more relaxed inclusion criteria. In that case, the entailment holds between the statement and the broader population of patients eligible for the \"primary\" trial but not necessarily for the CTR.</s>",
        "contradict": "The statement \"Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial\" is contradicted by the information present in the CTRs because the CTRs explicitly state that patients with stage IV breast cancer are excluded from the primary trial.</s>"
    },
    "c7c745d6-03ee-4740-9ef4-641fb6546e46": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00544167",
        "Statement": "Every adverse event in the primary trial occurred more than 8 times.",
        "Label": "Contradiction",
        "entail": "The statement \"Every adverse event in the primary trial occurred more than 8 times\" is not entailed by the information present in the CTRs. The CTR reports the frequency of each adverse event in the primary trial, which clearly states that each event occurred only one time in the cohort of 45 participants. Therefore, the frequency of each event is less than eight times. Hence, the statement contradicts the information provided in the CTRs and cannot be entailed from it.</s>",
        "contradict": "The statement \"Every adverse event in the primary trial occurred more than 8 times\" is contradicted by the information in the CTRs, as the total number of participants in the primary trial was 45, and no single adverse event occurred more than 2.22 times. The frequency of each adverse event was given for every participant in the cohort (1/45), which is less than 8 occurrences.</s>"
    },
    "c5c8ab0b-8062-4467-8ecd-bb15f35f54c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00617942",
        "Secondary_id": "NCT00388726",
        "Statement": "the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as the primary trial had a lower total number of adverse events (18.92%) compared to the secondary trial (25.84%).</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as the percentage of patients experiencing adverse events in the primary trial (18.92%) is actually higher than that of the secondary trial (25.84%).</s>"
    },
    "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01827787",
        "Statement": "The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin.",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the information present in the CTRs based on the following:\n\n1. ORR in Cohort 1 (HR+/HER2-) is 35.6% (24-49%).\n2. ORR in Cohort 2 (TNBC) is 13.2% (5-26%).\n3. Both cohorts underwent the same treatment regimen with Eribulin 1.4 mg/m2 administered in the same manner.\n4. The lower percentage of participants with ORR in Cohort 2 (TNBC) compared to Cohort 1 (HR+/HER2-) implies that the Triple-Negative Breast Cancer cohort had a much lower ORR.</s>",
        "contradict": "The statement \"The Triple-Negative Breast Cancer cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin\" can be contradicted by the CTRs information as follows:\n\nThe ORR values for the two cohorts are given as 13.2% (5-26) for TNBC cohort and 35.6% (24-49) for HR+/HER2- cohort. However, the CTRs provide the ORR values as percentages of participants, not as differences between groups. Therefore, without additional context or comparison of the absolute numbers of responders in both cohorts, it is not possible to definitively conclude that the TNBC cohort had a much lower ORR than the other cohort based on the CTR information alone.</s>"
    },
    "8f1959e4-b93a-4112-9726-27a4034f0e07": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00191854",
        "Statement": "Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria do not explicitly mention the requirement of a one bi-dimensional, measurable indicator lesion. However, since the trial is for patients with breast cancer and metastatic disease, it is a reasonable assumption that the presence of a measurable lesion is implied, as measurable lesions are often used as an objective measure for response assessment in solid tumor studies. The secondary trial might have a specific requirement for a measurable lesion due to its therapeutic focus or study design. The CTRs, however, do not provide enough information to definitively confirm or contradict this statement, as it is not mentioned in either trial's inclusion criteria. Therefore, while it might be a reasonable assumption, it is not a strict entailment.</s>",
        "contradict": "The statement \"Patients must have a one bi-dimensional, measurable indicator lesion to be included in the primary trial\" contradicts the information in the CTRs as there is no mention of such a requirement in the inclusion criteria of either the primary or secondary trial. In the provided CTR for the primary trial, the inclusion criteria only state that female patients with histological or cytological proven diagnosis of breast cancer, stage IV disease, and meeting certain performance status, adjuvant/neo-adjuvant therapy history, and organ function requirements are eligible. No mention is made of a requirement for a one bi-dimensional, measurable indicator lesion.</s>"
    },
    "e1782960-8d44-4acc-aaae-bfa4f8e38de0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00254592",
        "Statement": "Patients must have an ECOG score below 3 to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The ECOG score is a component of the patient's performance status assessment, which is mentioned in the Primary Trial's Inclusion Criteria as one of the conditions that patients must meet (performance status of 0-2 by Zubrod criteria). The ECOG score, which evaluates patients' functionality and general health condition, is a widely-used tool in clinical trials, and a score below 3 indicates that the patient is fully ambulatory and capable of performing all pre-specified activities. Since this requirement aligns with the performance status criterion outlined in the CTR, the expert's statement is entailed by the information provided.</s>",
        "contradict": "The given statement can be contradicted by the information present in the CTRs because the CTRs do not mention the ECOG (Eastern Cooperative Oncology Group) score as an inclusion criterion for the primary trial. Instead, it specifies that patients must have a performance status of 0-2 by Zubrod criteria. Although both scales are used to assess a patient's performance status, the specific criteria differ between these scales, with an ECOG score below 3 corresponding to a performance status of 0 or 1 by Zubrod criteria. This discrepancy can lead to potential contradictions if statements are not carefully examined in relation to the trial's specific eligibility criteria.</s>"
    },
    "61bd93b2-b38f-496d-acd9-f8b188d28a39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365599",
        "Secondary_id": "NCT01771666",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L,Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial\" is entailed by the CTRs as follows:\n\n1. The primary trial includes patients with an ECOG performance status of 0-2, and the statement specifies ECOG <=2.\n2. The primary trial requires ANC >1.5 x 10^9/L, Bilirubin < 2.0 mg/dl, and PLT >100 x 10^9/L for eligibility; the statement specifies ANC >1.5 x 10^9/L and Bilirubin > 2.0 mg/dl but not explicitly PLT >100 x 10^9/L, but since this requirement is not a reason for exclusion, it's assumed that the statement also complies with this condition. However, it's important to note that this interpretation assumes consistency in the interpretation and application of laboratory values between institutions.\n3. The primary trial excludes patients with a history of blood clots, which is mentioned in the statement as a reason for exclusion from the secondary trial.\n4. Both trials share other eligibility requirements, such as age >18, cytologically/histologically documented breast cancer with estrogen or progesterone receptor expression, and measurable disease by RECIST criteria; the statement does not conflict with these requirements.\n5. The secondary trial specifically includes women undergoing sentinel lymph node biopsy and women with breast cancer with known or suspected lymph node involvement, which is not mentioned in the primary trial. Thus, the statement excludes Black men who meet the eligibility criteria for the primary trial but would not satisfy the additional inclusion criteria for the secondary trial.</s>",
        "contradict": "The statement that \"Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, Bilirubin > 2.0 mg/dl, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial\" is contradicted by the CTR information as follows:\n\n1. Eligibility Criteria for Primary Trial: \n- Black men are included in the primary trial. (There is no exclusion for race mentioned in the primary trial eligibility criteria.)\n\n2. Eligibility Criteria for Secondary Trial:\n- ECOG <=2: Black men meet the inclusion criterion for ECOG status.\n- ANC >1.5 x 10^9/L: Black men meet the inclusion criterion for ANC.\n- Bilirubin > 2.0 mg/dl: Black men do not meet the exclusion criterion for Bilirubin.\n- PLT >100 x 10^9/L: Black men meet the inclusion criterion for PLT.\n- No prior history of blood clots: Black men meet the inclusion criterion for this.\n\nHowever, Black men are excluded from the Secondary Trial due to the following reasons not mentioned in the given statement: \n- Women are the only population targeted in the Secondary Trial.\n- No mention of race in the inclusion or exclusion criteria.\n\nThus, although Black men meet the individual criteria mentioned in the expert's statement, they are still ineligible for the secondary trial due to the gender restriction, which is not specified in the statement. Therefore, the statement can be contradicted by the information present in the CTRs.</s>"
    },
    "741c95c7-825c-4321-8d12-9037bb701ab8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail information from the CTRs as the trials described in the CTRs do not involve testing of Adjuvant Letrozole for post-menopausal women. The primary trial focuses on testing the web-based educational tool (SCPR) with additional resources, prompts, and adherence reminders for young breast cancer participants. The secondary trial mentioned in the expert statement refers to a separate trial investigating the effects of Adjuvant Letrozole on post-menopausal women, which is not directly related to the content in the provided CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert is not directly contradictory to the information in the CTRs as they focus on different interventions being tested in each trial. The primary trial is indeed testing a web-based educational tool (SCPR), whereas the secondary trial is not explicitly mentioned to involve the same tool in its intervention. The statement's inaccuracy lies in the assumption that the second trial is also testing the same intervention as the first one, when in fact it is testing Adjuvant Letrozole for post-menopausal women.</s>"
    },
    "6ce047b6-c18f-4f63-90ec-8643f5145efe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Statement": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR). ",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the information in the CTRs as follows:\n\n1. The statement \"At least 11 patients in both cohorts...\" requires a minimum of 11 patients in each cohort with ORR.\n2. In the Primary Trial, the ORR for Fulvestrant 250 mg cohort is 11.1% with a total number of participants analyzed as 45, which satisfies the condition of having 11 or more participants with ORR.\n3. Similarly, in the Primary Trial, the ORR for Fulvestrant 250 mg + Loading Dose cohort is 17.6% with a total number of participants analyzed as 51, which also satisfies the condition of having 11 or more participants with ORR.\n4. Hence, the statement is entailed by the information in the CTRs, as it is a logical consequence of the given data.</s>",
        "contradict": "The expert's statement \"At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR)\" cannot be directly contradicted by the data provided in the CTRs. However, it could potentially be misleading. \n\nBased on the information provided, the statement is true for Cohort 1 (Fulvestrant 250 mg) as there were 5 participants with CR and 11 participants with PR in this group, totaling 16 out of 45 patients with a response, which is more than the minimum of 11 required by the expert's statement. \n\nHowever, the statement could be contradicted for Cohort 2 (Fulvestrant 250 mg + Loading Dose) if we consider the expert's statement to refer to individual patients rather than unique occurrences of CR or PR. In this case, there could be overlap in the patients having CR or PR between the two cohorts. However, we do not have enough information from the CTRs to definitively determine if there were fewer than 11 unique patients with CR or PR across the two cohorts.</s>"
    },
    "d647aad0-47f7-4b77-a265-e77dcf5e0983": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, in contrast a full year of daily physical exercise is explicitly required for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trial expert is entailed by the information in the CTRs as follows:\n\n1. The primary trial specifies that participants will wear a Fitbit for the 12-week intervention period.\n2. The statement acknowledges that participants in the primary trial exercise for 12 weeks while wearing a Fitbit.\n3. The secondary trial does not provide explicit details on the use of a Fitbit in their intervention, but the statement clarifies that no such requirement is mentioned for the full year of daily physical exercise in the secondary trial.\n4. The primary trial's 12-week intervention duration is shorter than the secondary trial's full year requirement, making the statement's assertion consistent with both trial interventions.\n\nTherefore, the expert's statement is an entailed consequence of the information presented in the provided CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert contradicts the information in the CTRs in that the primary trial requires participants to undergo a 12-week physical activity intervention with a 6-month follow up, which does not explicitly state a requirement for daily exercise for the entire year as stated in the expert's comment. The secondary trial also lacks sufficient information to support the assertion that it requires a full year of daily physical exercise.</s>"
    },
    "74fed085-3389-49c6-bdd2-a95c97071f2d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial\" can be entailed by the information present in the CTRs as follows: In the primary trial, the percentage of participants with pCR in Arm 1 (EC -> D + Lapatinib) was 23.5% (11.9 to 35.1) and in Arm 2 (EC -> D + Trastuzumab) was 47.9% (33.8 to 62.0). In the secondary trial, Cohort 1P (HER2 Positive) had 100.0% pCR (4 out of 4 patients), and Cohort 1T (HER2 Positive) had 100.0% pCR (all 6 patients). Since the percentage values in the primary trial are lower than the 100.0% pCR in the secondary trial, the statement holds true.</s>",
        "contradict": "The statement \"All cohorts in the primary trial had lower percentage of participants with pCR compared to cohort 1 of the secondary trial\" cannot be confirmed by the information presented in the CTRs. The primary trial has two arms (Arm 1 and Arm 2), each with a different treatment regimen, but no explicit comparison of their pCR rates is provided. Additionally, the secondary trial consists of two cohorts (1P and 1T), each with 5 or 6 participants, respectively, and different treatment regimens and molecular subtypes. The comparison between the primary and secondary trials is not directly valid, as there is no information regarding the same treatment groups being compared across trials. To establish entailment, a more specific comparison between appropriate groups with similar treatment regimens and patient characteristics would be needed.</s>"
    },
    "986ffe33-8e8b-4cbf-8408-eb9489fb2314": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00450723",
        "Statement": "There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to take part in the primary trial\" is entailed by the information provided in the CTRs as follows:\n\n1. In the Primary Trial CTR, under PRIOR CONCURRENT THERAPY, there is a statement \"No prior radiotherapy to the mediastinum\". Since radiotherapy is mentioned in the expert's statement, this part of the CTR implies that this treatment is not allowed for patients participating in the primary trial.\n\n2. The expert's statement also mentions Appendectomies as one of the treatments not allowed. There is no explicit mention of Appendectomies in the Primary Trial CTR. However, the CTR states \"No prior thoracic or cardiac surgery\". Since Appendectomy is a surgical procedure, and the primary CTR does not allow patients to have undergone prior thoracic or cardiac surgeries, it follows that Appendectomies are not allowed as well.\n\nTherefore, the expert's statement is entailed by the information provided in the CTRs, as it correctly reflects the exclusionary conditions mentioned in the trials.</s>",
        "contradict": "The statement \"There are several types of surgical and therapeutic treatments, such as Appendectomies and radiotherapy, which are banned for patients wanting to participate in the primary trial\" is contradictory to the information present in the CTRs. \n\nExplanation: \n\nThe primary CTR does not mention any ban on Appendectomies or radiotherapy for patients. In fact, the CTR for the primary trial lists the allowed surgical procedures as \"no prior thoracic or cardiac surgery,\" but it does not explicitly mention a ban on Appendectomies or radiotherapy. The CTR for the secondary trial is also silent on any such ban for these treatments. Therefore, the statement made by the clinical trials expert is contradictory to the information provided in the CTRs.</s>"
    },
    "aeac5b1c-26f9-44bc-b1c4-3bd0d498914e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00483223",
        "Secondary_id": "NCT00811135",
        "Statement": "There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"There are more cases of Intestinal perforation, Chest pain, death, Hyperglycemia and Pneumonia in the secondary trial than in the primary trial\" is entailed by the information present in the CTRs as follows:\n\n- Intestinal perforation: The secondary trial reports 1 occurrence (1.14%) compared to none in the primary trial.\n- Chest pain: The secondary trial reports 1 occurrence (1.14%) compared to 1 occurrence (1.16%) in the primary trial.\n- Death: The secondary trial reports 1 occurrence (1.14%) compared to none in the primary trial.\n- Hyperglycemia: The primary trial reports 1 occurrence (1.16%) and the secondary trial reports 1 occurrence (1.14%). Since neither trial has more than the other in terms of the number of occurrences, this condition does not support the entailment. However, if we consider the percentage of total participants affected, the secondary trial has a higher percentage (1.14% vs. 1.16%).\n- Pneumonia: The secondary trial reports 1 occurrence (1.14%) compared to none in the primary trial.\n\nTherefore, the statement is entailed by the information in the CTRs, with the exception of Hyperglycemia, where both trials have the same number of occurrences but different percentages. However, this minor discrepancy does not contradict the overall meaning of the statement.</s>",
        "contradict": "The statement cannot be directly entailed from the given CTRs due to the absence of exact numbers of Intestinal perforation, Chest pain, Hyperglycemia, and Pneumonia in the primary trial. The statement only mentions that there are fewer cases of these conditions in the primary trial compared to the secondary trial, which is not directly contradicted by the CTR information, but it does not establish entailment either as the necessary comparison data is missing from the primary trial's adverse events section.\n\nHowever, the statement does include an incorrect comparison for Hyperglycemia, as both trials report the same number of cases (1/86 in the primary trial, 1.14% in the secondary trial). This discrepancy, even though it is minor, makes the statement inconsistent with the primary trial's reported data, making it a contradiction rather than an entailment. The rest of the statements comparing the number of cases for Intestinal perforation, Chest pain, and Pneumonia remain ambiguous without the exact numbers from the primary trial for comparison.</s>"
    },
    "3f98cd71-ec28-4fd1-9ca0-2184eef3390a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 +, PR and ER -, are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with tumors that are HER2+, PR and ER- are eligible for the primary trial\" is entailed by the CTR's inclusion criteria as follows: \"Patient must have any one of the following types of breast cancer (primary or metastatic): ER+/PgR+/HER2-, or ER+/PgR-/HER2-\" and \"Immunohistochemistry (IHC) is the primary assay methodology for HER2. HER2- refers to HER2 of 0, 1+ by IHC or negative by fluorescence in situ hybridization (FISH)\". Given that HER2 is defined as + when detected by IHC or FISH, the statement \"Patients with tumors that are HER2+, PR and ER-\" matches the ER- and HER2+ conditions specified in the CTR. The PR status is also addressed in the CTR's inclusion criteria, but it doesn't affect the eligibility in terms of HER2 status.</s>",
        "contradict": "The statement \"Patients with tumors that are HER2+, PR and ER- are eligible for the primary trial\" contradicts the information in the CTR because the CTR specifies that patients must have ER+/PgR+/HER2- or ER+/PgR-/HER2- tumors to be eligible for the primary trial. The statement, on the other hand, states that patients with HER2+, PR, and ER- tumors are eligible, which is not a permissible combination according to the CTR.</s>"
    },
    "11138479-1666-4973-84c2-c6779b5444f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the same intervention.",
        "Label": "Contradiction",
        "entail": "The statement that \"In the primary trial, only 1 cohort is administered the intervention, whereas in the secondary trial, both cohorts receive the same intervention\" is entailed by the information in the CTRs because, in the primary trial, Arm 1 (Patients With Pain) is the only arm that receives the intervention of Duloxetine. In contrast, the secondary trial has two arms, Intervention 1 (Monotherapy: Alobresib 0.6 mg) and Intervention 2 (Monotherapy: Alobresib 1.4 mg), but both receive the same intervention of Alobresib, just with different dosages.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the primary trial involves two cohorts - Arm 1 receiving Duloxetine and Arm 2 serving as the control - whereas the secondary trial also involves two cohorts, but both are administered the same intervention with alobresib. However, the primary trial's interventions have different dosage schedules and treatment lengths for Duloxetine, making it incomparable to the secondary trial with identical interventions for alobresib.</s>"
    },
    "35c62055-2832-4119-9080-5603beea1934": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02402764",
        "Secondary_id": "NCT00490646",
        "Statement": "There were no cases of Pneumopathy in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "There is no record of \"Pneumopathy\" as an adverse event in any of the given trial reports, neither in the primary trial nor in the secondary trial. Consequently, the expert's statement entails that no such cases were observed in these trials.</s>",
        "contradict": "The statement \"There were no cases of Pneumopathy in either the primary trial or the secondary trial\" is contradicted by the information present in the CTRs because Pneumopathy is not mentioned as an adverse event in either trial.</s>"
    },
    "59ff0501-f6af-4739-bd07-71e12e8cd8a7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT01901146",
        "Statement": "Patients with undetermined  human epidermal growth factor receptor 2 expression cannot be accepted by either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial excludes patients with \"any other clinically significant disorder, condition or disease\" (as per the Exclusion Criteria) that could pose a risk to subject safety or interfere with the study. This category includes patients with undetermined HER2 expression. Similarly, the secondary trial excludes patients with unknown HER2 status, as it targets HER2-positive breast cancer. Consequently, patients with undetermined HER2 expression cannot be accepted in either trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because:\n\n1. In the primary trial, patients are excluded if ER, PgR, and HER2 expression have not been determined (ELIGIBILITY CRITERIA). Therefore, patients with undetermined HER2 expression cannot satisfy the inclusion criteria of the primary trial, not that they cannot be accepted by it.\n\n2. In the secondary trial, there's no mention of HER2 expression in the inclusion or exclusion criteria sections. However, it is specified that HER2 positive disease is among the criteria for participation. This suggests that patients with determined HER2 positivity are accepted, while those with undetermined HER2 expression are not explicitly mentioned. Therefore, the statement is not directly contradicted by this trial.\n\nHowever, it's important to note that the statement does not hold true for both trials since each trial has different criteria.</s>"
    },
    "ab52c559-5712-44ff-becd-1c491e107472": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00605267",
        "Statement": "Men are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Men are not eligible for the primary trial\" is entailed by the CTR information because the primary trial's inclusion criteria specify that only premenopausal, estrogen receptor positive women are eligible, with an age requirement of 20 years or older. The exclusion criteria state that individuals with a medical history of chemotherapy or endocrine therapy for breast cancer, radiotherapy, or unwillingness to stop taking drugs affecting sex hormone status (including HRT) are not eligible. Men do not possess breast cancer or estrogen receptors and do not undergo hormonal treatments like HRT. Therefore, the statement that \"Men are not eligible for the primary trial\" follows logically from the CTR information.</s>",
        "contradict": "The statement \"Men are not eligible for the primary trial\" is contradicted by the information present in the CTRs, as the inclusion criteria specify that the trial only includes premenopausal, estrogen receptor positive women. Therefore, men do not meet these conditions and are not intended to be part of the trial.</s>"
    },
    "4619b957-3368-47b9-b949-01ec91208f96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial recorded more cardiac related adverse events than the primary trial\" can be entailed by the information present in the CTRs, as the secondary trial reported a higher total number of adverse events, including cardiac-related events, compared to the primary trial. The secondary trial reported 11 cardiac-related events (0.00% in the primary trial + 3/93 * 0.01 for the additional section), while the primary trial reported 4 such events (1.00% in total). Therefore, the statement is an accurate observation based on the provided data.</s>",
        "contradict": "The statement can be contradicted by the information presented in the CTRs as there are no cardiac related adverse events reported in Adverse Events section of the Primary Trial, while in the Secondary Trial, some participants experienced cardiac failure congestive (3/93), cardiomyopathy (2/93), and atrial fibrillation (1/93). However, the number of participants in each trial and specific types of cardiac adverse events differ, making a direct comparison of the total number of cardiac events between the two trials inaccurate without qualification. Therefore, a more nuanced comparison is required to determine if the secondary trial truly recorded more 'cardiac related' adverse events, considering the different types and incidence rates.</s>"
    },
    "5bb09d7b-622f-4bdd-8dfd-809ea014a278": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559754",
        "Secondary_id": "NCT02924883",
        "Statement": "A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A higher percent of patients in cohort 1 of the secondary trial experienced adverse events, than in cohort 1 of the primary trial\" is entailed by the CTR data because the secondary trial had a higher overall adverse event rate (39.10%) compared to the primary trial (18.06%). Although the types of adverse events may differ between cohorts within each trial, the overall occurrence of adverse events is a quantifiable comparison and the data provided in the CTRs supports this entailment.</s>",
        "contradict": "The expert's statement can be contradicted by the information present in the CTRs due to the difference in types and frequencies of adverse events between the trials. The percentage of patients experiencing adverse events is higher in the secondary trial (39.10%), but this increase cannot be attributed to cohort 1 alone, as the statement assumes, because the types and frequencies of specific adverse events differ significantly between the trials. For instance, while mucositis/stomatitis and febrile neutropaenia are prominent adverse events in the primary trial, they are absent in the secondary trial. Instead, the secondary trial exhibits adverse events such as thrombocytopenia, anaemia, and cardiac failure, which are not present or only occur infrequently in the primary trial. Consequently, a direct comparison of the overall percentage of patients experiencing adverse events between the two trials does not provide an accurate representation of cohort 1 adverse event frequencies.</s>"
    },
    "07327b61-973b-48bb-b42b-dfde1efcfb7d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial\" is entailed by the information presented in the CTRs as follows:\n\n1. The shortest PFS mentioned in the statement can be identified in the secondary trial by looking for the lowest reported median PFS in either the Bosutinib arm (5.4 to 6.8 months based on investigator assessment and 5.4 to 7.6 months based on independent radiology assessment) in Results 2 of the CTR for the secondary trial.\n\n2. The longest recorded PFS can be identified in the primary trial by finding the longest reported median PFS, which is 5.5 months (investigator assessment) and 5.5 to 6.0 months (independent radiology assessment) for the Sunitinib + Capecitabine arm in Results 1 of the CTR for the primary trial.\n\nThus, the information in the CTRs entails the statement that the patient with the shortest PFS came from the secondary trial and the patient with the longest recorded PFS came from the primary trial.</s>",
        "contradict": "The statement \"The patient with the shortest PFS was in the secondary trial and the longest recorded PFS was in the primary trial\" is not directly contradictory to the information in the CTRs based on the given descriptions. However, it is important to note that the definition of PFS and the methods used to calculate it differ between the two trials. In the primary trial, PFS is calculated in months and is the time from randomization to the first documented objective tumor progression or death, while in the secondary trial, PFS is calculated in weeks from the start of study treatment to the first documentation of objective tumor progression or death. Furthermore, the percentage of participants with PFS beyond a certain time point (Week 16 in the secondary trial) is reported. Therefore, comparing PFS durations directly based on the given statement without taking into account the differences in calculation methods and time frames could lead to incorrect conclusions.</s>"
    },
    "3307a083-0c8a-47b8-94cb-0bf4095b9c3b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00633750",
        "Statement": "Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial\" is entailed by the CTR as follows: \n\nThe CTR explicitly lists \"Fixed axillary lymph node metastases (N2)\" in the exclusion criteria for the primary trial. Therefore, patients with N2 lymph node involvement are not eligible for the trial. Additionally, the statement specifies \"Clinical stage II (T2 N2)\" which includes patients with N2 nodal involvement. Thus, the statement is entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"Patients with Clinical stage II (T2 N2) invasive mammary carcinoma are not eligible for the primary trial\" is contradictory to the CTR as the CTR excludes only patients with N3 disease, but not those with N2 disease in the Nodes category. This discrepancy results from the difference in definitions between N2 and N3 in the TNM staging system for breast cancer. N2 denotes metastasis to axillary lymph nodes, while N3 indicates fixation of axillary lymph node metastases. Therefore, the CTR includes patients with T2N2, whereas the statement excludes them, creating a contradiction.</s>"
    },
    "bda2752e-082e-4d06-926a-04ade3f61c26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03165955",
        "Secondary_id": "NCT00912340",
        "Statement": "11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial\" does not entail any information from the provided Adverse Events sections. The given sections report on types and frequencies of adverse events, but they do not explicitly mention liver diseases among them for either trial. Therefore, there is no entailment relationship between the statement and the CTR information presented.</s>",
        "contradict": "The statement \"11 patients in the primary trial suffer from a liver disease, 0 in the secondary trial\" is contradicted by the data in the CTRs as no mention of liver disease is found in either of them. There is no mention of any adverse event related to liver disease in either the primary or secondary trials.</s>"
    },
    "d4d73d33-4f71-46b2-b0c1-eac6741fd8f3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00118157",
        "Statement": "Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response.",
        "Label": "Entailment",
        "entail": "The statement \"Only one the primary trial patient treated with oral lapatinib and oral tamoxifen achieved either Complete and Partial tumour response\" can be entailed by the information present in the CTRs because:\n\n1. The statement claims that only one patient from Arm 1 in the primary trial experienced a Complete or Partial tumour response. The CTR for the primary trial specifies that the outcome measure was Tumor Response Rate (Complete and Partial) Assessed by RECIST within a 4-week time frame.\n2. The CTR states that 17 participants were analyzed in Arm 1 of the primary trial, and all received oral lapatinib and oral tamoxifen once daily.\n3. The statement and the CTR both use the same outcome measure and the same patient population (participants in Arm 1 of the primary trial receiving oral lapatinib and oral tamoxifen).\n4. The number of patients who achieved a Complete or Partial tumour response, as indicated by the CTR's result, is consistent with the expert's statement that only one such response was observed.\n5. The statement's assertion that \"one\" patient achieved a Complete or Partial tumour response harmonizes with the clinical trial data, finds substantiation in the CTR, and avoids contradiction with the provided descriptions.\n\nTherefore, the information contained in the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert that \"only one patient in the primary trial achieved either Complete and Partial tumor response\" is not directly contradictory to the information given in the CTR, but it can be contradicted if there is additional information available in the primary trial report that contradicts it. However, the CTR provided does not specify the number of patients who achieved complete or partial response. Therefore, based on the information given, the statement is not directly contradictory but inconclusive. To determine if the statement is entailed or contradicted, a more comprehensive analysis of all the trial reports, including the number of participants in each arm who achieved complete or partial response, would be required.</s>"
    },
    "f418c027-439a-4b19-bfb0-e1c1241886d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "There were 4 more cases of Dyspnea than Dehydration in the primary trial.",
        "Label": "Contradiction",
        "entail": "In the primary CTR, there were 2 cases of Dyspnea and 1 case of Dehydration. A difference of 3 (2 cases of Dyspnea - 1 case of Dehydration) exists. The statement asserts there were \"4 more cases of Dyspnea than Dehydration,\" which is equivalent to stating there is a difference of 4 between the number of cases of Dyspnea and Dehydration. Since the difference is 3 in the CTR and 4 in the statement, it is important to consider that the statement may be rounding up the number of cases of Dyspnea to 4 instead of precisely stating there are 3 more cases. Given this interpretation, the statement is entailed by the CTR as the rounding up of the number of cases of Dyspnea does not contradict the information in the CTR and is still a valid reflection of the data presented.</s>",
        "contradict": "Although the statement does not directly contradict the information in the CTRs, it can be misleading without further context. The statement only mentions the number of cases for Dyspnea and Dehydration in the primary trial. However, it does not provide this information for the same time frame or patient population in both trials. The number of adverse events per participant might differ between trials, affecting the total number of cases for each event. Therefore, it is crucial to consider the context, specifically the trial length, sample size, and patient demographics, to ensure that the statement's meaning aligns with the CTR information. If both trials cover the same time frame with the same patient population, the statement's conclusion would be an accurate observation based on the data from the CTRs.</s>"
    },
    "4805e49a-b99e-46d8-b937-13ac2501c4a4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial\" can be entailed by the information present in the CTR as follows:\n\nAccording to the CTR, for patients with a positive sentinel node biopsy, if it is histologically positive by H&E or histologically suspicious on H&E and confirmed positive by IHC, they are required to have a completion axillary dissection. Axillary dissection involves the removal of lymph nodes from the axilla. In the CTR, it is stated that node-positive patients are eligible for certain clinical trials, provided they meet the requirements of a specific protocol. However, for node-positive patients, the requirement of having undergone a completion axillary dissection (which involves the removal of lymph nodes from the axilla) is a common condition for eligibility in these trials (as stated in the CTR for protocols MA.20 and S9927). Therefore, it can be inferred that patients who have undergone a sentinel node biopsy and have a positive result but have not yet had surgery to remove lymph nodes (completion axillary dissection) will not meet the eligibility criteria for these clinical trials. Consequently, they will not be eligible for the primary trial either, as the primary trial likely follows the same eligibility criteria as these clinical trials.</s>",
        "contradict": "The statement \"Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the groin or they will not be eligible for the primary trial\" contradicts the information present in the CTRs in the following ways:\n\n1. For patients with a positive sentinel node biopsy, the CTRs allow for the requirement of a completion axillary dissection, but they do not explicitly state that surgery to remove lymph nodes from the groin (a procedure known as an inguinal lymph node dissection) is necessary for eligibility.\n\n2. Some patients in the CTRs, specifically those participating in the National Cancer Institute of Canada Clinical Trials Group protocol MA.20 and Southwest Oncology Group protocol S9927, are allowed to have node-positive breast cancer and undergo sentinel node biopsy without requiring a completion axillary dissection. These patients are still eligible for the primary trial.\n\n3. The requirement of a negative sentinel node biopsy is mentioned for lumpectomy patients to be followed by breast radiation therapy, but no such requirement exists for eligibility in the primary trial.\n\nTherefore, the statement is contradictory to the information presented in the CTRs.</s>"
    },
    "9a3cb836-66a8-4c68-980c-97e5841f331f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01091428",
        "Statement": "The Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With Paclitaxel, supported by the primary trial results, is 40 mg orally, twice daily (BID) on Days 1-3, 8-10 and 15-17",
        "Label": "Entailment",
        "entail": "The statement entails the information in the CTR as it correctly reflects the identified MTD of 40 mg for Alisertib in combination with Paclitaxel, based on the primary trial data. The trial defined the MTD as the dose range at which one of six evaluable participants experienced DLT, and 1 of 6 participants indeed experienced DLT at the 40 mg dose. The statement also matches the dosing schedule described in the CTR, specifying BID administration on Days 1-3, 8-10, and 15-17.</s>",
        "contradict": "The statement does not contradict the information in the CTR directly, as it aligns with the reported MTD of 40 mg. However, it does not accurately represent the entirety of the RP2D determination, which may include considerations beyond the MTD, such as efficacy, safety, and tolerability in the Phase 1 trial that might not be mentioned in the statement. Therefore, while not an outright contradiction, the statement's scope is narrower than the actual information presented in the primary CTR.</s>"
    },
    "45d4f78f-04d4-434c-9679-fd92291e97b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553410",
        "Statement": "A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prevent prolonged follow-up.",
        "Label": "Entailment",
        "entail": "The statement entails that a 55-year-old postmenopausal patient with sarcoidosis would be excluded from the primary trial due to having \"any other nonmalignant systemic diseases that would prevent prolonged follow-up.\" The CTR clearly states that such patients are ineligible for the study. Therefore, the assertion in the expert statement is harmonious with the clinical trial data, and there is no contradiction with the provided description in the CTR.</s>",
        "contradict": "The statement \"A 55 year old postmenopausal patient with sarcoidosis would be excluded from the primary trial as it would prevent prolonged follow-up\" is not contradictory to the information present in the CTR as sarcoidosis is not listed as a nonmalignant systemic disease that would prevent prolonged follow-up in the PRIOR CONCURRENT THERAPY section of the Primary Trial CTR. Therefore, no semantic entailment relationship can be established between the statement and the CTR based on the provided information.</s>"
    },
    "5338f894-aecb-4678-bb67-fe058653e12b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01365845",
        "Statement": "Less than a quarter of participants in the primary trial had radiation dermatitis.",
        "Label": "Entailment",
        "entail": "The statement \"Less than a quarter of participants in the primary trial had radiation dermatitis\" is entailed by the information present in the CTR as 22.22% of participants in the primary trial experienced radiation dermatitis (i.e., 2/18 or 11.11% had severe radiation dermatitis, and 1/18 or 5.56% had mild radiation dermatitis, totaling 22.22%).</s>",
        "contradict": "The expert's statement \"Less than a quarter of participants in the primary trial had radiation dermatitis\" is contradictory to the information in the CTR because the CTR reports that 22.22% of participants in the primary trial had radiation dermatitis, which is higher than 25% that the expert's statement implies is the threshold for \"less than a quarter\" of the participants.</s>"
    },
    "2cebae78-f4a3-4e09-ac54-cd2388670274": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01953003",
        "Statement": "Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients receiving intervention 1 of the primary trial, will be administered medication topically and intraveinously,\" is not entailed by the information present in the CTRs. \n\nThe CTR specifies that Intervention 1 (Arm A) of the primary trial consists of vinflunine administered intraveinously on day 1 of each cycle every 3 weeks, and Capecitabine administered orally in a dose of 825 mg/m\u00b2 twice daily for 14 days, starting from day 1 of each cycle, followed by a 1-week rest period. \n\nTherefore, there is no mention or entailment of topical medication administration for either vinflunine or Capecitabine in the CTR for Intervention 1. Thus, the statement cannot be entailed based on the information provided in the CTRs.</s>",
        "contradict": "The information in the statement that patients receiving intervention 1 of the primary trial will be administered medication topically is contradictory to the CTR as the intervention for Arm A in the primary trial involves intravenous administration of Vinflunine and oral administration of Capecitabine.</s>"
    },
    "d8a98ace-009c-47e4-a812-3bc0df91ed2b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01516736",
        "Secondary_id": "NCT00733408",
        "Statement": "the primary trial and the secondary trial have non comparable results as the metrics they records are completely different.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial have non-comparable results as the metrics they record are completely different\" is entailed by the information present in the CTRs, as the trials report on different outcome measures. The primary trial focuses on the mean duration of severe neutropenia during Cycle 1 of chemotherapy, while the secondary trial measures progression-free survival. The statement's assertion harmonizes with the clinical trial data, finds substantiation in the provided descriptions, and avoids contradiction.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have non-comparable results as the metrics they record are completely different\" is not directly contradicted by the provided CTRs information. However, it's important to note that the trials assess different outcome measures: Mean Duration of Severe Neutropenia in the primary trial, and Progression-free Survival in the secondary trial. While the statement is true that these measures are not directly comparable, the trials are not necessarily non-comparable in their entirety, as they both investigate the effect of interventions on different aspects of patient treatment. The trials can still be compared within the context of evaluating the efficacy and safety of the interventions for the given diseases.</s>"
    },
    "c8cfd67e-5fac-4bff-9296-6e42dcb09f80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00300781",
        "Statement": "Participants of the primary trial are assigned an intervention depending on their hormone recpetor status.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Participants of the primary trial are assigned an intervention depending on their hormone receptor status.\" is entailed by the information in the CTRs because:\n\n1. The CTRs clearly state that Intervention 1 is for participants with \"prior trastuzumab treatment,\" implying that these subjects have been identified based on their hormone receptor status or HER2 status, as trastuzumab is a targeted treatment for HER2-positive breast cancer.\n\n2. Intervention 2, on the other hand, is for participants with \"no prior trastuzumab treatment,\" indicating a different hormone receptor profile, as these subjects have not received the HER2-targeted therapy. \n\nThus, the information in the CTRs implies that the assignment of the intervention to each participant is indeed based on their hormone receptor status, as stated by the clinical trials expert.</s>",
        "contradict": "The statement \"Participants of the primary trial are assigned an intervention depending on their hormone receptor status\" is not directly contradicted by the CTR information. However, the CTR does not provide sufficient data to definitively confirm this statement's entailment. The CTR focuses on the differences in interventions based on prior trastuzumab treatment, not hormone receptor status.</s>"
    },
    "57cf3760-1692-439f-bbe2-82a6bc8862ce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01912612",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 receives Duloxetine 30 mg daily.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1\" is entailed by the information in the CTRs because:\n\n1. In the primary trial, Intervention 1 (Arm I) for cohort 1 uses a low dose (3.25 mg) of vaginal DHEA gel, and Intervention 2 (Arm II) for cohort 2 uses a high dose (6.5 mg) of vaginal DHEA gel.\n2. The difference between the doses is 3.25 mg.\n3. In the secondary trial, Intervention 1 (Arm 1) for cohort 1 receives Duloxetine, but cohort 2 (Arm 2) does not. Therefore, there is no comparison regarding DHEA doses between the two cohorts in the secondary trial.\n\nHence, the statement's assertion harmonizes with the data presented in the CTRs and avoids contradiction, making it entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not hold true based on the information in the CTRs. In the primary trial, both cohorts receive DHEA gel; cohort 1 receives a lower dose (3.25 mg) and cohort 2 receives a higher dose (6.5 mg). However, the secondary trial does not involve DHEA gel administration, but rather involves Duloxetine treatment with varying doses. Therefore, no meaningful comparison regarding the quantity of DHEA gel received between the two trials or their respective cohorts can be inferred.</s>"
    },
    "7db1447c-b4e8-49c6-a125-8161bcd98560": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with wounds that havent healed within five to eight weeks are ineligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The exclusion criteria in the primary CTR specify that subjects with \"the presence of any non-healing wound, fracture, or ulcer\" are ineligible. The statement made by the expert can be entailed as a more specific instance of this broader exclusion criterion in the CTR, since a wound that hasn't healed within five to eight weeks can be considered a non-healing wound.</s>",
        "contradict": "The expert's statement is contradictory to the inclusion criteria of the primary trial, which state that subjects with no clinically significant (>= Grade 2) peripheral vascular disease or non-healing wound, fracture, or ulcer are eligible. However, the expert's statement specifies a healing requirement for wounds within five to eight weeks, which is more stringent than the eligibility criteria. Thus, the statement contradicts the CTR by imposing a more restrictive condition for patient eligibility.</s>"
    },
    "626a05e9-2caf-4e73-a132-5432a5b2c7d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Secondary_id": "NCT00143390",
        "Statement": "over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows: In the primary trial, the definition of a Level 1 cardiac event includes myocardial infarction or arrhythmia. The statement mentions that over 20% of patients in both trials experienced myocardial infarction or arrhythmia. Therefore, this percentage applies to the primary trial as well, given that these events are included in the definition of a Level 1 cardiac event for that trial. Additionally, the majority of these events occurred in the secondary trial, which is consistent with the information in the CTRs, as there were 11 participants in the secondary trial that experienced a cardiac event compared to 5 in the primary trial.</s>",
        "contradict": "The statement \"over 20% of patients in the primary trial and the secondary trial Experienced myocardial infarction or arrhythmia, with the majority of those coming from the secondary trial\" cannot be directly contradicted by the information provided in the CTRs, as the CTRs do not contain explicit data on the occurrence of myocardial infarction or arrhythmia for individual participants in each trial. However, the statement may contradict the information if it is later found that less than 20% of the participants experienced these conditions and/or if a majority did not come from the secondary trial.</s>"
    },
    "fe6f3faf-8be6-4ec6-8622-b4d36e8c2876": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 0 cases of night blindness in the primary trial, and 1 in the secondary trial\" can be entailed by the information in the CTRs as follows: \n\n1. According to the primary CTR, there were 0 cases of Nyctalopia (night blindness) reported in the Adverse Events section (Adverse Events 1). \n2. Similarly, the secondary CTR reports 1 case of Nyctalopia in the Adverse Events section (Adverse Events 1). \n\nTherefore, the statement is an accurate reflection of the data present in the CTRs, and its assertion harmonizes with the clinical trial data.</s>",
        "contradict": "The information contained in the statement can be contradicted by the data in the CTRs because the statement asserts that there were \"0 cases of night blindness\" in the primary trial, but the CTR for the primary trial lists \"1 case\" of nyctalopia (night blindness) under the Adverse Events section. Similarly, the statement asserts that there was \"1 case\" of night blindness in the secondary trial, but the CTR for the secondary trial lists 0 cases under the Adverse Events section for nyctalopia. Thus, the statement contradicts the information in the CTRs by either under-reporting or omitting the occurrence of nyctalopia.</s>"
    },
    "b1cd4818-9623-45e5-a2b3-4c80016e3c82": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00186121",
        "Statement": "Patients with E2 outside the premenopausal range are ineligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" can be entailed by the information present in the CTRs as follows: \n\n1. The Primary Trial's Inclusion Criteria state that either estrogen or progesterone receptor determination by Immunohistochemistry (IHC) or competitive binding assay is a requirement for patient eligibility. \n2. The CTRs do not specify an upper limit for estradiol (E2) concentration in the premenopausal range. However, in the Primary Trial's Inclusion Criteria, it is stated that plasma estradiol must be in the premenopausal range if tamoxifen has been administered within the past 3 months. \n3. This suggests that, in general, patients with high estradiol levels (outside the premenopausal range) are considered ineligible based on their hormonal status, as indicated by the CTRs.\n4. The statement \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" directly aligns with this interpretation of the CTRs, making it entailed by the information provided.</s>",
        "contradict": "The statement that \"Patients with E2 outside the premenopausal range are ineligible for the primary trial\" can be contradicted by the information present in the CTRs, as the CTRs specify that patients who have received tamoxifen within the past 3 months or have had a hysterectomy without bilateral oophorectomy and are in the premenopausal range, but with plasma estradiol in the premenopausal range, are also eligible for the trial. These patients, despite being postmenopausal by other definitions, may have estradiol levels (E2) outside the typical premenopausal range but still meet the eligibility criteria as per the CTR.</s>"
    },
    "3050bca2-a8bc-412e-b679-5be1055e3749": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial receives a consistent dose of Daratumumab for the full study.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study\" entails that during some part of the study, Cohort 1 in the secondary trial receives a different dose of Daratumumab than the one they receive at other times. \n\nIn the primary trial CTR, it is explicitly stated that patients in Arm I (Cohort 1) receive Daratumumab IV \"Q2W (weeks 9-24)\" which implies a consistent dose throughout that period. \n\nHowever, in the secondary trial CTR for Cohort 1 in Intervention 1, they receive Daratumumab IV \"Q1W (weeks 1 to 8)\" followed by \"Q2W (weeks 9-24)\". Thus, the dosing regimen for Cohort 1 of the secondary trial differs from the consistent dosing regimen described in the primary trial and, therefore, the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement is not directly contradictory to the CTR information, but it makes an inference about the dosing frequency of Daratumumab in Cohort 1 of the secondary trial without specifying the exact doses. However, the CTRs clearly state the different dosing schedules for Cohort 1 in each trial. In the primary trial, patients receive the same Daratumumab dose consistently throughout the study, while in the secondary trial, Cohort 1 receives different doses in the beginning and later stages of the trial. Therefore, while the statement implies inconsistency in dosing frequency, it does not contradict the CTRs as they describe distinct trials with different interventions, including different dosing regimens for Daratumumab.</s>"
    },
    "a49666fd-f278-4dcf-b6bf-287ace3969aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Metastasis to the CNS were recorded in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"No cases of Metastasis to the CNS were recorded in the primary trial.\" is entailed by the CTR data if we consider that the CTRs explicitly report zero occurrences of Metastasis to central nervous system in the Adverse Events sections of both the primary and secondary trials. Thus, no recorded cases of Metastasis to the CNS contradict or conflict with the statement made by the clinical trial expert.</s>",
        "contradict": "The statement \"No cases of Metastasis to the CNS were recorded in the primary trial\" contradicts the information in the CTRs because the CTR for the primary trial reports one case (1/4) of Metastasis to central nervous system in the Adverse Events section.</s>"
    },
    "f6c014af-63db-4578-9b2d-74ea95901842": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Secondary_id": "NCT00950742",
        "Statement": "the primary trial and the secondary trial measure the DLT of their respective interventions, using the same time frame and the same unit of measure.",
        "Label": "Contradiction",
        "entail": "Both trials measure the incidence of dose limiting toxicities (DLT) within a 28-day time frame, using the same unit of measure - the number of participants. In the primary trial, the measurement is reported separately for two different dosing regimens of neratinib in combination with paclitaxel, yielding zero DLTs for each arm. In the secondary trial, the measurement is reported for two different dosing regimens of Afatinib in combination with Herceptin, resulting in a total of 6 participants experiencing DLTs across both arms. Despite the differences in specific arms and interventions, the consistency in the time frame and unit of measure allows for the statement to be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTRs because:\n\n1. In the primary CTR, the outcome measurement for DLT is specifically reported for the combination of neratinib and paclitaxel within the given time frame of 28 days. However, the statement does not mention the combination of interventions, but rather just refers to both trials measuring DLT.\n\n2. Additionally, in the secondary CTR, the measurement for DLT is reported for the first cycle of Afatinib and Herceptin administration, which lasts beyond 28 days as patients received treatment until disease progression or lack of clinical benefit. Therefore, the time frames and possibly the number of participants analyzed are not directly comparable between the primary and secondary trial results.\n\n3. Furthermore, the units of measure are reported as \"participants\" in both CTRs. However, the number of participants with DLT and the overall number of participants analyzed might not be directly comparable, as the primary CTR only reports on the incidence of DLT without mentioning the number of participants who experienced DLT specifically.\n\nIn summary, although the statement mentions that both trials measure DLT using the same time frame and same unit of measure, the combination of interventions and potentially the patient cohorts are not directly comparable, and the number of participants with DLT might not be directly comparable due to differing study designs.</s>"
    },
    "c8ef1457-63a9-4eac-a98b-edb805afd35b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02660788",
        "Secondary_id": "NCT01490892",
        "Statement": "the primary trial is investigating different ways to communicate with women aged 51-73 years old , whereas the secondary trial is evaluating the impact of regular exercise and dieting.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial is investigating different ways to communicate with women aged 51-73 years old\" is not entailed by the given CTRs since the primary trial's Intervention sections do not provide enough evidence for the communication aspect. The secondary trial's Intervention sections focus on the 3D Harmonic imaging (HI) and subharmonic imaging (SHI) procedures for UCA, which is not related to communication methods. The statement regarding the secondary trial investigating the impact of regular exercise and dieting is also not directly entailed by the CTRs, as there is no explicit mention of these interventions in the secondary trial's Intervention sections.</s>",
        "contradict": "The statement made by the clinical trial expert is contradictory to the information present in the CTRs. The primary trial described in the CTRs mentions two intervention arms \u2013 one with a standard reminder postcard via mail and the other with a family physician reminder letter in addition to a standard reminder postcard via mail. There's no indication that the trial is evaluating ways of communicating with women or investigating different ways to communicate regarding regular exercise and dieting. \n\nSimilarly, the secondary trial described in the CTRs involves two intervention arms, both administering Perflutren injection followed by 3D Harmonic imaging and 3D subharmonic imaging for Ultrasound contrast agents. No evidence in these CTRs indicates that this trial is related to the evaluation of communication methods with women or assessing the impact of regular exercise and dieting.</s>"
    },
    "515d0710-429b-4c28-b881-8a6531ee973e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03097653",
        "Secondary_id": "NCT00662129",
        "Statement": "Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial\" is entailed by the information present in the CTRs because:\n\nFor the primary trial, the explication is as follows: The inclusion criteria state \"Women aged 45-69\" and the exclusion criteria are empty. The age range of 45-69 excludes females aged between 18-25. The disease characteristic section of the secondary trial lists \"Bone lesions\" and \"Leptomeningeal disease\" among the exclusion criteria, thus women aged between 18-25 with these conditions are also excluded from this trial. Therefore, the statement is entailed by the information in both CTRs.</s>",
        "contradict": "The statement \"Females aged between 18-25 with Bone lesions or Leptomeningeal disease cannot be included in either the secondary trial or the primary trial\" is contradicted by the information present in the CTRs. \n\nIn the primary CTR, bone lesions and other non-measurable lesions are mentioned as exclusion criteria under \"DISEASE CHARACTERISTICS\", but the age range of the participants is specified as Women aged 45-69. \n\nIn the secondary CTR, the exclusion criteria for bone lesions and Leptomeningeal disease are mentioned under \"DISEASE CHARACTERISTICS\", but the age range of the participants is not specified. \n\nTherefore, the statement is contradictory because it extends the exclusion criterion of bone lesions and Leptomeningeal disease to females aged between 18-25, which is not mentioned in either CTR.</s>"
    },
    "b4d261a4-9b42-4158-9b21-159859b59e2a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally or by IV.",
        "Label": "Entailment",
        "entail": "The given statement does not entail any information directly from the provided CTR sections since neither the primary nor the secondary trial descriptions mention the administration of medications orally or via intravenous (IV) routes in their intervention details. Hence, the statement does not contradict or follow from the information in the CTRs. However, it's important to note that the absence of oral or IV medication information in the CTRs does not necessarily imply the absence of such treatments in the trials. It is just that the CTRs do not mention these details.</s>",
        "contradict": "The statement \"Neither cohorts of the primary trial receive any medication orally or by IV\" is contradicted by the information in the CTRs because they do not provide any information about medications administered to the cohorts orally or intravenously. The CTRs only specify the interventions as WBI and APBI, which are radiotherapy procedures and do not involve medications given orally or by IV.</s>"
    },
    "1c043d17-15a9-496c-a69b-9ec95a7ab8df": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00293540",
        "Statement": "Males are not eligible for the primary trial, because they do not produce oestrogen.",
        "Label": "Contradiction",
        "entail": "The statement \"Males are not eligible for the primary trial, because they do not produce oestrogen\" is entailed by the information in the CTRs, as the primary trial's inclusion criterion explicitly states \"Estrogen receptor or progesterone receptor positive breast cancer,\" meaning that participants must have breast cancer that responds to these hormones. Males do not have breast tissue and thus do not produce estrogen, making them ineligible for the trial according to the provided criteria.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the CTRs explicitly state that the primary trial only includes individuals with estrogen receptor or progesterone receptor positive breast cancer, but do not mention any restriction based on gender. Therefore, males who have breast cancer with positive estrogen and progesterone receptors could potentially be included in the trial, contrary to the expert's claim that only females are eligible.</s>"
    },
    "79c69498-7dd5-41fa-8946-36d452a5b9ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00328783",
        "Statement": "Patients with a COPD diagnosis through spirometry are ineligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a COPD diagnosis through spirometry are ineligible for the primary trial\" is entailed by the information in the CTRs since there is no mention of any respiratory condition, such as COPD, included in the Eligibility Criteria section of the Primary Trial CTR. Therefore, the presence of COPD is an exclusionary factor, making the statement consistent with the trial data.</s>",
        "contradict": "The statement \"Patients with a COPD diagnosis through spirometry are ineligible for the primary trial\" is contradictory to the information present in the provided CTR as the CTR does not mention anything about COPD (Chronic Obstructive Pulmonary Disease) being an exclusion criterion for the primary trial.</s>"
    },
    "93fc76a9-5f3d-490b-8802-21d0fa806728": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "Cohort 2 of the primary trial reported worse results than cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial reported worse results than cohort 1\" can be entailed by the information in the CTRs if the percentage of participants with objective response in cohort 2 (35.9%, 21.2-52.8) is lower than that of cohort 1 (30.0%, 16.6-46.5). This can be determined by comparing the confidence intervals around the percentage values, with the interval of cohort 2 falling below that of cohort 1. This indicates that a smaller proportion of participants in cohort 2 achieved an objective response compared to cohort 1, implying that cohort 2 reported worse results.</s>",
        "contradict": "The statement cannot be directly contradicted by the information present in the CTRs based on the provided data alone. However, the statement is ambiguous as it does not specify which outcome measure is being compared between cohorts 1 and 2. The CTRs only provide data on the percentage of participants with objective response (OR) using RECIST criteria. To determine if one cohort reported worse results than the other based on OR, we would need access to the OR data for each cohort. Additionally, other factors, such as safety, progression-free survival, or overall survival, should also be considered when evaluating trial results.</s>"
    },
    "9f5e55af-8a94-4531-ab00-f16199795b64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02104895",
        "Statement": "Neither cohorts of the primary trial receive any medication orally, by IV or by radiation.",
        "Label": "Contradiction",
        "entail": "The statement \"Neither cohort of the primary trial receives any medication orally, by IV or by radiation\" is entailed by the information in the CTRs as neither the Intervention 1 (WBI) nor Intervention 2 (APBI) mentions the use of any oral or intravenous medications or radiation as part of their treatment protocols. Additionally, the description for APBI specifies \"using intensity modulated radiotherapy (IMRT),\" which is a type of radiation therapy but is still classified as a form of radiation therapy delivered locally and not systemically, which aligns with the statement that no cohort receives any radiation \"by radiation\" in the broader sense.</s>",
        "contradict": "The provided statement can be contradicted by the information in the CTRs due to the mention of interventions involving radiation therapy in the form of WBI and APBI. The statement incorrectly assumes that radiation therapy is not a form of treatment that falls under the category of medications or interventions, while in fact, it is a common modality used in clinical trials to investigate treatment efficacy and safety.</s>"
    },
    "ee85e355-3d0a-4e40-8a8d-6a0b71c77148": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00945061",
        "Statement": "patients with Multicentric breast cancer can be accepted for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"patients with multicentric breast cancer can be accepted for the primary trial\" is not entailed by the information in the CTRs. According to the Primary Trial's Exclusion Criteria, patients with multicentric carcinoma, defined as tumors in different quadrants of the breast or tumors separated by at least 4 cm, are excluded. The Secondary Trial does not provide any information that contradicts or changes this exclusion criterion in the Primary Trial, hence the statement is not entailed.</s>",
        "contradict": "The statement \"patients with Multicentric breast cancer can be accepted for the primary trial\" is contradicted by the CTR inclusion criteria, which explicitly states that patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm) are excluded from the trial.</s>"
    },
    "c4a2ca0b-c4a7-4366-92c7-145dadd38af3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with peripheral neuropathy resulting in intolerable paresthesias, are excluded from the primary trial\" can be entailed by the CTRs inclusion criteria stated as \"Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.\" As the statement explicitly mentions \"intolerable paresthesias\" which goes beyond NCI CTCAE grade 1, the statement is still in accordance with the CTR but provides more specificity about the degree of peripheral neuropathy that would exclude a patient from the trial, thus it is entailed by the information in the CTR.</s>",
        "contradict": "The statement is contradicted by the inclusion criteria of the primary CTR, specifically the requirement that \"pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.\" This implies that patients with peripheral neuropathy of grade 1 or lower are allowed to participate in the trial, and not excluded as stated in the expert's claim.</s>"
    },
    "c6ca8c6a-7eae-4671-9eff-c44a1222fadb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00399529",
        "Statement": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatement, are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Women with rheumatoid arthritis that does not require systemic corticosteroids for treatment, are eligible for the primary trial\" is entailed by the CTR inclusion criteria since the CTR does not exclude women with rheumatoid arthritis, provided they do not require systemic corticosteroids.</s>",
        "contradict": "The statement \"Women with rheumatoid arthritis that does not require systemic corticosteroids for treatment, are eligible for the primary trial\" is contradicted by the information present in the CTRs, as the CTRs explicitly exclude participants with active autoimmune disease requiring management with systemic immunosuppression, which includes rheumatoid arthritis that necessitates systemic corticosteroids.</s>"
    },
    "e591b3bb-0628-46e7-9d60-28989fd6a3d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01674062",
        "Statement": "One patient in the primary trial was observed vomiting blood.",
        "Label": "Entailment",
        "entail": "The statement \"One patient in the primary trial was observed vomiting blood\" (hereafter referred to as Statement S) can be entailed by the information present in the CTRs as follows: \n\n1. There is at least one occurrence of Haematemesis (blood vomiting) reported in the Primary Trial under Adverse Events, with a rate of 1/66 (1.52%). \n\n2. Statement S claims that \"one patient\" in the Primary Trial experienced the condition \"vomiting blood\".\n\n3. The reported event in Statement S (vomiting blood) aligns with the CTR data (Haematemesis) in nature and description. \n\n4. Statement S does not contradict any information given in the CTRs, as it does not claim that no patients in the trial had any other adverse event or that no other trial had different adverse events. \n\n5. The entailment holds since Statement S is a logical consequence of the CTR data and does not contradict it.</s>",
        "contradict": "The statement by the clinical trial expert that \"One patient in the primary trial was observed vomiting blood\" cannot be directly contradicted by the provided adverse event data from the CTR. However, it can be noted that the CTR does not explicitly mention the occurrence of hematemesis (vomiting blood) as an adverse event, but it is listed under the primary trial adverse events with one instance reported. Therefore, while there is not an apparent contradiction, the expert statement does not fully align with the CTR data as the CTR provides a more detailed and specific listing of the adverse events.</s>"
    },
    "75da6329-e8a1-4808-bb0f-78fd3a2dde9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was 10.3% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs because the primary trial's Results 1 and Results 2 report the percentage of participants with best overall response (BOR) in cohorts 1 (Cisplatin and Cetuximab) and 2 (Cisplatin only), respectively. The difference in BOR percentages can be calculated directly from the provided data: 20.0% (13.1-28.5) for cohort 1 and 10.3% (3.9-21.2) for cohort 2. A 10.3% difference (20.0% - 10.3% = 9.7%) falls within the range of the reported confidence intervals, indicating that the data does not contradict the statement.</s>",
        "contradict": "The statement cannot be directly contradicted by the CTR information. However, it does not follow semantically due to the lack of comparability of the data. The statement compares the percentage of participants achieving Best Overall Response (BOR) between cohorts 1 and 2 of the primary trial. However, the CTR only provides BOR percentages for each cohort individually, not in comparison to each other. Therefore, it is unclear whether the difference stated in the expert's claim is statistically significant or accurate. The CTR data cannot definitively establish or contradict the entailment of the given statement.</s>"
    },
    "dab9d582-eaf3-443f-bdb9-073aec304ee6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial recorded more cardiac related adverse events than the primary trial\" can be entailed by the information in the CTRs as follows: \n\n1. The term \"cardiac related adverse events\" can be inferred to include conditions such as cardiac failure congestive, cardiomyopathy, pericardial effusion, arrhythmia, and atrial fibrillation based on their inclusion in both trial's Adverse Events sections.\n\n2. The frequency of these cardiac related conditions in the secondary trial (3/93 = 3.23%) is higher than that observed in the primary trial (0/50 and 0/50 for arrhythmia and atrial fibration, 0/50 and 1/50 for cardiac failure congestive, 0/50 for cardiomyopathy, 0/50 for pericardial effusion) when considering the individual occurrences. If we combine the cardiac related conditions for each trial, the secondary trial had a total of 3/93 = 3.23% versus 0/50 and 0/50 or 0/100 for the primary trial. \n\n3. The statement does not contradict any information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as neither trial reported any cardiac related adverse events, as per the listed Adverse Events sections.</s>"
    },
    "8b9bb672-1de3-4220-956c-9e86ed78063d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00265759",
        "Secondary_id": "NCT00866905",
        "Statement": "One case of hematolysis was recorded in the primary trial, none in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"One case of hematolysis was recorded in the primary trial, none in the secondary trial\" can be entailed by the information present in the CTRs because:\n\n1. The CTR for the primary trial reports one case (0.64%) of hematolysis out of 157 participants.\n2. The CTR for the secondary trial reports no cases (0.00%) of hematolysis out of 168 participants.\n3. The statement's assertion (one case in the primary trial, none in the secondary trial) harmonizes with both CTRs' data.\n4. The statement does not contradict any information presented in the CTRs.</s>",
        "contradict": "The statement \"One case of hematolysis was recorded in the primary trial, none in the secondary trial\" is contradicted by the data in the CTRs as the number of hematolysis cases differs between the trials, with one reported in the primary trial but none reported in the secondary trial.</s>"
    },
    "3194a043-d156-49d6-97bb-81867ed188f0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00712985",
        "Secondary_id": "NCT02038010",
        "Statement": "Patients in the primary trial receive a lower dose of Zometa by IV than the secondary trial patients receive of PI3K inhibitor BYL719  by IV.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the primary trial receive a lower dose of Zometa (Zoledronic Acid) by IV than the secondary trial patients receive of PI3K inhibitor BYL719 by IV\" is entailed by the information in the CTRs as follows:\n\n1. In the primary trial, the dose of Zoledronic Acid given by IV is 5 mg.\n2. In the secondary trial, the dose of BYL719 given by IV in both cohorts is 3.6 mg/kg.\n3. The doses of both Zoledronic Acid and BYL719 given by IV are relevant to the comparison in the statement.\n4. To compare the doses, we need to calculate the equivalent amount for Zoledronic Acid based on body weight (since BYL719 dose is given in terms of mg/kg), assuming an average body weight.\n5. Let's assume an average body weight of 70 kg for both trials.\n6. The equivalent dose of Zoledronic Acid for an average body weight of 70 kg would be 3.57 mg (according to the package insert for Zoledronic Acid).\n7. Comparing 5 mg of Zoledronic Acid given in the primary trial with 3.6 mg/kg of BYL719 given in the secondary trial, we can see that patients in the primary trial receive a lower dose of Zoledronic Acid by IV.\n\nThe statement is entailed by the CTRs as it correctly infers a lower dose of Zoledronic Acid administered intravenously in the primary trial compared to the secondary trial's BYL719 dosing.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it fails to capture the essential difference between the interventions, leading to a misleading implication. While the primary trial administers a lower dose of Zometa (Zoledronic Acid) by IV (5 mg) compared to the secondary trial's dose of BYL719 given by IV (3.6mg/kg), it neglects to consider the different medications and treatment schedules. The primary trial involves a one-time dose of Zometa, while the secondary trial administers BYL719 repeatedly every 21 days. Therefore, a more accurate statement would be: \"In the primary trial, patients receive a lower total dose of Zoledronic Acid by IV compared to the repeated doses of PI3K inhibitor BYL719 given in the secondary trial, even though the doses of each treatment per administration differ.\"</s>"
    },
    "8c3ab1eb-c473-4399-b18c-512ef16e4a47": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01027416",
        "Statement": "To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a -ive human chorionic gonadotropin urine test.",
        "Label": "Entailment",
        "entail": "The statement \"To be eligible for the primary trial, patients must have an invasive carcinoma confirmed by core biopsy, and a negative human chorionic gonadotropin ( beta-hCG) urine test\" is entailed by the information present in the CTRs. \n\nThe primary trial's inclusion criteria state \"Core biopsy should definitively demonstrate invasive carcinoma\" and \"Negative serum or urine beta-hCG pregnancy test at screening for patients of child-bearing potential.\" The statement requires both of these conditions to be met for trial eligibility. Therefore, the information in the statement is an implication of the information provided in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because:\n\n1. The statement specifies that patients must have a negative human chorionic gonadotropin (hCG) urine test to be eligible for the primary trial. However, according to the primary trial's inclusion criteria in the CTR, only patients of child-bearing potential are required to undergo this test at screening.\n\n2. The CTR states that pregnant or lactating women are excluded from the trial, which contradicts the statement's implication that hCG test results are a requirement for eligibility.\n\nTherefore, the statement is not semantically entailed in the information presented in the CTRs.</s>"
    },
    "aeac1009-91c3-40ad-8583-5b548e1f4b3b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "the primary trial and the secondary trial only have test cohorts in their studies.",
        "Label": "Contradiction",
        "entail": "Both trials involve randomly assigned study groups, referred to as arms, where participants receive distinct interventions: CES (Arm I) or sham CES (Arm II) in the primary trial, and Treatment Gel + Oral Placebo (Intervention 1) orPlacebo Gel + Oral Treatment (Intervention 2) in the secondary trial. These arms are considered test cohorts as they are designed to evaluate the effect of each intervention on the study outcome.\n\nThe statement \"the primary trial and the secondary trial only have test cohorts in their studies\" is entailed by the information provided in the CTRs because the CTRs clearly define the study arms as test cohorts, with each arm receiving a distinct intervention for comparison purposes. The statement accurately reflects this information by stating that both trials only involve test cohorts.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial only have test cohorts in their studies\" cannot be directly contradicted by the information present in the CTRs as the CTRs do not provide sufficient details about the study designs to conclusively determine if they involve only test cohorts or include control groups as well. While the CTRs describe the interventions and their durations for each arm, they do not explicitly mention the presence or absence of control groups.</s>"
    },
    "3058d104-172e-41be-b641-9f0f9cb172be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial survived over 200 days without documented disease progression.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information presented in the CTRs if one of the participants in the \"Avastin (Bevacizumab) Plus Hormone\" arm/group survived for over 200 days without disease progression. The median PFS for this arm was 125.5 days (90 to 256), which indicates that some participants lived beyond this time frame. Since the CTR reports the overall number of participants analyzed as 30, it is plausible for at least one individual to have survived beyond 200 days without disease progression. This statement does not contradict any information presented in the CTRs and is consistent with the data reported.</s>",
        "contradict": "The statement \"At least one participant of the primary trial survived over 200 days without documented disease progression\" is not directly contradicted by the information in the CTR. However, it does not follow entailment as there is no explicit statement in the CTR indicating that any participant in the Avastin (Bevacizumab) Plus Hormone arm survived over 200 days without documented disease progression. The longest survival time reported in the CTR is the median PFS, which is 125.5 days (90 to 256 days). The statement does not contradict this information, but it also does not follow directly from it.</s>"
    },
    "bc845a3d-1f69-41a3-bf84-36a62e8127a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01439282",
        "Statement": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
        "Label": "Entailment",
        "entail": "The statement entails that the total number of adverse events in cohort 1 of the primary trial is more than 10 times the number of adverse events in cohort 2. According to the provided CTRs, the total number of adverse events in cohort 1 is 14/67 (20.90%), while in cohort 2 it is 1/10 (10.00%). To calculate the number of adverse events in each cohort, we need to multiply the given percentages with the respective total number of participants:\n\n14/67 * 67 = 14\n1/10 * 10 = 1\n\nSo, there are indeed more than 10 times the number of adverse events in cohort 1 compared to cohort 2 (14 vs. 1). This information can be directly derived from the CTRs and is an entailed relationship between the expert's statement and the provided trial data.</s>",
        "contradict": "The given statement is contradictory to the information in the CTRs based on the following reasons:\n\n1. The primary CTR reports a total of 14/67 (20.90%) adverse events in cohort 1, while the secondary CTR reports a total of 1/10 (10.00%) adverse events in cohort 2. However, the statement claims that cohort 1 had more than 10 times the number of adverse events than cohort 2.\n2. The discrepancy between the statement and the CTRs lies in the comparison of the total number of adverse events. According to the CTRs, cohort 1 had fewer adverse events than what the statement suggests.\n3. Therefore, the statement cannot be entailed by the information present in the CTRs.</s>"
    },
    "69ced998-f3c9-460a-a272-b2c95421b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00570323",
        "Secondary_id": "NCT00193180",
        "Statement": "Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Female patients over 6 months pregnant cannot take part in either the secondary trial or the primary trial\" is entailed by the information present in the CTRs. This is because both trials have identical inclusion criteria that specify \"All subjects must be female.\" However, the primary trial further states that \"All subjects must be postmenopausal,\" which includes the condition of \"Documented history of bilateral oophorectomy\" or \"Age 60 years or more\" or \"Age 45 to 59 and satisfying one or more of the following criteria: Amenorrhea for at least 12 months and intact uterus... or Amenorrhea for less than 12 months and a follicle stimulating hormone (FSH) and estradiol concentration within postmenopausal range.\" Since pregnancy is a definitive sign of non-postmenopausal status and a female patient cannot be pregnant and postmenopausal at the same time, a female patient over 6 months pregnant cannot fulfill the inclusion criteria for either trial. Consequently, the statement is entailed by the CTRs.</s>",
        "contradict": "The given statement contradicts the inclusion criteria in the primary CTR where female patients who are postmenopausal (including those defined as having amenorrhea and a FSH and estradiol concentration within postmenopausal range) are eligible for the trial. This statement does not provide an exclusion of pregnant women specifically for the primary trial. Therefore, the statement cannot be entailed by the information presented in the primary CTR. Similarly, pregnant women are not mentioned as exclusion criteria in the secondary CTR, so the statement does not apply to this trial either. Thus, the statement is contradictory to the information provided in the CTRs.</s>"
    },
    "45fb84a3-674c-40f5-ac8c-26a3c7844e7b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole.",
        "Label": "Entailment",
        "entail": "The statement \"Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole\" can be entailed by the information present in the CTRs as follows:\n\n1. According to the primary CTR, the dosage of simvastatin is given as 40 milligrams per day, and the dosage of anastrozole is given as 1 milligram per day.\n2. To determine if patients take \"4 times as much\" simvastatin as anastrozole, we need to calculate the ratio of the dosages: \n   Ratio = (Dosage of Simvastatin) / (Dosage of Anastrozole)\n3. Plugging in the dosage values, we get: Ratio = (40 milligrams) / (1 milligram)\n4. Simplifying the ratio, we obtain: Ratio = 40\n5. Since the ratio of the dosages is 40 (or equivalently, 4 times), the statement that \"Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole\" is contradicted by the information in the CTRs as the given dosages do not satisfy this condition. Simvastatin is prescribed as a 40mg tablet taken once daily (QD) for 14 days, while anastrozole is prescribed as a 1mg tablet taken once daily (QD) for 14 days. The dosage of simvastatin is indeed greater than anastrozole, but it's not 4 times as much. The statement overestimates the difference between the prescribed dosages.</s>"
    },
    "c349cad6-8b63-4e5e-9b87-4fc08bb6fc30": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00146172",
        "Statement": "Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinb.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinb\" is entailed by the information in the CTRs because:\n\n1. Cohort 1 of the primary trial receives Neratinib 40 mg qd, and Cohort 2 receives Neratinib 80 mg qd.\n2. To determine if Cohort 1 receives less than 60% of Cohort 2's dose, first, calculate the daily dosage difference: 80 mg - 40 mg = 40 mg.\n3. Next, calculate the percentage difference: 40 mg / 80 mg = 0.5 or 50%.\n4. Since the statement asserts that cohort 1 receives less than 60% of cohort 2's dose, it is entailed by the information in the CTRs as 50% is less than 60%.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial receives less than 60% of cohort 2's dose of Neratinib\" cannot be definitively determined from the provided CTRs as they do not contain information about the number of participants, or the total amount of Neratinib administered to each cohort. The dosage information provided only indicates the dose per participant (40 mg and 80 mg, respectively) for each cohort. Therefore, the statement is not semantically entailed by the CTRs and can be contradicted based on the lack of sufficient information for verification.</s>"
    },
    "f4ce0687-a0b8-47e8-a3ba-dcf279c1dde9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00912340",
        "Statement": "More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1\" can be entailed by the CTR information as follows:\n\n1. The number of Pleural effusions in cohort 1 was 0/24 (0.00%).\n2. The number of Pleural effusions in cohort 2 was 2/30 (6.67%).\n3. Comparing the number of Pleural effusions between the two cohorts shows that there were more cases in cohort 2 (2 versus 0).\n4. The information in the CTRs does not contradict the statement and provides substantiation for it.</s>",
        "contradict": "The statement \"More patients in cohort 2 of the primary trial suffered from Pleural effusions than in cohort 1\" is contradicted by the information in the CTRs because the number of participants with Pleural effusion in cohort 1 (0/24 or 0.00%) was less than that in cohort 2 (2/30 or 6.67%). However, the statement asserts that \"More\" patients in cohort 2 experienced this condition.</s>"
    },
    "b3effb24-6ec0-4fa3-9c91-74a45bcc4602": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01448447",
        "Secondary_id": "NCT03252145",
        "Statement": "the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels.",
        "Label": "Contradiction",
        "entail": "The statement entailed by the CTRs is that the primary trial involves a radiotherapy intervention (HDR brachytherapy using Mammosite ML) and the secondary trial tests a self-administered medical device (Manual Lymph Drainage or PhysioTouch). These statements are harmonious with the CTR descriptions as the primary trial specifies a radiotherapy intervention using Mammosite ML, and the secondary trial outlines a manual lymph drainage intervention that patients perform themselves. The provided statements neither contain contradictory assertions nor contradict the information present in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial is testing a novel hand-held medical device, which patients must use themselves to drain their lymph vessels\" contradicts the information in the CTRs as neither trial involves patients self-administering radiation nor a hand-held medical device designed solely for draining lymph vessels. In the primary trial, healthcare professionals deliver HDR brachytherapy using the Mammosite ML applicator, while in the secondary trial, patients undergo manual lymph drainage or PhysioTouch therapy, which are practitioner-administered techniques and do not involve the use of a hand-held device for self-administration of lymph drainage.</s>"
    },
    "9026c2ff-2dd8-4aa9-b2fb-f6bef856189d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03106077",
        "Statement": "Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial receive at least 150mg of IMGN853 by IV every 3 weeks\" can be entailed by the information present in the primary CTR as follows:\n\nThe primary CTR specifies the Intervention for Cohort A as \"6 mg/kg IMGN853 IV Q3W.\" Given a patient's weight, the amount of IMGN853 administered can be calculated. For example, a 70kg patient would receive 6 * 70 = 420mg IMGN853 every 3 weeks, which is more than the stated 150mg minimum. Since the statement does not contradict the information in the CTR, the statement is entailed by the CTR.</s>",
        "contradict": "The information in the statement is not an exact entailment of the CTR data, as the statement asserts that patients receive at least 150mg of IMGN853 per IV administration, while the CTR specifies a dose of 6 mg/kg administered every 3 weeks. The dose for each patient will depend on their weight and thus may vary, resulting in some patients receiving less than 150mg with each dose. Consequently, the statement is not a direct implication of the CTR data, and there is a possibility for contradiction depending on the individual participant doses in the trial.</s>"
    },
    "341c0861-b9a3-491d-8d49-aa61a8501a4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00083174",
        "Secondary_id": "NCT00190671",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 39.",
        "Label": "Contradiction",
        "entail": "The statement \"The highest number of occurrences for any adverse event in both the primary trial and the secondary trial was 39\" can be entailed by the information present in the CTRs because the primary trial reports a total of 39 adverse events out of 2240 participants (1.74%) and the statement doesn't specify which particular adverse event among the given ones in the trials has the highest occurrence. The secondary trial reports a total of 13 adverse events out of 61 participants, but this information is not directly compared to the primary trial's data in the statement. Instead, the statement focuses on the total number of adverse events across both trials, which is reported as 39 in the primary trial. Therefore, the statement is entailed by the CTRs since it is derived from the aggregate number of adverse events mentioned in those reports.</s>",
        "contradict": "The statement is incorrect based on the provided CTR data. The total number of adverse events in the primary trial was 39/2240 (1.74%), but this is a different adverse event occurrence from the one in the secondary trial being compared. Therefore, neither trial has a single adverse event with an occurrence of 39.</s>"
    },
    "16d6e554-a1df-42f9-b051-947d70595cbb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of Leukopenia in the primary trial occurred in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"The only cases of Leukopenia in the primary trial occurred in cohort 1\" is entailed by the CTR data if we assume that the trials refer to the same study with two different reports for each arm or cohort. In this case, the CTR for cohort 1 of the primary trial reports 2 participants experiencing Leukopenia among 240 participants (a frequency of 0.83%). The CTR for the secondary trial does not report any Leukopenia cases for the 234 participants in its Adverse Events section. Therefore, the statement's implication that all instances of Leukopenia occurred in cohort 1 is consistent with the CTR data.</s>",
        "contradict": "The statement \"The only cases of Leukopenia in the primary trial occurred in cohort 1\" contradicts the information in the CTR if there is any occurrence of Leukopenia in cohorts other than cohort 1 in the primary trial but that information is not mentioned or reported clearly in the given Adverse Events 1 section. The CTR states that there was only one instance of Leukopenia in the primary trial; however, it does not specify which cohort this occurred in. Therefore, the expert's statement, which makes an absolute claim about Leukopenia cases being exclusive to cohort 1, goes beyond the information in the CTR, potentially leading to contradictions.</s>"
    },
    "8f0159ce-1044-4f31-94b7-e394cf91d4e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00316199",
        "Statement": "Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the CTR inclusion criteria because the CTR states that \"Female patients of Chinese origin with histologically or cytologically proven diagnosis of breast cancer. Unresectable, locally recurrent breast cancer or stage IV disease\" are eligible for the primary trial. Thus, any women with stage 4 or unresectable, locally recurrent breast cancer fall under this description and are eligible for the trial, as stated by the expert.</s>",
        "contradict": "The statement \"Any women with stage 4 or Unresectable, locally recurrent cancer breast cancer are eligible for the primary trial\" is not an accurate reflection of the CTR inclusion criteria. The expert's statement is overly generalized and omits important requirements such as the need for histologically or cytologically proven breast cancer diagnosis, measurable lesions, performance status of 0 or 1, treatment with an anthracycline-based chemotherapy regimen in the adjuvant/neoadjuvant setting with subsequent disease relapse, and the exclusion of prior chemotherapy. Therefore, it contradicts the CTR information by potentially allowing ineligible patients into the trial.</s>"
    },
    "ccc5e420-dda4-4fb9-8d68-82551d69017f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00129376",
        "Statement": "Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in both the primary trial and the secondary trial suffered from Pulmonary embolisms\" is entailed by the CTRs as follows:\n\nIn the primary CTR, there is one reported case of Pulmonary embolism out of a total of 261 patients (1/261 or 0.38%).\n\nIn the secondary CTR, there is also one reported case of Pulmonary embolism out of a total of 63 patients (1/63 or 1.59%).\n\nBoth trials report at least one instance of Pulmonary embolism, indicating that patients in both trials have experienced this condition. Therefore, the expert's statement is an entailed consequence of data from the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial reported zero Pulmonary embolisms, while the secondary trial reported only one case. The combined total of Pulmonary embolisms across both trials, as stated in the expert's claim, is two or more, which contradicts the actual reported numbers in the CTRs.</s>"
    },
    "89f8ba8c-e626-4bd4-9994-3d0264018932": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with end-stage liver disease are excluded from the primary trial\" is entailed by the information presented in the CTRs under the \"Exclusion Criteria\" section for the primary trial, where it is explicitly stated that \"Chronic active hepatitis or cirrhosis\" is a condition that would exclude a patient from participation in the trial.</s>",
        "contradict": "The statement \"Patients with end-stage liver disease are excluded from the primary trial\" is contradictory to the information provided in the CTR under exclusion criteria, as chronic liver disease (cirrhosis) is explicitly stated as an exclusion criterion. However, it's worth noting that the term \"end-stage liver disease\" is broader than cirrhosis. If the expert meant to refer specifically to cirrhosis, then the statement is in line with the CTR. If the statement was meant to exclude all advanced or severe liver disease beyond cirrhosis, then the CTR does not contradict it. The statement can be contradictory depending on the exact meaning of \"end-stage liver disease\" in this context.</s>"
    },
    "0bd8f61d-0b89-4c5d-89e0-9ba86e06b13d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in the test group had better health outcomes than the control group.",
        "Label": "Entailment",
        "entail": "The expert's statement \"In the primary trial, patients in the test group had better health outcomes than the control group\" can be entailed by the information in the CTRs based on the following reasoning:\n\n1. From the primary trial CTR, we know that the test group received Zoledronic Acid (Zometa), while the control group received a placebo.\n2. The outcome measurement in the primary trial was the change in bone mineral density (BMD) at lumbar spine (L2-L4) from baseline to month 24.\n3. The results section indicates that the mean Z-score for the placebo group was -0.075 (0.041), suggesting a decrease in BMD, while the mean Z-score for the Zometa group was 0.037 (0.042), suggesting a slight increase in BMD over the 24-month period.\n4. Generally, an increase in bone mineral density is considered a positive health outcome.\n5. Since the mean BMD increase in the test group (Zometa) is positive and higher than that of the control group (placebo), the expert's statement that \"patients in the test group had better health outcomes than the control group\" is entailed by the information in the CTRs.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the information present in the CTRs. However, the statement is not semantically entailed by the data in the CTRs as it goes beyond the specific findings reported. The CTRs only provide data regarding changes in bone mineral density (BMD) at the lumbar spine (L2-L4) using DXA measurements, and do not report on overall health outcomes or which group had \"better health outcomes\" as claimed in the statement.</s>"
    },
    "57e6f0e1-6157-43bc-8bdf-c3649ed49133": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "More than half the participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.",
        "Label": "Contradiction",
        "entail": "In the primary trial, the numbers of censored participants (6 in the arm without bone metastases and 10 in the arm with bone metastases) are provided in the results section. Therefore, more than half of the participants in the trial (15 + 10 = 25, while 25 > 12 (which is half of the total participants analyzed, i.e., 15 + 29 = 44) can be accounted for by the number of participants in the results. \n\nIn contrast, the secondary trial does not mention any censored patients in its results section. However, the absence of censored patients is not directly stated but can be inferred from the statement that all participants were followed until \"radiographic disease progression as determined by the central IRF, unacceptable toxicity, consent withdrawal, physician's decision to terminate treatment, or sponsor's decision to terminate the trial (up to a maximum of 45.3 months)\". As all events (radiographic disease progression, unacceptable toxicity, consent withdrawal, physician's decision, or sponsor's decision) were documented, there were no missing data and no censored patients.\n\nSince there are no conflicting statements or contradictions in the information presented in the CTRs and the expert's statement, the entailment holds. The expert's statement is semantically entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"more than half the participants of the primary trial are considered to be censored. the secondary trial had no censored patients\" can be contradicted by the information present in the CTRs because the primary trial reported 6 censored patients out of 15 total participants in the group without bone metastases and 10 censored patients out of 29 total participants with bone metastases. Contrarily, the secondary trial reported no censored patients in both arms. The discrepancy lies in the number of censored patients between the trials.</s>"
    },
    "300dbe96-0be8-4ca0-aa3b-41bc059bac7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02725801",
        "Secondary_id": "NCT04030104",
        "Statement": "Neither the primary trial or the secondary trial have control groups.",
        "Label": "Contradiction",
        "entail": "The statement does not directly mention the sections Eligibility Criteria, Results, or Adverse Events from the CTRs. However, it can be inferred that the absence of a control group in the trials is implied in the Intervention sections. The CTRs do not specify the presence or absence of a control group, but the use of randomization between one-port and two-port tissue expanders in both primary and secondary trials implies that the trials are not designed with a control group. Therefore, the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Neither the primary trial nor the secondary trial have control groups\" contradicts the information in the CTRs because, in the primary trial, there is no explicit mention of a control group in the provided Intervention sections, but it does not imply the absence of a control group in the entire trial. In contrast, the secondary trial does involve a control group, as evidenced by the use of the term \"IUS alone\" in Intervention 1, which suggests a comparison group to Intervention 2, \"IUS+OA.\" Therefore, the statement's claim that \"Neither trial has control groups,\" is not semantically entailed by the information in the provided CTRs.</s>"
    },
    "f40c8d92-2921-45fd-8389-15048b08e229": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Neutropenia was the most prevalent adverse event in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Neutropenia was the most prevalent adverse event in the primary trial\" can be entailed by the information present in the CTR as Neutropenia had the highest frequency (5/29 or 17.24%) among all the adverse events mentioned in the CTR of the primary trial.</s>",
        "contradict": "Although the statement \"Neutropenia was the most prevalent adverse event in the primary trial\" appears consistent with the information in the CTR, it can be contradicted by the exact adverse event frequencies presented. The statement assumes that the frequency of Neutropenia is higher than all other adverse events, but the CTR data reveals that Neutropenia was the fourth most common adverse event, after Abdominal Pain, Surgical Intervention, and Perforated Appendix, each of which occurred in 3.45% of the participants. Therefore, the statement's generalization does not strictly follow from the given CTR data.</s>"
    },
    "31387af4-aad1-4f3c-bd81-641340ad4096": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT03573804",
        "Statement": "the primary trial and the secondary trial use completely different drugs and techniques for their interventions.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as both trials utilize distinct interventions: In the primary trial, patients received Fulvestrant and Anastrozole as separate agents, while in the secondary trial, participants underwent Magnetic Resonance Imaging (MRI) with radiologists A and B assessing the scans in prone and supine positions. These interventions do not share any common drug or technique.</s>",
        "contradict": "While the statement asserts that the primary and secondary trials use different drugs for their interventions, it does not necessarily entail a difference in techniques for MRI evaluation, which is stated in the secondary trial's Intervention 1. However, the CTRs provided focus on the drugs administered without specifying the MRI evaluation techniques used. Hence, it is possible that both trials use the same MRI technique for evaluation, which would contradict the statement.</s>"
    },
    "eabe9a78-965e-4984-82c2-25598b6b35da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00534417",
        "Statement": "The median TTP in cohort one of the primary trial is just under 27 months.",
        "Label": "Entailment",
        "entail": "The statement entails the information from the CTRs as follows:\n\n1. The statement mentions \"the median TTP in cohort one\" which corresponds to the \"Results 1\" section of the CTR.\n2. The statement provides the value of the median TTP, \"just under 27 months,\" which matches the median TTP value in the CTR, \"26.94 months\" (7.26 to NA).\n3. The CTR specifies that TTP is measured \"until time of progression (assessed every 8 weeks), up to 29 months,\" indicating that TTP was measured for all participants in the trial, including cohort one, and the median TTP value represents the TTP for the entire cohort.\n4. The CTR also confirms that cohort one in the primary trial was treated with Capecitabine and Fulvestrant as described in the statement.\n5. No inconsistencies or contradictions with the CTR are observed in the statement.\n\nHence, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The median TTP in cohort one of the primary trial is just under 27 months\" can be contradicted by the information present in the CTRs as follows:\n\nThe median TTP value given in the CTR for the Capecitabine and Fulvestrant arm is 26.94 months (with a 95% confidence interval from 7.26 to NA), which is less than 27 months, but the statement does not specify which cohort it refers to. Therefore, the statement is not directly contradictory to the information in the CTR, as it could potentially be true for the primary trial as a whole rather than for a specific cohort. However, without knowing which cohort the expert's statement pertains to, it cannot be definitively determined that the statement is in accord with the CTRs.\n\nTo establish semantic entailment, the expert's statement should include a clear specification of the cohort or arm in question to ensure alignment with the CTR data.</s>"
    },
    "006f6b4e-6245-4f09-9786-327bbed3d766": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01328249",
        "Statement": "The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement that \"The Percentage of Participants With Feasibility was 10% higher in cohort 1 of the primary trial than in cohort 2\" is entailed by the information in the CTRs because, according to the CTR, the feasibility percentage for Cohort 1 was 70.4% (58.5-80.4%) and for Cohort 2 was 60.0% (41.7-76.4%). A difference of 10 percentage points is equivalent to 10% higher for Cohort 1 compared to Cohort 2.</s>",
        "contradict": "The percentage difference stated between the two cohorts is not supported by the provided data. The feasibility rates for Cohort 1 and Cohort 2 were 70.4% (58.5-80.4) and 60.0% (41.7-76.4), respectively. A 10% difference would correspond to a rate of 80.4% in Cohort 1 and 50.0% in Cohort 2. However, the data shows that the feasibility rate for Cohort 1 is actually lower than that of Cohort 2. Therefore, the statement made by the clinical trials expert cannot be entailed from the given information in the primary trial's CTRs.</s>"
    },
    "88b13330-b937-4bbc-80ea-4bf8ccc17bd1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "3/4 participants in the primary trial suffered from Dose-limiting toxicities.",
        "Label": "Entailment",
        "entail": "The statement \"3/4 participants in the primary trial suffered from Dose-limiting toxicities\" can be entailed by the information in the CTRs as follows:\n\nFrom the Primary Trial Results 1 and 2 provided, it can be calculated that a total of 6 participants were analyzed across both dose levels. According to the information in the Primary Trial CTR, there were 2 DLTs reported for the Arm/Group titled Dose Level 1 with 3 participants, and 1 DLT reported for the Arm/Group titled Dose Level -1 with 1 participant. Therefore, 3 out of the 6 participants (or 3/4 when considering the 6 participants as a quartet) in the primary trial suffered from Dose-limiting toxicities. This aligns with the expert's statement, and no contradiction exists with the provided descriptions in the CTRs.</s>",
        "contradict": "The information in the statement \"3/4 participants in the primary trial suffered from Dose-limiting toxicities\" conflicts with the data in the CTRs since the number of patients reporting DLTs at each dose level is explicitly stated as 2 for Arm/Group Title: Dose Level 1 and 1 for Arm/Group Title: Dose Level -1. Therefore, only 3 out of the total analyzed participants (2 from Dose Level 1 and 1 from Dose Level -1) experienced DLTs, contrary to the statement suggesting 3/4 of all participants had DLTs.</s>"
    },
    "e90e2368-808d-454d-8080-30427235b89d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01009918",
        "Secondary_id": "NCT01688609",
        "Statement": "There are no racial criteria for entry into the primary trial, but there are for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There are no racial criteria for entry into the primary trial, but there are for the secondary trial\" is entailed by the information present in the Clinical Trial Reports (CTRs) as follows:\n\nIn the primary CTR, there is no mention of any racial criteria listed among the inclusion or exclusion criteria.\n\nIn contrast, the secondary CTR explicitly states \"Only Japanese women are eligible for the trial\" under inclusion criteria and does not mention any racial exclusion criteria in its exclusion criteria. Therefore, the secondary trial includes a racial criterion for eligibility.\n\nThus, the statement \"There are no racial criteria for entry into the primary trial, but there are for the secondary trial\" can be entailed from the given information in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the primary trial includes no mention of racial criteria for entry, while the secondary trial specifically states that only Japanese women are eligible to participate.</s>"
    },
    "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with both type 1 and 2 Diabetes are not suitable for the primary trial.",
        "Label": "Entailment",
        "entail": "Diabetes mellitus is an exclusion criterion for the primary trial as stated in its CTR. Therefore, neither type 1 nor type 2 diabetes is a suitable condition for participation in the trial. Consequently, the expert's statement that \"Patients with both type 1 and 2 Diabetes are not suitable for the primary trial\" is entailed by the information provided in the primary trial's CTR.</s>",
        "contradict": "The statement \"Patients with both type 1 and 2 Diabetes are not suitable for the primary trial\" is contradictory to the information present in the CTRs as Diabetes mellitus is explicitly listed as an exclusion criterion for the primary trial. The CTR states that patients with Diabetes mellitus are not allowed to participate in the trial.</s>"
    },
    "2f2301cd-b8fa-47cc-94cc-e31150ce8f9e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial only have test groups, so all patients are receiving novel (FDA approved) interventions.",
        "Label": "Contradiction",
        "entail": "The statement asserts that all patients in both trials are receiving novel interventions approved by the FDA. In the primary trial, Intervention 1 involves health tracking, which while not a novel drug or treatment, can be considered a novel intervention in the context of clinical trials, especially when compared to standard care. In Intervention 2, patients receive peer support, another non-pharmacological intervention that can be considered novel. In the secondary trial, both Intervention 1 and Intervention 2 involve FDA-approved treatments: exemestane and celecoxib, respectively. Therefore, the statement is entailed by the CTRs since all treatments, including non-pharmacological ones, qualify as novel interventions within the clinical trial context.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because:\n\n1. In the Primary Trial, Intervention 1 (Health Tracking) does not involve a novel intervention, as patients receive usual care and do not attend any meetings.\n2. Therefore, the statement is inaccurate for the Primary Trial as not all patients are receiving novel interventions.\n3. In the Secondary Trial, Intervention 1 (Exemestane Alone) is an FDA-approved intervention. However, Intervention 2 (Exemestane + Celecoxib) is also a novel intervention as it involves the combination of two FDA-approved drugs.\n4. So, while all patients in both trials are receiving some form of novel intervention (either a single approved drug or a combination of approved drugs), not all patients are receiving the same novel intervention.\n5. Therefore, the statement is partially correct but incomplete in its description, as it does not account for the distinction between the trials or the types of novel interventions being administered.</s>"
    },
    "eea73ae4-0985-4f74-957d-e2aad7ab453c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00248170",
        "Secondary_id": "NCT01299038",
        "Statement": "Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary and primary trials\" cannot be directly entailed by the information present in the CTRs. \n\nExplanation: \n\nThe primary trial includes postmenopausal women, which typically refers to women who have gone through menopause naturally or artificially for at least 12 months. The age limit for the secondary trial is a minimum of 18 years. Ae-Cha being a 32-year-old woman does not meet the age requirement for either trial. However, the statement also claims that Ae-Cha is \"too old\" for both trials, which is not necessarily true, as her age falls within the eligible age range for the secondary trial. Additionally, the statement specifies that she has an inoperable breast cancer and is of Korean descent, but these factors do not appear as exclusion criteria in the provided CTRs. Therefore, the statement goes beyond the information in the CTRs and cannot be directly entailed from it.</s>",
        "contradict": "The statement \"Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial\" is contradicted by the information present in the CTRs in the following ways:\n\n1. The primary trial inclusion criteria state that participants must be postmenopausal, but it does not specify a minimum age. Thus, Ae-Cha's age is not a definitive exclusion from the primary trial based on the given information alone.\n2. The secondary trial includes participants aged 18 or above. Ae-Cha being 32 years old meets this requirement.\n3. The exclusion of Ae-Cha from both trials based on her nationality (Korean) is not explicitly stated in the provided CTRs.\n4. The primary trial exclusion criteria for metastatic disease and contralateral breast cancer including DCIS are not applicable to Ae-Cha's case as her breast cancer is inoperable and inoperable breast cancer is not considered an explicit exclusion for the primary trial.\n5. Her condition of an inoperable breast cancer does not automatically exclude her from either trial based on the information provided in the CTRs. It's essential to consider other factors and protocol-defined criteria to determine her eligibility.\n\nThus, the statement \"Ae-Cha is a 32 year old Korean woman with an inoperable breast cancer, she is too old to participate in both the secondary trial and the primary trial\" contradicts the information in the given CTRs, as her age and nationality may not be the sole determinants of her eligibility.</s>"
    },
    "6550c068-14e6-4e93-8f98-756338c91e35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00313170",
        "Statement": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
        "Label": "Entailment",
        "entail": "The Objective Response Rate for the Fulvestrant 250 mg arm was 8.5% (2.4-20.4) compared to 5.9% (1.2-16.2) in the Fulvestrant 250 mg + Loading Dose arm in the primary trial. This means that a higher percentage of patients in the Fulvestrant 250 mg group experienced an objective response (complete or partial response) than in the Fulvestrant 250 mg + Loading Dose group. This is consistent with the expert's statement that \"Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.\"</s>",
        "contradict": "The statement \"Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose\" contradicts the information in the CTR when considering only the percentage data provided. The percentage of patients with objective response (ORR) for the Fulvestrant 250 mg arm was 8.5% (2.4 to 20.4), and for the Fulvestrant 250 mg + Loading Dose arm was 5.9% (1.2 to 16.2). Based on the percentages alone, it appears that a smaller percentage of patients in the Fulvestrant 250 mg + Loading Dose arm had an objective response compared to those in the Fulvestrant 250 mg arm. However, the CIs (confidence intervals) around these percentages overlap, indicating the possibility that the differences between the ORRs in the two treatment arms could be due to chance alone. Therefore, the information contained in the statement cannot be definitively concluded from the information presented in the CTRs. Further statistical analysis, such as performing a significance test, would be required to determine if the differences are statistically significant.</s>"
    },
    "0f5b81f0-b422-4000-8e0e-9f09c612ebc3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01293032",
        "Secondary_id": "NCT00849472",
        "Statement": "None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course\" can be entailed by the information present in the CTRs as neither trial description includes any mention of radiotherapy or support group courses being a part of the interventions for the patients.</s>",
        "contradict": "The statement \"None of the patients in the primary trial or the secondary trial are required to undergo radiotherapy or a support group course\" is contradictory to some trials as the CTR for the primary trial does not specify whether radiotherapy or a support group course is required for patients in Group 2, while the secondary trial involves chemotherapy (doxorubicin and cyclophosphamide) and targeted therapy (pazopanib), but no mention is made of radiotherapy or support groups in the provided treatment details. Therefore, the statement cannot be definitively determined to be true or false based on the given information alone. However, it can be contradicted by CTRs where radiotherapy or support groups form part of the treatment regimen.</s>"
    },
    "f6bba549-3d18-4a53-8685-96b4e321b1a7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00645333",
        "Secondary_id": "NCT00006110",
        "Statement": "the primary trial records several immune system related adverse events in its patients, whereas the secondary trial does not.",
        "Label": "Entailment",
        "entail": "The expert's statement entails that the primary trial reports a higher incidence of adverse events related to the immune system than the secondary trial. This is consistent with the CTR data, which indicates that 6.67% of participants in the primary trial experienced immune system disorders (including autoimmune disorder and immune system disorder), compared to no such cases in the secondary trial. Thus, the expert's statement is entailed by the information contained in the CTRs.</s>",
        "contradict": "The expert's statement contradicts the CTR data since the secondary trial also records an immune system disorder, specifically mentioned as \"Nervous system disorders - Other, specify\" in Adverse Events 1 section, with a frequency of 1.92%. Therefore, the statement is incorrect in asserting that the secondary trial does not record any immune system related adverse events.</s>"
    },
    "1fe36432-40f8-4c53-ac2b-0f8e50e5743f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial and the primary trial are administered by mouth.",
        "Label": "Contradiction",
        "entail": "The statement \"Several treatments in the secondary trial and the primary trial are administered by mouth\" is entailed by the CTRs as follows:\n\nIn both primary and secondary trials, some of the interventions are stated to be given \"PO\" (orally), specifically:\n- In the primary trial, for Intervention 1 (Diagnostic FES): \"Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.\" Here, the standard FDG-PET/CT is not explicitly stated to be administered intravenously, suggesting it could be taken orally. Furthermore, \"Patients begin clinically indicated endocrine therapy,\" and endocrine therapies are typically administered orally.\n- In the primary trial, for Intervention 2 (Diagnostic FES): \"Patients begin clinically indicated endocrine therapy.\"\n- In the secondary trial, for Intervention 1 (Vorinostat, AI Therapy): \"Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks.\"\n\nThus, the statement \"Several treatments in the secondary trial and the primary trial are administered by mouth\" harmonizes with clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "Although both trials involve patients receiving some medications orally (PO), the statement does not explicitly acknowledge the distinction between the treatments given in the primary and secondary trials. The primary trial involves [^18F] FES PET scan and clinically indicated endocrine therapy, whereas the secondary trial includes treatment with vorinostat, AI therapy (anastrozole, letrozole, or exemestane), and various correlative studies. The statement's scope is too broad and could include various oral therapies not directly related to the trials under discussion. As a result, it may be contradicted by the specific treatments and contexts mentioned in the CTRs.</s>"
    },
    "3576f3e7-a1b9-4a75-934a-1ad2165b69dd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and vomiting in the primary trial than the secondary trial.",
        "Label": "Entailment",
        "entail": "In the primary CTR, there were 4 cases of Anemia reported out of 48 participants, whereas in the secondary CTR, there was 1 case out of 39 participants. The frequency of Anemia in the primary trial is higher (4/48 = 0.0833) than in the secondary trial (1/39 = 0.0256).\n\nRegarding vomiting, the primary CTR reports 2 cases out of 48 participants, whereas in the secondary trial, there is 1 case out of 39 participants. The frequency of vomiting in the primary trial is higher (2/48 = 0.0417) than in the secondary trial (1/39 = 0.0256).\n\nThus, the expert's statement that \"There were more cases of Anemia and vomiting in the primary trial than the secondary trial\" is in line with the data provided in the CTRs.</s>",
        "contradict": "The expert's statement contradicts the CTR data as the number of cases for anemia is lower (1 vs 4) in the primary trial and the number of cases for vomiting is the same (2) in both trials. Therefore, the statement does not entail the information provided in the CTRs and is contradictory.</s>"
    },
    "de71f285-4382-465f-9e7e-d163662f6d9c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 66 patients in across both its cohorts.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial only had a total of 66 patients in across both its cohorts\" does not directly entail any information from the CTRs provided, as the CTRs do not state the total number of patients in the trials. However, it's possible to determine this number from the given data by observing that there are 3 patients in each cohort of the primary trial, making for a total of 6 patients in the trial. Since there are usually two cohorts in a trial, this implies a total of 12 patients in the primary trial. However, the expert statement specifies a total of 66 patients which is not mentioned in the CTR. This discrepancy indicates that the expert statement does not directly entail any information from the CTRs.</s>",
        "contradict": "The statement \"the primary trial only had a total of 66 patients in across both its cohorts\" cannot be directly determined from the provided CTR data, as the number of patients is not explicitly stated in the descriptions. The Adverse Events sections only list the incidence of specific adverse events among the enrolled participants, not the total number of patients. Therefore, no entailment relationship can be established based on the provided information alone.</s>"
    },
    "406247fb-003a-47b7-8fe4-b6b963b98f08": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00281697",
        "Statement": "the primary trial does not record any pain related adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not record any pain related adverse events\" is entailed by the information in the CTRs as neither the primary nor the secondary trial report mentions any adverse event related to pain, such as tachycardia or atrial fibrilation, which are sometimes associated with pain symptoms. Additionally, no adverse events like myocardial infarction or pericardial effusion, which might indicate pain, are reported in the primary trial. Therefore, the absence of pain-related adverse events in the statement is consistent with the CTR data.</s>",
        "contradict": "The expert's statement is contradicted by the information in the CTRs as both the primary and secondary trials list instances of tachycardia, which can be a symptom of pain or discomfort. The presence of tachycardia in the reported adverse events for both trials contradicts the statement that the primary trial does not record any pain related adverse events.</s>"
    },
    "47553222-0aff-4394-bcfc-9f19c0863835": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00325598",
        "Statement": "the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial does not have a defined end date, whereas the primary trial lasted 2 weeks\" is entailed by the information in the CTRs because, in the Primary Trial, the time frame for outcome measurement is explicitly stated to be \"Baseline, 2 Weeks,\" while in the Secondary Trial, there is no such explicit statement regarding the time frame for the outcome measurement. Instead, the secondary trial only states that the results will be collected \"Within 1 year of protocol registration.\" This means that the end date for collecting and reporting the results in the secondary trial is not explicitly stated like in the primary trial. Therefore, the statement that the secondary trial does not have a defined end date is an accurate observation based on the information presented in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs in that it incorrectly asserts that the secondary trial does not have a defined end date, whereas both the primary trials had clearly defined treatment durations of 16 weeks. The statement's assertion is based on an incomplete understanding or misinterpretation of the available information.</s>"
    },
    "e4756896-55c2-46e1-be19-14697ad3b39f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had blood calcium levels far above normal.",
        "Label": "Entailment",
        "entail": "The expert's statement \"One patient in the primary trial had blood calcium levels far above normal\" can be entailed by the CTR information under the Adverse Events section of the Primary Trial, specifically the event \"Hypercalcemia\" which occurred in 1/40 (2.50%) patients.</s>",
        "contradict": "The expert's statement \"One patient in the primary trial had blood calcium levels far above normal\" cannot be directly contradicted by the data presented in the provided CTRs, as there is one instance of a patient with hypercalcemia (defined as high blood calcium level). However, the expert's statement might be considered an overstatement, as it suggests that there was only a single patient with this issue among all patients in the trial, while the CTR states that there was one patient with hypercalcemia out of a total of 40 participants. Therefore, the expert's statement could be seen as a stronger claim than what is explicitly stated in the CTR, but it does not directly contradict it. If the expert meant to assert that only one patient in the trial had severe (far above normal) hypercalcemia, then the statement might contradict the data if there were other participants with less pronounced hypercalcemia that were not explicitly mentioned in the CTR.</s>"
    },
    "594c9a79-d601-46b4-ae30-0b48a1117693": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as the difference in cohort sizes between Adverse Events 2 of the secondary trial and Adverse Events 2 of the primary trial is evident from the provided data (537 participants in secondary trial vs. 1 participant in primary trial). Therefore, the statement regarding the size difference making it impossible to make meaningful comparisons is harmonious with the clinical trial data and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"The difference in cohort size between cohort 2 of the secondary trial and cohort 2 of the primary trial makes it impossible to make meaningful comparisons\" is contradicted by the information in the CTRs because the CTRs provide the number of adverse events in each cohort, and no comparisons are being made based on the cohort size alone. The comparisons, if any, should be made on the basis of the frequency or percentage of adverse events between the two trials, rather than just the cohort size. In the absence of such information, it is premature to conclude that meaningful comparisons cannot be made.</s>"
    },
    "99e8ee0e-d72d-4e19-9424-20e5891bb2b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02447003",
        "Secondary_id": "NCT00917735",
        "Statement": "It is appropriate to make clinical conclusions comparing cohort 2 of the secondary trial and cohort 2  the primary trial, despite the difference in cohort size.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as the comparison is limited to adverse event percentages between the two trials' cohorts 2 and does not require a direct comparison of individual cases or absolute numbers of adverse events within each cohort. The statement does not contradict the provided data and is harmonious with clinical trial data as it acknowledges the difference in cohort size.</s>",
        "contradict": "The statement does not provide enough context to determine if it can be contradicted by the CTRs. However, a potential problem lies in the fact that the statement refers to \"cohort 2\" in both trials without specifying which adverse event sections correspond to cohort 2 in each trial. The CTRs presented only include data for the entire trial population, not separate cohorts. Therefore, direct comparison of adverse event rates between \"cohort 2\" of the secondary and primary trials, as stated in the expert's claim, cannot be made based on the available information in the CTRs.</s>"
    },
    "f1b0653f-b5ce-4558-b325-56244940c0cd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01273896",
        "Statement": "There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs if the following conditions hold:\n\n1. Cohort 1 refers to the same group of participants in both trials.\n2. In the primary trial, the number of Dyspnea cases is twice the number of Cardiac adverse events.\n\nFrom the provided CTR data:\n\n- In the primary trial, there were 2 cases of Dyspnea and 1 case of Cardiac General, other.\n\nGiven the above conditions, the statement is entailed by the CTR data. However, it's important to note that this is only true if the conditions hold. In practice, it's essential to ensure that the trials refer to the same cohort before making such comparisons.</s>",
        "contradict": "The statement \"There was twice as many cases of Dyspnea as Cardiac adverse events in cohort 1 of the primary trial\" can be contradicted by the information present in the CTRs as follows: The number of Dyspnea cases is 2, while the number of Cardiac adverse events is 1. Hence, the statement does not entail the information provided in the CTRs, as the number of Dyspnea cases stated in the expert's claim is not twice the number of Cardiac events.</s>"
    },
    "24b24d36-2500-4841-99a3-13cba905d77d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234402",
        "Statement": "the primary trial at least 8 different types of cardiac related adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial reported at least 8 different types of cardiac related adverse events\" can be entailed by the information in the CTRs as follows: The primary CTR lists the following cardiac related adverse events: Cardiac failure (1/52), Cardiogenic shock (1/52), Atrial fibrillation (0/52), and Palpitations (0/52). Additionally, there is mention of one instance of Right Ventricular Failure and one instance of Cardiac failure in the section titled \"Cardiac failure\", making the total count of unique cardiac related adverse events reported as 7. However, the secondary CTR also includes Pericardial effusion (4/49), which represents an additional distinct cardiac related adverse event not mentioned in the primary CTR. Therefore, the total count of unique cardiac related adverse events across both trials is 8. This observation aligns with the statement, making it an entailment of the provided CTR data.</s>",
        "contradict": "The statement made by the clinical trial expert that \"the primary trial at least 8 different types of cardiac related adverse events\" cannot be directly contradicted by the information provided in the CTRs as the statement is not explicitly false. However, the CTR data does not support the statement as there are only 7 distinct cardiac related adverse events mentioned for the primary trial (Cardiac failure, Cardiogenic shock, Palpitations, Pericardial effusion, Right ventricular failure, and Atrial fibrillation). Therefore, the statement is not entailed by the CTR data, but it is also not contradictory. However, if we take into consideration both the primary and secondary trials, there are 9 distinct cardiac related adverse events (8 from the primary trial and 1 from the secondary trial), and the statement would be entailed by the combined CTR data.</s>"
    },
    "0797ff90-f847-4442-92fd-017c539bb38f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00546104",
        "Statement": "1 patient in the primary trial suffered from a blood clot blocking their trachea.",
        "Label": "Contradiction",
        "entail": "The statement \"1 patient in the primary trial suffered from a blood clot blocking their trachea\" can be entailed by the information in the primary trial's Adverse Events section if there exists a patient with the adverse event \"Thrombosis\" (which implies the presence of a blood clot) reported in the throat or trachea region (which can be inferred as \"trachea\" in common language). However, the provided CTR does not mention any such specific occurrence. Thus, based on the information provided, the statement cannot be directly entailed by the Adverse Events section of the CTR.</s>",
        "contradict": "The statement \"1 patient in the primary trial suffered from a blood clot blocking their trachea\" cannot be directly contradicted by the information in the provided CTRs. However, thrombosis (a type of blood clot) is listed as an adverse event in the primary trial, but it is not specified whether it occurred in the trachea or another location. The CTR provides no evidence to support or refute the statement that a patient experienced a blood clot blocking their trachea.</s>"
    },
    "6b595151-7e51-4062-b587-3207ea251677": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00606931",
        "Statement": "the primary trial tests positron emission tomography as a technique for guiding a medical procedure.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR as the Intervention section of the Primary Trial explicitly states that PET Guided Biopsy is the expected procedure for all enrolled participants. The term \"testing PET as a technique\" aligns with the PET Guided Biopsy procedure described in the CTR, thus ensuring harmonization with the clinical trial data and avoiding contradiction.</s>",
        "contradict": "The information in the statement is not contradictory to the CTR, but it may not fully capture the details of the intervention described. The CTR states that the primary trial utilized PET guided biopsy, meaning that the PET scan was used as a guidance method for performing the biopsy procedure. However, the statement only focuses on PET as a technique, potentially implying that it was the actual intervention instead of just a guiding mechanism. Thus, while there's no contradiction, the statement might require additional context or clarification to precisely reflect the details in the CTR.</s>"
    },
    "e802b1f6-62fb-4759-b261-c69dbdc1d7ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial receive higher doses of Q-122 than either of the secondary trial cohorts receive of AZD9496 variants.",
        "Label": "Contradiction",
        "entail": "The statement entails that the doses of Q-122 given in the primary trial are greater than the doses of AZD9496-Variant and AZD9496-Reference in the secondary trial. \n\nExplanation: \n\nIn the primary trial, the dose of Q-122 for Intervention 1 is 100 mg/day (2 * 50 mg), and for Intervention 2 it is 200 mg/day (4 * 50 mg). \n\nIn the secondary trial, the dose of AZD9496 for both treatment periods is 100 mg. \n\nSince 100 mg < 100 mg Q-122 (Intervention 1) and 100 mg < 200 mg Q-122 (Intervention 2), it follows that both cohorts in the primary trial receive higher doses of Q-122 compared to each cohort in the secondary trial, which is stated in the expert's claim.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because although the dosage of Q-122 given to the primary trial cohorts is higher than the dose of AZD9496 given to the secondary trial cohorts, it does not necessarily mean that Q-122 is a direct equivalent to AZD9496. The two compounds may have different pharmacokinetics, efficacy, or safety profiles, and therefore, the same dosage does not ensure a comparable therapeutic effect. The statement's assumption of a direct comparison between the two trials based on dosage alone is an oversimplification and may lead to incorrect conclusions.</s>"
    },
    "0a24a07e-2cb4-4591-aea4-a370f462cc49": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00593346",
        "Secondary_id": "NCT00902330",
        "Statement": "the primary trial treament last for a shorter period of time than the secondary trial treatment.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial treatment lasts for a shorter period of time than the secondary trial treatment\" is entailed by the information presented in the CTRs because:\n\n1. Primary Trial: The total dose of accelerated partial breast brachytherapy is 3400 cGy, delivered in 10 fractions of 340 cGy each. The treatment is given twice daily over 5-7 days. Therefore, the total treatment duration for the primary trial is 5-7 days.\n2. Secondary Trial: The CES intervention and sham intervention are given once daily for 18 weeks each. \n\nSince 18 weeks (126 days) is longer than 5-7 days (between 35-49 days), the statement that the primary trial treatment lasts for a shorter period of time than the secondary trial treatment is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"the primary trial treatment lasts for a shorter period of time than the secondary trial treatment\" is contradicted by the CTRs because the primary trial intervention involves 10 twice-daily fractions of accelerated partial breast brachytherapy, amounting to a total of 20 sessions within 5-7 days. This is in contrast to the secondary trial, where each arm (I and II) receives treatment once a day for 18 weeks. Hence, the number of sessions and duration of treatment in the primary trial is longer than in the secondary trial, and not shorter as stated in the expert's claim.</s>"
    },
    "97d0bbf0-c2c5-409b-820b-6e14a6326b06": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02322814",
        "Secondary_id": "NCT00356148",
        "Statement": "A patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The patient described matches the inclusion criteria for the primary trial, specifically for ER-negative, PR-negative, and HER2-positive breast cancer, and no brain metastases or history of cardiac dysfunction. The patient does not meet the exclusion criteria for the primary trial related to prior systemic anticancer therapy, prior exposure to experimental treatments targeting MAPK pathway or specific atezolizumab exclusions. The patient also meets the inclusion criteria for the secondary trial, being a woman with early stage breast cancer and an ASA score of I or II. The patient does not have any of the exclusion criteria for the secondary trial, such as receiving neoadjuvant therapy, history of immunodeficiency, having a remote infection, history of reaction to study antibiotics, or denial of signing the consent form. Therefore, the statement that \"a patient with Histologically confirmed estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor 2 positive breast cancer, with no known Brain metastases and no prior history of cardiac dysfunction, could be eligible for both the secondary trial and the primary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The patient described in the statement does not meet the inclusion criteria of the primary trial due to having HER2-positive breast cancer, which is an exclusion criterion mentioned in the CTR. Therefore, the statement is contradicted by the information provided in the primary CTR.</s>"
    },
    "bbb5ebc0-83c8-46cb-89b4-e1c67e042350": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00859651",
        "Statement": "Helen had stage III ovarian cancer 7 years prior, but has been disease-free for 5 years., she is excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "Helen's medical history of having stage III ovarian cancer, being disease-free for 5 years, does not meet the inclusion criteria of the primary trial due to her previous malignancy history. The CTR states that \"Other prior malignancy\" is an exclusion criteria. Therefore, the statement is entailed by the information present in the CTR.</s>",
        "contradict": "Helen's exclusion from the primary trial based on her prior history of ovarian cancer (which she has been disease-free from for 5 years) contradicts the statement in the CTR allowing participation for patients with a history of breast, ductal carcinoma in situ, or other cancer (including breast cancer), provided they have been disease-free for 5 years.</s>"
    },
    "620106e8-2a7f-4078-80b6-d5f1840c66e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00699491",
        "Statement": "the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as the RPTD, defined as the dose level at which no more than one patient experiences a DLT, is specified as 3 mg/ks cixutumumab for the arm with the title \"Dose Level 1\" in the primary CTR, which had only one DLT reported. Additionally, no DLTs were reported for the next highest dose level in the same trial. The expert's statement is a logical conclusion based on the given CTR data.</s>",
        "contradict": "The statement \"the primary trial results show that the Recommended Dose Level for Phase II Testing (RPTD) (Phase I) is 3 mg/ks cixutumumab\" contradicts the information in the CTRs because the CTRs do not explicitly state that the RPTD for phase II testing for cixutumumab is 3 mg/ks. Instead, the CTRs only report the number of DLTs observed at different dose levels for both temsirolimus and cixutumumab. The expert's statement infers the RPTD based on the given data, but this inference is not directly stated in the CTRs and could be subject to interpretation. Therefore, the expert's statement might not be a semantically entailed relationship with the CTR information, as it is not an accurate representation of the data.</s>"
    },
    "94a7b007-0332-4d01-979e-9677e5da4316": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial, the FEC-75 Then Paclitaxel/Trastuzumab group had more Invasive Tumor Remaining in the Breast than the Paclitazumab/Trastuzumab Then Trastuzumab/FEC-75 group\" can be entailed by the information in the CTRs as follows:\n\nThe pCR rates, which represent the absence of invasive tumor, are presented in the CTRs for both arms. The pCR rate for the FEC-75 Then Paclitaxel/Trastuzumab group (56.5% with a 95% Confidence Interval of 47.8-64.9%) is higher than the pCR rate for the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group (54.2% with a 95% Confidence Interval of 45.7-62.6%). Therefore, the inverse of the percentage, which is the proportion of participants with invasive tumor remaining, follows the stated condition. The FEC-75 Then Paclitaxel/Trastuzumab group had a lower proportion of participants achieving pCR and, consequently, a higher proportion of participants with invasive tumor remaining compared to the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs as the data provided does not support the claim of more invasive tumor remaining in the breast in the FEC-75 Then Paclitaxel/Trastuzumab group compared to the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group. Instead, the CTRs report pCR rates based on blinded central review of institutional pathology reports for both treatment arms, with no clear indication of a difference in pCR rates between the two groups based on the given data. The statement, however, makes a direct comparison regarding the presence or absence of invasive tumor, which is not directly reported in the CTRs.</s>"
    },
    "2849d0ce-fed2-4c49-bec1-777c440caaeb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127205",
        "Statement": "More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole.",
        "Label": "Contradiction",
        "entail": "The statement \"More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole\" cannot be directly entailed by the provided CTR data. \n\nThe reason being: \n\nThe CTRs do not report any instances of ventricular contractions dysfunctions (e.g., ventricular tachycardia, ventricular fibrillation, or ventricular extrasystoles) in either trial. \n\nInstead, the CTRs report on left ventricular diastolic dysfunction and left ventricular systolic dysfunction. While these conditions are related to ventricular function, the statement made by the expert focuses specifically on \"dysfunctions with ventricular contractions,\" a more narrow concept.\n\nTherefore, the statement \"More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular systole\" is not entailed by the provided CTR data.</s>",
        "contradict": "The expert's statement is not entailed by the data in the CTRs, as both trials report zero instances of left ventricular diastolic dysfunction and left ventricular systolic dysfunction in the primary trial, while the secondary trial reports only a few instances for both conditions. There is no evidence to support the expert's claim that more patients suffered from dysfunctions with ventricular contractions in the primary trial than ventricular systole based on the information presented in the CTRs.</s>"
    },
    "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.",
        "Label": "Entailment",
        "entail": "The statement \"Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.\" is entailed by the CTR data because there are only two types of adverse events - sepsis and dehydration - that were reported more than once in the primary trial, with frequencies of 6.06% each. The other listed adverse event types - constipation, dysphagia, ileus, nausea, vomiting, fatigue, pain, urinary tract infection, increased Alanine aminotransferase, and increased Aspartate aminotransferase - each occurred only once. Therefore, the statement correctly summarizes the CTR data.</s>",
        "contradict": "The statement \"Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once\" can be contradicted by the information present in the CTRs because, in the primary trial CTR, there are actually three adverse events that occurred more than once. Specifically, the adverse events Sepsis and Dehydration each occurred twice.</s>"
    },
    "01a57096-0278-4c70-be43-acd57010cd6f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01332630",
        "Secondary_id": "NCT00121134",
        "Statement": "There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were more patients with significantly elevated blood pressure in cohort 1 of the primary trial, than in cohort 1 of the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe primary trial reported an occurrence of hypertension in 14.29% (3 out of 21) of the patients in its cohort 1, and no such instance was reported in the secondary trial with a cohort size of 40. Therefore, the percentage of patients with hypertension is higher in the primary trial than the secondary trial. However, to confirm \"significantly elevated,\" further statistical analysis beyond the provided data is required.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary and secondary trials report different rates of hypertension in the first cohort (14.29% in primary trial vs. 0.00% in secondary trial). However, the statement does not explicitly mention the specific condition of hypertension, but rather speaks of \"significantly elevated blood pressure.\" This ambiguity may lead to potential confusion or misinterpretation of the data. To establish accurate entailment, the statement should more precisely describe the nature of the blood pressure elevation and reference the specific trials and their respective cohorts to align with the data provided in the CTRs.</s>"
    },
    "49213077-0a5b-4368-a48a-282d2ca9d77a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02953860",
        "Statement": "Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial states that patients receive 160mg of Enzalutamide PO daily, while they receive 500mg of Fulvestrant IM every 4 weeks.\n\n2. The dose of Enzalutamide is greater both in terms of quantity (160mg vs 500mg) and frequency (daily vs every 4 weeks).\n\n3. The statement is consistent with the data in the CTR, as it correctly reflects the differences in treatment dosages.\n\n4. The statement does not contradict any information provided in the CTRs, and therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial receive more mg of Enzalutamide than Fulvestrant over the course of the study\" is contradicted by the information in the CTRs because the amount of Fulvestant given is 500mg every 4 weeks, which amounts to 1250mg over the course of one full cycle of treatment (considering days 1, 15, 28, and every 4 weeks thereafter). In contrast, patients receive 160mg of Enzalutamide daily, so the total amount administered over the same time period would depend on the length of treatment but is generally less than the total amount of Fulvestrant given. The statement oversimplifies the dosing schedules, failing to consider the differences in dosing regimens between the two drugs and leading to a contradiction with the information provided in the CTRs.</s>"
    },
    "426d3ecd-73e3-4226-83c6-cfcb9212ed62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00263588",
        "Statement": "All the primary trial subjects either had Progressive disease, Complete CNS objective response rate or partial response rate.",
        "Label": "Contradiction",
        "entail": "The statement \"All the primary trial subjects either had Progressive disease, Complete CNS objective response rate, or partial response rate\" can be entailed by the information present in the CTRs as follows:\n\n1. Progressive disease: The CTRs provide the number of participants with Progressive disease in each cohort (Cohort A: 40, Cohort B: 70). These participants comprise a part of the primary trial subjects.\n\n2. Complete CNS objective response rate: The CTRs specify the definition of Complete response (CR), which is a 50% or greater volumetric reduction in sum of CNS target lesions without any new or progressive CNS or non-CNS lesions, no increases in tumor-related steroid requirements, and no worsening of neurological signs or symptoms. Although there are no reported cases of CR in either Cohort A or B, the possibility remains that a participant could have experienced this outcome, even if it's not explicitly stated in the provided data.\n\n3. Partial response rate: The CTRs indicate the percentage of Partial responders (PR) in each cohort (Cohort A: 6.4%, Cohort B: 6.3%). These participants make up another part of the primary trial subjects. \n\nThus, the statement \"All the primary trial subjects either had Progressive disease, Complete CNS objective response rate, or partial response rate\" follows from the data in the CTRs, as all participants in the trial belong to either of these three categories according to the definition of their responses.</s>",
        "contradict": "The statement cannot be entailed by the information in the CTRs as it goes beyond the scope of the reported data. The CTRs only provide information on the outcomes (CR, PR, SD, PD) for each cohort, but they don't specify if any participants had a complete CNS objective response. Additionally, the statement assumes that every participant falls under one of these three categories, but the CTRs report that some participants' outcomes are unknown.</s>"
    },
    "7c12676c-7973-4e9d-b1fc-3b14d241d0c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "20 patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Entailment",
        "entail": "According to the CTRs, in the primary trial, there were 20 participants in the Dasatinib + Letrozole arm who had a Disease Free Interval (DFI) greater than 2 years. This statement is entailed by the information in the CTRs because the number of participants with DFI greater than 2 years, for the Dasatinib + Letrozole arm, is explicitly stated in the CTR as 20 (Results 1: CBR, DFI > 2 Years).</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the data in the CTRs, but it may be an overgeneralization. The CTR data indicate that there were 20 patients with a CBR and a DFI greater than 2 years in each of the Dasatinib + Letrozole and Letrozole arms. The statement, however, only refers to patients who were treated with Dasatinib and Letrozole specifically, which could be a subset of the 20 patients with DFI > 2 years in the Dasatinib + Letrozole arm, or it could refer to a combination of patients from both arms. Without further context, the statement's assertion aligns with the data, but its scope might be broader than what is described in the CTRs.</s>"
    },
    "3419e901-5880-488d-912c-023e8d1b51c7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Secondary_id": "NCT01446159",
        "Statement": "the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more\" cannot be entailed directly by the given Clinical Trial Reports (CTRs) data as both trials report the absence of congestive cardiac failure in the adverse events sections.</s>",
        "contradict": "The statement \"the primary trial recorded one patient with congestive Cardiac failure, the secondary trial recorded more\" is contradictory to the information in the CTRs because neither trial reported a patient with congestive Cardiac failure in their Adverse Events sections. The Primary Trial reported one instance of Pleural effusion, which can be a sign of heart failure, but it does not guarantee the presence of congestive Cardiac failure. The Secondary Trial did not report any cases of Cardiac failure or Pleural effusion. Therefore, no trial reported more instances of congestive Cardiac failure than the other because neither reported any.</s>"
    },
    "cd645637-0a31-4f54-bc75-4a52349cf100": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00748553",
        "Statement": "Patients in the primary trial receive 50mg/m2, 75mg/m2 and 80mg/m2 daily every 5 days for each 4-week cycle",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs if we consider that the expert's statement is a generalization of the dosages mentioned in the primary trial. The primary trial specifies that patients receive either 50mg/m2, 75mg/m2, or 100mg/m2 of Azacitidine daily for 5 days each 4-week cycle. The expert's statement includes 50mg/m2 and 75mg/m2 dosages, while adding an additional dosage of 80mg/m2, which is not explicitly mentioned in the primary trial. However, the expert statement does not contradict the primary CTR since it stays within the given dosage range (50mg/m2 to 100mg/m2) for Azacitidine. Similarly, the expert's statement for Nab-paclitaxel remains unchanged with the CTR, which states patients receive 100mg/m2 weekly for 3 weeks every 4 weeks. Thus, the information in the expert statement is entailed by the information provided in the primary and secondary CTRs.</s>",
        "contradict": "The statement made by the clinical trials expert is contradictory to the information in the primary CTR because it mentions the administration of 80mg/m2 daily instead of the specified dosages of 50mg/m2, 75mg/m2, and 100mg/m2 for Azacitidine. The statement also does not mention the specific dosage of Nab-paclitaxel given in the primary trial, which is 100mg/m2 weekly. These discrepancies make the statement contradictory to the information provided in the CTR.</s>"
    },
    "adfc79ba-2996-47ce-9986-7d287931df89": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115984",
        "Statement": "A total of 3 patients in the primary trial experience a Herpes related adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"A total of 3 patients in the primary trial experience a Herpes related adverse event\" can be entailed by the CTR information as follows: \n\n1. The CTR for the primary trial reports 0 occurrences of Herpetic eruption in the Adverse Events section for the experimental group of 33 patients (0/33).\n2. However, the CTR for the secondary trial reports 3 occurrences of Herpetic eruption in the Adverse Events section for the experimental group of 23 patients (3/23).\n3. The primary trial has a total of 57 participants (57/57) and the secondary trial has a total of 23 participants (23/23).\n4. Since both trials involve the same treatment, the adverse events data from the secondary trial provides additional information not reported in the primary trial.\n5. Thus, the 3 Herpetic eruption occurrences in the secondary trial translate to an additional 3 patients (23 total participants - 20 without Herpetic eruption) in the primary trial experiencing this adverse event.\n6. Therefore, the statement \"A total of 3 patients in the primary trial experience a Herpes related adverse event\" holds true, as it follows from the CTR information.</s>",
        "contradict": "The expert's statement is contradicted by the CTRs as neither trial reports any herpetic eruption in the 33 participants of the primary trial, with a total of 0/33 (0.00%) herpetic eruptions being recorded for both trial arms. Therefore, the statement suggesting that \"3 patients in the primary trial experience a Herpes related adverse event\" is inconsistent with the provided CTR data.</s>"
    },
    "414ae027-b420-4f01-afd5-164cd8146a30": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01129336",
        "Secondary_id": "NCT01945775",
        "Statement": "16 participants of the primary trial are considered to be censored. the secondary trial used the same outcome measurement, but had no censored patients.",
        "Label": "Entailment",
        "entail": "The statement that \"16 participants of the primary trial are considered to be censored\" means that for those participants, the PFS data is missing due to either being lost to follow-up or because they didn't experience the outcome event before the completion of the trial. In the CTR, this is evident from the provided numbers of participants (Event) and those who are censored (Censor) in each arm. \n\nThe secondary trial, on the other hand, did not report any censored patients, meaning all participants had documented radiologic progressive disease or died before the end of the study. However, it does not contradict the information from the primary trial, as the trials involve different patient cohorts. Therefore, the statement is entailed by the information in the CTRs since it is a valid observation derived from the data given.</s>",
        "contradict": "The statement \"16 participants of the primary trial are considered to be censored. the secondary trial had no censored patients.\" is contradicted by the information in the CTRs because the number of censored patients in the primary trial (15 for patients without bone metastases and 10 for patients with bone metastases) and the absence of censored patients in the secondary trial (Talazoparib and Physician's Choice Treatment arms) are explicitly stated in the provided information. The statement misrepresents the number of censored patients in the primary trial, implying 16 participants being censored instead of the actual 15 + 10 = 25.</s>"
    },
    "45b2b9ec-ba58-4323-810a-4baed9c84a0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00470847",
        "Statement": "the primary trial participants will not receive any Lapatinib post WBRT.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants will not receive any Lapatinib post WBRT\" is entailed by the information present in the CTRs as the primary trial specifies that Lapatinib is administered \"before and during Whole Brain Radiation Therapy (WBRT)\" but there is no mention of Lapatinib being given after WBRT. In contrast, Herceptin is stated to be given \"weekly\" after WBRT completion. Hence, based on the provided CTR details, it can be inferred that participants will not receive any Lapatinib post WBRT.</s>",
        "contradict": "The statement \"the primary trial participants will not receive any Lapatinib post WBRT\" contradicts the information present in the CTR of the primary trial, as it specifies that Lapatinib is given \"after\" Whole Brain Radiation Therapy (WBRT) before Herceptin is administered, which indicates that participants in the primary trial do receive Lapatinib after WBRT.</s>"
    },
    "72ffdfbf-aa72-4d44-814a-1d6ab8883898": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Statement": "Patients must have already participated in a specific clinical study to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have already participated in a specific clinical study to participate in the primary trial\" is entailed by the information in the CTRs because both reports specify that patients in the primary trial had previously participated in a phase II clinical study. This requirement is explicitly stated in the primary trial's inclusion criteria, \"among the patients with advanced or recurrent breast cancer who had met the selection criteria and participated in the preceding phase II clinical study.\" The secondary trial does not include this information, but it is an assumption given that patients are being recruited from the same population and follow-up trial, which is already known from the primary trial's CTR.</s>",
        "contradict": "The statement \"Patients must have already participated in a specific clinical study to participate in the primary trial\" is not necessarily contradictory to the CTR information given. However, it is not an exact entailment either. The CTR states that subjects must have participated in a preceding phase II clinical study and responded to at least two courses of weekly paclitaxel therapy to be eligible for the primary trial. While the statement implies that any clinical study participation is sufficient for entry into the primary trial, the CTR specifies a more particular requirement of response to paclitaxel in a prior study. Thus, the statement can be seen as a broader condition for eligibility that includes, but is not limited to, the specific requirement mentioned in the CTR. However, if the expert meant the statement to be an exact entailment of the CTR, then it would be incorrect because the CTR provides more specific information about the required clinical study participation.</s>"
    },
    "db613a72-e300-41a7-987f-788c306d94a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00403130",
        "Statement": "There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial\" can be entailed by the information in the CTRs as neither condition is mentioned in the list of adverse events for the primary trial. Leukopenia is a condition characterized by a decreased level of white blood cells, and Arrhythmia refers to an irregular heartbeat. Since neither condition appears in the primary trial's adverse events section, the expert's statement is an accurate reflection of the CTR data.</s>",
        "contradict": "The statement \"there were no cases of Leukopenia or Arrhythmia observed in patients participating in the primary trial\" contradicts the information in the CTRs because Leukopenia is not mentioned in the list of adverse events for the primary trial, and Arrhythmia is not mentioned at all in either the primary or secondary trial's adverse events sections.</s>"
    },
    "2667d301-2efb-4d92-bc12-ccfc869e4835": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Entailment",
        "entail": "The expert's statement asserts that patients in cohort 2 of the primary trial undergo an additional drain insertion compared to cohort 1. This claim aligns with the CTR information since cohort 1 utilizes a single drain (as specified by the text: \"A negative pressure drain will be inserted below the lower flap directing to the axilla\" for both pre- and post-removal stages), while cohort 2 receives two drains (as stated: \"Two negative pressure drains will be inserted into the axilla and below the lower flap\"). Thus, the expert's statement is entailed by the CTR.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs as both Intervention 1 and Intervention 2 in the primary trial involve the use of negative pressure drains. However, the statement only accurately describes a difference in the number of drains (single vs double) for patients in the two cohorts and does not mention the insertion locations explicitly. The CTRs state that in both interventions, negative pressure drains will be inserted in the axilla and below the lower flap, with an additional drain being placed for the double drain group. Thus, the statement is technically correct but does not fully capture the information in the CTRs regarding the drain insertion locations.</s>"
    },
    "60bff573-0251-4f05-b2b7-dec74c7363cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00934856",
        "Statement": "In total, across both cohorts of the primary trial, there was at least 2 fatigued patients.",
        "Label": "Contradiction",
        "entail": "The statement \"In total, across both cohorts of the primary trial, there was at least 2 fatigued patients\" cannot be directly entailed by the information in the given CTRs, as no instances of fatigue were reported in either cohort. However, the absence of fatigue in the CTRs does not contradict the statement, as the trial reports only cover the observed adverse events and do not provide an exhaustive list of all possible adverse events that could have occurred. Therefore, while the statement goes beyond the information provided in the CTRs, it does not contradict it. The statement is not a strict entailment but a valid implication, assuming a more comprehensive knowledge of the trials beyond the provided data.</s>",
        "contradict": "The statement \"In total, across both cohorts of the primary trial, there was at least 2 fatigued patients\" contradicts the information in the CTRs because neither of the two CTRs reports any instance of fatigue among their participant cohorts.</s>"
    },
    "f6f8a0d3-6288-44cf-9b34-27444110dd10": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT01008150",
        "Statement": "histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"histologically confirmed extensive intraductal component of primary breast carcinoma would result in exclusion from the primary trial, but not from the secondary trial,\" can be entailed by the following reasons derived from the CTRs:\n\n1. In the primary trial, the exclusion criteria explicitly state \"No histologic evidence of EIC.\" EIC stands for Extensive Intraductal Component, which refers to the presence of invasive carcinoma within the intraluminal ducts, often associated with a larger tumor size, higher tumor stage, and poorer prognosis.\n\n2. In contrast, the secondary trial does not contain an exclusion criterion related to the histologic presence of EIC.\n\n3. Given that the primary trial has a stricter inclusion and exclusion criteria than the secondary trial, patients with a histologically confirmed extensive intraductal component of primary breast carcinoma may not meet the eligibility for the primary trial, but they could still be eligible for the secondary trial as the exclusion criteria do not apply.</s>",
        "contradict": "The statement is not entailed by the information in either CTR, as the primary trial explicitly includes patients with Grade I or II DCIS (ductal carcinoma in situ), which is a type of extensively intraductal component of breast carcinoma. Therefore, the presence of this condition would not result in exclusion from the primary trial, contrary to the statement. Furthermore, the secondary trial does not mention anything about exclusion based on the presence of histologically confirmed extensive intraductal component in the primary breast carcinoma.</s>"
    },
    "8b0482c1-74d4-48ae-96bc-d80f8f1a0f50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00572728",
        "Secondary_id": "NCT02472964",
        "Statement": "Patients in the primary trial and the secondary trial will take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Intervention 1 specifies that patients undergo Herceptin\u00a9 (trastuzumab) as part of the first and second part of the treatment regimen. In the secondary trial, Intervention 1 for both trial arms also involves Herceptin\u00a9 (trastuzumab), making both trials consistent in their use of Herceptin\u00a9 (trastuzumab). Additionally, Intervention 1 in both trials provides an option for paclitaxel intravenously as part of the first part of the treatment regimen. Therefore, the statement that \"Patients in the primary trial and the secondary trial will take Herceptin\u00ac\u00a8\u00ac\u00a9 (trastuzumab) or paclitaxel intravenously\" is entailed by the information in the provided CTRs.</s>",
        "contradict": "The statement \"Patients in the primary trial and the secondary trial will take Herceptin\u00a9 (trastuzumab) or paclitaxel intravenously\" is not contradictory to the information in the CTRs. However, it is not a semantic entailment either as the statement does not specify which trial, or which intervention within the trials, pertains to Herceptin\u00a9 or paclitaxel alone. The CTRs provide details of different interventions for each trial: the primary trial includes 18F-FLT PET/CT scans and correlative laboratory biomarker analysis, while the secondary trial involves the use of Herceptin\u00a9 in combination with taxanes for two different treatment regimens. The given statement is too general and does not accurately reflect the specific interventions mentioned in the CTRs.</s>"
    },
    "878dcfeb-c3db-4077-9a3e-8098efa80a99": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of race or ethnicity.",
        "Label": "Entailment",
        "entail": "The statement \"Patients cannot be excluded from the primary trial on the basis of race or ethnicity\" is entailed by the information in the CTRs because the ELIGIBILITY CRITERIA section for both the primary and secondary trials does not list race or ethnicity as an exclusion criterion for the primary trial.</s>",
        "contradict": "The statement \"Patients cannot be excluded from the primary trial on the basis of race or ethnicity\" contradicts the CTR inclusion criteria, which explicitly state \"Women of all races and ethnic groups are eligible for this trial\" (inclusion criterion) but also include several other eligibility criteria. This explanation highlights that the statement is contradictory because it implies a restriction on eligibility that is not present in the CTR, while the CTR specifies that race and ethnicity are not factors that limit eligibility for the trial.</s>"
    },
    "fc5dbfec-ba79-4c5d-9e38-3c97d0397570": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Secondary_id": "NCT00493636",
        "Statement": "Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Contradiction",
        "entail": "The statement \"Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet.\" is entailed by the information present in the CTRs since both primary and secondary trials require patients to provide informed consent and have the capability to use the internet for inclusion. The secondary trial, in addition to the common criteria, has specific eligibility and exclusion criteria that patients must meet to participate. These criteria do not contradict the statement, and the statement's scope covers both trials.</s>",
        "contradict": "The statement \"Any patient can enter into the primary trial or the secondary trial; as long as they are willing to provide Informed consent and are capable of using the internet\" is contradicted by the inclusion and exclusion criteria presented in the CTRs. The primary trial has additional inclusion criteria of no breast cancer diagnosis during the intervention, whereas the secondary trial has specific inclusion criteria related to breast cancer diagnosis, age, disease progression, prior treatment history, and ECOG Performance Status. Additionally, there are exclusion criteria present in both trials that are not mentioned in the statement, such as HER-2 overexpression in the primary trial and various medical conditions and medications in both trials.</s>"
    },
    "a8514489-cb31-4c8a-abca-e1f7b3a8d4ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01234337",
        "Secondary_id": "NCT00217672",
        "Statement": "No cases of Anaphylaxis occurred in either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"No cases of Anaphylaxis occurred in either the primary trial or the secondary trial\" can be entailed by the information present in the CTRs as Anaphylaxis is not listed as an adverse event in any of the Adverse Events sections for either trial.</s>",
        "contradict": "Although the statement asserts that no cases of Anaphylaxis occurred in both trials, Anaphylaxis is not listed as an adverse event in either the primary or the secondary CTRs. Therefore, the absence of Anaphylaxis in the trials cannot be determined based on the information provided in the CTRs alone. Thus, the statement contradicts the CTRs if it is assumed that the expert's knowledge includes Anaphylaxis as a possible adverse event, which is not explicitly stated in the provided data.</s>"
    },
    "64411610-090b-42d2-a176-d2b13ffef591": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03210220",
        "Secondary_id": "NCT00290745",
        "Statement": "Unlike the primary trial, the secondary trial has no control group.",
        "Label": "Entailment",
        "entail": "In the provided CTRs, the primary trial describes the use of two different interventions in its treatment group: a pectoral nerve block using ropivacaine and the absence of a nerve block in the control group. The secondary trial, on the other hand, does not involve a control group and instead focuses on two forms of treatment for women with ductal carcinoma in situ: tamoxifen or letrozole. \n\nDespite the differences in interventions and trial types, the expert's statement that \"the secondary trial has no control group\" can be entailed by the information present in the CTRs. The CTRs explicitly describe the absence of a control group in the primary trial's control group section, while the secondary trial never mentions or implies the presence of one. The expert's statement correctly reflects the shared feature of having no control group between the two trials.</s>",
        "contradict": "The statement \"Unlike the primary trial, the secondary trial has no control group\" is not directly contradictory to the provided information from the CTRs. However, the statement does make a claim about the secondary trial not having a control group, which is not mentioned in the provided CTR for the secondary trial. Therefore, while there is no direct contradiction, the statement does not necessarily entail the information in the CTRs. In the context of semantic entailment, the statement does not fully capture or convey the information in the CTRs, as it lacks specific details about the design of the secondary trial beyond stating it does not have a control group.</s>"
    },
    "82bd50ac-9407-413b-9eb8-653cef49706c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02364388",
        "Secondary_id": "NCT01425268",
        "Statement": "warm saline solution is used in both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "In the primary trial, although not explicitly stated, the type of tissue expander is MAESTRO which is not specified to be filled with warm saline solution. However, in the secondary trial, both Intervention 1 and Intervention 2 (AeroForm Tissue Expansion and Saline Tissue Expansion) use solutions for filling the expander - carbon dioxide in case of AeroForm and saline in case of Saline Tissue Expansion. Since the statement refers to \"warm saline solution,\" it is applicable to Saline Tissue Expansion in the secondary trial. There's no contradiction with the CTR information as the statement does not claim that the same solution, specifically warm saline, is used for both types of tissue expanders in the primary and secondary trials, but rather that warm saline solution is used in the secondary trial for tissue expansion.</s>",
        "contradict": "The statement \"warm saline solution is used in both the primary trial and the secondary trial\" can be contradicted by the information present in the CTRs, as the primary trial uses an intervention of MAESTRO which does not involve the use of warm saline solution, whereas the secondary trial uses two interventions - AeroForm Tissue Expansion inflated by carbon dioxide and Saline Tissue Expansion inflated by needle injections - but neither specification mentions the usage of warm saline solution.</s>"
    },
    "470611af-16b2-4094-ae2a-c9c6155e2672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01575522",
        "Statement": "The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement does not require the type or duration of intervention to be explicitly stated in the primary trial's intervention section for entailment, as the statement only mentions that the information in the primary trial's intervention section is less detailed than the secondary trial, not that it is contradictory or incorrect. The primary trial only indicates that patients undergo mastectomy surgery, whereas the secondary trial specifies that patients receive tivantinib orally twice daily for a specific duration, but this difference does not negate the fact that a surgical intervention is mentioned in the primary trial.</s>",
        "contradict": "The statement \"The intervention section for the primary trial does not detail the type or duration of the intervention, unlike the secondary trial\" is contradictory to the information in the CTRs if the primary trial involves mastectomy surgery as stated. The intervention section of the primary trial specifies \"Patients Undergoing Mastectomy Surgery,\" which defines the type of intervention. Although it does not explicitly mention the duration of the intervention, mastectomy is typically a surgical procedure with a fixed duration based on the extent of the tumor removal. In contrast, the secondary trial's intervention with Tivantinib involves a defined dosing regimen and periodic assessments. The statement's focus on the lack of details regarding the type and duration for the primary trial is misleading when the primary trial's intervention indeed has a well-defined type.</s>"
    },
    "f3a03aec-194d-4538-9be3-cea8281d995c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 3 different Adverse Events .",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded less than 3 different Adverse Events\" can be entailed by the information in the CTR as there are a total of 4 distinct adverse events reported in the Primary Trial: Bleeding, Pain, Dehydration, and Dyspnea. However, the number of distinct events is less than 3 when considering the statement's perspective that counts the total number of unique events rather than the number of unique event types and instances.</s>",
        "contradict": "The statement \"the primary trial recorded less than 3 different Adverse Events\" contradicts the information present in the CTRs because, in the Primary Trial section, five distinct adverse events are reported - Bleeding, Pain, Dehydration, Dyspnea, and a total of four events occurred.</s>"
    },
    "14a5e557-b223-4649-9867-0ff0e9001f5e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Secondary_id": "NCT02352779",
        "Statement": "the primary trial and the secondary trial do not explain their interventions in the intervention section.",
        "Label": "Contradiction",
        "entail": "The statement does not entail anything about the interventions being explained in the intervention sections of the CTRs. However, the information in the CTRs clearly states that the interventions are indeed described in the intervention sections. Therefore, the statement does not contradict the information in the CTRs and is consistent with them. Thus, the statement can be considered entailed by the information in the CTRs, as it does not negate the presence of intervention descriptions in the trial reports.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because the CTRs explicitly describe the interventions in detail, including the name of the intervention (MM-111 in the primary trial and omega-3 fatty acid in the secondary trial), the way it is administered (PO BID for both low-dose and high-dose groups in the secondary trial), and the duration of treatment (6 weeks for both groups in the secondary trial). Therefore, it is incorrect to assert that the trials do not explain their interventions in the intervention section.</s>"
    },
    "c8df3461-4063-4fb0-ae48-f57062eb0a68": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03329937",
        "Statement": "the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the CTR as it accurately summarizes the dosing regimen (niraparib 200 mg PO once daily in 28-day cycles for a total of 3 cycles), but it does not include the optional surgery or additional niraparab cycles after neoadjuvant chemotherapy. This slight discrepancy in detail is not enough to contradict the information in the CTR and can be considered an acceptable level of abstraction for the expert's statement. Additionally, the expert's statement does not contradict or misrepresent any information within the CTR.</s>",
        "contradict": "The statement \"the primary trial Participants received niraparib 200 milligrams (mg) PO once daily for a 28 day cycle, for 3 cycles, after which all participants undergo neoadjuvant chemotherapy\" is contradictory to the information in the primary CTR as it incorrectly specifies that all participants received the same number of treatment cycles (3 cycles) with niraparib before undergoing neoadjuvant chemotherapy. However, the CTR states that participants either undergo surgery, receive additional cycles of niraparib, or receive neoadjuvant chemotherapy at the end of cycle 2, not after 3 cycles as stated in the expert's claim. Additionally, there is no mention of all participants undergoing neoadjuvant chemotherapy in the CTR.</s>"
    },
    "1cd7cf90-bf66-480b-9227-2f7d2eccd647": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments\" is entailed by the information in the CTRs because in the primary trial, the interventions mentioned are \"Topical Saline\" and \"Topical liquid lidocaine,\" which are topical interventions. In contrast, in the secondary trial, the interventions specified are \"eribulin mesilate, injection, intravenously\" and \"capecitabine, tablets, orally,\" which are intravenous and oral interventions, respectively. Therefore, the statement correctly summarizes the mode of administration for each trial's interventions.</s>",
        "contradict": "The statement \"the primary trial uses a topical intervention and the secondary trial exclusively uses intravenous treatments\" is contradicted by the information present in the CTRs as both trials involve the use of topical lidocaine in INTERVENTION 1 for both trials.</s>"
    },
    "15f9d033-ebf7-44b3-94e2-3b8ee90b862b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00370552",
        "Statement": "There over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the Information in the CTRs as follows:\n\nThe difference in percentage of participants with best tumor response (PR or CR) between the two cohorts can be calculated by subtracting the percentage in the Arm/Group with lower response rate from the percentage in the Arm/Group with higher response rate.\n\nFor Results 1: 47.8% (32.9-63.1)\nFor Results 2: 71.1% (55.7-83.6)\n\nThe difference is therefore: 23.3% (17.4-29.3)\n\nThis difference is over 20% and is consistent with the statement.</s>",
        "contradict": "The statement \"There is over 20% difference in the Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) between the 2 cohorts of the primary trial\" cannot be directly contradicted by the information present in the CTRs, as the statement does not specify which CTR or results (Results 1 or Results 2) it is comparing or the exact percentage differences it is referencing. However, it's important to note that making such a comparison based on the given data alone might not be statistically valid due to differences in patient numbers and treatment regimens between the 2 cohorts. To make a valid comparison, further statistical analysis is required, such as calculating the confidence intervals and conducting a test of statistical significance.</s>"
    },
    "ab6a9d30-eb92-4503-a69c-bdf3f3e6c38d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had Acute coronary syndrome.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in cohort 1 of the primary trial had Acute coronary syndrome\" does not directly entail any information from the provided Adverse Events sections in the CTRs, as Acute coronary syndrome is not listed as an adverse event in either section. However, the absence of Acute coronary syndrome as an adverse event in the Primary Trial's Adverse Events 1 (for 98 patients) and the secondary trial's information implies that none of the patients experienced this condition. Since the trial's eligibility criteria, intervention details, results, and adverse events do not mention Acute coronary syndrome, it is a reasonable assumption that the condition was not present in the trials. Consequently, the expert's statement is entailed by the information presented in the CTRs, as no contradiction or false assumption arises from the statement.</s>",
        "contradict": "The statement \"None of the patients in cohort 1 of the primary trial had Acute coronary syndrome\" cannot be definitively contradicted by the information in the CTRs as the information about acute coronary syndrome is not explicitly stated. However, it can be tested for inconsistency based on the presence or absence of related adverse events. In the primary trial's Adverse Events 1, there are no reported cases of Acute Coronary Syndrome. In the secondary trial's Adverse Events, Acute Coronary Syndrome is not mentioned either. Given the lack of any mention of this condition in either trial, it cannot be concluded that the statement is contradicted by the information in the CTRs. However, it is essential to note that the absence of data on a particular condition does not necessarily mean that the condition did not occur within the trial cohort.</s>"
    },
    "51cf1333-78b1-410a-82fe-aabfaa00a840": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63, a severe iodinated contrast allergy and with BI-RADS category c breast tissue would be eligilbe for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the provided CTR information. The patient described in the statement does not meet all inclusion criteria (signed informed consent, at least 19 years old, Glomerular filtration rate > 60, and heterogeneously or extremely dense breasts) and has an additional exclusion criterion (history of severe iodinated contrast allergy). Therefore, according to the CTR, the patient would not be eligible for participation in the primary trial.</s>",
        "contradict": "The patient with a Glomerular filtration rate of 63 would meet the minimum inclusion criterion (GFR > 60). However, the presence of a severe iodinated contrast allergy is an exclusion criterion in the primary trial. Therefore, a patient with both a GFR of 63 and a severe iodinated contrast allergy would not be eligible for the primary trial, as stated in the CTR. Thus, the expert's statement is contradictory to the information provided in the CTR.</s>"
    },
    "d2e957c3-1e20-4ccd-9cf7-4cc2da63f74d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00662025",
        "Statement": "on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions.",
        "Label": "Entailment",
        "entail": "The statement \"on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions\" cannot be directly entailed by the information presented in the CTRs. \n\nIn the primary CTR, the information provided regarding the outcome measurement indicates that confirmed responses, which are those that persist on repeat evaluation 4 weeks after initial documentation of response, are reported for CR and PR according to RECIST criteria. However, the CTR does not provide any information about all participants in the trial having a confirmed disappearance of all target and non-target lesions on assessment 0. Therefore, the expert statement goes beyond the information presented in the CTR and cannot be directly entailed by it.</s>",
        "contradict": "The statement made by the expert that \"on assessment 0 the primary trial Participants had a confirmed disappearance of all target and non-target lesions\" is contradicted by the information in the CTRs because:\n\n1. The term \"assessment 0\" is not defined or used in the CTRs. The outcome measurement in the primary trial is based on RECIST criteria with specific time points.\n2. The statement implies that all participants in the primary trial had a confirmed disappearance of all target and non-target lesions at assessment 0, whereas the actual data in the CTR shows that 19 participants had CR+PR, but no participant achieved a CR. This contradicts the statement as no participant in the primary trial had a confirmed disappearance of all lesions at any timepoint according to the provided data.</s>"
    },
    "aef2367d-78a5-4dc7-a6f7-d96415082362": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is one case of Cardiopulmonary failure in cohort 2 of the secondary trial, but none in cohort 1 of the primary trial\" is entailed by the information in the CTRs because the CTRs explicitly report the number of adverse events for each type and trial. Therefore, the absence of Cardiopulmonary failure cases in the primary trial's cohort 1, and the presence of one case in the secondary trial's cohort 2, can be directly inferred from the data provided.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it does overlook crucial details. The statement only mentions cohort-level information regarding occurrences of cardiopulmonary failure, while the CTRs report individual-level adverse events. The primary trial has one participant with cardiopulmonary failure out of 33 (3.03%), but this information is not mentioned in the statement. Therefore, the statement is not a semantically entailed claim based on the provided CTR data.</s>"
    },
    "29ae75a2-d8d2-4427-bba3-ab2c411d5718": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201851",
        "Statement": "There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial\" is entailed by the CTRs as:\n\n1. Oesophageal spasming is not mentioned in either Adverse Events 1 or 2. Therefore, there were no instances of Oesophageal spasming observed in the trials.\n2. Diastolic dysfunction is not mentioned in either Adverse Events 1 or 2. Therefore, there were no cases of Diastolic dysfunction reported in the trials.\n3. The Adverse Events sections do not mention any cases of thrombosis in the primary trial, which matches the expert's claim of no thrombosis cases observed.\n\nTherefore, the expert's statement is entailed by the given CTRs.</s>",
        "contradict": "The statement \"There were no cases of Oesophageal spasming, Diastolic dysfunction or thrombosis observed in the primary trial\" cannot be directly contradicted by the information present in the CTRs as these conditions were not reported as adverse events. The statement only mentions conditions not observed in the trials, while the CTRs only report specific adverse events observed in the trials. However, the statement could be contradicted if it was assumed that the trials tested for or reported these conditions and no cases were found, whereas the CTRs do not mention testing or reporting for these conditions at all.</s>"
    },
    "985c4cb3-2684-4a67-a479-998602044a0d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00475670",
        "Statement": "compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2. ",
        "Label": "Contradiction",
        "entail": "The provided statement asserts that there are more cases of each observed adverse event in cohort 2 of the secondary trial compared to cohort 1 of the primary trial, except for sudden death. The CTRs indicate the number of instances for each adverse event in both cohorts for both trials. By comparing the total number of instances for each adverse event between the two cohorts in each trial and subtracting the number of instances in cohort 1 of the primary trial from the number of instances in cohort 2 of the secondary trial (except for sudden death), the statement can be entailed by the data in the CTRs. For example:\n\n(Total instances in cohort 2 of adverse event X) - (Total instances in cohort 1 of adverse event X) > 0 for all observed adverse events except sudden death.</s>",
        "contradict": "The expert's statement is not directly contradictory to the information in the CTRs, but it could be misleading without further context. The CTRs indicate that there are zero cases of all adverse events in cohort 1 of the primary trial and more cases of each adverse event in cohort 2 of the secondary trial, except for sudden death, which has one case in both cohorts. However, the CTRs do not provide the total number of participants in each cohort. The expert's statement assumes that both cohorts have the same number of participants, but this might not be the case. If cohort 2 has a larger number of participants than cohort 1, the observation of more cases of each adverse event in cohort 2 is expected. Therefore, the expert's statement needs to be evaluated in conjunction with the information on the participant counts to establish entailment or contradiction.</s>"
    },
    "39e8a353-4eb0-4cf6-b0c2-f36c4bf589f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00107276",
        "Secondary_id": "NCT00232505",
        "Statement": "Less than 5% of patients undergoing the intervention in the primary trial had adverse events, in comparison almost 10% patients in cohort 1 of the secondary trial  experienced an adverse event, and less than a 1/3 of those in cohort 2 of the secondary trial had adverse events.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that the percentage of patients with adverse events in the secondary trial's cohort 1 (approximately 10%) is higher than that of the primary trial (approximately 4.21%). Additionally, the percentage of patients with adverse events in the secondary trial's cohort 2 (less than 1/3, which is approximately 33.33% < 4.21%) is lower than that in the primary trial. This information aligns with the total adverse event percentages provided in the CTRs: 4.21% for primary trial and various percentages for secondary trial's cohorts, none of which exceed 33.33%. No contradictory information exists, ensuring entailment.</s>",
        "contradict": "The statement's assertion that \"less than 1/3 of those in cohort 2 of the secondary trial had adverse events\" contradicts the information in the CTR for the secondary trial, where the total adverse events percentage for cohort 2 is 0%. This discrepancy results in an incorrect comparison of adverse event percentages between the primary and secondary trials.</s>"
    },
    "d695120e-db68-481d-9023-881e48654e29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases are still permited to enter in the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's eligibility criteria state that extracranial metastases are allowed in the patient selection. Therefore, the expert's statement that \"Patients with Extracranial metastases are still permited to enter in the primary trial\" is an entailed statement.</s>",
        "contradict": "The statement \"Patients with Extracranial metastases are still permitted to enter the primary trial\" can be contradicted by the information present in the CTRs if we focus on the Disease Characteristics section. The primary CTR explicitly states \"Extracranial metastases allowed,\" but it also requires \"Disease progression in the CNS must meet one of the following criteria.\" This condition may exclude patients with only extracranial progression. If we assume that the expert's statement is more general than the CTR, it could potentially lead to contradictions when applying it to individual patients not meeting the specific CTR inclusion criteria.</s>"
    },
    "5319ac1a-07ae-4531-bf93-5fce83016c87": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00941330",
        "Statement": "Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan\" can be entailed by the information present in the CTRs as follows:\n\n1. The primary trial has two cohorts/arms: Arm A receiving Exemestane and Arm B receiving Docetaxel and Cytoxan.\n2. The Exemestane dosage in Arm A is 25 mg daily for 6 to 12 months, which translates to approximately 182-364 doses for each patient.\n3. The Cytoxan dosage in Arm B is 600 mg/m\u00b2 once every 3 weeks for 6 cycles, which translates to a total of 6 doses for each patient.\n4. The statement asserts that patients in cohort 1 receive Exemestane more often than patients in cohort 2 receive Cytoxan.\n5. Comparing the dosing information, we see that Arm A patients receive Exemestane more frequently than Arm B patients receive Cytoxan.\n6. Since the information in the CTRs does not contradict the statement and provides evidence for its validity, the statement can be entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Patients in cohort 1 of the primary trial receive Exemestane more often than cohort 2 patients receive Cytoxan\" is incorrect based on the information given in the CTRs. Both cohorts (A and B) receive their respective interventions, Exemestane (Arm A) and Docetaxel & Cytoxan (Arm B), for the same duration: 6 to 12 months for Exemestane and approximately 24 weeks for Docetaxel and Cytoxan (6 cycles). The number of treatment administrations for each intervention is different: Exemestane is taken daily, whereas Docetaxel and Cytoxan are given once every 3 weeks for 6 cycles. However, the statement implies that patients in Cohort 1 receive more total treatments or doses of Exemestane than patients in Cohort 2 receive of Cytoxan, which contradicts the information presented in the CTRs.</s>"
    },
    "087aba29-40c6-4453-a44b-e63c3867e5b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Age: The patient is 75, and the CTR states the minimum age for eligibility is 18 years. Therefore, the patient is old enough to participate.\n\n2. ECOG Performance Status: The patient has an ECOG score of 3, which corresponds to \"moderate restriction\" in performing normal activity as defined by the Eastern Cooperative Oncology Group (ECOG) scale. The CTR specifies that eligible patients must have a Performance Status of 0 to 2. While a Performance Status of 0 corresponds to \"fully active, able to carry on all pre-disease activities without restriction,\" and a Performance Status of 1 corresponds to \"restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature,\" a Performance Status of 2 indicates \"ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours,\" which is a broader category than \"moderate restriction.\" Thus, the patient's ECOG Performance Status of 3 would fall within the allowed range of 0 to 2.\n\n3. Life Expectancy: The patient has an estimated life expectancy of more than a year. The CTR specifies that patients must have a life expectancy of at least 3 months. The patient's life expectancy exceeds this threshold.\n\nTherefore, the patient (a 75-year-old female with an ECOG of 3 and a life expectancy of more than a year) satisfies the age, performance status, and life expectancy requirements stated in the inclusion criteria of the primary trial.\n\nThe remaining criteria (eligibility based on tumor history, prior therapy, histology, and laboratory values, and exclusion criteria) are not directly mentioned or implicated in the expert statement, and thus, there is no entailment for those criteria based on the given information.</s>",
        "contradict": "The statement that \"A 75 year old female patient, with an ECOG of 3 and an estimated life expectancy of more than a year would be eligible for the primary trial\" contradicts the eligibility criteria in the CTR as stated: (1) ECOG Performance Status of 0 to 2, and (2) life expectancy of >= 3 months. Since the given patient's ECOG is 3, which is outside the permitted range for this trial, and her life expectancy is greater than 1 year, which does not meet the minimum life expectancy requirement, she would not be eligible for the primary trial according to the provided information in the CTRs.</s>"
    },
    "c66f3e9e-f232-4035-b705-2785946d1542": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information presented in the CTRs due to the inclusion criteria for both trials specifying the exclusion of patients with severe mental illness, including dementia.</s>",
        "contradict": "The statement \"A 72 year old patient suffering from dementia would be excluded from both the secondary trial and the primary trial\" is contradicted by the CTRs, as neither trial explicitly lists dementia as an exclusion criteria for patient participation. The primary trial does exclude patients with overt cognitive dysfunction or psychiatric disturbance or severe mental illness, but these conditions are not synonymous with dementia. The secondary trial also does not mention dementia as an exclusion. Therefore, the statement's claim is not harmonious with clinical trial data and is contradictory to the CTRs.</s>"
    },
    "c679f426-b235-4ae9-ad6c-4f1a46a494d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01390064",
        "Secondary_id": "NCT00485953",
        "Statement": "All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration.",
        "Label": "Contradiction",
        "entail": "The statement \"All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration\" is entailed by the CTR information as follows:\n\n1. In the primary trial, both the Initial Cohort and the Escalation Cohort receive Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous administration, according to the given interventions.\n2. In the secondary trial, both the Active Medicine Group and the Placebo Group receive their treatments (risedronate or placebo, respectively) via weekly subcutaneous injections, although this information is not explicitly stated in the provided CTR excerpt. However, it is a common method of administering some medications subcutaneously. Since all treatments in the trial are given subcutaneously, the expert's assertion that \"All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration\" is an entailed consequence of the provided CTR information.</s>",
        "contradict": "The statement \"All Cohorts of the primary trial and the secondary trial receive their treatment via Subcutaneous administration\" can be contradicted by the information present in the CTRs because while both the primary and secondary trials involve subcutaneous administration in the primary trial for the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine, the secondary trial involves treatments (risedronate and placebo) that are not given via subcutaneous administration.</s>"
    },
    "122b1aef-4506-464d-9852-47caa508b047": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00879086",
        "Statement": "Cohort 1 and 2 of the primary trial had the same number of patients with anaemia and Neutropenia, but Cohort 1 had 8 more cases of Leukopenia than cohort 2.",
        "Label": "Contradiction",
        "entail": "Both Cohort 1 and Cohort 2 of the primary trial had an equal number of patients with anaemia (1/51 in Cohort 1 and 1/50 in Cohort 2). Similarly, they had the same number of patients with Neutropenia (1/51 in Cohort 1 and 1/50 in Cohort 2). However, there was a difference in the occurrence of Leukopenia between the cohorts: Cohort 1 had 1 more case than Cohort 2 (1/51 vs. 0/50). Thus, the statement is an entailed consequence of the information provided in the Adverse Events sections of the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the CTRs do not report the same number of patients for Cohort 1 and Cohort 2. In the Primary Trial, Cohort 1 had 51 patients and Cohort 2 did not have the patient count explicitly stated. In contrast, in the Secondary Trial, Cohort 1 is not identified, and the patient count of 50 is provided for Cohort 2. As a result, it's impossible to determine if the cohorts in the statement refer to the primary or secondary trial or if they contain the same number of patients. Additionally, the information regarding the number of cases of Leukopenia for each cohort in the statement contradicts the CTR data, as Cohort 1 had 8 more cases than Cohort 2, which is incompatible with the information provided in the CTRs. (1 case in Cohort 1 vs 0 cases in Cohort 2 for Leukopenia in Primary Trial and no Leukopenia cases reported in Secondary Trial)</s>"
    },
    "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00841828",
        "Secondary_id": "NCT01959490",
        "Statement": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial reports the percentage of participants with pCR in Arm 1 (EC -> D + Lapatinib) as 23.5% (11.9-35.1%) and in Arm 2 (EC -> D + Trastuzumab) as 47.9% (33.8-62.0%). The secondary trial reports the number of participants with pCR in Cohort 1P (HER2 Positive) as 4 out of 5 (80.0%) and in Cohort 1T (HER2 Positive) as 6 out of 6 (100.0%). Since the percentage values are higher in the secondary trial cohorts compared to the primary trial arms, it follows that the number of participants with pCR is lower in the primary trial arms than in Cohort 1 of the secondary trial. This observation is in line with the data presented in the CTRs, making the expert's statement entailed.</s>",
        "contradict": "The statement \"All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial\" is contradictory to the information in the CTRs. The primary trial reports the percentage of participants with pCR for Arm 1 and Arm 2, which are 23.5% (11.9 to 35.1) and 47.9% (33.8 to 62.0), respectively. Neither of these percentages is lower than the 80.0% and 100.0% reported for Cohorts 1P and 1T in the secondary trial. Therefore, the statement is not an entailed consequence of the information in the CTRs.</s>"
    },
    "9f7dc38b-1945-4035-a0ff-e08ead55145b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients who completed a trastuzumab regiment, to treat the current breast cancer  > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n1. The primary trial includes patients who have received a trastuzumab regimen > 2 weeks before study entry (CTR: \"Patients may have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab\"). These patients meet the inclusion criteria for the primary trial but are explicitly excluded from the secondary trial (CTR: \"Patients with a history of other cancers except curatively-treated carcinoma of the cervix in situ or non-melanomatous skin cancer, unless it is HER2-positive breast cancer, are ineligible.\" Since the secondary trial focuses on HER2-negative tumors, those who had trastuzumab treatment for HER2-positive disease are excluded).\n\nTherefore, the statement \"Patients who completed a trastuzumab regiment, to treat the current breast cancer > 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial\" can be derived from the CTRs.</s>",
        "contradict": "The primary trial allows patients who have received one prior trastuzumab/chemotherapy containing regimen or prior single agent trastuzumab, while the secondary trial excludes patients who have received any prior cytotoxic chemotherapy or radiation for the current breast cancer. The statement is contradictory as it implies that a patient who completed a trastuzumab regimen is eligible for the primary trial, while the CTR specifies that they are excluded from the secondary trial.</s>"
    },
    "b259774e-410a-49aa-b5d4-31b8d9505fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01525589",
        "Statement": "People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR's inclusion criteria for the primary trial specify that patients with known deleterious germline mutation of BRCA1/2 are eligible for inclusion in Cohorts A and A1. This statement made by the clinical trial expert is entailed, as it indicates that individuals with undamaged variants of BRCA1/2 are not eligible for the trial (the negation of the stated condition), but the CTR explicitly states that those with deleterious mutations are included. Therefore, the statement is consistent with the CTR information and can be entailed.</s>",
        "contradict": "The statement \"People who inherit undamaged variants of the BReast CAncer gene 1 or 2 are eligible for the primary trial\" contradicts the information present in the CTRs because the primary trial specifically includes patients with a known deleterious germline mutation of BRCA1/2 in Cohorts A and A1, but it does not state that those with undamaged variants are eligible.</s>"
    },
    "e09a11e4-afc8-4351-a5bc-d847424c79ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565499",
        "Secondary_id": "NCT01234402",
        "Statement": "Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues.",
        "Label": "Contradiction",
        "entail": "The statement \"Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues\" is entailed by the information in the CTRs as follows: \n\n1. In the primary trial, two patients (2/81 or 2.47%) experienced neurotoxicity, a condition that could manifest as cardiac symptoms. This meets the requirement of \"heart related adverse events\" mentioned in the statement.\n\n2. In the secondary trial, one patient (1/52 or 1.92%) had cardiac failure, another (1/52 or 1.92%) had cardiogenic shock, and there were no occurrences of acute myocardial infarction, atrial fibrillation, or palpitations. However, the statement does not contradict the possibility that other heart-related adverse events could have occurred in this trial without being explicitly listed.\n\n3. In the secondary trial, there were four cases of pericardial effusion (8.16%). This condition could cause respiratory difficulties and meets the condition of \"breathing related issues\" mentioned in the statement.\n\n4. Additionally, in the secondary trial, there were three cases of ascites (5.77%). This condition could also lead to breathing issues and further supports the statement.\n\nTherefore, the statement is entailed by the CTRs as it accurately summarizes some of the adverse events observed in each trial, without contradicting the data provided.</s>",
        "contradict": "The statement \"Some of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different breathing related issues\" is not directly contradicted by the provided CTRs as neither report indicates that all adverse events in a trial were heart- or breathing-related, respectively. However, the statement can be misleading as it suggests a significant difference in the types of adverse events between trials based on the limited information provided, while the CTRs show that there were heart-related adverse events in the primary trial and breathing-related adverse events in the secondary trial, but both trials also had adverse events unrelated to those systems. Therefore, a more nuanced analysis of the CTRs would be required to fully evaluate the statement.</s>"
    },
    "d22f01f0-b2be-45b9-8996-11727750b91e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial.",
        "Label": "Contradiction",
        "entail": "In the primary trial, patients receive vorinostat and AI therapy (anastrozole, letrozole, or exemestane) concurrently. Each AI therapy drug has a different dosing schedule: anastrozole is given daily, letrozole is given daily, and exemestane is given daily. Since patients receive each AI therapy for 4 weeks, they will receive more total doses of anastrozole, letrozole, and exemestane than patients in the secondary trial who receive only fulvestrant and tipifarnib. Fulvestrant is given intramuscularly on day 1 and tipifarnib is given orally twice daily on days 1-21, resulting in a different treatment regimen that does not involve continuous administration of the AI therapy for 4 weeks. Therefore, the statement that \"Primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial\" is entailed by the provided CTR information.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs as the primary trial involves patients receiving either anastrozole, letrozole, or exemestane as part of AI therapy, while the secondary trial involves patients receiving fulvestrant and tipifarnib. Therefore, the number of patients receiving anastrozole, Fulvestrant, letrozole, or exemestane is not directly comparable between the two trials.</s>"
    },
    "893d5684-03f8-4acd-86e4-6d38eea3ce16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129935",
        "Statement": "There were 80% more cases of embolisms in cohort 2 of the primary trial than cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs if we assume that \"cohort 1\" refers to the group of patients in the primary trial with fewer occurrences of thrombosis/embolism events, and \"cohort 2\" refers to the group with more occurrences. Based on the CTR data, cohort 1 had 0.15% (1/669) instances of thrombosis/embolism, and cohort 2 had 0.42% (3/715) or 0.28% (2/715) instances when considering the two separate mentions of this adverse event. An increase of 80% corresponds to a multiplicative factor of 1.8, and indeed, 0.42% is 1.8 times larger than 0.15%. Therefore, the statement that there were 80% more cases of embolisms in cohort 2 than in cohort 1 can be entailed by the information presented in the primary and secondary trial CTRs.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the data in the CTRs, as the provided information does not allow for a comparison of the exact number of embolism cases between cohorts 1 and 2. The CTRs only provide the number of total adverse events with embolisms for each trial and its respective cohorts. To establish contradiction, more detailed information about the number of participants in each cohort and the number of embolism cases would be needed.</s>"
    },
    "4b46164d-a4c2-4738-be36-588ab231ceb1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts.",
        "Label": "Entailment",
        "entail": "The expert's statement, \"There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts,\" is entailed by the provided CTRs since:\n\n1. The CTR for the primary trial states that there were no instances of Dysphagia (0/5) and Fever (0/5) among the patients.\n2. The CTR for the secondary trial states that there was only one instance of Dysphagia (1/110) and no instances of Fever (0/110).\n\nSince the expert's statement matches the data presented in the CTRs and does not contradict any given information, it is an entailed statement.</s>",
        "contradict": "The statement that \"There were 0 patients with Dysphagia or Fever in the primary trial and the secondary trial cohorts\" is contradicted by the information present in the CTRs because, in the primary trial, there were 0/5 (0.00%) instances of Dysphagia and 0/5 (0.00%) instances of Fever, while in the secondary trial, there was 1/110 (0.91%) instance of Dysphagia and 1/110 (0.91%) instance of Fever. Therefore, the statement does not harmonize with the clinical trial data and is incorrect.</s>"
    },
    "d9236874-7f3d-4402-9699-2889db9f5c61": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320541",
        "Statement": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1\" can be entailed by the information present in the CTRs as follows:\n\n1. From Adverse Events 1 in the primary trial, the number of Leukopenia cases in cohort 1 is 3, and from Adverse Events 2, the number of Leukopenia cases in cohort 2 is 4.\n2. A 10% difference between the two cohorts can be calculated as (4 - 3) x 100 / 3 = 33.33%. However, since the difference cannot be exactly 10% due to the discrete nature of the data, the closest approximate entailing the statement is that cohort 2 has 10% more cases than cohort 1 (i.e., a 10.33% difference if rounded to two decimal places).\n3. The statement does not contradict the CTRs and is harmonious with the clinical trial data.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1\" contradicts the information present in the CTRs because:\n\n1. The number of cases for Cohort 1 in the primary trial is 94, and the number of cases for Leukopenia is 3.\n2. The number of cases for Cohort 2 in the primary trial is 93, and the number of cases for Leukopenia is 4.\n3. A difference of 1 case between the two cohorts does not equate to a 10% increase.\n4. The CTRs do not provide information on the size of each cohort, so it is not possible to determine if a 10% difference in the number of cases is clinically significant or not.\n5. The statement implies that the data in the CTRs are incompatible, but it does not provide any evidence to support this claim.\n\nTherefore, the statement cannot be entailed by the information in the CTRs as it contradicts the provided data and makes an unwarranted assumption about the clinical significance of the difference in case numbers.</s>"
    },
    "e33825f1-45df-41f5-ba07-e9059636a146": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00057941",
        "Secondary_id": "NCT01806259",
        "Statement": "DLT occurence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics. ",
        "Label": "Contradiction",
        "entail": "The statement \"DLT occurrence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics\" can be entailed by the information present in the CTRs.  This is because:\n\n1. The statement acknowledges that DLT (Dose-Limiting Toxicity) and Clinical Benefit Rate are different outcome measurements.\n2. The primary trial reports the use of Clinical Benefit Rate (complete response, partial response, or stable disease) as the outcome measure.\n3. The secondary trial reports the occurrence of DLT as the outcome measure.\n4. The statement also explains that these outcomes represent different patient characteristics.\n\nTherefore, the clinical trial reports explicitly state that different outcome measures were used in each trial and that these measures signify distinct patient characteristics, which is in agreement with the statement.</s>",
        "contradict": "The statement \"DLT occurrence, used as the outcome measurement in the secondary trial and Clinical Benefit Rate, used in the primary trial are not synonymous, and represent entirely different patient characteristics\" cannot be contradicted by the information present in the CTRs as they do not provide enough evidence to directly compare the DLT occurrence and Clinical Benefit Rate or their corresponding patient populations in the primary and secondary trials. Both outcomes serve distinct purposes - DLTs refer to dose-limiting toxicities, typically measured during dose-escalation studies, while Clinical Benefit Rate represents the proportion of patients experiencing a clinical response, as per predefined criteria. The CTRs merely provide data on the patient count, treatment, and outcome measures for each arm/group in their respective trials. To assess contradiction, more information about the nature and relationship between these outcomes would be required, including the trials' objectives, design, and patient populations.</s>"
    },
    "5b0295e1-a322-40af-9acf-9cc1d55d3e64": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00295620",
        "Secondary_id": "NCT03366428",
        "Statement": "the secondary trial and the primary trial use similar outcome measures, evaluating how long patients survive after treatment.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information contained in the CTRs as neither trial's primary outcome measurement explicitly focuses on survival after treatment in the same manner as the statement. The primary trial evaluates Disease-free Survival (DFS) after prolonged Anastrozole treatment, while the secondary trial reports on changes in QTcF in patients receiving DS-8201a treatment. Although the concept of survival is present in the primary trial through DFS, the statement's broad assertion does not directly follow the information presented in the provided CTRs.</s>",
        "contradict": "The statement that the secondary and primary trials use similar outcome measures, evaluating how long patients survive after treatment, is contradicted by the information presented in the CTRs. The primary trial measures disease-free survival (DFS), defined as the time from two years after randomization to the earliest occurrence of certain events, while the secondary trial reports changes in QTcF (a measure of heart function) in participants receiving DS-8201a treatment. These two outcome measures are not equivalent and do not assess the same aspect of survival after treatment.</s>"
    },
    "3658f2f7-a497-4abb-badb-c877036456f2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00077857",
        "Statement": "Patients must be older than 18, female, have three or more target lesions and more than 1 regiment of chemotherapy to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert statement entails the primary trial's inclusion criteria by requiring older females with multiple target lesions and at least one regimen of chemotherapy. The statement does not explicitly mention the condition of having demonstrated resistance to anthracyclines or the presence of locally advanced or metastatic breast cancer. However, these conditions are not contradictory to the expert statement and are implied within the context of the primary trial's eligibility criteria provided in the CTR.\n\nThe expert statement does not precisely match the exclusion criteria mentioned in the CTR. The statement does not mention any restrictions regarding previous treatments with specific chemotherapies or Xeloda, continuous 5-fluorouracil infusions, or docetaxel or paclitaxel for advanced/metastatic disease. However, the expert statement does not contradict the CTR's exclusion criteria, as it does not include statements that would be incompatible with the provided information.</s>",
        "contradict": "The information in the expert statement cannot be directly contradicted by the primary CTR inclusion criteria. However, it is in contrast with some aspects of the CTR. \n\nThe primary CTR specifies that patients must have \">=1 target lesion,\" not three or more. Additionally, the CTR states that patients have \"demonstrated resistance to anthracycline\" and have \">=2 regimens of chemotherapy for advanced/metastatic disease,\" which is not mentioned in the expert statement.\n\nThus, while the age and gender criteria align, the other requirements in the expert statement go beyond the scope of the primary CTR.</s>"
    },
    "37bc71d5-d9c0-4174-8da5-725d2d53a91b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "The Cohort of the primary trial which received D+C and Taxane Na\u201a\u00e0\u00f6\u221a\u00f2ve, produced marginally better results than the other cohort.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs if we assume \"marginally better results\" is equivalent to a difference in Objective Response Rate (ORR) between the two cohorts, which is not defined as a significant difference but rather a small one. The ORR for the D+C and Taxane Naive cohort is 30.8% (17.0-47.6) compared to 31.0% (17.6-47.1) for the D+C and Taxane Pretreated cohort. A difference in percentages, though small, implies that one cohort produced better results than the other, which matches the statement's claim.</s>",
        "contradict": "The statement does not provide sufficient information to determine if it can be contradicted by the CTR data. While it mentions that the D+C and Taxane Naive cohort produced \"marginally better\" results, it does not specify in what regard the betterment occurred. This could refer to any number of outcomes, including Objective Response Rate (ORR), Progression-Free Survival (PFS), Overall Survival (OS), or other endpoints.\n\nThe CTRs, however, only report ORR data for both cohorts, with percentages of 30.8 (17.0 to 47.6) for the D+C and Taxane Naive group and 31.0 (17.6 to 47.1) for the D+C and Taxane Pretreated group. Based on this information, it is not possible to determine if one cohort had a significantly better ORR than the other, as the confidence intervals for both percentages overlap.\n\nTherefore, neither the statement nor the CTR data contradict each other, as there is insufficient evidence to make such a determination based on the information provided.</s>"
    },
    "51ac9fe0-2bfa-42f5-aaec-69e0c5cdff7c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02781051",
        "Secondary_id": "NCT01067976",
        "Statement": "The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a fitbit, no physical activity is explicitly required for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a Fitbit, no physical activity is explicitly required for the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, it is stated that the physical activity intervention lasts for 12 weeks and that participants are given a Fitbit to wear daily. This implies that participants are required to engage in physical activity for 12 weeks while wearing the Fitbit. However, the secondary trial CTR does not explicitly require participants to engage in physical activity, but rather mentions a comparison between two interventions (CMRM and UMRM) without specification. \n\nGiven this information, the statement \"no physical activity is explicitly required for the secondary trial\" can be inferred as holding true based on the lack of explicit requirement for physical activity in the secondary trial's intervention description. This does not contradict the information present in the primary trial CTR, as the requirement for physical activity in the primary trial is explicitly stated, whereas the secondary trial only states a comparison between two interventions without specifying their components in the same level of detail. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The intervention for the primary trial requires participants to exercise for 12 weeks while wearing a Fitbit, no physical activity is explicitly required for the secondary trial\" can be contradicted by the information present in the CTRs because the secondary trial's INTERVENTION 1 section is not provided, and it cannot be assumed that there is no requirement for physical activity based on its absence in the given information. In the primary trial, there are multiple components of the intervention including print-based education, Fitbit usage, and Active Living counseling, all of which involve some form of physical activity. However, it cannot be determined from the given information whether the secondary trial's intervention involves any physical activity component or not.</s>"
    },
    "8bcc9fa3-0317-471a-a5b5-b115b5b72dea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01302379",
        "Statement": "Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%.",
        "Label": "Entailment",
        "entail": "The information in the statement can be entailed by the data in the CTRs as follows:\n\n1. Both patient cohorts (Metformin + Lifestyle Intervention and Placebo + Lifestyle Intervention) had a median Insulin change from baseline lower than -15%.\n   \n2. For Metformin + Lifestyle Intervention cohort, the least squares mean percent change from baseline was -21.8% (-29.7 to -13.0). Since the median is a measure of central tendency that is less affected by extreme values than the mean, it can be assumed that this value is lower than the median for this group.\n\n3. For Placebo + Lifestyle Intervention cohort, the least squares mean percent change from baseline was -17.7% (-25.9 to -8.6). Similar to the Metformin cohort, this value indicates that the median for this group is also likely to be lower than -15%.\n\n4. Therefore, the statement is entailed by the information in the CTRs, as it correctly describes the observed Insulin changes for both patient cohorts in the clinical trial.</s>",
        "contradict": "The statement \"Both patient cohorts of the primary trial had a median Insulin change from baseline lower than -15%\" is contradicted by the data in the CTRs because the provided Least Squares Means and their confidence intervals for each arm do not fall below -15%. The values given for the Metformin + Lifestyle Intervention arm's change from baseline are -21.8% (-29.7 to -13.0), which is above -15%, and for the Placebo + Lifestyle Intervention arm's change from baseline are -17.7% (-25.9 to -8.6), also above -15%. Therefore, the median value for each cohort is likely to be higher than -15% as well, contradicting the expert's statement.</s>"
    },
    "52610141-321d-4e3d-8660-ebc14b9f1696": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00082433",
        "Statement": "the primary trial results suggest that 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle + Capecitabine, triples patient OS, compared to Capecitabine alone.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information presented in the CTRs as it makes a stronger claim about the treatment effect (tripling of OS) than what's shown in the trial results (difference in median OS). The CTRs only provide the median OS with 95% CI for each treatment arm, which is insufficient to infer a tripling effect.</s>",
        "contradict": "The statement made by the clinical trial expert is contradicted by the information provided in the CTRs because the statement asserts that the Ixabepilone + Capecitabine arm triples the patient OS compared to Capecitabine alone based on the primary trial results. However, the CTRs do not report any such finding. The CTRs only present the median OS with 95% CI for each treatment arm, but they do not directly compare the OS between the two arms or suggest that the difference is threefold.</s>"
    },
    "90203158-6477-4486-b8d9-09dcaca63617": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00570921",
        "Secondary_id": "NCT00274456",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs since the CTRs report that there was one instance of Cardiopulmonary failure in Adverse Events of the secondary trial (1/76), but none in the primary trial's Adverse Events (0/33).</s>",
        "contradict": "Despite the statement mentioning a case of Cardiopulmonary failure in cohort 1 of the secondary trial, neither of the given CTRs report any instances of Cardiopulmonary failure occurring in cohort 1, whether primary or secondary. This contradicts the statement made by the clinical trial expert.</s>"
    },
    "03334f23-49ab-47e5-b420-a6753ce6e832": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00574587",
        "Secondary_id": "NCT00777049",
        "Statement": "There were no cases of Myocardial ischaemia in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no cases of Myocardial ischaemia in the primary trial or the secondary trial\" is entailed by the information present in the CTRs because neither trial reported any cases of Myocardial ischaemia in their respective Adverse Events sections. The CTR for the primary trial states \"Myocardial ischaemia 1/32 (3.13%)\" in Adverse Events 1 but the number in the parentheses indicates the occurrence of one case among 32 participants. Since the statement asserts that there were \"no cases,\" it contradicts the single reported case from the CTR. However, the statement is consistent with the absence of reported cases in the second trial's Adverse Events section. Therefore, since both trials did not have any recorded instances of Myocardial ischaemia, the statement can be considered entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"There were no cases of Myocardial ischaemia in the primary trial or the secondary trial\" is contradicted by the information presented in the CTRs because, in the primary trial, there was 1 reported case of Myocardial ischaemia in Adverse Events 1 section, and in the secondary trial, there were 1 reported case in Adverse Events 1 section and 1 reported case in Adverse Events 2 section, totaling 2 cases.</s>"
    },
    "a847cfc1-9556-4a55-9698-69c22696148f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were 2 cases of Angina in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 2 cases of Angina in the primary trial\" cannot be entailed by the provided CTR data directly. Angina is not mentioned as an adverse event in either of the CTRs. However, non-cardiac chest pain, which could potentially be Angina, was reported in 2 instances across the two trials. The statement could be considered a possible inference or error based on the given CTR data, but it does not entail the CTR information strictly.</s>",
        "contradict": "The expert's statement is in contradiction to the information presented in the CTRs as there is no mention of Angina among the adverse events reported in either the primary or secondary trials.</s>"
    },
    "fcbb7e0f-d106-44bd-a252-9b57adc6f071": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Statement": "No mental health issues were observed in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"No mental health issues were observed in the primary trial\" is entailed by the information in the CTRs as no adverse events related to mental health, such as depression, anxiety, or psychosis, are reported in either CTR under the section \"ADVERSE EVENTS.\" The absence of these events in both trials supports the expert's statement.</s>",
        "contradict": "The information in the statement \"No mental health issues were observed in the primary trial\" cannot be directly contradicted by the provided CTR data since mental health issues are not mentioned among the adverse events reported for the primary trial. However, the absence of information about mental health issues does not necessarily imply that no such issues were observed during the trial. The CTR data does not provide enough evidence to either confirm or contradict the expert's statement.</s>"
    },
    "f82d94fe-c633-4bae-b28d-074196a08577": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03584009",
        "Statement": "Participants in the primary trial administered with Fulvestrant 500mg via intramuscular injection had a higher % of clinical benefit than participants who were administered an additional 160 mg of Neratinib.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\n1. Both trials used the same definition of clinical benefit (CR, PR, or SD lasting \u2265 24 weeks) and RECIST v1.1 criteria to evaluate response.\n2. The statement compares clinical benefit between participants in each arm of the primary trial; one arm receiving Fulvestrant monotherapy and the other receiving Venetoclax + Fulvestrant.\n3. The CTRs provide the percentage of participants with clinical benefit for each trial arm: for Fulvestrant monotherapy, it is 13.7% (5.7-26.26), and for Venetoclax + Fulvestrant, it is 11.8% (4.44-23.87).\n4. The statement claims that participants in the Fulvestrant monotherapy arm had a higher percentage of clinical benefit, which is consistent with the provided data (13.7% > 11.8%).\n5. The CTRs do not provide data on the additional 160 mg of Neratinib referred to in the statement. However, since the statement compares Fulvestrant monotherapy to Fulvestrant + another treatment, it does not contradict the information in the CTRs.\n\nThus, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement cannot be directly contradicted by the CTRs provided as there is no mention of Neratinib in the primary trial, and thus, no valid comparison can be made between the Fulvestrant-only and Fulvestrant + Neratinib arms.</s>"
    },
    "e5379a89-f880-44c1-bee0-a0d8ad2abfce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00659373",
        "Secondary_id": "NCT02202252",
        "Statement": "the primary trial has a 5 year long intervention, the duration of the secondary trial is not specified in the intervention section.",
        "Label": "Entailment",
        "entail": "The primary trial's intervention lasts for 5 years, while the secondary trial's intervention duration is not explicitly stated in the intervention section. However, this difference does not affect the entailment relationship between the two pieces of information. Entailment holds as the primary trial's intervention duration is longer than the one specified for ultrasonography examinations and examination procedures in the secondary trial, which is not contradictory to or in conflict with the information provided in the primary CTR.</s>",
        "contradict": "The primary trial specifies a 5-year intervention duration for both Tamoxifen and the combination of Tamoxifen with ovarian function suppression (OFS), which can imply that the duration of the primary trial is 5 years long. However, the secondary trial describes the intervention as having no specified duration mentioned in its section. While the duration of surgery, drainage, and ultrasonography examinations are mentioned for both single and double drain groups, the overall duration of the secondary trial is not stated. Therefore, the statement that \"the primary trial has a 5-year long intervention, the duration of the secondary trial is not specified in the intervention section\" could be contradicted by the information in the primary trial CTR. However, it is essential to note that the absence of a stated duration for the secondary trial does not necessarily imply that it is shorter or longer than the primary trial, as other factors such as trial design and study duration could influence the overall study length.</s>"
    },
    "d811aaec-b3bd-4376-a9d6-d14eacae875a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00717886",
        "Statement": "Prior axillary surgery, axillary radiation, breast cancer and breast radiation are not permitted for entry to the primary trial, patients with prior High-dose chemotherapy can still enter if they satisfy all other inclusion criteria.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR information as the CTR specifies exclusion of prior axillary surgery, axillary radiation, breast cancer, and breast radiation for entry into the primary trial. The statement allows for entry of patients with prior high-dose chemotherapy, which is not explicitly mentioned as an exclusion criterion in the CTR. Therefore, the statement's assertion is harmonious with the CTR data and does not contradict the provided descriptions.</s>",
        "contradict": "The statement allows for entry to the primary trial for individuals with prior high-dose chemotherapy, but not for those with prior axillary surgery, axillary radiation, breast cancer, or breast radiation. However, the CTR for the primary trial explicitly lists these conditions as exclusion criteria, meaning that they prevent individuals from participating in the trial. Therefore, the information in the statement contradicts the CTR.</s>"
    },
    "99312d82-614c-4422-b6e6-104fe5a7fa54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": "Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement \"Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial specifies that patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible, while those with pN2b (metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis) are not eligible, and those with infraclavicular lymph node involvement are not eligible. Since the CTR does not mention anything about metastasis in infraclavicular lymph nodes beyond 9 nodes, the given statement can be seen as a specific instance of the eligibility criteria mentioned in the CTR. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Only Patients with metastasis in less than 9 infraclavicular lymph nodes are eligible for the primary trial\" is contradicted by the following information in the CTR: \n1. Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible. This includes patients with metastasis in infraclavicular lymph nodes.\n2. Patients with infraclavicular lymph node involvement are NOT eligible in the neoadjuvant setting but eligible in the adjuvant setting. However, the statement refers to the primary trial without specifying the setting.\n\nTherefore, the statement can include patients with metastasis in more than nine infraclavicular lymph nodes, which contradicts the inclusion criteria stated in the CTR.</s>"
    },
    "b02c99f3-70bd-4404-8d80-c57c6dfef7b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02049957",
        "Secondary_id": "NCT01506609",
        "Statement": "There is are the same total number of patients in the primary trial as in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There are the same total number of patients in the primary trial as in the secondary trial\" does not directly entail any specific information from the CTRs. However, it is entailed by the given data in the CTRs that there are 6 patients in the primary trial (from both Adverse Events 1 and 2) and 2 patients in the secondary trial (from both Adverse Events 1 and 2). Therefore, the statement is consistent with the information in the CTRs, as it does not contradict any of the given data, and the total number of patients in both trials adds up to the same number (6+2=8, but the statement only mentions the total number of patients, which is 6). Hence, the statement is semantically entailed by the given CTRs.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the provided CTR data, as the number of patients in each trial is not stated. However, the statement can be contradicted if it is assumed that the number of patients is the same in both trials based on the presented adverse event data alone. The discrepancy between the number of participants in each trial is not mentioned in the CTRs and cannot be inferred from the adverse event data alone. Thus, the statement itself is neither confirmed nor contradicted based on the provided CTR data.</s>"
    },
    "3cbf2726-ddb0-460c-9dd2-082b8dda495d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 in the primary trial experienced adverse events, but more than 45% of patients cohort 2 did experience adverse events.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as the adverse event rates for cohort 1 (5/11 or 45.45%) are less than half of the adverse event rates for cohort 2 (22/11 or 45.45% in primary trial and 0/6 or 0% in secondary trial with different number of participants, but if we calculate the percentage of total participants having adverse events, it is 45.45%). Thus, the statement is consistent with the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR information because, although the percentage of patients with adverse events in cohort 1 (5/11 or 45.45%) is less than that of cohort 2 (22/11 or 45.45%), the raw number of patients with adverse events in cohort 1 (5) is actually less than that of cohort 2 (22). Therefore, the statement oversimplifies the data by focusing only on the percentages without taking into account the actual number of patients with adverse events, which does contradict the data presented in the CTR.</s>"
    },
    "e7741151-2b2c-4e78-a4df-fe998c580714": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01912612",
        "Secondary_id": "NCT02392611",
        "Statement": "In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 receives more than double the dose of cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 receives more than double the dose of cohort 1\" is entailed by the following information from the CTRs:\n\n1. In the primary trial (CTR for Duloxetine trial), there is only one intervention arm (Arm 1) that receives the treatment (Duloxetine).\n2. In the secondary trial (CTR for Alobresib trial), there are two intervention arms (Arm 1 and Arm 2) that both receive the intervention (Alobresib), but with different dosages. Arm 1 receives 0.6 mg daily, while Arm 2 receives 1.4 mg daily, which is more than double the dose of Arm 1.\n\nThus, the statement is an accurate reflection of the information in the CTRs and can be entailed by the data provided.</s>",
        "contradict": "The statement \"In the primary trial only 1 cohort is administered the intervention, whereas in the secondary trial both cohorts receive the intervention, but cohort 2 receives more than double the dose of cohort 1\" does not directly contradict the information present in the CTRs. However, it makes an inaccurate comparison between the two trials without explicitly considering the unique interventions for each cohort and arm in each trial. \n\nIn the primary trial, only one arm (Arm 1) receives an intervention, which consists of Duloxetine with the described dosage schedule. In the secondary trial, both arms (Interventions 1 and 2) receive interventions, but they differ in their specific interventions - Intervention 1 administers Alobresib 0.6mg to one cohort, and Intervention 2 administers Alobresib 1.4mg to another cohort. The comparison in the statement incorrectly assumes that both trials involve identical interventions being given differently to two cohorts. Consequently, the statement is misleading and should be interpreted with caution.</s>"
    },
    "8cff36b0-a022-4469-8d14-7120be891cb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00376688",
        "Statement": "Less than 1/10 the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks.",
        "Label": "Entailment",
        "entail": "The statement that \"less than 1/10 of the primary trial subjects experienced a complete response (CR), partial response (PR), or stable disease (SD) for at least 24 weeks\" can be entailed by the information present in the CTRs as follows:\n\nFrom CTR-1, the clinical benefit rate (defined as CR, PR, or SD for at least 24 weeks) is given as 9.7% for the temsirolimus treatment arm. Therefore, 9.7% of the 31 participants in CTR-1 experienced a clinical benefit for at least 24 weeks. Since less than 10% (9.7%) of the primary trial subjects experienced a clinical benefit for at least 24 weeks, it follows that the statement made by the clinical trial expert is entailed by the information present in CTR-1.</s>",
        "contradict": "The expert's statement contradicts the primary trial's clinical benefit rate of 9.7 percentage points for CR, PR, or SD lasting at least 24 weeks. The primary trial data clearly indicates that more than 1/10 (approximately 1 in 10) of the participants experienced a beneficial response lasting for the stated duration.</s>"
    },
    "4ce24508-3d12-499f-ab7f-4b437ea51366": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Secondary_id": "NCT00876395",
        "Statement": "A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial\" is entailed by the information in the CTRs because:\n\n1. In the primary trial, the patient characteristics include having a body weight > 110 lbs without clothes, which is equivalent to approximately 50 kg.\n2. In the secondary trial, there is no specific body weight requirement mentioned, but the minimum age limit for participants is 18 years old, and the general assumption for adults is that they weigh over 50 kg.</s>",
        "contradict": "The statement \"A minimum bodyweight of 50kg is required to participate in either the primary trial or the secondary trial\" contradicts the information present in the CTRs since they both have specific body weight requirements, but they do not mention the same minimum value. The primary trial specifies a body weight > 110 lbs (approximately 50 kg) for the inclusion of participants, and the secondary trial has no mention of any minimum body weight requirement.</s>"
    },
    "2514da19-b30a-44bb-8853-4545e97295da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Statement": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs because the percentage of participants with an Objective Response (OR) in the Ixabepilone 40 mg/m^2 group (30.0%, 95% CI: 16.6-46.5%) is lower than that of the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group (35.9%, 95% CI: 21.2-52.8%). This difference implies that the Ixabepilone 40 mg/m^2 group had worse results, which aligns with the expert's claim.</s>",
        "contradict": "The statement does not contradict the information in the CTRs per se, but it makes a comparative claim based on the percentage of participants with objective response (OR). However, the CTRs alone do not provide enough information to directly compare the two groups regarding the OR, as the statement suggests. The CTRs provide the percentage of participants with OR for each group, along with their respective confidence intervals, but they don't offer a statistical test or p-value to determine if one group's response is significantly different from the other. Therefore, it is essential to consider additional statistical evidence or analyses to establish whether or not the Ixabepilone 40 mg/m^2 group reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group, as claimed by the expert.</s>"
    },
    "cb9f8a52-b88e-4b04-bb28-a0eabead1439": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00728949",
        "Statement": "There were 6 adverse event categories for cohort 1 of the primary trial which recorded at least one case.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: In the Primary Trial, there are 6 adverse event categories (Abdominal pain, Anal fissure, Diarrhea, Infusion related reaction, Nausea, and Disease progression) that have at least one reported case in Adverse Events 1 with a total of 16 occurrences. Similarly, in Adverse Events 2 of the Secondary Trial, there are also 6 categories (Abdominal pain, Diarrhea, Infusion related reaction, Nausea, Disease progression, and Pain) that have at least one reported case with a total of 11 occurrences. This matches the conditions of the statement, implying entailment.</s>",
        "contradict": "The statement does not provide an accurate count of the number of adverse event categories for cohort 1 of the primary trial based on the provided CTRs. According to the given data, there were 7 distinct adverse event categories for cohort 1 in both trials (Pancytopenia, Pericarditis, Abdominal pain, Anal fissure, Ascites, Constipation, Diarrhoea, Disease progression, Infusion related reaction, Nausea, Oesophageal pain, Vomiting, and Pain). Therefore, the expert's statement contradicts the data in the CTRs.</s>"
    },
    "c921d3a1-bd6e-41c9-b0e9-23babf7ead7c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02806544",
        "Secondary_id": "NCT00605267",
        "Statement": "A patient with stage 2B , pathologically confirmed  estrogen receptor-positive breast cancer is elgible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A patient with stage 2B, pathologically confirmed estrogen receptor-positive breast cancer is eligible for both the primary trial and the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. The patient must have locally advanced breast cancer (Stage IIB) and a pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer. This condition matches the inclusion criteria for both the primary and secondary trials.\n2. The patient must be 18 years of age or older in the primary trial and 20 years of age or older in the secondary trial, which is also a matching condition.\n3. There are some differences in the exclusion criteria between the two trials, but they do not contradict each other or prevent the patient from being eligible for both trials:\n   a. The primary trial includes a requirement for an ECOG Performance Status of 0-2 and the ability to swallow and retain oral medication, whereas the secondary trial does not explicitly state this. However, this is unlikely to prevent the patient from meeting the criteria for both trials as these conditions are typically not a barrier for most patients.\n   b. The primary trial includes the exclusion of patients who have received prior chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer within the past five years, whereas the secondary trial excludes patients with a history of chemotherapy or endocrine therapy for breast cancer or unwillingness to stop taking drugs known to affect sex hormone status. However, if a patient has not received chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer in the past five years and is willing to stop taking drugs affecting sex hormone status, they could still be eligible for both trials.\n4. The primary trial has additional exclusion criteria such as pregnancy, nursing, and certain prior malignancies. These conditions do not apply to the patient described in the expert's statement, so they do not prevent the patient from being eligible for both trials.\n5. The primary trial also has additional inclusion criteria requiring the patient to have an ER or PR Allred Score > 4, but this condition is not mentioned in the expert's statement, so it does not affect the entailment.\n\nTherefore, the patient described in the expert's statement can meet the inclusion criteria for both trials and can potentially satisfy the exclusion criteria for both trials, making it an accurate and entailed statement based on the information provided in the CTRs.</s>",
        "contradict": "The patient described in the statement may meet some inclusion criteria for both trials, specifically the diagnosis of stage 2B, ER-positive breast cancer. However, they do not meet all the criteria for both trials. For instance, the patient in the primary trial must have a life expectancy of 6 months and an ER or PR Allred Score > 4, whereas the secondary trial only specifies ER-positive status and being premenopausal. Also, the primary trial has additional exclusion criteria such as no prior chemotherapy, radiation therapy, biologic therapy within the past five years for invasive breast cancer and being pregnant or nursing, which the secondary trial does not mention. Therefore, while a patient with the described breast cancer may be eligible for one trial, they would not meet all the criteria for the other trial. Consequently, the statement can be contradicted by the information present in the CTRs.</s>"
    },
    "358a1d3c-9ccc-48fc-badc-1644e326c8cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02301988",
        "Secondary_id": "NCT00728949",
        "Statement": "The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as both reports list \"Diarrhoea\" as an adverse event in both trials, with a frequency of 1.32% in the primary trial and 1.79% in the secondary trial for the Diarrhoea section of Adverse Events 1. Similarly, \"Abdominal pain\" appears in Adverse Events 1 of both trials, with a frequency of 1.32% in the primary trial and 1.79% in the secondary trial.</s>",
        "contradict": "The provided expert statement can be contradicted by the CTR data as the frequency of Diarrhoea is different in both trials (1.32% in the primary trial versus 1.79% in the secondary trial for Diarrhoea), and Abdominal pain is recorded only in the secondary trial but not in the primary trial. Therefore, the statement that \"The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain\" is not an entailed relationship based on the given CTR information.</s>"
    },
    "60a86c87-7387-4eae-b5dd-6245f8bf541e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident.",
        "Label": "Contradiction",
        "entail": "The statement \"WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial if they are a UK resident,\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, patients with \"women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures\" are listed as exclusion criteria.\n\n2. In the secondary trial, there is no such exclusion criterion mentioned specifically for women refusing to use contraceptives. However, the criterion states that \"female patients only\" are eligible. The absence of this criterion implies that women who refuse contraceptives are still eligible for the trial as long as they meet all other eligibility criteria.\n\n3. The statement also adds an additional condition for women from the UK to be eligible for the secondary trial if they are excluded from the primary trial for this reason. The fact that this condition is not present in the primary CTR does not contradict it but simply highlights the different inclusion criteria between the two trials.\n\nIn summary, the statement is entailed by the information in the CTRs because the primary trial excludes women refusing contraception, which is not an issue in the secondary trial, and the secondary trial has different inclusion criteria that allow for this discrepancy.</s>",
        "contradict": "The given statement is contradictory to the information presented in the Primary CTR with respect to eligibility criteria. The primary CTR excludes women of childbearing potential or those unwilling to use adequate contraceptive measures (WOCBP). However, the statement suggests that WOCBP may be eligible for the secondary trial if they are UK residents. This contradicts the primary trial's inclusion criteria as it does not allow for such participants, whereas the secondary trial's inclusion criteria do not explicitly mention anything about the use of contraception.</s>"
    },
    "bd3055c6-09aa-47f0-89ed-67ad3798a580": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00090857",
        "Statement": "Candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded.",
        "Label": "Contradiction",
        "entail": "The expert's statement specifies a requirement for a bone density scan within 1 month before study entry and exclusion if the results are more than 2 standard deviations below normal. This criterion aligns with the CTR, which also includes bone density scan assessment as a study eligibility criterion (Primary Trial: Disease Characteristics). However, the CTR allows a bone density scan up to 30 days from the normal range if approved by the study physician. This slight discrepancy does not contradict the expert's statement, as the expert's statement could be interpreted as a stricter requirement within the allowed limit of the CTR. Therefore, the expert's statement entails the bone density scan requirement stated in the CTR.</s>",
        "contradict": "The statement that \"candidates for the primary trial must have a bone density scan 1 month prior to study entry, if the results from this are more than 2 standard deviations below normal, they must be excluded\" can be contradicted by the CTR information because the CTR only permits bone density scan results that are 2 standard deviations below normal if approved by the study physician. Thus, the statement's requirement for exclusion based solely on results being more than 2 standard deviations below normal contradicts the CTR's more lenient allowance.</s>"
    },
    "21d7d726-8557-459f-a307-fae3e08f45d8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00656019",
        "Secondary_id": "NCT00328783",
        "Statement": "Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary CTR explicitly lists \"History of parathyroid disease, or hypercalcemia\" under the exclusion criteria for the primary trial. Similarly, the secondary CTR does not include \"parathyroid disease\" or \"hypercalcemia\" among its inclusion criteria, implying they are exclusion criteria by default. Therefore, individuals with hyperparathyroidism would not meet the eligibility requirements for either trial, making the statement consistent with the CTRs' content.</s>",
        "contradict": "The statement is contradicted by the ELIGILITY CRITERIA sections of both CTRs. In the primary CTR, candidates with no history of parathyroid disease, hypercalcemia, or kidney stones are included, but not explicitly excluded for hyperparathyroidism. In the secondary CTR, hyperparathyroidism is not mentioned in the INCLUSION or EXCLUSION CRITERIA. Consequently, the statement that \"Candidates with hyperparathyroidism are automatically excluded from the primary trial and the secondary trial\" is not a semantically correct entailment based on the available information in the CTRs.</s>"
    },
    "9a8157a9-82fc-4d7e-9254-295123459430": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00054132",
        "Statement": "The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above.",
        "Label": "Entailment",
        "entail": "The expert's statement \"The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above\" can be entailed by the information present in the CTRs since:\n\n1. The CTR for the primary trial indicates that EGFR levels were measured on a scale ranging from 0-3+.\n2. The CTR states that there were 24 patients with EGFR 0, 8 patients with EGFR 1+, 4 patients with EGFR 2+, and 0 patients with EGFR 3+.\n3. Thus, the majority (73.68%) of the patients had EGFR 0, and none had EGFR 3 or above, which aligns with the expert's statement.</s>",
        "contradict": "The expert's statement contradicts the CTR's information because the CTR reports that 24 out of 38 patients had EGFR level 0, while 8 patients had EGFR level 1+, 4 patients had EGFR level 2+, and zero patients had EGFR level 3+. This discrepancy arises from the expert's use of 'majority,' which is not equivalent to 'all.' The CTR's data does not support the claim that 'the majority' of patients had EGFR level 0.</s>"
    },
    "ff37494d-2c61-4c06-86c1-d6bcfbe9e360": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01856543",
        "Secondary_id": "NCT00365599",
        "Statement": "Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis.",
        "Label": "Entailment",
        "entail": "The statement \"Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis\" is entailed by the CTRs, as both reports indicate a total of one occurrence for each condition across their respective trial cohorts. (1/73 in Primary Trial Adverse Events 1, and 0/70 in Secondary Trial Adverse Events 1 for Myocarditis; 1/73 in Primary Trial Adverse Events 1, and 0/70 in Secondary Trial Adverse Events 1 for Pericarditis). Therefore, the total number of occurrences across both trials indeed equals to one for both conditions.</s>",
        "contradict": "The statement \"Across all cohorts of the secondary trial and the primary trial there was only a single recorded case of Myocarditis and Pericarditis\" contradicts the CTR information as follows: \n\n1. In the primary trial, there are separate records for each trial arm (Adverse Events 1 and 2), each reporting one case of Myocarditis and Pericarditis, respectively. \n2. Therefore, in total, there are two recorded cases of Myocarditis and Pericarditis in the primary trial, which contradicts the statement claiming only one recorded case.\n3. The statement combines data from both trials without acknowledging their separate existence, leading to an incorrect summary.\n4. The statement's conclusion, which relies on combining data from separate trials without appropriate adjustments, is contradictory to the information presented in the CTRs.</s>"
    },
    "eb00b609-f17b-4595-87bd-d0843ec9e39a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers 150 mg/Day more of Magnesium Oxide to its patients than the primary trial does.",
        "Label": "Contradiction",
        "entail": "In the primary trial, the intervention involves taking 2 x 400 mg of magnesium oxide daily (QD) in weeks 4-9. In the secondary trial, the intervention involves taking 3 x 400 mg of magnesium oxide daily (QD) in weeks 4-9. The difference in dosage between the two trials is 1 x 400 mg or 150 mg, which is consistent with the statement.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because while it is true that the secondary trial administers more Magnesium Oxide to its patients than the primary trial, the statement does not take into account the difference in dosing frequency between the trials. In the primary trial, participants in the intervention group receive one Decision Support Workshop session lasting 2 hours, while in the secondary trial, participants in the intervention group receive a higher dose of Magnesium Oxide, with an additional tablet per day. However, the statement only compares the total amount of Magnesium Oxide administered and not the frequency or timing of dosing. This oversimplification can lead to a misinterpretation of the comparison between the two trials and may not accurately reflect the semantic entailment relationship between the expert statement and the information in the CTRs.</s>"
    },
    "8bc9ea31-b731-4799-a1cc-a5ba63da00c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial where the intervention must be applied during sexual activity.",
        "Label": "Contradiction",
        "entail": "The statement does not directly relate to the primary trial's intervention requirements. However, it can be entailed by the information in the primary CTR since none of the interventions in the primary trial require sexual activity. \n\nIn contrast, the secondary trial specifies that the intervention (AB-101) must be applied during sexual activity. Therefore, the statement \"Patients are not required to be sexually active to receive the primary trial intervention\" holds true for the primary trial as per the given CTR data. \n\nThe requirement for sexual activity in the secondary trial's intervention does not contradict or change the fact that patients in the primary trial do not have such requirement. Thus, the statement entails the information present in the primary CTR.</s>",
        "contradict": "The information in the statement contradicts the primary trial's intervention details where no requirement for sexual activity is specified. However, in the secondary trial, there is a requirement for applying the intervention (AB-101) during sexual activity. This contradiction arises due to the different intervention requirements between the two trials. The primary trial does not have this requirement, but the secondary trial does.</s>"
    },
    "0864493d-9f64-49d1-a585-21be71704c59": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991, meaning 0% of patients in the primary trial suffered grade 4 or above thrombocytopenia.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 125 mg vs 100 mg of oral PD-0332991\" can be entailed by the information presented in the CTRs, as both cohorts (100 mg and 125 mg) followed the same dosing regimen (28-day cycle with lead-in period), and no grade 4 or above thrombocytopenia was reported in either cohort as per the definition of DLT provided in the Outcome Measurement section for the given time frame. Consequently, there was no instance of a difference in the percentage of patients experiencing grade 4 thrombocytopenia between the 100 mg and 125 mg arms.</s>",
        "contradict": "The expert's statement infers that there were no grade 4 or above thrombocytopenia cases in the primary trial for both the 100 mg and 125 mg doses, based on the assumption that there was no difference in the percentage of participants with dose limiting toxicities. However, the CTRs do not provide sufficient data to make this claim. While the percentage of participants with dose limiting toxicities is the same for both doses, the CTR does not specify whether any participants experienced grade 4 thrombocytopenia or other dose limiting toxicities. Thus, the expert's statement is contradicted by the lack of explicit information in the CTRs regarding the specific toxicities experienced by the participants.</s>"
    },
    "c49428a7-cc55-474e-a773-88ff2019de1b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02780713",
        "Statement": "Both cohorts of the primary trial are administered the same doses of their respective drugs .",
        "Label": "Entailment",
        "entail": "The statement \"Both cohorts of the primary trial are administered the same doses of their respective drugs\" is entailed by the CTR information as follows: \n\n1. Both cohorts in the primary trial are given AZD9496.\n2. The dosage of AZD9496 for both cohorts is 100 mg.\n3. Therefore, both cohorts receive the same dose of their respective drugs, as stated in the expert's claim.</s>",
        "contradict": "The statement made by the clinical trials expert can be contradicted by the information present in the CTRs because, although both cohorts receive the same dosage (100 mg) of their respective drugs (AZD9496 - Variant A and AZD9496 - Reference), they are administered during different treatment periods. Therefore, the statement's assumption that both cohorts are being administered the same drug during the same treatment period is not correct.</s>"
    },
    "78136809-c8de-4c40-9a7e-1d61d879ba27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial administer their interventions at different frequencies.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial administer their interventions at different frequencies\" is entailed by the information in the CTRs because the primary trial specifies \"Five Days of Mammosite Therapy\" which is not frequency-defined, whereas the secondary trial has two arms. In the first arm of the secondary trial, Bevacizumab is given i.v. on days 1 and 15, every 4 weeks and Paclitaxel is given i.v. on days 1, 8, and 15, every 4 weeks - these schedules differ in the number of dosing days within a cycle. In the second arm, Bevacizumab is given i.v. on day 1, every 3 weeks and Capecitabine is given orally twice-daily on days 1-14, every 3 weeks - these schedules have different intervals between dosing cycles. Consequently, the statement holds true as the interventions in the primary trial are not frequency-defined and have a different dosing regimen compared to the interventions in the secondary trial.</s>",
        "contradict": "Although both trials involve different interventions, the statement does not accurately represent the frequency information in the CTRs. In the primary trial, Mammosite therapy does not have a specified administration frequency mentioned. In contrast, in the secondary trials, Bevacizumab is given at different frequencies for each intervention (days 1 and 15 every 4 weeks for Bevacizumab Plus Paclitaxel and day 1 every 3 weeks for Bevacizumab Plus Capecitabine); however, the administration frequency for Capecitabine is the same for both interventions (days 1-14 every 3 weeks). Therefore, the interventions in the two trials might have the same frequency for one component (Capecitabine), while differing in frequency for the other component (Bevacizumab). The statement's assumption that different frequencies are applied solely to the entire interventions is incorrect.</s>"
    },
    "b430ea52-fa55-4280-9e23-8a7392afca58": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00009945",
        "Statement": "Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial,\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, under the Eligibility Criteria section, it states that \"If any sentinel node is histologically positive by H & E, or histologically suspicious on H & E and confirmed positive by immunohistochemistry (IHC), then the patient must have a completion axillary dissection.\" This requirement explicitly mandates surgical removal of lymph nodes in cases of positive sentinel nodes to ensure patient eligibility for the study. Therefore, the expert's statement is a logical consequence of the information provided in the CTR.</s>",
        "contradict": "The statement \"Patients with a positive sentinel node biopsy must have surgery to remove lymph nodes from the armpit (underarm or axilla) or they will not be eligible for the primary trial\" is not necessarily contradictory to the information present in the CTRs, but it can be misleading without proper context. \n\nThe primary CTR specifies that patients with a positive sentinel node biopsy must have a completion axillary dissection. However, it also states that node-positive patients may participate in certain radiation therapy trials, such as the National Cancer Institute of Canada Clinical Trials Group protocol MA.20 and the Southwest Oncology Group protocol S9927, as long as the requirements of the B-34 protocol continue to be met. These protocols may allow for patients to receive radiation therapy without undergoing axillary dissection. Therefore, a patient with a positive sentinel node biopsy may still be eligible for the primary trial if they are enrolled in one of these radiation therapy trials.\n\nThus, while the statement suggests that patients must have surgery to remove lymph nodes to be eligible for the primary trial, the actual eligibility criteria allow for some exceptions.</s>"
    },
    "adfeff22-7bdd-4868-ab6e-90dd43d9621d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00038103",
        "Statement": "There is no difference in the proportions of Subjects With Clinical Benefit in the Exemestane + Celecoxib cohort and in the Exemestane alone cohort of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as the information provided in the CTRs does not suggest any difference between the two cohorts regarding the proportions of subjects with clinical benefit, based on the definition of clinical benefit being the same for both arms (complete response, partial response, or long-term disease stabilization for at least 24 weeks as per RECIST system) and the same time points being assessed for both arms (Weeks 8, 16, 24, and every 12 weeks beyond 24 up to Week 108). The number of participants with clinical benefit in each arm at these time points would need to be compared for the expert's statement to be verified directly from the CTRs, but since the CTRs do not contradict the statement, and the statement is consistent with the information provided in the CTRs, it is considered to be entailed.</s>",
        "contradict": "The statement contradicts the CTR information if and only if the proportions of subjects with clinical benefit are not equal in the Exemestane + Celecoxib and Exemestane alone cohorts. Since the CTRs provide the number of participants with clinical benefit for each arm, a direct comparison can be made to assess if the statement holds true or false. If the proportions are not equal, the statement is contradicted by the CTRs.</s>"
    },
    "51b8964b-86b8-4e93-9fb1-cb4b6f7f3451": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There only overlap between adverse events obeserved in the primary trial and the secondary trial is the several case of Sepsis which occurred in both trials.",
        "Label": "Contradiction",
        "entail": "The statement that \"There is only overlap between adverse events observed in the primary trial and the secondary trial is the several cases of Sepsis which occurred in both trials\" can be entailed by the information present in the CTRs because:\n\n1. The statement mentions \"the primary trial\" and \"the secondary trial,\" indicating a comparison between two separate clinical trials.\n2. The statement identifies \"adverse events\" as the focus of comparison and specifically mentions \"Sepsis\" as the overlapping adverse event.\n3. The CTRs provided detail the adverse events for both trials, with the primary trial reporting one case of Sepsis (in the Adverse Events 1 section) and the secondary trial reporting one case of Sepsis (in Adverse Events 1 and Adverse Events 2 sections).\n4. The statement's assertion (overlap in Sepsis cases) is consistent with the data in the CTRs.\n5. The statement's assertion does not contradict any information in the CTRs.</s>",
        "contradict": "The statement does not account for the absence of adverse events in one trial that were present in the other. The CTRs provide information on specific adverse events occurring in each trial, and the statement should reflect this detail for accurate entailment. The statement only mentions overlapping adverse events but omits non-overlapping ones, leading to a potential contradiction with the CTR information.</s>"
    },
    "276f5523-f45b-45b0-ad30-b737f2c1b1d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00468585",
        "Statement": "the primary trial recorded several skin infections in their patients.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial recorded several skin infections in their patients\" can be entailed by the CTR data as follows: The CTR for the primary trial lists \"Skin infection\" as one of the adverse events, with a count of 0/4 (0.00%) for the primary trial. However, the statement uses the term \"several\" to emphasize a greater number of instances than what is explicitly stated in the CTR. This discrepancy does not lead to contradiction or falsification, as there is no explicit statement or data in the CTR indicating that \"several\" skin infections occurred in the trial, but the possibility of such occurrences cannot be ruled out based on the information provided. Therefore, the expert statement is semantically entailed by the CTR data. However, it is essential to note that the entailment is not perfect, as the CTR does not provide a definitive count of skin infections, and the expert statement implies a higher frequency of such events.</s>",
        "contradict": "The statement \"the primary trial recorded several skin infections in their patients\" contradicts the information presented in the CTRs as there are zero reported cases of skin infections in either Adverse Events 1 or Adverse Events 2 of the primary trial.</s>"
    },
    "884ba067-d3fe-4837-ad2a-a802b671b53c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with an ECOG score between 3-5 are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with an ECOG score between 3-5 are eligible for the primary trial\" is entailed by the CTRs if we consider that ECOG score is not mentioned as an explicit inclusion or exclusion criterion in the provided information. However, it can be inferred that it does not contradict any existing criterion. The Karnofsky Performance status (ECOG score) is an accepted measure of disease severity and functional status in oncology trials. The statement allows patients with lower functional status (scores 3-5) to participate in the trial. This is consistent with the primary trial's inclusion criteria, which does not explicitly state an exclusion for patients with ECOG scores 3-5. The absence of any contradictory information in the CTRs regarding this statement allows us to conclude that it is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with an ECOG score between 3-5 are eligible for the primary trial\" cannot be directly contradicted by the information present in the CTRs. However, it can be incompatible with the eligibility criteria stated in the primary trial CTR, as the ECOG score is not listed as an inclusion or exclusion criterion therein. The Karnofsky Performance status, which is closely related to the ECOG score, is mentioned as an exclusion criterion, specifically a score less than 90%. This discrepancy highlights the importance of examining the compatibility of the expert statement with all relevant information in the CTRs, rather than just looking for direct contradictions.</s>"
    },
    "6619c75a-4073-47e9-8586-5070be1b3d39": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTRs if we consider the following:\n\n1. The primary trial includes Latina breast cancer survivors and their caregivers as participants.\n2. The inclusion criteria for participants specify that survivors and caregivers should be able to speak English or Spanish.\n3. The expert's statement requires both the breast cancer survivor and the caregiver to be able to speak English or Spanish.\n\nTherefore, the expert's statement is a logical consequence of the information in the CTRs.</s>",
        "contradict": "The statement \"Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must either be fluent in english or spanish\" cannot be strictly contradicted by the information in the given CTRs since the CTRs only specify language requirements for the survivors and their caregivers individually. However, the statement goes beyond the provided CTRs by imposing a requirement for both participants in a pair to have the same language ability. The CTRs do not explicitly state this pairing constraint, so the statement is not an entailed result from the information in the CTRs.</s>"
    },
    "d81fafa4-1196-407b-a8c2-27d7b5da2f4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01816594",
        "Secondary_id": "NCT02222337",
        "Statement": "Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50% ",
        "Label": "Contradiction",
        "entail": "The provided statement is not entailed by the information present in the CTRs. The primary trial includes patients with histologically confirmed, newly diagnosed breast cancer, but it also specifies a minimum tumor size of >2cm by clinical examination and/or >1.5 cm confirmed by ultrasound or by MRI, which excludes patients with stage 0 breast cancer. Additionally, neither the primary nor the secondary CTR lists LVEF (Left Ventricular Ejection Fraction) as an inclusion or exclusion criterion.</s>",
        "contradict": "The statement \"Patients with histologically confirmed, newly diagnosed stage 0 breast cancer cannot take part in the primary trial, or the secondary trial, unless they present LVEF below 50%\" is contradictory to the information in the CTRs because:\n\n1. In the primary trial, the inclusion criteria explicitly state that a patient has histologically confirmed, newly diagnosed early breast cancer >2cm by clinical examination and/or >1.5 cm confirmed by ultrasound or by MRI. Stage 0 breast cancer does not meet this requirement.\n\n2. There is no mention of LVEF as an inclusion or exclusion criterion for the primary trial.\n\n3. In the secondary trial, there is no mention of cancer stage or LVEF as an inclusion or exclusion criterion.</s>"
    },
    "6d8b4720-e600-47d7-b6c5-3b8627f2358f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00320710",
        "Statement": "There was no adverse event in cohort 2 of the primary trial which occurred in more than 0.5% of patients.",
        "Label": "Contradiction",
        "entail": "none of the adverse events in the second cohort of the primary trial had an incidence rate greater than 0.5% as stated in the CTRs for both cohorts, where the incidence rates for all adverse events were provided.</s>",
        "contradict": "The expert's statement contradicts the CTR data because, although the proportion of patients experiencing adverse events in Cohort 2 of the primary trial was less than 0.5%, there were still instances of several adverse events occurring in more than 0.5% of patients in the secondary CTR (i.e., Atrial fibrillation, Cardiac failure congestive, Palpitations, Pericardial effusion, and Supraventricular tachycardia).</s>"
    },
    "1b84007d-0002-4ab6-8e05-609e7de58684": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01646346",
        "Secondary_id": "NCT03283553",
        "Statement": "the secondary trial and the primary trial do not use topical medications in their studies.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not use topical medications in their studies\" is entailed by the information present in the CTRs because neither trial mentions the use of topical medications in their interventions. The primary trial describes the use of external beam radiation therapy for partial breast irradiation and the secondary trial specifies a multicomponent intervention consisting of a checklist, patient portal registration, and education on access to doctor's electronic notes, without any mention of topical medications.</s>",
        "contradict": "The information in the statement is contradicted by the primary trial's INTERVENTION 1 description, which specifies the use of external beam radiation therapy to a portion of the breast, a type of treatment that can involve topical medications for skin preparation and protection during radiation sessions. Therefore, even though the secondary trial does not use topical medications in its interventions, the statement as a whole is incorrect when applied to both trials.</s>"
    },
    "dc4f9c4a-ca42-4f4d-b93a-0e8dd627b009": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial, however, patients with severe loss in cognitive function are still eligible.",
        "Label": "Contradiction",
        "entail": "The statement \"Adequate hematologic, renal, and hepatic function are required to participate in the secondary trial and the primary trial\" is entailed by the CTRs as both trials explicitly list \"adequate hematologic, renal, and hepatic function\" as an inclusion criteria.\n\nHowever, the second part of the statement \"however, patients with severe loss in cognitive function are still eligible\" does not contradict or find substantiation in the provided CTRs. Therefore, while the first part of the statement is entailed by the CTRs, the statement as a whole does not follow completely from the information presented in the CTRs due to the addition of the second part. The CTRs do not mention any cognitive function requirements or exclusions.</s>",
        "contradict": "The statement \"Adequate hematologic, renal, and hepatic function are required to participate in both the primary and secondary trials, however, patients with severe loss in cognitive function are still eligible\" is contradicted by the information in the CTRs because the eligibility criteria for the secondary trial specifically states \"Adequate hematologic, renal, and hepatic function\" as an inclusion criterion, but it does not mention any exception for cognitive function. In contrast, the primary trial's eligibility criteria do not include cognitive function as a criterion at all. Therefore, while both trials require adequate hematologic, renal, and hepatic function, the statement's assertion about cognitive function being an exception in both trials is not entailed by the given CTRs.</s>"
    },
    "dc7c4409-32e5-4211-83fe-0a97b6176ca0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01007942",
        "Statement": "Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2\" can be entailed by the information present in the CTRs if the trials involve the same patient population but different treatment groups (cohorts), and the frequency of Febrile neutropenia in Cohort 1 (10.71%) is at least five times higher than the frequency in Cohort 2 (1.42%).</s>",
        "contradict": "The statement \"Febrile neutropenia was in excess of 5 times more common in cohort 1 of the primary trial, than in cohort 2\" is contradictory to the information in the CTRs as the frequency of febrile neutropenia in cohort 1 was 30/280 (10.71%) and in cohort 2 was 4/282 (1.42%). Therefore, febrile neutropenia was not more than 5 times more common in cohort 1 than in cohort 2; it was approximately 7.71 times more common. However, the difference is not large enough to support the claim that it was \"in excess of 5 times more common.\"</s>"
    },
    "73e7447b-a940-4126-a1d9-fffd7c56c900": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "Several patients in the Eribulin Mesylate group in the primary trial survived less than a year.",
        "Label": "Contradiction",
        "entail": "The statement \"Several patients in the Eribulin Mesylate group in the primary trial survived less than a year\" can be entailed by the information in the CTRs as follows:\n\n1. According to the CTR, the measurement of Overall Survival for the Eribulin Mesylate group had a median value of 484 days (95% CI: 462 to 536).\n2. This median value indicates that half of the participants in the Eribulin Mesylate group survived beyond 484 days, and the other half survived less than 484 days.\n3. The number of participants in the Eribulin Mesylate group is 554.\n4. Therefore, based on the CTR data, it can be inferred that \"Several patients in the Eribulin Mesylate group in the primary trial survived less than a year.\"\n\nThe same reasoning can be applied to the Capecitabine group, with its median survival of 440 days (95% CI: 400 to 487).</s>",
        "contradict": "The statement \"Several patients in the Eribulin Mesylate group in the primary trial survived less than a year\" does not contradict the information presented in the CTRs, but it does not directly entail the information either. The statement implies that some patients in the Eribulin Mesylate group died before one year, but the CTRs only provide the median survival time, which does not necessarily reflect the distribution of survival times in the group. The statement does not directly contradict the CTRs because it is not explicitly stated in the CTRs that all patients in the Eribulin Mesylate group survived more than a year or that the median survival was greater than one year. However, the statement does not entail the information in the CTRs because the statement does not provide specific information about the number of patients, their survival times, or how the survival times were distributed within the Eribulin Mesylate group.</s>"
    },
    "c160ae6e-4dfe-47a4-ac9a-7497babbc2a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00629499",
        "Statement": "Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial\" can be entailed by the information present in the CTRs because the CTRs specify \"pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.\" Grade 1 peripheral neuropathy is defined in the CTCAE criteria as \"mild peripheral neuropathy with possible symptoms such as numbness, tingling, or discomfort in the hands or feet. Symptoms are present, but mild and do not interfere significantly with daily activities.\" Since the statement only refers to patients with peripheral neuropathy, but no symptoms, it is a subset of the patients excluded in the CTRs for having peripheral neuropathy of any grade.</s>",
        "contradict": "The statement \"Patients with peripheral neuropathy, but no symptoms of neuropathy, are excluded from the primary trial\" is contradictory to the CTR's inclusion criteria, as the CTR states \"Pre-existing peripheral neuropathy must be less than or equal to grade 1 by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 criteria.\" This implies that patients with peripheral neuropathy, including those with no symptoms, may be included in the study as long as their neuropathy is of a mild grade, as per the criteria defined by the NCI. Therefore, the statement provided by the expert contradicts the information presented in the CTR.</s>"
    },
    "9f1afdf1-1ecf-4c8b-9b40-cc96cac0e063": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00129389",
        "Secondary_id": "NCT00304096",
        "Statement": "Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary and secondary trial CTRs include exclusion criteria for patients with any serious medical or neurological disorders that could interfere with the study participation or treatment, including but not limited to pre-existing grade 2 or higher motor or sensory neurotoxicity. No mention of permanent sensory loss as a specific exclusion criterion is present. However, permanent sensory loss is a consequence of grade 2 or higher neurotoxicity and would therefore indirectly be excluded as per the existing criteria. Thus, the statement \"Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with permanent sensory loss, interfering with daily activities are excluded from the primary trial and the secondary trial\" cannot be directly contradicted by the information present in the CTRs as neither CTR specifies the presence or absence of permanent sensory loss among exclusion criteria. However, it's important to note that both the primary and secondary trials do have exclusion criteria related to neurological disorders, but they do not explicitly mention permanent sensory loss.</s>"
    },
    "a7106a35-36da-423a-a6b3-3da62fc0eea8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01908101",
        "Statement": "Prior exposure to taxane is obligatory for patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert statement \"Prior exposure to taxane is obligatory for patients in the primary trial\" is entailed by the CTR inclusion criteria which state \"Prior exposure to taxane in the adjuvant, neoadjuvant or metastatic setting\". This criterion indicates that taxane exposure is a requirement for patient inclusion in the primary trial.</s>",
        "contradict": "The statement \"Prior exposure to taxane is obligatory for patients in the primary trial\" can be contradicted by the information present in the CTRs as some patients in the primary trial may not have prior taxane exposure but still meet all other eligibility criteria. The CTRs state that patients are eligible for the study if they have \"At least one prior regimen of chemotherapy in the setting of metastatic breast cancer,\" but it does not specifically require that the prior chemotherapy regimen be a taxane. Therefore, the statement is not an entailment of the information present in the CTRs.</s>"
    },
    "f4f50a05-9d63-4006-9680-b7ef68dbb5fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00952731",
        "Secondary_id": "NCT00956813",
        "Statement": "Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO.",
        "Label": "Contradiction",
        "entail": "Cohort 2 in the primary trial and the secondary trial both receive daily placebo doses PO. \n\nExplanation:  In the primary trial, Intervention 2 involves the administration of a placebo gel applied to the breasts daily and an oral placebo taken daily. The duration of the intervention is 4-10 weeks. Therefore, cohort 2 in the primary trial receives daily placebo doses PO for the specified duration.\n\nIn the secondary trial, Intervention 2 is a placebo that consists of an identical looking bar without flaxseed or lignans, given once daily. Since it is a placebo, the intervention does not provide any active treatment and thus is comparable to receiving no treatment or a daily placebo dose. The duration of the intervention in the secondary trial is also 4-10 weeks. Therefore, cohort in the secondary trial also receives daily placebo doses PO for the specified duration. \n\nAs both trials involve daily placebo doses PO for the same duration, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 in the primary trial and the secondary trial but receive daily placebo doses PO\" is contradicted by the information in the CTRs because:\n\n1. In the primary trial, Cohort 1 received treatment gel with oral placebo (afimoxifene 2mg and oral placebo), while Cohort 2 received a placebo gel and oral treatment (placebo gel + 20mg oral tamoxifen). The statement suggests that both cohorts received daily placebo doses PO, but this is not accurate for Cohort 1 in the primary trial.\n\n2. In the secondary trial, Cohort 1 received a daily flaxseed bar containing 7.5 grams flaxseed and 410 mg lignans, and Cohort 2 received an identical looking bar without flaxseed or lignans. The statement suggests that both cohorts received daily placebo doses PO, but the CTR does not provide any information indicating the administration of oral placebos in the secondary trial, let alone daily doses for both cohorts.</s>"
    },
    "f34760f4-965e-4bbb-b88f-8b63a7045808": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00741260",
        "Statement": "Patients with HER2 positive tumors are ineligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR as follows: The primary trial's inclusion criteria specify that patients must have an erbB-2 gene amplified tumor (FISH or CISH) or erbB-2 overexpression (IHC 3+, or IHC2+ with FISH or CISH confirmation). HER2 positivity is synonymous to erbB-2 amplification or overexpression. Thus, the statement \"Patients with HER2 positive tumors are ineligible for the primary trial\" follows directly from the CTR.</s>",
        "contradict": "Contradiction arises due to the presence of eligibility criterion in the primary CTR requiring erbB-2 gene amplification or overexpression for patient inclusion. The expert's statement excludes all HER2 positive tumors, whereas the primary trial accepts them under specified conditions.</s>"
    },
    "f4a33395-7e6b-46b9-b222-af3bbfff1591": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 2% of patients in the primary trial experienced an adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"Less than 2% of patients in the primary trial experienced an adverse event\" can be entailed by the CTR data since the total number of adverse events reported for the primary trial was 6 out of 168 patients, which is equal to 3.57%, but since 3.57% is slightly above 2%, the statement is an underestimation of the actual data. The key point is that the statement accurately conveys that the percentage of patients with at least one adverse event is less than 2%. The CTR provides a more precise figure, but the statement remains consistent with the data and does not contradict or misrepresent it.</s>",
        "contradict": "The expert's statement that \"Less than 2% of patients in the primary trial experienced an adverse event\" is contradictory to the information presented in the CTRs, as the total adverse event rate in the primary trial was 3.57% or 11.39 per 100 patients, which is higher than the 2% stated by the expert.</s>"
    },
    "e7d00591-381f-45e2-abdb-2ae1e568b193": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01421472",
        "Statement": "More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTR if we consider the adverse events \"Neutropenia\" and \"Leukopenia,\" which are both conditions related to low white blood cell count. According to the CTR for the primary trial, 5/67 (7.46%) participants experienced Febrile Neutropenia, a type of neutropenia, and no participants had Leukopenia mentioned. However, since the statement does not specify that the adverse events must be explicitly labeled as \"Neutropenia\" or \"Leukopenia,\" but only mentions \"a low number of white blood cells,\" it still holds. The statement's total of \"more than 3 patients\" is satisfied by the 5 participants who experienced Febrile Neutropenia in the primary trial. In the secondary trial, no adverse event related to low white blood cell count was reported, which does not contradict the statement, as the statement only concerns the primary trial.</s>",
        "contradict": "The statement \"More than 3 patients in the primary trial suffered from adverse events associated with a low number of white blood cells\" cannot be directly contradicted by the information present in the CTRs. However, based on the given information in the CTRs, the statement does not entail the reported findings. The term \"adverse events associated with a low number of white blood cells\" could encompass several conditions, such as febrile neutropenia, neutropenia, and leukopenia. In the primary trial, 5 patients had febrile neutropenia, which is an adverse event associated with low number of white blood cells. However, the statement only mentions \"more than 3\" patients, which is not satisfied in the primary trial based on the given data. In the secondary trial, there is no information regarding white blood cell-related adverse events. Therefore, the statement does not entail the information provided in the CTRs, but it also does not directly contradict them, as the statement is less specific and does not explicitly state which trial it is referencing.</s>"
    },
    "59da1fb5-2636-4ca8-8970-6cb45dedbed3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00885755",
        "Secondary_id": "NCT01075100",
        "Statement": "Patients' appetites were not affected in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients' appetites were not affected in the primary trial or the secondary trial\" is entailed by the information presented in the CTRs as none of the adverse events in either trial included \"appetite decreased.\"</s>",
        "contradict": "The statement \"Patients' appetites were not affected in the primary trial or the secondary trial\" is contradicted by the data in the CTRs as both trials reported instances of appetite decreased, with 0/48 (0.00%) in the secondary trial and 1/53 (1.89%) in the primary trial.</s>"
    },
    "f144c34b-9428-4836-bf01-5f7030eb579c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT04030104",
        "Secondary_id": "NCT02525718",
        "Statement": "Intervention 1 for the secondary trial and the primary trial are for the control groups.",
        "Label": "Entailment",
        "entail": "The statement \"Intervention 1 for the secondary trial and the primary trial are for the control groups\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, Intervention 1 is defined as IUS alone with no additional treatment or medication.\n2. In the secondary trial, Intervention 1 is defined as a placebo, which is an inactive treatment or substance used for comparison purposes.\n3. Both trials have a control group where the patients do not receive the primary intervention, and in both trials, this group is identified as Intervention 1.\n4. The statement correctly identifies Intervention 1 in both trials as the control group.</s>",
        "contradict": "The statement is not necessarily contradicted by the information in the CTRs, but it does make an assumption that the interventions specified as control groups in the secondary trial have the same role as those in the primary trial. However, based on the given descriptions, the interventions in the primary trial are different from those in the secondary trial. In the primary trial, Intervention 1 involves IUS alone, whereas in the secondary trial, Intervention 1 specifies a placebo with an intraoperative injection of saline. Although the primary and secondary trials may involve placebo groups, the nature and administration of the interventions are not identical. Therefore, the statement's assumption may not hold true for all instances and requires further context or clarification for accurate determination of entailment.</s>"
    },
    "e7e87023-2227-4594-931a-0a3d89ec686e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02073487",
        "Secondary_id": "NCT03371732",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy for opiod addiction are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not directly entailed by the information provided in the CTRs. The primary trial inclusion criteria explicitly exclude individuals with a history of substance abuse (alcohol or other drugs), and the secondary trial focuses on substance use specifically. The statement suggests that heavy smokers and patients undergoing methadone or buprenorphine therapy for opiod addiction are eligible for both the primary and secondary trials which contradicts the information given in the CTRs. Therefore, the statement does not hold under the given CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary CTR explicitly states that smokers are eligible only if they have an AUDIT-C score >1 or smoke more than one cigarette per day, and are not included if they are undergoing methadone or buprenorphine maintenance therapy for opioid addiction. The secondary CTR also includes these same conditions in its inclusion criteria, but the statement extends the eligibility criteria to include heavy smokers (more than 5 cigarettes smoked per day) and patients undergoing methadone or buprenorphine maintenance therapy. This goes beyond the information provided in the CTRs.</s>"
    },
    "ca4a190a-9007-4f8f-a199-b8fe4064e55b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02149524",
        "Statement": "Several adverse events which occurred in the primary trial were not heart related.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs as none of the adverse events listed in the Cardiac failure congestive and Myocardial infarction categories occurred in a frequency greater than 0% in both trials for the primary and secondary trial's Adverse Events 1 and 2 sections. Thus, the expert's statement is in agreement with the data presented and is an accurate observation based on the trial results.</s>",
        "contradict": "The statement \"Several adverse events which occurred in the primary trial were not heart related\" is contradicted by the information in the CTRs because the given statement is not entailed by the data presented. While it is true that some of the adverse events mentioned in the CTRs are not heart-related (e.g., febrile neutropenia, anemia, thrombocytopenia, haemolytic anemia, leukopenia, vertigo), the statement goes beyond this information and makes a more general claim about \"several\" adverse events not being heart related, while not specifying a number or providing evidence from the CTRs to support this claim. The CTRs do not provide sufficient information to determine if there are indeed \"several\" heart-related adverse events in comparison to non-heart related adverse events in the trials. Thus, the statement is contradictory to the information in the CTRs.</s>"
    },
    "4f790768-7fa4-4729-bcd6-cf7bcb44fa3c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00711529",
        "Secondary_id": "NCT02835625",
        "Statement": "the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial\" is not entailed by the information present in the CTRs. \n\nExplanation: \n\nThe statement asserts that cognitive behavioural therapy (CBT) is used in the primary trial but not in the secondary trial. However, the provided CTRs do not mention CBT as an intervention for either trial. Thus, the statement is not directly entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"the primary trial participants are treated with Cognitive behavioural therapy, this is not used at all in the secondary trial\" is contradictory to the information provided in the CTRs because hypnotherapy and not cognitive behavioural therapy is specified as the intervention for Participants in the Primary Trial. In contrast, no mention or indication of cognitive behavioural therapy as an intervention exists in the Secondary Trial.</s>"
    },
    "cb133915-dc40-4f93-a6a7-076e4d7f07a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02685566",
        "Secondary_id": "NCT03076190",
        "Statement": "the primary trial and the secondary trial have the same number of study groups, but are testing different interventions.",
        "Label": "Entailment",
        "entail": "Both primary and secondary trials each have two intervention groups. The primary trial compares FFDM Plus DBT and FFDM alone, while the secondary trial compares an Active Control Group and the My Surgical Success Intervention Group. The number of study groups being equal between the trials is a result of this pairing of interventions in each trial, not a shared intervention. Therefore, this statement's assertion that both trials have the same number of study groups is consistent with the information in the CTRs, and no contradiction exists.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have the same number of study groups\" is not directly contradictory to the information in the CTRs. However, the statement \"but are testing different interventions\" is contradictory. While both trials do have the same number of study groups, namely two, the interventions being tested are not the same. The primary trial compares FFDM Plus DBT with FFDM, whereas the secondary trial compares an Active Control Group with the My Surgical Success Intervention Group.</s>"
    },
    "1f0825b6-8e32-44ff-96b7-ab082e24b493": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00045032",
        "Secondary_id": "NCT00416572",
        "Statement": "WOCBP that refuse to use contraception are excluded from the primary trial, but may be eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial excludes women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures (WOCBP). The secondary trial includes female patients only, but does not mention any contraceptive requirement. WOCBP who refuse to use contraception are not explicitly mentioned in the primary trial as eligible for any trial participation, but they are not explicitly excluded from the secondary trial either. However, the secondary trial's inclusion criteria do not conflict with the primary trial's exclusion criteria for WOCBP not using contraception. Therefore, WOCBP who refuse to use contraception can be considered eligible for the secondary trial according to the information given, and this entails that their exclusion from the primary trial does not preclude their potential participation in the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the primary CTR due to its exclusion criteria for women of childbearing potential or less than 1 year post-menopause who are unwilling to use adequate contraceptive measures. This criterion directly opposes the statement that WOCBP who refuse to use contraception are eligible for the secondary trial.</s>"
    },
    "db96c4d6-ffcd-401a-8af3-807f665f16f7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs information as follows:\n\nPatients diagnosed with osteonecrosis (ONJ) are eligible for the primary trial but excluded from the secondary trial.\n\nExplanation:\n\n1. Primary Trial: Osteonecrosis is listed as an exclusion criteria for the secondary trial but not for the primary trial in the provided CTR. This implies that patients with osteonecrosis are potentially eligible for the primary trial.\n\n2. Secondary Trial: Osteonecrosis is listed as an exclusion criteria for the secondary trial with no mention of its inclusion in any of the provided CTR sections. This implies that patients with osteonecrosis are excluded from participating in the secondary trial.\n\nSince patients are eligible for a trial but excluded from another based on their osteonecrosis diagnosis as stated in the expert's claim, this information is entailed by the CTRs provided.</s>",
        "contradict": "The statement \"Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial\" is contradicted by the information present in the CTRs as follows:\n\nIn the primary trial: Osteonecrosis of the jaw (ONJ) is listed among the exclusion criteria.\n\nIn the secondary trial: Osteonecrosis is not mentioned as an inclusion or exclusion criterion. However, it is explicitly stated as an exclusion criterion in the primary trial, so patients with osteonecrosis cannot participate in the primary trial based on the provided CTR information. Since the statement suggests that patients with osteonecrosis can participate in the primary trial but are excluded from the secondary trial, it is a contradiction.</s>"
    },
    "b74dc1bc-76c3-4ce6-9735-634e7a507ff5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00976989",
        "Statement": "Patients with LVEF equal to 53.5% are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR specifies that the inclusion criteria for the primary trial include patients with baseline LVEF greater than or equal to 55%. The statement by the clinical trial expert can be entailed by this information as 53.5 falls within the range of 55% specified in the CTR. Thus, a patient with an LVEF of 53.5% still satisfies the LVEF requirement for trial participation according to the CTR.</s>",
        "contradict": "The statement that \"Patients with LVEF equal to 53.5% are eligible for the primary trial\" contradicts the inclusion criterion in the CTR, which specifies that \"baseline left ventricular ejection fraction (LVEF) >/=55%.\" Therefore, according to the CTR information, patients with an LVEF of 53.5% would not be eligible for the primary trial.</s>"
    },
    "f078c722-b879-40f2-ac72-c733001b93dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01740323",
        "Secondary_id": "NCT00127205",
        "Statement": "the secondary trial and the primary trial only accept 18 year olds.",
        "Label": "Contradiction",
        "entail": "Both trials include the inclusion criteria that patients must be 18 years old or older. Therefore, the statement that the secondary trial and the primary trial only accept 18 year olds is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial only accept 18 year olds\" is not directly contradicted by the information in the CTRs, as both trials explicitly state that participants must be 18 years old or older. However, the primary trial includes additional exclusion criteria that are not mentioned in the statement, such as pregnancy, major psychiatric disorders, autoimmune or inflammatory disorders, chronic infectious diseases, neurologic disorders, uncontrolled cardiovascular, metabolic, pulmonary or renal disease, substance abuse or dependence, and use of drugs known to affect the immune system or certain supplements or natural products. The secondary trial has additional eligibility criteria related to disease characteristics and prior concurrent therapy, but these do not conflict with the age requirement stated in the expert's statement. Therefore, the statement is not contradicted by the CTRs, but it is also not a complete representation of the inclusion criteria for either trial.</s>"
    },
    "c33d78e5-13be-4cde-b36e-7cc097f180a2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00068588",
        "Statement": "the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes.",
        "Label": "Contradiction",
        "entail": "Both trials assess the Maximum Tolerated Dose (MTD) of drugs using the same outcome measurement, i.e., dose-limiting toxicities (DLTs). The trials employ ruxolitinib and paclitaxel, which are identical in both trials. The cohort size for determining MTD in each trial consists of 3 patients per cohort for the first observation, followed by 3 additional patients per cohort if no DLTs are initially observed. These similarities align with the statement provided.</s>",
        "contradict": "The statement that \"the primary trial and the secondary trial use the same outcome measurements, same drugs and the same cohort sizes\" can be contradicted by the information present in the CTRs as follows:\n\n1. Different Outcome Measurement: In the primary trial, the MTD of ruxolitinib is determined based on the number of patients who have dose limiting toxicity (DLT) within a cohort. In contrast, the secondary trial determines the MTD through a different escalation schema based on the number of DLTs observed on each arm, and considers arms with at most 1/6 DLTs to be the MTD.\n\n2. Different Drugs: Although both trials use ruxolitinib, the secondary trial also uses GTI-2040, which is not used in the primary trial.\n\n3. Different Cohort Sizes: The cohort sizes are mentioned to be different in both trials. In the primary trial, 18 patients have been analyzed, while in the secondary trial, no patients have been analyzed on Arm 1 and only 3 patients on Arm 2.\n\nThus, the statement that the trials have the same outcome measurements, same drugs, and the same cohort sizes is not consistent with the information provided in the CTRs.</s>"
    },
    "58dbc33b-d32c-4e91-a940-ca1148bbdae4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00075270",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial is testing a chemotherapy treatment whereas the secondary trial is testing an implant\" is entailed by the information in the CTRs since:\n\n1. In the primary trial, Intervention 1 involves the use of lapatinib and paclitaxel, which are recognized chemotherapy treatments.\n2. In the secondary trial, neither Intervention 1 nor Intervention 2 involves chemotherapy; therefore, they represent a different class of interventions, namely implants, with AlloDerm RTU and SurgiMend PRS being specific types of such interventions.\n\nThus, the statement accurately describes the differences between the trials based on the information provided in the CTRs.</s>",
        "contradict": "Although the statement asserts that the primary trial is testing a chemotherapy treatment and the secondary trial is testing an implant, this is not necessarily a contradiction to the information present in the CTRs, as both trials involve interventions that include different types of treatments. In the primary trial, participants received lapatinib and paclitaxel, with lapatinib classified as a targeted therapy that works by inhibiting certain proteins (a type of chemotherapy), and paclitaxel as a standard chemotherapy drug. In contrast, the secondary trial involves the use of acellular dermal matrices, AlloDerm RTU and SurgiMend PRS, which are implant materials, not chemotherapies. Therefore, the statement is not a contradiction, but a correct observation, as long as the distinction between the types of interventions in each trial is acknowledged.</s>"
    },
    "fbbad9dc-58a9-4527-86c5-49cb0a3e7d0e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00602043",
        "Secondary_id": "NCT01720602",
        "Statement": "Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route.",
        "Label": "Entailment",
        "entail": "The statement asserts that none of the treatments in the primary trial are given by mouth. The interventions in the primary trial involve patients undergoing various imaging scans and beginning clinically indicated endocrine therapy, but there is no mention of any treatment being administered orally. In contrast, the secondary trial explicitly states that patients receive vorinostat, anastrozole, letrozole, or exemestane by mouth. As there is no overlap between the treatments given in the primary and secondary trials and no contradictory information regarding route of administration, the statement can be entailed by the data in the CTRs.</s>",
        "contradict": "The statement \"Several treatments in the secondary trial are administered by mouth, none of the treatments in the primary trial are given via this route\" is contradicted by the CTR information as follows: \n\n1. In the primary trial, patients undergo clinically indicated endocrine therapy. Endocrine therapy can be given by mouth, which contradicts the statement that no treatments in the primary trial are given via this route.\n2. In the secondary trial, patients receive vorinostat PO (by mouth) 5 days a week for 3 weeks. This directly contradicts the statement that no treatments in the primary trial are given via this route.\n3. In the secondary trial, anastrozole, letrozole, and exemestane are given PO (by mouth) daily for 4 weeks. These treatments also contradict the statement that no treatments in the primary trial are given via this route.\n\nHence, the statement is contradicted by the CTR information.</s>"
    },
    "2c462296-35f5-482a-9ece-3b4ed4c2f53a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the only recorded adverse event in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Urosepsis was the only recorded adverse event in the primary trial\" can be entailed by the information present in the CTRs because the CTR for the primary trial reports \"Urosepsis 2/12 (16.67%)\" under the Adverse Events section. The expert's assertion that \"Urosepsis was the only recorded adverse event\" is a specific instance of the more general information provided in the CTR.</s>",
        "contradict": "The statement \"Urosepsis was the only recorded adverse event in the primary trial\" is contradicted by the CTR information because, while urosepsis was an adverse event observed in the primary trial, there were also instances of brain hemorrhage complicating CNS metastasis and rash reported. Therefore, urosepsis was not the sole recorded adverse event.</s>"
    },
    "16358be6-3895-48f7-8006-4effeb3f74b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01196052",
        "Statement": "Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy\" can be entailed by the CTR information as follows:\n\n1. The CTR states \"Willingness to receive anthracycline-based chemotherapy or have received doxorubicin/cyclophosphamide (AC) OR 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) in a similar dose and schedule as described in the protocol as part of neoadjuvant or adjuvant treatment.\" This condition explicitly permits patients to have undergone cyclophosphamide-based chemotherapy.\n2. Although the CTR mentions the specific chemotherapy regimens (AC and FEC), it acknowledges patients may have already received these therapies. Therefore, the willingness to undergo cyclophoshamide-based chemotherapy is still required for those patients who have already received the treatment.\n3. The statement \"Participants in the primary trial must be willing to undergo cyclophosphamide-based chemotherapy\" can be seen as a more generalized version of the CTR condition. Thus, the former statement is entailed by the latter as the requirement is present and explicitly mentioned in the CTR.</s>",
        "contradict": "The statement can be contradicted by the inclusion criteria of the primary CTR, specifically, the condition that participants may have received doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (FU)/epirubicin/ cyclophosphamide (FEC) as part of their previous treatment. However, this statement does not specify that the cyclophosphamide should be part of the study treatment, which contradicts the assumption made in the expert statement.</s>"
    },
    "6d4ecb16-6586-4ea8-a1dc-f825e951e060": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00703326",
        "Secondary_id": "NCT00274768",
        "Statement": "Participants with HER2- primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Participants with HER2-positive primary liver tumors, confirmed by fluorescence in-situ hybridization are eligible for the secondary trial and the primary trial\" is entailed by the information present in both CTRs because:\n\n1. The primary trial includes participants with metastatic or locally-recurrent and inoperable breast cancer that is HER2-negative by various methods including FISH or IHC. However, the statement extends this eligibility to those with HER2-positive primary liver tumors.\n2. The secondary trial includes participants with adenocarcinoma of the breast and evidence of metastatic involvement, but the eligibility criteria for HER2 status are not explicitly stated. The statement makes it clear that participants with HER2-positive primary liver tumors, confirmed by FISH, meet the eligibility criteria for both trials. \n3. There is no contradiction in either CTR regarding HER2-positive liver tumors, as neither explicitly excludes them. Therefore, the statement harmonizes with clinical trial data and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The given statement can be contradicted by the information present in the CTRs because the primary trial inclusion criteria explicitly state that the participant's primary tumor must be HER2-negative, which is a prerequisite for eligibility. The secondary trial, on the other hand, mentions participants with HER2-positive liver tumors as eligible; this contradicts the primary trial's inclusion criteria.</s>"
    },
    "5bb009f0-bc19-4a85-85b8-bd7bf0675f3f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Secondary_id": "NCT00479674",
        "Statement": "Unlike the secondary trial, the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial does not record any instances of Anemia, Dyspepsia, Nausea or vomiting\" can be entailed by the information present in the CTRs because the CTR for the primary trial states that there were no reported instances of Anemia (0/35), Dyspepsia (0/35), Nausea (0/35), or vomiting (0/35) in the adverse events section. The absence of reported instances for these conditions in the primary trial is consistent with the statement made by the clinical trials expert.</s>",
        "contradict": "The statement contradicts the information in the CTRs as the primary trial records 0 instances (0%) of Anemia, Dyspepsia, Nausea, and vomiting while the CTR for the primary trial reports 1 instance (2.86%) of each of these adverse events (Anemia, Dyspepsia, and vomiting) occurring. Similarly, the primary trial records 1 instance (2.86%) of Nausea but the statement asserts that it did not record any instances at all.</s>"
    },
    "2731552d-195a-4f43-b6b5-02a3fbda81d9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01323530",
        "Secondary_id": "NCT01106040",
        "Statement": "the secondary trial and the primary trial do not have comparable Outcome Measurements.",
        "Label": "Entailment",
        "entail": "In the primary trial, the outcome measurements are defined as the number and percentage of participants experiencing Dose-limiting Toxicities (DLTs) according to NCI CTCAE v3.0 criteria. This is a distinct concept from the outcome measurement in the secondary trial, which is the concordance of blue dye and Lymphoseek in detecting lymph nodes during surgery. Therefore, the statement \"the secondary trial and the primary trial do not have comparable Outcome Measurements\" is entailed by the information provided in the CTRs as their outcome measurements are measuring different constructs.</s>",
        "contradict": "The information contained in the expert's statement can be contradicted by the following facts from the CTRs:\n\n1. The primary trial reports on the occurrence of Dose-limiting Toxicities (DLTs) using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 (NCI CTCAE v3.0), whereas the secondary trial reports on the concordance of blue dye and Lymphoseek in detecting lymph nodes during surgery. These are two distinct outcome measurements, and the primary trial focuses on safety while the secondary trial evaluates the efficacy of a diagnostic tool.\n\n2. Despite their differences in outcome measurements, both trials share some characteristics, like the clinical trial design (Phase 1b), and the presence of control or comparison arms, with different treatments or dosages. This common structure might lead to confusion, but it does not imply that the trials have comparable outcome measurements.\n\n3. The expert's statement implies that the trials are incomparable because they have different outcome measurements, which is a valid assumption. However, the statement is contradictory if it is used to claim that there is an entailment issue between the CTRs and the expert's statement, given that the trials have different outcome measurements by design.</s>"
    },
    "8fee5ce4-3e46-4731-842e-a5b1df451c7d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01231659",
        "Statement": "Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR).",
        "Label": "Entailment",
        "entail": "The statement \"Less than 40% of the primary trial participants achieved either complete response (CR) or partial response (PR)\" entails the information presented in the CTRs, specifically in the primary trial's RESULTS 1 section, as follows:\n\n1. ORR, defined as the sum of CR and PR percentages, is given as 37.2%.\n2. This implies that the percentage of participants with CR or PR is equal to or less than 37.2%.\n3. The expert's statement, claiming that less than 40% of participants achieved CR or PR, is therefore consistent with the data provided in the CTR.\n\nHence, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The expert's statement contradicts the information in the primary CTR as the ORR, which includes both CR and PR, was reported to be 37.2% for the Everolimus + Letrozole arm, meaning over 37.2% of the participants achieved some form of response according to the trial definitions.</s>"
    },
    "def4199f-a22d-4939-b15d-66fd073fb280": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group.",
        "Label": "Entailment",
        "entail": "The control group in clinical trials is typically the group that receives the standard of care or a placebo, not the experimental treatment. In the provided CTR, Intervention 2 does not involve the administration of GnRHa to patients with breast cancer undergoing chemotherapy. Therefore, the patients in this group are considered as not receiving any additional treatment, similar to a placebo group. Thus, according to the given trial design, cohort 1 (GnRHa group) can be regarded as the experimental group, and cohort 2 (no GnRHa group) is, in fact, the control group. This assertion aligns with the CTR information and does not contradict it, making it an entailed statement.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial is the control group\" cannot be directly contradicted by the information in the CTRs provided, but it can be misleading without additional context. However, the statement is not an entailed relationship because the CTRs do not explicitly label the \"None GnRHa (Gonadotrophin-releasing Hormone Analogues) Group\" as the control group. In the primary trial, the control group is not necessarily defined by the absence of GnRHa treatment alone. Therefore, more context or information is required to determine if the statement holds true in this case.</s>"
    },
    "c16dcd52-f2f0-40b7-9b2b-af3fd7f438b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00871858",
        "Statement": "1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma\" can be entailed by the information in the CTRs, as both reports state that there was 1 occurrence of Clear cell kidney cancer in their respective patient cohorts (0.00% in the primary trial with 60 patients and 1.72% in the secondary trial with 58 patients). Despite the difference in prevalence rates, the presence of at least one patient with this diagnosis in both trials satisfies the requirement for semantic entailment.</s>",
        "contradict": "The statement \"1 patient in the primary trial was diagnosed with a Clear cell renal cell carcinoma\" contradicts the information in the CTRs as both reports state that no patients in the respective trials were diagnosed with Clear cell kidney cancer (0/60 in Primary Trial and 0/58 in Secondary Trial).</s>"
    },
    "d97c3981-50f9-4221-aec6-60661b831c8e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03624972",
        "Secondary_id": "NCT01216176",
        "Statement": "A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because both trials have exclusion criteria that specify patients with overt cognitive dysfunction or psychiatric disturbance as ineligible. Memory loss, especially occasional, could potentially fall under the category of cognitive dysfunction. Therefore, according to the CTRs, a patient with occasional memory loss would not meet the eligibility criteria for either trial and thus would be excluded.</s>",
        "contradict": "The statement that \"A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial\" is contradictory to the information present in the CTRs because neither trial includes memory loss as an exclusion criterion. The primary trial excludes patients with severe mental illness, but memory loss is not specifically mentioned. The secondary trial does not mention memory loss as an exclusion criterion either. Therefore, a 56 year old patient presenting occasional memory loss would not be excluded based on the provided CTRs.</s>"
    },
    "86c1430c-553b-4388-a034-b82f78afdc0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01028352",
        "Statement": "Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial\" can be entailed by the inclusion criteria specified in the CTR. Specifically, this statement aligns with the CTR's definition of \"AI-associated musculoskeletal symptoms\" and the corresponding eligibility criterion for the trial. This statement also avoids contradiction with provided descriptions.</s>",
        "contradict": "The statement \"Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or grade 0 sensory neuropathy, are eligible for the primary trial\" is not contradictory to the CTR information, but it can be incomplete. The CTR explicitly states that patients must have AI-associated musculoskeletal symptoms (either Grade 1 or higher musculoskeletal pain or sensory neuropathy) to be eligible. However, the expert statement does not mention that the patients must also have a histologically proven stage 0-III invasive carcinoma of the breast that is ER and/or PR positive by immunohistochemical staining and receiving a standard dose of aromatase inhibitor therapy. Therefore, while the statement does not contradict the CTR, it does not capture the full inclusion criteria for the trial and may not be accurate in all contexts.</s>"
    },
    "b7cef0e1-7bd8-4c0e-a044-b11708cf927c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01905592",
        "Statement": "both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies.",
        "Label": "Contradiction",
        "entail": "The statement \"both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies\" is entailed in the CTRs since:\n\n1. In the primary trial, Intervention 1 specifies that patients receive \"Physician's Choice\" among 4 standard of care metastatic breast cancer chemotherapies.\n2. In the secondary trial, no specific intervention is mentioned, implying that patients also receive the standard of care treatments, which aligns with the \"Physician's Choice\" option described in the primary trial.</s>",
        "contradict": "The statement \"both the primary trial cohorts receive Physician selection from 4 standard of care metastatic breast cancer chemotherapies\" is contradictory to the information provided in the CTRs because, in the primary trial, the intervention indeed includes physician selection from 4 standard of care chemotherapies. However, in the secondary trial, the intervention does not mention such physician selection but instead specifies Niraparib as the specific intervention. Thus, while both trials involve the use of standard of care chemotherapies, they differ in the method of intervention assignment, which is a crucial distinction that undermines the entailment of the expert's statement given the information from the CTRs.</s>"
    },
    "0b55d5b7-5e71-497f-96ad-9dc2f872c4aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00444587",
        "Statement": "A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"A total of 2/93 patients in the primary trial were observed with either Leukopenia, Cardiopulmonary failure or Diarrhoea\" is entailed by the CTR data as follows: \n\n1. The number of patients with Leukopenia is 2.\n2. The number of patients with Cardiopulmonary failure is 2.\n3. The number of patients with Diarrhoea is 3. However, since the expert's statement specifies exactly two patients with any of the mentioned conditions, it does not entail the information about Diarrhoea. Nonetheless, the information about Leukopenia and Cardiopulmonary failure is directly entailed by the CTR data. \n\nThe expert's statement can be strengthened if it includes the specific condition (Leukopenia and Cardiopulmonary failure) instead of the general class (Leukopenia, Cardiopulmonary failure, or Diarrhoea) to fully entail the provided data.</s>",
        "contradict": "The information in the expert's statement can be contradicted by the data in the CTRs because the statement claims that 2 patients had either Leukopenia, Cardiopulmonary failure, or Diarrhoea, while the CTR reports distinct numbers of patients for each condition: 2 for Leukopenia, 2 for Cardiopulmonary failure, and 3 for Diarrhoea. Therefore, according to the CTR data, more than 2 patients had one of the mentioned conditions.</s>"
    },
    "225f95a5-7c22-4cb7-a463-1c57d5b69d7a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01217385",
        "Secondary_id": "NCT01202591",
        "Statement": "Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Prior exposure to exemestane is not explicitly banned for patients in the secondary trial or the primary trial\" can be entailed by the information in the CTRs as neither CTR explicitly mentions \"prior exposure to exemestane\" as a specific exclusion criterion. In the secondary trial CTR, \"Prior exposure to fulvestrant or any agent known to inhibit FGFRs\" is mentioned as an exclusion criterion, but it does not include exemestane. Similarly, in the primary trial CTR, \"Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy\" is a general inclusion exclusion criterion, but it does not specifically mention exemestane. Therefore, the statement is harmonious with the CTR data and does not contradict the provided descriptions, making it an instance of semantic entailment.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as the primary CTR explicitly states \"Exclusion Criteria: Previous treatment (chemotherapy, radiation, or surgery) to involved breast; including hormone therapy\" and the secondary CTR states \"Prior exposure to exemestane (safety run-in)\" as an exclusion criterion. Exemestane is a form of hormone therapy. Consequently, the statement, which claims that prior exposure to exemestane is not an exclusion criterion for both trials, is contradicted by the information provided in the CTRs.</s>"
    },
    "5464e8a7-159c-4e00-8710-45a44ceaeda3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03061175",
        "Secondary_id": "NCT03098550",
        "Statement": "Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study\" is entailed by the following information in the CTRs:\n\nPrimary Trial INTERVENTION 1, Arm I: \"Patients receive a website address, a secure username and password, and instructions for using the web-based CPM-DA.\" - This statement does not contain any information regarding the dosage or duration of the intervention.\n\nSecondary Trial INTERVENTION 1, Cohort 1 (TNBC): \"Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" - The dosage and duration for Daratumumab in this cohort are not constant throughout the study.\n\nSecondary Trial INTERVENTION 1, Cohort 1 (NSCLC): \"Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)\" - The dosage and duration for Daratumumab in this cohort are also not constant throughout the study.\n\nThus, the statement is entailed by the information present in the CTRs as it accurately describes the different dosing regimens for Daratumumab in the two cohorts of the secondary trial, compared to the lack of dosing information for the intervention in the primary trial.</s>",
        "contradict": "The statement \"Cohort 1 of the secondary trial does not receive the same doses of Daratumumab for the entire duration of the study, whereas Cohort 1 of the primary trial has the same intervention for the full study\" is not directly contradicted by the information present in the CTRs. However, it implies a difference in Daratumumab dosing frequency between the two trials, while the CTRs only specify the different treatment regimens for each trial without mentioning specific differences in dosing frequency for Cohort 1. The statement is not contradictory, but it goes beyond the information given in the CTRs.</s>"
    },
    "98965d07-e2db-41bf-ac3e-a5c130513275": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00382018",
        "Secondary_id": "NCT03012477",
        "Statement": "Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis.",
        "Label": "Contradiction",
        "entail": "The statement \"Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis.\" can be entailed by the information present in the CTRs as neither trial has a reported instance of sepsis in the Gastrointestinal-Other category of Adverse Events for the primary trial, and only one instance is reported for the secondary trial.</s>",
        "contradict": "The statement \"Between the patients in the primary trial and the secondary trial, only 1.56% suffered from sepsis\" contradicts the information present in the CTRs since none of the patients in the primary trial (0/161) experienced sepsis, whereas one patient (1/64) in the secondary trial did. Therefore, the percentage of patients suffering from sepsis is higher in the secondary trial (1.56%) than in the primary trial (0.00%).</s>"
    },
    "784cc905-937f-43fd-96a6-34ea8dce9e8d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429104",
        "Secondary_id": "NCT00878709",
        "Statement": "Patients with end-stage liver disease are excluded from the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails that the primary and secondary trials both exclude patients with liver disease. This is inferred as both sets of inclusion criteria specifically mention adequate liver function, and the exclusion criteria list chronic active hepatitis or cirrhosis as conditions that disqualify participants. No mention of end-stage liver disease is present in either set of criteria, and its exclusion aligns consistently with the stated conditions. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Patients with end-stage liver disease are excluded from the primary trial and the secondary trial\" is not directly contradicted by the information in the provided CTRs. However, the primary CTR includes \"adequate liver function\" as an inclusion criteria, but it doesn't specify what constitutes end-stage liver disease or its opposite (adequate liver function). The secondary trial's exclusion criteria mention no liver disease related exclusion, but it also doesn't define end-stage liver disease. The statement can't be definitively proved or disproved based on the information provided in the CTRs alone.</s>"
    },
    "2e3f2fde-569e-46ef-958d-710599fec9a1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00706030",
        "Secondary_id": "NCT00171704",
        "Statement": "the primary trial studies the interventions impact on target lesions and the secondary trial measures changes in Bone Mineral Density, the results from these two studies are therefore not directly comparable.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs due to the following reasons. First, the primary trial and the secondary trial focus on distinct outcome measurements. The primary trial measures the Overall Response Rate of ErbB-2-positive breast cancer patients to the combination therapy of neratinib and vinorelbine using RECIST v1.0 criteria. In contrast, the secondary trial measures the Percent Change From Baseline of Bone Mineral Density (BMD) of the lumbar spine (L2-l4) in postmenopausal women with early breast cancer receiving letrozole or the combination of tamoxifen and letrozole.\n\nSecond, the trials involve different study populations. While the primary trial examines the effects on ErbB-2-positive breast cancer patients, the secondary trial focuses on hormone receptor-positive early breast cancer patients. These differences in patient populations make it challenging to draw direct comparisons between the trials.\n\nIn summary, the statement that the primary trial and secondary trial results are not directly comparable follows from the information provided in the CTRs that the trials investigate different outcome measurements and populations.</s>",
        "contradict": "Despite the difference in outcome measurements between the two trials - target lesions in the primary trial and bone mineral density in the secondary trial - the statement does not necessarily imply contradiction. The trials' focus on different aspects of treatment effect does not automatically mean their results cannot be compared in certain contexts. For instance, understanding the impact of the interventions on overall patient health, including bone mineral density, could provide a more comprehensive assessment of their safety and efficacy. The expert statement's limitation lies in its oversimplification, implying that comparisons between trials with varying outcome measurements cannot be made at all, whereas the CTRs do not inherently preclude such comparisons.\n\nHowever, based on the given information, there is no clear semantic entailment between the statement and the CTRs. The CTRs do not provide sufficient details to directly compare the trials, such as the patient populations' baseline characteristics or the treatments' potential effects on bone mineral density. Thus, further analysis would be required to establish a relationship between the trials.</s>"
    },
    "d1080199-2591-44bd-bdad-0dea3830e657": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial participants are treated with 600 mg/m2 of Pemetrexed intravenously every 2 weeks until complete response or disease progression.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trial expert is entailed by the information present in the CTRs as it accurately reflects the intervention section of the primary trial. Both the statement and the CTR specify the same dose (600 mg/m2), route of administration (intravenous), frequency (every 2 weeks), and duration of treatment (until complete response or disease progression) for Pemetrexed. Therefore, the statement is a logical consequence of the data in the CTR and does not contradict it, making it entailed by the CTR information.</s>",
        "contradict": "The statement made by the clinical trial expert is identical to the description of the intervention in the primary CTR. Therefore, there is no contradiction between the statement and the CTR information. However, a potential source of confusion or contradiction could arise if the secondary trial involved a different treatment or dosage for Pemetrexed, which would not entail the same conditions described in the primary CTR. In this case, a comparative analysis between the two trials would need to account for their differences.</s>"
    },
    "c37c21f5-19a0-4fcc-af92-89690fb64091": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort receives a 750mg Low-dose Omega-3 Fatty Acid and the other 500mg, in contrast the difference in the secondary trial is patient characteristics.",
        "Label": "Contradiction",
        "entail": "The expert's statement refers to differences between groups in terms of intervention dosage in the primary trial and patient characteristics in the secondary trial. In the primary trial, one cohort (Arm I) receives low-dose omega-3 fatty acid (500mg) and the other cohort (Arm II) receives high-dose omega-3 fatty acid (750mg). In the secondary trial, Cohort A and Cohort B both receive identical lapatinib dosage (750mg), but differ in their patient characteristics (performance status and number of prior trastuzumab regimens). \n\nThe expert's statement is entailed by the information in the CTRs because:\n1) The primary trial clearly states the different dosages of omega-3 fatty acid given to each cohort.\n2) The secondary trial explicitly describes the differences in patient characteristics between the two cohorts.\n3) The expert's statement accurately summarizes the nature of these differences.\n\nTherefore, the expert's statement is an entailed conclusion based on the data presented in the CTRs.</s>",
        "contradict": "The statement's assertion that the differences between cohorts in the primary trial are related to the dose of Omega-3 Fatty Acid (750mg vs. 500mg), whereas the differences in the secondary trial are about patient characteristics, contradicts the information provided in the CTRs. In the primary trial, both cohorts received the same type and route of Omega-3 Fatty Acid administration (both given PO), and the difference lies in the dose (low-dose vs. high-dose). In the secondary trial, the differences are in the patient characteristics (ECOG performance status and number of prior trastuzumab-containing regimens) and the type of intervention (lapatinib instead of Omega-3 Fatty Acid). The statement's assertion of 750mg being a low-dose and 500mg being a high-dose contradicts the information in the primary trial.</s>"
    },
    "bea7f10e-09d6-42c3-9e89-dfd1112a33d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01276041",
        "Secondary_id": "NCT00688909",
        "Statement": "0 patients in the primary trial or the secondary trial died.",
        "Label": "Contradiction",
        "entail": "The statement \"0 patients in the primary trial or the secondary trial died\" is entailed by the information in the CTRs as none of the Adverse Events sections list any deaths due to a specified cause, and the total adverse events in both trials add up to less than the stated number. In the Primary Trial, there was 1 death NOS (death of unspecified cause, 1.43%). However, this event is not mentioned in the statement as it is an unspecified death. Similarly, in the Secondary Trial, there are no mentions of deaths in the given Adverse Events sections. Thus, the statement is harmonious with the clinical trial data and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"0 patients in the primary trial or the secondary trial died\" is contradicted by the information present in the CTRs as follows: \n\n1. In the primary trial, one patient experienced death NOS (death of unknown cause), which is recorded as an adverse event with a frequency of 1.43%.\n2. In the secondary trial, there is no mention of any death reported in the provided adverse events section, but the statement does not explicitly state that no death occurred in this trial. However, based on the information given, it cannot be inferred that the secondary trial had no deaths at all.</s>"
    },
    "3d41d86b-f53f-4bf9-a4dd-eae2412c485e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy .",
        "Label": "Contradiction",
        "entail": "The statement \"Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy\" is entailed by the CTRs because, in the Primary Trial's Intervention 1, patients in Arm A receive endocrine treatment consisting of letrozole. In Intervention 2, patients in both Arms A and B receive endocrine treatment. Thus, both cohorts undergo Endocrine Therapy, and only one arm (cohort 2) receives letrozole as part of that therapy.</s>",
        "contradict": "The statement \"Only cohort 2 of the primary trial receive letrozole, but both cohorts undergo Endocrine Therapy\" is contradictory to the information in the CTR. The contradiction lies in the fact that, according to the CTR, both cohorts (Arm A and Arm B) indeed undergo Endocrine Therapy, but Cohort 2 in addition receives bevacizumab. Hence, the statement incorrectly suggests that only one cohort receives endocrine therapy, while the other does not.</s>"
    },
    "0159bfb3-231e-4711-b3ee-2798c66f5f6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01015131",
        "Secondary_id": "NCT00312208",
        "Statement": "Both the primary trial and the secondary trial record instances of Rectal Hemorrhage within their patient cohorts.",
        "Label": "Contradiction",
        "entail": "neither of the CTRs directly report instances of \"Rectal Hemorrhage\" in their Adverse Events sections. However, the statement can be entailed indirectly since the term \"hemorrhage\" implies bleeding, and one instance of bleeding in the form of \"Vaginal Hemorrhage\" is reported in the secondary trial. While the exact site of bleeding in the primary trial is specified as \"Rectal,\" the absence of this detail in the CTR does not contradict or negate the expert's statement. The overall meaning of the expert's statement can be derived from the data in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because neither the primary nor the secondary trial reports record any instances of \"Rectal Hemorrhage\" as an adverse event. The provided CTRs list \"Rectal bleeding\" in the primary trial, but it does not equal \"Rectal Hemorrhage.\" The two terms may have similar meanings, but they are not identical. The expert's statement, as it stands, is not entailed by the information presented in the CTRs.</s>"
    },
    "9e7628cd-931e-4b1f-b4c1-f03f0449ac27": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the cranial and foot area, the secondary trial does not record any types of pain in its participants. ",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because, in the primary trial, the types of pain mentioned in the adverse events section are \"Pain - Chest\" and \"Pain - Abdomen,\" which do not correspond to \"pain in the cranial or foot area.\" However, the statement only compares the presence or absence of \"types of pain,\" not specifically \"pain in the cranial or foot area.\" The secondary trial does not report any types of pain mentioned in the primary trial, including pain in the cranial or foot area, making the statement consistent with the information in both CTRs.</s>",
        "contradict": "The information in the statement can be contradicted by the CTRs because both trials report adverse events that include instances of pain (in the primary trial, pain - abdomen, pain - chest, and in the secondary trial, peripheral neuropathy, which can be considered a pain-related condition). Despite the statement suggesting that the secondary trial does not record any types of pain in its participants, the data in the CTR indicates otherwise.</s>"
    },
    "f1108cbc-db27-431d-9154-1a267278bda4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and  Leukopenia were only observed in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Cases of Cardiomyopathy and Leukopenia were only observed in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs because:\n\n1. Cardiomyopathy: In the primary trial, CTR1, there is one reported case of Cardiomyopathy in the Adverse Events section under the Total count (1/1634).\n2. Leukopenia: In the primary trial, CTR1, there are 18 cases of Leukopenia reported in the Adverse Events section under the specific count (18/1634). However, in the secondary trial, CTR2, there are 56 cases reported in the Adverse Events section under the specific count (56/1635). Since the statement specifies that these conditions were only observed in CTR1, the absence of these conditions in CTR2 supports the statement.\n\nAdditionally, there are no reported cases of Cardiomyopathy or Leukopenia in CTR2, and the other mentioned adverse events are present in both trials, either with the same name or slightly different forms (e.g., Arrhythmia vs. Arrhythmia Ventricular). This absence of reported cases in CTR2, along with the presence of the conditions in CTR1 and the absence of contradictory information, allows the statement to be entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR data as there is a report of one case of Cardiomyopathy in the primary trial (Section: Adverse Events 1, Total: 1/1634), and Leukopenia was observed in both cohorts 1 (18/1611) and 2 (56/1623) of the primary trial (Section: Adverse Events 1) and in the secondary trial (Section: Adverse Events, exact number not provided), making it not exclusively limited to cohort 1.</s>"
    },
    "8eb69e3e-ac08-4e85-98be-211aecd4525d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04396665",
        "Statement": "Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet.",
        "Label": "Entailment",
        "entail": "The statement \"Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet\" is entailed by the primary CTR's inclusion criteria stating \"Informed consent signed\" and \"Capability to use internet.\" There is no contradictory information in the CTRs that would negate this statement, as the exclusion criteria do not mention any other requirements for trial entry. The statement accurately summarizes the inclusion criteria presented in the CTR.</s>",
        "contradict": "The statement \"Any patient can enter into the primary trial as long as they are willing to provide Informed consent and are capable of using the internet\" is not entirely accurate based on the information in the CTRs provided. The primary trial's inclusion criteria specify only the requirement of informed consent and capability to use the internet. However, the exclusion criteria state that patients with a breast cancer diagnosis during the intervention are not eligible for the trial. Thus, the statement contradicts the CTRs by implying that breast cancer diagnosis is not a factor for exclusion from the trial.</s>"
    },
    "baf7e338-91fd-47d0-b766-a4e039efc5d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01432886",
        "Statement": "None of the patients in either cohort of the primary trial experienced DLT.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in either cohort of the primary trial experienced DLT\" does not directly entail the information present in the CTRs. However, it can be derived from the given data if we make certain assumptions and interpretations. \n\nFirst, we need to understand that DLT evaluation was based on CTCAE v4.0 guidelines, and the defined DLTs include specific conditions like grade 4 neutropenia persisting for more than 7 days, grade 3 or above febrile neutropenia, grade 4 thrombocytopenia or grade 3 thrombocytopenia requiring blood transfusion, and non-hematologic toxicity greater than or equal to grade 3, among others.\n\nSecond, in the given CTR, the number of participants with DLT is not explicitly mentioned. Instead, the text describes the criteria for DLT evaluation and the occurrence of day 8 administration delays or skips due to subjects not meeting dosing criteria within the cycle. \n\nThird, based on these descriptions, and assuming that all other conditions were met, it can be inferred that no participants in either arm experienced any of the defined DLTs. However, we cannot definitively assert this conclusion without access to additional information, such as specific details about individual participants' adverse events, laboratory values, and treatment responses.\n\nIn summary, the expert's statement can be entailed by the information in the CTRs with some assumptions and interpretations, but it is not directly entailed based on the given data alone.\n\nAdditionally, the expert's statement is consistent with the information in the CTRs, as there are no contradictions or inconsistencies.</s>",
        "contradict": "The expert's statement contradicts the information in the CTRs as the CTRs define DLTs as specific adverse events (e.g., grade 4 neutropenia persisting for more than 7 days), which were not explicitly stated to have occurred in zero participants for both arms of the primary trial. The CTRs only report the number of participants analyzed for each arm without specifying if any of them experienced DLTs. Thus, the statement cannot be definitively confirmed or denied based on the provided CTR information.</s>"
    },
    "9401b12d-3888-4a41-93a1-b2075930098b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00458237",
        "Statement": "Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The CTR for the primary trial includes an exclusion criterion stating that patients who have undergone major surgery within 2 weeks before study entry are not eligible. The secondary statement, however, allows patients who have undergone external beam radiation therapy and major surgery in the last two weeks to participate in the trial. This apparent discrepancy can be explained by the different meanings of the term \"major surgery.\" While the CTR uses a broad definition of \"major surgery\" that encompasses all major surgical procedures, the clinical trials expert in the secondary statement might be referring specifically to non-radiotherapy surgical interventions. As external beam radiation therapy is not classified as a form of major surgery in the primary trial's context, this statement can be considered entailed by the CTR, as it does not contradict any of its inclusion or exclusion criteria.</s>",
        "contradict": "The statement \"Patient who have undergone External beam radiation therapy and major surgery in the last two weeks are eligible for the primary trial\" contradicts the CTR inclusion criteria as specified in the primary trial's exclusion criteria where it mentions \"Major surgery within 2 weeks before study entry\" as a reason for exclusion.</s>"
    },
    "c7aa030a-6b76-4bd7-a934-f02a4638a1ac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00908791",
        "Secondary_id": "NCT00297596",
        "Statement": "Female patients over the age of 60, with Histologically confirmed breast cancer and advanced Alzheimer's disease are ineligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\nIn primary CTR: The patients must have sufficient cognitive ability to give informed consent and comply with the protocol, excluding those with dementia or significantly altered mental status (Section \"Exclusion criteria: A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment, Significant cardiac disease, including uncontrolled high blood pressure, unstable angina, and congestive heart failure, myocardial infarction within the previous 3 months or serious cardiac arrhythmias, Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.\"). \n\nIn secondary CTR: The patients must have adequate mental capacity to comply with the treatment protocol and understand the requirements of informed consent, excluding those with dementia or significantly altered mental status (Section \"Exclusion Criteria: Dementia or significantly altered mental status that would interfere with proper consenting.\").\n\nThus, the statement is entailed by the CTRs since female patients suffering from advanced Alzheimer's disease would not meet these mental capacity criteria, making them ineligible for participation in both trials.\n\nAdditionally, the statement's age requirement is also consistent with the minimum age requirement in both CTRs (18 years and above). Therefore, the statement is further harmonious with the CTRs.\n\nThe statement does not contradict the provided descriptions in any way, and it can be derived directly from the eligibility criteria in the CTRs.</s>",
        "contradict": "The statement contradicts the information presented in both CTRs as neither trial includes patients with advanced Alzheimer's disease as a specific inclusion or exclusion criterion. The statement incorrectly assumes that advanced Alzheimer's disease is a reason for ineligibility in both cases, when in fact, it is not mentioned in the given eligibility criteria for either trial.</s>"
    },
    "94f9a957-33bb-4409-8878-ba734d6b0d5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01823107",
        "Statement": "several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts.",
        "Label": "Contradiction",
        "entail": "The statement \"several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts\" can be entailed by the information presented in the CTRs if the following conditions are met:\n\n1. Some patients from the Meso BioMatrix Acellular Peritoneum Matrix arm of the primary trial experienced Breast Related Adverse Events in both reconstructed breasts.\n2. The definition of a Breast Related Adverse Event in the primary trial encompasses adverse events in both reconstructed breasts.\n3. The number of participants in the primary trial who suffered Breast Related Adverse Events in both breasts is within the range of \"several\". This term is not well-defined, but if we assume a conservative estimate of \"several\" being fewer than 10, then the reported 12 cases of breast-related adverse events in 25 participants would meet this criterion.\n\nTherefore, if these conditions hold, then the statement can be considered entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement that \"several Patients implanted with a Meso BioMatrix Acellular Peritoneum Matrix suffered Breast Related Adverse Events in both reconstructed breasts\" contradicts the information in the CTR as the CTR reports a total of 12 breast related adverse events affecting 12 out of 25 participants (48%). However, the statement does not specify whether the adverse events occurred in one or both breasts, leaving open the possibility of the contradiction. If the expert's statement is referring to cases where both breasts were affected for some of the 12 participants, then the statement is consistent with the data in the CTRs. If the expert's statement is referring to more than two of the 12 participants having adverse events in both breasts or to additional participants beyond the 12 reported in the CTRs, then the statement contradicts the information in the CTRs.</s>"
    },
    "04fd88c2-cf92-468d-bbc4-567cae19948d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00087152",
        "Secondary_id": "NCT00203502",
        "Statement": "the primary trial recorded less patients with nausea than the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial reported 1 instance of nausea in 20 patients (5.00%), whereas the secondary trial reported 4 instances in 39 patients (10.26%). The statement \"the primary trial recorded less patients with nausea than the secondary trial\" is entailed by the information in the CTRs as it accurately compares the frequencies of nausea occurrences between the two trials and reflects the numerical data presented.</s>",
        "contradict": "The statement \"the primary trial recorded less patients with nausea than the secondary trial\" is contradicted by the information present in the CTRs because the primary trial report recorded one patient (5.00%) experiencing nausea, whereas the secondary trial report recorded four patients (10.26%) with nausea or vomiting. Consequently, the secondary trial had more instances of nausea or vomiting compared to the primary trial.</s>"
    },
    "8a0d98d1-3a04-4fe4-8dc9-a41fdad5acdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00499122",
        "Secondary_id": "NCT00454805",
        "Statement": "There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial\" is entailed by the information present in the CTRs as neither of the trials reported any case of Multi-Organ Failure in cohort 1. In the primary trial, there were 0 cases out of 41 participants, while in the secondary trial, there was 0 case out of 31 participants in cohort 1. Hence, the statement is an accurate reflection of the data presented in the CTRs.</s>",
        "contradict": "The statement \"There were no cases of Multi-Organ Failure in both cohort 1 of the secondary trial and cohort 1 of the primary trial\" can be contradicted by the information present in the CTRs because, in the primary trial, there was 1 case (1/41 or 2.44%) reported in the first cohort under Adverse Events section.</s>"
    },
    "8074c35f-b74c-4250-94f1-9ad22fa315d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Secondary_id": "NCT00579826",
        "Statement": "Patients diagnosed with osteoporosis are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial includes patients with histologically confirmed Stage IV breast cancer, some of whom may have been diagnosed with osteoporosis. However, the secondary trial specifically excludes patients with a prior history of osteoporosis or osteoporotic fracture. Therefore, while some patients in the primary trial may have osteoporosis, the CTRs provide sufficient information to entail that such patients would be excluded from the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as the primary trial includes patients with a history of osteoporosis or osteoporotic fractures as a criterion for exclusion. However, according to the statement, these patients are eligible for the primary trial instead.</s>"
    },
    "afc4a45b-6592-4ca8-b174-033fb6a0624a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy less than 12 weeks to particpate in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's exclusion criteria specify that subjects with a life expectancy of less than 12 weeks are not eligible. This condition is also present in the statement regarding the trials, indicating that the statement is a logical consequence of the information in the primary CTR. Similarly, the secondary trial's exclusion criteria do not mention a life expectancy limit, but it is reasonable to assume that the trials have similar eligibility requirements since they are both clinical trials for breast cancer treatments. Thus, the statement can be entailed by the information in both the primary and secondary CTRs.</s>",
        "contradict": "The statement \"Candidates must have a life expectancy less than 12 weeks to participate in the primary trial and the secondary trial\" is contradicted by the eligibility criteria in both CTRs. In the primary CTR, the life expectancy of less than 12 weeks is not an inclusion criterion, but an exclusion criterion. In the secondary CTR, there is no mention of life expectancy as an inclusion or exclusion criterion.</s>"
    },
    "2e1d4811-ae58-4b81-b53a-dbcb8c980a08": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Elizabeth has HER2 positive breast cancer, she is eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Elizabeth's eligibility for the primary trial is entailed by the CTR inclusion criteria. She meets the conditions stated in the report: she is a woman aged > 18 years; has histologically confirmed metastatic breast cancer; is HER2 positive according to FISH; has a life expectancy of > 3 months; and uses effective means of contraception. Furthermore, the CTR permits women who have previously received treatment for their metastatic disease (as stated in the primary trial inclusion criteria for phase I) and those with measureable disease (as stated for phase II, but Elizabeth's disease measures > 2 cm) to participate. Since Elizabeth's eligibility aligns with the conditions outlined in the CTRs, the expert's statement is entailed.</s>",
        "contradict": "Elizabeth's eligibility for the primary trial, as stated, is consistent with the trial's inclusion criteria regarding HER2 positivity and the absence of prior Herceptin for metastatic disease. However, there is a contradiction with the trial's exclusion criteria for Phase II, which states that patients cannot have prior cytotoxic chemotherapy for their metastatic disease. Since the information provided about Elizabeth does not specify the trial phase she would enter, it is impossible to determine with certainty whether she would be eligible for the phase II portion of the trial based on the information provided in the CTR.</s>"
    },
    "d4f738c5-c99a-4d8d-b335-5821ce97fbd5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criteria specify that women with a histologically or cytologically confirmed diagnosis of adenocarcinoma originating in the breast are eligible, while those who have undergone three or more lines of chemotherapy in the metastatic setting are excluded. The secondary trial inclusion criteria state that adult participants must be candidates for chemotherapy, but exclude those with a history of prior chemotherapy for metastatic breast cancer or recurrent locally advanced disease within the last 6 months. \n\nThe statement made by the clinical trials expert can be entailed by the information in the CTRs as follows: The primary trial includes women who may become \"completely disabled\" due to breast cancer but are not excluded if they have undergone fewer than three lines of chemotherapy in the metastatic setting. The secondary trial, however, excludes participants who are \"completely disabled\" and have a history of chemotherapy, ensuring that those who are unable to care for themselves and meet the other inclusion criteria of the secondary trial are not eligible for participation. Therefore, the statement is consistent with the information in the CTRs, as it accurately describes the patient population eligible for the primary trial and the exclusion criteria of the secondary trial.</s>",
        "contradict": "The statement \"Completely disabled patients, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial\" is contradicted by the information present in the CTRs because the primary trial explicitly includes a criterion of \"Women 20 years and above\" while the secondary trial includes \"Adult participants >=18 years of age\" but does not mention any specific disability criteria. Furthermore, the secondary trial excludes participants who have \"Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1,\" which implies good performance status and functional ability.</s>"
    },
    "f27b25bd-c28e-4aac-8ad6-951fd7381ce4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01262027",
        "Statement": "More than 1 patient in the primary trial suffered an adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"More than 1 patient in the primary trial suffered an adverse event\" can be entailed by the information present in the CTRs, since the primary trial's Adverse Events section reports that 1/22 or 4.55% of patients experienced an adverse event (in this case, an increase in blood bilirubin or alkaline phosphatase). This percentage translates to more than one patient (22 x 0.0455 = 1.01, rounded up to 2 patients for the presence of multiple affected individuals).</s>",
        "contradict": "The statement \"More than 1 patient in the primary trial suffered an adverse event\" is not directly contradicted by the information provided in the CTRs. However, the statement is less specific than the information in the CTR, as it does not specify the type of adverse event or which patients experienced it. The CTR reports that exactly one patient each had an increased blood bilirubin and alkaline phosphatase level. These incidents are classified as adverse events, and they occurred in separate patients. Therefore, the statement does not contradict the CTR, but it is also not entailed by the data presented.</s>"
    },
    "5311216c-94e0-4d04-acd2-b95b932ddc02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00127933",
        "Secondary_id": "NCT00191789",
        "Statement": "the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial recorded at least one patient with an infection, whereas in the secondary trial none were observed\" is entailed by the CTR data because, in the primary trial, there is a mention of one case (1/34) of infection in the Adverse Events section of Trial 2. However, there is no mention of infection in the Adverse Events section of Trial 1 or Trial 2 of the secondary trial. This difference implies that, although there was at least one instance of infection in the primary trial, none was reported in the secondary trial. This is consistent with the statement's assertion. The statement does not contradict or misrepresent the information in the CTRs and is based on a clear comparison between the trials' Adverse Events sections.</s>",
        "contradict": "The statement \"the primary trial recorded at least one patient with an infection, whereas in the secondary trial none were observed\" is contradicted by the information present in the CTRs because the CTR for the secondary trial reports one case (1/34) of infection. Therefore, the statement's assertion that no infections were observed in the secondary trial contradicts the clinical trial data. However, the statement is not contradicted by the primary CTR since it correctly reports one infection (1/122).</s>"
    },
    "01dfa37b-ce65-4e90-addc-395241c92f5f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191451",
        "Statement": "Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events\" can be entailed by the CTRs as follows:\n\n1. Oesophagital adverse events are present in both trials (Oesophageal spasm in primary CTR and Oesophagitis in neither CTR nor secondary one, but the statement does not specify these conditions).\n2. Cardiac adverse events, specifically Diastolic dysfunction, are reported in the primary CTR.\n3. Neither CTR explicitly states that no cardiac adverse events occurred in the secondary trial, leaving room for possible but unreported cardiac adverse events.\n\nTherefore, the statement is entailed by the CTRs, as the CTRs do not contradict the statement but rather provide evidence for it.</s>",
        "contradict": "The statement \"Patients in the primary trial experienced a variety of Oesophageal and cardiac adverse events\" is not contradicted by the information in the CTRs, as there are reports of Oesophageal spasms in both trials. However, the statement is not entailed by the data, as the CTRs do not mention any cardiac adverse events.</s>"
    },
    "43588c50-7dc4-4d46-a53d-e94576e8ab55": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03197389",
        "Statement": "Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial\" can be entailed by the following information in the CTRs:\n\nFemale subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception as outlined in Section 5.7.2 - Contraception, for the course of the study through 120 days after receiving the study medication.\nMale subjects of childbearing potential (Section 5.7.1) must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, until 120 after receiving the study therapy.\n\nBoth male and female subjects of childbearing potential are required to use adequate methods of contraception according to the CTRs. Therefore, the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Both men and women of child bearing potential must use adequate methods of contraception to be eligible for the primary trial\" can be contradicted by the information present in the CTR, specifically in the inclusion criteria for male subjects under section 5.7.1: \"Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section 5.7.1- Contraception, until 120 after receiving the study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\" Contraception is not explicitly stated as a requirement for male subjects in the given statement, but the CTR allows them to be enrolled using abstinence as an acceptable method of contraception. Therefore, the statement contradicts the flexibility in contraceptive methods offered by the trial as described in the CTR.</s>"
    },
    "f419f810-ca53-4168-86fd-d1d9a9154d3a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02683083",
        "Statement": "sufferers of hyperthyroidism are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"sufferers of hyperthyroidism are excluded from the primary trial\" is entailed by the CTR data since hyperthyroidism is not explicitly mentioned in the inclusion criteria, but it is listed as an exclusion criterion for both trials under \"Patients with previous thyroid disorders.\"</s>",
        "contradict": "The statement \"sufferers of hyperthyroidism are excluded from the primary trial\" cannot be directly contradicted by the information present in the CTRs, as hyperthyroidism is not listed as an exclusion criteria for the primary trial. However, it should be noted that patients with previous thyroid disorders are excluded from the trial. Hyperthyroidism is a condition resulting from an overactive thyroid gland, while thyroid disorders can also encompass conditions such as hypothyroidism. Without further context, it is unclear if the expert meant to refer to hyperthyroidism specifically or to thyroid disorders in general. Thus, the statement may be misleading without clarification.</s>"
    },
    "630a8241-b776-4799-a7ca-b1fddf17686c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00206518",
        "Statement": "The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C.",
        "Label": "Contradiction",
        "entail": "The statement \"The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D, and 3C\" can be entailed by the information in the CTRs as follows:\n\nThe CTR specifies that in Arm A, patients receive four cycles of neoadjuvant Taxotere/Docetaxel, followed by surgery and adjuvant AC. The overall number of participants analyzed in Arm A is 83. The results section indicates the number of patients with Chevalier grades 1, 3D, and 3C, which correspond to the least common grades. Therefore, the statement is in line with the data presented in the CTR and is entailed by it. Similar reasoning applies to the information regarding Arm B, but with the least common Chevalier grades being different.</s>",
        "contradict": "The expert's statement \"The least common Chevalier grades for patients in the primary trial treated with Taxotere/Docetaxel were 1, 3D and 3C\" cannot be directly contradicted by the information in the CTRs. However, it does not entail the information presented. The CTRs do not specify the frequency or distribution of Chevalier grades for patients in each arm. The statement provides information about the least common grades, while the CTRs only provide the number of participants for each Chevalier grade.</s>"
    },
    "8f3fddf2-97ab-4456-bff7-8f83b27e3849": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00675259",
        "Secondary_id": "NCT01875367",
        "Statement": "Patients with an ImmunoHistoChemistry test result of 3+ are excluded from the primary trial but included in the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial excludes patients with IHC 3+, whereas the secondary trial includes patients with this test result. However, the primary trial requires HER-2 neu overexpression either by IHC 3+ or FISH+, which aligns with IHC 3+ in the secondary trial. Therefore, the information in the statement is entailed by the CTRs since patients meeting the secondary trial's inclusion of IHC 3+ still satisfy the primary trial's requirement of HER-2 neu overexpression.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial excludes patients with an IHC test result of 3+ for HER-2 neu, while the secondary trial includes them, provided they also meet other specific conditions. This discrepancy between the trials in how they handle the same HER-2 neu test result contradicts the statement that patients with an IHC test result of 3+ are excluded from the primary trial but included in the secondary trial.</s>"
    },
    "11617367-193f-4f6b-bc3e-e58ea76d1052": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00485953",
        "Secondary_id": "NCT00068601",
        "Statement": "the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD.",
        "Label": "Contradiction",
        "entail": "In the primary trial, the cyclophosphamide dose is not explicitly stated. However, the statement mentions that the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks, which is not mentioned in the primary trial. Yet, the statement does not contradict the information in the CTRs. \n\nIn the primary trial, the patients in Intervention 1 receive risedronate 35 mg weekly, while those in the Intervention 2 receive placebo once weekly. There is no mention of cyclophosphamide. In the secondary trial, patients in Intervention 1 receive cyclophosphamide as part of the planned chemotherapy regimen, but the dosage and frequency are not explicitly stated. However, the statement mentions that the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks. Although this dosage is different from what's mentioned in the primary trial, the statement does not contradict the CTRs since there is no explicit mention of cyclophosphamide dosages in the primary trial, and the statement does not contradict the stated facts that patients in Intervention 1 of the secondary trial receive cyclophosphamide and that it is part of the planned chemotherapy regimen. \n\nSimilarly, the statement mentions that the Placebo dose in the primary trial is 12mg QD. In the primary trial, the Intervention 2 group receives placebo medication once weekly. Since the frequency is the same as stated in the CTR, this statement is entailed by the information present in the CTRs. \n\nTherefore, even though the statement does not explicitly agree with the information in the CTRs due to the difference in cyclophosphamide dosage, it does not contradict the CTRs either. The statement is neutral as no contradiction can be established based on the given data.</s>",
        "contradict": "The statement \"the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD\" is contradictory to the information present in the CTRs in the following ways:\n\n1. In the primary trial, risedronate (not cyclophosphamide) is the active medicine in intervention group 1 and the placebo is given once weekly. The dosage information for cyclophoshamide is not provided in the primary trial, and thus it cannot be 150mg once every 4 weeks.\n\n2. In the secondary trial, cyclophosphamide is given as part of a chemotherapy regimen, and the dosage is not explicitly mentioned in the statement. However, the statement incorrectly states that the dose is 150mg once every 4 weeks. According to the provided CTR, the exact dosage information for cyclophosphamide is not given.\n\n3. The statement mentions a placebo dose of 12mg QD in the primary trial, but the placebo dose information is not explicitly stated in the provided CTR. In the provided information in the primary trial, the placebo group receives placebo medication once weekly.\n\nTherefore, the statement \"the cyclophosphamide dose in the secondary trial is 150mg once every 4 weeks and the Placebo dose in the primary trial is 12mg QD\" contradicts the available information in the CTRs as it provides incorrect or misleading dosage information for both trials and incorrectly identifies the nature of treatments in the primary trial.</s>"
    },
    "882f22f6-36d9-4c2f-8f49-52469d570977": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01840163",
        "Secondary_id": "NCT02005549",
        "Statement": "the primary trial and the secondary trial do not exclude patients with non-melanoma skin cancer.",
        "Label": "Entailment",
        "entail": "The Primary Trial's exclusion criteria state that there are no mentions of excluding patients with non-melanoma skin cancer. The Secondary Trial's inclusion criteria specifically list non-melanoma skin cancer as a condition that does not disqualify patients from participation. Therefore, the statement that the Primary and Secondary Trials do not exclude patients with non-melanoma skin cancer is entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the Primary Trial's Exclusion Criteria explicitly lists \"Male\" as an exclusion criterion, but it does not mention \"non-melanoma skin cancer\" as an exclusion. In contrast, the Secondary Trial's Inclusion Criteria state that patients with non-melanoma skin cancer are included in the trial. Therefore, the statement implies that both trials allow patients with non-melanoma skin cancer, whereas the actual trial data contradicts this, as the Primary Trial excludes such patients.</s>"
    },
    "8f5423c9-17b5-4f66-aa9f-1fc9763958b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as none of the Adverse Events sections for either trial report list any occurrences of Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome, or Atrial fibrillation. The statement's claim matches the data presented without contradiction.</s>",
        "contradict": "The statement \"None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation\" is contradicted by the information present in the CTRs since the primary trial reported occurrences of Thrombocytopenia (0/238 (0.00%) vs. 5/245 (2.04%)), heart failure (1/238 (0.42%) vs. 2/245 (0.82%)), and Atrial fibrillation (0/238 (0.00%) vs. 1/245 (0.41%)). Therefore, this statement is not entailed by the information presented in the CTRs.</s>"
    },
    "0c45a782-1a3d-4e9b-a258-136ab080dbb6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00846027",
        "Statement": "None of the adverse events recorded for the primary trial occurred less than twice.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the adverse events recorded for the primary trial occurred less than twice\" is entailed by the CTR data since each adverse event is reported to have occurred at least twice (1.22% of the cohort experienced each event) according to the given data.</s>",
        "contradict": "The statement that \"none of the adverse events recorded for the primary trial occurred less than twice\" contradicts the information in the CTR since several adverse events were reported only once for each arm. Specifically, Neutrophils count decreased, Cardiac ischemia/infarction, Left ventricular systolic dysfunction, Hypertension, Supraventricular and nodal arrhythmia, Anorexia, Gastrointestinal perforation, Vomiting, Dehydration, and Diarrhoea occurred once for each of the 82 participants in the primary trial.</s>"
    },
    "4e42302d-2cd9-4a91-9338-8e3b0ffb9292": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00654836",
        "Statement": "Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial\" is entailed by the information presented in the CTRs because the primary trial explicitly states that patients with HER-2 positive breast cancer are only included if they are unable to receive trastuzumab or have previously received trastuzumab in the past. Trastuzumab is a monoclonal antibody that targets the HER2 receptor, making HER-2 positive patients ineligible for the primary trial as stated. Furthermore, metastatic disease is listed as a specific inclusion criterion for the secondary trial, but it contradicts the exclusion criteria for the primary trial. Hence, the statement is entailed by the provided CTRs.</s>",
        "contradict": "The statement \"Patients with metastatic HER-2 positive adenocarcinoma of the breast can never be eligible for the primary trial\" is contradicted by the information present in the CTRs because the primary trial does include patients with HER-2-positive breast cancer, but only if they are unable to receive trastuzumab or have previously received it in the past. Thus, some patients with HER-2-positive disease may meet the eligibility criteria for the primary trial despite the expert's statement suggesting they cannot.</s>"
    },
    "a5d5e6da-f3cd-49c7-92a7-f789468c4c4c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00270894",
        "Statement": "60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule.",
        "Label": "Entailment",
        "entail": "The expert statement, \"60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule,\" aligns with the CTR information as follows:\n\n1. In the primary trial, the outcome measure for evaluating feasibility is the percentage of subjects able to complete the neoadjuvant portion of the study on time with > 85% of the protocol-specified dose.\n2. From the results section of the primary CTR, it's stated that 60 participants were analyzed, and 60% of them completed > 85% of the planned neoadjuvant therapy dose on schedule, as per the definition in the eligibility criteria section. Therefore, this expert statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"60% of Subjects in the primary trial were able to Complete at least 85% of the Planned Dose on Schedule\" can be contradicted by the information in the CTR if the actual number of participants who completed > 85% of their planned doses on schedule is less than 60%. The CTR specifies that 30 participants were analyzed in the Neoadjuvant Therapy arm of the trial, and no information is provided about the exact percentage of participants who met the feasibility criterion of completing > 85% of their planned doses on schedule. Therefore, it is possible that fewer than 60% of the participants achieved this outcome, which would contradict the expert's statement.</s>"
    },
    "da2ea2e9-3109-433e-9033-9ae322c30c4b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981812",
        "Statement": "Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Women who have undergone a breast enlargement procedure in the last 2 years are excluded from the primary trial\" is entailed by the CTR's Eligibility Criteria Exclusion Criteria, specifically the statement \"subject has breast implants.\" The CTR explicitly lists breast implants as a condition for exclusion, implying that women with breast implants are not eligible for participation in the clinical trial. Since a breast enlargement procedure typically involves the insertion of breast implants, the statement made by the clinical trial expert is a logically valid inference from the given information.</s>",
        "contradict": "The information in the statement contradicts the CTRs because the primary trial's exclusion criteria do not specifically mention women who have undergone breast enlargement procedures within the last 2 years.</s>"
    },
    "c77c8e02-7abb-4b63-8917-01babe5cd372": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00863655",
        "Statement": "There were 5 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "Label": "Entailment",
        "entail": "The statement asserts that there is a difference in the incidence of anemia and disseminated intravascular coagulation between cohorts 1 and 2, with cohort 1 exhibiting 5 more instances of anemia and 1 additional instance of disseminated intravascular coagulation. This claim is entailed by the CTRs since the data shows that cohort 1 in the primary trial had 1.66% (8 anemia cases) and 0.41% (1 case) disseminated intravascular coagulation compared to cohort 2 in the primary trial, which had 0.84% (2 anemia cases) and no cases of disseminated intravascular coagulation in cohort 2. In the secondary trial, cohort 2 showed 0.84% (2 anemia cases) with no cases of disseminated intravascular coagulation. The difference in anemia cases between cohorts is 5 (8 - 3), and the difference in disseminated intravascular coagulation cases is 1 (1-0). The statement's information is derived from the CTRs and does not contradict the given data.</s>",
        "contradict": "The statement cannot be directly contradicted by the information present in the CTRs alone. However, it can be inconsistent with the CTRs if it is assumed that the trials involved the exact same patient population and interventions in each cohort, but the CTRs reported different numbers of adverse events. If that is not the case and the trials differed in their patient populations or interventions, then the statement is not contradictory but descriptive of a difference between the trials. The contradiction or inconsistency would arise if the expert's statement is based on incorrect assumptions about the similarity of the trials.</s>"
    },
    "f2b14720-6ff2-4ff7-a5bc-3841b93f647e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary trial does not explain its intervention in the intervention section.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not explain its intervention in the intervention section\" is entailed by the CTR information as follows: The CTR for the primary trial specifies the intervention as MM-111 given to all participants, but it does not provide additional details such as dosage, frequency, or duration of administration beyond the statement that it is the intervention used in the trial. The secondary trial's statement, on the other hand, only claims that the primary trial does not provide a detailed explanation of the intervention in its intervention section. This statement is entailed by the CTR because it accurately reflects the level of detail provided in the CTR about the intervention.</s>",
        "contradict": "The expert's statement is contradictory to the information in the primary CTR as the CTR does explicitly mention the intervention in the intervention section, specifying that all participants received MM-111.</s>"
    },
    "03e9368b-18a7-4643-a38b-a7b002403bf1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00568022",
        "Secondary_id": "NCT01120184",
        "Statement": "Completely disabled patients below the age of 20, totally confined to bed or chair and unable to carry on any selfcare are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's inclusion criteria state that women aged 20 years with a histologically or cytologically confirmed breast adenocarcinoma diagnosis are eligible. The statement adds an condition that these women can be completely disabled and confined to bed or chair without self-care abilities. Since the age criterion aligns with the primary trial and there are no specific exclusion criteria related to disability, the statement can be entailed by the information present in the primary CTR. In contrast, the secondary trial's inclusion criteria state that participants must be adult (>18 years old) with a different set of disease characteristics and exclusion criteria that include no history of prior chemotherapy for metastatic breast cancer within specific timeframes and absence of certain therapies. The statement about completely disabled patients below the age of 20 is not mentioned in these criteria; thus, it cannot be directly entailed by the secondary trial CTR.</s>",
        "contradict": "The statement is contradictory to the information present in the CTRs as:\n\n1. The primary trial includes women aged 20 years and above while the statement talks about completely disabled patients below the age of 20.\n2. The secondary trial has inclusion criteria for HER2-positive breast cancer and locally advanced disease, which does not specify any condition related to complete disability or inability to carry on self-care.\n3. The primary trial excludes patients with 3 lines of chemotherapy in the metastatic setting while the statement does not mention any exclusion criteria related to chemotherapy treatment history.\n\nHence, the statement contradicts the CTRs in terms of patient age and inclusion/exclusion criteria.</s>"
    },
    "c5dbd52d-01d4-4919-bfe9-2b7885490d6a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00422903",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: \n\n1. The outcome measure in the primary trial specifies the use of an Independent Radiological Evaluation Monitoring Committee to evaluate cOR in the breast.\n2. Results 1 and 2 from the primary trial report the percentage of participants with cOR (CR and PR) in each treatment group.\n3. The statement asserts that the cohort with the highest percentage of participants with cOR is from the secondary trial (which is not provided).\n4. However, we can compare the percentage of participants with cOR between the two treatment groups from the primary trial.\n5. According to the provided data, the Letrozole + Lapatinib group has a higher percentage of participants with cOR (PR: 54%) compared to the Letrozole + Placebo group (PR: 58%).\n6. Therefore, if cohort 2 from the secondary trial also received Letrozole + Lapatinib treatment, its percentage of participants with cOR would be expected to be higher than the Letrozole + Placebo group from the primary trial, which is consistent with the expert's statement.\n\nThis explanation demonstrates that the statement can be entailed by the provided information in the CTRs without contradiction.</s>",
        "contradict": "The statement can be contradicted by the information presented in the CTRs because the comparison is made between unspecified \"cohorts\" or \"arms\" in the statement, while the CTRs provide details on specific arms titled \"Letrozole + Placebo\" and \"Letrozole + Lapatinib.\" The percentage of participants with cOR in each arm can be compared directly from the given data instead of making an assumption based on unspecified cohorts. Based on the provided data, the percentage of participants with cOR in Letrozole + Placebo (2/48 = 4.2%) is lower than that in Letrozole + Lapatinib (12/41 = 29.2%). Therefore, the statement is contradicted by the information in the CTRs if \"cohorts\" are assumed to refer to these specific arms.</s>"
    },
    "83115abd-1c07-4ee7-8ba5-b4575be2d50f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed bone metatases are excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement can be entailed by the information present in the CTRs because the primary trial exclusion criteria include \"any clinically or radiologically suspect and non-explored damage to the contralateral breast,\" which could potentially include radiologically confirmed bone metastases. Similarly, the secondary trial exclusion criteria explicitly state the presence of \"CNS (central nervous system) metastases\" and \"any clinically significant bony metastasis,\" which is a type of bone metastasis. Therefore, the statement that \"patients with radiologically confirmed bone metastases are excluded from both the secondary trial and the primary trial\" aligns with the exclusion criteria stated in each CTR.</s>",
        "contradict": "The primary trial inclusion criteria state that patients with metastatic impairment, including bone metastases, are excluded. However, the secondary trial specifically includes patients with histologically confirmed breast cancer and evidence of metastatic disease, which by definition includes bone metastases. Consequently, the statement that patients with radiologically confirmed bone metastases are excluded from both trials contradicts the information present in the CTRs.</s>"
    },
    "784872db-8ccf-4ddc-a432-6ee00fd0b0cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01857882",
        "Secondary_id": "NCT01439945",
        "Statement": "the secondary trial administers Magnesium Oxide to its patients whereas the primary trial tests an education intervention.",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert can be entailed by the information in the CTRs as follows:\n\n1. Both trials involve the administration of Magnesium Oxide to patients within their respective interventions.\n2. The primary trial is not mentioned to administer Magnesium Oxide but focuses on the education intervention (Decision Support Workshop).\n3. Hence, the statement's assertion that \"the secondary trial administers Magnesium Oxide to its patients\" is entailed by the presence of Magnesium Oxide administration details in the CTR of the secondary trial.\n4. Furthermore, the statement's claim that \"the primary trial tests an education intervention\" is also entailed by the information in the CTR of the primary trial, as it clearly describes the components and facilitators of the Decision Support Workshop.\n5. No contradiction exists between the CTR descriptions and the statement.</s>",
        "contradict": "The statement does not provide sufficient detail to determine whether it is contradicted by the information in the CTRs. Although it is stated that the secondary trial administers Magnesium Oxide to its patients, the primary trial's Intervention 1 does not mention Magnesium Oxide. However, it is an unrelated education intervention. Therefore, there is no contradiction based on the information provided.</s>"
    },
    "adae7d81-bc8e-48e4-b966-27c2633eb72d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02131064",
        "Statement": "over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR) Assessed Based on Tumor Samples.",
        "Label": "Entailment",
        "entail": "To establish entailment, the statement should harmonize with clinical trial data and find substantiation in the CTRs without contradiction. The given statement asserts that over 100 participants in the TCH + P group of the primary trial achieved total pathological complete response (tpCR). \n\nThe CTR provides the percentage of participants with tpCR in the TCH + P group, reported as 56.1% with a 95% confidence interval of (49.29-62.76). If we multiply the overall number of participants in the TCH + P group (221) by the percentage reported, we get a total of 124.31 participants with tpCR. However, this value is slightly over the stated threshold of \"over 100 participants\". This discrepancy might seem concerning, but considering the 95% confidence interval, it is reasonable to infer that the true number of participants with tpCR is indeed over 100.\n\nTherefore, the assertion in the statement can be entailed by the information in the CTR.</s>",
        "contradict": "The statement \"over 100 participants in the TCH + P group of the primary trial achieved Total Pathological Complete Response (tpCR)\" cannot be directly contradicted by the information present in the CTRs. However, it is important to note that the CTRs report the percentage of participants with tpCR, which is 56.1% (49.29-62.76) for the TCH + P group. If there were over 100 participants in this group, then it follows that more than 56.1% of them must have achieved tpCR, as each participant can only have one outcome. However, the CTR does not directly report the exact number of participants achieving tpCR, only the percentage. Therefore, while the statement is not an outright contradiction, it does provide additional, unverified information not explicitly stated in the CTR.</s>"
    },
    "4ee4061e-a532-459e-8d03-3055bd92419c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00082810",
        "Statement": "Throughout the duration of the primary trial, participants receive tipifarnib more often than Fulvestrant.",
        "Label": "Entailment",
        "entail": "The statement \"Throughout the duration of the primary trial, participants receive tipifarnib more often than Fulvestrant\" is entailed by the Intervention section of the CTR for the primary trial, as follows:\n\n1. In the primary trial, participants receive Fulvestrant 250 mg intramuscularly once per month, specifically on day 1.\n2. Participants also receive tipifarnib 300 mg orally twice daily, for 21 days each month.\n3. Since there are approximately 28 days in a month (ignoring the variations due to leap years), participants spend roughly 14 days receiving fulvestrant and 14 days receiving tipifarnib.\n4. However, tipifarnib is administered twice daily for 14 days each month, which is more frequent than the monthly Fulvestrant administration.\n5. Therefore, the statement \"Throughout the duration of the primary trial, participants receive tipifarnib more often than Fulvestrant\" is entailed by the provided CTR information.</s>",
        "contradict": "The statement \"Throughout the duration of the primary trial, participants receive tipifarnib more often than Fulvestrant\" is contradicted by the CTR information because, although tipifarnib is administered twice daily on days 1-21, Fulvestrant is given intramuscularly once a month (every 28 days). This means that each participant undergoes a Fulvestrant administration approximately every 28 days, while tipifarnib is taken every day during this timeframe. Consequently, over the course of one Fulvestrant administration cycle, participants receive fewer administrations of Fulvestrant compared to the number of tipifarnib doses they receive. Therefore, the statement is incorrect as it implies that each participant receives more tipifarnib administrations than Fulvestrant administrations throughout the entire trial period.</s>"
    },
    "4cbb7f8f-ea60-453d-b4ab-e967944426d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992225",
        "Statement": "Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once.",
        "Label": "Contradiction",
        "entail": "The statement \"Only 2 of the 16 adverse event types recorded in the primary trial, occurred more than once\" can be entailed by the information present in the CTRs because, according to the provided data, only Sepsis and Dehydration occurred more than once, with frequencies 2/33 (6.06%) and 2/33 (6.06%), respectively. Thus, this statement accurately summarizes the frequency of occurrence of certain adverse event types, which aligns with the data presented in the CTR.</s>",
        "contradict": "The expert's statement asserts that only 2 unique adverse event types appeared more than once in the primary trial. However, this claim contradicts the data in the provided CTRs as 7 distinct adverse event types occurred more than once: Sepsis, Urinary tract infection, and the laboratory abnormalities Alanine aminotransferase increased and Aspartate aminotransferase increased. Therefore, the statement is not semantically entailed by the data in the CTRs.</s>"
    },
    "47f11df7-6c82-4c50-9249-5085313a5064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Secondary_id": "NCT00631852",
        "Statement": "A patient with a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging would be accepted for the primary trial, but not for the secondary trial.",
        "Label": "Entailment",
        "entail": "The patient described in the statement, having cytologically confirmed breast cancer with a greatest diameter of 5 millimeters on imaging, falls under the inclusion criteria for the primary trial. However, the secondary trial's requirements specify a minimum tumor size of at least 1.0 cm (1000 millimeters) for inclusion. This discrepancy results in the patient's ineligibility for the secondary trial. The eligibility criteria for both trials, as presented in their respective CTRs, are consistent with the statement and do not contradict any information within the trials.</s>",
        "contradict": "The patient described in the expert statement, having a cytologically confirmed breast cancer with a 5 millimeter greatest diameter on imaging, would be accepted in the primary trial but not in the secondary trial based on the information given. However, this statement is contradictory to the inclusion criteria of the Primary Trial, where the greatest diameter of the breast cancer is required to be at least 1.0 cm. Therefore, a patient with a 5 millimeter tumor would not meet the inclusion criteria for the Primary Trial. Hence, the statement is incorrect and contradicts the given CTR information.</s>"
    },
    "3114ff0f-184c-48ba-b33d-631505cffeef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1.",
        "Label": "Entailment",
        "entail": "The expert's statement \"the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1\" is entailed by the CTR information as follows:\n\n1. The CTR for the primary trial reports the total number of adverse events as 20, and the proportion of these events is given as 19.80%.\n2. The expert's statement reports a total of 3 adverse events for Ascites, Asthenia, and Gastritis combined.\n3. The number of adverse events for Ascites in the primary trial is 1; for Asthenia, it is 1; and for Gastritis, it is 1.\n4. Multiplying the total number of participants in the primary trial (101) by the proportion of patients with these adverse events (0.0198) results in approximately 2 total cases (2.01\u22482). Rounding the result does not alter the fact that there is at least 2 cases of the combined adverse events reported in the trial. However, since the statement specifically mentions a total of 3 cases, it is not an exact match with the reported data, but it is still entailed given the rounding of numbers.\n5. The expert's statement does not contradict any information provided in the CTRs, making it a semantically entailed claim.</s>",
        "contradict": "The expert's statement \"the primary trial reported a combined total of 3 cases of Ascites, Asthenia and Gastritis in cohort 1\" is inconsistent with the CTR data because the CTR reports a total of 4 instances of these adverse events (1 each for Ascites, Asthenia, and Gastritis), not 3 as stated by the expert.</s>"
    },
    "edf31a43-a774-4f2a-8a02-89b84de941bb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02595372",
        "Statement": "27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response.",
        "Label": "Entailment",
        "entail": "1. In the primary CTR, patients are defined as having FASN expression if the positivity is >= 15% at baseline or after 4-7 days of Omeprazole monotherapy.\n2. The secondary trial states that patients in the High Dose Omeprazole arm will be treated with Omeprazole for at least 4-7 days.\n3. Therefore, the patients in the secondary trial who have FASN expression also fall under the category of patients with FASN expression in the primary trial.\n4. The primary trial reports that 22.6% of patients with FASN expression did not have pCR.\n5. The statement by the expert implies that 72.4% of patients with FASN expression in the High Dose Omeprazole arm had pCR, so 27.6% did not have pCR.\n6. This is consistent with the data in the primary trial.\n7. Thus, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"27.6% of Patients Who Have Fatty Acid Synthase (FASN) Expression in the primary trial treated with High Dose Omeprazole did not have Pathological Complete Response\" contradicts the information in the CTR as follows: The CTR reports 72.4% (52.8-87.3) of participants in the High Dose Omeprazole arm with pCR (no invasive disease), which is the opposite of having no pCR (no pathological complete response). Therefore, it cannot be that 27.6% of FASN expressing patients within this arm did not have pCR.</s>"
    },
    "ffdc4c5b-a091-4fa6-b2c1-49a131d7d109": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01596751",
        "Secondary_id": "NCT00193050",
        "Statement": "There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts.",
        "Label": "Contradiction",
        "entail": "The statement \"There were at least 15 patients with Dysphagia or Fever between the primary trial and the secondary trial patient cohorts\" can be entailed by the information present in the CTRs as follows: The primary trial reports 0/5 (0.00%) instances of Dysphagia and 0/5 (0.00%) instances of Fever. In the secondary trial, there is 1/110 (0.91%) instance of Dysphagia and 1/110 (0.91%) instance of Fever. The total number of subjects in the primary trial is 5, and in the secondary trial it is 110. So, the minimum number of patients with Dysphagia or Fever in both trials that would make the statement true is 15 (5 from Primary Trial + 10 from Secondary Trial). Since the number of patients with Dysphagia (0 in Primary and 1 in Secondary) or Fever (0 in Primary and 1 in Secondary) is less than 15, the statement is only satisfied as a lower bound. Therefore, the statement is entailed by the CTRs, as it is a valid inference based on the reported data.</s>",
        "contradict": "The statement cannot be entailed by the information in the provided CTRs. While there is one instance of Dysphagia reported in each trial and one instance of Fever in the secondary trial, the total occurrences of these adverse events do not add up to 15 or more patients. Therefore, the statement contradicts the CTR information.</s>"
    },
    "df3e8e6b-fcfd-4909-bbb5-0d69df23f2c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight.",
        "Label": "Contradiction",
        "entail": "The primary trial reports that in Intervention 1 and Intervention 2, Capecitabine dosages range from 825 mg/m2 to 1250 mg/m2 orally BID based on the patient's body surface area (BSA). This indicates that the dosages of Capecitabine are adjusted according to body weight. Contrastingly, the statement from the clinical trials expert mentions that only the dosage of Lapatinib is fixed at 1000 mg PO daily, and the dosage of Capecitabine changes with patients' body weight. The information in the statement is entailed by the primary trial data since the trial reports that the Capecitabine dose depends on body weight, and the expert's statement explicitly states this fact.\n\nTherefore, the expert's statement is a logical consequence of the information in the primary trial report.</s>",
        "contradict": "The statement \"the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with patients body weight\" is contradicted by the information present in the CTRs because the CTRs do not indicate that the dose of Lapatinib varies based on body weight. Both in the Intervention 1 and Intervention 2 sections, the dose of Lapatinib is specified as \"1000 mg PO daily.\" Conversely, the dose of Capecitabine does vary based on patient body weight, with a dose range of 825 mg/m2 to 1250 mg/m2.</s>"
    },
    "5a076708-c8d4-4341-9c1d-3ee762f57be5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03456427",
        "Secondary_id": "NCT02685566",
        "Statement": "There are no details concerning the types of imaging that are being used in the intervention sections of the primary trial and the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the CTRs as the statement is general and does not explicitly mention the types of imaging used in the trials, which are specified in the CTRs as \"Patient-Assisted Compression (PAC) and Technologist-controlled (TC) Compression for the primary trial\" and \"FFDM Plus DBT and FFDM for the secondary trial.\" However, the statement does not contradict the CTRs and leaves room for the possibility that the imaging types match the ones described in the CTRs. Thus, the statement is consistent with the CTRs and can be considered semantically entailed to a certain degree.</s>",
        "contradict": "The statement contradicts the information in the CTRs as they explicitly specify the types of imaging used in both trials, with the primary trial employing Patient-Assisted Compression (PAC) and Technologist-controlled (TC) Compression, and both trials using the FujiFilm Aspire Cristalle System for Full-Field Digital Mammography (FFDM).</s>"
    },
    "98a946b0-2be1-474c-b373-043f329ba261": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038010",
        "Secondary_id": "NCT00764322",
        "Statement": "Neither the primary trial or the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib.",
        "Label": "Entailment",
        "entail": "The statement \"Neither the primary trial nor the secondary trial are measuring Percentage of Participants With Overall Response Rate (ORR) Following Administration of Ispinesib\" is entailed by the information in the CTRs as neither trial includes information regarding Ispinesib administration or ORR measurements. The CTRs solely report on the outcome measurements for Dose Limiting Toxicity of BYL719 in combination with T-DM1 in the primary trial and endoxifen concentrations in participants receiving Tamoxifen Citrate in the secondary trial.</s>",
        "contradict": "The statement made by the clinical trials expert contradicts the information present in the CTRs because neither trial reports measurement of the Percentage of Participants With Overall Response Rate (ORR) following administration of Ispinesib. Instead, the primary trial measures Dose Limiting Toxicity (DLT) of BYL719 in combination with T-DM1 and the secondary trial measures endoxifen concentrations stratified by CYP2D6 genotypes.</s>"
    },
    "b82e6861-3908-43e9-8e54-cf60c7d96a4e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00721409",
        "Secondary_id": "NCT02413320",
        "Statement": "Patients with ER-positive tumours are eligible for the primary trial but not for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial includes patients with inoperable estrogen receptor positive (ER+) and HER2 negative breast cancer, while the secondary trial specifies patients with hormone receptor-poor (i.e., ER- and/or progesterone receptor-negative) triple negative breast cancer. Although there is a difference in the specificity of hormone receptor status between the trials (ER+ in the primary trial versus ER- and/or PR-negative in the secondary trial), the primary trial does entail ER-positive tumors because a subset of ER+ breast cancers falls under the broader category of hormone receptor-positive tumors. However, the secondary trial excludes ER+ breast cancers, as they do not meet the hormone receptor-poor requirement. Thus, while ER+ tumors can be entailed by the primary trial, they are not entailed by the secondary trial.</s>",
        "contradict": "The statement that \"Patients with ER-positive tumors are eligible for the primary trial but not for the secondary trial\" is contradicted by the information present in the CTRs in the following manner:\n\nIn Primary Trial: ER-positive tumors are included (Inclusion Criteria).\nIn Secondary Trial: ER-positive tumors are excluded (Exclusion Criteria).\n\nTherefore, the statement contradicts the information provided in the CTRs.</s>"
    },
    "b8e5baf7-ddc5-407f-84d3-4c93224477cd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event\" is entailed by the information in the CTRs as follows:\n\n1. The statement \"More than half of patients in the primary trial experienced adverse events\" is entailed by the data in the primary trial's Adverse Events section, which shows that 59.62% of patients experienced adverse events.\n\n2. The statement \"and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event\" is entailed by the data in the secondary trial's Adverse Events sections, which shows that 100.00% of patients in both sections experienced adverse events.</s>",
        "contradict": "The statement \"More than half of patients in the primary trial experienced adverse events, and there was not a single patient in either cohort of the secondary trial that did not experience an adverse event\" is contradicted by the data in the CTRs as follows:\n\n1. In the primary trial, 59.62% or 31 out of 52 patients experienced adverse events. More than half, as mentioned in the statement.\n2. However, the statement further asserts that there were no patients in either cohort of the secondary trial without adverse events. But according to the CTR, the total number of patients in the secondary trial was 57. Therefore, the statement is contradicted because the CTR shows that one patient (0.00%) in the secondary trial did not experience an adverse event.</s>"
    },
    "79c34b71-a90f-4ddb-9aee-5f61f71f0846": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01277757",
        "Statement": "the primary trial is not testing a novel Physiotherapy or chemotherapy intervention.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial is not testing a novel Physiotherapy or chemotherapy intervention\" is entailed by the information present in the CTR as follows: \n\nThe CTR for the primary trial specifies that the intervention is \"Akt Inhibitor MK-2206,\" which is an orally administered drug. This information contradicts the alternative options stated in the expert's statement, i.e., Physiotherapy or chemotherapy. Since the information in the statement does not contradict or contradict the CTR's description, it can be considered entailed.</s>",
        "contradict": "The expert's statement \"the primary trial is not testing a novel Physiotherapy or chemotherapy intervention\" contradicts the information in the CTR for the primary trial as it involves the use of Akt Inhibitor MK-2206, which is clearly stated as an orally administered intervention, and not a novel physiotherapy or chemotherapy method.</s>"
    },
    "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02995980",
        "Statement": "A patient presenting Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligilbe for the primary trial.",
        "Label": "Entailment",
        "entail": "The patient meeting the condition of having a Glomerular filtration rate (GFR) of 63 falls within the inclusion criterion of having a GFR > 60 as stated in the Primary Trial's Inclusion Criteria section. Additionally, having heterogeneously or extremely dense breasts (BI-RADS category c) is another inclusion criterion mentioned in the Primary Trial's Eligibility Criteria section. Therefore, the patient's eligibility for the primary trial, as stated in the expert's assertion, is entailed by the information present in the CTRs.</s>",
        "contradict": "The patient described in the statement may meet the inclusion criteria regarding the glomerular filtration rate (GFR > 60) but does not necessarily fulfill the requirement of having heterogeneously or extremely dense breasts (BI-RADS category c or d). This is because, as per the provided CTR, this specific inclusion criterion is different from the secondary trial. The primary trial includes patients with BI-RADS category c or d breast tissue, whereas the statement does not explicitly mention this requirement for the patient. Thus, the statement can be contradicted by the information present in the CTRs.</s>"
    },
    "02d5fe7a-60e2-422f-98c0-92461b8fa13f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00438659",
        "Secondary_id": "NCT01271725",
        "Statement": "the primary trial and the secondary trial have a topical intervention, to be applied to the breast or face.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Intervention 1 specifies the use of mometasone furoate cream, which is a topical treatment, applied to the breast or chest wall. In the secondary trial, Intervention 1 for both arms A and B involves Afatinib monotherapy, which is not a topical intervention, but the experts' statement only mentions \"topical intervention.\" However, the statement does not mention any specific trial or intervention regarding the face, which is not mentioned in either CTR. The statement's focus is on the breast or face having a topical intervention, which is satisfied by the primary trial's Intervention 1 for the breast/chest wall. The secondary trial's topical intervention, Intervention 2, is irrelevant to the statement as it is a placebo cream. Therefore, the statement's assertion harmonizes with the information within the CTRs, as it finds substantiation in the primary trial and does not contradict the provided descriptions.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the primary trial involves topical application of mometasone furoate cream on the breast or chest wall, while the secondary trial involves oral administration of Afatinib and intravenous infusion of Paclitaxel or Vinorelbine for patients. There is no common intervention that is topically applied to the breast or face between the primary and secondary trials.</s>"
    },
    "869e413e-01c5-4a9e-8a4a-b6079f7ae300": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00996632",
        "Secondary_id": "NCT01644890",
        "Statement": "Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Emily has an Inoperable non-metastatic breast cancer, she is eligible for both the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Emily has inoperable, non-metastatic breast cancer. This condition falls under the inclusion criteria of both trials since neither trial has a specific criterion excluding inoperable or non-metastatic breast cancer, as long as the other stated inclusion criteria are met.\n\n2. The primary trial does not have an explicit criterion for metastatic breast cancer as an exclusion criterion. However, it does have exclusion criteria of inoperable breast cancer and carcinomastitis, but these conditions do not imply metastatic disease. Since Emily has non-metastatic breast cancer, she can be eligible for both trials based on the information provided.\n\n3. Emily's body mass index (BMI) is not given in the statement. However, her weight or size does not seem to be an issue as per the exclusion criteria in either trial.\n\n4. Emily has not undergone neoadjuvant radioterapy, which is listed as an exclusion criterion in the primary trial. This means she is eligible for the primary trial.\n\n5. The secondary trial excludes patients with prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer. However, there is no such exclusion criterion in the primary trial. Thus, Emily's prior chemotherapy history does not affect her eligibility for the primary trial.\n\nIn summary, Emily can be eligible for both the primary and secondary trials as per the information in the CTRs and the statement since her conditions meet all applicable inclusion criteria and do not violate any exclusion criteria in either CTR.</s>",
        "contradict": "Emily having an inoperable non-metastatic breast cancer contradicts her eligibility for the primary trial, as inoperable breast cancer and non-metastatic breast cancer are exclusion criteria in that trial. Additionally, Emily not meeting the inclusion criterion of operable breast cancer further invalidates her eligibility for the primary trial. The statement, thus, does not entail the information present in the CTRs.</s>"
    },
    "c0b528ef-ae9f-4c01-8915-b47856f07c95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01142661",
        "Statement": "the primary trial accepts patients with grade  3 neuropathy.",
        "Label": "Contradiction",
        "entail": "The primary trial specifies that \"existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.\" This exception for Grade 2 neuropathy implies that patients with a neuropathy grade of 3, which is a more severe form, are still eligible for the study. Therefore, the statement made by the clinical trials expert, that \"the primary trial accepts patients with grade 3 neuropathy,\" is entailed by the information provided in the CTR.</s>",
        "contradict": "The statement \"the primary trial accepts patients with grade 3 neuropathy\" is contradictory to the information presented in the CTR, as per the following reasons:\n\nAccording to the CTR, one of the exclusion criteria is \"existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.\" While grade 2 neuropathy is considered acceptable, grade 3 neuropathy is explicitly stated as being unacceptable. Therefore, the statement made by the expert contradicts the information provided in the CTR regarding inclusion criteria and eligibility of patients with grade 3 neuropathy.</s>"
    },
    "b6e484ff-d0c7-48bc-ab98-f0bd570d4b4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial the majority of patients had Stable Disease, none of them had complete or partial response.",
        "Label": "Contradiction",
        "entail": "The statement \"By week 48 of the primary trial, the majority of patients had Stable Disease, none of them had complete or partial response\" can be entailed by the information present in the CTRs as follows:\n\n1. The ORR at week 48, as defined in the CTR, is the proportion of patients with a best OR of confirmed CR or PR.\n2. According to the CTR, there were no CR or PR observed at week 48.\n3. However, there were 18 patients with SD, which is not considered a CR or PR but still indicates disease stability.\n4. Therefore, the majority (18 out of 49) of patients in the primary trial indeed had SD by week 48.\n5. Hence, the statement \"By week 48 of the primary trial, the majority of patients had Stable Disease\" is an entailed statement according to the information provided in the CTRs.\n6. Additionally, the statement \"none of them had complete or partial response\" is also entailed since, as per the CTR, there were no CR or PR reported by week 48.</s>",
        "contradict": "The expert's statement contradicts the CTR's statement that there were 7 patients with a best overall response (BOR) of partial response (PR) at week 48, as well as the definition of overall response rate (ORR) in the CTR as the proportion of patients with a best OR of confirmed CR or PR. Therefore, it is incorrect for the expert to claim that no patients had a complete or partial response at week 48 in the primary trial.</s>"
    },
    "da15fae6-7fa1-4fe0-b61c-e043df3e9e74": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01011946",
        "Statement": "All patients in the primary trial must have a bilateral breast MRI prior to study entry.",
        "Label": "Entailment",
        "entail": "The statement that \"All patients in the primary trial must have a bilateral breast MRI prior to study entry\" is not directly entailed by the information provided in the CTRs. The primary trial's inclusion criteria only specify that patients should be women 18-75 years old with newly diagnosed breast cancer who are candidates for breast conserving surgery. The exclusion criteria list conditions that prevent certain patient populations from participating. However, nowhere in the CTRs does it mention that all patients must undergo a bilateral breast MRI as a prerequisite for study entry. Therefore, the statement made by the clinical trial expert is not entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"All patients in the primary trial must have a bilateral breast MRI prior to study entry\" is contradicted by the CTR inclusion criteria which explicitly states that, \"Patients who have NOT undergone a standard of care bilateral breast MRI at UC\" are excluded from the trial.</s>"
    },
    "8ce665b5-20fb-44a3-b3c9-25493e8dd7ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02455453",
        "Statement": "Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTR as it aligns with the inclusion criteria specifying eligible types of breast cancer: ER+/PgR+/HER2- or ER+/PgR-/HER2-. The CTR defines ER+ as Allred score of at least 4 and greater, and PgR+ as Allred score of at least 4 and greater. Additionally, the statement's requirement for HER2 negativity aligns with HER2- defined as HER2 of 0, 1+ by IHC or negative by FISH. The CTR also allows patients with at least one measurable lesion according to RECIST 1.1 which includes evaluable lesions, and the statement does not restrict eligibility beyond this criterion.</s>",
        "contradict": "The statement \"Patients with tumors that are HER2 negative, PR and ER positive are eligible for the primary trial\" is contradicted by the CTR because the eligibility criteria for the primary trial also include patients with HER2-positive tumors if they are ER+/PgR+ and receive HER2-targeted therapy. The CTR does not restrict eligibility only to HER2-negative tumors.</s>"
    },
    "01236718-14da-450c-8051-0207d31743a5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02555657",
        "Statement": "The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2\" can be entailed by the information present in the CTRs as follows:\n\n1. From Results 1 and 2 in the primary trial, we know that the median OS for participants in the Pembrolizumab arm was 12.7 (9.9 to 16.3) months and in the TPC arm was 11.6 (8.3 to 13.7) months.\n2. A month longer survival for Pembrolizumab participants implies a median OS of at least 13.7 months.\n3. The given statement \"The Median time from randomization to death due to any cause, was a month longer for patients in cohort 1 of the primary trial, compared to those in cohort 2\" can be true if the median OS for Pembrolizumab is 13.7 months or more, which is greater than the median OS of 11.6 (8.3 to 13.7) months in the TPC arm.\n\nThus, the information contained in the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement does not entail the information presented in the CTRs due to the absence of specific reference to the cohorts or groups in question. The CTRs provide data for two distinct groups, labeled \"Pembrolizumab\" and \"Chemotherapy.\" However, the expert's statement does not explicitly identify these as cohorts 1 and 2, respectively, or provide any information about their PD-L1 CPS scores. Consequently, it is impossible to determine whether the statement is consistent with the CTR data based on the available information. Additionally, the unit of measure in the statement is not explicitly stated, which may lead to potential misinterpretations.</s>"
    },
    "3419af1a-7923-419d-a673-2de96d41eabb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03719677",
        "Statement": "Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2.",
        "Label": "Entailment",
        "entail": "The expert statement \"Potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2\" can be entailed by the information in the CTRs as follows:\n\nIn the primary CTR, the inclusion criteria specify breast cancer patients, but it does not exclude participants based on hormone receptivity, except for HER2 positive BCS cases. The expert statement aligns with this by stating that participants will be considered regardless of hormone receptivity, with the exception of HER2 overexpressing cases.\n\nThe expert statement does not contradict any information provided in the CTRs. Therefore, the assertion in the expert statement is entailed by the information in the CTRs since both statements allow for the participation of hormone receptive and hormone non-receptive breast cancer patients, with the exception of HER2 overexpressing cases.</s>",
        "contradict": "The statement that \"potential participants will be considered regardless of the hormone receptivity of their breast cancer, except if they are overexpressing ERBB2\" conflicts with the CTR as it excludes participants who have HER2 positive BCS (Breast Cancer Subtype). This contradiction is not apparent at first glance, but upon further inspection of the inclusion criteria in the CTR, it is evident that this subtype, which is characterized by the overexpression of ERBB2, is specifically stated as an exclusion criterion.</s>"
    },
    "2048912d-9e9f-4cbc-89cc-19020f20a976": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01966471",
        "Secondary_id": "NCT00981812",
        "Statement": "A patient who had a total bilateral mastectomy in the year prior to study entry would be excluded from both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs because:\n\nIn the primary trial, the exclusion criteria state that \"No more than 9 weeks (63 days) may elapse between definitive breast surgery (or the last surgery if additional resection required for breast cancer) and randomization.\" Therefore, a patient who had a total bilateral mastectomy in the year prior to study entry would not meet this requirement, and thus would be excluded.\n\nIn the secondary trial, the exclusion criteria state that \"subject has had surgery on the study breast within the past 12 months,\" meaning that a patient who had a total bilateral mastectomy in the year prior to study entry would still be excluded from the secondary trial.</s>",
        "contradict": "The statement is contradictory to the primary trial inclusion criteria where participants with \"no more than 9 weeks (63 days) may elapse between definitive breast surgery (or the last surgery if additional resection required for breast cancer) and randomization.\" A total bilateral mastectomy performed within a year but less than 9 weeks prior to study entry would not meet this requirement. \n\nFor the secondary trial, the patient undergoing a total bilateral mastectomy would not be explicitly mentioned in the exclusion criteria. Therefore, their eligibility would depend on the other inclusion and exclusion criteria specified in the secondary trial.</s>"
    },
    "f5907902-d4d1-4d73-a196-7fbe0dcb44ad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245219",
        "Secondary_id": "NCT00038103",
        "Statement": "the primary trial and the secondary trial both have control groups. ",
        "Label": "Entailment",
        "entail": "The primary and secondary trials both have control groups because, in the primary trial, the control group received health tracking as the intervention, which involved no additional treatment or intervention beyond usual care. In the secondary trial, no specific control group description is mentioned in the provided text, but it can be inferred that a control group exists since the trial involves two intervention groups (Exemestane Alone and Combination). Therefore, the statement is entailed by the information present in the CTRs as both trials have sections dedicated to the control or comparison groups.</s>",
        "contradict": "The statement that \"the primary trial and the secondary trial both have control groups\" is not contradicted by the CTR information, as both trials do indeed have control groups (health tracking in the primary trial and no intervention in the secondary trial's control group). However, the statement does not provide enough detail to determine whether the nature or specifics of the control groups in the two trials are comparable or not. This is a separate issue from entailment and should not be confused with it. Entailment refers to the logical relationship where the truth of a claim can be inferred from the truth of another claim, and there is no contradiction involved. In this case, the statement is true but does not fully capture the information provided in the CTRs, which focuses on the differences in interventions rather than control groups.</s>"
    },
    "93a8e018-ac25-48b2-81d2-fd5b01be8f37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows: The primary trial reports an incidence of 1 infection among 41 patients (2.44%), and the secondary trial reports an incidence of 2 infections among 81 patients (2.47%). Therefore, the statement \"A higher number of patients in the secondary trial suffered from infection compared to those in the primary trial\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"A higher number of patients in the secondary trial suffered from infection compared to those in the primary trial\" is contradicted by the data presented in the Adverse Events sections of the CTRs because the primary trial reported 1 instance of infection (2.44%) among 41 patients, whereas the secondary trial reported 2 instances of infection (2.47%) among 81 patients. However, the total number of patients experiencing any adverse event is higher in the secondary trial (14/81 vs 1/41). This means that, while there are more instances of infection in the secondary trial, the proportion of patients experiencing infection is not significantly greater. Therefore, the statement oversimplifies the data and may lead to a misinterpretation of the clinical trial findings.</s>"
    },
    "d72c45e5-6654-4afe-91a0-1f47b0c13dc0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Anna's diagnosis of HER2-positive invasive adenocarcinoma of the breast with ipsilateral nodes pN2 makes her eligible for Cohort A according to the provided CTR. The CTR's inclusion criteria for Cohort A state that patients must have invasive adenocarcinoma of the breast, a breast or axilla tumor greater than or equal to 2.0 cm or invasive carcinoma of inflammatory type without measurable disease, clinical Stage IIIA, IIIB, or IIIC disease, and ipsilateral nodes that are pN2 or pN3. Anna's diagnosis meets all of these requirements.\n\nAdditionally, Anna's ECOG performance status of 0 and her age of 57 are compatible with the CTR's inclusion criteria for all patients which require the patient to have a female gender, be greater than or equal to 18 years old, and to have an ECOG performance status of 0 or 1.\n\nThus, the information in the expert's statement that Anna is a 57-year-old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2, is entailed by the information present in the CTRs since she meets the inclusion criteria for Cohort A.</s>",
        "contradict": "The statement that \"Anna is a 57 year old female with an ECOG of 0, diagnosed with a HER2-positive invasive adenocarcinoma of the breast, with ipsilateral nodes pN2. She is eligible for the primary trial\" is not contradicted by the information present in the CTRs.\n\nHowever, there are certain exclusion criteria in the CTRs that could make Anna ineligible for the primary trial despite her diagnosis and eligibility based on the given statement. For instance, the CTRs state that patients must have clinical Stage IIIA, IIIB, or IIIC disease with a mass in the breast or axilla that is greater than or equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma. Anna's diagnosis and ipsilateral nodes pN2 alone don't necessarily imply that she meets this criterion. Additionally, the CTRs specify that for patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and DCIS as determined by the local pathologist. The statement doesn't provide any information about the resection margins. If Anna's margin status is unclear or positive, she may not meet the eligibility criteria. Furthermore, there might be other exclusion criteria mentioned in the CTRs that Anna may not meet, such as certain comorbidities or prior treatments.\n\nTherefore, even though the statement itself doesn't contradict the information in the CTRs, there might be additional criteria in the CTRs that could make Anna ineligible for the primary trial. A thorough review of the entire CTR would be required to determine her eligibility accurately.</s>"
    },
    "e68b5690-11fd-4567-8dcc-dec91d1e4bb8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01033032",
        "Statement": "The only adverse event recorded in the primary trial was one single case of spinal fracture.",
        "Label": "Contradiction",
        "entail": "The statement \"The only adverse event recorded in the primary trial was one single case of spinal fracture\" does not directly entail the information present in the CTRs since the CTR for the primary trial reports \"PLEURAL EFFUSION 1/3 (33.33%)\". However, there is no mention of a spinal fracture event in the given Adverse Events section for the primary trial. Thus, the statement contradicts the information in the CTR and is not entailed by it. \n\nTherefore, the expert's statement cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The only adverse event recorded in the primary trial was one single case of spinal fracture\" cannot be concluded from the CTRs alone, as the CTRs only report the incidence of specific adverse events, and the statement does not mention the type of trial or the source of the information about the single case of spinal fracture. The statement could be correct if the single case of spinal fracture occurred in the primary trial and was not reported in the CTR. However, based on the provided CTRs, there is no entailment relationship, as the statement contradicts the information in CTR 1, which reports an incidence of 33.33% for adverse events overall and does not mention any cases of spinal fracture.</s>"
    },
    "e1417a26-2f40-4dd6-b598-e66e57312595": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01931163",
        "Secondary_id": "NCT00274469",
        "Statement": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER.",
        "Label": "Contradiction",
        "entail": "The statement that \"Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER\" can be entailed by the information present in the CTRs because neither trial reported a single instance of LACRIMAL DISORDER in either the primary trial with 22 participants (0/22 = 0%) or the secondary trial with 103 participants (0/103 = 0%), while other reported adverse events vary in frequency between the two trials.</s>",
        "contradict": "The statement \"Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER\" is contradicted by the information present in the CTRs because, according to the provided data, there were no instances of LACRIMAL DISORDER reported in either cohort or trial, in both the primary and secondary trials. However, the statement suggests that a significant difference exists between the two trials in terms of the occurrence of LACRIMAL DISORDER, with a lower rate in the primary trial and no occurrences in the secondary trial, which conflicts with the actual data provided.</s>"
    },
    "6ee89773-958b-4eb9-bc67-18fa98a70c2d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial only recorded one type of acute adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial only recorded one type of acute adverse event\" is entailed by the information in the CTRs because both trials report only one instance each of myocardial infarction as an acute adverse event across all participants. Therefore, the statement accurately summarizes the information present in the CTRs by stating that only one type of acute adverse event was recorded in the primary trial (myocardial infarction).</s>",
        "contradict": "The information in the statement contradicts the CTR data as the primary trial reported multiple types of acute adverse events, including febrile neutropenia, neutropenia, thrombocytopenia, acute coronary syndrome, cardiac failure congestive, myocardial infarction, cardiomyopathy, abdominal pain, diarrhea, and upper gastrointestinal hemorrhage.</s>"
    },
    "4d776c28-8ed1-4f3f-9837-0821029d3775": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00063570",
        "Statement": "None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated. ",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in cohort 1 of the primary trial had a thrombocytopenia, and none of the patients in cohort 2 were constipated\" is entailed by the CTRs given. \n\nJustification:\nIn the primary trial's adverse events section for cohort 1, there are no recorded occurrences of thrombocytopenia (0/52), and in cohort 2, there are no reports of constipation (0/21). The statement made by the expert matches the information present in the CTRs, as it correctly asserts the absence of thrombocytopenia in cohort 1 and the absence of constipation in cohort 2. This relationship establishes semantic entailment.</s>",
        "contradict": "The statement \"None of the patients in cohort 1 of the primary trial had a thrombocytopenia, and none of the patients in cohort 2 were constipated\" is contradicted by the information in the CTRs because, in the primary trial, there was one case of thrombocytopenia in the entire cohort (1/52), while in the secondary trial, there was no mention of thrombocytopenia in cohort 2, but there is no information about the presence or absence of constipation in cohort 2. The statement's assertion that \"none\" of the patients in cohort 2 were constipated is not contradicted by the CTR, but its claim about cohort 1 and thrombocytopenia is.</s>"
    },
    "50e54a67-9cfb-4259-b810-2e9bc0b09b4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00611624",
        "Secondary_id": "NCT00600340",
        "Statement": "the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy.",
        "Label": "Contradiction",
        "entail": "The statement cannot be directly entailed by the information in the CTRs. In the primary trial, there is no mention of a minimum duration for Mammosite Therapy. In the secondary trials, Bevacizumab is given in combination with Paclitaxel or Capecitabine, not Mammosite Therapy. Therefore, no CTR provides evidence that participants in any of the trials are required to undergo a minimum of two weeks of Mammosite Therapy.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial require patients to undergo a minimum of two weeks of Mammosite Therapy\" is contradicted by the information in the CTRs because the primary trial does not specify the duration of Mammosite Therapy. In the secondary trials, patients receive Bevacizumab and Capecitabine or Bevacizumab and Paclitaxel, which are not Mammosite Therapy. Therefore, there is no basis for the statement to make a claim about Mammosite Therapy duration for both trials.</s>"
    },
    "9f23f617-b8ec-4665-ad0b-9a9bc8b19691": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00688740",
        "Secondary_id": "NCT00191815",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Contradiction",
        "entail": "The statement that \"The most common adverse event in both the primary and secondary trials is Neutropenia with a total of 3 cases\" is entailed by the data presented in the CTRs because:\n\n1. The statement claims that Neutropenia is the most common adverse event, and it indeed appears as an adverse event in both trials with a total of 3 cases (2 in the primary trial and 1 in the secondary trial).\n2. The data in the CTRs for both trials provide the number of cases for each adverse event, and it is clear that Neutropenia has the highest number of cases across all reported adverse events in both trials.\n\nThus, the statement is entailed by the data in the CTRs and does not contradict it in any way.</s>",
        "contradict": "The statement's assertion that \"The most common adverse event in both primary and secondary trials is Neutropenia with a total of 3 cases across all cohorts\" contradicts the information provided in the CTRs because the total number of Neutropenia cases in the primary trial is 2, and in the secondary trial it is 1. The statement's claim of having a total of 3 cases across both trials is incorrect according to the data given in the CTRs.</s>"
    },
    "b76c9c21-64f7-487b-bf08-e232a9da0174": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01490892",
        "Secondary_id": "NCT02364388",
        "Statement": "The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment.",
        "Label": "Contradiction",
        "entail": "The statement \"The intervention in the primary trial requires an injection and two different imaging modalities, whereas the secondary trial firstly requires a consultation followed by an intensive radiotherapy treatment\" does not directly entail information from the provided CTRs, as it makes a comparative claim about the interventions in the primary and secondary trials, rather than making a claim solely based on the information in the CTRs. \n\nHowever, we can infer that the statement is not contradictory to the information in the CTRs, as the statement accurately describes the procedures for the interventions in their respective trials. In the primary trial, the intervention involves an injection (Perflutren) followed by two imaging modalities (3D Harmonic imaging and 3D subharmonic imaging). In contrast, the secondary trial involves a consultation, which is not present in the primary trial, followed by intensive radiotherapy treatment. These procedures are distinct from the procedures in the primary trial and do not contradict the information in the CTRs. Therefore, while the statement goes beyond the specific information in the CTRs, it does not contradict or misrepresent any information contained therein.</s>",
        "contradict": "The statement made by the clinical trials expert is contradictory to the information presented in the CTRs because the interventions described differ significantly. The primary trial involves an injection of Perflutren suspension followed by two imaging modalities: 3D Harmonic imaging (HI) and 3D subharmonic imaging (SHI). In contrast, the secondary trial's intervention consists of a consultation without any mention of an injection or imaging modalities. There is no evidence in the CTRs to support that the interventions in both trials are comparable or entail each other.</s>"
    },
    "66aaca41-f5f9-4ed4-b165-9510b7c64456": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients who identify as female are eligible for the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement's assertion harmonizes with the CTRs' inclusion criteria that exclusively specify eligibility for female individuals in both trials. Therefore, the statement's claim is entailed by the CTRs' information, as both share the commonality of limiting participation to females.</s>",
        "contradict": "The statement \"Only patients who identify as female are eligible for the secondary trial and the primary trial\" is contradicted by the information present in the CTRs in several ways:\n\n1. In the primary trial, there are exclusion criteria for transgender men and women, meaning men are explicitly mentioned as not eligible.\n2. In the secondary trial, the exclusion criteria mention males directly as not eligible. \n3. There are inclusion/exclusion criteria in both trials that have nothing to do with gender, such as age, tumor stage, and surgical history, indicating that both male and female subjects can meet those criteria. Thus, the statement oversimplifies the eligibility criteria and overlooks important distinctions between the two trials.\n\nIn summary, the statement is contradicted by the CTRs as it overlooks the gender exclusion criteria for males in both trials and disregards the presence of non-gender related criteria that could apply to either male or female patients.</s>"
    },
    "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a fungal infection of the mouth.",
        "Label": "Entailment",
        "entail": "The statement \"A patient in the primary trial had a fungal infection of the mouth\" can be entailed by the information in the CTRs because the statement \"Infection-oral thrush *1/49 (2.04%)\" is present in the Primary Trial's Adverse Events section, indicating that one patient in the trial experienced an oral thrush infection, which is a type of fungal infection.</s>",
        "contradict": "The statement \"A patient in the primary trial had a fungal infection of the mouth\" cannot be definitively contradicted by the information in the provided CTRs. However, it is important to note that the CTR for the primary trial does list \"Infection-oral thrush\" as an adverse event, which is a type of fungal infection. Therefore, it is possible that the statement refers to this recorded event. Thus, the statement is not an outright contradiction based on the given data, but it might not fully capture the depth of information available in the CTRs.</s>"
    },
    "d6b09c0f-979c-4151-87f9-830b964e275d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Statement": "Urosepsis was the most common adverse event in the primary trial.",
        "Label": "Entailment",
        "entail": "The frequency of Urosepsis in the primary trial being the highest among all the reported adverse events (16.67%) is consistent with the expert's statement that it was the most common adverse event.</s>",
        "contradict": "The statement \"Urosepsis was the most common adverse event in the primary trial,\" can be contradicted by the information present in the CTRs because, according to the data provided, Urosepsis occurred in only 2 out of 12 participants (16.67%). The most common adverse event, with a higher occurrence rate, was actually Brain hemorrhage complicating CNS metastasis, which happened to 1 out of 12 participants (8.33%).</s>"
    },
    "92da8d30-a7e9-4fb4-95e4-484b53279ad7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years.",
        "Label": "Entailment",
        "entail": "The statement asserts that both trials monitor disease-free survival (DFS) but report DFS statistics for different time periods. The primary trial reports the percentage of patients with DFS at 24 months (DFS at 2 years), while the secondary trial reports the percentage of participants with DFS for up to 5 years. This difference is consistent with the information in the CTRs, where the primary trial outlines a 30-month treatment duration for DFS assessment, while the secondary trial outlines a 5-year follow-up period. Therefore, the statement's claim that the trials report DFS statistics for different timeframes is entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial reports disease-free survival (DFS) at 24 months, while the secondary trial reports percentage of participants with DFS at 5 years. The primary trial and secondary trial monitor DFS, but they refer to different time frames. The primary trial's outcome measurement is DFS at 24 months, and the secondary trial's outcome measurement is DFS at or before 5 years. Therefore, the statement can be misleading as it does not account for the time difference in the reporting of DFS between the two trials.</s>"
    },
    "762c3b23-547a-40cb-86c9-767294f4a142": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial, due to her age.",
        "Label": "Contradiction",
        "entail": "The statement that \"A 56 year old patient with a mastectomy would not be eligible for the primary trial, due to her age\" is entailed by the CTR inclusion criteria, which specify that only females aged 18 and older are eligible for the trial. Since the patient described in the statement (a 56-year-old woman with a mastectomy) is not 18 years old, she would not meet the age requirement for inclusion in the trial. Therefore, the statement is entailed by the inclusion criteria in the CTR.</s>",
        "contradict": "The patient described in the expert statement, a 56-year-old female with a mastectomy, can still be eligible for the primary trial according to the provided inclusion criteria. Age is specified as a requirement for female patients being 18 years or older, which is satisfied by the mentioned patient. The other inclusion criteria, such as breast cancer diagnosis, intact breast, planned radiotherapy treatments, and ability to comply with the study requirements, are also met for this patient, except for the surgery history (mastectomy). However, the trial's inclusion criteria do not explicitly mention surgical history, and it does not appear on the list of exclusion criteria. Therefore, the patient described in the expert statement can still be eligible for the trial, and the statement contradicts the information in the CTR if taken at face value.\n\nIt should be noted that this answer only focuses on the age aspect mentioned in the expert statement. If other aspects, like the surgery or the specific treatment type, are considered, the conclusion might change. The provided CTR does not give enough information for an accurate assessment in that regard.</s>"
    },
    "95a509d6-2990-49ac-b36c-aedf842f17ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01111825",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that no cases of constipation, diarrhea, oedemas (which includes eyelid edema), or febrile neutropenia were observed in patient cohorts 1 and 2 of the primary trial. This claim is entailed by the information in the CTRs because:\n\n- Constipation: In both Adverse Events 1 and 2, the number of cases for constipation is 0/8 and 0/6, respectively, which means there were no observed cases in either patient cohort.\n- Diarrhea: Similarly, in both Adverse Events 1 and 2, the number of cases for diarrhea is 0/8 and 0/6, respectively, indicating no reported cases in either patient cohort.\n- Oedemas: The expert's statement refers to oedemas in general. In the CTRs, eyelid edema is reported as a type of oedema, but no other types are mentioned. Since there are no reported cases of eyelid edema in either cohort, it follows that there were no reported cases of other types of oedemas as well, making the expert's statement entailed by the information in the CTRs.\n- Febrile neutropenia: In both Adverse Events 1 and 2, the number of cases for febrile neutropenia is 0/8 and 0/6, respectively, indicating that none of the patients in either cohort experienced febrile neutropenia.</s>",
        "contradict": "The statement \"There were no observed cases of Constipation, Diarrhoea, oedemas or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial\" is contradictory to the information present in the CTRs, as the following adverse events were reported in the primary trial:\n\n1. Constipation: 0/8 (0.00%) for patient cohort 1\n    and 0/6 (0.00%) for patient cohort 2\n\n2. Diarrhea: 0/8 (0.00%) for patient cohort 1\n    and 0/6 (0.00%) for patient cohort 2\n\n3. Eyelid oedema: Present in 1/8 (12.50%) patients in patient cohort 1\n    and 0/6 (0.00%) patients in patient cohort 2\n\n4. Febrile neutropenia: 0/8 (0.00%) for patient cohort 1\n    and 0/6 (0.00%) for patient cohort 2.\n\nAlthough the statement does not contradict the absence of these adverse events for all patients in both patient cohorts for the primary trial, it incorrectly implies that none of the patients from any of these cohorts experienced these adverse events at all.</s>"
    },
    "9bdc9efc-89eb-4b6b-961c-ceb5d686ebe6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Statement": "One patient in the primary trial experienced a grade 4 adverse event.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR as the primary trial report lists an instance of a participant experiencing neutropenia grade 4, which is classified as a grade 4 adverse event according to the Common Terminology Criteria for Adverse Events (CTCAE).</s>",
        "contradict": "The statement made by the clinical trial expert, \"One patient in the primary trial experienced a grade 4 adverse event,\" is contradictory to the information presented in the CTRs, as there is no record of a grade 4 adverse event among the reported events in the Primary Trial's Adverse Events section.</s>"
    },
    "19c2c2d7-4c33-4842-9ed4-02cfae663ce2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00066573",
        "Secondary_id": "NCT01091454",
        "Statement": "There was 1 case of night blindness in the primary trial, and 0 in the secondary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement \"There was 1 case of night blindness in the primary trial, and 0 in the secondary trial\" is entailed by the data in the CTRs if we consider the following:\n\n1. In the primary trial, there is one case of 'Nyctalopia' listed under 'Ocular - Other' in Adverse Events 1, which corresponds to night blindness. The total number of adverse events in the primary trial is stated as 19, and the proportion of cases with Nyctalopia is 1/3761 or 0.03%.\n2. In the secondary trial, there are no reported cases of 'Nyctalopia' in either Adverse Events 1 or Adverse Events 2.\n\nSince the expert's statement mentions one case of night blindness in the primary trial and none in the secondary trial, and the CTRs report one case of night blindness in the primary trial (as 'Nyctalopia') and no cases in the secondary trial, the expert's statement follows from the data in the CTRs without contradiction.</s>",
        "contradict": "The expert's statement asserts that there was one case (0.03%) of nyctalopia (night blindness) in the primary trial but none (0.00%) in the secondary trial. However, this information contradicts the data presented in the Adverse Events sections of the CTRs, as the primary CTR indicates one occurrence of nyctalopia in 3761 participants (0.03%), whereas the secondary CTR indicates none among 48 participants (0.00%). The discrepancy lies in the numbers reported for each trial.</s>"
    },
    "1fdaafdc-766b-488e-9cc4-cbcad74ade97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are Doxorubicin and Veliparib.",
        "Label": "Contradiction",
        "entail": "In the given CTRs, both in the primary and secondary trials, the drugs Veliparib (in intervention 1 and 2 of the primary trial) and Doxorubicin (in both trials) are stated to be given orally (PO) in the secondary trial's intervention and intravenously (IV) in the primary trial's interventions. However, the statement focuses solely on the orally administered drugs. Since the primary trial specifies Veliparib as PO in arm 2 but IV in arms 1, the statement is focusing on arm 2 of the primary trial where Veliparib is given orally, which aligns with the statement's claim. This entails that the statement is a valid inference from the provided CTR information, as the statement and CTR both agree that Doxorubicin is given orally in the secondary trial and Veliparib is given orally in the primary trial (in arm 2).</s>",
        "contradict": "Contradiction exists because the primary CTRs also mention Doxorubicin being administered intravenously in both arms, while the statement only acknowledges oral administration.</s>"
    },
    "2e591059-5a3b-4a69-84c5-59d9604394a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02040857",
        "Statement": "All genders are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The CTR states that both pre- and postmenopausal women are eligible for the primary trial. While the term \"pre-menopausal\" is often associated with women, it is not explicitly stated that men are excluded. The CTR also includes no gender restrictions for the secondary trial. Therefore, the statement that \"All genders are eligible for the primary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"All genders are eligible for the primary trial\" is contradicted by the CTR information as it specifies that only women are eligible for the trial due to the nature of the condition being studied, hormone receptor positive (HR+) breast cancer.</s>"
    },
    "94a54cdf-4c1c-4994-929a-ced7a33f2b43": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00866905",
        "Statement": "Less than 1% of patients in the primary trial became depressed.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 1% of patients in the primary trial became depressed\" is entailed by the information presented in the CTR, as the CTR states that 1/168 or 0.60% of patients experienced depression as an adverse event.</s>",
        "contradict": "The statement \"Less than 1% of patients in the primary trial became depressed\" is contradicted by the information in the CTR because the CTR reports that there was 1 patient with depression out of a total of 168 participants (0.60%), which is above the stated threshold of less than 1%.</s>"
    },
    "b217583e-2dbb-4951-8f73-cac08e365a7a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00562718",
        "Statement": "Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion.",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial includes eligibility criteria that state \"No other serious uncontrolled medical conditions that the investigator feels might compromise study participation.\" This broad statement allows for discretion on the part of the investigator. The secondary statement specifies two types of medical conditions, pacemakers and stents, and allows their patients to participate with the investigator's discretion. As pacemakers and stents are considered medical devices, rather than conditions, they can be seen as a form of medical intervention. The primary CTR's eligibility criteria already permits participants with unspecified serious medical conditions if the investigator deems it acceptable. Thus, the secondary statement is entailed by the information in the primary CTR.</s>",
        "contradict": "The statement that \"Patients with pacemakers or stents may be allowed to participate in the primary trial at their physician's discretion\" cannot be entailed by the information present in the given CTRs because the CTRs explicitly state that there are certain conditions under which patients are not eligible for the study. Among these conditions are \"Any cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease, or cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.\" Pacemakers and stents are typically used to treat cardiac conditions, and their presence would fall under these eligibility criteria unless otherwise specified by the physician's discretion. However, the CTRs do not mention any such allowance or exception for patients with pacemakers or stents. Therefore, the statement goes beyond the information given in the CTRs and contradicts the stated exclusion criteria.</s>"
    },
    "42086f11-1fb1-4041-8d1e-e150d4cc09ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00304096",
        "Statement": "A minimum bodyweight of 50kg is required to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"A minimum bodyweight of 50kg is required to participate in the primary trial\" can be entailed by the information present in the CTR as follows: \"Body weight > 110 lbs (without clothes)\" can be converted to a minimum bodyweight of 110 lbs or approximately 50 kg with clothes on. Therefore, the statement sets a lower minimum bodyweight requirement compared to the CTR, but still falls within the range of the stated eligibility criterion.</s>",
        "contradict": "The statement \"A minimum bodyweight of 50kg is required to participate in the primary trial\" contradicts the information in the CTRs as they specify \"Body weight > 110 lbs (without clothes)\" which translates to > 49.8 kg or 50.2 kg in kilograms, making it lighter than the stated minimum.</s>"
    },
    "0d75c493-58ce-4a45-8823-a9a1126751b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of chemotherapy and radiotherapy.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs as the primary trial described in the first CTR involves the use of chemotherapy (capecitabine) in combination with radiotherapy. According to the provided text, capecitabine is given when patients receive radiotherapy, and the radiotherapy doses are specified. This combination of chemotherapy and radiotherapy is the essence of the expert's claim.</s>",
        "contradict": "The statement \"the primary trial is testing a combination of chemotherapy and radiotherapy\" cannot be directly contradicted by the information present in the CTRs. However, based on the provided CTR descriptions, it seems that the trial is testing capecitabine (a type of chemotherapy) in conjunction with radiotherapy, but they are not being administered at the same time in the same dose. Therefore, it might be more accurate to say that the trial is evaluating the sequential use of chemotherapy and radiotherapy, rather than a combination therapy given simultaneously. The statement is not incorrect, but it may not fully capture the details of the trial design as described in the CTRs.</s>"
    },
    "d0d4e184-0764-4c28-9af7-4535c7ed1aad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00303108",
        "Statement": "Cohort 2 of the primary trial produced marginally better results than cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 2 of the primary trial produced marginally better results than cohort 1\" can be entailed by the information in the CTRs as follows:\n\n1. According to the results provided in the CTR, the percentage of participants in cohort 1 (Doxil, Carboplatin, and Taxane naive) who achieved an objective response was 30.8% (95% CI: 17.0-47.6).\n2. In cohort 2 (Doxil, Carboplatin, and Taxane pretreated), the percentage of participants who achieved an objective response was 31.0% (95% CI: 17.6-47.1).\n3. Since both cohorts' response rates have overlapping confidence intervals, it suggests that cohort 2 had a marginally better response rate than cohort 1, which is consistent with the statement.\n\nHence, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 2 of the primary trial produced marginally better results than cohort 1\" cannot be definitively concluded from the given CTR data. Although the percentage of participants with objective response in cohort 2 is slightly higher (31.0% vs 30.8%), the confidence intervals for both groups overlap, indicating that the difference in response rates could be due to chance and not a clinically meaningful difference. Moreover, the statement does not provide any specific information about the type or magnitude of better results, making it unclear whether it is related to the primary outcome measure or other factors. Consequently, the statement contradicts the precision and completeness of the data provided by the CTRs.</s>"
    },
    "e45886af-1edd-4987-a280-2609a86fd3dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02413320",
        "Statement": "Females over the age of 20 that have recieved chemotherapy in the last 4 weeks , are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Females over the age of 20 that have received chemotherapy in the last 4 weeks, are eligible for the primary trial,\" is not entailed by the information present in the CTRs. \n\nExplanation:\n\nThe CTRs specify that \"No prior chemotherapy\" is a requirement for inclusion in the primary trial. The statement suggests that females who have received chemotherapy within 4 weeks of the trial are eligible, which is in direct contradiction to the CTRs. Therefore, the statement cannot be entailed by the information present in the CTRs. \n\nHowever, if we assume that the expert meant to say that females who have completed chemotherapy more than 4 weeks ago are eligible, then the statement is consistent with the CTRs, and entailment could be established. But based on the given statement, no entailment can be established as the information provided in the statement contradicts the CTRs.</s>",
        "contradict": "The statement \"Females over the age of 20 that have received chemotherapy in the last 4 weeks, are eligible for the primary trial\" contradicts the CTR's inclusion criteria, specifically the line \"No prior chemotherapy\" for the primary trial.</s>"
    },
    "c207ff16-b7d0-49e4-9177-0597044f3008": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Some primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by subcutaneous injection\" does not directly contradict or contradict the information provided in the CTRs. The CTRs state that patients in Group I of the primary trial receive topical keratin at least BID (twice daily) for approximately 3-6 weeks. However, the CTRs do not mention anything about the method of administration (topical or subcutaneous) for Group II, the standard of care group, in the secondary trial. The expert's statement goes beyond the information provided in the CTRs by introducing the possibility of subcutaneous injection for the primary trial, but it does not contradict the stated information. Therefore, the expert's statement can be considered semantically entailed by the CTRs, as long as it is understood that the expert's statement refers to the primary trial only (since the CTR for the secondary trial does not provide enough information to make any conclusions about its administration method).</s>",
        "contradict": "The statement \"Some the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks, others participants may have it administered by ubcutaneous injection\" is contradicted by the information present in the CTRs as only topical administration of keratin is specified in the given trial descriptions. No mention of subcutaneous injection is made in the provided CTRs.</s>"
    },
    "35234f08-cf01-478f-b739-600b5a6ea3d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00550771",
        "Statement": "16/179  patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2\" can be entailed by the information in the CTRs as follows:\n\nGiven that the CTRs provide information on the number of participants in each arm who experienced cardiac events, we can calculate the number of cardiac events in the primary trial by summing the number of cardiac events in both the PLD and doxorubicin-based regimens. According to Results 1 and 2, the number of participants in the PLD and doxorubicin-based regimens are 120 and 59, respectively. Thus, the total number of participants in the trial is 179.\n\nRegarding the number of cardiac events, Result 1 states that \"Number of Participants Who Experienced Cardiac Events\" for the PLD-based regimen is given. However, the number of participants who experienced cardiac events is not explicitly stated in the Results section for the doxorubicin-based regimen. Nonetheless, we know from the text that the majority of cardiac events occurred in cohort 2. Since cohort 2 corresponds to the doxorubicin-based regimen, we can infer that the number of cardiac events in the doxorubicin-based regimen is greater than in the PLD-based regimen.\n\nThus, we can calculate the total number of cardiac events by summing the number of cardiac events from both arms: \n\nCardiac events in PLD-based regimen = Number of participants in PLD-based regimen * Percentage of participants who experienced cardiac events (from Results 1)\n= 120 * X (where X is the percentage of participants in the PLD-based regimen who experienced cardiac events)\n\nCardiac events in doxorubicin-based regimen = Number of participants in doxorubicin-based regimen * Percentage of participants who experienced cardiac events (which we know is greater than in the PLD-based regimen)\n= 59 * Y (where Y is the percentage of participants in the doxorubicin-based regimen who experienced cardiac events, and Y > X)\n\nTotal cardiac events = Cardiac events in PLD-based regimen + Cardiac events in doxorubicin-based regimen\n= 120X + 59Y\n\nThe expert statement \"16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2\" can be entailed since it is derived from the total number of cardiac events (16) and the fact that the majority of those events occurred in cohort 2. This information can be calculated from the data provided in the CTRs.</s>",
        "contradict": "The statement \"16/179 patients in the primary trial Experienced Cardiac Events, with the majority of those coming from cohort 2\" cannot be definitively contradicted by the information in the CTRs. However, it can potentially be misleading without additional context. The CTRs do not provide the exact number of patients in each cohort who experienced cardiac events, or the proportion of cardiac events that occurred in cohort 2 compared to cohort 1. The statement does not necessarily contradict the CTRs, but it could lead to confusion or inaccurate conclusions if not interpreted within the proper context. The number of cardiac events and the distribution across cohorts may have been affected by various factors not accounted for in the provided information, including differences in baseline characteristics, treatment regimens, or other confounding factors. To accurately assess the semantic entailment, it is necessary to examine the complete set of trial data, as well as any additional context or information that may impact the statement's validity.</s>"
    },
    "87adb323-6f56-4e1a-a04d-8437ac571eab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "Patients with Lactiferous duct carcinomas are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "Lactiferous duct carcinomas are a subtype of ductal carcinoma in situ, which falls under the category of breast cancer covered by the primary trial's inclusion criteria. Therefore, the statement that \"Patients with Lactiferous duct carcinomas are eligible for the primary trial\" is entailed by the information in the primary CTR's inclusion criteria.</s>",
        "contradict": "Lactiferous duct carcinomas are not explicitly mentioned in the inclusion criteria of the primary trial. The primary trial includes patients with ductal carcinoma in situ, lobular carcinoma in situ, or stages 1-3 breast cancer. While lactiferous duct carcinomas can fall under the category of ductal carcinoma, the statement is too specific and does not align with the inclusion criteria as stated in the CTR.</s>"
    },
    "94410f2c-9c1c-4130-b479-738e343ba9f7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "Both the primary and secondary trials involve interventions with at least one drug administration route in common: intravenous (IV) for doxorubicin hydrochloride, trastuzumab, and methotrexate; oral (PO) for cyclophosphamide, capecitabine, filgrastim, tamoxifen citrate, letrozole, and Q-122 in both trials.</s>",
        "contradict": "The statement \"There is a least one route of administration shared by the interventions used in the primary trial and the secondary trial.\" does not contradict the information present in the CTRs, as both trials involve oral administration of Q-122 in the secondary trial and various intravenous and oral administrations of other agents in the primary trial. However, it is important to note that this statement does not necessarily establish semantic entailment, as it does not specifically reference the information within the ELIGIBILITY CRITERIA, RESULTS, or ADVERSE EVENTS sections, and the statement does not contradict the CTR data.</s>"
    },
    "b811e872-90ef-4649-9c8d-f5488f316ccc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00671918",
        "Secondary_id": "NCT00571987",
        "Statement": "Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, the inclusion criteria state that patients with pure ductal carcinoma in situ (DCIS) are eligible if lymph node biopsy is part of the surgical plan. In the secondary trial, the inclusion criteria do not specify any restrictions regarding DCIS, implying that they are included in the study. Both trials do not have any exclusion criteria related to DCIS. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Patients with pure ductal carcinoma in situ (DCIS) are eligible for both the secondary trial and the primary trial\" contradicts the CTR information because the primary trial explicitly excludes patients with DCIS unless lymph node biopsy is part of the surgical plan. In contrast, the secondary trial includes patients with DCIS as a specific criterion for inclusion. Therefore, according to the CTRs, patients with pure DCIS cannot meet both the inclusion criteria for both trials.</s>"
    },
    "f66f4c30-2d39-4e29-876a-487bca9a8ccf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02835625",
        "Secondary_id": "NCT00486525",
        "Statement": "the primary trial and the secondary trial do not use any chemotherapy or radiotherapy in their interventions ",
        "Label": "Entailment",
        "entail": "The statement that the primary and secondary trials do not use any chemotherapy or radiotherapy in their interventions is entailed by the information present in the CTRs because neither the primary nor the secondary trial mentions the use of chemotherapy or radiotherapy in their intervention descriptions. The primary trial involves Intervention 1 with Digital Breast Tomosynthesis and Intervention 2 with Digital Mammography, while the secondary trial includes Intervention 1 with Yoga Therapy and Intervention 2 with Wait-List. No mention of chemotherapy or radiotherapy is made in any of the Interventions for either trial.</s>",
        "contradict": "The statement does not provide accurate information when compared to the given CTRs because the CTRs do not explicitly mention the absence of chemotherapy or radiotherapy in their interventions, but rather focus on the specific imaging modalities used. The statement's assumption of general applicability to both trials is not supported by the provided data.</s>"
    },
    "34f50f3f-d6a7-4e22-84cb-6a41f0b8c1f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00452673",
        "Statement": "7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities.",
        "Label": "Contradiction",
        "entail": "The statement \"7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" can be entailed by the information in the CTRs, given that:\n\n1. The CTRs provide details about the occurrence of dose-limiting toxicities (DLTs) in the primary trial, as described in the Outcome Measurement section, with specifics on the number of participants experiencing DLTs per dose level.\n\n2. The information in Results 1 indicates that 1 DLT was observed in the first 3 participants of cohort 1 (Arm/Group Title: 50 mg Dasatinib + 825 mg/m^2Capecitabine), and 3 additional participants were studied, resulting in a total of 6 participants who experienced DLTs in this cohort. The statement matches the number given in the CTR. Therefore, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"7 patients in cohort 1 of the primary trial suffered dose-limiting toxicities\" is not directly contradictory to the information presented in the CTRs, but it is incomplete and potentially misleading without additional context. The CTR specifies criteria for defining dose-limiting toxicity, and the statement only mentions the number of patients who experienced these events. However, the CTR also states that if 1 or 2 DLTs were observed, additional participants were studied. Therefore, it is possible that the number of patients in cohort 1 who experienced DLTs was indeed 7, but more participants were enrolled to determine if the maximum tolerated dose had been exceeded. Thus, the statement alone does not establish entailment with the CTR information and should be evaluated in context to avoid misunderstandings about the trial's outcomes.</s>"
    },
    "011991a5-724d-4b95-b9ab-9e1371d77368": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00086957",
        "Statement": "All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia.",
        "Label": "Contradiction",
        "entail": "The statement \"All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia\" is entailed by the information in the CTRs because:\n\n1. The CTR for Primary Trial states that out of 2 patients in cohort 1, 1 patient experienced Leukopenia (100.00% in cohort 1) and both patients (100.00% in total) experienced Febrile neutropenia.\n2. The statement's condition that \"All of the patients in cohort 1 of the primary trial\" refers to the exact same cohort as described in the CTR.\n3. The CTR's information on Leukopenia and Febrile neutropenia in cohort 1 is consistent with the statement that \"All of the patients in cohort 1\" experienced these conditions.\n4. The statement's conditions (Leukopenia and Febrile neutropenia) are subsumed within the CTR's descriptions (Leukopenia: 1/2 patients, Febrile neutropenia: 2/2 patients).\n\nTherefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"All of the patients in cohort 1 of the primary trial experienced Leukopenia and Febrile neutropenia\" is contradicted by the information in the CTR, as only one patient in the primary trial's cohort 1 experienced Leukopenia and both patients experienced Febrile neutropenia.</s>"
    },
    "8421197a-3a35-4738-b1c8-83cce0ac4115": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02896855",
        "Secondary_id": "NCT00171314",
        "Statement": "the secondary trial recorded more total occurences of cardiac adverse events than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial recorded more total occurrences of cardiac adverse events than the primary trial\" can be entailed by the information present in the CTRs, since the secondary trial had a higher total count of cardiac adverse events (56/269 = 20.82%) compared to the primary trial (4/120 = 1.67% for intervention arm and 1/120 = 0.83% for control arm, summing to 5.5% in total).</s>",
        "contradict": "The statement that \"the secondary trial recorded more total occurrences of cardiac adverse events than the primary trial\" is contradicted by the information in the CTRs because the primary trial recorded 4 cardiac-related adverse events and the secondary trial recorded 5 cardiac-related adverse events, but the statement does not take into account the different number of participants between the two trials. When we consider that the primary trial had 120 participants and the secondary trial had 254 participants, it becomes clear that the secondary trial had a higher number of participants and therefore, it is expected to have more adverse events overall. Thus, the raw count of adverse events does not provide sufficient context to make such a comparison, and the statement is misleading.</s>"
    },
    "d09091f1-3fc5-498b-8c59-4678590c8464": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Secondary_id": "NCT01498458",
        "Statement": "Although there is a much higher percentage of patients with Enterocolitis in the secondary trial than in cohort 1 of the primary trial, no robust comparisons can be made due to the significant differences in cohort sizes.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the given CTRs as it introduces a new concept - Enterocolitis - which is not mentioned in the provided data. However, it is possible to infer that no robust comparisons can be made regarding adverse event percentages between the trials due to differences in cohort sizes, which is a valid conclusion based on the information in the CTRs.</s>",
        "contradict": "The expert's statement does not provide specific information about the incidence of Enterocolitis in the CTRs. Therefore, it is impossible to determine if the statement can be contradicted by the data presented in the Adverse Events sections of the primary and secondary trials. The statement only mentions a difference in the number of patients between trials without providing concrete numbers. To assess entailment or contradiction, a direct comparison of the relevant data from both trials is required.</s>"
    },
    "203a2e22-cae9-4bfe-b82d-6dc665a66ce6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00821886",
        "Statement": "Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are excluded from the primary trial\" can be entailed by the information present in the CTRs under the Exclusion Criteria section. Specifically, it falls under \"Cardiac risk factors or history of cardiac disease.\" Patients with \"any documented cardiac arrhythmia\" are excluded from the primary trial. Atrial fibrillation is a type of cardiac arrhythmia; hence, patients prescribed with bisoprolol or labetalol to treat atrial fibrillation are effectively excluded from the trial.</s>",
        "contradict": "Bisoprolol and labetalol are not mentioned in the inclusion or exclusion criteria of the Primary Trial described in the CTR. The statement made by the expert is not directly related to the information contained in the CTRs.</s>"
    },
    "f4909215-5b14-42d9-bda4-4d112cf2a108": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Contradiction",
        "entail": "26.74% (0.2674) is more than 1/3 (0.3333) when 0.2674 > 0.3333 is simplified to 0.2674 > 0.3333 which is false. However, a mistake in the statement is observed: it should be \"More than 1/3 of patients in the primary trial's cohort experienced an adverse event.\" or \"More than 1/3 of patients in the primary trial experienced an adverse event.\" instead. With the corrected statement, the information can be entailed as 26.74% (0.2674) is more than 1/3 (0.3333) when 0.2674 > 0.3333 is simplified to 0.2674 >= 0.3333, which is true.</s>",
        "contradict": "The statement \"More than 1/3 patients in cohort 1 of the primary trial experienced an adverse event\" cannot be directly contradicted by the CTR data. However, it is important to note that the CTRs only provide the number of adverse events for the entire cohort (258 in the primary trial), not for cohort 1 specifically. Without knowing the size of cohort 1, it is impossible to determine whether more than 1/3 of its patients experienced an adverse event based on the information given in the CTRs alone. Therefore, while the statement is not contradicted, it is also not fully supported by the information presented in the CTRs.</s>"
    },
    "9c27202c-7090-4be5-840e-351992aeb81c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same number of dehydrated patients during the studies.",
        "Label": "Entailment",
        "entail": "Both trials' Adverse Events sections report the occurrence of dehydration in 1/46 (Primary) and 1/50 (Secondary) participants, respectively. This number is equal, and the percentage of dehydrated patients in each trial is consistent (2.17% for Primary and 2.00% for Secondary), implying no discrepancy between the trials regarding the reported number of dehydrated patients. Thus, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "Despite the statement suggesting equal incidence of dehydration in both trials, the Primary Trial reported 1 instance of dehydration among 46 participants, whereas the Secondary Trial reported 2 instances among 50 participants. Therefore, the statement is contradicted by the information provided in the CTRs.</s>"
    },
    "fc7d8ffd-9896-4806-a095-d435cde83c88": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00528567",
        "Secondary_id": "NCT01196052",
        "Statement": "The total number of patients affected by adverse events in cohort 2 the primary trial, is larger than the cohort size of the secondary trial.",
        "Label": "Entailment",
        "entail": "The total number of patients with adverse events in cohort 1 of the primary trial (379/1288, or 29.43%) is larger than the total number of participants in the secondary trial (148). Therefore, even though the specific adverse events listed in each trial differ, the statement that \"the total number of patients affected by adverse events in cohort 2 of the primary trial, is larger than the cohort size of the secondary trial\" is entailed by the provided information in the CTRs. This is because the total percentage of patients with adverse events in the primary trial exceeds 100% of the secondary trial's participant count.</s>",
        "contradict": "The statement \"The total number of patients affected by adverse events in cohort 2 of the primary trial, is larger than the cohort size of the secondary trial,\" is contradicted by the information in the CTRs because the number of patients with adverse events in cohort 2 of the primary trial (15) is smaller than the number of participants in the secondary trial (148). Therefore, the assumption that the number of patients with adverse events in the larger cohort of the primary trial would be greater than the number in the smaller cohort of the secondary trial is incorrect.</s>"
    },
    "23116aca-0064-4426-b147-7af688a82443": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Secondary_id": "NCT02287675",
        "Statement": "Men suffering from Ulcerative colitis are excluded from the primary trial, but eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial excludes patients with a history of ulcerative colitis (UC). The secondary trial, however, does not have specific inclusion or exclusion criteria related to UC. The statement is entailed by the CTRs as it correctly identifies that men suffering from UC are excluded from the primary trial but are eligible for the secondary trial based on the provided CTR information.</s>",
        "contradict": "The statement is contradictory to the information present in CTRs as:\n\n1. The primary trial excludes participants with \"Impairment of gastrointestinal (GI) function or GI disease or active ulceration of the upper gastrointestinal tract,\" which includes individuals suffering from Ulcerative Colitis.\n2. However, Ulcerative Colitis patients are eligible for the secondary trial as per its inclusion criteria, as it only requires the subject to be a female and 18 years of age or older, have a diagnosis of primary breast cancer, and be a candidate for surgical intervention.\n\nThus, the statement is contradictory as it asserts Ulcerative Colitis patients being excluded from the primary trial but eligible for the secondary trial, whereas the actual CTRs state the opposite.</s>"
    },
    "7dd79595-4bdf-48e6-af94-fe39aa2e5fd4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005879",
        "Secondary_id": "NCT01217385",
        "Statement": "The only criterias for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and british.",
        "Label": "Contradiction",
        "entail": "The statement \"The only criteria for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and British\" is not entailed by the information provided in the CTRs. \n\nExplanation:\n\nThe statement makes a claim about the inclusion criteria being limited to female, over 21 years old, and British. However, the CTRs provide detailed and specific eligibility criteria, which go beyond just gender, age, and nationality. The primary CTR mentions various conditions related to breast diseases, hormonal status, genetic factors, prior therapy, and imaging requirements. The secondary CTR mentions conditions related to breast cancer diagnosis, tumor size, prior therapy, age, performance status, organ function, pregnancy status, and informed consent. These criteria are far more detailed than the statement's claim that the only criteria are being female, over 21, and British.\n\nTherefore, the information contained in the statement can not be entailed by the information present in the CTRs. The statement makes a generalized and incomplete claim, while the CTRs provide detailed and comprehensive information regarding the eligibility criteria for both trials.</s>",
        "contradict": "The statement \"The only criteria for entry to the primary trial and the secondary trial is that patients must be female, over the age of 21 and British\" is contradicted by the CTRs in numerous ways. \n\n1. In the primary trial CTR, patients must be female but the age requirement is 18 and over. \n2. The primary trial includes premenopausal women and requires FNA to be taken during certain days of the menstrual cycle, while the statement only mentions an age requirement and does not mention anything about menopausal status or specific days for FNA. \n3. The secondary trial includes females aged 18 years or older. \n4. Neither CTR specifies that patients must be British, which contradicts the statement's requirement for this criterion. \n5. The primary trial has multiple other eligibility criteria beyond being female and over the age of 21, including but not limited to disease characteristics, prior therapy, and laboratory values. The secondary trial also has several eligibility criteria beyond being female and over the age of 21, such as having a pathologically confirmed diagnosis of invasive breast cancer, being a candidate for primary systemic therapy, tumor size, etc. \n\nHence, the statement is contradicted by the information presented in the CTRs as it is incomplete and does not reflect the actual eligibility criteria for the primary and secondary trials.</s>"
    },
    "98850daf-738c-4005-b476-8c5479ad3b79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00033514",
        "Statement": "Mark has HER2 positive breast cancer, he is eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "Mark's HER2 positive breast cancer, and him being eligible for the primary trial, is entailed by the following inclusion criteria in the CTR: \n\n1. HER2 positive using Fluorescence In Situ Hybridization (FISH)\n2. Women aged > 18 years.\n\nThese criteria ensure that Mark meets the requirements for patient eligibility. Therefore, the expert's statement is in line with the CTR.</s>",
        "contradict": "Mark being eligible for the primary trial based on having HER2 positive breast cancer does not necessarily mean that the statement is not contradicting the information in the CTRs. However, there are some potential discrepancies if Mark has prior cytotoxic chemotherapy or Herceptin for his metastatic disease, as per the exclusion criteria stated in the CTR. If Mark has undergone such treatments, then he would not be eligible for the primary trial according to the provided CTR information.</s>"
    },
    "fd8ddc92-4625-4392-b7ef-0ea218e2eb1c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00916578",
        "Statement": "the primary trial is testing a combination of capecitabine once daily with radiotherapy.",
        "Label": "Contradiction",
        "entail": "The primary trial's intervention specifies that patients receive capecitabine twice daily, and one of the two daily doses is taken 2 hours before radiotherapy. While the secondary trial's statement suggests capecitabine being given once daily in combination with radiotherapy, the first dose alignment (one daily dose received before radiotherapy) aligns with the primary trial's intervention details. Consequently, the secondary trial's statement can be entailed by the primary CTR's intervention section.</s>",
        "contradict": "The statement made by the clinical trial expert can be contradicted by the information in the CTRs as the primary trial described in the CTRs is not testing capecitabine once daily in combination with radiotherapy. Instead, patients in the primary trial received capecitabine at a dose of 825 mg/m2 bid (twice daily) with one dose given 2 hours before radiotherapy. The frequency of radiotherapy doses is also specified in the CTRs.</s>"
    },
    "a4ed4cc0-9444-4a5d-863c-578fd42b8794": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly\" can be entailed by the CTR information as follows:\n\n1. Afatinib: The expert's statement and the CTR both refer to the same treatment, Afatinib.\n2. Dose: The expert's statement specifies the dose as 50 mg, which matches the dose stated in the CTR.\n3. Route of Administration: Both statements agree that Afatinib is taken orally, as stated in the CTR.\n4. Frequency: The CTR states that the dose is taken daily (qd), but the expert's statement refers to every two weeks (bi-weekly). However, this discrepancy does not contradict the information in the CTR since it is not explicit about the dosing schedule beyond \"qd.\" A dosing frequency of qd every two weeks is still consistent with the CTR.\n\nHence, the expert's statement can be entailed by the CTR information, given the interpretation that \"bi-weekly\" implies \"qd every two weeks.\"</s>",
        "contradict": "The statement that \"Intervention of Cohort B is described as Afatinib 50 mg, taken orally, bi-weekly\" contradicts the information in the CTR as the CTR specifies that \"Cohort B patients receive an oral dose of Afatinib 50 mg qd\" (once daily). Therefore, the stated frequency (bi-weekly) is inconsistent with the frequency described in the CTR.</s>"
    },
    "a4dcb9b6-7b6f-4467-a159-d6e770f6762f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions.",
        "Label": "Entailment",
        "entail": "In the primary trial's inclusion criteria, it is mentioned that pregnant or breastfeeding patients are excluded. This implies that nursing patients, who have recently given birth, are also excluded due to potential harm to the nursing infant from the study therapy. Similarly, in the secondary trial's exclusion criteria, pregnant or breastfeeding patients are mentioned, which includes nursing patients as well. Therefore, the statement that \"Nursing patients are not eligible for the primary trial or the secondary trial\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the nursing infant from the study interventions\" contradicts the information present in both CTRs as neither CTR explicitly mentions nursing patients as a group to be excluded. While both CTRs mention pregnant patients as an exclusion, they do not extend this exclusion to patients who are breastfeeding, and thus the statement is not in accordance with the clinical trial data.</s>"
    },
    "be1c82e6-200d-4bef-b723-c78655fa40e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291694",
        "Statement": "the primary trial does not specificy the route of administration of its intervention.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not specify the route of administration of its intervention\" can be entailed by the information present in the CTRs because neither of the two interventions (celecoxib or placebo) mentioned in the primary trial has the route of administration explicitly stated. The CTR only indicates that participants were randomized to receive celecoxib or placebo daily for 12 months without specifying how they were to be administered (orally, intravenously, etc.). The secondary trial statement correctly identifies this missing detail and is an accurate reflection of the information provided in the primary trial CTR.</s>",
        "contradict": "The information in the statement contradicts the CTR as the primary trial specification for the intervention \"Celecoxib\" does indicate the route of administration: it is taken daily for 12 months, implying an oral administration.</s>"
    },
    "790047b1-43e3-486e-b41c-eaa89026eae7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11.1% of patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients had Unexpected adverse events.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR data as follows: \n1. The CTR indicates that 11.1% (5.2%-20.1%) of patients in the single-arm group (fulvestrant) had serious adverse events.\n2. The CTR states that there were no serious Adverse Drug Reactions (ADRs) in the single-arm group.\n3. The CTR indicates that 50.4% (40.5%-60.5%) of patients in the single-arm group had unexpected adverse events, which can be interpreted as having unexpected AEs or ADRs. However, the statement specifically refers to 'unexpected adverse events' and not 'unexpected adverse drug reactions', so it aligns perfectly with the CTR data. \n\nTherefore, the statement can be entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement that \"in the primary trial 11.1% of patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients had Unexpected adverse events\" contradicts the information present in the CTR, as the CTR states that \"11.1 (5.2-20.1)% of patients had serious adverse events\" and \"0 (0-4.4)% of patients had serious Adverse Drug Reactions\", which are not identical to the statement's assertions. Furthermore, the CTR reports \"71.6 (60.5-81.1)% of participants had Unexpected adverse events\", which is more than half and different from the statement's claim of \"over half of patients had Unexpected adverse events\".</s>"
    },
    "fc8ed290-e2b3-4eea-a837-d369dcd9b5da": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00875979",
        "Statement": "None of the 3 patients in cohort 1 of the primary trial experienced any adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"None of the 3 patients in cohort 1 of the primary trial experienced any adverse events\" is entailed by the Adverse Events 1 data in the CTR of the primary trial, as the data reports that all 0 adverse events occurred in 0/3 patients in the trial. The statement does not contradict the provided descriptions, and its assertion harmonizes with the clinical trial data.</s>",
        "contradict": "The statement \"None of the 3 patients in cohort 1 of the primary trial experienced any adverse events\" contradicts the information in the CTR as the total number of adverse events reported for cohort 1 of the primary trial is 22, not zero.</s>"
    },
    "207b0895-91de-4238-8d50-e2b8b7420fb0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in the secondary trial than in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"In total, there were more adverse events in the secondary trial than in the primary trial\" can be entailed by the information present in the CTRs since the total number of adverse events in the secondary trial (6/17 = 0.3529 x 17 = 6.0452 \u2248 6) is greater than the total number of adverse events in the primary trial (8/54 = 0.1481 x 54 = 8).</s>",
        "contradict": "The statement \"In total there were more adverse events in the secondary trial than in the primary trial\" is contradicted by the information in the CTRs because the primary trial had a larger number of participants (54 versus 17 in the secondary trial), yet the total number of adverse events was lower in the primary trial (15 versus 12 in the secondary trial).</s>"
    },
    "1340769c-b55c-480c-a4c4-130034e128ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317720",
        "Statement": "Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial\" is entailed by the CTR's inclusion criteria stating \"History of trastuzumab resistance, defined as the development of progressive disease after trastuzumab-based therapy for metastatic breast cancer. Patient may not have received more than 2 prior trastuzumab-based regimens and one lapatinib-based regimen (either as single agent or in combination with chemotherapy) for metastatic breast cancer.\" This implies that patients with a history of response to trastuzumab are not eligible, and thus, patients must have at least 1 prior treatment with trastuzumab to be eligible for the trial.</s>",
        "contradict": "The statement \"Patients must have at least 1 prior treatment with trastuzumab to be eligible for the primary trial\" is contradicted by the CTR's inclusion criteria, which state that \"patients who develop metastatic disease during or after adjuvant or neoadjuvant trastuzumab are eligible.\" This means that some patients in the trial may not have had any prior trastuzumab treatment. The CTR also mentions that patients who have received trastuzumab for metastatic breast cancer but have developed resistance are eligible, which further demonstrates that not all patients have to have prior trastuzumab treatment.</s>"
    },
    "a4d6e27f-737b-4597-86e1-79b3f064cbee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02694029",
        "Statement": "Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds.",
        "Label": "Contradiction",
        "entail": "The statement \"Candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds\" can be entailed by the information in the CTRs if we assume that the expertise of the clinical trial expert includes understanding the term \"maintain a 30 second breath hold\" mentioned in the inclusion criteria of the primary trial, and interprets it as the ability to hold one's breath underwater for 30 seconds. The expert's statement is consistent with the trial inclusion criteria and does not contradict or go beyond the information provided in the CTRs.</s>",
        "contradict": "The information contained in the statement that candidates for the primary trial are expected to be capable of holding their breath underwater for 30 seconds is not explicitly stated in the provided inclusion criteria in the CTRs. The CTRs only specify that patients must be able to maintain a 30 second breath hold for the radiation treatment procedure. The statement made by the clinical trial expert is an unwarranted extension of the information presented in the CTRs, and it contradicts the actual requirements for trial participation.</s>"
    },
    "3edf0cf2-62ea-4ac6-82aa-2bb1566c6c43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00887575",
        "Secondary_id": "NCT01610284",
        "Statement": "Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail information from the CTRs, as it concerns the size of the cohorts rather than the adverse events data provided. However, it can be inferred that the larger cohort size in the secondary trial could potentially lead to a higher number of adverse events. To establish entailment, it would be necessary to compare the rates of adverse events per participant between the two trials or directly analyze whether the specific adverse events mentioned in the expert statement can be derived from the data in the CTRs. In this case, the statement alone does not provide that information, so it cannot be definitively concluded that it is entailed by the CTR data.</s>",
        "contradict": "The statement \"Cohort 1 of the secondary trial had more than 3x the cohort size of cohort 1 of the primary trial\" does not directly contradict the information presented in the CTRs. However, it cannot be definitively determined to be true or false based on the data provided. The statement relates to the size of the cohorts and does not provide information about the occurrence or absence of adverse events or any other information contained in the CTRs. Therefore, there is no semantic entailment or contradiction relationship between the statement and the given CTRs.</s>"
    },
    "030eded8-6513-4028-b1fe-fefd6dd388ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02429427",
        "Statement": "Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial\" can be entailed by the information present in the CTR's inclusion criteria since it specifies \"Platelets greater or equal to 100 x 109/l\" for patient eligibility.</s>",
        "contradict": "The statement \"Patients with a platelet count of 50,0000 x 109/l are not eligible for the primary trial\" contradicts the inclusion criteria stated in the CTR, which specifies a requirement of platelets greater or equal to 100 x 109/l.</s>"
    },
    "412d3ee2-bbfb-4e24-b159-684ae144e742": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00054275",
        "Statement": "A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The patient described in the expert statement, having minimal symptoms but a severe obstruction of the left main coronary artery, does not meet the Cardiovascular eligibility criteria specified in the primary CTR. The CTR states that \"No New York Heart Association class III or IV heart disease,\" and \"No symptomatic congestive heart failure,\" implying that patients with severe coronary artery obstructions or significant cardiac symptoms are excluded from participation. Therefore, the expert statement is entailed by the information present in the CTR.</s>",
        "contradict": "The patient description in the statement, \"A patient with minimal symptoms but a severe obstruction of the left main coronary artery would be unable to participate in the primary trial,\" contradicts the cardiovascular inclusion criteria stated in the primary CTR, as the CTR does not include any restrictions related to severe coronary artery obstruction.</s>"
    },
    "d1d77877-9c85-41c8-9eca-6fd75b254a15": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial due to her age.",
        "Label": "Contradiction",
        "entail": "Rachel's exclusion from the primary trial due to her age (19 instead of 18 years or older) and her medical conditions (skin ulcerations and triclosan allergy) aligns with the stated inclusion and exclusion criteria of the trial as outlined in the provided CTR. The exclusion criteria in the CTR specify individuals with skin ulceration and known allergy or intolerance to triclosan, making Rachel ineligible for the trial based on the provided information.</s>",
        "contradict": "The statement that Rachel, being 19 years old with skin ulcerations and allergic reactions to triclosan, cannot participate in the primary trial due to her age contradicts the information present in the CTRs. The primary trial inclusion criteria specify that individuals must be 18 years of age or older, while the expert statement mentions Rachel being 19 and thus being younger than the minimum age requirement. Despite her other exclusionary conditions (skin ulcerations and triclosan allergy), the age criterion is the reason why Rachel cannot partake in the trial as stated in the expert's comment, yet it is in contradiction with the CTR information.</s>"
    },
    "c32d1b74-07ab-4afb-9db6-878e20727661": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02279108",
        "Statement": "Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer that have not had Previous lumpectomy or same side mammary reduction and have no Contra-indication to surgery are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails the primary trial's inclusion criteria, as it references \"Adult Patients with Histologically proven Unifocal HER2- infiltrating breast cancer.\" This aligns with the CTR's inclusion criteria of \" Histologically proved infiltrating breast cancer (ductal, lobular carcinoma\u2026) or a carcinoma in-situ with an elevated risk of micro-invasion.\" The statement also excludes individuals who have undergone previous lumpectomy or same-side mammary reduction, which matches the exclusion criteria in the CTR. Additionally, the statement includes the adult patient age restriction and the requirement of no contraindication to surgery, which are also present within the CTR's inclusion criteria. Overall, the statement entails the inclusion and exclusion criteria of the primary trial, making it consistent and non-contradictory with the provided information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the CTR as it incorrectly assumes that adults with unifocal HER2- infiltrating breast cancer who have not undergone lumpectomy or same side mammary reduction and have no contraindication to surgery are excluded from the primary trial. However, the CTR specifies that these patients are part of the inclusion criteria, as stated by \"Unifocal or multifocal but in the same quarter\" and \"Clinically or ultrasound axillary N0,\" which do not exclude patients based on their previous surgical history or contraindications to surgery.</s>"
    },
    "ba0c0dc6-826b-426f-8738-eec23e47f6b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 2 months prior, she is not elgible for the primary trial.",
        "Label": "Contradiction",
        "entail": "Sharone's ineligibility for the primary trial can be entailed by her recent hip replacement surgery within 4 weeks before study treatment, as outlined in the CTR under exclusion criteria.</s>",
        "contradict": "The statement \"Sharone had a hip replacement 2 months prior, she is not eligible for the primary trial,\" contradicts the inclusion criteria of the primary trial, specifically the exclusion of \"major surgery (excluding placement of vascular access) within 4 weeks before study treatment.\" While Sharone's hip replacement falls under \"major surgery,\" the 2-month timeframe between her surgery and her potential eligibility for the trial falls outside of the 4-week window stated in the CTR.</s>"
    },
    "77982c81-d147-48d9-909c-18b9a98224e9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT02129556",
        "Statement": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement \"Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial lists \"Infection\" as one of the adverse events with a frequency of 3.13%.\n\nThe CTR for the secondary trial lists \"Gastroenteritis\" as one of the adverse events with a frequency of 16.67%.\n\nDespite having different names for the infection type, \"Infection\" in the primary trial and \"Gastroenteritis\" in the secondary trial, they both refer to the same concept - a disease or disorder caused by the presence of pathogenic microorganisms. Thus, the expert's statement \"Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial\" is an entailed statement based on the CTRs as they both report instances of infection, even if they use different terms to describe it.</s>",
        "contradict": "The statement that \"only 1 type of infection was recorded across the duration of both the secondary trial and the primary trial\" is contradictory to the information present in the CTRs because the primary trial reported two types of infections, upper respiratory tract infection and infection, while the secondary trial reported three types of infections, gastroenteritis, vomiting, and diarrhea. Therefore, the claim that only one type of infection was observed in both trials is not entailed by the information provided in the CTRs.</s>"
    },
    "7f1af51d-e22b-4285-aea4-3dc80c3ab2ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00687440",
        "Secondary_id": "NCT01307891",
        "Statement": "Results from the primary trial and the secondary trial indicate Abraxane + Tigatuzumab produce better ORR than Caelyx, Docetaxe and Trastuzumab.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the following reasoning: \n\n1. From the primary CTR, the objective response rate (ORR) for Caelyx, Docetaxel, and Trastuzumab arm was 15/26 * 100% = 57.69% (11 out of 19 participants who had a response, 2 complete responses and 9 partial responses).\n2. From the secondary CTR, the ORR for Abraxane + Tigatuzumab arm was 14/39 * 100% = 35.9% (5 complete responses and 9 partial responses) and for Abraxane Alone arm, the ORR was 8/21 * 100% = 38.1% (with all responses being partial).\n3. Comparing the ORR percentages between the primary and secondary trials shows Abraxane + Tigatuzumab producing a higher ORR (35.9%) compared to Caelyx, Docetaxel, and Trastuzumab (57.69%). However, to ensure that this difference is statistically significant, a proper statistical test should be conducted.\n4. Since no contradictory information exists in the CTRs and the statement is based on the provided data, it can be inferred that the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement's assertion cannot be definitively contradicted or confirmed based on the presented data in the two CTRs alone. The primary trial reports the number of participants with complete and partial responses, while the secondary trial reports the percentage of patients with objective response rate. Direct comparisons of these metrics between the trials are not feasible due to the difference in the reported outcome measures and the patient cohort sizes. To make an accurate assessment of which treatment combination produces better ORR, a more detailed analysis would be needed, including a comparison of the same outcome measure and timeframes between the trials.</s>"
    },
    "2e03f6f1-0d4f-4ebf-8781-20918d70d78f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165605",
        "Statement": "A 56 year old patient with a masectomy would not be eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"A 56 year old patient with a mastectomy would not be eligible for the primary trial\" is entailed by the CTRs as follows: The primary trial's inclusion criteria specify \"Intact breast (not surgically absent).\" Since the patient described in the experts' statement has undergone a mastectomy, which involves surgical removal of the breast, they do not meet the inclusion criteria, and thus cannot participate in the primary trial.</s>",
        "contradict": "The patient described in the expert statement, being 56 years old and having undergone a mastectomy, does not meet the inclusion criteria for the primary trial. However, the exclusion criteria listed do not mention having undergone a mastectomy, and the primary trial's inclusion criteria explicitly state \"Intact breast (not surgically absent)\". Therefore, the expert statement is not necessarily contradictory to the CTR information, but it does overlook the condition that an intact breast is required for eligibility. Consequently, the statement is not an entailed consequence based on the provided CTR information alone.</s>"
    },
    "57e74ef2-f170-47bd-a908-2a7b3cec150d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with No QT prolongation are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR as the primary trial's exclusion criteria specifically state \"No QT prolongation (> 500 ms)\".</s>",
        "contradict": "The statement \"Patients with No QT prolongation are excluded from the primary trial\" is contradicted by the CTR information because the CTR explicitly states \"No QT prolongation (> 500 ms)\" as a criterion for patient inclusion in the primary trial, not exclusion.</s>"
    },
    "b5957a75-140f-445b-99dc-199b8182b8ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01805089",
        "Statement": "pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial\" is not entailed by the information present in the given CTR. The primary trial's inclusion criteria state that the participants must be postmenopausal. Therefore, pre-menopausal patients, regardless of their type of breast cancer, do not meet the eligibility criteria for the primary trial. The CTR does not mention anything about Lactiferous duct carcinomas being a specific inclusion criterion for the primary trial. Consequently, the expert's statement contradicts the CTR and, thus, it is not entailed by the CTR information.</s>",
        "contradict": "The statement \"pre-menopausal patients with Lactiferous duct carcinomas are eligible for the primary trial\" is contradicted by the information present in the CTRs as the Primary Trial's Inclusion Criteria explicitly state that participants must be postmenopausal.</s>"
    },
    "142cc983-b0cc-4f9f-b3ef-4eb57e2a317b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00486525",
        "Statement": "The difference between the two cohorts of the primary trial is that cohort 1 received higher doses of IMGN853, whereas cohort 2 received lower doses more frequently.",
        "Label": "Contradiction",
        "entail": "The statement does not entail information directly from the provided CTRs as the statement is about a drug dosing regimen in a hypothetical secondary trial, whereas the provided CTRs only describe the yoga interventions in the primary trial. Therefore, there is no entailment relationship between the expert's statement and the CTR information.</s>",
        "contradict": "The statement is contradictory to the information present in the CTRs as the trials described are not investigating the effect of different dosages of a drug (IMGN853) on two cohorts but rather the effect of yoga therapy in one cohort and the absence of yoga therapy in another. The trials do not involve any pharmacological intervention, making this statement inconsistent with the provided information.</s>"
    },
    "f57350c2-ac90-47ea-92b4-d903509bf07a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03252431",
        "Statement": "patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time. There was no recorded difference whatsoever. ",
        "Label": "Contradiction",
        "entail": "The information in the statement is entailed by the CTRs because:\n\n1. Both F-627 and Neulasta arms in the primary trial involved the same number of chemotherapy cycles (up to 4 cycles), and participants remained in their assigned treatment arm throughout the study.\n2. The definition of Grade 4 neutropenia is consistent between the CTR and the statement (ANC <0.5 \u00d7 109/L within the first 12 days of chemotherapy).\n3. Both the F-627 and Neulasta groups were administered on Day 2 of each chemotherapy cycle (results 1 and 2).\n4. The results in the CTR show that the mean duration of Grade 4 neutropenia for F-627 was 0.2 days (with Standard Deviation 0.51), and for Neulasta was 0.2 days (with Standard Deviation 0.45). Though not explicitly stated in the CTRs, these mean values are identical, indicating no statistically significant difference between the groups.\n5. The expert's statement acknowledges no recorded difference in the duration of Grade 4 neutropenia between the two arms, which aligns with the identical mean values observed in the CTRs.</s>",
        "contradict": "The expert's statement \"patients from both arms of the primary trial experienced the same amount of Grade 4 Neutropenia\" contradicts the information in the CTRs as the mean duration of Grade 4 neutropenia is different between the two treatment arms: 0.2 days (F-627) and 0.45 days (Neulasta).</s>"
    },
    "77c61307-567d-4ac2-a7f7-85feffd30473": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients do not need to have a known hormone receptor status to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients do not need to have a known hormone receptor status to participate in the primary trial\" is entailed by the CTR information because the CTR does not include hormone receptor status as an inclusion or exclusion criterion. The CTR only specifies conditions related to age, KPS score, number and location of metastatic sites, lesion size, previously treated lesions, concurrent therapy, informed consent, pregnancy test, inability to be followed longitudinally, technical inability to achieve required doses, and contraindications to radiation as inclusion and exclusion criteria.</s>",
        "contradict": "The statement \"Patients do not need to have a known hormone receptor status to participate in the primary trial\" is contradicted by the CTR's Inclusion Criteria, which does not mention hormone receptor status as a requirement for patient eligibility. However, the primary trial's eligibility criteria do mention the presence of metastatic sites involving one or more different organs (liver, lung, or bone). These organs are commonly associated with hormone receptor-positive tumors. Thus, the absence of a hormone receptor status requirement in the statement is inconsistent with the information provided in the CTR.</s>"
    },
    "35dd977f-53d8-4400-b5cb-34caaa938e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00764322",
        "Statement": "The Ultra-rapid Metabolizers group of the primary trial had average increase of Endoxifen Concentration over 6 mg/m2 over 4 months.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR information as follows: The Ultra-rapid Metabolizers group in the primary trial had an average increase of 15.35 ng/mL (difference between 4-month and baseline endoxifen concentrations) for 5 participants, which is equivalent to an average increase of approximately 6.14 mg/m2 (considering the conversion of ng/mL to mg/m2 using the conversion factor of 1 ng/mL = 0.0015 mg/m2). This value is slightly above the stated threshold of over 6 mg/m2.</s>",
        "contradict": "The statement's assertion cannot be definitively contradicted by the information in the CTRs; however, it cannot be definitively confirmed either. The statement makes a claim about an average increase in endoxifen concentration for the Ultra-rapid Metabolizers group, while the CTR provides data on the mean endoxifen concentration for this group at baseline and after 4 months. The statement does not specify the number of participants or the exact increase in concentration for each individual. The mean increases for the Ultra-rapid Metabolizers in the CTR are 8.4 ng/mL at baseline and 15.35 ng/mL after 4 months. To determine the average increase for this group, the differences in individual endoxifen concentrations between baseline and 4 months need to be calculated for the 5 participants in this group and the results averaged. Without this information, it is impossible to definitively confirm or contradict the statement with the provided data in the CTRs.</s>"
    },
    "54554da5-e67f-4da5-819b-a85b7bc5d52c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00444535",
        "Statement": "Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment.",
        "Label": "Entailment",
        "entail": "The statement \"Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment\" can be entailed by the information in the CTRs because:\n\n1. The CTR specifies the number of participants with no disease progression and the number of participants with disease progression or death within 12 weeks in the Lapatinib + Bevacizumab arm.\n2. The statement's condition for less than 1/3 participants to have achieved Progression-free Survival Rate After 12 Weeks of Study Treatment translates to fewer than 16.67 participants (1/3 of 52) having disease progression or death by Week 12.\n3. The CTR reports 16 participants (30.8%) with disease progression or death by Week 12.\n\nHence, the information in the statement can be entailed by the data presented in the CTR.</s>",
        "contradict": "The statement \"Less than 1/3 participants in the primary trial achieved Progression-free Survival Rate After 12 Weeks of Study Treatment\" contradicts the information presented in the CTRs because 30.8%, or approximately one-third of the participants in the Lapatinib + Bevacizumab arm (16 out of 52), experienced disease progression or death by Week 12. However, it's important to note that the statement does not directly claim a Progression-free Survival Rate, but rather states that less than one-third of participants achieved it. According to the provided information, this is not the case for the Lapatinib + Bevacizumab arm.</s>"
    },
    "592edd64-7841-4c19-ba75-583066308137": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00343863",
        "Statement": "On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because both Intervention 1 and Intervention 2 in the primary trial specify that all patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7. Furthermore, for both interventions, patients receive dexamethasone IV or orally on day 1 prior to each dose of doxorubicin hydrochloride, and in Intervention 1, patients receive ondansetron IV on day 1 as well. Therefore, Cohort 1 of the primary trial receiving doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally, and ondansetron IV on days 1-7 is a consequence of the details provided in the CTRs.</s>",
        "contradict": "The statement \"On days 1-7 Cohort 1 of the primary trial receive doxorubicin hydrochloride IV, oral cyclophosphamide, dexamethasone IV or orally and ondansetron IV\" can be contradicted by the information present in the CTRs because the CTRs specify that all patients, not just Cohort 1, receive doxorubicin hydrochloride IV and oral cyclophosphamide on days 1-7. However, only Cohort 1 in the primary trial receives ondansetron IV, while Cohort 2 receives palonosetron IV instead. Therefore, the statement incorrectly implies that all patients in the primary trial receive ondansetron IV on days 1-7, which contradicts the information provided in the CTRs.</s>"
    },
    "a1d207c8-2d57-4c49-89fa-60ceacf65829": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00228943",
        "Statement": "Clinically depressed patients are not able to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Clinically depressed patients are not able to participate in the primary trial\" is entailed by the information present in the CTRs since \"exclusion criteria are current depression\" is stated under the secondary trial's exclusion criteria. This directly implies that clinically depressed patients are excluded from participating in the trial.</s>",
        "contradict": "The statement \"Clinically depressed patients are not able to participate in the primary trial\" is contradictory to the information presented in the CTR as the CTR does not mention depression as an exclusion criterion. The inclusion criteria state that patients are able to provide informed consent indicating their mental and emotional capacity to participate in the trial.</s>"
    },
    "4a8f0562-355b-4a68-8790-c283d93ce766": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00093808",
        "Secondary_id": "NCT00394082",
        "Statement": "the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial reported the same percentage of dehydrated patients during the studies\" is entailed by the information presented in the CTRs because both trials report a dehydration adverse event occurrence rate of 2.17% in the primary trial and 2.00% in the secondary trial, which, when calculated based on total participants, results in identical percentages of 2.17% and 2.00%, respectively (when expressed as percentages, the difference is insignificant due to rounding).</s>",
        "contradict": "Despite the similarity in the percentage (2.17% in Primary Trial and 2.00% in Secondary Trial) of participants experiencing dehydration in each trial, the statement may be contradicted by the data provided in the CTRs. This contradiction arises due to the difference in the total number of participants between the trials, with 46 participants in the Primary Trial and 50 participants in the Secondary Trial. As a result, the absolute number of dehydration cases differs between the trials, and the percentage alone does not account for this discrepancy. Thus, the statement's assumption that the trials reported the same number of dehydrated patients during the studies is not directly entailed by the CTR data.</s>"
    },
    "04a9b8af-d01f-4090-97e2-0c0fcf8f7fe4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial\" can be entailed by the information present in the CTRs because the CTR for the secondary trial reports 2 instances of diarrhea and 2 instances of dyspepsia in cohort 1, while the CTR for the primary trial reports 0 instances of diarrhea and 0 instances of dyspepsia in cohort 1. The number of cases reported in the secondary trial for these two adverse events is higher than the number reported in the primary trial for the same cohorts.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the number of cases of diarrhea reported in cohort 1 of the primary trial is zero (0), while the number of cases reported in the secondary trial is one (1). Similarly, the number of cases of dyspepsia reported in cohort 1 of the primary trial is also zero (0), while in the secondary trial it is one (1). Therefore, the statement that \"cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial\" is not entailed by the information present in the CTRs.</s>"
    },
    "3cd353ed-af0d-4356-8f45-efc1e91a2a0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02878057",
        "Statement": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial\" can be entailed by the information present in the CTRs under the eligibility criteria section with the condition \"Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\" An ECOG performance status of 0 indicates fully active, able to carry out all pre-assigned work tasks, and able to work full time. A performance status of 1 indicates restricted in physically strenuous activity but ambulatory and capable of self-care. However, patients with a performance status of 1 cannot carry out any work activities as per the statement, which aligns with the exclusion from the trial as per the given statement. Therefore, the statement is entailed by the CTR's eligibility criteria.</s>",
        "contradict": "The statement \"Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial\" is contradictory to the eligibility criteria of the primary trial as outlined in the CTR. According to the CTR, patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 are eligible for the study. An ECOG performance status of 0 indicates fully active, no restriction in normal activities, while an ECOG performance status of 1 indicates restricted in physically strenuous activity, ambulatory and capable of all self-care but unable to carry out all work activities. Therefore, the statement's assertion that \"Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial\" contradicts the stated eligibility criteria for ECOG performance status 1 patients in the primary trial.</s>"
    },
    "b8473ae8-11c9-4578-aab8-ee96e6287715": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00580333",
        "Secondary_id": "NCT00934856",
        "Statement": "Candidates must have a life expectancy exceeding 3 months to particpate in the primary trial, there is no mimimum life expectancy define for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criterion specifies a life expectancy of at least 12 weeks, which translates to a life expectancy greater than 3 months. The secondary trial does not explicitly state a minimum life expectancy, but its exclusion criteria mention no such requirement. However, the participants in the secondary trial have advanced or metastatic cancer, which typically has a shorter life expectancy compared to the early-stage cancer population in the primary trial. Thus, the statement's requirement of a life expectancy exceeding 3 months for the primary trial candidates is a more stringent condition that entails the life expectancy requirement, if any, in the secondary trial.</s>",
        "contradict": "The statement \"Candidates must have a life expectancy exceeding 3 months to participate in the primary trial, there is no minimum life expectancy defined for the secondary trial\" can be contradicted by the information present in the CTRs as follows:\n\n- For the primary trial, the exclusion criteria state \"Life expectancy of less than 12 weeks.\" This clearly contradicts the statement, which suggests a lower minimum life expectancy requirement for the primary trial.\n- For the secondary trial, there is no minimum life expectancy mentioned in the provided inclusion criteria. However, the exclusion criteria for MBC participants state \"Life expectancy of less than 12 weeks\" and for LABC participants state \"Participants must not have received any systemic or loco-regional anti-cancer therapy for the treatment of locally advanced disease.\" These conditions may indirectly imply a minimum life expectancy requirement, depending on the clinical context. However, the statement directly specifies that \"there is no minimum life expectancy defined for the secondary trial,\" which contradicts this implication if the minimum life expectancy is inferred to be less than 12 weeks.\n\nTherefore, the statement is contradicted by the information contained in the CTRs if the minimum life expectancy requirement in the primary trial is inferred to be less than 12 weeks or if the statement is taken to directly contradict the indirect minimum life expectancy requirement in the secondary trial.</s>"
    },
    "4243dc45-5a64-486d-ae2a-11448db00dcf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00246090",
        "Secondary_id": "NCT00266799",
        "Statement": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial has 15% less total adverse events than cohort 2 of the secondary trial\" can be entailed by the information present in the CTRs if the total number of adverse events in Cohort 1 of the primary trial is 30.24% * 291 = 44.74 (rounded down to 44), and the total number of adverse events in Cohort 2 of the secondary trial is 45.10% * 98 = 44.69 (rounded up to 45). The difference between these two totals is 45 - 44 = 1, and a 15% decrease from 45 is 0.15 * 45 = 6.75, which is approximately equal to the difference in total adverse events (1 less adverse event in the primary trial). Therefore, the statement is consistent with the data presented in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial had a total of 88 adverse events in 291 participants (30.24%), while the secondary trial had a total of 46 adverse events in 102 participants (45.10%). However, the statement claims that cohort 1 of the primary trial had 15% fewer total adverse events than cohort 2 of the secondary trial, which is not accurate based on the provided data.</s>"
    },
    "fb5fc14d-2bd9-4a02-9f6a-635c0055a8d5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the information in the CTRs as follows:\n\n1. From the Outcome Measurement section of the Primary Trial, we know that the PFS is defined for up to 46 months, while for the Secondary Trial, TTDP is defined up to 82 months. This means the observation period is longer for the Secondary Trial.\n2. From Results 1 and 2 of the Primary Trial, we see that Arm/Group 1 had 89 participants and Arm/Group 2 had 82, with 82.4% and 79.3% of participants analyzed, respectively. These numbers suggest that there might be some difference in participant drop-out rates or other factors affecting the analysis of PFS. However, without further information, it is impossible to determine the exact reason for this difference.\n3. From Results 1 and 2 of the Secondary Trial, we see that the median PFS for Arm/Group 1 (Gemcitabine Plus Docetaxel) is 9.28 months (95% CI 7.73-10.79) and for Arm/Group 2 (Docetaxel Plus Capecitabine), it is 8.88 months (95% CI 7.37-11.05).\n4. Given the longer observation period in the Secondary Trial and the longer median PFS in Arm/Group 1, it is plausible that Arm/Group 1 had a much longer PFS than Arm/Group 1 in the Primary Trial.\n\nSo, the expert's statement is entailed by the information present in the CTRs because the CTRs provide evidence that supports the longer median PFS in the secondary trial, and the observation period is longer in the secondary trial, increasing the likelihood that cohort 1 of the secondary trial had a much longer median PFS than cohort 1 of the primary trial.</s>",
        "contradict": "The statement cannot be definitively confirmed or contradicted based on the information provided in the CTRs alone. While the primary trial reports the number of participants with PFS for two arms (placebo + letrozole, lapatinib + letrozole), the secondary trial provides TTDP data for two different treatment combinations (gemcitabine + docetaxel, docetaxel + capecitabine), but there is no direct comparison of PFS between the two trials or cohorts mentioned in the statement. Therefore, it is not feasible to establish entailment or contradiction between the statement and the CTRs without further relevant information.</s>"
    },
    "f616e3d8-6c1a-4b99-ac79-ea87895e37b7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00902330",
        "Secondary_id": "NCT00952731",
        "Statement": "Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial.",
        "Label": "Entailment",
        "entail": "In both trials, the label \"control group\" implies a comparison or reference group. In the primary trial, neither cohort (Arm I or II) explicitly has a stated comparator or active treatment. Therefore, both arms serve as control groups in relation to each other. In the secondary trial, the placebo interventions (gel and oral) serve as the control groups in the study comparing 4-hydroxytamoxifen gel and oral tamoxifen. Thus, the statement that \"Cohort 2 of the primary trial is the control group and cohort 1 is the control group in the secondary trial\" follows from the information in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as:\n1. In the primary trial, cohort 1 receives Cranial Microcurrent Electrical Stimulation (CES), which is the active intervention, and cohort 2 receives a sham intervention (placebo CES).\n2. In the secondary trial, cohort 1 receives 4-hydroxytamoxifen gel, the active intervention, and cohort 2 receives placebo gel, which is not exactly a match to the placebo intervention in the primary trial (placebo CES) but could possibly be considered a similar control intervention.\nHowever, the statement claims that in both trials, cohort 2 is the control group receiving a placebo intervention and cohort 1 is the control group as well. This contradicts with the fact that the interventions in both trials for the control groups are not identical.</s>"
    },
    "2f700407-8baf-4e5f-8fc0-378a294512f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01313039",
        "Secondary_id": "NCT01031446",
        "Statement": "Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions.",
        "Label": "Contradiction",
        "entail": "The statement \"Nursing patients are not eligible for the primary trial or the secondary trial, due to potential harm to the father from the study interventions.\" cannot be entailed from the information present in the CTRs, as the CTRs explicitly exclude pregnant or breast-feeding patients due to potential harm to the fetus or nursing infant, rather than to the father.</s>",
        "contradict": "The statement contradicts the CTR information as neither CTR mentions anything regarding harm to the father from the study interventions. The CTRs focus exclusively on patient eligibility criteria, including age, disease stage, hormonal receptor status, previous treatments, laboratory values, and other health conditions. Therefore, the statement goes beyond the scope of the presented CTR information and contains an erroneous assumption.</s>"
    },
    "cebee448-235d-49ff-8e87-56639399548b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02287675",
        "Statement": "Informed consent is optional for entry in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Informed consent is optional for entry in the primary trial\" is not entailed by the information present in the CTRs as per the following reasons: \n\n1. The primary trial CTR explicitly states that \"The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study.\" This requirement indicates that informed consent is a necessary condition for trial entry, contradicting the assertion made in the statement. \n\nTherefore, the statement is not entailed by the CTR information.</s>",
        "contradict": "The statement \"Informed consent is optional for entry in the primary trial\" contradicts the information present in the CTRs as per the following reasons:\n\n1. The CTRs explicitly state that \"The subject must provide written informed consent with HIPAA authorization before participating in the study.\" (Primary Trial: Inclusion Criteria)\n2. The statement implies that informed consent is not mandatory for trial participation, which directly contradicts the requirement stated in the CTRs.</s>"
    },
    "d3f0dd2f-a5b9-4ff4-8a6b-65c9947cb710": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01073865",
        "Statement": "Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The given statement \"Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial\" can be entailed by the inclusion criteria stated in the CTR as follows:\n\n1. Female gender: The statement's eligibility criterion matches the female gender requirement in the CTR.\n2. Above 18 years of age: The stated age requirement (18 years) is included in the CTR as there is no minimum age mentioned.\n3. Last period was within 2 years of randomisation: This criterion aligns with the pre-menopausal definition in the CTR (last menses within 2 years).\n\nTherefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Females over the age of 18, whose last period was 2 years prior to randomisation are eligible for the primary trial\" is contradicted by the inclusion criteria stated in the CTR for the primary trial. According to the CTR, females must be pre-menopausal and have had their last menstruation within 1 year of randomization. Therefore, females whose last period was 2 years prior to randomization do not meet the inclusion criteria and are not eligible for the trial.</s>"
    },
    "7a981da3-dc7f-4e1f-ae5b-26e5399ba2a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187744",
        "Statement": "sepsis, due to the presence of an implanted device was a common adverse event in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"sepsis, due to the presence of an implanted device was a common adverse event in the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. The term \"sepsis\" can be inferred from the mention of \"Device related sepsis\" as an adverse event in both trials.\n2. The presence of \"a common adverse event\" can be inferred from the occurrence of at least one case of \"Device related sepsis\" in both trials, i.e., 1/113 in the primary trial and 1/112 in the secondary trial.\n3. The statement does not contradict the information in the CTRs, as it is a valid conclusion based on the data presented.</s>",
        "contradict": "The statement \"sepsis, due to the presence of an implanted device was a common adverse event in the primary trial\" cannot be conclusively established as an entailed fact from the provided data, as:\n\n1. The frequency of device-related sepsis events in both primary (1/113 or 0.88%) and secondary (0/112 or 0.00%) trials do not align with the assertion of \"common adverse event.\"\n2. The total adverse event frequencies between both trials differ, which might influence the perception of the frequency of device-related sepsis events in comparison.\n\nHowever, it should be noted that absence of data in the secondary trial regarding device-related sepsis does not definitively rule out the occurrence of such events, and the primary trial's data alone does not necessarily prove that device-related sepsis is a common occurrence in the context of all trials investigating the same intervention. Further analysis and context from multiple trials would be necessary to make a more robust assessment of the statement's accuracy.</s>"
    },
    "af677d94-a376-42ea-93fe-91963a071199": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. In the secondary trial, there is an inclusion criterion specifying that patients must be able to swallow and retain oral medication. Dysphagia (difficulty swallowing) contradicts this criterion, making patients ineligible for the secondary trial.\n2. However, in the primary trial's inclusion criteria, there is no such requirement for patients to retain or swallow oral medication. This implies that patients with dysphagia, who cannot swallow and retain oral medication for the secondary trial, are still eligible for the primary trial.\n\nHence, the statement is entailed by the CTRs, as it reflects an accurate interpretation of the eligibility criteria present in both trials.</s>",
        "contradict": "The statement \"Patients with dysphagia cannot participate in the secondary trial, but may be eligible for the primary trial\" is contradicted by the information present in the CTRs since there is no mention of dysphagia as an inclusion or exclusion criterion for either trial.</s>"
    },
    "6579e25e-8dcf-44b5-a50d-7c84672cba89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00981305",
        "Statement": "Only people who have previously been diagnosed with cancer and are currently receiving ongoing treatment for their primary tumor are eliglbe for the primary trial, as long as they are over the age of 20.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as it correctly identifies the eligibility criteria for the primary trial, which are that participants must be breast cancer survivors over 20 years old who are premenopausal and have undergone both surgery and chemotherapy treatment for their cancer. The statement also specifies that participants must currently be receiving ongoing treatment for their primary tumor. These conditions align with the inclusion criteria stated in the CTRs. The statement does not contradict any information in the CTRs and therefore is an entailed statement.</s>",
        "contradict": "The statement can be contradicted by the CTR information because it overgeneralizes eligibility criteria for the primary trial. The CTR specifically includes the condition \"newly developed dyspareunia after cancer treatment,\" which is not mentioned in the expert statement. This difference in criteria may lead to exclusion of certain patients from the trial who do not fit the overgeneralized statement but meet the criteria in the CTR.</s>"
    },
    "1ac9c526-91e6-4e0d-8570-0a78e3ec78db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00451555",
        "Statement": "Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events\" can be entailed by the information present in the CTRs as follows:\n\nFirst, calculate the percentage of each adverse event for Cohort 1 and Cohort 2 in the primary trial separately:\n\nCohort 1: Total: 17/94 (18.09%), Anaemia: 2/94 (2.13%), ..., Oedema peripheral: 1/94 (1.06%)\nPercentage of each adverse event for Cohort 1 = (Number of occurrences for each event / Total number of participants) x 100%\n\nCohort 2: Total: 9/39 (23.08%), Anaemia: 2/39 (5.13%), ..., Oedema peripheral: 1/39 (2.56%)\nPercentage of each adverse event for Cohort 2 = (Number of occurrences for each event / Total number of participants) x 100%\n\nNow, compare the percentages for each adverse event between the two cohorts:\n\nAnaemia: 2.13% (Cohort 1) = 5.13% (Cohort 2)\nLymphadenopathy: 0.00% (Cohort 1) = 0.00% (Cohort 2)\nAngina pectoris: 0.00% (Cohort 1) = 0.00% (Cohort 2)\nIschaemic cardiomyopathy: 0.00% (Cohort 1) = 0.00% (Cohort 2)\nMyocardial infarction: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nHaemorrhoids: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nIleus: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nNausea: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nVomiting: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nAsthenia: 1.06% (Cohort 1) = 2.56% (Cohort 2)\nDisease progression: 0.00% (Cohort 1) = 0.00% (Cohort 2)\nOedema peripheral: 1.06% (Cohort 1) = 2.56% (Cohort 2)\n\nSince all the percentages match for each adverse event, the statement \"Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial recorded exactly the same percentage of each type of adverse events\" contradicts the information in the CTRs because the data provided shows different adverse event percentages for each cohort. The total percentage of adverse events for Cohort 1 is 18.09%, while for Cohort 2, it is 23.08%, indicating that the percentages of individual adverse event types are also likely to differ.</s>"
    },
    "79c07f36-daf9-4844-ad8a-f362fbbaaf81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same precentage of patients vomiting during the trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Both cohorts of the primary trial reported the same percentage of patients vomiting during the trial\" can be entailed by the information present in the CTRs if the percentage of patients experiencing vomiting is equal in both Adverse Events sections (1 and 2). The statement does not contradict any information in the CTRs as it only makes a comparison between the two trial sections, and both sections are from the same primary trial. The percentage of patients vomiting in both sections is given as 2/79 (2.53%) for the primary trial and 2/76 (2.63%) for the secondary trial. Therefore, the percentage is the same, and the statement is entailed by the information in the CTRs.</s>",
        "contradict": "Despite the expert's statement suggesting equivalent vomiting percentages between the two trial cohorts, the CTRs provide discrepant data. The primary trial recorded 2 cases of vomiting out of 79 participants (2.53%), while the secondary trial reported only 1 case out of 76 participants (1.32%). Therefore, the statement cannot be considered entailed by the information presented in the CTRs.</s>"
    },
    "bced9c90-5ce0-416c-a168-f9e74359b332": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01381874",
        "Statement": "The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group.",
        "Label": "Contradiction",
        "entail": "The statement \"The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group\" can be entailed by the information in the CTRs as follows:\n\n1. According to the primary CTR, the outcome measure used for both arms was Progression-Free Survival (PFS).\n2. The statement \"The Exemestane group had a better median Tumor Response than the Abiraterone Acetate + Prednisone group\" can be inferred to mean that the median PFS was longer in the Exemestane arm compared to the Abiraterone Acetate + Prednisone arm.\n3. From the Results 1 and 2, it is clear that the median (95% Confidence Interval) for PFS in the Exemestane group was 3.68 (1.94 to 5.26) months and in the Abiraterone Acetate + Prednisone group was 3.65 (2.73 to 5.59) months.\n4. Since 3.68 (the median PFS in the Exemestane group) is greater than 3.65 (the median PFS in the Abiraterone Acetate + Prednisone group), the statement is entailed by the information in the CTRs.\n\nTherefore, the statement \"The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group\" is consistent with the information in the CTRs and does not contradict it.\n\nThe second part of the statement \"however, the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group\" cannot be determined from the information in the CTRs alone and requires additional data.</s>",
        "contradict": "The statement \"The Exemestane group in the primary trial had a better median Tumor Response than the Abiraterone Acetate + Prednisone group, however the patient with the maximum TR was in the Abiraterone Acetate + Prednisone group\" is contradicted by the information in the CTRs because the CTRs do not provide information on Tumor Response (TR). The statement makes an assumption about TR based on the difference in median PFS, but it's not explicitly stated in the CTRs that longer PFS equates to better TR. Additionally, no data is given regarding TR for individual participants in either group.</s>"
    },
    "ce88c763-0062-48dc-b5e1-f81af32f2628": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00593827",
        "Secondary_id": "NCT00478257",
        "Statement": "Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because, according to the Primary Trial's inclusion criteria, patients who have HER2 negative breast cancer are eligible for the study (CTR for Primary Trial, Inclusion Criteria: Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer). Similarly, based on the Secondary Trial's inclusion criteria, patients with HER2 negative breast cancer are also eligible for the secondary trial (CTR for Secondary Trial, Inclusion Criteria: stage I-III breast cancer, Has Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer). No contradictory information is present that would prevent the entailment.</s>",
        "contradict": "The statement that \"Patients with HER2 negative BC are eligible for both the primary trial and the secondary trial\" is contradicted by the information present in the CTRs because the primary trial explicitly states that HER2 negative breast cancer patients are included, whereas the secondary trial does not mention HER2 status as an inclusion criterion.</s>"
    },
    "982469a3-2fc1-40b4-92a9-d531b6c0ab5d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00296036",
        "Statement": "the primary trial administers the Urea/Lactic Acid Cream topically, twice daily, and the placebo is administered orally once a day.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trials expert is not entailed by the information in the provided CTRs. The primary trial's intervention involves topical application of the Urea/Lactic Acid Cream to the palms and soles twice daily, while the placebo is also topically applied to these areas. The statement, however, incorrectly specifies that the Urea/Lactic Acid Cream is administered orally, and the placebo is administered orally once a day instead. Therefore, the statement contradicts the information present in the CTRs, and entailment cannot be established.</s>",
        "contradict": "The statement made by the clinical trials expert contradicts the CTR information because in the primary trial, the intervention is specified as topical application of Urea/Lactic Acid Cream to the palms and soles twice daily, while in the secondary trial statement, no such application method or frequency for the placebo is provided. However, the statement incorrectly asserts that the placebo is administered orally once a day in the primary trial, which is not mentioned in the CTR. Therefore, the statement is inconsistent with the provided Clinical Trial Reports.</s>"
    },
    "71d16ba8-2cc9-4cb0-aa14-6b6adf0dd625": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00334802",
        "Secondary_id": "NCT00167414",
        "Statement": "There is no age limit for either the secondary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is no age limit for either the secondary trial or the primary trial\" is entailed by the CTRs as follows:\n\nFor the primary trial: The CTR does not mention any explicit age limit for inclusion in the trial. \n\nFor the secondary trial: The CTR states \"Age: no limit\" in the inclusion criteria.</s>",
        "contradict": "The statement \"There is no age limit for either the secondary trial or the primary trial\" is contradicted by the information present in the CTRs. In the primary trial, there is an inclusion criterion specifying that patients must have \"Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1,\" which is a measure of performance status and can be affected by age. Additionally, there is an exclusion criterion stating that patients cannot have \"severe complication (cardiac infarction, infection, drug hypersensitivity or diabetes)\" which can also be associated with age. In the secondary trial, there is an inclusion criterion stating that patients must have a Karnofsky performance status (KPS) of 70, which can be affected by age. Therefore, although there is no explicit age limit mentioned in the secondary trial, the inclusion criteria imply a limit based on performance status. Hence, the statement is contradicted by the information present in the CTRs.</s>"
    },
    "e6901a45-4c97-4618-bfcb-6f6dd046ef0c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00143390",
        "Statement": "In the primary trial There was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group.",
        "Label": "Contradiction",
        "entail": "The statement \"In the primary trial, there was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group\" can be entailed by the information in the CTRs as both reports provide the median TTP for the Exemestane group to be 13.8 months with a 95% confidence interval of (10.8 to 16.5) months. Since the median is the value that divides the data into two equal parts, it is also the value that is most centrally located in the dataset. Thus, neither the minimum nor the maximum recorded TTP in the Exemestane group can be more than 3 months away from the median value. Similarly, the median TTP for the Anastrozole group is reported to be 11.1 months with a 95% confidence interval of (10.8 to 16.6) months. This information also supports the statement as it illustrates that the difference between the maximum and minimum TTP in the Exemestane group is less than 3 months, given that their median values are within 0.7 months of each other.</s>",
        "contradict": "The statement \"In the primary trial, there was less than 3 months difference between the maximum and minimum recorded TTP of the Exemestane group\" cannot be directly contradicted by the information in the CTRs. However, it can be misleading without further context, as it does not account for the median TTP values given in the CTR, which are 13.8 (10.8-16.5) months for the Exemestane group and 11.1 (10.8-16.6) months for the Anastrozole group. These median TTP values indicate that the majority of participants in the Exemestane group had a TTP greater than 3 months longer than the minimum recorded in the study. Therefore, the statement can be considered an oversimplification of the trial data and should be interpreted with caution.\n\nTo establish semantic entailment, it would be essential to evaluate whether the statement is an accurate representation of the CTR data and avoid contradictory information or misleading interpretations of the results. In this case, the statement does not provide a clear contradiction to the CTR information, but it may create confusion by focusing on the minimum and maximum TTP values without considering the medians, which provide a more comprehensive understanding of the trial results.\n\nTo determine if the statement is entailed by the information in the CTRs, it is essential to examine the relationship between the data and the statement's claim, ensuring that it does not contradict the provided descriptions and that its assertion is based on accurate and complete data from the CTRs. In this case, the statement's claim about the 3 months difference between the maximum and minimum recorded TTP in the Exemestane group can be seen as an oversimplification of the trial data, but it does not directly contradict the information provided in the CTRs.</s>"
    },
    "e94ea1b1-1816-4bac-b1ca-f6d66b95702a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00004888",
        "Statement": "Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study.",
        "Label": "Contradiction",
        "entail": "The statement \"Most the primary trial participants suffered Grade 3 or above Cardiotoxicity Events After Cycle 8 of the study\" cannot be entailed by the information present in the CTRs as none of the CTRs report that most participants in Arm I or Arm II suffered Grade 3 or above Cardiotoxicity Events after Cycle 8. The given CTRs only provide the number of participants who experienced Cardiotoxicity Events of different grades at specified time points. The information in the CTRs does not support the claim made by the clinical trial expert.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as none of the participants in either Arm I or Arm II suffered a Grade 3 Cardiotoxicity Event After Cycle 8. According to the provided data, the maximum instances of Grade 3 Cardiotoxicity Events occurred after Cycle 4 for Arm I, and there were no instances after Cycle 8 for either arm. Conversely, the expert's statement implies a majority of participants in the primary trial suffered Grade 3 or above Cardiotoxicity Events After Cycle 8.</s>"
    },
    "0e3c62f7-a152-4370-9d09-b69a715c0a21": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01216319",
        "Secondary_id": "NCT03346161",
        "Statement": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies.",
        "Label": "Contradiction",
        "entail": "Both trials in question, as stated in their Intervention sections, focus on breast reconstruction for patients who have undergone a mastectomy. This aligns with the statement's assertion of surgical interventions for breast reconstruction for patients with a mastectomy history.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies\" is in line with the information present in the CTRs, as both trials involve patients who have undergone mastectomies and focus on breast reconstruction. However, the statement does not provide enough detail to determine if the specific surgical interventions being compared in the trials are the same, or if there are any other differences between the trials beyond the patient population and general intervention focus. Therefore, while the statement does not contradict the information in the CTRs, it may be an incomplete representation of the trials' content, particularly if one assumes that the trials are directly comparable without further context. To establish stronger entailment, the statement would need to more closely align with the specific details of the interventions being tested, including any differences or similarities beyond the general intervention focus and patient population.</s>"
    },
    "7191b5e9-4f29-4261-8a64-51653ee151fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00410813",
        "Statement": "In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The statement asserts that \"Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.\"\n\n2. From the CTRs, it is evident that the median PFS for the Dasatinib, 100 mg, Daily arm is 10.3 (8.4 to 16.7) weeks, and for the Dasatinib, 70 mg, Twice Daily arm is 15.3 (8.7 to 20.1) weeks.\n\n3. A better median PFS indicates that the group with the higher median value, i.e., 15.3 weeks in this case, has a superior outcome.\n\n4. The information in the CTRs supports this claim by providing the median PFS values for each arm, which can be directly compared. Therefore, the statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement made by the expert contradicts the information presented in the CTRs as the median PFS for the Dasatinib, 100 mg, Daily arm is 10.3 weeks (8.4 to 16.7 weeks) and for the Dasatinib, 70 mg, Twice Daily arm is 15.3 weeks (8.7 to 20.1 weeks). Based on these values, the Dasatinib, 100 mg, Daily arm has a shorter median PFS than the Dasatinib, 70 mg, Twice Daily arm. Therefore, the expert's statement is not consistent with the data provided in the CTRs.</s>"
    },
    "639ccada-370d-4709-bdd7-1b29bbcc8769": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial\" is not entailed by the information presented in the CTRs. The primary CTR includes the ECOG status of 0 or 1 as an inclusion criterion and a life expectancy of at least 3 months. Conversely, the expert statement implies a stricter criterion (ECOG > 1 and a life expectancy over 12 weeks), which is not explicitly mentioned in the CTRs. Therefore, the statement is not entailed by the CTR information.</s>",
        "contradict": "The statement \"ECOG > 1 and a life expectancy over 12 weeks are necessary to participate in the primary trial\" is contradicted by the inclusion criteria of the primary trial, which state: \"Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1\" and \"Estimated life expectancy of at least 3 months\". These criteria clearly indicate that ECOG status can be 0 or 1 and that participants must have an estimated life expectancy of at least 3 months (less than 12 weeks). Hence, the expert's statement contradicts the information in the CTRs.</s>"
    },
    "8c6e6c06-c409-4c42-b195-e9d2a1065b97": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02069093",
        "Statement": "All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet.",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information in the CTRs. \n\nExplanation: \n\nThe primary CTR specifies that two participants out of 86 had stomatitis grade 2, whereas the remaining participants had either stomatitis grade 1 or grade not evaluable. The statement, however, asserts that all participants had minimal stomatitis symptoms and a normal diet, which contradicts the reported data, as some participants had stomatitis grade 2, and grade 2 symptoms include those that affect diet (symptomatic, able to swallow a modified diet, not normal). Therefore, the statement cannot be derived as an entailed conclusion based on the given CTR data.</s>",
        "contradict": "The statement that \"All of the patients in the primary trial had minimal Stomatitis symptoms and a normal diet\" contradicts the data in the CTR because the information in the CTR indicates that 2 participants in the Dexamethasone Based Mouthwash arm of the primary trial experienced Stomatitis grade 2, which means they had symptomatic but able to swallow a modified diet. The statement, therefore, is inconsistent with the facts presented in the CTR.</s>"
    },
    "b5183c1c-adb5-4877-b061-50a16d6a5b52": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Secondary_id": "NCT01301729",
        "Statement": "None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in the primary trial committed suicide, however there was one such case in the secondary trial\" is entailed by the information present in the CTRs as there is no occurrence of suicide reported in the primary trial (zero instances out of 67 patients), whereas there is a reported case of suicide in the secondary trial (one instance out of 32 patients). The statement correctly infers the absence of suicide in one trial and the presence in the other based on the provided data.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs due to the absence of a reported suicide case in the Adverse Events section of the Primary Trial, while there is a reported case in the Adverse Events section of the Secondary Trial. However, the statement does not take into account that there are different patient cohorts in the two trials, and it makes a direct comparison between them without acknowledging the difference in sample sizes or patient populations. Consequently, the statement's assertion cannot be entailed by the information in the CTRs as they describe distinct trial contexts.</s>"
    },
    "69f57cdb-22e9-4a3a-8f19-6095c66c6497": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Clinical Benefit (CBR) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial measures the Proportion of Participants With a Pathologic Complete Response Rate, while the secondary trial measures the Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years. The difference in outcome measurements between the two trials indicates that they investigate distinct aspects of the therapeutic interventions.\n\nThe statement that the secondary trial uses Clinical Benefit (CBR) as outcome measurement doesn't contradict the information in the CTRs. The Proportion of Participants With a Pathologic Complete Response Rate in the primary trial refers to the absence of invasive cancer cells at the primary tumor site and axillary lymph nodes in the surgical specimen after treatment. In contrast, CBR in the secondary trial is defined as participants with complete response (CR) + participants with partial response (PR) + participants with stable disease (SD) for a length of time greater than, equal to 6 months.\n\nThese outcome measures are not the same but are complementary and related. Achieving a pathologic complete response (pCR) in the primary trial is a crucial milestone, as it indicates the absence of residual cancer after treatment. The secondary trial, however, investigates how long participants experience clinical benefit from the interventions and whether their disease-free interval lasts more than 2 years. Thus, the information in the statement can be entailed by the information provided in the CTRs as the trials assess different aspects of treatment efficacy.</s>",
        "contradict": "The primary trial assesses the pCR rate, which measures the absence of invasive cancer cells in the surgical specimen, while the secondary trial evaluates CBR, which includes participants with complete response (CR), partial response (PR), and stable disease (SD) for a minimum of 6 months. These outcome measures serve distinct purposes and are not interchangeable, as they assess different aspects of treatment efficacy. Consequently, the statement does not contradict the CTR information directly; however, it incorrectly implies that the secondary trial also investigates pCR, which is not the case.</s>"
    },
    "ea505463-c509-416e-ad88-11576764b734": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01771666",
        "Secondary_id": "NCT01256567",
        "Statement": "Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nFor the primary trial, the inclusion criteria state that women must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. For the secondary trial, the inclusion criteria state that participants must also have an ECOG performance status of 0 or 1. Since Japanese participants meet the ECOG requirement for both trials, they are eligible for both trials based on this criterion alone. However, there are additional criteria for each trial, but as long as participants meet the ECOG requirement and do not meet any exclusion criteria, they can be considered eligible for both trials according to the CTR information.</s>",
        "contradict": "The statement \"Japanese participants with an ECOG <=1 are eligible for the secondary trial and the primary trial\" is contradicted by the information present in the CTRs because the eligibility criteria for the two trials differ in other aspects beyond just the ECOG performance status. For example, there are differences in inclusion criteria regarding cancer type, prior therapies, geographic location, and other factors. Therefore, just having an ECOG <=1 does not necessarily mean a participant is eligible for both trials as outlined in the CTRs.</s>"
    },
    "81669281-db01-4493-a797-0d60f448f706": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00930930",
        "Statement": "The overall most frequent adverse event in the primary trial was Dehydration.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: The total number of adverse events in the primary trial was 22, representing 22.92% of the total number of participants (96), while in the secondary trial there were 6 adverse events, which represents 12.24% of the total number of participants (49). Among the adverse events listed in both trials, Dehydration appears in both with a frequency of 5 in the primary trial (5.21% of the total number of participants) and 1 in the secondary trial (2.04% of the total number of participants). Since Dehydration is the adverse event with the highest occurrence frequency in the primary trial (5 out of 22 adverse events), it can be concluded that it is the overall most frequent adverse event across both trials, in accordance with the expert's statement.</s>",
        "contradict": "The statement \"The overall most frequent adverse event in the primary trial was Dehydration\" cannot be directly contradicted by the provided CTR data as the information in the statement is not entailed within the CTRs. While the frequency of dehydration events being the highest in the primary trial according to the statement, it is not explicitly stated as such within the CTRs. Thus, there is no contradiction, but also no entailment.</s>"
    },
    "40dbf023-ead5-45fc-bdce-bf40e1955578": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00382785",
        "Secondary_id": "NCT00784849",
        "Statement": "Neither the primary trial or the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention.",
        "Label": "Entailment",
        "entail": "The statement \"Neither the primary trial nor the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention\" is entailed by the CTRs as neither of the provided Interventions in either trial includes the mentioned substances.</s>",
        "contradict": "The statement \"Neither the primary trial nor the secondary trial use Low Dose Magnesium Oxide, High Dose Magnesium Oxide or Mometasone in their intervention\" contradicts the information in the CTRs as neither of the CTRs mention the use of Low Dose Magnesium Oxide, High Dose Magnesium Oxide, or Mometasone in their intervention descriptions. The statement asserts that these substances are not used in both trials, while the CTRs do not provide information regarding their absence or inclusion.</s>"
    },
    "b64ae9c9-956a-421e-a41f-1886408fec2a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "One of the cohorts in the primary trial had more than 5% of patients experiencing side effects.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs since the total number of adverse events in Adverse Events 1 is 3.78%, which is above the 5% threshold mentioned in the expert statement for one of the cohorts in the primary trial experiencing side effects. The expert's statement does not specify which cohort or which type of side effects, allowing the generalization to any cohort in the primary trial that may have an adverse event rate above 5%. This is consistent with the information in the CTRs for the given trial.</s>",
        "contradict": "The statement \"One of the cohorts in the primary trial had more than 5% of patients experiencing side effects\" is contradicted by the data in the Adverse Events sections of the Primary and Secondary CTRs as neither of them show any cohort having more than 5% of patients experiencing adverse events. The percentages provided in the CTRs are the total adverse events across all cohorts or arms.</s>"
    },
    "e0980234-0611-44de-9165-54bdd086663d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01539317",
        "Secondary_id": "NCT01323530",
        "Statement": "the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments.",
        "Label": "Entailment",
        "entail": "The primary CTR describes two interventions, one using topical saline and the other using topical liquid lidocaine, both applied to the hypersensitive mucosa of the vulvar vestibule. The statement, however, does not concern the specific interventions in the primary trial but rather the type of interventions used in the primary and secondary trials. The secondary trial, as described in its CTR, uses a combination of oral (capecitabine) and intravenous (eribulin mesilate) treatments. Since the primary trial uses topical interventions (which are distinct from oral and intravenous treatments), and the secondary trial uses a different type of intervention, the statement is entailed by the information present in the CTRs, as it accurately describes the differences between the trials in terms of intervention types.</s>",
        "contradict": "The statement \"the primary trial uses a topical intervention and the secondary trial uses a combination of oral and intravenous treatments\" is contradicted by the information in the CTRs. Contrary to the statement, the primary trial actually uses topical interventions (topical saline and topical liquid lidocaine) for both arms, and the secondary trial uses an intravenous intervention (eribulin mesilate) along with oral capecitabine. Hence, neither trial solely utilizes a topical intervention, and the secondary trial does not only involve a combination of oral and intravenous treatments.</s>"
    },
    "3366c10a-3d41-48ae-bfa8-26b9e655761e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005908",
        "Statement": "There were 8 cases of pharyngitis in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 8 cases of pharyngitis in cohort 2 of the primary trial\" can be entailed by the information in the CTRs if there exists at least one patient in cohort 2 of the primary trial who experienced pharyngitis, which is indicated in the statement, and this event was reported as an adverse event in the CTRs. However, the CTR provided only mentions one case of stomatitis/pharyngitis (oral/pharyngeal/mucositis) in cohort 1 of the primary trial under the Adverse Events 1 section. To entail the expert's statement, there should be a clear identification of cohort 2 within the given CTR and an occurrence of eight cases of pharyngitis reported in this cohort as adverse events. Without this additional information, the statement cannot be definitively entailed by the provided CTRs.</s>",
        "contradict": "The statement \"There were 8 cases of pharyngitis in cohort 2 of the primary trial\" contradicts the information in the CTR as there is no instance of pharyngitis mentioned in the Adverse Events section of either the primary or secondary trials.</s>"
    },
    "be29030a-98e8-40ad-9138-90076fdb50d3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01572727",
        "Statement": "Cohort 1 of the primary trial recorded more white blood cell related adversse events than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs if the term \"white blood cell related adverse events\" is taken to include FEBRILE NEUTROPENIA, LEUKOPENIA, and NEUTROPENIA, which are mentioned as such in both CTRs. The primary trial reported 3 adverse events of this kind in 202 participants (1.5% of the cohort), while the secondary trial reported 2 such events in 201 participants (1% of the cohort). The primary trial therefore recorded a higher incidence of these adverse events compared to the secondary trial (1.5% vs 1%), which is consistent with the statement's claim that \"Cohort 1 of the primary trial recorded more white blood cell related adverse events than cohort 2\".</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial recorded more white blood cell related adverse events than cohort 2\" is contradicted by the information presented in the CTRs because the total number of participants in each cohort is different (202 in the primary trial versus 201 in the secondary trial), and the number of participants with leukopenia (a type of white blood cell disorder) is identical in both cohorts (1 out of 201 in each). Therefore, the statement is not entailed by the CTR data. The number of cases of febrile neutropenia also differs between the cohorts (1 in Cohort 1 versus 0 in Cohort 2), but the statement does not mention this specific type of white blood cell event. Thus, the statement is not accurate in its entirety and is contradicted by the CTR data.</s>"
    },
    "a31298d5-20ae-4a3d-a57b-e97288fff6c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01097460",
        "Statement": "Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years.",
        "Label": "Entailment",
        "entail": "The statement \"Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years\" is entailed by the CTR information as follows:\n\n1. The CTR for the primary trial specifies the outcome measure as the incidence of treatment-emergent adverse events (AEs).\n2. The time frame for this outcome measure is explicitly stated as 2 years.\n3. The results section reports a total number of 16 participants analyzed in the MM-111 + Herceptin arm/group.\n4. Although the CTR does not explicitly state that every participant had at least one AE, the absence of such a declaration does not necessarily contradict this assumption given the accepted understanding in clinical trials that patients often experience AEs.\n\nHence, the statement \"Every patient in the primary trial suffered at least 1 Treatment-emergent adverse event over a span of 2 years\" can be inferred from the CTR data, and it remains consistent with the provided information.</s>",
        "contradict": "The statement made by the expert contradicts the CTR information if there is no mention or evidence of treatment-emergent adverse events (AEs) occurring in the primary trial's MM-111 + Herceptin arm within the 2-year time frame specified in the statement. Since the CTR only indicates the number of participants in the arm (16), it does not provide enough details about the occurrence of treatment-emergent AEs for all 16 individuals. Therefore, the expert's statement cannot be definitively proven or disproven based on the information available in the CTRs alone.</s>"
    },
    "54e93334-0f21-4ea2-b0f2-34473385da53": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003830",
        "Statement": "The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients.",
        "Label": "Entailment",
        "entail": "Both primary trial Adverse Events sections report the number of anaphylaxis cases (5 for each trial). Dividing the number of anaphylaxis cases by the total number of participants yields the percentage of anaphylaxis patients, which is less than 1% for both trials (0.18% for each). Therefore, the statement that \"The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients\" is entailed by the data presented in the CTRs.</s>",
        "contradict": "The statement \"The most common adverse event in both cohorts of the primary trial was Anaphylaxis, which affected less than 1% of patients\" is not directly contradicted by the information present in the CTRs, as the CTRs do not provide sufficient data to determine which adverse event was the most common across both cohorts. However, the statement could be contradicted if it were established through further investigation or analysis that a different adverse event was actually more common. The CTRs only indicate the frequency of specific adverse events and do not provide an overall comparison between the two cohorts.</s>"
    },
    "fbedd8fc-05e8-4438-b780-d7483aed3b45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00404066",
        "Statement": "Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial\" is entailed by the information present in the CTRs under the EXCLUSION CRITERIA section of both trials. In the primary trial, the exclusion criteria include \"Congestive heart failure, abnormal left ventricular ejection fraction (LVEF), angina pectoris, uncontrolled cardiac arrhythmias, or other significant heart disease, or who have had a myocardial infarction within the past year\" and \"Pregnant or lactating.\" In the secondary trial, the exclusion criteria include \"Congestive heart failure or a history of significant cardiac disease, including uncontrolled angina pectoris, symptomatic congestive heart failure, or a history of myocardial infarction, and patients who are pregnant or lactating.\" Since both trials exclude patients with abnormal LVEF, pregnancy, or lactating, the expert's statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Abnormal LVEF, Pregnancy or lactating automatically eliminates patients from participating in the primary trial\" is inconsistent with the CTR information as follows:\n\n1. Abnormal LVEF: The CTR includes LVEF as an eligibility criterion within the institutional normal range, meaning patients with abnormal LVEF can still participate if it falls within the acceptable limits.\n2. Pregnancy or lactating: The CTR specifies that women of childbearing potential must have a negative pregnancy test and use adequate contraception to participate, but it does not state that pregnant or lactating women are automatically excluded.</s>"
    },
    "4bd9f061-6420-443d-8f84-b703733644ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01202591",
        "Statement": "100% of patients in the primary trial suffered life threatening adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"100% of patients in the primary trial suffered life threatening adverse events\" is not entailed by the information provided in the CTRs. The CTRs only report the number of participants in each arm and do not specify whether or not any participant experienced life-threatening adverse events. Therefore, the statement is not a logical consequence of the data presented in the CTRs, and it contradicts the available information.</s>",
        "contradict": "The statement \"100% of patients in the primary trial suffered life threatening adverse events\" contradicts the information presented in the CTRs as no such adverse event was reported in the trial for either arm/group. The statement exceeds the scope of the provided data, as it asserts a universal claim (affecting all participants) that is not substantiated by the CTRs, which only report the number of participants in each arm and do not specify any life-threatening adverse events.</s>"
    },
    "e6d3354b-b36a-42b9-b406-61a9af594686": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00046891",
        "Statement": "cohort 1 of the primary trial receives 120 mg of Ginkgo Biloba twice daily.",
        "Label": "Contradiction",
        "entail": "The statement \"cohort 1 of the primary trial receives 120 mg of Ginkgo Biloba twice daily\" is entailed by the CTR information under Intervention 1, which specifies \"Patients will take 120 mg per day (60 mg BID)\". The statement accurately conveys the dosage regimen for the Ginkgo Biloba cohort in the primary trial as described in the CTR. There is no contradiction or discrepancy with the information provided.</s>",
        "contradict": "The statement \"cohort 1 of the primary trial receives 120 mg of Ginkgo Biloba twice daily\" is not a direct entailment of the information provided in the CTR, as the CTR specifies that patients in intervention group 1 of the primary trial will take 120 mg of Ginkgo Biloba per day, which is equivalent to 60 mg BID (twice a day). Hence, the provided statement is a slight overstatement, as it states that patients receive the dosage of 120 mg twice daily, while the CTR states they take 120 mg in total per day.</s>"
    },
    "62b3d09e-6b2a-4827-8ceb-96ccafca18d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00896649",
        "Statement": "prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial\" is entailed by the information in the CTRs as there is no mention or specification of prior hormonal treatment(s) in the Primary Trial's inclusion or exclusion criteria.</s>",
        "contradict": "The statement contradicts the CTR information because the primary trial's inclusion criteria do not exclude patients based on prior hormonal treatment(s) in the metastatic or adjuvant setting. The CTR provides no such specification.</s>"
    },
    "065a6cfe-3991-4dd5-8a55-22b9b31d1fc3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00317603",
        "Statement": "Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants of the primary trial must be older than 18, have histologically confirmed stage 3 or above breast cancer, ECOG<2 and a life expectancy exceeding 6 months\" is entailed by the information in the CTRs as follows:\n\n1. Age Requirement: Participants in the primary trial are required to be \"18 years of age or older\" (CTR).\n2. Cancer Type and Stage: Participants have \"histologically confirmed Stage IV breast cancer\" (CTR), which by definition falls under stage 3 or above according to the American Joint Committee on Cancer staging system.\n3. Performance Status: Participants have an \"ECOG performance status 0 or 1\" (CTR), which is equivalent to an ECOG<2.\n4. Life Expectancy: Participants are required to have an \"estimated life expectancy of greater than or equal to 6 months\" (CTR), which meets the stated life expectancy requirement.</s>",
        "contradict": "The participants in the primary trial must meet additional inclusion criteria beyond being older than 18 and having a histologically confirmed stage 3 or above breast cancer, an ECOG performance status of less than 2, and a life expectancy exceeding 6 months, as stated in the secondary trial statement. Specifically, they must have histologically confirmed Stage IV breast cancer, a prior banked malignant effusion or significant malignant effusion for tumor harvest or surgically-accessible tumor nodule of at least 2cm in greatest diameter, have received at least one prior regimen of chemotherapy for metastatic disease, and meet various other eligibility criteria and exclusions as listed in the CTRs. The secondary trial statement contradicts the primary trial's CTRs since it omits some essential inclusion criteria.</s>"
    },
    "85c315e5-7ae4-4764-8b02-87d36f67a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00278109",
        "Secondary_id": "NCT01881230",
        "Statement": "Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Gemcitabine is not used in the primary trial, and used in only one of the arms of the secondary trial\" is entailed by the information present in the CTRs. \n\nIn the primary trial, Intervention 1 lists cyclophosphamide and doxorubicin hydrochloride as the specific chemotherapies administered, while radiation therapy is also mentioned as a type of chemotherapy. There is no mention of gemcitabine in Intervention 1 of the primary trial.\n\nIn the secondary trial, Intervention 1 (Arm A) includes Nab-Paclitaxel and Gemcitabine as the combination therapy. Intervention 2 (Arm B) includes Nab-Paclitaxel and Carboplatin. According to the expert's statement, gemcitabine is used in only one of the arms. This aligns with the information in the CTR, as gemcitabine is indeed only used in Arm A of the secondary trial.\n\nSince the statement's assertion matches the information within the CTRs, and it avoids contradiction, the statement can be said to be entailed by the information in the Clinical Trial Reports.</s>",
        "contradict": "The statement does not necessarily contradict the information in the CTRs as it accurately describes the absence and limited use of gemcitabine in the specified trials. However, the statement does not directly address semantic entailment with the data within the sections. To establish entailment, it's essential to examine if this statement harmonizes with clinical trial data, finds substantiation, and avoids contradiction with the provided descriptions, which it does in this instance. However, the absence of entailment does not necessarily indicate contradiction. Instead, it highlights the differences between the trials, emphasizing the distinct use of interventions between the primary and secondary trials.</s>"
    },
    "497188e0-9d88-406f-b163-c154516cb12c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01560416",
        "Statement": "There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial\" can be entailed by the given CTR data if cohort 2 from the secondary trial corresponds to treatment or patient group with a higher adverse event incidence compared to cohort 1 in the primary trial. The difference in total adverse event counts between the two cohorts, which is 11/35 (31.43%) for the secondary trial versus 2/15 (13.33%) for the primary trial, exceeds 10%. This difference supports the expert's claim.</s>",
        "contradict": "The statement \"There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial\" cannot be directly contradicted by the given data in the CTRs. However, it can be inferred that the statement is incorrect based on the provided data, as the numbers of adverse events reported in both trials do not meet the criteria for a 10% difference. Specifically, the total number of adverse events in cohort 1 was 2/15 (13.33%) and in cohort 2 was 11/35 (31.43%), which is an 18% difference rather than a 10% difference. Therefore, while the statement may not be an explicit contradiction, it is inconsistent with the data in the CTRs.</s>"
    },
    "abc437e1-9e38-4d68-ab9f-fdbaf37d20f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Secondary_id": "NCT00662025",
        "Statement": "Patients with BUN < 20 mg/dL,  Platelet count: <90,000/mm3, Leukocyte count of 5,000/mm3 to 8,000/mm3 may be eligible for both the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary CTR includes the inclusion criterion for a normal creatinine level within the upper limit in the institution, implying a BUN within the normal range as creatinine and BUN are closely related. While the specific BUN value is not explicitly mentioned in the primary CTR, a BUN below 25 mg/dL is within the normal range in the given institution. Furthermore, the primary CTR includes platelet count and leukocyte count requirements that overlap with the stated range. Consequently, patients meeting these requirements (BUN<25 mg/dL, platelet count <90,000/mm3, and leukocyte count between 5,000/mm3 and 8,000/mm3) could potentially qualify for the primary trial. \n\nThe secondary CTR does not have a specific mention of BUN or leukocyte count as inclusion criteria; however, the platelet count requirement of >100,000/mm3 is higher than the stated value, but the overlap in other requirements (histologically-or cytologically-proven breast cancer, measurable disease, prior treatment with anthracycline and taxane, and exclusion of certain conditions) indicates these patients could still be considered for the secondary trial. Therefore, the patients meeting these criteria (BUN<20 mg/dL, platelet count <90,000/mm3, leukocyte count between 5,000/mm3 and 8,000/mm3) can be inferred as being eligible for both trials, assuming other inclusion and exclusion criteria are also met.</s>",
        "contradict": "The primary trial's inclusion criteria specify a BUN upper limit of 25 mg/dL, while the secondary trial's inclusion criteria do not provide a specific BUN upper limit. However, the patient population in the secondary trial may not have the same kidney function as in the primary trial, given that the trials have different inclusion criteria, such as the presence of measurable disease and prior treatment with certain agents. Therefore, it cannot be definitively determined whether patients with BUN < 20 mg/dL, Platelet count: <90,000/mm3, and Leukocyte count between 5,000/mm3 and 8,000/mm3 are eligible for both trials based on the provided CTR information alone. The statement may be contradictory as it implies eligibility for both trials based on a single set of criteria, whereas the CTRs dictate different eligibility requirements for each trial.</s>"
    },
    "f26fb90b-a9a5-4614-9680-2e9f6f0ba649": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01828021",
        "Secondary_id": "NCT01326481",
        "Statement": "Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial lists adverse events for all participants, with a total of 6 occurrences in 25 patients (24.00%). Each individual adverse event is mentioned with its frequency (number of occurrences and percentage).\n\nSimilarly, the CTR for the secondary trial lists adverse events for all participants, with a total of 6 occurrences in 19 patients (31.58%). In this trial, some adverse events are listed more than once (Febrile neutropenia, Fatigue, and Pyrexia are mentioned twice each).\n\nThe expert statement asserts that all the same adverse events did not occur across both trials, except for Supraventricular extrasystoles. According to the provided CTRs:\n\n1. There is no overlap in adverse events mentioned in the CTRs (aside from Supraventricular extrasystoles).\n2. Supraventricular extrasystoles is present in both trials as the most common adverse event, which matches the expert statement.\n\nTherefore, the information in the expert statement harmonizes with the data presented in the CTRs and can be entailed by it.</s>",
        "contradict": "The statement can be contradicted by the CTR information due to the following: \n\nIn the primary trial, Supraventricular extrasystoles (SVE) were reported by 1/25 (4.00%) patients, making it the most common adverse event.\n\nIn the secondary trial, SVE was also reported by 1/19 (5.26%) patients.\n\nBoth trials report occurrence of SVE in their respective patient populations. However, the statement asserts that there were no shared adverse events between the primary and secondary trials, except for SVE.\n\nThe statement is contradicted because it incorrectly assumes that there were no other shared adverse events besides SVE, despite the CTRs reporting occurrences of common adverse events such as Nausea (1/25 or 1/19) and Vomiting (1/25 or 1/19).</s>"
    },
    "90dd042b-c16c-4ea7-b360-625bd5e64590": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00388726",
        "Statement": "A 75 year old female patient, with an ECOG of 1 and an estimated life expectancy of more than a year would be eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The patient's female gender, age (>=18 years), ECOG Performance Status of 0-2, and estimated life expectancy (>=3 months) satisfy the inclusion criteria specified in the primary CTR. The statement made by the expert does not contradict any exclusion criteria either. Therefore, the entailment relationship exists between the expert's statement and the primary CTR.</s>",
        "contradict": "The patient described in the expert statement, having an ECOG of 1 and a life expectancy of over a year, does not necessarily meet the eligibility criteria in the Primary Trial CTR as there is no explicit mention of a life expectancy requirement in those criteria, which are focused mainly on the patient's breast cancer history, prior chemotherapy regimens, HER2/neu status, and current health conditions.</s>"
    },
    "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01271725",
        "Statement": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\nFrom the primary CTR, we have the Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy (10 to 28%) and the Percentage of Participants With Objective Response (OR) for Afatinib and Paclitaxel or Vinorelbine Combination Therapy (17 to 48%). A difference of 13% can be calculated as |17% - 10%| = 7%, but since the statement specifies a lower difference, it follows that the actual difference must be greater than 7%. Therefore, the statement \"The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.\" can be derived from the given CTR data.</s>",
        "contradict": "The statement's assertion cannot be directly contradicted by the provided data in the CTRs. However, it can be misleading without additional context. The percentage differences mentioned in the statement do not account for the different time frames and populations between the two trial arms. The statement should be qualified with information about the time frame of response assessment and the baseline characteristics of the patient populations to ensure accurate comparison.</s>"
    },
    "20cc98f8-a71a-466d-a39c-735899791613": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00915603",
        "Secondary_id": "NCT02511730",
        "Statement": "INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's inclusion criterion specifies a maximal INR of 1.5 or within normal limits if the patient is not on anti-coagulation therapy. However, it allows for enrollment of patients on anti-coagulation treatment as long as the INR is stable and within the therapeutic range prior to study treatment initiation. In contrast, the secondary trial does not mention any INR requirement. Since the secondary trial only involves female subjects enrolled in the FMSU004A protocol, it is reasonable that no INR criterion is necessary as this information is already accounted for within the FMSU004A protocol. Therefore, the statement that INR equal to or above 1.5 is mandatory for the primary trial but not necessary for the secondary trial, can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"INR equal to or above 1.5 is mandatory for participation in the primary trial, it is not necessary for the secondary trial\" contradicts the information present in the CTRs because the CTR for the primary trial specifies \"International normalized ratio (INR) <=1.5 or prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits (WNL)\" as one of the inclusion criteria, indicating that an INR below 1.5 is a requirement for participation in the primary trial. Additionally, the statement implies that the INR requirement is not a factor for the secondary trial, but the CTR for the secondary trial does not provide any information regarding the INR requirement, making it impossible to determine whether it is a requirement or not for that trial.</s>"
    },
    "fa1c6f63-ae37-4c18-918b-7b9ba445fd81": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00391092",
        "Statement": "In total there were 32 cases of Febrile neutropenia in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement, \"In total there were 32 cases of Febrile neutropenia in the primary trial,\" can be entailed by the information present in the CTRs as follows:\n\n1. The total number of cases for each adverse event is given for both trials.\n2. The number of cases for Febrile neutropenia is specified in the Adverse Events section for each trial.\n3. By adding the number of cases of Febrile neutropenia in the primary trial (14/206 = 0.068 \u00d7 206 = 13.65 \u2248 14), we obtain a total of 14 cases.\n4. Since the expert's statement refers to \"32 cases,\" this could be an error or a rounding-up of the actual data, and the entailment still holds.\n\nThus, the expert's statement, \"In total there were 32 cases of Febrile neutropenia in the primary trial,\" is entailed by the CTRs.</s>",
        "contradict": "The statement \"In total there were 32 cases of Febrile neutropenia in the primary trial\" contradicts the information presented in the CTRs because the CTRs report 14 cases (6.80%) of Febrile neutropenia in the primary trial (Total: 206) and no such event occurred in the secondary trial (Total: 215). Therefore, 32 cases in total cannot be inferred from the data provided.</s>"
    },
    "6d0b2acc-11f4-479f-9a86-004e2f5f7599": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT04080297",
        "Statement": "IV is used as route of administration by the interventions in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as both the primary and secondary trials involve intravenous (IV) administration of certain treatments, including doxorubicin hydrochloride, methotrexate, trastuzumab, and tamoxifen citrate, in the primary trial, and a Q-122 compound without explicit dosage information but specified as administered orally, in the secondary trial. However, no information regarding Q-122's route of administration is provided in the primary trial. Nevertheless, since IV is mentioned as the route of administration for some treatments in the primary trial, and no contrary information exists, the statement that IV is used as the route of administration in both trials is valid. In the secondary trial, the absence of information regarding the route of administration for Q-122 does not contradict the statement. Thus, the statement is entailed by the CTRs.</s>",
        "contradict": "The statement \"IV is used as route of administration by the interventions in the primary trial and the secondary trial\" is consistent with the information in the CTRs for the use of IV administration for certain treatments in both trials (doxorubicin hydrochloride, methotrexate, trastuzumab, and filgrastim). However, the statement does not take into account other treatments in the primary trial that are given by different routes (oral administration for capecitabine, letrozole, and tamoxifen citrate). Therefore, while the statement is true for some treatments in both trials, it does not accurately reflect the entirety of the administration routes used in the primary trial, which can be contradictory to the statement.</s>"
    },
    "7e9c3980-9f12-40c7-920e-76594db26fd1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02352779",
        "Secondary_id": "NCT00263588",
        "Statement": "The differences between cohorts in the primary trial is once cohort receives a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics.",
        "Label": "Entailment",
        "entail": "In the primary trial, both arms receive omega-3 fatty acids and placebo through oral administration (PO), but differ in the dosage levels (low-dose vs high-dose). The expert's statement correctly highlights this difference in intervention. In the secondary trial, two cohorts, A and B, have identical interventions with lapatinib administration and dosage but distinct patient characteristics (ECOG performance status and prior trastuzumab regimens). The expert's statement correctly identifies this difference as being in patient characteristics.\n\nTherefore, the statement's assertion harmonizes with the clinical trial data, as it accurately describes how the primary trial compares the effects of low-dose vs high-dose omega-3 fatty acid, while the secondary trial compares the efficacy of lapatinib between cohorts with different patient characteristics. No contradiction is present, as the statements do not challenge the provided descriptions in the CTRs.\n\nHence, the information contained in the expert's statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The differences between cohorts in the primary trial is once cohort receives a placebo and the other Low-dose Omega-3 Fatty Acid, in contrast the difference in the secondary trial is patient characteristics\" can be contradicted by the information present in the CTRs as follows:\n\n1. In the primary trial, both arms (I and II) receive omega-3 fatty acid supplementation, albeit at different doses. The statement erroneously suggests otherwise.\n2. In the secondary trial, both cohorts A and B receive identical interventions (750mg lapatinib twice daily). The statement correctly identifies the difference being in patient characteristics, but it is incomplete since the similarities in interventions are also crucial.\n\nThe statement is partially correct, but it overlooks the essential similarities and differences between the trials and their respective cohorts, leading to potential contradictions with the information in the provided CTRs.</s>"
    },
    "c83e003d-d12d-4f72-ab1f-c39f3a13326b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 negative breast cancer.",
        "Label": "Entailment",
        "entail": "The statement's assertion is entailed by the CTRs as both trials specify that patients must be female. The secondary trial includes the criterion \"Female\" in its Inclusion Criteria. The primary trial, though not mentioning a minimum age, does not exclude females, and the specified age range (18-70 years) is inclusive of females. Regarding HER2 negativity, the primary trial requires HER2/neu-negative tumors, while the secondary trial includes this condition in both its Inclusion Criteria (\"Histologically confirmed HER2 negative breast cancer\") and Exclusion Criteria (\"HER2 positive breast cancer is an exclusion criteria in both trials.\"). Lastly, both trials require ECOG performance status <2, with the primary trial specifying ECOG 0-1 and the secondary trial specifying ECOG <2, which is inclusive of ECOG 0-1. Therefore, all the conditions in the statement can be found within the eligibility criteria of both trials, establishing entailment.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial has additional requirements for histological confirmation of invasive breast cancer, including specific tumor size, lymph node status, survivin and/or CEA expression, HER2/neu status with additional testing, and hormone receptor status. The secondary trial also has different eligibility criteria regarding HER2/neu status (negative on primary tumor or biopsy of metastasis), disease-free time of relapsed patients, prior therapy, and availability of archival tumor sample or fresh biopsy. Thus, patients may meet the gender and ECOG criteria but fail to meet the full eligibility requirements for both trials.</s>"
    },
    "cae58656-76e7-447a-940e-dfcc78159173": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00244933",
        "Statement": "the primary trial monitors the occurrence of anemia in its adverse events.",
        "Label": "Contradiction",
        "entail": "The term \"anemia\" relates to reduced levels or function of hemoglobin or absolute red blood cell count in the blood. The primary CTR reports an adverse event of hemoglobin decrease (occurring in 1/19 or 5.26% of patients) and absolute neutrophil count decrease (occurring in 5/19 or 26.32% of patients), which can be indicative of anemia. Thus, the statement that the primary trial monitors the occurrence of anemia in its adverse events is entailed by the information present in the CTR.</s>",
        "contradict": "The statement \"the primary trial monitors the occurrence of anemia in its adverse events\" cannot be directly contradicted by the information in the CTRs provided, as anemia is not mentioned explicitly in the Adverse Events section of the primary trial. However, the statement can be questioned for its accuracy since \"anemia\" is not specifically mentioned among the listed adverse events, and the only mention related to hemoglobin is 1 instance out of 19. The absence of anemia in the provided CTR doesn't necessarily mean that it didn't occur in the trial; it only indicates that it was not reported as an adverse event. Therefore, the statement is semantically entailed, but it could be considered imprecise or incomplete in its description of the primary trial. To establish a stronger entailment relationship, the statement should explicitly mention that anemia was not reported as an adverse event in the provided CTR.</s>"
    },
    "94c4c3fc-7bcb-407b-86b5-6699305d3dbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02481050",
        "Statement": "There are no adverse events in the primary trial that occurred more than once.",
        "Label": "Contradiction",
        "entail": "The statement that \"there are no adverse events in the primary trial that occurred more than once\" can be entailed by the information present in the CTRs because all adverse events mentioned in the Primary Trial section of the first CTR are listed individually with their respective frequencies. Since each adverse event is listed only once, it follows that no adverse event occurred more than once.</s>",
        "contradict": "The statement \"There are no adverse events in the primary trial that occurred more than once\" is contradicted by the CTR because there were two instances of Sepsis reported in the primary trial (2/58 or 3.45%).</s>"
    },
    "103fbaa8-1852-402a-9368-36bbf6c747b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00022516",
        "Statement": "At most 3 patients in the primary trial suffered from Neutropenia.",
        "Label": "Contradiction",
        "entail": "The statement \"At most 3 patients in the primary trial suffered from Neutropenia\" can be entailed by the information in the CTR since the total number of patients with Neutropenia in the primary trial, as reported, is 5. The statement limits the number to a maximum of 3 and thus is entailed by the CTR data.</s>",
        "contradict": "The statement \"At most 3 patients in the primary trial suffered from Neutropenia\" is contradicted by the data in the CTR, specifically in Adverse Events 1 and 2 of the primary trial. According to the CTR, a total of 5 patients experienced Neutropenia in the primary trial (5/473 or 1.06%). Therefore, the statement that at most 3 patients had Neutropenia is incorrect.</s>"
    },
    "731dc36f-983d-4d4c-97ac-6e3eeee23a40": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00581256",
        "Statement": "Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial\" is entailed by the CTR's Inclusion Criteria and Exclusion Criteria. The Inclusion Criteria states, \"Performance status should be 0-2 by ECOG criteria.\" This indicates that only patients with a performance status of 0, 1, or 2 are eligible for the trial. The Exclusion Criteria explicitly states, \"Patients with a performance status > 2 by ECOG criteria.\" Combined, these two statements imply that patients with a performance status of 3 are excluded, and that those with left-sided breast cancer are part of the patient population under consideration. Therefore, the statement is entailed by the CTRs.</s>",
        "contradict": "The statement \"Patients with left-sided breast cancer and an ECOG of 3 are excluded from the primary trial\" is contradicted by the information present in the CTRs because the CTRs specify that patients with a performance status of 0-2 by ECOG criteria are eligible for inclusion in the trial, but do not mention a specific exclusion for patients with a performance status of 3.</s>"
    },
    "b2883781-f4e9-405e-9231-7a07e46c35b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00429299",
        "Statement": "Only one cohort in the primary trial is administered trastuzumab at 4 milligrams per kilogram.",
        "Label": "Entailment",
        "entail": "The statement \"Only one cohort in the primary trial is administered trastuzumab at 4 mg/kg\" can be entailed by the information present in the CTR as follows: In the Intervention 1 section of the primary trial CTR, it is stated that \"The first dose of trastuzumab was administered at 4 mg/kg IV for 60 minutes on the day of the first paclitaxel course.\" This indicates that participants in this cohort received a first dose of trastuzumab at 4 mg/kg. Since the statement only claims that one cohort in the primary trial receives this dose, it is a valid entailment.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the CTRs as the statement focuses on the dosage of trastuzumab at the beginning of intervention 1, which is specified as 4 mg/kg in the primary trial. However, both trials administer trastuzumab in different ways, and the statement only mentions the dosage at the initial administration, while the CTRs provide detailed information on the dosage schedules throughout the trials. The trials differ in the dosing frequency, duration, and timing of trastuzumab administration (weekly vs. initially followed by weekly), making a direct comparison based only on the initial dose of 4 mg/kg insufficient. The statement does not contradict the CTRs but may lead to an incomplete understanding of the trastuzumab usage in each trial.</s>"
    },
    "932c2135-381a-4675-a782-e683eca8d935": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT00606931",
        "Statement": "the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both use vaccine based interventions, however this is done in different intervals and for a different duration of time\" is entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, the vaccine therapy involves the use of HER2/neu peptide vaccine given intradermally (ID) on specific days and a booster vaccine at later intervals. This constitutes a vaccine-based intervention.\n\nIn the secondary CTR, the intervention involves PET guided biopsy, which is not a vaccine-based therapy per se. However, the primary statement mentions that \"both trials use vaccine based interventions\" in a broader context. While the primary trial employs a vaccine-based treatment, the secondary trial's intervention (PET guided biopsy) does not directly involve the use of a vaccine. However, the primary statement correctly points out the difference in the implementation of these vaccine-based interventions between the two trials, which is explicitly stated in the provided CTRs. The duration and intervals for each intervention also differ, as mentioned in the CTRs and in the statement.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it is incomplete and fails to provide sufficient context for a definitive entailment judgment. The statement acknowledges that both trials involve vaccine-based interventions but does not specify which trial refers to the primary trial's HER2/neu peptide vaccine or the secondary trial's PET-guided biopsy as a vaccine. Moreover, the statement does not provide enough detail on the timing, dosage, or frequency of the vaccine administration in the secondary trial, making it impossible to determine if there is a difference in the intervals and durations of vaccine usage between the trials. To evaluate the entailment relationship, a more precise statement with clear references to the specific interventions and their details in both trials is required.</s>"
    },
    "6461007d-fc18-43e2-a797-11cb0a4512ce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01648322",
        "Secondary_id": "NCT00436566",
        "Statement": "the primary trial has a shorter time frame than the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial has a shorter time frame than the secondary trial\" is entailed by the information in the CTRs because the outcome measurement in the primary trial is measured for a duration of 4 cycles of chemotherapy, while the outcome measurement in the secondary trial lasts for a period of 6 months. The duration of the primary trial's outcome measurement is thus clearly shorter than that of the secondary trial.</s>",
        "contradict": "The statement that \"the primary trial has a shorter time frame than the secondary trial\" contradicts the information in the CTRs since the time frames specified in the CTRs for both trials (4 cycles of chemotherapy in the primary trial, and 6 months in the secondary trial) are not directly comparable. The length of a trial is not solely determined by the number of days within a specific phase or treatment period, but also by the overall duration of the study. Therefore, a shorter number of days during chemotherapy administration in the primary trial does not necessarily imply that the primary trial is of a shorter duration than the secondary trial.</s>"
    },
    "819e85b0-2d4e-4535-b920-4e18868da883": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00630032",
        "Secondary_id": "NCT00428922",
        "Statement": "Patients with radiologically confirmed metatases in the CNS are excluded from both the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as both trials explicitly mention CNS metastases as an exclusion criterion. (Primary Trial: Exclusion criteria: Any clinically or radiologically suspect and non-explored damage to the contralateral breast, including CNS metastases...; Secondary Trial: Exclusion Criteria: CNS metastases.)</s>",
        "contradict": "The statement is inconsistent with the information provided in the Primary CTR as it excludes patients with CNS metastases only from the secondary trial, not from the primary trial.</s>"
    },
    "cc0d6fe8-69c4-49d3-b321-00e47c155db6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03098550",
        "Statement": "There results from cohort 3 of the primary trial were inconclusive.",
        "Label": "Contradiction",
        "entail": "The statement \"There results from cohort 3 of the primary trial were inconclusive\" cannot be directly entailed by the information presented in the CTRs, as there is no mention of a cohort 3 in the provided trial data. Consequently, the statement does not harmonize with the clinical trial data, and there is no substantiation or avoidance of contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"There results from cohort 3 of the primary trial were inconclusive\" cannot be definitively contradicted by the information present in the CTRs without further context. The CTRs only provide information on the two arms or groups of the primary trial - one for TNBC and the other for NSCLC. The existence and results of a hypothetical third cohort are not mentioned. Hence, based on the given data, it is not possible to determine if the statement is contradictory or not. However, the statement itself suggests a lack of significant findings or conclusions from the unspecified cohort 3 of the primary trial. This could potentially be incongruous with any conclusive or significant findings reported in the CTRs for the TNBC or NSCLC groups.</s>"
    },
    "0fbb4fb4-620b-4ee9-aaa8-956992026cef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Statement": "Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Less than half of patients in cohorts 1 and 2 in the primary trial experienced adverse events\" can be entailed by the information in the CTRs since the total number of adverse events reported in each cohort (21/11 for cohort 1 and 20/6 for cohort 2) is less than the total number of patients in each cohort (11 for cohort 1 and 6 for cohort 2). Therefore, adverse events affected less than half of the patients in both cohorts.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the provided CTR data, as the statement does not specify which types of adverse events or cohorts are included. However, it is contradicted if we assume that the statement refers to the total adverse events and all cohorts in the primary trial, since more than half of the patients in some cohorts (hemorrhage, GI-abdomen NOS, pain-liver, hemorrhage gu-bladder, and pain-breast) experienced adverse events.</s>"
    },
    "69b12ff4-6bb4-4207-b400-67795709c3c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.",
        "Label": "Entailment",
        "entail": "The statement \"Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events\" is entailed by the information in the CTRs as all participants in the Australia Cohort, according to the definition of TEAEs provided in the Eligibility Criteria section, experienced adverse events (AEs) after initiating study drug treatment. The CTR Results 2 section specifies that every participant in this cohort had reported at least one AE (152/152 = 100.0%), which aligns with the expert's claim.</s>",
        "contradict": "Contradiction occurs due to the difference in the percentage of participants with treatment-emergent adverse events between the Palbociclib+Letrozole India Cohort (92.0%) and Palbociclib+Letrozole Australia Cohort (100.0%). The expert's statement, \"Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events,\" implies that 100.0% of participants in the Australia Cohort had TEAEs, which is a stronger statement than what the CTRs provide. The CTRs show that 100.0% of participants in the Australia Cohort had adverse events, but not all adverse events were treatment-emergent. Some adverse events might have started before the treatment and continued during it, making them not necessarily treatment-emergent. Therefore, the expert's statement cannot be entailed by the information provided in the CTRs, as the statement makes a stronger claim regarding all adverse events being treatment-emergent.</s>"
    },
    "9c0b258d-1e66-4eaa-b4e7-a9098eaed1d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's exclusion criteria explicitly list peripheral neuropathy of Grade 3 or 4 as a reason for ineligibility (NCI-CTCAE, Version 3.0). Therefore, the statement that female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial follows logically from the CTR information.</s>",
        "contradict": "The statement \"Female patients with Peripheral neuropathy grade 3 or 4 are excluded from the primary trial\" is not necessarily contradictory to the CTRs, as the CTRs explicitly state that \"Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0\" is an exclusion criterion. However, the statement can be considered redundant, as it restates the same information already provided in the CTRs, but with a narrower focus on female patients and a slightly different grade specification. The contradiction would arise if the statement implied that the primary trial excluded only male patients with Peripheral neuropathy grade 3 or 4, which is not the case according to the CTRs.</s>"
    },
    "9872cf9f-6f43-44d3-97ce-e205e0e5fc6c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00464646",
        "Statement": "Anna is a 57 year old female with an ECOG of 0, diagnosed with an invasive adenocarcinoma of the breast, IHC results were 1+. She is eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "Anna's age (57 years old), ECOG performance status (0), and diagnosis of invasive adenocarcinoma of the breast (IHC results were 1+) meet the eligibility criteria for patient eligibility mentioned in the CTR (female, ECOG performance status 0 or 1, invasive adenocarcinoma of the breast). Her diagnosis was made by core needle biopsy, which is also an allowed method of diagnosis as per the CTR (core needle biopsy or limited incisional biopsy). Therefore, Anna is eligible to participate in the primary clinical trial according to the stated inclusion criteria.</s>",
        "contradict": "Although Anna is diagnosed with invasive adenocarcinoma of the breast, IHC results showing a 1+ score does not automatically make her eligible for the primary trial as per the CTR's eligibility criteria, which requires HER2-positivity (FISH or strongly positive 3+ IHC). Therefore, the statement contradicts the CTR by stating Anna is eligible when she does not meet the HER2 positivity requirement.</s>"
    },
    "efc15257-5e19-4b7e-8b51-da94840784d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623233",
        "Secondary_id": "NCT01525589",
        "Statement": "the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency where found in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency were found in the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nExplanation:\n\nThe statement mentions two trials and the number of patients with thrombocytopenia (platelet deficiency) in each trial. The primary trial had a total of 52 participants, with 1 patient having thrombocytopenia as an adverse event. The secondary trial had a total of 54 participants, with 6 patients exhibiting thrombocytopenia as an adverse event.\n\nThe statement does not contradict the information provided in the CTRs. It is a valid comparison that correctly summarizes the data from each trial and identifies the discrepancy in the number of patients with thrombocytopenia between the studies. This comparison can be considered an entailed statement, as it follows from the information given in the CTRs.</s>",
        "contradict": "The statement \"the primary trial recorded 1 patient with a deficiency of platelets in the blood, whereas a total of 6 patients with a platelet deficiency were found in the secondary trial\" contradicts the information presented in the CTRs. \n\nExplanation: \n\nThe primary CTR lists 1 instance of Thrombocytopenia (platelet deficiency) among the adverse events, affecting 1.92% of the participants. The secondary CTR lists 6 instances of Thrombocytopenia, affecting 11.11% of the participants. The discrepancy between the number of patients with a platelet deficiency (1 vs. 6) is not reflected in the statement, and therefore, contradicts the information presented in the CTRs.</s>"
    },
    "0d4ea69b-5e78-48c2-ba3e-d51dc5336ee1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01310231",
        "Secondary_id": "NCT00093808",
        "Statement": "19.57% of patients in the secondary trial developed an eating disorder, there were no cases of this happening in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is not entailed by the information present in the CTRs. No mention of eating disorders or similar conditions can be found in either CTR's adverse events sections, making it incompatible with the data provided.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because there is no mention of eating disorders as an adverse event in either the primary or secondary trials.</s>"
    },
    "7990b9bf-ac76-4f21-b9a1-5e0b4d91b9a9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher number of deaths than cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 of the primary trial had a much higher number of deaths than cohort 2\" can be entailed by the information present in the CTRs based on the following reasons:\n\n1. Cohort 1 in the primary trial had 2/6 (33.33%) deaths, while cohort 2 in the secondary trial had 1/52 (1.92%) deaths.\n2. The number of deaths in cohort 1 is indeed much higher than that in cohort 2.</s>",
        "contradict": "The statement \"Cohort 1 of the primary trial had a much higher number of deaths than cohort 2\" cannot be definitively contradicted by the provided data in the CTRs. However, it does not entail the information in the CTRs as well, because the CTRs do not specify the number of participants or the exact death counts for each cohort. Therefore, no clear semantic entailment relationship exists between the statement and the CTR data.</s>"
    },
    "e4961c1a-83e2-40ed-93ac-64d5cef1f84a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01819233",
        "Statement": "All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study.",
        "Label": "Entailment",
        "entail": "The statement \"All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study\" can be entailed by the information present in the CTRs. The CTR for the primary trial indicates that patients receive dietary counseling and are given guidelines to reduce their caloric intake by 25%. Therefore, all primary trial participants are indeed required to follow a caloric restricted diet, entailing the expert's statement.</s>",
        "contradict": "The statement \"All the primary trial participants must reduce the number of calories in their diets by a quarter throughout the duration of the study\" is not a direct contradiction to the information in the CTRs. However, it is an incomplete representation of the facts. \n\nThe CTRs specify that participants receive caloric restricted dietary intervention, but they do not explicitly state that all participants must reduce their caloric intake by a quarter. Rather, they describe the procedure for implementing the dietary intervention. Therefore, while the statement is consistent with a possible interpretation of the CTRs (i.e., that all participants reduce their calories by a quarter), it does not follow directly from the information given in the CTRs and may overlook other relevant details (such as the timing and duration of the intervention).</s>"
    },
    "9cb1c975-0d49-4437-af56-1a4f97e30aef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01663727",
        "Secondary_id": "NCT00072293",
        "Statement": "There is no maximum or minimum age defined for participation in the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is no maximum or minimum age defined for participation in the primary trial or the secondary trial\" is entailed by the information in the CTRs as both trials do not explicitly state any age restrictions in their inclusion criteria.</s>",
        "contradict": "The statement that \"there is no maximum or minimum age defined for participation in the primary trial or the secondary trial\" is contradicted by the inclusion criteria in the Primary CTR stating \"For women of childbearing potential, use of an acceptable and effective method of non-hormonal contraception\" and the statement \"Any age\" in the Secondary CTR PATIENT CHARACTERISTICS section, which implies that there is a lower age limit. Additionally, no upper age limit is explicitly stated in either CTR, but general exclusion criteria such as \"Life expectancy of < 12 weeks\" could indirectly set an upper limit. However, the statement is not directly contradicted by the information in both CTRs since it does not mention any specific age limits that conflict with the provided information.</s>"
    },
    "51699ae8-d297-4635-95c1-4ed38c8706c3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02732119",
        "Statement": "Mark suffered Refractory ventricular fibrillation twice in the last month he is therefore excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "Mark's exclusion from the primary trial based on refractory ventricular fibrillation is entailed by the CTRs' Exclusion Criteria for Patient Safety, specifically: \n\n\"Clinically significant, uncontrolled heart disease and/or recent cardiac events.\"\n\nThis criterion excludes patients with such conditions from participating in the primary trial. Refractory ventricular fibrillation falls under the category of uncontrolled heart disease, making Mark ineligible for inclusion according to the CTRs.</s>",
        "contradict": "Mark's exclusion based on refractory ventricular fibrillation is not directly mentioned in the provided Primary Trial's Inclusion and Exclusion Criteria. The statement contradicts the CTR as it introduces a new condition for exclusion (refractory ventricular fibrillation) which is not mentioned in the CTR.</s>"
    },
    "c2c73b99-f89c-4dd3-8362-295f9a7965f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry, ",
        "Label": "Entailment",
        "entail": "The statement \"In order to meet the inclusion criteria for the primary trial, patients must have had ineffective aromatestasis inhibitor (AI) therapy before study entry,\" is entailed by the CTR as it specifies \"Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy\" as one of the inclusion criteria.</s>",
        "contradict": "The statement \"In order to meet the inclusion criteria for the primary trial, patients must have had ineffective aromatase inhibitor (AI) therapy before study entry,\" can be contradicted by the information present in the CTRs if a patient met the criteria for Progressive Disease (PD) during prior AI therapy but the trial also accepts patients with stable brain metastases who have undergone treatment and have been disease-free for a specific period. In these cases, the patient's AI therapy might not be considered ineffective according to the expert's statement, but they still meet the eligibility criteria for the trial.</s>"
    },
    "180d7b66-9ee9-40fb-b4c7-a6060e6f67b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02129556",
        "Statement": "Cohort 1 of the primary trial had a much higher mortality rate than cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 of the primary trial had a much higher mortality rate than cohort 2\" is entailed by the information in the CTRs, as evidenced by the following:\n\n1. The primary trial reports the total number of adverse events, including deaths, for both cohorts: cohort 1 had 2/6 (33.33%) deaths, and cohort 2 had 9/52 (17.31%) deaths.\n2. The percentage of deaths for cohort 1 is indeed \"much higher\" than that for cohort 2, as stated in the expert's claim.\n\nTherefore, the information contained in the statement is harmonious with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The expert statement \"Cohort 1 of the primary trial had a much higher mortality rate than cohort 2\" cannot be directly contradicted by the given Adverse Events data from the CTRs alone. However, it's essential to note that the Adverse Events sections provide information on total numbers of occurrences for a given adverse event within each cohort but not mortality rates. The mortality rate calculation requires the number of deaths in each cohort divided by the total number of participants in each cohort. Without this data, we cannot confirm or deny the expert statement based on the provided CTR information.</s>"
    },
    "949ac54b-a871-4134-a507-c98a4de55720": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00394082",
        "Secondary_id": "NCT01033032",
        "Statement": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial.",
        "Label": "Entailment",
        "entail": "According to the CTRs provided, there is a difference in the occurrence of adverse events between the primary and secondary trials. Specifically, the primary trial reported cases of anaphylactic reaction (1/50 or 2.00%) and spinal compression fracture (1/50 or 2.00%), whereas the secondary trial did not report any occurrences of anaphylactic reaction or spinal compression fracture. The expert's statement that \"the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial,\" is entailed by this data as it accurately reflects the differences between the trials' adverse events.</s>",
        "contradict": "The statement does not account for the difference in participant counts between the primary and secondary trials when making the comparison. The primary trial had 50 participants and recorded adverse events for all of them, while the secondary trial had only 3 participants. The absence of Anaphylaxis and Spinal compression fracture in the secondary trial does not contradict the primary trial data, it is simply a result of the smaller sample size in the secondary trial.</s>"
    },
    "02407f87-235d-4240-98fe-498b352cce75": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00167414",
        "Statement": "Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary CTR does not explicitly state that patients must have HER2 overexpressive tumors for trial participation. However, the CTR does not include HER2 overexpression as an explicit inclusion criterion, but it does not exclude it either. Since there are no contradictory statements in the CTR, the expert's statement can still be entailed as it does not contradict any information in the CTR. The trial interventions or treatment details do not necessarily rely on HER2 overexpression, so the statement applies to the primary trial as a whole rather than a specific intervention within the trial.</s>",
        "contradict": "The statement \"Patients must have Human epidermal growth factor receptor 2 (HER2) overexpressive tumors to participate in the primary trial\" is contradicted by the inclusion criteria in the CTR, where there is no such requirement mentioned. The primary trial inclusion criteria only state that there is no limit on age, Karnofsky performance status (KPS) must be 70, no more than 5 metastatic sites involving one or more different organs, the lesion size must be such that it can be safely treated to sterilizing radiation doses, previously treated lesions are eligible if the prescribed dose can be safely delivered, concurrent therapy is allowed and recommended, informed consent must be obtained, pregnancy test must be negative for women of child bearing potential, inability to be followed longitudinally, technical inability to achieve required dose based on safe dose constraints required for radiosurgery, women who are pregnant or nursing, and failure to meet requirements in Inclusion Criteria, and contraindications to radiation are exclusion criteria. Therefore, the statement about HER2 overexpression being a requirement is not entailed by the primary trial's CTR.</s>"
    },
    "61a524d4-1697-4a10-b36a-a0c6cda79526": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00030823",
        "Statement": "Patients with stage I, II, III or IV triple negative breast cancer are not eliglbe for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR as triple negative breast cancer is not mentioned as a specified disease condition for eligibility in the primary trial. The trial includes breast cancer at high risk for recurrence, but it does not specify that the cancer must be triple negative. Therefore, patients with other types of breast cancer besides triple negative are eligible for the trial, making the statement that patients with triple negative breast cancer are not eligible consistent with the trial eligibility criteria.</s>",
        "contradict": "The statement \"Patients with stage I, II, III or IV triple negative breast cancer are not eligible for the primary trial\" is contradicted by the CTR information as the primary trial includes patients with Stage I, II, or III breast cancer who have rising CA 15-3 or CEA levels and have completed adjuvant therapy no more than 24 months ago. These patients may have triple negative breast cancer. Therefore, the eligibility criteria for stage I, II, or III breast cancer in the primary trial contradicts the statement that these patients are not eligible for the trial.</s>"
    },
    "304977b6-9742-4c3b-84fd-e5ef1737a143": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01597193",
        "Statement": "ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial\" is entailed by the following inclusion criteria from the primary CTR: \n\n1. Eastern Cooperative Oncology Group performance (ECOG) status of 0 or 1\n2. Estimated life expectancy of at least 3 months\n\nThe inclusion criteria stated in the CTR specify that participants in the primary trial must have an ECOG status of 0 or 1, which is equivalent to an ECOG performance status of less than 2 as mentioned in the expert's statement. Furthermore, participants must have an estimated life expectancy of at least 3 months, which is longer than the 12-week threshold mentioned in the expert's statement. Therefore, the statement made by the expert is an accurate summary of the CTR inclusion criteria that is entailed by the original data.</s>",
        "contradict": "The statement \"ECOG < 2 and a life expectancy over 12 weeks are necessary to participate in the primary trial\" is contradicted by the information presented in the CTRs because the CTRs specify an ECOG status of 0 or 1 and an estimated life expectancy of at least 3 months as inclusion criteria, which falls short of the stated requirement of ECOG < 2 and a life expectancy over 12 weeks.</s>"
    },
    "87c65217-85d9-4f05-87aa-f4dfacd9f25a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01790932",
        "Statement": "patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria as \"Have received previous treatment with PI3K inhibitors\" is listed among the exclusion criteria for the primary trial.</s>",
        "contradict": "The statement \"patients with Phosphoinositide 3-kinase inhibitor based treatments are ineligible for the primary trial\" can be contradicted by the information present in the CTRs since the primary trial explicitly states \"Have not received previous treatment with PI3K inhibitors\" under the inclusion criteria section, indicating that patients without a history of PI3K inhibitor treatment are eligible for participation in the trial.</s>"
    },
    "19e89ebc-a417-47a8-bfa7-1778baead178": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01385137",
        "Secondary_id": "NCT00593346",
        "Statement": "Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial.",
        "Label": "Entailment",
        "entail": "In the secondary trial, the placebo group is referred to in the context of the intervention section. The primary trial, however, does not explicitly mention a placebo group in its intervention section but rather states that patients in Arm II received oral placebo. The absence of a separate placebo arm in the primary trial does not contradict the existence of placebo treatment in the secondary trial, and the statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Placebo treatment is used in the secondary trial, but there is only a test group in the primary trial\" is contradictory to the information in the CTRs because the primary trial has a control group that received placebo, while the secondary trial is focused on a distinct intervention - accelerated partial breast brachytherapy, which is not comparable to the omega-3-fatty acid intervention in the primary trial.</s>"
    },
    "561a0631-1eb3-48d1-baa2-81eb3fa79b98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00950300",
        "Secondary_id": "NCT00615901",
        "Statement": "the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain.",
        "Label": "Entailment",
        "entail": "The statement does not directly entail information from the CTRs as it only describes different types of adverse events observed in each trial, and does not relate to the frequencies, percentages, or specific patient counts of adverse events as presented in the CTRs. However, the statement does not contradict any information in the CTRs either, and can coexist with the data provided.</s>",
        "contradict": "The statement \"the primary trial recorded a patient with chest pain, whereas the secondary trial observed a patient with abdominal pain\" does not directly contradict the CTR data provided. However, it is important to note that the statements \"the primary trial recorded a patient with chest pain\" and \"the secondary trial observed a patient with abdominal pain\" do not entail any information about the adverse events sections presented in the CTRs. The provided CTRs only mention the occurrence of specific adverse events and their frequencies within each trial cohort, but they do not provide information about any individual patient's adverse events. Therefore, it cannot be determined from the CTR data whether or not there was a patient in the primary trial with chest pain, or a patient in the secondary trial with abdominal pain. Thus, the statement does not directly contradict the CTR information, but it is also not entailed by it.</s>"
    },
    "bc617e84-a0c1-400b-9ad5-88b56d1805e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01671319",
        "Statement": "1/42 patients in cohort 1 of the primary trial fainted.",
        "Label": "Entailment",
        "entail": "The statement \"1/42 patients in cohort 1 of the primary trial fainted\" can be entailed by the information present in the CTRs as \"Syncope\" was reported as an adverse event with a frequency of 1/42.</s>",
        "contradict": "The statement \"1/42 patients in cohort 1 of the primary trial fainted\" is contradicted by the information in the CTRs because syncope, which is a type of fainting, is reported to have occurred in only 1 participant out of 42 in the primary trial (as stated in the CTR under the 'Adverse Events' section). However, the statement specifies that \"1/42 patients in cohort 1\" of the primary trial fainted, implying that different patients are being referred to in the CTR and the statement, which is contradictory.</s>"
    },
    "8a8b7b19-9328-4cb3-b01c-8f4c358f4ac5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01097642",
        "Statement": "Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The given expert statement \"Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0) are eligible for the primary trial\" is entailed by the CTR inclusion criteria as follows:\n\n1. \"Patients with histologic confirmation of invasive breast carcinoma.\"\n2. \"Patients with T1N1-3M0 or T2-4 N0-3M0.\"\n\nIn the given expert statement, T3 denotes TNM Stage 3, which falls within the range of T2-4 for the primary trial. N1 represents the presence of metastasis in axillary nodes, and M0 indicates that no distant metastases are present. Therefore, the statement \"Adult Patients with histologic confirmation of invasive bilateral breast carcinoma (T3 N1 M0)\" is an eligible population according to the provided Primary Trial's Inclusion Criteria.\n\nThus, the expert statement can be considered entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement is contradicted by the eligibility criteria in the primary CTR, as it includes patients with T3 N1 M0 invasive bilateral breast carcinoma, which is not explicitly stated as eligible in the provided criteria. The CTR specifies T1N1-3M0 or T2-4 N0-3M0 for primary tumor staging. T3 is considered a more advanced T stage, and the statement therefore goes beyond the scope of the given inclusion criteria.</s>"
    },
    "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00354640",
        "Statement": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin.",
        "Label": "Contradiction",
        "entail": "Anastrozole is prescribed at a dose of 1 milligram per day, while simvastatin is given at a dose of 40 milligrams. A higher dose signifies a greater quantity of a substance. Therefore, the statement \"Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement that \"Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin\" is inconsistent with the given CTR information, as both anastrozole and simvastatin have the same dosage in Intervention 1 of the primary trial (anastrozole: 1 mg/day, simvastatin: 40 mg/day). Therefore, patients in Intervention 1 do not receive higher doses of anastrozole than they do of simvastatin.</s>"
    },
    "b059e44b-9830-4c45-858e-ebd007fbaf69": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00148668",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia\" is not entailed by the provided CTRs information since both CTRs report zero instances of Febrile Neutropenia for their respective cohorts.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia\" is contradicted by the information in the CTRs since there were no cases of Febrile Neutropenia reported in Cohort 1 of the primary trial [(0/41)] while there was one case reported in Cohort 2 of the secondary trial [(1/40)].</s>"
    },
    "fec065ca-fbde-476d-ab0d-7e7054e29858": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00436917",
        "Statement": "Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial, as these would interfere with the necessary CT and MRI scans for the study.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial\" is entailed by the CTR information because:\n\n1. Scoliosis with a Cobb angle > 15 degrees at the lumbar spine is a contraindication to spine dual energy x-ray absorptiometry (DXA) in the primary trial as stated in the \"NO CONDITION THAT WOULD PRECLUDE STUDY FOLLOW-UP OR COMPLIANCE\" section.\n2. A higher degree of scoliosis (> 20 degrees) would certainly interfere with necessary CT and MRI scans, as stated in the expert statement, and this level of scoliosis falls under the category of conditions that would prevent proper acquisition of a lumbar spine DXA scan in the CTR.\n3. A prior surgery at the lumbosacral spine is listed as a contraindication to spine dual energy x-ray absorptiometry (DXA) in the CTR under \"NO CONDITION THAT WOULD PRECLUDE STUDY FOLLOW-UP OR COMPLIANCE,\" and the expert statement explains this exclusion based on the interference it causes with necessary CT and MRI scans.</s>",
        "contradict": "The statement that \"Patients with Scoliosis with a Cobb angle exceeding 20 degrees at the lumbar spine, or with a prior surgery at the lumbosacral spine are excluded from the primary trial\" is contradicted by the information present in the CTR, as the exclusion criteria for the primary trial specify that \"Scoliosis with a Cobb angle > 15 degrees at the lumbar spine\" and \"history of surgery at the lumbosacral spine, with or without implantable devices\" are only conditions that would preclude the proper acquisition of a lumbar spine DXA scan, but not an explicit reason for exclusion from the trial itself.</s>"
    },
    "ea3bd229-001c-487f-9cda-edf2e699dbb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01153672",
        "Secondary_id": "NCT01432145",
        "Statement": "Patients in the primary trial receive vorinostat at the same frequency, dosage and through the same route of administration as the secondary trial receive 6-Mercaptopurine.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if the following conditions are met:\n\n1. Vorinostat and 6-Mercaptopurine serve as treatments in their respective trials.\n2. Vorinostat is administered PO QD (once a day) in the primary trial, which is the same as the PO administration of 6-Mercaptopurine in the secondary trial.\n3. The frequency of treatment courses for both therapies are the same, with no significant deviation between the two trials (every 8 weeks in the absence of disease progression or unacceptable toxicity for vorinostat, and continuously until disease progression for 6-Mercaptopurine).\n\nThus, the statement is in line with the provided data in the CTRs and can be considered entailed.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial involves patients receiving vorinostat PO QD (once daily) for 2 weeks followed by AI therapy, while patients in the secondary trial receive 6-Mercaptopurine PO od (once daily) but on a continuous schedule, and not vorinostat. Therefore, patients do not receive vorinostat at the same frequency, dosage, or through the same route of administration as the secondary trial receives 6-Mercaptopurine.</s>"
    },
    "576e519a-1ef3-43e5-a13c-6058ad71f388": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00297596",
        "Secondary_id": "NCT00580333",
        "Statement": "Patients have received prior radiation treatment, to treat the current breast cancer, in the last two 2 weeks before study entry are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as follows: In the primary CTR, patients are allowed to have prior radiation therapy, provided it was not to the only site of evaluable disease and was completed > 2 weeks before enrollment. In contrast, the secondary CTR explicitly states that patients who have received radiation therapy for the current breast cancer within 2 weeks prior to study entry are excluded. Since the primary trial allows such patients to participate if they meet other eligibility criteria, and the statement focuses on these specific patients, the statement is a logical consequence of the CTR information. The secondary trial, however, has a stricter exclusion criterion for radiation therapy, which makes it incompatible with such patients, hence excluding them from the trial.</s>",
        "contradict": "The statement is contradictory to both CTRs. In the primary trial CTR, patients who have received radiation therapy in the adjuvant setting or for metastatic disease, provided it was not to the only site of evaluable disease, are eligible. However, they must have completed the therapy > 2 weeks before enrollment. In contrast, the statement includes patients who have received radiation treatment within the last 2 weeks before study entry.\n\nIn the secondary trial CTR, there is no mention of radiation therapy as an inclusion or exclusion criteria. However, the statement contradicts the general exclusion criteria of \"any prior radiation therapy for the current breast cancer.\" Since this information is not mentioned in the CTR, it is unclear how it can be contradicted. But if we assume that the CTR follows the same radiation therapy criteria as the primary trial (i.e., radiation therapy allowed if it was not to the only site of evaluable disease and if completed > 2 weeks before enrollment), then the statement would be contradictory.\n\nTherefore, based on the provided CTRs, the statement is contradictory to both trials.</s>"
    },
    "699d0cb5-1ebb-441d-aa7e-041a48923b00": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03374995",
        "Statement": "the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks\" is entailed by the information in the CTRs as both trials specify that the patients in Group I receive topical keratin \"at least BID\" or \"twice daily\" during the radiation therapy, which lasts for approximately 3-6 weeks. Therefore, the statement accurately reflects the frequency and duration of keratin application described in the CTRs.</s>",
        "contradict": "The statement \"the primary trial subjects receiving keratin are administered it topically twice daily for approximately 3-6 weeks\" is not an exact match with the information in the CTRs. While the statement correctly identifies that the keratin is administered topically and the duration is approximately 3-6 weeks, it does not exactly entail the frequency given in the CTR, which specifies that patients receive topical keratin at least BID (twice a day or more). Therefore, while the statement is not an outright contradiction, it is less precise than the information given in the CTR.</s>"
    },
    "6ec27be7-aa61-4ba8-b92a-98dcaee1eb0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01127373",
        "Statement": "Patients with T1N1M0, T2N1M0, T3N1M0 and TxN1M0 tumors are eliglbe for the primary trial.",
        "Label": "Entailment",
        "entail": "According to the primary CTR, patients with N1 disease are eligible for participation. T1, T2, T3, and X are T-stages representing the size of the primary breast tumor. N1 denotes the presence of metastasis in one regional lymph node. Therefore, patients with T1N1M0, T2N1M0, T3N1M0, and TxN1M0 tumors (where Tx signifies unknown or unmeasurable tumor size) satisfy the eligibility criteria of having a regional lymph node metastasis (N1) and thus, can be included in the trial as per the information provided in the CTR.</s>",
        "contradict": "The given expert statement is not directly contradictory to the CTR inclusion criteria, which indeed allow for various T stages as long as N stage is 1 and M stage is 0. However, the expert statement only mentions specific T stage (T1, T2, T3, Tx) and N stage (N1) combinations and does not explicitly state that M stage is 0, which is a required criterion according to the CTR. Thus, while the statement does not contradict the CTR in a strict sense, it does not fully capture the inclusion scope as described in the CTR.</s>"
    },
    "6e882de6-e55f-40a4-95a1-bdb176e68a18": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00266799",
        "Statement": "None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome.",
        "Label": "Contradiction",
        "entail": "The statement \"None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR SYNDROME\" is entailed by the information in the provided CTRs, as none of the patients in cohort 1 of the primary trial experienced acute vestibular syndrome based on the reported adverse events data. Similarly, the statement \"nor had acute coronary syndrome\" can also be entailed since acute coronary syndrome (ACS) is not listed as an adverse event for either the primary or secondary trials.</s>",
        "contradict": "The statement \"None of the patients in cohort 1 of the primary trial had ACUTE VESTIBULAR or acute coronary syndrome\" is contradicted by the information present in the CTRs because in Adverse Events 1 of Primary Trial, there is a report of one participant experiencing ACUTE VESTIBULAR SYNDROME, while there is no information regarding acute coronary syndrome in either the Primary or Secondary trial CTRs.</s>"
    },
    "525ed182-07e9-4548-87b3-c831e0b7389e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients with lymphopenia can participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with lymphopenia can participate in the primary trial\" is entailed by the CTR information under the section \"PATIENT CHARACTERISTICS\" with the following reasoning: \n\nThe CTR states that \"WBC (white blood cells) > 1,500/mm\u00b3\" is a requirement for patient inclusion. Lymphopenia is a condition characterized by a decrease in the number of lymphocytes, a type of white blood cell, in the blood. However, the CTR does not explicitly mention lymphocyte count as a criterion. Since lymphopenia is a type of white blood cell condition, and the minimum WBC count specified in the CTR (1,500/mm\u00b3) is higher than the lower limit of normal lymphocyte count (typically around 1,000/mm\u00b3), it can be inferred that patients with lymphopenia, which may have WBC counts below 1,500/mm\u00b3 but above the lower limit of normal, still meet the WBC eligibility criterion. Therefore, the statement \"Patients with lymphopenia can participate in the primary trial\" is an entailed claim based on the CTR information.</s>",
        "contradict": "The statement \"Patients with lymphopenia can participate in the primary trial\" is contradicted by the information in the CTR as WBC (White Blood Cell) count is a requirement for patient eligibility and it must be greater than 1,500/mm\u00b3. Lymphopenia is a condition characterized by a decrease in the number of lymphocytes (a type of white blood cell) in the blood. This requirement excludes patients with lymphopenia from participating in the trial based on the provided information in the CTR.</s>"
    },
    "233d2ec1-1383-4088-90af-c5a948847631": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00110084",
        "Secondary_id": "NCT01961544",
        "Statement": "the primary trial and the secondary trial both reported cases of Pseudomonal sepsis in their patients.",
        "Label": "Contradiction",
        "entail": "The statement entails that both trials reported an instance of \"Pseudomonal sepsis\" among their participants. The CTRs detail the occurrence of \"Pseudomonal sepsis\" in each trial's Adverse Events sections, with 1 instance in the Primary Trial and 1 instance in the Secondary Trial. The statement is an accurate representation of the data presented, and no contradictions are present. Thus, the statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The information contained in the statement can be contradicted by the information present in the CTRs if the trials did not involve the same patient population or if the occurrence of Pseudomonal sepsis in the secondary trial was not an adverse event but rather a part of the intervention or treatment for another condition. In the CTRs provided, Pseudomonal sepsis was listed as an adverse event in the Primary Trial but was not mentioned in the Secondary Trial. Therefore, the statement is not necessarily an entailment based on the given information. It is important to note that comparing trials and making statements about entailment requires careful consideration of the specifics of the trials and their populations.</s>"
    },
    "8e3fe244-d47d-48ce-ab29-4a5226024aad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00426556",
        "Statement": "There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement cannot be entailed by the given information in the CTRs as there were no cases of Febrile neutropenia, Leukopenia, or Neutropenia reported in either cohort of the primary trial, according to the provided data.</s>",
        "contradict": "The statement \"There were an equal number of cases of Febrile neutropenia, Leukopenia and Neutropenia across cohorts in the primary trial\" is contradictory to the information present in the provided CTRs as there were no cases reported for any of these adverse events in the Adverse Events sections of both cohorts (primary and secondary) in the trial reports.</s>"
    },
    "670443b0-89bf-4af4-a9ab-4cdff26d09a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00005957",
        "Statement": "T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial\" is entailed by the CTR information because the CTR states that \"Node positive or high-risk node negative\" patients are eligible for the primary trial. A T4 N3 M0 tumor is a specific type of node-positive breast cancer (N+), and thus falls under the category of eligible patients according to the CTR.</s>",
        "contradict": "The statement \"T4 N3 M0 adenocarcinoma of the breast are eligible for the primary trial\" is contradicted by the information present in the CTRs because T4 and N2-3 represent advanced stages of breast cancer, which are explicitly stated in the eligibility criteria of the primary trial to be ineligible (section 1: \"No evidence of T4, N2-3, or M1 disease prior to surgery\").</s>"
    },
    "455748bf-8e12-4834-8126-ab77cab16200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00332709",
        "Secondary_id": "NCT00659373",
        "Statement": "All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane.",
        "Label": "Entailment",
        "entail": "The statement \"All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane\" can be entailed by the information present in the CTRs as follows:\n\n1. Both primary and secondary trials involve the use of Letrozole in one of their intervention arms (INTERVENTION 1 in the primary trial and INTERVENTION 1 in the secondary trial).\n2. All participants in the primary trial receive Letrozole 2.5 mg/day for 3 years (as stated in INTERVENTION 1 of the primary trial).\n3. In the secondary trial, not all participants receive Exemestane; it is only an additional intervention for a subset of patients in INTERVENTION 2 (Tamoxifen plus ovarian function suppression).\n4. The statement \"only certain patients in the secondary trial are administered Exemestane\" holds true as per the information in the secondary trial's INTERVENTION 2, where Exemestane is one of the options for ovarian function suppression alongside triptorelin, surgical oophorectomy, and ovarian irradiation. \n\nTherefore, the given statement can be entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane\" can be contradicted by the information present in the CTRs as follows:\n\n1. The primary trial has two intervention groups: one with Letrozole alone and the other with Letrozole combined with Zoledronic acid. Both groups receive Letrozole 2.5 mg/day for 3 years but differ in the administration of Zoledronic acid. Thus, not all participants receive the same dose of Letrozole, as the statement suggests.\n\n2. In the secondary trial, there are two intervention groups: one with Tamoxifen alone, and another with Tamoxifen combined with either OFS (Ovarian Function Suppression) or exemestane. The participants receiving OFS also receive Tamoxifen 20mg orally daily for 5 years, which is the same dose as the first intervention group. However, the contradiction comes from the fact that only some patients in the secondary trial are administered Exemestane, whereas all participants in the primary trial receive Letrozole.\n\nTherefore, the statement \"All the primary trial participants receive the same dose of Letrozole, only certain patients in the secondary trial are administered Exemestane\" contradicts the information present in the CTRs due to the presence of intervention groups with differing treatments within each trial.</s>"
    },
    "d29bd9dd-b52e-4b18-82ea-e2914dfb9579": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "the primary trial Patients receiving Neratinib Plus Capecitabine had a Mean (95% Confidence Interval)  Progression Free Survival more than 2 months longer than patients administered with Lapatinib Plus Capecitabine.",
        "Label": "Entailment",
        "entail": "The statement entails that the mean progression-free survival (PFS) for patients in the Neratinib Plus Capecitabine arm is more than 2 months longer than that in the Lapatinib Plus Capecitabine arm based on the reported data in the CTRs. This relationship is evident from the provided mean (95% Confidence Intervals) values for both arms. Specifically, the Neratinib Plus Capecitabine arm had a mean PFS of 8.8 (7.8-9.8) months, while the Lapatinib Plus Capecitabine arm had a mean PFS of 6.6 (5.9-7.4) months. The difference between these values, 2.2 months (8.8-6.6), meets the criteria for being more than 2 months longer, and thus, the statement is in line with the data in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the mean progression-free survival (PFS) for the Neratinib Plus Capecitabine arm is reported as 8.8 (7.8 to 9.8) months, which is indeed greater than 6.6 (5.9 to 7.4) months for the Lapatinib Plus Capecitabine arm. However, the expert's statement asserts that the difference in PFS between the two arms is more than 2 months. This is not directly stated in the provided CTR information. To accurately determine the statement's validity, one should either compare the exact difference between the reported means or consider the statistical significance of the difference between the two groups.</s>"
    },
    "2649c857-f98d-4529-9a4a-4f8b17813cb8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00337103",
        "Statement": "The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial\" can be entailed by the information in the CTRs since:\n\n1. The CTRs provide the Median Overall Survival (OS) for both cohorts 1 (Eribulin Mesylate 1.4 mg/m^2 group) and 2 (Capecitabine 2.5 g/m^2/day group).\n2. The provided statement indicates a difference of 44 days in Median OS between cohort 1 and 2.\n3. The CTRs state the Median OS for cohort 1 as 484 days and for cohort 2 as 440 days.\n4. The difference between these two Median OS values is 44 days (484 days - 440 days = 44 days), aligning with the statement.\n5. The statement does not contradict any information in the CTRs.\n\nThus, the statement is entailed by the information contained in the CTRs.</s>",
        "contradict": "The statement \"The Median Overall Survival for cohort 1 patients was 44 days longer than for patients in cohort 2 of the primary trial\" cannot be definitively established as true or false based on the information provided in the CTRs alone due to insufficient data. The statement makes a direct comparison of the median overall survival between two cohorts, whereas the CTRs only present the median overall survival and the overall number of participants analyzed for each individual cohort. Without knowing the median overall survival for both cohorts within the same time frame and under the same censoring rules, it's not possible to determine if the difference is 44 days or not.</s>"
    },
    "0a6e8720-ea47-4520-bd02-e0eb8fcd880f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00399802",
        "Statement": "The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group",
        "Label": "Entailment",
        "entail": "The expert's statement entails that the Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen in the Single IV Infusion of ZA 4 mg group was less than that in the Odanacatib 5 mg group. \n\nThis is entailed by the CTR data, as the Mean Percentage Change (95% Confidence Interval) for the Single IV Infusion of ZA 4 mg group is lower than that for the Odanacatib 5 mg group (\u221273 (-80 to -62) < \u221277 (-82 to -71)).</s>",
        "contradict": "The statement \"The Single IV Infusion of ZA 4 mg group of the primary trial had a smaller Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen than the Odanacatib 5 mg group\" cannot be directly contradicted by the information present in the CTRs. However, without further context or information about potential confounding factors or other relevant results, it is not possible to definitively establish semantic entailment or contradiction between the statement and the trial data.\n\nExplanation: \nThe statement asserts that the Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen for the Single IV Infusion of ZA 4 mg group was smaller than that for the Odanacatib 5 mg group based on the results provided in the CTRs. The CTRs, however, do not contain any direct comparison between the two groups' u-NTx changes. The only data available are the mean (95% CI) percentage changes from baseline for each group. The statement's claim can neither be proven nor refuted solely based on the presented information in the CTRs. Further analysis, such as statistical comparisons between the two groups, would be necessary to validate or contradict the statement.</s>"
    },
    "ce6630d3-d3b7-4870-a486-9b6284a454f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02679755",
        "Statement": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.",
        "Label": "Contradiction",
        "entail": "The statement \"More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort\" is entailed by the information in the CTRs as follows:\n\nThe CTRs provide the number of participants in each cohort who experienced Treatment-Emergent Adverse Events (TEAEs). Specifically, there are 152 participants with TEAEs in the Palbociclib+Letrozole Australia Cohort, and 92 participants in the Palbociclib+Letrozole India Cohort. The percentage of participants with TEAEs is therefore higher in the Australia Cohort (100.0%) compared to the India Cohort (92.0%).\n\nThis difference holds true for various subcategories of TEAEs including serious, grade 3 or 4, or grade 5 events, as well as for the number of participants discontinued due to adverse events. The percentages of participants with these types of TEAEs and the number of discontinuations are higher in the Australia Cohort compared to the India Cohort.\n\nTherefore, the statement \"More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbocicliclib+Letrozole India Cohort\" is an entailed assertion based on the data presented in the CTRs.</s>",
        "contradict": "Both cohorts received identical interventions with respect to Palbociclib and Letrozole administration schedules. Therefore, the difference in the percentage of participants with treatment-emergent adverse events (TEAEs) between the two cohorts could be attributable to other factors, such as population demographics, comorbidities, or geographical variations in the occurrence of certain adverse events. The statement does not contradict the CTR information directly, but it oversimplifies the potential reasons for the observed difference and may lead to incorrect conclusions if not considered within the context of other relevant factors.</s>"
    },
    "27e31574-5a73-4a68-997d-daa84797a65a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02162719",
        "Statement": "Both the primary trial and the secondary trial at least partly administer their interventions intravenously.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs because both trials involve the administration of paclitaxel intravenously. In the primary trial, paclitaxel is infused intravenously on Days 1, 8, and 15, while in the secondary trial, paclitaxel is infused intravenously on the same days (Days 1, 8, and 15) in both the ipatasertib and placebo arms. Therefore, the assertion of the statement that both trials partly administer their interventions intravenously is a valid inference drawn from the information provided in the CTRs. Additionally, suramin in the primary trial is also administered intravenously, but the statement only requires that one part of the interventions be given intravenously in each trial, which is satisfied.</s>",
        "contradict": "The statement \"Both the primary trial and the secondary trial at least partly administer their interventions intravenously\" is not contradicted by the provided CTR information. However, the statement does not entail that the interventions in both trials are identical, which may be the implicit assumption in the statement given the presence of ipatasertib, an oral medication, in the secondary trial.\n\nThe contradiction would arise if the statement claimed that both trials only used intravenous interventions when, in fact, the secondary trial also utilized oral medication. The CTRs, as presented, do not contradict the given statement but do demonstrate that the interventions in each study differ in their components (suramin + paclitaxel versus ipatasertib + paclitaxel or placebo + paclitaxel).</s>"
    },
    "e21171de-ad49-4fc5-9c5d-aa362ca61c8a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00014222",
        "Statement": "Cohort one of the primary trial reported 2/680 patients experiecing eye-related adverse events, whereas cohort two recorded 41.",
        "Label": "Contradiction",
        "entail": "The statement that \"cohort one of the primary trial reported 2/680 patients experiencing eye-related adverse events, whereas cohort two recorded 41\" can be entailed by the information present in the CTRs as follows:\n\n1. There is a mention of two separate cohorts in both primary and secondary trials.\n2. In the primary trial's adverse events sections, there are records of one patient with keratitis (eye-related adverse event) in cohort one and zero in cohort two.\n3. In the secondary trial's adverse events section, there are records of forty-one patients with eye-related adverse events in cohort two.\n4. The total number of patients in the primary trial's cohort one is 680 and in cohort two is not mentioned, but since both trials have the same treatment and patient demographics, the total patients in cohort two can be assumed to be 688 (as given in the secondary trial). Therefore, the ratio of patients with eye-related adverse events in each cohort can be calculated as 2/680 for cohort one and 41/688 for cohort two.\n5. The difference between these ratios is due to the different number of patients in each cohort. The statement that \"cohort one of the primary trial reported 2/680 patients experiencing eye-related adverse events, whereas cohort two recorded 41\" can be derived from the given ratios by multiplying each ratio by the respective total number of patients in the cohort and subtracting the result from the total number of patients in the primary trial for cohort one and from the total number of patients in both trials for cohort two.\n\nSo, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Cohort one of the primary trial reported 2/680 patients experiencing eye-related adverse events, whereas cohort two recorded 41\" contradicts the CTRs as no eye-related adverse events were reported in cohort one (zero cases of keratitis, double vision, or colitis) and only one instance in cohort two (keratitis). The statement's total number of eye-related adverse events for cohort one is a summation error, as it includes the total number of adverse events for the entire primary trial.</s>"
    },
    "5dcdeac8-1c4a-4c24-9074-bbe93fcf4d32": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02518191",
        "Statement": "Cohort 2 of the primary trial is the control group, as the Eligible patients with breast cancer treated with GnRHa every 28 days.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information presented in the CTRs because the CTR specifies that Intervention 1 of the primary trial involves the use of Gonadotrophin-releasing Hormone Analogues (GnRHa) given every 28 days to eligible breast cancer patients receiving chemotherapy (ELIGIBILITY CRITERIA and INTERVENTION 1 of the primary CTR). Additionally, the statement identifies this group as the control group in the primary trial, which aligns with the typical definition of a control group in clinical trials as the group that does not receive a new treatment or intervention (as is the case with Intervention 2 in the primary trial, which involves no GnRHa treatment). Therefore, the statement's assertion that Cohort 2 of the primary trial is the control group, consisting of patients with breast cancer treated with GnRHa every 28 days, is in harmony with the provided CTR data and does not contradict it.</s>",
        "contradict": "The statement is contradicted by the information in the CTR because the control group in the primary trial does not consist of patients who received GnRHa every 28 days. Instead, the control group is defined as the group of patients with breast cancer who did not receive GnRHa while receiving chemotherapy.</s>"
    },
    "38f47a03-f71d-4072-a005-b954fb6069da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00684983",
        "Statement": "The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as the median PFS in Arm A is reported as 6.0 months (4.3 to 8.6) in the CTR. Half a year corresponds to 6 months.</s>",
        "contradict": "The statement \"The Median length of time that a patient in Arm A of the primary trial lived with the disease without it getting worse was half a year\" is in contradiction with the information presented in the CTRs. Based on the Results 1 section in the Primary Trial CTR, the median PFS for Arm A was 6.0 months (4.3 to 8.6) and not 0.5 years, which is half a year.</s>"
    },
    "e41917b8-d921-4797-b845-0121a75104a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00129376",
        "Statement": "More than 2% of patients in the primary trial experienced a clinically significant inflammation of the back of the throat.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTR as \"Acute Pharyngitis,\" reported in the primary trial's adverse events, meets the definition of inflammation of the back of the throat and affects 1/63 or 1.59% of the patients.</s>",
        "contradict": "The expert statement does not entail the information in the CTR, as there is no mention of throat inflammation (pharyngitis) in the Adverse Events section of the primary trial. The statement's claim of clinically significant inflammation of the back of the throat pertains to an event that is not explicitly reported in the provided trial data.</s>"
    },
    "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 patients in the primary trial surivied almost twice as long as those in cohort 2.",
        "Label": "Contradiction",
        "entail": "To entail the expert's statement that \"Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2,\" we must find substantiation in the CTRs for the following facts:\n\n1. The duration of survival for participants in each cohort (Cohort 1 and Cohort 2).\n2. Cohort 1 survived significantly longer than Cohort 2.\n\nFrom the provided information, we can find the duration of treatment and analysis only for each arm/group, not for the entire cohort (primary trial participants that received the same treatment regimen). However, we can calculate the survival duration based on the information given.\n\n1. Calculate the median survival time for each arm/group in the primary trial (Cohort 1 and Cohort 2). Since the trial's data was analyzed up to the primary completion date, we can estimate the median survival time as the time between the first dose of study drug administration and the median time of disease progression or death for each arm/group.\n\nFrom Results 1 and 2, we have:\n- Cohort 1 (Stratum 1): The trial lasted up to 3 years 11 months, and there were 66 participants with a 25.8% response rate.\n- Cohort 2 (Stratum 2): The trial lasted up to 3 years 11 months, and there were 101 participants with a 21.8% response rate.\n\nWe cannot determine the exact number of participants who experienced disease progression or death; however, we can estimate it based on the response rates and the total number of participants.\n\n- Cohort 1: Let X be the time (in years) at which 50% of the participants (33) experienced disease progression or death.\n- Cohort 2: Let Y be the time (in years) at which 50% of the participants (50) experienced disease progression or death.\n\nFrom the given data, we have:\n- 25.8% * 66 = 17 participants responded to the treatment in Cohort 1, so 49 participants did not respond and experienced disease progression or death.\n- 21.8% * 101 = 22 participants responded to the treatment in Cohort 2, so 79 participants did not respond and experienced disease progression or death.\n\nWe know that there are 66 participants in Cohort 1 and 101 participants in Cohort 2, so we have:\n- 33/66 * X = 49\n- 50/101 * Y = 79\n\nSolving for X and Y:\nX = (49 * 101) / 33\nX = 138.12 years\nY = (79 * 66) / 50\nY = 115.28 years\n\nSince the trial lasted up to 3 years 11 months (approximately 3.3 years), we can assume that both cohorts reached their median survival points within the trial.\n\n2. Cohort 1 patients survived significantly longer than Cohort 2.\n\nComparing the median survival times calculated above, we find that Cohort 1 patients survived for approximately 138.12 years, while Cohort 2 patients survived for approximately 115.28 years. The difference is 22.84 years. Since the expert's statement claims that Cohort 1 patients survived \"almost twice as long\" as Cohort 2, a 2x difference would be 2 * 115.28 = 230.56 years. Although the actual difference is smaller, it still represents a substantial improvement in survival for Cohort 1 patients.\n\nIn conclusion, the statement \"Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2\" can be entailed by the information present in the CTRs, as the CTRs provide the necessary data (response rates) to estimate the median survival times for each cohort and demonstrate a significant survival advantage for Cohort 1.</s>",
        "contradict": "The statement \"Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2\" is contradicted by the CTRs provided, as they do not contain any information about the survival duration of individual participants in the respective cohorts. The given CTRs only provide data regarding the outcome measure (Objective Response Rate or ORR) and the percentage of participants achieving ORR for each treatment arm in the primary trial (Stratum 1 and Stratum 2). The statement's assertion about survival is not based on the data presented in the CTRs.</s>"
    },
    "3e56c28c-6d5c-49c4-aaf7-b4e2cb3ca2d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02491892",
        "Secondary_id": "NCT00887575",
        "Statement": "Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as follows: The statement asserts that cohort 1 of the secondary trial reported more cases of diarrhea and dyspepsia than cohort 1 of the primary trial due to a difference in cohort size. The CTRs provide information on the number of adverse events for each condition in both trials, allowing comparison between them. The secondary trial's cohort 1 had 2 instances of diarrhea and 1 instance of dyspepsia, while the primary trial's cohort 1 had 0 instances of diarrhea and 1 instance of dyspepsia. This difference can be attributed to their respective cohort sizes, which were 41 and 37 participants, respectively. Therefore, the statement is in line with the data presented in the CTRs, harmonizing with clinical trial data and avoiding contradiction.</s>",
        "contradict": "The statement \"Cohort 1 of the secondary trial recorded more cases of diarrhea and dyspepsia than cohort 1 of the primary trial, this is due to the significant difference in cohort size\" is contradicted by the data presented in the Adverse Events sections of the CTRs, as the number of cases for diarrhea and dyspepsia in cohort 1 of each trial are equal (1 case for each). Therefore, the statement's claim about the secondary trial having more cases is not supported by the provided information.</s>"
    },
    "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01881230",
        "Statement": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
        "Label": "Contradiction",
        "entail": "The statement entails that the difference in median PFS between the Gemcitabine and Carboplatin groups in the primary trial is greater than 2.65 months (83% of 3.25 months, which is the difference between the medians in the CTRs). This is inferred from the provided data in the CTRs: Arm A (Gemcitabine) had a median PFS of 5.5 months (95% CI: 4.1-7.0), and Arm B (Carboplatin) had a median PFS of 8.3 months (95% CI: 5.7-10.6).</s>",
        "contradict": "The statement that \"The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group\" is contradictory to the information in the CTRs. \n\nThe CTRs provide the Median (95% Confidence Interval) of Progression-Free Survival for both Arm A (Nab-Paclitaxel + Gemcitabine) and Arm B (Nab-Paclitaxel + Carboplatin) in the primary trial. The Median (95% Confidence Interval) for Arm A is 5.5 months (4.1 to 7.0), and for Arm B is 8.3 months (5.7 to 10.6). \n\nThe difference between the two medians is approximately 2.8 months, which is much less than 83% of the median for Arm B (83% of 8.3 months is 6.9 months). Therefore, the statement that the Gemcitabine group had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group is incorrect.</s>"
    },
    "6214280f-f665-48d3-b33f-9d798deff71f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01855828",
        "Secondary_id": "NCT00696072",
        "Statement": "the secondary trial uses Overall Survival (OS) as outcome measurement, which is different from Proportion of Participants With a Pathologic Complete Response Rate which is used for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not necessarily entail the information presented in the CTRs since the outcome measurements used in each trial are different. The primary trial focuses on estimating the pCR rate of HER2-positive breast cancer when pertuzumab is added to neoadjuvant chemotherapy using proportion of participants as a measuring unit. In contrast, the secondary trial evaluates the CBR and DFI in postmenopausal women with hormone-receptor positive advanced breast cancer, using number of participants as a measuring unit. The statement's assertion about the different outcome measurements is valid based on the trial descriptions provided in the CTRs.</s>",
        "contradict": "The expert statement that the secondary trial uses Overall Survival (OS) as outcome measurement, while the primary trial uses Proportion of Participants With a Pathologic Complete Response Rate as outcome measurement, is not directly contradictory to the information present in the CTRs. However, it implies a difference in the primary endpoints of the two trials, which is true. The contradiction would arise if the expert's statement contained inaccurate information regarding the outcome measurement used in the trials or misrepresented the information in the CTRs.</s>"
    },
    "108b54a9-b5cc-4f31-956f-e4e2e653d756": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089999",
        "Statement": "In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.",
        "Label": "Entailment",
        "entail": "The statement \"In total, more participants in the primary trial had no tumor response, than partial response, and 0 participants had a complete response\" can be entailed by the information present in the CTRs as follows:\n\n1. The definition of CR and PR as per RECIST v1.0 in the Outcome Measurement section states that CR is the disappearance of all target and non-target lesions and PR is at least a 30% decrease in the sum of diameters of target lesions.\n2. Results 1 and 2 from the CTRs both show that none of the participants in either arm (Lapatinib 1500 mg QD or Lapatinib 500 mg BID) had a CR.\n3. The Results sections provide the number of participants with PR for each arm (15 for Lapatinib 1500 mg QD and 18 for Lapatinib 500 mg BID).\n4. By subtracting the number of participants with PR in each arm from the overall number of participants analyzed, we find that there were more participants with no response to the treatment in the primary trial: 69 (overall number of participants) - 15 (Lapatinib 1500 mg QD PRs) - 18 (Lapatinib 500 mg BID PRs) = 36.\n\nThus, the expert's statement is entailed by the information in the CTRs, since it correctly reflects the number of participants with no response to the treatment, which is higher than the number of participants with PR for both arms combined.</s>",
        "contradict": "The statement \"In total more participants in the primary trial had no tumor response, than partial response, and 0 participants had a complete response\" can be contradicted by the information present in the CTRs as follows:\n\nIn the primary trial, for the Arm/Group titled \"Lapatinib 1500 mg QD\":\n- The number of participants with no tumor response is not mentioned in the Results.\nIn the primary trial, for the Arm/Group titled \"Lapatinib 500 mg BID\":\n- The number of participants with a complete response is 0, but the number of participants with partial response is 18.\n\nHence, the statement that \"more participants in the primary trial had no tumor response, than partial response, and 0 participants had a complete response\" is not consistent with the information provided in the CTRs.</s>"
    },
    "662f4992-0155-4a82-926f-b1821539aab7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00723125",
        "Secondary_id": "NCT00617942",
        "Statement": "57% of patients in cohort 1 of the primary trial had Pathological Complete Response Rates at Surgery, compared to 60% in cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\n1. The percentage of patients with Pathological Complete Response Rates at Surgery in each cohort can be calculated by dividing the number of participants in that cohort with Pathological Complete Response Rates at Surgery by the overall number of participants analyzed in that cohort. \n\n2. In the primary trial, 16 out of 28 participants in Cohort 1 had Pathological Complete Response Rates at Surgery (as stated in Results 1). Therefore, the percentage is 16/28 \u00d7 100% = 57.14% (rounded to 57%).\n\n3. In the secondary trial, 12 out of 37 participants in Cohort 1 had Pathological Complete Response Rates at Surgery (as stated in Results 1). Therefore, the percentage is 12/37 \u00d7 100% = 32.43% (rounded to 32%). However, the statement mentions 'Cohort 1 of the secondary trial' with 60% Pathological Complete Response Rates, which is actually true for Cohort 2 in the secondary trial (as stated in Results 2). The discrepancy in the statement is a mistake and should be corrected to 60% for Cohort 2 instead.\n\nDespite this error, the statement can still be entailed by the information present in the CTRs if we correct the percentage for Cohort 1 in the secondary trial to 60%. This corrected version of the statement states that 60% of patients in Cohort 1 (in the secondary trial) had Pathological Complete Response Rates at Surgery, compared to 57% in Cohort 1 (in the primary trial). This statement is true since it is based on the correct data.</s>",
        "contradict": "The statement cannot be determined to entail the information in the CTRs as there is a lack of consistency in the definition of \"Cohort 1\" between the two trials. In the primary trial, \"Cohort 1\" refers to a specific combination of treatments, while in the secondary trial, the title \"Cohort 1\" is not accompanied by a description of the treatment regimen. Thus, it is unclear whether the cohorts are comparable, making it impossible to establish entailment based on the provided information.</s>"
    },
    "398f744b-97cf-4f95-b162-99ec6652d327": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01091454",
        "Secondary_id": "NCT00054275",
        "Statement": "There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial\" is entailed by the information present in the CTRs because the primary trial reported 4 cases of Anemia and 0 cases in the secondary trial, and 7 cases of Leukopenia in the primary trial and 4 cases in the secondary trial. Thus, the primary trial had more instances of both Anemia and Leukopenia than the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the number of cases of Anemia is the same (1/48 in the primary trial and 1/39 in the secondary trial), while the number of cases of Leukopenia is higher in the secondary trial (4/39) than in the primary trial (1/48). Therefore, the statement is incorrect in its assertion that there were more cases of Anemia and Leukopenia in the primary trial.</s>"
    },
    "43421f19-878e-46f7-b456-8031835af649": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area.",
        "Label": "Entailment",
        "entail": "The primary trial CTR specifies that in Intervention 1 and Intervention 2, Capecitabine dosing is determined by body surface area ranging from 825 mg/m2 to 1250 mg/m2, given orally twice daily for 14 days out of every 21 days. The expert's statement acknowledges that Capecitabine's dose changes based on body surface area. However, the statement also mentions that in the primary trial, the set dosage for Lapatinib is 1000 mg PO daily. This information is consistent with the CTR as Lapatinib's dosage is not mentioned as varying in either Intervention 1 or Intervention 2 and is specified as 1000 mg PO daily. Therefore, the expert's statement entails the information in the CTRs since the statement correctly reflects the dosing information provided.</s>",
        "contradict": "The statement \"the primary trial uses a set dosage of 1000 mg PO daily of Lapatinib, whereas the dose of Capecitabine changes with Body surface area\" is contradictory to the information provided in the CTRs. According to the CTRs for both Intervention 1 and Intervention 2, Capecitabine dosing is based on body surface area, while Lapatinib is given at a fixed dose of 1000 mg PO daily. Thus, the statement contains inaccurate information regarding the dosing regimens for Lapatinib and Capecitabine in the primary trial described in the CTRs.</s>"
    },
    "13fa44e7-38be-48fb-a0eb-6b212549f526": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02260531",
        "Statement": "the percentage of participants achieving complete response (CR) or partial response (PR) was much lower in the HER2-positive group in the primary trial,than in the ER+ and/or PR+ group.",
        "Label": "Entailment",
        "entail": "The statement's claim can be entailed by the information in the CTRs as follows: \n\n1. The CTRs provide the ORR definitions for both HER2-positive and ER+ and/or PR+ groups, which include criteria for CR and PR.\n2. CTR Results 1 specifies the number of participants and their response rates (including CR and PR) for the HER2-positive group.\n3. CTR Results 2 specifies the number of participants and their response rates (including CR and PR) for the ER+ and/or PR+ group.\n4. The statement compares the percentage of participants achieving CR or PR between the two groups, which can be calculated based on the numbers provided in the CTRs.\n5. No information in the CTRs contradicts the statement, as the statement is about the comparison of response rates between groups and the CTRs only provide the response rates for each group. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, but it does not align precisely with the data presented. The statement implies that the HER2-positive group had a lower CR or PR percentage compared to the ER+ and/or PR+ group across both trials. However, the CTRs only report separate CR or PR percentages for each cohort (HER2-positive and ER+ and/or PR+) within the primary trial, without a direct comparison between them. Therefore, the statement may be an inaccurate generalization based on the information provided in the CTRs.</s>"
    },
    "12ae2315-cc50-43ac-a595-762c85c1ec58": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02308020",
        "Statement": "There were no participants in cohort 1 of the primary trial with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as there are no participants in cohort 1 (Part A) of the primary trial who achieved a Complete Response (CR) or Partial Response (PR) based on the RANO-BM response criteria, as indicated by an OIRR of 0% in the provided Results 1. Additionally, the statement does not contradict any information presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because, in Results 1, the primary trial reports that there were participants in cohort A of the trial who achieved PR based on RANO-BM response criteria. The overall number of participants analyzed in cohort A was 23, and the percentage of participants achieving PR is not explicitly stated but can be calculated as 5.8% - 0% = 5.8%, based on the given information in Results 1 and 2. Therefore, there were indeed participants in cohort 1 of the primary trial with a PR based on RANO-BM response criteria, which contradicts the assertion in the expert's statement.</s>"
    },
    "11403f92-661b-4334-8dfb-098586610ec6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02536339",
        "Secondary_id": "NCT00371345",
        "Statement": "Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "In the primary CTR, adverse events include \"Pneumonia\" in 1/39 (2.56%) of the patients and \"Sinusitis\" in 1/39 (2.56%) of the patients. In the secondary CTR, adverse events include \"Pneumonia\" in 1/70 (1.43%) of the patients and \"Lobar Pneumonia\" in 1/70 (1.43%) of the patients, as well as \"Sinusitis\" in 1/70 (1.43%) of the patients. The total number of patients in the primary trial is 39, and in the secondary trial is 70. Given these numbers, respiratory illnesses were indeed observed in most patients in both trials. The specific types of respiratory illnesses mentioned in the expert statement are entailed by the data presented in the CTRs.</s>",
        "contradict": "The statement \"Respiratory illnesses were observed in most of the patients in the primary trial and the secondary trial\" is not directly contradicted by the data presented in the Adverse Events sections of the CTRs. However, it can be inferred that the statement may not be entirely accurate based on the provided information. In the primary trial, there was one patient each with pneumonia and sinusitis, while in the secondary trial, there was one patient with pneumonia and one with lobar pneumonia. However, none of the other respiratory illnesses mentioned in the statement are present in the CTRs. Therefore, while respiratory illnesses were observed in some patients in both trials, the statement may overstate the extent and types of these illnesses.</s>"
    },
    "2823adfc-b3a4-4626-9690-0c292aa8da04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01422408",
        "Statement": "the primary trial is a phase II trial in which all participants will recieve topical fluocinonide 0.05% face cream twice daily for two weeks.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail the information in the CTRs, as it refers to \"topical fluocinonide 0.05% face cream\" instead of the \"vaginal cream\" stated in the CTRs. However, the error lies in the specificity of the application site mentioned in the statement, not the phase II designation, the dose, or the duration of treatment, all of which are consistent with the CTR. The statement does not contradict the CTR information. If the statement was about a phase II trial with topical fluocinonide 0.05% cream for vaginal use, it would be entailed by the CTRs.</s>",
        "contradict": "The statement \"the primary trial is a phase II trial in which all participants will receive topical fluocinonide 0.05% face cream twice daily for two weeks\" is contradicted by the CTR information as the primary trial actually involves topical fluocinonide 0.05% cream applied to the vagina, not the face.</s>"
    },
    "1cda051f-27d0-4027-94cf-7b5340173ca2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial do not have the same number of study groups.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial do not have the same number of study groups\" is entailed by the information present in the CTRs since the Primary Trial involves only one intervention group (AeroForm Tissue Expander), whereas the Secondary Trial consists of two intervention groups (IUS alone and IUS+OA).</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because while both trials have an Intervention 1, they differ in the specific interventions used: in the primary trial, Intervention 1 is a AeroForm Tissue Expander activated by remote control, while in the secondary trial, Intervention 1 is an Intrauterine System (IUS) without an additional agent, and Intervention 2 is a combination of IUS and an osteoanabolic agent. The trials have different interventions, and each intervention has a distinct nature, making the trials non-identical and resulting in different study groups. However, the statement does not consider this distinction and asserts a contradiction solely based on the number of study groups, which is an insufficient basis for contradiction given the unique interventions in each trial.</s>"
    },
    "2ca24749-7c1d-4697-a1aa-8bf5d13fb8c3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00435409",
        "Secondary_id": "NCT00319254",
        "Statement": "The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail information from the CTRs as it compares PFS durations across two separate trials without specifying which arm/group from each trial the shortest and longest PFS belong to. However, assuming the expert had access to more context and knew which trials and arms/groups the shortest (5 days) and longest (78 months) PFS belong to, then the statement can be entailed if those values align with the reported median PFS from the CTRs. For example, if the expert knew that the shortest PFS was in the Capecitabine arm of the primary trial with a reported median PFS of 5.4 months, and the longest PFS was in the Sunitinib + Capecitabine arm of the secondary trial with a reported PFS rate of 39.6% at Week 16, implying a median PFS longer than 78 months based on the calculation method provided, then the statement would be entailed.</s>",
        "contradict": "The statement \"The patient with the shortest PFS was in the secondary trial, at only 5 days, and the longest recorded PFS was in the primary trial at 78 months\" is not in line with the information present in the CTRs. \n\nFirstly, the CTRs do not provide any information about the shortest or longest individual PFS cases. They only report the median PFS and its corresponding 95% confidence intervals for each trial's arms.\n\nMoreover, the units of measurement between the two studies for PFS calculation are different - months in the primary trial and weeks in the secondary trial. This inconsistency in time units makes direct comparison of individual PFS cases inaccurate.\n\nHence, the statement contradicts the information present in the CTRs as it is derived from incorrect assumptions and incomparable PFS measurements.</s>"
    },
    "1e91c023-96e8-459b-9070-02df13339617": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Statement": "In the primary trial the FEC-75 Then Paclitaxel/Trastuzumab group produced better Pathological complete response (pCR) rates than the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group.",
        "Label": "Entailment",
        "entail": "The primary trial CTR indicates that the FEC-75 Then Paclitaxel/Trastuzumab group had a higher pCR rate of 56.5% (47.8-64.9) compared to the Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75 group's 54.2% (45.7-62.6) in the final analysis based on blinded central review. This difference in pCR rates between the two groups implies that the FEC-75 Then Paclitaxel/Trastuzumab group had better pCR rates, which aligns with the assertion made in the expert's statement.</s>",
        "contradict": "The information in the statement cannot be definitively contradicted by the information in the CTRs based on the data provided. However, it is essential to note that the statement infers a causal relationship between the sequence of interventions and the observed pCR rates, which may not be directly supported by the data presented in the CTRs. The CTRs only report descriptive statistics for pCR rates in each arm, and no direct head-to-head comparison or statistical testing is mentioned to establish superiority of one arm over the other regarding pCR rates. Therefore, while the FEC-75 Then Paclitaxel/Trastuzumab group may have higher pCR rates, it doesn't necessarily follow that it is causally related to the treatment sequence. Further analysis, such as a statistical comparison between groups, would be necessary to establish entailment.</s>"
    },
    "a15b4c0c-232b-4209-bf60-35d160e41d2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03012477",
        "Statement": "One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality. However, the most common adverse event was Anemia.",
        "Label": "Contradiction",
        "entail": "The statement that \"One patient in the primary trial experienced a thromboembolic event\" and \"the most common adverse event was Anemia\" can be entailed by the CTRs information as follows:\n\nThe CTR for the primary trial states that out of 34 patients, one patient experienced a thromboembolic event (2.94%). This information matches the statement's assertion about a patient in the primary trial having a thromboembolic event.\n\nFurthermore, the CTR also indicates that there were 2 cases (5.88%) of Anemia among the 34 patients. The most frequent adverse event in the primary trial was Anemia, as stated in the expert's comment, and this condition is mentioned explicitly in the CTR. The information presented in the expert's statement does not contradict any data given in the CTRs; instead, it accurately summarizes the findings reported in the CTRs.</s>",
        "contradict": "The information in the statement that \"the most common adverse event was Anemia\" contradicts the information in the CTRS that \"One patient in the primary trial experienced a thromboembolic event, a condition associated with a high degree of morbidity and mortality\" because the statement that \"the most common adverse event was Anemia\" is incorrect according to the CTR data, where the most frequent adverse event was Diarrhea (7/34 or 20.59%) instead of Anemia (1/34 or 2.94%).</s>"
    },
    "795d634a-9f9c-49a2-a4e7-ec99bd3600f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02667626",
        "Statement": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women.",
        "Label": "Contradiction",
        "entail": "The statement does not entail any information directly from the CTRs as the trials described in the CTRs are focused on young breast cancer patients and their use of a web-based reproductive health survivorship care plan (SCPR) for this specific population, while the expert statement refers to trials testing a web-based educational tool in the primary trial and a medical device in the secondary trial on post-menopausal women. The trials and patient populations are not the same, making the entailment impossible based on the provided context.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the primary trial involves testing a web-based educational tool, the SCPR, along with additional web-based resources and text-based reminders for young breast cancer participants, not a medical device. The secondary trial, on the other hand, is not explicitly stated to involve a medical device in its description. The discrepancy arises from the misconception that the primary trial is testing a medical device rather than a web-based educational tool.</s>"
    },
    "e2d4c56c-a68f-4751-907d-9c2355c9528b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01463007",
        "Secondary_id": "NCT00965523",
        "Statement": "A significantly higher proportion of patients in the secondary trial suffured from infection compared to the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the information in the CTRs if the following conditions are met:\n\n1. The term \"suffered from\" in the statement can be mapped to the reported \"Total\" number of adverse events for each trial.\n2. The statement claims a \"significantly higher proportion\" of infections in the secondary trial. This can be established by calculating the infection rates (as a percentage of total adverse events) for both trials and confirming that the rate in the secondary trial is indeed higher than that in the primary trial (17.28% vs. 2.44%).\n\nThus, the expert's statement is entailed by the data presented in the CTRs.</s>",
        "contradict": "The provided statement cannot be directly contradicted by the CTRs, as they both report instances of infection in their respective trials. However, the statement's claim of a \"significantly higher proportion\" in the secondary trial needs further investigation to be definitively established. The CTRs alone do not offer sufficient data to determine if the difference in infection rates between the two trials is statistically significant.</s>"
    },
    "50f1c6c5-abe6-4178-93cf-32b5a8a3e9e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00193050",
        "Secondary_id": "NCT00232479",
        "Statement": "Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial\" is entailed by the information presented in the CTRs, since both trials include the criterion that participants \"Be informed of the investigational nature of this study\" (implying they are expected to have a sufficient life expectancy for the study), and explicitly state that patients with a life expectancy under 6 months are excluded from the primary trial. While the secondary trial lacks such an explicit exclusion criterion related to life expectancy in the provided description, it's reasonable to assume it's implicitly included since it's a common standard in clinical trials, and the trial specifically focuses on clinical stage 2-3B patients, who typically have a life expectancy greater than 6 months.</s>",
        "contradict": "The statement \"Patients must be over the age of 18 and have a life expectancy over 6 months to participate in the primary trial or the secondary trial\" is not a direct entailment of the information in the provided CTRs as it contradicts the inclusion criteria of the primary trial stating that patients with a life expectancy of less than 6 months are excluded.</s>"
    },
    "9ad3444c-143d-4c28-a08a-e0c9cda44900": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00243503",
        "Secondary_id": "NCT00448279",
        "Statement": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients.",
        "Label": "Contradiction",
        "entail": "none of the adverse events listed in the secondary trial are present in the primary trial. The primary trial reported adverse events such as anemia, febrile neutropenia, idiopathic thrombocytopenic purpura, thrombocytopenia, cardiac failure, cardiac failure acute, cardiogenic shock, leftventricular dysfunction, anal fistula, and none of these correspond to the adverse events in the secondary trial which were febrile neutropenia, gastric volvulus, hospitalisation for intrapleuric chemotherapy and thoracentesis, general malaise, and acute renal failure. Therefore, the statement that \"the primary trial and the secondary trial did not observe any of the same adverse events in their patients\" follows from the information given in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial reported occurrences of anemia, idiopathic thrombocytopenic purpura, cardiac failure, cardiac failure acute, cardiogenic shock, left ventricular dysfunction, and anal fistula as adverse events, none of which were mentioned in the secondary trial. However, the secondary trial reported a significantly higher incidence of febrile neutropenia than the primary trial. While the primary trial had two cases of febrile neutropenia among 60 participants (3.33%), the secondary trial had one case among 26 participants (3.85%). Although the incidences are not exactly the same, the difference may not be clinically significant and could potentially be due to chance. Nevertheless, it is important to note that the presence of different adverse events in each trial and the varying frequencies of febrile neutropenia contradict the statement's claim that there were no shared adverse events between the two trials.</s>"
    },
    "43061a8b-c1b2-4b5e-b935-73733d674fb4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01401959",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial designates specific interventions to its patients depending on their tumour response, patients with complete response go to cohort A and all other in cohort B, in contrast the secondary trial assigns interventions randomly.",
        "Label": "Contradiction",
        "entail": "The statement asserts that in the primary trial, patients are allocated to different cohorts based on their tumor response, with those achieving a complete response assigned to cohort A and the remainder to cohort B. In contrast, the secondary trial assigns interventions randomly. \n\nThis statement entails the following semantic relationships with the information contained in the CTRs:\n\n1. In the primary trial, the interventions (eribulin for cohort A, and eribulin for cohort B) are contingent upon patients' tumor response.\n2. Patients who experience a complete response are allocated to cohort A, while those who do not go to cohort B.\n3. In the secondary trial, interventions are allocated randomly, without reference to patients' tumor response or outcome.\n\nThese relationships harmonize with the descriptions in the CTRs as stated, and there is no contradiction. The expert's statement is a correct generalization from the provided CTR information about patient selection for the interventions in each trial.</s>",
        "contradict": "The statement made by the clinical trials expert contradicts the information in the CTRs because the interventions in the primary trial are not assigned randomly, but rather based on the patients' tumor response following neoadjuvant therapy and surgery, with those who have a complete response assigned to a different cohort than those who do not. Conversely, the secondary trial does indeed assign interventions randomly. The statement incorrectly generalizes that all trials follow the same intervention assignment method, which is not accurate based on the information provided in these specific CTRs.</s>"
    },
    "fc7369dc-0fc5-4823-a8eb-5ac85188fd60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00416572",
        "Statement": "Patients suffering from ovarian or lung cancer are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients suffering from ovarian or lung cancer are excluded from the primary trial\" is entailed by the CTR as follows:\n\nIn the primary CTR, under the Disease Characteristics section, there are inclusion criteria specifying the diagnosis of breast cancer, and exclusion criteria mentioning other prior malignancies except skin cancer. The statement made by the expert is in line with the latter exclusion criterion, which is present in the CTR. The CTR does not include patients with ovarian or lung cancer, making the expert's statement an entailed conclusion derived from the available data in the report.</s>",
        "contradict": "The statement \"Patients suffering from ovarian or lung cancer are excluded from the primary trial\" is contradicted by the information in the CTR as it pertains to the disease characteristics inclusion criteria, which explicitly includes breast cancer patients only. No mention of exclusion for ovarian or lung cancer is present.</s>"
    },
    "25ec56f0-e472-4423-92ae-8d4840b067b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03475992",
        "Secondary_id": "NCT03106077",
        "Statement": "Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\n1. In the primary trial, the first intervention is applied to patients with pre-diagnosed breast cancer (biopsy confirmed), while the second intervention is applied to patients with a pre-diagnosed breast cyst.\n2. In both interventions of the primary trial, a low-power microwave breast imaging system is used.\n3. The first intervention in the secondary trial involves Cohort A patients who have advanced Triple-Negative Breast Cancer (TNBC) and receive a treatment of 6 mg/kg IMGN853 IV Q3W.\n4. The statement \"Participants in the primary trial receive different interventions depending on their pre-diagnosis, whereas all patients in the secondary trial took the same intervention\" can be derived from these facts.\n5. In the primary trial, the interventions differ based on the breast condition (breast cancer vs cyst), while in the secondary trial, all patients receive the same intervention regardless of their breast condition or any other factor.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial involves participants receiving different interventions (microwave breast imaging with or without prior biopsy) based on their pre-diagnosis (breast cancer vs. breast cyst), whereas the secondary trial involves all patients receiving the same intervention (IMGN853 with a specific dosage). Therefore, the statement does not hold true for both trials and contradicts the information provided in the CTRs.</s>"
    },
    "2c9e9407-e990-41bd-a87b-9d294c78f727": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02286843",
        "Statement": "the primary trial is testing a novel radiotracer called PET/CT to evaluate its use for visualization of HER2+ lesions.",
        "Label": "Contradiction",
        "entail": "The expert's statement is entailed by the CTR information as it correctly identifies the novel radiotracers being tested (89Zr-trastuzumab and 89Zr-pertuzumab) for their potential in visualizing HER2+ lesions using PET/CT, aligning with the primary trial's stated intervention.</s>",
        "contradict": "The expert statement is not directly contradictory to the CTR information, as the statement also mentions \"testing a novel radiotracer called PET/CT,\" which is consistent with the CTR's description of \"89Zr-trastuzumab\" and \"89Zr-pertuzumab\" as novel radiotracers. However, the expert statement does not explicitly mention that the trial involves HER2-positive breast cancer patients or that the radiotracers are specifically used for visualization of HER2+ lesions, which are important details in the CTR. While not contradictory, the expert statement is less precise and detailed than the CTR information.</s>"
    },
    "f3cebdf7-be0c-45ad-85bd-bde827524e20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00693719",
        "Statement": "the primary trial recorded less than 5 different Adverse Events .",
        "Label": "Entailment",
        "entail": "Based on the provided information, the statement \"the primary trial recorded less than 5 different Adverse Events\" can be entailed by the given CTR data as there are five distinct adverse events mentioned in the Primary Trial's Adverse Events section: Bleeding, Pain, Dehydration, Dyspnea, and a total of 4 distinct events reported out of 31 participants.</s>",
        "contradict": "The statement \"the primary trial recorded less than 5 different Adverse Events\" contradicts the information in the CTR as there are clearly more than 5 distinct Adverse Events reported. The primary trial recorded Bleeding, Pain, Dehydration, Dyspnea, and a total Adverse Event count of 4/31 (12.90%). Therefore, the statement is not an entailed relationship with the CTR data.</s>"
    },
    "b5c7bfd2-d491-400c-8444-8bc424cd5dbf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01705691",
        "Statement": "A patient in the primary trial suffered from Kidney stones.",
        "Label": "Entailment",
        "entail": "The statement \"A patient in the primary trial suffered from Nephrolithiasis\" is entailed by the information present in the CTRs since the term \"Nephrolithiasis\" is mentioned in Adverse Events 1 with a count of 0/19 (0.00%), indicating no occurrences within the primary trial. However, the statement does not contradict the information in the CTRs since there is no mention of a patient specifically in the CTRs suffering from Nephrolithiasis. The expert's statement is a general claim that could potentially apply to any patient in the study, even if no cases were reported in the primary trial. Therefore, it doesn't contradict the CTR information, but it might be less specific or comprehensive. In comparison, the secondary trial's data does show one instance of Nephrolithiasis. So, the statement could also potentially be entailed by the secondary trial data, but it is not a direct comparison or entailment between the two trials.</s>",
        "contradict": "The statement \"A patient in the primary trial suffered from Kidney stones\" cannot be entailed by the given CTRs as no instance of nephrolithiasis (kidney stones) was reported in either the primary or secondary trial's adverse events.</s>"
    },
    "53c62057-d6ea-4639-adaf-98cb1544a394": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425672",
        "Statement": "Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR because it accurately summarizes the repetition, duration, and conditions for discontinuation of ONTAK treatment in Arm I of the primary trial as described. The expert statement mentions a 21-day treatment cycle and a maximum of 6 courses, which matches the CTR's information on ONTAK treatment administration repeating every 21 days for up to 6 courses. The expert statement also includes the condition for earlier discontinuation if disease progression or unacceptable toxicity occurs, which is explicitly stated in the CTR.</s>",
        "contradict": "The expert's statement is not contradictory to the information in the CTRs. The CTR specifies that patients stop receiving intervention 1 if they experience disease progression or unacceptable toxicity, whereas the expert's statement only mentions that they may stop earlier due to these reasons. The expert's statement does not contradict the possibility of patients completing the maximum number of 6 treatment cycles if they do not experience disease progression or unacceptable toxicity.</s>"
    },
    "599b37cd-f380-48ac-864d-e766a7af963e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01570036",
        "Secondary_id": "NCT00021255",
        "Statement": "the primary trial and the secondary trial monitor the %  of their patient cohorts with DFS < 6years.",
        "Label": "Contradiction",
        "entail": "The primary and secondary trials both report the use of disease-free survival (DFS) as an outcome measure. In the primary trial, DFS is measured and reported at 24 months after completion of primary therapies for each treatment arm (Herceptin + NeuVax Vaccine and Herceptin + GM-CSF Only). In the secondary trial, DFS is estimated using the Kaplan-Meier method up to 5 years from randomization for each treatment arm (Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC\u2192T) and AC Followed by Docetaxel + Herceptin (AC\u2192TH)). Therefore, the statement that the primary and secondary trials monitor the percentage of their patient cohorts with DFS less than 6 years can be entailed by the information provided in the CTRs, as DFS is being reported for all trials and time frames include the 6-year mark.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial monitor the % of their patient cohorts with DFS < 6 years\" cannot be definitively determined to be either true or false based on the given information in the CTRs. Neither CTR explicitly states the percentage of patients with disease-free survival (DFS) less than 6 years, and the outcome measurement of both trials is defined as disease-free survival until relapse, death, or 5 years, whichever occurs first. Therefore, the comparison of DFS rates less than 6 years between the primary and secondary trials is not directly addressed in the provided CTRs.</s>"
    },
    "c428ec76-4d22-4d2d-8c06-1675bd431d41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02222337",
        "Statement": "Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic\" follows from the information in the CTRs because:\n\n1. The CTR for the primary trial states that the breast cancer survivors must be Hispanic.\n2. The CTR also states that each survivor must have a caregiver who is willing to participate, and there is no mention of a requirement that the caregiver be of a specific ethnicity.\n3. However, the statement in question adds that both the survivor and caregiver must be ethnically Hispanic, and this condition is consistent with the information in the CTR, as both the survivor and caregiver meet the ethnicity requirement stated in the CTR.\n4. The statement does not contradict any information in the CTRs, so it is semantically entailed.</s>",
        "contradict": "The statement \"Participants for the primary trial must be in pairs, a breast cancer survivor and a caregiver, both must be ethnically Hispanic\" cannot be directly contradicted by the information present in the CTRs as the CTRs do not explicitly state that trial participants must be in pairs or that both the survivor and caregiver must be ethnically Hispanic. However, the statement is inconsistent with the CTRs if the trials are assumed to be independent of each other and do not require pairs or have ethnicity as a requirement for participation.</s>"
    },
    "6cbc1567-2b51-45c0-ab1b-cac0b5fc7c38": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03283553",
        "Statement": "the primary trial has two cohorts.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial has two cohorts\" can be entailed by the information present in the CTRs as both trials involve two distinct groups of participants receiving different interventions: Intervention 1 and Intervention 2 in the primary trial, and the unspecified intervention in the secondary trial. No contradictory information is presented in the CTRs that would prevent this statement's entailment.</s>",
        "contradict": "The statement \"the primary trial has two cohorts\" is not contradicted by the information present in the CTRs. However, the CTRs only describe two interventions (INTERVENTION 1 and INTERVENTION 2) in the primary trial, not explicitly mentioning the presence of two cohorts. It is possible that each intervention represents a different cohort, or that the CTRs only provide information for one cohort per intervention. Without further context, it can't be definitively concluded that the primary trial has exactly two cohorts based on the given information.</s>"
    },
    "a9d5c664-896f-4bb1-95e7-1deaa88848ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00089479",
        "Secondary_id": "NCT02964234",
        "Statement": "Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white british origin. she is eligible for the primary trial but not the secondary trial, due to her age.",
        "Label": "Contradiction",
        "entail": "The statement \"Agatha had her 53rd birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. Agatha is of white British origin. she is eligible for the primary trial but not the secondary trial, due to her age\" can be entailed by the information present in the CTRs as follows:\n\n1. Agatha's eligibility for the primary trial: \n   - She meets the age criterion: Female patients 18-70 years of age. (Agatha is 53 years old)\n   - She has a histologically confirmed adenocarcinoma of the breast.\n   - She has no evidence of metastatic disease.\n\n2. Agatha's ineligibility for the secondary trial:\n   - She does not meet the age criterion: Age 52-75 years old. (Agatha is 53 years old)\n   - The statement does not provide information about her ethnicity, but the CTRs do not have ethnicity as an inclusion criterion for either trial.\n\nTherefore, the statement is entailed by the primary CTR as Agatha meets the eligibility criteria, but it is not entailed by the secondary trial due to her age being outside the inclusion criteria.</s>",
        "contradict": "The statement that Agatha is eligible for the primary trial but not the secondary trial, due to her age, is not a contradiction of the CTRs' information; however, it does not follow directly from the provided CTRs. Agatha's eligibility for the primary trial is based on her having a histologically confirmed adenocarcinoma of the breast, no evidence of metastatic disease, and meeting the age range of 18-70 years. The secondary trial has additional inclusion criteria, such as specific demographic factors (Latina/Hispanic/Chicana female and residence in specific neighborhoods), which do not apply to Agatha. Therefore, Agatha's eligibility status for the primary versus the secondary trial does not contradict the CTRs' information, although the statement does not follow directly from the provided CTRs.</s>"
    },
    "62b5fe62-470d-46e3-82a6-d57cd6cab452": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00471276",
        "Secondary_id": "NCT00951665",
        "Statement": "Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial\" can be entailed by the information present in the CTRs because:\n\nIn the primary CTR, there was 1 instance of Gastrointestinal Hemorrhage reported in cohort 1 with a total of 83 patients (1.20% incidence rate). In contrast, there were no instances reported in cohort 1 of the secondary CTR with a total of 26 patients. Therefore, the incidence rate of Gastrointestinal Hemorrhage in cohort 1 of the primary trial is higher than that in cohort 1 of the secondary trial.</s>",
        "contradict": "The statement \"Gastrointestinal haemorrhage was more common in patients from cohort 1 of the primary trial than cohort 1 of the secondary trial\" is contradicted by the information present in the CTRs because the frequency of gastrointestinal haemorrhage in cohort 1 was 1.20% in the primary trial and 0.00% in the secondary trial. A percentage lower than 1.20 is not more common.</s>"
    },
    "de349a2d-80ee-4c34-ab9f-38eb467c77d7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01106040",
        "Secondary_id": "NCT01441596",
        "Statement": "the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial and the secondary trial are not studying patient Progression-Free Survival (PFS), Objective Response Rate (ORR), or Dose-Limiting Toxicities (DLTs)\" can be entailed by the following reasons derived from the CTRs:\n\nIn the primary trial:\n- The outcome measurement in the primary trial is about the concordance of blue dye and Lymphoseek in detecting lymph nodes during surgery. No mention of PFS, ORR, or DLTs is given.\n\nIn the secondary trials:\n- Both secondary trials report the percentage of patients with patient benefit at 12 weeks, which is defined as the absence of CNS disease progression, no tumor-related worsening of neurological signs and symptoms, no tumor-related increase in corticosteroid dosage, and no progression of extra CNS disease according to RECIST 1.1. None of these measures directly correspond to PFS, ORR, or DLTs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial are not studying patient PFS, ORR or DLTs\" is contradicted by the information present in the CTRs. While the statement implies that the trials do not address Progression-Free Survival (PFS), Objective Response Rate (ORR), and Dose-Limiting Toxicities (DLTs), neither of the trials explicitly mentions these measures in their outcome measurements. However, the primary trial focuses on the detection rate of lymph nodes using blue dye and Lymphoseek, and the secondary trials report the percentage of patients experiencing patient benefit at week 12. Both trials provide results in the form of numbers with units of measure, which can be interpreted as measurements. Consequently, the trials are indeed studying some form of measurement; it's just not explicitly stated that they are measuring PFS, ORR, or DLTs in the given outcome measurements. Hence, the statement made by the clinical trials expert is contradictory to the information presented in the CTRs.</s>"
    },
    "0d37bf26-bc74-4a01-9bc9-61e2fa3051da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00446030",
        "Secondary_id": "NCT00975676",
        "Statement": "the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.",
        "Label": "Entailment",
        "entail": "The statement entails that the primary trial and the secondary trial do not share any common drugs in their interventions. This is evident from the information in the CTRs as Intervention 1 of the primary trial utilizes TAC, doxorubicin, cyclosphosphamide, bevacizumab for HER2 negative participants, and Intervention 1 of the secondary trial employs triptorelin and tamoxifen. Intervention 2 of the primary trial uses TCH, carboplatin, trastuzumab, and bevacizumab for HER2 positive participants, whereas Intervention 2 of the secondary trial uses triptorelin and exemestane. No drug is shared between the two trials, thereby satisfying the requirement stated in the expert's statement.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have no overlap in the drugs they use for their interventions\" is contradicted by the information present in the CTRs because, in the primary trial, HER2 negative participants receive TAC, doxorubicin, cyclosphosphamide, and bevacizumab, while HER2 positive participants receive TCH, carboplatin, trastuzumab, and bevacazumab. Meanwhile, in the secondary trial, participants in both interventions receive triptorelin. However, the interventions in the primary trial also include bevacizumab, which is a drug that appears in both the primary and secondary trials. Therefore, the statement is incorrect.</s>"
    },
    "69f7a93d-7134-40ec-aff3-50acd7119d2c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02425891",
        "Secondary_id": "NCT00593827",
        "Statement": "the secondary trial and the primary trial both measure PFS of their patient cohorts.",
        "Label": "Entailment",
        "entail": "Both trials report Progression-Free Survival (PFS) as an outcome measure. In the primary trial, PFS is measured using the time to disease progression or death from randomization up to approximately 34 months. In contrast, the secondary trial measures the 6-month PFS rate, which is the proportion of participants who did not progress or die within the first 6 months. Despite the different methods used to assess PFS in each trial, they both evaluate the duration or duration proportion of patients not experiencing disease progression or death. The statement is entailed since both trials share the common outcome measure, PFS, and investigate its measurement in their respective patient cohorts.</s>",
        "contradict": "The statement does not provide sufficient information to determine if it can be contradicted by the CTRs, as it only mentions that both trials measure PFS. However, the primary trial measures PFS using the time from randomization to disease progression or death, while the secondary trial measures PFS at 6 months as the proportion of participants who are progression-free at that time. These two measurements are not directly comparable, so no contradiction can be definitively established without additional context.</s>"
    },
    "8de31b0f-7127-4c8b-b5e0-060e7a83fae5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01299038",
        "Statement": "Joe has a known history of Hepatitis. However as he is over the age of 18 is still eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trial expert is entailed by the primary CTR inclusion criteria as the patient, identified as Joe, satisfies the age requirement (minimum age 18 years) stated in the CTR. However, the statement does not explicitly contradict or fail to align with any of the exclusion criteria mentioned in the CTR. The CTR mentions that participants with \"known history of Hepatitis C or active hepatitis B infection (baseline testing not required)\" are excluded from the study. Although the statement does mention \"known history of Hepatitis\" without specifying the type, it does not contradict the CTR as Hepatitis is a broader term that includes Hepatitis B and C, but the statement does not explicitly state that Joe has Hepatitis B or C. Thus, the statement made by the expert is harmonious with the clinical trial data and can be entailed by the information presented in the primary CTR.</s>",
        "contradict": "The patient \"Joe\" being eligible for the primary trial despite having a known history of hepatitis is contradictory to the exclusion criteria stated in the CTR. Hepatitis is listed as a condition that would make a participant ineligible for the trial (known history of Hepatitis C or active hepatitis B infection, with baseline testing not required).</s>"
    },
    "207a1d82-a61b-4b5f-bebf-0706def6729d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008150",
        "Secondary_id": "NCT00375427",
        "Statement": "In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"In total the secondary trial recorded only 1 more case of Mucosal inflammation than the primary trial\" can be entailed by the information present in the CTRs since both report a total of zero cases in Adverse Events 1 for the primary trial and one case in Adverse Events 2 for the secondary trial in the Mucosal inflammation category. Therefore, the difference between the number of cases reported is exactly one.</s>",
        "contradict": "The statement can be contradicted by the CTR information as the counts of Mucosal inflammation reported in the primary and secondary trials are equal (each reporting 0 cases), not one more in the secondary trial as stated.</s>"
    },
    "968aeaf1-44b9-4454-8c99-e3c207037485": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01491737",
        "Statement": "There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial\" does not directly entail the information present in the CTRs since there is a contradiction between the number of reported cases and the data presented. \n\nIn the CTR for the primary trial, there are separate counts for each type of adverse event. The number of cases for Febrile neutropenia is 4, but there is no reported occurrence of heart failure in cohort 1, as shown in the given data.\n\nTherefore, the information contained in the expert statement cannot be directly entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There were 4 cases of Febrile neutropenia and heart failure in cohort 1 of the primary trial\" cannot be directly inferred or is contradictory to the information present in the provided CTRs. According to the CTR, there were only 3 cases of Febrile neutropenia in the primary trial (in cohort 1 and cohort 2 combined) and no cases of heart failure were reported in either the primary or secondary trial.</s>"
    },
    "2b79f9cc-4262-4353-ad28-91cda07a9b9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02988986",
        "Statement": "Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have AST, ALT and ALP < 1.5 ULN to participate in the primary trial\" is entailed by the information present in the CTRs, as the CTRs specify that \"Renal status: Creatinine clearance 50 mL/min based on Cockcroft-Gault estimate or based on urine collection; Hepatic status: Serum total bilirubin 1 x ULN, aspartate aminotransferase and alanine aminotransferase 1.5 x ULN, and alkaline phosphatase 1.5 x ULN.\" Since AST, ALT, and ALP are all liver enzymes, and the CTRs state that their values should not exceed their respective upper limits of normal (ULN), it follows that patients must have these values less than 1.5 times the ULN to participate in the primary trial.</s>",
        "contradict": "The statement \"Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial\" is contradicted by the CTRs because they state different liver function test values as inclusion criteria. Specifically, the CTRs allow for a higher serum total bilirubin (up to 1.5 x ULN) and higher values for aspartate aminotransferase and alanine aminotransferase (up to 1.5 x ULN) for some patients.</s>"
    },
    "d56ffd81-4007-477b-b3c3-0fdb89806931": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00723398",
        "Statement": "Patients with diabetes insipidusare not suitable for the primary trial.",
        "Label": "Contradiction",
        "entail": "Diabetes mellitus is listed as an exclusion criteria in the Primary Trial's Eligibility Criteria section. Diabetes insipidus and diabetes mellitus are distinct medical conditions. Diabetes mellitus is a metabolic disorder characterized by hyperglycemia, while diabetes insipidus is a disorder of water homeostasis. Therefore, since diabetes mellitus is an exclusion criteria in the primary trial, it logically follows that diabetes insipidus is also an exclusion criteria, as the former condition includes the latter. Hence, the statement is entailed by the information present in the Primary Trial's CTR.</s>",
        "contradict": "Diabetes mellitus is listed as an exclusion criterion in the primary trial's eligibility criteria. Therefore, patients with diabetes mellitus are not eligible for inclusion in this trial. Diabetes insipidus, however, is a different condition from diabetes mellitus; it is not mentioned as an exclusion criterion. Patients with diabetes insipidus could potentially meet the other inclusion criteria and thus, they are not explicitly ruled out by the CTR, contradicting the expert's statement.</s>"
    },
    "f62e6c20-862b-4ce3-9121-0d93ff050839": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01373671",
        "Secondary_id": "NCT00686127",
        "Statement": "Lidoderm products are used in a intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Lidoderm products are used in intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial\" is entailed by the CTR data as follows:\n\n1. FFDM (Full Field Digital Mammography) is a type of intervention mentioned in the PRIMARY CTR, specifically in Intervention 1.\n2. Lidocaine Patch is a type of intervention mentioned in the SECONDARY CTR, specifically in Intervention 1.\n3. FFDM exam and DBT scan are the specific procedures under Intervention 1 in the PRIMARY CTR, but FFDM is the common component, making it an FFDM product.\n4. Lidocaine patch is applied topically in Intervention 1 of the SECONDARY CTR, making it a product.\n5. Both FFDM product (PRIMARY CTR) and Lidocaine product (SECONDARY CTR) are used in their respective trial arms, as stated in the expert's claim.\n\nTherefore, the entailment exists because the statement is logically derived from the information provided in the CTRs.</s>",
        "contradict": "The statement \"Lidoderm products are used in intervention arm 1 of the secondary trial, and an FFDM product is used in arm 1 of the primary trial\" can be contradicted by the information present in the given CTRs. While Lidoderm products are indeed used in intervention arm 1 of the secondary trial, the primary trial's arm 1 involves the use of both FFDM (Full-Field Digital Mammography) and DBT (Digital Breast Tomosynthesis), neither of which are specifically stated to be Lidoderm products. Therefore, the statement makes an unwarranted assumption about the content of arm 1 in the primary trial.</s>"
    },
    "833eeb4b-4921-468a-947d-bacfc7816ae6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02162719",
        "Secondary_id": "NCT02131064",
        "Statement": "the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR\" can be entailed by the information present in the CTRs because both trials involve the use of pertuzumab, which is a common intervention in both trials. The secondary trial specifically assesses tpCR, as stated in its outcome measurement description. The primary trial may not have explicitly mentioned tpCR in its outcome measurement, but the progression-free survival (PFS) measurement, which is reported in the trial's results, indirectly suggests the evaluation of the treatment's impact on tumor response and disease progression. Since tpCR is an important indicator of the treatment effect on the tumor before surgery, it can be inferred that both trials are investigating the effect of their interventions, ipatasertib plus paclitaxel in the primary trial and TCH + P and T-DM1 + P in the secondary trial, on patient tpCR.</s>",
        "contradict": "The statement that \"the primary trial and the secondary trial investigate the effects of their intervention on patient tpCR\" is not directly contradicted by the information present in the CTRs. However, the trials may differ in their primary outcomes and the assessment of tpCR is a secondary outcome in both trials, so it is essential to note that any comparative analysis of the effect of interventions on tpCR should be made with caution, considering other potential confounding factors or differences between trials. The trials might employ distinct treatment regimens, patient selection criteria, or assessment methods for tpCR, which could influence the observed outcomes. Therefore, it's crucial to examine the full context and details of each trial, including their study designs, methods, and results, before drawing definitive conclusions about the entailment relationship between the statement and the CTRs.</s>"
    },
    "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn't record any GI adverse events\" is entailed by the CTRs as follows:\n\n1. In the CTR for the primary trial, under Adverse Events 1 section, there are no records of any GI-related adverse events (Hemorrhage, GI - stomach; Perforation, GI - colon; Ulcer, GI - stomach) among the 52 participants.\n2. In contrast, in the CTR for the secondary trial, under Adverse Events 1 section, there are records of several GI-related adverse events (Hemorrhage, GI - stomach; Perforation, GI - colon; Ulcer, GI - stomach) among the 76 participants.\n\nHence, the statement that the secondary trial records several GI adverse events, whereas the primary trial doesn't, is an accurate reflection of the data presented in the provided CTRs.</s>",
        "contradict": "The statement does not take into account the specific types of gastrointestinal adverse events reported in each CTR. In the primary trial, there were no reports of hemorrhage, perforation, or ulcer in the GI tract. However, the secondary trial recorded one instance each of hemorrhage and perforation in the GI tract. While the primary trial does not report any GI adverse events, the secondary trial does report some, but they are different in nature from those in the primary trial. Therefore, the statement is not an entailed relation between the CTRs. Instead, it is a statement that may be true or false depending on the specific definitions and types of GI adverse events under consideration.</s>"
    },
    "c317750d-6ef7-494d-8040-2c7fa3d777fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary trial and the primary trial both used MRI for their interventions.",
        "Label": "Entailment",
        "entail": "Both trials involve Magnetic Resonance Imaging (MRI) in their interventions. In the primary CTR, MRI is mentioned as part of the intervention for the Letrozole study, where breast MRIs are conducted for healthy postmenopausal women before and after the treatment. In the secondary CTR, the intervention includes MRI for both breast cancer patients and healthy volunteers, with detailed descriptions of the imaging protocol. Given that MRI is an essential aspect of both interventions in both trials, the expert's statement is an entailed conclusion from the provided CTRs.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial both used MRI for their interventions\" is not contradicted by the information present in the CTRs. However, it can be misleading as the use of MRI and the details of the MRI intervention differ significantly between the two trials. \n\nIn the primary trial, MRI is used to assess the safety of breast enhancement with Letrozole, and patients undergo only two MRI scans - one at baseline and another post-treatment. Letrozole is administered just prior to the second MRI scan. In contrast, in the secondary trial, MRI is used for diagnostic purposes, and the workflow involves screening for contraindications, contrast injection, and SWIFT acquisition. The SWIFT acquisition includes obtaining pre-contrast T1-weighted images, continuous acquisition during and after contrast injection, and potential acquisition of late enhancement images. The number of patients to be scanned and the diagnostic performance analysis also vary.\n\nTherefore, while both trials involve MRI, the specific applications, procedures, and purposes vary, and the statement could be considered misleading without further context to clarify the differences between the trials.</s>"
    },
    "87eca8d2-72fe-4285-9884-6d2ec7bae6df": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00567190",
        "Statement": "There was exactly the same proportion of anemic patinets in both cohorts of the primary trial.",
        "Label": "Contradiction",
        "entail": "Both the primary and secondary trial's adverse events sections report the number of participants with anemia, specifically 3/396 in the primary trial and 3/408 in the secondary trial. The proportion of anemic patients in both trials is equal, as claimed in the statement, since the number of anemic patients is identical for each. The information in the statement is entailed by the data in the CTRs, as the assertion is supported by the reported numbers and does not contradict any descriptions in the CTRs.</s>",
        "contradict": "The statement \"There was exactly the same proportion of anemic patients in both cohorts of the primary trial\" is contradicted by the information in the CTRs because the proportion of anemic patients is different between the two cohorts, with a rate of 0.76% in the first cohort (3/396) and 0.74% in the second cohort (3/408).</s>"
    },
    "7a87c605-fc41-4d0a-9291-85e88f6eb510": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s).",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial is testing a Gel which is applied inside the vagina, and the primary trial is testing an intervention which requires daily radiation of the breast(s)\" is entailed by the CTRs, as follows:\n\n1. Both trials involve interventions that are applied to different parts of the body:\n   a. Secondary trial: Vaginal application of gel (INTERVENTION 1 and 2)\n   b. Primary trial: Radiation therapy to the breast (INTERVENTION 1 and 2)\n\n2. The statement accurately describes that the interventions in each trial are administered differently:\n   a. Secondary trial: Gel application inside the vagina\n   b. Primary trial: Daily radiation of the breast(s)</s>",
        "contradict": "The statement by the clinical trial expert does not contradict the information present in the CTRs directly, but it does omit crucial details about the nature of the interventions being tested in each trial. The CTRs provide more specific information regarding the interventions, including the use of radiation therapy in the primary trial and vaginal gels in the secondary trial. The statement's oversimplification of the interventions may lead to misunderstandings or incorrect assumptions, as it does not account for the differences in intervention types between trials. However, it does not contradict any specific information within the CTRs themselves.</s>"
    },
    "fbb853c9-bed4-4cde-a283-2d91b23d35bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report results on pathologic evidence of invasive disease withing their patient cohorts after their interventions, using different outcome measurements.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial both report results on pathologic evidence of invasive disease within their patient cohorts after their interventions, using different outcome measurements\" is entailed by the information present in the CTRs because:\n\n1. The primary trial reports on the absence of invasive disease (i.e., pCR) in the breast and lymph nodes for 5.4% of participants using RECIST 1.1 criteria after 6 months of therapy with trametinib (singly and in combination with Akt inhibitor GSK2141795).\n2. The secondary trial reports on the percentage of participants with pCR in the breast and lymph nodes after 26 weeks of therapy, including 2 weeks of run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel (alone or in combination). While the definition of pCR slightly varies between trials, they both refer to the absence of invasive disease. The primary trial measures ORR, while the secondary trial reports the percentage of participants who achieved pCR, but both trials focus on the presence or absence of invasive disease in their patient cohorts.\n\nHence, the statement that the trials report results on pathologic evidence of invasive disease within their patient cohorts after their interventions, using different outcome measurements, can be entailed by the data presented in both CTRs.</s>",
        "contradict": "The statement does not provide sufficient detail to be directly contradicted by the given CTRs. However, it contains an inaccuracy: the statement asserts that both trials report results \"on pathologic evidence of invasive disease,\" but the primary trial does not report results in this format; instead, it uses objective response rate (ORR) as its outcome measurement. This discrepancy between the statement and the CTRs' content could lead to misunderstandings or incorrect conclusions. To avoid confusion, it is necessary to clarify the specific meaning of each trial's outcome measurement and results.</s>"
    },
    "c3cc3621-a8ce-4f0d-a150-7e627f36e7c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00482391",
        "Statement": "Patients with a QT interval longer than half a second are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a QT interval longer than half a second are excluded from the primary trial\" is entailed by the information in the CTR as there is an explicit exclusion criterion in the Primary Trial section: \"No QT prolongation (> 500 ms)\". The statement is a consequence of this exclusion criterion, as a QT interval longer than half a second is indicative of QT prolongation.</s>",
        "contradict": "The statement is contradictory to the CTR information because the CTR explicitly states that no QT prolongation (> 500 ms) is allowed, whereas the expert statement mentions a QT interval longer than half a second as an exclusion criterion, which is shorter than the specified 500 ms limit.</s>"
    },
    "84aa97cf-efce-484e-825e-5af509e5988f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01441596",
        "Statement": "Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy, up to 160% of the starting dose.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR as follows: In the primary trial's Intervention 1, the starting dose of Afatinib monotherapy is 40 mg per day. The statement allows for doses up to 160% of the starting dose, which is 80 mg per day. This is within the range of dosages mentioned in the CTR, as the dosage can be escalated to 50 mg per day if well tolerated. Therefore, the statement does not contradict the CTR and is harmonized with the data provided, thus establishing entailment.</s>",
        "contradict": "The statement is contradictory to the information presented in the CTR because the primary trial Intervention 1 specifies a maximum dose escalation to 50 mg per day, which is not 160% of the starting dose (40 mg). Therefore, patients in cohort 1 cannot be receiving doses up to 160% of the starting dose based on the information provided by the CTR.</s>"
    },
    "a40e172a-8839-499d-896d-be71a7ca4905": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03076190",
        "Secondary_id": "NCT03196635",
        "Statement": "Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions, however all participants taking part in these studies will need to receive stem cell transplants.",
        "Label": "Contradiction",
        "entail": "The statement does not follow directly from the information in the given CTRs as there is no mention of stem cell transplants in either the primary or secondary trial interventions. The CTRs merely detail the image evaluation process for both trials, and no entailment can be established based on the provided information.</s>",
        "contradict": "The statement that \"Molecular Breast Imaging is not applied in either the primary trial or the secondary trial interventions\" is consistent with the provided CTR information. However, the subsequent part of the statement, that \"however all participants taking part in these studies will need to receive stem cell transplants,\" is contradictory to the information in the CTRs. The CTRs do not contain any mention of stem cell transplants as part of the interventions for either the primary or secondary trials.</s>"
    },
    "9e972e33-9ecd-4a8b-8337-7bee209f790b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02202252",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is assesment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2.",
        "Label": "Contradiction",
        "entail": "The statement \"The difference between cohort 1 and 2 of the primary trial is assessment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2\" can be entailed by the CTR information as follows:\n\nCohort 1 of the primary trial involves the insertion of a single drain below the lower flap, directing it to the axilla. Ultrasonography after drain removal is also mentioned for examining seroma under the flaps and in the axilla.  (From Intervention 1 section in the CTR).\n\nCohort 2 of the primary trial involves the insertion of two negative pressure drains; one into the axilla and the other below the lower flap. Ultrasonography after drain removal is also mentioned for examining seroma under the flaps and in the axilla. (From Intervention 2 section in the CTR).\n\nThus, the only difference between the two cohorts as per the CTR is the number of drains inserted (one vs. two) and the ultrasonography examination, which is explicitly stated in the expert's claim. Therefore, the expert's statement is entailed by the CTR information.</s>",
        "contradict": "The statement \"The difference between cohort 1 and 2 of the primary trial is assessment by ultrasonography and the insertion of an additional negative pressure drain for patients in cohort 2\" can be contradicted by the information present in the CTRs because both cohorts undergo ultrasonography after the removal of the drains, and both groups, whether having one or two negative pressure drains inserted, undergo the same procedure. Therefore, the statement does not accurately convey the difference between the two cohorts as specified in the CTRs.</s>"
    },
    "f29768ba-5d79-4528-839f-933ab13faaa1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01943916",
        "Secondary_id": "NCT01653964",
        "Statement": "All subjects in the primary trial and the secondary trial will be adminstered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging.",
        "Label": "Contradiction",
        "entail": "In the primary trial, Intervention 1 states that molecular breast imaging is performed for each subject after the injection of 4 mCi Tc-99m sestamibi. In the secondary trial, Intervention 1 also specifies that molecular breast imaging is carried out after the administration of 4 mCi Tc-99m sestamibi. Therefore, the statement made by the clinical trial expert is entailed by the data provided in both trials since it aligns with the identical condition stated (the use of 4 mCi Tc-99m sestamibi for molecular breast imaging).</s>",
        "contradict": "The statement's assertion that \"All subjects in the primary trial and the secondary trial will be administered 4 mCi Tc-99m sestamibi and undergo Molecular breast imaging\" is contradicted by the information in the CTRs, as the primary trial specifies each subject serving as their own control and receiving both test and control modalities with 4 mCi and 8 mCi of Tc-99m sestamibi, respectively. The secondary trial also administers two different doses, but it's only stated for Molecular breast imaging in that trial, not for both trials combined. Therefore, it does not entail that all subjects in both trials will receive the same dose and undergo imaging with the same dose only.</s>"
    },
    "343e0a32-aebe-4bbb-97c0-b2c597c36802": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00392392",
        "Secondary_id": "NCT00503906",
        "Statement": "the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants. ",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial records two different types of pain in its adverse events, in the abdomen and chest area, the secondary trial does not record any types of pain in its participants\" is entailed by the information in the CTRs because:\n\n1. The CTR for the primary trial specifies that there was one case (1/29) of pain in the abdomen and one case (1/29) of pain in the chest.\n2. The CTR for the secondary trial does not mention any cases of pain in any part of the body.\n3. The absence of pain records in the secondary trial does not contradict the presence of pain records in the primary trial, as the trials involved different participant cohorts.\n\nTherefore, the statement is logically consistent with the information in the CTRs and can be considered entailed by it.</s>",
        "contradict": "The statement can be contradicted by the CTRs because, while it's true that the Primary Trial records instances of pain in the abdomen and chest area, the Secondary Trial reports pain-related adverse events as well, including pain in the peripheral nerves (Peripheral Neuropathy) and shortness of breath (Shortness of breath), which can also be considered types of pain. The statement's assertion that the secondary trial doesn't report any types of pain is not in line with the CTR data.</s>"
    },
    "4d51608c-b0d8-4019-9b9a-34cf1c3d5087": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg.",
        "Label": "Contradiction",
        "entail": "The statement \"All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg\" is entailed by the CTR data in the following ways for each intervention cohort:\n\nCohort 1 (Lapatinib + Placebo):\n- Participants receive Lapatinib 1500 mg PO QD: Matches the stated Lapatinib dose.\n- Participants receive Placebo: Does not directly entail Pazopanib 800 mg, but since the expert statement includes both Lapatinib and Pazopanib, it is implicit that Pazopanib 800 mg is given to the placebo group in the secondary trial, making it consistent with the CTR.\n\nCohort 2 (Lapatinib + Pazopanib):\n- Participants receive Lapatinib 1500 mg PO QD: Matches the stated Lapatinib dose.\n- Participants receive Pazopanib 800 mg: Matches the stated Pazopanib dose.\n\nTherefore, the statement is entailed by the CTRs.</s>",
        "contradict": "The statement \"All participants in the primary trial are administered with Lapatinib 1500 mg PO QD and Pazopanib 800 mg\" cannot be directly derived from the CTRs. While some participants in Cohort 1 of the primary trial did receive both Lapatinib 1500 mg and Pazopanib 800 mg, others received Lapatinib 1500 mg and a placebo instead. Thus, the statement does not entail the information in the CTRs and can be contradicted by them.</s>"
    },
    "7bb88699-1536-4fdc-9cb2-c5ef350d559b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00331552",
        "Secondary_id": "NCT01306942",
        "Statement": " trastuzumab was used for the interventions in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "Both trials, primary and secondary, include the use of trastuzumab in their respective interventions as follows:\n\nPrimary Trial: Trastuzumab is mentioned as a possible treatment option for patients with HER2/neu 3+ disease, given IV.\n\nSecondary Trial: Trastuzumab is an integral part of the interventions for both cohorts in the secondary trial. It is administered IV weekly or every 3 weeks in combination with other drugs.\n\nHence, the statement that \"trastuzumab was used for the interventions in the primary trial and the secondary trial\" can be entailed by the information presented in the CTRs.</s>",
        "contradict": "Although trastuzumab is indeed used in both the primary and secondary trials, the statement can be misleading because it does not specify that the use of trastuzumab differs between the trials. In the primary trial, trastuzumab is used in combination with cyclophosphamide and pegylated doxorubicin, while in the secondary trial, trastuzumab is used in combination with dasatinib and paclitaxel. This difference in intervention combinations can lead to different effects and implications, making it essential to consider the context in which the drug is used when evaluating clinical data.</s>"
    },
    "c86ef61b-7565-465a-82ba-25e7ac050ccc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02139358",
        "Secondary_id": "NCT02574455",
        "Statement": "There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial\" can be entailed by the information present in the CTRs if we define \"hemorrhaging\" as an event inclusive of duodenal hemorrhage, as both trials report the same adverse effect in the primary trial, and no such event is reported in the secondary trial.</s>",
        "contradict": "The statement \"There was one case of hemorrhaging in the primary trial, and no recorded cases in the secondary trial\" can be contradicted by the information present in the CTRs as follows: \n\n- Contradiction with respect to the primary trial: In the primary trial, there was one reported case of Duodenal hemorrhage (a type of hemorrhaging), whereas the statement claims that there was one \"case of hemorrhaging.\" However, the statement does not mention which specific type of hemorrhaging it refers to.\n\n- Contradiction with respect to both primary and secondary trials: The statement claims that there were no recorded cases of hemorrhaging in the secondary trial. However, the CTRs report one case of Skin infection in the secondary trial, which is listed as an adverse event and can potentially include bleeding as a symptom.\n\nThus, the statement is contradictory to the information present in the CTRs due to both the lack of specification regarding which type of hemorrhaging the statement refers to in the primary trial and the potential for unreported hemorrhaging cases in the secondary trial.</s>"
    },
    "58dec898-e0af-41c1-96f9-7163d3e3e855": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02019277",
        "Secondary_id": "NCT00863655",
        "Statement": "the primary trial and the secondary trial recorded three of the same types of adverse events",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial recorded three of the same types of adverse events\" can be entailed by the information present in the CTRs because both trials report occurrences of \"Febrile neutropenia,\" \"Anaemia,\" and \"Pyrexia.\" These adverse events appear in both trials, with varying frequencies: Febrile neutropenia in both trials, Anaemia in primary (1/50) and secondary (28/482, 22/238), and Pyrexia in primary (7/50) and secondary (21/482, 21/238). The difference in frequencies does not contradict or negate the presence of the same types of adverse events across the trials.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial recorded three of the same types of adverse events\" cannot be directly contradicted by the provided CTR data. However, it can be misleading without additional context since the CTRs list several different adverse event types. The statement is true that three types of adverse events were shared between the trials (anaemia, febrile neutropenia, and diarrhea). Yet, the statement does not convey the full scope and extent of the adverse events in both trials, potentially leading to inaccurate conclusions. The number, frequency, and severity of these adverse events could be significantly different between trials. To accurately determine the semantic entailment relationship, a more comprehensive comparison would be needed, including the total number, percentage, and specific details of each adverse event type in both trials.</s>"
    },
    "5cf74526-9f91-498d-a13a-6393dcd45b7b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02291913",
        "Statement": "One patient in the primary trial suffered from an inflammation of the liver.",
        "Label": "Contradiction",
        "entail": "The statement \"One patient in the primary trial suffered from an inflammation of the liver\" cannot be directly entailed from the information in the CTRs. The CTRs do not provide any mention of liver inflammation or any related conditions such as hepatitis, hepatitis-related symptoms, or liver function tests in either the adverse events sections or the results sections. The information in the statement contradicts the given CTR data as no instances of hepatitis, hepatitis-related symptoms, or any other liver conditions were reported in the Primary Trial's Adverse Events section.</s>",
        "contradict": "The expert's statement does not contradict the information in the CTR directly, as no mention of liver inflammation (hepatitis) is present in either the primary or secondary CTRs. However, the statement can be contradicted if it is implied that the patient experiencing liver inflammation was from the primary trial, as no such condition is listed among the adverse events.</s>"
    },
    "154caa20-3be1-4cee-a838-2d90b44566c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00191269",
        "Statement": "the primary trial did not use PFS to evaluate the performance of its interventions.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial did not use PFS (Progression-Free Survival) to evaluate the performance of its interventions\" can be entailed by the information present in the CTRs since PFS was not explicitly mentioned in the \"RESULTS\" section of the primary trial as a measure used to evaluate treatment effectiveness. In both \"RESULTS 1\" and \"RESULTS 2,\" the outcome measurement used is \"Tumor Response\" based on RECIST criteria.</s>",
        "contradict": "The statement \"the primary trial did not use PFS to evaluate the performance of its interventions\" is contradicted by the lack of information aboutProgression-free Survival (PFS) in the provided CTRs. The statement implies that PFS was not considered as an outcome measure in the primary trial, but the CTRs do not provide any details about PFS assessment. The absence of evidence for or against the use of PFS in the primary trial does not equate to it not being used.</s>"
    },
    "c40d8532-4e66-4eef-9644-91f20a02066d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02001974",
        "Statement": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"No cases of Oesophageal adenocarcinoma were recorded in the primary trial\" is entailed by the CTR data as the Adverse Events section of the primary trial reports 0/4 instances of Oesophageal adenocarcinoma among the trial participants.</s>",
        "contradict": "The statement \"No cases of Oesophageal adenocarcinoma were recorded in the primary trial\" is contradictory to the CTR information because the CTR for the primary trial reports that zero out of the four participants exhibited Oesophageal adenocarcinoma (0/4 or 0.00%). However, the statement claims that \"No cases\" of this condition were recorded at all in the trial, which goes beyond the information in the CTR and is not directly entailed by it.</s>"
    },
    "3d450be5-4587-48e5-ae2e-745623606631": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01289353",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary trial and the secondary trial both administer bi-weekly oral Carboplatin to their test groups.",
        "Label": "Contradiction",
        "entail": "Neither of the trials administers oral Carboplatin on a bi-weekly basis as stated. In the primary trial, Carboplatin is administered intravenously (IV) weekly for 6 weeks with a specific AUC. In the secondary trial, Carboplatin doses are given IV prior to stem cell transplantation, also not on a bi-weekly basis.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as neither trial describes the administration of Carboplatin as bi-weekly or oral. In the primary trial, Carboplatin is given intravenously (IV) weekly for six weeks with a specific dose and schedule. In the secondary trial, it is given IV as part of a high-dose chemotherapy regimen with a different dosing schedule. Neither trial mentions oral administration for Carboplatin.</s>"
    },
    "fa28753a-aa3b-4642-9fd4-a2414fd8a472": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00943670",
        "Statement": "The Change From Baseline in Mean Duration of the QTcF Interval for patients in the primary trial was at its highest on Day 1 of the third cycle, post T-DM1 intravenous (IV) infusion.",
        "Label": "Entailment",
        "entail": "The expert's statement entails the CTR data because it correctly references the primary trial and the T-DM1 arm, and it accurately reflects the trend in the change from baseline in mean QTcF interval observed in the CTR. The CTR states that the greatest change from baseline in mean QTcF interval occurred on Cycle 3 Day 1, 15 minutes post-dose (4.7 milliseconds, Standard Deviation: 9.6) and on Cycle 3 Day 1, 60 minutes post-dose (4.7 milliseconds, Standard Deviation: 10.9), which is consistent with the expert's description of the highest change occurring on Day 1 of the third cycle post-T-DM1 infusion.</s>",
        "contradict": "The expert's statement is not directly contradictory with the CTR data; however, it can be misleading. The CTR data shows that the mean change from baseline in QTcF interval was highest at 4.7 milliseconds for both Cycle 3 Day 1 measurements (pre-dose and 15 minutes post-dose), and second highest at Cycle 1 Day 8 (-4.0 milliseconds). Therefore, the expert's statement is an oversimplification, as it fails to acknowledge the existence of a higher change in the primary trial during Cycle 1.</s>"
    },
    "5e700303-cd26-4024-a260-62f6a1c297ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01000662",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial is testing a Gel which is applied to the breast, whereas the primary trial is testing an intervention which requires daily radiation of the breast\" is entailed by the information in the CTRs as follows:\n\n1. The primary trial involves radiation therapy as an intervention, which is applied to the breast.\n2. The secondary trial involves vaginal gel as an intervention.\n3. The statement correctly identifies the breast as the site of application for the intervention in the primary trial.\n4. The statement incorrectly states that the secondary trial is testing a gel applied to the breast. However, the CTR for the secondary trial specifies that the gel is administered vaginally, not to the breast.\n5. Despite this error in the statement, the general distinction between the trials testing different interventions - radiation therapy and vaginal gel - is entailed by the information in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the secondary trial described in the statement does not match the actual intervention described in the given CTRs, which involve vaginal gels rather than breast application as stated.</s>"
    },
    "4c4c191c-de68-44c8-a23c-2455acc43d46": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00371345",
        "Secondary_id": "NCT00475670",
        "Statement": "There is no overlap between adverse events obeserved in the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"There is no overlap between adverse events observed in the primary trial and the secondary trial\" can beentailed by the information present in the CTRs as neither of the trials share any common adverse event types among their lists. The primary trial lists adverse events including Nausea, Vomiting, Diarrhea, Abdominal Pain, Abdominal Pain Lower, Fatigue, Pyrexia, Oedema Peripheral, General Physical Health Deterioration, Pneumonia, Sinusitis, and Lobar Pneumonia. The secondary trial lists adverse events including Febrile Neutropenia, Neutropenia, Sudden Death, Bacterial Infection, Bronchitis, Sepsis, and Lymphoedema. Since none of these adverse event types appear in both trials, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There is no overlap between adverse events observed in the primary trial and the secondary trial\" is contradicted by the information present in the CTRs because the primary trial reported occurrences of ABDOMINAL PAIN LOWER, OEDEMA PERIPHERAL, GENERAL PHYSICAL HEALTH DETERIORATION, and PNEUMONIA, while the secondary trial reported occurrences of LYMPHOEDEMA, which are types of adverse events that overlap between the trials.</s>"
    },
    "e5a4cb11-2a00-4144-93ba-f5462d7efbf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01818063",
        "Secondary_id": "NCT00559507",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib.",
        "Label": "Entailment",
        "entail": "The statement asserts that in both primary and secondary trials, only saracatinib and veliparib are administered orally. This claim is in agreement with the CTR data. In the primary trial, arm 1 receives paclitaxel, carboplatin, doxorubicin, and cyclophosphamide intravenously, while arm 2 receives veliparib orally in addition to intravenous administration of paclitaxel and carboplatin. The secondary trial involves intravenous administration of saracatinib in arm 1 and oral administration of veliparib in the primary trial and intravenous administration of saracatinib in the secondary trial. Therefore, the statement is an entailed subset of the provided CTR information.</s>",
        "contradict": "The statement \"In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib\" is contradictory to the information present in the CTRs because in the primary trial, Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide are given intravenously, while in the secondary trial, Saracatinib is given orally but Paclitaxel and Carboplatin are still given intravenously. Therefore, there are drugs administered orally (Saracatinib) as well as intravenously (Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide) in both trials, contradicting the statement's assertion that only Saracatinib and Veliparib are given orally.</s>"
    },
    "03d72e5f-b921-4aeb-802c-4dc4ee1a7e4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01720602",
        "Secondary_id": "NCT00082810",
        "Statement": "the primary trial participants receive more anastrozole, letrozole and exemestane than patients in the secondary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, patients receive either anastrozole, letrozole, or exemestane as part of the AI therapy in addition to vorinostat. The frequency of AI therapy administration is for 4 weeks in the primary trial, whereas, in the secondary trial, patients receive fulvestrant and tipifarnib as a combination treatment instead of AI therapy. However, the primary trial patients do receive AI therapy for more weeks (4 weeks) than the secondary trial participants (no mention of AI therapy duration in the secondary trial). Since the primary trial patients receive AI therapy for more weeks and they receive more doses of anastrozole, letrozole, and exemestane during that time than patients in the secondary trial, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the primary trial involves the use of anastrozole, Letrozole, and exemestane as part of a combination therapy with vorinostat, whereas in the secondary trial, fulvestrant and tipifarnib are the administered agents. The statement does not take into account that both trials involve different treatments, and it solely focuses on the mentioned hormonal therapies. Therefore, it is incorrect to assume that primary trial participants receive more of these specific hormonal therapies based on the given information.</s>"
    },
    "27a4d1a8-185b-4483-85ce-0fbb3d323b99": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01945775",
        "Statement": "The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration.",
        "Label": "Contradiction",
        "entail": "The shortest PFS in the Talazoparib group (Result 1) was 8.6 months (7.2-9.3), which is over a month longer than the trial's maximum duration of 36.9 months. The statement's claim does not contradict the information in the CTR since no participant in the Talazoparib group reached the minimum definition of PFS (radiologic progressive disease or death due to any cause) within the trial's maximum duration. Therefore, the shortest PFS observed in the Talazoparib group was indeed longer than the study duration.\n\nFor Reference:\nThe primary trial defines PFS as \"time from randomization until the date of first documented radiologic progressive disease or death from any cause, whichever occurs first.\" The shortest PFS recorded in the CTR for the Talazoparib group is 8.6 months, and there is no evidence of a participant in this group experiencing radiologic progressive disease within 36.9 months, as per the CTR's description. Thus, the statement is entailed by the information in the CTR.</s>",
        "contradict": "The statement \"The shortest PFS in the Talazoparib group of the primary trial was over a month longer than the study duration\" is contradictory to the CTR information because, as stated in the CTR:\n\n1. The PFS analysis was performed by Kaplan-Meier method.\n2. In the Talazoparib group, the median PFS was 8.6 months with a 95% confidence interval of 7.2-9.3 months.\n3. The maximum duration of the trial was 36.9 months.\n\nThere is no indication in the CTR that any Talazoparib participant experienced a PFS shorter than one month or the study duration. Hence, the statement contradicts the CTR information.</s>"
    },
    "ff797dd4-0b4d-42fc-808d-27c439563ce2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01743560",
        "Statement": "By week 48 of the primary trial none of the patients had Complete Response, 7 had partial response and 15 had progressive disease.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR information as follows:\n\nIn the primary trial, there were no participants with a best overall response of Complete Response (CR) by week 48, 7 participants had a best overall response of Partial Response (PR), and 15 participants had a best overall response of Progressive Disease (PD) at week 48. The expert's statement directly mirrors these findings reported in the CTR. Additionally, the time frame of the expert's statement aligns with the specified time frame of week 48 as outlined in the CTR.</s>",
        "contradict": "The statement does not directly contradict the given CTR data. However, it omits mentioning the number of patients with stable disease (18 in the CTR), which, when considered in the context of the overall number analyzed (49), can result in a different interpretation of the proportion of patients who had progressive disease (15 in the CTR) compared to the expert's statement. This discrepancy could potentially lead to misunderstandings when comparing the results of the two trials.</s>"
    },
    "9f666667-0fde-4d79-b53c-33c0ffbbed90": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had fell down a flight of stairs and fractured her hip, she is excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "Paula's exclusion based on recent significant trauma (hip fracture) aligns with the primary trial's exclusion criteria stating subjects with \"significant cardiac events, arrhythmias or other cardiac conditions.\" Although her injury is not explicitly mentioned as a cardiac condition, it could be considered a significant trauma leading to potential complications or need for intervention, which falls under the broader category \"other conditions\" mentioned in the exclusion criteria. This interpretation is consistent with the provided clinical trial data, and Paula's exclusion is an entailed consequence.</s>",
        "contradict": "Paula's exclusion from the primary trial based on her hip fracture does not contradict the information provided in the CTRs, as they do not explicitly address eligibility criteria for hip fractures or falls. The given statement introduces new information not stated in the CTRs. However, Paula's exclusion based on her hip fracture can be inferred from the secondary exclusion criteria mentioned in the CTRs, as significant cardiac events, arrhythmias or other cardiac conditions were not specified as the reason for her exclusion.</s>"
    },
    "47084742-d031-4e59-865c-d8687282c782": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00494481",
        "Statement": "Paula recently had a heart attack, she is excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "Paula's exclusion from the trial based on her recent heart attack is entailed by the Primary Trial's Exclusion Criteria, which state that subjects with significant cardiac events or arrhythmias are excluded from participation.</s>",
        "contradict": "The statement \"Paula recently had a heart attack, she is excluded from the primary trial\" contradicts the information present in the CTRs because Paula's condition of having a significant cardiac event makes her ineligible for inclusion in the primary trial according to its exclusion criteria. However, the statement does not conform to the information provided as Paula's status as an excluded individual is stated as a result of her heart attack, whereas the CTR specifies \"Significant cardiac events\" as a reason for exclusion.</s>"
    },
    "ae583ea3-36a5-472c-acda-825cd7d513b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454805",
        "Statement": "In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2.",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2\" is entailed by the information in the CTRs because the CTRs do not report any cases of subendocardial myocardial infarction for either cohort 1 or 2 (as this condition is not listed under the Adverse Events section for either). The absence of a reported event in the CTRs implies that there were no cases of that event during the trial, and thus the expert's statement harmonizes with this information without contradiction.</s>",
        "contradict": "The statement \"In the primary trial there were no cases of subendocardial myocardial infarction in cohort 1 or 2\" cannot be determined to be either entailed or contradictory based on the given CTR information. Subendocardial myocardial infarction is not mentioned in the provided CTRs as an adverse event for cohort 1 or 2 in either trial. Hence, the statement is neutral with respect to the given CTR data.</s>"
    },
    "a18c447b-de08-48ef-8e65-0ecaa775c2b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00206427",
        "Statement": "A patient in the primary trial had a vaginal fungal infection.",
        "Label": "Contradiction",
        "entail": "The statement \"A patient in the primary trial had a vaginal fungal infection\" cannot be directly entailed by the provided CTR information as there is no mention of any type of infection related to the vaginal area in either of the trials. The CTR only reports on adverse events such as Neutropenia, Hypocalcemia, Left Ventricular Systolic Dysfunction, Constipation, Mucositis-oral, Infection-oral thrush, and rash, but none of these conditions specify a vaginal fungal infection. Consequently, the given statement is not substantiated by the provided clinical trial data and does not harmonize with the descriptions in the CTRs.</s>",
        "contradict": "The statement \"A patient in the primary trial had a vaginal fungal infection\" cannot be definitively contradicted by the given CTR information. However, it does not find substantiation in the CTRs as there is no mention of vaginal infections or fungal infections in either the primary or secondary CTRs. Therefore, the statement is not semantically entailed by the provided Clinical Trial Reports.</s>"
    },
    "18b900fb-b071-43df-b37d-c68a89ef78c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00050167",
        "Statement": " Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial\" is entailed by the CTR inclusion criteria as stated: \"Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible.\"</s>",
        "contradict": "The statement \"Patients with metastasis in four or more axillary lymph nodes are eligible for the primary trial\" contradicts the information present in the CTRs as per the exclusion criteria. According to the CTR for the primary trial, patients with N2 (metastasis in four to nine axillary lymph nodes) are eligible, but those with pN2b (metastasis in clinically apparent internal mammary lymph nodes in the absence of axillary lymph node metastasis) are not eligible. However, the statement incorrectly implies that all patients with metastasis in four or more axillary lymph nodes are eligible when in fact only those with axillary lymph node metastasis are eligible based on the provided CTR information.</s>"
    },
    "ebdf2841-b5e0-431a-8dc7-e100c5d27ccf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with Grade III peripheral neuropathy or above are eliminated from participation in the primary trial\" is entailed by the information in the CTRs as the CTR for the primary trial specifies \"Grade 2 peripheral neuropathy\" as an exclusion criterion. Therefore, patients with a higher degree of peripheral neuropathy, namely Grade III or above, are implicitly excluded from the trial.</s>",
        "contradict": "The statement contradicts the CTR as it mentions the exclusion of patients with \"Grade III peripheral neuropathy or above,\" while the primary trial's inclusion/exclusion criteria do not explicitly state this condition in the exclusion list. The stated condition, Grade III peripheral neuropathy, is not listed among the exclusion criteria for the given CTR.</s>"
    },
    "d56745c3-ba0b-4b42-b3cf-ac060f658d83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00670982",
        "Statement": "Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia .",
        "Label": "Contradiction",
        "entail": "The statement \"Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia\" cannot be strictly entailed by the provided CTRs as there is no mention of acute coronary syndrome as an adverse event in the Primary Trial's Adverse Events 1 section. However, it can be inferred that the statement is likely inaccurate based on the provided data, as the frequency of acute coronary syndrome (0/29) is lower than any individual adverse event reported in the Primary Trial (ranging from 3.45% to 17.24%), contradicting the claim of it being the most prevalent adverse event.</s>",
        "contradict": "The statement \"Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia\" is contradicted by the data in the CTR as no case of acute coronary syndrome was reported in the primary trial's Adverse Events 1 section.</s>"
    },
    "0ef77b5d-684a-4a87-bf61-8d4bc9975b7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01446159",
        "Statement": "the primary trial only had a total of 6 patients in across both its cohorts.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial only had a total of 6 patients in across both its cohorts\" can be entailed by the information in the CTRs as follows: \n\nThe Adverse Events sections of the CTRs provide the number of patients (3 in each cohort) who experienced specific adverse events. Since the total number of patients across both cohorts is 6, the statement is an entailed consequence of the CTR data.</s>",
        "contradict": "The statement \"the primary trial only had a total of 6 patients in across both its cohorts\" contradicts the information present in the CTRs as each CTR indicates a total of 3 patients in the respective trials.</s>"
    },
    "03c7f31f-788c-4edb-a885-b6cb0fca05da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00375505",
        "Statement": "In the primary trial patients in control group had a Z-score of 0.037, higher than the test group score. ",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR information as follows:\n\n1. The statement refers to the \"primary trial\" which aligns with the first set of CTR data provided.\n2. The statement mentions the \"control group\" and \"test group\" which corresponds to the \"Placebo\" and \"Zometa\" groups in the CTRs.\n3. The statement asserts that the mean Z-score for the control group (Placebo) was higher than the test group (Zometa).\n4. The CTRs provide the mean Z-score values for both groups. In the primary trial, the mean Z-score for the Placebo group is indeed -0.075 and for the Zometa group is 0.037.\n5. The difference in mean Z-scores supports the statement, implying that the patients in the control group had a higher Z-score than those in the test group.</s>",
        "contradict": "The information in the expert's statement contradicts the CTR data, as the results for the Placebo group (Arm/Group Title: Placebo) in the CTR indicate a mean (Standard Deviation) Z-score of -0.075 (0.041). This value is lower than the Z-score for the Zometa group (Arm/Group Title: Zometa) with a mean (Standard Deviation) Z-score of 0.037 (0.042). Therefore, the expert's statement, which suggests the opposite, is not entailed by the CTR information.</s>"
    },
    "e43c01e9-20a2-4435-a32b-224d5f460d7c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months.",
        "Label": "Entailment",
        "entail": "The statement that \"The minimum Progression Free Survival (PFS) for patients in cohort 1 of the primary trial was 1.6 months\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the outcome measure for assessing treatment efficacy was PFS (defined as the time from randomization to the earlier of disease progression or death due to any cause).\n2. PFS was evaluated every 6-9 weeks following treatment initiation using RECIST v1.1 criteria for disease progression, which includes a 20% increase in the sum of the longest diameter of target lesions, progression in a non-target lesion, or the appearance of new lesions.\n3. The results for cohort 1 (Arm/Group Title: Capecitabine) in the primary trial reported a median (95% CI) PFS of 1.6 (1.6 to 3.2) months. The minimum value within this interval (1.6 months) can be considered the smallest PFS duration observed in this cohort. Thus, the statement \"The minimum Progression Free Survival for patients in cohort 1 of the primary trial was 1.6 months\" is entailed by the information in the CTR.\n\nThe expert's statement does not contradict any information provided in the CTRs and is based on the data given.</s>",
        "contradict": "The statement \"The minimum Progression Free Survival for patients in cohort 1 the primary trial was 1.6 months\" is in contradiction with the information present in the CTRs, as according to the provided text, the median PFS for the Capecitabine arm in the primary trial was 2.8 months (1.6 to 3.2), not a minimum of 1.6 months.</s>"
    },
    "c55f34ab-b883-465e-89dc-75bbeb8afa77": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00369655",
        "Secondary_id": "NCT00091832",
        "Statement": "One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response.",
        "Label": "Entailment",
        "entail": "The statement that \"One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response\" entails the information in the CTRs because:\n\n1. The statement agrees that one patient in the primary trial achieved a Confirmed tumor partial response, which aligns with the CTR reporting \"Confirmed tumor partial response: 1\" for the Ziv-afibercept group.\n2. The statement also correctly reports that no patients in the secondary trial were evaluated for tumor response, consistent with the CTRs which do not provide any information on tumor response for the Bisphosphonate IV Q4W and Denosumab 30 mg Q4W groups.\n3. The statement avoids contradicting the descriptions in the CTRs as it does not claim anything that would contradict the information provided.\n4. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"One patient in the primary trial had a Confirmed tumor partial response, No patients in the secondary trial were evaluated for tumor response\" is contradictory to the CTRs because the primary and secondary trials assessed different outcome measurements. The primary trial evaluated tumor response using the Proportion of Patients With Confirmed Tumor Response, while the secondary trial assessed changes in Creatinine-adjusted Urinary N-telopeptide (uNTx/Cr) at Week 13. Therefore, it is not valid to compare tumor response between the two trials.</s>"
    },
    "0ee36ceb-5790-440e-b6ad-10a0b7a23f43": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01925170",
        "Secondary_id": "NCT00324259",
        "Statement": "Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography.",
        "Label": "Entailment",
        "entail": "The statement \"Participant in cohort 1 of the primary trial undergo a Mammography, whereas patients in cohort 1 of the secondary trial receive 6 mg Estradiol, and no Mammography\" is entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, patients in cohort 1 received mammography for their intervention (as stated, \"Interpretation and analysis was done with mammography only\" for cohort 1 in the primary trial).\n2. In the secondary trial, patients in cohort 1 did not receive mammography for their intervention (as stated, they received only 6 mg Estradiol with no mention of mammography in intervention details for cohort 1 of the secondary trial).\n\nThe statement is consistent with the information in the CTRs since it specifies that patients in cohort 1 of the primary trial underwent mammography, while patients in cohort 1 of the secondary trial received a different intervention (Estradiol) without mammography. No contradiction exists between the statement and the CTR information.</s>",
        "contradict": "The statement asserts that cohort 1 participants in the primary trial received mammography, while those in the secondary trial received 6mg Estradiol without mammography. However, this contradicts the given information in the CTRs. In the primary trial, cohort 1 underwent mammography only, meaning no estrogen therapy was administered. In contrast, in the secondary trial, cohort 1 received 6mg Estradiol daily, which is a form of hormone therapy and not mammography. Hence, the two trial cohorts cannot be directly compared based on the given statement.</s>"
    },
    "2535da13-e0f7-44df-aa02-89765d8d51cb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02419807",
        "Secondary_id": "NCT00777101",
        "Statement": "Patients with HER2 + breast cancer stage 1-4  are eligible for both the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement that \"Patients with HER2+ breast cancer stage 1-4 are eligible for both the primary trial and the secondary trial\" can be entailed by the information present in the CTRs, as follows:\n\n1. The primary trial includes patients with clinical stage 1 or 2 breast cancer, which is a subset of stage 1-4 breast cancer and falls under the HER2 positive category, as stated in the secondary trial.\n2. The primary trial also includes participants undergoing breast cancer surgery with lumpectomy or mastectomy and planned axillary sentinel node biopsy procedure, which are common treatment procedures for all stages of breast cancer, including stages IIIB, IIIC, and IV, as long as the other inclusion criteria for the secondary trial are met.\n3. Although the primary trial excludes some patients, such as those with cancer > 3 cm, clinically positive nodes, and prior surgery for breast cancer in the index breast, among others, the secondary trial also has its exclusion criteria. Thus, the overlap between inclusion and exclusion criteria for both trials does not contradict the statement.\n\nHence, the statement can be entailed by the information present in both CTRs.</s>",
        "contradict": "The information in the statement is contradicted by the CTRs as the inclusion criteria for the two trials are not identical. The primary trial includes patients with stages 1 and 2 breast cancer, while the secondary trial specifically focuses on stages IIIB, IIIC, and IV HER2 positive breast cancer. Additionally, the secondary trial requires prior use of Herceptin and a taxane, which is not a requirement for the primary trial. Furthermore, there are several exclusion criteria that differ between the two trials.</s>"
    },
    "94fc6e05-8a73-43d9-a48c-531d36dfbbcd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00548184",
        "Statement": "The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.",
        "Label": "Entailment",
        "entail": "The statement \"The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks\" can be entailed by the information present in the CTRs because:\n\n1. The trial specified that all participants in the Lapatinib + Trastuzumab arm received both lapatinib and trastuzumab for 12 weeks (as per the INTERVENTION section of the CTR).\n2. The RESULTS 1 section of the CTR reports that a total of 64 participants were analyzed in the Lapatinib + Trastuzumab arm.\n3. The RESULTS 1 section also provides data on the number of participants who achieved Complete Pathologic Response (18) and Near Complete Pathologic Response (16).\n4. Therefore, by calculating the percentage of participants who experienced at least a Near Complete Pathologic Response, we have (18 for Complete Pathologic Response + 16 for Near Complete Pathologic Response = 34) 34 participants out of 64 (53.13%) experienced at least a Near Complete Pathologic Response.\n5. The statement \"The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks\" is entailed by the information provided in the CTR as this percentage is above 50%.</s>",
        "contradict": "The statement can be contradicted by the information in the CTR because while it asserts that the majority of participants in the Lapatinib + Trastuzumab arm had at least Near Complete Pathologic Response or better, the CTR states that there were only 18 complete pathologic responses and 16 near complete pathologic responses, making a total of 34 participants with these responses, leaving 30 participants without a Near Complete or Complete Pathologic Response. Therefore, it is not the case that the majority (>50%) of participants experienced these responses according to the CTR.</s>"
    },
    "0057172f-d019-401b-a516-993a7b46a67b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01306942",
        "Statement": "Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement \"Participants of cohort 1 in the primary trial received more Dasatinib than those in cohort 2\" is entailed by the information in the CTRs because the dosage of Dasatinib given in cohort 1 was 100mg, whereas in cohort 2 it was 140mg.</s>",
        "contradict": "Although participants in cohort 1 and cohort 2 received the same regimen of trastuzumab and paclitaxel, they differ in Dasatinib dosage, with cohort 1 receiving a lower dose of Dasatinib (100mg) compared to cohort 2 (140mg). However, the statement does not acknowledge the difference in dosage and only refers to the number of participants receiving each Dasatinib dose, leading to an erroneous conclusion. Therefore, the information in the statement contradicts the data provided in the CTRs.</s>"
    },
    "bb23e8b8-c7d6-4e58-80a2-0555db5645e9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03096847",
        "Secondary_id": "NCT01840163",
        "Statement": "Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english.",
        "Label": "Entailment",
        "entail": "The statement \"Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english\" is entailed by the information in the CTRs as follows:\n\n1. Female patients recently prescribed Rapamycin are not eligible for the primary trial: The exclusion criteria in the primary trial specify that a patient has received any mTOR inhibitor, including Rapamycin, making these patients ineligible for the trial. \n\n2. Female patients with DCIS (Ductal Carcinoma In Situ) may be eligible for the secondary trial: Inclusion criteria for the secondary trial state that patients with invasive breast cancer diagnosis and DCIS are eligible. Therefore, female patients with DCIS who have not received any mTOR inhibitors can participate in the secondary trial. \n\n3. Ability to read English is an inclusion criterion for the secondary trial: The secondary trial includes the ability to read English as an inclusion criterion. \n\nThus, the statement \"Female Patients recently prescribed Rapamycin are not eligible for the primary trial, but may be eligible for the secondary trial as long as they have a stage 1 to 2 Ductal carcinoma in situ and can speak english\" is an accurate representation of the eligibility criteria for the primary and secondary trials as per the information provided in the CTRs.</s>",
        "contradict": "The statement is contradictory to the primary trial's inclusion criteria since patients who have received mTOR inhibitors, including Rapamycin, are explicitly excluded from the primary trial. Therefore, the statement that Female Patients recently prescribed Rapamycin are eligible for the primary trial is incorrect. However, the statement is consistent with the secondary trial's inclusion criteria, which allow patients with a history of treatment with mTOR inhibitors to participate, provided they have a stage 1 to 2 Ductal carcinoma in situ and can speak English.</s>"
    },
    "c4588d2c-b0d4-428d-a958-29787b9d4ec5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00545077",
        "Statement": "Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy .",
        "Label": "Entailment",
        "entail": "The statement \"Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy\" is entailed by the information in the CTRs. \n\nReason: \n\nIn the Primary Trial's INTERVENTION 1, Arm A patients receive endocrine treatment (Letrozole or Fulvestrant) alone, while Arm B patients of INTERVENTION 2 receive endocrine treatment in combination with bevacizumab. Both interventions involve endocrine therapy for every patient, as stated in the common phrasing \"Endocrine treatment consisting of either letrozole or fulvestrant.\" Therefore, the assertion that \"both cohorts undergo Endocrine Therapy\" is an entailed conclusion from the given CTRs. Additionally, the statement \"Only cohort 2 of the primary trial receive Bevacizumab\" is also an accurate reflection of the CTR data.</s>",
        "contradict": "The statement \"Only cohort 2 of the primary trial receive Bevacizumab, but both cohorts undergo Endocrine Therapy\" is contradicted by the information in the CTRs because both cohorts in the primary trial, Arm A and Arm B, do receive Endocrine Therapy as specified in the INTERVENTION sections. However, it is true that only Arm B receives Bevacizumab addition to Endocrine Therapy.</s>"
    },
    "ee1f81d1-7e99-44dc-bb6a-ed002a78c9f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00364611",
        "Statement": "Patients with clinically significant grade 3 PVD are eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with clinically significant grade 3 PVD are eligible for the primary trial\" can be entailed by the information present in the CTRs as follows:\n\nThe CTRs state that there are exclusion criteria for the primary trial, which include \"Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease.\" However, the statement specifically mentions \"clinically significant grade 3 PVD,\" which is a more severe form of peripheral vascular disease. Therefore, if a patient has clinically significant grade 3 PVD, they would not fall under the exclusion criteria stated in the CTRs and would be eligible for the primary trial.</s>",
        "contradict": "The statement \"Patients with clinically significant grade 3 PVD are eligible for the primary trial\" is contradicted by the EXCLUSION CRITERIA in the CTR. Specifically, the CTR states that \"Presence of any non-healing wound, fracture, or ulcer, or the presence of clinically significant (>/= Grade 2) peripheral vascular disease\" is an exclusion criterion for the primary trial. Therefore, patients with grade 3 peripheral vascular disease are excluded from the trial, and the statement made by the clinical trial expert is incorrect.</s>"
    },
    "00466f98-52b8-41f3-9bf1-2edaad950be9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02504424",
        "Secondary_id": "NCT03708393",
        "Statement": "the primary trial and the secondary trial both require the patients to activate the interventions by remote control.",
        "Label": "Contradiction",
        "entail": "In the primary trial, the AeroForm Tissue Expander is described as being activated by remote control for inflation. In the secondary trial, Intervention 1 is specified as the IUS (Intrauterine System) alone, and no remote control activation is explicitly mentioned, but no contradictory information is provided regarding this aspect. However, for Intervention 2 in the secondary trial, Imagio (IUS+OA), remote control activation is not mentioned in the CTR description, but the statement does not assert that this intervention is activated remotely, only that the first intervention (IUS alone) is. Therefore, the statement that both trials require patients to activate interventions by remote control is an accurate summary, as the first intervention in the secondary trial does satisfy the condition stated in the statement.\n\nThus, the information in the statement is entailed by the information in the CTRs since it correctly summarizes the remote control activation aspect for the primary trial and does not contradict the information in the secondary trial.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both require the patients to activate the interventions by remote control\" is contradicted by the information present in the CTRs because the primary trial involves the use of an AeroForm Tissue Expander, which is activated by carbon dioxide inflation from an internal reservoir released by remote control, whereas the secondary trial involves the use of Intrauterine Systems (IUS) alone and Intrauterine Systems with Oralerone Acetate (IUS+OA), which are not activated by remote control but inserted and left in place.</s>"
    },
    "50a524ae-2135-45f7-ae9b-515fd4e2e404": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02445586",
        "Secondary_id": "NCT02115984",
        "Statement": "More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event.",
        "Label": "Contradiction",
        "entail": "The statement \"More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial did not experience an adverse event\" is entailed by the data in the CTRs because:\n1. The statement that \"More than half of patients in the primary trial experienced adverse events\" is entailed by the data that 31/52 (59.62%) of patients in the primary trial experienced adverse events.\n2. The statement that \"100% of patients in the secondary trial did not experience an adverse event\" is entailed by the data that 0/33 (0.00%) patients in the secondary trial experienced herpetic eruption, and 0/33 (0.00%) patients in the secondary trial experienced other adverse events besides nausea after CT (before day 7), as the statement \"did not experience an adverse event\" implies the absence of any adverse event mentioned in the CTRs. Additionally, the fact that all 57 patients in the secondary trial experienced nausea after CT (before day 7) is not contradictory to the statement, as this particular adverse event is not the one being compared between the trials in the statement.</s>",
        "contradict": "The statement \"More than half of patients in the primary trial experienced adverse events, and 100% of patients in the secondary trial didnot experience an adverse event\" is contradictory to the information present in the CTRs as follows:\n\n1. The statement asserts that more than half of patients in the primary trial experienced adverse events. However, the provided Adverse Events section of the primary trial indicates that 59.62% of patients (31/52) experienced adverse events. The statement's quantification is incorrect.\n2. The statement asserts that no patient in the secondary trial experienced an adverse event. However, the Adverse Events section of the secondary trial indicates that 100.00% of patients (57/57) experienced Nausea after the CT (before day 7), which is considered an adverse event. The statement's assertion is false.\n\nHence, the statement contains contradictory information when compared to the information provided in the CTRs.</s>"
    },
    "b2062e01-0ea6-4ee8-94a1-b59dc40901d3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01688609",
        "Statement": " Patients must have histologically or cytologically confirmed ERBB2+ invasive breast cancer, with Primary tumor > 2 cm in diameter to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR as it shares identical conditions for patient inclusion in terms of histologically or cytologically confirmed ERBB2+ invasive breast cancer and having a primary tumor larger than 2 cm in diameter (T2) as measured by caliper or ultrasound. The expert's statement does not include any conflicting information or additional requirements, making it an entailed statement based on the CTR.</s>",
        "contradict": "The statement does not contradict the information in the CTR for the primary trial regarding the inclusion criteria related to cancer type (ERBB2+ invasive breast cancer) and tumor size (larger than 2 cm). However, the expert statement does not explicitly mention the requirements for HER2 overexpression/amplification, receipt of prior therapies, Karnofsky percentage, and other inclusion/exclusion criteria stated in the CTR. The statement's lack of specificity regarding these criteria makes it potentially contradictory if the primary trial has additional requirements that are not met by some patients with ERBB2+ invasive breast cancer larger than 2 cm in diameter. The CTR should be consulted for a definitive assessment of entailment between the statement and the trial information.</s>"
    },
    "4dbce51b-1cfc-4d5f-82bb-ce9319ace3af": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00826267",
        "Statement": "Cohort 1 and 2 of the primary trial receive different quantities of different drugs.",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial receive different quantities of different drugs\" is entailed by the information in the CTRs, as each cohort receives a distinct drug (Afatinib and Lapatinib, respectively) and a different quantity of that drug (50 mg for Afatinib and 1500 mg for Lapatinib) for the same duration (each treatment course lasts 21 days, and there are 2 treatment courses in total).</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial receive different quantities of different drugs\" is not contradicted by the information present in the CTRs. However, it does not exactly entail the information in the CTRs either, as the CTRs provide more specific details about the drugs (Afatinib and Lapatinib) and their dosages (50 mg and 1500 mg respectively) that the statement does not explicitly mention. But, the statement is consistent with the CTRs in that it correctly states that patients in different cohorts are receiving different drugs and different quantities of those drugs.</s>"
    },
    "43a9cc96-4020-459c-8fa4-4bbde7173f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02447328",
        "Statement": "In the primary trial 11 patients had serious adverse events, no patients had serious  Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"In the primary trial 11 patients had serious adverse events, no patients had serious Adverse Drug Reactions, and over half of patients passed away from Unexpected adverse events\" is entailed by the CTR information as follows:\n\n11 patients had serious adverse events: The CTR reports \"Serious AE: 11.1 (5.2 to 20.1)\" which implies that there were 11.1% (5.2% to 20.1%) of patients with serious adverse events.\n\nNo patients had serious Adverse Drug Reactions: The CTR reports \"Serious ADR: 0 (0 to 4.4)\". Since no patients had a serious Adverse Drug Reaction based on the provided data, the expert's statement matches this information.\n\nOver half of patients passed away from Unexpected adverse events: The CTR reports \"Unexpected AE: 71.6 (60.5 to 81.1)\"; \"Unexpected ADR: 24.7 (15.8 to 35.5)\". The expert's phrase \"passed away from\" can be interpreted as a severe outcome, and in combination, these data indicate that more than half of patients (46.9 to 56.1%) experienced unexpected adverse events resulting in their death, as stated in the expert's claim.</s>",
        "contradict": "The statement made by the clinical trial expert contradicts the information presented in the CTRs because the statement asserts that \"no patients had serious Adverse Drug Reactions\" in the primary trial, while the CTR indicates that there were 0 serious Adverse Drug Reactions but a percentage of 38.3 (27.7-49.7) for Adverse Drug Reactions overall. These are not identical statements. Additionally, the expert's statement claims \"over half of patients passed away from Unexpected adverse events,\" while the CTR reports \"71.6 (60.5-81.1) % of participants had Unexpected AEs and 24.7 (15.8-35.5) % Unexpected ADRs,\" not all of which led to deaths.</s>"
    },
    "ff319fa6-89b6-4f1a-871d-456edb91b69b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03045653",
        "Statement": "Sharone had a hip replacement 3 weeks prior, she is not elgible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Sharone had a hip replacement 3 weeks prior, she is not eligible for the primary trial\" is entailed by the inclusion criteria of the CTR as follows:\n\n1. Exclusion Criteria:\n   - Major surgery (excluding placement of vascular access) within 4 weeks before study treatment\n\nSince Sharone had a hip replacement surgery within 4 weeks prior to the trial, she is not eligible for the trial according to the CTR.</s>",
        "contradict": "The statement is not directly contradicted by the information in the CTRs as the eligibility criteria for the primary trial explicitly lists \"major surgery (excluding placement of vascular access) within 4 weeks before study treatment\" as an exclusion criterion. Sharone's situation of having a hip replacement surgery 3 weeks prior makes her ineligible for the trial according to this criterion. However, the statement is not in contradiction with the provided information in the CTRs because it directly addresses Sharone's situation, and not the trial's eligibility criteria in general.</s>"
    },
    "a321acf0-2296-4588-bf96-85b22bf1420f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 14 cases of neutropenia related adverse events in the primary trial across both cohorts.",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR data since both the total number of participants (76 in each CTR) and the number of neutropenia cases (10 in the first CTR and 2 in the second CTR, totaling 12) are provided. Therefore, by calculating the total number of neutropenia cases across both trials, the expert's statement (14 cases) is derived. No contradictory information is presented in the CTRs, and the assertion is supported by the clinical trial data.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs because it asserts that there are a total of 14 cases of neutropenia-related adverse events across both cohorts in the primary trial. However, the CTRs specify that the total number of neutropenia cases for Cohort 1 is 10/76 (13.16%) and for Cohort 2 is 2/43 (4.65%). Therefore, the total number of neutropenia cases across both cohorts is 12 (10+2), which is less than the 14 stated in the expert's claim. This contradiction undermines the semantic entailment of the expert's statement with the CTRs.</s>"
    },
    "b841dfd8-4676-4d3c-a57d-6ba1055b8597": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The patient's history of Pertuzumab treatment and recovery from side effects does not contradict or contradict the primary trial's inclusion criteria. The statement implies that the patient has no uncontrolled brain metastases, no significant liver, renal, or pancreatic disease, no impaired cardiac function, and is not taking any medications or receiving treatments that would make them ineligible according to the primary trial's exclusion criteria. The time frame of Pertuzumab treatment and discontinuation aligns with the exclusion criteria concerning previous treatment with biologic therapy and recovery period. Therefore, the information in the expert's statement is entailed by the information present in the primary trial's inclusion and exclusion criteria.</s>",
        "contradict": "The patient being eligible for the primary trial based on the statement does not harmonize with the CTR's exclusion criteria. The statement mentions that the patient was previously treated with Pertuzumab, and although it specifies that the treatment was discontinued 2 months prior to study entry and the patient has recovered from the side effects, it does not provide any information about the specific type or dosage of the Pertuzumab administered or the time since the patient's last chemotherapy or biologic therapy. According to the CTR, patients who have received biologic therapy, including Pertuzumab, within 4 weeks prior to starting study drug are excluded. The statement's assertion contradicts the clinical trial data by not adhering to the specified exclusion criteria for the primary trial.</s>"
    },
    "1dd4acd1-657c-40c0-b5ab-9c7adbe4ebf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042535",
        "Statement": "The Maximum Tolerated Dose (MTD) of of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg.",
        "Label": "Contradiction",
        "entail": "The statement that \"The Maximum Tolerated Dose (MTD) of 1-methyl-d-tryptophan (indoximod) observed in the primary trial was 800 mg\" can be entailed by the information present in the CTRs. The CTR of the primary trial specifies that the MTD for indoximod was determined to be 800 mg (given twice daily with up to 6 Ad.p53 DC vaccinations every 2 weeks) based on the 3+3 design and assessment according to NCI CTCAE v4.0. This MTD is the highest dose level below the maximally administered dose (MAD) where no more than 1 out of 6 patients experienced a dose limiting toxicity (DLT). Thus, the expert's statement, which reports the MTD as 800 mg, aligns with the CTR's data and is a valid entailment.</s>",
        "contradict": "The expert's statement that \"The Maximum Tolerated Dose (MTD) of 1-Pemetrexed-d-tryptophan (indoximod) observed in the primary trial was 800 mg\" contradicts the information in the CTR for the following reasons:\n1. The CTR mentions that the MTD for indoximod in the primary trial was the dose level below the maximally administered dose that was safely tolerated by 6 out of 7 patients in a 3+3 study design, which could not be precisely determined as 800 mg from the provided information.\n2. The CTR also indicates that in the secondary trial, patients receive 1-methyl-d-tryptophan (indoximod) orally daily for 21 days every 28 days. This regimen is different from the 1-methyl-d-tryptophan administered in the primary trial as part of the MTD determination process, and it is not explicitly stated that the MTD of indoximod is 800 mg for this regimen.\n\nTherefore, while the expert's statement may align with a particular interpretation based on the given information, it contradicts the CTR as it does not account for the full context, such as the study design, the determination method, and the different treatment regimens in the primary and secondary trials.</s>"
    },
    "48d40c7e-3514-43c3-a31a-7b391727f012": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01209195",
        "Statement": "Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2, Paclitaxel doses are the same for both cohorts.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTRs because the CTR for the primary trial explicitly states that in cohort 1, participants receive a MM-121 loading dose of 20 mg/kg followed by a weekly dose of 12 mg/kg (a total of 32 mg/kg per cycle), while in cohort 2, participants receive a loading dose of 40 mg/kg followed by a weekly dose of 20 mg/kg (a total of 60 mg/kg per cycle). Thus, the statement that \"Lower doses of MM-121 are used in cohort 1 than in cohort 2\" holds true. Regarding Paclitaxel, the CTR indicates that both cohorts receive an \"80mg/m2 weekly IV\" dose, which is consistent with the statement's claim that Paclitaxel doses are the same for both cohorts.</s>",
        "contradict": "The statement \"Lower doses of MM-121 are utilised in cohort1 of the primary trial than in cohort 2\" is inconsistent with the information in the CTRs, as stated in the Intervention section, where it is mentioned that cohort 1 receives a loading dose of 20 mg/kg followed by 12 mg/kg weekly of MM-121, while cohort 2 receives a loading dose of 40 mg/kg followed by 20 mg/kg weekly. Although the weekly dosage is the same in both cohorts, the loading doses are different, and the statement incorrectly suggests that the ongoing weekly dosage is the only difference between them.</s>"
    },
    "dd98fca1-27a7-41c2-ba0c-3ff90aceab54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01305941",
        "Statement": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive.",
        "Label": "Entailment",
        "entail": "The inclusion criteria in the primary CTR specify that patients must have histologically-confirmed HER2-positive breast adenocarcinoma. The statement from the clinical trials expert echoes this requirement, as it states that patients must present with IHC 3+ or FISH amplified results to participate in the trial. Therefore, the statement is entailed by the information in the CTRs, since it accurately conveys a necessary condition for eligibility in the trial.</s>",
        "contradict": "While the statement implies that patients must have IHC 3+ or FISH amplified results to participate in the primary trial, implying a direct requirement for these test results, the CTR specifies that patients can also have histologically-confirmed HER2-positive adenocarcinoma of the breast, allowing for the possibility of other diagnostic methods beyond IHC and FISH. Contradictorily, the statement overlooks this broader definition of HER2-positivity in the CTR.</s>"
    },
    "b975dc12-757e-4ef5-af33-83dfce12e6cc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01989676",
        "Statement": "the primary trial only records GI adverse events.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial only records GI adverse events\" cannot be determined to be entailed by the CTRs as there is no information provided in the CTRs regarding GI adverse events in either trial. Therefore, the statement is not entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"the primary trial only records GI adverse events\" is contradicted by the information in the CTRs as both reports list various types of adverse events other than GI events, such as cardiac, respiratory, hematological, and neurological events.</s>"
    },
    "2c4254c9-9c40-492f-aa45-2a9ab47579b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02658734",
        "Secondary_id": "NCT02073487",
        "Statement": "Female Patients with LVEF > 50%,  who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"Female Patients with LVEF > 50%, who have previously undergone treatment with trastuzumab emtansine or lapatinib are still eligible for the secondary trial but are excluded from the primary trial\" is entailed by the information in the CTRs because:\n\n1. The primary trial excludes patients with prior treatment with trastuzumab emtansine or lapatinib (Primary Trial: Exclusion Criteria).\n2. The secondary trial does not mention any exclusion based on prior treatment with trastuzumab emtansine or lapatinib, but does specify LVEF > 50% as an inclusion criterion (Secondary Trial: Inclusion Criteria). \n3. The statement acknowledges that LVEF > 50% is an inclusion criterion for the secondary trial but adds the condition that these patients have been previously treated with trastuzumab emtansine or lapatinib, meaning they are still eligible for the secondary trial despite their prior treatment history. \n\nTherefore, the statement is in harmony with the clinical trial data, is substantiated by the CTRs, and avoids contradiction with the descriptions provided.</s>",
        "contradict": "The statement contradicts the primary trial's inclusion criteria, which explicitly exclude female patients who have previously undergone treatment with trastuzumab emtansine or lapatinib. Therefore, these patients cannot meet the conditions for participation in the primary trial. However, the secondary trial's inclusion criteria do not have this restriction, allowing such patients to be considered for enrollment in that trial.</s>"
    },
    "e140b055-b7fc-4802-a79b-9dfe7d136876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01575522",
        "Secondary_id": "NCT00181363",
        "Statement": "the primary trial and the secondary trial are testing completely different modalities of interventions.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\nThe primary trial and the secondary trial involve distinct interventions. In the primary trial, patients receive Tivantinib in a particular dosage and schedule. Meanwhile, in the secondary trial, patients are subjected to different positions (prone and supine) without any mention of a specific intervention or treatment. Since the interventions in both trials are unique, the statement is an entailed conclusion.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial are testing completely different modalities of interventions\" can be contradicted by the information present in the CTRs because the primary trial involves an intervention of administering a drug, tivantinib, to patients in a particular position (not explicitly mentioned), while the secondary trial also involves interventions, but of a completely different type - positioning, specifically prone and supine positions. However, there is no mention of any correlation or interaction between the positioning interventions and the drug intervention in either CTR, implying they may be independent modalities of intervention. Therefore, the statement can be considered accurate based on the given information, but it does not follow directly from the CTR data alone, as it goes beyond the provided information by implying that the positioning interventions are not related to the drug intervention in any way.</s>"
    },
    "0a6418c8-63a6-4900-bfc9-1659acbe1ad7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02581839",
        "Statement": "At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.",
        "Label": "Entailment",
        "entail": "The statement \"At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months\" can be entailed by the information in the CTRs, as follows:\n\n1. In the primary CTR, it is stated that the MRI will be completed every 12 weeks after the first three cycles (at 12 weeks, 24 weeks, 36 weeks, etc.) while participants are on eribulin mesylate. This implies that the CNS PFS for participants will be assessed at least three times during the study period.\n\n2. The results section of the primary CTR reports that 88.9% (51% to 99.7%) of subjects had CNS PFS at 12 weeks. Although not explicitly mentioned, it can be inferred that the other participants either progressed (below 50%) or were still being evaluated. Given the frequency of MRI assessments, it's reasonable to assume that a few subjects might have had a CNS PFS of more than 12 weeks.\n\n3. Therefore, it is plausible that at least 8 participants had a CNS PFS of 3 months (i.e., 12 weeks + 12 weeks = 24 weeks), as stated in the clinical trial expert's claim.\n\n4. Additionally, the CTRs provide no contradictory information that would negate the entailment.</s>",
        "contradict": "The statement that \"at least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months\" contradicts the information in the CTRs if the 3-month mark for CNS PFS assessment was missed for some participants, or if the statement refers to a different subset of participants. The CTR states that an MRI is completed at week 12 and every 12 weeks after cycles 4+, which may not cover the 3-month threshold for all participants. Additionally, the statement is about a subset of participants, while the CTR reports the percentage of participants with CNS PFS >= 3 months (88.9%). If the statement's \"at least 8 participants\" refers to a different subset, the contradiction could be more apparent.</s>"
    },
    "2db9e0c7-d94b-47d2-a61f-55a0896d714e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00789581",
        "Secondary_id": "NCT02445586",
        "Statement": "the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia.",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial reported more cases of Haematemesis, but the primary trial had more cases of Sinus tachycardia\" can be entailed by the information present in the CTRs as follows: The secondary trial reported \"1/52 (1.92%)\" cases of Haematemesis, and the primary trial reported \"0/305 (0.00%)\" cases for Adverse Event 1, but reported \"1/305 (0.33%)\" cases for Sinus tachycardia. Since the number of cases of Haematemesis in the secondary trial is greater than the number of cases of Sinus tachycardia in the primary trial, the statement is entailed by the data in the CTRs.</s>",
        "contradict": "The information in the statement cannot be directly contradicted by the provided CTR data. However, it does not establish semantic entailment either, as the statement makes a comparative claim about the frequency of specific adverse events across two trials without considering their overall adverse event rates or the total number of participants. The CTRs only provide absolute numbers of cases for each adverse event in each trial but do not enable comparison based on the stated criterion alone. To determine if the statement entails information present in the CTRs, a more comprehensive comparison accounting for trial size and specific event frequencies should be performed.</s>"
    },
    "3129e58d-0c16-42a5-90b4-f26e048dfe58": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01644890",
        "Statement": "Throughout the primary trial, one patient in cohort 1 developed issues with their vision.",
        "Label": "Contradiction",
        "entail": "The statement \"Throughout the primary trial, one patient in cohort 1 developed issues with their vision\" can be entailed by the information present in the CTRs since:\n\n1. The CTR for the primary trial reports the occurrence of a case of macular fibrosis, which is a type of vision issue, in one patient out of 214 (section \"Adverse Events 1\").\n2. The statement and the CTR both refer to the primary trial.\n3. The CTR does not contradict the statement, and the statement does not claim anything beyond the scope of the CTR.</s>",
        "contradict": "The statement \"Throughout the primary trial, one patient in cohort 1 developed issues with their vision\" cannot be directly contradicted by the information present in the CTRs as there is no mention of any vision-related adverse events in either cohort 1 of the primary trial or in the secondary trial. However, the statement is not entailed by the CTR data as the trials' adverse event sections do not provide enough detail to confirm that a single patient in cohort 1 of the primary trial experienced vision issues.</s>"
    },
    "7be7cecb-d265-4098-9969-a40555702573": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00679211",
        "Statement": "1 patient in the primary trial was diangosed with Influenza.",
        "Label": "Contradiction",
        "entail": "The statement \"1 patient in the primary trial was diagnosed with Influenza\" can be entailed by the information present in the CTR under Adverse Events 1, as there is a reported instance (1/110) of Influenza-like illness in the primary trial.</s>",
        "contradict": "The statement \"1 patient in the primary trial was diagnosed with Influenza\" does not contradict the information present in the CTRs, as the given statement neither asserts that this specific patient experienced an adverse event nor provides any information about the severity or timing of the influenza diagnosis in relation to the trial participation. However, it cannot be definitively determined if this statement entails any information from the CTRs, as the statement is not specific enough to do so. The CTR only reports one instance of \"Influenza like illness\" in the primary trial adverse events, which is not necessarily equivalent to a confirmed diagnosis of Influenza. Therefore, while the statement is consistent with the CTRs, it does not necessarily follow from them due to the lack of sufficient detail in the statement.</s>"
    },
    "5b0d3709-7879-4dea-96c3-29178cd9f162": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00767520",
        "Statement": "Both cohorts of the primary trial reported the same number of patients vomiting during the trial.",
        "Label": "Entailment",
        "entail": "Both cohorts in the primary trial reported the same number of patients with vomiting as an adverse event, which is indicated by the number \"2\" for each cohort in the CTRs.</s>",
        "contradict": "The statement is not entailed by the information in the CTRs because the number of patients who vomited is not the same in both cohorts. The primary trial reported two patients vomiting out of 79, while the secondary trial reported two patients vomiting out of 76.</s>"
    },
    "af70a3a9-d2d0-4d65-81fe-15a1becb5e95": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01420146",
        "Secondary_id": "NCT00077376",
        "Statement": "the primary trial and the secondary trial both have a control arm, and several test arms.",
        "Label": "Contradiction",
        "entail": "In the primary trial, no explicit control arm information is provided in the given Intervention section. However, the absence of a control arm in this context does not preclude the possibility of its existence in the rest of the trial report. \n\nIn the secondary trial, the Intervention section mentions the use of two distinct treatments (Ixabepilone/Carboplatin and Trastuzumab) for different phases (induction and maintenance), which can be considered as separate test arms. \n\nTherefore, the statement \"the primary trial and the secondary trial both have a control arm, and several test arms\" is a reasonable inference that can be drawn from the available information. It is important to note that the absence of a control arm in the given Intervention sections does not definitively disprove the existence of a control arm in the trials, as more comprehensive analysis of the full trial reports would be required to make such a definitive conclusion.</s>",
        "contradict": "Contradiction: The statement assumes both trials have control arms and multiple test arms, which is incorrect based on the provided information. The primary trial only has one intervention arm using Zr89-trastuzumab for PET/CT, while the secondary trial has one control arm and two treatment arms, with patients receiving Ixabepilone/Carboplatin and Trastuzumab respectively.</s>"
    },
    "a378f448-eef0-465a-abc0-8b4dd1156bb5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00372424",
        "Secondary_id": "NCT00041067",
        "Statement": "Patients with HER2 positive breast tumors are eligible for the primary trial and the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement entails that patients with HER2 positive breast tumors are eligible for both trials. This is entailed by the CTR information since the primary trial includes patients with breast cancer that over-express Her-2, and the secondary trial specifies that HER2 positivity is a requirement for participation.</s>",
        "contradict": "The statement is not necessarily contradictory to the CTRs, but it may not hold true for all patients. While both trials involve HER2-positive breast cancer, the primary trial specifically includes patients who over-express Her-2 (based on immunohistochemistry or FISH testing), whereas the secondary trial only confirms HER2 positivity through FISH or immunohistochemistry. Thus, some patients eligible for the primary trial might not meet the criteria for the secondary trial, or vice versa. The discrepancy lies in the methodology used to determine HER2 positivity.</s>"
    },
    "f30182a1-b82a-497c-885c-9bd2e805db62": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01487954",
        "Statement": "All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in.",
        "Label": "Entailment",
        "entail": "The statement \"All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in\" is entailed by the information present in the CTRs because:\n\n1. The CTRs specify that patients in both arms drink 8 ounces (approximately 236.59 ml) of either alkaline or distilled water within 30 minutes before and after undergoing radiation therapy daily for 6 weeks.\n2. The statement's assertion (patients drank 237 ml of water) aligns with the volume mentioned in the CTRs (236.59 ml).\n3. The statement does not contradict any information in the CTRs and only adds an aggregate perspective on the water consumption requirement across both cohorts.</s>",
        "contradict": "The statement \"All patients in the primary trial had to drink 237 ml of water, either Alkaline Water or Distilled, depending on which cohort they are in\" does not directly entail the information in the CTR. While it is true that patients in both arms drank 8 ounces, which is equivalent to 237 ml, the CTR specifies that this amount was consumed in the form of alkaline water for one arm and distilled water for the other. The statement fails to convey this important distinction and could potentially misrepresent the information from the CTR.</s>"
    },
    "ae87e5a3-fdd8-4003-ae80-4b370cade158": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "2% of the primary trial patients had Recurrence-free Survival < 3 years.",
        "Label": "Entailment",
        "entail": "The statement \"2% of the primary trial patients had Recurrence-free Survival < 3 years\" can be entailed by the information in the CTRs since the CTR provides the data that out of 100 participants, 98 had Recurrence-free Survival of 3 years or more (ranging from 92.2% to 99.5%). This leaves room for 2 participants (or 2%) to have Recurrence-free Survival less than 3 years. The statement does not contradict the information in the CTRs.</s>",
        "contradict": "The statement \"2% of the primary trial patients had Recurrence-free Survival < 3 years\" cannot be definitively contradicted by the information in the CTRs provided. However, the data in the CTRs do not entail this statement since they do not report specific information on Recurrence-free Survival duration for individual patients. The CTR only indicates that Recurrence-free survival will be plotted and assessed up to 3 years. Thus, while the statement could potentially be true based on the data, it is not entailed by the information in the CTRs.</s>"
    },
    "9f3062db-16fb-41b8-ac10-f205f66070c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00696072",
        "Statement": "Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years.",
        "Label": "Contradiction",
        "entail": "The statement \"Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years\" can be entailed by the information present in the CTRs because both trials report that 20 out of 56 participants (35.7%) in the Dasatinib plus Letrozole arm and 20 out of 61 participants (32.8%) in the Letrozole-only arm experienced DFI greater than 2 years. Although the percentage might be slightly different between the two arms, the statement does not contradict any information in the CTRs and is supported by the reported data.</s>",
        "contradict": "The statement \"Most patients treated with Dasatinib and Letrozole in the primary trial had a Disease Free Interval (DFI) Greater Than 2 Years\" cannot be directly contradicted by the information present in the CTRs, but it may be misleading without additional context. While both the Dasatinib Plus Letrozole and Letrozole arms of the trial had 20 participants each with a DFI greater than 2 years, there were also 20 participants in each arm with a DFI less than or equal to 2 years. Thus, half of the patients in each arm had a DFI greater than 2 years, which is consistent with the expert's statement. However, the statement does not specify that the comparison is between the two arms of the trial, and it may be interpreted to mean that a majority of all patients in the trial had a DFI greater than 2 years, which is not the case based on the information provided. To determine the semantic entailment relationship, it is necessary to consider the context and potential ambiguities in the expert's statement.</s>"
    },
    "a1c5685a-8e6e-4733-aa8b-7040bac1a397": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00022672",
        "Statement": "There were no patients in either cohort of the primary trial with a PFS exceeding 6 months.",
        "Label": "Contradiction",
        "entail": "The statement \"There were no patients in either cohort of the primary trial with a PFS exceeding 6 months\" is entailed by the information in the CTRs because the median PFS for both the Trastuzumab + Anastrozole arm (4.8 months) and the Anastrozole arm (2.4 months) are both less than 6 months. This means that more than half of the patients in each arm had a PFS shorter than 6 months, implying that no patient in either arm had a PFS exceeding 6 months.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs as there are participants in both arms (Trastuzumab + Anastrozole and Anastrozole alone) who experienced PFS longer than 6 months. According to the provided results, the median PFS for the Trastuzumab + Anastrozole arm was 4.8 months (3.7-7) in the primary phase and 5.8 months (4.6-8.3) in the extension phase. In contrast, the median PFS for the Anastrozole arm was 2.4 months (2-4.6) in the primary phase and 2.9 months (2.1-4.5) in the extension phase. There are likely patients in both groups whose PFS exceeds 6 months based on the presented data.</s>"
    },
    "d58683e2-d276-4184-a8e9-c9df6ffd8047": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00559507",
        "Statement": "the primary trial participants are given saracatinib PO for a maximum of 28 days.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"the primary trial participants are given saracatinib PO for a maximum of 28 days\" is entailed by the information in the CTRs, as stated in the primary trial's INTERVENTION section: \"Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.\" The expert's statement aligns with the CTR data as it accurately reflects the maximum duration of saracatinib administration mentioned in the trial.</s>",
        "contradict": "The expert's statement is not an exact entailment of the CTR information since it omits the important fact mentioned in the CTR that participants receive saracatinib for 28 days only as long as they do not experience disease progression or unacceptable toxicity. The expert's statement implies that all participants receive saracatinib for exactly 28 days regardless of their clinical status. This contradicts the CTR which states that treatment continuation is contingent on the absence of disease progression or intolerance.</s>"
    },
    "28d8f88a-e8cb-40c0-a12b-ef555f83ff59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01904903",
        "Secondary_id": "NCT01663727",
        "Statement": "Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial\" is entailed by the information present in the CTRs as follows:\n\nIn the primary trial CTR, patients with LVEF < 50% are included in the study as a part of the Eligibility Criteria.\n\nIn the secondary trial CTR, patients with LVEF < 50% are also included in the study as a part of the Eligibility Criteria.\n\nTherefore, the statement \"Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial\" is an accurate representation of the information presented in the CTRs.</s>",
        "contradict": "The statement \"Patients must have LVEF < 50% to be eligible for the primary trial and the secondary trial\" is contradicted by the information present in the CTRs, as the primary trial includes patients with LVEF < 50%, but the secondary trial does not have this criterion as part of its inclusion criteria.</s>"
    },
    "0ee4c935-18bd-4807-a2af-041a3d84e125": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02721147",
        "Statement": "Stephanie has been living with her boyfriend for 2 months, she is eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "Stephanie's eligibility for the primary trial is established based on her meeting the following inclusion criteria: she is female, aged over 21 years, has a diagnosis of non-recurrent stage I-III breast cancer, has completed active treatment with a 6-months to 5-years time frame, and lives with a romantic partner. The statement that she has been living with her boyfriend for 2 months does not contradict any information provided in the CTRs, and it falls under the \"lives with a romantic partner\" inclusion criterion, which specifies a relationship duration exceeding 6 months. Therefore, the information contained in the expert's statement is entailed by the information present in the CTRs. Additionally, none of the exclusion criteria are violated based on the given information.</s>",
        "contradict": "Stephanie's eligibility for the primary trial based on her current living situation with her boyfriend for 2 months contradicts the CTR's inclusion criterion which states that she must have lived with her partner for more than 6 months.</s>"
    },
    "355fb813-cbe0-44f5-b04a-87813e060d54": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00371254",
        "Statement": "Patients must have eceptorsestrogen receptor (ER) -, progesterone receptor (PR) - and human epidermal growth factor receptor 2 (HER2) - breast cancer, aswell as not having Dysphagia.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have ER--, PR- and HER2- breast cancer, as well as not having Dysphagia\" is entailed by the Primary CTR's Inclusion Criteria, specifically the condition \"females, 18 or older with locally advanced, or 'triple negative' metastatic breast cancer.\" Triple negative breast cancer is a sub type characterized by the absence of ER, PR, and HER2 receptors. The statement's requirement of the absence of Dysphagia is not explicitly stated in the CTR but is compatible with the inclusion criteria, as there is no mention of any restriction related to this condition. Therefore, the CTR data entails the statement.</s>",
        "contradict": "The statement \"Patients must have ER-, PR- and HER2- breast cancer, as well as not having Dysphagia\" contradicts the information in the Primary CTR as it imposes stricter inclusion criteria for the female gender with breast cancer, specifically requiring triple negative (ER-, PR-, HER2-) status and lack of Dysphagia. However, the CTR inclusion criteria allow for females with recurrent or progressive locally advanced, or triple negative metastatic breast cancer to participate, without specifying ER, PR, or HER2 status, or the presence or absence of Dysphagia. Therefore, the statement's conditions are not entailed by the Primary CTR's inclusion criteria.</s>"
    },
    "274d9d2b-9227-4496-a525-d5477b0003ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00796978",
        "Secondary_id": "NCT01276041",
        "Statement": "More patients in cohort 1 of the secondary trial suffered from oedema in their limbs, compared to patients in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if there is at least one limb edema case in cohort 1 of the secondary trial that is greater in number than the limb edema cases in cohort 2 of the primary trial. The given CTRs do not explicitly state the number of limb edema cases for each cohort. However, if the number of participants is used as a proxy for the number of potential cases, then there are more patients in cohort 1 of the secondary trial (70) compared to cohort 2 of the primary trial (56). Therefore, assuming a higher occurrence rate of limb edema in the secondary trial (as suggested by the statement), it's possible that the number of limb edema cases is still higher in cohort 1, given the larger cohort size. However, without specific numbers, a definitive answer cannot be given.</s>",
        "contradict": "The statement \"More patients in cohort 1 of the secondary trial suffered from edema in their limbs, compared to patients in cohort 2 of the primary trial,\" cannot be definitively determined as true or false based on the given information. \n\nExplanation: \n\nThe CTRs provide the number of participants who experienced edema in each trial but not in which cohort(s) specifically. Without this information, it's not possible to make a direct comparison between the primary and secondary trials regarding the occurrence of edema in their respective cohorts.</s>"
    },
    "3ab9c66c-06fc-4bc5-b504-d9193efa8701": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290745",
        "Statement": "in the primary trial participants from different ethnicities receive different interventions.",
        "Label": "Contradiction",
        "entail": "The CTRs provide information on the primary trial involving two interventions, tamoxifen and letrozole, used for treating women with ductal carcinoma in situ. There is no explicit statement in the CTRs indicating that participants belong to different ethnicities receive different interventions. However, the absence of a statement contradicting that assertion, combined with the lack of any information suggesting all participants are of the same ethnicity, allows this statement to be entailed by the information in the CTRs.</s>",
        "contradict": "The information in the statement can be contradictory to the CTRs if the primary trial does not report any differences in interventions based on ethnicity. The CTR for the primary trial mentions tamoxifen or letrozole as the interventions, without any indication of ethnicity-related differences in treatment assignments.</s>"
    },
    "d39078d9-9bc3-4b91-a012-e95f14813c9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01252277",
        "Statement": "Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "Fiona's eligibility for the primary trial is determined by her having a first-degree relative with breast cancer diagnosed under the age of 60. This criterion is explicitly stated in the primary trial's inclusion criteria.</s>",
        "contradict": "The statement \"Fiona's step sister, who is 34 years old was diagnosed with a ductal carcinoma, therefore fiona may be eligible for the primary trial\" can be contradicted by the information present in the CTRs for the following reasons:\n\n1. Age: Fiona must be premenopausal and between the ages of 25 and 54 to be eligible for the trial, and she is not explicitly stated to be in this age range.\n2. Cancer Diagnosis: Fiona's eligibility for the trial is based on being at increased risk for breast cancer, and having a first degree relative with breast cancer under the age of 60 or multiple second degree relatives with breast cancer. The statement does not mention Fiona's family history or any other eligibility criteria. Additionally, having breast cancer herself makes Fiona ineligible for the trial according to the exclusion criteria stated in the CTR.\n3. Cancer Treatment: The CTR specifies that subjects cannot have had any radiation therapy to the breast being studied or to the contralateral breast within a certain time frame, which is not stated in the expert statement.\n\nTherefore, the expert statement may not be entirely compatible with the information in the CTRs, as it may include eligibility criteria not explicitly stated in the CTR or may overlook ineligibility criteria.</s>"
    },
    "02538194-97ac-4749-9301-83f108927478": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00041067",
        "Secondary_id": "NCT01273896",
        "Statement": "Patients with ER positive, PR positive or HER2 positive tumors may be eligible for the secondary trial or the primary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as follows:\n\nPrimary Trial:\n- The inclusion criteria specify \"HER2-positive\" disease, which is a subset of ER+, PR+, and HER2+ tumors.\n\nSecondary Trial:\n- The inclusion criteria include patients with \"ER and/or PR+ disease.\" \n\nBoth trials' criteria overlap in allowing patients with ER+, PR+, or HER2+ tumors, making the expert's statement entailed by the CTRs.</s>",
        "contradict": "The statement is not directly contradictory to the information in the CTRs, but it can be misleading without further context. In the primary trial, hormone receptor status was not specified. In the secondary trial, patients with ER and/or PR positive disease were mentioned as eligible. Therefore, the statement seems correct based on the secondary trial. However, without knowing whether the primary trial only included ER negative, ER positive, PR negative, or both ER and PR positive patients, it is impossible to definitively conclude entailment between the statement and the primary CTR. In contrast, the secondary trial explicitly states that HER2 positive patients must have received prior treatment with Trastuzumab, which is not mentioned in the primary trial. Thus, some patients with HER2 positive tumors might not be eligible for the primary trial, contradicting the statement if it is interpreted universally for all trials.</s>"
    },
    "6d9113b4-9d18-4a1b-bc78-cc3ac1150876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572038",
        "Secondary_id": "NCT00826267",
        "Statement": "Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients receive 1 of 2 possible drugs.",
        "Label": "Entailment",
        "entail": "The Primary CTR specifies that participants receive pertuzumab, trastuzumab, and taxane, either docetaxel, paclitaxel, or nab-paclitaxel, during each treatment cycle. Therefore, each patient gets exposed to three different drugs in the primary trial. On the other hand, the Secondary CTR states that patients receive either afatinib or lapatinib during each treatment course, meaning that each patient receives one out of two possible drugs. This relationship is consistent with the given statement, where the primary trial administers three distinct drugs, and the secondary trial administers one out of two possible drugs. No contradiction or misrepresentation is evident, allowing for semantic entailment.</s>",
        "contradict": "The statement does not account for the fact that in the primary trial, taxane chemotherapy is also considered a drug that patients receive in addition to pertuzumab and trastuzumab. Thus, each patient in the primary trial is indeed receiving more than one drug, contrary to the statement's assertion that patients in the secondary trial receive 1 of 2 possible drugs while each patient in the primary trial receives 3 different drugs. However, the statement fails to acknowledge the presence of taxane chemotherapy as a drug in the primary trial, leading to an erroneous comparison.</s>"
    },
    "99599b71-85d7-4c15-8d23-4294732f87cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00558103",
        "Statement": "All participants in the primary trial are administered with Lapatinib 1500 mg PO QD.",
        "Label": "Entailment",
        "entail": "The statement \"All participants in the primary trial are administered with Lapatinib 1500 mg PO QD\" is entailed by the CTRs because:\n\n1. In both Intervention 1 and Intervention 2 of the primary trial, participants in Cohort 1 received Lapatinib 1500 mg PO QD.\n2. There is no contradictory information in the CTR stating that participants were not administered Lapatinib 1500 mg PO QD.\n3. The statement made by the expert does not specify any other conditions or requirements, which makes it a valid and accurate summary of the information presented in the CTRs.</s>",
        "contradict": "The statement \"All participants in the primary trial are administered with Lapatinib 1500 mg PO QD\" is not entirely accurate based on the provided CTR data. While it is true that participants in the first cohort of the primary trial received Lapatinib 1500 mg PO QD, those in the second cohort received Lapatinib 1500 mg PO in combination with Pazopanib 800 mg PO QD. The inaccuracy arises from the statement's omission of information regarding different dosing regimens for the different cohorts.</s>"
    },
    "adbc193f-ffd6-49ce-9acd-7b1675adf0c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00768222",
        "Statement": "Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Rachel is 19 years old and has skin ulcerations and allergic reactions to triclosan, she cannot take part in the primary trial\" is entailed by the information in the CTRs since the primary trial's exclusion criteria include \"Has skin ulceration\" and \"Has known allergy or intolerance to triclosan.\" Therefore, the statement harmonizes with the clinical trial data, finds substantiation in the CTR, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "Rachel's age (19 years) and her conditions (skin ulcerations and allergy to triclosan) are reasons for exclusion stated in the Primary Trial's Inclusion and Exclusion Criteria, respectively. The information in the statement by the expert is in agreement with the CTR. However, the contradiction occurs if the statement suggests that Rachel can participate in the trial, contrary to the explicit exclusion criteria outlined in the CTR.</s>"
    },
    "c476f92a-a450-4e5c-9688-6557ff3d822b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01617668",
        "Statement": "Patients must have healthy kidneys, liver and ovaries to participate in the primary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Patients must have healthy kidneys, liver, and ovaries to participate in the primary trial\" is entailed by the CTR's inclusion criteria stating \"Adequate renal function\", \"Adequate liver function and serum transaminases\", and no explicit exclusion for ovarian function. The CTR specifies these conditions for patient eligibility, thereby implying that only patients with healthy kidneys, liver, and ovaries meet the inclusion criteria and are eligible for the trial.</s>",
        "contradict": "The statement \"Patients must have healthy kidneys, liver and ovaries to participate in the primary trial\" is not an exact entailment of the information present in the CTRs for the primary trial. The CTR specifies adequate renal, liver, and bone marrow function, but it does not explicitly state that healthy ovaries are a requirement for trial participation. Therefore, while kidney and liver health is an inclusion criterion, ovarian health is not explicitly mentioned. Consequently, the statement made by the expert can be contradicted by the CTR as it adds unnecessary detail about ovarian health.</s>"
    },
    "39d685a4-b179-4687-a273-2a44e675f2c6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00900627",
        "Statement": "The two groups in the primary trial receive the same drug treatment, but group 2 gets double the dose.",
        "Label": "Contradiction",
        "entail": "Both groups in the primary trial indeed receive the same drug, AZD8931, for the intervention. The statement is factually correct regarding this point. However, the dose of AZD8931 differs between the groups, with group 1 receiving 160 mg twice daily (bd) and group 2 receiving 120 mg bd. This difference in dosage is explicitly stated in the CTR under the INTERVENTION section for each group. Despite the difference in doses, the drugs administered and the paclitaxel regimen are identical, making this statement entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement is not entirely accurate based on the information provided in the CTRs. While it is true that both groups are receiving the same drug, AZD8931, the dosage levels are different: 160 mg bd for group 1 in the primary trial and 120 mg bd for group 2 in both the primary and secondary trials. Consequently, group 2 does not merely receive \"double the dose\" of the drug for the interventions described in the CTRs.</s>"
    },
    "c66963b9-19e0-4c0f-bb65-2fec15e60b8f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00965523",
        "Statement": "The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients.",
        "Label": "Contradiction",
        "entail": "The expert's statement entails that Infection and Stomatitis are among the most frequent adverse events observed in the primary trial, with a combined occurrence of 14 cases out of a total of 81 participants (17.28%). This information is in harmony with the CTR data, as Infection and Stomatitis are explicitly mentioned, and their respective frequencies (2.47% for Stomatitis and 2.47% for Infection) add up to the total adverse event rate given in the CTR (17.28%).</s>",
        "contradict": "The statement \"The most common adverse events in the primary trial where Infection and Stomatitis, affecting a total of 14 patients\" can be contradicted by the information present in the CTRs because the provided statement suggests that both Infection and Stomatitis are the most frequent adverse events with a total count of 14, whereas the CTR data shows that Stomatitis occurred 2 times, and Infection occurred 2 times, making a total of 4 instances. The statement's claim of a total of 14 instances is an error, and the actual most common adverse events are Stomatitis and Nausea, each occurring 2 times.</s>"
    },
    "f541ce25-c43e-496b-98e6-8470fe23f840": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00559845",
        "Secondary_id": "NCT00426556",
        "Statement": "In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial\" can be entailed by the information present in the CTRs as follows: \n\n1. The number of adverse events in the primary trial is 8/54 (14.81%).\n2. The number of adverse events in the secondary trial for cohort 1 is 3/6 (50.00%) and in cohort 2 is 6/17 (35.29%). \n3. Comparing the number of adverse events between the two trials, we have: cohort 1 of secondary trial > cohort 2 of primary trial (3 > 1.85 + 1.85 + ...). \n\nHence, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"In total there were more adverse events in cohort 1 of the secondary trial than in cohort 2 of the primary trial\" is contradictory to the information present in the CTRs because the number of adverse events in each cohort is different, but the number of participants in each cohort is also different. The primary trial had 54 participants in cohort 1 with a total of 8 adverse events (14.81%), while the secondary trial had 6 participants in cohort 1 with a total of 3 adverse events (50.00%). However, without information about the number of participants in cohort 2 of the secondary trial, it is impossible to make a direct comparison based on the total number of adverse events alone. Therefore, the statement is an oversimplification that ignores the confounding factor of different patient numbers and does not accurately reflect the information contained in the CTRs.</s>"
    },
    "dafe9dce-420e-46dc-a8ed-ac2f4c84b49b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01224678",
        "Statement": "Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1.",
        "Label": "Entailment",
        "entail": "The statement \"Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1\" can be entailed by the information present in the CTRs, as follows:\n\n1. The CTR for the primary trial specifies that the study aims to evaluate change in mammographic density using the Boyd method after one year of vitamin D supplementation compared to placebo in premenopausal women. (ELIGIBILITY CRITERIA & OUTCOME MEASUREMENT)\n\n2. For the placebo arm, the CTR reports that 46 participants received placebo for 12 months, and the mean percentage change in mammographic density was -3.4 (7.1). (RESULTS 1)\n\n3. For the vitamin D arm, the CTR reports that 40 participants received vitamin D (2000 IU) once daily for 12 months, and the mean percentage change in mammographic density was -1.4 (11.9). (RESULTS 2)\n\n4. Comparing the results directly, the percentage change in mammographic density in the vitamin D arm (-1.4) is lower than the percentage change in the placebo arm (-3.4), supporting the expert's statement that the intervention with vitamin D led to a lower percentage of mammographic density than the intervention using a placebo.</s>",
        "contradict": "The statement \"Intervention 2 of the primary trial resulted in a lower percentage in Mammographic Density than intervention 1\" cannot be definitively determined as true based on the information provided in the CTRs. While it is stated that the mean percent change in breast density for the placebo group (-3.4) is greater than that of the vitamin D group (-1.4), it does not necessarily mean that intervention 2 resulted in a lower percentage change in mammographic density than intervention 1 for all participants or that the difference is statistically significant. Further analysis and comparison of the data, including the standard deviations and statistical testing, would be necessary to establish such a conclusion.</s>"
    },
    "24d81b18-ce9c-4927-9386-9ebef969a159": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00291135",
        "Secondary_id": "NCT00291694",
        "Statement": "The duration of treatment in the primary trial is half as long as in the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"The duration of treatment in the primary trial is half as long as in the secondary trial\" can be entailed by the information in the CTRs as follows:\n\nIn the primary trial, Letrozole is administered for six months (2.5 mg daily), which represents half the duration of the secondary trial. In the secondary trial, Celecoxib is given for 12 months, and the Placebo group also receives treatment for 12 months. Therefore, the duration of treatment in the primary trial is indeed half as long as in the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the duration of treatment for Intervention 1 in the primary trial is six months, which is indeed less than half of the 12 months of treatment in the secondary trial for both Intervention 1 (celecoxib) and Intervention 2 (placebo). However, it is important to note that the statement only compares the durations of Intervention 1 between the trials, and it doesn't take into account the difference in treatments or the potential existence of Intervention 2 in the primary trial. Thus, a more precise statement that accurately represents the entailment relationship would be:\n\nThe duration of Letrozole treatment in the primary trial is shorter than the duration of celecoxib treatment (or placebo treatment) in the secondary trial.\n\nSuch a statement correctly acknowledges the difference in treatments and avoids contradiction with the CTR data while maintaining the intended claim of the statement.</s>"
    },
    "0046e113-8ac5-4725-a285-e78b8c26f825": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02756364",
        "Statement": "In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTR inclusion criteria, which specify that patients must have \"Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy\" to meet eligibility. The expert's statement, while not using the exact term \"complete tumor response,\" implies that the patients experienced a positive response to prior AI therapy that was sufficient for them to meet the trial's eligibility. The presence of PD implies that the AI therapy did not result in a complete tumor response, but the expert's statement suggests that the patients had a response, albeit an incomplete one. This subtle distinction does not negate the entailment, as the expert's statement is consistent with the information presented in the CTR.</s>",
        "contradict": "The statement contradicts the CTR inclusion criteria in several ways. First, it asserts that patients must have had complete tumor response from prior aromatase inhibitor (AI) therapy in order to meet the inclusion criteria for the primary trial. However, the CTR states that participants must have progressive disease (PD) during prior AI therapy to be eligible. Second, it does not mention any requirement for a histologically proven diagnosis of breast cancer, estrogen receptor (ER)-positive status, or human epidermal growth factor receptor-2 (HER2)-negative status, which are all essential inclusion criteria specified in the CTR. Therefore, the statement is not in agreement with the CTR inclusion criteria and cannot be entailed from the information presented.</s>"
    },
    "e90f7748-f4b4-4822-8768-586c3f2f9980": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00499083",
        "Secondary_id": "NCT03045653",
        "Statement": "In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer.",
        "Label": "Contradiction",
        "entail": "The statement \"In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2+ breast cancer\" is entailed by the information present in the CTRs because:\n\n1. The primary trial specifies that patients must be female.\n2. The primary trial also mentions no age limit, so patients can be over the age of 18.\n3. The primary trial's ECOG performance status requirement is 0-1, allowing a score of under 2 for patients.\n4. The primary trial's disease characteristic includes Histologically confirmed invasive breast cancer, which can be HER2+ based on the provided criteria (IHC and/or FISH testing).\n\nFor the secondary trial, all the mentioned requirements are also fulfilled:\n\n1. Female: Already stated for the primary trial.\n2. Over the age of 18: Already stated for the primary trial.\n3. ECOG <2: Already stated for the primary trial.\n4. Histologically confirmed HER2+ breast cancer: The secondary trial includes HER2 negative in its exclusion criteria, but it also mentions HER2 positive in its inclusion criteria. Therefore, HER2+ breast cancer is a requirement for the secondary trial.\n\nThus, the information in the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"In order to be eligible for both the secondary trial and the primary trial, patients must be female, over the age of 18, ECOG <2 and have Histologically confirmed HER2 + breast cancer\" is contradicted by the information in the CTRs as follows:\n\n1. Primary Trial: The primary trial includes patients with HER2/neu-negative tumors. Therefore, patients cannot have HER2 positive breast cancer to be eligible for this trial.\n\n2. Secondary Trial: The secondary trial includes patients with Histologically confirmed HER2 negative breast cancer. Therefore, patients cannot have HER2 positive breast cancer to be eligible for this trial either. \n\nThus, the statement is contradicted by both trials in the CTRs.</s>"
    },
    "fb8f09d6-c393-4943-bc67-fa0f0a6bdd86": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429572",
        "Secondary_id": "NCT02455453",
        "Statement": "post-menopausal patients are excluded from the secondary trial, but eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\nIn the primary CTR, there are no explicit exclusion criteria for post-menopausal patients, whereas in the secondary CTR, post-menopausal patients are defined as inclusion criteria. This means that post-menopausal patients can satisfy the inclusion criteria of the primary trial but might not necessarily meet all the conditions specified in the secondary trial. Consequently, they are excluded from the secondary trial due to different eligibility criteria. However, being excluded from the secondary trial does not imply ineligibility for the primary trial.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as the inclusion criteria for the secondary trial specifies that post-menopausal patients are eligible, while the statement claims they are excluded.</s>"
    },
    "3c3fb5e3-1994-455a-bae4-6d267c5c89d7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00932373",
        "Statement": "Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Grade I peripheral neuropathy or above are eliminated from participation in the primary trial\" is entailed by the CTR inclusion criteria which state \"Grade 2 peripheral neuropathy\" as an exclusion criterion, implying that patients with a lower grade of peripheral neuropathy (Grade I) would also be excluded based on the given trial's eligibility criteria.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial exclusion criteria do not explicitly mention Grade I peripheral neuropathy as a reason for exclusion. Therefore, patients with Grade I peripheral neuropathy may be eligible for the primary trial according to the provided CTR information.</s>"
    },
    "2ecd62df-f5ea-417d-8783-2174a6d77087": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03573804",
        "Secondary_id": "NCT02781051",
        "Statement": "Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a fitbit.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a Fitbit\" is entailed by the information in the CTRs as follows:\n\nIn the primary trial, both intervention groups involve MRI evaluations by different radiologists (A and B), indicating that an MRI is part of the intervention for both groups. However, the CTR does not explicitly state that all participants undergo chemotherapy. The statement, therefore, overstates the requirement for chemotherapy in the primary trial but does not contradict the presence of MRI.\n\nIn the secondary trial, there is no mention of chemotherapy in the intervention section. Instead, participants undergo a physical activity intervention that includes using a Fitbit. The statement correctly identifies this difference in interventions between the two trials.\n\nTherefore, the statement is not a direct entailment of the information in the CTRs, but it correctly identifies the differences between the interventions in the two trials without contradicting the available information.</s>",
        "contradict": "The statement \"Participants of the primary trial must undergo at least one MRI during the intervention and a strict chemotherapy regiment, whereas in the secondary trial patients must use a Fitbit\" is contradicted by the information present in the CTRs because:\n\n1. In the primary trial, participants undergo MRI evaluation by two different radiologists (A and B) as part of the intervention, but there is no mention of a chemotherapy regiment.\n2. In the secondary trial, participants undergo a physical activity intervention instead of an MRI or chemotherapy regiment, and they are required to use a Fitbit as part of this intervention.\n\nTherefore, the statement incorrectly combines elements of both trials, and the requirement for MRI and strict chemotherapy regiment in the primary trial, and the requirement for using a Fitbit in the secondary trial are not compatible.</s>"
    },
    "b43c02bf-c4b0-495f-b7ba-879f409cb685": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01781299",
        "Statement": "all subjects in the primary trial must commit to a regular exercise schedule.",
        "Label": "Contradiction",
        "entail": "The statement \"all subjects in the primary trial must commit to a regular exercise schedule\" cannot be entailed by the information present in the CTRs as there is no mention of exercise requirements or schedules specified in either of the INTERVENTION sections for the primary or secondary trial.</s>",
        "contradict": "The statement \"all subjects in the primary trial must commit to a regular exercise schedule\" cannot be directly contradicted by the information present in the CTRs as no information regarding exercise schedules for participants is provided in the given CTR sections. Therefore, the statement is neutral or neither entailed nor contradictory to the CTRs.</s>"
    },
    "fdff0cf1-a0a2-4516-bdf7-109ac7adb266": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03136367",
        "Secondary_id": "NCT00129935",
        "Statement": "Only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criteria explicitly state that participants must be assigned female at birth. The secondary trial inclusion criteria also specify that patients must be female. Both trials share the same inclusion criterion for gender. Therefore, the statement that \"only patients which have been assigned as female at birth are eligible for the secondary trial and the primary trial\" is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the secondary trial's inclusion criteria include males with HER2 negative, operable invasive adenocarcinoma of the breast (T1-T3) who meet the other stated requirements, despite the primary trial only allowing female patients to participate.</s>"
    },
    "6babfc60-5043-4f2b-9605-3e44744265e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00398567",
        "Statement": "80% of patients in the primary trial did not suffer any adverse events.",
        "Label": "Contradiction",
        "entail": "75% of patients in the primary trial had no adverse events based on the given data; however, the expert's statement that \"80% of patients in the primary trial did not suffer any adverse events\" is an overapproximation of the actual data. Although the expert's statement is a close approximation of the data, it is not an exact entailment because the percentage given by the expert is slightly higher than the actual percentage stated in the CTR. However, the statement does not contradict the CTR and is consistent with the clinical trial findings. The discrepancy between the statement and the CTR can be attributed to rounding or slight variation in interpretation. Thus, the statement can be considered entailed with a qualification, taking into account the difference in quantification between the statement and the CTR.</s>",
        "contradict": "The expert statement that \"80% of patients in the primary trial did not suffer any adverse events\" contradicts the information in the CTR, as the CTR reports that 75.00% of patients in the primary trial experienced at least one adverse event (i.e., none of the patients had zero adverse events). The expert statement overshoots the actual number of patients with no adverse events and thus contradicts the data presented in the CTR.</s>"
    },
    "5ca02204-6120-4b02-bf3b-fba94d6fac4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274469",
        "Statement": "No more than 1% of either cohorts of the primary trial felt nauseous.",
        "Label": "Entailment",
        "entail": "The statement \"No more than 1% of either cohorts of the primary trial felt nauseous\" is entailed by the information in the CTRs as neither trial reported more than 1% of participants experiencing nausea (0.99% in the primary trial and 0% in the secondary trial).</s>",
        "contradict": "The statement \"No more than 1% of either cohorts of the primary trial felt nauseous\" directly contradicts the information presented in the CTRs as NAUSEA was reported in both trials with a frequency of 1 occurrence for each cohort in trial 1 (1/101 or 0.99%) and no occurrences in trial 2 (0/103). Although the percentages may seem close to 1%, there is still a discrepancy between the two as trial 1 does report a case of nausea.</s>"
    },
    "625c2690-ec9e-4ecc-85c0-9b5ca8467848": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00836186",
        "Statement": "Patients cannot be excluded from the primary trial on the basis of gender or ethnicity.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients cannot be excluded from the primary trial on the basis of gender or ethnicity\" is entailed by the information in the CTR because the CTR explicitly states under inclusion criteria, \"Women of all races and ethnic groups are eligible for this trial.\" This statement does not contradict any of the exclusion criteria and is in harmony with the information in the CTR.</s>",
        "contradict": "The statement that \"Patients cannot be excluded from the primary trial on the basis of gender or ethnicity,\" contradicts the information in the primary CTR under EXCLUSION CRITERIA, where it specifies that \"Women of all races and ethnic groups are eligible for this trial.\" However, this does not mean that the statement is necessarily incorrect, but rather that it is not fully entailed by the information present in the CTRs. In reality, the statement could be a simplification or oversimplification of the eligibility criteria, as the CTRs also contain other conditions for patient exclusion besides gender and ethnicity, which are not mentioned in the statement.</s>"
    },
    "c28ad685-4c91-492a-85ab-180f37d9cef5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00290758",
        "Statement": "There was one GU and three GI adverse events recorded in the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"There was one GU and three GI adverse events recorded in the primary trial\" can be entailed by the CTR information as follows:\n\n1. From the CTRs, we can observe that there is one adverse event related to \"Obstruction, GU: Uterus\" in the primary trial, which can be categorized as a Genitourinary adverse event (GU). \n\n2. Additionally, there are a total of three adverse events related to \"Ulceration\" in the primary trial, which can be categorized as Gastrointestinal adverse events (GI).\n\nTherefore, the statement's assertion (one GU and three GI adverse events) is in agreement with the CTR data, as it correctly identifies the presence of one Genitourinary and three Gastrointestinal adverse events.</s>",
        "contradict": "The statement \"There was one GU and three GI adverse events recorded in the primary trial\" contradicts the information present in the CTRs because there is no evidence in the provided data to suggest that there were three GI adverse events in the primary trial. The data in the CTRs only indicate one adverse event in the Primary Trial under the category \"Obstruction, GU: Uterus\" which can be considered a genitourinary (GU) event. The statement also does not mention any specific GI adverse events, and the data in the CTRs does not indicate any GI adverse events occurring in the primary trial besides ulceration which is not counted in the statement. Therefore, the statement's assertion does not harmonize with the clinical trial data, and it contradicts the provided descriptions in the CTRs.</s>"
    },
    "52e8d676-1744-4fdb-bab4-a553874329bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00829166",
        "Statement": "Female patients with Peripheral neuropathy >0 are excluded from the primary trial.",
        "Label": "Contradiction",
        "entail": "The primary trial's exclusion criteria specify that participants should not have peripheral neuropathy of Grade >= 3 based on NCI-CTCAE, Version 3.0. The expert's statement excludes female patients with any degree of peripheral neuropathy (>0). Since Grade 0 is considered as having no neuropathy, the expert's statement is a more inclusive version of the CTR's exclusion criteria. Therefore, the information contained in the expert's statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradictory to the eligibility criteria of the primary trial which includes the exclusion of participants with peripheral neuropathy of Grade >= 3 per NCI-CTCAE, Version 3.0. However, the expert's statement focuses on peripheral neuropathy > 0, which is less stringent than the trial's eligibility criteria. This discrepancy can result in contradictory interpretations of who is eligible to participate in the primary trial.</s>"
    },
    "beff8878-9405-412d-af3a-0f2720275bf3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00068601",
        "Secondary_id": "NCT01684215",
        "Statement": "the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions\" can be entailed by the information present in the CTRs because:\n\n1. In the primary trial, goserelin acetate is given subcutaneously according to the intervention section.\n2. In the secondary trial, there is no mention of a subcutaneous route for any intervention; however, the statement does not contradict the information in the CTR since no information suggests that PD-0332991 is administered subcutaneously in this trial. The statement's focus is on the primary trials using subcutaneous injections, and the secondary trial's administration method is not contradictory.\n\nIn summary, the statement can be entailed by the information in the CTRs as the primary trial indeed uses subcutaneous injections for an intervention, and the secondary trial does not contradict this fact.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both use subcutaneous injections as the route of administration for their interventions\" is incorrect. The primary trial involves intravenous administration of cyclophosphamide as part of the chemotherapy regimen, while goserelin is given subcutaneously. The secondary trial involves oral administration of PD-0332991. Therefore, there are no subcutaneous injections in common between the two trials.</s>"
    },
    "96f41881-6ba5-4688-8471-9462fc727919": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00089661",
        "Statement": "On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density.",
        "Label": "Entailment",
        "entail": "The expert's statement \"On average, cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density\" is entailed by the CTR information as follows:\n\n1. From the primary trial's results, it is clear that participants in the Denosumab 60 mg Q6M arm (cohort 1) had a mean percent change from baseline of 4.8 (95% CI: 4.3-5.4), which is a positive value, indicating an increase in Bone Mineral Density (BMD) on average.\n2. Conversely, participants in the placebo arm (cohort 2) had a mean percent change from baseline of -.7 (95% CI: -1.3 to -.1), which is a negative value, indicating a loss of BMD on average.\n\nThus, the expert's statement, which asserts that cohort 1 participants had an increase in BMD on average and cohort 2 had a loss in BMD on average, can be inferred directly from the data provided in the CTRs and is an entailed relationship.</s>",
        "contradict": "The statement \"On average cohort 1 participants in the primary trial had an increased Lumbar Spine Bone Mineral Density, whereas those in cohort 2 lost mineral density\" cannot be directly contradicted by the information present in the CTRs. However, it is important to note that the statement goes beyond the information provided in the CTRs. The CTRs only state the least squares mean (with 95% confidence interval) percentage change from baseline for each cohort, but they do not provide information about the distribution of the data or the average change for each individual participant. Thus, while the statement is consistent with the means reported in the CTRs, it may not hold true for every individual in each cohort, and there could be some participants in cohort 1 with a decreased bone mineral density and some participants in cohort 2 with an increased bone mineral density. Therefore, the statement should be interpreted with caution and in the context of the full data set, not just the means reported in the CTRs.</s>"
    },
    "9dbf55d5-6af3-4250-b5cb-97799cdf778a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were no cases of Intracranial hemorrhage in the primary trial.",
        "Label": "Entailment",
        "entail": "There are no cases of Intracranial hemorrhage reported in either Adverse Events 1 or Adverse Events 2 of the primary trial as per the provided data in the CTRs. Therefore, the statement \"There were no cases of Intracranial hemorrhage in the primary trial\" is entailed by the information in the CTRs.</s>",
        "contradict": "Although the statement claims there were no cases of intracranial hemorrhage in the primary trial based on the information presented, the CTRs do not explicitly mention the occurrence or non-occurrence of intracranial hemorrhage in any of the adverse events listed for each trial. The CTRs only report on various other adverse events, and intracranial hemorrhage is not among them. Consequently, the statement's contradiction with the CTR data arises due to an absence of direct information in the CTRs regarding the occurrence or non-occurrence of intracranial hemorrhage.</s>"
    },
    "e8ce8686-8d5f-4d31-b442-0cb52b7b2bec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00338728",
        "Statement": "Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often.",
        "Label": "Contradiction",
        "entail": "The statement \"Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often\" can be entailed by the information present in the CTRs as follows:\n\n1. In the primary trial, the dose of Imatinib mesylate is 400 mg twice a day, which amounts to a daily intake of 800 mg, and the dose of Letrozole is 2.5 mg once a day. \n2. To calculate the total daily doses for both drugs, we find that the patients in the primary trial receive 800 mg of Imatinib mesylate daily and 2.5 mg of Letrozole daily.\n3. Therefore, the total daily intake of Imatinib mesylate is indeed greater than that of Letrozole (800 mg vs. 2.5 mg).\n4. Regarding administration frequency, the patients take Letrozole once a day, while they take Imatinib mesylate twice a day; this means the patients in the primary trial take Letrozole twice as often as they take Imatinib mesylate (once daily vs. twice daily). \n\nThus, the statement that \"Participants of the primary trial receive higher doses of Imatinib mesylate than Letrozole but are administered Letrozole twice as often\" is an entailed claim based on the information in the CTRs.</s>",
        "contradict": "The statement \"Participants of the primary trial higher doses of Imatinib mesylate than Letrozole, but are administered Letrozole twice as often\" is contradictory to the information in the CTRs. \n\nExplanation: \n\nIn the primary CTR, participants receive 400 mg Imatinib mesylate twice a day daily for 28 days, which equals 840 mg Imatinib mesylate per cycle. In contrast, participants in the primary trial receive Letrozole 2.5 mg once a day daily for 28 days, which equals 2.5 mg Letrozole per day and 67.5 mg Letrozole per cycle. Therefore, the dosage of Imatinib mesylate is more than Letrozole in each cycle. However, the statement suggests that the dosage of Imatinib mesylate is lower, and participants receive Letrozole twice as often. This contradicts the CTR information.\n\nMoreover, the statement implies that Letrozole is given more frequently, but the CTR shows that Letrozole is given once a day. The expert's statement is incorrect because it contains inconsistent information regarding the number of daily administrations and the total dosages for each medication.</s>"
    },
    "d72709fd-e94e-4c27-bf56-3f028c0bbd3f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01118624",
        "Statement": "The majority of the primary trial participants achieved CR or PR.",
        "Label": "Contradiction",
        "entail": "The statement \"The majority of the primary trial participants achieved CR or PR\" can be entailed by the information in the CTRs as follows:\n\n1. The primary trial reports the objective response rate (ORR) as the outcome measure.\n2. ORR is the proportion of patients achieving a complete response (CR) or partial response (PR).\n3. In the Pralatrexate arm/group of the primary trial, 11 out of 22 participants achieved CR (5 out of 22 achieved PR, but PR is considered a subset of CR and PR plus CR equals ORR), meaning 27/22 = 1.23 times the number of patients achieved a CR or PR.\n4. Since \"majority\" is typically defined as more than 50% in clinical trials, and 1.23 exceeds 1.5 times 11 (which is 16.5, more than 11 and greater than 50% of the 22 participants), this statement can be entailed by the given CTR information.\n\nThere are several ways to calculate the majority, and in clinical trials, a commonly used definition is more than 50%. However, some trials use stricter definitions, such as more than 60% or more than 75% of participants. The exact definition of \"majority\" should be considered when evaluating such statements and the CTRs. In this answer, we assumed a definition of more than 50%.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the information provided in the CTRs. However, it is essential to note that the CTR for the primary trial does not provide a definitive number of participants who achieved CR or PR. Therefore, making a claim about the \"majority\" of participants in this context might exceed the information given in the CTR and could potentially be contradictory if the actual percentage turns out to be lower than a majority.</s>"
    },
    "bdf078ad-37b0-4f8f-80a3-35fa8e59fd2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00463788",
        "Statement": "Best Overall Response (BOR) was less than 10% higher in cohort 1 of the primary trial than in cohort 2.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as follows: \n\n1. The percentage of participants with best overall response (BOR) for each cohort in the primary trial can be calculated based on the provided data in Results 1 and Results 2. \n2. For cohort 1 (Cisplatin and Cetuximab), the percentage is 20.0 (13.1 to 28.5).\n3. For cohort 2 (Cisplatin alone), the percentage is 10.3 (3.9 to 21.2).\n4. To determine if BOR was less than 10% higher in cohort 1, we need to calculate the difference and check if it is less than 10%.\n5. The difference is 20.0 - 10.3 = 9.7.\n6. Since 9.7 is less than 10%, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement is inconsistent with the data from the CTRs due to the lack of information on the actual BOR percentages for both cohorts in the primary trial. The statement asserts that the difference between the percentages of cohort 1 and cohort 2 is less than 10%. However, the CTR only provides the percentage of participants with BOR for each cohort (20.0% for cohort 1 and 10.3% for cohort 2). Without knowing the actual BOR percentages, it is impossible to definitively conclude whether the difference is less than 10%. Therefore, the statement could be contradicted by the CTR data if the actual difference between the BOR percentages is more than 10%.</s>"
    },
    "49f44497-2382-4658-b716-38e66c5c52b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00425854",
        "Statement": "Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study.",
        "Label": "Entailment",
        "entail": "The expert's statement \"Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study\" is entailed by the following information in the given CTRs:\n\n1. Primary Trial: Cohort B received Afatinib 50 mg as the intervention.\n2. Primary Trial: The administration route for Afatinib in Cohort B was oral.\n3. Primary Trial: Afatinib was given to patients daily in Cohort B.\n\nThus, the expert's statement is a logical consequence of the provided CTRs and is semantically entailed.</s>",
        "contradict": "The statement \"Intervention of Cohort B is described as Afatinib 50 mg, taken orally, for every day of the study\" is not contradictory to the information in the CTRs. However, it is redundant since the same information is already provided in the CTR for the primary trial. The CTR states that \"Cohort B patients received Afatinib 50 mg qd (oral).\" Both statements convey that patients in Cohort B were given Afatinib at a dose of 50 mg per day, orally, for the duration of the study. The potential for contradiction exists if the statement contained different dosage, frequency, or duration information.</s>"
    },
    "4a6dc84a-3afd-4060-b8c5-981895f31099": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00312208",
        "Statement": "Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs as no cases of cardiomyopathy were reported in the secondary trial's Adverse Events section (0/1635), and only one case was observed in the primary trial's Adverse Events 1 section for cohort 1 (1/1634). Similarly, no cases of coagulation disorders were reported in the secondary trial's Adverse Events section (0/1635), and only one case was observed in the primary trial's Adverse Events 1 section for cohort 1 (1/1634). Therefore, the statement that \"Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial\" is entailed by the CTRs as it correctly describes the reported findings in the trials.</s>",
        "contradict": "The statement \"Cases of Cardiomyopathy and Coagulation disorders were only observed in cohort 1 of the primary trial\" cannot be conclusively affirmed or refuted based on the provided information in the CTRs. While it's true that only Cohort 1 of the Primary Trial reported one case of Cardiomyopathy, there is no such report for Cohort 1 in the Secondary Trial. However, the Secondary Trial does report one case of Coagulation disorders in Cohort 2, which contradicts the expert's statement that these conditions were exclusively observed in Cohort 1 of the Primary Trial.</s>"
    },
    "11e84dc4-6573-4ad7-b2d9-cfc66b626e1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02574455",
        "Statement": "More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event.",
        "Label": "Entailment",
        "entail": "The statement \"More than a quarter of patients in cohort 1 of the primary trial experienced an adverse event\" is entailed by the CTR data because the CTR reports that a total of 69 adverse events occurred in 258 patients (26.74%), which is more than a quarter of the total patient count. This percentage applies to the entire patient population in the primary trial, which is equivalent to \"cohort 1\" as mentioned in the expert statement.</s>",
        "contradict": "The expert's statement does not provide sufficient information to determine if it is contradicted by the CTR data. While the statement mentions that more than a quarter of patients in cohort 1 of the primary trial experienced an adverse event, it does not specify which trial (primary or secondary) the cohort refers to. Since the CTRs provided describe adverse events for each trial separately, it's necessary to identify which trial's cohort 1 the expert is referring to in order to evaluate if the statement contradicts the information in the CTRs.</s>"
    },
    "f1f2e066-a016-422f-8627-d0e477933352": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00193063",
        "Statement": "In the primary trial patient cohort, 3 different types of infections are observed. ",
        "Label": "Entailment",
        "entail": "The statement \"In the primary trial patient cohort, 3 different types of infections are observed\" is entailed by the data in the CTR. The mentioned types of infections are \"pneumonia,\" \"port site infection,\" and \"urinary tract infection,\" which are all present in the CTR under the adverse events section.</s>",
        "contradict": "The statement \"In the primary trial patient cohort, 3 different types of infections are observed\" can be contradicted by the information present in the CTR as only two distinct types of infections, pneumonia and urinary tract infections, are specifically mentioned. Although the statement does not explicitly mention the number of instances for each type of infection, it implies that there are at least three distinct types based on the plural form of \"types\". However, the CTR data only supports the presence of two distinct types, which contradicts the statement.</s>"
    },
    "efbd87d7-f8ac-42c6-ac9a-e3a35d354885": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00295867",
        "Statement": "Patients with a Karnofsky status of 94% are eligible for the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with a Karnofsky status of 94% are eligible for the primary trial\" can be entailed by the information present in the CTR as follows:\n\nThe CTR specifies \"Karnofsky Performance status < 90%\" as an exclusion criterion for the primary trial. Conversely, the absence of this condition implies inclusion. Therefore, a Karnofsky Performance status of 94%, which is greater than 90%, does not contradict any information provided in the CTR and can be inferred as a valid inclusion criterion.</s>",
        "contradict": "The statement \"Patients with a Karnofsky status of 94% are eligible for the primary trial\" contradicts the information present in the CTRs, as the CTRs explicitly list a Karnofsky Performance status < 90% as an exclusion criterion for the primary trial.</s>"
    },
    "a604244f-789f-4c12-8c5a-96c86d1b976e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.",
        "Label": "Entailment",
        "entail": "The expert's statement asserts that the maximum percentage change in betaCTX observed in the primary trial was -75.9% from baseline in the AZD0530 175 mg group. According to the CTR information, the geometric mean percentage change in betaCTX for the AZD0530 175 mg group at Week 4 was -71.1 (-75.9 to -65.4). Since -75.9 falls within the 95% confidence interval of -71.1, it can be inferred that the statement is entailed by the CTR data for the AZD0530 175 mg arm as it lies within the range of possible values reported for this group.\n\nAdditionally, the statement does not contradict the other sections of the CTRs. It focuses on the betaCTX outcome and the percentage change from baseline for the primary trial, harmonizing with the provided data.</s>",
        "contradict": "The statement made by the clinical trial expert can be contradicted by the information in the CTRs because the expert's statement mentions a specific patient in the AZD0530 175 mg group with a -75.9% change from baseline, which is outside the reported geometric mean (GM) of -71.1 (-75.9 to -65.4) in the CTR. The expert's statement might not be an accurate representation of the overall findings in the trial. The CTR reports the GM change for the entire AZD0530 175 mg group.</s>"
    },
    "2b543cc7-e295-4dc6-ad04-a2e43e9b3d97": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01565083",
        "Statement": "Two different types of tachycardia occurred to patients in cohort 2 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Two different types of tachycardia occurred to patients in cohort 2 of the primary trial\" can be entailed by the information in the CTRs as both trials report the occurrence of tachycardia, each with one instance in the respective cohorts. Therefore, the statement is consistent with the trial results.</s>",
        "contradict": "The statement \"Two different types of tachycardia occurred to patients in cohort 2 of the primary trial\" cannot be directly contradicted by the information present in the CTRs, as tachycardia only occurred once in cohort 2 according to Adverse Events 1, and once in cohort 2 according to Adverse Events 2. However, it can be contradicted if the expert intended to make a comparison between primary and secondary trials, as tachycardia was not reported in cohorts of the secondary trial.</s>"
    },
    "987b1da5-0276-417d-a659-8e298529ccac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01684215",
        "Statement": "In the primary trial there was no recorded difference in the Number/percentage of Participants With Dose Limiting Toxicities taking 100 mg vs 125 mg of oral PD-0332991.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTRs as both the CTR for the PD-0332991 100 mg and 125 mg dose escalation cohorts specify identical dosing regimens (28-day cycle with a 7-day lead-in period and a 21-day on-treatment phase) and identical criteria for defining DLTs (CTCAE version 4.0, with grade 4 neutropenia, febrile neutropenia, grade >=3 thrombocytopenia with bleeding, grade 4 thrombocytopenia, grade >=3 non-hematologic toxicity except controllable grade 3/4 nausea, vomiting, or electrolyte abnormality, and grade 3 QTc prolongation as DLTs). The CTRs also provide that the same number of participants (6 in each group) were analyzed for both doses. Since the identical dosing regimen, DLT definition, and equal participant numbers in both groups ensure that any difference or lack of difference in DLTs between the two doses can be observed directly from the data presented, the expert's statement is an entailed consequence from the information contained in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs due to the absence of explicit data comparing the number or percentage of participants with dose-limiting toxicities (DLTs) between the two groups (PD-0332991 100 mg and PD-0333991 125 mg) directly within the provided text. Although both CTRs report the same DLT definitions and time frames, and identical percentages of participants (16.7%) are analyzed in each group, no statistical analysis or direct comparison of DLT occurrence is presented in the CTRs. Therefore, making a definitive statement about a nonexistent comparison in the data is not valid.</s>"
    },
    "b9e8a0b3-574f-4079-9191-214af99e97a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01176916",
        "Secondary_id": "NCT00186121",
        "Statement": "postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancerare eligible for the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\nIn the Primary Trial: \nThe inclusion criteria specify that the patient is a postmenopausal woman with early invasive breast cancer (T1-4N1-3M0), ER-positive. This means that postmenopausal women with T1-4N1-3M1 breast cancer also meet the criteria, as M0 indicates no evidence of distant metastasis.\n\nIn the Secondary Trial: \nThe inclusion criteria for this trial include patients with \"histologically-confirmed, bi-dimensionally measurable, recurrent or metastatic carcinoma of the breast that is progressive.\" This includes patients with T4 tumors, which represent advanced stages of breast cancer. Furthermore, there is no age restriction stated, allowing both pre- and postmenopausal women with T4 tumors to be eligible. However, the statement specifically mentions Premenopausal women, so it is important to consider that the eligibility criteria for the secondary trial also include premenopausal women with early invasive breast cancer (T1-4N1-3M1, M1 indicating the presence of distant metastasis). This condition is not explicitly stated in the provided CTR for the secondary trial, but it is implied based on the definition of \"metastatic carcinoma.\" \n\nTherefore, the statement is entailed by the information present in the CTRs, as it correctly identifies different populations eligible for the primary and secondary trials based on patient characteristics, including menopausal status and tumor stage.</s>",
        "contradict": "The statement \"postmenopausal women with T1-4N1-3M1 Early invasive breast cancer are eligible for the primary trial, and Premenopausal women with T4-4N1-3M1 Early invasive breast cancer are eligible for the secondary trial\" is contradictory to the information present in the CTRs as follows:\n\n1. In the primary CTR, only postmenopausal women are eligible (as stated in the inclusion criteria). Premenopausal women are expressly excluded (as stated in the exclusion criteria).\n2. In the secondary CTR, premenopausal women are included (as stated in the inclusion criteria).\n\nThus, the statement contradicts the eligibility criteria for both trials based on the patient's menopausal status and the stage of breast cancer.</s>"
    },
    "0151d1fa-05c8-45a0-b21e-f08478ea5110": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01697345",
        "Secondary_id": "NCT00513292",
        "Statement": "Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement asserts that Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in the secondary trial, but not in the primary trial for cohort 1. This can be entailed by the information presented in the CTRs as follows:\n\n1. In the primary trial's Intervention 1, testosterone is mentioned but FEC is not, indicating that it is not used.\n2. In the secondary trial, Intervention 1 for both arms includes FEC in combination with other drugs. However, Intervention 2 in arm 2 of the secondary trial mentions FEC following the administration of paclitaxel and trastuzumab, which was not used in cohort 1 of the primary trial.\n\nTherefore, the statement's assertion is harmonious with the clinical trial data, finds substantiation in the CTR, and avoids contradiction with the provided descriptions, making it entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"Fluorouracil, testosterone, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial\" is contradictory to the information provided in the CTRs because:\n\nPrimary Trial: \nThe primary trial does not involve the use of FEC as stated in the intervention section, only the FSFI Total Score is mentioned for both pretest and posttest in two different interventions.\n\nSecondary Trial:\nAlthough FEC is mentioned in both cohorts of the secondary trial in the intervention section, it is not used in the same way in each cohort:\nCohort 1: FEC is followed by Paclitaxel/Trastuzumab and then Trastuzumab/FEC-75.\nCohort 2: Paclitaxel/Trastuzumab is followed by FEC-75 and then Trastuzumab.\n\nTherefore, the statement is contradictory to the information present in the CTRs as FEC is indeed used in the secondary trial but not in the same manner as claimed in the statement.</s>"
    },
    "b4b3ebdf-0e46-48fd-a57d-7d2a6c8a48de": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01075100",
        "Secondary_id": "NCT00290758",
        "Statement": "several different mental health issues were observed in the primary trial and the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"several different mental health issues were observed in the primary trial and the secondary trial\" can be entailed by the information present in the CTRs as both trials report the occurrence of Mood Alteration: Depression in one participant each.</s>",
        "contradict": "The statement \"several different mental health issues were observed in the primary trial and the secondary trial\" cannot be conclusively determined to be an entailed relationship with the information in the CTRs based on the provided data. The CTRs list adverse events such as depression under the category of 'Mood Alteration', but they do not explicitly state that mental health issues other than depression were observed in either trial. Therefore, the statement could be contradicted if mental health issues other than depression were not present in the trials, but the statement implies that they were.</s>"
    },
    "b838a265-99e4-42f0-bd72-b4f72d7eb16e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02027376",
        "Statement": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement does not directly entail any specific information from the primary CTR as it mentions a different treatment (Pertuzumab) and does not provide details matching the inclusion or exclusion criteria of the primary trial. However, it can be inferred that the patient's ineligibility in the secondary trial due to recent Pertuzumab treatment may align with the primary trial's exclusion criteria regarding receiving \"any other investigational agents 5 t1/2 or 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy.\" This alignment can be considered an implication, but not a direct entailment.</s>",
        "contradict": "The statement contradicts the exclusion criteria in the primary trial, specifically the patient has received a small molecule therapeutic less than the required duration prior to study entry.</s>"
    },
    "240e9cb0-3e40-4478-9d2c-fb4ff22e1e21": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00676793",
        "Secondary_id": "NCT01931163",
        "Statement": "Patients suffering from vomiting are still eligible for both  the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial\" does not contradict the inclusion criteria of either CTR. Neither the primary nor the secondary CTR lists vomiting as an exclusion criterion. Therefore, the semantic entailment relationship between the statement and the CTRs holds true.</s>",
        "contradict": "The statement \"Patients suffering from vomiting are still eligible for both the secondary trial and the primary trial\" is contradicted by the information present in the CTRs. In the primary trial, no mention of vomiting being an inclusion or exclusion criterion is present. However, for the secondary trial, there is no specific mention of vomiting as an inclusion criterion, but it could potentially be an exclusion criterion under \"concurrent severe, uncontrolled infection or intercurrent illness\" if it is a symptom of an underlying condition. Therefore, the presence of vomiting may not necessarily disqualify a patient from participating in the secondary trial. However, the primary CTR explicitly states that liver function must be normal, and vomiting can potentially indicate gastrointestinal dysfunction, which may interfere with drug absorption or liver function. Therefore, a patient suffering from significant vomiting could potentially fail to meet eligibility criteria for the primary trial, even if they meet all other inclusion/exclusion criteria. Thus, the statement is contradictory to the information presented in the CTRs.</s>"
    },
    "a1644573-fba8-4598-8353-a40d3ef1968c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00428922",
        "Secondary_id": "NCT00499083",
        "Statement": "Patients with prior chemotherapy for the treatment of stage 4 cancer are not eligible for either the primary trial or the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs as both trials have identical exclusion criterion regarding prior chemotherapy in the metastatic setting. (CTR for Primary Trial: \"No prior chemotherapy in the metastatic setting.\" CTR for Secondary Trial: \"No prior chemotherapy.\")</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial explicitly includes the statement \"No prior chemotherapy in the metastatic setting,\" whereas the secondary trial does not mention prior chemotherapy eligibility criteria at all. This means that according to the provided information, patients with prior chemotherapy for the treatment of stage 4 cancer could potentially be eligible for the secondary trial.</s>"
    },
    "ba533122-db9d-49e1-a2d1-936c8fdfdd00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01298193",
        "Statement": "More than 15 patients in cohort 1 of the primary trial experienced adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"More than 15 patients in cohort 1 of the primary trial experienced adverse events\" can be entailed by the information present in the CTR under the \"Adverse Events\" section of the primary trial. The total number of adverse events reported for cohort 1 was 31, which is more than 15 when considering that there were 185 participants in the cohort (31/185 > 15/185). Therefore, the statement is in agreement with the provided data and does not contradict the descriptions in the CTRs.</s>",
        "contradict": "The statement \"More than 15 patients in cohort 1 of the primary trial experienced adverse events\" cannot be directly contradicted by the information present in the CTRs. However, it is important to note that the CTR only lists 16 adverse events for a total of 185 patients, without specifying how many patients experienced each event. Therefore, it is possible that more than 15 patients in cohort 1 experienced an adverse event, but it is also possible that fewer than 15 did. The statement is not contradicted by the information given, but it may not be fully accurate based on the information provided in the CTR.</s>"
    },
    "f20cd859-7159-457a-a1cb-56bdb01d521b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00274456",
        "Statement": "There are a total of 7 cases of Gastritis in the primary trial across both cohorts.",
        "Label": "Contradiction",
        "entail": "The statement \"There are a total of 7 cases of Gastritis in the primary trial across both cohorts\" is not entailed by the information in the CTRs. No instance of Gastritis is reported in either the Adverse Events 1 or Adverse Events 2 sections of the Primary Trial CTR, and neither cohort in the Secondary Trial is specified in the statement.</s>",
        "contradict": "The statement \"There are a total of 7 cases of Gastritis in the primary trial across both cohorts\" is contradicted by the information present in the Adverse Events sections of the primary CTR, as neither cohort in the primary trial reports a single instance of Gastritis (0/76 in both sections).</s>"
    },
    "d33df923-6c12-4135-b339-5cefdd240985": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00003782",
        "Statement": "Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects.",
        "Label": "Entailment",
        "entail": "The statement \"Neither of the cohorts in the primary trial had more than 5% of patients experiencing side effects\" can be entailed by the data in the CTRs as follows:\n\nTotal adverse events in each cohort:\n- Cohort 1 in Primary Trial: 66/1748 = 3.78%\n- Cohort 2 in Primary Trial: 43/1748 = 2.46%\n\nBoth cohorts' adverse event rates are less than 5%.</s>",
        "contradict": "The statement can be contradicted by the CTR data as the total proportion of participants experiencing adverse events in both cohorts of the primary trial was above 3.78% and 2.46% for Adverse Events 1 and Adverse Events 2, respectively. These proportions exceed the threshold of 5% mentioned in the expert's statement.</s>"
    },
    "0f49a1ec-ed73-465b-be20-b70fe990b1f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00333775",
        "Secondary_id": "NCT00201864",
        "Statement": "There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial.",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial\" can be entailed by the information presented in the CTRs as follows:\n\n1. In the primary trial, adverse events include Atrial fibrillation (a type of arrhythmia), Atrioventricular block first degree, Arteriospasm coronary (a type of arterial event potentially related to coagulation), and Thrombocytopenia (a condition associated with impaired coagulation). These events collectively represent coagulative adverse events.\n2. The primary trial reports 37.79% (82/217) adverse events, while the secondary trial reports 15.00% (6/40) adverse events.\n3. None of the reported adverse events in the secondary trial relate to coagulation (there's no Thrombocytopenia, Atrial fibrillation, Atrioventricular block first degree, or Arteriospasm coronary).\n4. Thus, the expert's statement \"There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial\" is entailed by the CTRs as the primary trial contains several coagulative adverse events, and there are no coagulative adverse events reported in the secondary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the term \"coagulative adverse events\" is not explicitly defined in the provided context. The statement infers that coagulative adverse events are synonymous with thromboembolism and Atrioventricular block first degree, as they are the only types of adverse events mentioned in the statement that are not listed in either CTR. However, other coagulative adverse events like Atrial fibrillation, Arrhythmia, and Arteriospasm coronary are mentioned in the CTRs of the primary trial but are not specified in the statement. Therefore, the statement does not accurately reflect the content of both CTRs and can be contradicted by the data provided.</s>"
    },
    "7370c10d-f6e7-4153-9649-9d2598ce1ed7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03196635",
        "Secondary_id": "NCT01943916",
        "Statement": "the primary trial and the secondary trial are both evaluating imaging techniques.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial are both evaluating imaging techniques\" is entailed by the information in the CTRs because both trials mention the use of image sets and the assessment of their clinical image quality. In the primary trial, image sets for both PA and TC compressions are evaluated (INTERVENTION 1 for both PA and TC compression image sets), while in the secondary trial, each participant serves as their own control, and imaging is conducted using both test and control modalities (INTERVENTION 1: \"Each subject served as her own control, with imaging of each mass by both the test and control modalities\"). This implies that both trials involve imaging techniques as the interventions being assessed.</s>",
        "contradict": "While the statement is generally correct that both trials are evaluating imaging techniques, it does not capture the specific imaging evaluation processes described in the CTRs. In the primary trial, two readers evaluated the clinical image quality of PA and TC compression image sets from all study participants. In contrast, the secondary trial employed a within-subject design, where each participant served as her own control, and imaging was done using both test and control modalities for each mass. These different evaluation methods and designs can lead to varying results and interpretations, and the statement does not provide sufficient information to establish entailment with the CTRs.</s>"
    },
    "3f89537a-479e-4314-b9de-4caf845850fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the Zoledronic Acid 4 mg group, with a -73.0 % change from baseline.",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that the maximal percentage change in betaCTX at Week 4 in the primary trial was observed in a patient in the Zoledronic Acid 4 mg group with a change of -73.0%. The CTRs report that the geometric mean (minimally influenced by outliers) change from baseline in percentage of betaCTX for the Zoledronic Acid 4 mg group at Week 4 was -73.0% (95% CI: -73.0 to -63.2). Since the expert's statement is consistent with the data reported in the CTRs without contradiction, the entailment is established.</s>",
        "contradict": "The expert's statement is not directly contradictible to the information in the CTRs; however, it does not perfectly match the information either. The expert mentions a specific patient with a -73.0% change, whereas the CTR provides the geometric mean and 95% confidence interval for the entire Zoledronic Acid 4 mg group. These statistics do not necessarily correspond to the value seen in a single individual, especially since they represent the average change across all participants in the group and come with statistical uncertainty. Therefore, the expert's statement could hold true for a particular patient but does not definitively entail the data in the CTRs.</s>"
    },
    "8e9f417a-dc0f-4c20-9cf7-5f8586c23df2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01985971",
        "Secondary_id": "NCT03273426",
        "Statement": "Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial, for the primary trial patients will also need to have a brain MR and PET imaging, after study entry.",
        "Label": "Contradiction",
        "entail": "Both CTRs mention the requirement for MR imaging for study participants. For the primary trial, MR imaging of the brain and PET imaging are stated as necessary for inclusion. For the secondary trial, an MRI scan of the spine is required before entry. Since the expert's statement does not contradict these conditions and includes the common requirement of MR imaging, it can be entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Patients will have to undergo an MRI scan of the spine for before entry for both the secondary trial and the primary trial\" is not directly contradicted by the information in the CTRs. However, it is important to note that while MRI scans of the spine are mentioned in the secondary trial's inclusion process, it is not explicitly stated in the primary trial's inclusion criteria that all patients undergo a spine MRI before study entry. The primary trial does mention that subjects must undergo brain MRI and PET imaging as part of their inclusion criteria, but there is no mention of a spine MRI. Therefore, the statement could be considered a generalization or assumption that may not align exactly with the specific requirements outlined in the primary trial's CTR.</s>"
    },
    "8ba451be-606a-4a57-a85e-82b5e5b286fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT03366428",
        "Statement": "3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms.",
        "Label": "Entailment",
        "entail": "The expert's statement \"3/49 the primary trial Participants had a Maximum change from baseline in QTcF of over 30 ms\" can be entailed by the information presented in the CTR, as follows:\n\n1. The CTR specifies a maximum change from baseline in QTcF of over 30 ms for 3 out of the 49 participants in the DS-8201a arm (6.1%).\n2. The expert's statement states that 3 out of 49 participants in the primary trial (6.1%) had a maximum change from baseline in QTcF of over 30 ms, which aligns with the information in the CTR.\n3. No contradiction exists between the expert's statement and the CTR, as they both refer to the same trial and section of the CTR and present the same data.</s>",
        "contradict": "The statement \"3/49 the primary trial Participants With HER2-expressing Metastatic and/or Unresectable Breast Cancer had a Maximum change from baseline in QTcF of over 30 ms\" contradicts the CTR information as the CTR reports that only 3 out of the 49 participants (6.1%) in the DS-8201a arm had a maximum change from baseline in QTcF over 30 ms. The expert's statement misrepresents the number of participants with this specific outcome, stating that 3 out of every 49 participants experienced it.</s>"
    },
    "46906361-5133-4db9-b9e5-b9b7f80a8666": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00721630",
        "Secondary_id": "NCT00364611",
        "Statement": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea\" is entailed by the information present in the CTRs because both trials reported 1.92% (or 1 out of 52) of patients experiencing nausea in their respective adverse events sections.</s>",
        "contradict": "The statement is contradicted by the information present in the CTRs because the Primary Trial reported 1/23 (4.35%) cases of nausea while the Secondary Trial reported 0/52 (0.00%), which are not the same proportion of patients experiencing nausea.</s>"
    },
    "ab17f223-3f70-4b63-bfc5-1fca5d6ec05d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy , and must have T1-3, N0 and M0 breast cancer.",
        "Label": "Entailment",
        "entail": "The statement \"In order to be eligible for the primary trial, patients must not have prior radiation, anthracycline or systemic anticancer therapy, and must have T1-3, N0 and M0 breast cancer\" is entailed by the CTR inclusion criteria. The CTR explicitly states that \"No prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy), no prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy, no prior radiation therapy for breast cancer\" are inclusion criteria. Furthermore, the CTR states that patients must have operable breast cancer with T1-T3 tumor stage and negative axillary lymph nodes (N0), and M0 indicates absence of distant metastasis. Therefore, the statement made by the clinical trial expert falls within the scope of the CTR's inclusion criteria.</s>",
        "contradict": "The expert's statement contradicts the CTR inclusion criteria in several ways. First, it incorrectly states that patients must have T1-3, N0, and M0 breast cancer to be eligible, whereas the CTR includes patients with negative axillary lymph nodes (N0) but does not specify T or M stages beyond T1-T3. Second, the expert's statement excludes patients with any prior radiation therapy, while the CTR includes patients who have undergone definitive surgical treatment with histologically free margins following radiation therapy. Lastly, the expert's statement excludes patients with prior systemic anticancer therapy but does not mention the exclusion of patients receiving corticosteroids or other experimental drugs, which are explicitly stated in the CTR's exclusion criteria.</s>"
    },
    "3320983d-55cb-49f9-9265-ca4e77acf62a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01094184",
        "Statement": "A patient who had a Joint injection in the last month would not be eligible for the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement entails that a patient with a joint injection in the past month would not meet the eligibility criteria of the primary trial due to unspecified reasons. However, the CTR provides the eligibility criteria for the primary trial which includes the condition that the participant has measurable or non-measurable metastatic disease, requires combination therapy for their disease, and has a life expectancy of greater than or equal to 12 weeks, among other conditions. The CTR does not mention any exclusion related to joint injections. \n\nHowever, we need to consider the implications of the statement made by the clinical trial expert. A joint injection is a common medical intervention used to treat various conditions, and it may be administered for different reasons, including but not limited to pain management, arthritis, or joint inflammation. Some medications used in joint injections may interfere with certain chemotherapy agents used in combination therapy or have other interactions that may affect the study outcomes. \n\nTherefore, the expert's statement can be entailed by the information present in the CTR, as the exclusion criteria in the CTR may not capture all the potential reasons for ineligibility, and the expert's statement addresses one of the potential reasons based on their clinical knowledge and experience.</s>",
        "contradict": "The patient eligibility criterion for the primary trial specifies that there are no exclusions based on previous joint injections. Therefore, the statement made by the clinical trial expert can be contradicted by the information present in the CTRs.</s>"
    },
    "6c57e451-a706-4b32-ae71-254e9d0e04de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01250379",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Entailment",
        "entail": "The statement \"None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation\" is entailed by the CTR data, as the Adverse Events sections explicitly report zero occurrences of Thrombocytopenia, congestive Cardiac failure, and Atrial fibrillation in the primary trial, and no mentions of Pancytopenia or Acute coronary syndrome with specific event labels in the provided data.</s>",
        "contradict": "The expert's statement is contradicted by the data in the CTRs as both reports list occurrences of Thrombocytopenia, congestive Cardiac failure, and Atrial fibrillation in their respective adverse event sections. In the primary trial, there was 1 instance of Thrombocytopenia, 0 instances of congestive Cardiac failure, and 1 instance of Atrial fibrillation. In the secondary trial, there were 5 instances of Thrombocytopenia, 2 instances of congestive Cardiac failure, and 1 instance of Atrial fibrillation.</s>"
    },
    "73a5f715-6d4c-43f3-ace4-9f1217d3d0c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00383500",
        "Statement": "the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch.",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch\" can be entailed by the information present in the CTRs as follows:\n\nThe CTR for the primary trial specifies that the intervention involves the use of a Flexitouch Device for lymphedema management. A Flexitouch Device is categorized as a medical device and not a drug. Therefore, the statement that the trial is testing a medical device called the Flexitouch is a valid conclusion that can be drawn from the CTR and is entailed by the given statement made by the expert.</s>",
        "contradict": "The statement \"the primary trial is not testing a drug based intervention, it is testing a Medical device called the Flexitouch\" can be contradicted by the information present in the CTR of the primary trial if it contains interventions other than the Flexitouch device that involve drug-based interventions. Even though the primary trial is primarily testing the Flexitouch device, the presence of drug interventions in the trial would make the statement false.</s>"
    },
    "83883edd-ea16-4b20-8a97-2a545f957add": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00006110",
        "Secondary_id": "NCT00464646",
        "Statement": "the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events.",
        "Label": "Contradiction",
        "entail": "The statement that \"the secondary trial records only gastrointestinal adverse events, whereas the primary trial doesn\u2019t record any GI adverse events\" is entailed by the information present in the CTRs because:\n\n1. In the primary CTR, no adverse events related to the gastrointestinal system are reported in the first or second set of Adverse Events.\n2. In the secondary CTR, all adverse events are related to the gastrointestinal system, as evidenced by the presence of multiple entries under hemorrhage (GI - stomach, colon), perforation (GI - colon), ulcer (GI - stomach), and diarrhea.\n\nTherefore, the statement that the secondary trial records only gastrointestinal adverse events and the primary trial doesn't record any is consistent with the data in the CTRs and can be entailed by that information.</s>",
        "contradict": "The statement is contradicted by the CTR data as the Adverse Events section of the primary trial reports no occurrences of gastrointestinal adverse events (0/52 for Adverse Events 1 and 0/52 for Adverse Events 2). Conversely, the secondary trial reports some occurrences of gastrointestinal adverse events (1/76 and 1/29 for Adverse Events 1 and 2, respectively). Therefore, the statement's claim that the secondary trial \"records only gastrointestinal adverse events\" while the primary trial \"doesn't record any GI adverse events\" is incorrect.</s>"
    },
    "ad0628ef-be51-4d54-a5c6-7608df258629": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00895414",
        "Statement": "Orange juice is banned for patients undertaking the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Orange juice is banned for patients undertaking the primary trial\" is entailed by the CTRs as the patients in the primary trial are excluded from consuming grapefruit juice (not orange juice) while on the study. However, the exclusion of orange juice can be inferred due to the similarity between grapefruit juice and orange juice in their inhibitory effects on certain cytochromes P450, which may interact with the drugs in the trial and affect their metabolism. This unintended interaction could potentially impact the trial's outcome, leading to exclusion of both grapefruit and orange juice from the patient's diet.</s>",
        "contradict": "The statement \"Orange juice is banned for patients undertaking the primary trial\" cannot be directly contradicted by the information present in the given CTRs. However, it contradicts the information in the primary CTR when taken out of context. The primary CTR mentions a patient Agreement to \"agrees not to consume grapefruit juice while on the study.\" While both grapefruit juice and orange juice are citrus juices, the statement from the clinical trials expert specifically mentions \"orange juice,\" which is not listed as an exclusion or prohibition in the CTR. Consequently, the information in the statement can be considered an overgeneralization or misinterpretation of the trial conditions, but it does not contradict the data explicitly stated in the CTR.</s>"
    },
    "619d88fd-cef5-4f1a-83dc-3cc710c1c93d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00203502",
        "Statement": "Less than 30% of patients in the primary trial experienced at least 1 adverse event.",
        "Label": "Contradiction",
        "entail": "To entail the statement \"Less than 30% of patients in the primary trial experienced at least 1 adverse event,\" we need to calculate the percentage of patients experiencing at least one adverse event. The total number of adverse events reported in the CTR is 39, and there were 39 patients in the trial. However, not all patients experienced each type of adverse event, so we cannot simply add up the percentages of each event to find the total. Instead, we can calculate the percentage of patients who experienced any adverse event by dividing the total number of adverse events by the total number of patients and then multiplying by 100.\n\nTotal number of adverse events = 39\nTotal number of patients = 39\n\nPercentage of patients with at least one adverse event = (total number of adverse events) / (total number of patients) * 100.0\n= 39 / 39 * 100.0\n= 100.0\n\nThe percentage of patients with at least one adverse event is 100.0, which is greater than 30%. Therefore, it initially appears that the statement is contradictory to the information in the CTR. However, we must consider that the calculation above includes each adverse event as a separate event for each patient who experienced it. Since some patients experienced multiple types of adverse events, this calculation overestimates the number of patients with at least one adverse event. \n\nTo obtain the correct percentage, we need to count the number of unique patients who experienced at least one adverse event. From the CTR, we can see that each adverse event was experienced by a specific number of patients. Therefore, we can calculate the percentage of unique patients with at least one adverse event by summing up the number of patients with each adverse event and dividing by the total number of patients.\n\nTotal number of unique patients with at least one adverse event = \u03a3(number of patients with each adverse event)\n= 1 + 1 + 3 + 4 + 3 + 4 + 3 + 1 + 2 + 6\n= 19\n\nPercentage of unique patients with at least one adverse event = (total number of unique patients with at least one adverse event) / (total number of patients) * 100.0\n= 19 / 39 * 100.0\n= 48.72%\n\nThe percentage of unique patients with at least one adverse event is 48.72%, which is less than 30%. Therefore, the statement \"Less than 30% of patients in the primary trial experienced at least 1 adverse event\" is entailed by the information in the CTR. This is because the calculation above that initially appeared to contradict the CTR actually overestimated the number of patients with at least one adverse event, and the correct calculation shows that fewer than 30% of patients experienced a unique adverse event.</s>",
        "contradict": "The expert's statement, \"Less than 30% of patients in the primary trial experienced at least 1 adverse event,\" contradicts the information in the CTR because the total percentage of patients who experienced an adverse event in the primary trial was 100.00%, or 100%, not less than 30%. The CTR data shows that every patient in the trial (39 out of 39) experienced at least one adverse event.</s>"
    },
    "42d6a15e-fa43-4ebc-b627-70f4dd0233f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00322374",
        "Statement": "Cohort 2 of the primary trial receive a higher dose of Ixabepilone than cohort 1, but the same dose of Epirubicin.",
        "Label": "Entailment",
        "entail": "The statement that cohort 2 of the primary trial receives a higher dose of Ixabepilone than cohort 1 (30 mg/m^2 versus 25 mg/m^2), is entailed by the information present in the CTRs because the dosing information for each cohort is explicitly stated. There is no contradiction or inconsistency between the statements in the CTRs and the statement made by the clinical trial expert. Both the CTRs and the expert's statement confirm that the dose of Epirubicin is the same for both cohorts (75 mg/m^2), allowing the conclusion that the difference lies in the dose of Ixabepilone alone.</s>",
        "contradict": "Although cohort 2 in the primary trial receives a higher dose of Ixabepilone (30 mg/m2) than cohort 1 (25 mg/m2), both cohorts receive the same dose of Epirubicin (75 mg/m2). However, the statement does not explicitly state that the Epirubicin dose is the same in both cohorts. If we assume that the Epirubicin dose is different between the cohorts based on the given statement, it contradicts the information in the CTRs. The contradiction arises because the CTRs clearly state that both cohorts receive the same Epirubicin dose.</s>"
    },
    "fc60c272-ceeb-47b5-b25b-dca832a2a57e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02203565",
        "Secondary_id": "NCT00194779",
        "Statement": "laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial\" is entailed by the information in the CTRs since both trials (primary and secondary) include \"laboratory biomarker analysis\" as an optional correlative study. In the primary CTR, this analysis is mentioned in the INTERVENTION 1: RESULTS, whereas in the secondary CTR, it is listed under the specific interventions. Furthermore, \"questionnaires\" are also mentioned in the primary CTR as ancillary studies in the INTERVENTION 1: RESULTS section.</s>",
        "contradict": "The statement \"laboratory biomarker analysis and questionnaires are used in the secondary trial and the primary trial\" is not contradictory to the information in the CTRs; however, the use of laboratory biomarker analysis in both trials is not identical. In the primary trial, laboratory biomarker analysis is optional, while in the secondary trial it is specified as a correlative study. The statement does not mention the optional nature of biomarker analysis in the primary trial, which could lead to a potential misinterpretation or oversimplification of the information provided in the CTRs.</s>"
    },
    "dfe1236f-ac29-4c1c-a287-6f46abb7703d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00810797",
        "Secondary_id": "NCT00828074",
        "Statement": "Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as follows:\n\n1. The frequency of skin infections is higher in cohort 2 of the secondary trial compared to cohort 1 of the primary trial based on the provided data:\n   - In the primary trial, there is one instance of skin infection among 36 patients (1/36 or 2.78%).\n   - In the secondary trial, there are two instances of skin infections among 41 patients in Adverse Events 1 (4.88%). In Adverse Events 2, there is also one instance of skin infection among 5 patients (20.00%).\n   - Combining both sections of the secondary trial, the total number of skin infections is three (3/82 = 3.72%) in 82 patients. However, the frequency remains higher in cohort 2 of the secondary trial (1 in 5 or 20.00%) compared to cohort 1 of the primary trial. \n\nTherefore, the statement can be entailed by the information in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the data presented in the CTRs because the number of skin infections reported is equal between the two trials (2 in cohort 2 of the secondary trial and 1 in cohort 1 of the primary trial). Therefore, the statement that \"Skin infections were more common in patients in cohort 2 of the secondary trial, than in cohort 1 of the primary trial,\" is not an entailed statement based on the data provided in the CTRs.</s>"
    },
    "b1060434-0f7c-4c4a-bcff-53c3124bb51e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02513472",
        "Statement": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.",
        "Label": "Entailment",
        "entail": "The Objective Response Rate (ORR) in cohort 1 was 25.8% (15.8-38.0) compared to 21.8% (14.2-31.1) in cohort 2 from the primary trial. Both cohorts received the same combination treatment of eribulin mesylate and pembrolizumab but with different patient stratifications \u2013 cohort 1 included participants who had never been treated with systemic anticancer therapy in the metastatic setting, while cohort 2 included those who had received 1 to 2 lines of systemic anticancer therapy. The CTRs provide the number of participants and their respective ORRs for each cohort. As a result, the statement that cohort 1 produced better ORR results than cohort 2 is an entailed conclusion, given the data presented in the CTRs.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs if the Objective Response Rate (ORR) in Stratum 1 (where participants were never treated with any systemic anticancer therapy in the metastatic setting) is not statistically significantly different from Stratum 2 (where participants were previously treated with 1 to 2 lines of systemic anticancer therapy in the metastatic setting). The ORR percentages and confidence intervals provided in the CTRs (25.8% [15.8-38.0] for Stratum 1 and 21.8% [14.2-31.1] for Stratum 2) do not allow us to definitively conclude whether Cohort 1 produced better ORR results than Cohort 2. To determine that, additional statistical analysis should be conducted to compare ORR between the two groups. Therefore, the expert's statement is premature without access to the specific statistical results.</s>"
    },
    "e2862bbf-562f-4c96-abf1-fc9f07655b46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00627978",
        "Statement": "Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events.",
        "Label": "Entailment",
        "entail": "The statement \"Women with leptomeningeal metastases are unfortunately excluded from the primary trial, as this would complicate the evaluation of neurologic and other adverse events\" can be entailed by the information present in the CTRs as patients with known and active brain and/or leptomeningeal metastases are explicitly mentioned in the exclusion criteria of the primary trial.</s>",
        "contradict": "The expert statement contradicts the CTR inclusion criteria as women with leptomeningeal metastases are specifically mentioned as a patient population to be excluded from the primary trial.</s>"
    },
    "aed75656-1594-4d99-be42-7097f7926c18": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00240071",
        "Statement": "At least one participant of the primary trial died in under a 100 days.",
        "Label": "Contradiction",
        "entail": "The statement \"At least one participant of the primary trial died in under a 100 days\" can be entailed by the information in the CTRs as follows:\n\nFrom the Primary Trial Results 1:\n1. Median PFS for the Avastin (Bevacizumab) Plus Hormone Arm is 125.5 days (90 to 256).\n\nSince the median PFS represents the time at which 50% of the population has progressed or died, it means that 50% of the participants had a survival greater than 125.5 days, and 50% had a survival less than 125.5 days.\n\nGiven that the lower bound of the confidence interval is 90 days, this indicates that there were participants with survival shorter than 125.5 days (the median).\n\nSince the statement \"At least one participant of the primary trial died in under a 100 days\" is a weaker condition than having one participant with a survival of 90 days, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The information in the expert statement cannot be directly contradicted by the data provided in the CTR. However, it does not entail that a participant died within 100 days based on the available data. The median PFS for the Avastin plus hormone arm is 125.5 days with a 95% confidence interval ranging from 90 to 256 days. While there is no explicit statement about the number of participants who died before 100 days, the data does not disprove the possibility that at least one participant did. Therefore, the statement neither contradicts nor entails the information in the CTRs.</s>"
    },
    "6ce5a9d7-5793-43b0-92ed-980cca3be02b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01961544",
        "Statement": "the primary trial reported a combined total of 3 cases of Pericardial effusion, Asthenia and Gastritis in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n1. Pericardial effusion occurred in 2 participants out of 101 in the primary trial (2.0%).\n2. Asthenia occurred in 1 participant out of 101 (1.0%).\n3. Gastritis occurred in 1 participant out of 101 (1.0%).\n\nThus, a combined total of 3 cases (2+1) for Pericardial effusion, Asthenia, and Gastritis falls within the reported incidence rates in the primary trial for each condition.</s>",
        "contradict": "The statement reports a combined total of 3 cases for Pericardial effusion, Asthenia, and Gastritis in cohort 1 of the primary trial. However, this information contradicts the data provided in the Adverse Events section of the primary trial report. \n\nThe CTR reports a total of 20 adverse events in cohort 1 of the primary trial, with 1.98% being cases of Pericardial effusion, 0.99% being cases each of Asthenia and Gastritis. The combined total of these reported cases, as per the CTR, is 3.96 (1.98% + 0.99% + 0.99%), which is different from the 3 cases reported in the expert statement. Therefore, the statement contradicts the information provided in the primary trial report.</s>"
    },
    "b2a4f905-c6b5-4977-95de-5aa6424a5bb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00217399",
        "Statement": "To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility.",
        "Label": "Contradiction",
        "entail": "The statement \"To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility\" can be entailed by the information present in the CTRs as follows:\n\n1. Primary Trial: Inclusion Criteria states that \"Measurable disease, defined as >= 1 unidimensionally measurable lesion.\"\n2. There is no explicit size boundary mentioned in the Inclusion Criteria for the measurable lesion.\n3. The expert's statement does not contradict any information in the CTR.\n\nTherefore, the statement \"To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, there are no size boundaries for eligibility\" is an entailed statement based on the information provided in the CTRs.</s>",
        "contradict": "The information in the statement that \"there are no size boundaries for eligibility in the primary trial, as long as there is at least 1 unidimensionally measurable lesion,\" can be contradicted by the information in the CTRs because the CTRs explicitly specify size boundaries for measurable disease: Lesion >= 10 mm on CT scan (5 mm sections), Lesion >= 20 mm on CT scan or MRI (10 mm sections), Bone disease that is >= 10 mm on MRI, Lytic bone lesions that are >= 10 mm on CT scan (with 5 mm sections) OR >= 20 mm on plain film or CT scan (with 10 mm sections,) and Lesion >= 10 mm on physical exam. Therefore, the size of measurable lesions is an inclusion criterion and contradicts the statement that there are no size boundaries for eligibility.</s>"
    },
    "a611e8dd-cafc-46dd-b8ed-3fa7c5f5a7b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00591851",
        "Statement": "There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement that \"There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. Diarrhea, Lower gastrointestinal hemorrhage, Nausea, and Abdominal Pain are all considered Gastrointestinal adverse events as per their descriptions in the CTR (Section: Adverse Events). \n2. These adverse events were recorded in cohort 1 of the primary trial since the CTR provides their frequency counts specifically for that cohort (Section: Adverse Events). \n\nHence, the statement's assertion (the presence of 4 different Gastrointestinal adverse events in cohort 1) harmonizes with the clinical trial data in the CTRs, finds substantiation in the CTRs, and does not contradict the provided descriptions, making it entailed.</s>",
        "contradict": "The statement \"There were 4 different Gastrointestinal adverse events recorded in cohort 1 of the primary trial\" is contradicted by the CTR data as only three distinct gastrointestinal adverse events are mentioned: Diarrhea, Abdominal Pain, and Lower gastrointestinal hemorrhage.</s>"
    },
    "4db02d9b-d96e-4ced-947c-71cebcccc933": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00847171",
        "Secondary_id": "NCT01764022",
        "Statement": "Sufferers of Systemic lupus erythematosus are excluded from the primary trial but may still be eligible for the secondary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Sufferers of Systemic lupus erythematosis are excluded from the primary trial but may still be eligible for the secondary trial\" is entailed by the information presented in the CTRs due to the following reasons:\n\nIn the primary trial, the exclusion criteria include \"No evidence of active autoimmune disease* requiring management with systemic immunosuppression, including any of the following: Systemic lupus erythematosus\". This explicitly states that individuals with Systemic lupus erythematosus are excluded from the primary trial.\n\nHowever, the secondary trial has a different inclusion/exclusion profile. While it also lists Systemic lupus erythematosus as an exclusion criterion, it is not explicitly mentioned in the primary trial's exclusion criteria for the secondary trial. Instead, the secondary trial has different inclusion criteria that do not include this restriction for individuals with Systemic lupus erythematosus. Therefore, the statement is entailed by the information present in the CTRs as it acknowledges the exclusion of Systemic lupus erythematosus from the primary trial and the potential eligibility for the secondary trial.</s>",
        "contradict": "The statement is contradictory to the information present in the CTRs because:\n\nIn the primary trial, Systemic lupus erythematosis is listed as an exclusion criterion for participating in the study (no prior or currently active autoimmune disease requiring management with systemic immunosuppression, including Systemic lupus erythematosus).\n\nIn contrast, the secondary trial does not explicitly list Systemic lupus erythematosus as an exclusion criterion. However, it's essential to note that the secondary trial has specific inclusion and exclusion criteria that may or may not align with the primary trial. The statement's assertion about eligibility for the secondary trial does not account for this possibility and creates a potential contradiction with the primary trial's exclusion criteria.\n\nTherefore, the information in the statement is not semantically entailed by the data in the CTRs, as it may not be valid or applicable to both trials.</s>"
    },
    "cfb07772-e485-491c-8ae3-9009e3d04415": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00201864",
        "Statement": "One patient in the primary trial had a WBC count far below normal.",
        "Label": "Contradiction",
        "entail": "The statement \"One patient in the primary trial had a WBC count far below normal\" does not have direct entailment relationship with the provided Adverse Events section of the CTRs. The CTRs only provide information on certain specific adverse events and patient demographics, such as number of participants, sex, age, and some adverse events like nausea, vomiting, chest pain, hypercalcemia, and thromboembolism. The statement about a patient with a low WBC count is neither mentioned nor can be inferred directly from the given information in the Adverse Events sections. The CTRs may include additional sections such as Baseline Characteristics which could potentially include WBC count data, but that information is not provided in the given descriptions. Without further context or information, it is not possible to establish semantic entailment between the statement and the given CTRs.</s>",
        "contradict": "The statement \"One patient in the primary trial had a WBC count far below normal\" cannot be definitively contradicted by the information present in the CTRs, as there is no mention of white blood cell counts (WBC) for individual patients in either the primary or secondary CTRs provided.</s>"
    },
    "a283b69c-0f36-4773-a711-9e6088a8ee63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01712009",
        "Secondary_id": "NCT00343382",
        "Statement": "Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine.",
        "Label": "Entailment",
        "entail": "In the primary trial, cohort 2 patients received naproxen 500 mg BID (twice a day) for 5 days in each of the 4 cycles, starting on the day of pegfilgrastim administration. In the secondary trial, cohort 2 patients received pilocarpine 5mg 2 times a day for 6 weeks.\n\nThe statement asserts that the frequency of naproxen administration in cohort 2 of the primary trial is the same as the frequency of pilocarpine administration in cohort 2 of the secondary trial.\n\nComparing the two interventions, we find that the frequency of naproxen administration in the primary trial (5 days every 3 weeks) is not directly equivalent to that of pilocarpine in the secondary trial (every day for 6 weeks). However, we can consider the number of pills taken per day:\n- Naproxen: 500 mg BID = 1000 mg per day\n- Pilocarpine: 5mg 2 times per day = 10 mg per day\n\nBoth interventions involve taking medication for an equivalent amount of daily dosage. The statement holds true when we focus on the daily dosing frequency rather than the number of dosing occasions within each treatment cycle.\n\nThus, the information in the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement that \"Cohort 2 patients in the primary trial receive naproxen at the same frequency as cohort 2 patients in the secondary trial receive Pilocarpine\" is contradictory to the information present in the CTRs. In the primary trial, Intervention 2 for Cohort 2 includes receiving naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, starting on the day of pegfilgrastim administration. In the secondary trial, Intervention 2 for Cohort 2 includes receiving 5mg of Pilocarpine 2 times per day for 6 weeks. Naproxen is given for a total of 10 days per cycle for 4 cycles, which totals 40 days, whereas Pilocarpine is given for 6 weeks, which is approximately 42 days. Therefore, the frequency of administration is not the same, as the expert's statement suggests.</s>"
    },
    "8d90d538-3b56-48dd-bd58-007d266c923c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00915018",
        "Statement": "The only cases of cardiac problems in the primary trial occurred in cohort 1.",
        "Label": "Contradiction",
        "entail": "The statement that \"The only cases of cardiac problems in the primary trial occurred in cohort 1\" can be entailed by the CTRs if:\n\n1. Both trials involve the same treatments.\n2. Cohort 1 in each trial represents the identical patient group.\n3. The cardiac problems mentioned in the statement are among those listed in the CTRs (cardiac failure congestive, cardiac tamponade, cardio-respiratory arrest, left ventricular dysfunction).\n4. All reported cardiac events occurred in cohort 1 in the primary trial.\n\nFrom the provided CTRs, it can be observed that:\n\n1. Both trials involve the same treatments, as they are not explicitly stated, but the same conditions, interventions, and adverse events are described in both sections.\n2. Since there are no cohort descriptions given in the CTRs, it is impossible to confirm that the identical patient groups are being compared between trials. However, if this condition is true, the statement can be entailed.\n3. The cardiac problems listed in the statement are present in the CTRs.\n4. In Adverse Events 1 of the primary trial, there are 2 cases of cardiac failure congestive and 1 case each of cardiac tamponade and cardio-respiratory arrest in cohort 1 (out of a total of 240 participants).\n\nHence, if the patient groups are identical across the trials, the statement that \"The only cases of cardiac problems in the primary trial occurred in cohort 1\" can be entailed by the information in the CTRs.</s>",
        "contradict": "The information in the statement can be contradicted by the CTR data because both trials reported instances of cardiac problems in their respective adverse event sections. In the primary trial, there were two cases reported (Cardiac failure congestive and Cardio-respiratory arrest), while in the secondary trial, there was one reported case (Left ventricular dysfunction). The statement incorrectly implies that only cohort 1 from the primary trial had cardiac problems, but the CTR data shows that there were cardiac problems reported in both trials, albeit in different cohorts and trial participant groups.</s>"
    },
    "fa0fe1a0-2b89-4b78-8fdb-04dee84b4421": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Secondary_id": "NCT03592121",
        "Statement": "Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial.",
        "Label": "Entailment",
        "entail": "In the primary trial, patients in both the Calcitriol Arm and the Calcitriol+ Exercise Arm do not have any explicit requirement mentioned related to sexual activity for receiving the intervention. Hence, patients not being sexually active to receive the primary trial intervention is in line with the information provided in the CTR. \n\nConversely, the secondary trial specifies that patients must apply the intervention (AB-101) to their nipple/areola regions approximately 1 hour prior to sexual activity. This requirement is not a condition for receiving the intervention in the primary trial. Therefore, the statement that patients are not required to be sexually active to receive the primary trial intervention is an accurate generalization that does not contradict the information presented in the CTRs.</s>",
        "contradict": "The statement \"Patients are not required to be sexually active to receive the primary trial intervention, this is however a requirement for the secondary trial\" contradicts the information in the CTRs because:\n\n1. In the primary trial (INTERVENTION 1 for both arms), there is no requirement or mention of sexual activity for receiving the intervention. Patients in the No Exercise arm and the Calcitriol Arm receive the intervention by not exercising and taking a Calcitriol pill once per week, respectively.\n2. In contrast, in the secondary trial (INTERVENTION 1 for both arms), the intervention involves applying AB-101 to the nipple/areola regions approximately 1 hour prior to sexual activity for both the AB-101 and the Placebo arms. This directly contradicts the statement that patients are not required to be sexually active for the primary trial intervention.\n\nTherefore, the statement is contradicted by the provided CTR information.</s>"
    },
    "8502cb9e-e382-41bc-b547-02d2d7beb381": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00620373",
        "Statement": "the primary trial tests two different breast imaging modalities, namely X-ray and gamma imaging.",
        "Label": "Entailment",
        "entail": "The expert's statement entails that the primary trial investigates the use of two distinct breast imaging modalities. This assertion is compatible with the CTRs since they describe two separate reporting arms, each employing unique imaging techniques: Intervention 1 utilizes mammography (an X-ray technique), while Intervention 2 employs gamma imaging (a gamma ray-based imaging technique). The CTRs' information does not contradict the statement, and the statement finds substantiation in the provided details.</s>",
        "contradict": "The expert's statement can be contradicted by the CTRs as they do not indicate that mammography (X-ray imaging) was used in addition to gamma imaging in the primary trial for any reporting arm. The CTRs specify that interpretation and analysis for each arm were done using either mammography only or gamma imaging only.</s>"
    },
    "f6c64bb3-1836-4685-8541-8856f003524b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01105312",
        "Statement": "Patients with non-measurable diseases are only eligible for phase I of the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with non-measurable diseases are only eligible for phase I of the primary trial\" is entailed by the CTR information as the CTR specifies that \"Measurable or non-measurable disease for phase I study,\" and \"Measurable disease only for phase II study.\" Therefore, patients with non-measurable diseases can only participate in phase I of the trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTR as the primary trial also accepts patients with non-measurable diseases in phase II, under specific conditions such as having triple-negative disease with tumor progression in the adjuvant or metastatic setting.</s>"
    },
    "79272218-91b9-4331-ba44-6a3709a13f62": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00073528",
        "Secondary_id": "NCT00191152",
        "Statement": "the secondary trial and the primary trial study the Progression Free Survival (PFS) of their participants, however they use different Units of Measure.",
        "Label": "Entailment",
        "entail": "Both trials assess the Progression Free Survival (PFS) of their participants. In the primary trial, PFS is measured as the time from randomization until the earliest date of disease progression or death due to any cause (if sooner), which is reported in participants' counts for up to 46 months. In contrast, the secondary trial measures Time to Disease Progression (TTDP) at initial treatment, which is defined as the number of months between the date of randomization and the first documented disease progression or death due to the study disease, and is reported as medians with confidence intervals for up to 82 months. Although the units of measure differ between the trials, the trials' objectives and the concept of measuring PFS or its related term (Time to Disease Progression) are entailed in the information provided by the CTRs.</s>",
        "contradict": "The statement does not explicitly indicate which trial's PFS is being compared. The primary trial's outcome measurement describes PFS using the number of participants with the event occurring, while the secondary trial's outcome measurement describes TTDP (Time to Disease Progression), not PFS directly. Thus, the comparison of the units of measure alone does not provide sufficient information to establish entailment or contradiction between the expert statement and the CTRs.</s>"
    },
    "97e3b0d7-3320-4eb5-bc42-5031db87692e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01964924",
        "Secondary_id": "NCT00524303",
        "Statement": "the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients.",
        "Label": "Contradiction",
        "entail": "Both trials evaluate the effectiveness of different treatments (Trametinib vs. Trastuzumab/Lapatinib) and report Objective Response Rates (ORR) within a specific time frame. In the primary trial, ORR is defined using RECIST 1.1 and measured as the proportion of patients experiencing a partial response (PR) or complete response (CR) within 6 months after treatment initiation. In the secondary trials, ORR is measured as the proportion of participants achieving pCR after 26 weeks of combined therapy with chemotherapeutic agents and either trastuzumab or lapatinib. The trials' ORR measurements are comparable because they both report the percentage of patients responding to a specific treatment within a defined time frame.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial both report Objective Response Rate (ORR) of their patients\" is generally true, however, the ORR definition and assessment methodologies differ in each trial. The primary trial reports ORR based on RECIST 1.1 criteria using MRI for measuring tumor response and time frame is 6 months post-therapy initiation. In contrast, the secondary trial reports ORR in terms of percentage of participants with pCR after 26 weeks of therapy. The definition of pCR includes the absence of invasive breast cancer and cancer cells in the axillary lymph nodes. The assessment methods and time frames for ORR are not directly comparable. Therefore, while both trials report ORR, their specific definitions and measurements make it impossible to make direct semantic entailment statements between the two trials.</s>"
    },
    "83251670-803e-4fec-a5cf-50f052932752": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708214",
        "Statement": "All Participants with disease progression (After 16 Weeks of Treatment) in the primary trial were in the Afatinib 50 mg With Letrozole group.",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as all participants with disease progression (PD) in the primary trial were explicitly stated to be in the Afatinib 50 mg With Letrozole group in both the Outcome Measurement and Results 1 sections. No participant with PD was reported in the Results 2 section for the Afatinib 40 mg With Letrozole group. Therefore, the statement is in harmony with the clinical trial data and avoids contradiction with the descriptions in the CTRs.</s>",
        "contradict": "The statement cannot be definitively contradicted by the information in the provided CTRs, but it is not entirely entailed by the information either. The statement asserts that all participants who experienced disease progression were in the Afatinib 50 mg With Letrozole group. However, the CTR does not provide sufficient information to determine that all participants who experienced progression were in the Afatinib 50 mg With Letrozole group, as it does not indicate the number or percentage of participants in each group who experienced progression. Furthermore, the CTR does not specify that there were no participants who experienced progression in the Afatinib 40 mg With Letrozole group. Therefore, the statement could be true, but it is not necessarily entailed by the information in the CTRs. However, it is not a contradiction since the statement does not assert that there were no participants who experienced progression in the Afatinib 40 mg With Letrozole group.</s>"
    },
    "efd950a8-ae79-4d4a-9ce7-3f1d0a37e6de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01610284",
        "Statement": "1 patient in the primary trial had an abrupt loss of heart function.",
        "Label": "Entailment",
        "entail": "The statement \"1 patient in the primary trial had an acute cardiac arrest\" is entailed by the data in Adverse Events 1 section of the CTR as both describe the occurrence of one patient experiencing a loss of heart function (cardiac arrest) in the primary trial.</s>",
        "contradict": "The statement \"1 patient in the primary trial had an abrupt loss of heart function\" cannot be definitively contradicted by the information in the CTRs, as neither trial includes a listed adverse event specifically describing heart function loss. However, the statement could be contradicted if such an event was mentioned in the text of the CTR outside of the listed adverse events, or if it was determined that no such event occurred in the primary trial based on a thorough reading and understanding of the reports.\n\nHowever, if we assume that the expert meant \"cardiac arrest,\" which is mentioned in both trials as an adverse event, we cannot contradict the statement based on the provided CTRs. The statement is semantically entailed by the CTR since the CTR reports 1 occurrence of cardiac arrest in each trial.\n\nSo, depending on the intended meaning of the statement, it can be either contradicted or entailed based on the CTRs.</s>"
    },
    "e00b0ccc-e53b-44ba-9555-b6f8d6d5e55a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT01926886",
        "Statement": "The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).",
        "Label": "Entailment",
        "entail": "The statement \"The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%)\":\n\n1. The statement identifies the most frequent adverse event for each of the two trials.\n2. In the first trial (primary trial), the CTR states that the most common adverse event was Febrile neutropenia with an occurrence of 3/7 or 42.86%.\n3. In the second trial (secondary trial), the CTR states that the most common adverse event was a decrease in Ejection fraction with an occurrence of 5/101 or 4.95%.\n4. The statement's assertion harmonizes with the clinical trial data, finds substantiation in the CTRs, and does not contradict the provided descriptions.\n5. Therefore, the statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"The most common adverse event in the primary trial was Febrile neutropenia (42.86%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%)\" is contradictory to the information present in the given CTRs. According to the provided data, the most common adverse event in the primary trial was indeed Febrile neutropenia (42.86%), but in the secondary trial, the most frequent adverse event was a tie between pleural effusion (2/101, 1.98%) and a decrease in ejection fraction (5/101, 4.95%). Neither of these frequencies surpasses that of Febrile neutropenia in the primary trial. Therefore, the statement contradicts the CTRs.</s>"
    },
    "97812fde-57f3-4299-be34-dd436757adde": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00093795",
        "Statement": "Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial\" is entailed by the information present in the CTRs because it directly corresponds to the specified criterion for ineligibility related to nodal involvement. In the primary trial's eligibility section for axillary lymph nodes, there is a mention of ineligibility for patients with suspicious nodes in the contralateral axilla or suspicious supraclavicular nodes. The statement does not explicitly state \"above the collarbone,\" but the implication is clear as the supraclavicular node is located above the collarbone. Additionally, the CTR specifies that patients with pathologic nodal stages including pN0(i+), pN2b, pN3b with clinically apparent internal mammary nodes, or pN3c are ineligible. These nodal stages involve nodes located above the collarbone. Thus, the statement is entailed by the information within the CTRs.</s>",
        "contradict": "The given statement is contradicted by the inclusion criteria of the primary trial. Specifically, the primary trial allows for inclusion of patients with pN2a, pN3a, or pN3b staging, which indicates the presence of cancer cells in lymph nodes above the collarbone (internal mammary nodes). This contradicts the statement that patients with cancer cells in lymph nodes above the collarbone cannot enter the primary trial.</s>"
    },
    "f37774f4-db96-4aa6-b3a1-626953faeecf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00213980",
        "Secondary_id": "NCT02536339",
        "Statement": "Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial.",
        "Label": "Entailment",
        "entail": "The primary trial inclusion criteria do not explicitly mention the requirement for adequate blood, kidney, and hepatic function, whereas the secondary trial inclusion criteria do. However, this discrepancy in specification does not entail a contradiction or falsehood, as the primary trial may implicitly assume or require these functions for participant safety and eligibility, which is not necessarily stated explicitly. Therefore, the statement that adequate blood, kidney, and hepatic function are a requirement for the secondary trial but not explicitly stated in the primary trial, is entailed by the information presented in the CTRs, as long as the assumption of implicit requirements for these functions in the primary trial is valid.</s>",
        "contradict": "The statement \"Adequate blood, kidney, and hepatic function are required to participate in the secondary trial, however this condition is not specified in the primary trial\" can be contradicted by the information in the CTRs as the inclusion criteria for the primary trial do specify that participants should have \"adequate hematologic, renal, and hepatic function.\"</s>"
    },
    "4fef4cdf-53bf-4239-9d31-4710fd3edc6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01605396",
        "Statement": "The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months.",
        "Label": "Contradiction",
        "entail": "The statement \"The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 38.43 months\" cannot be entailed directly from the CTRs provided, as the median PFS for this treatment group was reported as 23.29 weeks (8.71 to 38.43), which is lower than the specified value in the statement. However, it's essential to understand that the statement's unit of measurement is not the same as in the CTRs; the expert in clinical trials likely meant months instead of weeks. Consequently, if we convert the reported PFS of 23.29 weeks to months (52.6 weeks in a year), the Ridaforolimus + Dalotuzumab + Exemestane group's median PFS is indeed over 38.43 months. So, while the CTR does not explicitly state the median PFS of 38.43 months for this treatment group, the conversion of the reported value in weeks makes the statement consistent with the data in the CTR.</s>",
        "contradict": "The information in the statement cannot be directly derived from the data provided in the CTRs because the median PFS for the Ridaforolimus + Dalotuzumab + Exemestane group, as reported in the CTR (8.71 to 38.43 weeks), is not equivalent to 38.43 months (which is equal to 1,528.64 weeks). Therefore, this statement contradicts the information in the CTR.</s>"
    },
    "331affb2-f8e9-4a55-ac4c-62d2ecc4f80b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00181363",
        "Statement": "The only difference between the interventions used in the primary trial is the patients position.",
        "Label": "Entailment",
        "entail": "The statement entails that there is only one variation between the interventions in the primary trial, which is the position of patients. This aligns with the information in the CTRs, as Intervention 1 specifies the use of the prone position, while Intervention 2 details the application of the supine position. The trial's interventions indeed only differ in this aspect.</s>",
        "contradict": "The statement \"The only difference between the interventions used in the primary trial is the patients position\" can be contradicted by the information in the CTRs if the trials involve more than just position changes as interventions. If the primary trial includes additional differences in treatment type, dosage, frequency, or duration, then the statement is an oversimplification and contradicts the more comprehensive information in the CTRs.</s>"
    },
    "a577e819-c928-4217-8743-f4809e852919": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00834678",
        "Statement": "Patients must have a white blood cell count above 1,500/mm\u00ac\u00a8\u201a\u00e2\u2022 to participate in the primary trial.",
        "Label": "Entailment",
        "entail": "The statement \"Patients must have a white blood cell count above 1,500/mm\u00b3 to participate in the primary trial\" is entailed by the CTR as it specifies \"WBC > 1,500/mm\u00b3\" as a patient eligibility criterion.</s>",
        "contradict": "The statement does not contradict the information in the CTRs as it is consistent with the inclusion criterion mentioned under \"PATIENT CHARACTERISTICS\" section in the Primary Trial that \"WBC > 1,500/mm\u00b3\" is a requirement for patient eligibility. However, it's essential to note that the statement only addresses the white blood cell count requirement, while the CTRs provide comprehensive eligibility criteria involving multiple aspects.</s>"
    },
    "bd073d05-3ba2-4898-9d86-a51951a7ad1f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01004172",
        "Secondary_id": "NCT00802945",
        "Statement": "the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions.",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions\" can be entailed by the information present in the CTRs as follows:\n\nIn the primary trial, the outcome measurement is specified as \"Central Nervous System (CNS) Objective Response Rate,\" which includes CNS complete response (CR) and CNS partial response (PR), defined as the percentage of participants achieving these response categories. Similarly, in the secondary trial, the outcome measurement is \"Objective Response Rate (ORR)\" using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), defined as the percentage of subjects achieving a complete response (CR) or partial response (PR) based on the sum of the longest diameter of target lesions. Although the response criteria and assessment methods differ slightly between trials, the common use of percentage change in the objective response rate to evaluate treatment effects establishes the entailment relationship between the two trials' outcome measurements.</s>",
        "contradict": "The statement does not provide sufficient specificity regarding the type of \"tumor Objective response rate\" being compared between the primary and secondary trials. The primary trial reports CNS objective response rate using specific criteria, while the secondary trial reports overall response rate (ORR) using RECIST v1.0. These two types of response rates are not directly comparable due to differences in the measurement methods and assessment time frames. Thus, the statement may not be an entailed claim based on the provided CTRs.</s>"
    },
    "1adc970c-d433-44d0-aa09-d3834986f7a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a 13.2% difference between the results from the two the primary trial cohorts",
        "Label": "Contradiction",
        "entail": "The statement \"there is a 13.2% difference between the results from the two primary trial cohorts\" can be entailed by the information in the CTRs because:\n\n1. The CTRs provide the percentage of participants in each arm/group (Exemestane: 87-89% and Anastrozole: 88-90%). \n2. Subtracting the percentage of participants in the Exemestane arm from the percentage of participants in the Anastrozole arm yields the difference: 89% - 87% = 2% or 2.1%, and 90% - 88% = 2% or 2%.\n3. The statement mentions a difference of \"13.2%\" between the two trial cohorts, but it does not explicitly state whether it represents an absolute difference or a percentage difference. Therefore, to make the statement entailed, we should consider the percentages in the CTRs as percentages of the total number of participants and calculate the difference as a percentage. Thus, the difference between the two percentages is (91.3% - 87.9%) = 3.4%, but since the statement's absolute difference is higher (13.2%), it is not a perfect entailment but can still be considered close enough given that the statement is not definitive about the type of difference it represents.\n\nTherefore, the statement can be entailed by the information in the CTRs with some assumptions and calculations. However, a perfect entailment cannot be achieved due to the ambiguity in the type of difference the statement represents.</s>",
        "contradict": "The statement \"there is a 13.2% difference between the results from the two primary trial cohorts\" is contradictory to the information in the CTRs if we consider the percentage values as the basis for comparison. According to the provided data, 88% of patients in the exemestane group and 89% of patients in the anastrozole group completed the study. Therefore, the difference is 1 percentage point, not 13.2 percentage points.</s>"
    },
    "6b9162d0-0816-46d4-81af-c60028dcc63b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over",
        "Label": "Contradiction",
        "entail": "The primary trial excludes patients with cardiac left ventricular function with resting ejection fraction below 50% (ELIGIBILITY CRITERIA of Primary Trial), whereas, the secondary trial does not include this criterion for exclusion. Instead, it focuses on eligibility of premenopausal women aged 55 years or younger (INCLUSION CRITERIA of Secondary Trial) and makes no reference to the ejection fraction. Therefore, the statement \"Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over\" is entailed by the information present in the CTRs as it is based on the age eligibility criterion difference between the two studies.</s>",
        "contradict": "The primary trial exclusion criteria state that patients with cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal) are excluded. There is no mention of any upper limit for ejection fraction in the secondary trial inclusion criteria. Therefore, the statement \"Patients with significantly elevated ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or over\" is incorrect, as there is no evidence in the CTRs that supports the possibility of patients with elevated ejection fraction being included in the secondary trial.</s>"
    },
    "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if the total number of participants who experienced Enterocolitis in both trials exceeds a \"significant number.\" However, the CTRs provided do not specify the exact number of participants who suffered from Enterocolitis in the primary trial. Yet, it is mentioned that there were 2 cases out of a total of 167 participants. In the secondary trial, the number of participants who experienced Enterocolitis is not mentioned at all. \n\nTherefore, it is unclear from the given information if the statement \"a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis\" can be entailed by the information present in the CTRs, as the term \"a significant number\" is not defined in the context of this problem.</s>",
        "contradict": "The statement \"a significant number of the participants in the secondary trial and the primary trial suffered from Enterocolitis\" cannot be directly contradicted by the information in the CTRs as the CTRs do not provide information about the number of participants who suffered from Enterocolitis in both trials. However, the statement can be contradicted if the expert meant to imply that the frequency or rate of Enterocolitis was the same or higher in the secondary trial compared to the primary trial, but the data in the CTRs shows that the incidence rate of Enterocolitis was lower in the secondary trial (0.60% vs 1.20% in Adverse Events 1 for the primary and secondary trial, respectively). Contradiction occurs because the statement goes beyond the scope of the provided data.</s>"
    },
    "cc1f712a-2116-4e40-9810-f315e3fa5ff8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial does not report the PFS or objective response rate of its patient cohort\" is entailed by the information in the CTRs as neither the primary CTR nor the secondary CTR provide explicit data on Progression-Free Survival (PFS) or objective response rate for the patient cohorts. The primary CTR reports local control using ipsilateral breast tumor recurrence rates at 2 years post-treatment completion, but it does not mention PFS or objective response rate. The secondary CTR does not contain any relevant information regarding PFS or objective response rate either. Therefore, the lack of such data in the primary CTR entails that it does not report the PFS or objective response rate of its patient cohort.</s>",
        "contradict": "Despite the statement claiming that the primary trial does not report theProgression-Free Survival (PFS) or objective response rate of its patient cohort, the CTR does provide data related to local control using ipsilateral Breast Tumor Recurrence Rates (IBTRR), which can indirectly infer something about the effectiveness of accelerated partial breast brachytherapy in terms of preventing breast cancer recurrence within 2 years. While the statement is not directly contradicted by the information in the CTR, it is an incomplete representation of the data provided.</s>"
    },
    "904061c0-14fa-4f13-9118-9a41e24fa8eb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor will not prevent a patient from participating in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because the primary trial's inclusion criteria state that participants with prior treatment experience with fulvestrant or PI3K inhibitors are still eligible to join the study, provided that certain other eligibility conditions are met. This is evident in the inclusion criteria section of the CTR, where it states that \"Participants for whom endocrine therapy (example, fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study\" is one of the inclusion conditions. Additionally, there is no mention of these prior treatments as exclusion criteria.</s>",
        "contradict": "The expert statement \"Prior treatment with fulvestrant or with a PI3K inhibitor will not prevent a patient from participating in the primary trial\" is contradictory to the CTR inclusion criteria. The CTR explicitly states that participants with a history of prior treatment with fulvestrant or PI3K inhibitors are excluded from the study.</s>"
    },
    "43ee7645-ce1e-42d5-9a74-3e379f6f367b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "only patients with a HER2-positive status can take part in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"only patients with a HER2-positive status can take part in the primary trial\" is entailed by the information presented in the CTRs under the Exclusion Criteria section. The CTR explicitly states \"HER2-positive status (patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study)\" but also \"HER2-positive status is an exclusion criterion.\" This means that only patients with an unknown or negative HER2 status can participate in the trial, effectively making HER2-positive patients ineligible for enrollment.</s>",
        "contradict": "The statement \"only patients with a HER2-positive status can take part in the primary trial\" is contradicted by the information in the inclusion criteria of the CTR. The CTR specifies that patients with unknown HER2 status are eligible for the study, and for those with an unknown status, determination of HER2 status is not a requirement for participation.</s>"
    },
    "0cef8c8e-7986-46c7-a597-c5733a9899c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "the shortest PFS in cohort 1 of the primary trial was under 7 months, in cohort 2 the shortest was just over 7 months",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information presented in the CTRs as follows: The shortest reported PFS in Cohort 1 of the primary trial, which received Placebo, was 5.6 months (part of the 95% Confidence Interval for the Median PFS of 7.1 months). This value is under 7 months. In Cohort 2 of the primary trial, which received Paclitaxel/Bevacizumab/Everolimus, the reported Median PFS was 9.1 months (with a 95% Confidence Interval of 6.8-10.8 months). While the lower bound of this interval (6.8 months) is just over 7 months and could be considered the shortest PFS, it is important to note that the median value itself (9.1 months) is longer than 7 months. However, the statement only mentions the shortest PFS, and it does not specify which cohort's lower bound or median value it is referring to. Since the lower bound of 5.6 months in Cohort 1 is under 7 months, the statement is still entailed by the information in the CTRs. The potential ambiguity in the statement regarding which lower bound value is being referred to does not contradict the CTR data, as both cohorts are mentioned, and the value reported for Cohort 1 is indeed under 7 months.</s>",
        "contradict": "The statement can be contradicted by the information in the CTR as it implies the existence of a cohort 2 in the primary trial with a participant experiencing a PFS of less than 7 months, which is not stated in the provided results (shortest PFS in cohort 2 was just over 7 months). However, the CTR only specifies the median PFS for each treatment group and does not mention any individual participant's PFS below the median.</s>"
    },
    "43ce26e5-03fa-4e9d-b0eb-6ea356295753": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks .",
        "Label": "Entailment",
        "entail": "Both cohorts in the primary trial experience a total of 17 cycles. In Intervention 1, participants receive trastuzumab for a maximum of 17 cycles with 3-week cycles in between, as detailed in the CTR. Similarly, Intervention 2 specifies 3-week cycles for 10 cycles of chemotherapy (Cycles 1-10). Thus, the total number of cycles for both interventions equals 17.</s>",
        "contradict": "The information contained in the statement that \"both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks\" is contradicted by the Intervention sections of the CTRs, as the number of cycles and the cycle lengths differ between the HER2+ TC and HER2+ C cohorts. Specifically, the HER2+ TC cohort receives a maximum of 17 cycles with trastuzumab, but this does not necessarily equate to 17 cycles of 3 weeks each. Similarly, the cycle lengths for the HER2+ C cohort differ from those stated in the expert's claim. Therefore, the statement is contradicted due to these inconsistencies between the trial details and the statement.</s>"
    },
    "3facad41-0221-42f8-834d-470e65c4aad5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease ",
        "Label": "Contradiction",
        "entail": "The statement \"the outcome measurement of the primary trial is the length of time during and after the treatment that a patient survives with the disease\" can be entailed by the information present in the CTR as follows: \n\n1. The primary trial is designed to measure Progression-free Survival (PFS). \n2. Progression-free Survival is a type of survival measurement that refers to the length of time a patient lives without their disease progressing. \n3. The primary trial aims to evaluate the safety and efficacy of Trastuzumab, Bevacizumab, and Docetaxel regimen based on the median PFS of 12 months (uninteresting) versus 20 months (worthy of further study) after the treatment. \n4. The results section of the primary trial reports the median PFS of the study cohort as 14.3 months (9.3 to 35 months), which represents the length of time during and after the treatment that the analyzed patients survived with the disease before experiencing progression.</s>",
        "contradict": "The expert's statement \"the outcome measurement of the primary trial is The length of time during and after the treatment that a patient survives with the disease\" is not an exact contradiction to the information in the CTRs. However, it can be considered a broader or more generalized interpretation of the outcome measurement. The term \"progression-free survival (PFS)\" used in the CTRs specifically denotes the duration of time that a patient survives without disease progression, whereas the expert's statement includes both progression-free survival and overall survival (OS), which is the total time a patient survives with or without disease progression. The information can be viewed as compatible, but not an exact entailment.</s>"
    },
    "9cbc00e9-3a2d-4471-a93e-72c95132fb6a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "The only case of congestive heart failure in the primary trial occurred in cohort 1",
        "Label": "Entailment",
        "entail": "The statement \"The only case of congestive heart failure in the primary trial occurred in cohort 1\" is entailed by the CTRs if we make the additional assumption that all cases of congestive heart failure were reported from cohort 1 in the primary trial. The CTR for the primary trial states that there was one instance of congestive heart failure (1/35) in the entire trial population, while there were no instances reported in the secondary trial (0/40). Therefore, since the CTR does not mention any cases of congestive heart failure in cohort 2 or any other cohorts of the primary trial, and the statement specifically mentions cohort 1, the statement can be entailed by the information in the CTRs.\n\nFormally, we can express the entailment relationship as follows:\n\nStatement \u2291 CTRs\n\n\u2200x [(x is a case of congestive heart failure in the primary trial) \u2192 (x belongs to cohort 1)]\n\nTherefore, given the CTR information and the above assumption, if a case of congestive heart failure is identified as belonging to cohort 1, it follows that this case is the only one reported in the entire primary trial, as stated in the expert's claim.</s>",
        "contradict": "The expert's statement cannot be directly contradicted by the provided CTR data as it makes an additional assumption, i.e., that all adverse events in cohort 1 of the primary trial were included in the given Adverse Events 1 section. However, this assumption is not explicitly stated or proven by the CTR. If it can be confirmed that all adverse events in cohort 1 are indeed included in Adverse Events 1 or if the expert has access to additional information about the distribution of adverse events in cohorts, then the statement could be evaluated for entailment accordingly. Otherwise, it is currently indeterminate based on the given information.</s>"
    },
    "8b91cab9-d858-45f3-bf8d-3d6fc55b4818": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements",
        "Label": "Entailment",
        "entail": "The statement made by the clinical trials expert that \"the primary trial results section reports two different measurements\" is entailed by the information present in the CTRs because the CTR for the primary trial explicitly states that the two methods used for detecting sentinel lymph nodes (SLNs), Technetium Tc-99m sulfur colloid (Tc) and Indocyanine green (ICG), result in the detection of different numbers of SNs, and thus different proportions of SNs being detected. Therefore, the statement made by the expert is a valid observation derived from the data presented in the CTR.</s>",
        "contradict": "The statement does not provide sufficient details to determine if it can be contradicted by the CTRs. The statement only mentions that there are two different measurements reported in the primary trial results section, but it does not specify which measurements or what the contradiction might be. The CTRs, on the other hand, provide detailed information about the outcome measurement in the primary trial, which is the proportion of sentinel lymph nodes (SLNs) detected by Tc and ICG methods. Without further context or information, it is impossible to determine if the statement is contradictory to the CTRs.</s>"
    },
    "4a75574c-fa86-4e62-a210-81c7b98a3807": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T4 N2 M4 patients are eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"T4 N2 M4 patients are eligible for the primary trial\" is not directly entailed by the information present in the CTRs for the primary trial. The CTRs specify that T4 disease is allowed only if it has minimal dermal invasion, and T4 disease with ulceration of skin, infiltration of skin, peau d'orange, or inflammatory breast cancer is excluded. Furthermore, N2 indicates the presence of metastatic lymph nodes which is a condition not explicitly stated as eligible for the trial. M1, indicating distant metastases, is explicitly stated as a condition for exclusion. Consequently, \"T4 N2 M4 patients\" are not explicitly stated to be eligible for the trial according to the provided CTRs.</s>",
        "contradict": "The statement \"T4 N2 M4 patients are eligible for the primary trial\" is contradicted by the information in the CTR, as stated in the Disease Characteristics section: \"No T4 disease with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange, or inflammatory breast cancer. N2 designates lymph node involvement and M4 signifies distant metastases, which are explicitly excluded from the eligibility criteria in the CTR.</s>"
    },
    "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02419807",
        "Statement": "The the primary trial results section reports two different measurements, for all 3 cohorts.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trial expert can be entailed by the provided CTRs because both reports describe separate methods for detecting sentinel lymph nodes (SLNs) within different study groups. In the primary CTR, the methods used are Tc-labeled radiotracer and ICG, whereas in the secondary CTR, the method is not explicitly stated but can be inferred to be different based on the expert's description. Since the expert's statement acknowledges that there are two different measurement methods reported in the primary trial results, it is consistent with the information in the CTRs, as they indeed present findings based on two distinct techniques (Tc-labeled radiotracer and ICG). Therefore, the statement is an entailed consequence of the information provided in the CTRs.</s>",
        "contradict": "The statement \"The primary trial results section reports two different measurements, for all 3 cohorts\" is not directly contradictory to the information present in the CTRs. However, the CTRs only report proportions of sentinel nodes (SNs) detected by Tc and ICG methods for a single group of participants in the primary trial. The statement implies that there are three cohorts in the primary trial with different measurements, while the information provided only pertains to a single group's measurements. This potential misinterpretation can create a contradiction if the statement is taken to mean that the CTRs report different measurements for multiple cohorts within the primary trial, when in fact they only report the measurements for a single cohort.</s>"
    },
    "b0b61978-57db-4a1c-812c-509e8b05f2dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have",
        "Label": "Entailment",
        "entail": "The statement \"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have\" is entailed by the CTR information as follows: \n\n1. Both cohorts receive identical interventions: The intervention details for each cohort are identical in terms of the drugs used (Nivolumab and Daratumumab), the dosages, frequencies, and durations.\n\n2. The difference between the cohorts is the types of cancer: The distinction between the two cohorts lies in the type of cancer that is being treated, as explicitly stated in the primary trial description - TNBC for one cohort and NSCLC for the other.</s>",
        "contradict": "Although both cohorts in the primary trial receive the same interventions, the statement that \"the difference between the two cohorts is the types of cancer that the patients have\" can be contradicted by the information presented in the CTRs because, while it's true that the patient cohorts have different cancer types (TNBC and NSCLC), this difference does not fully capture the content of the statement. The statement suggests that the only difference between the cohorts lies in the type of cancer, but according to the CTRs, there are also differences in the cancer treatments themselves (TNBC versus NSCLC), which are not explicitly mentioned in the statement.</s>"
    },
    "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have a palpable carcinoma to be included in the primary trial",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTR as both Phase 1 and Phase 2 inclusion criteria specify that patients must have a histologic diagnosis of invasive breast cancer or ductal carcinoma in situ which is palpable in Phase 1 and non-palpable but visible on imaging in Phase 2.</s>",
        "contradict": "The statement \"Patients must have a palpable carcinoma to be included in the primary trial\" is contradicted by the information present in the CTRs because patients with a non-palpable neoplasm that enhances on breast MRI imaging and who desire breast surgery are also eligible for inclusion in Phase 1 of the primary trial. This information is stated clearly in the CTR, contradicting the expert's claim that a palpable carcinoma is a requirement for inclusion.</s>"
    },
    "fbb62216-2cf2-4813-ad41-12a86940610f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial\" can be entailed by the information present in the CTRs because, in CTR 1, anaemia had an occurrence rate of 3.52% (7 cases out of 199 participants), making it the most frequent adverse event in cohort 1. Similarly, in CTR 2, anaemia had an occurrence rate of 5.56% (2 cases out of 36 participants), making it the most frequent adverse event in cohort 2 as well. The combined occurrence rate of anaemia in both cohorts is 5.04% (9 cases out of 176 participants), which is still lower than the rates in each individual CTR but supports the overall trend that anaemia was a relatively common adverse event in the primary trial. Therefore, the expert's statement is entailed by the data in the CTRs.</s>",
        "contradict": "Although the statement \"Anaemia was the most common adverse event in cohort 1 and 2 of the primary trial\" might initially seem to align with the information present in the CTRs, a closer examination reveals that this is not the case. The statement is contradicted by the data, as the frequency of anaemia is not the highest across all adverse events in both cohorts of either trial. In Cohort 1 of the primary trial, the highest frequency occurs in the case of Cardiopulmonary failure (6 instances out of 199 participants), and in Cohort 2 of the primary trial, the highest frequency is observed for Supraventricular tachycardia (3 instances out of 36 participants). Therefore, the statement is not entailed by the information present in the CTRs.</s>"
    },
    "961a956e-fece-4baa-a2ad-d3a5320bd9d2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was less than 3 weeks",
        "Label": "Contradiction",
        "entail": "The statement \"The shortest PFS in cohort 1 of the primary trial was less than 3 weeks\" cannot be directly entailed by the information present in the given CTRs. \n\nExplanation: \n\nAlthough the CTRs provide information on the PFS for each study arm, they do not specify the minimum or maximum PFS for individual participants in cohort 1. The CTR only reports the median PFS and the range of 95% confidence intervals for both arms. Therefore, based on the given information, it is impossible to determine if there was a participant in cohort 1 with a PFS shorter than 3 weeks.</s>",
        "contradict": "The statement \"The shortest PFS in cohort 1 of the primary trial was less than 3 weeks\" cannot be directly contradicted by the information present in the CTRs. However, the statement does not entail the information in the CTRs since there is no mention of PFS durations less than 3 weeks for any participant in cohort 1 or in the overall analysis of the trial. The CTRs only provide the median PFS and 95% confidence intervals. The shortest PFS for an individual participant is not stated in the CTRs.</s>"
    },
    "97fd111c-6969-43ab-93af-b3dff09960e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is reports the incidence rate of 12 different Aes",
        "Label": "Contradiction",
        "entail": "The expert's statement does not directly entail the information presented in the CTRs since the primary trial's Adverse Events section reports a total of 0/0, which means there were no reported adverse events during the trial. The expert's statement, on the other hand, mentions an incidence rate, indicating that there are at least some reported adverse events. However, if we assume that the expert's statement is intended to refer to the secondary trial, then the information can be consistent with the CTR if the secondary trial did report 12 different adverse events and the expert's statement is an error or an oversight in referencing the correct trial. In this case, the entailment would depend on the accuracy of the expert's statement.</s>",
        "contradict": "The statement made by the clinical trial expert that \"The adverse events section in the primary trial is reports the incidence rate of 12 different AEs\" cannot be entailed by the information present in the CTR as it contradicts the data given. In the CTR for the primary trial, the adverse events section states that there were no adverse events reported, with a total of 0/0. The statement by the clinical trial expert suggests that there were incident reports for 12 different adverse events, which is not consistent with the CTR data as it states the absence of any adverse events.</s>"
    },
    "eb1bfb08-eba0-4130-b328-00f56c0f84a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "Diarrhoea is the most common adverse event in the primary trial and the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Diarrhea is the most common adverse event in the primary trial and the secondary trial\" can be entailed by the information in the CTRs since the absolute frequencies of diarrhea events (5 occurrences out of 65 participants in the primary trial, and 40 occurrences out of 1110 participants across the secondary trial) are the highest among all the listed adverse events for both trials. The proportion of participants experiencing diarrhea is also the highest in both trials (7.69% for the primary trial and 16.81% for the secondary trial).</s>",
        "contradict": "The statement \"Diarrhea is the most common adverse event in the primary trial and the secondary trial\" is contradicted by the information provided in the CTRs because the frequency of diarrhea in the primary trial is 5/65 (7.69%), and in the secondary trial it is 1/238 (0.42%). Thus, the statement that diarrhea is the most common adverse event in both trials is incorrect based on the information presented in the CTRs.</s>"
    },
    "b1219e71-fbf5-4bba-8a93-a27ae444e3e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, but can not have received any previous treatment for this advanced cancer",
        "Label": "Entailment",
        "entail": "The expert statement \"to be eligible for the primary trial, patients must be diagnosed with hormone receptor positive advanced breast cancer, but cannot have received any previous treatment for this advanced cancer\" is entailed by the CTR's inclusion and exclusion criteria. The primary trial includes patients with hormone receptor positive advanced breast cancer and excludes those with previous treatment for advanced breast cancer. The expert statement aligns with these conditions, stating that patients must have hormone receptor positive advanced breast cancer but cannot have previous advanced breast cancer treatment.</s>",
        "contradict": "The information contained in the expert's statement is not an exact entailment of the primary trial's inclusion and exclusion criteria. While the statement correctly asserts that patients in the primary trial must have hormone receptor positive advanced breast cancer, it incorrectly states that they cannot have received any previous treatment for advanced breast cancer. The primary trial's exclusion criteria indeed specify that patients with previous treatment for advanced breast cancer are not eligible. However, it also permits patients with a history of early breast cancer and its treatment. Therefore, patients with a history of early breast cancer but no prior treatment for advanced breast cancer could potentially be eligible for the primary trial, which contradicts the expert's claim that \"they cannot have received any previous treatment for this advanced cancer.\"</s>"
    },
    "f10f3b84-e039-4a02-a98b-86d149d9a16f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are not permitted for participants of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"ongoing flucytosine treatments are not permitted for participants of the primary trial\" is entailed by the CTR as it explicitly lists \"Being treated with flucytosine\" under the exclusion criteria for the primary trial.</s>",
        "contradict": "The statement \"ongoing flucytosine treatments are not permitted for participants of the primary trial\" contradicts the CTR because flucytosine is explicitly listed as an exclusion criterion in the primary trial's exclusion list. This means that individuals receiving flucytosine treatment are not eligible for participation in the primary trial. Thus, there should be no ongoing flucytosine treatments amongst the primary trial's participants. However, the statement suggests the existence of ongoing flucytosine treatments in participants, which contradicts the information presented in the CTR.</s>"
    },
    "0ddb07ae-6e70-436d-8723-f609e59c57da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve doses of Pralatrexate that are calculated based on bodyweight",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial participants receive doses of Pralatrexate that are calculated based on bodyweight\" can be entailed by the information present in the CTR, specifically the part that states \"Study drug 190 mg/m^2\" in the INTERVENTION 1 section of the primary trial CTR. The dose is expressed as mg/m^2, which is a unit that denotes dose per square meter of body surface area, indicating that the dosage is indeed calculated based on bodyweight.</s>",
        "contradict": "The information in the expert's statement cannot be directly contradicted by the CTR data, as both state that the primary trial participants receive Pralatrexate doses, with the CTR specifying a particular dosage (190 mg/m^2) for a specific duration. However, the expert's statement does not contradict the CTR, as it implies a general process of dose calculation based on body weight, which is not necessarily in conflict with the CTR's stated dosage. The discrepancy, if any, is in the level of detail and not in the underlying facts.</s>"
    },
    "c10eea1a-5768-442d-ae07-20b4f8f4b583": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with triple negative breast cancer are eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The inclusion criterion in the primary trial specifies that the cancer type must be HER-2 positive BC. Triple negative breast cancer (TNBC) is defined by the absence of expression or amplification of HER-2, estrogen receptors (ER), and progesterone receptors (PR). Given that HER-2 positive BC is a subset of TNBC and the primary trial only enrolls patients with HER-2 positive BC, the statement that \"Only patients with triple negative breast cancer are eligible for the primary trial\" is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"Only patients with triple negative breast cancer are eligible for the primary trial\" contradicts the information present in the CTR, as the eligibility criteria for the primary trial include patients with HER-2 positive BC as well.</s>"
    },
    "2ef186d0-b4ab-44de-b785-a63e9e95851a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02273973",
        "Secondary_id": "NCT00281697",
        "Statement": "most participants in the secondary trial and the primary trial did not suffer from Enterocolitis",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information in the CTRs because neither Adverse Events 1 nor Adverse Events 2 of the primary nor the secondary trial report any instance of Enterocolitis, and the statement asserts that \"most\" participants did not suffer from this condition in both trials.</s>",
        "contradict": "The statement \"most participants in the secondary trial and the primary trial did not suffer from Enterocolitis\" cannot be directly contradicted by the information presented in the Adverse Events sections of the CTRs, as the CTRs do not provide sufficient information for a comparison of Enterocolitis occurrence between the two trials in terms of a majority of participants. However, the statement could be contradicted if new information emerged in other sections of the CTRs, such as the Eligibility Criteria or Intervention sections, that showed a higher incidence of Enterocolitis in one trial compared to the other, despite the Adverse Events sections reporting lower numbers for both trials.</s>"
    },
    "fef5aedb-21c0-4130-b8a3-cb1df5017c7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00328783",
        "Statement": "The adverse events section in the primary trial is empty",
        "Label": "Entailment",
        "entail": "The expert's statement \"The adverse events section in the primary trial is empty\" is entailed by the information in the CTRs as both statements describe the absence of adverse events data in the primary trial's adverse events section.</s>",
        "contradict": "The statement \"The adverse events section in the primary trial is empty\" can be contradicted by the information present in the CTRs if the CTR for the primary trial does in fact contain data on adverse events but it was inadvertently left out or misrepresented in the given excerpt. The statement assumes that the absence of adverse events data in the excerpt provided is a reflection of the actual CTR, which may not be the case. It's important to note that a '0/0' count in the CTR can still represent the absence of adverse events or the absence of data being reported. Therefore, the statement's contradiction with the CTR information would stem from potential incomplete reporting or misinterpretation of the data rather than an inherent contradiction.</s>"
    },
    "2655c892-216e-4b96-a8f2-6f64403215c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "Label": "Contradiction",
        "entail": "The statement that \"there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" is entailed by the CTR data as follows: \n\nThe CTRs specify that for Adverse Events 1 in Cohort 1 of the primary trial, there were no cases reported for Nausea, Vomiting, Constipation, and Abdominal pain. Since the statement mentions exactly these 4 adverse events that did not affect any patients in Cohort 1, it follows logically that this statement is entailed by the data provided in the CTRs.</s>",
        "contradict": "The statement \"there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" cannot be directly contradicted by the information present in the CTRs, as the CTRs do not provide sufficient data to determine which specific adverse events did not occur in Cohort 1. However, the statement is inconsistent with the provided data if we assume that there were only 12 types of adverse events (6 from each CTR) and the expert intended to refer to those. According to the CTRs, all 12 adverse events were reported in Cohort 1 of the primary trial (even if none of the patients experienced Thrombocytopenia), contradicting the claim that there were 4 types unaffected by any patient.</s>"
    },
    "2825d63b-8f22-4fb8-829f-9567845251c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "adults and children can take part in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"adults and children can take part in the primary trial\" is not entailed by the information present in the CTRs. \n\nThe primary CTR's inclusion criteria explicitly list \"Female\" as a requirement for trial participation, and there is no mention of children or males being eligible for the trial. The CTR's exclusion criteria also state \"any race/ethnicity,\" further implying that it is intended for human participants, but it does not specify an age range beyond \"18 years.\" \n\nTherefore, since the CTRs do not include information that allows the entailment of the statement that \"adults and children can take part in the primary trial,\" the statement is not entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"adults and children can take part in the primary trial\" contradicts the information in the CTRs as they only include patients who are female, aged 18 years or older, and have metastatic breast cancer with specific inclusion and exclusion criteria. No information regarding children's eligibility is mentioned.</s>"
    },
    "6b35bc10-f591-4b84-abac-40a74be949fa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02340221",
        "Statement": "Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR inclusion criteria, which explicitly state \"Prior treatment with fulvestrant\" and \"Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor\" as exclusion criteria, meaning individuals who have undergone such treatments are not eligible for the trial.</s>",
        "contradict": "Contradiction exists as the CTR specifies \"Prior treatment with fulvestrant\" in the Primary Trial's Inclusion Criteria as an exclusion factor, whereas the expert statement asserts \"Prior treatment with fulvestrant is not admissible,\" which contradicts this requirement. Similarly, the CTR includes \"Prior treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor\" as an exclusion factor under both the Primary and Secondary Trial's sections, while the expert statement only mentions PI3K inhibitors in relation to the primary trial.</s>"
    },
    "a5baab2c-9c32-4301-a574-4ba5a0c2eb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial.",
        "Label": "Contradiction",
        "entail": "The statement \"Presence of hot flashes for at least 4 months prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial\" can be entailed by the information present in the CTRs as follows:\n\nFor the Primary Trial: The CTR specifies that hot flashes should have occurred for 30 days prior to study registration. Since 30 days is a subset of 4 months, the statement is not contradictory to the CTR and is therefore entailed.\n\nFor the Secondary Trial: Although the CTR does not explicitly mention the duration of hot flashes required for the secondary trial, there is no contradiction with the statement since the statement imposes a longer duration requirement (4 months) that could still be satisfied by the patients meeting the secondary trial's inclusion criteria.</s>",
        "contradict": "The statement \"Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial\" is contradicted by the information presented in the given Primary CTR as it specifies the presence of hot flashes for 30 days prior to study registration, which is less than 4 months. Therefore, the presence of hot flashes for at least 4 months is not a requirement for the primary trial as stated by the CTR. Furthermore, the secondary CTR does not provide information regarding the duration of hot flashes prior to study registration.</s>"
    },
    "70677d5f-7022-404c-8410-d1f89366d92f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trials expert does not directly relate to the information in the provided CTRs as neither of them report tumor diameter measurements. However, the statement can be assumed to be entailed if we consider the context that both trials investigate breast cancer treatments and use the outcome measure of pCR. Therefore, the statement's implication - both trials focus on measuring pCR in their patient cohorts - can be inferred as entailed, given the CTR information about the primary trial's pCR rate measurement and the expert's statement regarding pCR being a measure in the secondary trial.</s>",
        "contradict": "The statement that \"the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts\" is not directly contradicted by the information present in the CTRs. However, the CTRs do not provide information on whether the secondary trial measures tumor diameter. The primary trial measures pCR but not tumor diameter, while the secondary trial measures disease-free survival and does not explicitly state that it measures pCR or tumor diameter. Hence, the statement is not contradicted but also not directly confirmed by the CTRs.</s>"
    },
    "f46a7d27-a94f-4389-a1a0-4a8f5177b354": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than than one patient",
        "Label": "Contradiction",
        "entail": "The statement \"None of the individual AEs (Adverse Events) recorded in the primary trial affect more than one patient\" is entailed by the CTR data as follows: \n\n1. The CTRs provide separate Adverse Events sections for each trial, with distinct patient counts.\n2. Each Adverse Event in the CTR is identified by the number of occurrences within the patient cohort, along with the percentage.\n3. The number of patients affected by each specific Adverse Event is explicitly stated for both primary and secondary trials.\n4. The Adverse Event counts in the primary and secondary trials do not overlap since the trials involve distinct patient populations.\n5. Therefore, the statement that \"None of the individual AEs recorded in the primary trial affect more than one patient\" is consistent with the CTR data, as no single Adverse Event in the primary trial affected multiple patients based on the reported data.</s>",
        "contradict": "The expert's statement can be contradicted by the CTR data due to the presence of shared adverse events (AEs) between the two trials for anaemia and stress cardiomyopathy, which affected multiple patients in each trial. \n\nPrimary Trial:  Anaemia (4 cases out of 100 patients), Stress cardiomyopathy (1 case out of 100 patients)\nSecondary Trial:  Anaemia (1 case out of 152 patients), Stress cardiomyopathy (1 case out of 152 patients)\n\nThus, the expert's statement does not hold true for the CTR data provided.</s>"
    },
    "fe876bb0-7ce3-4197-81ad-920f1f77938e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00066573",
        "Statement": "there is a minimal difference between the results from the two the primary trial cohorts",
        "Label": "Entailment",
        "entail": "The statement \"there is a minimal difference between the results from the two primary trial cohorts\" is entailed by the CTRs as both trials involve identical intervention type (oral administration), identical length of treatment (5 years), and similar percentage of participants in each arm (88-89% for exemestane and 88-90% for anastrozole). The minor differences in percentages are within statistical variability and do not indicate clinically significant discrepancies.</s>",
        "contradict": "The statement \"there is a minimal difference between the results from the two primary trial cohorts\" can be contradicted by the information present in the CTRs because the percentage of participants with event-free survival in the exemestane arm (87-89%) is lower than in the anastrozole arm (88-90%). This discrepancy implies a difference rather than minimality between the trial results.</s>"
    },
    "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Contradiction",
        "entail": "The statement \"to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions as well as Adequate hematology levels\" is entailed by the information present in the CTR's Inclusion Criteria. The age restriction (over 18 years) and the requirements for adequate hepatic, renal, and heart functions, as well as adequate hematology levels, are clearly stated in the provided CTR. The statement's additional requirement for candidates to have a severe disability is not explicitly mentioned in the CTR, but there is no contradiction to this condition in the given inclusion criteria. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement by the clinical trials expert can be contradicted by the inclusion criteria of the primary trial in several ways:\n\n1. Age: Candidates for the primary trial must be between 18 and 70 years old, which is narrower than the stated age range of \"over 18 years.\"\n2. Disability: There is no requirement for candidates to have a severe disability as stated in the expert's statement. Instead, they must meet the Karnofsky performance status index > 80 %.\n3. Organ function requirements: While the expert's statement mentions adequate hepatic, renal, and heart functions, the inclusion criteria for the primary trial list specific requirements for each of these functions (e.g., Adequate hepatic function: Total bilirubin <1.5 times the upper limit of normal; AST and ALT \u22642.5 times the upper limit of normal; ALT \u22645 times the upper limit of normal if liver metastases are present). These more detailed criteria are not mentioned in the expert's statement.\n\nTherefore, the expert's statement contradicts the inclusion criteria for the primary trial in several respects.</s>"
    },
    "4f705481-5dd0-414c-b375-c56e8c235b42": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The most common adverse event in the primary trial was skin infection",
        "Label": "Entailment",
        "entail": "The statement \"The most common adverse event in the primary trial was skin infection\" is entailed by the information in the CTRs as follows:\n\nThe CTR of the primary trial reports a total of 14 adverse events out of 41 participants (34.15%), and among these, 2 participants experienced skin infections (4.88%). The frequency of skin infection (4.88%) is higher than that of all other reported adverse events. Therefore, the statement \"The most common adverse event in the primary trial was skin infection\" correctly summarizes the data presented in the CTR.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the most common adverse event in the primary trial, with an occurrence rate of 4.88%, was skin infection in the secondary trial. However, in the primary CTR, the most frequent adverse event occurred equally among multiple adverse events, each with a rate of 2.44%. Therefore, the expert's statement implies a different interpretation of the most common adverse event, potentially leading to a contradiction with the data presented in the primary CTR.</s>"
    },
    "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial",
        "Label": "Contradiction",
        "entail": "The statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial\" can be entailed by the information present in the CTRs as follows: The frequency of Febrile Neutropenia (3/56 or 5.36%) is higher than the frequency of any other adverse event listed in the Primary Trial's Adverse Events section. Therefore, Febrile Neutropenia is the most frequent adverse event in the trial in terms of occurrence and it did affect more patients than any other adverse event.</s>",
        "contradict": "The expert's statement is contradicted by the CTR data as the frequency of Febrile Neutropenia (3/56 or 5.36%) does not exceed the frequency of any other adverse event mentioned in the CTR. Therefore, it's inaccurate to claim that \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial.\"</s>"
    },
    "c09fa61c-967a-40ae-96b0-c87b7cde237b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02679755",
        "Statement": "None of the individual Aes recorded in the primary trial affect more than 10% of the population.",
        "Label": "Entailment",
        "entail": "The statement \"None of the individual AEs recorded in the primary trial affect more than 10% of the population\" can be entailed by the information in the CTRs because the total frequency of each individual AE in the primary trial is below 10% of the total participant count (i.e., 18/100 = 0.18, which is less than 10%). Similarly, in the secondary trial, none of the individual AEs reach a frequency above 10% (the highest frequency being 1.32% for abdominal pain and abdominal pain upper).</s>",
        "contradict": "The statement \"None of the individual AEs recorded in the primary trial affect more than 10% of the population\" is contradicted by the data in the Adverse Events sections of both the primary and secondary trials. The data reveals that in the primary trial, the frequencies for Anaemia, Febrile neutropenia, Neutropenia, and Pancytopenia exceed 10.00% (4.00%, 3.00%, 1.00%, and 0.66% respectively), whereas in the secondary trial, the frequency for Stress cardiomyopathy is 0.66%, which is also above 10.00% when expressed as a percentage of the total number of participants in the trial.</s>"
    },
    "4309860d-042d-45a4-8a0a-a9fdd075247a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion",
        "Label": "Contradiction",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" is entailed by the information present in the CTRs as follows:\n\n1. In Group A of the primary trial, NKTR-102 is administered to patients, but the manner of administration is specified as \"as a 90-minute intravenous (IV) infusion\" which clearly indicates that NKTR-102 is given by infusion to this cohort.\n2. In contrast, Group B (Cohort 2) of the primary trial does not have such an explicit specification for NKT-102 administration. Instead, it is stated that \"Patients randomized to TPC will receive single-agent IV chemotherapy,\" which indicates that they will receive chemotherapy by IV infusion, but not NKTR-102.\n3. Therefore, based on the information in the CTRs, neither Group A nor Group B in the primary trial receives NKTR-102 by infusion for Cohort 1, since it is explicitly stated for Group A, and for Cohort 2, it is inferred due to the absence of such information and the statement that they receive \"single-agent IV chemotherapy\" instead.\n4. Therefore, the expert's statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" is an accurate reflection of the information in the CTRs and is entailed by the information present.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" is contradicted by the information present in the CTRs. According to the information provided in the CTRs, Cohort 1 does indeed receive NKTR-102 by infusion, specifically at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle. The statement incorrectly asserts that neither cohort receives NKTR-102 by infusion.</s>"
    },
    "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use identical outcome measurements",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial use identical outcome measurements\" can be entailed by the information present in the CTRs as follows: \n\nBoth trials measure response to treatment in participants with cancer. In the primary trial, outcome measurement is based on the Response Evaluation Criteria In Solid Tumors (RECIST), specifically measuring the number of participants with Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Mixed Response. In the secondary trial, the outcome measurement is also based on response evaluation, but specifically measuring the percentage of participants with Pathological Complete Response (pCR) in breast and axilla as defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System. While the specific definitions and measurement units differ (number vs percentage), they both involve response evaluation and are applicable to cancer treatment trials. Therefore, the trials use identical types of outcome measurements, even if not identical in definition or measurement unit.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial use identical outcome measurements\" can be contradicted by the information present in the CTRs because the outcome measurements in the two trials are not identical. \n\nThe primary trial reports overall response (CR, PR, or SD) using RECIST criteria with a time frame of 6 months, whereas the secondary trial reports the percentage of participants with pCR in breast and axilla using AJCC Staging System with the time frame being surgery visit (weeks 14 to 19). These outcomes are not the same, as RECIST is used for evaluating response during the course of treatment, while pCR is determined based on surgical pathology results.</s>"
    },
    "59cd7909-00c3-4c23-9a08-a42dbc8eabdd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression",
        "Label": "Entailment",
        "entail": "The statement is entailed by the information present in the CTRs as both trials specify that treatment cycles continue until disease progression. The primary trial outlines that each treatment cycle lasts 28 days and participants will be treated until disease progression for all three interventions (Abraxane, Avastin, and Gemcitabine). The secondary trial also states that participants will not receive the intervention for a set number of cycles but will continue treatment until disease progression, which aligns with the information in the primary CTR. There is no contradiction with the descriptions in either CTR.</s>",
        "contradict": "The expert's statement contradicts the information provided in the CTRs because in the primary trial, the participants will receive the interventions of Abraxane, Avastin, and Gemcitabine for each cycle until disease progression, according to the specified protocol. The expert's statement implies that the participants will not receive the intervention for a set number of cycles, which is not consistent with the information given in the CTRs.</s>"
    },
    "e6a4e9a6-56b8-4a30-9743-eb02688c090f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
        "Label": "Entailment",
        "entail": "Both the patient with node-positive T2 N2 M0 breast cancer and the patient with node-negative adenocarcinoma of the breast with a tumor diameter of 1.5 cm meet the eligibility criteria stated in the CTR. The statement that a patient with these conditions would be eligible for the primary trial is entailed by the CTR since:\n\n1. Node-positive breast cancer: Tumors T1-3, node-positive (N1-2) and M0 are explicitly included in the eligibility criteria.\n2. Node-negative breast cancer with a tumor diameter of 1.5 cm: This patient meets the criteria of having a tumor >1 cm. However, the CTR also states that if the node-negative patient has a tumor <=1 cm, they can still be eligible as long as they have at least one of the other listed features. This patient does not have negative ER/PR status, but the CTR does not exclude patients with positive ER/PR status. Therefore, the patient meets the eligibility requirement for this feature as well.\n\nHence, the statement can be entailed by the information in the CTR, as both patients meet the stated eligibility conditions for the primary trial.</s>",
        "contradict": "The statement does not contradict the information present in the CTRs for the primary trial, as the patients described in the statement meet the inclusion criteria, specifically having HER2-positive breast cancer and satisfying the relevant tumor and nodal stage conditions. However, it's essential to note that the statement only addresses two specific patient scenarios and does not account for other inclusion/exclusion factors mentioned in the CTRs, such as age, hormone receptor status, surgical status, and laboratory values.</s>"
    },
    "82a3e542-f784-44d7-90f6-34d7e969283c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants receive more than one type of medication during the study",
        "Label": "Entailment",
        "entail": "The statement that \"primary trial participants receive more than one type of medication during the study\" is entailed by the CTR information as stated: \"All patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking.\" In this case, each patient in the primary trial is receiving and combining two distinct types of medications - Bevacizumab (Avastin) and hormonal therapy.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because it is not explicit that the participants in the secondary trial receive more than one type of medication. In the primary trial, patients received both Avastin (Bevacizumab) and hormonal therapy, whereas the secondary trial description did not mention the use of any additional medication. However, the statement does not limit the condition to the primary trial, making it possible for other participants or trials to receive more than one type of medication. Thus, the statement is not necessarily entailed by the information in the CTRs, as it could hold true for other trials with different designs.</s>"
    },
    "fb360514-14be-45ab-8b74-ea5a7eb181d7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial do not report adverse events",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial do not report adverse events\" is entailed by the information present in the CTRs since both trials report having zero occurrences of adverse events in their respective sections.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not report adverse events\" contradicts the information present in the CTRs because, although no adverse events were reported in both trials in the statement, the CTRs provide details about the number of participants with no adverse events but do not indicate an absence of adverse events for the entire trial population.</s>"
    },
    "7137dec6-5c98-4156-8035-7bbaaf0b649d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score < 2 is necessary to be eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"ECOG score < 2 is necessary to be eligible for the primary trial\" is entailed by the CTR's inclusion criteria stating that \"Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\" is required for participation in the trial. Therefore, an ECOG score lower than 2, which falls within the range of 0 and 1, would satisfy this requirement.</s>",
        "contradict": "The statement \"ECOG score < 2 is necessary to be eligible for the primary trial\" cannot be directly contradicted by the inclusion criteria provided in the CTR for the primary trial, which states \"Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\". However, it is possible for the statement to be contradicted if we consider the secondary trial with different eligibility criteria. Since the statement refers to the primary trial in general, it could potentially be in conflict with the inclusion criteria of other trials with different ECOG score requirements. Therefore, the statement may not universally hold for all trials meeting the description in the CTR and should be evaluated against each trial's specific eligibility criteria.</s>"
    },
    "015dd869-db90-45a9-a951-9dc7dc2b2e01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs as neither condition explicitly excludes patients with a malignant brain tumor or colon cancer diagnosis from the primary trial. The inclusion criteria state that the disease \"must be able to be measured,\" which is a broad criterion that applies to many types of cancers, including brain tumors and colon cancer. Conversely, the explicit exclusion criteria do not mention brain tumors or colon cancer as conditions that would disqualify a patient from the trial. Consequently, patients with these diagnoses can be eligible for the trial according to the CTR information.</s>",
        "contradict": "The statement \"patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial\" is contradictory to the CTR inclusion criteria since the CTR specifies that patients with a cancer diagnosis involving the brain are excluded from the trial.</s>"
    },
    "3a4003f6-ff1c-43d8-be48-f767266b2cf5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "the secondary trial and the primary trial do not have the same inclusion and exclusion conditions",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not have the same inclusion and exclusion conditions\" is entailed by the information presented in the CTRs because the CTRs provide distinct eligibility criteria and exclusion criteria for each trial. While both trials require participants to have signed informed consent and be able to swallow an oral medication, the primary trial includes patients with invasive adenocarcinoma of the breast, regardless of hormonal receptor status, while the secondary trial specifically requires ErbB2(HER2) overexpressing breast cancer. The secondary trial also restricts participants with a history of severe cerebral vascular disease, which is not mentioned as an exclusion factor in the primary trial. Additionally, the secondary trial allows for prior treatment with trastuzumab and WBR/SRS, which are not mentioned in the primary trial's inclusion criteria. These differences in inclusion and exclusion factors between the two trials entail that they do not have identical conditions.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial do not have the same inclusion and exclusion conditions\" can be contradicted by the information present in the CTRs. Both trials have some overlapping inclusion criteria, such as signed informed consent, ability to swallow an oral medication, and adequate organ function. However, they have significant differences in other inclusion criteria, such as the type and stage of breast cancer, prior therapies, and presence of brain lesions. Additionally, the exclusion criteria differ in various aspects, such as pregnancy, cardiac conditions, and history of seizures. Therefore, the statement is not an entailed outcome based on the provided CTRs.</s>"
    },
    "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00915603",
        "Statement": "at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months",
        "Label": "Entailment",
        "entail": "The statement \"at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months\" is entailed by the CTR data, as both cohorts report a 95% Confidence Interval for the Paclitaxel/Bevacizumab/Everolimus group containing 10.8 months, and it's not contradictory to the provided descriptions. The statement does not require the specific identification of those participants, so no contradiction is present in the given CTR data.</s>",
        "contradict": "The statement \"at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months\" is contradicted by the information in the CTR as neither of the reported medians for Progression-Free Survival in Arm/Group 1 (Paclitaxel/Bevacizumab/Everolimus) and Arm/Group 2 (Paclitaxel/Bevacizumab/Placebo) reach 10.8 months. The reported medians for Arm/Group 1 and Arm/Group 2 are 9.1 months (6.8 to 10.8) and 7.1 months (5.6 to 10.8) respectively. Therefore, no participant in the trial had a Progression-Free Survival of 10.8 months according to the reported data.</s>"
    },
    "f3cb9150-32c6-4877-9a87-4fac45a24948": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded casesof Musculoskeletal adverse events occurred in cohort 2 of the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTR information if the following conditions hold:\n\n1. In both trials, all Musculoskeletal adverse events are recorded in their respective \"Adverse Events\" sections.\n2. In the secondary trial, there is at least one Musculoskeletal adverse event reported in cohort 2, which is not present in any cohort of the primary trial.\n\nGiven the CTR data provided, these conditions are met:\n\n1. The CTRs clearly indicate an \"Adverse Events\" section for both trials, and all adverse events are documented within this section.\n2. In the secondary trial, there is one Musculoskeletal adverse event recorded (1/62). However, no Musculoskeletal adverse events are reported in the primary trial (0/34).\n\nThus, the statement can be entailed by the CTR data, as it correctly describes the absence of Musculoskeletal adverse events in cohort 1 of the secondary trial and the presence of one such event in cohort 2.</s>",
        "contradict": "The statement is contradicted by the data in the CTRs because there are no recorded Musculoskeletal adverse events in cohort 2 of the secondary trial, according to the provided data. However, the statement asserts that all Musculoskeletal adverse events occurred in cohort 2 of the secondary trial.</s>"
    },
    "9d8b26d6-d574-4717-88b6-77458bc683f3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Syncope was the most common adverse event recorded in the primary trial",
        "Label": "Contradiction",
        "entail": "The expert's statement \"Syncope was the most common adverse event recorded in the primary trial\" cannot be entailed by the information present in the CTRs, as no occurrence of syncope is reported among the adverse events in either the primary or secondary trial. Therefore, the statement is not an entailed conclusion based on the provided CTRs.</s>",
        "contradict": "The statement \"Syncope was the most common adverse event recorded in the primary trial\" cannot be entailed from the information provided in the CTRs. According to the provided data, the most common adverse events were Infection and Pain or Muscle Weakness, depending on whether they are counted as unique instances (Infection: 3.64%, Pain or Muscle Weakness: 1.82% each) or total occurrences (Infection: 2/55, Pain or Muscle Weakness: 2/55). Syncope is not mentioned as an adverse event in either trial.</s>"
    },
    "51be7c95-8da4-419c-950c-91ebdd2c3fe5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement cannot be entailed by the information present in the CTRs, as the CTRs do not provide sufficient data to determine dosages of BKM120 received by patients in the primary trial or in the secondary trial. The CTRs only specify that patients in the primary trial received BKM120 in addition to paclitaxel, and patients in the secondary trial used an Active Breathing Coordinator (ABC) during radiation therapy. No details regarding dosages are mentioned for either trial or group.</s>",
        "contradict": "The statement \"All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial\" contradicts the information in the CTRs as there is no mention of the dosages of BKM120 received by patients in either trial in the provided information. The statement makes an assumption not supported by the data in the CTRs.</s>"
    },
    "07042b0f-d422-49c3-8d53-81319927a4b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "Label": "Entailment",
        "entail": "The statement entails that participants in the primary trial have stage 2 or 3 invasive breast cancer, which aligns with the inclusion criteria of the primary trial stating \"Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III according to AJCC 6th edition.\" In contrast, the secondary trial has a broader inclusion criterion for breast cancer patients, \"women with histologically or cytologically confirmed triple negative breast carcinoma.\" Therefore, the absence of a specific requirement for stage in the secondary trial does not contradict the information in the primary trial, and there is no entailing claim made from the secondary trial to the primary trial.</s>",
        "contradict": "The statement \"all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer\" is inconsistent with the CTR's inclusion criteria for the primary trial, which states that eligible patients have invasive breast cancer with stages II-III based on the AJCC 6th edition. This statement implies that only stages 2 and 3 breast cancers are included in the primary trial, but the CTR allows for stages II and III. The secondary trial, on the other hand, does not specify a required stage for breast cancer.</s>"
    },
    "32361e21-ee57-4c34-9390-833ba5048a10": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally",
        "Label": "Contradiction",
        "entail": "The expert's statement can be entailed by the information present in the CTRs as neither the administration routes nor the dosage schedules contradict each other. In the primary trial, Fulvestrant is administered intramuscularly (to the gluteus maximus), while Everolimus is administered orally. In the expert's statement, Fulvestrant is incorrectly stated as being administered intramuscularly (to the deltoid) instead of the gluteus maximus mentioned in the CTR. However, since the deltoid and gluteus maximus are both valid muscle sites for intramuscular injections, the difference in injection sites does not alter the overall treatment regimens. Additionally, the expert's statement correctly mentions the administration of Everolimus orally, which matches the information provided in the CTRs. Therefore, the expert's statement is entailed by the CTRs.</s>",
        "contradict": "The statement that \"the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally\" is contradictory to the CTR information, as the primary trial participants received Fulvestrant intramuscularly in the gluteus maximus and Everolimus orally, but not in the deltoid muscle.</s>"
    },
    "88668508-dfd4-4a39-91cd-cf1654a6dfc4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00593346",
        "Statement": "the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis",
        "Label": "Contradiction",
        "entail": "The expert's statement does not claim anything about the outcome measure or time frame used in the primary trial. Instead, it focuses on the reported results, stating that no PFS (Progression-free Survival) or objective response rate is reported but the proportion of patients with dermatitis is mentioned.\n\nThe CTRs, however, only provide details about the outcome measure (Local Control using Ipsilateral Breast Tumor Recurrence Rates), and the timeframe for its assessment (2 years after treatment completion). They do not contain information on the PFS or objective response rate for the primary trial's cohort. The CTRs merely report the occurrence of dermatitis as an adverse event.\n\nTherefore, the expert's statement is entailed by the information in the CTRs, as it does not contradict the provided data, and it focuses on a different aspect (the reported results, specifically the lack of reporting on PFS or objective response rate, while the CTRs only report a different outcome measure).</s>",
        "contradict": "The expert's statement contradicts the CTRs because the primary trial reports an outcome measure using Ipsilateral Breast Tumor Recurrence Rates at a 2-year time frame (which can be associated with Progression-Free Survival in some contexts), while the expert's statement mentions the lack of reporting for Progression-Free Survival (PFS) or objective response rate. However, the CTR does not provide information directly related to PFS or objective response rate as stated by the expert, but it does report the local control measure which can be a surrogate endpoint for PFS and provides information about dermatitis as an adverse event, not an outcome measure. Thus, while the statement might be true that the CTR does not directly report PFS or objective response rate in the manner the expert specifies, it does not contradict the CTR in the strictest sense, as both discuss different aspects of the trial data, one focusing on the primary outcome measure and the other on the absence of a specific secondary outcome measure mentioned.</s>"
    },
    "dca4c9f7-bb2a-4f73-b390-93b7ced87c73": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial are non-comparable",
        "Label": "Entailment",
        "entail": "The results from the secondary trial and the primary trial are non-comparable due to differences in outcome measurements and patient populations. The primary trial measures the number of participants with complete pathologic response, a categorical variable, while the secondary trial measures the change in Masood Score, a continuous variable. Additionally, the two trials involve different treatments (placebo vs. Trastuzumab and Abraxane followed by Trastuzumab and Vinorelbine) and different patient populations (HER2-positive breast cancer patients in the primary trial vs. postmenopausal women with hormone receptor\u2013positive or receptor-unknown breast cancer in the secondary trial). These factors limit the ability to directly compare the results between the two trials.</s>",
        "contradict": "The statement \"The results from the secondary trial and the primary trial are non-comparable\" can be contradicted by the information present in the CTRs as the trials assess different outcome measures. The primary trial measures the number of participants with a pathologic complete response (pCR), while the secondary trial measures the change in Masood Score. These two measures cannot be directly compared as they represent different aspects of the disease and treatment response.</s>"
    },
    "e7604382-09cd-43b4-998f-a51b33f25c5a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication orally",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial participants do not receive any medication orally\" is entailed by the information present in the CTRs because:\n\n1. In the primary trial, participants received intraductal administration of dextrose or PLD, which are not given orally.\n2. In the secondary trial, participants received cetuximab IV, which is also not given orally.\n\nTherefore, the statement is harmonious with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "In the primary trial, participants in Intervention 1 received intraductal administration of dextrose and dextrose with PLD, which are not oral medications. However, the statement does not account for Intervention 2 in the primary trial, where some participants may have undergone conventional surgery following intraductal administration, likely receiving oral medications as part of their surgical care. \n\nIn the secondary trial, participants in Intervention 1 receive cetuximab intravenously, while those in Intervention 2 receive cetuximab and carboplatin; neither are oral medications during their administration. However, the statement fails to consider any potential oral medications these patients may have taken prior to or concurrently with their participation in the trial, which could potentially contradict the statement. For instance, patients might have taken other drugs for managing side effects, interacting with study medications, or maintaining general health. \n\nTherefore, the statement is incomplete as it fails to account for all potential medication administration routes and contexts within the trials.</s>"
    },
    "75affd49-4905-4d43-9a5c-ef795281bac4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
        "Label": "Entailment",
        "entail": "Based on the provided CTRs, the ORR for Arm A (Liposomal Doxorubicin Then Docetaxel) is 28% (16-42) and for Arm B (Docetaxel Then Liposomal Doxorubicin) is 31% (18-45). Neither percentage exceeds 40%. Therefore, the expert's statement is entailed by the data in the CTRs.</s>",
        "contradict": "The expert's statement can be contradicted by the information in the CTRs because the ORR data for both arms (Arm A and Arm B) in the primary trial show that more than 40% of patients experienced an objectively beneficial response to the interventions. For Arm A, 31% of participants had CR or PR after Liposomal Doxorubicin treatment, and 28% of participants had CR or PR after Docetaxel treatment in Arm B. The sum of these percentages (59%) exceeds 40%.</s>"
    },
    "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00274469",
        "Statement": "to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer.",
        "Label": "Contradiction",
        "entail": "The given statement entails the Primary Trial's Inclusion Criteria stating \"confirmed hormone receptor positive advanced breast cancer.\" However, it goes beyond the provided CTR by adding the requirement of \"previous chemotherapy for this cancer\" as an additional inclusion criterion. Since the original CTR does not mention any such criterion, the statement does not exactly entail the information in the CTR but is a modification that could be true for some trials within the study. To establish entailment, the statement should only reference criteria directly stated or logically derived from the CTR.</s>",
        "contradict": "The statement can be contradicted by the CTRs as it introduces an additional eligibility criterion (previous chemotherapy for advanced breast cancer) that is not present in the primary trial's eligibility criteria. According to the information provided in the CTRs, patients for the primary trial are required to have hormone receptor positive advanced breast cancer, but there is no mention of a previous chemotherapy requirement for eligibility.</s>"
    },
    "8c6314f7-34f5-42a7-ba66-b95d050a6315": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01644890",
        "Statement": "The shortest PFS in cohort 1 of the primary trial was 1.4 months below average",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTRs as follows: \n\nIn the primary trial, the median PFS for cohort receiving NK105 was 8.4 months with a 95% confidence interval of (7.0 to 9.9) months. This implies that some participants in cohort 1 experienced a PFS shorter than the median. Specifically, the shortest PFS could be 8.4 - 1.4 = 7.0 months. The given statement claims that the shortest PFS was 1.4 months below average, which is equivalent to stating that the shortest PFS in cohort 1 was 7.0 months, making it an entailed statement.\n\nSimilarly, in the secondary trial, we do not have access to the specific PFS data for individual participants. However, if we assume that the participant characteristics and treatment protocols in the two trials are comparable, then it is reasonable to assume that the shortest PFS in cohort 1 of the secondary trial would also be below average, given the similar treatment regimens and overall patient population. Thus, the statement can still be entailed based on the assumption that the trials are similar enough for comparisons to be valid.</s>",
        "contradict": "The statement cannot be directly contradicted by the information in the CTRs, but it cannot be definitively confirmed either without additional information about the distribution of PFS durations in cohort 1. The CTRs provide the medians and confidence intervals for the overall PFS in each arm of the trial, but they do not provide sufficient detail about the distribution of PFS durations below the median. Therefore, it is not possible to determine if there was actually a participant in cohort 1 with a PFS as short as 1.4 months below the median, or if this statement is an exaggeration or misinterpretation of the data.</s>"
    },
    "f114846e-79d8-4712-add0-bb34b65d418f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2.",
        "Label": "Contradiction",
        "entail": "The expert's statement that \"there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2\" can be entailed by the information present in the CTRs. In the primary trial's Results 1 and Results 2 sections, the number of participants who were event-free (including those without death, DTC positive, or clinical disease recurrence) at 12 months following randomisation is reported for Fulvestrant + Anastrozole and Anastrozole arms, respectively, with a total number of 6 participants in the former and 7 in the latter. Since the expert's statement mentions recorded deaths, and not the number of event-free participants, it does not directly contradict the CTR data. However, the number of deaths in each arm can be inferred from the difference between the initial number of participants (6 in Results 1 and 7 in Results 2) and the number of event-free participants reported in the CTRs. Therefore, the expert's statement entails the information in the CTRs, as the reported deaths are a subset of the participants in each arm.</s>",
        "contradict": "The given statement does not contradict the CTR data directly, but it could potentially be misleading in the context of the outcome measurement in the primary trial. In the CTR, it is stated that the outcome measurement in the primary trial is \"Patients Event-free at 12 Months,\" and the events include death, DTC positivity, or clinical disease recurrence. However, the statement only mentions the number of recorded deaths in each cohort, without specifying whether these deaths occurred during the 12-month period following randomization or not. Therefore, the statement might imply that the deaths were the only events considered in the study, whereas the actual outcome measurement includes multiple event types. This misalignment between the statement and the CTR information could lead to incorrect conclusions.</s>"
    },
    "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in the number of lesions for patients in its cohorts.",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical trials expert does not directly entail the information present in the CTRs as the CTRs report the change in tumor size, not the number of lesions. However, the statement does not contradict the information present in the CTRs either. Therefore, it can be considered consistent with the data provided.\n\nTo establish entailment, the statement's assertion should harmonize with clinical trial data, find substantiation in the CTR, and avoid contradiction with the provided descriptions. Although, in this case, the statement does not entail the information present in the CTRs, it is important to note that the information reported in the statement is not in contradiction with the data provided.</s>",
        "contradict": "The expert statement \"the primary trial reports the changes in the number of lesions for patients in its cohorts\" conflicts with the information in the CTRs as the primary trial does not report changes in the number of lesions but rather reports changes in tumor size using the log ratio of tumor size at Cycle 2 to tumor size at baseline.</s>"
    },
    "b1d28450-fc7d-496a-9c7c-bf711b28f8e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs, as pregnant patients are not explicitly listed as an exclusion criterion for endocrine therapy in the Primary Trial's Inclusion Criteria. However, it is stated that patients treated with endocrine therapy prior to randomization are allowed, and there is no restriction on their pregnancy status. Therefore, it's possible, although not explicitly stated, for pregnant patients to have undergone prior endocrine therapy and still be accepted into the trial.</s>",
        "contradict": "The statement \"all pregnant patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" is contradicted by the information in the CTRs. According to the primary trial's inclusion criteria, \"Documentation of negative pregnancy test\" is a requirement for participation. This means no pregnant patients were accepted into the trial. Therefore, there are no pregnant patients who have undergone prior endocrine therapy in the trial.</s>"
    },
    "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or neural adverse events were recorded in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"no cardiac or neural adverse events were recorded in the primary trial\" is entailed by the information in the CTRs as there is no mention of such events in the Adverse Events section of the Primary Trial. The given CTR only lists Dry Eyes and Diarrhea as the adverse events observed in the study, neither of which fall under the categories of cardiac or neural adverse events.</s>",
        "contradict": "The statement \"no cardiac or neural adverse events were recorded in the primary trial\" cannot be definitively concluded from the information presented in the Adverse Events sections of the primary CTR, as it does not entail the absence of such events based on the given data. Only dry eyes and diarrhea were reported, while no mention was made concerning cardiac or neural adverse events. The CTR does not entail the statement's negation, and the statement could potentially be false if undisclosed cardiac or neural adverse events occurred.</s>"
    },
    "a805f174-2707-4302-a195-05153ea8523e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02186015",
        "Statement": "Only adults can take part in the primary trial",
        "Label": "Entailment",
        "entail": "The CTR states that inclusion criteria include \"Female\" and \"Age 18 years,\" which implies that only adults are eligible for the trial.</s>",
        "contradict": "The statement \"Only adults can take part in the primary trial\" is contradicted by the CTR inclusion criteria which state that female patients with an age of 18 years can participate in the trial.</s>"
    },
    "e4aeb013-7713-4b73-acbd-f8379cc6a494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "Label": "Entailment",
        "entail": "The statement \"there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1\" is entailed by the information present in the CTRs because the CTR for the primary trial indicates that there was one case of a slipped disk (1.02%) in cohort 2, while there were no cases (0.00%) in cohort 1. A higher percentage of patients with an event implies that there are more occurrences in one group compared to another, which is consistent with the information in the CTRs.</s>",
        "contradict": "Although the statement implies a difference in the prevalence of \"slipped disks\" between cohorts 1 and 2 of the primary trial, the CTRs provide conflicting evidence. Both CTRs report identical rates of \"slipped disk\" occurrence within each cohort: 1/101 (1.02%) for cohort 1 of Adverse Events 1 and 1/98 (1.02%) for cohort 1 of Adverse Events 2. The statement is contradictory since it infers a disparity that is not substantiated by the data in the CTRs.</s>"
    },
    "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n1) In the primary trial, the outcome measurement for PFS was reported to range up to 38 months.\n2) Results 1 reports a mean PFS of 8.8 months (7.8 to 9.8) for the Neratinib Plus Capecitabine arm/group, which is above 7 months.\n3) Results 2 reports a mean PFS of 6.6 months (5.9 to 7.4) for the Lapatinib Plus Capecitabine arm/group, but since the statement focuses on cohort 1 (Neratinib Plus Capecitabine), it is valid. \n4) No contradictory information in the CTRs exists that would invalidate the statement.</s>",
        "contradict": "The statement \"All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months\" cannot be directly contradicted by the information in the CTRs, as the CTRs do not provide the specific PFS values for individual patients in the neratinib plus capecitabine arm. However, the statement can be questioned for accuracy as it is based on an assumption that every patient in the trial had PFS data available up to the maximum reported time frame of 38 months. According to the provided CTR information, the PFS data was only reported as the restricted mean survival time up to 24 months. Conclusions based on data beyond this timepoint may not be supported by the available data in the CTRs.</s>"
    },
    "2729a321-709b-4392-9604-dd7237bedb17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years.",
        "Label": "Entailment",
        "entail": "The statement \"the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years\" can be entailed by the information present in the CTRs as follows:\n\n1. Both CTRs (Results 1 and Results 2) report the percentage of disease-free survivors (Disease-free Survival) for each cohort (Group 1 and Group 2) after a 5-year time frame.\n    - Results 1: 80.1% (78.0-82.0) of participants in Group 1 (TAC X 6) achieved disease-free survival for 5 years.\n    - Results 2: 82.2% (80.2-84.0) of participants in Group 2 (AC X 4 Then P X 4) achieved disease-free survival for 5 years.\n2. The statement \"the majority\" implies a substantial proportion, typically above 50%. In the context of the provided CTR data, it can be inferred that the majority of participants in both cohorts (Groups 1 and 2) achieved disease-free survival for 5 years based on the given percentage values.\n3. The statement does not contradict nor goes beyond the data presented in the CTRs, as it simply summarizes the percentage of disease-free survivors in the primary trial's two cohorts, which is explicitly stated in the CTRs.\n\nTherefore, the statement \"the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years\" contradicts the information present in the CTRs if we interpret the term \"majority\" as meaning more than 50% of the participants. While both CTRs mention the Disease-free Survival percentage for their respective arms (80.1% for Group 1 and 82.2% for Group 2), neither explicitly states that more than 50% of all participants in both groups achieved the 5-year Disease-free Survival.</s>"
    },
    "8e9611fc-89f8-44cb-af09-8d71a13ca082": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02915744",
        "Statement": "Cohort 1 and 2 of the primary trial do not receive the same intervention",
        "Label": "Entailment",
        "entail": "The statement \"Cohort 1 and 2 of the primary trial do not receive the same intervention\" can be entailed by the information present in the CTRs because the CTR specifies that in Cohort A, NKTR-102 is administered at a specific dose level, schedule, and infusion type, whereas in Cohort B, patients receive Treatment of Physician's Choice (TPC), which can be any one of seven distinct single-agent IV chemotherapies. Since the interventions in each cohort differ, it follows that they do not receive the same intervention.</s>",
        "contradict": "The statement \"Cohort 1 and 2 of the primary trial do not receive the same intervention\" is not contradicted by the information present in the CTRs provided. In fact, the information in the CTRs explicitly states that Group A receives NKTR-102 and Group B receives TPC, which are distinct interventions according to the statement. However, it is important to note that the statement is only addressing cohorts 1 and 2 in the primary trial, and not the secondary trial, which may involve different interventions. The contradiction would only arise if the statement implied that cohorts 1 and 2 in the primary trial received the same intervention and the CTRs stated otherwise.</s>"
    },
    "b9491012-49ba-4eb1-8230-1966f54ea012": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients with Extracranial metastases can be eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Patients with Extracranial metastases can be eligible for the primary trial\" can be entailed by the information present in the CTRs because the primary CTR explicitly states \"Extracranial metastases allowed\" under the Disease Characteristics section. This means patients with extracranial metastases do meet the inclusion criteria for the trial.</s>",
        "contradict": "Contradiction lies in the eligibility criteria section of the primary CTR. The statement allows the presence of extracranial metastases for patient eligibility, while the primary CTR explicitly mentions that \"Extracranial metastases are allowed,\" but there are additional conditions for eligibility in cases of brain metastases progression, which the expert statement does not account for.</s>"
    },
    "62e449ad-16b3-479d-94a5-ffc435b5e99c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00063570",
        "Statement": "patients with a Malignant brain tumour diagnosis are excluded from the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"patients with a Malignant brain tumour diagnosis are excluded from the primary trial\" is entailed by the CTR as stated in the Exclusion Criteria section: \"Must not have cancer that has spread to the brain.\" While \"Malignant brain tumor\" and \"cancer that has spread to the brain\" are equivalent terms, the former is more specific to the type of cancer in question. Therefore, the statement's assertion harmonizes with the CTR, finds substantiation, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement \"patients with a Malignant brain tumour diagnosis are excluded from the primary trial\" is not in contradiction with the CTR information, but rather an addition to it. The CTR clearly states that \"Must not have cancer that has spread to the brain\" under the exclusion criteria, which implies that malignant brain tumors are excluded from the trial. The expert's statement reaffirms this fact but uses a more specific terminology.</s>"
    },
    "565d7982-aa9a-4c01-987c-1d67bc9c212d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00438100",
        "Statement": "ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry",
        "Label": "Contradiction",
        "entail": "The statement \"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry\" is not explicitly stated in the provided CTRs. However, flucytosine is mentioned as an exclusion criterion in the first CTR. Thus, it can be inferred that no participant in the primary trial is receiving flucytosine treatment during the study. Since the statement suggests that all participants in the primary trial are receiving ongoing flucytosine treatments, it contradicts the information in the CTR, and therefore, it cannot be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry\" is contradictory to the exclusion criteria in the primary CTR, which states that \"being treated with flucytosine\" is grounds for exclusion. Therefore, the statement cannot be entailed by the CTR information.</s>"
    },
    "7271e0db-bb82-423f-ad95-5ffa84fab97e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Urosepsis in the primary trial than in the secondary trial",
        "Label": "Entailment",
        "entail": "The statement \"There are more cases of Urosepsis in the primary trial than in the secondary trial\" can be entailed by the information present in the CTRs as follows: \n\nThe primary trial has 2 instances of Urosepsis out of a total of 12 participants (a rate of 16.67%), while the secondary trial has only 1 instance of Urosepsis out of a total of 66 participants (a rate of 1.52%). The statement accurately compares the frequency of Urosepsis between the two trials, and since the CTRs report the exact number of cases in each trial, the statement is entailed by the provided information.</s>",
        "contradict": "The statement \"There are more cases of Urosepsis in the primary trial than in the secondary trial\" is contradicted by the information in the CTRs because the primary trial reported 2 cases of Urosepsis out of 12 participants (16.67%) and the secondary trial reported 1 case out of 66 participants (1.52%). Therefore, the primary trial had a smaller number of cases of Urosepsis than the secondary trial.</s>"
    },
    "6402e13a-7cfb-4774-b7f9-80ecb79fda2a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally.",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally\" is entailed by the information present in the CTRs because:\n\n1. In the Primary Trial's Intervention 1 section, no mention of any oral medication is given for treatment. The only mentioned interventions are breast and axillary Positron Emission Mammography (PEM), mammography, DCE-MRI, US of the breast and axilla, and ultrasound guided biopsy of axillary lymph node.\n\n2. In the Secondary Trial's Intervention 1 and Intervention 2 sections, it is explicitly stated that patients receive oral medications (exemestane and anastrozole) as part of their treatment regimens.\n\nSince the primary trial participants are not administered any oral medication, as stated in the CTR, and the secondary trial patients only receive treatment orally, according to the CTR, the expert's statement is entailed by the provided data.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs as the primary trial involves the use of Positron Emission Mammography (PEM) which is not an oral medication, whereas patients in the secondary trial receive oral medications (exemestane and anastrozole).</s>"
    },
    "734423d5-4b47-4448-ab98-811015d626f0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There were multiple patients which suffered Neutropenia in both cohorts of the primary trial",
        "Label": "Contradiction",
        "entail": "The expert's statement \"There were multiple patients which suffered Neutropenia in both cohorts of the primary trial\" is entailed by the provided data in the CTRs, as both report the presence of at least one patient in each cohort experiencing Neutropenia (2.56% in both).</s>",
        "contradict": "The information in the statement cannot be directly entailed by the information present in the CTRs. According to the CTRs, there is one patient with Neutropenia in the cohort of the primary trial with a total of 39 patients, and one patient with Neutropenia in the cohort of the secondary trial with a total of 21 patients. However, the statement suggests that \"multiple\" patients suffered from Neutropenia in both cohorts, indicating more than one patient. Since the CTRs do not support the presence of additional patients with Neutropenia in both cohorts, the statement is contradictory to the information provided.</s>"
    },
    "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole",
        "Label": "Contradiction",
        "entail": "In the primary trial, Arm A participants receive Anastrazole in the form of a pill (1 mg per day), while Arm B participants do not. In the secondary trial, no participants receive Anastrazole as a pill or any other form, as they are only receiving AZD0530. Therefore, the statement is entailed by the information in the CTRs, as it correctly reflects the absence of Anastrazole administration in the secondary trial.</s>",
        "contradict": "The statement is contradictory to the CTRs because, in the primary trial, participants in Arm A receive Anastrazole as part of their intervention, while in Arm B, they do not. However, in the secondary trial, there is a separate intervention (Phase 1 - Cohort A) where participants are administered Anastrazole. The primary trial statement incorrectly assumes that there is no Anastrazole administration in the secondary trial, while the CTRs provide evidence that some participants in the secondary trial do receive Anastrazole.</s>"
    },
    "32ed503c-1cfd-44f6-b8bb-23d9d175d73d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "Patients must be able to undergo a PET scan to participate in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Patients must be able to undergo a PET scan to participate in the primary trial\" is entailed by the eligibility criteria of the Primary CTR, which specifically includes the condition \"Able to lie still for 1.5 hours for PET scanning.\" This implies that the trial involves the use of PET scanning for all patients, and hence, every participant must be capable of undergoing the procedure.</s>",
        "contradict": "The statement \"Patients must be able to undergo a PET scan to participate in the primary trial\" can be contradicted by the information present in the CTRs because some patients with conditions such as \"medically unstable,\" \"condition requiring anesthesia for PET scanning,\" or \"unable to lie still for 1.5 hours\" are explicitly stated as not meeting the inclusion criteria for the primary trial, and therefore would not be allowed to participate even if they could undergo a PET scan.</s>"
    },
    "175044aa-72b1-405d-8506-30002f5098e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information in the CTRs as stated, as the CTRs do not provide the number of patients who suffered Hypotension, Hemorrhage, or Bradycardia in the primary trial's adverse events section, as stated in the CTRs, there were no adverse events reported (Total: 0).</s>",
        "contradict": "The expert's statement is contradicted by the information present in the CTRs because the primary trial adverse events section does not mention the occurrence of any Hypotension, Hemorrhage, or Bradycardia cases. The primary trial adverse events section states that the total number of adverse events was 0.</s>"
    },
    "045ad91e-44fa-42cc-ac22-a7aab26a9009": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00240071",
        "Statement": "the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention",
        "Label": "Contradiction",
        "entail": "The statement made by the clinical expert is not directly entailed by the information in the CTRs. While the primary trial participants received Avastin and continued with their hormonal therapy, the statement introduces the addition of radiotherapy to the intervention which is not mentioned in the given CTR. Therefore, the statement goes beyond the information provided in the CTRs and cannot be deemed a semantic entailment.</s>",
        "contradict": "The statement made by the clinical trial expert is contradicted by the information in the CTRs as the primary trial participants were not administered radiotherapy as part of the intervention. They only received Avastin (Bevacizumab) and continued their hormonal therapy.</s>"
    },
    "00822101-fa21-4a26-bf45-3b1f535da005": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00281697",
        "Statement": "a patient with a HER2-positive status can not take part in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"a patient with a HER2-positive status cannot take part in the primary trial\" is entailed by the information in the CTR's exclusion criteria, which explicitly states that \"HER2-positive status\" is a reason for exclusion from the trial.</s>",
        "contradict": "The statement \"a patient with a HER2-positive status can not take part in the primary trial\" is contradicted by the information present in the CTR as the CTR states that \"Patients who have unknown HER2 status, and for whom determination of HER2 status is not possible, are eligible for this study.\" This implies that patients with HER2-positive status can still participate in the primary trial if their HER2 status cannot be definitively determined.</s>"
    },
    "06f798d1-2956-4903-83e9-58a41fa425f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information in the CTRs as both reports indicate that there were no cardiac or infection-related adverse events recorded in either trial, as evidenced by the reported total counts of 0 for these categories in each trial's Adverse Events sections.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial do not record any cardiac or infection related adverse events\" cannot be directly contradicted by the information present in the CTRs since no explicit mentions of cardiac or infection-related adverse events are given. However, the absence of such information does not necessarily imply the absence of such events. The CTRs only report the total number of adverse events for each trial, but they do not provide detailed information about the types of adverse events that occurred. Therefore, it is possible that there were cardiac or infection-related adverse events that were not reported, recorded differently, or considered insignificant by the investigators. Hence, the statement may be an oversimplification based on the limited information provided in the CTRs.</s>"
    },
    "8648c7df-582a-42a9-9330-414b2430ac56": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events",
        "Label": "Contradiction",
        "entail": "The statement \"none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events\" is entailed by the CTR data as follows:\n\n1. Each adverse event type in the primary trial, as listed, has a count less than 100 (e.g., Anemia: 10/1612 = 0.62%, which is approximately 99 cases if we assume 1612 total participants represent 100%).\n2. The total number of adverse events across all types in the primary trial is 340/1612 (approximately 21.09%), which, if assuming all participants experience an adverse event, would equal 3322 events. However, the percentage of participants who experienced an adverse event is less than 21.09%, meaning less than 3,322 events occurred in total. This total is less than 30.\n\nThus, the CTR data entails that none of the individual adverse events affect more than 100 patients and that fewer than 30 patients in total suffered adverse events.</s>",
        "contradict": "The statement \"none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events\" contradicts the data present in the provided CTRs. In the Primary Trial CTR, the number of participants was 1612, and 340 (21.09%) of them suffered adverse events. Several adverse events occurred in more than 100 patients: Anemia (10), Cardiac disorders - Other (6), and Myocardial infarction (6). Additionally, the total number of participants in the Secondary Trial was 1623, with 350 (21.57%) reporting adverse events. Therefore, the statement does not harmonize with the clinical trial data and should be considered contradictory.</s>"
    },
    "89f610a7-9e81-43a4-8c1e-5503233b2be1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented stable disease to participate in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Breast cancer patients must have documented stable disease to participate in the primary trial\" can be entailed by the CTR inclusion criteria that state \"measurable disease, as defined by RECIST guidelines or evaluable disease\" and \"disease amenable to core biopsy.\" These criteria indicate that patients can only enroll if they have measurable or evaluable disease, which implies that the disease is not progressing and is stable.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial also allows for inclusion of patients with measurable disease, evaluable disease, and even patients with pulmonary metastases as their only site of disease, who may not undergo biopsy. These patients do not necessarily have stable disease.</s>"
    },
    "b0046821-ba27-4a90-8869-cb708b843aa4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00612560",
        "Secondary_id": "NCT01216176",
        "Statement": "All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTRs because, in the primary trial, Arm A participants receive flaxseed (25 g per day ground) in conjunction with anastrozole (1 mg per day), while Arm B participants receive only flaxseed (25 g per day ground) and a placebo pill. However, in the secondary trial, there is no mention of flaxseed being administered to any of the participants. The statement correctly captures the absence of flaxseed in the secondary trial. Additionally, the information in the primary trial does not contradict the statement, as it only describes the presence of flaxseed in one trial but not in the other.</s>",
        "contradict": "The primary trial involves two arms: Arm A and Arm B. Arm A participants receive both flaxseed (25 g per day ground) and anastrozole (1 mg per day), while Arm B participants receive flaxseed (25 g per day ground) alone and a placebo pill for anastrozole. Therefore, not all primary trial participants are administered flaxseed alone as per the statement, but rather, a subset of them receive a combination of flaxseed and anastrozole. Conversely, in the secondary trial, no participants are administered flaxseed as stated. Thus, the statements are contradictory with respect to the presence/absence of flaxseed in the two trials.</s>"
    },
    "d1b217ae-76f3-4ba6-958e-5b2558703ba4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01912612",
        "Statement": "several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if the following conditions are met:\n\n1. Both trials involve at least two cohorts or arms: The statement implies that there are two cohorts (cohort 1 in the primary trial and cohort 2 in the secondary trial), so it's essential that the trials meet this condition.\n\n2. Congestive heart failure cases are reported in CTRs: The statement talks about cases of congestive heart failure, which are reported in the primary CTR.\n\n3. The number of congestive heart failure cases differs between cohorts: In the primary trial, there is one reported case (2.86%) in cohort 1, and none (0.00%) in cohort 2, according to the CTR data provided.\n\n4. No contradictory information in the CTRs: The CTRs do not mention any cases of congestive heart failure in cohort 2 of the primary trial, which aligns with the statement's claim that no such cases were found.\n\nTherefore, the expert's statement \"several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2\" can be entailed by the information present in the CTRs, as all conditions are met.</s>",
        "contradict": "Given the data in the CTRs, the stated claim \"several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2\" contradicts the CTR information because, according to Adverse Events 1, there was only one instance of congestive heart failure in the entire primary trial (occurring in cohort 1), while Adverse Events 2 indicates none in the secondary trial. The statement implies multiple instances of congestive heart failure in cohort 1 of the primary trial, but the data does not support this claim.</s>"
    },
    "8ddf8b88-6e06-4c71-9e28-45f73a637af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01011946",
        "Secondary_id": "NCT00066573",
        "Statement": "the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally.",
        "Label": "Contradiction",
        "entail": "The primary trial's intervention includes Positron Emission Mammography (PEM) which is an invasive, non-oral procedure performed on both breast and axilla, in addition to oral exemestane. Conversely, the secondary trial administers oral medications (exemestane and anastrozole) to its patients only. Based on this information comparison, the statement can be entailed by the CTRs as the primary trial participants indeed receive both oral and non-oral interventions, while the secondary trial patients receive only oral medication.</s>",
        "contradict": "The statement \"the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally\" is contradicted by the information in the CTRs, as the primary trial involves the use of Positron Emission Mammography (PEM) which is not considered a topical medication and is administered through scans, not orally, while the secondary trial involves the use of exemestane and anastrozole, which are oral medications only.</s>"
    },
    "0ea29bd5-20be-40ea-8ad7-705d283d1d48": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00093795",
        "Statement": "the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as both trials report the outcome measure as Disease-free Survival with respective percentages of patients, 80.1% (78.0-82.0) for Group 1 and 82.2% (80.2-84.0) for Group 2. The lower percentages indicate the presence of events like Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer, which is consistent with the expert's statement about the majority of participants in cohort 1 and 2 suffering from one or more of these conditions.</s>",
        "contradict": "The statement cannot be directly contradicted by the information presented in the CTRs, as the statement speaks of the majority of participants in both cohorts 1 and 2 suffering from the specified events, while the CTRs only provide disease-free survival percentages for each group. However, it's important to note that the disease-free survival percentages reported do not indicate the total absence of events such as disease recurrence, contralateral breast cancer, or second primary cancer; they represent the percentage of patients who did not experience those events during the study's 5-year follow-up period. To fully evaluate the statement, additional information, such as the absolute number of participants experiencing the mentioned events or the total number of participants in each cohort, would be required.</s>"
    },
    "e147796d-2edd-42d1-ac53-300fb8bd5eb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "80% of patients in the primary trial received a placebo intervention",
        "Label": "Contradiction",
        "entail": "In the primary trial, the number of patients receiving placebo intervention is not explicitly stated in the CTR. However, the total number of participants in the trial is provided, and it is mentioned that half of them received lapatinib and the other half received placebo. Therefore, by simple arithmetic calculation, 80% of the cohort indeed received a placebo intervention. The statement harmonizes with the clinical trial data and finds substantiation in the CTR.</s>",
        "contradict": "The statement that \"80% of patients in the primary trial received a placebo intervention\" cannot be directly entailed from the provided information in the CTRs, as the CTRs specify that 50% of patients received lapatinib and 50% received placebo.</s>"
    },
    "6b33b4ae-36f2-4a53-a954-6f246f6e023d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)",
        "Label": "Entailment",
        "entail": "The statement \"Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)\" is entailed by the following eligibility criteria from the CTR of the primary trial: \"Known and documented HER2-positive\" and \"Adequate organ function: Left Ventricular Ejection Fraction (LVEF) \u2265 50%.\" The statement explicitly mentions the requirement for HER2 positivity, which is a condition in the CTR for inclusion in the trial. The statement also mentions an LVEF requirement of at least 50%, which is consistent with the LVEF criterion for eligibility in the CTR.</s>",
        "contradict": "The expert's statement contradicts the CTR as it does not mention any conditions related to patient sex, childbearing potential, histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease, or a negative serum beta-HCG test for women of childbearing potential. These conditions are essential for eligibility as per the CTR, and their absence in the expert's statement makes the statements contradictory.</s>"
    },
    "06fad978-1dc3-46f5-b45f-5ac6577f28b9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial\" cannot be entailed from the primary and secondary CTRs as they describe different trials for different types of cancer (breast cancer for the primary trial and hormone receptor positive advanced breast cancer for the secondary trial).</s>",
        "contradict": "The statement \"Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial\" can be contradicted by the information present in the CTRs as follows:\n\n1. The primary trial inclusion criteria state that patients must have a histologic or cytologic diagnosis of advanced breast cancer, not advanced colon cancer.\n2. The secondary trial inclusion criteria state that patients must have confirmed hormone receptor positive advanced breast cancer, but the primary does not mention anything about the nature of the cancer being breast or colon.\n3. Therefore, the statement that patients must have confirmed advanced colon cancer for both trials is inconsistent with the eligibility criteria specified in the CTRs.</s>"
    },
    "878c09e7-3fd9-404e-921e-5b549e9578fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4.",
        "Label": "Entailment",
        "entail": "The statement \"Most patients in the primary trial experienced a grade 1 adverse event, the least common severity was grade 4\" can be entailed by the CTRs' information as follows:\n1. Most participants in the Trastuzumab Emtansine arm/group experienced grade 1 adverse events: The CTR states that 53 out of 70 participants (75.7%) experienced grade 1 adverse events.\n2. Grade 4 adverse events were the least common severity: The CTR lists 2 participants (2.9%) as having grade 4 adverse events, which is the least frequent grade.\n\nTherefore, the information in the CTRs entails the clinical trial expert's statement.</s>",
        "contradict": "The expert's statement contradicts the CTR information as it misrepresents the distribution of participants across different grades of adverse events. While most participants did experience a grade 1 adverse event (75.7%), the least common severity was not grade 4 (only 2.9% of participants experienced grade 4 adverse events) but rather grade 5 (17.1%) based on the data presented.</s>"
    },
    "3a0c517d-9b9a-4497-9675-50ff12cd02b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain",
        "Label": "Entailment",
        "entail": "The primary CTR reports 2 cases of Left ventricular dysfunction in 219 participants (0.91%). The secondary CTR does not provide data on Left ventricular dysfunction. However, the primary CTR does not report any case of Left ventricular dysfunction in cohort 1 specifically. However, the statement \"in cohort 1 of the primary trial there were more cases of Left ventricular dysfunction than Abdominal pain\" is a false statement, as there are no cases of Left ventricular dysfunction reported in cohort 1. Therefore, the statement cannot be entailed by the information in the CTRs since it contradicts the provided data.\n\nHowever, if the question had been posed as \"in cohort 1 of the primary trial, were there fewer cases of Abdominal pain than Left ventricular dysfunction?\", the answer would be yes, as there are no reported cases of Left ventricular dysfunction in either cohort 1 or in the secondary trial, while there is 1 case of Abdominal pain in the primary trial for cohort 1. This statement would be entailed by the information in the CTRs as it is consistent with the reported data.</s>",
        "contradict": "The statement \"in cohort 1 of the primary trial, there were more cases of Left ventricular dysfunction than Abdominal pain\" is contradicted by the CTR data because in the Adverse Events 1 section of the Primary Trial, there were only 2 instances of Left ventricular dysfunction, whereas there was only 1 instance of Abdominal pain reported. Therefore, the statement does not hold true based on the information provided in the CTRs.</s>"
    },
    "9abb10d7-496e-44fd-915d-d86aedf6c9b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02445586",
        "Statement": "Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)",
        "Label": "Contradiction",
        "entail": "The statement entails that patients in the primary trial have a documented TNBC (triple-negative breast cancer) status in addition to an LVEF of at least 50%. The CTR specifies that patients must have histologically or cytologically confirmed adenocarcinoma of the breast, and one of the subtypes mentioned is TNBC. The statement does not contradict the inclusion criteria, and it aligns with the information provided. The LVEF requirement is also present in the primary CTR, which supports the entailment.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because it omits the requirement that patients must have histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection, and they must be HER2-positive. These requirements are essential conditions for eligibility in the primary trial, as specified in the CTRs' inclusion criteria. Therefore, a patient who only meets the stated conditions of having TNBC status and an LVEF of at least 50% would not be eligible for the trial according to the CTR information.</s>"
    },
    "8460a212-8054-4bd2-b4e6-af1d137a2f79": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results using different units of measure",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial and the secondary trial report their results using different units of measure\" is entailed by the information presented in the CTRs because the Primary Trial uses percentage for reporting the Objective Response Rate, while the Secondary Trial reports the proportion of Sentinel Lymph Nodes detected by each method (Tc and ICG). These units, percentage and proportion, although related to frequency, are distinct and do not contradict the information provided in the CTRs.</s>",
        "contradict": "The statement does not contradict the information present in the CTRs, but it is not directly related to semantic entailment between the trials' sections and the expert's statement, as the statement is comparing the units of measure used in reporting the results rather than the information within the trial's sections itself.</s>"
    },
    "a3390ae6-d41d-4dc7-899e-de9534adfd6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib",
        "Label": "Entailment",
        "entail": "The statement that \"the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib\" is entailed by the information presented in the CTRs because:\n\n1. Capecitabine dosage: In the primary trial, Capecitabine is given at 1000 mg/m^2^ twice daily on the first day through the fourteenth day of each cycle.\n2. Lapatinib dosage: In the primary trial, Lapatinib is given at 1250 mg once daily.\n\nComparing the dosages directly, Capecitabine's dose (1000 mg/m^2^ \u00d7 2 doses/day \u00d7 14 days/cycle) amounts to 42,000 mg/m^2^ per cycle.\nLapatinib's dose is 1250 mg/day, which amounts to 37,500 mg/cycle for comparison.\n\nSince 42,000 mg/m^2^ > 37,500 mg, the participants indeed receive significantly higher doses of Capecitabine than of Lapatinib.</s>",
        "contradict": "The statement \"the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib\" cannot be directly contradicted by the information in the CTRs, as the CTRs do not provide enough information to determine if the doses administered to the participants in the primary trial represent significantly higher doses of Capecitabine compared to Lapatinib. However, the statement could be incorrect if it is applied in the context of other trials with different dosing regimens, where the opposite is true. The statement's contradiction depends on the comparison of doses between specific trials. In this case, the CTRs alone do not provide enough information to establish entailment or contradiction.</s>"
    },
    "17bbea92-8f92-41f3-9b9d-cf6e62cf6798": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.",
        "Label": "Entailment",
        "entail": "The expert's statement asserts that the primary trial reports on the percentage of patients experiencing dose-limiting toxicity (DLT) while receiving Neratinib in combination with Paclitaxel. According to the CTRs provided, both arms (Neratinib 160 mg + Paclitaxel 80 mg/m\u00b2 and Neratinib 240 mg + Paclitaxel 80 mg/m\u00b2) report no occurrences of DLT in their respective participant groups within the given time frame. Therefore, the percentage of patients suffering from DLT in either arm is 0.0%. Since the statement aligns with the data in CTRs, stating no DLT occurrences equates to reporting the percentage of patients who experienced toxicity serious enough to prevent a dose increase, it can be considered entailed by the data in the CTRs.</s>",
        "contradict": "The statement made by the clinical trial expert is not directly contradictible with the information in the CTRs, but it cannot be entailed from the provided data either. The CTRs report the number of participants in each arm who experienced dose-limiting toxicity (DLT), but they do not provide the percentage of participants in the overall trial or in each arm who suffered DLTs. Therefore, the statement goes beyond the scope of the information presented in the CTRs.</s>"
    },
    "794269ca-e7ec-4a65-ace5-b0f24a8cdc15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS\" can be entailed by the information present in the CTRs as follows:\n\n1. In both trials, the outcome measures are related to the evaluation of treatment response. However, they focus on different aspects:\n\n   a. The primary trial measures the Percentage of Participants with Objective Response using RECIST criteria.\n   \n   b. The secondary trial measures Progression-Free Survival (PFS), which is the time from randomization to the first observation of disease progression.\n\n2. The primary trial and the secondary trial are independent studies investigating different treatments (ixabepilone and cetuximab vs. NK105 and Paclitaxel). The fact that they have different outcome measures does not contradict their validity or entail any inconsistency.\n\n3. Both trials are conducted according to established clinical procedures, and the outcome measures used in each study are well-defined and relevant to evaluating the efficacy and safety of the treatments.\n\nTherefore, the statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS\" is an accurate reflection of the information contained in the provided CTRs, and it is semantically entailed by the information in the texts.</s>",
        "contradict": "The statement does not directly contradict the information present in the CTRs, but the measurements used in the two trials are not directly comparable. The primary trial measures the Percentage of Participants with Objective Response using RECIST criteria, while the secondary trial measures Progression Free Survival. Although both trials involve clinical trials with cancer patients, they assess different aspects of treatment effectiveness. Therefore, the statement does not establish entailment as it does not necessarily follow that the percentage of participants with objective response directly correlates with progression-free survival.</s>"
    },
    "4dfff980-6a2b-4f01-9194-6ec831d6fed7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00733408",
        "Statement": "Infections were the most common adverse events recorded in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Infections were the most common adverse events recorded in the primary trial\" can be entailed by the CTR information as follows: The CTR for the primary trial indicates that a total of 5 adverse events occurred among 55 participants, representing a frequency of 9.09%. One of these adverse events was an infection, occurring in 2 out of 55 participants (a frequency of 3.64%). Since the frequency of infections is greater than the frequency of any other adverse event listed in the CTR, the statement correctly identifies infections as the most common adverse event in the trial.</s>",
        "contradict": "Although the statement \"Infections were the most common adverse events recorded in the primary trial\" appears to be plausible given the mention of two infections out of 55 participants (3.64%), it can be contradicted by the information present in the CTRs because the statement is not an exact entailment of the given data. The data in the CTRs also indicates that other types of adverse events, such as pain and muscle weakness (each reported once in 55 participants, 1.82%), were also observed. Thus, while infections were the second most common type of adverse event, they were not the most common overall. Therefore, the expert's statement is not an accurate representation of the data in the CTRs.</s>"
    },
    "dc4c57b0-8c75-494e-81b0-3528df85ebff": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts",
        "Label": "Contradiction",
        "entail": "Both the primary and secondary CTRs focus on different outcome measurements - LDex change for the primary trial and Overall Survival (OS) for the secondary trial. Therefore, there is no direct comparison or measurement of OS in either CTR. Thus, the statement that \"neither the secondary trial nor the primary trial record the Overall Survival (OS) of Patients in their cohorts\" is entailed by the information present in the CTRs, as both trials indeed do not provide such data.</s>",
        "contradict": "The statement is contradictory to the information presented in the CTRs as both trials do report data on the Overall Survival (OS) of their respective patient cohorts, as evidenced by the inclusion of OS as an outcome measurement and the presentation of median OS with confidence intervals in each trial's Results section.</s>"
    },
    "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions, however they use different definitions of complete response ",
        "Label": "Contradiction",
        "entail": "Both trials employ the term \"Objective Response\" (OR) for measuring the effectiveness of their interventions. However, the definitions of OR and complete response (CR) vary between the trials. In the primary trial, CR is specifically defined as a patient having overall response of CR or PR on one visit and meeting confirmation criteria per RECIST. In contrast, the secondary trial defines OR as CR and PR, and it is the primary endpoint only for a specific cohort. Despite the difference in CR definitions, both trials use the Response Evaluation Criteria in Solid Tumors (RECIST) for assessing OR, ensuring that the assessment methodology is consistent. The statement is entailed by the CTRs since it accurately reflects the distinct CR definitions used in each trial while acknowledging the common usage of OR and RECIST in both studies.</s>",
        "contradict": "The statement is contradicted by the CTR information as the definition of complete response (CR) is not the same between the two trials. In the primary trial, a CR is defined as a patient having an overall response of CR or PR on one visit and meeting the confirmation criteria per RECIST. In contrast, the secondary trial defines CR as the primary endpoint but does not specify the confirmation criteria used. These differences in CR definition make the objective response measurements from the two trials incomparable, and thus, the statement's claim is contradictory to the CTR details.</s>"
    },
    "251a20d8-2555-4929-9d01-c02311bdc93f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1",
        "Label": "Entailment",
        "entail": "The statement \"a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1\" is entailed by the information present in the CTRs due to the following reasons:\n\n1. The number of participants with Disease Progression or Death in each cohort is given in Results 1 and Results 2, which are sections of the Primary Trial report. \n2. The number of participants in each cohort is also given, allowing for calculation of the proportion of participants who suffered Disease Progression or Death in each cohort.\n3. Based on the provided information, there are 35 participants in Cohort 1 (Arm 1) and 40 participants in Cohort 2 (Arm 2).\n4. The number of participants in each cohort who suffered Disease Progression or Death is 12 (Result 1) and 18 (Result 2), respectively.\n5. To calculate the proportion of participants who suffered Disease Progression or Death in each cohort, divide the number of participants who experienced the event by the total number of participants in the cohort.\n\nProportion of Participants Suffering Disease Progression or Death in Cohort 1 (Arm 1): 12/35 = 0.3429 (approximately 34.3%)\nProportion of Participants Suffering Disease Progression or Death in Cohort 2 (Arm 2): 18/40 = 0.45 (approximately 45%)\n\n6. The proportion of participants in Cohort 2 (0.45) who suffered Disease Progression or Death is higher than the proportion in Cohort 1 (0.3429).\n\nHence, the statement \"a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"a higher proportion of patients suffered Disease Progression or Death in cohort 2 of the primary trial than in cohort 1\" contradicts the information presented in the CTRs due to the difference in total number of participants analyzed between the two arms. Cohort 1 (Fulvestrant and Dasatinib) had 35 participants, while cohort 2 (Fulvestrant only) had only 40 participants. Comparing proportions without adjusting for sample size can lead to erroneous conclusions. The statement needs to be qualified with the correct sample size information to ensure accurate comparisons.</s>"
    },
    "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00852930",
        "Secondary_id": "NCT02915744",
        "Statement": "the secondary trial and the primary trial do not record the same metrics in their results section",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not record the same metrics in their results section\" is entailed by the information contained in the CTRs, as the primary trial measures LDex changes, and the secondary trial measures Overall Survival in months. The trials are not comparing the same outcome metric.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs since the primary trial measures LDex change as the outcome metric, while the secondary trial measures Overall Survival (OS) in its results section. Therefore, the two trials do not record the same metrics.</s>"
    },
    "f0273b8c-460d-46fe-9c52-8ff4b08e439b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and elizabeth is a 32 year old woman, both eliane and elizabeth can both be eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement that \"Eliane (age 56) and Elizabeth (age 32) can both be eligible for the primary trial\" is entailed by the CTR information as follows:\n\n1. Both Eliane and Elizabeth meet the inclusion criteria:\n   a. Both women are above 18 years old: Eliane (age 56) and Elizabeth (age 32) both meet this condition.\n   b. Both have been diagnosed with breast cancer: No specific age restriction is imposed in the inclusion criteria.\n   c. Both have HER2-neu-negative or HER2-neu-positive breast cancer: The statement does not specify their HER2-neu status, but the CTR states that both types of patients are eligible.\n\n2. Both women meet some exclusion criteria but not others:\n   a. Neither has evidence of metastatic disease, except ipsilateral axillary lymph nodes: The given statement does not mention any metastatic disease.\n   b. Neither has undergone any previous systemic or local primary treatment: The statement does not provide any information regarding previous treatments.\n\nThus, the statement can be entailed by the CTRs as both Eliane and Elizabeth meet the common inclusion criteria and do not contradict the exclusion criteria mentioned in the CTR.</s>",
        "contradict": "The statement \"Eliane is a 56 year old woman, and Elizabeth is a 32 year old woman, both Eliane and Elizabeth can both be eligible for the primary trial\" is contradicted by the CTR inclusion criteria stating \"women >=18 years of age.\" Eliane (age 56) meets the age requirement, but Elizabeth (age 32) does not. Therefore, she cannot be eligible according to the CTR information.</s>"
    },
    "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01596751",
        "Statement": "Breast cancer patients must have documented progressive disease to participate in the primary trial",
        "Label": "Entailment",
        "entail": "The statement that \"Breast cancer patients must have documented progressive disease to participate in the primary trial\" is entailed by the CTR's inclusion criteria, as it specifically states that patients in the trial must have \"pathologically confirmed diagnosis of breast cancer with documented progressive disease.\"</s>",
        "contradict": "The statement \"Breast cancer patients must have documented progressive disease to participate in the primary trial\" is not necessarily contradicted by the inclusion criteria in the provided CTR. However, it can be misleading as the statement does not consider other inclusion criteria such as measurable or evaluable disease, or disease amenable to core biopsy, which do not necessarily imply progressive disease. Additionally, for Phase I, patients can have HER2 overexpressing disease but must have progressed after prior treatment with trastuzumab. For Phase II, patients must have HER2 negative disease. Therefore, the statement is not a semantic entailment of the CTRs.</s>"
    },
    "c2217d42-e90c-4ffe-b084-e653b9ace4d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01830933",
        "Secondary_id": "NCT00852930",
        "Statement": "the primary trial and the secondary trial do not record any cardiac or infection related adverse events, but they both record several instances of epilepsy",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the CTRs as neither of them report any adverse events related to cardiac or infection issues in any participant for both trials (as stated in the CTR under \"Adverse Events 1\" and \"Adverse Events 2,\" with a total of 0 instances for each trial and condition). Furthermore, the statement correctly identifies that both trials report instances of epilepsy (implicitly stated in the CTRs as there are participants with this condition in the \"Total\" count under \"Adverse Events 1\" for both trials). Therefore, the statement is consistent with and can be inferred from the data present in the CTRs.</s>",
        "contradict": "The statement does not directly contradict the information in the CTRs, as the statement only mentions the absence of cardiac or infection related adverse events, which is in alignment with the zero count reported in the CTRs for both trials. However, the statement does contradict the CTRs if we consider the second part of the statement, which asserts that \"they both record several instances of epilepsy.\" This claim is contradictory to the CTRs' reports of having no adverse events related to epilepsy in both trials (0/655 and 0/15 for the primary and secondary trials, respectively).</s>"
    },
    "080da381-b5dd-46d3-99c4-18112da153c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There less cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"There are less cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial than in cohort 2 of the primary trial\" can be entailed by the information present in the CTRs as follows:\n\n1. The number of cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial is zero for Acute myocardial infarction, and 0.00% for Cardiopulmonary failure and Supraventricular tachycardia in total.\n2. The number of cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 2 of the primary trial is zero for Supraventricular tachycardia, and 0.00% in total if considering only these three conditions. However, for Acute myocardial infarction, it is 0/199 (0.00%).\n3. Since both cohorts have zero cases for two out of the three conditions and fewer cases for the third condition in cohort 1 compared to cohort 2 (zero vs. one) for Acute myocardial infarction, the entailment holds.\n\nTherefore, the expert statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement cannot be directly derived from the CTR data provided. While the CTR for the primary trial indicates no instances of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia in the Adverse Events section, the absence of events does not imply fewer cases compared to another cohort. In the secondary trial, the data shows a total of 16/36 (44.44%) adverse events, yet it does not provide enough information to establish a definitive comparison with the primary trial's cohort 1. The statement's assumption of fewer cases requires more data, such as the total number of participants in both trials, to be validated.</s>"
    },
    "c100a7cd-e3a2-4901-a3e0-12336f769c7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16",
        "Label": "Contradiction",
        "entail": "The statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16\" entails that the secondary trial had a lower frequency of Conjunctivitis cases compared to the primary trial. The statement does not contradict the information provided in the CTRs, as it accurately reflects the number of reported cases for Conjunctivitis in each trial. The discrepancy between the trials' adverse event sections supports the statement, as the primary trial reported a higher incidence of Conjunctivitis than the secondary trial.</s>",
        "contradict": "The statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial reported 16\" is contradictory to the information in the CTRs. In the primary CTR, there is one instance of Conjunctivitis reported under Adverse Events 1 with a total of 16 adverse events reported in that section. However, in the secondary CTR, there is only one instance of Conjunctivitis reported under Adverse Events 1, but there is also an additional section, Adverse Events 2, where no instances of Conjunctivitis are reported. The discrepancy in the total number of adverse events (22.37% in the secondary trial versus 33.33% in the primary trial) could also be a source of confusion, but the statement specifically mentions Conjunctivitis, which is not the source of the discrepancy in total adverse events.</s>"
    },
    "ec1e269e-470d-43d9-8f23-8a19a5c96fcc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03176238",
        "Statement": "Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2",
        "Label": "Contradiction",
        "entail": "The statement \"Anaemia was the most common adverse event in cohort 1 of the primary trial and tachycardia was the most common in cohort 2\" can be entailed by the information present in the CTRs if we assume that:\n\n1. Cohort 1 refers to the group of participants in the primary trial who experienced a specific adverse event. In this case, cohort 1 would correspond to the group of participants who experienced Anaemia, as stated in the first CTR under Adverse Events 1: \"Anemia 7/199 (3.52%)\".\n2. Cohort 2 refers to the group of participants in the secondary trial who experienced a specific adverse event. In this case, cohort 2 would correspond to the group of participants who experienced tachycardia, as stated in the secondary CTR under Adverse Events: \"Supraventricular tachycardia 1/36 (2.78%) and Ventricular tachycardia 0/36 (0.00%)\". Since tachycardia includes both Supraventricular tachycardia and Ventricular tachycardia, cohort 2 can be inferred to have a higher prevalence of tachycardia compared to cohort 1's prevalence of Anaemia.\n\nThus, the statement can be entailed by the CTRs as it accurately reflects the frequency of each adverse event in their respective cohorts.</s>",
        "contradict": "The statement can be contradicted by the information in the CTRs because the frequencies of specific adverse events, such as anemia and tachycardia, differ between the two cohorts, but the statement does not specify which cohort's adverse event totals (29.65% vs 44.44%) are being compared when making the claim about the \"most common\" events. The statement only mentions the individual events, not the proportions of their occurrence in each cohort, leading to a potential misrepresentation of the facts.</s>"
    },
    "21611c2a-e6eb-4012-a209-9b6781e1f260": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00606931",
        "Statement": "There is no adverse events section in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"There is no adverse events section in the primary trial\" is entailed by the information present in the CTRs since the primary trial's Adverse Events section states that \"Total: 0.\" The absence of any adverse events being reported in the primary trial implies the absence of an adverse events section as well.</s>",
        "contradict": "The statement \"There is no adverse events section in the primary trial\" is contradicted by the information present in the CTRs, as the first CTR provided does in fact have an adverse events section, with a total count of 0.</s>"
    },
    "d1b7105d-0b7d-4b10-92a7-d63243ff0629": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00425854",
        "Secondary_id": "NCT01224678",
        "Statement": "Patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger ",
        "Label": "Entailment",
        "entail": "The primary trial exclusion criteria specify that patients with cardiac left ventricular function with resting ejection fraction less than 50% are not eligible. However, the secondary trial criteria state that premenopausal women, including those with significantly low ejection fraction, are eligible. Given that the primary trial specifically mentions age as a factor in eligibility for the exclusion of patients with low ejection fraction, and the secondary trial specifically targets premenopausal women, it follows logically that premenopausal women with significantly low ejection fraction are not explicitly excluded from the secondary trial, allowing the potential inclusion of these individuals. This reasoning aligns with the provided information within the CTRs.</s>",
        "contradict": "The statement contradicts the eligibility criteria of the Primary Trial which excludes patients with a cardiac left ventricular function with resting ejection fraction < 50%, while the Secondary Trial has no such exclusion criterion for ejection fraction. However, the Secondary Trial does not mention anything about significantly low ejection fraction, making the statement's use of this term ambiguous. The discrepancy between the two trials' eligibility criteria is the primary reason for the possible contradiction.</s>"
    },
    "7f3fe97e-68ee-470f-b06e-21cdddb67aa8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121134",
        "Secondary_id": "NCT03098550",
        "Statement": "all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement is entailed by the information in the CTRs because:\n\nIn the primary trial, the inclusion criteria state that patients must have histologically or cytologically confirmed invasive breast cancer, with no specific mention of cancer stage. However, the criteria further specify that patients must have stage II-III cancer based on the AJCC 6th edition. Therefore, it can be inferred that the trial primarily focuses on participants with stage II or III breast cancer. However, the statement specifically mentions stage 3 disease, which is a subset of stage II-III.\n\nThe secondary trial's inclusion criteria do not specify a cancer stage as a requirement for entry. This means that participants can have any stage of cancer. The statement's claim that primary trial participants have stage 3 disease but secondary trial participants do not require a specific stage is, thus, entailed by the CTRs as the former trial's patient population primarily consists of stage II-III patients (including stage 3), while the latter has a broader scope of inclusion.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial includes patients with stage II-III breast cancer, according to the provided inclusion criteria. The statement, however, asserts that all participants of the primary trial have stage 3 cancer, which does not align with the trial's eligibility criteria. In contrast, the secondary trial does not mention any specific stage requirement for breast cancer.</s>"
    },
    "ce8464bd-951e-44aa-97d9-10b917b055ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00005879",
        "Statement": "there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1",
        "Label": "Contradiction",
        "entail": "The statement \"there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1\" can be entailed by the information present in the CTRs if there is a difference in the number of slipped disks reported between the two cohorts, with a statistically significant p-value. \n\nFrom the provided CTRs, we have that in the Primary Trial, the number of patients with slipped disks in cohort 1 is 0/101 (0.00%), and in cohort 2 it is 1/98 (1.02%). \n\nTo test if this difference is statistically significant, we would need more information, such as the total number of patients in each cohort and the standard errors or confidence intervals for each percentage. Assuming we had this information and the difference was statistically significant, the expert's statement would be entailed by the data in the CTRs.</s>",
        "contradict": "The statement \"there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1\" cannot be entailed by the information provided in the CTR, because the number of patients with slipped disks in both cohorts is reported as zero (0.00%) according to the given data, and no information is available regarding the size or demographic differences of the cohorts that could suggest a causative factor for the discrepancy.</s>"
    },
    "0131ebe3-746b-45a5-ba60-fdd326974fec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01262027",
        "Secondary_id": "NCT02301988",
        "Statement": "the primary trial and the secondary trial use comparable outcome measurements",
        "Label": "Entailment",
        "entail": "Both trials use the outcome measurement of response to treatment. In the primary trial, participants' responses are categorized as Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD), while in the secondary trial, the outcome measures are defined as percentage of participants with Pathological Complete Response (pCR) in breast and axilla. Despite the different terminologies, the concepts of response evaluation are similar. Furthermore, the time frames for response assessment are within six months for the primary trial and at surgery visit (approximately Weeks 14 to 19) for the secondary trial. Both trials report the number of participants and their response status, making the outcome measurements comparably informative about the trials' effectiveness.</s>",
        "contradict": "The outcome measurements in the two trials are not directly comparable as they assess different response criteria. The primary trial reports on overall response based on RECIST criteria, while the secondary trial reports on the percentage of participants with pCR using the AJCC Staging System. The former includes CR, PR, SD, PD, and MR, whereas the latter focuses on the complete absence of tumor in the breast and axilla. These measures do not correspond, and their comparison requires additional context or a more nuanced analysis to establish entailment.</s>"
    },
    "b1dd7632-ed92-40a9-9293-bce68619c658": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible\" is entailed by the information in the CTRs since the CTRs specify \"Newly diagnosed with stage I-III cancer\" as the eligibility criterion, which explicitly excludes patients with stage 4 cancer.</s>",
        "contradict": "The statement is contradicted by the information present in the primary trial's Eligibility Criteria section, as it explicitly states that patients with stage I-III breast cancer are eligible for participation.</s>"
    },
    "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00570921",
        "Statement": "the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally\" can be entailed by the CTRs as follows:\n- Fulvestrant is administered intramuscularly in the primary trial, specifically in the gluteus maximus, in a loading dose schedule and then every 4 weeks.\n- Everolimus is administered orally in the primary trial, initially at a dose of 5 mg daily for the first month, then increased to 10 mg daily after that.\n\nTherefore, the statement is consistent with the CTR information, as it correctly describes the routes of administration for both Fulvestrant and Everolimus in the primary trial.</s>",
        "contradict": "The statement can be contradicted by the information present in the CTRs because the primary trial specifies that Fulvestrant is administered intramuscularly and Everolimus is administered orally in a different manner than stated in the expert's assertion. According to the CTR, Fulvestrant is given intramuscularly in the gluteus maximus using a loading dose schedule, while Everolimus is initially administered at a lower dose (5 mg daily) orally and then increased to a higher dose (10 mg daily) later on. Therefore, the statement's claim that both drugs are administered orally to primary trial participants is inconsistent with the provided CTR information.</s>"
    },
    "4a15ec5e-4904-4f01-a0a2-c51e83c8c070": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort\" is entailed by the information in the CTRs as follows:\n\n1. Both the CTR for the primary trial and the statement agree that the trial investigates the severity of dermatitis in radiation treatment sites for two different groups: Curcumin C3 Complex and Placebo.\n\n2. The CTRs explicitly describe the measurement of radiation dermatitis severity using the Radiation Dermatitis Severity (RDS) scale, which ranges from 0.0 to 4.0 with increments of 0.5 (Primary CTR: \"The worst dermatitis...was used for the primary analysis of severity of radiation dermatitis in each treatment group.\").\n\n3. The statement and the CTRs both mention the presence of data for both the Curcumin C3 Complex group and the Placebo group.\n\nTherefore, the statement is entailed by the information present in the CTRs, as it accurately summarizes the trial's focus on the severity of dermatitis in radiation treatment sites for both the Curcumin C3 Complex and Placebo groups.</s>",
        "contradict": "The statement \"the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort\" is not contradictory to the provided CTR information. However, it is important to note that the statement itself does not contain any quantitative data or specific values from the CTRs. \n\nA contradiction would arise if the statement asserted that the severity of dermatitis was lower (or higher) in the Curcumin C3 Complex arm compared to the placebo arm based on the reported means or standard deviations, without proper justification from the CTRs. In the absence of any specific quantitative comparison in the expert statement, it cannot be contradicted by the information present in the CTRs.</s>"
    },
    "b9e29ea8-6847-40d4-b5c3-81c496101695": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01808573",
        "Statement": "All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months",
        "Label": "Contradiction",
        "entail": "The statement \"All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months\" is entailed by the information in the CTRs because:\n\n1. The statement specifies that all patients in cohort 1 had a PFS greater than 8.8 months, which aligns with the reported mean PFS (8.8 months, 95%CI 7.8-9.8) for the Neratinib Plus Capecitabine arm.\n2. The statement further specifies that the highest PFS was just under 10 months, which is a valid observation from the reported data since the maximum observed PFS in the Neratinib Plus Capecitabine arm is 9.8 months.\n\nThe statement neither contradicts nor goes beyond the information provided in the CTRs.</s>",
        "contradict": "The statement \"All patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months\" contradicts the information presented in the CTR, as the mean PFS for cohort 1 was 8.8 months (7.8 to 9.8), and there is no mention of the highest PFS being just under 10 months for any specific patient in the given cohort.</s>"
    },
    "2a2c16a7-f427-4fdb-8153-94aac304e4b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01998906",
        "Statement": "Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks , patients receive the same types and dosages of medication throughout all 17 cycles",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the CTRs as follows:\n\nFor INTERVENTION 1 and INTERVENTION 2, all cycles last for 3 weeks. In the primary trial's first intervention, participants undergo cycles 1-3 with trastuzumab, doxorubicin, and paclitaxel; cycles 4-7 with paclitaxel and trastuzumab; cycles 8-10 with trastuzumab and CMF; and cycles 11-17 with trastuzumab (postoperatively, with a maximum of 17 cycles). The types of medications remain constant throughout all 17 cycles, and the statement specifies \"the same types and dosages of medication\" for both cohorts. Therefore, the statement is entailed by the information presented in the CTRs.</s>",
        "contradict": "The statement \"Both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks, patients receive the same types and dosages of medication throughout all 17 cycles\" is contradicted by the information presented in the CTRs because:\n\n1. While both cohorts undergo a total of 17 cycles (as stated), their durations and medication types/dosages differ.\n2. The first cohort (INTERVENTION 1) receives trastuzumab, doxorubicin, paclitaxel, and CMF in various cycles with different dosages, while the second cohort (INTERVENTION 2) only receives doxorubicin and paclitaxel with no trastuzumab or CMF. \n3. Thus, the statement is contradictory to the CTR data as the medication types and dosages vary between the cohorts throughout the trial.</s>"
    },
    "618a3ae1-b22c-4c35-86a6-190c1b5b5d21": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of at least 1 year to enroll in the primary trial",
        "Label": "Entailment",
        "entail": "The statement's assertion \"Patients must have a Life expectancy of at least 1 year to enroll in the primary trial\" is entailed by the CTR's inclusion criterion \"Life expectancy  1 year.\" Therefore, the statement harmonizes with clinical trial data, finds substantiation in the CTR, and avoids contradiction with provided descriptions.</s>",
        "contradict": "The statement \"Patients must have a Life expectancy of at least 1 year to enroll in the primary trial\" can be contradicted by the inclusion criteria of the primary CTR which specifies \"Life expectancy 1 year\" as a requirement for patient eligibility. However, the statement is not a direct contradiction as it only sets a minimum threshold for life expectancy, while the CTR's inclusion criteria provide an exact requirement. The contradiction arises from the ambiguity of the statement, as it could potentially imply that any life expectancy greater than 1 year is acceptable. In the primary CTR, the inclusion criteria state that only patients with a life expectancy of exactly 1 year are eligible.</s>"
    },
    "e62f5a3f-0091-4980-9822-db8f4dc2502a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01042938",
        "Statement": "the primary trial reports the Severity of Dermatitis in Radiation Treatment Site for the Curcumin C3 Complex cohort and the placebo cohort, there is no difference in the results from these two cohorts",
        "Label": "Contradiction",
        "entail": "The statement that \"there is no difference in the results from the Curcumin C3 Complex cohort and the placebo cohort based on the primary trial's report of the Severity of Dermatitis in Radiation Treatment Site\" can be entailed by the information present in the CTRs. \n\nExplanation: \n\nThe statement does not contradict the CTRs since both the Curcumin C3 Complex and Placebo groups were administered the same treatment duration (4-7 weeks) and the severity of dermatitis in each group was measured using the same RDS scale. The CTRs provide the means and standard deviations for each group, and the statement does not claim a difference beyond what the data already shows. The means of the Curcumin C3 Complex group (2.6) and the Placebo group (3.4) do not have a statistically significant difference, as evidenced by the small standard deviations, indicating that the groups may overlap. Thus, the statement that there is no difference is an appropriate conclusion based on the data in the CTRs.</s>",
        "contradict": "The expert's statement can be contradicted by the CTR information due to the following reasons:\n\n1. Differing mean scores: The mean RDS scores reported for the Curcumin C3 Complex arm (2.6) and the placebo arm (3.4) indicate that there is, in fact, a difference in severity of dermatitis between the two treatment groups.\n\n2. Lack of statistical analysis: The expert's statement assumes there is no difference based on casual observation of mean values. However, a statistical test is required to determine if the difference is significant, which the statement fails to address.\n\nTo establish semantic entailment, a proper comparison of the data would necessitate conducting a suitable statistical analysis (such as an independent t-test or ANOVA) to determine if there is a significant difference between the two groups' mean RDS scores.</s>"
    },
    "4a41ac73-538a-43e5-b7ce-8c8e2d56286e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial, unless they are recieiving adjuvant therapy.",
        "Label": "Contradiction",
        "entail": "The statement entails that women receiving endocrine therapy are excluded from both primary and secondary trials, with the exception of those undergoing adjuvant therapy. This is entailed by the exclusion criteria in both CTRs. In the primary CTR, it states, \"No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago.\" Similarly, in the secondary CTR, it states, \"Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously.\" However, the primary CTR includes an additional condition for endocrine therapy: \"Female patient.\" Therefore, the statement only applies to females. In summary, the statement is a logical consequence of the information provided in the CTRs.</s>",
        "contradict": "The statement is contradictory to the information in the CTRs because the primary trial includes women who have previously undergone endocrine therapy but only if they have completed it at least one year ago. Conversely, the secondary trial excludes women currently receiving endocrine therapy, regardless of the timing of its administration. Therefore, the statement does not hold true for both trials and contains contradictory information.</s>"
    },
    "75a65913-5655-4377-b441-ecdd4dd75175": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00376597",
        "Statement": "Patients with stage 4 cancer are excluded from the primary trial",
        "Label": "Entailment",
        "entail": "The information in the statement \"Patients with stage 4 cancer are excluded from the primary trial\" is entailed by the information in the CTR under the Eligibility Criteria section, which specifies that patients with \"newly diagnosed with stage I-III cancer of the female breast\" are eligible for the trial, and those with \"any other invasive malignancies\" are eligible as long as they have completed treatment and are 5 years post-diagnosis. Since stage 4 cancer is considered an advanced stage of breast cancer beyond III, it follows that patients with stage 4 cancer are excluded from the trial as per the CTR information.</s>",
        "contradict": "The information contained in the expert statement can be contradicted by the information present in the CTRs as they do not exclude patients with stage 4 cancer. Instead, the CTRs allow participation for patients with a history of other invasive malignancies as long as they have completed treatment and are 5 years post-diagnosis. Therefore, it's possible for patients with stage 4 breast cancer to meet these criteria and be eligible for the primary trial.</s>"
    },
    "1329dec6-fb2c-4219-9db6-3fef9d94b316": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02131064",
        "Statement": "in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain",
        "Label": "Contradiction",
        "entail": "The statement \"in cohort 1 of the primary trial, there were 10 more cases of Left ventricular dysfunction than Abdominal pain\" can be entailed by the information present in the CTRs, as follows:\n\n1. The CTRs report the number of cases for Left ventricular dysfunction and Abdominal pain in the primary trial: 2 occurrences for Left ventricular dysfunction, and 1 occurrence for Abdominal pain.\n2. To satisfy the statement, we need to have 10 more cases of Left ventricular dysfunction than Abdominal pain, which is equivalent to having 12 cases of Left ventricular dysfunction and 2 cases of Abdominal pain.\n3. Since there are already 2 cases of Left ventricular dysfunction reported, we need to determine if there is enough room for an additional 10 cases within the cohort of the primary trial.\n4. The total number of reported adverse events for the primary trial was 70, and the percentage of participants affected by adverse events was 31.96%.\n5. To determine the maximum possible number of adverse events in the cohort 1 of the primary trial (which has 219 participants), we calculate 31.96% of 219: 70.17 \u2248 71 (since we cannot have a fraction of an event).\n6. Therefore, there are 71 reported adverse events in cohort 1, leaving room for 3 more adverse events to reach 12 cases for Left ventricular dysfunction.\n\nThus, the statement can be entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"in cohort 1 of the primary trial, there were 10 more cases of Left ventricular dysfunction than Abdominal pain\" cannot be directly derived from the provided data in the CTRs. While there are 2 cases of Left ventricular dysfunction reported in the Primary Trial, there is only 1 reported case in the Secondary Trial. Similarly, there is only 1 reported case of Abdominal pain in both Primary and Secondary Trials. Therefore, the statement does not hold true based on the available data in the provided CTRs.</s>"
    },
    "29b2fa29-5a76-4877-95bb-1a8de7973d33": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "Only 6/67 patients in cohort 1 of the primary trial suffered adverse events",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the CTR data, as both assert the same number (6) of patients in the primary trial's cohort 1 experienced adverse events. The percentages provided in the CTR do not contradict this claim, as the percentage of patients experiencing adverse events also totals to 100% for cohort 1. Therefore, the statement is a logical consequence of the data presented in the CTRs.</s>",
        "contradict": "The statement \"Only 6/67 patients in cohort 1 of the primary trial suffered adverse events\" contradicts the information in the CTRs because the CTRs report that a total of 6 adverse events occurred among 67 patients in the cohort, meaning more than 6 patients experienced an adverse event. The expert's statement incorrectly implies that only 6 unique patients experienced an adverse event.</s>"
    },
    "7edba90d-076d-4f55-b9d6-a1765ceb48bd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00290732",
        "Secondary_id": "NCT00232505",
        "Statement": "the primary trial and the secondary trial participants do not receive any medication by IV",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial participants do not receive any medication by IV\" is not entailed by the information in the CTRs. In the primary trial, intraductal administration of dextrose or dextrose with PLD is given prior to conventional surgery, which is not an IV medication. However, in the secondary trial, cetuximab is given intravenously, which contradicts the statement that no medication is given intravenously in either trial.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs since both interventions in the primary trial involve intraductal administration of dextrose or dextrose with PLD, which is not given intravenously. In contrast, in the secondary trial, patients receive cetuximab intravenously. Therefore, the statement, which asserts that no medication is given intravenously to any participants in both trials, is inconsistent with the CTR information.</s>"
    },
    "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00754325",
        "Statement": "in the primary trial, patients that received Fulvestrant were much more likely  to suffer Disease Progression or Death than patients receiving herceptin",
        "Label": "Contradiction",
        "entail": "The statement \"in the primary trial, patients that received Fulvestrant were much more likely to suffer Disease Progression or Death than patients receiving Herceptin\" cannot be directly entailed by the provided information in the CTRs. Herceptin is not listed as a treatment arm in the primary trial; instead, it compares Fulvestrant with a combination of Fulvestrant and Dasatinib. To make an entailing statement based on the provided CTRs, one could compare the number of participants experiencing progression or death in the Fulvestrant and Fulvestrant plus Dasatinib arms directly. However, the statement made by the expert refers to a comparison with Herceptin, which is not presented in the CTRs. Therefore, the statement is not entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"in the primary trial, patients that received Fulvestrant were much more likely to suffer Disease Progression or Death than patients receiving herceptin\" is contradicted by the information in the CTRs as no information about an arm of the trial using Herceptin is provided. The comparison made in the expert statement is not grounded in data from the trials described in the CTRs.</s>"
    },
    "1314146f-2869-4525-8034-7f732d238385": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00009945",
        "Statement": "none of the individual adverse events in the primary trial affect more than 100 patients.",
        "Label": "Entailment",
        "entail": "The statement \"none of the individual adverse events in the primary trial affect more than 100 patients\" can be entailed by the CTR data because the total number of participants in each trial (1612 for the primary trial and 1623 for the secondary trial) is given. By calculating the difference between the total number of participants and the number of participants affected by each individual adverse event in the primary trial, it can be confirmed that none of them exceed 100 patients. For instance, Anemia has 10 affected patients in the primary trial, and the difference between 1612 (total participants) and 10 (affected patients) equals 1602, which is indeed less than 1000 (1000 being the threshold for more than 100 patients). This holds true for all individual adverse events in the primary trial.</s>",
        "contradict": "The statement \"none of the individual adverse events in the primary trial affect more than 100 patients\" is contradictory to the information in the CTR as some of the adverse events do affect more than 100 patients. \n\nFor example, in the primary trial, there were 6 cases of Myocardial Infarction, which is more than 100 patients if we combine the 6 cases from both the primary and secondary trials (10 cases in total). Similarly, there were 12 cases of Cardiac disorders - Other, specified in total across both trials (6 in primary and 6 in secondary). Therefore, the statement is incorrect based on the data provided in the CTRs.</s>"
    },
    "7c7418d2-32d7-4517-874b-eb3db24ea16a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00121992",
        "Statement": "to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels.",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the CTR inclusion criteria, as the CTR specifies that patients must be over the age of 18, have a Karnofsky performance status index over 80%, and adequate hepatic, renal, and heart functions as well as adequate hematology levels to be eligible for the primary trial.</s>",
        "contradict": "The statement can be contradicted by the CTRs' Eligibility Criteria section because it omits several essential inclusion criteria, such as histologically proven breast cancer, operable breast cancer (T1-T3) with negative axillary lymph nodes, and definitive surgical treatment with either mastectomy or breast conservative surgery with histologically free margins. These criteria are not mentioned in the expert statement, which may lead to potential contradictions when assessing eligibility for the trial.</s>"
    },
    "1f6a14ae-e22b-4b40-b389-217570dbf38e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered  Dose Limiting Toxicities ",
        "Label": "Entailment",
        "entail": "The statement \"50% of cohort 2 patients in the primary trial suffered Dose Limiting Toxicities\" can be entailed by the information in the CTRs as follows:\n\nGiven the definitions of DLTs and the time frame for monitoring in the primary trial, it is reasonable to assume that any toxicity event meeting the DLT criteria during the weekly safety monitoring period would be considered a Dose Limiting Toxicity.\n\nIn the Results 1 section, it is stated that there were 2 DLTs observed in the cohort receiving 160 mg bd of AZD8931 in combination with weekly paclitaxel (Cohort 1), and these DLTs affected 2 out of the 6 participants.\n\nIn the Results 2 section, it is stated that there was 1 DLT observed in the cohort receiving 120 mg bd of AZD8931 in combination with weekly paclitaxel (Cohort 2), and this DLT affected 1 out of the 2 participants.\n\nSince there were 4 participants in total in Cohort 2 (as stated in the provided information, but not explicitly shown in the Results 2 section), and 1 out of these 4 participants experienced a DLT, it follows that 25% of the participants in Cohort 2 suffered a DLT. However, the expert's statement claims that \"50%\" of the participants in Cohort 2 suffered DLTs. This discrepancy could be due to a misunderstanding of the data, a mistake in the expert's calculation, or other factors. Nevertheless, assuming that the expert intended to state that at least half of the participants in Cohort 2 experienced a DLT, the statement can still be entailed by the information in the CTRs. This is because, even though the exact percentage (50%) might not be explicitly stated in the CTRs, the presence of at least one DLT in Cohort 2 implies that more than 25% of the participants (i.e., at least half if there are exactly two participants) experienced a DLT. The expert's statement is therefore consistent with the available data, even if it is not an identical match.</s>",
        "contradict": "The statement \"50% of cohort 2 patients in the primary trial suffered Dose Limiting Toxicities (DLT)\" cannot be directly determined from the information provided in the CTRs. The CTRs indicate the total number of DLTs observed in each arm of the trial, but they do not provide information about the total number of patients in each arm or the distribution of DLTs among individual patients. Therefore, the percentage of patients experiencing DLTs in cohort 2 cannot be determined based on this data alone.</s>"
    },
    "5c1e360c-fd93-4dd4-b855-71ba416d34cb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must be able to receive medication orally to participate in the primary trial",
        "Label": "Entailment",
        "entail": "The CTR for the primary trial explicitly states that patients must be \"Able to swallow an oral medication\" as an inclusion criterion. This condition ensures that patients can receive oral medication as part of the trial. Therefore, the statement \"patients must be able to receive medication orally to participate in the primary trial\" is entailed by the information provided in the CTR.</s>",
        "contradict": "The statement can be contradicted by the CTR as it only mentions that patients must be \"able to swallow an oral medication\" for inclusion in the primary trial. The statement, however, makes a stronger claim that \"patients must be able to receive medication orally.\" The CTR does not explicitly state that intravenous or other forms of medication administration are excluded.</s>"
    },
    "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01852032",
        "Secondary_id": "NCT01830933",
        "Statement": "the primary trial and the secondary trial report the same types of adverse events",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs if there is no mention of different types of adverse events reported in each trial aside from the absence of adverse events in both. The statement does not contradict the information in the CTRs as it only asserts a type equivalence, which is harmonious with the reported absence of adverse events in both trials.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial report the same types of adverse events\" cannot be definitively established as an entailment based on the given CTR information. While both trials have the same absence of reported adverse events, it does not guarantee that the same types of adverse events were evaluated or observed between the trials. The absence of adverse events in one trial does not automatically imply that the same holds true for another trial, especially when dealing with different cohort sizes. Therefore, additional information regarding the types of adverse events assessed in each trial would be necessary to establish the semantic entailment relationship.</s>"
    },
    "48f516ff-abb4-4312-9b00-02f53fb16218": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "Label": "Contradiction",
        "entail": "Based on the given CTR data, 26 out of 32 participants in the Intervention Arm underwent Pathologic Complete Response. This represents approximately 81.25% of the participants. Therefore, under a quarter (25%) of the participants in the Intervention Arm, which is equal to or less than 8 individuals, did not experience Pathologic Complete Response.</s>",
        "contradict": "The statement \"under a quarter of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" cannot be directly contradicted by the information present in the CTRs as the CTR does not provide the actual number of patients in the intervention arm who achieved a Pathologic Complete Response. The CTR only states that \"Overall Number of Participants Analyzed: 32\" but does not specify how many of these participants achieved a Pathologic Complete Response in the intervention arm. Therefore, the statement does not contradict the CTR as it is not based on the CTR data but rather an interpretation or conclusion drawn from it. However, if the statement was to contradict the CTR by stating a specific number of patients in the intervention arm that did not achieve a Pathologic Complete Response, then it would contradict the CTR if that number was incorrect or inconsistent with the trial data.</s>"
    },
    "978d19fc-e7f6-485e-b8bd-cfcde06441ab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00022516",
        "Statement": "T1 N0 M0 patients are eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"T1 N0 M0 patients are eligible for the primary trial\" can be entailed by the information present in the CTR as follows:\n\nAccording to the CTR, the disease characteristics include \"T1-3, N0-2, M0,\" which means that T1, N0, M0 stage patients meet the inclusion criteria stated by the expert. Hence, the statement is entailed by the provided CTR information.</s>",
        "contradict": "The statement \"T1 N0 M0 patients are eligible for the primary trial\" can be contradicted by the following conditions in the CTR:\n\n1. Patients with T1-3, N0-2, M0 disease are eligible for the trial, but it explicitly states that T4 disease is not allowed, which includes some T1 patients with certain characteristics (ulceration of skin, infiltration of skin, etc.).\n2. Patients must have undergone a prior total mastectomy or breast-conserving procedure with negative margins and radiotherapy planned. T1 patients may not necessarily have undergone these procedures based on the information given in the CTR.\n3. Patients must begin or have begun an approved induction chemotherapy regimen within 8 weeks after definitive surgery. This could potentially exclude some T1 patients depending on their individual treatment plans.\n4. Patients must have negative surgical margins, which may or may not be the case for T1 patients depending on their treatment and surgical outcome.\n5. Patients with positive hormone receptors (ER and/or PR) and more than 10% positive tumor cells are not eligible for the trial. This information is not provided for T1 patients in the CTR, so their eligibility status cannot be definitively determined based on the given statement.\n\nTherefore, the statement \"T1 N0 M0 patients are eligible for the primary trial\" may not always hold true due to these inconsistencies in the CTR.</s>"
    },
    "0a6d1b4c-244e-44e2-a229-62e4cbdfa979": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial are non-comparable",
        "Label": "Entailment",
        "entail": "The statement \"the results of the secondary trial and the primary trial are non-comparable\" is entailed by the information presented in the CTRs due to the following reasons:\n\n1. Different Outcome Measures: The primary trial measures the safety of External-beam PBI using specific toxicity outcomes within 2 years, while the secondary trial assesses overall tumor response using RECIST criteria, with evaluations every 3 cycles or until disease progression.\n\n2. Different Treatments: The primary trial evaluates the safety of External-beam PBI in selected stages 0 and I breast cancer patients with 40 Gy in ten daily fractions over two weeks. In contrast, the secondary trial investigates the efficacy of Pemetrexed, a chemotherapeutic agent, given as 600 mg/m2, intravenously every 14 days until complete response or disease progression.\n\n3. Different Participant Populations: The primary trial focuses on a specific patient population (stage 0 and I female breast cancer patients undergoing External-beam PBI) and measures toxicity outcomes within 2 years. Meanwhile, the secondary trial enrolls participants with various solid tumors (not limited to breast cancer), and the outcome assessment is continuous throughout the study until disease progression or complete response.\n\nThus, the differences in outcome measures, treatments, and participant populations make the results of the primary and secondary trials non-comparable.</s>",
        "contradict": "The statement \"the results of the secondary trial and the primary trial are non-comparable\" is not directly contradicted by the information provided in the CTRs. However, the statement assumes comparability as a prerequisite for non-comparability. Since no information is given in the CTRs about the similarities and differences between the two trials (such as patient populations, types of treatments, outcome measures, or time frames), it is impossible to definitively establish entailment or contradiction based solely on the provided data. Therefore, while the statement is not directly contradicted, it also does not follow logically from the CTRs alone.</s>"
    },
    "9bcc31df-c1f6-4785-9235-f673213acf3a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel ",
        "Label": "Entailment",
        "entail": "Both interventions in the primary trial administer Docetaxel at a dose of 100 mg/m^2 to the participants. The statement made by the clinical trials expert is a specialization of the information presented in the CTRs, as it focuses on just the dose of Docetaxel being identical between the groups without mentioning the administration of placebo or bevacizumab. The statement is consistent with the data and does not contradict the provided descriptions in the CTRs.</s>",
        "contradict": "Although both trial cohorts receive the same dose of Docetaxel (100 mg/m^2), they do not receive identical interventions as they differ in the administration of Bevacizumab. In the primary trial, participants received a placebo for Bevacizumab, while in the secondary trial, participants received Bevacizumab (7.5 mg/kg). Therefore, the statement can be contradicted by the CTR information.</s>"
    },
    "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention",
        "Label": "Contradiction",
        "entail": "The statement \"neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention, other than the Calcitriol pill taken once per week\" is entailed by the CTR information as follows:\n\n1. For the No Exercise Arm and Calcitriol Arm, no surgery or oral medications other than the Calcitriol pill are specified in the INTERVENTION 1 section.\n2. For the Exercise Arm and Calcitriol+ Exercise Arm in INTERVENTION 2, both arms receive a Calcitriol pill taken once a week, and there is no mention of surgery or additional oral medications as part of their intervention.\n\nTherefore, the statement neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention is consistent with the data in the CTRs and can be entailed from this information.</s>",
        "contradict": "The statement contradicts the information in the CTRs as Intervention 1 of the primary trial explicitly mentions no exercise and intake of a multivitamin only, while Intervention 2 includes exercise and calcitriol intake once per week. The statement overlooks the presence of calcitriol as an oral medication, thereby leading to the contradiction.</s>"
    },
    "75cf4ec2-9f2b-4d5b-8772-af247eaca07b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement is not entailed by the information present in the CTRs as the primary trial specifically includes patients with metastatic breast cancer (Stage IV), while the statement excludes patients with Stage I-III breast cancer.</s>",
        "contradict": "The statement \"Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial\" contradicts the information in the CTR as it specifies a different inclusion criteria for the trial, where the primary trial only includes patients with metastatic breast cancer (Stage IV) with measurable disease by RECIST criteria. Therefore, patients with breast cancer in stages I-III do not meet the eligibility criteria for the primary trial according to the CTR.</s>"
    },
    "553f00ea-5197-4233-b1e0-e5727856b599": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00331630",
        "Statement": "no cardiac or bowel-related adverse events were recorded in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"no cardiac or bowel-related adverse events were recorded in the primary trial\" does not directly entail with the information provided in the CTRs, as the CTRs do not specify the types of adverse events related to cardiac or bowel systems. However, the statement is consistent with the information given in the CTRs if we consider the specific adverse events recorded in the trial. Since no cardiac or bowel-related adverse events (as defined by the Dry Eyes and Diarrhea mentioned in the CTRs) were reported in the primary trial, the statement is true and can be inferred from the information in the CTRs according to the given context.</s>",
        "contradict": "The statement \"no cardiac or bowel-related adverse events were recorded in the primary trial\" contradicts the information in the CTRs because the CTRs report 1 instance each of diarrhea (bowel-related) and no explicit mention or denial of cardiac-related adverse events, while the trial involved 30 participants. Therefore, the statement's assertion that no adverse events of the mentioned types occurred in the primary trial is not entailed by the information provided in the CTRs.</s>"
    },
    "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS  and Anemia in the secondary trial than in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial than in the primary trial\" cannot be entailed by the information presented in the CTRs.\n\nThe CTR for the primary trial reports no Adverse Events related to mental health disorders, Pleuropericarditis, or Atrial Thrombosis. Therefore, the statement that there were more cases of these conditions in the secondary trial is incorrect.\n\nRegarding Anemia, the CTR for the secondary trial reports 1 case out of 41 participants (2.44%). The statement, however, does not specify if it is comparing the total number of cases between the primary and secondary trials, or if it is comparing the percentage of participants with Anemia. Since the CTR does not provide enough information to determine if there are more cases of Anemia in the secondary trial in terms of either total number or percentage of participants affected, the statement cannot be entailed.\n\nThere is no mention of any of these conditions in the Adverse Events section of the primary trial CTR. Thus, the statement as a whole is not entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement is contradictory to the CTR information as it incorrectly implies a higher occurrence of mental health disorders in the secondary trial. However, the CTRs provided do not mention any information related to mental health disorders in either trial's Adverse Events sections. Additionally, the number of reported anemia cases is actually higher in the primary trial (0 cases vs. 1 case in the secondary trial), which also contradicts the statement. No cases of pleurpericarditis or atrial thrombosis are mentioned in either CTR either, so the comparison for these conditions is invalid.</s>"
    },
    "215a5c4a-d90c-4500-8284-0679ce311734": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00263588",
        "Statement": "patients must have HER2- breast cancer to participate in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"patients must have HER2- breast cancer to participate in the primary trial\" is entailed by the information in the Primary Trial's Eligibility Criteria, specifically the condition: \"ErbB2(HER2)overexpressing breast cancer.\"</s>",
        "contradict": "The information in the statement \"patients must have HER2- breast cancer to participate in the primary trial\" is not a direct contradiction to the inclusion criteria stated in the CTRs for the primary trial. However, the statement is an oversimplification and does not account for the full complexity of the inclusion criteria. While it is true that patients must have HER2-overexpressing breast cancer to be eligible for the primary trial, the statement fails to acknowledge the presence of other inclusion criteria, such as a brain lesion, prior treatment history, cardiac function, and ability to swallow an oral medication. The statement could lead to a misunderstanding of the eligibility requirements for the trial.</s>"
    },
    "e9a4bd91-f58b-4234-9037-75e0699d1bbd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01118624",
        "Statement": "the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate",
        "Label": "Entailment",
        "entail": "The statement \"the primary trial participants receive less than 300mg/m^2 doses of Pralatrexate\" is entailed by the information in the CTR as the stated intervention dose for Pralatrexate in the primary trial is 190 mg/m^2. Therefore, 190 mg/m^2 is less than 300 mg/m^2.</s>",
        "contradict": "The statement \"the primary trial participants receive less than 300mg/m^2 doses of Pralatrexate\" contradicts the CTR information as the primary trial specifies a dosage of 190 mg/m^2 for 2 to 4 weeks, which is above 300mg/m^2 when considering the total dose administered over the given duration.</s>"
    },
    "7d52734c-0801-413d-9ae2-d190b972cde5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00503750",
        "Secondary_id": "NCT00005879",
        "Statement": "The results from the secondary trial and the primary trial can be compared by changing the units from days to months",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information in the CTRs as follows:\n\nIn the primary trial, the measurement of \"Number of Participants With Complete Pathologic Response\" is assessed at 8 weeks. To compare this with the secondary trial, we need to convert the time frame from weeks to months, since the Masood Score is measured from Baseline to 6 months. Thus, 8 weeks is equivalent to approximately 2 months. Therefore, the comparison is valid since both trials assess the outcomes within similar time frames.</s>",
        "contradict": "The statement \"The results from the secondary trial and the primary trial can be compared by changing the units from days to months\" is not directly contradicted by the information presented in the CTRs. However, it is important to note that while the time frame for the outcome measurement in the primary trial is given in weeks, the time frame for the outcome measurement in the secondary trial is given in months. Changing the units from days to months for the primary trial results may not accurately reflect the data provided, as the time frames are not directly comparable. Therefore, while the statement is not contradictory, it may lead to misinterpretation or incorrect conclusions when comparing the trials without proper consideration of the differing time frames.</s>"
    },
    "5de9caeb-9dd5-4535-8fe3-289450d9c626": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information present in the CTRs because:\n\n1. The CTRs provide details about the number of participants with Central Nervous System (CNS) Metastases for both the Lapatinib Plus Capecitabine and Trastuzumab Plus Capecitabine groups.\n2. The statement asserts that the Trastuzumab Plus Capecitabine group had a higher percentage of patients with CNS Metastases.\n3. To determine if one group had a higher percentage, we can calculate the percentages based on the provided number of participants.\n4. According to Result 1, there were 251 participants in the Lapatinib Plus Capecitabine group.\n5. According to Result 2, there were 250 participants in the Trastuzumab Plus Capecitabine group.\n6. By calculating the percentages from these results, we can find that the Trastuzumab Plus Capecitabine group had a slightly higher percentage of patients with CNS Metastases (96/250 = 0.384 or 38.4%) compared to the Lapatinib Plus Capecitabine group (52/251 = 0.207 or 20.7%).\n7. The expert's statement is consistent with these percentages, as the CTRs do not contradict it.\n\nTherefore, based on the semantically entailed relationships between the statement and the CTRs, the expert's statement is a valid inference.</s>",
        "contradict": "The expert's statement contradicts the information in the CTRs because the CTRs do not provide data on the percentage of participants with CNS Metastases in each group. Instead, they only specify the criteria for defining and assessing CNS relapse and the number of participants in each group.</s>"
    },
    "bebfc78e-b35f-4677-8342-9567a7e795a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is one case of Diarrhea in the secondary trial and none in the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" can be entailed by the information present in the CTRs because, in Adverse Events 2 of the secondary trial, there is a report of one instance of Diarrhea out of 93 participants, whereas, in Adverse Events 1 and 2 of the primary trial, there are no reports of Diarrhea among the 373 participants. The absence of Diarrhea in the primary trial, as reported in both Adverse Events 1 and 2, implies that the statement \"There is none in the primary trial\" is a valid conclusion from the information in the CTR. Since the statement \"and none in the primary trial\" is a part of the expert's statement, the entire statement is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" is contradicted by the information present in the CTRs because, in the primary trial, there are no instances of Diarrhea reported in either Adverse Events 1 or Adverse Events 2, while in the secondary trial, there is one reported case of Diarrhea in both Adverse Events 1 and Adverse Events 2.</s>"
    },
    "faa65e54-aa04-4595-8dae-05cf00b4c887": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "Only cohort 1 patients of the primary trial are administered Ipatasertib",
        "Label": "Entailment",
        "entail": "The statement \"Only cohort 1 patients of the primary trial are administered Ipatasertib\" is entailed by the information present in the CTRs because the first intervention in the primary trial explicitly states that participants in that cohort received Ipatasertib orally daily, whereas the second intervention specifies the use of a placebo instead. Therefore, the statement correctly describes the allocation of treatments within the primary trial, which is consistent with the provided CTRs.</s>",
        "contradict": "The statement \"Only cohort 1 patients of the primary trial are administered Ipatasertib\" is contradicted by the CTR information because Intervention 1 of the primary trial states that both ipatasertib and placebo were given orally daily on Days 1-21 of each 28-day cycle for 3 cycles to different cohorts, not just cohort 1. Therefore, according to the CTR, there are indeed patients in cohort 2 receiving placebo instead of ipatasertib. However, ipatasertib is only administered to the patients in Cohort 1 as per the statement, which contradicts the CTR information.</s>"
    },
    "751fd763-89fa-4d52-8bda-f09b490a5e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00357110",
        "Statement": "there were no recorded deaths in the primary trial cohorts.",
        "Label": "Entailment",
        "entail": "The expert's statement can be entailed by the information present in the CTRs if there were no recorded deaths from any cause in both the Fulvestrant + Anastrozole and Anastrozole arms during the 12-month follow-up period. According to the CTR, the outcome measurement for the primary trial includes death from any cause as an event. Moreover, the Results section indicates that there were no deaths reported in either arm. Therefore, the expert's statement is consistent with the CTR data. Additionally, this statement does not contradict any information provided in the CTRs.</s>",
        "contradict": "The statement \"there were no recorded deaths in the primary trial cohorts\" contradicts the information provided in the CTRs as both reports indicate participants in each arm experienced events (death, DTC positive at 12 months, or clinical disease recurrence) during the 12-month period following randomisation. The number of participants event-free is given for each arm, which implies that some patients in both groups did experience an event.</s>"
    },
    "c40fdf91-9f81-454a-bba9-ec5c950cef6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00374322",
        "Statement": "One patient cohort in the primary trial received a placebo intervention",
        "Label": "Entailment",
        "entail": "The statement \"One patient cohort in the primary trial received a placebo intervention\" is entailed by the CTR as both trials have identical design and structure, with half of the participants in each trial receiving placebo interventions according to their respective intervention sections.</s>",
        "contradict": "The statement \"One patient cohort in the primary trial received a placebo intervention\" is consistent with the information in the CTR for the placebo group. However, it is an incomplete representation of the primary trial since both an active intervention (lapatinib) and a placebo were involved. The CTR indicates that there were two intervention groups - lapatinib and placebo. Therefore, stating that \"one patient cohort\" received a placebo intervention does not accurately reflect the entirety of the information in the primary trial report.</s>"
    },
    "31105b43-832b-48bc-a78d-ee90c155ca44": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439945",
        "Secondary_id": "NCT01998906",
        "Statement": "Presence of hot flashes for  30 days prior to study registration is required for all patients that want to participate in the primary trial, but not necessary for entry to the secondary trial.",
        "Label": "Entailment",
        "entail": "The primary trial's eligibility criteria state that participants must experience bothersome hot flashes for 30 days prior to registration. This requirement is not explicitly stated for the secondary trial. However, the non-entailment does not equate to contradiction. The absence of a requirement for hot flashes in the secondary trial's eligibility criteria does not contradict or negate the presence of this requirement in the primary trial. The statement's assertion, therefore, is entailed by the information in the CTRs, as it correctly acknowledges the presence of a hot flashes requirement in the primary trial but not in the secondary trial.</s>",
        "contradict": "The statement is contradictory to the information in the CTRS since the primary trial requires the presence of hot flashes for 30 days prior to study registration, while the secondary trial does not list this as a requirement for participation.</s>"
    },
    "49ba06b2-576d-4db2-80b6-51673416f2ba": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts\" is entailed by the information in the CTRs because:\n\n1. Both primary and secondary trials use FLT PET scanning procedure to measure Ki-67 (a cell proliferation marker) in breast tumors.\n2. The primary trial states that patients undergo FLT PET scan at baseline and 1-6 weeks after the start of endocrine treatment, and the change in Ki value will be computed during this time frame. (Section: Results 1 - Arm/Group Title: Diagnostic (FLT PET)).\n3. The secondary trial describes that participants undergo FLT PET scan at baseline and then at various time points during the study. However, the exact time frame for the post-therapy scan isn't mentioned (Section: Results 1 - Arm/Group Title: Baseline and Follow-up Evaluation).\n4. Despite the difference in the time frame, the primary and secondary trials have a consistent objective: evaluating the change in Ki value using FLT PET in breast cancer patients.\n\nThus, the statement can be entailed by the information in the CTRs, as both trials involve measuring the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts.</s>",
        "contradict": "The statement cannot be directly confirmed or contradicted based on the provided CTR information since:\n\n1. The primary trial reports the use of Ki-67 as a reference for early response evaluation in the context of the Percent Change in Net Influx Constant (Ki) by FLT PET measurement. However, the secondary trial does not mention any correlation analysis between Ki and Ki-67.\n\n2. The primary trial measures the Percent Change in Ki by FLT PET between pre-treatment and post-therapy PET measurements in breast tumors, while the secondary trial does not mention any FLT PET measurement at all.\n\nTherefore, the statement is not contradicted by the information present in the CTRs, but it cannot be confirmed either, as it combines elements from both trials without sufficient context.</s>"
    },
    "3cb71095-8e01-40dc-bbf5-eeffed55f354": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00232505",
        "Statement": "Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients with Histologically confirmed breast cancer stage I-IV are not eligible for the primary trial\" is entailed by the information in the CTR as it explicitly states \"DISEASE CHARACTERISTICS: Metastatic (stage IV) disease\" and \"INCLUSION CRITERIA: At least 1 EXCLUSION CRITERIA: Lesions identifiable only by PET (not measurable disease), more than three prior chemotherapy regimens, or histologically confirmed breast cancer stage I-III are not eligible for the study.\"</s>",
        "contradict": "The given statement is contradicted by the information in the CTRs as they specifically mention patients with histologically confirmed breast cancer stage IV, meeting all other eligibility criteria, are permitted to participate in the primary trial. This contradicts the statement that all patients with histologically confirmed breast cancer stages I-IV are ineligible for the primary trial.</s>"
    },
    "09fc4356-6154-427e-b710-ed5df6470aff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00900627",
        "Statement": "50% of cohort 2 patients in the primary trial suffered Keratitis",
        "Label": "Contradiction",
        "entail": "The statement \"50% of cohort 2 patients in the primary trial suffered Keratitis\" can be entailed by the information present in the CTRs if we make the assumption that Cohort 2 in the primary trial refers to the arm/group titled \"AZD8931 120 mg bd.\" According to the CTR, there was one participant in this cohort who suffered from Keratitis (as per Results 2). Therefore, if we assume that all participants in this cohort are accounted for in the CTR, then 1 out of 2 participants suffered from Keratitis, which equals a 50% incidence rate.</s>",
        "contradict": "The statement \"50% of cohort 2 patients in the primary trial suffered Keratitis\" contradicts the information present in the CTRs as there was no participant in cohort 2 who experienced Keratitis according to the reported results.</s>"
    },
    "446f3c69-0de5-475c-a8e2-ff40ece90672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02924883",
        "Statement": "Only patients with HER2+ve breast cancer are eligible for the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Only patients with HER2+ve breast cancer are eligible for the primary trial\" is entailed by the CTRs' inclusion criteria specifying that \"HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies.\"</s>",
        "contradict": "The information in the statement is contradicted by the CTR as it includes an additional eligibility criterion for HER2 positivity, but the CTR specifies more detailed criteria for HER2 positivity using immunohistochemistry score, gene amplification, or both. Thus, the statement is not entailed by the CTR as it oversimplifies the inclusion criteria for HER2+ve breast cancer.</s>"
    },
    "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00445458",
        "Statement": "the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as both report zero percentage (0.0%) of participants suffering from side effects (Dose Limiting Toxicity Incidence) in the Neratinib + Paclitaxel arms of the trials for both Neratinib dosages (160 mg and 240 mg qd) given in the CTRs.</s>",
        "contradict": "The expert's statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer 0 side effects\" contradicts the CTR information as there is no data reported in either Results 1 or Results 2 regarding the percentage of participants suffering from \"0 side effects.\" The CTR only provides counts of participants for each arm of the study without specifying the number of participants experiencing side effects.</s>"
    },
    "f0e845f9-8991-45b5-a520-51e934756f7a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Entailment",
        "entail": "The primary CTR states that participants received Letrozole orally once daily for 24 weeks. The secondary CTR does not specify the intervention in detail, only that it is a medical procedure (Sentinel Lymph Node Biopsy). However, the intervention type being different in nature (drug vs medical procedure) does not contradict or challenge the information in the primary CTR. Therefore, the statement's assertion is harmonious with the CTR data and can be considered entailed.</s>",
        "contradict": "Although the statement \"The primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" is generally true as it pertains to the nature of the interventions in the given CTRs, it fails to account for the specifics within each trial. The primary trial intervention in the first CTR indeed entails a drug (Letrozole) taken orally. However, the secondary trial intervention, despite being labeled as a medical procedure in the second CTR, is actually not specified with any details. Thus, while the statement is generally true, it can be contradicted by the lack of detail and clarity regarding the nature of the intervention in the secondary trial.</s>"
    },
    "a0065d58-e03b-4dd0-9c81-cbbf651a6d45": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00820170",
        "Secondary_id": "NCT00263588",
        "Statement": "any patient eligible for the secondary trial will also be eligible for the primary trial ",
        "Label": "Contradiction",
        "entail": "The statement \"any patient eligible for the secondary trial will also be eligible for the primary trial\" is entailed by the information in the CTRs because the secondary trial includes the following inclusion criteria: ErbB2(HER2)overexpressing breast cancer, prior treatment of brain metastases with Whole Brain Radiotherapy (WBR) and/or Stereotactic Radiosurgery (SRS), prior treatment with trastuzumab (Herceptin), and able to swallow an oral medication. All of these criteria are also mentioned in the primary trial's inclusion criteria, with the exception of the requirement for HER2 overexpression. However, the primary trial's inclusion criteria state that patients must have a diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC and evidence of recurrent or progressive locally advanced or metastatic breast cancer. These criteria implicitly include the requirement for HER2 overexpression because HER2 status is a well-established prognostic factor in breast cancer and is routinely tested in clinical practice. Therefore, any patient who meets the inclusion criteria for the secondary trial will also meet the inclusion criteria for the primary trial, with the exception of the specific eligibility criteria for the phase I and phase II portions, which are not applicable to the secondary trial. The statement is also not contradictory to the CTRs and finds substantiation in the shared inclusion criteria.</s>",
        "contradict": "The statement \"any patient eligible for the secondary trial will also be eligible for the primary trial\" is contradicted by the information present in the CTRs due to several reasons:\n\n1. Inclusion criteria:\n  a) The primary trial has specific eligibility criteria for breast cancer, such as invasive adenocarcinoma, ER/PR/HER2 disease status, and availability of a paraffin-embedded tissue block or unstained slides. These criteria are not explicitly stated for the secondary trial, meaning that some patients might be eligible for the secondary trial but not the primary one.\n  b) The secondary trial specifically requires ErbB2(HER2) overexpressing breast cancer, which is a subset of breast cancer. Not all patients with breast cancer will meet this criterion, so the statement would not apply to them.\n\n2. Exclusion criteria:\n  a) The primary trial has specific exclusion criteria, such as life expectancy less than 3 months, prior severe allergic reaction to paclitaxel therapy, and cardiovascular conditions. These criteria are not explicitly stated for the secondary trial, meaning that some patients might be excluded from the primary trial but eligible for the secondary one.\n\nTherefore, the statement \"any patient eligible for the secondary trial will also be eligible for the primary trial\" is not necessarily true, as the eligibility and exclusion criteria differ in the two trials.</s>"
    },
    "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01125566",
        "Statement": "ECOG score > 2 is necessary to be eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"ECOG score > 2 is necessary to be eligible for the primary trial\" is not entailed by the information present in the CTRs. The primary trial's inclusion criteria clearly specify that an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 is a requirement for patient eligibility.</s>",
        "contradict": "The statement \"ECOG score > 2 is necessary to be eligible for the primary trial\" is contradicted by the information in the CTR as the eligibility criteria clearly states that \"Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\" is a requirement for participation in the trial. Therefore, an ECOG score greater than 2 is not a necessary condition for eligibility.</s>"
    },
    "973f090a-8967-4d75-bb8e-6166c868337c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02301988",
        "Statement": "cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and  Placebo than cohort 2 patients",
        "Label": "Contradiction",
        "entail": "The statement does not entail the information presented in the CTRs. The CTRs describe that both cohorts received ipatasertib orally daily for 3 cycles and placebo orally daily for the same duration in the primary trial. There is no mention of different doses for each cohort. Therefore, the statement goes beyond the information given in the CTRs.</s>",
        "contradict": "The information in the statement \"cohort 1 patients of the primary trial are administered higher doses of Ipatasertib and Placebo than cohort 2 patients\" cannot be directly contradicted by the provided CTR information since no specific dosing details are given for each cohort in the CTR. However, based on the information in the CTR, both cohorts received the same dosing regimens for ipatasertib (orally daily on Days 1-21 of each 28-day cycle for 3 cycles) and placebo (orally daily on the same schedule), as well as the same paclitaxel dosing regimen (IV infusion every week for 3 cycles). Therefore, there isn't any contradiction with regard to the dosing information provided in the statement and the CTR. However, the statement itself is not entailed by the CTR, as the CTR does not mention anything about different doses for the two cohorts.</s>"
    },
    "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01929395",
        "Statement": "Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial\" cannot be entailed by the information present in the CTRs, as the primary trial's inclusion criteria only pertain to invasive breast cancer or ductal carcinoma in situ, and there is no mention of carcinomas in the stomach or neck areas.</s>",
        "contradict": "The statement \"Patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial\" contradicts the information present in the CTRs, as the trials only focus on breast cancer patients and do not mention any involvement of stomach or neck carcinomas.</s>"
    },
    "1d1f57f8-85f7-448c-a4bb-15957da568fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression",
        "Label": "Entailment",
        "entail": "The statement made by the clinical expert is entailed by the information in the CTRs because both the primary and secondary trials specify that the intervention will continue until patients achieve a complete response or suffer disease progression. Therefore, the expert's statement aligns with the clinical trial data, finds substantiation in the CTRs, and does not contradict the provided descriptions.</s>",
        "contradict": "The statement by the clinical trial expert is identical to the description of the intervention protocol in the primary CTR. Therefore, it does not contradict the CTR but rather reaffirms the information presented. However, the question asks for an explanation of a contradiction, so an answer focusing on potential discrepancies is as follows:\n\nThe statement could be contradicted if there were differences in the intervention protocols between the primary and secondary trial reports. For example, if the secondary trial used a different treatment or dosage, or if the frequency or duration of administration differed from the primary trial, then the statement could contradict the CTR for the secondary trial. However, without any additional context, the statement aligns with both CTRs in this example.</s>"
    },
    "9f7d476e-9db3-4c00-abe6-4c2f0160470a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00944047",
        "Statement": "under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response",
        "Label": "Entailment",
        "entail": "The statement is entailed by the CTR as follows: Out of the 32 participants in the intervention arm of the primary trial, the exact number of patients achieving Pathologic Complete Response within 22 weeks is not specified in the provided information. However, the statement \"under 30% of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" can be inferred based on the given information. Since there are 32 participants in total and 30% of 32 is less than or equal to 10 (which cannot be the exact number of participants as it is a fraction), it implies that fewer than 10 participants (but more than 0) experienced the response. The CTR indicates that \"Overall Number of Participants Analyzed: 32\" and the statement \"under 30% of the primary trial patients\" refers to the participants in the intervention arm, which is consistent with the information in the CTR. The statement does not contradict any information in the CTRs and is harmonious with the provided data, making it entailed.</s>",
        "contradict": "The information in the expert statement can be contradicted by the CTR results if the percentage of participants in the primary trial who experienced Pathologic Complete Response was higher than 30%. The CTR specifies that the primary trial had 32 participants in the intervention arm, but it does not provide the number of participants who achieved Pathologic Complete Response. However, it's important to note that a lack of information doesn't automatically imply that the expert statement is incorrect; it just creates uncertainty until more information is available. To definitively determine entailment, one would need to know the actual percentage of participants who achieved Pathologic Complete Response in the primary trial.</s>"
    },
    "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00333775",
        "Statement": "both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo",
        "Label": "Contradiction",
        "entail": "The statement \"both the primary trial cohorts receive identical doses of Docetaxel, with cohort 1 also receiving 100 mg/m^2 of Placebo\" is entailed by the information present in the CTRs as both intervention arms receive an identical dose of Docetaxel (100 mg/m^2). The difference lies only in the addition of placebo to cohort 1. This information is present in the description of INTERVENTION 1 in the primary trial CTR. The statement does not contradict any information provided in the CTRs and thus can be considered to entail the information in the CTRs.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because cohort 1 in the primary trial receives placebo to bevacizumab in addition to docetaxel 100 mg/m^2, whereas cohort 2 in the primary trial receives both docetaxel and bevacizumab. The statement implies that only cohort 1 receives a placebo, whereas cohort 2 in the primary trial and both cohorts in the secondary trial receive active treatment with bevacizumab.</s>"
    },
    "3adcc8fc-b76b-407a-a006-729a13f571fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03098550",
        "Statement": "both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have, with cohort 1 all being diagnosed with HER2 positive cancer and cohort 2 being PR-",
        "Label": "Contradiction",
        "entail": "The statement \"both cohorts of the primary trial receive identical interventions\" is entailed by the CTR information since both the TNBC and NSCLC cohorts in the primary trial are given the same combination of Nivolumab and Daratumumab, with similar dosages, frequencies, and durations specified for each treatment in both cohorts.\n\nThe statement \"the difference between the two cohorts is the types of cancer that the patients have\" is also entailed by the CTR information, as the CTR specifies that one cohort consists of TNBC patients and the other cohort consists of NSCLC patients.\n\nTogether, the statement \"both cohorts of the primary trial receive identical interventions, the difference between the two cohorts is the types of cancer that the patients have\" is entailed by the CTR information since the CTR already provides the required details about the interventions being identical and the patient populations being distinct based on cancer types.</s>",
        "contradict": "The statement asserts that both cohorts of the primary trial have identical interventions and the difference between the two lies in the types of cancer. However, the CTRs specify that the patients in cohort 1 have TNBC (Triple-negative breast cancer) and those in cohort 2 have NSCLC (Non-small cell lung cancer). Despite both cohorts receiving similar interventions in terms of treatment types (Nivolumab and Daratumumab), the dosages and frequencies are not identical, and the types of cancer differ. This contradicts the assertion in the statement that the two cohorts receive identical interventions.</s>"
    },
    "68379456-775b-463b-bfdb-d8aa42c9124b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00325234",
        "Secondary_id": "NCT00274469",
        "Statement": "Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial\" is entailed by the information present in the CTRs because, according to the Primary Trial's Inclusion Criteria, females with histologic or cytologic diagnosis of advanced breast cancer are eligible for the study. Similarly, the Secondary Trial's Inclusion Criteria specify that patients must have confirmed hormone receptor positive advanced breast cancer and be postmenopausal, which is a type of advanced breast cancer. Therefore, the statement entails that female patients with confirmed advanced breast cancer are eligible for both trials.</s>",
        "contradict": "The statement is contradicted by the information in the CTRs because the primary trial's inclusion criteria include females with advanced breast cancer, but it also specifies additional conditions that females must meet, such as histologic or cytologic diagnosis, performance status, prior chemotherapy, prior radiation therapy, measurable lesion criteria, antitumoral hormonal treatment discontinuation, adequate organ function, and compliance, which are not mentioned in the secondary trial's inclusion criteria. Therefore, the statement that \"Patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial\" does not hold true for all cases, as the primary trial has further specific eligibility requirements.</s>"
    },
    "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00290758",
        "Secondary_id": "NCT02370238",
        "Statement": "Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial",
        "Label": "Entailment",
        "entail": "The given statement is entailed by the information in the CTRs because both CTRs explicitly state that women with a previous history of breast cancer are excluded unless all systemic therapy (including endocrine therapy) was completed at least one year ago in the primary trial, and women with a history of breast cancer are excluded, regardless of whether they have undergone endocrine therapy or not, in the secondary trial. Therefore, the statement's assertion that women undergoing endocrine therapy are excluded from both trials harmonizes with the clinical trial data, finds substantiation in the CTRs, and avoids contradiction with the provided descriptions.</s>",
        "contradict": "The statement \"Women currently undergoing endocrine therapy are excluded from the secondary trial and the primary trial\" is contradicted by the information present in the CTRs because:\n\n1. In the primary trial, women with a history of breast cancer are eligible if they have completed all systemic therapy (including endocrine therapy ) at least one year ago.\n2. In the secondary trial, there is no explicit exclusion for women currently undergoing endocrine therapy but certain conditions apply such as a life expectancy of at least three months, and the presence of at least one baseline measurable lesion according to RECIST criteria version 1.1. These conditions may not be met by all women undergoing endocrine therapy.\n\nTherefore, the statement's assertion does not harmonize with the information in the CTRs and is, thus, contradicted.</s>"
    },
    "f04d9695-81b8-4d70-877b-59caddf901bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00450723",
        "Secondary_id": "NCT00290758",
        "Statement": "Between the secondary trial and the primary trial, all the recorded case of Dyspnea occurred in cohort 1 of the secondary trial",
        "Label": "Entailment",
        "entail": "The statement \"Between the secondary trial and the primary trial, all the recorded cases of Dyspnea occurred in cohort 1 of the secondary trial\" can be entailed by the following facts from the CTRs:\n\n1. In both trials, there is a section dedicated to Adverse Events.\n2. In the Adverse Events section of Trial 1 (Primary Trial), Dyspnea is reported 1/34 times (1.59%).\n3. In the Adverse Events section of Trial 2 (Secondary Trial), Dyspnea is reported 1/62 times in Adverse Events 1, and 0/64 times in Adverse Events 2. However, the statement focuses on the occurrence of Dyspnea within the same cohort in Trial 2.\n4. In Adverse Events 1 of Trial 2, Dyspnea occurred 1/62 times.\n5. The statement \"all the recorded cases of Dyspnea occurred in cohort 1 of the secondary trial\" implies that there is only one cohort in Trial 2. However, there is Adverse Events 1 and Adverse Events 2 in Trial 2.\n6. To fulfill the statement, we need to assume that both Adverse Events 1 and Adverse Events 2 belong to cohort 1 of Trial 2.\n7. Since the CTR does not provide this specific information, the statement is not directly entailed, but it can be made true under the assumption that both Adverse Events 1 and Adverse Events 2 belong to cohort 1.\n\nAssumptions made: \nThe statement assumes that both Adverse Events 1 and Adverse Events 2 from the secondary trial belong to the same cohort. This is not explicitly stated in the provided CTR information.</s>",
        "contradict": "The statement cannot be directly contradicted by the CTR information, but it can be questioned based on the absence of specific information. The CTRs provide the frequency of Dyspnea occurrence in each trial but do not indicate which cohort or arm of the secondary trial experienced the event. If we assume there were multiple cohorts in the secondary trial, the statement's assumption that the event occurred in cohort 1 could be incorrect. Therefore, the statement may not be conclusively determined to be true or false based on the information given. However, it cannot be directly contradicted, as it doesn't contradict any specific information in the CTRs.</s>"
    },
    "f42e1874-343a-43ed-bb0c-884509c4793c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00633464",
        "Secondary_id": "NCT01644890",
        "Statement": "the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death",
        "Label": "Contradiction",
        "entail": "The statement that that \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures Number of Participants With Disease Progression (PD) or Death\" is entailed by the information provided in the CTRs as follows:\n\nIn the primary trial, the outcome measure is stated as \"Percentage of Participants With Objective Response (OR)\" using RECIST criteria. This means the primary trial reports the number of participants who experienced either a complete response (CR) or a partial response (PR), based on the disappearance of all evidence of target lesions or a minimum 30% reduction in the sum of the longest diameters of target lesions, respectively.\n\nOn the other hand, in the secondary trial, the outcome measure is defined as \"Progression Free Survival (PFS)\" which is the time between randomization and the first observation of lesion progression or death from any cause. Although the statement mentions \"Number of Participants With Disease Progression (PD) or Death,\" this information is implicit within the definition of PFS. Since both the number of participants with PD and the number of participants who died during the study period contribute to PFS, it is entailed by the information in the secondary trial. \n\nThus, the statement's claim is entailed by the information provided in the CTRs, as it accurately summarizes the distinct outcome measures used in each trial.</s>",
        "contradict": "The statement is not directly contradictory to the information in the CTRs. However, it can be misleading as the primary trial and the secondary trial assess different outcome measures. The primary trial measures the percentage of participants with Objective Response using RECIST criteria, while the secondary trial measures the number of participants with Disease Progression or Death. While these measurements may indirectly correlate, they are not identical, and the statement does not account for this distinction.</s>"
    },
    "30483d7e-7703-459c-bd10-e2bd259c2a4f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01905592",
        "Statement": "there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" can be entailed by the CTRs as follows: The CTRs specify that for both trials, the listed adverse events occurred in specific percentages of the cohorts. The statement asserts that two of these adverse events did not occur in cohort 1 of the primary trial. This is consistent with the data in the CTRs, where Thrombocytopenia and Nausea are listed as having occurred in 0.00% frequency in cohort 1 of the primary trial. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The statement \"there were two types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" contradicts the information in the CTR because:\n\n1. The CTR lists out the types of adverse events that occurred in cohort 1.\n2. Nausea and Vomiting are mentioned as adverse events that occurred in cohort 1, with non-zero occurrences (0.00% has a technical meaning of no occurrence but 0 instances out of 65 is technically non-zero).\n3. Therefore, there were not two types of adverse events that did not affect any patients in cohort 1 according to the provided CTR information.</s>"
    },
    "7cde9a22-a91f-4feb-892d-7cbd35f96a27": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01416389",
        "Statement": "the primary trial reports the changes in tumor size for patients in its cohorts.",
        "Label": "Entailment",
        "entail": "The expert statement \"the primary trial reports the changes in tumor size for patients in its cohorts\" is entailed by the information presented in the CTRs due to the following reasons: \n\n1. The CTRs explicitly mention \"Outcome Measurement: Change in Tumor Size (CTS) From Baseline to the End of Cycle 2\" for both trials, signifying that the trials report tumor size changes.\n2. For both trials, the CTRs provide data on the mean log ratio change in tumor size from baseline to the end of Cycle 2, which is a measure of change in tumor size.\n3. The expert statement does not specify which trial's cohorts are in question, but the CTRs cover both trials, so the statement holds true for both sets of cohorts. \n4. The expert statement does not contain any contradictory information, as the CTRs do indeed report tumor size changes for their respective cohorts.</s>",
        "contradict": "The statement \"the primary trial reports the changes in tumor size for patients in its cohorts\" is not directly contradicted by the information in the CTRs provided. However, it is less specific than the CTRs, which report the changes in tumor size using log ratios of tumor size at Cycle 2 to baseline. The statement does not specify the measurement or calculation method, potentially allowing for misunderstanding or misinterpretation of the reported data.</s>"
    },
    "16c29502-4683-4087-9410-ff1b786556f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01042535",
        "Statement": "The least common adverse event in the primary trial was Constipation ",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that the least common adverse event in the primary trial was Constipation. The CTR data reveals that Constipation occurred in 1/41 participants (2.44%), which is, in fact, the least frequent adverse event listed in the primary trial. Therefore, the expert's statement is entailed by the data in the CTR.</s>",
        "contradict": "The statement \"The least common adverse event in the primary trial was Constipation\" is not an accurate representation of the information presented in the CTRs. Although constipation was reported in 1/41 participants (2.44%), other adverse events such as Skin infection were reported more infrequently with an occurrence of 2/41 (4.88%). The CTRs provide evidence that contradicts the statement, as it overlooks the occurrence of Skin infection with a lower incidence rate.</s>"
    },
    "5c975af8-6b7f-4a5d-b4a6-257c76763ce9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02244580",
        "Secondary_id": "NCT03176238",
        "Statement": "There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial",
        "Label": "Entailment",
        "entail": "The statement can be derived from the data in the CTRs as follows:\n\n1. The number of cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in the entire patient cohort of the primary trial is 0.\n2. The number of cases of Acute myocardial infarction in cohort 1 of the secondary trial is 1, and the total number of participants in cohort 1 is 36. Therefore, the frequency of Acute myocardial infarction in cohort 1 is 1/36.\n3. The number of cases of Cardiopulmonary failure in cohort 1 of the secondary trial is 1, and the total number of participants in cohort 1 is 36. Therefore, the frequency of Cardiopulmonary failure in cohort 1 is 1/36.\n4. The statement claims that there are more cases of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial.\n5. To establish entailment, the statement's assertion should harmonize with clinical trial data, find substantiation in the CTR, and avoid contradiction with the provided descriptions.\n6. Harmonization: The statement's assertion matches the data in the CTRs as the frequency of Acute myocardial infarction, Cardiopulmonary failure, and Supraventricular tachycardia in cohort 1 of the secondary trial is greater than 0.\n7. Substantiation: The statement's assertion is directly derived from the data in the CTRs.\n8. Avoiding contradiction: The statement's assertion is consistent with the information in the CTRs as the statement does not contradict the data on the occurrence of these adverse events in the respective trials.\n\nTherefore, the statement \"There more cases of Acute myocardial infarction, Cardiopulmonary failure and Supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial\" is entailed by the information present in the CTRs.</s>",
        "contradict": "The statement is contradicted by the CTRs because:\n1. There were no cases (0/0) of Acute myocardial infarction reported in the primary trial's adverse events section.\n2. The secondary trial reported 1 case of Cardiopulmonary failure and none of Supraventricular tachycardia. The stated claim suggests more cases, implying a greater number for both conditions in the secondary trial than what was observed.\n\nHence, the statement is in contradiction with the provided Clinical Trial Reports.</s>"
    },
    "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "There were more total AEs in cohort 1 of  the primary trial than cohort 2",
        "Label": "Contradiction",
        "entail": "The total number of adverse events (AEs) in the primary trial was 13/61 (21.31%), and in the secondary trial, it was 12/60 (20.00%). Comparing the two trials, cohort 1 of the primary trial had more total AEs than cohort 2 of the secondary trial (13 vs 12). This statement can be entailed by the provided CTR data as it accurately reflects the number of AEs within each study cohort.</s>",
        "contradict": "The statement \"There were more total AEs in cohort 1 of the primary trial than cohort 2\" cannot be definitively contradicted based on the given data from the CTRs. However, the statement could be incorrect due to the differing sample sizes between the two cohorts, as cohort 1 had 61 participants while cohort 2 had 60. Therefore, a higher total number of AEs in cohort 1 could simply be a result of the larger sample size, rather than a difference in the occurrence of AEs between the two groups. To establish entailment or contradiction, additional information, specifically the number of participants with each type of AE in both cohorts, would be required.</s>"
    },
    "8e91e404-086e-4063-8d54-83d1b8ebd969": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191815",
        "Statement": "over 1/6 patients in cohort 1 of the primary trial suffered adverse events",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that more than 1/60 (approximately 1.67%) of patients in cohort 1 of the primary trial experienced adverse events. The primary trial CTR reports a total of 6 adverse events out of 67 patients (approximately 1.49%). Although the percentages slightly differ, the expert's statement falls within the range stated in the CTR. Therefore, the statement entails the information provided in the CTR, as it does not contradict or negate the reported data.</s>",
        "contradict": "The statement \"over 1/6 patients in cohort 1 of the primary trial suffered adverse events\" cannot be directly contradicted by the information in the CTRs, but it is potentially misleading. The given data states that there were a total of 6 adverse events among 67 patients (1.49%). However, the statement implies that a larger proportion of patients experienced adverse events, which is not explicitly stated in the CTRs. It is essential to note that the statement does not contradict the data, but it can create confusion regarding the magnitude of the adverse event occurrence. To avoid misunderstandings, it is recommended that the exact number and percentage of patients who experienced adverse events be stated.</s>"
    },
    "b8322b23-a4f6-4cba-9761-be826b509de7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01224678",
        "Secondary_id": "NCT01042535",
        "Statement": "There were more cases of Eye disorders, Abdominal pain, Febrile neutropenia and Anemia in the secondary trial than in the primary trial",
        "Label": "Entailment",
        "entail": "The expert's statement is entailed by the information in the CTRs because:\n\n1. The number of Eye disorders cases in the secondary trial (1) is greater than the absence of Eye disorders in the primary trial (0).\n2. The number of Abdominal pain cases in the secondary trial (1) is greater than the absence of Abdominal pain reports in the primary trial (0).\n3. The number of Febrile neutropenia cases in the secondary trial (2) is greater than the absence of this adverse event in the primary trial (0).\n4. The number of Anemia cases in the secondary trial (1) is greater than the absence of this condition in the primary trial (0).\n5. The total number of adverse events in the secondary trial (14) is greater than the total absence of adverse events in the primary trial (0), as stated in the expert's statement.</s>",
        "contradict": "The expert's statement contradicts the data in the CTRs if we assume that \"cases\" in the statement refer to individual instances of adverse events. According to the CTRs, there was one case of \"Visual disturbance\" under Eye disorders in the secondary trial and none in the primary trial, whereas the statement suggests \"more cases\" implying multiple instances. The same discrepancy is observed for Abdominal pain, Febrile neutropenia, and Anemia. However, it's important to note that the statement does not contradict if the interpretation of \"cases\" is changed to represent the number of participants affected by each adverse event, as the total number of participants was 150 in the primary trial and 41 in the secondary trial.</s>"
    },
    "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00091442",
        "Secondary_id": "NCT01439945",
        "Statement": "There is only one case of Diarrhea in the secondary trial and over 14 different types of Aes recorded in the primary trial cohorts",
        "Label": "Contradiction",
        "entail": "The expert's statement asserts that in the secondary trial, there is only one case of Diarrhea, and in the primary trial, over 14 different types of adverse events (Aes) were recorded. The information in the CTRs supports this assertion, as the Adverse Events sections of each trial report indicate the number of instances of Diarrhea and the variety of different Aes observed. In the primary trial, the number of unique Aes types is 13 (Neutropenia, Febrile neutropenia, Leukopenia, Anaemia, Lymphadenopathy, cardiac failure, Atrial fibrillation, Pericardial effusion, Cardiac failure congestive, and Cardiomyopathy), plus Diarrhea, bringing the total number of unique Aes types to 14. The secondary trial reports no instances of any Aes other than Diarrhea. Thus, the expert's statement is in harmony with the CTR data and is a valid semantic entailment.</s>",
        "contradict": "The expert's statement implies that the secondary trial has no cases of adverse events (Aes) apart from diarrhea, while the primary trial has over 14 distinct types of Aes. However, the provided data contradicts this statement as there are cases of adverse events other than diarrhea recorded in the primary trial. In particular, the primary trials report instances of Neutropenia, Febrile neutropenia, Leukopenia, Anaemia, Lymphadenopathy, cardiac failure, Atrial fibrillation, Pericardial effusion, Cardiac failure congestive, and Cardiomyopathy. Therefore, the expert's assertion is not an entailment of the given clinical trial data.</s>"
    },
    "4b97a844-8d52-48bb-8eda-ca205268f016": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00375427",
        "Statement": "Patients must have a Life expectancy of 75+ years to enroll in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have a Life expectancy of 75+ years to enroll in the primary trial\" is not directly entailed by the information presented in the CTRs as there is no explicit requirement for a life expectancy of 75+ years mentioned in either the inclusion or exclusion criteria. However, the statement can be inferred indirectly by considering the following: \n\n1. The inclusion criteria state that patients have histologically confirmed Stage IV breast cancer, a serious and advanced form of the disease, and a life expectancy of 1 year.\n2. The statement \"Life expectancy 1 year\" is not necessarily equivalent to \"Life expectancy < 75 years\", but it does indicate that the patients in the trial have a relatively short remaining life expectancy.\n3. The statement \"Life expectancy 75+\" years may not be directly entailed by the CTRs, but it follows logically from the known characteristics of the patient population in the study and the understanding of what \"Life expectancy 1 year\" implies.\n\nThus, while not a direct entailment, the statement can be considered consistent with the information in the CTRs. However, this inference may not be robust and should be considered with caution. The statement would need to be evaluated in light of the overall context and goals of the trial.</s>",
        "contradict": "The statement \"Patients must have a Life expectancy of 75+ years to enroll in the primary trial\" is contradicted by the inclusion criterion \"Life expectancy 1 year\" stated in the primary trial's CTR.</s>"
    },
    "2a03c17f-3afe-40f1-a0db-4b876ee8c700": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01928186",
        "Secondary_id": "NCT02340221",
        "Statement": "the primary trial and the secondary trial have non-comparable outcome measurements for their results",
        "Label": "Entailment",
        "entail": "The statement that the primary and secondary trials have non-comparable outcome measurements is entailed by the information present in the CTRs due to the following reasons:\n\n1. Inconsistent Outcome Measures: The primary trial focuses on the percentage change in the net influx constant (Ki) by FLT-PET and the association between Ki-67 and Ki-FLT decline. In contrast, the secondary trial measures progression-free survival (PFS) using RECIST v1.1. These outcome measures are distinct from each other and do not directly compare.\n\n2. Different Time Frames: The primary trial measures change in Ki between pre-treatment and post-therapy (up to 6 weeks) while the secondary trial measures PFS from randomization until disease progression or death (up to approximately 2.5 years).\n\n3. Lack of Common Baseline: The primary trial uses Ki-67 as a biomarker for early response, while the secondary trial defines disease progression based on RECIST v1.1 criteria. These two measures do not share a common baseline and, therefore, are non-comparable.\n\nIn summary, the outcome measurements between the primary and secondary trials are non-comparable due to differences in measures, time frames, and baselines. These discrepancies are evident from the information provided in the CTRs.</s>",
        "contradict": "The statement \"the primary trial and the secondary trial have non-comparable outcome measurements for their results\" can be contradicted by the information in the CTRs because the primary trial measures the percentage change in Ki (Ki-67) by FLT PET, while the secondary trial measures progression-free survival (PFS) using RECIST v1.1. These outcome measurements are not directly comparable as they assess different aspects of treatment efficacy. However, the trials can still be compared in terms of their clinical utility, patient population, or other relevant factors.</s>"
    },
    "3ba42f68-a643-4d10-afd0-cbb358d05a6f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01572727",
        "Secondary_id": "NCT00328783",
        "Statement": "All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial",
        "Label": "Entailment",
        "entail": "The statement \"All patients in the primary trial receive higher doses of Paclitaxel than patients in the secondary trial\" does not entail the given information from the CTRs directly. The CTRs only specify the administration of Paclitaxel in both Interventions of the primary and secondary trials without providing the actual dosage details for each patient. The statement is an inference based on assumptions not directly stated in the provided CTRs. Therefore, it cannot be determined if the statement is entailed by the information present in the CTRs based on the given data alone.</s>",
        "contradict": "The statement cannot be definitively concluded based on the provided CTR information as the dosage of Paclitaxel for each intervention in both trials is not explicitly stated. The CTR only mentions that patients in both the primary and secondary trials received Paclitaxel in addition to Interventions 1 (BKM120 and ABC device, respectively). Therefore, without knowing the specific Paclitaxel dosages for each trial, it is impossible to establish entailment or contradiction between the expert statement and the CTR information.</s>"
    },
    "0a079cca-abde-42cf-9cec-a76e7a380e14": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00904033",
        "Statement": "neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention",
        "Label": "Entailment",
        "entail": "The statement \"neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention\" is entailed by the information present in the CTRs because:\n\n1. In the Primary Trial, Intervention 1 (No Exercise + Multivitamin Arm and Calcitriol Arm) does not mention anything about surgery as a part of the intervention for any of the cohorts.\n2. In Intervention 2 (Exercise + Exercise Arm and Calcitriol+ Exercise Arm), the exercise regimen includes progressive walking and resistance band training, which are non-surgical treatments. Calcitriol is administered through pills taken once a week, also not requiring surgery.\n\nThus, neither of the trials' interventions includes surgery, which aligns with the expert's statement.</s>",
        "contradict": "The statement \"neither of the cohorts in the primary trial are required to undergo surgery as part of the intervention\" is contradicted by the information in the CTRs because the CTRs do not specify that surgery was a part of the intervention for any of the arms in the primary trial. However, the absence of a mention of surgery in the intervention descriptions does not necessarily contradict the statement if it is understood to mean that no surgery was performed during the trial, not just as part of the intervention. But based on the given statement, it is not possible to determine that for certain.</s>"
    },
    "9c033072-5f94-4d79-af47-126d531f0d6e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01216176",
        "Secondary_id": "NCT00325234",
        "Statement": "There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial",
        "Label": "Contradiction",
        "entail": "The statement \"There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial\" cannot be directly entailed from the provided CTRs as there is no mention of Holocraneal cephale (a specific condition) in either Adverse Events section for either trial. Therefore, no semantic entailment relationship can be established based on the available information.</s>",
        "contradict": "The statement \"There are more cases of Holocraneal cephale and Catheter - related infections in the primary trial than in the secondary trial\" cannot be determined as true or false based on the provided information from the CTRs alone, as neither trial reports mention the occurrence of Holocraneal cephale or Catheter-related infections. Contradiction cannot be established as the statement is not substantiated nor contradicted by the data provided.</s>"
    },
    "a52b2d4f-0b06-4960-a9c3-88cb92df0980": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00477464",
        "Statement": "the primary trial participants receive Capecitabine less often than they receive Lapatinib",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial participants receive Capecitabine less often than they receive Lapatinib\" is entailed by the information in the CTRs, as follows:\n\n1. In the primary trial, participants took Capecitabine at 1000 mg/m^2 twice daily for 14 days in each 21-day cycle.\n2. In the primary trial, participants took Lapatinib at 1250 mg once daily.\n3. The frequency of Capecitabine administration is less than that of Lapatinib because Capecitabine is administered twice daily for 14 out of 21 days, while Lapatinib is administered once daily.</s>",
        "contradict": "Contradiction: The statement \"the primary trial participants receive Capecitabine less often than they receive Lapatinib\" is contradicted by the information in the CTRs because, although participants took Capecitabine twice daily on the first 14 days of every 21-day cycle, they took Lapatinib once daily every day. Hence, the frequency of Lapatinib administration is greater than that of Capecitabine in the primary trial.</s>"
    },
    "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00127933",
        "Statement": "eliane is a 56 year old woman, and alex is a 32 year old man, both eliane and alex can both be eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Eliane is a 56 year old woman, and Alex is a 32 year old man, both Eliane and Alex can both be eligible for the primary trial\" is entailed by the information present in the CTRs as follows:\n\n1. Eliane, being a woman, meets the first inclusion criterion (women >=18 years of age).\n2. Eliane, being newly diagnosed and with infiltrating (invasive) breast cancer, meets the second and third inclusion criteria (newly diagnosed and infiltrating [HER2-neu-negative or HER2-neu-positive] breast cancer).\n3. Eliane does not meet the first exclusion criterion (evidence of metastatic disease, except ipsilateral axillary lymph nodes), since the statement does not mention metastatic disease for Eliane.\n4. Eliane does not meet the second exclusion criterion (previous systemic or local primary treatment), since the statement does not mention any previous treatment for Eliane.\n\n5. Similarly, Alex also meets the first inclusion criterion (women >=18 years of age) due to being identified as a man (gender is implied as 'woman' being the opposite of 'man').\n6. Alex also meets the second inclusion criterion by fulfilling the condition of being newly diagnosed and having infiltrating (invasive) breast cancer.\n7. Alex does not meet any of the exclusion criteria mentioned in the CTRs, as there is no indication in the statement that he has evidence of metastatic disease or previous systemic or local primary treatment.\n\nThus, both Eliane and Alex are within the eligible age range, have breast cancer (infiltrating, invasive, and either HER2-neu-negative or HER2-neu-positive), and do not meet any exclusion criteria, which makes them candidates for the primary trial as stated in the CTRs. Therefore, the expert's statement is entailed by the information provided in the CTRs.</s>",
        "contradict": "The statement \"Eliane is a 56 year old woman, and Alex is a 32 year old man, both Eliane and Alex can both be eligible for the primary trial\" is contradicted by the CTR inclusion criteria as Eliane, being 56 years old, exceeds the minimum age requirement for the trial (18 years), while Alex, being 32 years old, is younger than the minimum age requirement. Therefore, according to the information provided in the CTR, only Eliane can be eligible for the trial, and Alex cannot.</s>"
    },
    "1842904b-5371-49ee-b6f4-8831b879098b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00924352",
        "Statement": "Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients",
        "Label": "Entailment",
        "entail": "The statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients\" is entailed by the information present in the CTRs as follows: The frequency of Febrile Neutropenia in the primary trial is reported as 3/56 (5.36%). Since this frequency exceeds 5%, the statement correctly describes the primary trial data, and no contradiction exists with the provided descriptions.</s>",
        "contradict": "The statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting more than 5% of patients\" is contradictory to the information presented in the CTRs because the reported frequency of Febrile Neutropenia in the primary trial was 5.36%, which is less than 5% and therefore does not meet the condition stated in the expert's claim.</s>"
    },
    "324562e6-2b61-4a07-b937-86f99689f2d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00191789",
        "Secondary_id": "NCT00876395",
        "Statement": "Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial",
        "Label": "Entailment",
        "entail": "The statement can be entailed by the information present in the CTRs because:\n\nFor the primary trial CTR, the frequency of diarrhea is given as 5 instances out of 65 participants (7.69%), which is the highest among all adverse events stated.\n\nFor the secondary trial CTR, the frequency of anemia is given as 6 instances out of 472 participants (1.27%), which is the highest among all adverse events stated in that trial's first Adverse Events section.\n\nThe statement correctly identifies the most common adverse event for each individual trial, based on the frequency data provided within the CTRs. The statement does not contradict or add new information; it only summarizes the existing data.</s>",
        "contradict": "The statement \"Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial\" is contradicted by the information present in the CTRs because the primary trial reports a higher total percentage of adverse events, and a higher percentage of participants experiencing diarrhea, compared to the secondary trial. However, anaemia is reported less frequently in both trials. Therefore, the statement that anemia is the most common adverse event in the secondary trial is incorrect. Consequently, the statement that diarrhea is the most common adverse event in the primary trial, while not directly contradicted by the data, cannot be confirmed either since it does not address the secondary trial's data. Thus, the statement as a whole is contradictory to the information presented in the CTRs.</s>"
    },
    "74e376d7-5713-43f3-93f1-9608059c9547": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00193037",
        "Statement": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
        "Label": "Contradiction",
        "entail": "The statement can be entailed by the information present in the CTRs as follows:\n\nIn the first arm (Arm A) of the primary trial, 57.1% of 42 patients (24 patients) experienced a complete or partial response (ORR). However, no information regarding fatal complications is given in the provided CTR.\n\nIn the second arm (Arm B) of the primary trial, 69.5% of 44 patients (30 patients) experienced a complete or partial response (ORR). No information about fatal complications is provided in the CTR for this arm either.\n\nHowever, the expert's statement indicates that over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention (Arm B) suffered fatal complications. This information cannot be directly extracted from the provided CTR data.\n\nNevertheless, the statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients,\" can be entailed by the information given in the Results section of the CTRs. In Arm A, 57.1% of 42 patients experienced a benefit (ORR), which is below the threshold of 40% stated in the expert's claim. Similarly, in Arm B, 69.5% of 44 patients experienced a benefit (ORR), which is also below the stated threshold.</s>",
        "contradict": "The expert's statement contradicts the information in the CTRs because it asserts that neither intervention led to an objective benefit for more than 40% of patients and that over 86% of Docetaxel Then Liposomal Doxorubicin patients suffered fatal complications. However, the CTRs do not provide data to support these claims. The ORR percentages mentioned in the CTRs for Arm A (Liposomal Doxorubicin) and Arm B (Docetaxel Then Liposomal Doxorubicin) do not exceed 40%. Yet, no information regarding fatal complications is mentioned in the given CTRs. Therefore, the expert's statement goes beyond the data provided in the CTRs and may not be accurate.</s>"
    },
    "0e609fad-9a28-4fb6-90b6-32a731e3b02c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03012477",
        "Secondary_id": "NCT02419807",
        "Statement": "the primary trial and the secondary trial report their results as perecentages but use different units of measure.",
        "Label": "Contradiction",
        "entail": "The statement \"the primary trial and the secondary trial report their results as percentages but use different units of measure\" describes a factual observation about the presentation of results in the two trials. This statement does not directly claim anything about the content of the trials' results or their entailment relationships. \n\nHowever, the information in the statement can be considered entailed by the information in the CTRs because both trials report their results as percentages, as stated in the given text. Although the units of measure for the percentages may differ (e.g., percentage of participants achieving objective response rate in the primary trial, and percentage of nodes detected by each method in the secondary trial), the use of the percentage as the unit of measure is a shared characteristic between the two trials. This shared characteristic is explicitly stated in the text provided for both trials. Thus, the statement is consistent with the CTRs and does not contradict their content.</s>",
        "contradict": "The statement itself does not contradict the information in the CTRs. However, the statement does not provide sufficient context to establish entailment with the CTRs. The percentage figures mentioned in the statement (percentages of participants and proportions of SNs) are not directly comparable due to differences in units of measure between the trials. The percentage of participants achieving objective response (ORR) in the primary trial and the proportion of SNs flagged by two methods in the secondary trial are not identical measurements, despite both being reported as percentages. The comparison requires more specific information, such as the percentage of participants achieving specific levels of ORR or the percentage of SNs flagged by each method within the same context. Therefore, while the statement does not contradict the information present in the CTRs, it does not fully establish entailment either.</s>"
    },
    "236780db-9e59-4dc9-8da0-e786287011cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00106002",
        "Statement": "the primary trial intervention protocol lasts a total of 14 days",
        "Label": "Contradiction",
        "entail": "The statement that \"the primary trial intervention protocol lasts a total of 14 days\" can be entailed by the information in the CTR as follows:\n\nThe primary trial intervention is administered every 14 days. Since each administration session takes place every 14 days, the total duration of the intervention protocol can be calculated by adding up the number of administration sessions. Assuming the trial runs until complete response or disease progression, the total number of administration sessions is not explicitly stated in the CTR. However, given that each administration is 14 days apart, it follows that the total duration of the intervention protocol is a multiple of 14 days. Therefore, the statement is an entailed consequence of the information provided in the CTR.</s>",
        "contradict": "The expert's statement \"the primary trial intervention protocol lasts a total of 14 days\" contradicts the information given in the CTR regarding the administration frequency of Pemetrexed in the primary trial, which states that Pemetrexed is given every 14 days. The statement implies that the entire intervention process, from start to finish, takes place within 14 days; however, this is not the case according to the CTR, which specifies that the treatment is given every 14 days until complete response or disease progression, which could last much longer than just 14 days.</s>"
    },
    "6d621974-c719-46df-8a50-d94e49583e33": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00876395",
        "Statement": "all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy",
        "Label": "Entailment",
        "entail": "The statement \"all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" is entailed by the information in the CTRs as follows. The inclusion criteria of the primary trial specify that \"Prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization.\" This statement acknowledges that prior endocrine therapy is permitted for trial participation, and the CTR further indicates that these patients can be included in the study. Therefore, every patient who meets all other inclusion criteria and has undergone prior endocrine therapy falls within the scope of the primary trial. Consequently, the statement \"all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" is a valid inference drawn from the CTRs.</s>",
        "contradict": "The statement \"all patients accepted into the primary trial have undergone Prior treatment for breast cancer with endocrine therapy\" contradicts the information presented in the CTR because it overgeneralizes a condition specified under the inclusion criteria. According to the CTR, endocrine therapy prior to randomization is allowed but not mandatory for patient eligibility in the primary trial. Therefore, not all patients have undergone prior endocrine therapy.</s>"
    },
    "a9907a2e-254a-45ca-af50-3e44fd2f7af3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01307891",
        "Statement": "There was one case of  Neutropenia in both cohorts of the primary trial",
        "Label": "Entailment",
        "entail": "The statement \"There was one case of Neutropenia in both cohorts of the primary trial\" is entailed by the information present in the CTRs as follows:\n1. The CTRs report one case of Neutropenia (an adverse event) in the primary trial, which occurred in 1/39 (2.56%) of the patients (CTR 1).\n2. The CTRs also report one case of Neutropenia (an adverse event) in the secondary trial, which occurred in 1/21 (4.76%) of the patients (CTR 2).\n3. Since the statement \"There was one case of Neutropenia in both cohorts of the primary trial\" refers to both cohorts, it is consistent with the information reported in each individual CTR.\n4. The statement does not contradict any information provided in the CTRs, making it an entailed claim based on the given information.</s>",
        "contradict": "The statement \"There was one case of Neutropenia in both cohorts of the primary trial\" contradicts the information in the CTR as the number of Neutropenia cases reported in each cohort was different (1 in the first cohort and 1 in the second cohort). Consequently, it is not possible for there to be only one case in both cohorts based on the given CTR data.</s>"
    },
    "40f699a1-fbc6-40de-8e80-85b28f71632f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02658734",
        "Statement": "Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
        "Label": "Contradiction",
        "entail": "The statement \"Most patients in the primary trial experienced a grade 1 adverse event, the least common severity was grade 5, which only affected 8/70 patients\" is entailed by the CTR as follows:\n\n1. The CTR specifies that the primary trial involved 70 participants, and their adverse events (AEs) were graded using the NCI CTCAE version 4.03.\n2. The CTR reports that 53 of these participants (75.7%) experienced a grade 1 adverse event.\n3. The CTR further reports that grade 5 adverse events, the least common severity, affected 12 patients (17.1%).\n4. The statement's claim that \"most patients\" experienced a grade 1 adverse event and that the least common severity was grade 5 and affected 8/70 patients is an accurate reflection of the CTR data.\n5. The statement does not contradict the information present in the CTR.</s>",
        "contradict": "The statement made by the clinical trial expert contradicts the information in the CTR in terms of the count and percentage of participants experiencing grade 5 adverse events. According to the CTR, 12 participants (17.1%) experienced grade 5 adverse events, while the statement asserts that only 8 out of 70 patients (11.4%) were affected.</s>"
    },
    "6499b181-7a23-4073-8459-ad46ff02b20f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00503906",
        "Statement": "Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)",
        "Label": "Contradiction",
        "entail": "The statement \"Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)\" is entailed by the CTR information as follows:\n\n1. Each cycle of the primary trial lasts for 28 days.\n2. Participants are treated with the intervention (Abraxane, Avastin and Gemcitabine) in every cycle.\n3. The number of cycles each participant undergoes is until disease progression.\n\nSince the intervention is given in every 28-day cycle, and treatment continues until disease progression, participants will complete a total of 12 cycles (28 days x 12 = 336 days, assuming disease progression happens after 3 cycles). However, the trial only reports the total treatment duration in terms of number of cycles, which is 12. Therefore, the expert's statement accurately reflects the information presented in the CTRs.</s>",
        "contradict": "The statement that \"Participants of the primary trial will receive the intervention for a total of 12 cycles (28 days)\" does not directly contradict the information in the CTRs. However, it is important to consider the full context. The CTR states that participants will be treated until disease progression. Therefore, some participants might receive more than 12 cycles depending on their individual response to treatment and disease progression. Hence, the statement can be an oversimplification or a limitation of the primary trial's data, not an outright contradiction.</s>"
    },
    "2da13cd4-7189-4f85-be4d-5c1e213ae293": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02370238",
        "Statement": "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
        "Label": "Entailment",
        "entail": "The statement \"The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1\" is entailed by the CTRs because in Adverse Events 1, the frequency of Non-cardiac chest pain is reported to be 2/61 (3.28%), which is less than 5% of 61 (the total number of participants in the primary trial).</s>",
        "contradict": "The statement is contradictory to the information in the CTRs as per the given definitions. According to the CTRs, Non-cardiac chest pain occurred in 2/61 (3.28%) and 0/60 (0.00%) participants in the primary and secondary trials, respectively. Therefore, it did not affect less than 5% of participants in cohort 1 of the primary trial.</s>"
    },
    "a9bb6de9-c6f8-4c99-81cd-f101cbaab387": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00617539",
        "Statement": "Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial\" is not directly stated in the CTR. However, the statement can be inferred to be entailed by the CTR based on the following reasons:\n\n1. The CTR specifies that patients in the primary trial must have \"Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain\" (Disease Characteristics). This implies that patients with no radiographically confirmed metastases to the brain would not meet the eligibility criteria for the primary trial.\n\n2. The absence of radiographically confirmed metastases to the brain in the secondary trial's eligibility criteria is a prerequisite that is more restrictive than the eligibility criteria for the primary trial (as patients in the primary trial can have radiographically confirmed brain metastases). Therefore, the more inclusive eligibility criteria in the CTR cannot entail the more restrictive criteria in the expert statement, but the reverse entailment holds. However, since the task asks for why the information contained in the expert statement can be entailed by the information present in the CTRs, the above arguments provide justification for this entailment.</s>",
        "contradict": "The statement \"Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial\" contradicts the information in the CTR as it does not align with the trial's eligibility criteria which specifically states \"Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain\" and \"Not a candidate for surgical resection and/or further stereotactic radiosurgery\", implying the presence of brain metastases for trial participants.</s>"
    },
    "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.",
        "Label": "Entailment",
        "entail": "The expert statement can be entailed by the primary trial CTR information as follows: \n\nThe CTR outlines that the outcome measurement for the primary trial involves patients having a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for a time frame of 24 weeks, as per RECIST, V1.0 assessment using MRI or CT. \n\nCR implies disappearance of all target lesions, PR signifies a \u226530% decrease in the sum of the longest diameter of target lesions, and SD refers to tumor neither growing nor shrinking. \n\nHence, the expert statement \"All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking\" directly correlates with the CR, PR, and SD definitions in the CTR, making it entailed.</s>",
        "contradict": "The expert's statement is not contradicted by the information in the CTRs, but it is not identical to the information in the CTRs either. While the expert's statement includes Disappearance of all target lesions, which is a type of Complete Response (CR), the CTRs only mention CR as one of several possible outcomes (CR, PR, or SD, each lasting >24 weeks), without specifying disappearance of all target lesions for all patients. Additionally, the expert's statement omits the requirement of MRI or CT assessment for the outcome measurement and does not explicitly state that the 24-week duration applies to all patients. Therefore, the expert's statement is not an exact entailment of the information in the CTRs, but it is consistent with it within the context of the clinical trial domain.</s>"
    },
    "016943fa-57ea-4293-8131-03292ea1836c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00550771",
        "Statement": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
        "Label": "Contradiction",
        "entail": "The statement that \"a patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm\" is entailed by the information present in the CTRs as follows:\n\n1. For a node-positive case, the CTR specifies that patients with node-positive breast carcinoma (T1-3, N1-2, M0) are eligible for the trial. The node-positive case with T2 tumor stage falls under T1-3 category.\n\n2. For a node-negative case, the CTR states that patients with otherwise high or intermediate risk node-negative breast carcinoma can also be included. One of the criteria for high or intermediate risk is a tumor diameter over 2 cm.\n\nTherefore, both node-positive T2 N2 M0 and node-negative Tx N0 M0 (with Tx representing any Tumor stage > T2) patients meet the inclusion criteria as per the CTRs.</s>",
        "contradict": "The statement does not directly contradict the CTR information; however, it is incompletely accurate. According to the CTR, a patient with a node-negative tumor is eligible only if it has at least one of the specified high-risk features, such as tumor size over 1 cm, negative ER/PR, malignancy grade 2-3, presence of peritumoral vascular invasion or age under 35. The statement only mentions a tumor diameter over 2cm as a criterion for node-negative patients, which is not a complete list of the eligibility criteria as per the CTR.</s>"
    },
    "402f0dbf-cf67-4425-b300-a0a3df4d59d3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00305448",
        "Secondary_id": "NCT00425854",
        "Statement": "the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions. ",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions\" can be entailed by the information presented in the CTRs as follows:\n\n1. In both trials, the term \"Objective Response\" is used to describe the outcome measurement for the interventions.\n2. The primary trial outlines that Objective Response is defined as a patient having a best overall response of either complete response or partial response, and is measured using the Response Evaluation Criteria in Solid Tumors (RECIST) for all patients in the study.\n3. The secondary trial also describes Objective Response as being assessed according to the RECIST criteria.\n\nHence, the statement is an accurate reflection of the outcome measurement descriptions provided in the CTRs, and no contradictory or false information is asserted. The statement is, therefore, entailed by the CTRs.</s>",
        "contradict": "Although both trials use the term \"Objective Response\" as an outcome measurement, the definitions and assessment methods vary. In the primary trial, Objective Response Rate (ORR) is defined as the percentage of patients with either a complete response (CR) or partial response (PR) based on RECIST criteria. In contrast, the secondary trial defines Objective Response (OR) as either a CR or PR but does not provide information on the assessment method or percentage of participants with OR. Additionally, the primary trial measures ORR at specific time points, whereas the secondary trial mentions tumour assessments at several time points but does not specify how OR is determined from those assessments. Therefore, while both trials use the same term, their definitions and measurement methods differ, which can lead to potential misunderstandings or contradictions.</s>"
    },
    "62be4676-099f-4c42-8029-773af8fde6f7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00572728",
        "Statement": "Patients must be bedbound or severaly disabled to participate in the primary trial",
        "Label": "Contradiction",
        "entail": "The statement \"Patients must be bedbound or severely disabled to participate in the primary trial\" is not entailed by the information provided in the CTRs, as there is no mention of bedbound or severely disabled patients in the inclusion or exclusion criteria for the primary trial.</s>",
        "contradict": "The statement \"Patients must be bedbound or severaly disabled to participate in the primary trial\" is contradicted by the inclusion criteria in the CTR, particularly the item \"Able to lie still for 1.5 hours for PET scanning.\" This statement implies that patients are expected to be able to lie still during a PET scan, which requires a level of mobility and alertness that contradicts the notion of being bedbound or severely disabled.</s>"
    },
    "1180dd58-61b8-4c48-ab00-7d458e68c85b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01581619",
        "Secondary_id": "NCT00106002",
        "Statement": "the results of the secondary trial and the primary trial report the same outcome measures",
        "Label": "Contradiction",
        "entail": "Both trials report outcomes using different measurement types and time frames. The primary trial focuses on safety outcomes and their occurrence within a specific time frame (2 years), while the secondary trial reports on tumor response using RECIST criteria and evaluating it every 3 cycles (approximately 6-7 weeks).\n\nDespite the differences in their outcome measures, the expert's statement that \"the results of the secondary trial and the primary trial report the same outcome measures\" can still be entailed by the information in the CTRs, as both reports present results from clinical trials and use the term 'outcomes.' This statement does not specify which type of outcome measures should be compared, allowing the broader interpretation to hold true.</s>",
        "contradict": "The statement \"the results of the secondary trial and the primary trial report the same outcome measures\" is contradicted by the information present in the CTRs as follows:\n\n1. In the primary CTR, the outcome measures involve safety assessments, specifically for skin/subcutaneous and pulmonary toxicity, clinical fat necrosis, and rib fractures.\n2. In contrast, in the secondary CTR, the outcome measure is overall tumor response using RECIST criteria.\n\nTherefore, the outcome measures in the two trials are not the same.</s>"
    },
    "566bdc2d-7c4a-4547-87da-ac81447ecca8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00820222",
        "Statement": "the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group.",
        "Label": "Contradiction",
        "entail": "The expert statement entails the information from the CTRs as both trials report the use of capecitabine, and the CTRs detail the dosing information for both lapatinib plus capecitabine and trastuzumab plus capecitabine arms. The expert statement mentions Grade 3 or 4 toxicities, and the CTRs specify that participants received their study medication until disease progression, unacceptable toxicity, or participant withdrawal, suggesting that the trials reported adverse events, including skin/subcutaneous and pulmonary toxicities. The expert statement's claim is harmonized with the provided descriptions, finds substantiation in the CTRs, and does not contradict the information given. The trials' results are directly comparable as they both use capecitabine in combination with different treatments, allowing for the comparison of toxicity percentages between the two treatment groups.</s>",
        "contradict": "Contradiction lies in the lack of explicit data regarding the incidence of Grade 3 or 4 skin/subcutaneous or pulmonary toxicities for each group in the CTRs. The CTRs only provide information on the type and administration of interventions and overall number of participants for each arm, but not specific toxicity data. Thus, no definitive conclusion on the percentage of participants experiencing Grade 3 or 4 toxicities in each group can be drawn from the available information in the CTRs, making it contradictory to the expert's statement based on the given data.</s>"
    },
    "d310ec4e-993e-4827-8dc5-9aca053972db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00688909",
        "Secondary_id": "NCT00450723",
        "Statement": "The the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure.",
        "Label": "Contradiction",
        "entail": "The primary CTR specifies that participants in the intervention received Letrozole orally once daily for 24 weeks. This meets the criteria for a drug taken orally. \n\nThe secondary CTR does not provide details about the intervention, only indicating that it is a medical procedure (Sentinel Lymph Node Biopsy) which is not taken orally. Therefore, the statement that the primary trial intervention is a drug taken orally and the secondary trial intervention is a medical procedure is not directly entailed by the information in the CTRs. However, the statement does not contradict the data in the CTRs and is generally known to be true based on the common understanding of clinical trials and medical interventions.</s>",
        "contradict": "The statement made by the clinical trial expert that \"the primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" is not directly contradicted by the provided CTR information. However, it is insufficient in capturing the full semantic entailment relationship with the CTRs as it does not specify which trial corresponds to which intervention. \n\nThe statement is true for the given CTRs as the primary trial involves Letrozole, an oral drug, and the secondary trial involves a medical procedure, Sentinel Lymph Node Biopsy. However, it does not provide any new information not already evident from the CTRs. \n\nTo establish semantic entailment, the expert statement should explicitly connect the interventions to their respective trials or make more specific claims based on the data presented in the CTRs. For example, the statement could read, \"Letrozole in the primary trial and Sentinel Lymph Node Biopsy in the secondary trial represent two distinct interventions, with Letrozole being administered orally and Sentinel Lymph Node Biopsy being a surgical procedure.\" This statement is semantically entailed by the given CTR data and provides additional insight.</s>"
    },
    "a5617ae4-05a3-42d0-9e14-141de5f8c010": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00258960",
        "Secondary_id": "NCT00121992",
        "Statement": "the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any\" entails that the secondary trial mentioned at least one instance of Conjunctivitis not present in the primary trial. The CTR for the primary trial does not report any cases of Conjunctivitis, while the CTR for the secondary trial reports one instance. Therefore, the statement is entailed by the information in the CTRs.</s>",
        "contradict": "The expert's statement that \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any\" can be contradicted by the information present in the CTRs because in the primary CTR, there is 1 reported case of Conjunctivitis listed under Adverse Events 2 of the secondary trial, whereas in the primary CTR, there is no mention of Conjunctivitis in the given Adverse Events section. Therefore, the expert's statement is not in agreement with the trial data and can be considered a contradiction.</s>"
    },
    "42d1fcd3-8faa-4065-bbba-42cc90ab67fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00856492",
        "Secondary_id": "NCT00009945",
        "Statement": "the secondary trial and the primary trial do not both measure the pCR of their patient cohorts.",
        "Label": "Entailment",
        "entail": "The statement \"the secondary trial and the primary trial do not both measure the pCR of their patient cohorts\" can be entailed by the information present in the CTRs, as the primary trial reports the number of participants with pathological complete response rate (pCR) in Arm 1 and Arm 2/3, but the secondary trial measures disease-free survival, which is a different outcome measurement. No information is provided in the CTRs indicating that either trial measures pCR at 8 years, as stated in the secondary trial. Therefore, the trials measure different outcomes and do not entail each other regarding pCR.</s>",
        "contradict": "The statement \"the secondary trial and the primary trial do not both measure the pCR of their patient cohorts\" can be contradicted by the information in the CTRs as neither trial explicitly reports pathologic complete response (pCR) rates for their patient cohorts. The primary trial only measures the number of participants with pCR, while the secondary trial measures disease-free survival, which is not equivalent to pCR. Therefore, it cannot definitively be determined whether both trials measure pCR based on the provided information.</s>"
    },
    "d01fda83-5dc8-4ad5-92b8-7553dabd7046": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00428922",
        "Statement": "the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse",
        "Label": "Entailment",
        "entail": "The expert's statement \"the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse\" is entailed by the primary trial's outcome measurement \"Progression-free Survival (PFS)\" as defined in the CTR. PFS is the length of time a patient remains disease-free, which aligns with the expert's description of living with the disease but it not getting worse.</s>",
        "contradict": "The expert's statement, \"the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse,\" and the information in the CTRs might be contradictory because:\n\n1. The expert's statement is referring to overall survival (OS) or time alive with the disease without worsening, whereas the primary outcome measurement in the CTR is specifically Progression-free Survival (PFS), meaning the time a patient lives without their disease progressing, not overall survival.\n\n2. Although the expert's statement can be interpreted as a type of survival outcome, it does not provide enough detail on the time frame or specific conditions, making it less precise and potentially less directly applicable to the CTR data compared to the PFS measure explicitly stated in the CTR.</s>"
    },
    "985bc5a0-bc21-447f-92f1-150e23ede3f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00217399",
        "Statement": "All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions",
        "Label": "Contradiction",
        "entail": "The expert statement \"All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions\" cannot be directly entailed by the information presented in the CTRs. The primary trial's outcome measurement in the CTR specifies that Complete Response, Partial Response, or Stable Disease should last for more than 24 weeks, not that there should be a minimum 50% decrease in the sum of the longest diameter of target lesions for all patients. Therefore, the expert statement goes beyond the information provided in the CTRs and is not an entailed relationship. The expert may have intended to refer to the Partial Response criterion (a >=30% decrease in the sum of longest diameter) but the wording of their statement is not consistent with the CTR.</s>",
        "contradict": "The expert's statement contradicts the information in the primary trial's CTR since there is no mention in the CTR that all patients experienced a minimum 50% decrease in the sum of the longest diameter of target lesions. Instead, the CTR describes the outcome measurement as CR, PR, and SD, which do not meet the criterion for a 50% decrease in the sum of the longest diameter of target lesions for all patients.</s>"
    }
}